Scp160p	O
,	O
a	O
multiple	O
KH	O
-	O
domain	O
protein	O
,	O
is	O
a	O
component	O
of	O
mRNP	O
complexes	O
in	O
yeast	B
Abstract	O
Scp160p	O
is	O
a	O
160	O
kDa	O
protein	O
in	O
the	O
yeast	B
Saccharomyces	B
cerevisiae	I
that	O
contains	O
14	O
repeats	O
of	O
the	O
hnRNP	O
K	O
-	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
and	O
demonstrates	O
significant	O
sequence	O
homology	O
to	O
a	O
family	O
of	O
proteins	O
collectively	O
known	O
as	O
vigilins	O
.	O

As	O
a	O
first	O
step	O
towards	O
defining	O
the	O
function	O
of	O
Scp160p	O
,	O
we	O
have	O
characterized	O
the	O
subcellular	O
distribution	O
and	O
in	O
vivo	O
interactions	O
of	O
this	O
protein	O
.	O

Using	O
sucrose	O
gradient	O
fractionation	O
studies	O
we	O
have	O
demonstrated	O
that	O
Scp160p	O
in	O
cytoplasmic	O
lysates	O
is	O
predominantly	O
associated	O
with	O
polyribosomes	O
.	O

Furthermore	O
,	O
we	O
have	O
found	O
that	O
Scp160p	O
is	O
released	O
from	O
polyribosomes	O
by	O
EDTA	O
in	O
the	O
form	O
of	O
a	O
large	O
complex	O
of	O
≥1300	O
kDa	O
that	O
is	O
sensitive	O
both	O
to	O
RNase	O
and	O
NaCl	O
.	O

Using	O
affinity	O
-	O
chromatography	O
to	O
isolate	O
these	O
complexes	O
,	O
we	O
have	O
identified	O
two	O
protein	O
components	O
other	O
than	O
Scp160p	O
:	O
poly	O
(	O
A	O
)	O
binding	O
protein	O
,	O
Pab1p	O
,	O
and	O
Bfr1p	O
.	O

The	O
presence	O
of	O
Pab1p	O
confirms	O
these	O
complexes	O
to	O
be	O
mRNPs	O
.	O

The	O
presence	O
of	O
Bfr1p	O
is	O
intriguing	O
because	O
the	O
null	O
phenotype	O
for	O
this	O
gene	O
is	O
essentially	O
the	O
same	O
as	O
that	O
reported	O
for	O
scp160-null	O
cells	O
:	O
increased	O
cell	O
size	O
and	O
aberrant	O
DNA	O
content	O
.	O

These	O
results	O
demonstrate	O
that	O
Scp160p	O
associates	O
with	O
polyribosome	O
-	O
bound	O
mRNP	O
complexes	O
in	O
vivo	O
,	O
implicating	O
a	O
role	O
for	O
this	O
protein	O
in	O
one	O
or	O
more	O
levels	O
of	O
mRNA	O
metabolism	O
in	O
yeast	B
.	O

INTRODUCTION	O
Scp160p	O
is	O
a	O
1222	O
amino	O
acid	O
Saccharomyces	B
cerevisiae	I
protein	O
that	O
contains	O
14	O
copies	O
of	O
the	O
hnRNP	O
K	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
a	O
highly	O
conserved	O
motif	O
found	O
in	O
many	O
proteins	O
involved	O
in	O
RNA	O
metabolism	O
(	O
1	O
)	O
.	O

KH	O
domain	O
-	O
containing	O
proteins	O
appear	O
to	O
have	O
diverse	O
functions	O
and	O
have	O
been	O
identified	O
in	O
all	O
kingdoms	O
of	O
life	O
,	O
including	O
the	O
ribosomal	O
protein	O
S3	O
from	O
Escherichia	B
coli	I
(	O
1	O
)	O
,	O
Mer1p	O
from	O
S.cerevisiae	B
,	O
a	O
meiosis	O
-	O
specific	O
splicing	O
factor	O
(	O
1	O
)	O
,	O
MEX-3	O
from	O
Caenorhabditis	B
elegans	I
,	O
presumably	O
involved	O
in	O
mRNA	O
localization	O
during	O
development	O
(	O
2	O
)	O
,	O
and	O
FMRP	O
,	O
the	O
fragile	O
-	O
X	O
mental	O
retardation	O
protein	O
in	O
humans	B
(	O
3	O
)	O
.	O

A	O
partial	O
clone	O
of	O
Scp160p	O
,	O
known	O
as	O
HX	O
,	O
was	O
one	O
of	O
the	O
first	O
multiple	O
-	O
KH	O
proteins	O
identified	O
(	O
1	O
)	O
.	O

Whole	O
cell	O
immunofluorescence	O
studies	O
have	O
demonstrated	O
that	O
Scp160p	O
localizes	O
to	O
the	O
cytoplasm	O
,	O
with	O
enrichment	O
around	O
the	O
nuclear	O
envelope	O
,	O
and	O
what	O
appears	O
to	O
be	O
the	O
endoplasmic	O
reticulum	O
(	O
3	O
)	O
.	O

Deletion	O
of	O
the	O
SCP160	O
locus	O
in	O
yeast	B
is	O
not	O
lethal	O
,	O
but	O
results	O
in	O
a	O
complex	O
phenotype	O
,	O
including	O
increased	O
DNA	O
content	O
per	O
cell	O
,	O
missegregation	O
of	O
genetic	O
markers	O
during	O
sporulation	O
,	O
and	O
abnormal	O
cell	O
morphology	O
,	O
including	O
increased	O
size	O
and	O
irregular	O
shape	O
(	O
4	O
)	O
.	O

Observation	O
of	O
this	O
phenotype	O
led	O
to	O
the	O
hypothesis	O
that	O
Scp160p	O
may	O
function	O
in	O
regulating	O
ploidy	O
during	O
cell	O
division	O
.	O

More	O
recently	O
,	O
Weber	O
and	O
colleagues	O
demonstrated	O
in	O
vitro	O
RNA	O
binding	O
activity	O
of	O
Scp160p	O
using	O
northwestern	O
blot	O
analyses	O
;	O
the	O
protein	O
was	O
found	O
to	O
bind	O
efficiently	O
to	O
ribohomopolymers	O
and	O
rRNA	O
,	O
but	O
not	O
to	O
tRNA	O
(	O
5	O
)	O
.	O

Cell	O
fractionation	O
studies	O
revealed	O
that	O
a	O
large	O
percentage	O
of	O
Scp160p	O
associates	O
with	O
membrane	O
-	O
pellets	O
,	O
and	O
is	O
released	O
by	O
treatment	O
with	O
either	O
10	O
mM	O
EDTA	O
or	O
500	O
mM	O
NaCl	O
(	O
5	O
)	O
.	O

While	O
these	O
authors	O
interpreted	O
these	O
results	O
to	O
suggest	O
that	O
the	O
nuclear	O
envelope	O
/	O
ER	O
localization	O
of	O
Scp160p	O
was	O
due	O
primarily	O
to	O
interactions	O
of	O
the	O
protein	O
with	O
membrane	O
-	O
bound	O
polyribosomes	O
,	O
clear	O
evidence	O
of	O
this	O
association	O
has	O
not	O
been	O
reported	O
(	O
5	O
)	O
.	O

Currently	O
,	O
the	O
relationship	O
between	O
the	O
phenotype	O
of	O
scp160	O
null	O
mutants	O
and	O
the	O
RNA	O
-	O
binding	O
activity	O
of	O
Scp160p	O
remains	O
unclear	O
.	O

Scp160p	O
demonstrates	O
significant	O
sequence	O
homology	O
(	O
~23	O
%	O
identity	O
and	O
~40	O
%	O
similarity	O
at	O
the	O
amino	O
acid	O
level	O
)	O
to	O
a	O
class	O
of	O
vertebrate	O
KH	O
-	O
domain	O
proteins	O
collectively	O
known	O
as	O
vigilins	O
.	O

First	O
identified	O
in	O
chicken	B
,	O
vigilin	O
homologues	O
have	O
now	O
been	O
found	O
in	O
human	B
(	O
6	O
)	O
,	O
Xenopus	B
laevis	I
(	O
7	O
)	O
,	O
Drosophila	B
melanogaster	I
(	O
8)	O
,	O
C.elegans	B
(	O
5	O
)	O
and	O
Schizosaccharomyces	B
pombe	I
.	O

While	O
all	O
of	O
the	O
vigilin	O
proteins	O
studied	O
to	O
date	O
are	O
reported	O
to	O
bind	O
nucleic	O
acid	O
,	O
both	O
the	O
type	O
of	O
nucleic	O
acid	O
bound	O
and	O
the	O
functional	O
significance	O
of	O
these	O
interactions	O
remain	O
unclear	O
.	O

For	O
example	O
,	O
Kruse	O
and	O
colleagues	O
reported	O
from	O
their	O
work	O
with	O
human	B
cells	O
in	O
culture	O
that	O
vigilin	O
may	O
be	O
involved	O
in	O
the	O
binding	O
and	O
transport	O
of	O
tRNA	O
(	O
9–11	O
)	O
.	O

In	O
contrast	O
,	O
Dodson	O
and	O
Shapiro	O
concluded	O
from	O
their	O
work	O
with	O
Xenopus	O
vigilin	O
that	O
,	O
in	O
response	O
to	O
estrogen	O
,	O
the	O
protein	O
bound	O
specifically	O
to	O
the	O
3′	O
UTR	O
of	O
vitellogenin	O
mRNA	O
(	O
7,12	O
)	O
,	O
potentially	O
stabilizing	O
the	O
message	O
(	O
13	O
)	O
.	O

Lastly	O
,	O
DDP1	O
,	O
the	O
Drosophila	O
homolog	O
of	O
vigilin	O
,	O
was	O
reported	O
recently	O
to	O
interact	O
with	O
the	O
dodeca	O
-	O
satellite	O
repeat	O
regions	O
of	O
centromeric	O
heterochromatin	O
in	O
embryonic	O
and	O
larval	O
cell	O
nuclei	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
this	O
protein	O
in	O
heterochromatin	O
structure	O
(	O
8)	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
begin	O
elucidating	O
the	O
function	O
of	O
Scp160p	O
in	O
yeast	B
by	O
characterizing	O
the	O
subcellular	O
distribution	O
and	O
macromolecular	O
interactions	O
of	O
this	O
protein	O
.	O

We	O
have	O
demonstrated	O
that	O
Scp160p	O
in	O
cytoplasmic	O
lysates	O
is	O
associated	O
predominantly	O
with	O
polyribosomes	O
,	O
and	O
that	O
following	O
treatment	O
with	O
EDTA	O
,	O
Scp160p	O
remains	O
in	O
an	O
RNase	O
/	O
NaCl	O
-	O
sensitive	O
complex	O
of	O
apparent	O
molecular	O
weight	O
approximately	O
≥1300	O
kDa	O
.	O

Affinity	O
purification	O
of	O
this	O
complex	O
revealed	O
the	O
presence	O
of	O
poly	O
(	O
A	O
)	O
-binding	O
protein	O
(	O
Pab1p	O
)	O
,	O
a	O
well	O
-	O
characterized	O
component	O
of	O
eukaryotic	O
mRNPs	O
(	O
14,15	O
)	O
.	O

Finally	O
,	O
a	O
third	O
abundant	O
protein	O
component	O
of	O
this	O
complex	O
was	O
identified	O
as	O
Bfr1p	O
,	O
a	O
protein	O
not	O
previously	O
reported	O
to	O
associate	O
with	O
mRNPs	O
.	O

While	O
the	O
function	O
of	O
Bfr1p	O
remains	O
unknown	O
,	O
gene	O
deletion	O
reportedly	O
leads	O
to	O
a	O
phenotype	O
remarkably	O
similar	O
to	O
that	O
of	O
scp160	O
deletion	O
(	O
16	O
)	O
.	O

These	O
results	O
indicate	O
a	O
role	O
for	O
Scp160p	O
in	O
mRNA	O
metabolism	O
in	O
yeast	B
,	O
and	O
by	O
extension	O
,	O
support	O
results	O
seen	O
with	O
Xenopus	O
vigilin	O
in	O
its	O
interactions	O
with	O
mRNA	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
data	O
reported	O
here	O
demonstrate	O
Scp160p	O
to	O
be	O
the	O
first	O
example	O
of	O
a	O
KH	O
-	O
domain	O
protein	O
that	O
functions	O
as	O
a	O
component	O
of	O
polyribosome	O
-	O
associated	O
mRNP	O
complexes	O
in	O
the	O
yeast	B
,	O
S.cerevisiae	B
.	O

MATERIALS	O
AND	O
METHODS	O
Plasmids	O
,	O
yeast	B
strains	O
and	O
culture	O
conditions	O
All	O
recombinant	O
DNA	O
manipulations	O
were	O
performed	O
according	O
to	O
standard	O
techniques	O
and	O
utilized	O
E.coli	B
strain	O
XL1-Blue	O
(	O
Stratagene	O
)	O
.	O

The	O
yeast	B
strain	O
JFy1511	O
,	O
expressing	O
FLAG	O
–	O
Scp160p	O
,	O
was	O
derived	O
by	O
two	O
-	O
step	O
gene	O
replacement	O
from	O
strain	O
yJJ52	O
(	O
MATα	O
gal7Δ102	O
ura3	O
-	O
52	O
trp1	O
-	O
289	O
ade1	O
lys1	O
leu2	O
-	O
3	O
,	O
112	O
;	O
generously	O
donated	O
by	O
Drs	O
Mark	O
Parthun	O
and	O
Judith	O
Jaehning	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
)	O
,	O
and	O
confirmed	O
by	O
PCR	O
.	O

The	O
wild	O
-	O
type	O
SCP160	O
coding	O
sequence	O
was	O
obtained	O
by	O
PCR	O
amplification	O
from	O
a	O
genomic	O
DNA	O
preparation	O
from	O
yJFK1	O
(	O
MATα	O
gal7Δ102	O
ura3	O
-	O
52	O
trp1	O
-	O
289	O
ade1	O
lys1	O
leu2	O
-	O
3	O
,	O
112	O
ΔGAL80::URA3	O
)	O
,	O
using	O
a	O
16:1	O
mixture	O
of	O
Taq	O
(	O
Fisher	O
Biotech	O
)	O
and	O
Pfu	O
(	O
Stratagene	O
)	O
DNA	O
polymerases	O
and	O
the	O
following	O
primers	O
:	O
Scp160F1	O
(	O
5′-GCCGGTCGA	O
-	O
CTAACTGCAATGTCTGAAGAACAAACCGCTATTG-3′	O
)	O
and	O
Scp160R1	O
(	O
5′-GCGCGTCGACGAGCTTGTCTATCTT	O
-	O
CTTAAGG-3′	O
)	O
.	O

A	O
wild	O
-	O
type	O
SCP160	O
genomic	O
clone	O
,	O
containing	O
1	O
kb	O
upstream	O
and	O
300	O
bp	O
downstream	O
sequence	O
was	O
PCR	O
amplified	O
from	O
yJFK1	O
genomic	O
DNA	O
using	O
the	O
primers	O
Scp160F0	O
(	O
5′-GCCGAGCTCACACCAGCTTTGTCCTGG-3′	O
)	O
and	O
Scp160R2	O
(	O
5′-GCGCAAGCTTGTGCGGTA	O
-	O
TCCCAGTCTATG-3′	O
)	O
.	O

The	O
resultant	O
clone	O
was	O
confirmed	O
by	O
dideoxy	O
sequencing	O
.	O

The	O
N	O
-	O
terminal	O
FLAG	O
and	O
HA	O
tags	O
were	O
added	O
using	O
PCR	O
with	O
the	O
primers	O
ScpFLAGF1	O
(	O
5′-CCAT	O
-	O
TATAACTGCAATGGACTACAAGGACGACGACGACGAC	O
-	O
AAGATGTCTGAAGAACAAACCGCTATTG-3′	O
)	O
and	O
ScpHAF1	O
(	O
5′-CCCCCTCCTGTCGACATTATAACTGCAATGCACCA	O
-	O
TCACCATCACCATTCTGAAGAACAAACCGCTATTG-3′	O
)	O
respectively	O
.	O

For	O
integration	O
,	O
constructs	O
containing	O
the	O
1	O
kb	O
upstream	O
and	O
300	O
bp	O
downstream	O
sequence	O
were	O
subcloned	O
into	O
the	O
plasmid	O
YIplac211	O
(	O
17	O
)	O
using	O
SacI	O
and	O
HindIII	O
restriction	O
sites	O
.	O

The	O
HA	O
-	O
tagged	O
construct	O
was	O
subcloned	O
into	O
the	O
low	O
copy	O
number	O
plasmid	O
,	O
YCplac22	O
using	O
SacI	O
and	O
HindIII	O
restriction	O
sites	O
.	O

The	O
SCP160	O
deletion	O
construct	O
was	O
made	O
by	O
removal	O
of	O
a	O
3.4	O
kb	O
ApaI	O
–	O
KpnI	O
fragment	O
from	O
the	O
coding	O
region	O
of	O
this	O
construct	O
,	O
followed	O
by	O
treatment	O
with	O
Klenow	O
fragment	O
and	O
re	O
-	O
ligation	O
following	O
attachment	O
of	O
BamHI	O
linker	O
oligonucleotides	O
.	O

Genomic	O
integration	O
of	O
the	O
plasmid	O
sequences	O
and	O
subsequent	O
removal	O
of	O
the	O
endogenous	O
SCP160	O
allele	O
were	O
achieved	O
by	O
standard	O
two	O
-	O
step	O
gene	O
replacement	O
techniques	O
(	O
18	O
)	O
and	O
confirmed	O
by	O
PCR	O
.	O

The	O
N	O
-	O
terminally	O
HA	O
-	O
tagged	O
allele	O
of	O
BFR1	O
was	O
generated	O
by	O
PCR	O
-	O
amplifiction	O
of	O
the	O
BFR1	O
locus	O
from	O
wild	O
-	O
type	O
(	O
W303	O
)	O
yeast	B
genomic	O
DNA	O
using	O
the	O
primers	O
BFR1HAF1	O
(	O
5′-CCGCGGATCCATGTACC	O
-	O
CATACGACGTCCCAGACTACGCTATGTCCTCCCAAC	O
-	O
AACACAA-3′	O
)	O
and	O
BFR1HINDR1	O
(	O
5′-CCGCAAGCTTGTCG	O
-	O
ACTATTTCATATGCCACAGGAAACAG-3′	O
)	O
,	O
and	O
subcloned	O
into	O
YIPlac211	O
.	O

The	O
BFR1	O
promoter	O
region	O
was	O
PCR	O
-	O
amplified	O
in	O
a	O
similar	O
manner	O
using	O
the	O
primers	O
BFR1SACF1	O
(	O
5′-CCGCGAG	O
-	O
CTCAGCATTAAGCATTCACGAGC-3′	O
)	O
and	O
BFR1BAMR1	O
(	O
5′-CCGCGGATCCGGCAATGGCTGTGTTGTTAGA-3′	O
)	O
and	O
subcloned	O
into	O
the	O
appropriate	O
position	O
upstream	O
of	O
the	O
HA	O
–	O
Bfr1p	O
open	O
reading	O
frame	O
in	O
the	O
plasmid	O
backbone	O
.	O

The	O
entire	O
open	O
reading	O
frame	O
was	O
confirmed	O
by	O
dideoxy	O
sequencing	O
.	O

Finally	O
,	O
the	O
HA	O
–	O
BFR1	O
allele	O
was	O
substituted	O
into	O
the	O
yeast	B
genome	O
in	O
place	O
of	O
the	O
native	O
allele	O
using	O
linearization	O
with	O
SphI	O
and	O
standard	O
two	O
-	O
step	O
gene	O
replacement	O
techniques	O
.	O

All	O
yeast	B
transformations	O
and	O
culture	O
manipulations	O
were	O
performed	O
according	O
to	O
standard	O
protocols	O
as	O
described	O
elsewhere	O
(	O
19	O
)	O
.	O

Confirmation	O
of	O
genomic	O
integrations	O
All	O
genomic	O
integrations	O
were	O
confirmed	O
by	O
PCR	O
amplifications	O
from	O
purified	O
yeast	B
genomic	O
DNA	O
.	O

For	O
scp160	O
deletion	O
mutants	O
,	O
the	O
primers	O
Scp160PF	O
(	O
5′-GATTTCCTAACTTTCC	O
-	O
GTCTA-3′	O
)	O
and	O
Scp160R5	O
(	O
5′-GCGCAAGCTTCACCGCCTTATAACGAAGAC-3′	O
)	O
that	O
flanked	O
the	O
deleted	O
region	O
were	O
used	O
.	O

Similarly	O
,	O
epitope	O
tags	O
on	O
Scp160p	O
were	O
confirmed	O
by	O
PCR	O
using	O
primers	O
that	O
flanked	O
the	O
tag	O
sequence	O
.	O

Positive	O
clones	O
were	O
further	O
confirmed	O
by	O
western	O
blot	O
analysis	O
of	O
crude	O
cell	O
lysates	O
using	O
the	O
appropriate	O
anti	O
-	O
tag	O
antibodies	O
.	O

The	O
presence	O
of	O
HA	O
–	O
Bfr1p	O
in	O
cells	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
of	O
soluble	O
cell	O
lysates	O
using	O
12CA5	O
mAb	O
(	O
Boehringer	O
Mannheim	O
)	O
.	O

Polyribosome	O
isolation	O
Polyribosomes	O
were	O
isolated	O
using	O
a	O
combination	O
of	O
protocols	O
described	O
by	O
Stansfield	O
and	O
colleagues	O
(	O
20	O
)	O
and	O
by	O
Dr	O
Maurice	O
Swanson	O
(	O
personal	O
communication	O
)	O
.	O

In	O
brief	O
,	O
a	O
100	O
ml	O
culture	O
of	O
yeast	B
was	O
grown	O
in	O
either	O
YEPD	O
or	O
Hartwell	O
synthetic	O
medium	O
,	O
to	O
early	O
-	O
log	O
phase	O
(	O
OD600	O
=	O
1.0	O
)	O
,	O
at	O
which	O
time	O
cyclohexamide	O
(	O
Sigma	O
)	O
was	O
added	O
directly	O
to	O
the	O
culture	O
to	O
a	O
final	O
concentration	O
of	O
100	O
µg	O
/	O
ml	O
.	O

The	O
culture	O
was	O
incubated	O
on	O
ice	O
for	O
15	O
min	O
,	O
and	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
4000	O
r.p.m.	O
/	O
10	O
min	O
)	O
.	O

Following	O
two	O
washes	O
in	O
10	O
ml	O
of	O
water	O
containing	O
100	O
µg	O
/	O
ml	O
cyclohexamide	O
,	O
cells	O
were	O
lysed	O
by	O
vortex	O
agitation	O
with	O
an	O
equal	O
volume	O
of	O
glass	O
beads	O
in	O
1	O
ml	O
lysis	O
buffer	O
(	O
25	O
mM	O
Tris	O
pH	O
7.2	O
,	O
50	O
mM	O
KCl	O
,	O
30	O
mM	O
MgCl2	O
,	O
5	O
mM	O
β	O
-	O
mercaptoethanol	O
,	O
200	O
µg	O
/	O
ml	O
cyclohexamide	O
,	O
2	O
µg	O
/	O
ml	O
aprotonin	O
,	O
1	O
mM	O
PMSF	O
,	O
0.5	O
µg	O
/	O
ml	O
leupeptin	O
,	O
2.9	O
µg	O
/	O
ml	O
E64	O
,	O
1	O
µg	O
/	O
ml	O
antipain	O
,	O
0.2	O
µg	O
/	O
ml	O
chymostatin	O
)	O
.	O

Lysate	O
was	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
,	O
and	O
centrifuged	O
10	O
min	O
at	O
3000	O
g	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatant	O
was	O
again	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
and	O
centrifuged	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
,	O
and	O
then	O
assayed	O
for	O
absorbance	O
at	O
260	O
nm	O
.	O

Approximately	O
12	O
OD260	O
units	O
were	O
loaded	O
onto	O
a	O
11	O
ml	O
15–45	O
%	O
sucrose	O
gradient	O
made	O
in	O
10	O
mM	O
Tris	O
,	O
pH	O
7.4	O
,	O
70	O
mM	O
NH4Cl	O
,	O
4	O
mM	O
MgOAc	O
,	O
using	O
a	O
Gradient	O
Master	O
automatic	O
system	O
,	O
and	O
the	O
gradient	O
was	O
centrifuged	O
in	O
a	O
SW41ti	O
rotor	O
(	O
Beckman	O
)	O
at	O
39	O
000	O
r.p.m	O
.	O

for	O
2.5	O
h.	O
0.5	O
ml	O
fractions	O
were	O
collected	O
using	O
an	O
Isco	O
gradient	O
fractionator	O
,	O
and	O
gradient	O
profiles	O
were	O
determined	O
by	O
monitoring	O
absorbance	O
at	O
254	O
nm	O
.	O

For	O
EDTA	O
controls	O
,	O
lysis	O
buffer	O
containing	O
5	O
mM	O
MgCl2	O
was	O
used	O
,	O
and	O
30	O
mM	O
EDTA	O
was	O
added	O
to	O
the	O
sample	O
before	O
loading	O
onto	O
the	O
gradient	O
.	O

Where	O
indicated	O
,	O
addition	O
of	O
50	O
U	O
/	O
ml	O
of	O
RNase	O
One	O
(	O
Promega	O
)	O
was	O
performed	O
prior	O
to	O
loading	O
the	O
sample	O
onto	O
the	O
gradient	O
.	O

Gel	O
filtration	O
chromatography	O
Gel	O
filtration	O
chromatography	O
was	O
performed	O
using	O
a	O
120	O
ml	O
Hi	O
-	O
Prep	O
S-300	O
Sephacryl	O
column	O
(	O
Pharmacia	O
)	O
with	O
a	O
cut	O
-	O
off	O
of	O
1300	O
kDa	O
,	O
attached	O
to	O
an	O
FPLC	O
system	O
(	O
Pharmacia	O
)	O
.	O

The	O
column	O
had	O
been	O
calibrated	O
previously	O
using	O
the	O
following	O
molecular	O
weight	O
standards	O
(	O
Sigma	O
)	O
:	O
blue	O
dextran	O
(	O
2000	O
kDa	O
)	O
,	O
thyroglobulin	O
(	O
669	O
kDa	O
)	O
,	O
apoferritin	O
(	O
443	O
kDa	O
)	O
,	O
alcohol	O
dehydrogenase	O
(	O
150	O
kDa	O
)	O
,	O
and	O
bovine	B
serum	O
albumin	O
(	O
66	O
kDa	O
)	O
.	O

Yeast	B
were	O
lysed	O
as	O
described	O
for	O
polyribosome	O
analysis	O
,	O
with	O
an	O
additional	O
clarification	O
by	O
passage	O
through	O
a	O
0.2	O
µm	O
syringe	O
-	O
tip	O
filter	O
(	O
Acrodisc	O
)	O
and	O
run	O
over	O
the	O
column	O
at	O
a	O
rate	O
of	O
0.5	O
ml	O
/	O
min	O
in	O
polyribosome	O
lysis	O
buffer	O
following	O
treatment	O
with	O
the	O
indicated	O
reagents	O
.	O

Fractions	O
(	O
2.0	O
ml	O
)	O
were	O
collected	O
,	O
from	O
which	O
12	O
µl	O
were	O
combined	O
with	O
sample	O
buffer	O
(	O
2	O
%	O
SDS	O
,	O
10	O
%	O
glycerol	O
,	O
100	O
mM	O
dithiothreitol	O
,	O
60	O
mM	O
Tris	O
pH	O
6.8	O
,	O
0.001	O
%	O
bromophenol	O
blue	O
)	O
and	O
analyzed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

α	O
-	O
FLAG	O
affinity	O
chromatography	O
For	O
most	O
experiments	O
,	O
one	O
liter	O
yeast	B
cultures	O
were	O
grown	O
to	O
early	O
log	O
-	O
phase	O
and	O
harvested	O
by	O
centrifugation	O
.	O

Cells	O
were	O
washed	O
twice	O
in	O
T75	O
buffer	O
(	O
25	O
mM	O
Tris	O
pH	O
7.5	O
,	O
75	O
mM	O
NaCl	O
)	O
and	O
then	O
were	O
lysed	O
by	O
vortex	O
agitation	O
with	O
an	O
equal	O
volume	O
of	O
glass	O
beads	O
in	O
4	O
ml	O
T75	O
buffer	O
containing	O
30	O
mM	O
EDTA	O
.	O

Lysate	O
was	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
,	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
3000	O
g	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatant	O
was	O
again	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
and	O
centrifuged	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
,	O
and	O
finally	O
passed	O
through	O
a	O
0.2	O
µm	O
syringe	O
filter	O
.	O

Lysate	O
was	O
then	O
pre	O
-	O
purified	O
by	O
running	O
over	O
the	O
S-300	O
gel	O
-	O
filtration	O
column	O
in	O
T75	O
buffer	O
,	O
with	O
pooling	O
of	O
the	O
void	O
volume	O
fractions	O
(	O
~10	O
ml	O
total	O
)	O
.	O

For	O
several	O
experiments	O
(	O
Fig.	O
5A	O
,	O
B	O
,	O
E	O
and	O
F	O
)	O
,	O
a	O
low	O
concentration	O
(	O
<	O
10	O
µg	O
/	O
ml	O
)	O
of	O
FLAG	O
peptide	O
(	O
N	O
-	O
DYKDDDDK	O
-	O
C	O
)	O
was	O
added	O
to	O
this	O
sample	O
.	O

This	O
void	O
material	O
was	O
then	O
loaded	O
onto	O
a	O
1	O
ml	O
M2	O
α	O
-	O
FLAG	O
column	O
(	O
Sigma	O
)	O
;	O
column	O
flow	O
-	O
through	O
was	O
passed	O
over	O
the	O
column	O
a	O
second	O
time	O
.	O

The	O
column	O
was	O
then	O
washed	O
extensively	O
with	O
75	O
ml	O
T75	O
buffer	O
;	O
material	O
bound	O
to	O
the	O
column	O
was	O
eluted	O
with	O
5	O
ml	O
T75	O
containing	O
184	O
mg	O
/	O
ml	O
FLAG	O
peptide	O
.	O

The	O
peptide	O
solution	O
was	O
allowed	O
to	O
incubate	O
on	O
the	O
column	O
for	O
20	O
min	O
prior	O
to	O
collection	O
of	O
the	O
first	O
1	O
ml	O
fraction	O
;	O
subsequent	O
fractions	O
were	O
collected	O
every	O
10	O
min	O
.	O

Samples	O
of	O
crude	O
material	O
,	O
S-300	O
void	O
,	O
α	O
-	O
FLAG	O
flow	O
-	O
through	O
,	O
first	O
and	O
last	O
wash	O
,	O
and	O
eluate	O
fractions	O
were	O
analyzed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

For	O
Figure	O
5A	O
and	O
E	O
,	O
samples	O
of	O
first	O
and	O
last	O
wash	O
and	O
eluate	O
fractions	O
were	O
concentrated	O
,	O
run	O
on	O
SDS	O
–	O
PAGE	O
and	O
stained	O
with	O
colloidal	O
G250	O
Coomassie	O
.	O

Concentration	O
of	O
samples	O
Where	O
indicated	O
,	O
samples	O
were	O
concentrated	O
using	O
the	O
method	O
of	O
Traub	O
et	O
al.	O
(	O
21	O
)	O
.	O

400	O
µl	O
of	O
sample	O
were	O
transferred	O
to	O
a	O
microfuge	O
tube	O
,	O
and	O
combined	O
with	O
400	O
µl	O
of	O
methanol	O
,	O
and	O
100	O
µl	O
of	O
chloroform	O
.	O

Samples	O
were	O
then	O
vortexed	O
vigorously	O
,	O
and	O
centrifuged	O
for	O
5	O
min	O
at	O
12	O
000	O
g.	O

The	O
supernatant	O
was	O
discarded	O
,	O
leaving	O
the	O
interface	O
intact	O
,	O
and	O
an	O
additional	O
400	O
µl	O
of	O
methanol	O
was	O
added	O
to	O
each	O
tube	O
.	O

Samples	O
were	O
then	O
inverted	O
several	O
times	O
,	O
and	O
centrifuged	O
again	O
for	O
5	O
min	O
.	O

The	O
supernatant	O
was	O
discarded	O
,	O
and	O
the	O
protein	O
pellet	O
was	O
air	O
-	O
dried	O
and	O
resuspended	O
in	O
1	O
×	O
sample	O
buffer	O
.	O

Western	O
blot	O
analysis	O
Western	O
blot	O
analysis	O
was	O
performed	O
essentially	O
as	O
described	O
previously	O
(	O
19	O
)	O
.	O

Briefly	O
,	O
samples	O
to	O
be	O
analyzed	O
were	O
mixed	O
with	O
sample	O
buffer	O
,	O
boiled	O
,	O
electrophoresed	O
through	O
a	O
10	O
%	O
SDS	O
–	O
polyacrylamide	O
gel	O
,	O
and	O
electro	O
-	O
blotted	O
onto	O
nitrocellulose	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

FLAG	O
–	O
Scp160p	O
fusion	O
protein	O
was	O
detected	O
by	O
incubation	O
of	O
the	O
filter	O
with	O
mouse	B
M2	O
anti	O
-	O
FLAG	O
monoclonal	O
antibody	O
(	O
10	O
µg	O
/	O
ml	O
final	O
concentration	O
)	O
,	O
followed	O
by	O
HRP	O
-	O
conjugated	O
sheep	B
anti	O
-	O
mouse	B
secondary	O
antibody	O
(	O
Amersham	O
)	O
,	O
diluted	O
1:5000	O
as	O
per	O
the	O
manufacturer	O
's	O
instructions	O
,	O
and	O
ECL	O
reagent	O
(	O
Amersham	O
)	O
,	O
followed	O
by	O
exposure	O
to	O
X	O
-	O
ray	O
film	O
.	O

HA	O
-	O
tagged	O
Scp160p	O
and	O
HA	O
-	O
tagged	O
Bfr1p	O
were	O
detected	O
using	O
the	O
12CA5	O
mAb	O
(	O
Boehringer	O
Mannheim	O
)	O
at	O
a	O
final	O
concentration	O
of	O
0.8	O
µg	O
/	O
ml	O
;	O
Pab1p	O
and	O
Pub1p	O
were	O
detected	O
using	O
1G1	O
mAb	O
at	O
1:5000	O
,	O
and	O
4C3	O
mAb	O
at	O
1:1000	O
,	O
respectively	O
,	O
both	O
generous	O
gifts	O
from	O
Dr	O
Maurice	O
Swanson	O
(	O
22,23	O
)	O
.	O

Where	O
appropriate	O
,	O
films	O
were	O
analyzed	O
by	O
scanning	O
densitometry	O
(	O
Molecular	O
Dynamics	O
)	O
,	O
and	O
quantitated	O
using	O
ImageQuant	O
software	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Colloidal	O
G250	O
coomassie	O
staining	O
Procedure	O
used	O
was	O
that	O
of	O
Neuhoff	O
(	O
24	O
)	O
.	O

Briefly	O
,	O
a	O
one	O
liter	O
stock	O
of	O
staining	O
solution	O
was	O
prepared	O
containing	O
1	O
g	O
Coomassie	O
brilliant	O
blue	O
G-250	O
(	O
Sigma	O
)	O
,	O
100	O
g	O
ammonium	O
sulfate	O
(	O
Sigma	O
)	O
,	O
and	O
11.76	O
ml	O
85	O
%	O
phosphoric	O
acid	O
(	O
Fisher	O
)	O
.	O

Following	O
SDS	O
–	O
PAGE	O
,	O
gels	O
were	O
fixed	O
in	O
40	O
%	O
methanol	O
,	O
10	O
%	O
acetic	O
acid	O
for	O
10	O
min	O
.	O

Gels	O
were	O
then	O
rinsed	O
several	O
times	O
in	O
water	O
,	O
then	O
stained	O
using	O
40	O
ml	O
of	O
the	O
stock	O
staining	O
solution	O
mixed	O
with	O
10	O
ml	O
methanol	O
,	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

Stain	O
was	O
then	O
poured	O
off	O
,	O
and	O
residual	O
stain	O
was	O
removed	O
by	O
rinsing	O
in	O
water	O
.	O

By	O
performing	O
a	O
standard	O
analysis	O
using	O
bovine	B
serum	O
albumin	O
,	O
the	O
stain	O
was	O
able	O
to	O
detect	O
~15	O
ng	O
total	O
protein	O
per	O
lane	O
.	O

Pichia	O
expression	O
system	O
An	O
N	O
-	O
terminally	O
HIS6	O
/	O
FLAG	O
-	O
tagged	O
allele	O
of	O
the	O
SCP160	O
coding	O
sequence	O
was	O
blunt	O
-	O
end	O
sub	O
-	O
cloned	O
into	O
the	O
BamHI	O
/	O
SnaBI	O
sites	O
of	O
the	O
Pichia	O
expression	O
vector	O
pPIC3.5	O
K	O
(	O
Invitrogen	O
)	O
.	O

The	O
construct	O
was	O
then	O
linearized	O
using	O
SalI	O
and	O
integrated	O
into	O
the	O
genome	O
of	O
the	O
Pichia	O
strain	O
GS115	O
(	O
Invitrogen	O
)	O
.	O

High	O
expression	O
transformants	O
were	O
selected	O
initially	O
on	O
histidine	O
-	O
deficient	O
medium	O
followed	O
by	O
selection	O
on	O
increasing	O
concentrations	O
of	O
G418	O
(	O
US	O
Biological	O
)	O
.	O

Crude	O
lysates	O
of	O
the	O
resultant	O
transformants	O
were	O
then	O
confirmed	O
by	O
western	O
blot	O
analysis	O
with	O
the	O
anti	O
-	O
FLAG	O
antibody	O
M2	O
,	O
and	O
the	O
best	O
expressing	O
strain	O
was	O
cultured	O
in	O
a	O
fermenter	O
,	O
harvested	O
,	O
and	O
lysed	O
by	O
agitation	O
with	O
glass	O
beads	O
.	O

To	O
purify	O
Scp160p	O
,	O
2	O
ml	O
of	O
crude	O
lysate	O
was	O
first	O
diluted	O
to	O
10	O
ml	O
with	O
25	O
mM	O
Tris	O
,	O
pH	O
7.5	O
,	O
1	O
M	O
NaCl	O
,	O
then	O
twice	O
passed	O
over	O
a	O
1	O
ml	O
α	O
-	O
FLAG	O
affinity	O
column	O
.	O

The	O
column	O
was	O
then	O
washed	O
with	O
75	O
ml	O
of	O
25	O
mM	O
Tris	O
,	O
pH	O
7.5	O
,	O
1	O
M	O
NaCl	O
,	O
and	O
then	O
eluted	O
with	O
184	O
µg	O
/	O
ml	O
FLAG	O
peptide	O
prepared	O
in	O
the	O
same	O
buffer	O
.	O

RESULTS	O
Expression	O
of	O
tagged	O
Scp160p	O
in	O
yeast	B
An	O
N	O
-	O
terminal	O
FLAG	O
-	O
tagged	O
form	O
of	O
Scp160p	O
was	O
created	O
to	O
facilitate	O
detection	O
of	O
the	O
protein	O
in	O
cells	O
and	O
extracts	O
(	O
Fig.	O
1A	O
)	O
.	O

To	O
probe	O
functionality	O
of	O
this	O
fusion	O
protein	O
,	O
we	O
used	O
two	O
-	O
step	O
gene	O
replacement	O
(	O
18	O
)	O
to	O
substitute	O
the	O
modified	O
allele	O
into	O
the	O
SCP160	O
locus	O
of	O
haploid	O
yeast	B
,	O
and	O
then	O
tested	O
the	O
morphological	O
phenotype	O
of	O
the	O
resultant	O
cells	O
.	O

All	O
strains	O
were	O
confirmed	O
by	O
PCR	O
analysis	O
of	O
the	O
SCP160	O
locus	O
with	O
appropriate	O
primers	O
(	O
Materials	O
and	O
Methods	O
)	O
,	O
and	O
expression	O
of	O
the	O
tagged	O
protein	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
with	O
the	O
appropriate	O
antibody	O
(	O
M2αFLAG	O
)	O
(	O
Fig.	O
1B	O
)	O
.	O

In	O
all	O
cases	O
,	O
yeast	B
expressing	O
tagged	O
Scp160p	O
in	O
place	O
of	O
the	O
native	O
protein	O
appeared	O
indistinguishable	O
from	O
the	O
corresponding	O
wild	O
-	O
type	O
strains	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
a	O
negative	O
control	O
,	O
we	O
also	O
deleted	O
almost	O
the	O
entire	O
SCP160	O
coding	O
region	O
from	O
the	O
genomes	O
of	O
these	O
yeast	B
strains	O
(	O
Fig.	O
1A	O
)	O
,	O
and	O
confirmed	O
the	O
expected	O
mutant	O
phenotype	O
(	O
data	O
not	O
shown	O
)	O
.	O

Scp160p	O
associates	O
with	O
polyribosomes	O
To	O
test	O
the	O
hypothesis	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
we	O
used	O
sucrose	O
gradient	O
ultracentrifugation	O
to	O
size	O
-	O
fractionate	O
subcellular	O
components	O
of	O
lysates	O
prepared	O
from	O
yeast	B
expressing	O
the	O
N	O
-	O
terminal	O
FLAG	O
-	O
tagged	O
Scp160p	O
protein	O
.	O

Western	O
blot	O
analyses	O
of	O
gradient	O
fractions	O
with	O
an	O
α	O
-	O
FLAG	O
antibody	O
(	O
M2	O
,	O
Boehringer	O
Mannheim	O
)	O
,	O
revealed	O
a	O
160	O
kDa	O
band	O
that	O
was	O
most	O
abundant	O
in	O
the	O
denser	O
fractions	O
,	O
consistent	O
with	O
the	O
location	O
of	O
polyribosomes	O
(	O
>	O
80S	O
)	O
(	O
Fig.	O
2A	O
,	O
solid	O
arrow	O
)	O
.	O

A	O
convenient	O
internal	O
control	O
for	O
these	O
gradients	O
was	O
provided	O
by	O
an	O
unknown	O
endogenous	O
yeast	B
cross	O
-	O
reacting	O
protein	O
at	O
~100	O
kDa	O
,	O
that	O
exemplified	O
the	O
migration	O
pattern	O
of	O
a	O
free	O
protein	O
,	O
appearing	O
only	O
in	O
the	O
upper	O
fractions	O
of	O
the	O
gradient	O
(	O
Fig.	O
2A	O
,	O
open	O
arrow	O
)	O
.	O

To	O
determine	O
whether	O
the	O
migration	O
pattern	O
of	O
Scp160p	O
in	O
these	O
sucrose	O
gradients	O
truly	O
reflected	O
association	O
with	O
yeast	B
polyribosomes	O
,	O
lysates	O
were	O
pre	O
-	O
treated	O
with	O
either	O
30	O
mM	O
EDTA	O
or	O
50	O
U	O
/	O
ml	O
RNase	O
One	O
(	O
Promega	O
)	O
immediately	O
prior	O
to	O
sucrose	O
gradient	O
fractionation	O
.	O

EDTA	O
chelates	O
Mg2	O
+	O
cations	O
,	O
resulting	O
in	O
the	O
dissociation	O
of	O
the	O
small	O
and	O
large	O
ribosomal	O
subunits	O
,	O
reflected	O
in	O
gradient	O
profiles	O
(	O
OD254	O
)	O
by	O
the	O
disappearance	O
of	O
80S	O
monosomes	O
and	O
polyribosomes	O
along	O
with	O
a	O
marked	O
increase	O
in	O
the	O
abundance	O
of	O
free	O
ribosomal	O
subunits	O
(	O
Fig.	O
2B	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
greatest	O
intensity	O
of	O
FLAG	O
–	O
Scp160p	O
signal	O
was	O
seen	O
only	O
in	O
the	O
upper	O
-	O
most	O
fractions	O
of	O
the	O
gradient	O
(	O
Fig.	O
2B	O
)	O
.	O

Alternatively	O
,	O
pre	O
-	O
treatment	O
of	O
lysates	O
with	O
RNase	O
,	O
which	O
results	O
in	O
inter	O
-	O
ribosomal	O
severing	O
of	O
translating	O
messages	O
,	O
gave	O
rise	O
to	O
a	O
large	O
pool	O
of	O
single	O
80S	O
ribosomes	O
(	O
Fig.	O
2C	O
)	O
.	O

Again	O
,	O
FLAG	O
–	O
Scp160p	O
was	O
shifted	O
to	O
the	O
uppermost	O
fractions	O
of	O
these	O
gradients	O
.	O

Although	O
some	O
of	O
the	O
Scp160p	O
signal	O
was	O
detected	O
in	O
fractions	O
larger	O
than	O
40S	O
,	O
the	O
migration	O
pattern	O
of	O
the	O
100	O
kDa	O
cross	O
-	O
reacting	O
protein	O
in	O
these	O
experiments	O
indicated	O
that	O
RNase	O
treatment	O
caused	O
an	O
apparent	O
diffusion	O
of	O
material	O
in	O
the	O
upper	O
portion	O
of	O
the	O
gradient	O
.	O

Characterization	O
of	O
Scp160p	O
-	O
containing	O
complexes	O
following	O
EDTA	O
and	O
RNase	O
treatment	O
Gel	O
-	O
filtration	O
chromatography	O
was	O
used	O
to	O
determine	O
the	O
apparent	O
molecular	O
weight	O
of	O
Scp160p	O
following	O
its	O
release	O
from	O
polyribosomes	O
by	O
both	O
EDTA	O
and	O
RNase	O
treatment	O
.	O

Lysates	O
were	O
prepared	O
as	O
described	O
above	O
for	O
sucrose	O
gradient	O
analysis	O
,	O
but	O
were	O
instead	O
size	O
fractionated	O
over	O
a	O
Sephacryl	O
S-300	O
Hi	O
-	O
Prep	O
column	O
,	O
with	O
an	O
inclusion	O
cut	O
-	O
off	O
of	O
1300	O
kDa	O
.	O

As	O
expected	O
,	O
Scp160p	O
from	O
untreated	O
lysates	O
eluted	O
in	O
the	O
void	O
volume	O
,	O
confirming	O
its	O
association	O
with	O
large	O
complexes	O
,	O
ostensibly	O
polyribosomes	O
(	O
Fig.	O
3A	O
,	O
solid	O
arrow	O
)	O
.	O

In	O
EDTA	O
treated	O
lysates	O
,	O
all	O
Scp160p	O
signal	O
was	O
still	O
detected	O
in	O
the	O
void	O
volume	O
,	O
indicating	O
it	O
remained	O
in	O
a	O
complex	O
of	O
>	O
1300	O
kDa	O
(	O
Fig.	O
3B	O
,	O
solid	O
arrow	O
)	O
.	O

In	O
contrast	O
,	O
limited	O
RNase	O
treatment	O
(	O
10	O
min	O
)	O
resulted	O
in	O
the	O
appearance	O
of	O
an	O
Scp160p	O
-	O
containing	O
species	O
of	O
~450	O
kDa	O
,	O
in	O
addition	O
to	O
a	O
fraction	O
still	O
visible	O
in	O
the	O
void	O
(	O
Fig.	O
3C	O
,	O
solid	O
arrow	O
)	O
.	O

More	O
extensive	O
RNase	O
treatment	O
(	O
30	O
min	O
)	O
led	O
to	O
complete	O
conversion	O
to	O
the	O
450	O
kDa	O
species	O
(	O
Fig.	O
3D	O
,	O
solid	O
arrow	O
)	O
.	O

Sequential	O
treatment	O
,	O
first	O
with	O
RNase	O
,	O
then	O
with	O
EDTA	O
,	O
also	O
resulted	O
in	O
a	O
450	O
kDa	O
species	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
all	O
components	O
of	O
this	O
apparent	O
450	O
kDa	O
complex	O
were	O
also	O
present	O
following	O
EDTA	O
treatment	O
alone	O
.	O

As	O
before	O
,	O
the	O
100	O
kDa	O
,	O
endogenous	O
α	O
-	O
FLAG	O
cross	O
-	O
reacting	O
protein	O
(	O
Fig.	O
3	O
,	O
open	O
arrows	O
)	O
served	O
as	O
a	O
convenient	O
internal	O
control	O
,	O
eluting	O
from	O
the	O
column	O
at	O
a	O
volume	O
consistent	O
with	O
its	O
expected	O
monomeric	O
size	O
.	O

To	O
characterize	O
further	O
the	O
stability	O
of	O
the	O
large	O
(	O
apparent	O
molecular	O
weight	O
>	O
1300	O
kDa	O
)	O
,	O
EDTA	O
-	O
resistant	O
complex	O
,	O
lysates	O
were	O
treated	O
with	O
increasing	O
concentrations	O
of	O
NaCl	O
prior	O
to	O
size	O
fractionation	O
(	O
Fig.	O
3	O
,	O
panels	O
E	O
,	O
F	O
and	O
G	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
3E	O
,	O
at	O
75	O
mM	O
NaCl	O
,	O
the	O
large	O
complex	O
remained	O
intact	O
.	O

However	O
,	O
at	O
a	O
NaCl	O
concentration	O
of	O
150	O
mM	O
,	O
the	O
Scp160p	O
complex	O
was	O
partially	O
reduced	O
to	O
450	O
kDa	O
,	O
with	O
some	O
signal	O
still	O
remaining	O
in	O
the	O
void	O
(	O
Fig.	O
3F	O
,	O
solid	O
arrow	O
)	O
.	O

Following	O
treatment	O
with	O
1	O
M	O
NaCl	O
,	O
Scp160p	O
was	O
only	O
visible	O
as	O
the	O
450	O
kDa	O
species	O
(	O
Fig.	O
3	O
G	O
,	O
solid	O
arrow	O
)	O
.	O

The	O
fact	O
that	O
RNase	O
treatment	O
and	O
high	O
salt	O
both	O
generated	O
Scp160p	O
species	O
of	O
similar	O
apparent	O
molecular	O
weight	O
suggests	O
that	O
these	O
high	O
salt	O
concentrations	O
resulted	O
in	O
the	O
disassociation	O
of	O
RNA	O
,	O
and	O
perhaps	O
other	O
components	O
,	O
from	O
Scp160p	O
.	O

Pab1p	O
and	O
Bfr1p	O
are	O
present	O
in	O
EDTA	O
-	O
resistant	O
Scp160p	O
-	O
containing	O
complexes	O
To	O
determine	O
if	O
the	O
>	O
1300	O
kDa	O
Scp160p	O
-	O
containing	O
complexes	O
remaining	O
after	O
EDTA	O
treatment	O
were	O
mRNPs	O
,	O
we	O
assayed	O
for	O
the	O
presence	O
of	O
the	O
yeast	B
poly	O
(	O
A	O
)	O
binding	O
protein	O
,	O
Pab1p	O
,	O
following	O
α	O
-	O
FLAG	O
affinity	O
purification	O
as	O
illustrated	O
in	O
Figure	O
4	O
.	O

Pab1p	O
is	O
an	O
abundant	O
and	O
well	O
-	O
characterized	O
component	O
of	O
mRNP	O
complexes	O
in	O
yeast	B
,	O
as	O
well	O
as	O
higher	O
eukaryotes	O
(	O
14,15,25	O
)	O
.	O

As	O
seen	O
in	O
Figure	O
5A	O
and	O
B	O
,	O
Pab1p	O
did	O
co	O
-	O
purify	O
with	O
FLAG	O
–	O
Scp160p	O
;	O
moreover	O
,	O
treatment	O
with	O
RNase	O
immediately	O
prior	O
to	O
FLAG	O
-	O
purification	O
completely	O
abolished	O
this	O
interaction	O
(	O
Fig.	O
5C	O
)	O
,	O
indicating	O
an	O
RNA	O
-	O
dependant	O
association	O
between	O
these	O
two	O
proteins	O
.	O

We	O
also	O
probed	O
the	O
isolated	O
complexes	O
for	O
the	O
presence	O
of	O
another	O
abundant	O
mRNP	O
-	O
component	O
protein	O
,	O
Pub1p	O
(	O
23,26	O
)	O
.	O

Pub1p	O
,	O
as	O
opposed	O
to	O
Pab1p	O
,	O
is	O
not	O
reported	O
to	O
associate	O
with	O
polyribosomes	O
,	O
and	O
is	O
hypothesized	O
to	O
bind	O
a	O
pool	O
of	O
non	O
-	O
translatable	O
mRNAs	O
(	O
23	O
)	O
.	O

As	O
predicted	O
,	O
Pub1p	O
did	O
not	O
co	O
-	O
purify	O
with	O
Scp160p	O
(	O
Fig.	O
5D	O
)	O
.	O

The	O
absence	O
of	O
Pub1p	O
in	O
Scp160p	O
-	O
containing	O
complexes	O
served	O
as	O
a	O
negative	O
control	O
,	O
demonstrating	O
that	O
abundant	O
RNA	O
-	O
binding	O
proteins	O
did	O
not	O
co	O
-	O
purify	O
non	O
-	O
specifically	O
by	O
this	O
protocol	O
.	O

In	O
addition	O
,	O
we	O
performed	O
mock	O
purifications	O
using	O
lysates	O
from	O
yeast	B
expressing	O
the	O
wild	O
-	O
type	O
allele	O
of	O
SCP160	O
without	O
the	O
FLAG	O
epitope	O
(	O
Fig.	O
5F	O
)	O
,	O
or	O
with	O
an	O
unrelated	O
FLAG	O
-	O
tagged	O
protein	O
,	O
human	B
galactose	O
1-phosphate	O
uridylyltransferase	O
(	O
GALT	O
)	O
(	O
Fig.	O
5	O
G	O
,	O
lower	O
panel	O
)	O
.	O

In	O
neither	O
case	O
did	O
Pab1p	O
bind	O
and	O
elute	O
from	O
the	O
FLAG	O
affinity	O
column	O
.	O

Finally	O
,	O
no	O
bands	O
were	O
visible	O
by	O
colloidal	O
G250	O
Coomassie	O
staining	O
of	O
samples	O
from	O
the	O
mock	O
(	O
wild	O
-	O
type	O
)	O
preparations	O
(	O
Fig.	O
5E	O
)	O
,	O
further	O
demonstrating	O
the	O
specificity	O
of	O
this	O
procedure	O
.	O

By	O
colloidal	O
G250	O
Coomassie	O
staining	O
(	O
Materials	O
and	O
Methods	O
)	O
of	O
the	O
FLAG	O
-	O
purified	O
complex	O
,	O
we	O
observed	O
in	O
addition	O
to	O
Scp160p	O
,	O
two	O
major	O
bands	O
,	O
at	O
~70	O
kDa	O
and	O
~55	O
kDa	O
,	O
which	O
ostensibly	O
represent	O
co	O
-	O
purifying	O
proteins	O
(	O
Fig.	O
5A	O
,	O
bottom	O
panel	O
)	O
.	O

Western	O
blot	O
analysis	O
suggested	O
that	O
the	O
~70	O
kDa	O
species	O
is	O
Pab1p	O
.	O

To	O
identify	O
the	O
55	O
kDa	O
protein	O
,	O
that	O
band	O
was	O
excised	O
from	O
the	O
gel	O
,	O
and	O
sent	O
to	O
the	O
Keck	O
microchemical	O
facility	O
at	O
Yale	O
University	O
for	O
analysis	O
by	O
in	O
gel	O
tryptic	O
digestion	O
,	O
followed	O
by	O
MALDI	O
-	O
mass	O
spectrometry	O
.	O

The	O
results	O
of	O
these	O
analyses	O
clearly	O
identified	O
the	O
unknown	O
protein	O
as	O
Bfr1p	O
.	O

To	O
confirm	O
this	O
result	O
,	O
an	O
N	O
-	O
terminal	O
HA	O
tag	O
was	O
engineered	O
onto	O
the	O
genomic	O
BFR1	O
locus	O
in	O
strains	O
expressing	O
FLAG	O
-	O
tagged	O
or	O
wild	O
-	O
type	O
Scp160p	O
.	O

Scp160p	O
complexes	O
were	O
then	O
isolated	O
from	O
both	O
of	O
these	O
strains	O
using	O
the	O
protocol	O
described	O
above	O
.	O

As	O
seen	O
in	O
Figure	O
6	O
,	O
an	O
HA	O
-	O
tagged	O
protein	O
of	O
~55	O
kDa	O
(	O
center	O
panel	O
)	O
appears	O
in	O
α	O
-	O
FLAG	O
column	O
elutions	O
only	O
when	O
FLAG	O
–	O
Scp160p	O
is	O
also	O
present	O
(	O
top	O
panel	O
)	O
.	O

No	O
signal	O
is	O
visible	O
in	O
mock	O
purifications	O
of	O
extracts	O
where	O
Scp160p	O
is	O
not	O
FLAG	O
-	O
tagged	O
(	O
bottom	O
panel	O
)	O
.	O

Monomeric	O
Scp160p	O
migrates	O
as	O
a	O
~450	O
kDa	O
protein	O
under	O
native	O
conditions	O
As	O
a	O
first	O
step	O
to	O
characterize	O
the	O
post	O
RNase	O
/	O
NaCl	O
450	O
kDa	O
Scp160p	O
species	O
we	O
compared	O
it	O
with	O
Scp160p	O
over	O
-	O
expressed	O
and	O
purified	O
from	O
an	O
exogenous	O
host	O
,	O
the	O
yeast	B
Pichia	B
pastoris	I
.	O

The	O
purified	O
N	O
-	O
terminal	O
FLAG	O
/	O
hexahistidine	O
-	O
tagged	O
Scp160p	O
was	O
run	O
over	O
an	O
S300	O
gel	O
filtration	O
column	O
;	O
2	O
ml	O
fractions	O
were	O
collected	O
and	O
analyzed	O
by	O
α	O
-	O
FLAG	O
western	O
blot	O
.	O

As	O
seen	O
in	O
Figure	O
7A	O
,	O
purified	O
Scp160p	O
eluted	O
at	O
a	O
volume	O
consistent	O
with	O
a	O
>	O
443	O
kDa	O
protein	O
.	O

To	O
confirm	O
that	O
no	O
other	O
proteins	O
were	O
associated	O
with	O
the	O
purified	O
Scp160p	O
,	O
12	O
µl	O
of	O
the	O
protein	O
was	O
run	O
on	O
SDS	O
–	O
PAGE	O
and	O
subjected	O
to	O
colloidal	O
G250	O
Coomassie	O
staining	O
before	O
loading	O
on	O
the	O
S-300	O
column	O
(	O
Fig.	O
7B	O
)	O
.	O

As	O
shown	O
,	O
no	O
bands	O
other	O
than	O
Scp160p	O
were	O
visible	O
.	O

Several	O
KH	O
-	O
domain	O
proteins	O
,	O
including	O
Sam68	O
and	O
FMRP	O
,	O
have	O
been	O
reported	O
to	O
form	O
homodimers	O
in	O
vivo	O
(	O
27	O
)	O
.	O

Therefore	O
,	O
we	O
explored	O
the	O
possibility	O
that	O
the	O
~450	O
kDa	O
Scp160p	O
species	O
might	O
contain	O
two	O
or	O
more	O
copies	O
of	O
Scp160p	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
yeast	B
expressing	O
FLAG	O
–	O
Scp160p	O
were	O
transfected	O
with	O
a	O
centromeric	O
plasmid	O
,	O
YCplac22–HA	O
–	O
Scp160p	O
,	O
encoding	O
a	O
distinct	O
,	O
HA	O
-	O
tagged	O
allele	O
of	O
the	O
protein	O
.	O

The	O
functionality	O
of	O
this	O
tagged	O
protein	O
had	O
previously	O
been	O
demonstrated	O
by	O
polyribosome	O
association	O
as	O
well	O
as	O
complementation	O
of	O
the	O
null	O
morphological	O
phenotype	O
in	O
cells	O
expressing	O
only	O
HA	O
–	O
Scp160p	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
seen	O
in	O
Figure	O
7C	O
,	O
when	O
yeast	B
co	O
-	O
expressing	O
the	O
two	O
alleles	O
were	O
lysed	O
and	O
the	O
FLAG	O
-	O
tagged	O
protein	O
was	O
isolated	O
as	O
described	O
above	O
,	O
no	O
HA	O
–	O
Scp160p	O
co	O
-	O
purified	O
with	O
the	O
FLAG	O
–	O
Scp160p	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
Scp160p	O
does	O
not	O
form	O
homo	O
-	O
dimers	O
or	O
higher	O
-	O
order	O
multimers	O
in	O
vivo	O
,	O
and	O
that	O
the	O
~450	O
kDa	O
species	O
of	O
Scp160p	O
observed	O
is	O
simply	O
the	O
monomeric	O
protein	O
.	O

DISCUSSION	O
The	O
data	O
presented	O
here	O
demonstrate	O
two	O
main	O
points	O
regarding	O
the	O
biochemical	O
associations	O
and	O
function	O
of	O
Scp160p	O
in	O
yeast	B
.	O

First	O
,	O
the	O
sucrose	O
gradient	O
fractionation	O
data	O
clearly	O
demonstrate	O
that	O
Scp160p	O
exists	O
primarily	O
associated	O
with	O
large	O
complexes	O
,	O
likely	O
to	O
be	O
polyribosomes	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
a	O
vigilin	O
family	O
member	O
has	O
been	O
shown	O
to	O
associate	O
with	O
polyribosomes	O
in	O
this	O
manner	O
.	O

Interestingly	O
,	O
Weber	O
and	O
colleagues	O
did	O
not	O
observe	O
sucrose	O
gradient	O
fractionation	O
data	O
consistent	O
with	O
polyribosome	O
association	O
of	O
Scp160p	O
(	O
5	O
)	O
.	O

These	O
authors	O
hypothesized	O
that	O
Scp160p	O
associates	O
only	O
with	O
membrane	O
-	O
bound	O
polyribosomes	O
,	O
and	O
that	O
Scp160p	O
is	O
not	O
found	O
complexed	O
with	O
cytosolic	O
polyribosomes	O
(	O
5	O
)	O
.	O

Our	O
data	O
do	O
not	O
support	O
this	O
hypothesis	O
,	O
since	O
unlike	O
Weber	O
and	O
colleagues	O
,	O
we	O
were	O
able	O
to	O
detect	O
significant	O
amounts	O
of	O
Scp160p	O
associated	O
with	O
polyribosomes	O
without	O
using	O
detergents	O
during	O
preparation	O
.	O

There	O
are	O
several	O
possible	O
explanations	O
for	O
this	O
discrepancy	O
.	O

First	O
,	O
the	O
lysate	O
buffer	O
utilized	O
by	O
that	O
group	O
contained	O
100	O
mM	O
NaCl	O
,	O
whereas	O
our	O
buffer	O
contained	O
50	O
mM	O
KCl	O
.	O

Our	O
data	O
shown	O
in	O
Figure	O
3	O
suggest	O
that	O
100	O
mM	O
NaCl	O
may	O
have	O
caused	O
an	O
instability	O
in	O
the	O
Scp160p	O
–	O
RNA	O
interaction	O
,	O
leading	O
to	O
release	O
from	O
polyribosomes	O
during	O
their	O
procedure	O
.	O

Secondly	O
,	O
Weber	O
's	O
lysate	O
buffer	O
reportedly	O
contained	O
heparin	O
to	O
inhibit	O
ribonucleases	O
;	O
a	O
number	O
of	O
reports	O
(	O
28,29	O
)	O
suggest	O
that	O
heparin	O
can	O
disrupt	O
RNA	O
–	O
protein	O
interactions	O
.	O

Although	O
we	O
have	O
not	O
in	O
the	O
past	O
included	O
heparin	O
in	O
any	O
of	O
our	O
experiments	O
,	O
we	O
have	O
observed	O
disruption	O
of	O
the	O
polyribosome	O
association	O
in	O
buffer	O
containing	O
residual	O
diethylpyrocarbonate	O
,	O
another	O
inhibitor	O
of	O
ribonucleases	O
(	O
data	O
not	O
shown	O
)	O
.	O

Second	O
,	O
our	O
data	O
provide	O
compelling	O
evidence	O
that	O
Scp160p	O
is	O
released	O
from	O
polyribosomes	O
as	O
a	O
component	O
of	O
an	O
mRNP	O
complex	O
.	O

Since	O
Scp160p	O
does	O
not	O
remain	O
associated	O
with	O
either	O
single	O
ribosomes	O
or	O
ribosomal	O
subunits	O
following	O
treatment	O
with	O
EDTA	O
or	O
RNase	O
,	O
it	O
seems	O
unlikely	O
that	O
Scp160p	O
is	O
a	O
constitutive	O
component	O
of	O
the	O
translational	O
machinery	O
.	O

Partial	O
purification	O
of	O
the	O
EDTA	O
-	O
resistant	O
Scp160p	O
complexes	O
allowed	O
us	O
to	O
demonstrate	O
the	O
presence	O
of	O
Pab1p	O
but	O
not	O
Pub1p	O
in	O
these	O
preparations	O
,	O
which	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
as	O
a	O
component	O
of	O
mRNP	O
complexes	O
.	O

Previously	O
,	O
Scp160p	O
had	O
been	O
shown	O
to	O
bind	O
ribohomopolymers	O
and	O
rRNA	O
in	O
vitro	O
,	O
although	O
the	O
in	O
vivo	O
nucleic	O
acid	O
targets	O
of	O
Scp160p	O
were	O
unknown	O
(	O
5	O
)	O
.	O

The	O
presence	O
of	O
Pab1p	O
in	O
RNase	O
-	O
sensitive	O
Scp160p	O
complexes	O
indicates	O
that	O
Scp160p	O
is	O
primarily	O
bound	O
to	O
polyadenylated	O
RNAs	O
.	O

Whether	O
or	O
not	O
Scp160p	O
binds	O
only	O
specific	O
sets	O
of	O
mRNAs	O
will	O
be	O
the	O
subject	O
of	O
future	O
studies	O
.	O

In	O
addition	O
to	O
Scp160p	O
and	O
Pab1p	O
,	O
we	O
have	O
identified	O
a	O
third	O
component	O
of	O
the	O
complex	O
,	O
the	O
protein	O
Bfr1p	O
.	O

The	O
gene	O
,	O
BFR1	O
,	O
was	O
originally	O
identified	O
in	O
a	O
screen	O
for	O
high	O
-	O
copy	O
suppressors	O
of	O
Brefeldin	O
-	O
A	O
induced	O
lethality	O
,	O
suggesting	O
a	O
role	O
in	O
the	O
secretory	O
pathway	O
(	O
16	O
)	O
.	O

Interestingly	O
,	O
however	O
,	O
bfr1	O
null	O
mutants	O
do	O
not	O
demonstrate	O
any	O
defects	O
in	O
the	O
secretory	O
pathway	O
,	O
but	O
rather	O
display	O
similar	O
phenotypes	O
to	O
scp160	O
null	O
mutants	O
,	O
most	O
notably	O
increased	O
ploidy	O
and	O
increased	O
cell	O
size	O
(	O
16	O
)	O
.	O

It	O
is	O
therefore	O
unclear	O
whether	O
Bfr1p	O
is	O
capable	O
of	O
functioning	O
in	O
both	O
RNA	O
metabolism	O
and	O
secretion	O
directly	O
,	O
or	O
if	O
the	O
Scp160p	O
–	O
Bfr1p	O
complex	O
regulates	O
the	O
expression	O
of	O
one	O
or	O
more	O
secretory	O
genes	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

Additionally	O
,	O
two	O
-	O
hybrid	O
analysis	O
indicated	O
an	O
interaction	O
of	O
Bfr1p	O
with	O
the	O
protein	O
Bbp1p	O
,	O
a	O
component	O
of	O
the	O
mitotic	O
spindle	O
apparatus	O
(	O
30	O
)	O
.	O

While	O
Bbp1p	O
is	O
an	O
essential	O
gene	O
,	O
overexpression	O
leads	O
to	O
a	O
phenotype	O
similar	O
to	O
both	O
bfr1	O
and	O
scp160	O
null	O
strains	O
(	O
30	O
)	O
.	O

Future	O
work	O
will	O
address	O
the	O
functional	O
relationship	O
between	O
Scp160p	O
and	O
Bfr1p	O
including	O
the	O
possibility	O
that	O
these	O
proteins	O
represent	O
a	O
regulatory	O
mechanism	O
connecting	O
the	O
translational	O
machinery	O
with	O
cell	O
division	O
and/or	O
the	O
secretory	O
pathway	O
.	O

Following	O
treatment	O
with	O
either	O
RNase	O
or	O
>	O
150	O
mM	O
NaCl	O
,	O
Scp160p	O
remained	O
as	O
an	O
apparent	O
~450	O
kDa	O
species	O
.	O

Considering	O
that	O
purified	O
Scp160p	O
alone	O
also	O
migrates	O
at	O
this	O
size	O
,	O
we	O
conclude	O
that	O
this	O
apparent	O
complex	O
may	O
consist	O
only	O
of	O
Scp160p	O
,	O
although	O
the	O
presence	O
of	O
other	O
small	O
components	O
can	O
not	O
be	O
ruled	O
out	O
at	O
this	O
time	O
.	O

Furthermore	O
,	O
by	O
utilizing	O
yeast	B
co	O
-	O
expressing	O
two	O
distinct	O
epitope	O
-	O
tagged	O
versions	O
of	O
Scp160p	O
,	O
we	O
have	O
ruled	O
out	O
the	O
possibility	O
of	O
self	O
-	O
association	O
of	O
Scp160p	O
.	O

Although	O
both	O
tagged	O
proteins	O
appear	O
functional	O
,	O
it	O
remains	O
a	O
formal	O
possibility	O
that	O
the	O
tags	O
somehow	O
prevented	O
formation	O
of	O
FLAG	O
–	O
HA	O
hetero	O
-	O
complexes	O
.	O

Nonetheless	O
,	O
it	O
seems	O
most	O
likely	O
that	O
native	O
Scp160p	O
monomers	O
may	O
simply	O
migrate	O
aberrantly	O
under	O
native	O
conditions	O
due	O
to	O
an	O
unusual	O
shape	O
or	O
some	O
other	O
physical	O
property	O
.	O

In	O
conclusion	O
we	O
have	O
shown	O
convincing	O
evidence	O
that	O
Scp160p	O
exists	O
in	O
yeast	B
cytoplasmic	O
extracts	O
primarily	O
associated	O
with	O
polyribosomes	O
.	O

We	O
have	O
purified	O
Scp160p	O
following	O
disruption	O
of	O
polyribosomes	O
with	O
EDTA	O
,	O
and	O
identified	O
two	O
associated	O
proteins	O
:	O
Pab1p	O
and	O
Bfr1p	O
.	O

The	O
presence	O
of	O
Pab1p	O
suggests	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
as	O
a	O
component	O
of	O
an	O
mRNP	O
,	O
demonstrating	O
Scp160p	O
to	O
be	O
the	O
first	O
S.cerevisiae	B
multiple	O
-	O
KH	O
domain	O
protein	O
characterized	O
to	O
function	O
in	O
this	O
way	O
.	O

Mutations	O
of	O
PIK3CA	O
in	O
gastric	O
adenocarcinoma	O
Abstract	O
Background	O
Activation	O
of	O
the	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3	O
K	O
)	O
through	O
mutational	O
inactivation	O
of	O
PTEN	O
tumour	O
suppressor	O
gene	O
is	O
common	O
in	O
diverse	O
cancer	O
types	O
,	O
but	O
rarely	O
reported	O
in	O
gastric	O
cancer	O
.	O

Recently	O
,	O
mutations	O
in	O
PIK3CA	O
,	O
which	O
encodes	O
the	O
p110α	O
catalytic	O
subunit	O
of	O
PI3	O
K	O
,	O
have	O
been	O
identified	O
in	O
various	O
human	B
cancers	O
,	O
including	O
3	O
of	O
12	O
gastric	O
cancers	O
.	O

Eighty	O
percent	O
of	O
these	O
reported	O
mutations	O
clustered	O
within	O
2	O
regions	O
involving	O
the	O
helical	O
and	O
kinase	O
domains	O
.	O

In	O
vitro	O
study	O
on	O
one	O
of	O
the	O
""""	O
hot	O
-	O
spot	O
""""	O
mutants	O
has	O
demonstrated	O
it	O
as	O
an	O
activating	O
mutation	O
.	O

Methods	O
Based	O
on	O
these	O
data	O
,	O
we	O
initiated	O
PIK3CA	O
mutation	O
screening	O
in	O
94	O
human	B
gastric	O
cancers	O
by	O
direct	O
sequencing	O
of	O
the	O
gene	O
regions	O
in	O
which	O
80	O
%	O
of	O
all	O
the	O
known	O
PIK3CA	O
mutations	O
were	O
found	O
.	O

We	O
also	O
examined	O
PIK3CA	O
expression	O
level	O
by	O
extracting	O
data	O
from	O
the	O
previous	O
large	O
-	O
scale	O
gene	O
expression	O
profiling	O
study	O
.	O

Using	O
Significance	O
Analysis	O
of	O
Microarrays	O
(	O
SAM	O
)	O
,	O
we	O
further	O
searched	O
for	O
genes	O
that	O
show	O
correlating	O
expression	O
with	O
PIK3CA	O
.	O

Results	O
We	O
have	O
identified	O
PIK3CA	O
mutations	O
in	O
4	O
cases	O
(	O
4.3	O
%	O
)	O
,	O
all	O
involving	O
the	O
previously	O
reported	O
hotspots	O
.	O

Among	O
these	O
4	O
cases	O
,	O
3	O
tumours	O
demonstrated	O
microsatellite	O
instability	O
and	O
2	O
tumours	O
harboured	O
concurrent	O
KRAS	O
mutation	O
.	O

Data	O
extracted	O
from	O
microarray	O
studies	O
showed	O
an	O
increased	O
expression	O
of	O
PIK3CA	O
in	O
gastric	O
cancers	O
when	O
compared	O
with	O
the	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
(	O
p	O
<	O
0.001	O
)	O
.	O

SAM	O
further	O
identified	O
2910	O
genes	O
whose	O
expression	O
levels	O
were	O
positively	O
associated	O
with	O
that	O
of	O
PIK3CA	O
.	O

Conclusion	O
Our	O
data	O
suggested	O
that	O
activation	O
of	O
the	O
PI3	O
K	O
signalling	O
pathway	O
in	O
gastric	O
cancer	O
may	O
be	O
achieved	O
through	O
up	O
-	O
regulation	O
or	O
mutation	O
of	O
PIK3CA	O
,	O
in	O
which	O
the	O
latter	O
may	O
be	O
a	O
consequence	O
of	O
mismatch	O
repair	O
deficiency	O
.	O

Background	O
The	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3K	O
)	O
-AKT	O
signalling	O
pathway	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
diverse	O
cellular	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
survival	O
and	O
motility	O
.	O

Abnormal	O
activation	O
of	O
this	O
pathway	O
is	O
frequently	O
observed	O
in	O
various	O
cancer	O
types	O
,	O
leading	O
to	O
aberrant	O
cell	O
cycle	O
progression	O
,	O
altered	O
adhesion	O
and	O
motility	O
,	O
inhibition	O
of	O
apoptosis	O
and	O
induction	O
of	O
angiogenesis	O
[	O
1	O
]	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
genetic	O
alterations	O
involving	O
various	O
members	O
along	O
this	O
signalling	O
pathway	O
could	O
lead	O
to	O
its	O
activation	O
in	O
cancer	O
.	O

These	O
include	O
mutation	O
,	O
allelic	O
loss	O
or	O
promoter	O
methylation	O
of	O
the	O
negative	O
regulator	O
PTEN	O
[	O
2	O
]	O
;	O
or	O
alternatively	O
,	O
chromosomal	O
amplification	O
or	O
over	O
-	O
expression	O
of	O
the	O
positive	O
regulators	O
PIK3CA	O
[	O
3	O
-	O
5	O
]	O
and	O
the	O
various	O
AKT	O
kinases	O
[	O
6,7	O
]	O
.	O

Furthermore	O
,	O
changes	O
in	O
other	O
related	O
pathways	O
that	O
are	O
commonly	O
altered	O
in	O
cancer	O
,	O
such	O
as	O
those	O
involved	O
in	O
growth	O
factor	O
stimulation	O
via	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
or	O
through	O
direct	O
interaction	O
with	O
the	O
activated	O
form	O
of	O
small	O
GTPase	O
RAS	O
,	O
can	O
also	O
lead	O
to	O
PI3K	O
-	O
AKT	O
pathway	O
activation	O
[	O
8	O
]	O
.	O

Activation	O
of	O
this	O
pathway	O
results	O
in	O
the	O
phosphorylation	O
of	O
AKT	O
at	O
Thr-308	O
/	O
309	O
and	O
Ser-473	O
/	O
474	O
.	O

These	O
phosphorylated	O
forms	O
of	O
AKT	O
proteins	O
have	O
been	O
detected	O
by	O
Western	O
blot	O
or	O
immunohistochemistry	O
in	O
various	O
cancer	O
types	O
,	O
suggesting	O
the	O
frequent	O
activation	O
of	O
PI3K	O
-	O
AKT	O
pathway	O
in	O
the	O
carcinogenic	O
process	O
[	O
7,9	O
]	O
.	O

Although	O
genetic	O
changes	O
along	O
the	O
PI3K	O
-	O
AKT	O
pathway	O
have	O
been	O
repeatedly	O
documented	O
in	O
brain	O
,	O
ovarian	O
,	O
endometrial	O
,	O
breast	O
,	O
prostate	O
and	O
thyroid	O
cancers	O
[	O
1,2	O
]	O
,	O
reports	O
on	O
its	O
mechanism	O
of	O
activation	O
in	O
gastric	O
cancer	O
are	O
limited	O
.	O

Gastric	O
cancer	O
is	O
the	O
second	O
most	O
common	O
cancer	O
worldwide	O
but	O
its	O
molecular	O
basis	O
of	O
tumourigenesis	O
is	O
still	O
poorly	O
understood	O
.	O

Previous	O
immunohistochemical	O
study	O
has	O
demonstrated	O
the	O
presence	O
of	O
the	O
phosphorylated	O
form	O
of	O
AKT	O
in	O
78	O
%	O
of	O
gastric	O
cancer	O
[	O
10	O
]	O
,	O
suggesting	O
that	O
activation	O
of	O
this	O
pathway	O
may	O
also	O
be	O
common	O
in	O
gastric	O
cancer	O
.	O

Though	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
involving	O
the	O
PTEN	O
locus	O
has	O
been	O
demonstrated	O
in	O
47	O
%	O
of	O
gastric	O
cancer	O
in	O
a	O
recent	O
study	O
,	O
mutation	O
or	O
promoter	O
methylation	O
was	O
absent	O
even	O
in	O
cases	O
with	O
LOH	O
[	O
11	O
]	O
.	O

Thus	O
data	O
from	O
this	O
study	O
could	O
not	O
support	O
the	O
two	O
-	O
hit	O
inactivation	O
of	O
PTEN	O
in	O
gastric	O
cancer	O
,	O
while	O
the	O
biological	O
significance	O
of	O
PTEN	O
haploinsufficiency	O
remains	O
controversial	O
.	O

Alternatively	O
,	O
amplification	O
of	O
AKT1	O
has	O
been	O
reported	O
in	O
a	O
single	O
case	O
of	O
gastric	O
cancer	O
[	O
12	O
]	O
,	O
and	O
amplification	O
of	O
PIK3CA	O
associated	O
with	O
elevated	O
mRNA	O
levels	O
has	O
been	O
found	O
in	O
36	O
%	O
of	O
gastric	O
cancer	O
[	O
11	O
]	O
.	O

More	O
recently	O
,	O
Samuels	O
et	O
al.	O
screened	O
a	O
diverse	O
spectrum	O
of	O
human	B
cancers	O
for	O
mutation	O
in	O
16	O
PI3	O
K	O
or	O
PI3K	O
-	O
like	O
genes	O
and	O
found	O
a	O
high	O
frequency	O
of	O
somatic	O
mutation	O
in	O
PIK3CA	O
,	O
which	O
encodes	O
the	O
p110α	O
catalytic	O
subunit	O
.	O

Major	O
screening	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
identified	O
PIK3CA	O
mutations	O
in	O
74	O
out	O
of	O
234	O
(	O
32	O
%	O
)	O
cases	O
,	O
while	O
mutations	O
were	O
also	O
noted	O
in	O
3	O
out	O
of	O
12	O
(	O
25	O
%	O
)	O
gastric	O
cancers	O
.	O

Reported	O
mutations	O
were	O
mostly	O
of	O
missense	O
type	O
,	O
and	O
clustered	O
within	O
2	O
regions	O
in	O
the	O
helical	O
and	O
kinase	O
domains	O
.	O

Expression	O
of	O
a	O
""""	O
hot	O
-	O
spot	O
""""	O
mutant	O
,	O
H1047R	O
,	O
conferred	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
lipid	O
kinase	O
activity	O
of	O
PIK3CA	O
,	O
suggesting	O
it	O
as	O
an	O
activating	O
mutation	O
[	O
13	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
a	O
series	O
of	O
94	O
human	B
gastric	O
adenocarcinomas	O
for	O
PIK3CA	O
mutation	O
.	O

We	O
have	O
also	O
examined	O
PIK3CA	O
expression	O
level	O
by	O
extracting	O
data	O
from	O
a	O
large	O
-	O
scale	O
gene	O
expression	O
profiling	O
study	O
previously	O
performed	O
for	O
these	O
cases	O
[	O
14,15	O
]	O
.	O

Using	O
SAM	O
,	O
genes	O
with	O
significant	O
correlating	O
expression	O
with	O
PIK3CA	O
have	O
also	O
been	O
identified	O
.	O

Methods	O
Patient	O
samples	O
preparation	O
DNA	O
samples	O
used	O
for	O
sequencing	O
were	O
prepared	O
from	O
frozen	O
tumour	O
and	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
from	O
94	O
gastric	O
cancer	O
patients	O
who	O
underwent	O
gastrectomy	O
in	O
the	O
Department	O
of	O
Surgery	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
The	O
University	O
of	O
Hong	O
Kong	O
,	O
as	O
previously	O
described	O
[	O
16	O
]	O
.	O

Majority	O
of	O
the	O
frozen	O
samples	O
(	O
n	O
=	O
81	O
)	O
showed	O
tumour	O
component	O
of	O
over	O
70	O
%	O
,	O
whereas	O
in	O
13	O
cases	O
a	O
lower	O
proportion	O
between	O
50	O
to	O
70	O
%	O
was	O
accepted	O
due	O
to	O
the	O
tumours	O
'	O
inherent	O
diffuse	O
infiltrative	O
nature	O
with	O
entrapment	O
of	O
non	O
-	O
neoplastic	O
components	O
.	O

Analysis	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
BRAF	O
and	O
KRAS	O
mutation	O
have	O
been	O
performed	O
and	O
reported	O
previously	O
[	O
16	O
]	O
.	O

RNA	O
preparation	O
and	O
gene	O
expression	O
profiling	O
using	O
a	O
cDNA	O
microarray	O
containing	O
44,500	O
cDNA	O
clones	O
,	O
representing	O
around	O
30,300	O
unique	O
genes	O
,	O
has	O
been	O
performed	O
and	O
reported	O
in	O
90	O
of	O
these	O
tumours	O
in	O
comparison	O
to	O
22	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
[	O
14,15	O
]	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Hong	O
Kong	O
.	O

Mutational	O
screening	O
Mutation	O
screening	O
of	O
PIK3CA	O
was	O
performed	O
for	O
exons	O
9	O
and	O
20	O
,	O
covering	O
the	O
mutational	O
hotspots	O
;	O
and	O
for	O
exon	O
18	O
,	O
from	O
which	O
a	O
mutation	O
was	O
found	O
in	O
a	O
gastric	O
cancer	O
.	O

Mutations	O
in	O
these	O
3	O
exons	O
constituted	O
80	O
%	O
of	O
all	O
PIK3CA	O
mutations	O
detected	O
in	O
the	O
previous	O
study	O
[	O
13	O
]	O
.	O

PIK3CA	O
intron	O
-	O
specific	O
external	O
amplification	O
primers	O
and	O
internal	O
sequencing	O
primers	O
were	O
designed	O
according	O
to	O
the	O
previous	O
study	O
[	O
13	O
]	O
with	O
some	O
modifications	O
[	O
see	O
Additional	O
file	O
1	O
]	O
.	O

In	O
particular	O
,	O
primers	O
for	O
exon	O
9	O
have	O
been	O
modified	O
to	O
avoid	O
amplification	O
of	O
homologous	O
sequences	O
located	O
in	O
other	O
chromosomes	O
.	O

PCR	O
products	O
were	O
generated	O
using	O
the	O
external	O
primers	O
and	O
directly	O
sequenced	O
using	O
the	O
internal	O
primers	O
with	O
the	O
DYEnamic	O
™	O
ET	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
(	O
Amersham	O
Biosciences	O
,	O
Freiburg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instruction	O
.	O

Electrophoresis	O
was	O
performed	O
in	O
the	O
ABI	O
Prism	O
®	O
3700	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
each	O
exon	O
,	O
PCR	O
products	O
were	O
generated	O
from	O
2	O
independent	O
PCR	O
reactions	O
for	O
sequencing	O
of	O
the	O
forward	O
and	O
reverse	O
strands	O
.	O

For	O
exon	O
9	O
,	O
2	O
independent	O
PCR	O
followed	O
by	O
sequencing	O
of	O
the	O
forward	O
strand	O
were	O
performed	O
.	O

Analysis	O
of	O
the	O
chromatograms	O
was	O
performed	O
using	O
the	O
mutation	O
analysis	O
software	O
Mutation	O
Explorer	O
™	O
(	O
SoftGenetics	O
,	O
State	O
College	O
,	O
PA	O
,	O
USA	O
)	O
.	O

Extraction	O
of	O
expression	O
data	O
and	O
statistical	O
analysis	O
Gene	O
expression	O
data	O
were	O
extracted	O
from	O
the	O
microarray	O
database	O
containing	O
126	O
samples	O
(	O
90	O
gastric	O
cancers	O
,	O
14	O
lymph	O
node	O
metastasis	O
and	O
22	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
)	O
based	O
on	O
a	O
3-fold	O
signal	O
above	O
background	O
ratio	O
for	O
either	O
channel	O
and	O
with	O
80	O
%	O
good	O
data	O
[	O
14	O
]	O
.	O

Gene	O
expression	O
data	O
from	O
20,336	O
cDNA	O
clones	O
satisfied	O
this	O
selection	O
criteria	O
and	O
were	O
extracted	O
,	O
which	O
included	O
a	O
cDNA	O
clone	O
corresponding	O
to	O
PIK3CA	O
(	O
IMAGE	O
clone	O
number	O
345430	O
,	O
GenBank	O
accession	O
no.	O
W72473	O
)	O
.	O

Expression	O
data	O
for	O
PIK3CA	O
was	O
extracted	O
and	O
the	O
differences	O
in	O
expression	O
levels	O
between	O
tumour	O
and	O
non	O
-	O
tumour	O
tissues	O
were	O
examined	O
using	O
the	O
Student	O
's	O
t	O
-	O
Test	O
.	O

SAM	O
was	O
performed	O
to	O
identify	O
genes	O
with	O
significant	O
correlating	O
expression	O
with	O
PIK3CA	O
[	O
17	O
]	O
.	O

The	O
missing	O
values	O
in	O
the	O
dataset	O
were	O
estimated	O
by	O
a	O
K	O
-	O
nearest	O
neighbours	O
impute	O
algorithm	O
using	O
10	O
nearest	O
neighbour	O
[	O
18	O
]	O
followed	O
by	O
5000	O
permutations	O
in	O
the	O
SAM	O
analysis	O
.	O

Results	O
Among	O
the	O
94	O
gastric	O
adenocarcinoma	O
analysed	O
,	O
we	O
have	O
detected	O
PIK3CA	O
mutation	O
in	O
4	O
cases	O
.	O

Two	O
cases	O
harboured	O
the	O
mutation	O
A3140	O
G	O
(	O
H1047R	O
)	O
in	O
exon	O
20	O
,	O
and	O
the	O
other	O
2	O
cases	O
with	O
mutations	O
G1624A	O
(	O
E542	O
K	O
)	O
and	O
G1633A	O
(	O
E545	O
K	O
)	O
in	O
exon	O
9	O
.	O

Representative	O
sequence	O
chromatograms	O
are	O
shown	O
in	O
figure	O
1	O
.	O

All	O
four	O
mutations	O
were	O
absent	O
in	O
the	O
corresponding	O
non	O
-	O
neoplastic	O
mucosae	O
and	O
thus	O
were	O
confirmed	O
as	O
somatic	O
mutations	O
.	O

Though	O
the	O
overall	O
mutation	O
frequency	O
(	O
4.3	O
%	O
)	O
was	O
lower	O
than	O
that	O
of	O
the	O
previous	O
study	O
,	O
the	O
nature	O
of	O
the	O
4	O
mutations	O
found	O
were	O
consistent	O
with	O
those	O
identified	O
at	O
the	O
reported	O
hotspots	O
.	O

In	O
particular	O
,	O
the	O
H1047R	O
mutation	O
has	O
been	O
reported	O
in	O
2	O
gastric	O
cancers	O
and	O
15	O
colorectal	O
cancers	O
[	O
13	O
]	O
.	O

While	O
the	O
E542	O
K	O
and	O
the	O
E545	O
K	O
mutations	O
were	O
not	O
found	O
in	O
gastric	O
cancer	O
in	O
the	O
previous	O
series	O
,	O
a	O
large	O
number	O
of	O
colorectal	O
tumours	O
did	O
harbour	O
these	O
2	O
mutations	O
.	O

PIK3CA	O
mutation	O
spectrum	O
and	O
their	O
corresponding	O
clinico	O
-	O
pathological	O
features	O
were	O
listed	O
in	O
Table	O
1	O
.	O

We	O
noted	O
a	O
higher	O
tendency	O
of	O
high	O
-	O
level	O
MSI	O
in	O
gastric	O
cancers	O
with	O
PIK3CA	O
mutations	O
(	O
3	O
in	O
4	O
,	O
75	O
%	O
)	O
than	O
in	O
those	O
without	O
(	O
18	O
in	O
90	O
,	O
20	O
%	O
)	O
.	O

Moreover	O
,	O
though	O
the	O
overall	O
incidence	O
of	O
KRAS	O
mutation	O
in	O
the	O
studied	O
population	O
was	O
low	O
(	O
8	O
in	O
94	O
)	O
,	O
2	O
of	O
the	O
4	O
gastric	O
cancers	O
with	O
PIK3CA	O
mutation	O
also	O
harboured	O
a	O
KRAS	O
mutation	O
.	O

Since	O
over	O
-	O
expression	O
of	O
PIK3CA	O
has	O
been	O
reported	O
in	O
gastric	O
cancer	O
[	O
11	O
]	O
,	O
we	O
have	O
also	O
extracted	O
PIK3CA	O
expression	O
data	O
from	O
our	O
previous	O
cDNA	O
microarray	O
study	O
of	O
these	O
cases	O
[	O
14,15	O
]	O
.	O

We	O
have	O
confirmed	O
that	O
expression	O
level	O
of	O
PIK3CA	O
was	O
significantly	O
higher	O
in	O
gastric	O
cancers	O
(	O
n	O
=	O
87	O
,	O
mean	O
=	O
0.099	O
,	O
SD	O
=	O
0.428	O
)	O
when	O
compared	O
with	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
(	O
n	O
=	O
22	O
,	O
mean	O
=	O
-0.418	O
,	O
SD	O
=	O
0.426	O
;	O
Student	O
's	O
t	O
-	O
Test	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Using	O
PIK3CA	O
expression	O
level	O
as	O
a	O
continuous	O
variable	O
for	O
SAM	O
analysis	O
[	O
17	O
]	O
,	O
we	O
found	O
2910	O
cDNA	O
clones	O
(	O
corresponding	O
to	O
about	O
2546	O
unique	O
genes	O
)	O
whose	O
expression	O
associated	O
positively	O
with	O
PIK3CA	O
expression	O
(	O
median	O
number	O
of	O
false	O
significant	O
=	O
0.372	O
,	O
Delta	O
=	O
1.107	O
)	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

Interestingly	O
,	O
no	O
gene	O
was	O
found	O
to	O
be	O
negatively	O
associated	O
with	O
PIK3CA	O
expression	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
we	O
have	O
reported	O
the	O
presence	O
of	O
PIK3CA	O
gene	O
mutation	O
in	O
4.3	O
%	O
of	O
gastric	O
cancer	O
.	O

A	O
high	O
tendency	O
(	O
3	O
in	O
4	O
)	O
of	O
mismatch	O
repair	O
deficiency	O
was	O
noted	O
in	O
cases	O
harbouring	O
PIK3CA	O
mutation	O
.	O

Though	O
the	O
small	O
number	O
of	O
PIK3CA	O
mutations	O
in	O
our	O
study	O
may	O
not	O
justify	O
statistical	O
claim	O
of	O
significance	O
;	O
suggestion	O
of	O
such	O
,	O
despite	O
of	O
its	O
not	O
being	O
mentioned	O
by	O
the	O
authors	O
,	O
can	O
be	O
found	O
from	O
a	O
previous	O
study	O
in	O
CRC	O
by	O
Samuels	O
et	O
al	O
..	O
From	O
their	O
study	O
of	O
33	O
MSI	O
and	O
201	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
CRC	O
cases	O
,	O
PIK3CA	O
mutation	O
was	O
present	O
in	O
48	O
%	O
of	O
the	O
MSI	O
tumours	O
,	O
but	O
only	O
in	O
29	O
%	O
of	O
the	O
MSS	O
tumours	O
.	O

A	O
significant	O
association	O
would	O
have	O
been	O
revealed	O
if	O
statistical	O
analysis	O
had	O
been	O
applied	O
(	O
Fisher	O
's	O
exact	O
test	O
,	O
p	O
=	O
0.014	O
)	O
[	O
13	O
]	O
.	O

Gastrointestinal	O
tract	O
cancers	O
with	O
MSI	O
are	O
known	O
to	O
have	O
a	O
different	O
molecular	O
pathway	O
of	O
tumour	O
evolution	O
compared	O
with	O
their	O
MSS	O
counterparts	O
[	O
19,20	O
]	O
.	O

This	O
can	O
be	O
attributed	O
to	O
their	O
propensity	O
for	O
frameshift	O
mutations	O
in	O
repeat	O
sequences	O
,	O
resulting	O
in	O
selective	O
disruption	O
of	O
genes	O
with	O
such	O
sequences	O
within	O
their	O
coding	O
regions	O
.	O

With	O
2	O
poly	O
-	O
adenine	O
tracts	O
within	O
its	O
coding	O
region	O
,	O
PTEN	O
can	O
be	O
inactivated	O
through	O
frameshift	O
mutations	O
in	O
MSI	O
CRC	O
,	O
resulting	O
in	O
the	O
selective	O
targeting	O
of	O
the	O
PI3K	O
-	O
AKT	O
signalling	O
pathway	O
[	O
21,22	O
]	O
.	O

It	O
is	O
also	O
known	O
that	O
mismatch	O
repair	O
deficiency	O
would	O
lead	O
to	O
an	O
elevated	O
rate	O
of	O
missense	O
mutation	O
due	O
to	O
impaired	O
single	O
nucleotide	O
mismatch	O
repair	O
[	O
23	O
]	O
.	O

Thus	O
,	O
the	O
observed	O
higher	O
incidence	O
of	O
PIK3CA	O
missense	O
mutation	O
in	O
MSI	O
colorectal	O
and	O
gastric	O
cancers	O
suggests	O
yet	O
another	O
mechanism	O
for	O
the	O
activation	O
of	O
the	O
PI3K	O
-	O
AKT	O
signalling	O
pathway	O
through	O
mismatch	O
repair	O
deficiency	O
.	O

Our	O
data	O
also	O
showed	O
a	O
higher	O
tendency	O
of	O
KRAS	O
mutation	O
in	O
cases	O
with	O
PIK3CA	O
mutations	O
(	O
2	O
in	O
4	O
)	O
than	O
in	O
those	O
without	O
(	O
6	O
in	O
90	O
)	O
.	O

Yet	O
again	O
due	O
to	O
the	O
low	O
incidence	O
of	O
both	O
mutations	O
in	O
our	O
samples	O
,	O
statistical	O
significance	O
may	O
not	O
be	O
claimed	O
.	O

In	O
the	O
study	O
by	O
Samuels	O
et	O
al.	O
,	O
some	O
of	O
the	O
colorectal	O
tumours	O
with	O
PIK3CA	O
mutation	O
also	O
harboured	O
KRAS	O
or	O
BRAF	O
mutation	O
[	O
13	O
]	O
.	O

The	O
PI3K	O
-	O
AKT	O
pathway	O
is	O
known	O
to	O
have	O
a	O
close	O
association	O
with	O
the	O
RAS	O
-	O
MEKK	O
signalling	O
pathway	O
[	O
8	O
]	O
.	O

Constitutively	O
active	O
RAS	O
can	O
interact	O
with	O
the	O
catalytic	O
subunit	O
of	O
PI3	O
K	O
and	O
lead	O
to	O
its	O
activation	O
.	O

Ras	O
-	O
dependent	O
PI3	O
K	O
activation	O
contributes	O
to	O
the	O
transforming	O
phenotype	O
by	O
mediating	O
anchorage	O
-	O
independent	O
growth	O
,	O
cytoskeletal	O
reorganisation	O
and	O
apoptosis	O
evasion	O
.	O

It	O
has	O
been	O
observed	O
that	O
genes	O
involved	O
in	O
the	O
same	O
signalling	O
pathway	O
may	O
manifest	O
mutations	O
in	O
cancer	O
cells	O
in	O
a	O
mutually	O
exclusive	O
manner	O
,	O
presumably	O
due	O
to	O
the	O
lack	O
of	O
selective	O
growth	O
advantage	O
in	O
having	O
a	O
second	O
hit	O
in	O
the	O
already	O
altered	O
pathway	O
.	O

A	O
prominent	O
example	O
is	O
the	O
mutually	O
exclusive	O
occurrence	O
of	O
the	O
BRAF	O
hotspot	O
mutation	O
(	O
V600E	O
)	O
and	O
KRAS	O
mutations	O
in	O
colorectal	O
cancer	O
[	O
24,25	O
]	O
.	O

However	O
,	O
there	O
exist	O
other	O
examples	O
of	O
alterations	O
in	O
multiple	O
components	O
of	O
the	O
same	O
signalling	O
pathway	O
that	O
may	O
lead	O
to	O
a	O
multi	O
-	O
level	O
modulation	O
of	O
its	O
activity	O
.	O

For	O
example	O
,	O
non	O
-	O
V600E	O
BRAF	O
mutations	O
tend	O
to	O
occur	O
together	O
with	O
KRAS	O
mutations	O
[	O
26	O
]	O
,	O
and	O
inactivation	O
of	O
the	O
secreted	O
frizzled	O
-	O
related	O
proteins	O
(	O
antagonists	O
of	O
WNT	O
)	O
by	O
promoter	O
methylation	O
frequently	O
coincides	O
with	O
mutations	O
in	O
the	O
Adenomatous	O
Polyposis	O
Coli	O
gene	O
to	O
achieve	O
multi	O
-	O
level	O
activation	O
of	O
the	O
WNT	O
signalling	O
pathway	O
in	O
colorectal	O
cancers	O
[	O
27	O
]	O
.	O

Whether	O
PIK3CA	O
functions	O
independently	O
from	O
RAS	O
,	O
or	O
acts	O
synergistically	O
with	O
RAS	O
to	O
produce	O
additive	O
effects	O
on	O
the	O
activation	O
of	O
the	O
same	O
pathway	O
awaits	O
further	O
clarification	O
.	O

By	O
extracting	O
data	O
from	O
microarray	O
,	O
we	O
have	O
confirmed	O
the	O
up	O
-	O
regulation	O
of	O
PIK3CA	O
expression	O
in	O
gastric	O
cancer	O
tissues	O
compared	O
with	O
the	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
and	O
identified	O
a	O
large	O
number	O
of	O
genes	O
that	O
showed	O
a	O
significant	O
positive	O
correlation	O
in	O
expression	O
level	O
with	O
PIK3CA	O
.	O

These	O
genes	O
participate	O
in	O
diverse	O
cellular	O
processes	O
with	O
177	O
as	O
putative	O
cell	O
cycle	O
-	O
regulated	O
genes	O
[	O
28	O
]	O
and	O
126	O
mapped	O
to	O
genes	O
with	O
known	O
functions	O
in	O
cell	O
cycle	O
regulation	O
,	O
cell	O
proliferation	O
or	O
DNA	O
replication	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

While	O
some	O
of	O
these	O
genes	O
maybe	O
induced	O
by	O
PIK3CA	O
,	O
others	O
maybe	O
co	O
-	O
ordinately	O
regulated	O
by	O
common	O
upstream	O
signals	O
.	O

Expression	O
data	O
set	O
at	O
one	O
point	O
was	O
limited	O
in	O
differentiating	O
the	O
above	O
cause	O
and	O
consequence	O
,	O
yet	O
it	O
certainly	O
revealed	O
the	O
complexity	O
of	O
the	O
carcinogenic	O
process	O
and	O
the	O
intricate	O
relationship	O
of	O
PIK3CA	O
signalling	O
with	O
other	O
cellular	O
processes	O
.	O

Contrary	O
to	O
our	O
expectation	O
,	O
the	O
incidence	O
of	O
PIK3CA	O
mutation	O
found	O
in	O
the	O
current	O
study	O
(	O
4	O
%	O
)	O
is	O
much	O
lower	O
compared	O
with	O
that	O
observed	O
by	O
Samuel	O
et	O
al.	O
(	O
25	O
%	O
)	O
[	O
13	O
]	O
.	O

The	O
reason	O
for	O
discrepancy	O
may	O
simply	O
be	O
a	O
result	O
of	O
sample	O
bias	O
as	O
the	O
previous	O
study	O
involved	O
only	O
a	O
small	O
number	O
of	O
gastric	O
cancers	O
(	O
n	O
=	O
12	O
)	O
.	O

However	O
,	O
ethnic	O
differences	O
can	O
also	O
be	O
another	O
possibility	O
.	O

The	O
diverse	O
pathological	O
spectrum	O
and	O
aetiological	O
factors	O
of	O
gastric	O
cancers	O
in	O
different	O
geographical	O
locations	O
may	O
be	O
paralleled	O
by	O
differences	O
in	O
molecular	O
pathway	O
of	O
tumour	O
development	O
.	O

Since	O
our	O
current	O
study	O
is	O
only	O
based	O
on	O
a	O
Chinese	O
population	O
with	O
an	O
intermediate	O
gastric	O
cancer	O
incidence	O
,	O
further	O
studies	O
involving	O
patients	O
from	O
different	O
ethnic	O
groups	O
will	O
be	O
able	O
to	O
address	O
this	O
possibility	O
.	O

Conclusion	O
Large	O
-	O
scale	O
screening	O
of	O
gastric	O
adenocarcinomas	O
for	O
PIK3CA	O
mutations	O
revealed	O
a	O
mutation	O
incidence	O
of	O
4.3	O
%	O
.	O

Increased	O
PIK3CA	O
expression	O
level	O
was	O
observed	O
in	O
gastric	O
tumours	O
compared	O
with	O
non	O
-	O
neoplastic	O
mucosae	O
.	O

This	O
increase	O
in	O
PIK3CA	O
level	O
was	O
associated	O
with	O
the	O
elevated	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
,	O
which	O
may	O
constitute	O
the	O
upstream	O
regulators	O
or	O
downstream	O
targets	O
of	O
PIK3CA	O
along	O
the	O
PI3	O
K	O
signalling	O
pathway	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
VSWL	O
carried	O
out	O
the	O
molecular	O
analysis	O
,	O
performed	O
data	O
analysis	O
and	O
drafted	O
the	O
manuscript	O
.	O

CWW	O
,	O
TLC	O
,	O
WZ	O
assisted	O
in	O
the	O
molecular	O
analysis	O
.	O

KMC	O
provided	O
the	O
clinical	O
data	O
.	O

ASWC	O
assisted	O
in	O
data	O
analysis	O
and	O
edited	O
the	O
manuscript	O
.	O

SS	O
and	O
XC	O
participated	O
in	O
the	O
microarray	O
study	O
and	O
data	O
analysis	O
.	O

STY	O
and	O
SYL	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
,	O
coordination	O
and	O
data	O
analysis	O
,	O
and	O
edited	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
Supplementary	O
Material	O

Structural	O
organization	O
and	O
interactions	O
of	O
transmembrane	O
domains	O
in	O
tetraspanin	O
proteins	O
Abstract	O
Background	O
Proteins	O
of	O
the	O
tetraspanin	O
family	O
contain	O
four	O
transmembrane	O
domains	O
(	O
TM1	O
-	O
4	O
)	O
linked	O
by	O
two	O
extracellular	O
loops	O
and	O
a	O
short	O
intracellular	O
loop	O
,	O
and	O
have	O
short	O
intracellular	O
N-	O
and	O
C	O
-	O
termini	O
.	O

While	O
structure	O
and	O
function	O
analysis	O
of	O
the	O
larger	O
extracellular	O
loop	O
has	O
been	O
performed	O
,	O
the	O
organization	O
and	O
role	O
of	O
transmembrane	O
domains	O
have	O
not	O
been	O
systematically	O
assessed	O
.	O

Results	O
Among	O
28	O
human	B
tetraspanin	O
proteins	O
,	O
the	O
TM1	O
-	O
3	O
sequences	O
display	O
a	O
distinct	O
heptad	O
repeat	O
motif	O
(	O
abcdefg	O
)	O
n	O
.	O

In	O
TM1	O
,	O
position	O
a	O
is	O
occupied	O
by	O
structurally	O
conserved	O
bulky	O
residues	O
and	O
position	O
d	O
contains	O
highly	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
.	O

In	O
TM2	O
,	O
position	O
a	O
is	O
occupied	O
by	O
conserved	O
small	O
residues	O
(	O
Gly	O
/	O
Ala	O
/	O
Thr	O
)	O
,	O
and	O
position	O
d	O
has	O
a	O
conserved	O
Gly	O
and	O
two	O
bulky	O
aliphatic	O
residues	O
.	O

In	O
TM3	O
,	O
three	O
a	O
positions	O
of	O
the	O
heptad	O
repeat	O
are	O
filled	O
by	O
two	O
leucines	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
,	O
and	O
two	O
d	O
positions	O
are	O
occupied	O
by	O
either	O
Phe	O
/	O
Tyr	O
or	O
Val	O
/	O
Ile	O
/	O
Leu	O
residues	O
.	O

No	O
heptad	O
motif	O
is	O
apparent	O
in	O
TM4	O
sequences	O
.	O

Mutations	O
of	O
conserved	O
glycines	O
in	O
human	B
CD9	O
(	O
Gly25	O
and	O
Gly32	O
in	O
TM1	O
;	O
Gly67	O
and	O
Gly74	O
in	O
TM2	O
)	O
caused	O
aggregation	O
of	O
mutant	O
proteins	O
inside	O
the	O
cell	O
.	O

Modeling	O
of	O
the	O
TM1-TM2	O
interface	O
in	O
CD9	O
,	O
using	O
a	O
novel	O
algorithm	O
,	O
predicts	O
tight	O
packing	O
of	O
conserved	O
bulky	O
residues	O
against	O
conserved	O
Gly	O
residues	O
along	O
the	O
two	O
helices	O
.	O

The	O
homodimeric	O
interface	O
of	O
CD9	O
was	O
mapped	O
,	O
by	O
disulfide	O
cross	O
-	O
linking	O
of	O
single	O
-	O
cysteine	O
mutants	O
,	O
to	O
the	O
vicinity	O
of	O
residues	O
Leu14	O
and	O
Phe17	O
in	O
TM1	O
(	O
positions	O
g	O
and	O
c	O
)	O
and	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
(	O
positions	O
d	O
,	O
g	O
and	O
a	O
,	O
respectively	O
)	O
.	O

Mutations	O
of	O
a	O
and	O
d	O
residues	O
in	O
both	O
TM1	O
and	O
TM2	O
(	O
Gly25	O
,	O
Gly32	O
,	O
Gly67	O
and	O
Gly74	O
)	O
,	O
involved	O
in	O
intramolecular	O
TM1-TM2	O
interaction	O
,	O
also	O
strongly	O
diminished	O
intermolecular	O
interaction	O
,	O
as	O
assessed	O
by	O
cross	O
-	O
linking	O
of	O
Cys80	O
.	O

Conclusion	O
Our	O
results	O
suggest	O
that	O
tetraspanin	O
intra-	O
and	O
intermolecular	O
interactions	O
are	O
mediated	O
by	O
conserved	O
residues	O
in	O
adjacent	O
,	O
but	O
distinct	O
regions	O
of	O
TM1	O
and	O
TM2	O
.	O

A	O
key	O
structural	O
element	O
that	O
defines	O
TM1-TM2	O
interaction	O
in	O
tetraspanins	O
is	O
the	O
specific	O
packing	O
of	O
bulky	O
residues	O
against	O
small	O
residues	O
.	O

Background	O
Tetraspanins	O
constitute	O
a	O
large	O
family	O
of	O
integral	O
membrane	O
proteins	O
,	O
characteristically	O
containing	O
4	O
,	O
6	O
or	O
8	O
conserved	O
cysteine	O
residues	O
in	O
the	O
large	O
extracellular	O
loop	O
(	O
including	O
the	O
CCG	O
and	O
PxxCC	O
motifs	O
)	O
,	O
which	O
form	O
disulfide	O
bonds	O
,	O
and	O
several	O
conserved	O
polar	O
residues	O
in	O
the	O
intracellular	O
loop	O
and	O
transmembrane	O
regions	O
[	O
1,2	O
]	O
.	O

There	O
are	O
32	O
putative	O
tetraspanin	O
family	O
members	O
in	O
mammals	O
,	O
37	O
in	O
Drosophila	B
melanogaster	I
and	O
20	O
in	O
Caenorhabditis	B
elegans	I
.	O

Tetraspanins	O
play	O
diverse	O
roles	O
in	O
cell	O
adhesion	O
,	O
migration	O
and	O
fusion	O
processes	O
,	O
cellular	O
activation	O
and	O
signaling	O
(	O
reviewed	O
in	O
refs	O
.	O

[	O
2	O
-	O
4	O
]	O
)	O
.	O

Mammalian	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
CD63	O
,	O
CD81	O
,	O
CD82	O
,	O
CD151	O
,	O
rds	O
/	O
peripherin	O
,	O
and	O
uroplakins	O
Ia	O
and	O
Ib	O
have	O
been	O
most	O
extensively	O
studied	O
,	O
with	O
mouse	B
knock	O
-	O
out	O
models	O
available	O
for	O
CD9	O
[	O
5	O
-	O
7	O
]	O
,	O
CD81	O
[	O
8,9	O
]	O
,	O
CD151	O
[	O
10	O
]	O
and	O
a	O
few	O
others	O
.	O

However	O
,	O
the	O
majority	O
of	O
tetraspanins	O
are	O
characterized	O
very	O
little	O
,	O
if	O
at	O
all	O
,	O
at	O
genetic	O
,	O
biochemical	O
or	O
structural	O
levels	O
.	O

The	O
large	O
extracellular	O
loop	O
(	O
LEL	O
)	O
of	O
tetraspanins	O
has	O
received	O
most	O
attention	O
,	O
since	O
it	O
contains	O
functionally	O
important	O
sites	O
.	O

Sequence	O
QRD	O
(	O
194–196	O
)	O
in	O
CD151	O
is	O
important	O
for	O
association	O
with	O
integrins	O
,	O
which	O
has	O
functional	O
consequences	O
for	O
integrin	O
-	O
dependent	O
cell	O
spreading	O
and	O
multicellular	O
cable	O
formation	O
[	O
11	O
]	O
.	O

A	O
site	O
in	O
the	O
LEL	O
of	O
CD9	O
,	O
SFQ	O
(	O
residues	O
173–175	O
)	O
,	O
is	O
essential	O
for	O
CD9	O
function	O
in	O
sperm	O
-	O
egg	O
fusion	O
[	O
12	O
]	O
.	O

The	O
crystal	O
structure	O
of	O
tetraspanin	O
CD81	O
LEL	O
revealed	O
five	O
α	O
-	O
helixes	O
,	O
A	O
-	O
E	O
[	O
13	O
]	O
.	O

Helices	O
A	O
,	O
B	O
and	O
E	O
form	O
a	O
relatively	O
conserved	O
region	O
in	O
tetraspanins	O
,	O
whereas	O
the	O
region	O
between	O
helices	O
B	O
and	O
E	O
is	O
the	O
most	O
variable	O
[	O
14	O
]	O
.	O

Interestingly	O
,	O
the	O
variable	O
region	O
contains	O
most	O
of	O
the	O
functionally	O
important	O
sites	O
involved	O
in	O
tetraspanin	O
protein	O
-	O
protein	O
interactions	O
.	O

A	O
remarkable	O
biochemical	O
property	O
of	O
tetraspanin	O
molecules	O
is	O
their	O
ability	O
to	O
associate	O
with	O
a	O
large	O
number	O
of	O
other	O
transmembrane	O
proteins	O
,	O
including	O
integrins	O
,	O
membrane	O
-	O
associated	O
growth	O
factors	O
and	O
receptors	O
,	O
MHC	O
class	O
II	O
molecules	O
,	O
Ig	O
superfamily	O
proteins	O
,	O
and	O
each	O
other	O
[	O
2,3,15	O
]	O
.	O

Several	O
of	O
these	O
lateral	O
associations	O
of	O
tetraspanins	O
are	O
detected	O
in	O
""""	O
mild	O
""""	O
detergents	O
(	O
Brij	O
series	O
,	O
CHAPS	O
)	O
,	O
but	O
are	O
disrupted	O
by	O
""""	O
strong	O
""""	O
detergents	O
such	O
as	O
Triton	O
X-100	O
or	O
SDS	O
.	O

Multiprotein	O
complexes	O
of	O
tetraspanins	O
and	O
associated	O
molecules	O
,	O
also	O
called	O
the	O
""""	O
tetraspanin	O
web	O
""""	O
[	O
16	O
]	O
,	O
may	O
represent	O
a	O
distinct	O
tetraspanin	O
-	O
enriched	O
membrane	O
microdomain	O
[	O
17,18	O
]	O
.	O

The	O
formation	O
of	O
this	O
microdomain	O
is	O
influenced	O
by	O
palmitoylation	O
of	O
several	O
conserved	O
juxtamembrane	O
cysteine	O
residues	O
in	O
tetraspanins	O
[	O
19	O
-	O
21	O
]	O
.	O

The	O
transmembrane	O
domains	O
,	O
encompassing	O
nearly	O
half	O
of	O
a	O
tetraspanin	O
protein	O
,	O
are	O
the	O
most	O
conserved	O
part	O
of	O
the	O
molecule	O
(	O
Stipp	O
et	O
al.	O
[	O
1	O
]	O
and	O
this	O
study	O
)	O
.	O

However	O
,	O
very	O
little	O
functional	O
information	O
is	O
available	O
on	O
these	O
domains	O
.	O

The	O
differential	O
detergent	O
sensitivity	O
of	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
suggests	O
that	O
hydrophobic	O
interactions	O
between	O
TM	O
helices	O
may	O
play	O
a	O
role	O
.	O

Indeed	O
,	O
when	O
the	O
large	O
extracellular	O
loop	O
(	O
LEL	O
)	O
of	O
CD151	O
is	O
deleted	O
,	O
the	O
molecule	O
is	O
still	O
able	O
to	O
associate	O
with	O
other	O
tetraspanins	O
[	O
22	O
]	O
.	O

Thus	O
,	O
TM	O
domains	O
are	O
strong	O
candidates	O
for	O
mediating	O
tetraspanin	O
-	O
tetraspanin	O
interactions	O
.	O

The	O
importance	O
of	O
TM	O
domain	O
interactions	O
in	O
intramolecular	O
organization	O
was	O
demonstrated	O
in	O
a	O
study	O
showing	O
that	O
CD82	O
fragment	O
TM2	O
-	O
4	O
,	O
lacking	O
TM1	O
,	O
was	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
but	O
was	O
transported	O
to	O
the	O
cell	O
surface	O
upon	O
co	O
-	O
expression	O
of	O
TM1	O
[	O
23	O
]	O
.	O

This	O
in	O
vivo	O
reconstitution	O
experiment	O
demonstrated	O
a	O
strong	O
interaction	O
between	O
TM1	O
and	O
the	O
rest	O
of	O
the	O
molecule	O
.	O

Expression	O
of	O
a	O
truncated	O
CD9	O
molecule	O
(	O
TM3-LEL	O
-	O
TM4	O
)	O
results	O
in	O
intracellular	O
accumulation	O
of	O
the	O
protein	O
and	O
significant	O
misfolding	O
of	O
the	O
LEL	O
,	O
as	O
judged	O
by	O
inappropriate	O
disulfide	O
formation	O
and	O
diminished	O
antibody	O
reactivity	O
(	O
our	O
unpublished	O
data	O
)	O
.	O

Similarly	O
,	O
a	O
CD9	O
epitope	O
in	O
the	O
LEL	O
is	O
lost	O
in	O
molecules	O
lacking	O
either	O
TM2+TM3	O
or	O
just	O
TM4	O
[	O
24	O
]	O
.	O

Thus	O
,	O
TM	O
domain	O
interactions	O
and	O
packing	O
are	O
crucial	O
for	O
proper	O
folding	O
,	O
stability	O
and	O
transport	O
of	O
tetraspanin	O
molecules	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
showed	O
that	O
covalent	O
cross	O
-	O
linking	O
of	O
membrane	O
-	O
proximal	O
cysteine	O
residues	O
can	O
be	O
used	O
as	O
a	O
tool	O
for	O
detection	O
of	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
[	O
25	O
]	O
.	O

Inhibition	O
of	O
cysteine	O
palmitoylation	O
by	O
2-bromopalmitate	O
(	O
2-BP	O
)	O
made	O
cysteines	O
available	O
for	O
cross	O
-	O
linking	O
and	O
enabled	O
demonstration	O
of	O
specific	O
tetraspanin	O
homodimerization	O
and	O
low	O
levels	O
of	O
heterodimerization	O
.	O

We	O
concluded	O
that	O
tetraspanin	O
homodimers	O
,	O
formed	O
in	O
the	O
Golgi	O
,	O
may	O
be	O
a	O
fundamental	O
structural	O
unit	O
within	O
tetraspanin	O
microdomains	O
.	O

In	O
this	O
study	O
,	O
we	O
carried	O
out	O
detailed	O
sequence	O
analysis	O
of	O
human	B
tetraspanin	O
TM	O
domains	O
.	O

We	O
show	O
that	O
a	O
heptad	O
repeat	O
containing	O
conserved	O
glycine	O
,	O
asparagine	O
and	O
large	O
hydrophobic	O
residues	O
occurs	O
in	O
TM1	O
and	O
TM2	O
domains	O
,	O
and	O
predict	O
tight	O
intramolecular	O
association	O
of	O
these	O
two	O
domains	O
by	O
packing	O
of	O
the	O
large	O
residues	O
against	O
the	O
small	O
residues	O
.	O

Moreover	O
,	O
by	O
using	O
cysteine	O
cross	O
-	O
linking	O
we	O
map	O
a	O
dimerization	O
interface	O
in	O
the	O
human	B
CD9	O
protein	O
,	O
and	O
show	O
that	O
conserved	O
heptad	O
motif	O
glycine	O
residues	O
are	O
also	O
important	O
for	O
intermolecular	O
CD9	O
associations	O
.	O

Results	O
Sequence	O
analysis	O
of	O
tetraspanin	O
transmembrane	O
domains	O
:	O
presence	O
of	O
the	O
heptad	O
repeat	O
motif	O
We	O
focused	O
our	O
attention	O
on	O
28	O
human	B
tetraspanins	O
identified	O
from	O
the	O
SWISS	O
-	O
PROT	O
and	O
GenBank	O
databases	O
.	O

All	O
tetraspanins	O
have	O
in	O
common	O
four	O
hydrophobic	O
stretches	O
(	O
TM	O
domains	O
)	O
of	O
20–25	O
residues	O
,	O
and	O
contain	O
highly	O
conserved	O
residues	O
in	O
the	O
second	O
extracellular	O
loop	O
,	O
in	O
particular	O
the	O
Cys	O
-	O
Cys	O
-	O
Gly	O
(	O
CCG	O
)	O
motif	O
.	O

Detailed	O
analysis	O
of	O
the	O
large	O
extracellular	O
loop	O
sequences	O
[	O
14	O
]	O
,	O
and	O
dendrograms	O
based	O
on	O
full	O
-	O
length	O
alignment	O
can	O
be	O
found	O
in	O
earlier	O
studies	O
[	O
26,27	O
]	O
.	O

The	O
length	O
of	O
each	O
transmembrane	O
domain	O
was	O
established	O
based	O
on	O
previous	O
sequence	O
analysis	O
of	O
tetraspanin	O
sequences	O
[	O
27,28	O
]	O
,	O
and	O
on	O
annotations	O
to	O
the	O
database	O
entries	O
.	O

Manual	O
adjustments	O
based	O
on	O
sequence	O
homology	O
and	O
hydrophobicity	O
profiles	O
were	O
done	O
to	O
fully	O
delineate	O
the	O
TM	O
domains	O
.	O

The	O
resulting	O
lengths	O
of	O
TM	O
domains	O
were	O
:	O
TM1	O
–	O
23	O
residues	O
;	O
TM2	O
–	O
21	O
residues	O
;	O
TM3	O
–	O
25	O
residues	O
;	O
TM4	O
–	O
25	O
residues	O
.	O

Two	O
more	O
residues	O
could	O
be	O
added	O
onto	O
the	O
N	O
-	O
terminal	O
part	O
of	O
TM2	O
;	O
however	O
,	O
relatively	O
small	O
sequence	O
conservation	O
of	O
these	O
residues	O
among	O
tetraspanins	O
and	O
occurrence	O
of	O
polar	O
/	O
charged	O
side	O
chains	O
in	O
some	O
tetraspanins	O
precluded	O
us	O
from	O
doing	O
so	O
for	O
the	O
global	O
alignment	O
.	O

Figures	O
1	O
and	O
2	O
show	O
a	O
multiple	O
sequence	O
alignment	O
of	O
four	O
TM	O
domains	O
of	O
28	O
human	B
tetraspanins	O
.	O

For	O
each	O
position	O
within	O
the	O
domains	O
,	O
consensus	O
residues	O
were	O
determined	O
and	O
classified	O
(	O
with	O
individual	O
color	O
code	O
)	O
in	O
4	O
categories	O
:	O
1	O
)	O
large	O
hydrophobic	O
residues	O
(	O
including	O
Val	O
,	O
Met	O
,	O
Leu	O
,	O
Ile	O
,	O
Phe	O
,	O
Tyr	O
,	O
Trp	O
)	O
,	O
2	O
)	O
small	O
residues	O
(	O
Gly	O
,	O
Ala	O
,	O
Ser	O
and	O
Thr	O
)	O
,	O
3	O
)	O
Cys	O
,	O
and	O
4	O
)	O
Asn	O
.	O

When	O
more	O
than	O
two	O
types	O
of	O
residues	O
occupied	O
a	O
given	O
position	O
in	O
a	O
TM	O
,	O
a	O
dual	O
-	O
color	O
pattern	O
that	O
reflected	O
the	O
prevalence	O
of	O
the	O
particular	O
residue	O
type	O
was	O
used	O
(	O
Figure	O
1	O
)	O
.	O

Cysteine	O
residues	O
were	O
shown	O
separately	O
due	O
to	O
their	O
importance	O
as	O
palmitoylation	O
target	O
sites	O
.	O

The	O
highly	O
conserved	O
asparagine	O
residue	O
in	O
TM1	O
was	O
considered	O
separately	O
.	O

No	O
proline	O
residues	O
are	O
found	O
in	O
TM	O
domains	O
1–3	O
of	O
human	B
tetraspanins	O
.	O

An	O
inspection	O
of	O
the	O
multiple	O
sequence	O
alignment	O
reveals	O
a	O
repeating	O
heptad	O
amino	O
acid	O
pattern	O
,	O
(	O
abcdefg	O
)	O
n	O
,	O
in	O
TM1	O
,	O
2	O
and	O
3	O
(	O
Figure	O
1	O
,	O
2	O
)	O
.	O

Heptad	O
repeats	O
promote	O
helical	O
coiled	O
coil	O
interactions	O
in	O
multiple	O
soluble	O
and	O
membrane	O
-	O
spanning	O
proteins	O
[	O
29	O
-	O
31	O
]	O
.	O

In	O
the	O
heptad	O
repeat	O
,	O
hydrophobic	O
residues	O
in	O
positions	O
a	O
and	O
d	O
are	O
of	O
special	O
importance	O
,	O
as	O
they	O
directly	O
mediate	O
interhelical	O
contacts	O
by	O
creating	O
a	O
tight	O
knobs	O
-	O
into	O
-	O
holes	O
packing	O
in	O
the	O
coiled	O
coil	O
structure	O
[	O
32	O
]	O
.	O

For	O
instance	O
,	O
in	O
the	O
leucine	O
zipper	O
of	O
the	O
yeast	B
transcription	O
factor	O
GCN4	O
,	O
positions	O
a	O
and	O
d	O
contain	O
Val	O
and	O
Leu	O
residues	O
,	O
respectively	O
,	O
with	O
an	O
Asn	O
residue	O
in	O
a	O
single	O
a	O
position	O
forming	O
a	O
hydrogen	O
bond	O
across	O
the	O
GCN4	O
dimer	O
interface	O
[	O
33	O
]	O
.	O

In	O
TM1	O
of	O
tetraspanins	O
,	O
highly	O
conserved	O
Asn	O
,	O
Gly	O
and	O
Gly	O
residues	O
(	O
numbers	O
18	O
,	O
25	O
and	O
32	O
in	O
the	O
CD9	O
sequence	O
)	O
appear	O
at	O
d	O
positions	O
of	O
the	O
heptad	O
repeats	O
,	O
and	O
residues	O
14	O
,	O
21	O
and	O
28	O
are	O
at	O
a	O
positions	O
(	O
Figure	O
1	O
)	O
.	O

In	O
TM2	O
,	O
residues	O
67	O
,	O
74	O
and	O
81	O
(	O
consensus	O
Gly	O
,	O
Gly	O
and	O
Ala	O
,	O
respectively	O
)	O
occupy	O
a	O
positions	O
,	O
whereas	O
residues	O
63	O
,	O
70	O
and	O
77	O
are	O
at	O
d	O
positions	O
.	O

Another	O
highly	O
conserved	O
glycine	O
,	O
Gly80	O
,	O
occupies	O
the	O
3rd	O
g	O
position	O
in	O
TM2	O
.	O

In	O
TM3	O
,	O
the	O
conserved	O
pattern	O
consists	O
of	O
two	O
leucine	O
residues	O
(	O
Leu89	O
and	O
Leu96	O
)	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
(	O
Glu	O
/	O
Gln103	O
)	O
in	O
a	O
positions	O
(	O
Figure	O
2	O
)	O
.	O

Two	O
d	O
positions	O
are	O
also	O
conserved	O
–	O
Phe	O
/	O
Tyr92	O
and	O
Ile	O
/	O
Val	O
/	O
Leu99	O
.	O

TM4	O
lacks	O
a	O
conserved	O
heptad	O
pattern	O
and	O
has	O
only	O
a	O
single	O
conserved	O
position	O
,	O
Glu	O
/	O
Gln209	O
(	O
with	O
four	O
exceptions	O
)	O
.	O

These	O
features	O
of	O
TM1	O
-	O
4	O
of	O
tetraspanins	O
are	O
displayed	O
on	O
helical	O
wheel	O
diagrams	O
(	O
Figure	O
3	O
)	O
.	O

Analysis	O
of	O
TM1	O
sequences	O
The	O
conserved	O
Asn	O
-	O
Gly	O
-	O
Gly	O
motif	O
,	O
occupying	O
designated	O
d	O
positions	O
of	O
the	O
heptad	O
repeat	O
,	O
is	O
the	O
most	O
prominent	O
structural	O
feature	O
of	O
TM1	O
.	O

We	O
also	O
compared	O
sequences	O
of	O
CD9	O
orthologs	O
from	O
10	O
different	O
organisms	O
(	O
the	O
most	O
available	O
for	O
any	O
tetraspanin	O
)	O
to	O
gain	O
further	O
insight	O
into	O
conservation	O
and	O
variability	O
of	O
the	O
TM1	O
sequence	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
,	O
positions	O
a	O
,	O
d	O
and	O
g	O
in	O
TM1	O
are	O
among	O
the	O
most	O
conserved	O
(	O
0	O
,	O
1	O
and	O
1	O
substitution	O
,	O
respectively	O
)	O
,	O
while	O
interspecies	O
variability	O
tends	O
to	O
occur	O
in	O
other	O
positions	O
:	O
b	O
(	O
5	O
substitutions	O
)	O
,	O
c	O
(	O
4	O
substitutions	O
)	O
,	O
e	O
(	O
4	O
substitutions	O
)	O
and	O
f	O
(	O
4	O
substitutions	O
)	O
.	O

Thus	O
,	O
the	O
positions	O
typically	O
involved	O
in	O
coiled	O
coil	O
interactions	O
(	O
a	O
and	O
d	O
)	O
are	O
the	O
most	O
conserved	O
.	O

When	O
residues	O
of	O
TM1	O
are	O
plotted	O
as	O
a	O
helical	O
wheel	O
,	O
additional	O
structural	O
features	O
are	O
revealed	O
(	O
Figure	O
3	O
)	O
.	O

There	O
are	O
highly	O
conserved	O
aliphatic	O
and	O
aromatic	O
residues	O
in	O
the	O
first	O
three	O
a	O
positions	O
of	O
the	O
heptad	O
motif	O
(	O
Phe15	O
,	O
Trp22	O
and	O
Leu29	O
in	O
CD9	O
)	O
,	O
as	O
well	O
as	O
in	O
g	O
positions	O
(	O
Leu14	O
,	O
Phe21	O
,	O
Val28	O
in	O
CD9	O
)	O
.	O

The	O
""""	O
ridges	O
""""	O
formed	O
by	O
these	O
bulky	O
residues	O
are	O
flanking	O
the	O
""""	O
groove	O
"""-"	O
forming	O
Gly	O
residues	O
of	O
the	O
Asn	O
-	O
Gly	O
-	O
Gly	O
position	O
d	O
motif	O
.	O

In	O
contrast	O
,	O
b	O
,	O
c	O
,	O
e	O
and	O
f	O
positions	O
show	O
an	O
overall	O
higher	O
variability	O
among	O
tetraspanins	O
,	O
as	O
also	O
seen	O
in	O
the	O
comparison	O
of	O
CD9	O
orthologs	O
described	O
above	O
.	O

Analysis	O
of	O
TM2	O
sequences	O
A	O
landmark	O
feature	O
of	O
TM2	O
in	O
tetraspanins	O
is	O
the	O
presence	O
of	O
highly	O
conserved	O
glycine	O
residues	O
(	O
Gly67	O
,	O
74	O
,	O
77	O
and	O
80	O
in	O
CD9	O
,	O
Figure	O
1	O
)	O
.	O

Other	O
substitutions	O
at	O
these	O
positions	O
are	O
almost	O
exclusively	O
small	O
residues	O
,	O
such	O
as	O
Ala	O
or	O
Ser	O
.	O

In	O
addition	O
,	O
Ala	O
,	O
Ser	O
or	O
Thr	O
occupy	O
position	O
81	O
.	O

This	O
residue	O
,	O
together	O
with	O
Gly67	O
and	O
Gly74	O
,	O
forms	O
face	O
a	O
of	O
the	O
helix	O
.	O

Residue	O
Gly77	O
(	O
position	O
d	O
)	O
is	O
preceded	O
by	O
conserved	O
,	O
chiefly	O
large	O
hydrophobic	O
residues	O
on	O
the	O
same	O
helical	O
face	O
(	O
Leu63	O
and	O
Met70	O
in	O
CD9	O
)	O
.	O

Extremely	O
conserved	O
Gly80	O
falls	O
into	O
heptad	O
position	O
g	O
(	O
Figure	O
3	O
)	O
.	O

Among	O
CD9	O
orthologs	O
,	O
heptad	O
positions	O
a	O
and	O
d	O
are	O
absolutely	O
conserved	O
,	O
whereas	O
other	O
positions	O
have	O
the	O
following	O
number	O
of	O
substitutions	O
:	O
b	O
–	O
3	O
;	O
c	O
–	O
2	O
;	O
e	O
–	O
1	O
;	O
f	O
–	O
3	O
;	O
g	O
–	O
1	O
(	O
Figure	O
4	O
)	O
.	O

Two	O
of	O
the	O
f	O
position	O
residues	O
in	O
TM2	O
(	O
65	O
and	O
79	O
)	O
also	O
show	O
higher	O
variability	O
among	O
different	O
tetraspanins	O
(	O
Figures	O
1	O
,	O
3	O
)	O
.	O

Cysteine	O
residues	O
are	O
frequently	O
found	O
near	O
the	O
cytoplasmic	O
end	O
of	O
TM2	O
helix	O
at	O
positions	O
78	O
and	O
79	O
;	O
these	O
cysteines	O
are	O
likely	O
to	O
be	O
palmitoylated	O
.	O

Analysis	O
of	O
TM3	O
and	O
TM4	O
sequences	O
The	O
TM3	O
domain	O
provides	O
another	O
example	O
of	O
the	O
heptad	O
repeat	O
pattern	O
.	O

Position	O
a	O
is	O
occupied	O
by	O
two	O
highly	O
conserved	O
leucine	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
(	O
Leu89	O
,	O
Leu96	O
and	O
Glu	O
/	O
Gln103	O
in	O
CD9	O
)	O
.	O

Furthermore	O
,	O
two	O
d	O
positions	O
are	O
conserved	O
–	O
Phe	O
/	O
Tyr92	O
(	O
aromatic	O
residue	O
)	O
and	O
Ile	O
/	O
Val99	O
(	O
β	O
-	O
branched	O
aliphatic	O
residue	O
;	O
Figures	O
2	O
,	O
3	O
)	O
.	O

In	O
addition	O
,	O
residue	O
100	O
in	O
position	O
e	O
is	O
generally	O
Phe	O
or	O
Leu	O
.	O

Among	O
CD9	O
orthologs	O
,	O
position	O
a	O
has	O
1	O
substitution	O
,	O
positions	O
b	O
,	O
c	O
and	O
f	O
each	O
have	O
6	O
,	O
positions	O
d	O
and	O
e	O
each	O
have	O
2	O
,	O
and	O
g	O
has	O
4	O
.	O

Thus	O
,	O
as	O
for	O
TM1	O
and	O
TM2	O
,	O
positions	O
a	O
and	O
d	O
are	O
among	O
the	O
most	O
conserved	O
,	O
but	O
overall	O
TM3	O
has	O
more	O
variable	O
positions	O
than	O
TM1	O
or	O
TM2	O
(	O
Figure	O
3	O
)	O
.	O

Less	O
than	O
half	O
of	O
TM3	O
sequences	O
contain	O
cysteine	O
residues	O
,	O
and	O
those	O
tend	O
to	O
occur	O
at	O
the	O
internal	O
positions	O
of	O
the	O
helix	O
(	O
Figure	O
2	O
)	O
.	O

TM4	O
shows	O
less	O
conservation	O
among	O
various	O
tetraspanin	O
family	O
members	O
than	O
the	O
other	O
TM	O
domains	O
(	O
Figures	O
2	O
,	O
3	O
)	O
.	O

The	O
only	O
highly	O
conserved	O
feature	O
is	O
the	O
glutamate	O
/	O
glutamine	O
residue	O
in	O
position	O
209	O
.	O

In	O
addition	O
,	O
one	O
or	O
two	O
cysteine	O
residues	O
can	O
be	O
found	O
at	O
the	O
C	O
-	O
terminal	O
end	O
of	O
TM4	O
in	O
some	O
tetraspanins	O
(	O
e.g.	O
CD9	O
,	O
CD81	O
,	O
CD151	O
)	O
,	O
and	O
many	O
sequences	O
contain	O
additional	O
polar	O
residues	O
(	O
Arg	O
,	O
Lys	O
,	O
His	O
,	O
Asn	O
,	O
Gln	O
)	O
.	O

No	O
conserved	O
heptad	O
motif	O
was	O
identified	O
in	O
TM4	O
,	O
as	O
also	O
confirmed	O
by	O
analysis	O
of	O
substitutions	O
in	O
CD9	O
orthologs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Mutational	O
analysis	O
of	O
conserved	O
glycine	O
residues	O
in	O
TM1	O
and	O
TM2	O
The	O
conserved	O
nature	O
of	O
the	O
Asn	O
and	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
prompted	O
an	O
analysis	O
of	O
their	O
functional	O
role	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
probed	O
whether	O
mutations	O
of	O
these	O
residues	O
destabilize	O
the	O
protein	O
molecule	O
.	O

We	O
expressed	O
a	O
construct	O
of	O
the	O
first	O
and	O
second	O
TMs	O
of	O
CD9	O
,	O
connected	O
by	O
the	O
small	O
extracellular	O
loop	O
,	O
and	O
tagged	O
with	O
a	O
C	O
-	O
terminal	O
green	O
fluorescent	O
protein	O
(	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
molecule	O
)	O
.	O

In	O
human	B
rhabdomyosarcoma	O
RD	O
cells	O
,	O
the	O
wild	O
-	O
type	O
fusion	O
protein	O
localized	O
mostly	O
in	O
a	O
reticular	O
,	O
intracellular	O
pattern	O
,	O
without	O
forming	O
any	O
large	O
aggregates	O
(	O
Figure	O
5	O
,	O
panel	O
A	O
)	O
.	O

Remarkably	O
,	O
when	O
double	O
mutants	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
Gly67Leu	O
+	O
Gly74Leu	O
were	O
expressed	O
,	O
the	O
protein	O
formed	O
distinct	O
large	O
aggregates	O
in	O
a	O
high	O
proportion	O
of	O
cells	O
(	O
Figure	O
5	O
,	O
panels	O
C	O
and	O
E	O
)	O
.	O

In	O
contrast	O
,	O
double	O
mutant	O
Gly77Leu	O
+	O
Gly80Leu	O
did	O
not	O
form	O
such	O
aggregates	O
(	O
Figure	O
5	O
,	O
panel	O
G	O
)	O
.	O

Results	O
with	O
respective	O
single	O
mutants	O
were	O
similar	O
to	O
that	O
with	O
double	O
mutants	O
,	O
with	O
the	O
aggregation	O
being	O
somewhat	O
more	O
pronounced	O
for	O
Leu	O
substitutions	O
of	O
Gly67	O
and	O
Gly74	O
compared	O
to	O
Gly25	O
and	O
Gly32	O
mutations	O
.	O

No	O
aggregation	O
was	O
observed	O
for	O
Asn18Ser	O
and	O
Asn18Tyr	O
mutants	O
(	O
data	O
not	O
shown	O
)	O
.	O

Also	O
,	O
nearly	O
identical	O
results	O
were	O
obtained	O
with	O
human	B
HT1080	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
interpret	O
these	O
results	O
as	O
an	O
indication	O
that	O
aggregating	O
mutants	O
are	O
destabilized	O
or	O
misfolded	O
while	O
non	O
-	O
aggregating	O
mutants	O
retain	O
the	O
wild	O
-	O
type	O
conformation	O
.	O

Intriguingly	O
,	O
mutations	O
to	O
the	O
conserved	O
GG7	O
motifs	O
caused	O
protein	O
aggregation	O
while	O
the	O
mutation	O
of	O
other	O
glycines	O
had	O
no	O
detectable	O
effect	O
.	O

These	O
results	O
also	O
suggest	O
that	O
wild	O
-	O
type	O
GFP	O
,	O
which	O
has	O
weak	O
tendency	O
to	O
self	O
-	O
associate	O
,	O
could	O
enhance	O
non	O
-	O
specific	O
interactions	O
of	O
destabilized	O
mutant	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
moieties	O
,	O
leading	O
to	O
their	O
aggregation	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
aggregation	O
of	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
Gly67Leu	O
+	O
Gly74Leu	O
double	O
mutants	O
was	O
suppressed	O
when	O
monomeric	O
GFP	O
molecule	O
,	O
Leu221Lys	O
[	O
34	O
]	O
was	O
used	O
(	O
Figure	O
5	O
,	O
panels	O
D	O
and	O
F	O
)	O
.	O

The	O
use	O
of	O
monomeric	O
GFP	O
did	O
not	O
affect	O
intercellular	O
localization	O
of	O
wild	O
-	O
type	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
(	O
Figure	O
5	O
,	O
panel	O
B	O
)	O
,	O
or	O
a	O
Gly77Leu	O
+	O
Gly80Leu	O
double	O
mutant	O
(	O
Figure	O
5	O
,	O
panel	O
H	O
)	O
.	O

In	O
summary	O
,	O
Leu	O
substitutions	O
of	O
Gly	O
residues	O
that	O
are	O
part	O
of	O
the	O
Asn	O
-	O
Gly	O
-	O
Gly	O
(	O
NGG7	O
)	O
motif	O
in	O
TM1	O
,	O
or	O
Gly	O
-	O
Gly	O
-	O
Ala	O
(	O
GGA7	O
)	O
motif	O
in	O
TM2	O
,	O
resulted	O
in	O
destabilization	O
and	O
aggregation	O
of	O
GFP	O
-	O
fused	O
TM	O
(	O
1	O
+	O
2	O
)	O
proteins	O
,	O
whereas	O
substitutions	O
of	O
Gly77	O
or	O
Gly80	O
,	O
which	O
are	O
not	O
part	O
of	O
these	O
motifs	O
(	O
Figure	O
3	O
)	O
,	O
failed	O
to	O
show	O
such	O
aggregation	O
.	O

Prediction	O
and	O
modelling	O
of	O
interaction	O
between	O
TM1	O
and	O
TM2	O
Consecutive	O
helices	O
in	O
polytopic	O
membrane	O
proteins	O
frequently	O
interact	O
[	O
35	O
]	O
.	O

Sequence	O
analysis	O
of	O
TM1	O
and	O
TM2	O
helices	O
of	O
tetraspanins	O
reveals	O
a	O
remarkable	O
complementarity	O
in	O
the	O
distribution	O
of	O
large	O
and	O
small	O
residues	O
at	O
heptad	O
positions	O
a	O
and	O
d	O
along	O
the	O
helical	O
axis	O
(	O
Figure	O
3	O
)	O
,	O
suggesting	O
that	O
these	O
residues	O
may	O
interact	O
.	O

To	O
further	O
elucidate	O
the	O
potential	O
for	O
TM1-TM2	O
interaction	O
,	O
the	O
putative	O
interface	O
was	O
modeled	O
using	O
a	O
novel	O
algorithm	O
that	O
considers	O
mutational	O
data	O
during	O
each	O
step	O
of	O
a	O
Monte	O
Carlo	O
simulated	O
annealing	O
cycle	O
(	O
see	O
Methods	O
for	O
details	O
)	O
.	O

Specifically	O
,	O
Gly25Leu	O
,	O
Gly32Leu	O
,	O
Gly67Leu	O
and	O
Gly74Leu	O
were	O
scored	O
as	O
disruptive	O
mutations	O
,	O
while	O
Asn18Ser	O
,	O
Gly77Leu	O
and	O
Gly80Leu	O
were	O
scored	O
as	O
silent	O
mutations	O
,	O
based	O
on	O
their	O
effects	O
on	O
protein	O
stability	O
(	O
Figure	O
5	O
and	O
data	O
not	O
shown	O
)	O
.	O

The	O
resulting	O
model	O
predicts	O
left	O
-	O
handed	O
crossing	O
of	O
TM1	O
and	O
TM2	O
helices	O
at	O
an	O
angle	O
of	O
+	O
28	O
°	O
.	O

The	O
key	O
element	O
of	O
the	O
structure	O
is	O
the	O
apposition	O
of	O
bulky	O
and	O
small	O
heptad	O
position	O
a	O
and	O
d	O
residues	O
,	O
as	O
follows	O
:	O
Gly32-Leu63	O
;	O
Gly67-Leu29	O
;	O
Gly25-Met70	O
;	O
Gly74-Trp22	O
;	O
Asn18-Gly77	O
;	O
Ala81-Phe15	O
(	O
Figure	O
6	O
)	O
.	O

Our	O
model	O
predicts	O
that	O
each	O
of	O
these	O
residue	O
pairs	O
are	O
in	O
van	O
der	O
Waals	O
contact	O
.	O

Additionally	O
,	O
two	O
potential	O
H	O
-	O
bonds	O
are	O
predicted	O
in	O
this	O
model	O
,	O
indicating	O
close	O
packing	O
:	O
Gly67	O
Cα	O
to	O
Gly25	O
carbonyl	O
oxygen	O
,	O
and	O
Trp22	O
Cα	O
to	O
Met70	O
carbonyl	O
oxygen	O
.	O

The	O
packing	O
is	O
tighter	O
in	O
the	O
ectodomain	O
-	O
proximal	O
portion	O
of	O
the	O
helices	O
(	O
Figure	O
6	O
,	O
panel	O
B	O
)	O
,	O
as	O
determined	O
by	O
Cα	O
-	O
Cα	O
distances	O
between	O
interacting	O
residue	O
pairs	O
.	O

The	O
key	O
elements	O
of	O
the	O
model	O
are	O
corroborated	O
by	O
the	O
presence	O
of	O
apparently	O
complementary	O
substitutions	O
in	O
TM1	O
and	O
TM2	O
sequences	O
of	O
different	O
tetraspanins	O
(	O
Figure	O
1	O
,	O
boxed	O
residues	O
)	O
.	O

For	O
example	O
,	O
Gly74	O
is	O
predicted	O
to	O
interact	O
with	O
Trp22	O
.	O

In	O
8	O
of	O
the	O
10	O
tetraspanins	O
that	O
contain	O
a	O
substitution	O
for	O
Gly74	O
,	O
a	O
compensatory	O
substitution	O
occurs	O
at	O
the	O
Trp22	O
position	O
(	O
Figure	O
1	O
)	O
.	O

Thus	O
,	O
a	O
larger	O
non	O
-	O
glycine	O
side	O
chain	O
at	O
position	O
74	O
may	O
necessitate	O
a	O
less	O
bulky	O
non	O
-	O
Trp	O
side	O
chain	O
in	O
position	O
22	O
.	O

Likewise	O
,	O
the	O
presence	O
of	O
a	O
Cβ	O
at	O
position	O
25	O
,	O
typically	O
occupied	O
by	O
glycine	O
,	O
necessitates	O
a	O
non	O
-	O
β	O
-	O
branched	O
amino	O
acid	O
at	O
position	O
70	O
,	O
which	O
is	O
occupied	O
by	O
a	O
β	O
-	O
branched	O
residue	O
in	O
nearly	O
half	O
of	O
all	O
cases	O
.	O

Indeed	O
,	O
we	O
find	O
that	O
in	O
each	O
of	O
5	O
cases	O
in	O
which	O
position	O
25	O
contains	O
a	O
Cβ	O
,	O
a	O
leucine	O
residue	O
occurs	O
in	O
position	O
70	O
.	O

This	O
analysis	O
is	O
consistent	O
with	O
our	O
molecular	O
model	O
that	O
suggests	O
Leu70	O
will	O
pack	O
most	O
favorably	O
against	O
a	O
Cβ	O
at	O
position	O
25	O
than	O
a	O
β	O
-	O
branched	O
residue	O
or	O
a	O
methionine	O
.	O

Role	O
of	O
TM1	O
and	O
TM2	O
heptad	O
motif	O
residues	O
in	O
CD9	O
dimerization	O
To	O
probe	O
CD9	O
dimerization	O
,	O
we	O
used	O
a	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
approach	O
.	O

We	O
established	O
previously	O
a	O
simple	O
and	O
efficient	O
method	O
for	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
[	O
25	O
]	O
.	O

After	O
cells	O
are	O
pre	O
-	O
treated	O
with	O
2-BP	O
for	O
16–24	O
hours	O
to	O
expose	O
normally	O
palmitoylated	O
cysteines	O
,	O
the	O
cysteines	O
can	O
be	O
cross	O
-	O
linked	O
using	O
any	O
of	O
the	O
following	O
methods	O
:	O
a	O
)	O
Spontaneous	O
oxidation	O
in	O
Brij97	O
lysates	O
(	O
a	O
condition	O
that	O
preserves	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
)	O
,	O
b	O
)	O
In	O
situ	O
cross	O
-	O
linking	O
,	O
by	O
pre	O
-	O
lysis	O
oxidation	O
of	O
cells	O
with	O
Cu2	O
+	O
-phenanthroline	O
(	O
CuP	O
)	O
to	O
promote	O
disulfide	O
bond	O
formation	O
.	O

c	O
)	O
In	O
situ	O
cross	O
-	O
linking	O
with	O
thiol	O
-	O
reactive	O
cross	O
-	O
linking	O
agents	O
of	O
defined	O
length	O
(	O
e.g.	O
DTME	O
,	O
BMB	O
)	O
.	O

The	O
first	O
two	O
approaches	O
produce	O
in	O
essence	O
""""	O
zero	O
-	O
length	O
""""	O
disulfides	O
,	O
indicative	O
of	O
close	O
proximity	O
of	O
target	O
cysteines	O
and	O
presumably	O
high	O
specificity	O
of	O
interaction	O
.	O

In	O
contrast	O
,	O
chemical	O
cross	O
-	O
linkers	O
with	O
6–20	O
Å	O
spacer	O
arm	O
may	O
cross	O
-	O
link	O
with	O
higher	O
efficiency	O
,	O
but	O
not	O
necessarily	O
higher	O
specificity	O
.	O

However	O
,	O
they	O
provide	O
advantages	O
such	O
as	O
variable	O
membrane	O
permeability	O
,	O
and	O
potential	O
linkage	O
cleavability	O
.	O

For	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
membrane	O
-	O
permeable	O
cross	O
-	O
linker	O
DTME	O
(	O
13.3	O
Å	O
-	O
long	O
,	O
reducible	O
)	O
provides	O
highly	O
specific	O
and	O
efficient	O
cross	O
-	O
linking	O
[	O
25	O
]	O
.	O

Here	O
we	O
have	O
used	O
a	O
cysteine	O
cross	O
-	O
linking	O
strategy	O
,	O
in	O
combination	O
with	O
cysteine	O
-	O
scanning	O
mutagenesis	O
,	O
to	O
map	O
the	O
residues	O
from	O
TM1	O
and	O
TM2	O
contributing	O
to	O
the	O
CD9	O
dimerization	O
interface	O
.	O

For	O
subsequent	O
cross	O
-	O
linking	O
experiments	O
using	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
protein	O
,	O
the	O
non	O
-	O
dimerizing	O
form	O
of	O
GFP	O
was	O
used	O
.	O

This	O
avoids	O
potential	O
GFP	O
-	O
dependent	O
dimerization	O
and	O
aggregation	O
that	O
can	O
be	O
observed	O
with	O
wild	O
-	O
type	O
GFP	O
,	O
especially	O
when	O
fusions	O
with	O
transmembrane	O
proteins	O
are	O
studied	O
[	O
36	O
]	O
.	O

Importantly	O
,	O
the	O
Leu221Lys	O
mutation	O
in	O
GFP	O
prevented	O
aggregation	O
of	O
mutant	O
forms	O
of	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
,	O
which	O
was	O
observed	O
with	O
wild	O
-	O
type	O
GFP	O
fusion	O
(	O
Figure	O
5	O
)	O
.	O

The	O
TM	O
(	O
1	O
+	O
2	O
)	O
fragment	O
of	O
CD9	O
contains	O
three	O
native	O
cysteines	O
–	O
Cys9	O
,	O
Cys78	O
and	O
Cys79	O
.	O

Single	O
-	O
cysteine	O
mutants	O
of	O
TM	O
(	O
1	O
+	O
2	O
)	O
were	O
constructed	O
,	O
in	O
which	O
a	O
cysteine	O
was	O
placed	O
at	O
various	O
faces	O
of	O
TM1	O
or	O
TM2	O
while	O
all	O
of	O
the	O
wild	O
-	O
type	O
cysteines	O
were	O
simultaneously	O
replaced	O
by	O
serines	O
.	O

The	O
mutant	O
proteins	O
were	O
transiently	O
expressed	O
in	O
RD	O
cells	O
(	O
having	O
little	O
endogenous	O
CD9	O
)	O
,	O
which	O
were	O
then	O
treated	O
for	O
16–18	O
hours	O
with	O
2-BP	O
.	O

To	O
achieve	O
maximal	O
specificity	O
in	O
cross	O
-	O
linking	O
we	O
used	O
a	O
""""	O
zero	O
-	O
length	O
""""	O
agent	O
,	O
CuP.	O
First	O
,	O
single	O
-	O
cysteine	O
replacements	O
were	O
constructed	O
for	O
residues	O
Leu14	O
,	O
Phe15	O
,	O
Gly16	O
,	O
Phe17	O
and	O
Asn18	O
,	O
covering	O
just	O
over	O
one	O
complete	O
helical	O
turn	O
at	O
the	O
beginning	O
of	O
TM1	O
.	O

While	O
residue	O
Asn18	O
is	O
highly	O
conserved	O
,	O
positions	O
14	O
,	O
15	O
and	O
17	O
are	O
occupied	O
by	O
bulky	O
hydrophobic	O
residues	O
in	O
most	O
tetraspanins	O
,	O
whereas	O
position	O
16	O
shows	O
less	O
conservation	O
(	O
Figures	O
1	O
,	O
4	O
)	O
.	O

All	O
of	O
the	O
single	O
-	O
cysteine	O
mutants	O
showed	O
diffused	O
pattern	O
of	O
protein	O
localization	O
,	O
without	O
any	O
signs	O
of	O
aggregation	O
.	O

As	O
shown	O
in	O
Figure	O
7A	O
,	O
the	O
highest	O
level	O
of	O
intermolecular	O
cross	O
-	O
linking	O
was	O
observed	O
for	O
Leu14Cys	O
and	O
Phe17Cys	O
mutants	O
,	O
a	O
lower	O
level	O
for	O
Phe15Cys	O
and	O
Gly16Cys	O
mutants	O
,	O
and	O
very	O
little	O
cross	O
-	O
linking	O
for	O
Asn18Cys	O
substitution	O
.	O

These	O
results	O
indicate	O
that	O
:	O
a	O
)	O
the	O
first	O
two	O
transmembrane	O
domains	O
of	O
CD9	O
alone	O
can	O
mediate	O
its	O
dimerization	O
,	O
and	O
b	O
)	O
the	O
g	O
and	O
c	O
residues	O
of	O
TM1	O
(	O
e.g.	O
Leu14	O
and	O
Phe17	O
,	O
Figure	O
3	O
)	O
are	O
likely	O
to	O
be	O
part	O
of	O
the	O
intermolecular	O
interface	O
.	O

Similarly	O
,	O
single	O
-	O
cysteine	O
substitutions	O
were	O
made	O
for	O
residues	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
;	O
in	O
addition	O
,	O
proteins	O
carrying	O
a	O
single	O
wild	O
-	O
type	O
cysteine	O
,	O
Cys9	O
,	O
Cys78	O
or	O
Cys79	O
,	O
were	O
tested	O
.	O

No	O
protein	O
aggregation	O
was	O
observed	O
for	O
any	O
of	O
these	O
single	O
-	O
cysteine	O
mutants	O
.	O

As	O
shown	O
in	O
Figure	O
7B	O
,	O
the	O
relatively	O
low	O
level	O
of	O
intermolecular	O
cross	O
-	O
linking	O
of	O
wild	O
-	O
type	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
protein	O
was	O
enhanced	O
dramatically	O
in	O
single	O
-	O
cysteine	O
TM2	O
mutants	O
Gly80Cys	O
and	O
Ala81Cys	O
.	O

The	O
Gly77Cys	O
mutant	O
also	O
had	O
an	O
elevated	O
level	O
of	O
cross	O
-	O
linking	O
.	O

In	O
contrast	O
,	O
any	O
of	O
the	O
three	O
native	O
cysteines	O
(	O
9	O
,	O
78	O
and	O
79	O
)	O
produced	O
level	O
of	O
cross	O
-	O
linking	O
not	O
much	O
greater	O
than	O
the	O
wild	O
-	O
type	O
TM	O
(	O
1	O
+	O
2	O
)	O
protein	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
cysteine	O
-	O
reactive	O
cross	O
-	O
linker	O
BMB	O
(	O
data	O
not	O
shown	O
)	O
.	O

Likewise	O
,	O
comparable	O
results	O
were	O
obtained	O
with	O
single	O
-	O
cysteine	O
mutants	O
of	O
untagged	O
,	O
full	O
-	O
length	O
CD9	O
,	O
using	O
CuP	O
(	O
Figure	O
7C	O
)	O
as	O
well	O
as	O
DTME	O
cross	O
-	O
linker	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
cross	O
-	O
linking	O
results	O
for	O
TM1	O
and	O
TM2	O
are	O
consistent	O
with	O
our	O
model	O
that	O
places	O
residues	O
Leu14	O
,	O
Phe17	O
and	O
Gly80	O
on	O
the	O
same	O
side	O
of	O
the	O
TM1-TM2	O
pair	O
(	O
Figure	O
6	O
,	O
panel	O
C	O
)	O
.	O

The	O
strong	O
cross	O
-	O
linking	O
with	O
Leu14Cys	O
,	O
Phe17Cys	O
and	O
Gly80Cys	O
places	O
the	O
intermolecular	O
interface	O
toward	O
the	O
c	O
and	O
g	O
phases	O
of	O
the	O
TM1	O
helix	O
,	O
and	O
the	O
g	O
phase	O
of	O
the	O
TM2	O
helix	O
,	O
away	O
from	O
its	O
e	O
and	O
f	O
faces	O
containing	O
wild	O
-	O
type	O
cysteines	O
78	O
and	O
79	O
.	O

Critical	O
residues	O
at	O
the	O
TM1-TM2	O
interface	O
also	O
affect	O
dimerization	O
indirectly	O
.	O

To	O
assess	O
specific	O
CD9	O
dimerization	O
,	O
we	O
used	O
a	O
Gly80Cys	O
substitution	O
at	O
the	O
intermolecular	O
interface	O
for	O
cross	O
-	O
linking	O
.	O

As	O
shown	O
in	O
Figure	O
8A	O
,	O
single	O
replacements	O
of	O
conserved	O
heptad	O
residues	O
in	O
positions	O
18	O
,	O
25	O
,	O
32	O
,	O
67	O
and	O
74	O
(	O
Asn18Ser	O
,	O
Gly25	O
/	O
32	O
/	O
67	O
/	O
74→Leu	O
)	O
strongly	O
decreased	O
the	O
cross	O
-	O
linking	O
mediated	O
by	O
Cys80	O
.	O

The	O
effect	O
was	O
most	O
pronounced	O
for	O
mutations	O
of	O
residues	O
,	O
Gly32	O
and	O
Gly67	O
,	O
located	O
in	O
the	O
tightly	O
packed	O
extracellular	O
end	O
of	O
TM	O
helices	O
(	O
Figure	O
6	O
)	O
.	O

In	O
contrast	O
,	O
mutations	O
of	O
residues	O
closer	O
to	O
the	O
cytoplasmic	O
end	O
of	O
TM2	O
(	O
Gly74	O
and	O
especially	O
Ala81	O
)	O
had	O
only	O
modest	O
to	O
very	O
little	O
effect	O
on	O
cross	O
-	O
linking	O
.	O

Relatively	O
low	O
efficiency	O
of	O
intermolecular	O
cross	O
-	O
linking	O
via	O
native	O
residues	O
Cys9	O
,	O
78	O
,	O
and	O
79	O
(	O
Figures	O
7B	O
,	O
C	O
)	O
correlates	O
well	O
with	O
the	O
predicted	O
location	O
of	O
Cys78	O
and	O
79	O
away	O
from	O
the	O
dimeric	O
interface	O
(	O
Figure	O
3	O
)	O
,	O
and	O
suggests	O
that	O
the	O
extramembrane	O
N	O
-	O
terminal	O
part	O
of	O
CD9	O
(	O
residues	O
1–13	O
)	O
does	O
not	O
self	O
-	O
associate	O
.	O

We	O
next	O
examined	O
whether	O
mutations	O
of	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
decreased	O
low	O
-	O
level	O
background	O
cross	O
-	O
linking	O
via	O
native	O
cysteines	O
.	O

As	O
expected	O
,	O
these	O
mutations	O
had	O
virtually	O
no	O
effect	O
on	O
dimer	O
formation	O
of	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
(	O
Figure	O
8B	O
)	O
.	O

The	O
level	O
of	O
covalent	O
dimer	O
formed	O
was	O
not	O
diminished	O
for	O
triple	O
Asn18Ser	O
+	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
double	O
Gly67Leu	O
+	O
Gly74Leu	O
mutants	O
,	O
compared	O
to	O
wild	O
-	O
type	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
molecule	O
.	O

Similarly	O
,	O
the	O
same	O
triple	O
and	O
double	O
mutations	O
in	O
the	O
context	O
of	O
full	O
-	O
length	O
CD9-GFP	O
protein	O
(	O
with	O
six	O
cysteines	O
)	O
produced	O
wild	O
-	O
type	O
levels	O
of	O
cross	O
-	O
linking	O
(	O
Figure	O
8C	O
)	O
.	O

We	O
interpret	O
these	O
findings	O
as	O
evidence	O
for	O
at	O
least	O
two	O
types	O
of	O
associations	O
between	O
CD9	O
molecules	O
:	O
primary	O
,	O
involving	O
residues	O
14	O
,	O
17	O
and	O
80	O
,	O
and	O
dependent	O
on	O
integrity	O
of	O
conserved	O
heptad	O
residues	O
in	O
TM1	O
and	O
TM2	O
,	O
and	O
less	O
efficient	O
secondary	O
interactions	O
,	O
probably	O
representing	O
random	O
collision	O
events	O
,	O
and	O
independent	O
of	O
the	O
heptad	O
residues	O
(	O
see	O
Discussion	O
for	O
more	O
details	O
)	O
.	O

TM3	O
and	O
TM4	O
cysteine	O
residues	O
in	O
CD9	O
dimerization	O
After	O
identifying	O
the	O
roles	O
of	O
conserved	O
TM1	O
and	O
TM2	O
residues	O
in	O
CD9	O
dimerization	O
,	O
we	O
next	O
probed	O
whether	O
residues	O
proximal	O
to	O
TM	O
domains	O
3	O
and	O
4	O
are	O
also	O
involved	O
.	O

To	O
this	O
end	O
,	O
disulfide	O
cross	O
-	O
linking	O
of	O
full	O
-	O
length	O
CD9	O
molecules	O
containing	O
3	O
C	O
-	O
terminal	O
cysteines	O
(	O
87	O
,	O
just	O
before	O
TM3	O
;	O
218	O
and	O
219	O
in	O
TM4	O
)	O
or	O
3	O
N	O
-	O
terminal	O
cysteines	O
(	O
9	O
,	O
78	O
and	O
79	O
)	O
was	O
compared	O
(	O
Figure	O
9	O
)	O
.	O

We	O
found	O
that	O
the	O
C	O
-	O
terminal	O
cysteines	O
were	O
only	O
slightly	O
better	O
than	O
N	O
-	O
terminal	O
cysteines	O
with	O
respect	O
to	O
detection	O
of	O
CD9	O
dimers	O
.	O

However	O
,	O
markedly	O
more	O
trimers	O
and	O
tetramers	O
were	O
detected	O
using	O
C	O
-	O
terminal	O
cysteines	O
.	O

Thus	O
,	O
residues	O
87	O
,	O
218	O
and	O
219	O
at	O
TM3	O
and	O
TM4	O
in	O
CD9	O
can	O
together	O
form	O
contacts	O
across	O
the	O
dimeric	O
interface	O
and	O
also	O
additional	O
contacts	O
with	O
other	O
neighboring	O
CD9	O
molecules	O
.	O

Discussion	O
Here	O
we	O
provide	O
the	O
first	O
detailed	O
analysis	O
of	O
tetraspanin	O
protein	O
transmembrane	O
domains	O
.	O

First	O
,	O
we	O
show	O
1	O
)	O
the	O
presence	O
of	O
a	O
heptad	O
repeat	O
motif	O
in	O
TM1	O
and	O
TM2	O
,	O
containing	O
highly	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
,	O
2	O
)	O
a	O
leucine	O
and	O
glutamate	O
/	O
glutamine	O
-	O
containing	O
heptad	O
motif	O
in	O
TM3	O
,	O
and	O
3	O
)	O
high	O
variability	O
and	O
absence	O
of	O
heptad	O
repeats	O
in	O
TM4	O
sequences	O
.	O

Second	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
specific	O
,	O
intramolecular	O
interaction	O
between	O
TM1	O
and	O
TM2	O
domains	O
,	O
in	O
which	O
bulky	O
hydrophobic	O
residues	O
pack	O
against	O
GG7	O
motif	O
,	O
and	O
present	O
a	O
molecular	O
model	O
for	O
this	O
interaction	O
.	O

Third	O
,	O
experimental	O
mapping	O
of	O
the	O
CD9	O
dimerization	O
interface	O
firmly	O
establishes	O
an	O
additional	O
role	O
for	O
conserved	O
TM1	O
and	O
TM2	O
residues	O
in	O
dimeric	O
intermolecular	O
interactions	O
.	O

Fourth	O
,	O
preliminary	O
evidence	O
is	O
provided	O
to	O
suggest	O
that	O
TM3	O
and	O
TM4	O
domains	O
contribute	O
to	O
expansion	O
of	O
CD9	O
dimers	O
into	O
higher	O
order	O
multimers	O
.	O

Conserved	O
residues	O
in	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
:	O
role	O
in	O
intramolecular	O
packing	O
We	O
hypothesized	O
that	O
the	O
first	O
two	O
transmembrane	O
domains	O
of	O
tetraspanins	O
might	O
interact	O
with	O
each	O
other	O
because	O
:	O
a	O
)	O
consecutive	O
TM	O
domains	O
frequently	O
associate	O
in	O
known	O
protein	O
3D	O
structures	O
[	O
35	O
]	O
,	O
and	O
b	O
)	O

they	O
both	O
contain	O
a	O
series	O
of	O
highly	O
conserved	O
amino	O
acids	O
–	O
several	O
Gly	O
residues	O
and	O
an	O
Asn	O
residue	O
(	O
Figure	O
1	O
)	O
.	O

Conserved	O
Gly	O
residues	O
are	O
a	O
frequent	O
theme	O
in	O
the	O
organization	O
of	O
interacting	O
transmembrane	O
domains	O
.	O

Analysis	O
of	O
3D	O
helix	O
packing	O
in	O
polytopic	O
membrane	O
proteins	O
reveals	O
that	O
Gly	O
residues	O
tend	O
to	O
localize	O
in	O
buried	O
positions	O
,	O
especially	O
at	O
the	O
helix	O
-	O
helix	O
interfaces	O
and	O
helix	O
crossing	O
points	O
[	O
37,38	O
]	O
.	O

Due	O
to	O
the	O
absence	O
of	O
a	O
side	O
chain	O
,	O
Gly	O
provides	O
a	O
flat	O
surface	O
for	O
packing	O
of	O
a	O
side	O
chain	O
from	O
another	O
residue	O
,	O
without	O
loss	O
of	O
side	O
-	O
chain	O
entropy	O
upon	O
interaction	O
.	O

The	O
most	O
common	O
Gly	O
-	O
containing	O
motif	O
is	O
GxxxG	O
[	O
39,40	O
]	O
.	O

In	O
glycophorin	O
A	O
(	O
GpA	O
)	O
,	O
the	O
major	O
glycoprotein	O
in	O
erythrocyte	O
cell	O
membranes	O
,	O
Gly79	O
and	O
Gly83	O
are	O
part	O
of	O
the	O
LIxxGVxxGVxxT	O
sequence	O
that	O
promotes	O
homodimerization	O
of	O
parallel	O
transmembrane	O
α	O
-	O
helixes	O
[	O
41,42	O
]	O
.	O

In	O
the	O
GpA	O
dimerization	O
motif	O
,	O
Gly	O
residues	O
allow	O
for	O
tight	O
packing	O
in	O
the	O
right	O
-	O
handed	O
helical	O
crossing	O
[	O
43	O
]	O
.	O

There	O
are	O
also	O
examples	O
of	O
left	O
-	O
handed	O
helical	O
crossing	O
in	O
the	O
context	O
of	O
a	O
GxxxG	O
motif	O
[	O
44	O
]	O
.	O

Other	O
membrane	O
proteins	O
that	O
use	O
the	O
GxxxG	O
motif	O
for	O
homo-	O
or	O
heterodimerization	O
include	O
bacteriophage	B
M13	I
coat	O
proteins	O
[	O
45	O
]	O
,	O
yeast	B
alpha	O
factor	O
receptor	O
[	O
46	O
]	O
,	O
integrin	O
α	O
IIb	O
subunit	O
[	O
47	O
]	O
,	O
and	O
ErbB1	O
receptor	O
tyrosine	O
kinase	O
[	O
48	O
]	O
.	O

Other	O
small	O
residues	O
,	O
such	O
as	O
Ala	O
and	O
Ser	O
,	O
can	O
substitute	O
for	O
Gly	O
in	O
this	O
motif	O
[	O
49	O
]	O
.	O

A	O
protein	O
motif	O
in	O
which	O
Gly	O
residues	O
are	O
separated	O
by	O
6	O
other	O
residues	O
(	O
GG7	O
)	O
is	O
also	O
common	O
in	O
transmembrane	O
helices	O
,	O
especially	O
in	O
transporter	O
/	O
channel	O
-	O
like	O
membrane	O
proteins	O
[	O
50	O
]	O
.	O

However	O
,	O
the	O
structural	O
features	O
associated	O
with	O
this	O
motif	O
are	O
not	O
well	O
known	O
.	O

In	O
particular	O
,	O
it	O
is	O
unclear	O
whether	O
left	O
-	O
handed	O
GG7	O
heptad	O
repeat	O
motif	O
(	O
as	O
opposed	O
to	O
the	O
""""	O
classic	O
""""	O
right	O
-	O
handed	O
GxxxG	O
motif	O
)	O
can	O
drive	O
membrane	O
helix	O
association	O
.	O

In	O
a	O
recent	O
work	O
addressing	O
this	O
issue	O
,	O
Lear	O
et	O
al.	O
[	O
51	O
]	O
showed	O
that	O
a	O
synthetic	O
peptide	O
containing	O
Gly	O
at	O
heptad	O
positions	O
a	O
and	O
d	O
could	O
self	O
-	O
associate	O
in	O
vitro	O
,	O
likely	O
in	O
an	O
antiparallel	O
orientation	O
.	O

Heptad	O
repeats	O
containing	O
conserved	O
Gly	O
residues	O
occur	O
in	O
TM	O
domains	O
of	O
α	O
and	O
β	O
chains	O
of	O
MHC	O
class	O
II	O
proteins	O
,	O
and	O
mutations	O
of	O
the	O
Gly	O
residues	O
disrupt	O
the	O
αβ	O
heterodimer	O
[	O
52	O
]	O
.	O

These	O
examples	O
demonstrate	O
that	O
Gly	O
-	O
based	O
heptad	O
motifs	O
may	O
be	O
used	O
for	O
both	O
intra-	O
and	O
intermolecular	O
associations	O
.	O

In	O
this	O
work	O
,	O
we	O
identified	O
a	O
highly	O
conserved	O
GG7	O
motif	O
in	O
the	O
first	O
two	O
tetraspanin	O
TM	O
domains	O
.	O

The	O
GG7	O
sequence	O
in	O
tetraspanins	O
is	O
a	O
part	O
of	O
a	O
larger	O
motif	O
that	O
also	O
includes	O
a	O
conserved	O
Asn	O
residue	O
in	O
TM1	O
(	O
NGG7	O
)	O
and	O
an	O
Ala	O
/	O
Ser	O
/	O
Thr	O
residue	O
in	O
TM2	O
(	O
GGA7	O
)	O
.	O

The	O
seven	O
-	O
residue	O
periodicity	O
of	O
these	O
motifs	O
strongly	O
suggests	O
their	O
involvement	O
in	O
left	O
-	O
handed	O
coiled	O
coil	O
packing	O
reminiscent	O
of	O
the	O
leucine	O
zipper	O
,	O
rather	O
than	O
right	O
-	O
handed	O
packing	O
of	O
the	O
GpA	O
-	O
like	O
GxxxG	O
motif	O
.	O

For	O
antiparallel	O
helices	O
,	O
the	O
left	O
-	O
handed	O
crossing	O
is	O
in	O
fact	O
predominant	O
over	O
the	O
right	O
-	O
handed	O
in	O
known	O
TM	O
domain	O
structures	O
[	O
44	O
]	O
.	O

In	O
our	O
model	O
,	O
heptad	O
Gly	O
residues	O
in	O
NGG7	O
and	O
GGA7	O
sequences	O
provide	O
specific	O
packing	O
between	O
antiparallel	O
tetraspanin	O
TM1	O
and	O
TM2	O
helices	O
by	O
allowing	O
tight	O
van	O
der	O
Waals	O
interactions	O
with	O
large	O
hydrophobic	O
residues	O
(	O
Figure	O
6	O
)	O
.	O

Highly	O
efficient	O
packing	O
of	O
bulky	O
side	O
chains	O
against	O
glycine	O
residues	O
is	O
observed	O
in	O
known	O
transmembrane	O
protein	O
3D	O
structures	O
[	O
38,53,54	O
]	O
.	O

An	O
example	O
includes	O
packing	O
of	O
helices	O
M1	O
and	O
M2	O
in	O
potassium	O
channel	O
KcsA	O
,	O
where	O
Val91	O
in	O
M2	O
is	O
paired	O
with	O
Gly43	O
in	O
M1	O
,	O
and	O
Leu36	O
in	O
M1	O
contacts	O
Ala98	O
and	O
Gly99	O
in	O
helix	O
M2	O
[	O
54,55	O
]	O
.	O

In	O
addition	O
to	O
facilitating	O
helix	O
-	O
helix	O
packing	O
,	O
Gly	O
residues	O
frequently	O
provide	O
additional	O
CαH	O
...	O

O	O
hydrogen	O
bonds	O
between	O
two	O
helices	O
[	O
44	O
]	O
.	O

In	O
our	O
model	O
,	O
two	O
Cα	O
-	O
backbone	O
carbonyl	O
H	O
-	O
bonds	O
are	O
predicted	O
–	O
between	O
residues	O
Gly27-Gly67	O
,	O
and	O
Trp22-Met70	O
.	O

Although	O
polar	O
and	O
charged	O
amino	O
acid	O
residues	O
(	O
such	O
as	O
Asn	O
in	O
the	O
TM1	O
heptad	O
motif	O
)	O
are	O
infrequent	O
in	O
transmembrane	O
domains	O
,	O
they	O
are	O
functionally	O
important	O
.	O

Polar	O
residues	O
such	O
as	O
glutamine	O
,	O
glutamic	O
acid	O
,	O
aspartic	O
acid	O
and	O
asparagine	O
can	O
promote	O
strong	O
oligomerization	O
of	O
model	O
membrane	O
-	O
associated	O
helices	O
[	O
56	O
-	O
58	O
]	O
.	O

Ruan	O
et	O
al.	O
[	O
59	O
]	O
used	O
asparagine	O
scanning	O
mutagenesis	O
to	O
probe	O
the	O
interface	O
of	O
self	O
-	O
associating	O
polyleucine	O
helices	O
by	O
detecting	O
their	O
enhanced	O
self	O
-	O
interaction	O
in	O
vitro	O
and	O
in	O
the	O
E.	B
coli	I
-	O
based	O
ToxR	O
assay	O
.	O

Thus	O
,	O
a	O
hydrogen	O
bond	O
in	O
an	O
apolar	O
environment	O
can	O
result	O
in	O
strong	O
,	O
though	O
not	O
necessarily	O
specific	O
,	O
association	O
of	O
transmembrane	O
helices	O
.	O

In	O
fact	O
,	O
mutations	O
to	O
polar	O
residues	O
in	O
transmembrane	O
proteins	O
are	O
commonly	O
associated	O
with	O
disease	O
[	O
60	O
]	O
.	O

Because	O
of	O
this	O
potential	O
for	O
non	O
-	O
specific	O
interactions	O
,	O
polar	O
residues	O
tend	O
to	O
localize	O
at	O
buried	O
positions	O
in	O
TM	O
domains	O
.	O

In	O
our	O
case	O
,	O
the	O
conserved	O
Asn18	O
residue	O
in	O
CD9	O
is	O
predicted	O
to	O
be	O
a	O
part	O
of	O
the	O
TM1-TM2	O
interface	O
,	O
though	O
our	O
model	O
does	O
not	O
predict	O
any	O
electrostatic	O
interaction	O
between	O
Asn18	O
and	O
TM2	O
(	O
Figure	O
6	O
)	O
.	O

Consistently	O
,	O
substitution	O
such	O
as	O
Asn18Tyr	O
(	O
and	O
Gly77Leu	O
)	O
in	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
protein	O
was	O
not	O
destabilizing	O
as	O
analyzed	O
by	O
protein	O
aggregation	O
.	O

Curiously	O
,	O
the	O
full	O
-	O
length	O
Asn18Ser	O
CD9	O
migrated	O
slightly	O
slower	O
on	O
SDS	O
-	O
PAGE	O
gel	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
Asn18	O
does	O
play	O
a	O
role	O
in	O
maintaining	O
conformation	O
of	O
the	O
molecule	O
.	O

The	O
Asn18Cys	O
single	O
-	O
cysteine	O
mutant	O
shows	O
very	O
little	O
intermolecular	O
cross	O
-	O
linking	O
(	O
Figure	O
7A	O
)	O
,	O
supporting	O
the	O
proposed	O
location	O
of	O
this	O
residue	O
at	O
the	O
intramolecular	O
interface	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
the	O
""""	O
pocket	O
""""	O
between	O
TM1	O
and	O
TM2	O
lined	O
by	O
Asn18	O
and	O
Gly77	O
might	O
be	O
important	O
for	O
accommodating	O
palmitate	O
moieties	O
that	O
target	O
Cys78	O
and	O
Cys79	O
residues	O
,	O
and/or	O
important	O
for	O
access	O
by	O
the	O
putative	O
palmitoyl	O
transferase	O
to	O
those	O
residues	O
.	O

Understanding	O
the	O
exact	O
role	O
of	O
these	O
highly	O
conserved	O
Asn18	O
and	O
Gly77	O
residues	O
in	O
tetraspanins	O
awaits	O
further	O
investigation	O
.	O

In	O
summary	O
,	O
we	O
identified	O
conserved	O
glycine	O
residues	O
of	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
as	O
key	O
elements	O
required	O
for	O
intramolecular	O
packing	O
.	O

Mutations	O
of	O
these	O
key	O
residues	O
(	O
Gly25	O
,	O
Gly32	O
,	O
Gly67	O
and	O
Gly74	O
in	O
CD9	O
)	O
resulted	O
in	O
protein	O
destabilization	O
and	O
aggregation	O
.	O

There	O
is	O
ample	O
evidence	O
in	O
the	O
literature	O
for	O
mutations	O
in	O
transmembrane	O
proteins	O
that	O
lead	O
to	O
protein	O
destabilization	O
,	O
misassembly	O
and	O
pathologic	O
conditions	O
[	O
61	O
]	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
conserved	O
heptad	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
as	O
plausible	O
targets	O
of	O
destabilizing	O
mutations	O
with	O
potential	O
functional	O
consequences	O
.	O

Intermolecular	O
interactions	O
in	O
tetraspanins	O
Tetraspanin	O
CD9	O
forms	O
mostly	O
homodimers	O
,	O
but	O
also	O
a	O
low	O
level	O
of	O
heterodimers	O
with	O
CD81	O
and	O
CD151	O
[	O
25	O
]	O
.	O

Thus	O
,	O
mapping	O
the	O
dimerization	O
interface	O
is	O
an	O
important	O
next	O
step	O
in	O
structure	O
-	O
function	O
analysis	O
of	O
tetraspanins	O
.	O

Disulfide	O
-	O
mediated	O
cross	O
-	O
linking	O
,	O
often	O
in	O
combination	O
with	O
cysteine	O
-	O
scanning	O
mutagenesis	O
,	O
is	O
a	O
common	O
strategy	O
to	O
probe	O
oligomerization	O
or	O
intersubunit	O
interactions	O
of	O
transmembrane	O
proteins	O
such	O
as	O
histidine	O
kinase	O
EnvZ	O
[	O
62	O
]	O
,	O
M	O
(	O
3	O
)	O
muscarinic	O
acetylcholine	O
receptor	O
[	O
63	O
]	O
,	O
E.	B
coli	I
lactose	O
permease	O
[	O
64	O
]	O
,	O
synaptobrevin	O
[	O
65	O
]	O
,	O
integrins	O
[	O
66	O
]	O
and	O
many	O
others	O
.	O

In	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
membrane	O
-	O
proximal	O
cysteine	O
residues	O
are	O
especially	O
useful	O
targets	O
for	O
disulfide	O
trapping	O
,	O
as	O
their	O
linkage	O
can	O
be	O
enhanced	O
by	O
pre	O
-	O
treating	O
cells	O
with	O
2-BP	O
.	O

While	O
the	O
ability	O
of	O
wild	O
-	O
type	O
cysteines	O
in	O
CD9	O
to	O
be	O
cross	O
-	O
linked	O
may	O
indicate	O
that	O
they	O
are	O
close	O
to	O
the	O
dimerization	O
interface	O
,	O
more	O
precise	O
mapping	O
was	O
achieved	O
here	O
using	O
cysteine	O
-	O
scanning	O
mutagenesis	O
.	O

Our	O
data	O
clearly	O
identify	O
regions	O
,	O
near	O
the	O
cytoplasmic	O
face	O
of	O
TM1	O
and	O
TM2	O
,	O
important	O
for	O
dimerization	O
.	O

Intermolecular	O
zero	O
-	O
length	O
cross	O
-	O
linking	O
was	O
highest	O
when	O
single	O
cysteines	O
were	O
placed	O
in	O
positions	O
14	O
,	O
17	O
,	O
77	O
,	O
80	O
and	O
81	O
in	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
molecule	O
,	O
or	O
at	O
positions	O
77	O
,	O
80	O
or	O
81	O
in	O
the	O
full	O
-	O
length	O
CD9	O
protein	O
.	O

Positions	O
14	O
,	O
17	O
and	O
80	O
are	O
distinct	O
from	O
the	O
intramolecular	O
interface	O
and	O
are	O
on	O
the	O
same	O
side	O
of	O
the	O
TM1-TM2	O
pair	O
(	O
Figure	O
6	O
)	O
.	O

Thus	O
,	O
they	O
are	O
well	O
-	O
positioned	O
to	O
participate	O
in	O
an	O
interaction	O
with	O
another	O
molecule	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
model	O
predicts	O
that	O
wild	O
-	O
type	O
cysteines	O
(	O
Cys78	O
,	O
79	O
)	O
,	O
which	O
do	O
not	O
yield	O
very	O
efficient	O
zero	O
-	O
length	O
cross	O
-	O
linking	O
,	O
are	O
on	O
the	O
other	O
side	O
of	O
TM1-TM2	O
pair	O
.	O

While	O
using	O
the	O
cysteine	O
at	O
position	O
80	O
as	O
the	O
dimeric	O
interface	O
probe	O
,	O
mutations	O
of	O
conserved	O
residues	O
in	O
TM1	O
and	O
TM2	O
(	O
especially	O
Gly32	O
and	O
Gly67	O
to	O
Leu	O
)	O
clearly	O
reduced	O
intermolecular	O
cross	O
-	O
linking	O
.	O

We	O
do	O
not	O
suggest	O
that	O
those	O
residues	O
are	O
directly	O
involved	O
in	O
intermolecular	O
interaction	O
.	O

Rather	O
,	O
we	O
propose	O
that	O
destabilization	O
of	O
the	O
intramolecular	O
TM1-TM2	O
interaction	O
by	O
Gly	O
to	O
Leu	O
substitutions	O
(	O
discussed	O
above	O
)	O
causes	O
an	O
overall	O
conformational	O
change	O
that	O
reduces	O
dimer	O
formation	O
.	O

An	O
Ala81Leu	O
mutation	O
did	O
not	O
reduce	O
cross	O
-	O
linking	O
via	O
Cys80	O
,	O
even	O
though	O
single	O
-	O
cysteine	O
Ala81Cys	O
molecules	O
themselves	O
produced	O
a	O
high	O
level	O
of	O
cross	O
-	O
linking	O
.	O

These	O
results	O
,	O
together	O
with	O
data	O
on	O
Gly32Leu	O
and	O
Gly67Leu	O
mutations	O
,	O
are	O
consistent	O
with	O
our	O
model	O
predicting	O
that	O
helices	O
1	O
and	O
2	O
interact	O
more	O
tightly	O
near	O
the	O
extracellular	O
end	O
and	O
less	O
at	O
the	O
cytoplasmic	O
end	O
.	O

This	O
would	O
give	O
more	O
flexibility	O
to	O
a	O
cysteine	O
at	O
position	O
81	O
and	O
also	O
limit	O
the	O
effect	O
of	O
an	O
Ala81Leu	O
mutation	O
.	O

Location	O
of	O
this	O
residue	O
at	O
the	O
membrane	O
/	O
cytoplasmic	O
border	O
could	O
also	O
make	O
it	O
more	O
accessible	O
to	O
CuP	O
reagent	O
as	O
compared	O
to	O
residues	O
buried	O
in	O
TM	O
domain	O
,	O
thus	O
elevating	O
the	O
efficiency	O
of	O
disulfide	O
formation	O
of	O
the	O
Ala81Cys	O
mutant	O
.	O

Multiple	O
interfaces	O
in	O
tetraspanin	O
molecules	O
In	O
the	O
full	O
-	O
length	O
CD9	O
molecules	O
,	O
the	O
3	O
C	O
-	O
terminal	O
cysteines	O
(	O
Cys87	O
,	O
218	O
and	O
219	O
)	O
located	O
at	O
or	O
in	O
TM3	O
and	O
TM4	O
promoted	O
efficient	O
dimer	O
and	O
even	O
more	O
efficient	O
oligomer	O
formation	O
compared	O
to	O
the	O
3	O
N	O
-	O
terminal	O
cysteines	O
(	O
Figure	O
9	O
)	O
.	O

Cys87	O
alone	O
can	O
be	O
used	O
to	O
capture	O
CD9	O
dimers	O
[	O
25	O
]	O
.	O

These	O
results	O
suggest	O
the	O
existence	O
of	O
two	O
dimeric	O
interfaces	O
in	O
CD9	O
molecule	O
–	O
the	O
TM	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
and	O
the	O
TM	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
interface	O
(	O
Figure	O
10	O
)	O
.	O

In	O
a	O
TM	O
(	O
1	O
+	O
2	O
)	O
molecule	O
,	O
the	O
destabilization	O
of	O
1–2	O
interaction	O
,	O
e.g.	O
by	O
Gly→Leu	O
mutations	O
,	O
would	O
affect	O
the	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
,	O
as	O
discussed	O
above	O
.	O

However	O
,	O
these	O
mutations	O
would	O
not	O
interfere	O
with	O
the	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
interface	O
in	O
a	O
full	O
-	O
length	O
molecule	O
,	O
which	O
includes	O
Cys87	O
,	O
218	O
and	O
219	O
.	O

Thus	O
,	O
cross	O
-	O
linking	O
of	O
full	O
-	O
length	O
molecules	O
,	O
containing	O
all	O
6	O
cysteine	O
residues	O
,	O
would	O
be	O
unaffected	O
,	O
as	O
seen	O
in	O
Figure	O
8C	O
.	O

Furthermore	O
,	O
wild	O
-	O
type	O
Cys9	O
,	O
Cys78	O
and	O
Cys79	O
are	O
apparently	O
not	O
at	O
the	O
primary	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
.	O

Their	O
relative	O
inefficiency	O
in	O
cross	O
-	O
linking	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
protein	O
likely	O
reflects	O
weak	O
secondary	O
contacts	O
between	O
the	O
molecules	O
,	O
or	O
possibly	O
random	O
collision	O
events	O
.	O

Such	O
events	O
should	O
be	O
independent	O
of	O
mutations	O
in	O
the	O
conserved	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
,	O
as	O
was	O
demonstrated	O
in	O
Figure	O
8B	O
.	O

The	O
potential	O
existence	O
of	O
two	O
interfaces	O
in	O
tetraspanin	O
molecules	O
,	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
and	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
,	O
should	O
provide	O
enhanced	O
flexibility	O
for	O
forming	O
additional	O
intermolecular	O
contacts	O
.	O

Current	O
understanding	O
of	O
tetraspanin	O
microdomains	O
assumes	O
a	O
few	O
strong	O
,	O
primary	O
homotypic	O
and	O
heterotypic	O
tetraspanin	O
complexes	O
(	O
e.g.	O
CD9-CD9	O
,	O
CD9-CD81	O
,	O
CD151-α3	O
integrin	O
,	O
CD81-EWI2	O
)	O
that	O
help	O
bring	O
together	O
various	O
other	O
proteins	O
,	O
forming	O
secondary	O
-	O
type	O
associations	O
.	O

Such	O
properties	O
of	O
tetraspanins	O
may	O
bring	O
signaling	O
molecules	O
such	O
as	O
protein	O
kinase	O
C	O
or	O
phosphatidylinositol	O
4-kinase	O
to	O
the	O
vicinity	O
of	O
integrins	O
[	O
67,68	O
]	O
.	O

The	O
organization	O
of	O
the	O
TM3	O
domain	O
points	O
to	O
a	O
potential	O
role	O
in	O
protein	O
-	O
protein	O
interactions	O
.	O

A	O
motif	O
of	O
Leu	O
-	O
Leu	O
-	O
Glu	O
(	O
Gln	O
)	O
spaced	O
7	O
residues	O
apart	O
(	O
heptad	O
positions	O
a	O
)	O
,	O
with	O
highly	O
conserved	O
residues	O
in	O
two	O
consecutive	O
positions	O
d	O
,	O
poses	O
as	O
a	O
likely	O
interaction	O
module	O
.	O

If	O
responsible	O
for	O
heterologous	O
protein	O
-	O
protein	O
interactions	O
,	O
it	O
would	O
form	O
another	O
distinct	O
interface	O
of	O
tetraspanin	O
molecule	O
.	O

Our	O
preliminary	O
data	O
indicate	O
that	O
replacing	O
the	O
Leu	O
and	O
Glu	O
residues	O
in	O
TM3	O
of	O
CD9	O
with	O
Ala	O
has	O
no	O
effect	O
on	O
cell	O
surface	O
expression	O
of	O
the	O
protein	O
and	O
its	O
dimerization	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
remains	O
to	O
be	O
tested	O
if	O
interactions	O
with	O
other	O
proteins	O
will	O
be	O
affected	O
.	O

Similarly	O
,	O
the	O
TM4	O
domain	O
may	O
provide	O
additional	O
contributions	O
to	O
lateral	O
tetraspanin	O
associations	O
.	O

Much	O
higher	O
sequence	O
variability	O
,	O
and	O
the	O
lack	O
of	O
a	O
distinct	O
heptad	O
pattern	O
suggests	O
that	O
TM4	O
is	O
a	O
major	O
contributor	O
to	O
diversity	O
among	O
tetraspanin	O
complexes	O
.	O

Structure	O
-	O
function	O
analysis	O
of	O
TM3	O
and	O
TM4	O
domains	O
in	O
tetraspanins	O
is	O
the	O
subject	O
of	O
ongoing	O
investigation	O
.	O

Conclusion	O
We	O
have	O
defined	O
the	O
TM1-TM2	O
intramolecular	O
interface	O
in	O
tetraspanin	O
CD9	O
,	O
providing	O
evidence	O
for	O
glycines	O
(	O
Gly25	O
and	O
Gly32	O
in	O
TM1	O
,	O
Gly67	O
and	O
Gly74	O
in	O
TM2	O
)	O
packing	O
against	O
apposing	O
bulky	O
aliphatic	O
residues	O
.	O

Second	O
,	O
we	O
mapped	O
an	O
intermolecular	O
CD9	O
interface	O
(	O
involved	O
in	O
CD9	O
homodimer	O
formation	O
)	O
to	O
the	O
vicinity	O
of	O
residues	O
Leu14	O
and	O
Phe17	O
in	O
TM1	O
and	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
.	O

Finally	O
,	O
we	O
provide	O
preliminary	O
evidence	O
that	O
TM3	O
and	O
TM4	O
in	O
CD9	O
may	O
contribute	O
to	O
a	O
second	O
intermolecular	O
interface	O
.	O

Key	O
CD9	O
residues	O
involved	O
in	O
intra-	O
and	O
intermolecular	O
interactions	O
are	O
highly	O
conserved	O
throughout	O
the	O
tetraspanin	O
family	O
,	O
thus	O
suggesting	O
that	O
our	O
findings	O
will	O
apply	O
to	O
most	O
tetraspanins	O
.	O

Methods	O
Materials	O
Cell	O
culture	O
reagents	O
were	O
from	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O

2-bromopalmitate	O
was	O
from	O
Fluka	O
(	O
Milwaukee	O
,	O
WI	O
)	O
,	O
N	O
-	O
ethylmaleimide	O
(	O
NEM	O
)	O
and	O
1,10-phenanthroline	O
were	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
,	O
and	O
chemical	O
cross	O
-	O
linkers	O
dithio	O
-	O
bis	O
-	O
maleimidoethane	O
(	O
DTME	O
)	O
and	O
1,4-Bis	O
-	O
maleimidobutane	O
(	O
BMB	O
)	O
were	O
purchased	O
from	O
Pierce	O
Endogen	O
(	O
Rockford	O
,	O
IL	O
)	O
.	O

Triton	O
X-100	O
,	O
protease	O
inhibitor	O
cocktail	O
and	O
FuGENE	O
6	O
transfection	O
reagent	O
were	O
obtained	O
from	O
Roche	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

Restriction	O
endonucleases	O
and	O
Pfu	O
DNA	O
polymerase	O
were	O
obtained	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
and	O
Stratagene	O
(	O
Carlsbad	O
,	O
CA	O
)	O
,	O
respectively	O
.	O

All	O
other	O
chemicals	O
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
or	O
Fisher	O
Scientific	O
(	O
Pittsburg	O
,	O
PA	O
)	O
.	O

Sequence	O
analysis	O
Tetraspanin	O
sequences	O
were	O
obtained	O
from	O
SWISS	O
-	O
PROT	O
and	O
GenBank	O
databases	O
.	O

Locus	O
designations	O
,	O
accession	O
numbers	O
and	O
the	O
most	O
commonly	O
used	O
protein	O
names	O
are	O
summarized	O
in	O
Tables	O
1	O
and	O
2	O
.	O

TM	O
segments	O
were	O
delineated	O
by	O
inspection	O
of	O
hydrophobicity	O
profiles	O
,	O
using	O
database	O
annotations	O
and	O
previous	O
analyses	O
of	O
TM	O
sequences	O
as	O
a	O
guide	O
(	O
[	O
28	O
]	O
,	O
M.	O
Hemler	O
,	O
unpublished	O
)	O
,	O
and	O
aligned	O
manually	O
.	O

Residue	O
numbers	O
in	O
human	B
CD9	O
sequence	O
are	O
used	O
a	O
reference	O
point	O
throughout	O
the	O
study	O
.	O

DNA	O
cloning	O
and	O
mutagenesis	O
Sequence	O
encoding	O
CD9	O
protein	O
was	O
cloned	O
into	O
vector	O
pcDNA3	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
and	O
pEGFP	O
-	O
N1	O
(	O
Clontech	O
,	O
Palo	O
Alto	O
,	O
CA	O
)	O
,	O
for	O
expression	O
of	O
untagged	O
and	O
C	O
-	O
terminally	O
GFP	O
-	O
tagged	O
CD9	O
,	O
respectively	O
.	O

pEGFP	O
-	O
N1	O
encoding	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
fusion	O
protein	O
was	O
constructed	O
by	O
subcloning	O
DNA	O
for	O
residues	O
1–83	O
of	O
CD9	O
into	O
HindIII	O
and	O
PstI	O
sites	O
of	O
the	O
vector	O
;	O
to	O
introduce	O
the	O
PstI	O
site	O
,	O
codon	O
GTG	O
for	O
Val82	O
was	O
changed	O
to	O
CTG	O
(	O
coding	O
for	O
Ala	O
)	O
.	O

In	O
the	O
resulting	O
fusion	O
protein	O
,	O
there	O
is	O
a	O
13-amino	O
acid	O
linker	O
(	O
with	O
no	O
cysteines	O
)	O
between	O
CD9	O
and	O
GFP	O
.	O

To	O
minimize	O
the	O
low	O
inherent	O
ability	O
of	O
GFP	O
to	O
homodimerize	O
,	O
which	O
could	O
potentially	O
influence	O
the	O
results	O
of	O
CD9	O
cross	O
-	O
linking	O
,	O
we	O
used	O
a	O
monomeric	O
GFP	O
mutant	O
,	O
Leu221→Lys	O
[	O
34	O
]	O
,	O
for	O
cross	O
-	O
linking	O
experiments	O
.	O

Mutations	O
were	O
introduced	O
in	O
full	O
-	O
length	O
and	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
proteins	O
by	O
a	O
PCR	O
-	O
based	O
strategy	O
using	O
mutagenic	O
primers	O
and	O
Pfu	O
DNA	O
polymerase	O
.	O

All	O
mutations	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Protein	O
expression	O
,	O
microscopy	O
,	O
cysteine	O
disulfide	O
cross	O
-	O
linking	O
and	O
Western	O
blotting	O
DNA	O
constructs	O
encoding	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
or	O
full	O
-	O
length	O
CD9	O
proteins	O
were	O
transfected	O
into	O
human	B
rhabdomyosarcoma	O
RD	O
cells	O
using	O
the	O
FuGENE	O
6	O
reagent	O
.	O

Cells	O
expressing	O
GFP	O
fusion	O
proteins	O
were	O
analysed	O
by	O
fluorescence	O
microscopy	O
18–28	O
hours	O
post	O
-	O
transfection	O
.	O

Images	O
were	O
captured	O
using	O
Spot	O
1.4.0	O
camera	O
(	O
Diagnostic	O
Instruments	O
,	O
Sterling	O
Heights	O
,	O
MI	O
)	O
attached	O
to	O
Nikon	O
Eclipse	O
TE300	O
microscope	O
.	O

For	O
experiments	O
involving	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
,	O
cells	O
were	O
treated	O
with	O
50	O
μM	O
2-BP	O
starting	O
24–26	O
hours	O
post	O
-	O
transfection	O
and	O
continuing	O
for	O
16–18	O
hours	O
.	O

Cross	O
-	O
linking	O
was	O
carried	O
out	O
by	O
incubating	O
cells	O
in	O
HBSM	O
buffer	O
(	O
25	O
mM	O
Hepes	O
-	O
NaOH	O
,	O
pH	O
7.2	O
,	O
150	O
mM	O
NaCl	O
,	O
2	O
mM	O
MgCl2	O
)	O
containing	O
either	O
a	O
)	O
0.6	O
mM	O
CuSO4	O
and	O
1.8	O
mM	O
1,10-phenanthroline	O
(	O
CuP	O
complex	O
)	O
or	O
b	O
)	O
0.2	O
mg	O
/	O
ml	O
homobifunctional	O
cysteine	O
-	O
reactive	O
cross	O
-	O
linker	O
(	O
e.g.	O
DTME	O
)	O
,	O
diluted	O
from	O
fresh	O
10	O
mg	O
/	O
ml	O
solution	O
in	O
DMSO	O
.	O

After	O
incubation	O
for	O
10–15	O
minutes	O
(	O
with	O
CuP	O
)	O
or	O
30–45	O
minutes	O
(	O
with	O
cross	O
-	O
linker	O
)	O
,	O
cells	O
were	O
washed	O
twice	O
for	O
10	O
minutes	O
with	O
HBSM	O
containing	O
10	O
mM	O
NEM	O
to	O
block	O
residual	O
free	O
cysteines	O
.	O

Cells	O
were	O
lysed	O
in	O
HBSM	O
containing	O
1	O
%	O
Triton	O
X-100	O
,	O
0.1	O
%	O
SDS	O
and	O
a	O
cocktail	O
of	O
protease	O
inhibitors	O
with	O
1	O
mM	O
EDTA	O
at	O
4	O
°	O
C	O
for	O
45–60	O
minutes	O
.	O

Cell	O
lysate	O
was	O
clarified	O
by	O
centrifugation	O
at	O
14,000	O
×	O
g	O
for	O
15	O
minutes	O
,	O
an	O
aliquot	O
was	O
removed	O
,	O
and	O
proteins	O
from	O
it	O
were	O
precipitated	O
by	O
addition	O
of	O
trichloroacetic	O
acid	O
to	O
10	O
%	O
on	O
ice	O
followed	O
by	O
centrifugation	O
at	O
14,000	O
×	O
g	O
for	O
10	O
minutes	O
.	O

After	O
two	O
washes	O
with	O
ice	O
-	O
cold	O
acetone	O
,	O
protein	O
pellet	O
was	O
solubilized	O
in	O
SDS	O
-	O
PAGE	O
sample	O
buffer	O
without	O
a	O
reducing	O
agent	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
6.8	O
,	O
1	O
%	O
SDS	O
,	O
8	O
%	O
glycerol	O
)	O
.	O

In	O
some	O
experiments	O
,	O
CD9	O
protein	O
was	O
immunoprecipitated	O
using	O
monoclonal	O
antibody	O
Alb6	O
(	O
Immunotech	O
,	O
Marseille	O
,	O
France	O
)	O
.	O

Proteins	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
analyzed	O
by	O
Western	O
blotting	O
using	O
monoclonal	O
antibody	O
JL-8	O
(	O
Clontech	O
)	O
for	O
GFP	O
or	O
Alb6	O
for	O
CD9	O
.	O

Bands	O
from	O
X	O
-	O
ray	O
films	O
were	O
quantitated	O
using	O
GeneTools	O
™	O
software	O
from	O
Syngene	O
(	O
Frederick	O
,	O
MD	O
)	O
.	O

Modeling	O
of	O
TM1-TM2	O
interaction	O
An	O
atomic	O
model	O
of	O
the	O
CD9	O
TM1-TM2	O
dimer	O
was	O
constructed	O
with	O
a	O
Monte	O
Carlo	O
-	O
simulated	O
annealing	O
(	O
MCSA	O
)	O
algorithm	O
[	O
69	O
]	O
.	O

Two	O
idealized	O
α	O
-	O
helices	O
corresponding	O
to	O
TM1	O
residues	O
Tyr12	O
through	O
Leu35	O
and	O
TM2	O
residues	O
Gly59	O
through	O
Val82	O
were	O
docked	O
with	O
six	O
orthogonal	O
parameters	O
:	O
three	O
rigid	O
body	O
translations	O
and	O
three	O
rotations	O
.	O

During	O
each	O
step	O
of	O
a	O
MCSA	O
cycle	O
,	O
there	O
was	O
an	O
equal	O
probability	O
of	O
changing	O
either	O
one	O
parameter	O
or	O
all	O
six	O
parameters	O
to	O
random	O
values	O
.	O

A	O
conformation	O
's	O
energy	O
was	O
calculated	O
in	O
vacuo	O
with	O
the	O
AMBER	O
united	O
-	O
atom	O
force	O
field	O
for	O
van	O
der	O
Waals	O
interactions	O
[	O
70	O
]	O
.	O

The	O
van	O
der	O
Waals	O
term	O
was	O
modified	O
as	O
described	O
by	O
Kuhlman	O
and	O
Baker	O
[	O
71	O
]	O
.	O

If	O
a	O
structure	O
had	O
favorable	O
dimerization	O
energy	O
,	O
the	O
energies	O
of	O
select	O
mutants	O
were	O
calculated	O
.	O

Structures	O
were	O
selected	O
with	O
a	O
novel	O
scoring	O
function	O
that	O
maximizes	O
the	O
Boltzmann	O
probability	O
of	O
dimerization	O
for	O
silent	O
mutations	O
while	O
minimizing	O
the	O
probability	O
for	O
disruptive	O
mutations	O
.	O

Asn18Ser	O
,	O
Gly77Leu	O
,	O
and	O
Gly80Leu	O
were	O
scored	O
as	O
silent	O
mutations	O
while	O
Gly25Leu	O
,	O
Gly32Leu	O
,	O
Gly67Leu	O
,	O
and	O
Gly74Leu	O
were	O
considered	O
to	O
be	O
disruptive	O
.	O

Each	O
MCSA	O
cycle	O
consisted	O
of	O
50,000	O
steps	O
with	O
an	O
exponential	O
temperature	O
decay	O
from	O
10,000	O
to	O
10	O
K.	O
Ten	O
MCSA	O
cycles	O
through	O
global	O
sample	O
space	O
were	O
used	O
to	O
restrict	O
the	O
search	O
area	O
.	O

Parameters	O
were	O
restricted	O
to	O
±	O
2	O
standard	O
deviations	O
from	O
their	O
mean	O
value	O
for	O
structures	O
within	O
10	O
kcal	O
of	O
the	O
best	O
structure	O
.	O

MCSA	O
cycles	O
were	O
repeated	O
as	O
described	O
above	O
with	O
additional	O
optimization	O
of	O
χ	O
values	O
:	O
rotamers	O
at	O
the	O
protein	O
-	O
protein	O
interface	O
were	O
optimized	O
with	O
Dead	O
End	O
Elimination	O
[	O
72	O
]	O
,	O
and	O
χ	O
values	O
were	O
further	O
optimized	O
with	O
Monte	O
Carlo	O
.	O

All	O
MCSA	O
cycles	O
converged	O
upon	O
structures	O
that	O
were	O
within	O
a	O
root	O
mean	O
squared	O
deviation	O
(	O
RMSD	O
)	O
of	O
1.5	O
Å	O
with	O
the	O
best	O
structure	O
,	O
and	O
structures	O
that	O
scored	O
within	O
5	O
kcal	O
of	O
the	O
best	O
score	O
had	O
an	O
RMSD	O
of	O
less	O
than	O
0.5	O
Å	O
with	O
the	O
best	O
structure	O
.	O

List	O
of	O
abbreviations	O
2-BP	O
,	O
2-bromopalmitate	O
;	O
CuP	O
,	O
Cu2	O
+	O
-phenanthroline	O
;	O
DTME	O
,	O
dithio	O
-	O
bis	O
-	O
maleimidoethane	O
;	O
LEL	O
,	O
large	O
extracellular	O
loop	O
;	O
NEM	O
,	O
N	O
-	O
ethylmaleimide	O
;	O
TM	O
,	O
transmembrane	O
(	O
domain	O
)	O
.	O

Authors	O
'	O
contributions	O
OVK	O
carried	O
out	O
sequence	O
comparisons	O
,	O
mutational	O
analysis	O
and	O
cross	O
-	O
linking	O
experiments	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

DGM	O
built	O
the	O
TM1-TM2	O
interaction	O
model	O
and	O
contributed	O
to	O
the	O
manuscript	O
.	O

WFD	O
supervised	O
DGM	O
's	O
work	O
.	O

MEH	O
coordinated	O
the	O
whole	O
study	O
and	O
prepared	O
the	O
final	O
manuscript	O
.	O

Gender	O
differences	O
in	O
factors	O
influencing	O
insulin	O
resistance	O
in	O
elderly	O
hyperlipemic	O
non	O
-	O
diabetic	O
subjects	O
Abstract	O
Background	O
The	O
increase	O
in	O
the	O
prevalence	O
of	O
insulin	O
resistance	O
-	O
related	O
metabolic	O
syndrome	O
,	O
a	O
disorder	O
that	O
greatly	O
increases	O
the	O
risk	O
of	O
diabetes	O
,	O
heart	O
attack	O
and	O
stroke	O
,	O
is	O
alarming	O
.	O

One	O
of	O
the	O
most	O
frequent	O
and	O
early	O
symptoms	O
of	O
metabolic	O
syndrome	O
is	O
hypertriglyceridemia	O
.	O

We	O
examined	O
the	O
gender	O
differences	O
between	O
various	O
metabolic	O
factors	O
related	O
to	O
insulin	O
resistance	O
in	O
elderly	O
non	O
-	O
diabetic	O
men	O
and	O
postmenopausal	O
women	O
of	O
comparable	O
age	O
suffering	O
from	O
hypertriglyceridemia	O
,	O
and	O
compared	O
them	O
with	O
healthy	O
subjects	O
of	O
equal	O
age	O
.	O

Results	O
The	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
were	O
significantly	O
higher	O
in	O
both	O
hyperlipemic	O
men	O
and	O
women	O
than	O
in	O
controls	O
;	O
95	O
%	O
confidence	O
limits	O
of	O
hyperlipemic	O
subjects	O
did	O
not	O
overlap	O
with	O
controls	O
.	O

In	O
both	O
normolipemic	O
and	O
hyperlipemic	O
men	O
and	O
women	O
serum	O
leptin	O
correlated	O
significantly	O
with	O
insulin	O
resistance	O
,	O
while	O
HDL	O
-	O
cholesterol	O
correlated	O
inversely	O
with	O
HOMA	O
-	O
IR	O
only	O
in	O
women	O
(	O
both	O
normo-	O
and	O
hyperlipemic	O
)	O
,	O
and	O
serum	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
only	O
in	O
hyperlipemic	O
women	O
.	O

According	O
to	O
results	O
of	O
multiple	O
regression	O
analysis	O
with	O
HOMA	O
-	O
IR	O
as	O
a	O
dependent	O
variable	O
,	O
leptin	O
played	O
a	O
significant	O
role	O
in	O
determining	O
insulin	O
resistance	O
in	O
both	O
genders	O
,	O
but	O
–	O
aside	O
from	O
leptin	O
–	O
triglycerides	O
,	O
TNFα	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
were	O
significant	O
determinants	O
in	O
women	O
,	O
while	O
body	O
mass	O
index	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
were	O
significant	O
determinants	O
in	O
men	O
.	O

The	O
coefficient	O
of	O
determination	O
(	O
R2	O
)	O
of	O
HOMA	O
IR	O
by	O
above	O
mentioned	O
metabolic	O
variables	O
was	O
in	O
women	O
above	O
60	O
%	O
,	O
in	O
men	O
only	O
about	O
40	O
%	O
.	O

Conclusion	O
The	O
significant	O
role	O
of	O
serum	O
leptin	O
in	O
determination	O
of	O
insulin	O
resistance	O
in	O
both	O
elderly	O
men	O
and	O
postmenopausal	O
women	O
of	O
equal	O
age	O
was	O
confirmed	O
.	O

However	O
,	O
the	O
study	O
also	O
revealed	O
significant	O
gender	O
differences	O
:	O
in	O
women	O
a	O
strong	O
influence	O
of	O
triglycerides	O
,	O
TNFα	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
,	O
in	O
men	O
only	O
a	O
mild	O
role	O
of	O
BMI	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
.	O

Background	O
In	O
association	O
with	O
pandemic	O
obesity	O
the	O
prevalence	O
of	O
the	O
insulin	O
resistance	O
-	O
related	O
metabolic	O
syndrome	O
is	O
constantly	O
growing	O
[	O
1	O
]	O
.	O

As	O
a	O
consequence	O
of	O
this	O
fact	O
,	O
type	O
2	O
diabetes	O
mellitus	O
and	O
cardiovascular	O
mortality	O
occurs	O
in	O
much	O
younger	O
age	O
groups	O
[	O
2	O
]	O
.	O

A	O
typical	O
hyperlipemia	O
,	O
consisting	O
of	O
an	O
increase	O
of	O
serum	O
triglycerides	O
and	O
a	O
decrease	O
of	O
serum	O
HDL	O
-	O
cholesterol	O
,	O
is	O
a	O
characteristic	O
and	O
an	O
early	O
symptom	O
of	O
this	O
syndrome	O
[	O
3	O
]	O
.	O

With	O
increasing	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
adiposity	O
,	O
insulin	O
sensitivity	O
declines	O
and	O
the	O
number	O
of	O
cardiovascular	O
risk	O
factors	O
increases	O
in	O
both	O
genders	O
[	O
4	O
-	O
6	O
]	O
.	O

It	O
was	O
repeatedly	O
demonstrated	O
that	O
plasma	O
concentration	O
of	O
leptin	O
–	O
a	O
hormone	O
produced	O
mainly	O
by	O
adipose	O
tissue	O
–	O
is	O
substantially	O
higher	O
in	O
all	O
age	O
groups	O
of	O
women	O
than	O
in	O
men	O
[	O
7	O
-	O
10	O
]	O
.	O

This	O
may	O
be	O
caused	O
by	O
different	O
size	O
and/or	O
distribution	O
of	O
fat	O
tissue	O
compartments	O
influenced	O
by	O
hormones	O
:	O
estrogens	O
stimulate	O
,	O
whereas	O
testosterone	O
inhibits	O
leptin	O
secretion	O
.	O

In	O
women	O
subcutaneous	O
fat	O
mass	O
prevails	O
–	O
and	O
during	O
augmentation	O
of	O
overweight	O
it	O
increases	O
–	O
while	O
in	O
men	O
intra	O
-	O
abdominal	O
fat	O
mass	O
prevails	O
[	O
11	O
-	O
13	O
]	O
.	O

Subcutaneous	O
fat	O
in	O
particular	O
serves	O
as	O
a	O
substantial	O
source	O
of	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
,	O
which	O
represents	O
one	O
of	O
the	O
factors	O
that	O
interfere	O
with	O
insulin	O
signal	O
transduction	O
into	O
the	O
cells	O
[	O
14	O
-	O
16	O
]	O
.	O

Leptin	O
,	O
TNFα	O
and	O
some	O
other	O
factors	O
are	O
abundantly	O
expressed	O
in	O
adipose	O
tissue	O
and	O
contribute	O
to	O
the	O
insulin	O
resistance	O
that	O
accompanies	O
overweight	O
and	O
obesity	O
.	O

Leptin	O
correlates	O
positively	O
with	O
hyperinsulinemia	O
,	O
BMI	O
,	O
fat	O
mass	O
and	O
hypertriglyceridemia	O
,	O
respectively	O
,	O
and	O
correlates	O
inversely	O
with	O
HDL	O
-	O
cholesterol	O
and	O
lean	O
body	O
mass	O
[	O
17	O
-	O
25	O
]	O
.	O

The	O
incidence	O
and	O
mortality	O
of	O
ischemic	O
heart	O
disease	O
and	O
of	O
other	O
consequences	O
of	O
atherosclerosis	O
increases	O
with	O
age	O
in	O
both	O
genders	O
,	O
especially	O
after	O
the	O
age	O
of	O
sixty	O
.	O

In	O
premenopausal	O
women	O
,	O
however	O
,	O
the	O
incidence	O
of	O
these	O
disorders	O
is	O
considerably	O
less	O
frequent	O
than	O
in	O
men	O
of	O
appropriate	O
age	O
.	O

After	O
the	O
menopause	O
the	O
prevalence	O
of	O
metabolic	O
syndrome	O
and	O
cardiovascular	O
mortality	O
in	O
women	O
gradually	O
increases	O
,	O
attaining	O
values	O
comparable	O
to	O
men	O
at	O
about	O
the	O
age	O
of	O
70	O
[	O
2,26	O
]	O
.	O

Paradoxically	O
,	O
it	O
takes	O
place	O
at	O
the	O
time	O
when	O
serum	O
leptin	O
concentration	O
in	O
women	O
has	O
relatively	O
decreased	O
[	O
27,28	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
interrelations	O
between	O
several	O
metabolic	O
variables	O
and	O
factors	O
related	O
to	O
insulin	O
resistance	O
in	O
groups	O
of	O
both	O
normal	O
and	O
hyperlipemic	O
postmenopausal	O
women	O
and	O
men	O
of	O
appropriate	O
age	O
,	O
and	O
to	O
attempt	O
to	O
elucidate	O
the	O
gender	O
differences	O
and	O
some	O
pathophysiologic	O
mechanisms	O
of	O
these	O
differences	O
.	O

We	O
compared	O
homeostatic	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
,	O
serum	O
lipid	O
and	O
insulin	O
parameters	O
,	O
uric	O
acid	O
,	O
leptin	O
and	O
TNFα	O
between	O
groups	O
of	O
subjects	O
without	O
apparent	O
symptoms	O
of	O
metabolic	O
syndrome	O
,	O
and	O
groups	O
showing	O
mild	O
hypertriglyceridemia	O
with	O
decreased	O
HDL	O
-	O
cholesterol	O
.	O

In	O
addition	O
,	O
serum	O
concentration	O
of	O
the	O
heart	O
fraction	O
of	O
fatty	O
acid	O
binding	O
protein	O
(	O
hFATP	O
)	O
was	O
explored	O
as	O
a	O
factor	O
that	O
might	O
reflect	O
the	O
regulative	O
role	O
of	O
PPAR	O
gamma	O
in	O
lipid	O
homeostasis	O
[	O
29,30	O
]	O
,	O
and	O
serum	O
IgG	O
anticardiolipin	O
(	O
ACL	O
-	O
IgG	O
)	O
was	O
investigated	O
as	O
an	O
indirect	O
indicator	O
of	O
oxidized	O
lipid	O
fractions	O
related	O
to	O
atherosclerotic	O
complications	O
[	O
31,32	O
]	O
.	O

Methods	O
Subjects	O
The	O
study	O
was	O
carried	O
out	O
on	O
70	O
out	O
-	O
patients	O
of	O
the	O
Metabolic	O
Center	O
at	O
the	O
hospital	O
in	O
Sternberk	O
,	O
Czech	O
Republic	O
.	O

From	O
these	O
,	O
40	O
patients	O
(	O
20	O
men	O
and	O
20	O
women	O
)	O
were	O
selected	O
with	O
mild	O
hyperlipidemia	O
,	O
i.e.	O
with	O
plasma	O
triglyceride	O
concentration	O
exceeding	O
2.0	O
mmol	O
/	O
l	O
,	O
total	O
cholesterol	O
exceeding	O
6.0	O
mmol	O
/	O
l	O
,	O
LDL	O
cholesterol	O
exceeding	O
4.0	O
mmol	O
/	O
l	O
,	O
and	O
with	O
HDL	O
cholesterol	O
concentration	O
in	O
men	O
under	O
1.0	O
mmol	O
/	O
l	O
,	O
and	O
in	O
women	O
under	O
1.2	O
mmol	O
/	O
l	O
.	O

These	O
groups	O
were	O
denominated	O
as	O
""""	O
hyperlipemic	O
""""	O
.	O

Two	O
other	O
groups	O
(	O
10	O
men	O
and	O
20	O
women	O
)	O
with	O
approximately	O
normal	O
serum	O
values	O
of	O
these	O
variables	O
were	O
taken	O
as	O
""""	O
controls	O
""""	O
.	O

The	O
average	O
age	O
in	O
men	O
was	O
59.1	O
±	O
10.6	O
y	O
,	O
and	O
in	O
women	O
59.4	O
±	O
10.1	O
y	O
,	O
respectively	O
.	O

The	O
differences	O
between	O
lipid	O
parameters	O
of	O
hyperlipemic	O
and	O
control	O
groups	O
were	O
highly	O
statistically	O
significant	O
,	O
while	O
the	O
age	O
differences	O
were	O
insignificant	O
(	O
see	O
Table	O
1	O
)	O
.	O

None	O
of	O
the	O
patients	O
had	O
clinically	O
apparent	O
diabetes	O
mellitus	O
,	O
but	O
some	O
of	O
the	O
hyperlipemic	O
patients	O
exerted	O
impaired	O
glucose	O
tolerance	O
or	O
impaired	O
fasting	O
glucose	O
(	O
values	O
between	O
6.1	O
and	O
7.0	O
mmol	O
/	O
l	O
,	O
or	O
between	O
6.1	O
and	O
7.8	O
mmol	O
/	O
l	O
,	O
respectively	O
)	O
.	O

None	O
of	O
the	O
patients	O
was	O
treated	O
with	O
insulin	O
,	O
peroral	O
antidiabetics	O
or	O
antihyperlipemic	O
drugs	O
;	O
some	O
of	O
them	O
were	O
treated	O
with	O
antihypertensive	O
therapy	O
.	O

No	O
signs	O
of	O
major	O
clinical	O
or	O
laboratory	O
symptoms	O
of	O
other	O
diseases	O
were	O
present	O
in	O
any	O
group	O
of	O
the	O
explored	O
patients	O
.	O

Blood	O
samples	O
were	O
obtained	O
in	O
the	O
morning	O
via	O
a	O
venipuncture	O
after	O
overnight	O
fasting	O
.	O

After	O
clotting	O
the	O
serum	O
was	O
separated	O
and	O
stored	O
at	O
-20	O
°	O
until	O
used	O
.	O

An	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
probands	O
.	O

Body	O
mass	O
indexes	O
(	O
BMI	O
)	O
,	O
defined	O
as	O
weight	O
in	O
kilograms	O
divided	O
by	O
the	O
square	O
of	O
height	O
in	O
meters	O
,	O
were	O
calculated	O
.	O

Biochemical	O
methods	O
Serum	O
leptin	O
concentrations	O
were	O
measured	O
by	O
a	O
sandwich	O
ELISA	O
test	O
kit	O
(	O
Human	B
Leptin	O
ELISA	O
,	O
BioVendor	O
Laboratory	O
Medicine	O
,	O
Inc	O
,	O
Czech	O
Republic	O
)	O
.	O

Its	O
sensitivity	O
limit	O
was	O
0.2	O
ng	O
/	O
ml	O
,	O
intraassay	O
CV	O
6.1	O
%	O
at	O
the	O
level	O
of	O
7.5	O
ng	O
/	O
m	O
,	O
inter	O
-	O
assay	O
CV	O
8.5	O
%	O
at	O
the	O
level	O
of	O
4.8	O
ng	O
/	O
ml	O
.	O

Tetramethylbenzidine	O
was	O
used	O
as	O
a	O
substrate	O
;	O
quality	O
controls	O
were	O
human	B
based	O
.	O

Several	O
other	O
hormones	O
and	O
peptides	O
were	O
estimated	O
by	O
routine	O
immunochemical	O
tests	O
:	O
insulin	O
,	O
C	O
-	O
peptide	O
,	O
TNFα	O
(	O
IMMULITE	O
,	O
Diagnostic	O
Products	O
Corporation	O
,	O
Los	O
Angeles	O
,	O
CA	O
,	O
U.S.A.	O
)	O
,	O
proinsulin	O
intact	O
(	O
DAKO	O
,	O
Denmark	O
)	O
,	O
IgG	O
anticardiolipin	O
(	O
ACL	O
-	O
IgG	O
,	O
IMMCO	O
Diagnostics	O
,	O
Buffalo	O
,	O
NY	O
,	O
U.S.A.	O
)	O
and	O
heart	O
fatty	O
acid	O
binding	O
protein	O
(	O
hFABP	O
,	O
Hbt	O
HUMAN	O
H	O
-	O
FABP	O
,	O
HyCult	O
Biotechnology	O
,	O
Uden	O
,	O
the	O
Netherlands	O
)	O
.	O

Serum	O
concentration	O
of	O
glucose	O
,	O
total	O
cholesterol	O
,	O
triglycerides	O
,	O
HDL	O
-	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
,	O
Apoprotein	O
B	O
and	O
uric	O
acid	O
were	O
measured	O
on	O
a	O
ILAB-600	O
biochemical	O
analyzer	O
(	O
Instrumentation	O
Laboratory	O
,	O
Lexington	O
,	O
Ma	O
,	O
U.S.A.	O
)	O
using	O
BioVendor	O
sets	O
.	O

All	O
samples	O
were	O
processed	O
and	O
examined	O
according	O
to	O
principles	O
of	O
good	O
laboratory	O
practice	O
and	O
under	O
constant	O
intralaboratory	O
and	O
external	O
quality	O
control	O
.	O

The	O
homeostatic	O
indexes	O
of	O
insulin	O
resistance	O
(	O
HOMA	O
IR	O
and	O
QUICKI	O
)	O
were	O
calculated	O
according	O
to	O
the	O
homeostasis	O
model	O
of	O
assessment	O
[	O
33	O
-	O
35	O
]	O
as	O
follows	O
:	O
HOMA	O
IR	O
=	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
*	O
fasting	O
glucose	O
(	O
mmol	O
/	O
l	O
)	O
/	O
22.5	O
;	O
QUICKI	O
=	O
1	O
/	O
[	O
log	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
+	O
log	O
fasting	O
glucose	O
(	O
mg	O
/	O
100	O
ml	O
)	O
]	O
.	O

Statistics	O
Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Version	O
6	O
SAS	O
/	O
STAT	O
software	O
(	O
SAS	O
Institute	O
,	O
Inc.	O
,	O
Cary	O
,	O
NC	O
,	O
U.S.A.	O
)	O
.	O

The	O
Shapiro	O
-	O
Wilks	O
tests	O
were	O
used	O
in	O
testing	O
the	O
normality	O
of	O
distribution	O
.	O

Some	O
of	O
the	O
data	O
obtained	O
were	O
not	O
normally	O
distributed	O
.	O

The	O
statistical	O
significance	O
of	O
differences	O
between	O
the	O
means	O
in	O
the	O
hyperlipemic	O
and	O
control	O
groups	O
were	O
evaluated	O
using	O
the	O
unpaired	O
Student	O
's	O
T	O
-	O
test	O
in	O
the	O
case	O
of	O
normal	O
distribution	O
of	O
data	O
sets	O
,	O
and	O
using	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
when	O
at	O
least	O
in	O
one	O
of	O
the	O
data	O
sets	O
the	O
normal	O
distribution	O
was	O
excluded	O
.	O

Spearman	O
's	O
rank	O
-	O
order	O
correlation	O
was	O
used	O
for	O
correlation	O
analysis	O
.	O

Multiple	O
regression	O
analysis	O
was	O
performed	O
using	O
HOMA	O
IR	O
indexes	O
of	O
insulin	O
resistance	O
as	O
dependent	O
variables	O
,	O
and	O
other	O
metabolic	O
and	O
hormonal	O
factors	O
(	O
lipid	O
parameters	O
,	O
BMI	O
,	O
leptin	O
,	O
TNFα	O
,	O
hFABP	O
,	O
ACL	O
-	O
IgG	O
)	O
as	O
independent	O
variables	O
.	O

The	O
so	O
-	O
called	O
step	O
-	O
down	O
regression	O
model	O
was	O
used	O
to	O
select	O
dominant	O
independent	O
variables	O
.	O

Various	O
four	O
-	O
member	O
groups	O
of	O
independent	O
(	O
explanatory	O
)	O
variables	O
were	O
used	O
for	O
the	O
analysis	O
and	O
the	O
non	O
-	O
zero	O
intercept	O
was	O
taken	O
into	O
account	O
.	O

The	O
independent	O
variables	O
were	O
then	O
dropped	O
,	O
one	O
at	O
a	O
time	O
;	O
at	O
each	O
stage	O
one	O
variable	O
making	O
the	O
least	O
contribution	O
to	O
the	O
dependent	O
variable	O
(	O
i.e.	O
that	O
showed	O
the	O
least	O
p	O
-	O
value	O
in	O
the	O
test	O
of	O
the	O
regression	O
coefficient	O
being	O
zero	O
)	O
was	O
excluded	O
.	O

The	O
coefficient	O
of	O
determination	O
R2	O
,	O
which	O
can	O
be	O
viewed	O
as	O
a	O
percentage	O
explaining	O
the	O
total	O
variance	O
,	O
was	O
simultaneously	O
monitored	O
.	O

A	O
great	O
drop	O
in	O
R2	O
after	O
excluding	O
some	O
independent	O
variable	O
enabled	O
selection	O
of	O
those	O
independent	O
variables	O
that	O
could	O
be	O
thought	O
to	O
be	O
the	O
most	O
important	O
determinants	O
of	O
the	O
dependent	O
variable	O
.	O

Results	O
Table	O
1	O
demonstrates	O
mean	O
parameters	O
in	O
individual	O
groups	O
of	O
subjects	O
matched	O
according	O
to	O
sex	O
,	O
lipid	O
parameters	O
and	O
age	O
.	O

While	O
the	O
age	O
of	O
all	O
four	O
groups	O
did	O
not	O
differ	O
substantially	O
,	O
the	O
concentrations	O
of	O
total	O
serum	O
cholesterol	O
,	O
triglycerides	O
,	O
HDL	O
-	O
cholesterol	O
and	O
LDL	O
-	O
cholesterol	O
differ	O
very	O
significantly	O
in	O
both	O
male	O
and	O
female	O
hyperlipemic	O
groups	O
as	O
compared	O
with	O
controls	O
.	O

In	O
addition	O
,	O
the	O
concentration	O
of	O
triglycerides	O
in	O
control	O
women	O
was	O
significantly	O
higher	O
than	O
in	O
control	O
men	O
,	O
the	O
concentration	O
of	O
triglycerides	O
in	O
hyperlipemic	O
women	O
was	O
lower	O
than	O
in	O
hyperlipemic	O
men	O
,	O
and	O
the	O
concentration	O
of	O
HDL	O
-	O
cholesterol	O
in	O
hyperlipemic	O
women	O
was	O
very	O
significantly	O
higher	O
when	O
compared	O
with	O
hyperlipemic	O
men	O
.	O

Table	O
2	O
shows	O
the	O
values	O
of	O
other	O
metabolic	O
and	O
insulin	O
parameters	O
,	O
factors	O
related	O
to	O
insulin	O
resistance	O
and	O
indexes	O
of	O
insulin	O
resistance	O
,	O
respectively	O
.	O

Body	O
mass	O
indexes	O
and	O
uric	O
acid	O
concentration	O
were	O
significantly	O
higher	O
in	O
hyperlipemic	O
men	O
as	O
compared	O
to	O
controls	O
,	O
but	O
not	O
in	O
hyperlipemic	O
women	O
.	O

Uric	O
acid	O
concentration	O
was	O
substantially	O
lower	O
in	O
hyperlipemic	O
women	O
than	O
in	O
hyperlipemic	O
men	O
.	O

Plasma	O
concentrations	O
of	O
glycemia	O
,	O
insulin	O
and	O
intact	O
proinsulin	O
were	O
significantly	O
higher	O
in	O
both	O
hyperlipemic	O
men	O
and	O
women	O
as	O
compared	O
with	O
controls	O
of	O
identical	O
gender	O
,	O
while	O
the	O
concentration	O
of	O
leptin	O
increased	O
only	O
in	O
hyperlipemic	O
men	O
.	O

However	O
,	O
serum	O
leptin	O
concentrations	O
of	O
both	O
control	O
and	O
hyperlipemic	O
women	O
were	O
significantly	O
higher	O
than	O
in	O
corresponding	O
groups	O
of	O
men	O
.	O

Serum	O
concentrations	O
of	O
TNFα	O
,	O
hFABP	O
and	O
ACL	O
-	O
IgG	O
in	O
hyperlipemic	O
groups	O
of	O
both	O
men	O
and	O
women	O
were	O
not	O
significantly	O
different	O
from	O
control	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
differed	O
very	O
significantly	O
in	O
hyperlipemic	O
groups	O
of	O
both	O
men	O
and	O
women	O
as	O
compared	O
with	O
corresponding	O
control	O
groups	O
,	O
more	O
distinctly	O
in	O
women	O
.	O

From	O
Fig.	O
1	O
,	O
presenting	O
95	O
%	O
confidence	O
limits	O
of	O
insulin	O
resistance	O
indexes	O
HOMA	O
IR	O
and	O
QUICKI	O
,	O
we	O
concluded	O
that	O
in	O
groups	O
of	O
hyperlipemic	O
patients	O
of	O
both	O
genders	O
the	O
insulin	O
resistance	O
was	O
substantially	O
higher	O
than	O
in	O
control	O
groups	O
;	O
the	O
groups	O
did	O
not	O
overlap	O
each	O
other	O
.	O

In	O
Table	O
3	O
the	O
results	O
of	O
Spearman	O
's	O
correlations	O
between	O
insulin	O
resistance	O
index	O
HOMA	O
IR	O
and	O
various	O
metabolic	O
parameters	O
are	O
presented	O
.	O

In	O
the	O
control	O
group	O
of	O
men	O
,	O
positive	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
leptin	O
concentration	O
,	O
and	O
inverse	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
ACL	O
IgG	O
,	O
respectively	O
,	O
were	O
found	O
.	O

In	O
the	O
control	O
group	O
of	O
women	O
,	O
the	O
significance	O
of	O
Spearman	O
's	O
correlation	O
between	O
HOMA	O
IR	O
and	O
leptin	O
was	O
more	O
expressive	O
;	O
inverse	O
correlation	O
between	O
HOMA	O
IR	O
and	O
HDL	O
-	O
cholesterol	O
was	O
also	O
present	O
.	O

In	O
the	O
hyperlipemic	O
group	O
of	O
men	O
,	O
the	O
significance	O
of	O
the	O
correlation	O
between	O
HOMA	O
IR	O
was	O
more	O
expressive	O
in	O
relation	O
to	O
the	O
control	O
group	O
,	O
and	O
no	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
ACL	O
IgG	O
was	O
found	O
.	O

In	O
the	O
hyperlipemic	O
group	O
of	O
women	O
,	O
however	O
,	O
the	O
significance	O
of	O
Spearman	O
's	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
leptin	O
concentration	O
weakened	O
,	O
the	O
inverse	O
correlation	O
between	O
HOMA	O
IR	O
and	O
HDL	O
-	O
cholesterol	O
remained	O
approximately	O
unchanged	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
concentration	O
of	O
TNFα	O
appeared	O
.	O

Table	O
4	O
shows	O
results	O
of	O
multiple	O
regression	O
analysis	O
,	O
when	O
data	O
from	O
both	O
control	O
and	O
hyperlipemic	O
groups	O
of	O
each	O
gender	O
were	O
judged	O
together	O
.	O

HOMA	O
IR	O
was	O
considered	O
as	O
a	O
dependent	O
variable	O
and	O
differently	O
changed	O
constellations	O
of	O
metabolic	O
and	O
other	O
factors	O
were	O
taken	O
as	O
independent	O
variables	O
.	O

In	O
men	O
,	O
BMI	O
and	O
leptin	O
seemed	O
to	O
play	O
a	O
main	O
role	O
in	O
influencing	O
the	O
insulin	O
resistance	O
index	O
HOMA	O
IR	O
,	O
while	O
TGL	O
,	O
ACL	O
IgG	O
and	O
LDL	O
-	O
cholesterol	O
did	O
n't	O
play	O
any	O
significant	O
role	O
(	O
see	O
left	O
columns	O
of	O
Table	O
4	O
)	O
.	O

The	O
decreasing	O
of	O
HDL	O
-	O
cholesterol	O
concentration	O
may	O
also	O
have	O
some	O
influence	O
(	O
see	O
a	O
significant	O
drop	O
of	O
R2	O
after	O
exclusion	O
of	O
this	O
factor	O
in	O
Table	O
4A	O
,	O
4B	O
)	O
.	O

But	O
in	O
the	O
presence	O
of	O
leptin	O
in	O
the	O
group	O
of	O
independent	O
factors	O
,	O
the	O
drop	O
of	O
R2	O
after	O
exclusion	O
of	O
HDL	O
-	O
cholesterol	O
from	O
these	O
factors	O
was	O
minimal	O
(	O
see	O
Table	O
4C	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
after	O
the	O
exclusion	O
of	O
TNFα	O
from	O
the	O
group	O
of	O
independent	O
variables	O
(	O
see	O
Table	O
4B	O
,	O
4D	O
)	O
the	O
value	O
of	O
R2	O
has	O
unexpectedly	O
risen	O
,	O
which	O
could	O
reflect	O
the	O
interference	O
of	O
TNFα	O
with	O
factors	O
increasing	O
the	O
insulin	O
resistance	O
.	O

In	O
women	O
(	O
see	O
right	O
columns	O
of	O
Table	O
4	O
)	O
,	O
the	O
maximal	O
values	O
of	O
R2	O
were	O
achieved	O
with	O
combination	O
of	O
independent	O
variables	O
containing	O
TGL	O
,	O
leptin	O
and	O
HDL	O
-	O
cholesterol	O
(	O
about	O
60	O
%	O
influence	O
on	O
HOMA	O
IR	O
!	O

–	O
see	O
Table	O
4A	O
,	O
4B	O
,	O
4C	O
)	O
.	O

TNFα	O
seemed	O
to	O
play	O
quite	O
a	O
different	O
role	O
than	O
in	O
men	O
:	O
after	O
exclusion	O
of	O
this	O
factor	O
from	O
the	O
group	O
of	O
independent	O
factors	O
R2significantly	O
decreased	O
(	O
see	O
Table	O
4B	O
,	O
4D	O
)	O
.	O

In	O
contrast	O
to	O
men	O
,	O
the	O
role	O
of	O
BMI	O
seemed	O
to	O
be	O
minimal	O
.	O

As	O
in	O
men	O
,	O
the	O
role	O
of	O
ACL	O
IgG	O
and	O
LDL	O
-	O
cholesterol	O
in	O
influencing	O
HOMA	O
IR	O
was	O
negligible	O
,	O
but	O
in	O
contrast	O
to	O
men	O
,	O
hFABP	O
might	O
play	O
a	O
certain	O
role	O
in	O
this	O
process	O
(	O
see	O
Table	O
4D	O
)	O
.	O

Generally	O
,	O
the	O
insulin	O
resistance	O
(	O
represented	O
by	O
HOMA	O
IR	O
)	O
was	O
in	O
men	O
much	O
less	O
influenced	O
by	O
metabolic	O
variables	O
than	O
in	O
women	O
;	O
while	O
in	O
women	O
in	O
some	O
combinations	O
of	O
dependent	O
variables	O
R2	O
reached	O
64	O
%	O
,	O
in	O
men	O
the	O
maximal	O
value	O
of	O
R2	O
was	O
only	O
39	O
%	O
.	O

Discussion	O
In	O
our	O
previous	O
paper	O
[	O
36	O
]	O
,	O
the	O
mean	O
value	O
of	O
HOMA	O
IR	O
in	O
healthy	O
subjects	O
of	O
both	O
genders	O
and	O
of	O
age	O
comparable	O
with	O
our	O
controls	O
was	O
1.57	O
±	O
0.87	O
,	O
and	O
the	O
mean	O
value	O
of	O
index	O
QUICKI	O
0.366	O
±	O
0.029	O
,	O
respectively	O
.	O

These	O
values	O
,	O
as	O
well	O
as	O
the	O
95	O
%	O
confidence	O
limits	O
,	O
correspond	O
to	O
values	O
found	O
in	O
controls	O
in	O
this	O
study	O
.	O

In	O
accordance	O
with	O
many	O
previous	O
papers	O
,	O
serum	O
concentrations	O
of	O
leptin	O
in	O
women	O
(	O
both	O
control	O
and	O
hyperlipemic	O
)	O
were	O
substantially	O
higher	O
than	O
in	O
men	O
.	O

In	O
the	O
control	O
group	O
of	O
women	O
the	O
correlation	O
between	O
leptin	O
and	O
HOMA	O
IR	O
was	O
highly	O
significant	O
.	O

However	O
,	O
in	O
hyperlipemic	O
women	O
the	O
significance	O
of	O
this	O
correlation	O
lessened	O
,	O
because	O
HOMA	O
IR	O
increased	O
considerably	O
(	O
and	O
significantly	O
)	O
but	O
serum	O
concentration	O
of	O
leptin	O
only	O
slightly	O
(	O
insignificantly	O
)	O
.	O

In	O
men	O
the	O
significance	O
of	O
correlations	O
between	O
serum	O
leptin	O
and	O
HOMA	O
IR	O
was	O
high	O
and	O
approximately	O
the	O
same	O
in	O
both	O
the	O
control	O
and	O
hyperlipemic	O
groups	O
,	O
because	O
the	O
values	O
of	O
HOMA	O
IR	O
as	O
well	O
as	O
serum	O
leptin	O
have	O
nearly	O
doubled	O
in	O
hyperlipemic	O
in	O
relation	O
to	O
control	O
groups	O
.	O

In	O
non	O
-	O
hyperlipemic	O
postmenopausal	O
women	O
the	O
high	O
concentration	O
of	O
serum	O
leptin	O
was	O
not	O
associated	O
with	O
higher	O
insulin	O
resistance	O
:	O
HOMA	O
IR	O
did	O
not	O
differ	O
substantially	O
from	O
men	O
.	O

A	O
significant	O
increase	O
of	O
insulin	O
resistance	O
in	O
hyperlipemic	O
women	O
was	O
associated	O
by	O
only	O
slight	O
and	O
insignificant	O
increase	O
of	O
leptin	O
concentration	O
.	O

According	O
to	O
Spearman	O
's	O
correlations	O
,	O
an	O
increase	O
of	O
serum	O
TNFα	O
and/or	O
a	O
decrease	O
of	O
HDL	O
-	O
cholesterol	O
might	O
also	O
play	O
a	O
distinct	O
role	O
in	O
this	O
respect	O
.	O

(	O
see	O
Table	O
3	O
)	O
.	O

In	O
contrast	O
to	O
women	O
,	O
in	O
hyperlipemic	O
men	O
the	O
increase	O
of	O
insulin	O
resistance	O
index	O
was	O
approximately	O
proportional	O
with	O
the	O
increase	O
of	O
leptin	O
concentration	O
.	O

Multiple	O
regression	O
analysis	O
affirmed	O
the	O
importance	O
of	O
leptin	O
serum	O
in	O
increasing	O
of	O
insulin	O
resistance	O
in	O
both	O
genders	O
.	O

In	O
men	O
,	O
only	O
BMI	O
and	O
HDL	O
-	O
cholesterol	O
from	O
other	O
factors	O
studied	O
seemed	O
to	O
play	O
a	O
certain	O
role	O
,	O
but	O
the	O
maximal	O
values	O
of	O
influencing	O
HOMA	O
IR	O
reached	O
only	O
39	O
%	O
,	O
with	O
leptin	O
and	O
BMI	O
being	O
the	O
more	O
important	O
factors	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
women	O
the	O
maximal	O
determination	O
of	O
HOMA	O
IR	O
as	O
high	O
as	O
60	O
%	O
was	O
registered	O
in	O
combination	O
of	O
serum	O
leptin	O
,	O
TGL	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
as	O
independent	O
factors	O
;	O
the	O
role	O
of	O
BMI	O
was	O
insignificant	O
.	O

It	O
is	O
not	O
known	O
how	O
leptin	O
is	O
regulated	O
.	O

A	O
strong	O
correlation	O
between	O
plasma	O
leptin	O
and	O
fasting	O
insulin	O
undoubtedly	O
exists	O
,	O
but	O
hyperleptinemia	O
in	O
both	O
obese	O
and	O
lean	O
humans	B
is	O
not	O
likely	O
the	O
result	O
of	O
hyperinsulinemia	O
[	O
37	O
]	O
.	O

A	O
relationship	O
between	O
leptin	O
and	O
insulin	O
dependent	O
on	O
sex	O
or	O
BMI	O
was	O
reported	O
,	O
but	O
relationship	O
between	O
triglyceride	O
concentrations	O
and	O
leptin	O
was	O
independent	O
of	O
sex	O
,	O
BMI	O
,	O
and	O
insulin	O
[	O
18,24	O
]	O
.	O

Hyperleptinemia	O
,	O
as	O
an	O
early	O
sign	O
of	O
obesity	O
,	O
was	O
closely	O
linked	O
to	O
subcutaneous	O
fat	O
mass	O
[	O
39,40	O
]	O
.	O

Percentage	O
of	O
body	O
fat	O
has	O
been	O
shown	O
to	O
be	O
the	O
strongest	O
predictor	O
of	O
leptin	O
levels	O
even	O
in	O
lean	O
women	O
[	O
41	O
]	O
.	O

Leptin	O
was	O
highly	O
correlated	O
with	O
percentage	O
of	O
body	O
fat	O
and	O
with	O
fat	O
mass	O
in	O
adults	O
irrespective	O
of	O
gender	O
and	O
age	O
;	O
however	O
,	O
the	O
mean	O
determinant	O
of	O
leptin	O
plasma	O
concentration	O
in	O
men	O
and	O
postmenopausal	O
women	O
was	O
BMI	O
,	O
while	O
in	O
premenopausal	O
women	O
it	O
was	O
only	O
the	O
fat	O
mass	O
[	O
42	O
]	O
.	O

These	O
findings	O
contrast	O
with	O
our	O
results	O
showing	O
minimal	O
influence	O
of	O
BMI	O
on	O
HOMA	O
IR	O
in	O
postmenopausal	O
women	O
.	O

All	O
factors	O
mentioned	O
are	O
connected	O
with	O
fat	O
tissue	O
:	O
leptin	O
and	O
TNFα	O
are	O
directly	O
produced	O
chiefly	O
by	O
adipocytes	O
,	O
BMI	O
growth	O
is	O
obviously	O
accompanied	O
by	O
fat	O
mass	O
increase	O
,	O
and	O
the	O
typical	O
hypertriglyceridemia	O
associated	O
with	O
a	O
decrease	O
of	O
HDL	O
-	O
cholesterol	O
goes	O
along	O
with	O
obesity	O
and	O
fat	O
mass	O
growth	O
.	O

The	O
gender	O
differences	O
in	O
circulating	O
leptin	O
were	O
best	O
explained	O
by	O
percentage	O
of	O
body	O
fat	O
and	O
–	O
inversely	O
–	O
by	O
lean	O
body	O
mass	O
[	O
25	O
]	O
.	O

In	O
both	O
genders	O
the	O
intra	O
-	O
abdominal	O
fat	O
correlated	O
with	O
insulin	O
resistance	O
,	O
while	O
the	O
subcutaneous	O
fat	O
correlated	O
with	O
circulating	O
leptin	O
[	O
11,12	O
]	O
.	O

In	O
men	O
obesity	O
led	O
to	O
a	O
prevalent	O
increase	O
of	O
intra	O
-	O
abdominal	O
fat	O
,	O
while	O
in	O
women	O
of	O
subcutaneous	O
fat	O
[	O
13	O
]	O
.	O

Influences	O
of	O
different	O
compartments	O
of	O
adipose	O
tissues	O
could	O
elucidate	O
the	O
variability	O
of	O
correlations	O
between	O
insulin	O
resistance	O
and	O
high	O
leptin	O
concentrations	O
in	O
lean	O
and	O
obese	O
subjects	O
of	O
both	O
genders	O
[	O
43	O
]	O
.	O

In	O
our	O
non	O
-	O
hyperlipemic	O
postmenopausal	O
women	O
the	O
content	O
of	O
subcutaneous	O
fat	O
mass	O
might	O
be	O
higher	O
than	O
in	O
non	O
-	O
hyperlipemic	O
men	O
of	O
appropriate	O
age	O
,	O
which	O
indicated	O
a	O
higher	O
serum	O
concentration	O
of	O
leptin	O
.	O

However	O
,	O
the	O
insulin	O
resistance	O
–	O
related	O
to	O
intra	O
-	O
abdominal	O
fat	O
mass	O
–	O
did	O
not	O
differ	O
from	O
men	O
.	O

The	O
significant	O
increase	O
of	O
insulin	O
resistance	O
and	O
leptin	O
concentration	O
in	O
hyperlipemic	O
men	O
might	O
reflect	O
the	O
growing	O
content	O
of	O
both	O
subcutaneous	O
and	O
intra	O
-	O
abdominal	O
fat	O
mass	O
(	O
see	O
the	O
significant	O
increase	O
of	O
BMI	O
)	O
.	O

In	O
hyperlipemic	O
women	O
the	O
significant	O
increase	O
of	O
insulin	O
resistance	O
accompanying	O
only	O
minimal	O
insignificant	O
increase	O
of	O
leptin	O
could	O
be	O
caused	O
by	O
prevalent	O
growing	O
of	O
intra	O
-	O
abdominal	O
fat	O
mass	O
.	O

In	O
elderly	O
postmenopausal	O
women	O
,	O
an	O
association	O
between	O
leptin	O
and	O
plasma	O
lipoprotein	O
concentration	O
was	O
found	O
which	O
depended	O
on	O
adiposity	O
[	O
17	O
]	O
,	O
and	O
inverse	O
correlations	O
between	O
serum	O
leptin	O
and	O
HDL	O
-	O
cholesterol	O
were	O
described	O
[	O
44	O
]	O
.	O

In	O
our	O
study	O
,	O
insulin	O
resistance	O
in	O
women	O
seemed	O
to	O
be	O
more	O
notably	O
than	O
in	O
men	O
influenced	O
by	O
lipid	O
disorders	O
,	O
i.e.	O
positively	O
by	O
serum	O
triglycerides	O
and	O
inversely	O
by	O
HDL	O
-	O
cholesterol	O
.	O

These	O
findings	O
might	O
be	O
important	O
in	O
considering	O
the	O
concept	O
of	O
treatment	O
of	O
insulin	O
resistance	O
-	O
related	O
disorders	O
in	O
postmenopausal	O
women	O
.	O

The	O
significant	O
role	O
of	O
TNFα	O
in	O
insulin	O
resistance	O
,	O
caused	O
by	O
inhibiting	O
the	O
transduction	O
of	O
insulin	O
signaling	O
and	O
by	O
down	O
-	O
regulation	O
of	O
glucose	O
transporter	O
GLUT-4	O
and	O
insulin	O
receptor	O
substrate-1	O
,	O
has	O
been	O
repeatedly	O
confirmed	O
[	O
45	O
-	O
48	O
]	O
.	O

Our	O
results	O
supported	O
these	O
findings	O
unambiguously	O
only	O
in	O
women	O
,	O
while	O
in	O
men	O
TNFα	O
seemed	O
paradoxically	O
to	O
interfere	O
with	O
other	O
factors	O
–	O
mainly	O
BMI	O
and	O
leptin	O
–	O
in	O
influencing	O
insulin	O
resistance	O
,	O
thus	O
playing	O
a	O
quite	O
different	O
role	O
.	O

Previously	O
it	O
was	O
found	O
[	O
46	O
]	O
that	O
correlation	O
between	O
serum	O
TNFα	O
on	O
the	O
one	O
side	O
,	O
and	O
insulin	O
,	O
HOMA	O
IR	O
,	O
serum	O
triglycerids	O
,	O
respectively	O
,	O
on	O
the	O
other	O
side	O
,	O
was	O
substantially	O
more	O
significant	O
in	O
women	O
than	O
in	O
men	O
.	O

Serum	O
concentration	O
of	O
TNFα	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
of	O
both	O
genders	O
correlated	O
only	O
with	O
the	O
quantity	O
of	O
intra	O
-	O
abdominal	O
fat	O
compartment	O
[	O
50	O
]	O
.	O

Visceral	O
obesity	O
correlated	O
with	O
plasmatic	O
aldosterone	O
and	O
with	O
insulin	O
resistance	O
only	O
in	O
premenopausal	O
women	O
,	O
but	O
not	O
in	O
men	O
[	O
51	O
]	O
.	O

From	O
all	O
these	O
data	O
we	O
might	O
support	O
our	O
above	O
mentioned	O
conclusion	O
–	O
that	O
rising	O
of	O
insulin	O
resistance	O
in	O
hyperlipemic	O
women	O
was	O
associated	O
with	O
an	O
increase	O
of	O
intra	O
-	O
abdominal	O
fat	O
,	O
because	O
this	O
fat	O
mass	O
in	O
particular	O
is	O
a	O
source	O
of	O
TNFα	O
,	O
which	O
interfered	O
with	O
insulin	O
sensitivity	O
only	O
in	O
women	O
.	O

We	O
came	O
to	O
this	O
conclusion	O
irrespective	O
of	O
the	O
finding	O
that	O
the	O
increase	O
of	O
serum	O
TNFα	O
in	O
hyperlipemic	O
women	O
was	O
statistically	O
insignificant	O
;	O
results	O
of	O
Spearman	O
's	O
correlation	O
(	O
Table	O
3	O
)	O
and	O
multiple	O
regression	O
analysis	O
confirm	O
a	O
distinct	O
role	O
of	O
this	O
factor	O
.	O

In	O
hyperlipemic	O
men	O
not	O
only	O
the	O
serum	O
concentration	O
of	O
TNFα	O
has	O
decreased	O
instead	O
of	O
increasing	O
,	O
but	O
according	O
to	O
multiple	O
regression	O
analysis	O
it	O
played	O
a	O
quite	O
different	O
role	O
in	O
influencing	O
insulin	O
sensitivity	O
,	O
interfering	O
with	O
factors	O
that	O
determined	O
insulin	O
resistance	O
(	O
leptin	O
and	O
BMI	O
)	O
.	O

In	O
the	O
control	O
group	O
of	O
men	O
IgG	O
anticardiolipin	O
was	O
inversely	O
correlated	O
to	O
HOMA	O
IR	O
.	O

The	O
significance	O
of	O
this	O
finding	O
is	O
not	O
clear	O
.	O

These	O
antibodies	O
indicate	O
vascular	O
and	O
thrombotic	O
complications	O
and	O
oxidative	O
modification	O
of	O
lipoproteins	O
[	O
52,53	O
]	O
and	O
may	O
represent	O
an	O
increased	O
risk	O
of	O
atherogenic	O
and	O
inflammatory	O
complications	O
.	O

In	O
this	O
case	O
,	O
however	O
,	O
their	O
growing	O
might	O
be	O
connected	O
with	O
an	O
increase	O
in	O
insulin	O
sensitivity	O
.	O

Anyway	O
,	O
ACL	O
IgG	O
evidently	O
did	O
not	O
participate	O
significantly	O
in	O
influencing	O
the	O
increase	O
of	O
insulin	O
resistance	O
associated	O
with	O
hyperlipidemia	O
,	O
although	O
other	O
anti	O
-	O
cardiolipin	O
correlations	O
could	O
be	O
masked	O
by	O
the	O
relatively	O
large	O
inter	O
-	O
individual	O
variations	O
in	O
this	O
parameter	O
.	O

Neither	O
serum	O
concentration	O
of	O
hFABP	O
,	O
a	O
factor	O
ensuring	O
transmembrane	O
transport	O
and	O
oxidative	O
metabolisation	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
[	O
54,55	O
]	O
,	O
was	O
significantly	O
changed	O
in	O
hyperlipemic	O
and	O
insulin	O
resistant	O
subjects	O
of	O
both	O
genders	O
.	O

This	O
factor	O
was	O
very	O
weakly	O
associated	O
only	O
with	O
HOMA	O
IR	O
in	O
women	O
(	O
see	O
Table	O
4D	O
)	O
,	O
indicating	O
that	O
enhanced	O
metabolisation	O
of	O
fatty	O
acids	O
in	O
cells	O
might	O
to	O
some	O
degree	O
contribute	O
to	O
insulin	O
resistance	O
.	O

Conclusions	O
In	O
postmenopausal	O
women	O
as	O
well	O
as	O
in	O
men	O
of	O
approximately	O
equal	O
age	O
serum	O
leptin	O
plays	O
a	O
significant	O
role	O
as	O
an	O
important	O
determinant	O
of	O
insulin	O
resistance	O
.	O

In	O
addition	O
to	O
this	O
factor	O
,	O
in	O
women	O
the	O
grade	O
of	O
insulin	O
resistance	O
is	O
very	O
considerably	O
influenced	O
by	O
serum	O
triglycerides	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
by	O
decreased	O
concentration	O
of	O
HDL	O
-	O
cholesterol	O
,	O
while	O
in	O
men	O
only	O
a	O
mild	O
influence	O
of	O
BMI	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
is	O
observed	O
.	O

These	O
findings	O
are	O
explained	O
as	O
a	O
consequence	O
of	O
gender	O
-	O
related	O
differences	O
in	O
adipose	O
tissue	O
composition	O
and/or	O
distribution	O
in	O
both	O
normal	O
-	O
weight	O
and	O
over	O
-	O
weight	O
subjects	O
and	O
should	O
be	O
taken	O
into	O
account	O
in	O
treatment	O
of	O
patients	O
with	O
metabolic	O
risk	O
factors	O
of	O
cardiovascular	O
diseases	O
.	O

List	O
of	O
abbreviations	O
HDL	O
-	O
Cholesterol	O
=	O
high	O
-	O
density	O
cholesterol	O
LDL	O
-	O
cholesterol	O
=	O
low	O
-	O
density	O
cholesterol	O
HOMA	O
IR	O
=	O
Homeostasis	O
Assessment	O
of	O
Insulin	O
Resistance	O
=	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
*	O
fasting	O
glucose	O
(	O
mmol	O
/	O
l	O
)	O
/	O
22,5	O
QUICKI	O
=	O
1	O
/	O
[	O
log	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
+	O
log	O
fasting	O
glucose	O
(	O
mg	O
/	O
100	O
ml	O
)	O
]	O
TNFα	O
=	O
tumor	O
necrosis	O
factor	O
alpha	O
BMI	O
=	O
body	O
mass	O
index	O
R2	O
=	O
coefficient	O
of	O
determination	O
hFABP	O
=	O
heart	O
fatty	O
acid	O
binding	O
protein	O
ACL	O
-	O
IgG	O
=	O
IgG	O
fraction	O
of	O
anticardiolipin	O
TGL	O
=	O
triglycerides	O
GLUT-4	O
=	O
glucose	O
transporter-4	O
PPARγ	O
=	O
Peroxisome	O
Proliferator	O
-	O
Associated	O
Receptor	O
gamma	O
CV	O
=	O
coefficient	O
of	O
variation	O
Authors	O
'	O
contributions	O
Dr.	O
Radka	O
Lichnovská	O
collected	O
the	O
clinical	O
material	O
,	O
performed	O
analysis	O
of	O
biochemical	O
values	O
and	O
edited	O
the	O
manuscript	O
.	O

Dr.	O
Simona	O
Gwozdziewiczová	O
performed	O
analysis	O
of	O
clinical	O
and	O
biochemical	O
data	O
and	O
edited	O
the	O
manuscript	O
.	O

Prof.	O
Jirí	O
Hrebícek	O
initiated	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
wrote	O
and	O
edited	O
the	O
manuscript	O
.	O

Enp1	O
,	O
a	O
yeast	B
protein	O
associated	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
,	O
is	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
and	O
40S	O
subunit	O
synthesis	O
Abstract	O
ENP1	O
is	O
an	O
essential	O
Saccharomyces	B
cerevisiae	I
gene	O
encoding	O
a	O
483	O
amino	O
acid	O
polypeptide	O
.	O

Enp1	O
protein	O
is	O
localized	O
in	O
the	O
nucleus	O
and	O
concentrated	O
in	O
the	O
nucleolus	O
.	O

An	O
enp1	O
-	O
1	O
temperature	O
-	O
sensitive	O
mutant	O
inhibited	O
35S	O
pre	O
-	O
rRNA	O
early	O
processing	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
as	O
shown	O
by	O
northern	O
analysis	O
of	O
steady	O
state	O
levels	O
of	O
rRNA	O
precursors	O
.	O

Pulse	O
-	O
chase	O
analysis	O
further	O
revealed	O
that	O
the	O
enp1	O
-	O
1	O
strain	O
was	O
defective	O
in	O
the	O
synthesis	O
of	O
20S	O
pre	O
-	O
rRNA	O
and	O
hence	O
18S	O
rRNA	O
,	O
which	O
led	O
to	O
reduced	O
formation	O
of	O
40S	O
ribosomal	O
subunits	O
.	O

Co	O
-	O
precipitation	O
analysis	O
revealed	O
that	O
Enp1	O
was	O
associated	O
with	O
Nop1	O
protein	O
,	O
as	O
well	O
as	O
with	O
U3	O
and	O
U14	O
RNAs	O
,	O
two	O
snoRNAs	O
implicated	O
in	O
early	O
pre	O
-	O
rRNA	O
processing	O
steps	O
.	O

These	O
results	O
suggest	O
a	O
direct	O
role	O
for	O
Enp1	O
in	O
the	O
early	O
steps	O
of	O
rRNA	O
processing	O
.	O

INTRODUCTION	O
Ribosome	O
biogenesis	O
is	O
one	O
of	O
the	O
major	O
cellular	O
activities	O
in	O
eukaryotic	O
cells	O
.	O

It	O
takes	O
place	O
primarily	O
in	O
a	O
specialized	O
subnuclear	O
compartment	O
,	O
the	O
nucleolus	O
(	O
1,2	O
)	O
.	O

In	O
the	O
yeast	B
Saccharomyces	B
cerevisiae	I
,	O
each	O
rRNA	O
gene	O
is	O
transcribed	O
by	O
RNA	O
polymerase	O
I	O
into	O
a	O
35S	O
rRNA	O
precursor	O
,	O
consisting	O
of	O
18S	O
,	O
5.8S	O
and	O
25S	O
rRNA	O
sequences	O
flanked	O
by	O
two	O
external	O
transcribed	O
spacers	O
(	O
ETS	O
)	O
and	O
separated	O
by	O
two	O
internal	O
transcribed	O
spacers	O
(	O
ITS	O
)	O
(	O
Fig.	O
1	O
)	O
.	O

This	O
35S	O
precursor	O
goes	O
through	O
a	O
series	O
of	O
modifications	O
and	O
processing	O
steps	O
to	O
generate	O
the	O
mature	O
18S	O
,	O
5.8S	O
and	O
25S	O
rRNAs	O
.	O

The	O
processing	O
occurs	O
first	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
,	O
resulting	O
in	O
the	O
20S	O
pre	O
-	O
rRNA	O
and	O
27SA2	O
pre	O
-	O
rRNA	O
.	O

The	O
20S	O
pre	O
-	O
rRNA	O
is	O
then	O
cleaved	O
,	O
leading	O
to	O
the	O
mature	O
18S	O
rRNA	O
found	O
in	O
the	O
40S	O
ribosomal	O
subunit	O
.	O

The	O
27SA2	O
pre	O
-	O
rRNA	O
is	O
processed	O
through	O
two	O
alternative	O
pathways	O
.	O

The	O
majority	O
of	O
27SA2	O
pre	O
-	O
rRNA	O
is	O
cleaved	O
at	O
sites	O
A3	O
and	O
B2	O
to	O
form	O
the	O
27SA3	O
pre	O
-	O
rRNA	O
,	O
which	O
is	O
subsequently	O
processed	O
to	O
produce	O
27SBS	O
.	O

Alternatively	O
,	O
27SA2	O
pre	O
-	O
rRNA	O
can	O
be	O
processed	O
at	O
sites	O
B1L	O
and	O
B2	O
to	O
generate	O
27SBL	O
pre	O
-	O
rRNA	O
.	O

Both	O
27SBS	O
and	O
27SBL	O
pre	O
-	O
rRNAs	O
are	O
then	O
cleaved	O
at	O
sites	O
C1	O
and	O
C2	O
to	O
generate	O
the	O
mature	O
25S	O
rRNA	O
,	O
and	O
7SS	O
or	O
7SL	O
intermediates	O
,	O
which	O
are	O
then	O
processed	O
to	O
mature	O
5.8SS	O
or	O
5.8SL	O
rRNAs	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
25S	O
rRNA	O
and	O
5.8S	O
rRNA	O
are	O
the	O
RNA	O
components	O
of	O
the	O
60S	O
ribosomal	O
subunit	O
(	O
3	O
)	O
.	O

During	O
the	O
course	O
of	O
rRNA	O
modification	O
and	O
processing	O
,	O
many	O
of	O
the	O
ribosomal	O
proteins	O
are	O
assembled	O
onto	O
the	O
rRNA	O
molecules	O
to	O
form	O
the	O
ribosome	O
complex	O
.	O

Ribosome	O
biogenesis	O
needs	O
a	O
large	O
number	O
of	O
trans	O
-	O
acting	O
factors	O
,	O
including	O
small	O
nucleolar	O
RNAs	O
(	O
snoRNAs	O
)	O
,	O
protein	O
components	O
of	O
the	O
snoRNP	O
complexes	O
,	O
rRNA	O
modifying	O
enzymes	O
,	O
endo-	O
and	O
exonucleases	O
,	O
putative	O
RNA	O
helicases	O
and	O
other	O
protein	O
factors	O
(	O
3,4	O
)	O
.	O

In	O
yeast	B
cells	O
there	O
are	O
more	O
than	O
100	O
different	O
snoRNAs	O
playing	O
important	O
roles	O
in	O
rRNA	O
modification	O
and	O
processing	O
.	O

On	O
the	O
basis	O
of	O
their	O
structure	O
,	O
the	O
snoRNAs	O
can	O
be	O
divided	O
into	O
two	O
groups	O
:	O
the	O
box	O
C	O
/	O
D	O
family	O
and	O
box	O
H	O
/	O
ACA	O
family	O
.	O

Only	O
one	O
snoRNA	O
,	O
MRP	O
RNA	O
,	O
belongs	O
to	O
neither	O
family	O
(	O
5–7	O
)	O
.	O

While	O
the	O
majority	O
of	O
the	O
snoRNAs	O
participate	O
in	O
RNA	O
pseudouridylation	O
and	O
2′-O	O
-	O
ribose	O
methylation	O
,	O
a	O
few	O
of	O
them	O
,	O
including	O
MRP	O
snoRNA	O
,	O
box	O
C	O
/	O
D	O
snoRNAs	O
U3	O
and	O
U14	O
,	O
and	O
box	O
H	O
/	O
ACA	O
snoRNAs	O
snR10	O
and	O
snR30	O
,	O
are	O
required	O
for	O
processing	O
of	O
the	O
pre	O
-	O
rRNA	O
(	O
8–12	O
)	O
.	O

Not	O
only	O
are	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
essential	O
for	O
early	O
cleavages	O
of	O
35S	O
pre	O
-	O
rRNA	O
to	O
18S	O
rRNA	O
,	O
the	O
proteins	O
associated	O
with	O
them	O
,	O
including	O
Nop1	O
,	O
Nop5	O
,	O
Gar1	O
and	O
Nop10	O
,	O
have	O
also	O
been	O
shown	O
to	O
be	O
required	O
for	O
18S	O
rRNA	O
synthesis	O
(	O
13–16	O
)	O
.	O

The	O
ENP1	O
(	O
Essential	O
Nuclear	O
Protein	O
1	O
)	O
gene	O
was	O
identified	O
in	O
a	O
genetic	O
screen	O
for	O
suppressors	O
of	O
an	O
ost4	O
mutation	O
(	O
oligosaccharide	O
transferase	O
4	O
)	O
(	O
17	O
)	O
.	O

However	O
,	O
in	O
subsequent	O
studies	O
it	O
was	O
found	O
not	O
to	O
be	O
involved	O
in	O
OST4	O
function	O
(	O
18	O
)	O
.	O

ENP1	O
is	O
an	O
essential	O
gene	O
encoding	O
a	O
483	O
amino	O
acid	O
polypeptide	O
.	O

The	O
Enp1	O
protein	O
is	O
highly	O
conserved	O
and	O
homologs	O
are	O
found	O
in	O
all	O
eukaryotes	O
.	O

The	O
yeast	B
protein	O
was	O
localized	O
to	O
the	O
nucleus	O
in	O
a	O
previous	O
study	O
(	O
18	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
Enp1	O
human	B
homolog	O
,	O
called	O
bystin	O
,	O
was	O
reported	O
to	O
localize	O
to	O
the	O
cytoplasm	O
and	O
was	O
proposed	O
to	O
be	O
involved	O
in	O
cell	O
adhesion	O
(	O
19	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
the	O
Enp1	O
protein	O
not	O
only	O
is	O
nuclear	O
but	O
is	O
enriched	O
in	O
the	O
nucleolus	O
.	O

We	O
also	O
found	O
that	O
Enp1	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
40S	O
ribosomal	O
subunits	O
,	O
and	O
its	O
presence	O
is	O
necessary	O
for	O
the	O
pre	O
-	O
rRNA	O
processing	O
to	O
form	O
20S	O
pre	O
-	O
rRNA	O
and	O
18S	O
rRNA	O
.	O

An	O
association	O
between	O
Enp1	O
and	O
U3	O
and	O
U14	O
snoRNAs	O
,	O
and	O
with	O
the	O
nucleolar	O
protein	O
Nop1	O
,	O
was	O
established	O
.	O

We	O
also	O
found	O
that	O
human	B
Enp1	O
,	O
expressed	O
in	O
yeast	B
,	O
was	O
located	O
in	O
the	O
nucleus	O
and	O
the	O
nucleolus	O
,	O
suggesting	O
that	O
the	O
function	O
of	O
this	O
protein	O
is	O
conserved	O
.	O

MATERIALS	O
AND	O
METHODS	O
Yeast	B
strains	O
and	O
media	O
The	O
S.cerevisiae	B
strains	O
used	O
in	O
this	O
study	O
are	O
all	O
derivatives	O
of	O
a	O
wild	O
-	O
type	O
diploid	O
strain	O
W303	O
(	O
MATa	O
/	O
MATα	O
ura3	O
-	O
1	O
/	O
ura3	O
-	O
1	O
leu2	O
-	O
3,112	O
/	O
leu2	O
-	O
3,112	O
trp1	O
-	O
1	O
/	O
trp1	O
-	O
1	O
his3	O
-	O
11,15	O
/	O
his3	O
-	O
11,15	O
ade2	O
-	O
1	O
/	O
ade2	O
-	O
1	O
can1	O
-	O
100	O
/	O
can1	O
-	O
100	O
)	O
except	O
for	O
strain	O
RS1938	O
.	O

Strain	O
JBY45	O
(	O
MATa	O
/	O
MATα	O
ENP1	O
/	O
Δenp1::his5	O
+	O
)	O
was	O
constructed	O
by	O
replacing	O
one	O
copy	O
of	O
the	O
ENP1	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
with	O
the	O
Schizosaccharomyces	B
pombe	I
his5	O
+	O
gene	O
(	O
18	O
)	O
.	O

Strain	O
JBY46	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB23	O
(	O
ENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
is	O
a	O
haploid	O
strain	O
derived	O
from	O
JBY45	O
with	O
wild	O
-	O
type	O
ENP1	O
on	O
a	O
low	O
copy	O
number	O
plasmid	O
.	O

Strain	O
JBY48	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB19	O
(	O
enp1	O
-	O
1	O
,	O
TRP1	O
,	O
CEN6	O
)	O
]	O
and	O
strain	O
JBY49	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB39	O
(	O
enp1	O
-	O
2	O
,	O
TRP1	O
,	O
CEN6	O
)	O
]	O
have	O
plasmids	O
with	O
enp1	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutations	O
.	O

Strain	O
JBY51	O
(	O
MATa	O
Δenp1::his5	O
+	O
TRP1::enp1	O
-	O
1	O
)	O
is	O
an	O
enp1	O
ts	O
strain	O
generated	O
by	O
integrating	O
the	O
enp1	O
-	O
1	O
gene	O
at	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
.	O

Strain	O
CWY13	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB24	O
(	O
pMET25-GFP	O
-	O
ENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
has	O
GFP	O
-	O
ENP1	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
.	O

Strain	O
CWY14	O
(	O
MATa	O
ENP1-TAP	O
)	O
was	O
created	O
by	O
fusing	O
sequences	O
encoding	O
a	O
Tandem	O
Affinity	O
Purification	O
(	O
TAP	O
)	O
tag	O
(	O
20,21	O
)	O
to	O
the	O
3′	O
end	O
of	O
ENP1	O
.	O

Strain	O
YRH39	O
(	O
MATα	O
HST2-TAP	O
)	O
was	O
created	O
by	O
fusing	O
sequences	O
encoding	O
a	O
TAP	O
tag	O
to	O
the	O
3′end	O
of	O
HST2	O
.	O

Strain	O
RS1938	O
(	O
Δnop1::URA3	O
pUN100-ProtA	O
-	O
NOP1	O
)	O
was	O
created	O
by	O
transforming	O
RS1935	O
(	O
MATa	O
/	O
α	O
leu2	O
/	O
leu2	O
ura3	O
/	O
ura3	O
lys2	O
/	O
lys2	O
ade2	O
/	O
ade2	O
Δnop1::URA3	O
/	O
NOP1	O
)	O
with	O
pUN100-ProtA	O
-	O
NOP1	O
(	O
strain	O
and	O
plasmid	O
supplied	O
by	O
T.	O
Schafer	O
)	O
,	O
followed	O
by	O
tetrad	O
dissection	O
.	O

Strain	O
CWY15	O
[	O
MATa	O
/	O
pCW109	O
(	O
pMET25-GFP	O
-	O
hENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
has	O
a	O
human	B
homolog	O
of	O
Enp1	O
expressed	O
in	O
W303	O
-	O
1a	O
.	O

The	O
media	O
used	O
were	O
prepared	O
as	O
described	O
(	O
22	O
)	O
.	O

Cloning	O
of	O
ENP1	O
pRS426-MEG1	O
(	O
The	O
original	O
name	O
of	O
ENP1	O
)	O
was	O
a	O
gift	O
from	O
Dr	O
William	O
J.	O
Lennarz	O
.	O

It	O
contains	O
the	O
ENP1	O
gene	O
within	O
a	O
2.6	O
kb	O
EcoRI	O
genomic	O
fragment	O
cloned	O
into	O
pRS426	O
(	O
18	O
)	O
.	O

The	O
EcoRI	O
fragment	O
was	O
subsequently	O
cloned	O
into	O
pRS314	O
(	O
TRP1	O
,	O
CEN6	O
)	O
,	O
pRS316	O
(	O
URA3	O
,	O
CEN6	O
)	O
and	O
pRS424	O
(	O
TRP1	O
,	O
2µ	O
)	O
to	O
create	O
pJB20	O
,	O
pJB23	O
and	O
pJB21	O
,	O
respectively	O
.	O

pGFP	O
-	O
N	O
-	O
FUS	O
is	O
a	O
centromeric	O
plasmid	O
for	O
fusing	O
green	O
fluorescence	O
protein	O
(	O
GFP	O
)	O
to	O
a	O
polypeptide	O
's	O
N	O
-	O
terminus	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
(	O
23	O
)	O
.	O

Cloning	O
the	O
ENP1	O
ORF	O
into	O
pGFP	O
-	O
N	O
-	O
FUS	O
via	O
XbaI	O
and	O
SalI	O
sites	O
generated	O
plasmid	O
pJB24	O
.	O

pJB19	O
(	O
enp1	O
-	O
1	O
,	O
TRP1	O
,	O
CEN6	O
)	O
contains	O
the	O
enp1	O
-	O
1	O
mutant	O
gene	O
.	O

The	O
human	B
homolog	O
of	O
yeast	B
Enp1	O
was	O
PCR	O
amplified	O
from	O
a	O
human	B
cDNA	O
clone	O
BC007340	O
(	O
Research	O
Genetics	O
)	O
,	O
then	O
cloned	O
into	O
pGFP	O
-	O
N	O
-	O
FUS	O
,	O
p415-ADH	O
,	O
p415-GPD	O
and	O
p415-TEF	O
(	O
24	O
)	O
via	O
XbaI	O
and	O
SalI	O
sites	O
to	O
generate	O
pCW109	O
,	O
pCW113	O
,	O
pCW115	O
and	O
pCW117	O
,	O
respectively	O
.	O

The	O
fragment	O
of	O
the	O
human	B
Enp1	O
homolog	O
(	O
amino	O
acids	O
152–437	O
)	O
was	O
also	O
cloned	O
into	O
these	O
vectors	O
to	O
generate	O
pCW110	O
,	O
pCW114	O
,	O
pCW116	O
and	O
pCW118	O
.	O

Random	O
mutagenesis	O
of	O
ENP1	O
to	O
generate	O
enp1	O
ts	O
mutants	O
The	O
enp1	O
ts	O
mutants	O
were	O
generated	O
with	O
a	O
protocol	O
introducing	O
random	O
mutations	O
by	O
PCR	O
(	O
25	O
)	O
.	O

The	O
PCR	O
was	O
performed	O
with	O
oligonucleotides	O
ENP1-MUT5′	O
(	O
5′-GGTGGTGTCAGT	O
AGGGGA-3′	O
)	O
,	O
ENP1-MUT3′	O
(	O
5′-CAGTCTGCAATATA	O
TGGAC-3′	O
)	O
and	O
plasmid	O
template	O
pJB20	O
(	O
see	O
above	O
)	O
.	O

The	O
nucleotide	O
concentrations	O
in	O
the	O
reaction	O
were	O
1	O
mM	O
each	O
for	O
dATP	O
,	O
dGTP	O
,	O
dCTP	O
and	O
dTTP	O
.	O

After	O
strain	O
JBY46	O
was	O
transformed	O
with	O
the	O
PCR	O
product	O
and	O
with	O
pJB20	O
gapped	O
by	O
NheI	O
and	O
NsiI	O
,	O
the	O
transformants	O
were	O
replica	O
-	O
plated	O
onto	O
two	O
plates	O
containing	O
5-FOA	O
synthetic	O
medium	O
without	O
tryptophan	O
;	O
one	O
replica	O
was	O
incubated	O
at	O
23	O
°	O
C	O
and	O
the	O
other	O
at	O
37	O
°	O
C	O
.	O

Colonies	O
growing	O
at	O
23	O
°	O
C	O
but	O
not	O
at	O
37	O
°	O
C	O
were	O
picked	O
as	O
candidates	O
.	O

Since	O
approximately	O
10	O
%	O
of	O
the	O
colonies	O
were	O
inviable	O
at	O
both	O
temperatures	O
,	O
we	O
knew	O
that	O
10	O
%	O
of	O
the	O
ENP1	O
PCR	O
products	O
lost	O
their	O
function	O
after	O
the	O
PCR	O
mutagenesis	O
.	O

This	O
confirmed	O
the	O
effectiveness	O
of	O
the	O
mutagenesis	O
procedure	O
.	O

Two	O
candidates	O
showed	O
good	O
growth	O
at	O
23	O
°	O
C	O
but	O
no	O
growth	O
at	O
37	O
°	O
C	O
.	O

They	O
were	O
named	O
strains	O
JBY48	O
and	O
JBY49	O
and	O
contained	O
plasmids	O
with	O
the	O
enp1	O
-	O
1	O
and	O
enp1	O
-	O
2	O
mutations	O
,	O
respectively	O
.	O

The	O
mutated	O
enp1	O
-	O
1	O
gene	O
on	O
pJB19	O
was	O
cloned	O
into	O
an	O
integration	O
vector	O
,	O
pRS304	O
,	O
as	O
an	O
EcoRI	O
fragment	O
.	O

The	O
plasmid	O
was	O
subsequently	O
linearized	O
with	O
SnaBI	O
within	O
the	O
TRP1	O
marker	O
and	O
was	O
integrated	O
at	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
of	O
strain	O
JBY46	O
.	O

Selection	O
on	O
5-FOA	O
was	O
used	O
to	O
remove	O
plasmid	O
pJB23	O
,	O
creating	O
strain	O
JBY51	O
.	O

Sucrose	O
gradient	O
analysis	O
Polyribosome	O
preparation	O
and	O
analysis	O
were	O
carried	O
out	O
essentially	O
as	O
described	O
(	O
26	O
)	O
.	O

Cells	O
grown	O
in	O
YPD	O
were	O
collected	O
at	O
mid	O
-	O
log	O
phase	O
(	O
OD600	O
0.8–1.0	O
)	O
and	O
were	O
broken	O
with	O
glass	O
beads	O
.	O

The	O
lysate	O
was	O
frozen	O
immediately	O
in	O
liquid	O
N2	O
and	O
was	O
stored	O
at	O
–80	O
°	O
C	O
.	O

Lysate	O
(	O
30	O
U	O
of	O
absorbance	O
at	O
OD260	O
)	O
was	O
layered	O
over	O
a	O
7–47	O
%	O
(	O
w	O
/	O
v	O
)	O
sucrose	O
gradient	O
,	O
which	O
was	O
centrifuged	O
at	O
28	O
000	O
r.p.m	O
.	O

for	O
5	O
h	O
at	O
4	O
°	O
C	O
in	O
a	O
SW28	O
rotor	O
and	O
was	O
analyzed	O
with	O
an	O
ISCO	O
UA-5	O
gradient	O
UV	O
detection	O
system	O
on	O
absorbency	O
at	O
254	O
nm	O
.	O

Immunofluorescence	O
Immunofluorescence	O
analysis	O
was	O
carried	O
out	O
essentially	O
as	O
described	O
(	O
27	O
)	O
.	O

Cells	O
were	O
fixed	O
with	O
3.7	O
%	O
formaldehyde	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O
Antibodies	O
included	O
a	O
mouse	B
monoclonal	O
anti	O
-	O
Nop1	O
(	O
a	O
gift	O
from	O
John	O
P.	O
Aris	O
,	O
University	O
of	O
Florida	O
,	O
Gainesville	O
,	O
Florida	O
)	O
and	O
a	O
Texas	O
-	O
red	O
-	O
conjugated	O
donkey	B
-	O
anti	O
-	O
mouse	B
antibody	O
(	O
Jackson	O
Lab	O
)	O
,	O
both	O
used	O
at	O
1:500	O
dilution	O
.	O

Images	O
were	O
taken	O
on	O
a	O
Zeiss	O
Axioplan2	O
microscope	O
equipped	O
with	O
a	O
Zeiss	O
AxioCam	O
camera	O
.	O

Pulse	O
-	O
chase	O
labeling	O
analysis	O
of	O
rRNA	O
For	O
[	O
methyl-3H	O
]	O
methionine	O
pulse	O
-	O
chase	O
analysis	O
,	O
cells	O
were	O
grown	O
in	O
synthetic	O
medium	O
without	O
methionine	O
at	O
room	O
temperature	O
or	O
37	O
°	O
C	O
for	O
2	O
h.	O
When	O
the	O
OD600	O
reached	O
1.0	O
,	O
6	O
ml	O
of	O
the	O
culture	O
were	O
pulse	O
-	O
labeled	O
with	O
250	O
µCi	O
[	O
methyl-3H	O
]	O
methionine	O
(	O
Amersham	O
Pharmacia	O
)	O
for	O
3	O
min	O
and	O
chased	O
with	O
cold	O
methionine	O
(	O
500	O
µg	O
/	O
ml	O
)	O
for	O
2	O
,	O
4	O
or	O
12	O
min	O
.	O

For	O
each	O
time	O
point	O
of	O
the	O
chase	O
1.25	O
ml	O
of	O
culture	O
was	O
mixed	O
with	O
ice	O
and	O
collected	O
.	O

The	O
pellets	O
were	O
frozen	O
immediately	O
in	O
liquid	O
N2	O
and	O
stored	O
at	O
–80	O
°	O
C	O
before	O
total	O
RNA	O
was	O
purified	O
using	O
a	O
hot	O
phenol	O
method	O
(	O
28	O
)	O
.	O

The	O
RNAs	O
were	O
separated	O
on	O
a	O
1.2	O
%	O
agarose	O
formaldehyde	O
gel	O
and	O
transferred	O
onto	O
Hybond	O
-	O
N+	O
nylon	O
membranes	O
(	O
Amersham	O
Pharmacia	O
)	O
.	O

After	O
being	O
sprayed	O
with	O
EN3HANCE	O
(	O
Du	O
Pont	O
)	O
,	O
the	O
membranes	O
were	O
exposed	O
to	O
film	O
at	O
–80	O
°	O
C	O
(	O
29	O
)	O
.	O

Northern	O
analysis	O
Cells	O
were	O
grown	O
inYPD	O
at	O
room	O
temperature	O
or	O
37	O
°	O
C	O
for	O
2–4	O
h.	O
When	O
the	O
OD600	O
reached	O
1.0	O
,	O
10	O
ml	O
of	O
cells	O
were	O
collected	O
and	O
frozen	O
immediately	O
.	O

Total	O
RNA	O
was	O
extracted	O
as	O
described	O
(	O
28	O
)	O
.	O

Five	O
micrograms	O
of	O
RNA	O
were	O
separated	O
on	O
1.2	O
%	O
agarose	O
formaldehyde	O
gels	O
(	O
for	O
high	O
molecular	O
weight	O
RNA	O
)	O
or	O
on	O
6	O
%	O
polyacrylamide	O
7	O
M	O
urea	O
denaturing	O
gels	O
(	O
for	O
low	O
molecular	O
weight	O
RNA	O
)	O
for	O
each	O
sample	O
.	O

The	O
RNA	O
was	O
then	O
transferred	O
to	O
Zeta	O
-	O
Probe	O
GT	O
nylon	O
membranes	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

Probes	O
for	O
hybridyzation	O
were	O
specific	O
oligonucleotides	O
end	O
-	O
labeled	O
using	O
[	O
γ-32P	O
]	O
ATP	O
.	O

After	O
hybridization	O
and	O
washes	O
,	O
membranes	O
were	O
exposed	O
to	O
phosphorimager	O
screens	O
or	O
X	O
-	O
ray	O
films	O
(	O
29	O
)	O
.	O

Oligonucleotides	O
specific	O
for	O
various	O
regions	O
of	O
35S	O
pre	O
-	O
rRNA	O
are	O
:	O
1	O
,	O
GGTCTCTCTGCTGCCG	O
GAAATG	O
;	O
3	O
,	O
AATGAGCCATTCGCAGTTTCACTG	O
;	O
4	O
,	O
GCTCTCATGCTCTTGCCAAAAC	O
;	O
5	O
,	O
TGTTTGTTACCT	O
CTGGGCCCCG	O
;	O
6	O
,	O
TCCAGTTACGAAAATTCTTG	O
;	O
7	O
,	O
CGTATCGCATTTCGCTGCGTTC	O
;	O
8	O
,	O
GTTCGCCTAGAC	O
GCTCTCTCTTC	O
;	O
9	O
,	O
GCGAGATTCCCCTACCCAC	O
.	O

The	O
regions	O
complementary	O
to	O
these	O
oligonucleotides	O
are	O
shown	O
in	O
Figure	O
6A	O
.	O

The	O
oligonucleotides	O
probing	O
box	O
C	O
/	O
D	O
snoRNAs	O
are	O
:	O
U3	O
,	O
TTCGGTTTCTCACTCACTCTGGGGTAC	O
;	O
U14	O
,	O
GGAACCAGTCTTTCATCACCGTG	O
.	O

The	O
oligonucleotides	O
probing	O
box	O
H	O
/	O
ACA	O
snoRNAs	O
are	O
:	O
snoRNA10	O
,	O
CCTTG	O
CAACGGTCCTCATCCGGG	O
;	O
snoRNA30	O
,	O
GTCCGAAGC	O
GCCATCTAGATGA	O
.	O

RNA	O
and	O
protein	O
precipitation	O
analysis	O
Cells	O
were	O
grown	O
in	O
YPD	O
(	O
1	O
l	O
)	O
to	O
OD600	O
1.0	O
,	O
then	O
collected	O
,	O
washed	O
once	O
in	O
ice	O
-	O
cold	O
PBS	O
and	O
broken	O
using	O
glass	O
beads	O
in	O
10	O
ml	O
IPP150	O
buffer	O
(	O
10	O
mM	O
Tris	O
pH	O
8.0	O
,	O
150	O
mM	O
NaCl	O
and	O
0.1	O
%	O
NP-40	O
)	O
with	O
protease	O
inhibitors	O
.	O

The	O
lysates	O
were	O
mixed	O
with	O
200	O
µl	O
IgG	O
agarose	O
beads	O
for	O
2	O
h	O
at	O
4	O
°	O
C	O
.	O

After	O
several	O
washes	O
with	O
50	O
ml	O
IPP150	O
buffer	O
,	O
the	O
IgG	O
beads	O
were	O
collected	O
and	O
the	O
RNA	O
associated	O
with	O
the	O
beads	O
extracted	O
by	O
the	O
hot	O
phenol	O
method	O
(	O
28	O
)	O
.	O

One	O
-	O
tenth	O
of	O
the	O
precipitated	O
RNA	O
was	O
then	O
separated	O
on	O
6	O
%	O
polyacrylamide	O
7	O
M	O
urea	O
denaturing	O
gels	O
and	O
electro	O
-	O
transferred	O
to	O
Zeta	O
-	O
Probe	O
GT	O
nylon	O
membranes	O
.	O

They	O
were	O
probed	O
with	O
[	O
γ-32P	O
]	O
ATP	O
labeled	O
oligonucleotides	O
.	O

For	O
the	O
lanes	O
showing	O
total	O
RNA	O
,	O
2	O
µg	O
RNA	O
prepared	O
from	O
exponentially	O
growing	O
cultures	O
were	O
loaded	O
.	O

For	O
co	O
-	O
precipitation	O
analysis	O
of	O
proteins	O
,	O
the	O
IgG	O
beads	O
were	O
resuspended	O
in	O
2	O
×	O
Laemmli	O
sample	O
buffer	O
,	O
boiled	O
for	O
5	O
min	O
and	O
separated	O
by	O
SDS	O
–	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Approximately	O
1	O
%	O
of	O
the	O
precipitate	O
was	O
loaded	O
onto	O
each	O
lane	O
.	O

For	O
the	O
total	O
protein	O
,	O
0.1	O
%	O
of	O
the	O
extract	O
prior	O
to	O
precipitation	O
was	O
loaded	O
onto	O
each	O
lane	O
.	O

Following	O
electrophoresis	O
,	O
the	O
proteins	O
were	O
transferred	O
to	O
nitrocellulose	O
membranes	O
and	O
detected	O
using	O
anti	O
-	O
Nop1	O
antibody	O
at	O
1:3000	O
dilution	O
(	O
provided	O
by	O
J.	O
Aris	O
)	O
and	O
anti	O
-	O
L3	O
antibody	O
(	O
provided	O
by	O
J.	O
Warner	O
)	O
at	O
1:3000	O
dilution	O
followed	O
by	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
mouse	B
secondary	O
antibody	O
at	O
1:5000	O
dilution	O
.	O

The	O
antibody	O
complexes	O
were	O
detected	O
using	O
ECL	O
-	O
Plus	O
reagents	O
(	O
Amersham	O
Pharmacia	O
)	O
as	O
specified	O
by	O
the	O
manufacturer	O
.	O

RESULTS	O
Construction	O
and	O
analysis	O
of	O
ENP1	O
temperature	O
-	O
sensitive	O
alleles	O
ENP1	O
is	O
an	O
essential	O
yeast	B
gene	O
conserved	O
among	O
eukaryotes	O
(	O
18	O
)	O
.	O

To	O
study	O
its	O
functions	O
,	O
we	O
first	O
created	O
a	O
diploid	O
strain	O
,	O
JBY45	O
,	O
heterozygous	O
for	O
the	O
Δenp1	O
mutation	O
.	O

Then	O
two	O
enp1	O
ts	O
mutant	O
alleles	O
(	O
enp1	O
-	O
1	O
and	O
enp1	O
-	O
2	O
)	O
were	O
generated	O
by	O
random	O
PCR	O
mutagenesis	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Both	O
mutant	O
alleles	O
were	O
recessive	O
to	O
the	O
wild	O
-	O
type	O
ENP1	O
gene	O
.	O

The	O
enp1	O
-	O
1	O
gene	O
was	O
integrated	O
into	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
to	O
create	O
strain	O
JBY51	O
and	O
all	O
subsequent	O
experiments	O
were	O
done	O
with	O
this	O
enp1	O
allele	O
.	O

At	O
23	O
°	O
C	O
the	O
growth	O
of	O
JBY51	O
was	O
comparable	O
to	O
that	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
,	O
but	O
at	O
37	O
°	O
C	O
it	O
did	O
not	O
grow	O
(	O
Fig.	O
2	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
enp1	O
-	O
1	O
contains	O
two	O
point	O
mutations	O
,	O
resulting	O
in	O
substitutions	O
of	O
two	O
amino	O
acids	O
:	O
W242→G	O
and	O
V415→A.	O
No	O
attempt	O
was	O
made	O
to	O
determine	O
whether	O
both	O
mutations	O
were	O
required	O
for	O
the	O
ts	O
phenotype	O
.	O

Flow	O
cytometry	O
of	O
strain	O
JBY51	O
showed	O
DNA	O
content	O
profiles	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
strain	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
ENP1	O
is	O
not	O
involved	O
in	O
cell	O
cycle	O
regulation	O
.	O

Enp1	O
is	O
enriched	O
in	O
the	O
nucleolus	O
Enp1	O
tagged	O
at	O
the	O
C	O
-	O
terminus	O
with	O
the	O
myc	O
epitope	O
was	O
previously	O
found	O
to	O
localize	O
to	O
the	O
nucleus	O
(	O
18	O
)	O
.	O

To	O
expand	O
this	O
analysis	O
,	O
we	O
fused	O
GFP	O
to	O
the	O
N	O
-	O
terminus	O
of	O
Enp1	O
,	O
and	O
expressed	O
the	O
tagged	O
Enp1	O
protein	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
as	O
the	O
sole	O
source	O
of	O
Enp1	O
protein	O
in	O
the	O
cells	O
.	O

Cells	O
of	O
strain	O
CWY13	O
(	O
pMET25-GFP	O
-	O
ENP1	O
)	O
were	O
grown	O
in	O
media	O
with	O
methionine	O
(	O
transcription	O
partially	O
repressed	O
)	O
or	O
without	O
methionine	O
(	O
transcription	O
not	O
repressed	O
)	O
.	O

Growth	O
of	O
CWY13	O
was	O
comparable	O
to	O
that	O
of	O
wild	O
-	O
type	O
cells	O
in	O
both	O
media	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
the	O
GFP	O
tagged	O
Enp1	O
protein	O
was	O
functional	O
.	O

In	O
cells	O
cultured	O
in	O
medium	O
without	O
methionine	O
,	O
in	O
which	O
the	O
ENP	O
transcription	O
was	O
not	O
repressed	O
,	O
the	O
GFP	O
-	O
Enp1	O
protein	O
was	O
expressed	O
at	O
a	O
high	O
level	O
and	O
showed	O
strong	O
green	O
fluorescence	O
distributed	O
throughout	O
the	O
nucleus	O
(	O
data	O
not	O
shown	O
)	O
,	O
consistent	O
with	O
the	O
original	O
observation	O
(	O
18	O
)	O
.	O

With	O
methionine	O
added	O
to	O
the	O
medium	O
,	O
however	O
,	O
the	O
fluorescent	O
signal	O
of	O
GFP	O
-	O
Enp1	O
was	O
weaker	O
and	O
surprisingly	O
showed	O
crescent	O
or	O
cap	O
-	O
like	O
patterns	O
typical	O
of	O
nucleolar	O
proteins	O
(	O
Fig.	O
3A	O
)	O
.	O

This	O
nucleolar	O
enrichment	O
was	O
confirmed	O
by	O
its	O
co	O
-	O
localization	O
with	O
the	O
nucleolar	O
protein	O
Nop1	O
(	O
Fig.	O
3B	O
)	O
.	O

ENP1	O
mutation	O
leads	O
to	O
reduced	O
levels	O
of	O
40S	O
ribosomal	O
subunits	O
The	O
nucleolar	O
enrichment	O
suggested	O
that	O
Enp1	O
might	O
play	O
some	O
role	O
in	O
ribosome	O
synthesis	O
.	O

To	O
test	O
this	O
possibility	O
,	O
cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
,	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
and	O
a	O
top2	O
ts	O
strain	O
RS191	O
(	O
30	O
)	O
were	O
grown	O
in	O
YPD	O
at	O
23	O
or	O
37	O
°	O
C	O
and	O
their	O
ribosome	O
profiles	O
analyzed	O
after	O
separation	O
on	O
sucrose	O
gradients	O
.	O

At	O
23	O
°	O
C	O
,	O
enp1	O
-	O
1	O
cells	O
showed	O
polysome	O
profiles	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
and	O
top2	O
-	O
1	O
strains	O
(	O
Fig.	O
4A	O
–	O
C	O
)	O
.	O

In	O
contrast	O
,	O
after	O
incubation	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
(	O
37	O
°	O
C	O
)	O
for	O
40	O
min	O
(	O
data	O
not	O
shown	O
)	O
and	O
2	O
h	O
,	O
enp1	O
-	O
1	O
cells	O
had	O
reduced	O
levels	O
of	O
40S	O
ribosomal	O
subunits	O
,	O
80S	O
monosomes	O
and	O
polysomes	O
,	O
along	O
with	O
a	O
dramatic	O
increase	O
in	O
the	O
free	O
60S	O
subunit	O
peak	O
(	O
Fig.	O
4F	O
)	O
,	O
while	O
the	O
wild	O
-	O
type	O
and	O
top2	O
-	O
1	O
cells	O
showed	O
little	O
change	O
in	O
polysome	O
profile	O
at	O
37	O
°	O
C	O
(	O
Fig.	O
4D	O
and	O
E	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
changes	O
of	O
the	O
enp1	O
-	O
1	O
polysome	O
profile	O
were	O
due	O
to	O
specific	O
defects	O
caused	O
by	O
the	O
enp1	O
-	O
1	O
mutation	O
,	O
and	O
not	O
due	O
simply	O
to	O
the	O
shift	O
to	O
37	O
°	O
C	O
for	O
a	O
wild	O
-	O
type	O
or	O
ts	O
strain	O
.	O

The	O
processing	O
of	O
pre	O
-	O
rRNA	O
for	O
18S	O
rRNA	O
is	O
impaired	O
in	O
enp1	O
mutants	O
In	O
most	O
cases	O
reductions	O
in	O
ribosomal	O
subunit	O
levels	O
are	O
the	O
results	O
of	O
defects	O
in	O
pre	O
-	O
rRNA	O
processing	O
or	O
ribosome	O
assembly	O
or	O
both	O
(	O
3	O
)	O
.	O

To	O
study	O
the	O
mechanism	O
by	O
which	O
Enp1	O
affects	O
the	O
40S	O
subunit	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
enp1	O
mutations	O
on	O
processing	O
of	O
the	O
pre	O
-	O
rRNA	O
using	O
pulse	O
-	O
chase	O
labeling	O
.	O

[	O
methyl-3H	O
]	O
methionine	O
is	O
preferred	O
for	O
labeling	O
rRNAs	O
in	O
pulse	O
-	O
chase	O
analysis	O
because	O
rRNAs	O
are	O
specifically	O
methylated	O
during	O
the	O
early	O
steps	O
of	O
the	O
processing	O
.	O

Cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
and	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
were	O
grown	O
at	O
23	O
or	O
37	O
°	O
C	O
for	O
2	O
h	O
before	O
they	O
were	O
labeled	O
with	O
[	O
methyl-3H	O
]	O
methionine	O
for	O
3	O
min	O
and	O
chased	O
with	O
cold	O
methionine	O
for	O
2	O
,	O
4	O
and	O
12	O
min	O
.	O

In	O
wild	O
-	O
type	O
cells	O
,	O
the	O
labeled	O
35S	O
rRNA	O
precursor	O
,	O
27S	O
and	O
20S	O
rRNA	O
intermediates	O
were	O
rapidly	O
chased	O
into	O
mature	O
25S	O
and	O
18S	O
rRNAs	O
(	O
Fig.	O
5	O
)	O
,	O
at	O
23	O
or	O
37	O
°	O
C	O
.	O

In	O
contrast	O
,	O
enp1	O
-	O
1	O
cells	O
showed	O
dramatic	O
changes	O
after	O
incubation	O
at	O
37	O
°	O
C	O
.	O

Although	O
at	O
23	O
°	O
C	O
the	O
synthesis	O
and	O
processing	O
were	O
comparable	O
to	O
those	O
of	O
wild	O
-	O
type	O
cells	O
,	O
cells	O
cultured	O
at	O
37	O
°	O
C	O
for	O
2	O
h	O
had	O
neither	O
20S	O
pre	O
-	O
rRNA	O
nor	O
18S	O
rRNA	O
,	O
while	O
25S	O
rRNA	O
was	O
generated	O
at	O
normal	O
levels	O
.	O

The	O
37	O
°	O
C	O
grown	O
enp1	O
-	O
1	O
cells	O
also	O
had	O
low	O
levels	O
of	O
aberrant	O
23S	O
and	O
possibly	O
21S	O
intermediates	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
defect	O
in	O
18S	O
rRNA	O
synthesis	O
was	O
further	O
supported	O
by	O
pulse	O
-	O
chase	O
experiments	O
carried	O
out	O
using	O
[	O
5,6	O
-	O
3H	O
]	O
uracil	O
.	O

The	O
results	O
obtained	O
were	O
essentially	O
the	O
same	O
;	O
no	O
20S	O
pre	O
-	O
rRNA	O
or	O
18S	O
rRNA	O
was	O
produced	O
,	O
while	O
processing	O
to	O
25S	O
rRNA	O
was	O
not	O
affected	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggested	O
that	O
the	O
enp1	O
mutation	O
leads	O
to	O
specific	O
defects	O
in	O
the	O
processing	O
pathway	O
for	O
20S	O
pre	O
-	O
rRNA	O
and	O
18S	O
rRNA	O
,	O
resulting	O
in	O
reduced	O
40S	O
subunit	O
synthesis	O
and	O
a	O
lowered	O
level	O
of	O
the	O
40S	O
subunit	O
.	O

Enp1	O
is	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
sites	O
To	O
define	O
the	O
processing	O
steps	O
affected	O
by	O
the	O
enp1	O
mutation	O
,	O
the	O
steady	O
state	O
levels	O
of	O
rRNA	O
precursors	O
and	O
mature	O
RNAs	O
were	O
analyzed	O
by	O
northern	O
blotting	O
.	O

Total	O
RNAs	O
were	O
isolated	O
from	O
cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
and	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
grown	O
at	O
37	O
°	O
C	O
for	O
2	O
or	O
4	O
h.	O
After	O
separation	O
on	O
formaldehyde	O
agarose	O
,	O
RNAs	O
were	O
transferred	O
onto	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
specific	O
to	O
various	O
regions	O
of	O
the	O
35S	O
pre	O
-	O
rRNA	O
(	O
Fig.	O
6A	O
)	O
.	O

After	O
incubation	O
at	O
37	O
°	O
C	O
,	O
enp1	O
-	O
1	O
cells	O
had	O
wild	O
-	O
type	O
levels	O
of	O
25S	O
rRNA	O
,	O
but	O
reduced	O
levels	O
of	O
18S	O
rRNA	O
(	O
Fig.	O
6B	O
)	O
.	O

A	O
probe	O
specific	O
to	O
ITS1	O
(	O
P5	O
)	O
further	O
revealed	O
that	O
enp1	O
-	O
1	O
cells	O
incubated	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
accumulated	O
two	O
aberrant	O
rRNAs	O
,	O
23S	O
and	O
21S	O
(	O
Fig.	O
6C	O
)	O
.	O

Aberrant	O
rRNA	O
processing	O
products	O
of	O
similar	O
sizes	O
have	O
been	O
described	O
in	O
numerous	O
studies	O
(	O
14,31–34	O
)	O
and	O
result	O
from	O
defects	O
in	O
processing	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
.	O

Additional	O
probes	O
were	O
used	O
to	O
verify	O
the	O
origins	O
of	O
the	O
23S	O
and	O
21S	O
RNAs	O
in	O
the	O
enp1	O
-	O
1	O
strain	O
.	O

The	O
23S	O
product	O
was	O
detected	O
by	O
oligos	O
1	O
,	O
2	O
,	O
4	O
and	O
5	O
,	O
but	O
not	O
by	O
oligos	O
6	O
,	O
7	O
or	O
8	O
(	O
Fig.	O
6D	O
,	O
E	O
,	O
C	O
,	O
F	O
,	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
this	O
RNA	O
extends	O
from	O
the	O
5′	O
end	O
of	O
the	O
35S	O
rRNA	O
to	O
the	O
A3	O
site	O
.	O

The	O
21S	O
product	O
was	O
detected	O
by	O
oligos	O
4	O
and	O
5	O
,	O
but	O
not	O
by	O
oligos	O
1	O
,	O
2	O
,	O
6	O
,	O
7	O
and	O
8	O
(	O
Fig.	O
6E	O
,	O
C	O
,	O
D	O
,	O
F	O
,	O
G	O
and	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
it	O
extends	O
from	O
the	O
A1	O
to	O
the	O
A3	O
site	O
.	O

At	O
37	O
°	O
C	O
the	O
enp1	O
-	O
1	O
cells	O
also	O
had	O
less	O
32S	O
and	O
20S	O
rRNA	O
intermediates	O
(	O
Fig.	O
6B	O
and	O
E	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
enp1	O
mutation	O
led	O
to	O
complete	O
or	O
nearly	O
complete	O
inhibition	O
of	O
processing	O
at	O
site	O
A0	O
and	O
A2	O
,	O
and	O
partial	O
inhibition	O
of	O
processing	O
at	O
site	O
A1	O
.	O

As	O
a	O
consequence	O
,	O
the	O
35S	O
pre	O
-	O
rRNA	O
was	O
cleaved	O
at	O
site	O
A3	O
instead	O
,	O
producing	O
23S	O
and	O
21S	O
rRNA	O
products	O
.	O

Consistent	O
with	O
this	O
theory	O
,	O
the	O
27SA2	O
rRNA	O
intermediate	O
level	O
was	O
greatly	O
reduced	O
in	O
enp1	O
cells	O
at	O
37	O
°	O
C	O
(	O
Fig.	O
6C	O
)	O
due	O
to	O
the	O
inhibition	O
of	O
processing	O
at	O
A2	O
,	O
while	O
the	O
27SB	O
pre	O
-	O
rRNA	O
level	O
was	O
similar	O
to	O
wild	O
-	O
type	O
cells	O
(	O
Fig.	O
6	O
G	O
)	O
.	O

Moreover	O
,	O
no	O
difference	O
in	O
the	O
5.8	O
rRNA	O
level	O
was	O
observed	O
between	O
the	O
wild	O
-	O
type	O
cells	O
and	O
enp1	O
cells	O
(	O
Fig.	O
6H	O
)	O
.	O

Enp1	O
is	O
associated	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
and	O
with	O
Nop1	O
It	O
has	O
previously	O
been	O
shown	O
that	O
mutations	O
in	O
the	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
and	O
in	O
their	O
associated	O
proteins	O
affect	O
processing	O
of	O
35S	O
pre	O
-	O
rRNA	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
.	O

Because	O
of	O
the	O
similarity	O
with	O
the	O
processing	O
defects	O
of	O
enp1	O
-	O
1	O
strains	O
,	O
we	O
tested	O
the	O
association	O
between	O
Enp1	O
and	O
snoRNAs	O
.	O

To	O
do	O
this	O
,	O
we	O
created	O
a	O
strain	O
in	O
which	O
a	O
TAP	O
tag	O
was	O
fused	O
to	O
the	O
C	O
-	O
terminus	O
of	O
Enp1	O
.	O

The	O
TAP	O
tag	O
contains	O
Staphylococcus	B
aureus	I
Protein	O
A	O
as	O
well	O
as	O
calmodulin	O
-	O
binding	O
peptide	O
sequences	O
,	O
so	O
the	O
tagged	O
Enp1	O
binds	O
IgG	O
beads	O
with	O
high	O
specificity	O
.	O

Cells	O
grew	O
well	O
with	O
the	O
TAP	O
-	O
tagged	O
Enp1	O
as	O
the	O
only	O
source	O
of	O
Enp1	O
protein	O
,	O
showing	O
that	O
it	O
was	O
functional	O
.	O

As	O
a	O
control	O
,	O
we	O
used	O
a	O
TAP	O
tag	O
on	O
an	O
unrelated	O
cytoplasmic	O
protein	O
,	O
Hst2	O
.	O

Strain	O
CWY14	O
(	O
ENP1-TAP	O
)	O
and	O
the	O
Hst2-TAP	O
tagged	O
strain	O
were	O
grown	O
in	O
YPD	O
to	O
mid	O
-	O
exponential	O
phase	O
before	O
being	O
harvested	O
.	O

Extracts	O
were	O
prepared	O
and	O
mixed	O
with	O
IgG	O
agarose	O
beads	O
to	O
precipitate	O
Enp1-TAP	O
and	O
associated	O
RNAs	O
.	O

Total	O
RNAs	O
were	O
extracted	O
from	O
washed	O
IgG	O
beads	O
,	O
separated	O
on	O
6	O
%	O
polyacrylamide	O
denaturing	O
gels	O
,	O
transferred	O
to	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
.	O

Northern	O
analysis	O
revealed	O
that	O
Enp1-TAP	O
precipitates	O
were	O
enriched	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
relative	O
to	O
precipitates	O
from	O
the	O
Hst2-tagged	O
strain	O
(	O
Fig.	O
7A	O
)	O
.	O

The	O
Enp1-TAP	O
samples	O
were	O
not	O
enriched	O
with	O
snR30	O
snoRNA	O
(	O
Fig.	O
7A	O
)	O
,	O
nor	O
with	O
U24	O
or	O
U18	O
snoRNAs	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
found	O
no	O
change	O
in	O
the	O
levels	O
of	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
in	O
the	O
enp1	O
mutant	O
,	O
indicating	O
that	O
the	O
mutation	O
did	O
not	O
affect	O
snoRNAs	O
levels	O
(	O
Fig.	O
6I	O
)	O
.	O

The	O
results	O
indicate	O
that	O
Enp1	O
associates	O
in	O
vivo	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
.	O

Much	O
less	O
U3	O
RNA	O
co	O
-	O
immunoprecipitated	O
with	O
Enp1-TAP	O
than	O
with	O
Protein	O
A	O
-	O
tagged	O
Nop1	O
,	O
which	O
is	O
known	O
to	O
associate	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
(	O
Fig.	O
7A	O
)	O
.	O

However	O
,	O
Protein	O
A	O
-	O
Nop1	O
was	O
much	O
more	O
efficiently	O
precipitated	O
than	O
was	O
the	O
Enp1-TAP	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
similar	O
amounts	O
of	O
RNAs	O
are	O
associated	O
with	O
the	O
two	O
proteins	O
and	O
that	O
the	O
proteins	O
are	O
part	O
of	O
the	O
same	O
complex	O
.	O

To	O
address	O
this	O
further	O
,	O
we	O
checked	O
for	O
the	O
presence	O
of	O
Nop1	O
in	O
the	O
Enp1-TAP	O
immunoprecipitates	O
.	O

Figure	O
7B	O
shows	O
that	O
Nop1	O
indeed	O
is	O
in	O
the	O
Enp1	O
precipitate	O
but	O
not	O
in	O
the	O
Hst2	O
control	O
,	O
whereas	O
an	O
abundant	O
ribosomal	O
protein	O
,	O
L3	O
,	O
is	O
in	O
neither	O
precipitate	O
.	O

U3	O
and	O
U14	O
snoRNAs	O
have	O
been	O
shown	O
to	O
interact	O
with	O
rRNA	O
precursors	O
and	O
these	O
interactions	O
are	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
(	O
35–37	O
)	O
.	O

Using	O
an	O
in	O
vitro	O
system	O
,	O
U3	O
was	O
also	O
shown	O
to	O
be	O
associated	O
with	O
its	O
rRNA	O
substrate	O
and	O
processing	O
product	O
(	O
38	O
)	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
Enp1	O
might	O
also	O
be	O
associated	O
with	O
rRNAs	O
since	O
its	O
function	O
in	O
rRNA	O
processing	O
appeared	O
linked	O
to	O
those	O
of	O
U3	O
and	O
U14	O
snoRNAs	O
.	O

To	O
test	O
this	O
possibility	O
,	O
we	O
further	O
analyzed	O
the	O
RNAs	O
that	O
co	O
-	O
precipiate	O
with	O
TAP	O
-	O
tagged	O
Enp1	O
.	O

The	O
RNAs	O
were	O
separated	O
on	O
1.2	O
%	O
agarose	O
formaldehyde	O
gels	O
or	O
on	O
polyacrylamide	O
denaturing	O
gels	O
,	O
transferred	O
to	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
for	O
pre	O
-	O
rRNAs	O
.	O

A	O
probe	O
(	O
P4	O
;	O
see	O
Fig.	O
6	O
)	O
specific	O
to	O
20s	O
and	O
its	O
precursors	O
revealed	O
that	O
pre	O
-	O
rRNAs	O
35S	O
,	O
33S	O
,	O
32S	O
and	O
20S	O
specifically	O
co	O
-	O
precipitated	O
with	O
Enp1-TAP	O
(	O
Fig.	O
7C	O
)	O
.	O

No	O
such	O
enrichment	O
was	O
found	O
using	O
a	O
probe	O
(	O
P8	O
;	O
see	O
Fig.	O
6	O
)	O
specific	O
for	O
27S	O
RNAs	O
or	O
a	O
probe	O
for	O
5.8S	O
RNA	O
(	O
Fig.	O
7C	O
)	O
.	O

These	O
results	O
clearly	O
demonstrated	O
that	O
Enp1	O
is	O
associated	O
with	O
substrates	O
and	O
products	O
of	O
the	O
early	O
steps	O
of	O
18S	O
rRNA	O
processing	O
.	O

Comparison	O
of	O
Enp1	O
with	O
homologs	O
in	O
other	O
organisms	O
Homologs	O
of	O
Enp1	O
protein	O
in	O
human	B
,	O
Drosophila	B
and	O
Caenorhabditis	B
elegans	I
have	O
been	O
reported	O
(	O
18	O
)	O
.	O

A	O
previously	O
described	O
human	B
homolog	O
,	O
bystin	O
,	O
was	O
only	O
306	O
amino	O
acids	O
in	O
length	O
,	O
and	O
lacked	O
sequences	O
corresponding	O
to	O
the	O
N	O
-	O
terminal	O
163	O
amino	O
acids	O
of	O
yeast	B
Enp1	O
(	O
19	O
)	O
.	O

In	O
contrast	O
,	O
we	O
identified	O
a	O
human	B
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
,	O
BC007340	O
in	O
a	O
Blast	O
search	O
that	O
revealed	O
an	O
ORF	O
of	O
1311	O
nucleotides	O
encoding	O
a	O
437	O
amino	O
acid	O
polypeptide	O
(	O
39	O
)	O
.	O

Comparison	O
of	O
this	O
437	O
amino	O
acid	O
polypeptide	O
with	O
human	B
bystin	O
(	O
19	O
)	O
showed	O
that	O
they	O
were	O
encoded	O
by	O
the	O
same	O
gene	O
on	O
human	B
chromosome	O
6	O
.	O

The	O
reported	O
sequence	O
for	O
human	B
bystin	O
is	O
a	O
fragment	O
of	O
the	O
437	O
amino	O
acid	O
human	B
Enp1	O
protein	O
,	O
due	O
to	O
a	O
truncated	O
cDNA	O
sequence	O
.	O

Also	O
,	O
a	O
sequence	O
discrepancy	O
at	O
the	O
C	O
-	O
terminus	O
is	O
due	O
to	O
inaccurate	O
DNA	O
sequence	O
of	O
the	O
human	B
bystin	O
,	O
as	O
confirmed	O
by	O
available	O
human	B
genome	O
and	O
EST	O
sequences	O
.	O

Searches	O
of	O
the	O
database	O
of	O
other	O
organisms	O
identified	O
Enp1	O
homologs	O
in	O
S.pombe	B
,	O
Arabidopsis	B
thaliana	I
,	O
C.elegans	B
,	O
Drosophila	B
melanogaster	I
and	O
mouse	B
.	O

The	O
alignment	O
of	O
the	O
homologs	O
showed	O
that	O
they	O
shared	O
homology	O
from	O
the	O
N	O
-	O
terminus	O
to	O
the	O
C	O
-	O
terminus	O
,	O
with	O
the	O
C	O
-	O
terminal	O
half	O
extremely	O
well	O
conserved	O
,	O
with	O
close	O
to	O
90	O
%	O
similarity	O
(	O
Fig.	O
8)	O
.	O

One	O
interesting	O
observation	O
is	O
that	O
the	O
two	O
amino	O
acids	O
changed	O
in	O
the	O
enp1	O
-	O
1	O
mutant	O
,	O
W242	O
and	O
V415	O
,	O
are	O
conserved	O
among	O
all	O
homologs	O
.	O

The	O
human	B
Enp1	O
homolog	O
was	O
cloned	O
and	O
expressed	O
in	O
yeast	B
and	O
tested	O
for	O
function	O
.	O

Expressed	O
under	O
the	O
control	O
of	O
ADH	O
,	O
TEF	O
or	O
GPD	O
promoter	O
,	O
the	O
human	B
Enp1	O
homolog	O
did	O
not	O
complement	O
a	O
yeast	B
enp1	O
null	O
mutant	O
.	O

However	O
,	O
a	O
GFP	O
fusion	O
to	O
the	O
N	O
-	O
terminus	O
of	O
human	B
Enp1	O
homolog	O
localized	O
to	O
the	O
nucleus	O
and	O
was	O
enriched	O
in	O
the	O
nucleolus	O
(	O
data	O
not	O
shown	O
)	O
.	O

DISCUSSION	O
ENP1	O
is	O
a	O
yeast	B
gene	O
first	O
identified	O
in	O
a	O
genetic	O
screen	O
for	O
complementation	O
of	O
mutations	O
in	O
ost4	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
oligosaccharide	O
transferase	O
(	O
17	O
)	O
,	O
although	O
subsequent	O
work	O
showed	O
that	O
it	O
is	O
unlikely	O
that	O
Enp1	O
has	O
any	O
connection	O
to	O
oligosaccharide	O
transferase	O
(	O
18	O
)	O
.	O

ENP1	O
was	O
shown	O
to	O
be	O
essential	O
for	O
viability	O
and	O
the	O
Enp1	O
protein	O
localized	O
to	O
the	O
nucleus	O
(	O
18	O
)	O
.	O

When	O
we	O
re	O
-	O
examined	O
the	O
localization	O
of	O
Enp1	O
,	O
we	O
observed	O
that	O
the	O
protein	O
was	O
enriched	O
in	O
the	O
nucleolus	O
.	O

This	O
finding	O
led	O
us	O
to	O
test	O
for	O
a	O
role	O
of	O
Enp1	O
in	O
ribosome	O
synthesis	O
.	O

Using	O
an	O
enp1	O
ts	O
mutant	O
,	O
we	O
found	O
that	O
depletion	O
of	O
Enp1	O
caused	O
a	O
40S	O
ribosomal	O
subunit	O
deficiency	O
.	O

Further	O
analysis	O
revealed	O
that	O
this	O
deficiency	O
was	O
not	O
due	O
to	O
a	O
change	O
of	O
the	O
subunit	O
's	O
stability	O
,	O
but	O
to	O
a	O
defect	O
in	O
the	O
synthesis	O
of	O
the	O
subunit	O
's	O
18S	O
rRNA	O
component	O
.	O

Pulse	O
-	O
chase	O
analysis	O
of	O
RNA	O
synthesis	O
in	O
an	O
enp1	O
-	O
1	O
strain	O
revealed	O
that	O
no	O
20S	O
pre	O
-	O
rRNA	O
or	O
18S	O
rRNA	O
was	O
made	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
,	O
while	O
levels	O
of	O
25S	O
rRNA	O
appeared	O
normal	O
.	O

Low	O
levels	O
of	O
precursors	O
to	O
18S	O
rRNA	O
were	O
detected	O
in	O
the	O
mutants	O
,	O
and	O
they	O
were	O
extremely	O
unstable	O
.	O

Northern	O
analysis	O
of	O
steady	O
state	O
RNA	O
levels	O
demonstrated	O
that	O
the	O
enp1	O
mutation	O
specifically	O
inhibited	O
the	O
pre	O
-	O
rRNA	O
early	O
cleavages	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
,	O
which	O
are	O
required	O
for	O
the	O
production	O
of	O
the	O
20S	O
pre	O
-	O
rRNA	O
and	O
the	O
18S	O
rRNA	O
.	O

These	O
defects	O
of	O
the	O
enp1	O
mutation	O
on	O
rRNA	O
processing	O
are	O
very	O
similar	O
to	O
those	O
caused	O
by	O
mutation	O
of	O
KRR1	O
,	O
another	O
essential	O
nucleolar	O
gene	O
required	O
for	O
synthesis	O
of	O
the	O
40S	O
,	O
but	O
not	O
the	O
60S	O
subunit	O
(	O
40	O
)	O
.	O

Co	O
-	O
precipitation	O
analyses	O
provided	O
strong	O
evidence	O
that	O
Enp1	O
is	O
directly	O
involved	O
in	O
pre	O
-	O
rRNA	O
processing	O
.	O

In	O
these	O
experiments	O
,	O
TAP	O
-	O
tagged	O
Enp1	O
bound	O
to	O
IgG	O
beads	O
specifically	O
co	O
-	O
precipitated	O
with	O
two	O
snoRNAs	O
,	O
U3	O
and	O
U14	O
,	O
and	O
with	O
the	O
35S	O
,	O
33S	O
,	O
32S	O
and	O
20S	O
pre	O
-	O
rRNAs	O
.	O

Among	O
the	O
more	O
than	O
100	O
snoRNAs	O
in	O
yeast	B
cells	O
,	O
U3	O
,	O
U14	O
,	O
snR10	O
,	O
snR30	O
and	O
MRP	O
RNA	O
are	O
the	O
only	O
ones	O
required	O
for	O
rRNA	O
processing	O
.	O

It	O
has	O
been	O
shown	O
that	O
mutations	O
in	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
and	O
protein	O
components	O
of	O
the	O
snoRNPs	O
affect	O
processing	O
at	O
sites	O
A0	O
,	O
A1	O
or	O
A2	O
(	O
15,16,41,42	O
)	O
.	O

Enp1	O
's	O
interaction	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
suggests	O
that	O
Enp1	O
's	O
function	O
in	O
rRNA	O
processing	O
involves	O
these	O
two	O
snoRNAs	O
.	O

The	O
fact	O
that	O
the	O
nucleolar	O
protein	O
,	O
Nop1	O
,	O
known	O
to	O
bind	O
to	O
U3	O
and	O
U14	O
RNAs	O
,	O
also	O
was	O
found	O
in	O
the	O
Enp1	O
precipitate	O
,	O
provides	O
additional	O
evidence	O
that	O
Enp1	O
is	O
part	O
of	O
a	O
complex	O
involved	O
in	O
processing	O
of	O
rRNA	O
.	O

Recently	O
,	O
a	O
genome	O
-	O
wide	O
study	O
of	O
yeast	B
protein	O
complexes	O
,	O
using	O
a	O
TAP	O
tag	O
method	O
similar	O
to	O
ours	O
,	O
reported	O
a	O
number	O
of	O
proteins	O
that	O
co	O
-	O
immunoprecipitated	O
with	O
Enp1	O
(	O
43	O
)	O
.	O

These	O
proteins	O
included	O
Imp4	O
,	O
Kre31	O
,	O
Kre33	O
,	O
Mpp10	O
,	O
Nop1	O
,	O
Nop14	O
and	O
Sof1	O
,	O
all	O
of	O
which	O
have	O
been	O
implicated	O
in	O
18S	O
RNA	O
processing	O
or	O
40S	O
biogenesis	O
.	O

Very	O
recently	O
(	O
after	O
the	O
studies	O
in	O
this	O
manuscript	O
were	O
concluded	O
)	O
Grandi	O
et	O
al.	O
published	O
an	O
analysis	O
of	O
components	O
of	O
the	O
90s	O
preribosomal	O
particle	O
,	O
which	O
include	O
the	O
35S	O
pre	O
-	O
rRNA	O
,	O
U3	O
snoRNP	O
and	O
rRNA	O
processing	O
factors	O
for	O
the	O
40S	O
subunit	O
(	O
44	O
)	O
.	O

In	O
agreement	O
with	O
our	O
findings	O
,	O
they	O
found	O
that	O
Enp1	O
is	O
a	O
component	O
of	O
this	O
90s	O
complex	O
and	O
also	O
of	O
a	O
smaller	O
complex	O
containing	O
the	O
20S	O
pre	O
-	O
rRNA	O
.	O

Surprisingly	O
,	O
none	O
of	O
the	O
other	O
proteins	O
involved	O
in	O
processing	O
of	O
pre	O
-	O
rRNAs	O
that	O
were	O
tested	O
associated	O
with	O
the	O
20S	O
rRNA	O
,	O
suggesting	O
that	O
those	O
proteins	O
,	O
but	O
not	O
Enp1	O
,	O
are	O
released	O
prior	O
to	O
20S	O
pre	O
-	O
rRNA	O
formation	O
(	O
44	O
)	O
.	O

The	O
authors	O
also	O
showed	O
co	O
-	O
precipitation	O
of	O
Enp1	O
with	O
dimethylated	O
20S	O
pre	O
-	O
rRNA	O
,	O
which	O
is	O
formed	O
after	O
export	O
of	O
20S	O
to	O
the	O
cytoplasm	O
.	O

These	O
results	O
of	O
Grandi	O
et	O
al.	O
suggest	O
that	O
Enp1	O
may	O
also	O
be	O
involved	O
in	O
later	O
steps	O
of	O
processing	O
or	O
nuclear	O
export	O
.	O

A	O
previous	O
study	O
on	O
the	O
Enp1	O
human	B
homolog	O
,	O
bystin	O
,	O
reported	O
that	O
the	O
protein	O
was	O
localized	O
in	O
the	O
cytoplasm	O
of	O
mammalian	O
cells	O
and	O
might	O
be	O
involved	O
in	O
cell	O
adhesion	O
(	O
19	O
)	O
.	O

Our	O
discovery	O
of	O
the	O
437	O
amino	O
acid	O
human	B
Enp1	O
homolog	O
revealed	O
that	O
the	O
bystin	O
studied	O
previously	O
was	O
from	O
a	O
truncated	O
library	O
cDNA	O
encoding	O
only	O
the	O
C	O
-	O
terminal	O
306	O
amino	O
acids	O
.	O

Although	O
the	O
human	B
homolog	O
of	O
Enp1	O
did	O
not	O
complement	O
a	O
yeast	B
Δenp1	O
mutant	O
,	O
we	O
did	O
show	O
that	O
it	O
was	O
localized	O
to	O
the	O
nucleus	O
and	O
enriched	O
in	O
the	O
nucleolus	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
strongly	O
suggests	O
that	O
the	O
conserved	O
function	O
of	O
Enp1	O
is	O
in	O
rRNA	O
processing	O
.	O

The	O
cytoplasmic	O
localization	O
of	O
bystin	O
and	O
its	O
proposed	O
function	O
in	O
cell	O
adhesion	O
are	O
unlikely	O
to	O
reflect	O
the	O
actual	O
function	O
of	O
the	O
human	B
Enp1	O
homolog	O
.	O

It	O
will	O
be	O
important	O
to	O
study	O
the	O
nature	O
of	O
the	O
associations	O
between	O
Enp1	O
and	O
U3	O
and	O
U14	O
snoRNPs	O
,	O
and	O
to	O
learn	O
more	O
about	O
the	O
exact	O
role	O
of	O
Enp1	O
in	O
ribosomal	O
RNA	O
processing	O
.	O

Piezoelectric	O
osteotomy	O
in	O
hand	O
surgery	O
:	O
first	O
experiences	O
with	O
a	O
new	O
technique	O
Abstract	O
Background	O
In	O
hand	O
and	O
spinal	O
surgery	O
nerve	O
lesions	O
are	O
feared	O
complications	O
with	O
the	O
use	O
of	O
standard	O
oscillating	O
saws	O
.	O

Oral	O
surgeons	O
have	O
started	O
using	O
a	O
newly	O
developed	O
ultrasound	O
bone	O
scalpel	O
when	O
performing	O
precise	O
osteotomies	O
.	O

By	O
using	O
a	O
frequency	O
of	O
25–29	O
kHz	O
only	O
mineralized	O
tissue	O
is	O
cut	O
,	O
sparing	O
the	O
soft	O
tissue	O
.	O

This	O
reduces	O
the	O
risk	O
of	O
nerve	O
lesions	O
.	O

As	O
there	O
is	O
a	O
lack	O
of	O
experience	O
with	O
this	O
technique	O
in	O
the	O
field	O
of	O
orthopaedic	O
bone	O
surgery	O
,	O
we	O
performed	O
the	O
first	O
ultrasound	O
osteotomy	O
in	O
hand	O
surgery	O
.	O

Method	O
While	O
performing	O
a	O
correctional	O
osteotomy	O
of	O
the	O
5th	O
metacarpal	O
bone	O
we	O
used	O
the	O
Piezosurgery	O
®	O
Device	O
from	O
Mectron	O
[	O
Italy	O
]	O
instead	O
of	O
the	O
usual	O
oscillating	O
saw	O
.	O

We	O
will	O
report	O
on	O
our	O
experience	O
with	O
one	O
case	O
,	O
with	O
a	O
follow	O
up	O
time	O
of	O
one	O
year	O
.	O

Results	O

The	O
cut	O
was	O
highly	O
precise	O
and	O
there	O
were	O
no	O
vibrations	O
of	O
the	O
bone	O
.	O

The	O
time	O
needed	O
for	O
the	O
operation	O
was	O
slightly	O
longer	O
than	O
the	O
time	O
needed	O
while	O
using	O
the	O
usual	O
saw	O
.	O

Bone	O
healing	O
was	O
good	O
and	O
at	O
no	O
point	O
were	O
there	O
any	O
neurovascular	O
disturbances	O
.	O

Conclusion	O

The	O
Piezosurgery	O
®	O
Device	O
is	O
useful	O
for	O
small	O
long	O
bone	O
osteotomies	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
curved	O
cutting	O
and	O
provides	O
an	O
opportunity	O
for	O
new	O
osteotomy	O
techniques	O
.	O

As	O
the	O
device	O
selectively	O
cuts	O
bone	O
we	O
feel	O
that	O
this	O
device	O
has	O
great	O
potential	O
in	O
the	O
field	O
of	O
hand-	O
and	O
spinal	O
surgery	O
.	O

Background	O
For	O
osteotomies	O
of	O
the	O
hand	O
oscillating	O
saws	O
are	O
usually	O
used	O
[	O
1	O
]	O
.	O

Even	O
though	O
they	O
are	O
varied	O
in	O
size	O
,	O
they	O
are	O
not	O
very	O
precise	O
for	O
use	O
in	O
the	O
vicinity	O
of	O
nerves	O
and	O
arteries	O
.	O

They	O
also	O
pose	O
problems	O
while	O
being	O
used	O
in	O
conjunction	O
with	O
magnification	O
,	O
as	O
one	O
's	O
range	O
of	O
sight	O
and	O
focus	O
is	O
restricted	O
when	O
wearing	O
magnifying	O
glasses	O
.	O

For	O
that	O
reason	O
oral	O
surgeons	O
have	O
moved	O
to	O
using	O
the	O
newly	O
developed	O
piezoelectrical	O
bone	O
scalpel	O
when	O
operating	O
in	O
the	O
near	O
vicinity	O
of	O
nerves	O
or	O
arteries	O
.	O

The	O
tip	O
of	O
this	O
instrument	O
oscillates	O
in	O
the	O
frequency	O
of	O
ultrasound	O
[	O
2	O
]	O
.	O

The	O
mechanism	O
of	O
this	O
device	O
is	O
based	O
on	O
the	O
so	O
called	O
Piezo	O
–	O
Effect	O
.	O

French	O
Physicists	O
Jean	O
and	O
Marie	O
Curie	O
first	O
mentioned	O
the	O
direct	O
Piezo	O
-	O
Effect	O
1880	O
,	O
whereby	O
certain	O
crystals	O
produce	O
electrical	O
current	O
while	O
under	O
mechanical	O
pressure	O
.	O

The	O
reciprocal	O
effect	O
,	O
by	O
which	O
the	O
crystals	O
are	O
deformed	O
when	O
under	O
electrical	O
current	O
,	O
was	O
then	O
discovered	O
a	O
while	O
later	O
.	O

This	O
is	O
the	O
effect	O
being	O
used	O
by	O
the	O
Piezosurgery	O
Device	O
®	O
.	O

In	O
this	O
device	O
,	O
the	O
electrical	O
field	O
is	O
located	O
in	O
the	O
handle	O
of	O
the	O
saw	O
[	O
3	O
]	O
.	O

Due	O
to	O
the	O
deformation	O
caused	O
by	O
the	O
electrical	O
current	O
,	O
a	O
cutting	O
–	O
hammering	O
movement	O
is	O
produced	O
at	O
the	O
tip	O
of	O
the	O
instrument	O
.	O

These	O
micro	O
movements	O
are	O
in	O
the	O
frequency	O
range	O
of	O
25	O
to	O
29	O
kHz	O
and	O
,	O
depending	O
on	O
the	O
insert	O
,	O
with	O
an	O
amplitude	O
of	O
60	O
to	O
210	O
μm	O
.	O

This	O
way	O
only	O
mineralized	O
tissue	O
is	O
selectively	O
cut	O
.	O

Neurovascular	O
tissue	O
and	O
other	O
soft	O
tissue	O
would	O
only	O
be	O
cut	O
by	O
a	O
frequency	O
of	O
above	O
50	O
kHz	O
[	O
3	O
-	O
5	O
]	O
.	O

Depending	O
on	O
the	O
strength	O
of	O
the	O
bone	O
and	O
the	O
blade	O
geometry	O
,	O
the	O
efficiency	O
of	O
the	O
cutting	O
can	O
be	O
regulated	O
by	O
the	O
frequency	O
modulator	O
and	O
the	O
power	O
level	O
.	O

For	O
cooling	O
there	O
is	O
an	O
integrated	O
pump	O
with	O
five	O
different	O
working	O
levels	O
.	O

This	O
pump	O
automatically	O
washes	O
physiological	O
solution	O
to	O
the	O
area	O
being	O
cut	O
.	O

The	O
cost	O
of	O
the	O
device	O
is	O
about	O
7.000	O
USD	O
.	O

Additional	O
costs	O
per	O
operation	O
are	O
for	O
the	O
cooling	O
liquid	O
and	O
are	O
in	O
the	O
range	O
of	O
a	O
few	O
dollars	O
.	O

We	O
have	O
used	O
the	O
Piezosurgery	O
Device	O
®	O
by	O
Mectron	O
[	O
Italy	O
]	O
[	O
3	O
]	O
for	O
the	O
first	O
time	O
in	O
osteotomies	O
of	O
the	O
long	O
bone	O
in	O
the	O
field	O
of	O
hand	O
surgery	O
.	O

We	O
will	O
report	O
on	O
our	O
experience	O
with	O
one	O
case	O
,	O
with	O
a	O
follow	O
up	O
time	O
of	O
one	O
year	O
.	O

Method	O
The	O
correctional	O
osteotomy	O
was	O
performed	O
on	O
a	O
23	O
year	O
old	O
worker	O
who	O
suffered	O
a	O
malunited	O
metacarpal	O
bone	O
fracture	O
of	O
the	O
fifth	O
finger	O
on	O
his	O
dominant	O
hand	O
.	O

The	O
X	O
-	O
ray	O
revealed	O
a	O
45	O
degree	O
angular	O
deformity	O
of	O
the	O
fifth	O
metacarpal	O
neck	O
with	O
internal	O
rotation	O
.	O

(	O
Figure	O
1	O
)	O
.	O

The	O
operation	O
was	O
performed	O
under	O
regional	O
anesthesia	O
.	O

A	O
longitudinal	O
incision	O
was	O
made	O
over	O
the	O
fifth	O
metacarpal	O
.	O

The	O
tendon	O
of	O
the	O
extensor	O
digiti	O
minimi	O
was	O
found	O
and	O
on	O
its	O
radial	O
side	O
the	O
periosteum	O
of	O
metacarpal	O
five	O
was	O
reached	O
.	O

The	O
periosteum	O
was	O
opened	O
longitudinally	O
over	O
the	O
defect	O
as	O
usual	O
.	O

For	O
the	O
correction	O
of	O
the	O
defect	O
of	O
45	O
degrees	O
,	O
a	O
bone	O
wedge	O
was	O
excised	O
.	O

Instead	O
of	O
using	O
the	O
traditional	O
oscillating	O
saw	O
,	O
the	O
Piezosurgery	O
Device	O
®	O
[	O
3	O
]	O
was	O
used	O
(	O
Figure	O
2	O
)	O
.	O

We	O
used	O
a	O
sharp	O
hardened	O
saw	O
coated	O
with	O
titannitrid	O
(	O
Figure	O
3	O
)	O
.	O

For	O
most	O
of	O
the	O
surgery	O
the	O
highest	O
power	O
level	O
,	O
the	O
boosted	O
burst	O
c	O
,	O
was	O
used	O
.	O

We	O
set	O
the	O
automatic	O
cooling	O
of	O
the	O
area	O
with	O
water	O
to	O
its	O
highest	O
level	O
.	O

The	O
angulation	O
and	O
rotation	O
was	O
corrected	O
and	O
fixed	O
with	O
a	O
1.5	O
mm	O
titanium	O
five	O
-	O
hole	O
plate	O
and	O
four	O
screws	O
.	O

Closure	O
of	O
the	O
wound	O
was	O
done	O
in	O
layers	O
.	O

Mobilization	O
was	O
started	O
on	O
the	O
10th	O
postoperative	O
day	O
.	O

The	O
overall	O
time	O
of	O
observation	O
was	O
one	O
year	O
.	O

Results	O
and	O
discussion	O
The	O
Piezosurgery	O
®	O
Device	O
is	O
ideally	O
sized	O
for	O
hand	O
surgery	O
.	O

The	O
cutting	O
was	O
very	O
precise	O
.	O

The	O
edges	O
of	O
the	O
osteotomy	O
were	O
all	O
sharp	O
to	O
the	O
edge	O
,	O
there	O
was	O
no	O
need	O
to	O
split	O
the	O
bone	O
with	O
a	O
chisel	O
,	O
nor	O
was	O
there	O
the	O
danger	O
of	O
a	O
break	O
out	O
.	O

During	O
the	O
osteotomy	O
there	O
were	O
no	O
disturbing	O
vibrations	O
in	O
the	O
area	O
of	O
operation	O
.	O

This	O
absence	O
of	O
vibration	O
is	O
very	O
practical	O
for	O
operations	O
using	O
a	O
magnifier	O
.	O

Vercellotti	O
mentions	O
that	O
to	O
overcome	O
any	O
problems	O
during	O
surgery	O
,	O
instead	O
of	O
increasing	O
pressure	O
on	O
the	O
hand	O
piece	O
,	O
as	O
in	O
traditional	O
techniques	O
,	O
it	O
is	O
necessary	O
to	O
find	O
the	O
correct	O
pressure	O
to	O
achieve	O
the	O
desired	O
result	O
.	O

With	O
piezoelectric	O
surgery	O
,	O
increasing	O
the	O
working	O
pressure	O
above	O
a	O
certain	O
limit	O
impedes	O
the	O
vibrations	O
of	O
the	O
insert	O
[	O
4	O
]	O
.	O

We	O
have	O
also	O
experienced	O
this	O
in	O
our	O
study	O
.	O

The	O
instrument	O
can	O
be	O
moved	O
in	O
all	O
directions	O
comparable	O
to	O
a	O
pen	O
.	O

The	O
tip	O
of	O
the	O
instrument	O
is	O
exchangeable	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
multiplanar	O
as	O
well	O
as	O
curved	O
cutting	O
.	O

Because	O
of	O
the	O
automatic	O
water	O
cooling	O
during	O
the	O
whole	O
procedure	O
,	O
there	O
is	O
always	O
a	O
clear	O
view	O
onto	O
the	O
object	O
.	O

This	O
is	O
something	O
oral	O
surgeons	O
found	O
especially	O
useful	O
[	O
6	O
]	O
.	O

The	O
authors	O
mention	O
that	O
the	O
downside	O
of	O
the	O
device	O
is	O
the	O
relative	O
slow	O
sawing	O
process	O
.	O

We	O
needed	O
about	O
30	O
seconds	O
for	O
one	O
cut	O
of	O
the	O
relatively	O
small	O
bone	O
.	O

This	O
is	O
about	O
20	O
seconds	O
longer	O
than	O
the	O
time	O
needed	O
for	O
cutting	O
with	O
the	O
usual	O
saw	O
.	O

Although	O
the	O
power	O
can	O
be	O
regulated	O
with	O
the	O
power	O
box	O
and	O
the	O
use	O
of	O
different	O
scalpels	O
,	O
we	O
agree	O
with	O
other	O
authors	O
that	O
the	O
optimal	O
use	O
of	O
this	O
device	O
is	O
in	O
surgeries	O
of	O
small	O
bones	O
where	O
precise	O
and	O
soft	O
tissue	O
friendly	O
cutting	O
is	O
required	O
[	O
7	O
]	O
.	O

As	O
other	O
literature	O
has	O
shown	O
,	O
the	O
device	O
selectively	O
cuts	O
bone	O
while	O
sparing	O
nerves	O
and	O
other	O
soft	O
tissue	O
[	O
2,3	O
]	O
.	O

This	O
allows	O
for	O
minimal	O
invasive	O
surgeries	O
with	O
limited	O
retraction	O
of	O
soft	O
tissue	O
and	O
minimal	O
stripping	O
of	O
the	O
periosteum	O
,	O
saves	O
time	O
and	O
might	O
have	O
a	O
positive	O
effect	O
on	O
the	O
healing	O
process	O
.	O

Our	O
aim	O
of	O
the	O
first	O
time	O
use	O
of	O
the	O
Piezosurgery	O
®	O
Device	O
in	O
hand	O
surgery	O
was	O
to	O
check	O
its	O
usability	O
in	O
osteotomies	O
of	O
tubular	O
bones	O
.	O

The	O
preparation	O
of	O
the	O
bone	O
was	O
done	O
in	O
the	O
usual	O
manner	O
as	O
is	O
done	O
when	O
cutting	O
with	O
an	O
oscillating	O
saw	O
.	O

The	O
reason	O
for	O
this	O
was	O
to	O
fully	O
visualize	O
the	O
cutting	O
process	O
using	O
this	O
new	O
device	O
,	O
although	O
in	O
the	O
future	O
,	O
it	O
should	O
be	O
possible	O
to	O
minimize	O
the	O
bony	O
exposure	O
.	O

In	O
our	O
patient	O
the	O
postoperative	O
healing	O
of	O
the	O
wound	O
and	O
the	O
bone	O
consolidation	O
(	O
Figure	O
4	O
)	O
were	O
smooth	O
.	O

The	O
duration	O
of	O
postoperative	O
sick	O
leave	O
was	O
four	O
weeks	O
which	O
is	O
more	O
rapid	O
than	O
the	O
usual	O
recovery	O
period	O
.	O

The	O
patient	O
regained	O
full	O
use	O
of	O
his	O
finger	O
according	O
to	O
the	O
state	O
before	O
the	O
fracture	O
.	O

At	O
no	O
point	O
was	O
there	O
any	O
loss	O
of	O
sensitivity	O
.	O

The	O
patient	O
as	O
well	O
as	O
the	O
surgeons	O
were	O
fully	O
satisfied	O
with	O
the	O
result	O
.	O

Conclusion	O

The	O
Piezosurgery	O
®	O
Device	O
is	O
a	O
useful	O
device	O
for	O
small	O
long	O
bone	O
osteotomies	O
.	O

We	O
feel	O
that	O
this	O
device	O
has	O
great	O
potential	O
in	O
the	O
field	O
of	O
hand-	O
and	O
spinal	O
surgery	O
.	O

As	O
the	O
device	O
selectively	O
cuts	O
bone	O
,	O
considerable	O
nerve	O
lesions	O
can	O
be	O
avoided	O
and	O
minimal	O
invasive	O
surgeries	O
are	O
possible	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
curved	O
cutting	O
and	O
provides	O
an	O
opportunity	O
for	O
new	O
osteotomy	O
techniques	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
DJH	O
initiated	O
and	O
coordinated	O
the	O
new	O
application	O
of	O
Piezosurgery	O
®	O
device	O
and	O
wrote	O
the	O
publication	O
.	O

StSt	O
lead	O
the	O
osteotomy	O
as	O
he	O
was	O
experienced	O
with	O
this	O
tool	O
from	O
oral	O
surgery	O
.	O

He	O
played	O
a	O
major	O
part	O
in	O
writing	O
the	O
technical	O
aspects	O
.	O

OVK	O
was	O
the	O
treating	O
surgeon	O
,	O
performed	O
the	O
operation	O
and	O
evaluated	O
the	O
new	O
tool	O
.	O

SS	O
performed	O
a	O
literature	O
review	O
and	O
wrote	O
part	O
of	O
the	O
publication	O
.	O

PH	O
was	O
the	O
treating	O
chief	O
surgeon	O
,	O
evaluated	O
the	O
new	O
tool	O
and	O
lead	O
the	O
treatment	O
in	O
all	O
aspects	O
.	O

Consent	O
We	O
obtained	O
oral	O
consent	O
from	O
the	O
patient	O
but	O
could	O
not	O
obtain	O
written	O
consent	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Alexithymia	O
and	O
anxiety	O
in	O
female	O
chronic	O
pain	O
patients	O
Abstract	O
Objectives	O
Alexithymia	O
is	O
highly	O
prevalent	O
among	O
chronic	O
pain	O
patients	O
.	O

Pain	O
is	O
a	O
remarkable	O
cause	O
for	O
high	O
levels	O
of	O
chronic	O
anxiety	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
alexithymia	O
and	O
to	O
determine	O
anxiety	O
levels	O
among	O
DSM	O
-	O
IV	O
somatoform	O
pain	O
disorder	O
(	O
chronic	O
pain	O
)	O
female	O
patients	O
and	O
to	O
examine	O
the	O
relationship	O
between	O
alexithymia	O
and	O
the	O
self	O
-	O
reporting	O
of	O
pain	O
.	O

Methods	O
Thirty	O
adult	O
females	O
(	O
mean	O
age	O
:	O
34,63	O
±	O
10,62	O
years	O
)	O
,	O
who	O
applied	O
to	O
the	O
outpatient	O
psychiatry	O
clinic	O
at	O
a	O
public	O
hospital	O
with	O
the	O
diagnosis	O
of	O
chronic	O
pain	O
disorder	O
(	O
DSM	O
-	O
IV	O
)	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Thirty	O
seven	O
healthy	O
females	O
(	O
mean	O
age	O
:	O
34,46	O
±	O
7,43	O
years	O
)	O
,	O
who	O
matched	O
for	O
sociodemographic	O
features	O
with	O
the	O
patient	O
group	O
,	O
consisted	O
the	O
control	O
group	O
.	O

A	O
sociodemographic	O
data	O
form	O
,	O
26-item	O
Toronto	O
Alexithymia	O
Scale	O
(	O
TAS-26	O
)	O
,	O
Spielberger	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
were	O
administered	O
to	O
each	O
subject	O
and	O
information	O
was	O
obtained	O
on	O
several	O
aspects	O
of	O
the	O
patients	O
'	O
pain	O
,	O
including	O
intensity	O
(	O
measured	O
by	O
VAS	O
)	O
,	O
and	O
duration	O
.	O

Results	O
Chronic	O
pain	O
patients	O
were	O
found	O
significantly	O
more	O
alexithymic	O
than	O
controls	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
TAS-26	O
scores	O
and	O
the	O
duration	O
of	O
pain	O
.	O

The	O
alexithymic	O
and	O
nonalexithymic	O
group	O
did	O
not	O
differ	O
in	O
their	O
perception	O
of	O
pain	O
.	O

Neither	O
positive	O
correlation	O
nor	O
significant	O
difference	O
was	O
found	O
between	O
alexithymia	O
and	O
trait	O
anxiety	O
in	O
pain	O
patients	O
.	O

Discussion	O
Alexithymia	O
may	O
be	O
important	O
in	O
addressing	O
the	O
diversity	O
of	O
subjective	O
factors	O
involved	O
in	O
pain	O
.	O

The	O
conceptualization	O
of	O
alexithymia	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
is	O
underlined	O
by	O
our	O
data	O
.	O

Background	O
The	O
original	O
definition	O
of	O
alexithymia	O
is	O
the	O
inability	O
to	O
identify	O
and	O
use	O
verbal	O
language	O
to	O
describe	O
feelings	O
[	O
1,2	O
]	O
.	O

Alexithymia	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
psychiatric	O
disorders	O
as	O
well	O
as	O
physical	O
illness	O
[	O
3	O
-	O
10	O
]	O
.	O

As	O
a	O
measure	O
,	O
Toronto	O
Alexithymia	O
Scale	O
was	O
significantly	O
correlated	O
with	O
the	O
measures	O
of	O
the	O
tendency	O
to	O
experience	O
and	O
report	O
physical	O
signs	O
and	O
symptoms	O
[	O
11	O
]	O
.	O

Several	O
studies	O
have	O
found	O
a	O
high	O
prevalence	O
of	O
alexithymia	O
in	O
pain	O
patients	O
.	O

Chronic	O
pain	O
patients	O
frequently	O
exhibit	O
many	O
of	O
the	O
core	O
features	O
of	O
alexithymia	O
,	O
such	O
as	O
problems	O
in	O
identifying	O
and	O
describing	O
subjective	O
feelings	O
,	O
impoverished	O
imaginative	O
abilities	O
,	O
and	O
excessive	O
preoccupation	O
with	O
physical	O
symptoms	O
and	O
external	O
events	O
.	O

Although	O
several	O
studies	O
have	O
found	O
a	O
high	O
prevalence	O
of	O
alexithymia	O
in	O
pain	O
patients	O
,	O
the	O
way	O
alexithymia	O
may	O
possibly	O
influence	O
pain	O
experience	O
is	O
still	O
unclear	O
[	O
12,13	O
]	O
.	O

DSM	O
-	O
IV	O
-	O
TR	O
defines	O
pain	O
disorder	O
as	O
the	O
presence	O
of	O
pain	O
that	O
is	O
""""	O
the	O
predominant	O
focus	O
of	O
clinical	O
attention	O
""""	O
[	O
14	O
]	O
.	O

In	O
chronic	O
pain	O
disorder	O
,	O
patients	O
complain	O
of	O
chronic	O
pain	O
,	O
for	O
which	O
no	O
physical	O
etiology	O
could	O
be	O
found	O
or	O
the	O
underlying	O
disorder	O
is	O
insufficient	O
in	O
explaining	O
the	O
symptoms	O
.	O

The	O
pain	O
causes	O
clinically	O
significant	O
distress	O
or	O
impairment	O
in	O
social	O
,	O
occupational	O
,	O
or	O
other	O
important	O
areas	O
of	O
functioning	O
.	O

Psychological	O
factors	O
are	O
judged	O
to	O
have	O
an	O
important	O
role	O
in	O
the	O
onset	O
,	O
severity	O
,	O
exacerbation	O
,	O
or	O
maintenance	O
of	O
the	O
pain	O
[	O
15	O
]	O
.	O

The	O
alexithymic	O
person	O
's	O
difficulty	O
in	O
identifying	O
and	O
describing	O
feelings	O
may	O
increase	O
symptom	O
reporting	O
by	O
several	O
mechanisms	O
.	O

Consequently	O
,	O
due	O
to	O
the	O
difficulty	O
to	O
experience	O
and	O
express	O
emotions	O
,	O
alexithymia	O
has	O
been	O
linked	O
with	O
somatosensory	O
amplification	O
,	O
which	O
is	O
the	O
tendency	O
to	O
focus	O
on	O
benign	O
somatic	O
sensations	O
.	O

Alexithymic	O
subjects	O
are	O
considered	O
to	O
focus	O
on	O
somatic	O
manifestations	O
of	O
emotional	O
arousal	O
,	O
resulting	O
in	O
misinterpretation	O
of	O
somatic	O
sensations	O
as	O
signs	O
of	O
physical	O
illness	O
[	O
12,13,16	O
]	O
.	O

Accordingly	O
,	O
previous	O
studies	O
have	O
found	O
evidence	O
of	O
an	O
association	O
between	O
alexithymia	O
and	O
the	O
development	O
of	O
functional	O
somatic	O
symptoms	O
,	O
as	O
seen	O
in	O
patients	O
with	O
somatoform	O
disorders	O
.	O

On	O
the	O
other	O
hand	O
,	O
alexithymia	O
may	O
also	O
occur	O
as	O
a	O
secondary	O
state	O
reaction	O
in	O
response	O
to	O
severe	O
and	O
chronic	O
medical	O
illness	O
[	O
17	O
-	O
21	O
]	O
.	O

Based	O
on	O
previous	O
findings	O
,	O
these	O
factors	O
are	O
worth	O
receiving	O
more	O
attention	O
in	O
terms	O
of	O
clinical	O
research	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
alexithymia	O
among	O
DSM	O
-	O
IV	O
somatoform	O
pain	O
disorder	O
(	O
chronic	O
pain	O
)	O
female	O
patients	O
and	O
to	O
examine	O
the	O
relationship	O
between	O
alexithymia	O
and	O
the	O
self	O
-	O
reporting	O
of	O
pain	O
in	O
this	O
group	O
of	O
patients	O
.	O

Besides	O
,	O
the	O
study	O
searched	O
for	O
the	O
anxiety	O
levels	O
of	O
chronic	O
pain	O
patients	O
with	O
or	O
without	O
alexithymia	O
.	O

Materials	O
and	O
methods	O
Sample	O
The	O
sample	O
consisted	O
of	O
30	O
females	O
who	O
applied	O
to	O
the	O
outpatient	O
psychiatry	O
clinic	O
at	O
a	O
public	O
hospital	O
and	O
who	O
met	O
DSM	O
-	O
IV	O
diagnostic	O
criteria	O
for	O
chronic	O
pain	O
disorder	O
.	O

Patients	O
with	O
concomitant	O
psychiatric	O
disorders	O
,	O
such	O
as	O
major	O
depression	O
,	O
anxiety	O
disorders	O
and	O
somatoform	O
disorders	O
other	O
than	O
pain	O
disorder	O
were	O
excluded	O
.	O

Patients	O
either	O
directly	O
applied	O
to	O
the	O
psychiatry	O
clinic	O
themselves	O
or	O
were	O
referred	O
for	O
psychiatric	O
assessment	O
from	O
another	O
outpatient	O
clinic	O
,	O
mainly	O
physical	O
medicine	O
and	O
rehabilitation	O
.	O

After	O
complete	O
description	O
of	O
the	O
study	O
,	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
subject	O
.	O

The	O
control	O
group	O
was	O
37	O
healthy	O
females	O
,	O
who	O
matched	O
for	O
age	O
,	O
and	O
education	O
with	O
the	O
subjects	O
.	O

All	O
subjects	O
participated	O
voluntarily	O
in	O
the	O
study	O
and	O
gave	O
consent	O
after	O
the	O
procedure	O
had	O
been	O
fully	O
explained	O
to	O
them	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
and	O
the	O
healthy	O
controls	O
was	O
34,63	O
±	O
10,62	O
(	O
range	O
:	O
16–62	O
)	O
and	O
34,46	O
±	O
7,43	O
(	O
range	O
:	O
22–57	O
)	O
years	O
and	O
the	O
educational	O
level	O
was	O
6,13	O
±	O
3,03	O
(	O
range	O
:	O
5–11	O
)	O
and	O
6,59	O
±	O
2,9	O
(	O
range	O
:	O
5–14	O
)	O
years	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
age	O
(	O
t	O
=	O
0,79	O
,	O
df	O
=	O
65	O
,	O
P	O
>	O
0,05	O
)	O
,	O
educational	O
level	O
(	O
t	O
=	O
1,02	O
,	O
df	O
=	O
65	O
,	O
P	O
>	O
0,05	O
)	O
,	O
and	O
marital	O
status	O
(	O
x2	O
=	O
0,51	O
,	O
df	O
=	O
1	O
,	O
P	O
>	O
0,05	O
)	O
.	O

Measures	O
A	O
detailed	O
sociodemographic	O
data	O
form	O
was	O
used	O
for	O
all	O
subjects	O
.	O

All	O
participants	O
were	O
applied	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	O
-	O
IV	O
(	O
SCID	O
-	O
I	O
)	O
[	O
22	O
]	O
,	O
Turkish	O
version	O
[	O
23	O
]	O
.	O

Regarding	O
the	O
pain	O
assessment	O
,	O
information	O
was	O
first	O
obtained	O
on	O
several	O
aspects	O
of	O
the	O
patients	O
'	O
pain	O
,	O
such	O
as	O
intensity	O
,	O
and	O
duration	O
.	O

Pain	O
intensity	O
was	O
measured	O
by	O
Visual	O
Analogue	O
Scale	O
(	O
VAS	O
)	O
,	O
using	O
a	O
horizontal	O
10-cm	O
line	O
with	O
the	O
statement	O
'	O
no	O
pain	O
at	O
all	O
'	O
at	O
the	O
extreme	O
left	O
-	O
hand	O
end	O
and	O
'	O
the	O
worst	O
possible	O
pain	O
'	O
or	O
'	O
unbearable	O
'	O
at	O
the	O
right	O
-	O
hand	O
extreme	O
.	O

VAS	O
is	O
scored	O
by	O
measuring	O
the	O
distance	O
from	O
the	O
end	O
of	O
the	O
scale	O
indicating	O
absence	O
of	O
pain	O
(	O
or	O
no	O
distress	O
or	O
no	O
pain	O
relief	O
)	O
to	O
the	O
place	O
marked	O
by	O
the	O
patient	O
[	O
24	O
]	O
.	O

The	O
psychometric	O
scales	O
used	O
in	O
the	O
study	O
were	O
the	O
26-item	O
Toronto	O
Alexithymia	O
Scale	O
(	O
TAS-26	O
]	O
and	O
the	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
,	O
which	O
were	O
both	O
validated	O
in	O
Turkish	O
population	O
studies	O
[	O
25	O
-	O
28	O
]	O
.	O

TAS	O
is	O
a	O
psychometrically	O
well	O
validated	O
and	O
reliable	O
instrument	O
in	O
the	O
assessment	O
of	O
alexithymia	O
.	O

TAS	O
has	O
been	O
validated	O
in	O
Turkish	O
studies	O
as	O
a	O
true	O
or	O
false	O
scale	O
.	O

Twenty	O
-	O
six	O
items	O
are	O
scored	O
either	O
as	O
1	O
or	O
0	O
and	O
the	O
higher	O
scores	O
indicate	O
higher	O
degrees	O
of	O
alexithymia	O
.	O

TAS	O
has	O
an	O
interval	O
consistency	O
of	O
0.65	O
[	O
Kuder	O
-	O
Richardson	O
)	O
and	O
test	O
-	O
retest	O
reliability	O
is	O
r	O
=	O
0.71	O
,	O
p	O
<	O
0.01	O
in	O
Turkish	O
reliability	O
and	O
validity	O
study	O
.	O

The	O
sample	O
was	O
divided	O
into	O
nonalexithymic	O
and	O
alexityhmic	O
groups	O
,	O
with	O
the	O
recommended	O
cut	O
-	O
off	O
score	O
of	O
11	O
[	O
27	O
]	O
.	O

Spielberger	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
is	O
one	O
of	O
the	O
two	O
sections	O
of	O
the	O
Spielberger	O
Anxiety	O
Inventory	O
(	O
the	O
other	O
,	O
measuring	O
state	O
anxiety	O
)	O
.	O
'	O

Trait	O
anxiety	O
'	O
has	O
been	O
defined	O
as	O
anxiety	O
proneness	O
,	O
that	O
is	O
,	O
the	O
tendency	O
to	O
respond	O
to	O
situations	O
perceived	O
as	O
threatening	O
with	O
elevations	O
in	O
the	O
intensity	O
of	O
state	O
anxiety	O
[	O
26	O
]	O
.	O

Statistical	O
analysis	O
In	O
order	O
to	O
determine	O
the	O
relative	O
importance	O
of	O
a	O
number	O
of	O
factors	O
in	O
pain	O
disorders	O
,	O
we	O
used	O
both	O
correlation	O
analyses	O
.	O

The	O
alexithymic	O
and	O
nonalexithymic	O
groups	O
were	O
compared	O
using	O
the	O
independent	O
sample	O
t	O
-	O
tests	O
on	O
scores	O
of	O
psychological	O
tests	O
.	O

The	O
statistical	O
procedure	O
,	O
which	O
was	O
carried	O
out	O
by	O
a	O
SPSS	O
package	O
program	O
for	O
Windows	O
using	O
Chi	O
-	O
square	O
,	O
Fisher	O
's	O
exact	O
test	O
,	O
two	O
tailed	O
t	O
test	O
and	O
Pearson	O
correlation	O
coefficients	O
,	O
was	O
also	O
used	O
to	O
determine	O
group	O
differences	O
(	O
alexithymics	O
versus	O
nonalexithymics	O
)	O
in	O
sociodemographic	O
variables	O
and	O
various	O
aspects	O
of	O
pain	O
.	O

Results	O
In	O
the	O
chronic	O
pain	O
group	O
,	O
56.7	O
%	O
of	O
patients	O
(	O
n	O
=	O
17	O
)	O
had	O
a	O
score	O
greater	O
than	O
11	O
on	O
the	O
TAS-26	O
,	O
and	O
were	O
considered	O
alexithymic	O
.	O

The	O
mean	O
TAS-26	O
score	O
of	O
the	O
alexithymic	O
group	O
(	O
n	O
=	O
17	O
)	O
was	O
17.88	O
±	O
3.43	O
and	O
the	O
nonalexithymic	O
group	O
(	O
n	O
=	O
13	O
)	O
was	O
8.39	O
±	O
2.02	O
.	O

Age	O
(	O
t	O
=	O
1,38	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,18	O
)	O
,	O
education	O
(	O
t	O
=	O
-0,21	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,16	O
)	O
and	O
marital	O
status	O
(	O
x2	O
=	O
0,27	O
,	O
df	O
=	O
1	O
,	O
p	O
>	O
0,87	O
)	O
were	O
not	O
associated	O
with	O
alexithymia	O
(	O
Table	O
1	O
)	O
.	O

In	O
the	O
control	O
group	O
,	O
24,3	O
%	O
of	O
patients	O
(	O
n	O
=	O
9	O
)	O
were	O
alexithymic	O
according	O
to	O
TAS-26	O
.	O

The	O
mean	O
TAS-26	O
score	O
of	O
the	O
alexithymic	O
group	O
(	O
n	O
=	O
9	O
)	O
was	O
13,82	O
±	O
1,93	O
and	O
the	O
nonalexithymic	O
group	O
(	O
n	O
=	O
28	O
)	O
was	O
10,33	O
±	O
0,86	O
.	O

Alexithymia	O
was	O
not	O
associated	O
with	O
age	O
(	O
t	O
=	O
-1,08	O
,	O
df	O
=	O
35	O
,	O
p	O
>	O
0,29	O
)	O
,	O
educational	O
level	O
(	O
t	O
=	O
1,1	O
,	O
df	O
=	O
35	O
,	O
p	O
>	O
0,28	O
)	O
,	O
or	O
marital	O
status	O
(	O
x2	O
=	O
0,74	O
,	O
df	O
=	O
1	O
,	O
p	O
>	O
0,79	O
)	O
or	O
anxiety	O
levels	O
in	O
the	O
control	O
subjects	O
(	O
Table	O
1	O
)	O
.	O

The	O
duration	O
and	O
severity	O
of	O
pain	O
,	O
TAS-26	O
scores	O
,	O
and	O
STAI	O
scores	O
of	O
the	O
female	O
pain	O
patients	O
are	O
shown	O
in	O
Table	O
2	O
.	O

Comparison	O
of	O
the	O
alexithymics	O
with	O
nonalexithymics	O
on	O
either	O
the	O
severity	O
of	O
pain	O
or	O
pain	O
duration	O
showed	O
no	O
statistical	O
significance	O
(	O
t	O
=	O
0,64	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,52	O
,	O
t	O
=	O
2,05	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,05	O
,	O
respectively	O
)	O
.	O

TAS-26	O
score	O
and	O
duration	O
of	O
pain	O
were	O
found	O
positively	O
correlated	O
(	O
r	O
=	O
0,50	O
,	O
n	O
=	O
30	O
,	O
p	O
>	O
0,005	O
)	O
.	O

STAI	O
(	O
trait	O
)	O
scores	O
of	O
the	O
alexithymics	O
in	O
the	O
pain	O
group	O
did	O
not	O
significantly	O
differ	O
from	O
the	O
nonlalexithymics	O
(	O
t	O
=	O
0,06	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,95	O
)	O
and	O
besides	O
,	O
TAS-26	O
and	O
STAI	O
scores	O
were	O
not	O
correlated	O
(	O
r	O
=	O
0,06	O
,	O
p	O
>	O
0,72	O
)	O
.	O

In	O
summary	O
,	O
there	O
are	O
three	O
points	O
to	O
be	O
emphasized	O
.	O

First	O
,	O
chronic	O
pain	O
patients	O
were	O
found	O
significantly	O
more	O
alexithymic	O
than	O
controls	O
(	O
56,7	O
%	O
to	O
24,3	O
%	O
)	O
.	O

Second	O
,	O
a	O
positive	O
correlation	O
was	O
observed	O
between	O
TAS-26	O
scores	O
and	O
duration	O
of	O
pain	O
.	O

Third	O
,	O
neither	O
positive	O
correlation	O
nor	O
significant	O
difference	O
was	O
found	O
between	O
alexithymia	O
and	O
trait	O
anxiety	O
in	O
pain	O
patients	O
.	O

Discussion	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
patients	O
with	O
chronic	O
pain	O
disorder	O
are	O
more	O
alexithymic	O
than	O
individuals	O
with	O
no	O
pain	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
results	O
obtained	O
with	O
earlier	O
measures	O
of	O
alexithymia	O
[	O
11	O
-	O
13	O
]	O
.	O

Although	O
they	O
may	O
share	O
common	O
clinical	O
features	O
,	O
alexithymia	O
and	O
somatoform	O
pain	O
are	O
independent	O
constructs	O
.	O

Alexithymia	O
may	O
be	O
a	O
consequence	O
to	O
the	O
effects	O
of	O
severe	O
physical	O
symptoms	O
,	O
such	O
as	O
a	O
reduced	O
quality	O
of	O
life	O
and	O
limitations	O
in	O
daily	O
activities	O
.	O

Besides	O
,	O
alexithymia	O
may	O
be	O
conceptualized	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
[	O
2,3,15	O
-	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
question	O
investigated	O
was	O
whether	O
alexithymia	O
has	O
any	O
correlation	O
with	O
the	O
duration	O
or	O
severity	O
of	O
the	O
pain	O
itself	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
alexithymic	O
and	O
nonalexitymic	O
patients	O
on	O
self	O
reports	O
of	O
current	O
pain	O
severity	O
.	O

This	O
is	O
in	O
accordance	O
with	O
Cox	O
's	O
study	O
[	O
1994	O
]	O
in	O
which	O
it	O
was	O
further	O
pointed	O
out	O
that	O
alexithymic	O
patients	O
were	O
found	O
to	O
use	O
significantly	O
more	O
verbal	O
descriptors	O
of	O
pain	O
compared	O
to	O
nonalexithymic	O
patients	O
[	O
13	O
]	O
.	O

In	O
our	O
study	O
,	O
pain	O
intensity	O
was	O
only	O
evaluated	O
by	O
using	O
VAS	O
.	O

One	O
problem	O
in	O
trying	O
to	O
measure	O
the	O
intensity	O
of	O
pain	O
is	O
the	O
lack	O
of	O
an	O
objective	O
way	O
.	O

Pain	O
is	O
a	O
subjective	O
experience	O
and	O
each	O
patient	O
may	O
communicate	O
in	O
a	O
different	O
way	O
,	O
verbally	O
or	O
nonverbally	O
[	O
29	O
]	O
.	O

Patients	O
in	O
this	O
sample	O
were	O
sufferers	O
of	O
chronic	O
pain	O
,	O
who	O
had	O
already	O
chosen	O
an	O
approved	O
way	O
of	O
expressing	O
their	O
distress	O
.	O

Since	O
this	O
is	O
true	O
regardless	O
of	O
alexithymia	O
,	O
alexithymic	O
groups	O
and	O
nonalexithymic	O
groups	O
in	O
this	O
sample	O
showed	O
no	O
difference	O
on	O
pain	O
severity	O
.	O

The	O
positive	O
correlation	O
between	O
alexithymia	O
and	O
the	O
duration	O
of	O
pain	O
in	O
this	O
sample	O
supports	O
the	O
assumption	O
of	O
a	O
two	O
-	O
way	O
hypothesis	O
.	O

It	O
is	O
often	O
assumed	O
that	O
pain	O
can	O
be	O
caused	O
by	O
alexithymic	O
personality	O
traits	O
and	O
also	O
that	O
severe	O
and	O
chronic	O
pain	O
may	O
cause	O
emotional	O
change	O
.	O

One	O
of	O
the	O
limitations	O
of	O
this	O
study	O
is	O
that	O
because	O
of	O
the	O
cross	O
-	O
sectional	O
design	O
,	O
we	O
are	O
unable	O
to	O
draw	O
conclusions	O
about	O
the	O
direction	O
of	O
causality	O
between	O
alexithymia	O
and	O
pain	O
.	O

The	O
duration	O
of	O
the	O
patients	O
'	O
pain	O
could	O
approximately	O
be	O
determined	O
,	O
yet	O
the	O
preexisting	O
level	O
of	O
alexithymia	O
was	O
not	O
known	O
.	O

In	O
the	O
usual	O
absence	O
of	O
internal	O
stimuli	O
,	O
alexithymic	O
person	O
may	O
be	O
expected	O
to	O
maintain	O
an	O
external	O
focus	O
of	O
attention	O
,	O
such	O
as	O
pain	O
.	O

Symptom	O
chronicity	O
may	O
force	O
the	O
alexithymic	O
person	O
to	O
attent	O
to	O
and	O
amplify	O
this	O
somatic	O
sensation	O
.	O

Difficulties	O
in	O
the	O
ability	O
to	O
identify	O
and	O
differentiate	O
emotions	O
and	O
somatic	O
experiences	O
are	O
core	O
features	O
of	O
the	O
alexithymic	O
construct	O
.	O

Therefore	O
,	O
alexithymic	O
patients	O
might	O
be	O
expected	O
to	O
differ	O
from	O
nonalexithymic	O
ones	O
in	O
their	O
anxiety	O
levels	O
.	O

Yet	O
,	O
in	O
our	O
pain	O
group	O
alexithymic	O
patients	O
showed	O
no	O
significant	O
difference	O
from	O
the	O
nonalexithymics	O
on	O
trait	O
anxiety	O
.	O

Besides	O
,	O
alexithymia	O
and	O
anxiety	O
were	O
not	O
correlated	O
at	O
all	O
.	O

The	O
reasons	O
may	O
be	O
lying	O
in	O
the	O
specific	O
characteristics	O
of	O
this	O
patient	O
group	O
itself	O
.	O

The	O
study	O
included	O
patients	O
suffering	O
from	O
chronic	O
symptoms	O
;	O
with	O
an	O
average	O
of	O
7,44	O
±	O
6,82	O
years	O
of	O
pain	O
in	O
the	O
alexithymic	O
and	O
3,31	O
±	O
2,79	O
years	O
in	O
the	O
nonalexithymic	O
groups	O
.	O

Persistency	O
of	O
any	O
physical	O
symptom	O
may	O
bring	O
along	O
alexithymia	O
as	O
a	O
coping	O
strategy	O
.	O

In	O
their	O
paper	O
,	O
Crook	O
and	O
Tunks	O
(	O
1988	O
)	O
examined	O
the	O
types	O
of	O
coping	O
strategies	O
used	O
by	O
persistent	O
pain	O
sufferers	O
and	O
addressed	O
to	O
the	O
importance	O
to	O
alter	O
their	O
attitudes	O
and	O
behavior	O
that	O
tend	O
toward	O
catastrophizing	O
,	O
avoidance	O
and	O
withdrawal	O
,	O
rather	O
than	O
simply	O
concentrate	O
on	O
trying	O
to	O
teach	O
them	O
techniques	O
for	O
'	O
coping	O
with	O
stress	O
'	O
to	O
help	O
persistent	O
pain	O
sufferers	O
[	O
30	O
]	O
.	O

Sufferers	O
of	O
chronic	O
symptoms	O
in	O
this	O
sample	O
were	O
members	O
of	O
a	O
subgroup	O
who	O
have	O
been	O
seeking	O
medical	O
care	O
for	O
a	O
long	O
time	O
and	O
besides	O
given	O
the	O
chance	O
of	O
being	O
referred	O
to	O
a	O
psychiatrist	O
.	O

Therefore	O
,	O
alexithymic	O
or	O
not	O
,	O
their	O
anxiety	O
might	O
have	O
induced	O
unique	O
coping	O
strategies	O
and	O
illness	O
behavior	O
.	O

Alexithymia	O
may	O
be	O
important	O
in	O
addressing	O
the	O
diversity	O
of	O
subjective	O
factors	O
involved	O
in	O
pain	O
[	O
31	O
]	O
.	O

It	O
is	O
not	O
known	O
whether	O
it	O
should	O
be	O
addressed	O
in	O
the	O
treatment	O
of	O
pain	O
patients	O
,	O
but	O
a	O
high	O
level	O
of	O
alexithymia	O
may	O
effect	O
the	O
nature	O
of	O
assessment	O
.	O

In	O
summary	O
,	O
the	O
conceptualization	O
of	O
alexithymia	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
is	O
underlined	O
by	O
our	O
data	O
.	O

However	O
,	O
regarding	O
the	O
cross	O
-	O
sectional	O
design	O
of	O
this	O
study	O
,	O
only	O
limited	O
conclusions	O
can	O
be	O
drawn	O
about	O
the	O
nature	O
of	O
the	O
causal	O
relationship	O
between	O
alexithymia	O
and	O
chronic	O
pain	O
.	O

Therefore	O
,	O
future	O
longitudinal	O
studies	O
assessing	O
the	O
cause	O
of	O
alexithymic	O
characteristics	O
are	O
required	O
to	O
fully	O
elucidate	O
the	O
concepts	O
of	O
primary	O
and	O
secondary	O
alexithymia	O
.	O

The	O
role	O
of	O
the	O
muscarinic	O
system	O
in	O
regulating	O
estradiol	O
secretion	O
varies	O
during	O
the	O
estrous	O
cycle	O
:	O
the	O
hemiovariectomized	O
rat	B
model	O
Abstract	O
There	O
is	O
evidence	O
that	O
one	O
gonad	O
has	O
functional	O
predominance	O
.	O

The	O
present	O
study	O
analyzed	O
the	O
acute	O
effects	O
of	O
unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
and	O
blocking	O
the	O
cholinergic	O
system	O
,	O
by	O
injecting	O
atropine	O
sulfate	O
(	O
ATR	O
)	O
,	O
on	O
estradiol	O
(	O
E2	O
)	O
serum	O
concentrations	O
during	O
the	O
estrous	O
cycle	O
.	O

The	O
results	O
indicate	O
that	O
ULO	O
effects	O
on	O
E2	O
concentrations	O
are	O
asymmetric	O
,	O
vary	O
during	O
the	O
estrous	O
cycle	O
,	O
and	O
partially	O
depend	O
on	O
the	O
cholinergic	O
innervation	O
.	O

Background	O
Estradiol	O
secretion	O
is	O
regulated	O
by	O
pituitary	O
[	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
and	O
luteinizing	O
hormones	O
(	O
LH	O
)	O
,	O
prolactin	O
,	O
and	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
]	O
.	O

The	O
effects	O
of	O
these	O
hormones	O
are	O
modulated	O
by	O
neurotransmitters	O
released	O
by	O
the	O
intrinsic	O
ovarian	O
innervation	O
near	O
the	O
follicular	O
wall	O
.	O

Acetylcholine	O
produced	O
by	O
the	O
follicle	O
may	O
be	O
one	O
of	O
the	O
neurotransmitters	O
participating	O
in	O
modulating	O
the	O
effects	O
of	O
pituitary	O
hormones	O
on	O
the	O
follicle	O
[	O
1	O
-	O
3	O
]	O
.	O

Evidence	O
suggesting	O
that	O
one	O
gonad	O
has	O
functional	O
predominance	O
in	O
mammals	O
and	O
birds	O
have	O
been	O
published	O
[	O
1,4	O
-	O
8	O
]	O
.	O

In	O
previous	O
studies	O
we	O
have	O
shown	O
that	O
unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
modifies	O
progesterone	O
and/or	O
testosterone	O
serum	O
concentrations	O
,	O
and	O
that	O
the	O
effects	O
of	O
ULO	O
depend	O
on	O
both	O
,	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
ULO	O
was	O
performed	O
and	O
the	O
ovary	O
(	O
left	O
or	O
right	O
)	O
remaining	O
in	O
situ	O
[	O
9	O
-	O
11	O
]	O
.	O

Asymmetry	O
in	O
ovarian	O
functions	O
has	O
been	O
explained	O
by	O
differences	O
in	O
the	O
ovarian	O
innervation	O
participating	O
in	O
modulating	O
the	O
effects	O
of	O
gonadotropin	O
on	O
the	O
ovarian	O
follicles	O
[	O
1,6	O
]	O
.	O

Kawakami	O
et	O
al	O
[	O
12	O
]	O
showed	O
that	O
electrical	O
stimulation	O
of	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
,	O
the	O
ventro	O
-	O
medial	O
hypothalamus	O
,	O
and	O
the	O
areas	O
in	O
the	O
mesencephalon	O
of	O
hypophysectomized	O
and	O
adrenalectomized	O
female	O
rats	B
resulted	O
in	O
a	O
significant	O
increase	O
of	O
estradiol	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
P4	O
)	O
plasma	O
concentrations	O
in	O
the	O
contra	O
-	O
lateral	O
ovarian	O
venous	O
blood	O
.	O

In	O
turn	O
,	O
stimulating	O
the	O
dorsal	O
hippocampus	O
,	O
the	O
lateral	O
amygdala	O
,	O
and	O
the	O
mesencephalic	O
areas	O
resulted	O
in	O
lower	O
E2	O
and	O
P4	O
concentrations	O
.	O

Ovarian	O
denervation	O
of	O
rats	B
in	O
proestrus	O
stage	O
blocks	O
E2	O
secretion	O
induced	O
by	O
stimulating	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
.	O

In	O
addition	O
,	O
the	O
electrochemical	O
stimulation	O
in	O
proestrus	O
day	O
of	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
of	O
untreated	O
rats	B
increased	O
E2	O
and	O
P4	O
concentrations	O
in	O
serum	O
.	O

This	O
effect	O
was	O
not	O
observed	O
when	O
stimulation	O
was	O
applied	O
to	O
the	O
pre	O
-	O
optic	O
supra	O
-	O
chiasmatic	O
area	O
.	O

According	O
to	O
the	O
authors	O
'	O
interpretation	O
of	O
the	O
results	O
,	O
the	O
efferent	O
neural	O
system	O
connecting	O
the	O
brain	O
and	O
the	O
ovaries	O
is	O
supplementary	O
to	O
the	O
brain	O
-	O
pituitary	O
-	O
ovarian	O
hormonal	O
mechanisms	O
regulating	O
ovarian	O
steroid	O
secretion	O
,	O
and	O
the	O
system	O
may	O
be	O
required	O
for	O
adjusting	O
ovarian	O
responsiveness	O
and	O
sensitivity	O
to	O
gonadotropins	O
[	O
12,13	O
]	O
.	O

Gerendai	O
et	O
al.	O
[	O
14	O
]	O
described	O
a	O
multi	O
-	O
synaptic	O
neural	O
pathway	O
between	O
the	O
central	O
nervous	O
system	O
and	O
the	O
ovaries	O
,	O
with	O
the	O
vagus	O
nerve	O
being	O
one	O
of	O
the	O
main	O
neural	O
pathways	O
.	O

In	O
ULO	O
treated	O
rats	B
,	O
bi	O
-	O
lateral	O
sectioning	O
the	O
vagus	O
nerve	O
(	O
ventral	O
or	O
dorsal	O
)	O
results	O
in	O
lower	O
compensatory	O
ovarian	O
hypertrophy	O
.	O

The	O
effects	O
of	O
sectioning	O
the	O
left	O
vagus	O
nerve	O
depend	O
on	O
the	O
remaining	O
ovary	O
in	O
situ	O
:	O
rats	B
with	O
the	O
left	O
ovary	O
in	O
situ	O
had	O
a	O
larger	O
proportion	O
of	O
ovulating	O
animals	O
,	O
compensatory	O
ovarian	O
hypertrophy	O
and	O
number	O
of	O
ova	O
shed	O
.	O

In	O
turn	O
,	O
rats	B
with	O
the	O
right	O
ovary	O
in	O
situ	O
showed	O
a	O
decrease	O
in	O
all	O
parameters	O
studied	O
[	O
15	O
]	O
.	O

Based	O
on	O
available	O
information	O
,	O
the	O
present	O
study	O
aims	O
to	O
analyze	O
if	O
changes	O
in	O
E2	O
secretion	O
by	O
the	O
left	O
and	O
right	O
ovaries	O
vary	O
during	O
the	O
estrous	O
cycle	O
,	O
using	O
the	O
unilateral	O
ovariectomized	O
animal	O
as	O
a	O
model	O
of	O
study	O
.	O

We	O
also	O
investigated	O
if	O
,	O
throughout	O
estrous	O
cycle	O
diestrus	O
1	O
(	O
D1	O
)	O
,	O
diestrus	O
2	O
(	O
D2	O
)	O
and	O
proestrus	O
(	O
P	O
)	O
,	O
the	O
cholinergic	O
system	O
modulates	O
E2	O
secretion	O
in	O
an	O
asymmetric	O
way	O
.	O

For	O
this	O
purpose	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
injecting	O
ATR	O
at	O
13.00	O
h	O
to	O
rats	B
on	O
D1	O
,	O
D2	O
or	O
P	O
with	O
or	O
without	O
unilateral	O
or	O
bilateral	O
ovariectomy	O
.	O

Materials	O
and	O
methods	O
The	O
study	O
was	O
performed	O
with	O
virgin	O
adult	O
female	O
rats	B
(	O
195–225-g	O
body	O
weight	O
)	O
of	O
the	O
CIIZ	O
-	O
V	O
strain	O
from	O
our	O
own	O
stock	O
.	O

Animals	O
were	O
kept	O
under	O
controlled	O
lighting	O
conditions	O
(	O
lights	O
on	O
from	O
05:00	O
to	O
19:00	O
h	O
)	O
,	O
with	O
free	O
access	O
to	O
food	O
(	O
Purina	O
S.A.	O
,	O
Mexico	O
)	O
and	O
tap	O
water	O
;	O
following	O
NIH	O
Guide	O
parameters	O
for	O
the	O
care	O
of	O
laboratory	O
animals	O
.	O

The	O
Committee	O
of	O
the	O
Facultad	O
de	O
Estudios	O
Superiores	O
Zaragoza	O
approved	O
the	O
experimental	O
protocols	O
.	O

Estrous	O
cycles	O
were	O
monitored	O
by	O
daily	O
vaginal	O
smears	O
.	O

Only	O
rats	B
showing	O
at	O
least	O
two	O
consecutive	O
4-day	O
cycles	O
were	O
used	O
in	O
the	O
experiment	O
.	O

All	O
surgeries	O
were	O
performed	O
under	O
ether	O
anesthesia	O
,	O
between	O
13:00–13:15	O
hours	O
.	O

Rats	B
were	O
sacrificed	O
by	O
decapitation	O
one	O
hour	O
after	O
treatment	O
.	O

Experimental	O
groups	O
Rats	B
were	O
randomly	O
allotted	O
to	O
one	O
of	O
the	O
experimental	O
groups	O
described	O
below	O
.	O

Animals	O
from	O
different	O
experimental	O
groups	O
were	O
treated	O
simultaneously	O
and	O
sacrificed	O
one	O
hour	O
after	O
surgery	O
.	O

The	O
number	O
of	O
animals	O
used	O
in	O
each	O
experimental	O
group	O
is	O
presented	O
in	O
Tables	O
1	O
,	O
2	O
and	O
3	O
.	O

Control	O
group	O
(	O
N	O
=	O
48	O
)	O
.	O

Non	O
-	O
treated	O
cyclic	O
rats	B
sacrificed	O
at	O
14:00	O
h	O
on	O
D1	O
(	O
17	O
rats	B
)	O
,	O
D2	O
(	O
19	O
rats	B
)	O
and	O
P	O
(	O
12	O
rats	B
)	O
.	O

Ether	O
anesthesia	O
(	O
N	O
=	O
24	O
)	O
:	O
Groups	O
of	O
rats	B
,	O
on	O
specific	O
stages	O
(	O
D1	O
,	O
D2	O
or	O
P	O
)	O
of	O
the	O
estrous	O
cycle	O
,	O
were	O
anesthetized	O
for	O
10	O
min	O
and	O
sacrificed	O
one	O
hour	O
later	O
.	O

Unilateral	O
peritoneal	O
perforation	O
(	O
sham	O
operation	O
)	O
(	O
N	O
=	O
53	O
)	O
:	O
A	O
unilateral	O
incision	O
was	O
performed	O
2-cm	O
below	O
the	O
last	O
rib	O
;	O
affecting	O
skin	O
,	O
muscle	O
,	O
and	O
peritoneum	O
.	O

The	O
ovaries	O
were	O
not	O
injured	O
or	O
manipulated	O
.	O

After	O
surgical	O
procedures	O
the	O
wound	O
was	O
sealed	O
.	O

Bilateral	O
peritoneal	O
perforation	O
(	O
sham	O
operation	O
2	O
)	O
(	O
N	O
=	O
27	O
)	O
.	O

A	O
bilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
,	O
was	O
performed	O
.	O

The	O
ovaries	O
were	O
not	O
injured	O
or	O
manipulated	O
.	O

After	O
surgical	O
procedures	O
the	O
wound	O
was	O
sealed	O
.	O

Unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
(	O
N	O
=	O
50	O
)	O
:	O
A	O
unilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
was	O
performed	O
,	O
and	O
the	O
right	O
or	O
left	O
ovary	O
was	O
extirpated	O
.	O

The	O
wound	O
was	O
subsequently	O
sealed	O
.	O

Bilateral	O
ovariectomy	O
(	O
N	O
=	O
23	O
)	O
:	O
A	O
bilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
was	O
performed	O
,	O
and	O
the	O
ovaries	O
removed	O
.	O

The	O
wound	O
was	O
subsequently	O
sealed	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
To	O
analyze	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
,	O
groups	O
of	O
animals	O
were	O
injected	O
with	O
atropine	O
sulfate	O
(	O
ATR	O
,	O
Sigma	O
Chem	O
.	O

Co.	O
St.	O
Louis	O
,	O
Mo.	O
)	O
.	O

ATR	O
was	O
injected	O
one	O
hour	O
before	O
surgery	O
at	O
doses	O
known	O
to	O
block	O
ovulation	O
:	O
in	O
D1	O
,	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
(	O
b.w	O
.	O
)	O
;	O
in	O
D2	O
,	O
300	O
mg	O
/	O
kg	O
b.w	O
.	O
;	O
and	O
in	O
P	O
,	O
700	O
mg	O
/	O
kg	O
b.w	O
.	O

[	O
16	O
]	O
.	O

One	O
hour	O
after	O
ATR	O
treatment	O
,	O
rats	B
were	O
randomly	O
allotted	O
to	O
one	O
of	O
the	O
following	O
treatments	O
:	O
unilateral	O
peritoneal	O
perforation	O
,	O
bilateral	O
peritoneal	O
perforation	O
,	O
ULO	O
,	O
or	O
bilateral	O
ovariectomy	O
.	O

All	O
animals	O
were	O
sacrificed	O
one	O
hour	O
after	O
surgery	O
.	O

For	O
control	O
purposes	O
,	O
untreated	O
rats	B
,	O
on	O
D1	O
,	O
D2	O
or	O
P	O
,	O
were	O
injected	O
with	O
ATR	O
in	O
the	O
same	O
dose	O
as	O
in	O
their	O
corresponding	O
treatment	O
group	O
.	O

The	O
animals	O
were	O
sacrificed	O
two	O
hours	O
after	O
treatment	O
.	O

Autopsy	O
procedures	O
Animals	O
were	O
sacrificed	O
by	O
decapitation	O
.	O

The	O
blood	O
of	O
the	O
trunk	O
was	O
collected	O
in	O
a	O
test	O
tube	O
,	O
allowed	O
to	O
clot	O
at	O
room	O
temperature	O
for	O
30	O
minutes	O
and	O
centrifuged	O
at	O
3,000	O
rpm	O
for	O
15	O
minutes	O
.	O

Serum	O
was	O
stored	O
at	O
-20	O
°	O
C	O
,	O
until	O
E2	O
concentrations	O
were	O
measured	O
.	O

Hormone	O
assay	O
Concentrations	O
of	O
E2	O
in	O
serum	O
were	O
measured	O
by	O
Radio	O
-	O
Immuno	O
-	O
Assay	O
(	O
RIA	O
)	O
;	O
using	O
kits	O
purchased	O
from	O
Diagnostic	O
Products	O
(	O
Los	O
Angeles	O
,	O
CA	O
)	O
.	O

Results	O
are	O
expressed	O
in	O
pg	O
/	O
ml	O
.	O

The	O
Intra-	O
and	O
inter	O
-	O
assay	O
variation	O
coefficients	O
were	O
6.9	O
%	O
and	O
10.8	O
%	O
,	O
respectively	O
.	O

Statistics	O
Data	O
on	O
hormonal	O
concentrations	O
in	O
serum	O
were	O
analyzed	O
using	O
multivariate	O
analysis	O
of	O
variance	O
(	O
MANOVA	O
)	O
followed	O
by	O
Tukey	O
's	O
test	O
.	O

Differences	O
in	O
serum	O
hormone	O
concentrations	O
between	O
two	O
groups	O
were	O
analyzed	O
by	O
Student	O
's	O
t	O
-	O
test	O
.	O

A	O
probability	O
value	O
of	O
less	O
than	O
5	O
%	O
was	O
considered	O
significant	O
.	O

Results	O
Effects	O
of	O
ether	O
anesthesia	O
and	O
unilateral	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
In	O
the	O
control	O
group	O
,	O
animals	O
sacrificed	O
on	O
P	O
showed	O
significantly	O
higher	O
E2	O
serum	O
concentration	O
than	O
animals	O
sacrificed	O
on	O
D1	O
or	O
D2	O
(	O
D1	O
:	O
55.3	O
±	O
8.0	O
;	O
D2	O
:	O
59.1	O
±	O
7.9	O
;	O
P	O
:	O
158.4	O
±	O
1.8	O
)	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
ether	O
anesthesia	O
treatment	O
did	O
not	O
modify	O
E2	O
serum	O
concentrations	O
(	O
D1	O
:	O
62.9	O
±	O
8.4	O
;	O
D2	O
:	O
69.5	O
±	O
12.0	O
;	O
P	O
:	O
164.1	O
±	O
17.6	O
)	O
.	O

Since	O
ether	O
anesthesia	O
did	O
not	O
modify	O
E2	O
serum	O
concentrations	O
,	O
treatment	O
results	O
are	O
compared	O
to	O
their	O
respective	O
control	O
group	O
.	O

The	O
effects	O
on	O
E2	O
serum	O
concentrations	O
of	O
unilaterally	O
or	O
bilaterally	O
perforating	O
the	O
peritoneum	O
depended	O
on	O
the	O
side	O
of	O
the	O
peritoneum	O
and	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
perforation	O
surgery	O
was	O
performed	O
.	O

Perforating	O
the	O
left	O
peritoneum	O
on	O
D1	O
resulted	O
in	O
lower	O
E2	O
serum	O
concentrations	O
(	O
55	O
%	O
)	O
,	O
while	O
bilateral	O
perforation	O
,	O
or	O
perforating	O
the	O
right	O
side	O
of	O
the	O
peritoneum	O
,	O
had	O
no	O
apparent	O
effects	O
(	O
Table	O
1	O
)	O
.	O

Perforating	O
the	O
right	O
side	O
of	O
the	O
peritoneum	O
on	O
D2	O
day	O
resulted	O
in	O
E2	O
concentration	O
increases	O
(	O
184	O
%	O
)	O
,	O
while	O
perforating	O
the	O
left	O
side	O
resulted	O
in	O
a	O
decrease	O
(	O
51	O
%	O
)	O
of	O
E2	O
serum	O
concentrations	O
.	O

Bilateral	O
perforation	O
had	O
no	O
apparent	O
effects	O
on	O
hormone	O
concentrations	O
.	O

Perforating	O
the	O
peritoneum	O
on	O
P	O
phase	O
(	O
left	O
,	O
right	O
or	O
bilateral	O
)	O
resulted	O
in	O
hormone	O
serum	O
concentration	O
decreases	O
(	O
Left	O
30	O
%	O
;	O
Right	O
50	O
%	O
;	O
Bilateral	O
41	O
%	O
)	O
.	O

Results	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Effects	O
of	O
unilateral	O
or	O
bilateral	O
ovariectomy	O
When	O
surgery	O
was	O
performed	O
on	O
D1	O
,	O
no	O
significant	O
differences	O
in	O
E2	O
serum	O
concentrations	O
were	O
observed	O
between	O
rats	B
with	O
ULO	O
(	O
animals	O
with	O
intact	O
left	O
or	O
right	O
ovary	O
in	O
situ	O
)	O
or	O
perforation	O
of	O
the	O
peritoneum	O
(	O
Figure	O
1	O
)	O
.	O

Animals	O
with	O
the	O
left	O
intact	O
ovary	O
in	O
situ	O
showed	O
significantly	O
higher	O
E2	O
serum	O
concentrations	O
than	O
animals	O
with	O
the	O
right	O
intact	O
ovary	O
in	O
situ	O
(	O
61.5	O
±	O
9.4	O
vs.	O
17.3	O
±	O
4.3	O
,	O
p	O
<	O
0.05	O
Student	O
's	O
t	O
test	O
)	O
.	O

Compared	O
to	O
animals	O
with	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
animals	O
with	O
right	O
ULO	O
(	O
left	O
ovary	O
in	O
situ	O
)	O
performed	O
on	O
D2	O
had	O
lower	O
E2	O
serum	O
concentrations	O
(	O
55	O
%	O
)	O
.	O

Such	O
differences	O
were	O
not	O
observed	O
in	O
rats	B
with	O
left	O
ULO	O
(	O
Figure	O
1	O
)	O
.	O

As	O
in	O
rats	B
treated	O
on	O
D1	O
,	O
E2	O
serum	O
concentrations	O
were	O
significantly	O
higher	O
in	O
animals	O
treated	O
on	O
D2	O
with	O
the	O
left	O
ovary	O
in	O
situ	O
(	O
right	O
ULO	O
)	O
than	O
in	O
animals	O
with	O
the	O
right	O
ovary	O
in	O
situ	O
(	O
49.5	O
±	O
10.8	O
vs.	O
26.0	O
±	O
6.9	O
)	O
.	O

In	O
animals	O
treated	O
on	O
P	O
,	O
right	O
ULO	O
(	O
left	O
ovary	O
in	O
situ	O
)	O
resulted	O
in	O
higher	O
E2	O
(	O
180	O
%	O
)	O
serum	O
concentrations	O
than	O
in	O
animals	O
with	O
unilateral	O
peritoneum	O
perforation	O
.	O

ULO	O
performed	O
on	O
the	O
left	O
side	O
(	O
right	O
ovary	O
in	O
situ	O
)	O
,	O
resulted	O
in	O
significantly	O
lower	O
(	O
45	O
%	O
)	O
E2	O
serum	O
concentrations	O
compared	O
to	O
rats	B
with	O
a	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
(	O
Figure	O
1	O
)	O
.	O

As	O
observed	O
in	O
rats	B
treated	O
on	O
D1	O
or	O
D2	O
,	O
when	O
the	O
intact	O
left	O
ovary	O
remains	O
in	O
situ	O
,	O
estradiol	O
serum	O
concentrations	O
were	O
significantly	O
higher	O
than	O
in	O
animals	O
with	O
the	O
intact	O
right	O
ovary	O
in	O
situ	O
(	O
142.0	O
±	O
14.1	O
vs.	O
61.5	O
±	O
6.0	O
)	O
.	O

Compared	O
to	O
animals	O
with	O
a	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
bilateral	O
ovariectomy	O
resulted	O
in	O
significantly	O
lower	O
E2	O
serum	O
concentrations	O
,	O
regardless	O
of	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
surgery	O
performed	O
(	O
D1	O
74	O
%	O
;	O
D2	O
73	O
%	O
;	O
P	O
84	O
%	O
)	O
.	O

Results	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

Effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
Injecting	O
ATR	O
on	O
D1	O
or	O
P	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
decreases	O
(	O
84	O
%	O
and	O
67	O
%	O
,	O
respectively	O
)	O
,	O
and	O
had	O
no	O
apparent	O
effects	O
on	O
E2	O
serum	O
concentrations	O
when	O
injected	O
on	O
D2	O
(	O
Table	O
3	O
)	O
.	O

Figure	O
2	O
shows	O
that	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
of	O
rats	B
with	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
depended	O
on	O
both	O
,	O
the	O
side	O
(	O
left	O
or	O
right	O
)	O
and	O
the	O
phase	O
of	O
the	O
estrous	O
when	O
surgery	O
was	O
performed	O
.	O

Injecting	O
ATR	O
on	O
D1	O
or	O
D2	O
resulted	O
in	O
a	O
significant	O
drop	O
in	O
E2	O
serum	O
concentrations	O
in	O
animals	O
with	O
sham	O
treatment	O
on	O
the	O
right	O
side	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
of	O
rats	B
with	O
left	O
side	O
peritoneum	O
perforation	O
on	O
D1	O
or	O
P	O
resulted	O
in	O
a	O
drop	O
in	O
E2	O
serum	O
concentrations	O
(	O
52	O
%	O
;	O
47	O
%	O
,	O
respectively	O
)	O
,	O
while	O
the	O
same	O
treatment	O
performed	O
on	O
D2	O
resulted	O
in	O
a	O
significant	O
E2	O
concentrations	O
increase	O
(	O
157	O
%	O
)	O
.	O

Figure	O
3	O
shows	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
of	O
rats	B
with	O
ULO	O
.	O

ATR	O
treatment	O
on	O
D1	O
or	O
P	O
stages	O
performed	O
on	O
rats	B
with	O
the	O
left	O
ovary	O
in	O
situ	O
resulted	O
in	O
a	O
significant	O
drop	O
of	O
E2	O
serum	O
concentrations	O
(	O
65	O
%	O
;	O
62	O
%	O
respectively	O
)	O
.	O

Such	O
effects	O
were	O
not	O
observed	O
in	O
rats	B
treated	O
on	O
D2	O
.	O

When	O
ATR	O
treatment	O
was	O
performed	O
on	O
rats	B
with	O
the	O
right	O
ovary	O
in	O
situ	O
on	O
D1	O
,	O
E2	O
serum	O
concentrations	O
were	O
lower	O
(	O
48	O
%	O
)	O
than	O
in	O
ULO	O
animals	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
on	O
D2	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
increase	O
(	O
159	O
%	O
)	O
.	O

When	O
the	O
treatment	O
was	O
performed	O
on	O
P	O
,	O
no	O
significant	O
differences	O
in	O
E2	O
serum	O
concentrations	O
were	O
observed	O
.	O

Compared	O
to	O
bilateral	O
treatment	O
,	O
perforation	O
of	O
the	O
peritoneum	O
or	O
bilateral	O
ovariectomy	O
,	O
ATR	O
treatment	O
on	O
D1	O
resulted	O
in	O
significant	O
E2	O
serum	O
concentrations	O
decreases	O
,	O
90	O
%	O
in	O
bilateral	O
peritoneal	O
perforation	O
and	O
60	O
%	O
in	O
bilateral	O
ovariectomized	O
animals	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
on	O
D2	O
,	O
to	O
rats	B
with	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
or	O
bilateral	O
ovariectomy	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
increases	O
(	O
159	O
%	O
and	O
253	O
%	O
respectively	O
)	O
,	O
while	O
injecting	O
ATR	O
to	O
animals	O
treated	O
on	O
P	O
had	O
no	O
apparent	O
effects	O
(	O
Figure	O
4	O
)	O
.	O

Discussion	O
The	O
results	O
obtained	O
in	O
the	O
present	O
study	O
suggest	O
that	O
the	O
ability	O
to	O
compensate	O
the	O
secretion	O
of	O
E2	O
by	O
the	O
missing	O
ovary	O
is	O
different	O
between	O
the	O
right	O
and	O
left	O
ovaries	O
and	O
varies	O
during	O
the	O
estrous	O
cycle	O
.	O

Similarly	O
,	O
our	O
results	O
suggest	O
that	O
the	O
cholinergic	O
system	O
participates	O
in	O
regulating	O
E2	O
secretion	O
by	O
the	O
ovary	O
,	O
and	O
that	O
such	O
participation	O
varies	O
depending	O
on	O
the	O
ovary	O
remaining	O
in	O
situ	O
and	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
the	O
surgical	O
procedure	O
was	O
performed	O
.	O

Previously	O
,	O
we	O
suggested	O
the	O
existence	O
of	O
a	O
neural	O
pathway	O
arising	O
from	O
the	O
peritoneum	O
that	O
participates	O
in	O
regulating	O
E2	O
[	O
9	O
]	O
,	O
P4	O
[	O
10	O
]	O
and	O
testosterone	O
secretion	O
[	O
11	O
]	O
.	O

In	O
the	O
rat	B
,	O
the	O
sensory	O
information	O
arising	O
from	O
the	O
peritoneum	O
is	O
sent	O
to	O
the	O
nucleus	O
tractus	O
solitarius	O
and	O
stimulates	O
neurokinine	O
-	O
B	O
receptors	O
[	O
17	O
]	O
.	O

Since	O
perforating	O
the	O
peritoneum	O
unilaterally	O
on	O
each	O
day	O
of	O
the	O
estrous	O
cycle	O
changed	O
E2	O
serum	O
concentrations	O
,	O
we	O
think	O
that	O
each	O
side	O
of	O
the	O
peritoneum	O
sends	O
different	O
neural	O
information	O
through	O
the	O
superior	O
ovarian	O
nerve	O
(	O
SON	O
)	O
to	O
the	O
ovary	O
and	O
the	O
central	O
nervous	O
system	O
,	O
perhaps	O
reaching	O
nuclei	O
related	O
to	O
the	O
vagus	O
nerve	O
.	O

A	O
study	O
analyzing	O
the	O
distribution	O
of	O
sensory	O
neurons	O
innervating	O
the	O
peritoneum	O
showed	O
that	O
when	O
tracer	O
was	O
placed	O
on	O
the	O
area	O
where	O
the	O
peritoneum	O
covers	O
the	O
abdominal	O
wall	O
,	O
labeled	O
neurons	O
were	O
observed	O
only	O
in	O
the	O
ipsilateral	O
dorsal	O
root	O
ganglia	O
[	O
18	O
]	O
.	O

The	O
authors	O
suggest	O
that	O
most	O
of	O
the	O
parietal	O
peritoneum	O
receives	O
sensory	O
nerves	O
from	O
dorsal	O
root	O
ganglia	O
,	O
and	O
visceral	O
peritoneum	O
from	O
both	O
,	O
the	O
spinal	O
and	O
vagus	O
nerves	O
.	O

According	O
to	O
Stener	O
-	O
Victorin	O
et	O
al.	O
(	O
19	O
)	O
repeated	O
electro	O
-	O
acupunture	O
treatments	O
in	O
rats	B
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCO	O
)	O
,	O
induced	O
by	O
a	O
single	O
injection	O
of	O
estradiol	O
valerate	O
,	O
resulted	O
in	O
lower	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
concentrations	O
at	O
the	O
ovarian	O
level	O
than	O
in	O
non	O
-	O
electro	O
-	O
acupunture	O
treated	O
PCO	O
rats	B
.	O

In	O
our	O
experiments	O
,	O
perforating	O
the	O
peritoneum	O
affected	O
the	O
same	O
somatic	O
segments	O
employed	O
by	O
Stener	O
-	O
Victorin	O
et	O
.	O

al.	O
[	O
19	O
]	O
.	O

We	O
presume	O
that	O
peritoneum	O
surgery	O
resulted	O
in	O
an	O
increase	O
of	O
NGF	O
concentrations	O
at	O
the	O
ovarian	O
level	O
,	O
which	O
in	O
turn	O
induced	O
hyper	O
-	O
androgenism	O
,	O
as	O
observed	O
in	O
women	O
with	O
PCO	O
[	O
20	O
]	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
results	O
in	O
a	O
significant	O
increase	O
in	O
testosterone	O
serum	O
concentrations	O
[	O
11	O
]	O
.	O

Because	O
E2	O
serum	O
concentrations	O
did	O
not	O
increase	O
after	O
left	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
we	O
suppose	O
that	O
the	O
neural	O
information	O
originating	O
from	O
the	O
peritoneum	O
inhibits	O
the	O
mechanisms	O
regulating	O
aromatase	O
activity	O
within	O
the	O
follicle	O
.	O

One	O
of	O
the	O
ovaries	O
'	O
sources	O
of	O
catecholamines	O
arrives	O
through	O
the	O
SON	O
.	O

In	O
the	O
ovary	O
,	O
the	O
SON	O
fibers	O
are	O
mainly	O
distributed	O
in	O
the	O
peri	O
-	O
follicular	O
theca	O
layer	O
,	O
and	O
in	O
close	O
relation	O
with	O
the	O
cells	O
of	O
the	O
theca	O
interna	O
[	O
21,22	O
]	O
.	O

Sectioning	O
the	O
SON	O
of	O
rats	B
in	O
P	O
results	O
in	O
a	O
sudden	O
drop	O
of	O
P4	O
and	O
E2	O
concentrations	O
in	O
the	O
ovarian	O
vein	O
effluent	O
[	O
23	O
]	O
,	O
while	O
the	O
same	O
procedure	O
on	O
estrus	O
did	O
not	O
modify	O
E2	O
concentrations	O
[	O
24	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
perforating	O
the	O
peritoneum	O
modifies	O
the	O
type	O
and/or	O
rate	O
of	O
information	O
arriving	O
to	O
the	O
ovary	O
via	O
the	O
SON	O
.	O

Another	O
possibility	O
is	O
that	O
perforating	O
the	O
left	O
side	O
of	O
the	O
peritoneum	O
results	O
in	O
an	O
increase	O
release	O
of	O
ovarian	O
gamma	O
amino	O
butyric	O
acid	O
(	O
GABA	O
)	O
,	O
and	O
a	O
subsequent	O
increase	O
of	O
E2	O
concentrations	O
.	O

According	O
to	O
Erdö	O
,	O
et	O
.	O

al.	O
[	O
25	O
]	O
and	O
Laszlo	O
,	O
et	O
.	O

al.	O
[	O
26	O
]	O
,	O
injecting	O
GABA	O
into	O
pseudo	O
-	O
pregnant	O
rats	B
increases	O
E2	O
concentration	O
in	O
the	O
blood	O
.	O

Present	O
results	O
indicate	O
that	O
injecting	O
ATR	O
,	O
before	O
unilateral	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
to	O
rats	B
in	O
D1	O
or	O
P	O
,	O
results	O
in	O
lower	O
E2serum	O
concentrations	O
;	O
leading	O
us	O
to	O
think	O
that	O
some	O
of	O
the	O
neural	O
fibers	O
present	O
in	O
the	O
peritoneum	O
are	O
muscarinic	O
.	O

It	O
is	O
also	O
possible	O
that	O
blocking	O
the	O
cholinergic	O
innervation	O
,	O
by	O
ATR	O
treatment	O
,	O
results	O
in	O
lower	O
adrenaline	O
and	O
norepinephrine	O
release	O
by	O
the	O
adrenal	O
medulla	O
.	O

Our	O
results	O
,	O
and	O
those	O
of	O
others	O
,	O
suggest	O
that	O
stimulating	O
on	O
D2	O
the	O
sensory	O
receptors	O
located	O
on	O
the	O
left	O
side	O
of	O
the	O
peritoneum	O
triggers	O
an	O
E2	O
secretion	O
inhibitory	O
mechanism	O
,	O
that	O
the	O
sensory	O
pathway	O
arising	O
from	O
the	O
right	O
side	O
has	O
a	O
stimulatory	O
effect	O
,	O
and	O
that	O
both	O
are	O
mediated	O
by	O
the	O
cholinergic	O
muscarinic	O
system	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
injecting	O
ATR	O
to	O
rats	B
in	O
D2	O
results	O
in	O
increases	O
of	O
P4	O
serum	O
concentrations	O
originating	O
from	O
the	O
adrenals	O
[	O
8	O
]	O
,	O
without	O
having	O
apparent	O
effects	O
on	O
testosterone	O
serum	O
concentrations	O
[	O
11	O
]	O
.	O

Since	O
P4	O
and	O
androgens	O
are	O
precursors	O
in	O
the	O
synthesis	O
of	O
E2	O
,	O
we	O
presume	O
that	O
this	O
mechanism	O
may	O
explain	O
the	O
increase	O
in	O
E2	O
serum	O
concentrations	O
observed	O
in	O
rats	B
with	O
peritoneum	O
perforation	O
previously	O
injected	O
with	O
ATR	O
.	O

Another	O
possibility	O
explaining	O
the	O
differences	O
on	O
E2	O
secretion	O
regulation	O
during	O
the	O
estrous	O
cycle	O
is	O
that	O
the	O
effects	O
of	O
the	O
cholinergic	O
system	O
take	O
place	O
through	O
changes	O
at	O
the	O
celiac	O
ganglion	O
level	O
.	O

According	O
to	O
Aguado	O
and	O
Ojeda	O
[	O
23	O
]	O
,	O
acetylcholine	O
inhibits	O
P4	O
secretion	O
in	O
the	O
celiac	O
ganglion	O
-	O
SON	O
-	O
ovary	O
preparation	O
obtained	O
from	O
rats	B
in	O
D1	O
or	O
D2	O
,	O
while	O
the	O
preparation	O
obtained	O
from	O
rats	B
in	O
P	O
resulted	O
in	O
only	O
a	O
moderate	O
stimulation	O
.	O

Since	O
there	O
is	O
evidence	O
that	O
fibers	O
from	O
the	O
vagus	O
nerve	O
innervate	O
neurons	O
in	O
the	O
celiac	O
ganglion	O
[	O
27	O
]	O
,	O
we	O
presume	O
that	O
the	O
cholinergic	O
system	O
modulates	O
the	O
sympathetic	O
post	O
-	O
ganglionar	O
activity	O
and	O
the	O
secretory	O
ability	O
of	O
the	O
ovaries	O
through	O
the	O
SON	O
.	O

Conclusion	O
Based	O
on	O
the	O
differences	O
in	O
E2	O
serum	O
concentrations	O
in	O
rats	B
with	O
ULO	O
,	O
present	O
results	O
suggest	O
that	O
the	O
capacity	O
to	O
release	O
E2	O
by	O
the	O
left	O
and	O
right	O
ovaries	O
varies	O
during	O
the	O
estrous	O
cycle	O
.	O

We	O
presume	O
that	O
the	O
left	O
ovary	O
releases	O
more	O
E2	O
than	O
the	O
right	O
one	O
.	O

As	O
previously	O
proposed	O
,	O
another	O
possibility	O
is	O
that	O
neural	O
communication	O
between	O
the	O
ovaries	O
modulates	O
E2	O
secretion	O
.	O

Molecular	O
polymorphism	O
,	O
differentiation	O
and	O
introgression	O
in	O
the	O
period	O
gene	O
between	O
Lutzomyia	B
intermedia	I
and	O
Lutzomyia	B
whitmani	I
Abstract	O
Background	O
Lutzomyia	B
intermedia	I
and	O
Lutzomyia	B
whitmani	I
(	O
Diptera	O
:	O
Psychodidae	O
)	O
are	O
important	O
and	O
very	O
closely	O
related	O
vector	O
species	O
of	O
cutaneous	O
leishmaniasis	O
in	O
Brazil	O
,	O
which	O
are	O
distinguishable	O
by	O
a	O
few	O
morphological	O
differences	O
.	O

There	O
is	O
evidence	O
of	O
mitochondrial	O
introgression	O
between	O
the	O
two	O
species	O
but	O
it	O
is	O
not	O
clear	O
whether	O
gene	O
flow	O
also	O
occurs	O
in	O
nuclear	O
genes	O
.	O

Results	O
We	O
analyzed	O
the	O
molecular	O
variation	O
within	O
the	O
clock	O
gene	O
period	O
(	O
per	O
)	O
of	O
these	O
two	O
species	O
in	O
five	O
different	O
localities	O
in	O
Eastern	O
Brazil	O
.	O

AMOVA	O
and	O
Fst	O
estimates	O
showed	O
no	O
evidence	O
for	O
geographical	O
differentiation	O
within	O
species	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
values	O
were	O
highly	O
significant	O
for	O
both	O
analyses	O
between	O
species	O
.	O

The	O
two	O
species	O
show	O
no	O
fixed	O
differences	O
and	O
a	O
higher	O
number	O
of	O
shared	O
polymorphisms	O
compared	O
to	O
exclusive	O
mutations	O
.	O

In	O
addition	O
,	O
some	O
haplotypes	O
that	O
are	O
""""	O
typical	O
""""	O
of	O
one	O
species	O
were	O
found	O
in	O
some	O
individuals	O
of	O
the	O
other	O
species	O
suggesting	O
either	O
the	O
persistence	O
of	O
old	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
.	O

Two	O
tests	O
of	O
gene	O
flow	O
,	O
one	O
based	O
on	O
linkage	O
disequilibrium	O
and	O
a	O
MCMC	O
analysis	O
based	O
on	O
coalescence	O
,	O
suggest	O
that	O
the	O
two	O
species	O
might	O
be	O
exchanging	O
alleles	O
at	O
the	O
per	O
locus	O
.	O

Conclusion	O
Introgression	O
might	O
be	O
occurring	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
in	O
period	O
,	O
a	O
gene	O
controlling	O
behavioral	O
rhythms	O
in	O
Drosophila	O
.	O

This	O
result	O
raises	O
the	O
question	O
of	O
whether	O
similar	O
phenomena	O
are	O
occurring	O
at	O
other	O
loci	O
controlling	O
important	O
aspects	O
of	O
behavior	O
and	O
vectorial	O
capacity	O
.	O

Background	O

The	O
Phlebotominae	O
sand	O
flies	O
Lutzomyia	B
intermedia	I
Lutz	O
&	O
Neiva	O
1912	O
and	O
Lutzomyia	B
whitmani	I
Antunes	O
&	O
Coutinho	O
1912	O
are	O
vectors	O
of	O
cutaneous	O
leishmaniasis	O
in	O
Brazil	O
.	O

These	O
are	O
closely	O
related	O
species	O
that	O
can	O
be	O
only	O
distinguished	O
by	O
a	O
few	O
morphological	O
differences	O
[	O
1	O
]	O
and	O
both	O
show	O
high	O
anthropophily	O
and	O
reported	O
natural	O
infections	O
with	O
Leishmania	O
in	O
different	O
regions	O
of	O
Brazil	O
[	O
2	O
]	O
.	O

Despite	O
their	O
importance	O
as	O
vectors	O
,	O
only	O
a	O
handful	O
of	O
studies	O
have	O
been	O
carried	O
out	O
in	O
these	O
two	O
species	O
using	O
molecular	O
techniques	O
[	O
3	O
-	O
6	O
]	O
.	O

One	O
of	O
the	O
most	O
important	O
findings	O
from	O
an	O
epidemiological	O
perspective	O
is	O
the	O
evidence	O
obtained	O
for	O
introgression	O
between	O
the	O
two	O
species	O
using	O
mitochondrial	O
DNA	O
[	O
4	O
]	O
.	O

This	O
was	O
particularly	O
interesting	O
because	O
apparently	O
,	O
only	O
lineages	O
of	O
L.	B
whitmani	I
sympatric	O
with	O
L.	B
intermedia	I
have	O
been	O
involved	O
in	O
cutaneous	O
leishmaniasis	O
transmission	O
in	O
the	O
peridomestic	O
environment	O
[	O
4	O
]	O
,	O
which	O
suggests	O
that	O
genes	O
controlling	O
aspects	O
of	O
vectorial	O
capacity	O
could	O
be	O
passing	O
from	O
one	O
species	O
to	O
the	O
other	O
.	O

In	O
fact	O
,	O
mitochondrial	O
introgression	O
has	O
been	O
reported	O
in	O
other	O
sand	O
fly	O
species	O
[	O
7,8	O
]	O
suggesting	O
that	O
might	O
be	O
a	O
common	O
phenomenon	O
in	O
these	O
insect	O
vectors	O
.	O

However	O
,	O
because	O
mitochondrial	O
genes	O
can	O
introgress	O
relatively	O
easily	O
between	O
closely	O
related	O
species	O
[	O
9	O
]	O
,	O
it	O
becomes	O
important	O
to	O
examine	O
whether	O
introgression	O
can	O
occur	O
with	O
nuclear	O
genes	O
.	O

The	O
Drosophila	O
period	O
(	O
per	O
)	O
gene	O
homologue	O
was	O
isolated	O
in	O
sand	O
flies	O
by	O
Peixoto	O
et	O
al.	O
[	O
10	O
]	O
.	O

This	O
circadian	O
clock	O
gene	O
was	O
originally	O
identified	O
using	O
mutagenesis	O
by	O
Konopka	O
and	O
Benzer	O
[	O
11	O
]	O
,	O
but	O
is	O
also	O
known	O
to	O
control	O
the	O
differences	O
in	O
the	O
""""	O
lovesong	O
""""	O
rhythms	O
between	O
D.	B
melanogaster	I
and	O
D.	B
simulans	I
[	O
12	O
]	O
,	O
that	O
are	O
important	O
to	O
the	O
sexual	O
isolation	O
between	O
these	O
two	O
species	O
[	O
13	O
-	O
15	O
]	O
.	O

In	O
addition	O
,	O
per	O
was	O
implicated	O
in	O
the	O
control	O
of	O
species	O
-	O
specific	O
circadian	O
mating	O
rhythms	O
in	O
Drosophila	O
and	O
Bractocera	O
,	O
which	O
might	O
also	O
constitute	O
a	O
reproductive	O
isolation	O
mechanism	O
[	O
16	O
-	O
18	O
]	O
.	O

Thus	O
per	O
may	O
possibly	O
represent	O
an	O
example	O
of	O
a	O
Drosophila	O
speciation	O
gene	O
[	O
19	O
]	O
,	O
and	O
in	O
fact	O
it	O
has	O
been	O
used	O
as	O
a	O
molecular	O
marker	O
in	O
a	O
number	O
of	O
speciation	O
and	O
evolutionary	O
studies	O
,	O
not	O
only	O
in	O
Drosophila	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
but	O
also	O
in	O
other	O
insects	O
(	O
e.g.	O
[	O
21	O
]	O
)	O
including	O
sand	O
flies	O
[	O
22	O
-	O
24	O
]	O
.	O

Because	O
per	O
controls	O
the	O
circadian	O
clock	O
in	O
different	O
insects	O
[	O
25	O
]	O
,	O
it	O
is	O
almost	O
certainly	O
involved	O
in	O
the	O
rhythms	O
of	O
activity	O
and	O
biting	O
of	O
sand	O
flies	O
[	O
26	O
]	O
,	O
which	O
are	O
very	O
important	O
to	O
leishmaniasis	O
transmission	O
.	O

In	O
addition	O
,	O
per	O
might	O
be	O
involved	O
in	O
reproductive	O
isolation	O
in	O
sand	O
flies	O
,	O
via	O
mating	O
rhythms	O
,	O
or	O
via	O
their	O
""""	O
lovesongs	O
""""	O
[	O
2,27	O
]	O
.	O

per	O
is	O
thus	O
a	O
particularly	O
interesting	O
marker	O
,	O
among	O
the	O
few	O
available	O
,	O
for	O
an	O
introgression	O
analysis	O
in	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

Evidence	O
for	O
introgression	O
in	O
per	O
might	O
suggest	O
that	O
gene	O
flow	O
between	O
these	O
two	O
vector	O
species	O
is	O
occurring	O
at	O
other	O
genes	O
controlling	O
important	O
aspects	O
of	O
behavior	O
and	O
vectorial	O
capacity	O
.	O

It	O
might	O
also	O
suggest	O
that	O
per	O
does	O
not	O
have	O
a	O
strong	O
role	O
in	O
their	O
reproductive	O
isolation	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
analyzed	O
the	O
molecular	O
variation	O
within	O
the	O
per	O
gene	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
in	O
five	O
different	O
localities	O
in	O
Eastern	O
Brazil	O
.	O

Results	O
Polymorphism	O
and	O
divergence	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
A	O
total	O
of	O
68	O
sequences	O
from	O
L.	B
intermedia	I
and	O
53	O
from	O
L.	B
whitmani	I
homologue	O
to	O
a	O
fragment	O
of	O
the	O
period	O
gene	O
were	O
analyzed	O
from	O
populations	O
of	O
five	O
localities	O
in	O
Eastern	O
Brazil	O
(	O
Fig	O
1	O
)	O
.	O

The	O
alignment	O
of	O
72	O
variable	O
sites	O
is	O
shown	O
in	O
Fig	O
2	O
.	O

Although	O
most	O
of	O
the	O
changes	O
are	O
either	O
synonymous	O
or	O
occur	O
within	O
the	O
58	O
bp	O
intron	O
,	O
non	O
-	O
synonymous	O
substitutions	O
are	O
observed	O
causing	O
9	O
amino	O
acid	O
differences	O
among	O
the	O
sequences	O
(	O
Fig	O
2	O
)	O
.	O

Table	O
1	O
shows	O
the	O
number	O
of	O
sequences	O
of	O
each	O
population	O
of	O
the	O
two	O
species	O
,	O
the	O
number	O
of	O
polymorphic	O
sites	O
(	O
S	O
)	O
and	O
the	O
estimates	O
of	O
molecular	O
polymorphism	O
θ	O
(	O
based	O
on	O
the	O
total	O
number	O
of	O
mutations	O
)	O
and	O
π	O
.	O

Table	O
1	O
also	O
shows	O
the	O
Tajima	O
's	O
[	O
28	O
]	O
and	O
Fu	O
&	O
Li	O
's	O
[	O
29	O
]	O
statistics	O
.	O

Within	O
each	O
species	O
,	O
all	O
populations	O
present	O
similar	O
levels	O
of	O
polymorphism	O
with	O
the	O
exception	O
of	O
L.	B
whitmani	I
from	O
Ilhéus	O
,	O
which	O
seems	O
to	O
be	O
less	O
polymorphic	O
than	O
the	O
others	O
.	O

This	O
population	O
was	O
also	O
the	O
only	O
one	O
presenting	O
a	O
significant	O
value	O
in	O
the	O
Fu	O
&	O
Li	O
test	O
but	O
only	O
at	O
the	O
5	O
%	O
level	O
.	O

Finally	O
,	O
the	O
last	O
column	O
of	O
Table	O
1	O
presents	O
the	O
recombination	O
estimator	O
γ	O
[	O
30	O
]	O
indicating	O
that	O
both	O
species	O
show	O
evidence	O
of	O
intragenic	O
recombination	O
in	O
the	O
per	O
gene	O
.	O

To	O
investigate	O
the	O
level	O
of	O
intra	O
and	O
interspecific	O
differences	O
,	O
initially	O
an	O
AMOVA	O
was	O
carried	O
out	O
as	O
shown	O
in	O
Table	O
2	O
.	O

The	O
results	O
show	O
a	O
non	O
-	O
significant	O
within	O
species	O
and	O
a	O
significant	O
between	O
species	O
molecular	O
variation	O
at	O
the	O
per	O
locus	O
.	O

Table	O
3	O
shows	O
a	O
more	O
detailed	O
analysis	O
of	O
the	O
intraspecific	O
differentiation	O
among	O
populations	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

None	O
of	O
the	O
pairwise	O
and	O
overall	O
fixation	O
indexes	O
(	O
Fst	O
)	O
are	O
significant	O
in	O
the	O
case	O
of	O
L.	B
intermedia	I
and	O
only	O
one	O
(	O
Posse	O
×	O
Ilhéus	O
)	O
has	O
a	O
borderline	O
significant	O
value	O
in	O
L.	B
whitmani	I
.	O

The	O
results	O
therefore	O
show	O
that	O
no	O
significant	O
geographical	O
heterogeneity	O
was	O
detected	O
among	O
the	O
populations	O
of	O
the	O
two	O
species	O
.	O

The	O
estimated	O
number	O
of	O
migrants	O
per	O
generation	O
,	O
based	O
on	O
the	O
overall	O
Fst	O
values	O
,	O
is	O
20.683	O
for	O
L.	B
intermedia	I
and	O
23.125	O
for	O
L.	B
whitmani	I
.	O

Table	O
4	O
shows	O
measures	O
for	O
DNA	O
divergence	O
between	O
species	O
(	O
Dxy	O
and	O
Da	O
)	O
,	O
as	O
well	O
as	O
the	O
Fst	O
and	O
Nm	O
values	O
considering	O
each	O
species	O
as	O
a	O
unique	O
population	O
.	O

Dxy	O
is	O
the	O
average	O
number	O
of	O
nucleotide	O
substitutions	O
per	O
site	O
between	O
alleles	O
from	O
two	O
different	O
populations	O
and	O
Da	O
is	O
the	O
number	O
of	O
net	O
nucleotide	O
substitutions	O
between	O
two	O
populations	O
.	O

Table	O
4	O
also	O
shows	O
the	O
number	O
of	O
polymorphisms	O
exclusive	O
for	O
each	O
species	O
(	O
Sint	O
and	O
Swhit	O
)	O
,	O
the	O
number	O
of	O
shared	O
polymorphisms	O
(	O
Ss	O
)	O
and	O
the	O
number	O
of	O
fixed	O
differences	O
(	O
Sf	O
)	O
between	O
species	O
.	O

As	O
one	O
can	O
note	O
,	O
there	O
is	O
a	O
high	O
number	O
of	O
shared	O
polymorphisms	O
between	O
species	O
,	O
and	O
no	O
fixed	O
differences	O
between	O
them	O
suggesting	O
either	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
.	O

In	O
fact	O
,	O
there	O
is	O
one	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
(	O
IPO13	O
,	O
WPO10	O
and	O
WPO19	O
)	O
and	O
three	O
L.	B
whitmani	I
sequences	O
(	O
WAC02	O
,	O
WPO13	O
and	O
WPO14	O
)	O
which	O
show	O
only	O
one	O
nucleotide	O
difference	O
to	O
""""	O
typical	O
""""	O
L.	B
intermedia	I
haplotypes	O
(	O
see	O
also	O
below	O
)	O
.	O

Genealogy	O
of	O
period	O
sequences	O
A	O
phylogenetic	O
analysis	O
of	O
the	O
period	O
gene	O
sequences	O
from	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
was	O
carried	O
out	O
with	O
the	O
Minimum	O
Evolution	O
method	O
using	O
the	O
Kimura	O
2-parameter	O
distance	O
(	O
Fig	O
3	O
)	O
.	O

A	O
sequence	O
from	O
L.	B
umbratilis	I
,	O
a	O
related	O
species	O
from	O
the	O
same	O
subgenus	O
Nyssomyia	O
,	O
was	O
used	O
as	O
outgroup	O
[	O
24	O
]	O
.	O

The	O
tree	O
shows	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
as	O
non	O
-	O
monophyletic	O
.	O

However	O
,	O
despite	O
the	O
low	O
bootstrap	O
values	O
,	O
which	O
are	O
below	O
50	O
%	O
in	O
most	O
cases	O
,	O
there	O
is	O
a	O
large	O
group	O
that	O
contains	O
most	O
L.	B
intermedia	I
sequences	O
and	O
a	O
second	O
large	O
group	O
with	O
most	O
L.	B
whitmani	I
sequences	O
.	O

A	O
few	O
other	O
sequences	O
are	O
clustered	O
outside	O
these	O
two	O
main	O
groups	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
there	O
are	O
three	O
L.	B
whitmani	I
alleles	O
(	O
WAC2	O
,	O
WPO13	O
and	O
WPO14	O
)	O
inside	O
L.	B
intermedia	I
main	O
group	O
,	O
as	O
well	O
as	O
one	O
L.	B
intermedia	I
allele	O
(	O
ICP16	O
)	O
inside	O
the	O
L.	B
whitmani	I
main	O
group	O
.	O

In	O
addition	O
,	O
a	O
second	O
L.	B
intermedia	I
allele	O
(	O
IPO13	O
)	O
is	O
a	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
as	O
mentioned	O
above	O
.	O

Again	O
,	O
the	O
results	O
suggest	O
either	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
between	O
the	O
two	O
species	O
.	O

Very	O
similar	O
results	O
were	O
obtained	O
using	O
the	O
maximum	O
likelihood	O
algorithm	O
as	O
implemented	O
in	O
PAUP	O
4.0b10	O
software	O
[	O
31	O
]	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
mentioned	O
before	O
,	O
there	O
is	O
evidence	O
of	O
intragenic	O
recombination	O
in	O
the	O
per	O
gene	O
fragment	O
of	O
both	O
species	O
(	O
see	O
Table	O
1	O
)	O
and	O
for	O
that	O
reason	O
the	O
bifurcating	O
tree	O
shown	O
in	O
Fig	O
3	O
has	O
to	O
be	O
viewed	O
with	O
caution	O
,	O
as	O
different	O
regions	O
of	O
the	O
gene	O
might	O
have	O
different	O
phylogenetic	O
histories	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
we	O
constructed	O
Minimum	O
Evolution	O
trees	O
with	O
the	O
two	O
most	O
polymorphic	O
non	O
-	O
recombining	O
blocks	O
of	O
the	O
per	O
gene	O
fragment	O
identified	O
using	O
the	O
Hudson	O
and	O
Kaplan	O
[	O
33	O
]	O
method	O
available	O
in	O
the	O
DNAsp	O
4.1	O
program	O
[	O
34	O
]	O
.	O

We	O
did	O
not	O
observed	O
major	O
changes	O
in	O
the	O
genealogy	O
of	O
the	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
per	O
sequences	O
,	O
especially	O
regarding	O
the	O
five	O
haplotypes	O
(	O
ICP16	O
,	O
IPO13	O
,	O
WAC2	O
,	O
WPO13	O
and	O
WPO14	O
)	O
that	O
clearly	O
cluster	O
with	O
sequences	O
of	O
the	O
other	O
species	O
(	O
data	O
not	O
shown	O
)	O
.	O

Finally	O
,	O
a	O
haplotype	O
network	O
was	O
estimated	O
from	O
per	O
sequences	O
using	O
statistical	O
parsimony	O
,	O
as	O
described	O
by	O
Templeton	O
et	O
al.	O
[	O
35	O
]	O
and	O
implemented	O
in	O
the	O
TCS1.21	O
software	O
[	O
36	O
]	O
(	O
Fig	O
4	O
)	O
.	O

A	O
small	O
number	O
of	O
ambiguities	O
were	O
resolved	O
as	O
suggested	O
by	O
Crandall	O
and	O
Templeton	O
[	O
37	O
]	O
.	O

The	O
haplotype	O
network	O
shows	O
connections	O
between	O
sequences	O
from	O
each	O
species	O
,	O
separating	O
most	O
of	O
the	O
sequences	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
in	O
two	O
groups	O
.	O

No	O
intraspecific	O
geographical	O
structuring	O
was	O
found	O
.	O

Once	O
again	O
,	O
some	O
of	O
the	O
L.	B
whitmani	I
sequences	O
(	O
WAC2	O
,	O
WAC10	O
,	O
WPO13	O
and	O
WPO14	O
)	O
appear	O
more	O
closely	O
related	O
to	O
L.	B
intermedia	I
haplotypes	O
.	O

In	O
addition	O
,	O
one	O
L.	B
intermedia	I
allele	O
(	O
ICP16	O
)	O
is	O
connected	O
by	O
a	O
small	O
number	O
of	O
mutations	O
to	O
some	O
of	O
the	O
main	O
L.	B
whitmani	I
haplotypes	O
and	O
IPO13	O
is	O
a	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
.	O

These	O
results	O
confirm	O
the	O
same	O
putative	O
introgressed	O
sequences	O
indicated	O
by	O
the	O
phylogenetic	O
reconstructions	O
.	O

LD	O
test	O
of	O
introgression	O
We	O
tested	O
the	O
hypothesis	O
of	O
gene	O
flow	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
using	O
a	O
method	O
based	O
on	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
developed	O
by	O
Machado	O
et	O
al.	O
[	O
38	O
]	O
.	O

In	O
this	O
test	O
,	O
x	O
is	O
the	O
difference	O
between	O
the	O
average	O
LD	O
found	O
among	O
all	O
pairs	O
of	O
shared	O
polymorphisms	O
(	O
DSS	O
)	O
between	O
the	O
two	O
species	O
and	O
the	O
average	O
LD	O
among	O
all	O
pairs	O
of	O
sites	O
for	O
which	O
one	O
member	O
is	O
a	O
shared	O
polymorphism	O
and	O
the	O
other	O
is	O
an	O
exclusive	O
polymorphism	O
(	O
DSX	O
)	O
.	O

In	O
case	O
of	O
gene	O
flow	O
x	O
should	O
tend	O
to	O
be	O
positive	O
[	O
see	O
[	O
38	O
]	O
for	O
more	O
details	O
]	O
.	O

Because	O
of	O
limitations	O
on	O
the	O
total	O
number	O
of	O
sequences	O
that	O
could	O
be	O
handled	O
by	O
the	O
WH	O
program	O
we	O
could	O
not	O
perform	O
the	O
simulations	O
with	O
all	O
sequences	O
.	O

Therefore	O
,	O
we	O
carried	O
out	O
the	O
LD	O
test	O
of	O
introgression	O
between	O
each	O
pair	O
of	O
sympatric	O
populations	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
from	O
the	O
localities	O
of	O
Posse	O
,	O
Afonso	O
Claudio	O
and	O
Corte	O
de	O
Pedra	O
.	O

The	O
input	O
files	O
were	O
prepared	O
using	O
the	O
values	O
of	O
recombination	O
and	O
linkage	O
disequilibrium	O
calculated	O
by	O
the	O
SITES	O
program	O
[	O
30	O
]	O
for	O
each	O
population	O
(	O
data	O
not	O
shown	O
)	O
.	O

Although	O
no	O
significant	O
values	O
were	O
found	O
for	O
the	O
smaller	O
samples	O
of	O
Afonso	O
Claudio	O
and	O
Corte	O
de	O
Pedra	O
,	O
the	O
results	O
(	O
Table	O
5	O
)	O
present	O
evidence	O
for	O
introgression	O
in	O
the	O
period	O
gene	O
in	O
both	O
directions	O
(	O
from	O
L.	B
intermedia	I
to	O
L.	B
whitmani	I
and	O
vice	O
-	O
versa	O
)	O
in	O
the	O
locality	O
of	O
Posse	O
.	O

Isolation	O
with	O
Migration	O
model	O
To	O
further	O
examine	O
the	O
gene	O
flow	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
we	O
used	O
the	O
IM	O
software	O
[	O
39	O
]	O
.	O

The	O
Isolation	O
with	O
Migration	O
model	O
has	O
six	O
demographic	O
parameters	O
that	O
include	O
two	O
migration	O
rates	O
,	O
one	O
for	O
each	O
population	O
.	O

The	O
IM	O
software	O
estimates	O
the	O
posterior	O
probability	O
for	O
each	O
of	O
the	O
model	O
parameters	O
,	O
fitting	O
the	O
Isolation	O
with	O
Migration	O
model	O
to	O
the	O
data	O
.	O

One	O
of	O
the	O
assumptions	O
of	O
this	O
model	O
is	O
that	O
the	O
loci	O
studied	O
do	O
not	O
have	O
internal	O
recombination	O
.	O

Therefore	O
,	O
we	O
identified	O
four	O
different	O
non	O
-	O
recombining	O
blocks	O
of	O
our	O
fragment	O
of	O
per	O
,	O
which	O
were	O
then	O
treated	O
as	O
different	O
loci	O
in	O
the	O
analysis	O
.	O

The	O
four	O
-	O
gametes	O
test	O
[	O
33	O
]	O
implemented	O
in	O
DnaSP4.1	O
was	O
used	O
for	O
the	O
identification	O
of	O
possible	O
recombination	O
events	O
.	O

Since	O
the	O
program	O
estimates	O
parameters	O
for	O
a	O
pair	O
of	O
closely	O
related	O
populations	O
or	O
species	O
,	O
all	O
sequences	O
of	O
each	O
species	O
were	O
used	O
in	O
the	O
analysis	O
as	O
a	O
single	O
population	O
.	O

We	O
performed	O
MCMC	O
runs	O
using	O
the	O
IM	O
software	O
with	O
different	O
seed	O
numbers	O
,	O
in	O
order	O
to	O
guarantee	O
convergence	O
of	O
the	O
sample	O
.	O

Maximum	O
likelihood	O
estimates	O
of	O
migration	O
parameters	O
revealed	O
a	O
non	O
-	O
zero	O
value	O
for	O
both	O
species	O
,	O
m1	O
=	O
1.398	O
and	O
m2	O
=	O
1.014	O
(	O
m1	O
–	O
from	O
L.	B
whitmani	I
towards	O
L.	B
intermedia	I
;	O
m2	O
–	O
from	O
L.	B
whitmani	I
towards	O
L.	B
intermedia	I
)	O
.	O

Fig	O
5	O
shows	O
the	O
posterior	O
distributions	O
for	O
migration	O
rates	O
and	O
reveals	O
a	O
null	O
probability	O
for	O
the	O
absence	O
of	O
migration	O
from	O
L.	B
whitmani	I
towards	O
L.	B
intermedia	I
.	O

In	O
addition	O
,	O
the	O
absence	O
of	O
migration	O
in	O
the	O
opposite	O
direction	O
is	O
not	O
included	O
in	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
values	O
range	O
from	O
0.222	O
to	O
8.898	O
)	O
,	O
thus	O
supporting	O
the	O
presence	O
of	O
migration	O
in	O
both	O
directions	O
.	O

The	O
conversion	O
of	O
the	O
migration	O
rate	O
estimate	O
to	O
population	O
migration	O
rate	O
per	O
generation	O
(	O
m1	O
and	O
m2	O
)	O
is	O
not	O
accurate	O
when	O
the	O
population	O
size	O
is	O
based	O
on	O
a	O
single	O
locus	O
.	O

However	O
,	O
the	O
average	O
of	O
the	O
migrant	O
number	O
per	O
generation	O
for	O
both	O
species	O
was	O
very	O
close	O
to	O
the	O
Nm	O
estimate	O
based	O
on	O
Fst	O
values	O
(	O
Nm	O
~0.49	O
in	O
Table	O
4	O
,	O
m1	O
~0.52	O
and	O
m2	O
~0.34	O
)	O
.	O

Discussion	O
There	O
is	O
some	O
evidence	O
that	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
might	O
represent	O
sibling	O
-	O
species	O
complexes	O
in	O
Brazil	O
.	O

Lutzomyia	B
neivai	I
Pinto	O
1926	O
,	O
a	O
sibling	O
of	O
L.	B
intermedia	I
is	O
found	O
in	O
parts	O
of	O
Southern	O
and	O
Western	O
Brazil	O
and	O
some	O
other	O
countries	O
of	O
South	O
America	O
[	O
40	O
]	O
.	O

The	O
present	O
study	O
did	O
not	O
include	O
populations	O
of	O
this	O
species	O
.	O

In	O
the	O
case	O
of	O
L.	B
whitmani	I
,	O
mitochondrial	O
data	O
[	O
3,6	O
]	O
indicates	O
three	O
main	O
lineages	O
in	O
Brazil	O
:	O
an	O
Amazonian	O
group	O
,	O
a	O
North	O
-	O
South	O
group	O
and	O
a	O
Northeast	O
group	O
.	O

We	O
did	O
not	O
find	O
strong	O
evidence	O
of	O
a	O
geographical	O
differentiation	O
in	O
the	O
period	O
gene	O
among	O
populations	O
of	O
L.	B
whitmani	I
although	O
one	O
of	O
the	O
pairwise	O
Fst	O
comparisons	O
(	O
Posse	O
×	O
Ilhéus	O
)	O
was	O
significant	O
at	O
the	O
5	O
%	O
level	O
.	O

When	O
we	O
compare	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
,	O
we	O
find	O
a	O
highly	O
significant	O
Fst	O
value	O
(	O
0.3373	O
)	O
,	O
which	O
is	O
however	O
smaller	O
than	O
that	O
observed	O
for	O
the	O
period	O
gene	O
between	O
sympatric	O
siblings	O
of	O
Lutzomyia	B
longipalpis	I
(	O
Fst	O
=	O
0.3952	O
)	O
[	O
23	O
]	O
,	O
a	O
complex	O
of	O
cryptic	O
species	O
that	O
are	O
vectors	O
of	O
American	O
visceral	O
leishmaniasis	O
.	O

Therefore	O
,	O
despite	O
the	O
presence	O
of	O
diagnostic	O
morphological	O
characters	O
to	O
identify	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
[	O
1	O
]	O
the	O
level	O
of	O
molecular	O
divergence	O
in	O
period	O
is	O
not	O
as	O
high	O
as	O
the	O
cryptic	O
L.	B
longipalpis	I
siblings	O
.	O

Even	O
though	O
it	O
is	O
hard	O
to	O
distinguish	O
introgression	O
from	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
,	O
a	O
test	O
of	O
gene	O
flow	O
based	O
on	O
the	O
signature	O
introgression	O
leaves	O
on	O
the	O
patterns	O
of	O
linkage	O
disequilibrium	O
[	O
38	O
]	O
as	O
well	O
as	O
simulations	O
that	O
fit	O
the	O
""""	O
Isolation	O
with	O
Migration	O
""""	O
model	O
to	O
the	O
data	O
suggest	O
that	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
might	O
be	O
exchanging	O
alleles	O
at	O
the	O
per	O
locus	O
.	O

This	O
is	O
further	O
supported	O
by	O
the	O
presence	O
of	O
shared	O
haplotypes	O
between	O
the	O
two	O
species	O
in	O
Posse	O
and	O
very	O
similar	O
sequences	O
in	O
all	O
sympatric	O
populations	O
.	O

There	O
is	O
mounting	O
evidence	O
that	O
introgression	O
plays	O
a	O
major	O
role	O
in	O
the	O
evolution	O
of	O
closely	O
related	O
insect	O
vector	O
species	O
.	O

Introgression	O
among	O
vectors	O
may	O
have	O
important	O
epidemiological	O
consequences	O
.	O

Gene	O
flow	O
in	O
loci	O
that	O
affect	O
vectorial	O
capacity	O
,	O
such	O
as	O
those	O
controlling	O
host	O
preference	O
and	O
susceptibility	O
to	O
parasite	O
infection	O
,	O
can	O
change	O
the	O
transmission	O
patterns	O
and	O
consequently	O
make	O
the	O
disease	O
control	O
a	O
harder	O
task	O
.	O

Introgression	O
of	O
genes	O
that	O
control	O
adaptation	O
to	O
particular	O
types	O
of	O
environment	O
can	O
also	O
have	O
a	O
major	O
impact	O
on	O
the	O
spread	O
of	O
vector	O
-	O
borne	O
diseases	O
as	O
was	O
proposed	O
for	O
the	O
major	O
African	O
malaria	O
vector	O
Anopheles	B
gambiae	I
[	O
41	O
]	O
.	O

The	O
same	O
can	O
be	O
said	O
about	O
genes	O
controlling	O
insecticide	O
resistance	O
.	O

For	O
example	O
,	O
Weill	O
et	O
al.	O
[	O
42	O
]	O
found	O
a	O
kdr	O
mutation	O
responsible	O
for	O
pyrethroid	O
resistance	O
in	O
the	O
Mopti	O
form	O
of	O
Anopheles	B
gambiae	I
,	O
a	O
normally	O
susceptible	O
taxon	O
of	O
this	O
species	O
complex	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
this	O
resistant	O
allele	O
probably	O
originates	O
through	O
introgression	O
from	O
the	O
Savanna	O
form	O
.	O

Although	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
are	O
closely	O
related	O
and	O
only	O
distinguished	O
by	O
a	O
few	O
morphological	O
differences	O
,	O
they	O
do	O
show	O
differentiation	O
in	O
some	O
other	O
important	O
traits	O
.	O

For	O
example	O
,	O
in	O
Posse	O
,	O
one	O
of	O
the	O
localities	O
we	O
studied	O
,	O
the	O
two	O
species	O
show	O
differences	O
in	O
abundance	O
during	O
the	O
year	O
.	O

L.	B
intermedia	I
is	O
more	O
abundant	O
in	O
the	O
summer	O
while	O
L.	B
whitmani	I
is	O
more	O
frequent	O
in	O
the	O
winter	O
months	O
[	O
2	O
]	O
.	O

They	O
also	O
show	O
differences	O
in	O
microhabitat	O
preferences	O
,	O
L.	B
intermedia	I
being	O
more	O
common	O
in	O
the	O
peridomestic	O
area	O
while	O
L.	B
whitmani	I
is	O
found	O
mainly	O
in	O
the	O
surrounding	O
forest	O
[	O
2	O
]	O
.	O

In	O
addition	O
,	O
the	O
two	O
species	O
show	O
marked	O
differences	O
in	O
their	O
tendencies	O
to	O
bite	O
humans	B
in	O
the	O
early	O
morning	O
,	O
with	O
L.	B
whitmani	I
showing	O
higher	O
feeding	O
rates	O
than	O
L.	B
intermedia	I
[	O
26	O
]	O
.	O

Therefore	O
,	O
despite	O
the	O
evidence	O
of	O
introgression	O
in	O
the	O
period	O
gene	O
in	O
this	O
locality	O
,	O
there	O
are	O
important	O
ecological	O
and	O
behavioral	O
differences	O
between	O
the	O
two	O
species	O
in	O
Posse	O
suggesting	O
that	O
gene	O
flow	O
is	O
probably	O
rather	O
limited	O
in	O
loci	O
controlling	O
these	O
traits	O
.	O

Hence	O
,	O
it	O
is	O
yet	O
not	O
clear	O
whether	O
introgression	O
has	O
played	O
an	O
important	O
role	O
in	O
the	O
evolution	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

Further	O
work	O
with	O
other	O
genes	O
might	O
help	O
clarify	O
the	O
issue	O
.	O

Conclusion	O
Evidence	O
for	O
introgression	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
obtained	O
using	O
mitochondrial	O
DNA	O
[	O
4	O
]	O
seems	O
to	O
be	O
corroborated	O
by	O
our	O
data	O
on	O
the	O
period	O
gene	O
,	O
a	O
nuclear	O
marker	O
.	O

Nevertheless	O
,	O
considering	O
that	O
period	O
is	O
potentially	O
involved	O
in	O
reproductive	O
isolation	O
and	O
might	O
be	O
,	O
therefore	O
,	O
less	O
prone	O
to	O
introgression	O
than	O
the	O
""""	O
average	O
""""	O
gene	O
[	O
43	O
]	O
,	O
it	O
is	O
possible	O
that	O
much	O
higher	O
levels	O
of	O
gene	O
flow	O
between	O
the	O
two	O
species	O
occur	O
at	O
other	O
genes	O
.	O

It	O
might	O
,	O
on	O
the	O
other	O
hand	O
,	O
suggest	O
that	O
this	O
behavioral	O
gene	O
,	O
or	O
at	O
least	O
the	O
fragment	O
we	O
analyzed	O
,	O
did	O
not	O
play	O
a	O
role	O
in	O
speciation	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

In	O
fact	O
the	O
same	O
has	O
been	O
suggested	O
for	O
some	O
Drosophila	O
species	O
[	O
44	O
]	O
despite	O
per	O
's	O
role	O
controlling	O
lovesong	O
and	O
mating	O
rhythm	O
differences	O
between	O
D.	B
melanogaster	I
and	O
D.	B
simulans	I
[	O
13	O
-	O
16	O
]	O
.	O

Although	O
the	O
evidence	O
for	O
introgression	O
in	O
the	O
per	O
gene	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
is	O
not	O
overwhelming	O
,	O
it	O
does	O
indicate	O
the	O
need	O
to	O
extend	O
this	O
analysis	O
to	O
other	O
loci	O
in	O
the	O
future	O
.	O

We	O
are	O
currently	O
isolating	O
new	O
molecular	O
markers	O
in	O
the	O
two	O
species	O
to	O
carry	O
out	O
a	O
multi	O
-	O
locus	O
approach	O
[	O
39	O
]	O
that	O
might	O
help	O
determining	O
how	O
much	O
variation	O
in	O
gene	O
flow	O
and	O
differentiation	O
there	O
is	O
across	O
the	O
genome	O
of	O
these	O
two	O
very	O
important	O
leishmaniasis	O
vectors	O
.	O

Methods	O
Sand	O
fly	O
samples	O
Sand	O
fly	O
samples	O
used	O
in	O
this	O
work	O
were	O
all	O
the	O
F1	O
generation	O
from	O
wild	O
collected	O
females	O
from	O
the	O
Brazilian	O
localities	O
of	O
Posse	O
(	O
Petrópolis	O
,	O
Rio	O
de	O
Janeiro	O
State	O
,	O
22	O
°	O
30	O
'S	O
43	O
°	O
10'W	O
)	O
,	O
Jacarepaguá	O
(	O
Rio	O
de	O
Janeiro	O
,	O
Rio	O
de	O
Janeiro	O
State	O
,	O
22	O
°	O
55	O
'S	O
43	O
°	O
21'W	O
)	O
,	O
Afonso	O
Claudio	O
(	O
Espírito	O
Santo	O
State	O
,	O
20	O
°	O
04	O
'S	O
41	O
°	O
07'W	O
)	O
,	O
Corte	O
de	O
Pedra	O
(	O
Presidente	O
Tancredo	O
Neves	O
,	O
Bahia	O
State	O
,	O
13	O
°	O
27	O
'S	O
39	O
°	O
25'W	O
)	O
and	O
Ilhéus	O
(	O
Bahia	O
State	O
,	O
14	O
°	O
50	O
'S	O
39	O
°	O
06'W	O
)	O
.	O

L.	B
intermedia	I
and	O
L.	B
whitmani	I
were	O
identified	O
according	O
to	O
Young	O
and	O
Duncan	O
[	O
1	O
]	O
.	O

The	O
progeny	O
of	O
each	O
wild	O
caught	O
female	O
was	O
raised	O
separately	O
according	O
to	O
Souza	O
et	O
al.	O
[	O
45	O
]	O
and	O
only	O
one	O
F1	O
male	O
of	O
each	O
female	O
was	O
used	O
for	O
the	O
molecular	O
analysis	O
,	O
which	O
included	O
68	O
individuals	O
of	O
L.	B
intermedia	I
(	O
12	O
from	O
Afonso	O
Claudio	O
,	O
18	O
from	O
Posse	O
,	O
20	O
from	O
Corte	O
de	O
Pedra	O
and	O
18	O
from	O
Jacarepaguá	O
)	O
and	O
51	O
individuals	O
of	O
L.	B
whitmani	I
(	O
12	O
from	O
Afonso	O
Claudio	O
,	O
17	O
from	O
Posse	O
,	O
3	O
from	O
Corte	O
de	O
Pedra	O
and	O
19	O
from	O
Ilhéus	O
)	O
.	O

Note	O
that	O
,	O
although	O
the	O
distribution	O
of	O
the	O
two	O
species	O
shows	O
considerable	O
overlap	O
in	O
Eastern	O
Brazil	O
,	O
in	O
many	O
localities	O
only	O
one	O
species	O
is	O
found	O
or	O
is	O
far	O
more	O
abundant	O
than	O
the	O
other	O
.	O

There	O
are	O
also	O
seasonal	O
and	O
microhabitat	O
differences	O
in	O
abundance	O
between	O
them	O
in	O
areas	O
of	O
sympatry	O
[	O
2	O
]	O
.	O

DNA	O
methods	O
Genomic	O
DNA	O
was	O
prepared	O
according	O
to	O
Jowett	O
[	O
46	O
]	O
with	O
slight	O
modifications	O
and	O
the	O
PCR	O
was	O
carried	O
out	O
for	O
30	O
cycles	O
at	O
95	O
°	O
C	O
for	O
30	O
sec	O
,	O
60	O
°	O
C	O
for	O
30	O
sec	O
and	O
72	O
°	O
C	O
for	O
30	O
sec	O
,	O
using	O
Abgene	O
,	O
Amersham	O
Biosciences	O
or	O
Biotools	O
reagents	O
according	O
to	O
manufacturers	O
directions	O
.	O

The	O
per	O
primer	O
sequences	O
are	O
:	O
5llper2	O
:	O
5'-AGCATCCTTTTGTAGCAAAC-3	O
'	O
(	O
forward	O
)	O
and	O
3llper2	O
:	O
5'-TCAGATGAACTCTTGCTGTC-3	O
'	O
(	O
reverse	O
)	O
.	O

These	O
primers	O
amplify	O
a	O
486	O
bp	O
fragment	O
of	O
the	O
sand	O
fly	O
per	O
gene	O
homologue	O
that	O
includes	O
part	O
of	O
the	O
PAS	O
/	O
CLD	O
domain	O
,	O
an	O
intron	O
(	O
58	O
bp	O
)	O
and	O
the	O
beginning	O
of	O
the	O
perS	O
domain	O
[	O
24	O
]	O
.	O

The	O
amplified	O
fragments	O
were	O
cloned	O
using	O
the	O
pMOSBlue	O
blunt	O
ended	O
cloning	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
plasmid	O
DNA	O
preparation	O
was	O
carried	O
out	O
using	O
the	O
""""	O
Flexiprep	O
""""	O
Kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Cloned	O
PCR	O
fragments	O
were	O
sequenced	O
at	O
Fundação	O
Oswaldo	O
Cruz	O
and	O
at	O
University	O
of	O
Leicester	O
using	O
ABI	O
377	O
sequencers	O
.	O

With	O
the	O
exception	O
of	O
two	O
L.	B
whitmani	I
individuals	O
from	O
Corte	O
de	O
Pedra	O
(	O
see	O
below	O
)	O
,	O
only	O
one	O
sequence	O
of	O
each	O
sand	O
fly	O
(	O
representing	O
one	O
of	O
the	O
two	O
possible	O
alleles	O
)	O
was	O
used	O
in	O
the	O
analysis	O
but	O
an	O
average	O
of	O
three	O
sequences	O
per	O
individual	O
were	O
obtained	O
in	O
order	O
to	O
check	O
possible	O
PCR	O
induced	O
mutations	O
.	O

In	O
addition	O
,	O
PCR	O
fragments	O
were	O
also	O
sequenced	O
directly	O
in	O
some	O
cases	O
for	O
the	O
same	O
reason	O
.	O

In	O
the	O
case	O
of	O
the	O
two	O
L.	B
whitmani	I
mentioned	O
above	O
6	O
and	O
9	O
clones	O
were	O
sequenced	O
respectively	O
from	O
specimens	O
WCP01	O
and	O
WCP03	O
to	O
determine	O
both	O
alleles	O
simply	O
to	O
increase	O
the	O
size	O
of	O
this	O
small	O
sample	O
.	O

Negative	O
controls	O
were	O
performed	O
for	O
all	O
amplification	O
reactions	O
.	O

In	O
addition	O
,	O
PCR	O
,	O
cloning	O
and	O
sequencing	O
were	O
repeated	O
for	O
two	O
individuals	O
to	O
confirm	O
putative	O
introgressed	O
sequences	O
and	O
to	O
exclude	O
the	O
possibility	O
that	O
they	O
were	O
the	O
result	O
of	O
PCR	O
contamination	O
.	O

Finally	O
,	O
for	O
at	O
least	O
two	O
individuals	O
with	O
putative	O
introgressed	O
sequences	O
,	O
we	O
could	O
define	O
the	O
other	O
allele	O
from	O
additional	O
clones	O
(	O
not	O
included	O
in	O
the	O
analysis	O
)	O
,	O
which	O
showed	O
to	O
be	O
typical	O
of	O
the	O
species	O
,	O
indicating	O
no	O
identification	O
problems	O
.	O

The	O
sequences	O
were	O
submitted	O
to	O
GenBank	O
(	O
accession	O
numbers	O
AY927062	O
to	O
AY927182	O
)	O
.	O

Sequence	O
analyses	O
The	O
preliminary	O
sequence	O
editing	O
was	O
carried	O
out	O
using	O
the	O
Wisconsin	O
Package	O
Version	O
9.1	O
,	O
Genetics	O
Computer	O
Group	O
(	O
GCG	O
)	O
,	O
Madison	O
,	O
and	O
ClustalX	O
[	O
47	O
]	O
was	O
used	O
to	O
perform	O
the	O
multiple	O
alignment	O
.	O

Analyses	O
of	O
population	O
polymorphisms	O
and	O
differentiation	O
between	O
populations	O
were	O
carried	O
out	O
using	O
DNAsp4.1	O
[	O
34	O
]	O
and	O
ProSeq	O
[	O
48	O
]	O
softwares	O
,	O
while	O
Arlequin	O
v.	O
2.0	O
[	O
49	O
]	O
was	O
used	O
for	O
an	O
analysis	O
of	O
molecular	O
variance	O
(	O
AMOVA	O
)	O
between	O
populations	O
.	O

The	O
Minimum	O
Evolution	O
phylogenetic	O
tree	O
was	O
constructed	O
using	O
MEGA	O
3.1	O
software	O
[	O
50	O
]	O
.	O

The	O
haplotype	O
network	O
was	O
estimated	O
using	O
TCS1.21	O
[	O
36	O
]	O
.	O

Recombination	O
and	O
linkage	O
disequilibrium	O
analyses	O
were	O
performed	O
using	O
the	O
DNAsp4.1	O
and	O
SITES	O
program	O
[	O
30	O
]	O
.	O

Linkage	O
disequilibrium	O
simulations	O
were	O
carried	O
out	O
by	O
the	O
WH	O
program	O
[	O
51,52	O
]	O
and	O
Markov	O
Chain	O
Monte	O
Carlo	O
(	O
MCMC	O
)	O
simulations	O
of	O
the	O
isolation	O
with	O
migration	O
model	O
were	O
performed	O
using	O
the	O
algorithm	O
implemented	O
in	O
the	O
IM	O
program	O
[	O
39	O
]	O
.	O

Authors	O
'	O
contributions	O
CJM	O
generate	O
and	O
analyzed	O
all	O
the	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O

NAS	O
and	O
CAC	O
collected	O
and	O
maintained	O
sand	O
fly	O
samples	O
.	O

CPK	O
helped	O
to	O
write	O
the	O
manuscript	O
and	O
supervised	O
CJM	O
during	O
her	O
stay	O
in	O
Leicester	O
.	O

AAP	O
is	O
the	O
principal	O
investigator	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
helped	O
to	O
write	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

A	O
disease	O
-	O
specific	O
measure	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
for	O
use	O
in	O
adults	O
with	O
immune	O
thrombocytopenic	O
purpura	O
:	O
Its	O
development	O
and	O
validation	O
Abstract	O
Background	O
No	O
validated	O
disease	O
-	O
specific	O
measures	O
are	O
available	O
to	O
assess	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
in	O
adult	O
subjects	O
with	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
develop	O
and	O
validate	O
the	O
ITP	O
-	O
Patient	O
Assessment	O
Questionnaire	O
(	O
ITP	O
-	O
PAQ	O
)	O
for	O
adult	O
subjects	O
with	O
ITP	O
.	O

Methods	O
Information	O
from	O
literature	O
reviews	O
,	O
focus	O
groups	O
with	O
subjects	O
,	O
and	O
clinicians	O
were	O
used	O
to	O
develop	O
50	O
ITP	O
-	O
PAQ	O
items	O
.	O

Factor	O
analyses	O
were	O
conducted	O
to	O
develop	O
the	O
scale	O
structure	O
and	O
reduce	O
the	O
number	O
of	O
items	O
.	O

The	O
final	O
44-item	O
ITP	O
-	O
PAQ	O
,	O
which	O
includes	O
ten	O
scales	O
[	O
Symptoms	O
(	O
S	O
)	O
,	O
Bother	O
-	O
Physical	O
Health	O
(	O
B	O
)	O
,	O
Fatigue	O
/	O
Sleep	O
(	O
FT	O
)	O
,	O
Activity	O
(	O
A	O
)	O
,	O
Fear	O
(	O
FR	O
)	O
,	O
Psychological	O
Health	O
(	O
PH	O
)	O
,	O
Work	O
(	O
W	O
)	O
,	O
Social	O
Activity	O
(	O
SA	O
)	O
,	O
Women	O
's	O
Reproductive	O
Health	O
(	O
RH	O
)	O
,	O
and	O
Overall	O
(	O
QoL	O
)	O
]	O
,	O
was	O
self	O
-	O
administered	O
to	O
adult	O
ITP	O
subjects	O
at	O
baseline	O
and	O
7–10	O
days	O
later	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
internal	O
consistency	O
reliability	O
,	O
construct	O
and	O
known	O
groups	O
validity	O
of	O
the	O
final	O
ITP	O
-	O
PAQ	O
were	O
evaluated	O
.	O

Results	O
Seventy	O
-	O
three	O
subjects	O
with	O
ITP	O
completed	O
the	O
questionnaire	O
twice	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
as	O
measured	O
by	O
the	O
intra	O
-	O
class	O
correlation	O
,	O
ranged	O
from	O
0.52–0.90	O
.	O

Internal	O
consistency	O
reliability	O
was	O
demonstrated	O
with	O
Cronbach	O
's	O
alpha	O
for	O
all	O
scales	O
above	O
the	O
acceptable	O
level	O
of	O
0.70	O
(	O
range	O
:	O
0.71–0.92	O
)	O
,	O
except	O
for	O
RH	O
(	O
0.66	O
)	O
.	O

Construct	O
validity	O
,	O
assessed	O
by	O
correlating	O
ITP	O
-	O
PAQ	O
scales	O
with	O
established	O
measures	O
(	O
Short	O
Form-36	O
v.1	O
,	O
SF-36	O
and	O
Center	O
for	O
Epidemiologic	O
Studies	O
Depression	O
Scale	O
,	O
CES	O
-	O
D	O
)	O
,	O
was	O
demonstrated	O
through	O
moderate	O
correlations	O
between	O
the	O
ITP	O
-	O
PAQ	O
SA	O
and	O
SF-36	O
Social	O
Function	O
scales	O
(	O
r	O
=	O
0.67	O
)	O
,	O
and	O
between	O
ITP	O
-	O
PAQ	O
PH	O
and	O
SF-36	O
Mental	O
Health	O
Scales	O
(	O
r	O
=	O
0.63	O
)	O
.	O

Moderate	O
to	O
strong	O
inter	O
-	O
scale	O
correlations	O
were	O
reported	O
between	O
ITP	O
-	O
PAQ	O
scales	O
and	O
the	O
CES	O
-	O
D	O
,	O
except	O
for	O
the	O
RH	O
scale	O
.	O

Known	O
groups	O
validity	O
was	O
evaluated	O
by	O
comparing	O
mean	O
scores	O
for	O
groups	O
that	O
differed	O
clinically	O
.	O

Statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.01	O
)	O
were	O
observed	O
when	O
subjects	O
were	O
categorized	O
by	O
treatment	O
status	O
[	O
S	O
,	O
FT	O
,	O
B	O
,	O
A	O
,	O
PH	O
,	O
and	O
QoL	O
,	O
perceived	O
effectiveness	O
of	O
ITP	O
treatment	O
[	O
S	O
]	O
,	O
and	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
[	O
PH	O
]	O
.	O

Conclusion	O
Results	O
provide	O
preliminary	O
evidence	O
of	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
ITP	O
-	O
PAQ	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Further	O
work	O
should	O
be	O
conducted	O
to	O
assess	O
the	O
responsiveness	O
and	O
to	O
estimate	O
the	O
minimal	O
clinical	O
important	O
difference	O
of	O
the	O
ITP	O
-	O
PAQ	O
to	O
more	O
fully	O
understand	O
the	O
impact	O
of	O
ITP	O
and	O
its	O
treatments	O
on	O
HRQoL.	O
Background	O
Immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
is	O
a	O
disorder	O
characterized	O
by	O
autoimmune	O
-	O
mediated	O
platelet	O
destruction	O
and	O
suboptimal	O
platelet	O
production	O
[	O
1	O
-	O
3	O
]	O
that	O
results	O
in	O
a	O
decrease	O
in	O
the	O
number	O
of	O
circulating	O
platelets	O
and	O
increases	O
the	O
risk	O
of	O
bleeding	O
events	O
.	O

The	O
estimated	O
prevalence	O
rate	O
for	O
ITP	O
in	O
the	O
United	O
States	O
is	O
9.5	O
/	O
100,000	O
[	O
4	O
]	O
.	O

Adult	O
women	O
are	O
disproportionately	O
affected	O
by	O
the	O
disorder	O
,	O
with	O
a	O
female	O
to	O
male	O
ratio	O
of	O
nearly	O
two	O
to	O
one	O
[	O
5	O
]	O
.	O

The	O
disorder	O
rarely	O
remits	O
spontaneously	O
in	O
adult	O
subjects	O
[	O
1	O
]	O
.	O

The	O
mortality	O
rate	O
is	O
relatively	O
low	O
(	O
<	O
1	O
%	O
)	O
[	O
6	O
]	O
in	O
adults	O
less	O
than	O
65	O
years	O
of	O
age	O
.	O

Morbidity	O
increases	O
above	O
age	O
65	O
,	O
primarily	O
as	O
a	O
result	O
of	O
an	O
increase	O
in	O
age	O
-	O
related	O
major	O
bleeding	O
events	O
[	O
7	O
]	O
.	O

Initial	O
therapy	O
for	O
ITP	O
consists	O
of	O
some	O
combination	O
of	O
glucocorticoids	O
,	O
intravenous	O
immune	O
globulin	O
(	O
IVIg	O
)	O
or	O
anti	O
-	O
D	O
[	O
8	O
]	O
.	O

Splenectomy	O
is	O
often	O
considered	O
if	O
these	O
therapies	O
fail	O
.	O

Approximately	O
two	O
-	O
thirds	O
of	O
patients	O
treated	O
with	O
splenectomy	O
achieve	O
a	O
sustained	O
remission	O
[	O
1,5,9	O
]	O
.	O

Patients	O
who	O
fail	O
splenectomy	O
are	O
treated	O
with	O
a	O
wide	O
variety	O
of	O
agents	O
including	O
corticosteroids	O
,	O
danazol	O
,	O
and	O
chemotherapeutic	O
agents	O
.	O

Morbidity	O
and	O
mortality	O
in	O
these	O
refractory	O
patients	O
are	O
substantial	O
[	O
1,6,8	O
]	O
.	O

Patient	O
-	O
reported	O
outcomes	O
(	O
PRO	O
)	O
,	O
including	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
measures	O
,	O
are	O
critical	O
components	O
for	O
evaluating	O
and	O
understanding	O
treatment	O
effects	O
from	O
the	O
subject	O
's	O
perspective	O
.	O

The	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
indicates	O
that	O
PRO	O
measures	O
are	O
important	O
to	O
assess	O
because	O
they	O
may	O
:	O
1	O
)	O
detect	O
treatment	O
effects	O
known	O
only	O
to	O
the	O
subject	O
;	O
2	O
)	O
understand	O
the	O
subject	O
's	O
perspective	O
regarding	O
treatment	O
effect	O
;	O
or	O
3	O
)	O
provide	O
information	O
not	O
included	O
in	O
a	O
clinician	O
's	O
subject	O
notes	O
[	O
10	O
]	O
.	O

Furthermore	O
,	O
the	O
Committee	O
for	O
Medicinal	O
Products	O
for	O
Human	B
Use	O
of	O
the	O
European	O
Medicines	O
Agency	O
defines	O
HRQoL	O
as	O
""""	O
the	O
subject	O
's	O
subjective	O
perception	O
of	O
the	O
impact	O
of	O
his	O
disease	O
and	O
its	O
treatment	O
(	O
s	O
)	O
on	O
his	O
daily	O
life	O
,	O
physical	O
,	O
psychological	O
and	O
social	O
functioning	O
and	O
well	O
-	O
being	O
""""	O
[	O
11	O
]	O
.	O

Currently	O
,	O
limited	O
data	O
are	O
available	O
on	O
the	O
assessment	O
of	O
the	O
impact	O
of	O
symptoms	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Symptoms	O
of	O
ITP	O
,	O
such	O
as	O
spontaneous	O
bruising	O
,	O
menorrhagia	O
,	O
mucosal	O
bleeding	O
and	O
prolonged	O
bleeding	O
with	O
injury	O
,	O
may	O
significantly	O
affect	O
HRQoL	O
in	O
ITP	O
subjects	O
[	O
12	O
]	O
.	O

Treatments	O
for	O
chronic	O
ITP	O
can	O
also	O
be	O
associated	O
with	O
substantial	O
side	O
effects	O
[	O
5,8	O
]	O
.	O

In	O
addition	O
,	O
subjects	O
who	O
are	O
resistant	O
to	O
current	O
therapies	O
are	O
likely	O
to	O
experience	O
an	O
even	O
greater	O
decrement	O
to	O
their	O
HRQoL	O
than	O
responders	O
to	O
treatment	O
.	O

Thus	O
,	O
restoring	O
and/or	O
maintaining	O
quality	O
of	O
life	O
should	O
be	O
an	O
important	O
goal	O
of	O
treatment	O
.	O

While	O
the	O
primary	O
markers	O
for	O
ITP	O
include	O
hematologic	O
measures	O
such	O
as	O
platelet	O
counts	O
,	O
clinical	O
measures	O
typically	O
do	O
not	O
assess	O
a	O
subject	O
's	O
functioning	O
and	O
well	O
-	O
being	O
.	O

Therefore	O
,	O
subjects	O
and	O
physicians	O
may	O
want	O
to	O
weigh	O
the	O
impact	O
of	O
ITP	O
therapies	O
on	O
HRQoL	O
endpoints	O
when	O
making	O
treatment	O
decisions	O
.	O

Previously	O
,	O
no	O
validated	O
disease	O
-	O
specific	O
measures	O
were	O
available	O
to	O
evaluate	O
quality	O
of	O
life	O
in	O
adult	O
ITP	O
subjects	O
;	O
however	O
,	O
two	O
disease	O
-	O
specific	O
HRQoL	O
questionnaires	O
have	O
been	O
developed	O
for	O
use	O
in	O
children	O
with	O
ITP	O
[	O
13,14	O
]	O
.	O

Thus	O
,	O
we	O
sought	O
to	O
develop	O
a	O
questionnaire	O
that	O
would	O
be	O
appropriate	O
to	O
assess	O
the	O
impact	O
of	O
ITP	O
symptoms	O
and	O
its	O
treatments	O
on	O
HRQoL	O
in	O
adult	O
subjects	O
.	O

The	O
objective	O
of	O
this	O
current	O
manuscript	O
is	O
to	O
describe	O
the	O
development	O
and	O
initial	O
validation	O
of	O
a	O
newly	O
developed	O
HRQoL	O
questionnaire	O
for	O
use	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Methods	O
Overview	O
A	O
newly	O
developed	O
questionnaire	O
,	O
which	O
assesses	O
issues	O
of	O
importance	O
to	O
ITP	O
subjects	O
,	O
was	O
developed	O
based	O
on	O
available	O
published	O
literature	O
,	O
existing	O
questionnaires	O
,	O
expert	O
clinical	O
opinion	O
,	O
and	O
input	O
from	O
subjects	O
with	O
ITP	O
.	O

Subjects	O
and	O
Procedures	O
To	O
develop	O
the	O
questionnaire	O
,	O
three	O
focus	O
groups	O
with	O
ITP	O
subjects	O
were	O
conducted	O
in	O
geographically	O
diverse	O
locations	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
New	O
York	O
,	O
NY	O
,	O
and	O
Oklahoma	O
City	O
,	O
OK	O
)	O
.	O

Each	O
of	O
the	O
three	O
sites	O
recruited	O
a	O
convenience	O
sample	O
of	O
five	O
to	O
eight	O
ITP	O
subjects	O
who	O
were	O
being	O
treated	O
on	O
an	O
outpatient	O
basis	O
.	O

To	O
be	O
eligible	O
,	O
subjects	O
were	O
required	O
to	O
have	O
active	O
disease	O
and	O
be	O
≥	O
18	O
years	O
of	O
age	O
.	O

Although	O
platelet	O
count	O
data	O
were	O
not	O
required	O
for	O
participation	O
in	O
the	O
focus	O
groups	O
,	O
clinicians	O
at	O
each	O
site	O
considered	O
the	O
subjects	O
to	O
have	O
active	O
disease	O
,	O
usually	O
an	O
indication	O
that	O
platelet	O
levels	O
have	O
dropped	O
below	O
120	O
×	O
109L	O
and	O
the	O
subject	O
requires	O
treatment	O
and/or	O
more	O
frequent	O
monitoring	O
.	O

In	O
total	O
,	O
23	O
ITP	O
subjects	O
participated	O
in	O
the	O
focus	O
groups	O
after	O
providing	O
their	O
informed	O
consent	O
.	O

To	O
validate	O
the	O
questionnaire	O
,	O
a	O
convenience	O
sample	O
of	O
subjects	O
was	O
recruited	O
from	O
the	O
same	O
three	O
clinical	O
sites	O
in	O
New	O
York	O
,	O
NY	O
,	O
Oklahoma	O
City	O
,	O
OK	O
,	O
and	O
La	O
Jolla	O
,	O
CA	O
.	O

Subjects	O
were	O
eligible	O
if	O
they	O
were	O
≥	O
18	O
years	O
of	O
age	O
,	O
had	O
active	O
disease	O
,	O
and	O
were	O
willing	O
to	O
complete	O
a	O
self	O
-	O
administered	O
questionnaire	O
at	O
two	O
time	O
points	O
.	O

Target	O
enrollment	O
was	O
roughly	O
72	O
subjects	O
(	O
24	O
subjects	O
from	O
each	O
site	O
)	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
a	O
local	O
institutional	O
review	O
board	O
at	O
each	O
site	O
and	O
was	O
carried	O
out	O
in	O
accordance	O
with	O
Good	O
Clinical	O
Practice	O
and	O
International	O
Conference	O
on	O
Harmonization	O
guidelines	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
subject	O
prior	O
to	O
enrollment	O
.	O

Creation	O
of	O
Questionnaire	O
/	O
Item	O
Selection	O
A	O
trained	O
moderator	O
led	O
all	O
focus	O
groups	O
using	O
a	O
detailed	O
discussion	O
guide	O
.	O

Subjects	O
discussed	O
their	O
ITP	O
history	O
,	O
treatment	O
,	O
ITP	O
symptoms	O
,	O
and	O
the	O
impact	O
of	O
ITP	O
on	O
daily	O
activities	O
.	O

Each	O
focus	O
group	O
lasted	O
approximately	O
three	O
hours	O
,	O
and	O
subjects	O
were	O
provided	O
with	O
an	O
honorarium	O
for	O
their	O
time	O
.	O

Following	O
the	O
focus	O
group	O
session	O
,	O
all	O
subjects	O
completed	O
a	O
questionnaire	O
which	O
included	O
the	O
SF-36	O
v1	O
[	O
15	O
]	O
and	O
ITP	O
-	O
specific	O
questions	O
.	O

The	O
ITP	O
-	O
specific	O
items	O
were	O
developed	O
based	O
on	O
clinical	O
input	O
[	O
12,16	O
-	O
18	O
]	O
.	O

The	O
ITP	O
-	O
specific	O
items	O
assessed	O
the	O
impact	O
of	O
ITP	O
on	O
the	O
subject	O
's	O
overall	O
quality	O
of	O
life	O
,	O
relationships	O
,	O
ability	O
to	O
sleep	O
,	O
menstruation	O
/	O
gynecological	O
history	O
,	O
and	O
sexual	O
activity	O
.	O

The	O
ITP	O
-	O
specific	O
questions	O
also	O
assessed	O
the	O
subject	O
's	O
response	O
to	O
ITP	O
treatments	O
and	O
any	O
side	O
effects	O
.	O

Transcripts	O
of	O
the	O
focus	O
groups	O
were	O
summarized	O
and	O
reviewed	O
by	O
the	O
study	O
team	O
.	O

The	O
initial	O
draft	O
of	O
the	O
ITP	O
Subject	O
Assessment	O
Questionnaire	O
(	O
ITP	O
-	O
PAQ	O
)	O
was	O
developed	O
after	O
reviewing	O
information	O
from	O
the	O
literature	O
searches	O
,	O
existing	O
questionnaires	O
,	O
expert	O
opinion	O
,	O
focus	O
group	O
transcripts	O
,	O
and	O
the	O
questionnaire	O
responses	O
from	O
the	O
focus	O
group	O
subjects	O
.	O

The	O
initial	O
ITP	O
-	O
PAQ	O
consisted	O
of	O
50	O
items	O
that	O
assesses	O
the	O
impact	O
of	O
ITP	O
in	O
the	O
areas	O
of	O
physical	O
health	O
,	O
mental	O
health	O
,	O
work	O
,	O
social	O
activity	O
,	O
reproductive	O
health	O
(	O
relevant	O
for	O
women	O
only	O
)	O
,	O
and	O
overall	O
quality	O
of	O
life	O
.	O

Factor	O
analyses	O
were	O
conducted	O
which	O
yielded	O
six	O
unique	O
domains	O
.	O

The	O
impact	O
of	O
ITP	O
on	O
physical	O
health	O
was	O
measured	O
by	O
four	O
scales	O
that	O
evaluated	O
ITP	O
-	O
related	O
symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
and	O
Activity	O
.	O

Its	O
impact	O
on	O
mental	O
health	O
was	O
measured	O
by	O
two	O
scales	O
that	O
evaluated	O
psychological	O
distress	O
and	O
fear	O
.	O

A	O
copy	O
of	O
the	O
questionnaire	O
can	O
be	O
obtained	O
by	O
contacting	O
Janet	O
L.	O
Nichol	O
and	O
sample	O
items	O
are	O
included	O
Table	O
2	O
.	O

Statistical	O
Analyses	O
A	O
validation	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
the	O
newly	O
developed	O
ITP	O
-	O
PAQ	O
questionnaire	O
so	O
that	O
it	O
could	O
be	O
used	O
to	O
measure	O
the	O
impact	O
of	O
ITP	O
in	O
adult	O
subjects	O
in	O
future	O
studies	O
.	O

Standard	O
psychometric	O
methods	O
were	O
used	O
to	O
evaluate	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
questionnaire	O
[	O
19,20	O
]	O
.	O

Eligible	O
subjects	O
completed	O
the	O
baseline	O
questionnaire	O
at	O
the	O
site	O
or	O
by	O
mail	O
after	O
providing	O
telephone	O
consent	O
.	O

An	O
informed	O
consent	O
form	O
and	O
baseline	O
questionnaire	O
was	O
mailed	O
to	O
those	O
subjects	O
who	O
gave	O
their	O
initial	O
consent	O
via	O
telephone	O
.	O

These	O
completed	O
documents	O
were	O
returned	O
by	O
mail	O
to	O
the	O
investigators	O
.	O

At	O
follow	O
up	O
,	O
each	O
subject	O
was	O
mailed	O
the	O
same	O
questionnaire	O
and	O
asked	O
to	O
complete	O
it	O
a	O
second	O
time	O
(	O
for	O
evaluating	O
test	O
-	O
retest	O
reliability	O
)	O
approximately	O
two	O
weeks	O
later	O
.	O

Additionally	O
,	O
subjects	O
completed	O
the	O
SF-36	O
and	O
the	O
CES	O
-	O
D	O
[	O
21	O
]	O
for	O
validation	O
purposes	O
at	O
both	O
assessments	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
were	O
also	O
solicited	O
in	O
order	O
to	O
more	O
fully	O
describe	O
the	O
study	O
population	O
.	O

Each	O
study	O
subject	O
received	O
an	O
honorarium	O
for	O
completing	O
the	O
questionnaires	O
.	O

Scale	O
creation	O
and	O
confirmatory	O
factor	O
analysis	O
Confirmatory	O
factor	O
analyses	O
were	O
conducted	O
to	O
test	O
the	O
hypothesized	O
structure	O
of	O
the	O
scales	O
.	O

Two	O
models	O
using	O
LISREL	O
version	O
8	O
were	O
tested	O
[	O
22	O
]	O
.	O

The	O
first	O
model	O
consisted	O
of	O
all	O
50	O
HRQoL	O
items	O
and	O
10	O
factors	O
,	O
whereas	O
the	O
second	O
model	O
consisted	O
of	O
a	O
subset	O
of	O
the	O
50-item	O
correlation	O
matrix	O
.	O

Only	O
women	O
respond	O
to	O
the	O
six	O
items	O
comprising	O
the	O
Reproductive	O
Health	O
scale	O
,	O
so	O
the	O
items	O
were	O
not	O
included	O
in	O
the	O
second	O
LISREL	O
model	O
to	O
avoid	O
estimation	O
biases	O
.	O

The	O
remaining	O
44	O
items	O
were	O
analyzed	O
.	O

Model	O
fit	O
was	O
evaluated	O
using	O
the	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
GFI	O
)	O
,	O
the	O
normed	O
fit	O
index	O
(	O
NFI	O
)	O
,	O
the	O
non	O
-	O
normed	O
fit	O
index	O
(	O
NNFI	O
)	O
,	O
the	O
comparative	O
fit	O
index	O
(	O
CIF	O
)	O
,	O
and	O
the	O
root	O
mean	O
square	O
error	O
of	O
approximation	O
(	O
RMSEA	O
)	O
.	O

For	O
the	O
confirmatory	O
models	O
,	O
index	O
values	O
greater	O
than	O
0.95	O
indicate	O
better	O
fit	O
,	O
and	O
RMSEA	O
values	O
less	O
than	O
0.05	O
are	O
considered	O
evidence	O
of	O
adequate	O
fit	O
[	O
23	O
]	O
.	O

Reliability	O
and	O
stability	O
Two	O
forms	O
of	O
reliability	O
were	O
assessed	O
:	O
test	O
-	O
retest	O
reliability	O
and	O
internal	O
consistency	O
reliability	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
a	O
measure	O
of	O
the	O
degree	O
to	O
which	O
the	O
questionnaire	O
yields	O
stable	O
scores	O
over	O
a	O
short	O
period	O
of	O
time	O
(	O
assuming	O
there	O
is	O
no	O
underlying	O
change	O
)	O
,	O
was	O
measured	O
by	O
the	O
intra	O
-	O
class	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
[	O
24,25	O
]	O
.	O

An	O
ICC	O
of	O
≥	O
0.70	O
was	O
considered	O
acceptable	O
[	O
26	O
]	O
.	O

Internal	O
consistency	O
reliability	O
,	O
the	O
extent	O
to	O
which	O
items	O
within	O
each	O
scale	O
correlate	O
with	O
each	O
other	O
to	O
form	O
a	O
multi	O
-	O
item	O
scale	O
,	O
was	O
assessed	O
using	O
Cronbach	O
's	O
alpha	O
[	O
25,27	O
]	O
.	O

Data	O
from	O
both	O
assessments	O
were	O
used	O
to	O
evaluate	O
internal	O
consistency	O
reliability	O
.	O

An	O
alpha	O
coefficient	O
of	O
≥	O
0.70	O
was	O
considered	O
acceptable	O
,	O
which	O
is	O
the	O
commonly	O
accepted	O
minimal	O
standard	O
for	O
reliability	O
coefficients	O
endorsed	O
by	O
the	O
Scientific	O
Advisory	O
Committee	O
of	O
the	O
Medical	O
Outcomes	O
Trust	O
[	O
26	O
]	O
.	O

Construct	O
Validity	O
Construct	O
validity	O
was	O
assessed	O
by	O
examining	O
the	O
inter	O
-	O
scale	O
correlations	O
between	O
the	O
ITP	O
-	O
PAQ	O
and	O
the	O
CES	O
-	O
D	O
and	O
the	O
ITP	O
-	O
PAQ	O
with	O
the	O
SF-36	O
and	O
by	O
examining	O
the	O
strength	O
of	O
the	O
within	O
ITP	O
-	O
PAQ	O
scale	O
correlations	O
[	O
25,28	O
]	O
.	O

For	O
both	O
inter	O
-	O
scale	O
and	O
intra	O
-	O
scale	O
correlations	O
,	O
we	O
made	O
a	O
priori	O
hypotheses	O
about	O
the	O
directionality	O
and	O
magnitude	O
of	O
the	O
correlation	O
and	O
observed	O
the	O
extent	O
to	O
which	O
hypothesized	O
relationships	O
held	O
.	O

For	O
example	O
,	O
we	O
hypothesized	O
that	O
the	O
scales	O
of	O
the	O
ITP	O
-	O
PAQ	O
would	O
be	O
negatively	O
correlated	O
with	O
the	O
CES	O
-	O
D	O
and	O
positively	O
correlated	O
with	O
those	O
of	O
the	O
SF-36	O
.	O

We	O
expected	O
the	O
Pearson	O
correlations	O
to	O
be	O
moderate	O
in	O
size	O
.	O

Known	O
Groups	O
Known	O
groups	O
validity	O
evaluates	O
the	O
ability	O
of	O
the	O
measure	O
to	O
discriminate	O
between	O
groups	O
known	O
to	O
be	O
clinically	O
different	O
[	O
28	O
]	O
.	O

We	O
only	O
collected	O
patient	O
-	O
reported	O
information	O
using	O
the	O
questionnaire	O
and	O
did	O
not	O
collect	O
clinical	O
information	O
such	O
as	O
platelet	O
counts	O
.	O

Therefore	O
,	O
the	O
following	O
four	O
criteria	O
were	O
identified	O
as	O
proxies	O
for	O
severity	O
:	O
•	O
Currently	O
on	O
treatment	O
•	O
Splenectomy	O
status	O
•	O
Subjects	O
'	O
self	O
-	O
perception	O
of	O
the	O
effectiveness	O
of	O
current	O
medication	O
•	O
Length	O
of	O
time	O
since	O
diagnosis	O

It	O
was	O
hypothesized	O
that	O
subjects	O
not	O
being	O
treated	O
,	O
who	O
did	O
not	O
have	O
a	O
splenectomy	O
,	O
who	O
perceived	O
their	O
medication	O
to	O
be	O
more	O
effective	O
,	O
and	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
a	O
longer	O
time	O
would	O
be	O
healthier	O
and	O
therefore	O
report	O
higher	O
HRQoL	O
scores	O
.	O

In	O
contrast	O
,	O
subjects	O
on	O
any	O
treatment	O
,	O
who	O
had	O
received	O
a	O
splenectomy	O
,	O
who	O
perceived	O
their	O
medication	O
to	O
be	O
less	O
effective	O
,	O
and	O
who	O
were	O
diagnosed	O
more	O
recently	O
would	O
report	O
worse	O
HRQoL.	O
In	O
addition	O
,	O
subjects	O
were	O
also	O
categorized	O
by	O
gender	O
.	O

Subjects	O
were	O
categorized	O
into	O
two	O
groups	O
for	O
each	O
of	O
the	O
analyses	O
:	O
female	O
vs.	O
male	O
,	O
intact	O
spleen	O
vs.	O
removed	O
spleen	O
,	O
currently	O
on	O
ITP	O
treatment	O
vs.	O
not	O
currently	O
on	O
ITP	O
treatment	O
,	O
subject	O
's	O
perception	O
of	O
the	O
effectiveness	O
of	O
their	O
current	O
ITP	O
medication	O
(	O
extremely	O
/	O
moderately	O
effective	O
vs.	O
not	O
at	O
all	O
effective	O
)	O
,	O
and	O
ITP	O
diagnosis	O
less	O
than	O
one	O
year	O
ago	O
vs.	O
ITP	O
diagnosis	O
more	O
than	O
one	O
year	O
ago	O
.	O

Results	O
Demographics	O
and	O
clinical	O
characteristics	O
Table	O
1	O
describes	O
the	O
demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
73	O
subjects	O
included	O
in	O
the	O
validation	O
analyses	O
.	O

The	O
majority	O
were	O
female	O
(	O
77	O
%	O
)	O
and	O
Caucasian	O
(	O
84	O
%	O
)	O
.	O

The	O
mean	O
age	O
was	O
45	O
years	O
(	O
SD	O
=	O
15.7	O
)	O
,	O
and	O
most	O
of	O
the	O
subjects	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
at	O
least	O
five	O
years	O
(	O
57	O
%	O
)	O
.	O

Fifty	O
-	O
two	O
percent	O
of	O
the	O
subjects	O
reported	O
that	O
they	O
were	O
currently	O
taking	O
medications	O
for	O
their	O
ITP	O
.	O

Furthermore	O
,	O
58	O
%	O
indicated	O
that	O
they	O
had	O
a	O
splenectomy	O
.	O

Among	O
the	O
42	O
subjects	O
who	O
had	O
a	O
splenectomy	O
,	O
55	O
%	O
reported	O
that	O
the	O
removal	O
of	O
their	O
spleen	O
did	O
not	O
cure	O
their	O
ITP	O
.	O

With	O
one	O
exception	O
,	O
the	O
remaining	O
subjects	O
did	O
not	O
provide	O
a	O
response	O
.	O

Confirmatory	O
factor	O
analysis	O
The	O
first	O
confirmatory	O
factor	O
analysis	O
of	O
the	O
50-item	O
and	O
ten	O
factors	O
model	O
converged	O
in	O
28	O
iterations	O
.	O

However	O
,	O
neither	O
the	O
inter	O
-	O
item	O
correlation	O
matrix	O
nor	O
the	O
inter	O
-	O
factor	O
correlation	O
matrix	O
was	O
positive	O
-	O
definite	O
,	O
which	O
suggests	O
that	O
the	O
proposed	O
model	O
is	O
wrong	O
for	O
the	O
data	O
or	O
the	O
data	O
are	O
inadequate	O
for	O
the	O
model	O
[	O
22	O
]	O
.	O

The	O
chi	O
-	O
square	O
value	O
of	O
the	O
model	O
was	O
316.64	O
with	O
1129	O
degrees	O
of	O
freedom	O
(	O
p	O
=	O
1.0	O
)	O
,	O
which	O
does	O
not	O
support	O
the	O
hypothesized	O
scale	O
structure	O
of	O
the	O
initial	O
ITP	O
-	O
PAQ	O
.	O

The	O
confirmatory	O
analysis	O
of	O
this	O
LISREL	O
model	O
indicate	O
that	O
computing	O
domain	O
scores	O
for	O
the	O
Physical	O
Health	O
and	O
Mental	O
Health	O
domains	O
is	O
not	O
appropriate	O
for	O
the	O
ITP	O
-	O
PAQ	O
.	O

The	O
second	O
LISREL	O
model	O
was	O
analyzed	O
to	O
confirm	O
the	O
scale	O
structure	O
,	O
excluding	O
the	O
Reproductive	O
Health	O
scale	O
.	O

For	O
this	O
model	O
,	O
126	O
parameters	O
were	O
estimated	O
:	O
46	O
factor	O
loadings	O
,	O
44	O
error	O
terms	O
,	O
and	O
36	O
inter	O
-	O
factor	O
correlations	O
.	O

The	O
model	O
converged	O
in	O
39	O
iterations	O
,	O
with	O
a	O
chi	O
-	O
square	O
value	O
of	O
1043.10	O
with	O
864	O
degrees	O
of	O
freedom	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
Goodness	O
of	O
Fit	O
Index	O
(	O
GFI	O
)	O
,	O
Normed	O
Fit	O
Index	O
(	O
NFI	O
)	O
,	O
Non	O
-	O
normed	O
Fit	O
Index	O
(	O
NNFI	O
)	O
,	O
and	O
Comparative	O
Fit	O
Index	O
(	O
CFI	O
)	O
was	O
0.60	O
,	O
0.63	O
,	O
0.91	O
,	O
and	O
0.92	O
,	O
respectively	O
,	O
and	O
the	O
RMSEA	O
was	O
0.05	O
[	O
90	O
%	O
CI	O
,	O
0.04–0.065	O
]	O
.	O

Furthermore	O
,	O
the	O
inter	O
-	O
factor	O
correlations	O
ranged	O
form	O
0.33	O
between	O
the	O
Symptoms	O
and	O
Work	O
scales	O
to	O
0.96	O
between	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Overall	O
QoL	O
scales	O
.	O

In	O
addition	O
to	O
the	O
confirmatory	O
factor	O
analyses	O
,	O
Cronbach	O
's	O
alphas	O
and	O
item	O
-	O
to	O
-	O
total	O
correlations	O
were	O
used	O
for	O
item	O
reduction	O
.	O

Items	O
with	O
low	O
factor	O
loadings	O
and	O
item	O
-	O
to	O
-	O
total	O
correlations	O
that	O
reduced	O
the	O
internal	O
consistency	O
were	O
eliminated	O
.	O

Although	O
initial	O
factor	O
analyses	O
identified	O
six	O
domains	O
for	O
future	O
use	O
,	O
the	O
final	O
version	O
of	O
the	O
ITP	O
-	O
PAQ	O
contained	O
44	O
items	O
that	O
included	O
the	O
following	O
ten	O
scales	O
:	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Activity	O
,	O
Fear	O
,	O
Psychological	O
Health	O
,	O
Work	O
,	O
Social	O
Activity	O
,	O
Women	O
's	O
Reproductive	O
Health	O
,	O
and	O
Overall	O
QoL.	O
Table	O
2	O
provides	O
information	O
on	O
the	O
number	O
of	O
items	O
,	O
item	O
variability	O
and	O
sample	O
items	O
from	O
each	O
scale	O
of	O
the	O
questionnaire	O
.	O

Each	O
scale	O
is	O
scored	O
from	O
0	O
to	O
100	O
,	O
with	O
higher	O
scores	O
representing	O
better	O
quality	O
of	O
life	O
.	O

Test	O
-	O
retest	O
reliability	O
Of	O
the	O
73	O
subjects	O
who	O
completed	O
the	O
first	O
administration	O
of	O
the	O
questionnaire	O
,	O
most	O
of	O
the	O
subjects	O
completed	O
the	O
second	O
questionnaire	O
within	O
a	O
15-day	O
period	O
(	O
75	O
%	O
)	O
,	O
during	O
which	O
subjects	O
were	O
expected	O
to	O
remain	O
clinically	O
stable	O
.	O

However	O
,	O
20	O
%	O
of	O
the	O
73	O
subjects	O
completed	O
the	O
questionnaire	O
within	O
three	O
weeks	O
following	O
the	O
first	O
administration	O
.	O

The	O
remaining	O
5	O
%	O
of	O
subjects	O
completed	O
it	O
between	O
four	O
and	O
nine	O
weeks	O
after	O
the	O
first	O
""""	O
test	O
.	O

""""	O
ICC	O
's	O
were	O
computed	O
for	O
the	O
entire	O
sample	O
(	O
n	O
=	O
73	O
)	O
and	O
for	O
a	O
sub	O
-	O
sample	O
of	O
respondents	O
who	O
completed	O
the	O
second	O
questionnaire	O
within	O
three	O
weeks	O
(	O
n	O
=	O
69	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
,	O
all	O
scales	O
had	O
acceptable	O
test	O
-	O
retest	O
reliability	O
(	O
ICC	O
≥	O
0.70	O
)	O
as	O
measured	O
by	O
the	O
ICC	O
(	O
Table	O
3	O
)	O
.	O

For	O
the	O
entire	O
sample	O
,	O
ICC	O
values	O
ranged	O
from	O
0.52–0.90	O
,	O
while	O
ICC	O
values	O
for	O
the	O
sub	O
-	O
sample	O
ranged	O
from	O
0.56–0.89	O
.	O

Internal	O
consistency	O
reliability	O
Internal	O
consistency	O
reliability	O
,	O
measured	O
by	O
Cronbach	O
's	O
alpha	O
,	O
ranged	O
from	O
0.66	O
to	O
0.92	O
(	O
Table	O
3	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
,	O
Cronbach	O
's	O
alpha	O
coefficients	O
exceeded	O
the	O
acceptable	O
level	O
of	O
0.70	O
.	O

Cronbach	O
's	O
alpha	O
for	O
the	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
ranged	O
from	O
0.71–0.89	O
,	O
while	O
Cronbach	O
's	O
alpha	O
for	O
the	O
Psychological	O
Health	O
and	O
Fear	O
scales	O
ranged	O
from	O
0.87–0.92	O
.	O

Additionally	O
,	O
Cronbach	O
's	O
alphas	O
for	O
the	O
Social	O
Activity	O
,	O
Work	O
,	O
Reproductive	O
Health	O
,	O
and	O
Overall	O
QoL	O
scales	O
were	O
0.72	O
,	O
0.86	O
,	O
0.66	O
,	O
and	O
0.89	O
,	O
respectively	O
.	O

Construct	O
validity	O
Table	O
4	O
displays	O
the	O
results	O
of	O
inter	O
-	O
scale	O
Pearson	O
correlation	O
coefficients	O
for	O
the	O
initial	O
test	O
administration	O
of	O
the	O
ITP	O
-	O
PAQ	O
.	O

As	O
expected	O
,	O
the	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
were	O
moderately	O
to	O
strongly	O
inter	O
-	O
correlated	O
based	O
on	O
the	O
data	O
from	O
the	O
initial	O
administration	O
(	O
correlation	O
coefficients	O
ranged	O
from	O
0.56–0.75	O
;	O
p	O
<	O
0.05	O
)	O
.	O

The	O
Overall	O
QoL	O
scale	O
was	O
moderately	O
to	O
strongly	O
correlated	O
with	O
the	O
other	O
ITP	O
-	O
PAQ	O
scales	O
,	O
with	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
.	O

In	O
addition	O
to	O
examining	O
the	O
correlations	O
within	O
the	O
ITP	O
-	O
PAQ	O
scales	O
,	O
construct	O
validity	O
was	O
also	O
assessed	O
by	O
comparing	O
the	O
ITP	O
-	O
PAQ	O
scale	O
scores	O
with	O
those	O
of	O
the	O
CES	O
-	O
D	O
and	O
the	O
SF-36	O
.	O

The	O
CES	O
-	O
D	O
was	O
negatively	O
correlated	O
with	O
all	O
ITP	O
-	O
PAQ	O
scales	O
,	O
except	O
for	O
the	O
Reproductive	O
Health	O
scale	O
.	O

Other	O
than	O
the	O
Reproductive	O
Health	O
scale	O
,	O
Pearson	O
correlations	O
ranged	O
from	O
-0.37	O
to	O
-0.70	O
(	O
p	O
<	O
0.05	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
moderately	O
correlated	O
with	O
the	O
SF-36	O
scales	O
;	O
however	O
,	O
the	O
Reproductive	O
Health	O
scale	O
was	O
not	O
significantly	O
correlated	O
with	O
any	O
of	O
the	O
SF-36	O
scales	O
.	O

The	O
mean	O
SF-36	O
scores	O
of	O
the	O
subjects	O
with	O
ITP	O
were	O
compared	O
to	O
those	O
of	O
the	O
general	O
U.S.	O
population	O
norms	O
[	O
15	O
]	O
.	O

Results	O
from	O
t	O
-	O
tests	O
indicate	O
that	O
there	O
were	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.05	O
)	O
in	O
SF-36	O
mean	O
scores	O
between	O
subjects	O
with	O
ITP	O
(	O
range	O
,	O
43.04–72.86	O
)	O
and	O
the	O
general	O
U.S.	O
population	O
(	O
range	O
,	O
60.86–84.15	O
)	O
.	O

Subjects	O
with	O
ITP	O
reported	O
lower	O
scores	O
on	O
each	O
SF-36	O
scale	O
compared	O
to	O
the	O
US	O
norm	O
(	O
data	O
not	O
shown	O
)	O
.	O

Known	O
groups	O
validity	O
Subjects	O
were	O
categorized	O
into	O
two	O
groups	O
according	O
to	O
gender	O
,	O
splenectomy	O
status	O
,	O
current	O
ITP	O
treatment	O
status	O
,	O
subject	O
's	O
perception	O
of	O
the	O
effectiveness	O
of	O
ITP	O
treatment	O
,	O
and	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
.	O

When	O
subjects	O
were	O
grouped	O
according	O
to	O
gender	O
or	O
splenectomy	O
status	O
,	O
no	O
statistically	O
significant	O
differences	O
were	O
observed	O
for	O
any	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
(	O
data	O
not	O
shown	O
)	O
.	O

Subjects	O
who	O
were	O
currently	O
receiving	O
treatment	O
for	O
ITP	O
reported	O
lower	O
scores	O
on	O
all	O
ITP	O
-	O
PAQ	O
scales	O
compared	O
to	O
subjects	O
who	O
were	O
not	O
currently	O
receiving	O
treatment	O
.	O

Statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.01	O
)	O
were	O
reported	O
for	O
the	O
following	O
ITP	O
-	O
PAQ	O
scales	O
when	O
subjects	O
were	O
categorized	O
by	O
treatment	O
status	O
:	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Activity	O
,	O
Psychological	O
Health	O
,	O
and	O
Overall	O
QoL	O
(	O
Figure	O
1	O
)	O
.	O

When	O
subjects	O
were	O
categorized	O
by	O
effectiveness	O
of	O
ITP	O
treatment	O
,	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.05	O
)	O
were	O
observed	O
for	O
the	O
Symptoms	O
and	O
Activity	O
scales	O
(	O
Figure	O
1	O
)	O
,	O
while	O
statistically	O
significant	O
differences	O
were	O
only	O
found	O
for	O
the	O
Psychological	O
Health	O
scale	O
when	O
subjects	O
were	O
categorized	O
according	O
to	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Subjects	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
<	O
1	O
year	O
had	O
a	O
lower	O
mean	O
score	O
on	O
the	O
Psychological	O
Health	O
scale	O
compared	O
to	O
subjects	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
at	O
least	O
one	O
year	O
(	O
50.38	O
vs.	O
66.46	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Discussion	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
undertake	O
initial	O
validation	O
analyses	O
of	O
the	O
ITP	O
-	O
PAQ	O
as	O
a	O
tool	O
for	O
measuring	O
HRQoL	O
specifically	O
related	O
to	O
adult	O
subjects	O
with	O
ITP	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
preliminary	O
evidence	O
of	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
ITP	O
-	O
PAQ	O
in	O
this	O
population	O
.	O

The	O
results	O
indicate	O
that	O
,	O
with	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
,	O
the	O
questionnaire	O
has	O
good	O
internal	O
consistency	O
.	O

The	O
Reproductive	O
Health	O
scale	O
may	O
not	O
have	O
reached	O
an	O
acceptable	O
level	O
because	O
the	O
items	O
could	O
in	O
fact	O
be	O
measuring	O
slightly	O
different	O
concepts	O
.	O

For	O
example	O
,	O
the	O
Reproductive	O
Health	O
scale	O
includes	O
items	O
that	O
assess	O
symptom	O
bother	O
related	O
to	O
menstruation	O
in	O
addition	O
to	O
items	O
that	O
ask	O
how	O
ITP	O
impacts	O
reproductive	O
choices	O
,	O
such	O
as	O
becoming	O
pregnant	O
,	O
giving	O
birth	O
,	O
and	O
adopting	O
children	O
.	O

Perhaps	O
,	O
the	O
symptom	O
bother	O
items	O
in	O
this	O
scale	O
may	O
fit	O
more	O
appropriately	O
with	O
the	O
Bother	O
-	O
Physical	O
Health	O
scale	O
,	O
and	O
the	O
reproductive	O
choice	O
items	O
could	O
comprise	O
a	O
separate	O
scale	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
also	O
demonstrated	O
acceptable	O
test	O
-	O
retest	O
reliability	O
,	O
even	O
though	O
the	O
time	O
interval	O
between	O
test	O
and	O
retest	O
administrations	O
of	O
the	O
questionnaire	O
exceeded	O
the	O
targeted	O
time	O
interval	O
of	O
seven	O
to	O
ten	O
days	O
.	O

However	O
,	O
two	O
scales	O
,	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
,	O
reported	O
ICC	O
values	O
below	O
the	O
acceptable	O
value	O
of	O
0.70	O
.	O

In	O
addition	O
to	O
the	O
lag	O
between	O
the	O
two	O
administrations	O
of	O
the	O
questionnaire	O
,	O
subjects	O
may	O
have	O
experienced	O
an	O
increase	O
in	O
bother	O
and/or	O
a	O
decrease	O
in	O
activity	O
due	O
to	O
ITP	O
during	O
the	O
extended	O
time	O
interval	O
.	O

Additionally	O
,	O
the	O
comparatively	O
low	O
ICC	O
values	O
of	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
relatively	O
low	O
number	O
of	O
items	O
contained	O
in	O
each	O
of	O
these	O
scales	O
(	O
four	O
and	O
two	O
items	O
,	O
respectively	O
)	O
compared	O
to	O
the	O
Symptoms	O
scale	O
which	O
contains	O
six	O
items	O
.	O

In	O
general	O
,	O
the	O
construct	O
validity	O
of	O
the	O
questionnaire	O
was	O
supported	O
by	O
inter	O
-	O
scale	O
correlations	O
.	O

As	O
expected	O
,	O
the	O
Bother	O
-	O
Physical	O
Health	O
,	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
were	O
more	O
strongly	O
correlated	O
to	O
one	O
another	O
than	O
with	O
other	O
scales	O
.	O

However	O
,	O
the	O
Reproductive	O
Health	O
scale	O
had	O
a	O
lower	O
internal	O
consistency	O
reliability	O
and	O
it	O
was	O
weakly	O
correlated	O
with	O
the	O
ITP	O
-	O
PAQ	O
scales	O
,	O
the	O
SF-36	O
,	O
and	O
the	O
CES	O
-	O
D	O
,	O
possibly	O
due	O
to	O
the	O
differing	O
concepts	O
measured	O
by	O
the	O
items	O
within	O
this	O
scale	O
or	O
the	O
all	O
-	O
female	O
sample	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
moderately	O
correlated	O
with	O
the	O
SF-36	O
scales	O
and	O
the	O
CES	O
-	O
D	O
;	O
however	O
,	O
correlations	O
between	O
some	O
of	O
the	O
scales	O
were	O
<	O
0.40	O
(	O
e.g.	O
,	O
Fear	O
and	O
SF-36	O
Mental	O
Health	O
,	O
0.30	O
;	O
p	O
<	O
0.05	O
)	O
.	O

This	O
low	O
correlation	O
could	O
be	O
due	O
to	O
the	O
ITP	O
-	O
PAQ	O
assessing	O
fear	O
associated	O
with	O
ITP	O
(	O
e.g.	O
,	O
fear	O
of	O
having	O
a	O
bleeding	O
episode	O
)	O
,	O
while	O
the	O
SF-36	O
provides	O
a	O
more	O
general	O
assessment	O
of	O
mental	O
health	O
issues	O
(	O
e.g.	O
,	O
felt	O
downhearted	O
and	O
blue	O
)	O
.	O

The	O
known	O
-	O
groups	O
validity	O
results	O
indicate	O
that	O
some	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
(	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Activity	O
,	O
Psychological	O
Health	O
,	O
and	O
Overall	O
QoL	O
scales	O
)	O
were	O
able	O
to	O
differentiate	O
ITP	O
subjects	O
who	O
were	O
currently	O
receiving	O
ITP	O
treatment	O
from	O
those	O
who	O
were	O
not	O
receiving	O
treatment	O
for	O
ITP	O
,	O
providing	O
preliminary	O
evidence	O
of	O
the	O
ITP	O
-	O
PAQ	O
's	O
ability	O
to	O
distinguish	O
between	O
groups	O
known	O
to	O
be	O
different	O
.	O

However	O
,	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
generally	O
unable	O
to	O
distinguish	O
between	O
subjects	O
when	O
they	O
were	O
grouped	O
by	O
gender	O
,	O
splenectomy	O
status	O
,	O
perceived	O
effectiveness	O
of	O
treatment	O
and	O
length	O
of	O
time	O
since	O
ITP	O
diagnosis	O
.	O

The	O
ITP	O
-	O
PAQ	O
may	O
not	O
be	O
able	O
to	O
differentiate	O
between	O
female	O
and	O
male	O
subjects	O
because	O
the	O
disorder	O
may	O
affect	O
females	O
and	O
males	O
similarly	O
.	O

Additionally	O
,	O
significant	O
differences	O
may	O
not	O
have	O
been	O
observed	O
between	O
subjects	O
who	O
have	O
undergone	O
splenectomy	O
and	O
subjects	O
who	O
have	O
not	O
because	O
55	O
%	O
of	O
subjects	O
who	O
had	O
a	O
splenectomy	O
indicated	O
that	O
it	O
did	O
not	O
cure	O
their	O
ITP	O
.	O

Specifically	O
,	O
the	O
known	O
-	O
groups	O
could	O
be	O
defined	O
as	O
'	O
subjects	O
without	O
a	O
splenectomy	O
'	O
versus	O
'	O
subjects	O
with	O
a	O
failed	O
splenectomy	O
'	O
(	O
for	O
whom	O
QoL	O
likely	O
worsened	O
)	O
versus	O
'	O
subjects	O
with	O
a	O
successful	O
splenectomy	O
'	O
(	O
for	O
whom	O
QoL	O
may	O
have	O
improved	O
)	O
.	O

In	O
the	O
future	O
,	O
to	O
assess	O
whether	O
the	O
ITP	O
-	O
PAQ	O
scales	O
can	O
differentiate	O
between	O
groups	O
of	O
subjects	O
,	O
it	O
may	O
be	O
worthwhile	O
to	O
categorize	O
subjects	O
by	O
a	O
more	O
clinically	O
relevant	O
measure	O
,	O
such	O
as	O
platelet	O
count	O
.	O

Several	O
limitations	O
should	O
be	O
considered	O
when	O
interpreting	O
our	O
findings	O
.	O

Subjects	O
were	O
drawn	O
from	O
a	O
convenience	O
sample	O
.	O

The	O
study	O
population	O
was	O
fairly	O
homogeneous	O
,	O
comprised	O
primarily	O
of	O
Caucasian	O
female	O
subjects	O
.	O

The	O
data	O
was	O
validated	O
using	O
only	O
patient	O
-	O
reported	O
data	O
collected	O
via	O
questionnaire	O
.	O

The	O
lack	O
of	O
clinical	O
data	O
in	O
this	O
initial	O
validation	O
study	O
will	O
be	O
addressed	O
in	O
on	O
-	O
going	O
pivotal	O
trials	O
that	O
will	O
collect	O
clinical	O
data	O
such	O
as	O
platelet	O
counts	O
and	O
platelet	O
response	O
.	O

In	O
addition	O
,	O
the	O
time	O
interval	O
between	O
the	O
initial	O
and	O
retest	O
administration	O
of	O
the	O
questionnaire	O
may	O
have	O
been	O
too	O
lengthy	O
to	O
properly	O
evaluate	O
the	O
test	O
-	O
retest	O
reliability	O
.	O

Because	O
25	O
%	O
of	O
subjects	O
did	O
not	O
complete	O
the	O
questionnaire	O
within	O
the	O
targeted	O
fifteen	O
day	O
interval	O
,	O
those	O
subjects	O
may	O
have	O
undergone	O
clinical	O
changes	O
that	O
may	O
have	O
affected	O
their	O
responses	O
.	O

In	O
future	O
validation	O
studies	O
platelet	O
counts	O
or	O
type	O
of	O
platelet	O
response	O
should	O
be	O
used	O
to	O
identify	O
a	O
stable	O
cohort	O
for	O
the	O
test	O
-	O
retest	O
analyses	O
.	O

Furthermore	O
,	O
the	O
criteria	O
used	O
to	O
categorize	O
the	O
subjects	O
for	O
the	O
known	O
groups	O
validity	O
evaluation	O
may	O
not	O
have	O
been	O
sufficient	O
to	O
allow	O
for	O
the	O
ITP	O
-	O
PAQ	O
scales	O
to	O
detect	O
differences	O
between	O
groups	O
.	O

Grouping	O
the	O
subjects	O
by	O
a	O
different	O
criterion	O
,	O
such	O
as	O
a	O
relevant	O
clinical	O
measure	O
,	O
may	O
bolster	O
the	O
findings	O
for	O
its	O
known	O
groups	O
validity	O
.	O

Conclusion	O
The	O
primary	O
goal	O
of	O
this	O
manuscript	O
was	O
to	O
describe	O
the	O
development	O
of	O
a	O
new	O
ITP	O
-	O
specific	O
HRQoL	O
questionnaire	O
for	O
adults	O
with	O
ITP	O
and	O
to	O
present	O
our	O
initial	O
findings	O
on	O
the	O
psychometric	O
properties	O
of	O
this	O
questionnaire	O
.	O

The	O
results	O
of	O
this	O
initial	O
validation	O
study	O
indicate	O
that	O
the	O
questionnaire	O
generally	O
has	O
acceptable	O
reliability	O
and	O
validity	O
.	O

We	O
plan	O
to	O
conduct	O
additional	O
analyses	O
using	O
more	O
objective	O
clinical	O
measures	O
such	O
as	O
platelet	O
counts	O
as	O
a	O
criterion	O
for	O
known	O
groups	O
validity	O
.	O

Further	O
validation	O
work	O
should	O
also	O
be	O
conducted	O
to	O
assess	O
its	O
responsiveness	O
and	O
to	O
estimate	O
its	O
minimal	O
clinical	O
important	O
difference	O
value	O
so	O
that	O
it	O
can	O
become	O
a	O
more	O
widely	O
used	O
HRQoL	O
measure	O
in	O
the	O
ITP	O
population	O
.	O

Competing	O
interests	O
The	O
validation	O
study	O
design	O
,	O
analysis	O
,	O
interpretation	O
of	O
results	O
,	O
and	O
the	O
writing	O
of	O
the	O
manuscript	O
represent	O
the	O
joint	O
collaboration	O
of	O
all	O
authors	O
of	O
this	O
study	O
,	O
which	O
was	O
funded	O
solely	O
by	O
Amgen	O
,	O
Inc	O
,	O
Thousand	O
Oaks	O
,	O
California	O
,	O
USA	O
.	O

Ovation	O
Research	O
Group	O
provided	O
no	O
additional	O
funding	O
for	O
this	O
study	O
.	O

The	O
decision	O
to	O
submit	O
this	O
manuscript	O
for	O
publication	O
was	O
subject	O
to	O
the	O
approval	O
of	O
Amgen	O
,	O
Inc.	O
and	O
all	O
authors	O
.	O

Gary	O
Okano	O
and	O
Janet	O
Nichol	O
are	O
employees	O
of	O
Amgen	O
,	O
Inc.	O
James	O
Bussel	O
is	O
an	O
employee	O
of	O
Weill	O
Cornell	O
Medical	O
Center	O
.	O

James	O
George	O
is	O
employed	O
by	O
the	O
University	O
of	O
Oklahoma	O
Health	O
Sciences	O
Center	O
.	O

Robert	O
McMillan	O
is	O
a	O
Professor	O
Emeritus	O
of	O
the	O
Scripps	O
Research	O
Institute	O
.	O

Susan	O
Mathias	O
is	O
an	O
employee	O
of	O
Ovation	O
Research	O
Group	O
.	O

Authors	O
'	O
contributions	O
SDM	O
supervised	O
the	O
interpretation	O
of	O
the	O
results	O
from	O
the	O
validation	O
study	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

JBB	O
,	O
JNG	O
,	O
RM	O
,	O
and	O
JLN	O
provided	O
clinical	O
expertise	O
in	O
the	O
development	O
of	O
the	O
questionnaire	O
,	O
and	O
participated	O
in	O
the	O
design	O
and	O
execution	O
of	O
the	O
study	O
.	O

GJO	O
assisted	O
in	O
interpreting	O
the	O
results	O
and	O
drafting	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Integration	O
in	O
primary	O
community	O
care	O
networks	O
(	O
PCCNs	O
)	O
:	O
examination	O
of	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
in	O
a	O
national	O
demonstration	O
project	O
in	O
Taiwan	O
Abstract	O
Background	O
Taiwan	O
's	O
primary	O
community	O
care	O
network	O
(	O
PCCN	O
)	O
demonstration	O
project	O
,	O
funded	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
on	O
March	O
2003	O
,	O
was	O
established	O
to	O
discourage	O
hospital	O
shopping	O
behavior	O
of	O
people	O
and	O
drive	O
the	O
traditional	O
fragmented	O
health	O
care	O
providers	O
into	O
cooperate	O
care	O
models	O
.	O

Between	O
2003	O
and	O
2005	O
,	O
268	O
PCCNs	O
were	O
established	O
.	O

This	O
study	O
profiled	O
the	O
individual	O
members	O
in	O
the	O
PCCNs	O
to	O
study	O
the	O
nature	O
and	O
extent	O
to	O
which	O
their	O
network	O
infrastructures	O
have	O
been	O
integrated	O
among	O
the	O
members	O
(	O
clinics	O
and	O
hospitals	O
)	O
within	O
individual	O
PCCNs	O
.	O

Methods	O
The	O
thorough	O
questionnaire	O
items	O
,	O
covering	O
the	O
network	O
working	O
infrastructures	O
–	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
integration	O
in	O
PCCNs	O
,	O
were	O
developed	O
with	O
validity	O
and	O
reliability	O
confirmed	O
.	O

One	O
thousand	O
five	O
hundred	O
and	O
fifty	O
-	O
seven	O
clinics	O
that	O
had	O
belonged	O
to	O
PCCNs	O
for	O
more	O
than	O
one	O
year	O
,	O
based	O
on	O
the	O
2003–2005	O
Taiwan	O
Primary	O
Community	O
Care	O
Network	O
List	O
,	O
were	O
surveyed	O
by	O
mail	O
.	O

Nine	O
hundred	O
and	O
twenty	O
-	O
eight	O
clinic	O
members	O
responded	O
to	O
the	O
surveys	O
giving	O
a	O
59.6	O
%	O
response	O
rate	O
.	O

Results	O

Overall	O
,	O
the	O
PCCNs	O
'	O
members	O
had	O
higher	O
involvement	O
in	O
the	O
governance	O
infrastructure	O
,	O
which	O
was	O
usually	O
viewed	O
as	O
the	O
most	O
important	O
for	O
establishment	O
of	O
core	O
values	O
in	O
PCCNs	O
'	O
organization	O
design	O
and	O
management	O
at	O
the	O
early	O
integration	O
stage	O
.	O

In	O
addition	O
,	O
it	O
found	O
that	O
there	O
existed	O
a	O
higher	O
extent	O
of	O
integration	O
of	O
clinical	O
,	O
marketing	O
,	O
and	O
information	O
infrastructures	O
among	O
the	O
hospital	O
-	O
clinic	O
member	O
relationship	O
than	O
those	O
among	O
clinic	O
members	O
within	O
individual	O
PCCNs	O
.	O

The	O
financial	O
infrastructure	O
was	O
shown	O
the	O
least	O
integrated	O
relative	O
to	O
other	O
functional	O
infrastructures	O
at	O
the	O
early	O
stage	O
of	O
PCCN	O
formation	O
.	O

Conclusion	O

There	O
was	O
still	O
room	O
for	O
better	O
integrated	O
partnerships	O
,	O
as	O
evidenced	O
by	O
the	O
great	O
variety	O
of	O
relationships	O
and	O
differences	O
in	O
extent	O
of	O
integration	O
in	O
this	O
study	O
.	O

In	O
addition	O
to	O
provide	O
how	O
the	O
network	O
members	O
have	O
done	O
for	O
their	O
initial	O
work	O
at	O
the	O
early	O
stage	O
of	O
network	O
forming	O
in	O
this	O
study	O
,	O
the	O
detailed	O
surveyed	O
items	O
,	O
the	O
concepts	O
proposed	O
by	O
the	O
managerial	O
and	O
theoretical	O
professionals	O
,	O
could	O
be	O
a	O
guide	O
for	O
those	O
health	O
care	O
providers	O
who	O
have	O
willingness	O
to	O
turn	O
their	O
business	O
into	O
multi	O
-	O
organizations	O
.	O

Background	O
Taiwan	O
's	O
National	O
Health	O
Insurance	O
(	O
NHI	O
)	O
under	O
the	O
control	O
of	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
,	O
was	O
launched	O
in	O
March	O
1995	O
to	O
replace	O
its	O
social	O
insurance	O
system	O
that	O
was	O
covering	O
59	O
%	O
of	O
its	O
population	O
:	O
government	O
employees	O
,	O
labourers	O
,	O
farmers	O
and	O
servicemen	O
[	O
1	O
]	O
.	O

By	O
June	O
2003	O
the	O
number	O
of	O
people	O
insured	O
had	O
reached	O
21,956,729	O
(	O
99	O
%	O
)	O
.	O

There	O
were	O
17,259	O
medical	O
providers	O
(	O
92	O
%	O
)	O
,	O
including	O
575	O
hospitals	O
and	O
16,684	O
clinics	O
contracted	O
with	O
the	O
BNHI	O
for	O
serving	O
the	O
enrolled	O
population	O
.	O

The	O
unique	O
phenomenon	O
characterized	O
in	O
Taiwan	O
health	O
care	O
industry	O
different	O
from	O
those	O
in	O
the	O
western	O
countries	O
is	O
the	O
freedom	O
of	O
patients	O
to	O
choose	O
the	O
health	O
care	O
providers	O
they	O
want	O
,	O
no	O
matter	O
what	O
their	O
disease	O
severity	O
is	O
.	O

Furthermore	O
,	O
Taiwan	O
people	O
favor	O
the	O
larger	O
scales	O
of	O
facilities	O
and	O
this	O
fallacy	O
leads	O
to	O
the	O
phenomenon	O
of	O
big	O
-	O
hospital	O
shopping	O
.	O

For	O
example	O
,	O
people	O
choose	O
the	O
medical	O
centers	O
which	O
are	O
accredited	O
as	O
the	O
highest	O
level	O
of	O
medical	O
science	O
in	O
Taiwan	O
when	O
they	O
only	O
suffer	O
from	O
a	O
common	O
cold	O
.	O

In	O
the	O
spring	O
of	O
2003	O
,	O
the	O
SARS	O
epidemic	O
viciously	O
attacked	O
the	O
health	O
of	O
Taiwan	O
's	O
people	O
.	O

The	O
people	O
's	O
freedom	O
to	O
choose	O
medical	O
providers	O
caused	O
the	O
national	O
health	O
authority	O
to	O
barely	O
control	O
and	O
traced	O
the	O
flow	O
of	O
epidemic	O
.	O

This	O
event	O
made	O
Taiwan	O
national	O
health	O
authorities	O
rethink	O
what	O
happened	O
and	O
how	O
it	O
damaged	O
under	O
the	O
traditional	O
fragmented	O
health	O
care	O
providers	O
in	O
Taiwan	O
.	O

One	O
health	O
reform	O
launched	O
was	O
named	O
the	O
""""	O
Primary	O
Community	O
Care	O
Network	O
(	O
PCCN	O
)	O
demonstration	O
project	O
""""	O
,	O
a	O
nationwide	O
health	O
care	O
financing	O
program	O
funded	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
in	O
March	O
2003	O
and	O
it	O
was	O
a	O
new	O
model	O
for	O
the	O
Taiwan	O
government	O
to	O
redefine	O
the	O
role	O
of	O
family	O
physicians	O
in	O
the	O
health	O
care	O
delivery	O
system	O
.	O

A	O
PCCN	O
in	O
Taiwan	O
consists	O
of	O
a	O
group	O
of	O
clinic	O
physicians	O
whose	O
medical	O
jobs	O
are	O
viewed	O
as	O
family	O
care	O
and	O
at	O
least	O
one	O
hospital	O
for	O
secondary	O
or	O
tertiary	O
care	O
.	O

The	O
idea	O
of	O
member	O
component	O
design	O
in	O
PCCNs	O
was	O
aimed	O
to	O
lead	O
the	O
Taiwan	O
citizens	O
to	O
choose	O
one	O
clinic	O
physician	O
as	O
their	O
personal	O
family	O
physician	O
for	O
health	O
maintenance	O
and	O
this	O
family	O
physician	O
also	O
would	O
have	O
the	O
responsibility	O
of	O
referring	O
the	O
patients	O
to	O
specialty	O
care	O
if	O
necessary	O
.	O

From	O
a	O
national	O
health	O
authority	O
perspective	O
,	O
they	O
expected	O
the	O
Taiwan	O
people	O
to	O
put	O
an	O
end	O
to	O
their	O
fallacy	O
that	O
""""	O
bigger	O
is	O
better	O
""""	O
for	O
health	O
care	O
organizations	O
and	O
establish	O
the	O
idea	O
of	O
""""	O
human	B
health	O
""""	O
,	O
starting	O
with	O
prevention	O
and	O
primary	O
care	O
,	O
followed	O
by	O
secondary	O
or	O
tertiary	O
care	O
,	O
emphasizing	O
health	O
promotion	O
and	O
maintenance	O
instead	O
of	O
disease	O
curing	O
.	O

Furthermore	O
,	O
it	O
could	O
decrease	O
the	O
inappropriateness	O
of	O
medical	O
usage	O
,	O
i.e.	O
,	O
over	O
-	O
uses	O
of	O
secondary	O
and	O
tertiary	O
medical	O
services	O
in	O
the	O
high	O
-	O
tech	O
hospitals	O
.	O

In	O
addition	O
,	O
the	O
national	O
health	O
authority	O
was	O
expected	O
to	O
drive	O
the	O
traditional	O
fragmented	O
heath	O
care	O
providers	O
into	O
coordinated	O
medical	O
multidisciplinary	O
teams	O
and	O
share	O
the	O
limited	O
medical	O
resources	O
through	O
the	O
PCCN	O
demonstration	O
project	O
.	O

In	O
summary	O
,	O
the	O
PCCN	O
demonstration	O
project	O
was	O
aimed	O
to	O
:	O
1	O
)	O
change	O
the	O
traditional	O
patients	O
'	O
customs	O
of	O
freely	O
choosing	O
health	O
care	O
organizations	O
and	O
establish	O
referral	O
channels	O
along	O
the	O
continuum	O
of	O
care	O
,	O
and	O
2	O
)	O
establish	O
partnerships	O
among	O
the	O
primary	O
care	O
clinics	O
and	O
hospitals	O
to	O
provide	O
a	O
continuum	O
of	O
health	O
care	O
services	O
.	O

It	O
was	O
also	O
expected	O
to	O
establish	O
the	O
primary	O
care	O
system	O
of	O
family	O
physicians	O
to	O
provide	O
whole	O
-	O
people	O
health	O
care	O
and	O
improve	O
care	O
quality	O
[	O
1	O
]	O
.	O

Partnership	O
structures	O
in	O
the	O
PCCNs	O
represent	O
the	O
virtual	O
vertical	O
(	O
i.e.	O
,	O
between	O
the	O
member	O
clinics	O
and	O
hospitals	O
)	O
and	O
virtual	O
horizontal	O
(	O
i.e.	O
,	O
among	O
the	O
member	O
clinics	O
)	O
aspects	O
of	O
organizing	O
,	O
which	O
designate	O
the	O
formal	O
relationships	O
between	O
individuals	O
and	O
the	O
total	O
network	O
and	O
include	O
organizational	O
design	O
to	O
ensure	O
effective	O
communication	O
,	O
coordination	O
,	O
and	O
integration	O
across	O
the	O
total	O
network	O
.	O

Each	O
PCCN	O
consists	O
of	O
five	O
to	O
ten	O
clinics	O
:	O
half	O
of	O
them	O
should	O
offer	O
the	O
services	O
of	O
general	O
medicine	O
,	O
internal	O
medicine	O
,	O
surgery	O
,	O
obstetrics	O
and	O
gynecology	O
,	O
pediatric	O
,	O
or	O
family	O
medicine	O
.	O

And	O
each	O
PCCN	O
has	O
a	O
central	O
headquarters	O
,	O
usually	O
in	O
one	O
of	O
the	O
clinic	O
facilities	O
,	O
to	O
coordinate	O
and	O
integrate	O
the	O
network	O
.	O

All	O
the	O
clinic	O
physicians	O
in	O
a	O
PCCN	O
are	O
assigned	O
the	O
roles	O
of	O
""""	O
family	O
physicians	O
""""	O
or	O
""""	O
gatekeepers	O
""""	O
who	O
recruit	O
people	O
from	O
the	O
local	O
community	O
,	O
keep	O
background	O
and	O
medical	O
files	O
on	O
them	O
,	O
certify	O
family	O
physician	O
education	O
training	O
programs	O
,	O
and	O
hold	O
office	O
hours	O
in	O
the	O
member	O
hospital	O
,	O
where	O
they	O
serve	O
as	O
joint	O
faculty	O
members	O
for	O
further	O
medical	O
consultations	O
or	O
medical	O
utilizations	O
of	O
labs	O
and	O
tests	O
,	O
if	O
necessary	O
.	O

In	O
addition	O
,	O
the	O
hospital	O
member	O
is	O
asked	O
to	O
help	O
clinic	O
physicians	O
in	O
their	O
network	O
to	O
set	O
up	O
a	O
medical	O
information	O
system	O
,	O
share	O
hospital	O
resources	O
(	O
medical	O
equipment	O
and	O
library	O
literature	O
)	O
with	O
the	O
clinic	O
physicians	O
in	O
their	O
network	O
and	O
establish	O
referral	O
channels	O
among	O
the	O
network	O
members	O
.	O

Furthermore	O
,	O
this	O
new	O
demonstration	O
model	O
tries	O
to	O
minimize	O
the	O
barriers	O
to	O
patient	O
access	O
by	O
setting	O
up	O
24-hour	O
a	O
day	O
,	O
7-day	O
a	O
week	O
medical	O
consultation	O
telephone	O
lines	O
for	O
providing	O
urgent	O
services	O
onsite	O
and	O
for	O
taking	O
care	O
of	O
the	O
patients	O
whose	O
family	O
physicians	O
'	O
practices	O
are	O
closed	O
to	O
assure	O
seamless	O
care	O
channels	O
.	O

The	O
BNHI	O
funded	O
these	O
extra	O
demonstration	O
actions	O
,	O
at	O
around	O
one	O
hundred	O
thousand	O
US	O
dollars	O
(	O
i.e.	O
,	O
NT$3,500,000	O
)	O
for	O
each	O
PCCN	O
under	O
the	O
current	O
fee	O
-	O
for	O
-	O
service	O
payment	O
system	O
[	O
1	O
]	O
.	O

Figure	O
1	O
describes	O
the	O
organizational	O
structure	O
of	O
individual	O
PCCNs	O
introduced	O
in	O
the	O
demonstration	O
project	O
in	O
Taiwan	O
.	O

To	O
date	O
,	O
the	O
PCCN	O
demonstration	O
project	O
has	O
been	O
in	O
operation	O
for	O
more	O
than	O
three	O
years	O
.	O

There	O
have	O
been	O
268	O
PCCNs	O
formed	O
in	O
the	O
period	O
of	O
2003	O
to	O
2005	O
around	O
Taiwan	O
.	O

The	O
geographical	O
distributions	O
of	O
PCCNs	O
and	O
their	O
members	O
were	O
described	O
in	O
Table	O
1	O
.	O

Analyzing	O
all	O
1,557	O
participating	O
clinic	O
members	O
in	O
the	O
demonstration	O
project	O
in	O
terms	O
of	O
medical	O
specialties	O
,	O
they	O
cover	O
general	O
medicine	O
,	O
internal	O
medicine	O
,	O
surgeries	O
,	O
obstetrics	O
and	O
gynecology	O
,	O
pediatrics	O
,	O
family	O
medicines	O
,	O
otolaryngology	O
,	O
ophthalmology	O
,	O
rehabilitation	O
medicine	O
,	O
dermatology	O
,	O
and	O
psychiatry	O
,	O
with	O
237	O
clinics	O
providing	O
more	O
than	O
two	O
specialties	O
.	O

On	O
the	O
other	O
hand	O
,	O
each	O
PCCN	O
recruits	O
at	O
least	O
one	O
district	O
or	O
regional	O
accredited	O
hospital	O
for	O
acute	O
care	O
demands	O
(	O
required	O
for	O
network	O
members	O
)	O
and	O
a	O
medical	O
center	O
for	O
tertiary	O
care	O
support	O
(	O
not	O
required	O
for	O
network	O
members	O
)	O
.	O

There	O
are	O
6	O
medical	O
centers	O
,	O
52	O
regional	O
hospitals	O
,	O
and	O
71	O
district	O
hospitals	O
joining	O
in	O
the	O
demonstration	O
project	O
.	O

See	O
Table	O
1	O
for	O
more	O
detailed	O
information	O
about	O
the	O
PCCN	O
members	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
few	O
empirical	O
studies	O
of	O
the	O
working	O
relationships	O
that	O
have	O
developed	O
between	O
members	O
of	O
the	O
PCCN	O
program	O
.	O

Partnership	O
needs	O
a	O
method	O
to	O
determine	O
at	O
an	O
early	O
stage	O
,	O
to	O
make	O
sure	O
whether	O
they	O
are	O
making	O
the	O
most	O
of	O
collaboration	O
[	O
2	O
]	O
and	O
the	O
acceptance	O
of	O
the	O
contracting	O
networks	O
in	O
Taiwan	O
as	O
an	O
organizational	O
innovation	O
worthy	O
of	O
greater	O
diffusion	O
deserves	O
to	O
be	O
explored	O
.	O

Therefore	O
,	O
this	O
study	O
used	O
a	O
structured	O
questionnaire	O
to	O
characterize	O
the	O
relationship	O
among	O
the	O
members	O
in	O
the	O
individual	O
PCCNs	O
,	O
with	O
regard	O
to	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financing	O
,	O
as	O
well	O
as	O
information	O
integration	O
infrastructures	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
descriptive	O
analyses	O
in	O
detail	O
to	O
map	O
the	O
partnership	O
developments	O
,	O
to	O
enrich	O
the	O
body	O
of	O
knowledge	O
of	O
the	O
partner	O
relationships	O
and	O
to	O
help	O
policy	O
makers	O
understand	O
the	O
coordinated	O
efforts	O
of	O
these	O
health	O
care	O
providers	O
which	O
have	O
developed	O
under	O
this	O
system	O
.	O

It	O
also	O
provides	O
the	O
recommendations	O
for	O
heath	O
policy	O
decision	O
-	O
making	O
and	O
management	O
of	O
networks	O
of	O
health	O
care	O
providers	O
for	O
the	O
future	O
involvement	O
.	O

Methods	O
This	O
study	O
was	O
aimed	O
at	O
providing	O
descriptive	O
analyses	O
to	O
map	O
the	O
partnership	O
development	O
.	O

To	O
understand	O
the	O
actual	O
integration	O
actions	O
done	O
by	O
network	O
members	O
,	O
the	O
theoretical	O
concept	O
employed	O
by	O
network	O
partnerships	O
were	O
described	O
and	O
then	O
the	O
derived	O
survey	O
instrument	O
was	O
developed	O
.	O

Theoretical	O
framework	O
for	O
organization	O
design	O
of	O
network	O
integration	O
The	O
rapid	O
organizational	O
changes	O
in	O
the	O
health	O
care	O
industry	O
have	O
driven	O
theorists	O
from	O
every	O
discipline	O
and	O
across	O
the	O
world	O
to	O
seek	O
an	O
approach	O
that	O
allows	O
organizations	O
to	O
flourish	O
.	O

Organization	O
theory	O
allows	O
investigators	O
to	O
profile	O
an	O
organization	O
from	O
the	O
aspect	O
of	O
patterns	O
and	O
regularities	O
in	O
organizational	O
design	O
and	O
behavior	O
.	O

In	O
the	O
early	O
20th	O
century	O
,	O
classical	O
management	O
theorists	O
claimed	O
that	O
an	O
organization	O
has	O
""""	O
a	O
best	O
way	O
""""	O
to	O
be	O
organized	O
and	O
managed	O
[	O
3	O
]	O
.	O

That	O
implied	O
that	O
all	O
organizations	O
would	O
own	O
the	O
""""	O
same	O
""""	O
organizational	O
styles	O
or	O
structures	O
.	O

In	O
the	O
1960s	O
,	O
several	O
theorists	O
[	O
4	O
-	O
8	O
]	O
challenged	O
this	O
assumption	O
by	O
applying	O
a	O
""""	O
contingency	O
approach	O
""""	O
to	O
propose	O
that	O
there	O
is	O
no	O
best	O
way	O
to	O
organize	O
an	O
organization	O
,	O
and	O
that	O
the	O
effectiveness	O
of	O
an	O
organizational	O
structure	O
varies	O
with	O
the	O
situation	O
of	O
an	O
organization	O
.	O

Furthermore	O
,	O
it	O
is	O
proposed	O
that	O
the	O
best	O
way	O
to	O
organize	O
an	O
organization	O
depends	O
on	O
the	O
nature	O
of	O
the	O
environment	O
to	O
which	O
the	O
organization	O
relates	O
.	O

Contingency	O
theory	O
delineates	O
the	O
concepts	O
""""	O
organization	O
's	O
internal	O
features	O
,	O
""""	O
""""	O
the	O
demands	O
of	O
organizational	O
environments	O
,	O
""""	O
""""	O
best	O
adaptation	O
,	O
""""	O
and	O
,	O
the	O
most	O
important	O
and	O
difficult	O
of	O
all	O
,	O
""""	O
best	O
match	O
""""	O
[	O
9	O
]	O
.	O

Lawrence	O
&	O
Lorsch	O
[	O
7	O
]	O
argued	O
that	O
environments	O
characterized	O
by	O
uncertainty	O
and	O
rapid	O
rates	O
of	O
change	O
in	O
market	O
conditions	O
or	O
technology	O
impose	O
different	O
demands	O
,	O
including	O
constraints	O
and	O
opportunities	O
,	O
on	O
organizations	O
than	O
do	O
placid	O
and	O
stable	O
environments	O
.	O

Similarly	O
to	O
Lawrence	O
and	O
Lorsch	O
's	O
views	O
mentioned	O
above	O
,	O
Galbraith	O
[	O
10,11	O
]	O
stressed	O
the	O
contingency	O
perspective	O
on	O
information	O
processing	O
.	O

The	O
information	O
-	O
processing	O
approach	O
emphasizes	O
that	O
environment	O
,	O
size	O
,	O
and	O
technology	O
impose	O
different	O
information	O
-	O
processing	O
requirements	O
on	O
organizations	O
,	O
and	O
thus	O
an	O
organization	O
must	O
be	O
designed	O
to	O
encourage	O
information	O
flow	O
in	O
both	O
vertical	O
and	O
horizontal	O
directions	O
to	O
achieve	O
the	O
overall	O
tasks	O
of	O
the	O
organization	O
and	O
,	O
finally	O
,	O
organizational	O
effectiveness	O
[	O
11	O
-	O
14	O
]	O
.	O

Some	O
theorists	O
have	O
criticized	O
conventional	O
contingency	O
theorists	O
who	O
presume	O
that	O
organizational	O
structure	O
is	O
driven	O
by	O
the	O
environment	O
.	O

Child	O
[	O
15	O
]	O
,	O
Miller	O
[	O
16	O
]	O
,	O
Van	O
de	O
Ven	O
and	O
Drazin	O
[	O
17	O
]	O
,	O
and	O
Tushman	O
and	O
Romanelli	O
[	O
18	O
]	O
raised	O
such	O
criticisms	O
;	O
they	O
argued	O
that	O
organizations	O
become	O
what	O
they	O
are	O
not	O
only	O
because	O
of	O
the	O
environment	O
,	O
but	O
also	O
because	O
of	O
choices	O
made	O
by	O
members	O
,	O
especially	O
choices	O
about	O
strategy	O
and	O
organizational	O
design	O
.	O

As	O
Thompson	O
's	O
words	O
in	O
the	O
book	O
Organizations	O
in	O
Action	O
[	O
8	O
]	O
put	O
it	O
,	O
""""	O
organizations	O
are	O
not	O
determined	O
simply	O
by	O
their	O
environments	O
(	O
p.27	O
)	O
.	O

""""	O
He	O
also	O
pointed	O
out	O
that	O
""""	O
administration	O
may	O
innovate	O
on	O
any	O
or	O
all	O
of	O
the	O
necessary	O
dimensions	O
,	O
but	O
only	O
to	O
the	O
extent	O
that	O
innovations	O
are	O
acceptable	O
to	O
those	O
on	O
whom	O
the	O
organization	O
can	O
and	O
must	O
depend	O
.	O
""""	O

Instead	O
of	O
assuming	O
that	O
administrators	O
are	O
highly	O
constrained	O
in	O
their	O
decisions	O
,	O
strategic	O
contingency	O
theorists	O
emphasized	O
""""	O
the	O
importance	O
of	O
choice	O
,	O
""""	O
that	O
is	O
,	O
""""	O
the	O
freedom	O
of	O
agency	O
""""	O
[	O
15	O
]	O
.	O

Furthermore	O
,	O
Pfeffer	O
[	O
19	O
]	O
explicitly	O
pointed	O
out	O
that	O
""""	O
organizational	O
structures	O
are	O
the	O
outcomes	O
of	O
political	O
contests	O
within	O
organizations	O
(	O
p.38	O
)	O
.	O

""""	O
Daft	O
[	O
14	O
]	O
proposed	O
a	O
top	O
management	O
model	O
to	O
delineate	O
how	O
""""	O
a	O
strategy	O
is	O
a	O
plan	O
for	O
interacting	O
with	O
the	O
competitive	O
environment	O
to	O
achieve	O
organizational	O
goals	O
.	O
""""	O

He	O
stated	O
that	O
the	O
major	O
responsibility	O
of	O
top	O
management	O
is	O
to	O
determine	O
the	O
goals	O
,	O
strategy	O
,	O
and	O
design	O
of	O
an	O
organization	O
to	O
adapt	O
to	O
a	O
changing	O
environment	O
.	O

To	O
assess	O
the	O
external	O
and	O
internal	O
environments	O
of	O
an	O
organization	O
seems	O
to	O
be	O
the	O
first	O
task	O
for	O
top	O
managers	O
in	O
defining	O
an	O
organization	O
's	O
goals	O
and	O
missions	O
.	O

Then	O
,	O
guided	O
by	O
the	O
goals	O
and	O
missions	O
of	O
the	O
organization	O
,	O
top	O
managers	O
shape	O
the	O
design	O
of	O
the	O
organization	O
,	O
including	O
structural	O
forms	O
,	O
information	O
system	O
,	O
technology	O
,	O
human	B
resources	O
,	O
organizational	O
culture	O
,	O
and	O
inter	O
-	O
organizational	O
linkages	O
,	O
to	O
achieve	O
the	O
final	O
organizational	O
performance	O
.	O

Integration	O
refers	O
to	O
the	O
mechanisms	O
of	O
coordination	O
,	O
the	O
ways	O
guided	O
to	O
partnership	O
goals	O
to	O
fit	O
internal	O
and	O
external	O
conditions	O
[	O
7,20,21	O
]	O
.	O

In	O
the	O
early	O
1990s	O
,	O
proposals	O
for	O
US	O
national	O
health	O
care	O
reform	O
recognized	O
the	O
need	O
for	O
integrating	O
mechanisms	O
to	O
achieve	O
both	O
financial	O
success	O
and	O
quality	O
of	O
care	O
of	O
a	O
well	O
-	O
organized	O
system	O
of	O
care	O
[	O
22,23	O
]	O
.	O

Several	O
researchers	O
also	O
viewed	O
inter	O
-	O
organizational	O
cooperation	O
as	O
resource	O
exchanges	O
,	O
including	O
client	O
referrals	O
,	O
money	O
,	O
and	O
staff	O
[	O
24	O
-	O
27	O
]	O
.	O

From	O
practical	O
ways	O
of	O
viewing	O
integration	O
,	O
the	O
success	O
of	O
integration	O
lies	O
in	O
the	O
coordinative	O
mechanisms	O
and	O
partnership	O
working	O
that	O
support	O
it	O
[	O
28	O
]	O
,	O
including	O
an	O
administrative	O
organization	O
that	O
coordinates	O
the	O
operations	O
of	O
various	O
health	O
care	O
services	O
;	O
a	O
management	O
information	O
system	O
that	O
integrates	O
clinical	O
,	O
utilization	O
,	O
and	O
financial	O
data	O
and	O
follows	O
clients	O
across	O
different	O
settings	O
;	O
a	O
care	O
coordination	O
program	O
such	O
as	O
case	O
management	O
or	O
disease	O
management	O
that	O
works	O
with	O
clients	O
to	O
arrange	O
health	O
care	O
services	O
;	O
and	O
a	O
financial	O
mechanism	O
that	O
enables	O
pooling	O
of	O
funds	O
across	O
services	O
[	O
29	O
-	O
35	O
]	O
.	O

Fox	O
[	O
36	O
]	O
suggested	O
the	O
success	O
of	O
integrated	O
health	O
networks	O
should	O
ensure	O
that	O
the	O
new	O
business	O
link	O
such	O
aspects	O
as	O
technology	O
,	O
functional	O
skills	O
,	O
customer	O
access	O
,	O
management	O
,	O
or	O
products	O
that	O
can	O
be	O
shared	O
across	O
both	O
the	O
core	O
and	O
the	O
new	O
business	O
;	O
to	O
conduct	O
market	O
financial	O
evaluation	O
;	O
to	O
share	O
the	O
risk	O
of	O
vertical	O
integration	O
with	O
outside	O
entities	O
,	O
to	O
develop	O
the	O
management	O
structure	O
that	O
can	O
reflect	O
the	O
degree	O
of	O
coordination	O
necessary	O
to	O
support	O
the	O
core	O
business	O
activities	O
;	O
to	O
ensure	O
that	O
the	O
integration	O
strategy	O
meets	O
the	O
needs	O
of	O
customers	O
,	O
including	O
medical	O
treatment	O
,	O
the	O
use	O
of	O
medical	O
technology	O
,	O
and	O
the	O
preferred	O
methods	O
of	O
purchase	O
;	O
and	O
to	O
measure	O
the	O
new	O
business	O
by	O
its	O
value	O
to	O
the	O
enterprise	O
as	O
a	O
whole	O
,	O
rather	O
than	O
by	O
its	O
profitability	O
as	O
a	O
stand	O
-	O
alone	O
entity	O
.	O

In	O
summary	O
,	O
the	O
effects	O
that	O
integration	O
in	O
inter	O
-	O
organizational	O
designs	O
has	O
on	O
network	O
management	O
were	O
substantial	O
from	O
a	O
managerial	O
perspective	O
.	O

Borrowing	O
the	O
ideas	O
of	O
strategic	O
contingency	O
perspective	O
[	O
8,15,19	O
]	O
and	O
top	O
management	O
model	O
[	O
14	O
]	O
,	O
it	O
could	O
be	O
imply	O
that	O
success	O
(	O
organization	O
performance	O
)	O
in	O
reengineering	O
a	O
network	O
lies	O
in	O
the	O
integration	O
of	O
process	O
and	O
services	O
(	O
see	O
Figure	O
1	O
)	O
,	O
including	O
leadership	O
/	O
governing	O
structure	O
,	O
teamwork	O
between	O
disciplines	O
and	O
patient	O
care	O
,	O
financial	O
planning	O
,	O
and	O
information	O
systems	O
,	O
characterized	O
as	O
the	O
constructs	O
of	O
governance	O
,	O
clinical	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
,	O
respectively	O
,	O
in	O
this	O
study	O
.	O

In	O
addition	O
,	O
another	O
construct	O
,	O
marketing	O
infrastructure	O
,	O
was	O
especially	O
important	O
and	O
designed	O
to	O
explore	O
for	O
PCCNs	O
in	O
this	O
study	O
because	O
of	O
patients	O
'	O
freedom	O
of	O
making	O
healthcare	O
choice	O
and	O
the	O
traditional	O
fragmented	O
health	O
care	O
systems	O
by	O
individual	O
health	O
care	O
organizations	O
in	O
Taiwan	O
.	O

One	O
major	O
reason	O
for	O
Taiwan	O
people	O
's	O
hospital	O
shopping	O
preferences	O
was	O
that	O
Taiwan	O
people	O
usually	O
believe	O
the	O
bigger	O
the	O
facility	O
,	O
the	O
better	O
capacities	O
a	O
facility	O
has	O
no	O
matter	O
on	O
any	O
aspect	O
from	O
medical	O
professionals	O
to	O
tangible	O
medical	O
equipment	O
and	O
plants	O
.	O

And	O
this	O
fallacy	O
made	O
the	O
public	O
want	O
to	O
overuse	O
the	O
facility	O
with	O
high	O
-	O
tech	O
medical	O
services	O
no	O
matter	O
if	O
it	O
fits	O
their	O
needs	O
.	O

From	O
the	O
health	O
policy	O
and	O
management	O
perspectives	O
,	O
therefore	O
,	O
the	O
health	O
care	O
providers	O
were	O
encouraged	O
to	O
market	O
their	O
services	O
as	O
a	O
new	O
corporate	O
identity	O
and	O
brand	O
strategy	O
[	O
37	O
]	O
,	O
including	O
offering	O
tangible	O
resources	O
such	O
as	O
books	O
,	O
libraries	O
,	O
medical	O
equipment	O
,	O
and	O
intangible	O
resources	O
such	O
as	O
knowledge	O
and	O
information	O
exchanges	O
(	O
education	O
)	O
and	O
reputation	O
sharing	O
one	O
another	O
among	O
PCCN	O
members	O
.	O

Furthermore	O
,	O
through	O
the	O
process	O
of	O
marketing	O
resource	O
exchanges	O
,	O
therefore	O
,	O
each	O
PCCN	O
could	O
establish	O
the	O
images	O
of	O
""""	O
one	O
system	O
,	O
one	O
brand	O
and	O
quality	O
""""	O
for	O
the	O
public	O
and	O
for	O
the	O
health	O
care	O
providers	O
.	O

It	O
also	O
makes	O
it	O
be	O
more	O
visible	O
to	O
the	O
public	O
.	O

The	O
five	O
integration	O
infrastructures	O
of	O
network	O
management	O
were	O
constructed	O
as	O
a	O
conceptual	O
framework	O
in	O
this	O
study	O
to	O
help	O
to	O
portray	O
how	O
the	O
PCCN	O
members	O
have	O
done	O
.	O

The	O
survey	O
instrument	O
development	O
was	O
described	O
in	O
the	O
following	O
.	O

Survey	O
instrument	O
development	O
:	O
integration	O
infrastructures	O
and	O
measurements	O
of	O
partnerships	O
Based	O
on	O
the	O
five	O
integration	O
infrastructures	O
of	O
network	O
management	O
,	O
the	O
structured	O
questionnaire	O
were	O
derived	O
from	O
extensive	O
literature	O
reviews	O
.	O

Governance	O
infrastructure	O
Governance	O
assumes	O
the	O
broad	O
responsibility	O
for	O
organizational	O
goals	O
and	O
survival	O
and	O
involves	O
the	O
series	O
process	O
of	O
setting	O
and	O
monitoring	O
organizational	O
goals	O
and	O
strategy	O
development	O
through	O
a	O
board	O
of	O
representatives	O
[	O
38	O
]	O
.	O

Governance	O
or	O
administrative	O
integration	O
infrastructure	O
in	O
establishing	O
network	O
partnerships	O
refers	O
to	O
administrative	O
structures	O
(	O
or	O
responsibilities	O
)	O
created	O
to	O
facilitate	O
communication	O
,	O
clear	O
lines	O
of	O
authority	O
,	O
accountability	O
,	O
and	O
responsibility	O
for	O
patient	O
care	O
services	O
;	O
to	O
negotiate	O
budgets	O
and	O
financial	O
trade	O
-	O
offs	O
;	O
and	O
to	O
present	O
a	O
cohesive	O
,	O
consistent	O
message	O
in	O
interactions	O
with	O
external	O
agencies	O
and	O
the	O
community	O
[	O
29,39	O
-	O
41	O
]	O
and	O
most	O
important	O
for	O
members	O
in	O
contract	O
agreements	O
,	O
to	O
manage	O
participation	O
[	O
33	O
]	O
.	O

From	O
a	O
multidisciplinary	O
perspective	O
,	O
Mitchell	O
and	O
Shortell	O
[	O
42	O
]	O
applied	O
the	O
concepts	O
of	O
governance	O
and	O
management	O
characteristics	O
in	O
effective	O
community	O
health	O
partnerships	O
.	O

The	O
construct	O
of	O
governance	O
involved	O
several	O
tasks	O
,	O
including	O
setting	O
priorities	O
for	O
strategic	O
goals	O
,	O
choosing	O
the	O
membership	O
composition	O
,	O
obtaining	O
the	O
necessary	O
financial	O
resources	O
,	O
and	O
setting	O
up	O
the	O
accountability	O
systems	O
,	O
and	O
so	O
on	O
.	O

The	O
construct	O
of	O
the	O
management	O
refers	O
to	O
the	O
tasks	O
of	O
engaging	O
and	O
maintaining	O
organizational	O
members	O
'	O
interest	O
in	O
a	O
shared	O
vision	O
and	O
mission	O
,	O
providing	O
appropriate	O
structures	O
and	O
coordination	O
mechanisms	O
for	O
the	O
specified	O
strategies	O
,	O
promoting	O
constructive	O
conflicts	O
and	O
managing	O
destructive	O
conflicts	O
,	O
implementing	O
information	O
systems	O
to	O
monitor	O
the	O
dynamics	O
,	O
adjusting	O
the	O
leadership	O
in	O
the	O
overall	O
membership	O
,	O
and	O
so	O
on	O
.	O

The	O
issues	O
of	O
governance	O
and	O
administrative	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
2,38,40,41,43	O
-	O
47	O
]	O
:	O
•	O
planning	O
the	O
shared	O
visions	O
and	O
missions	O
•	O
determining	O
the	O
shared	O
service	O
strategies	O
,	O
cooperation	O
priorities	O
,	O
policies	O
and	O
principles	O
•	O
identifying	O
the	O
information	O
needed	O
and	O
how	O
to	O
get	O
it	O
•	O
organizing	O
the	O
network	O
dynamics	O
and	O
member	O
roles	O
•	O
leading	O
and	O
managing	O
the	O
conflicts	O
and	O
communication	O
•	O
designing	O
and	O
controlling	O
the	O
shared	O
network	O
performance	O
systems	O
,	O
including	O
indicator	O
settings	O
,	O
feedbacks	O
,	O
and	O
accountability	O
.	O

Clinical	O
infrastructure	O
The	O
idea	O
of	O
care	O
integration	O
begins	O
through	O
such	O
public	O
programs	O
that	O
include	O
social	O
workers	O
in	O
public	O
welfare	O
departments	O
,	O
caseworkers	O
in	O
mental	O
health	O
,	O
or	O
nurses	O
in	O
public	O
health	O
departments	O
.	O

In	O
the	O
late	O
1980s	O
,	O
care	O
integration	O
was	O
deemed	O
necessary	O
for	O
the	O
streamlining	O
of	O
care	O
and	O
negotiating	O
the	O
maze	O
of	O
long	O
-	O
term	O
care	O
services	O
.	O

At	O
that	O
time	O
,	O
it	O
was	O
referred	O
to	O
as	O
service	O
coordination	O
or	O
case	O
management	O
,	O
or	O
in	O
other	O
related	O
terms	O
[	O
29	O
]	O
.	O

The	O
purpose	O
of	O
care	O
integration	O
is	O
to	O
work	O
directly	O
with	O
patients	O
and	O
their	O
families	O
over	O
time	O
to	O
help	O
them	O
arrange	O
and	O
manage	O
the	O
complex	O
resources	O
that	O
patients	O
may	O
need	O
to	O
maintain	O
health	O
and	O
independent	O
functioning	O
.	O

At	O
the	O
same	O
time	O
,	O
care	O
integration	O
is	O
used	O
to	O
achieve	O
the	O
most	O
cost	O
-	O
effective	O
use	O
possible	O
of	O
scarce	O
resources	O
,	O
by	O
steering	O
patients	O
to	O
the	O
health	O
,	O
social	O
,	O
and	O
support	O
services	O
most	O
appropriate	O
for	O
them	O
at	O
a	O
given	O
time	O
[	O
29	O
]	O
.	O

Conrad	O
and	O
Dowling	O
[	O
33	O
]	O
pointed	O
out	O
that	O
to	O
coordinate	O
and	O
integrate	O
patient	O
care	O
relies	O
on	O
connecting	O
patient	O
services	O
at	O
the	O
different	O
stages	O
of	O
the	O
patient	O
care	O
processes	O
.	O

Care	O
coordination	O
in	O
integrated	O
networks	O
can	O
be	O
achieved	O
through	O
integration	O
of	O
training	O
programs	O
and	O
some	O
clinical	O
services	O
,	O
provision	O
of	O
complementary	O
clinical	O
capabilities	O
,	O
clinical	O
geographic	O
proximity	O
design	O
,	O
clear	O
role	O
definition	O
of	O
each	O
institution	O
,	O
commitment	O
and	O
flexibility	O
of	O
leaderships	O
and	O
medical	O
staffs	O
,	O
and	O
the	O
support	O
of	O
a	O
large	O
referring	O
physician	O
groups	O
embracing	O
the	O
affiliation	O
concepts	O
[	O
48	O
]	O
.	O

The	O
issues	O
of	O
clinical	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
48	O
-	O
50	O
]	O
:	O
•	O
planning	O
and	O
differentiating	O
target	O
markets	O
based	O
on	O
the	O
clinical	O
services	O
of	O
the	O
network	O
members	O
•	O
uniting	O
individual	O
clinical	O
professionals	O
for	O
clinical	O
project	O
planning	O
•	O
designing	O
patient	O
-	O
centered	O
care	O
or	O
case	O
management	O
teams	O
•	O
establishing	O
committees	O
responsible	O
for	O
patient	O
-	O
centered	O
case	O
report	O
meetings	O
,	O
case	O
referral	O
,	O
transfer	O
,	O
and	O
tracing	O
,	O
file	O
management	O
(	O
record	O
and	O
information	O
exchanges	O
)	O
,	O
clinical	O
quality	O
management	O
(	O
quality	O
assurance	O
,	O
improvement	O
,	O
risk	O
and	O
malpractice	O
management	O
,	O
and	O
utilization	O
review	O
)	O
,	O
and	O
medical	O
continuing	O
education	O
and	O
on	O
-	O
job	O
education	O
.	O

Marketing	O
infrastructure	O
Marketing	O
integration	O
refers	O
to	O
how	O
to	O
work	O
together	O
as	O
a	O
whole	O
both	O
from	O
the	O
provider	O
and	O
patient	O
perspectives	O
.	O

One	O
of	O
the	O
case	O
reports	O
interviewing	O
developing	O
integrated	O
delivery	O
system	O
or	O
networks	O
realized	O
that	O
the	O
most	O
important	O
thing	O
is	O
how	O
an	O
integrated	O
system	O
or	O
network	O
is	O
promoted	O
and	O
what	O
is	O
promoted	O
for	O
the	O
consumers	O
[	O
51	O
]	O
,	O
including	O
focusing	O
on	O
product	O
development	O
,	O
making	O
sure	O
the	O
branding	O
holds	O
together	O
,	O
marketing	O
directly	O
to	O
consumers	O
,	O
demonstrating	O
values	O
to	O
consumers	O
,	O
and	O
even	O
conducting	O
marketing	O
research	O
to	O
make	O
efforts	O
for	O
the	O
long	O
term	O
.	O

In	O
a	O
health	O
care	O
network	O
with	O
several	O
organizational	O
members	O
and	O
target	O
patients	O
,	O
the	O
marketing	O
infrastructure	O
in	O
PCCNs	O
here	O
refers	O
to	O
provider	O
members	O
'	O
marketing	O
,	O
meaning	O
the	O
resource	O
sharing	O
and	O
market	O
development	O
in	O
a	O
PCCN	O
as	O
a	O
whole	O
.	O

The	O
issues	O
of	O
the	O
marketing	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
37,52	O
-	O
54	O
]	O
:	O
•	O
sharing	O
the	O
literature	O
and	O
facility	O
publications	O
among	O
the	O
network	O
members	O
•uniting	O
public	O
promotions	O
such	O
as	O
united	O
activities	O
,	O
electronic	O
and	O
paper	O
media	O
for	O
enhancing	O
the	O
network	O
reputation	O
as	O
""""	O
one	O
system	O
,	O
one	O
brand	O
and	O
quality	O
""""	O
•	O
differentiating	O
target	O
markets	O
of	O
the	O
network	O
for	O
competing	O
in	O
the	O
medical	O
industry	O
.	O

Financial	O
infrastructure	O
Comprehensive	O
,	O
flexible	O
,	O
and	O
adequate	O
financing	O
is	O
a	O
goal	O
of	O
the	O
ideal	O
continuum	O
of	O
care	O
.	O

That	O
component	O
is	O
the	O
most	O
critical	O
and	O
challenging	O
to	O
manage	O
under	O
the	O
changes	O
in	O
the	O
health	O
care	O
delivery	O
environment	O
.	O

Gillies	O
et	O
al.	O
[	O
30	O
]	O
suggested	O
that	O
integrating	O
financial	O
management	O
across	O
operating	O
units	O
adds	O
the	O
greatest	O
value	O
to	O
systems	O
or	O
organizations	O
.	O

In	O
one	O
case	O
study	O
,	O
Bramson	O
et	O
al.	O
[	O
55	O
]	O
also	O
showed	O
that	O
reducing	O
costs	O
through	O
joint	O
purchasing	O
by	O
the	O
radiology	O
departments	O
of	O
a	O
vertically	O
integrated	O
health	O
system	O
could	O
yield	O
substantial	O
savings	O
.	O

The	O
issues	O
of	O
the	O
financial	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
:	O
•	O
budgeting	O
•	O
uniting	O
equipment	O
,	O
medical	O
materials	O
,	O
and	O
drug	O
purchasing	O
and	O
routine	O
administrative	O
stuff	O
management	O
•	O
pooling	O
recruitment	O
funds	O
•	O
designing	O
a	O
financial	O
risk	O
and	O
sharing	O
mechanism	O
.	O

Information	O
infrastructure	O
Information	O
is	O
an	O
essential	O
component	O
of	O
an	O
organization	O
.	O

A	O
complete	O
information	O
system	O
can	O
help	O
an	O
organization	O
to	O
integrate	O
its	O
individual	O
units	O
and	O
efficiently	O
manage	O
the	O
continuum	O
.	O

The	O
ideal	O
information	O
system	O
for	O
a	O
continuum	O
of	O
care	O
was	O
conceived	O
of	O
and	O
formed	O
in	O
the	O
mid-1980s	O
[	O
56	O
]	O
.	O

During	O
the	O
late	O
1980s	O
,	O
computer	O
technology	O
began	O
to	O
make	O
an	O
information	O
system	O
feasible	O
and	O
affordable	O
through	O
new	O
computer	O
chips	O
with	O
expanded	O
capability	O
and	O
networking	O
technology	O
.	O

In	O
the	O
1990s	O
,	O
the	O
individual	O
services	O
of	O
the	O
continuum	O
upgraded	O
their	O
information	O
systems	O
to	O
combine	O
clinical	O
,	O
financial	O
,	O
and	O
utilization	O
data	O
[	O
29	O
]	O
.	O

Some	O
studies	O
have	O
argued	O
that	O
the	O
quality	O
of	O
information	O
systems	O
can	O
drive	O
costs	O
down	O
,	O
because	O
a	O
good	O
information	O
system	O
can	O
give	O
physicians	O
easy	O
electronic	O
access	O
to	O
complete	O
the	O
documentation	O
of	O
the	O
patients	O
'	O
clinical	O
records	O
,	O
better	O
inform	O
them	O
about	O
reimbursement	O
and	O
capitation	O
issues	O
,	O
help	O
them	O
easily	O
associate	O
and	O
manage	O
cases	O
together	O
,	O
and	O
achieve	O
a	O
higher	O
level	O
of	O
professional	O
satisfaction	O
[	O
57,58	O
]	O
.	O

Using	O
Inova	O
Health	O
System	O
,	O
an	O
integrated	O
delivery	O
system	O
in	O
northern	O
Virginia	O
,	O
as	O
an	O
example	O
,	O
Wager	O
,	O
Heda	O
,	O
and	O
Austin	O
[	O
59	O
]	O
showed	O
that	O
by	O
developing	O
a	O
health	O
information	O
network	O
within	O
an	O
integrated	O
delivery	O
system	O
,	O
Inova	O
can	O
have	O
a	O
clinical	O
transaction	O
system	O
for	O
hospitals	O
and	O
other	O
entities	O
,	O
a	O
data	O
repository	O
for	O
decision	O
support	O
and	O
outcome	O
management	O
,	O
a	O
managed	O
care	O
information	O
system	O
to	O
support	O
managed	O
care	O
and	O
capitation	O
contracts	O
,	O
and	O
greater	O
capability	O
to	O
acquire	O
physicians	O
.	O

The	O
issues	O
of	O
information	O
coordination	O
include	O
[	O
60	O
-	O
68	O
]	O
:	O
•	O
establishing	O
an	O
electronic	O
medical	O
record	O
system	O
,	O
regional	O
information	O
network	O
for	O
patient	O
clinical	O
and	O
administrative	O
data	O
,	O
clinical	O
service	O
arrangements	O
and	O
administrative	O
work	O
•	O
uniting	O
the	O
system	O
information	O
management	O
and	O
web	O
pages	O
.	O

The	O
structured	O
questionnaire	O
was	O
developed	O
with	O
the	O
wording	O
of	O
practical	O
managerial	O
actions	O
based	O
on	O
the	O
five	O
concepts	O
just	O
mentioned	O
.	O

There	O
were	O
19	O
survey	O
items	O
on	O
governance	O
infrastructure	O
,	O
25	O
on	O
clinical	O
infrastructure	O
,	O
13	O
on	O
marketing	O
infrastructure	O
,	O
20	O
on	O
financial	O
infrastructure	O
,	O
and	O
7	O
on	O
information	O
infrastructure	O
.	O

All	O
84	O
items	O
were	O
,	O
simultaneously	O
,	O
applied	O
to	O
examine	O
the	O
relationships	O
of	O
the	O
clinic	O
's	O
peer	O
members	O
and	O
the	O
relationship	O
of	O
clinic	O
and	O
hospital	O
members	O
in	O
a	O
PCCN	O
,	O
and	O
it	O
resulted	O
in	O
a	O
total	O
of	O
168	O
survey	O
questions	O
.	O

The	O
detailed	O
information	O
of	O
the	O
item	O
questions	O
was	O
listed	O
in	O
Table	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
.	O

The	O
structured	O
questionnaires	O
were	O
drafted	O
from	O
previous	O
literatures	O
and	O
then	O
examined	O
by	O
two	O
academic	O
professors	O
for	O
theoretical	O
accuracy	O
.	O

Then	O
one	O
pilot	O
study	O
was	O
pre	O
-	O
tested	O
for	O
the	O
PCCN	O
pioneers	O
(	O
i.e.	O
,	O
92	O
network	O
clinic	O
members	O
)	O
and	O
116	O
hospital	O
providers	O
which	O
have	O
partner	O
relationships	O
with	O
other	O
health	O
care	O
organizations	O
(	O
i.e.	O
,	O
hospitals	O
,	O
clinics	O
,	O
long	O
-	O
term	O
care	O
facilities	O
)	O
.	O

The	O
wordings	O
and	O
meanings	O
of	O
each	O
question	O
item	O
were	O
revised	O
to	O
assure	O
content	O
validity	O
.	O

The	O
Cronbach	O
α	O
values	O
for	O
the	O
five	O
integration	O
constructs	O
–	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
finance	O
,	O
and	O
information	O
infrastructure	O
were	O
0.946	O
,	O
0.958	O
,	O
0.932	O
,	O
0.944	O
,	O
and	O
0.898	O
for	O
the	O
measures	O
of	O
clinic	O
-	O
clinic	O
member	O
relationships	O
;	O
and	O
0.945	O
,	O
0.949	O
,	O
0.916	O
,	O
0.948	O
,	O
and	O
0.896	O
for	O
the	O
measures	O
of	O
clinic	O
-	O
hospital	O
member	O
relationships	O
.	O

Study	O
subjects	O
To	O
find	O
the	O
member	O
partnership	O
,	O
we	O
sent	O
questionnaires	O
to	O
1,557	O
individual	O
clinics	O
which	O
had	O
belonged	O
to	O
PCCNs	O
for	O
at	O
least	O
one	O
year	O
,	O
based	O
on	O
information	O
contained	O
in	O
the	O
Taiwan	O
Primary	O
Community	O
Care	O
Network	O
List	O
(	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
2003	O
,	O
2004	O
and	O
2005	O
)	O
.	O

We	O
let	O
clinic	O
members	O
in	O
all	O
PCCNs	O
point	O
out	O
how	O
they	O
coordinate	O
with	O
their	O
peer	O
clinic	O
members	O
and	O
hospital	O
members	O
within	O
a	O
PCCN	O
because	O
individual	O
clinic	O
members	O
could	O
be	O
better	O
informants	O
than	O
hospital	O
members	O
,	O
which	O
need	O
to	O
deal	O
with	O
multiple	O
clinic	O
relationships	O
and	O
therefore	O
might	O
find	O
it	O
hard	O
to	O
describe	O
the	O
coordination	O
involvement	O
one	O
by	O
one	O
with	O
clinic	O
members	O
.	O

Moreover	O
,	O
networks	O
form	O
for	O
various	O
reasons	O
and	O
it	O
might	O
lead	O
to	O
the	O
various	O
involvements	O
by	O
individual	O
network	O
members	O
(	O
i.e.	O
,	O
hospital	O
and	O
clinic	O
members	O
)	O
.	O

Therefore	O
,	O
using	O
the	O
participating	O
clinics	O
as	O
individual	O
survey	O
units	O
,	O
the	O
results	O
could	O
portray	O
the	O
overall	O
dynamics	O
and	O
processes	O
more	O
authentically	O
and	O
detailed	O
throughout	O
all	O
PCCNs	O
in	O
the	O
demonstration	O
project	O
.	O

Nine	O
hundred	O
and	O
twenty	O
-	O
eight	O
clinics	O
responded	O
(	O
59.6	O
%	O
)	O
,	O
with	O
239	O
clinics	O
in	O
the	O
Taipei	O
region	O
,	O
165	O
in	O
the	O
northern	O
region	O
,	O
241	O
in	O
the	O
central	O
region	O
,	O
108	O
in	O
the	O
southern	O
region	O
,	O
150	O
in	O
the	O
Kao	O
-	O
Ping	O
region	O
,	O
and	O
15	O
in	O
the	O
eastern	O
region	O
of	O
Taiwan	O
.	O

Ten	O
clinics	O
had	O
not	O
mentioned	O
their	O
practicing	O
locations	O
.	O

There	O
is	O
no	O
statistically	O
significant	O
difference	O
in	O
geographical	O
distribution	O
between	O
the	O
respondents	O
and	O
the	O
study	O
population	O
(	O
χ2	O
=	O
4.208	O
,	O
p	O
>	O
0.05	O
)	O
.	O

Analytical	O
techniques	O
The	O
data	O
was	O
first	O
analyzed	O
descriptively	O
with	O
frequency	O
counts	O
(	O
percentage	O
)	O
for	O
each	O
survey	O
item	O
,	O
instead	O
of	O
using	O
mean	O
as	O
a	O
statistical	O
method	O
,	O
because	O
the	O
variation	O
among	O
the	O
respondents	O
may	O
not	O
represent	O
the	O
normal	O
distribution	O
and	O
it	O
might	O
ignore	O
the	O
extreme	O
values	O
for	O
the	O
respondents	O
'	O
answers	O
.	O

To	O
compare	O
how	O
the	O
respondents	O
perceived	O
the	O
strength	O
of	O
integration	O
existing	O
in	O
clinic	O
-	O
clinic	O
and	O
clinic	O
-	O
hospital	O
relationships	O
,	O
paired	O
t	O
-	O
tests	O
were	O
performed	O
for	O
individual	O
survey	O
items	O
,	O
using	O
the	O
original	O
numerical	O
scores	O
.	O

Results	O
Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
governance	O
infrastructure	O
With	O
regard	O
to	O
the	O
governance	O
infrastructures	O
,	O
the	O
frequency	O
was	O
counted	O
for	O
each	O
survey	O
item	O
with	O
recalculated	O
scales	O
:	O
disagree	O
(	O
Likert	O
scale	O
1	O
and	O
2	O
)	O
,	O
fair	O
(	O
Likert	O
scale	O
3	O
)	O
,	O
and	O
agree	O
(	O
Likert	O
scale	O
4	O
and	O
5	O
)	O
with	O
individual	O
items	O
.	O

In	O
clinic	O
-	O
clinic	O
relationship	O
(	O
Table	O
2	O
)	O
,	O
the	O
majority	O
of	O
clinic	O
members	O
agree	O
that	O
the	O
determined	O
deals	O
were	O
obeyed	O
(	O
Table	O
2	O
,	O
item	O
1	O
:	O
88.69	O
%	O
)	O
,	O
the	O
goals	O
and	O
strategies	O
of	O
members	O
were	O
well	O
-	O
understood	O
(	O
Table	O
2	O
,	O
item	O
16	O
:	O
79.74	O
%	O
)	O
,	O
and	O
the	O
united	O
principals	O
for	O
individual	O
members	O
were	O
developed	O
(	O
Table	O
2	O
,	O
item	O
15	O
:	O
79.42	O
%	O
)	O
.	O

The	O
higher	O
percentages	O
were	O
also	O
found	O
in	O
clinic	O
-	O
hospital	O
relationship	O
in	O
the	O
same	O
items	O
(	O
Table	O
2	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
establishing	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
,	O
item	O
11	O
:	O
27.91	O
%	O
)	O
,	O
designing	O
and	O
employing	O
the	O
network	O
performance	O
indicators	O
(	O
Table	O
2	O
,	O
item	O
3	O
:	O
21.23	O
%	O
)	O
,	O
and	O
establishing	O
communication	O
models	O
and	O
channels	O
(	O
Table	O
2	O
,	O
item	O
12	O
:	O
19.94	O
%	O
)	O
still	O
occupied	O
higher	O
percentages	O
not	O
developed	O
and	O
deserved	O
to	O
been	O
made	O
the	O
focus	O
of	O
more	O
efforts	O
in	O
the	O
future	O
.	O

Paired	O
t	O
-	O
test	O
analyses	O
for	O
all	O
individual	O
survey	O
items	O
of	O
governance	O
infrastructure	O
showed	O
that	O
the	O
deals	O
obeyed	O
(	O
Table	O
2	O
,	O
item1	O
)	O
and	O
plans	O
and	O
goals	O
controlled	O
(	O
Table	O
2	O
,	O
item	O
2	O
)	O
were	O
achieved	O
more	O
in	O
clinic	O
-	O
clinic	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
hospital	O
relationships	O
;	O
however	O
,	O
the	O
design	O
of	O
network	O
performance	O
indicators	O
(	O
Table	O
2	O
,	O
item	O
3	O
)	O
,	O
development	O
of	O
disintegration	O
policy	O
and	O
principals	O
(	O
Table	O
2	O
,	O
item	O
8)	O
,	O
and	O
the	O
establishment	O
of	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
,	O
item	O
11	O
)	O
were	O
reached	O
more	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
clinic	O
relationships	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
clinical	O
infrastructure	O
Examining	O
the	O
extent	O
of	O
clinical	O
infrastructure	O
for	O
network	O
members	O
,	O
establishing	O
two	O
-	O
directed	O
patient	O
referral	O
systems	O
and	O
patient	O
referral	O
information	O
files	O
(	O
Table	O
3	O
,	O
items	O
35	O
&	O
37	O
)	O
and	O
uniting	O
medical	O
continuing	O
education	O
and	O
on	O
-	O
job	O
education	O
(	O
Table	O
3	O
,	O
item	O
34	O
)	O
were	O
shown	O
at	O
a	O
highly	O
implemented	O
rate	O
in	O
clinic	O
-	O
clinic	O
(	O
more	O
than	O
70	O
%	O
)	O
and	O
clinic	O
-	O
hospital	O
(	O
more	O
than	O
80	O
%	O
)	O
relationships	O
.	O

On	O
the	O
other	O
hand	O
,	O
network	O
members	O
had	O
higher	O
percentages	O
(	O
more	O
than	O
40	O
%	O
)	O
not	O
to	O
think	O
about	O
the	O
possible	O
integration	O
mechanisms	O
including	O
establishing	O
committees	O
to	O
deal	O
with	O
medical	O
malpractice	O
(	O
Table	O
3	O
,	O
item	O
44	O
)	O
,	O
planning	O
and	O
differentiating	O
clinical	O
market	O
areas	O
(	O
Table	O
3	O
,	O
item	O
20	O
)	O
,	O
and	O
designing	O
patient	O
-	O
centered	O
case	O
management	O
teams	O
(	O
Table	O
3	O
,	O
item	O
22	O
)	O
.	O

Overall	O
,	O
there	O
was	O
better	O
clinical	O
integration	O
involvement	O
for	O
all	O
the	O
described	O
items	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
clinic	O
relationships	O
within	O
a	O
network	O
in	O
this	O
study	O
(	O
see	O
Table	O
3	O
,	O
paired	O
t	O
-	O
tests	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
marketing	O
infrastructure	O
For	O
marketing	O
planning	O
,	O
the	O
clinics	O
had	O
better	O
integrated	O
marketing	O
activities	O
with	O
their	O
respective	O
hospitals	O
than	O
with	O
peer	O
clinic	O
members	O
within	O
PCCNs	O
for	O
all	O
studied	O
items	O
(	O
Table	O
4	O
,	O
paired	O
t	O
-	O
test	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Examining	O
the	O
clinic	O
-	O
clinic	O
relationships	O
,	O
uniting	O
social	O
activities	O
(	O
Table	O
4	O
,	O
item	O
53	O
)	O
,	O
sharing	O
the	O
individual	O
facility	O
reports	O
for	O
updated	O
services	O
(	O
Table	O
4	O
,	O
item	O
46	O
)	O
,	O
public	O
promotion	O
(	O
Table	O
4	O
,	O
item	O
54	O
)	O
,	O
and	O
uniting	O
and	O
joining	O
the	O
facility	O
activities	O
(	O
Table	O
4	O
,	O
item	O
51	O
)	O
were	O
the	O
top	O
four	O
marketing	O
works	O
done	O
among	O
clinic	O
members	O
(	O
more	O
than	O
60	O
%	O
implemented	O
rate	O
)	O
;	O
and	O
those	O
items	O
also	O
showed	O
a	O
higher	O
implemented	O
rate	O
(	O
more	O
than	O
70	O
%	O
)	O
between	O
clinic	O
and	O
hospital	O
members	O
.	O

On	O
the	O
other	O
hand	O
,	O
facility	O
assets	O
such	O
as	O
reports	O
(	O
Table	O
4	O
,	O
item	O
49	O
)	O
,	O
and	O
professional	O
literatures	O
and	O
books	O
(	O
Table	O
4	O
,	O
item	O
45	O
)	O
were	O
not	O
well	O
-	O
shared	O
among	O
clinic	O
members	O
(	O
""""	O
never	O
-	O
thinking	O
""""	O
rate	O
:	O
42.13	O
%	O
)	O
.	O

In	O
addition	O
,	O
uniting	O
the	O
network	O
publication	O
could	O
make	O
more	O
efforts	O
in	O
the	O
future	O
(	O
""""	O
never	O
-	O
thinking	O
""""	O
rate	O
in	O
item	O
50	O
:	O
39.98	O
%	O
)	O
.	O

The	O
room	O
for	O
clinic	O
-	O
hospital	O
partnership	O
to	O
think	O
about	O
acting	O
was	O
kind	O
of	O
different	O
from	O
those	O
in	O
the	O
clinic	O
-	O
clinic	O
relationship	O
.	O

In	O
addition	O
to	O
the	O
uniting	O
publication	O
that	O
can	O
be	O
encouraged	O
to	O
improve	O
the	O
clinic	O
-	O
hospital	O
relationship	O
(	O
Table	O
4	O
,	O
item	O
50	O
:	O
27.48	O
%	O
)	O
,	O
cooperating	O
in	O
research	O
projects	O
(	O
Table	O
4	O
,	O
item	O
52	O
:	O
25.00	O
%	O
)	O
and	O
identifying	O
and	O
differentiating	O
target	O
markets	O
(	O
Table	O
4	O
,	O
item	O
57	O
:	O
24.57	O
%	O
)	O
had	O
still	O
more	O
opportunities	O
to	O
be	O
focused	O
on	O
in	O
the	O
future	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
financial	O
infrastructure	O
The	O
PCCN	O
members	O
were	O
found	O
to	O
have	O
a	O
lower	O
extent	O
of	O
financial	O
integration	O
as	O
evidenced	O
by	O
higher	O
percentage	O
of	O
'	O
'	O
never	O
thinking	O
'	O
'	O
scale	O
about	O
the	O
survey	O
items	O
on	O
almost	O
all	O
items	O
(	O
see	O
Table	O
5	O
)	O
.	O

Slightly	O
more	O
integration	O
(	O
that	O
is	O
,	O
'	O
'	O
acting	O
'	O
'	O
rate	O
)	O
was	O
found	O
in	O
only	O
four	O
items	O
both	O
in	O
clinic	O
-	O
clinic	O
relationships	O
and	O
in	O
clinic	O
-	O
hospital	O
relationships	O
,	O
including	O
uniting	O
budget	O
planning	O
(	O
Table	O
5	O
:	O
item	O
58	O
)	O
,	O
sharing	O
places	O
,	O
materials	O
,	O
and	O
equipment	O
(	O
Table	O
5	O
:	O
item	O
68	O
)	O
,	O
uniting	O
budgeting	O
for	O
certain	O
services	O
(	O
Table	O
5	O
:	O
items	O
72	O
)	O
,	O
and	O
designing	O
the	O
resource	O
distribution	O
principals	O
based	O
on	O
the	O
whole	O
network	O
goals	O
(	O
Table	O
5	O
:	O
item	O
77	O
)	O
.	O

Further	O
examining	O
the	O
financial	O
infrastructure	O
in	O
clinic	O
-	O
clinic	O
relationship	O
and	O
clinic	O
-	O
hospital	O
relationship	O
,	O
paired	O
-	O
t	O
tests	O
revealed	O
that	O
clinic	O
-	O
hospital	O
partnerships	O
were	O
involved	O
more	O
in	O
places	O
,	O
materials	O
,	O
and	O
equipment	O
sharing	O
and	O
maintenance	O
(	O
Table	O
5	O
,	O
items	O
62	O
and	O
68	O
)	O
(	O
p	O
<	O
0.05	O
)	O
and	O
higher	O
financial	O
infrastructure	O
coordination	O
exists	O
in	O
clinic	O
-	O
clinic	O
relationships	O
(	O
Table	O
5	O
,	O
items	O
58	O
,	O
59	O
,	O
63–65	O
,	O
72	O
,	O
74	O
,	O
75	O
,	O
and	O
77	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
information	O
infrastructure	O
There	O
was	O
significantly	O
greater	O
integration	O
of	O
information	O
in	O
clinic	O
-	O
hospital	O
than	O
clinic	O
-	O
clinic	O
relationships	O
in	O
all	O
items	O
in	O
this	O
category	O
(	O
Table	O
6	O
,	O
paired	O
t	O
-	O
tests	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
greatest	O
integration	O
was	O
found	O
in	O
electronic	O
patient	O
records	O
(	O
Table	O
6	O
:	O
item	O
78	O
)	O
,	O
followed	O
by	O
information	O
integration	O
for	O
patient	O
data	O
(	O
Table	O
6	O
:	O
item	O
79	O
)	O
and	O
clinical	O
service	O
arrangements	O
(	O
Table	O
6	O
:	O
item	O
81	O
)	O
.	O

The	O
lowest	O
level	O
of	O
integration	O
in	O
information	O
infrastructure	O
was	O
found	O
in	O
administrative	O
works	O
such	O
as	O
registration	O
,	O
billing	O
and	O
so	O
on	O
(	O
Table	O
6	O
:	O
item	O
82	O
,	O
'	O
'	O
never	O
-	O
thinking	O
'	O
'	O
rate	O
more	O
than	O
50	O
%	O
)	O
within	O
network	O
members	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
we	O
surveyed	O
943	O
clinics	O
that	O
had	O
belonged	O
to	O
Taiwan	O
PCCNs	O
for	O
more	O
than	O
a	O
year	O
to	O
understand	O
the	O
nature	O
and	O
extent	O
of	O
integration	O
to	O
which	O
they	O
and	O
their	O
associated	O
PCCN	O
members	O
(	O
clinics	O
and	O
hospitals	O
)	O
had	O
in	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
.	O

It	O
was	O
found	O
a	O
wide	O
variance	O
in	O
the	O
kind	O
and	O
degree	O
of	O
integration	O
among	O
them	O
and	O
a	O
lot	O
of	O
room	O
for	O
better	O
integration	O
(	O
Table	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
)	O
.	O

From	O
the	O
governance	O
perspective	O
,	O
we	O
found	O
lower	O
integration	O
was	O
found	O
in	O
the	O
establishment	O
of	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
:	O
item	O
11	O
)	O
among	O
member	O
clinics	O
and	O
member	O
hospitals	O
.	O

Coordination	O
could	O
be	O
viewed	O
from	O
different	O
perspectives	O
,	O
including	O
the	O
use	O
of	O
standardized	O
languages	O
and	O
forms	O
,	O
organizational	O
rules	O
and	O
procedures	O
,	O
the	O
establishment	O
of	O
common	O
rules	O
,	O
policies	O
,	O
and	O
procedures	O
,	O
and	O
the	O
monitoring	O
through	O
memos	O
,	O
reports	O
,	O
and	O
a	O
computerized	O
information	O
system	O
[	O
69,70	O
]	O
.	O

Facing	O
the	O
cumbersome	O
integration	O
processes	O
,	O
it	O
suggests	O
that	O
each	O
PCCN	O
's	O
headquarters	O
should	O
become	O
actively	O
involved	O
and	O
clarify	O
the	O
authority	O
,	O
responsibility	O
and	O
accountability	O
of	O
individual	O
members	O
,	O
identify	O
the	O
potential	O
conflict	O
sources	O
,	O
and	O
publicize	O
the	O
rules	O
and	O
regulation	O
of	O
network	O
integration	O
dynamics	O
covering	O
decision	O
making	O
processes	O
,	O
market	O
planning	O
,	O
clinical	O
teamwork	O
designs	O
,	O
and	O
financial	O
reports	O
of	O
individual	O
network	O
members	O
.	O

These	O
actions	O
could	O
enhance	O
the	O
trust	O
and	O
respect	O
of	O
network	O
members	O
one	O
another	O
and	O
could	O
improve	O
the	O
small	O
extent	O
of	O
integration	O
found	O
in	O
this	O
study	O
about	O
the	O
mechanisms	O
for	O
communication	O
models	O
and	O
channels	O
in	O
the	O
PCCNs	O
(	O
Table	O
2	O
:	O
item	O
12	O
)	O
.	O

From	O
the	O
network	O
management	O
perspective	O
,	O
communication	O
could	O
occur	O
between	O
the	O
various	O
entities	O
such	O
as	O
between	O
hospital	O
and	O
clinics	O
,	O
primary	O
care	O
physicians	O
and	O
specialists	O
,	O
managers	O
and	O
clinical	O
professionals	O
,	O
and	O
even	O
among	O
the	O
clinical	O
professionals	O
in	O
the	O
network	O
.	O

To	O
develop	O
effective	O
and	O
timely	O
communication	O
channels	O
was	O
the	O
key	O
for	O
the	O
management	O
of	O
integrated	O
organizations	O
[	O
30	O
-	O
32	O
]	O
and	O
could	O
alleviate	O
the	O
tensions	O
that	O
sometimes	O
occur	O
in	O
the	O
dynamics	O
of	O
the	O
multi	O
-	O
organizations	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
found	O
a	O
low	O
level	O
of	O
involvement	O
of	O
medical	O
teams	O
in	O
medical	O
projects	O
,	O
patient	O
-	O
centered	O
case	O
management	O
,	O
and	O
case	O
report	O
meetings	O
among	O
the	O
network	O
members	O
(	O
Table	O
3	O
:	O
item	O
21	O
,	O
22	O
,	O
and	O
23	O
)	O
from	O
a	O
clinical	O
integration	O
perspective	O
.	O

Several	O
researchers	O
have	O
addressed	O
that	O
clinical	O
integration	O
providing	O
a	O
process	O
of	O
medical	O
management	O
,	O
care	O
management	O
,	O
case	O
management	O
,	O
and	O
patient	O
management	O
designed	O
to	O
transform	O
the	O
traditionally	O
fragmented	O
delivery	O
system	O
into	O
a	O
more	O
cohesive	O
system	O
[	O
71	O
]	O
,	O
and	O
lead	O
to	O
higher	O
service	O
quality	O
and	O
assure	O
financial	O
objectives	O
[	O
72,73	O
]	O
.	O

More	O
attention	O
could	O
be	O
paid	O
to	O
these	O
activities	O
in	O
the	O
future	O
.	O

In	O
addition	O
,	O
it	O
was	O
also	O
found	O
less	O
integration	O
in	O
planning	O
and	O
differentiating	O
clinical	O
market	O
areas	O
(	O
Table	O
3	O
,	O
item	O
20	O
)	O
among	O
the	O
network	O
members	O
in	O
the	O
category	O
of	O
clinical	O
infrastructure	O
.	O

This	O
may	O
result	O
from	O
the	O
existing	O
specialty	O
diversities	O
in	O
individual	O
PCCNs	O
,	O
which	O
might	O
not	O
need	O
to	O
involve	O
planning	O
and	O
differentiating	O
market	O
area	O
based	O
on	O
the	O
members	O
'	O
clinical	O
services	O
at	O
the	O
early	O
stage	O
of	O
network	O
development	O
.	O

There	O
was	O
more	O
involvement	O
in	O
marketing	O
efforts	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
in	O
clinic	O
-	O
clinic	O
relationships	O
.	O

Generally	O
speaking	O
,	O
hospitals	O
have	O
more	O
resources	O
(	O
i.e.	O
,	O
money	O
,	O
human	B
resources	O
,	O
materials	O
,	O
and	O
physical	O
assets	O
)	O
than	O
clinics	O
,	O
which	O
might	O
explain	O
the	O
stronger	O
marketing	O
involvements	O
between	O
the	O
clinic	O
and	O
hospital	O
members	O
,	O
including	O
the	O
library	O
sharing	O
(	O
books	O
and	O
literatures	O
)	O
,	O
facility	O
brochure	O
dissemination	O
,	O
public	O
promoting	O
,	O
and	O
medical	O
research	O
cooperation	O
.	O

These	O
integration	O
efforts	O
also	O
meet	O
the	O
expectation	O
of	O
the	O
national	O
health	O
authority	O
for	O
resource	O
sharing	O
and	O
medical	O
quality	O
image	O
enhancement	O
among	O
the	O
health	O
care	O
providers	O
.	O

Financial	O
infrastructure	O
was	O
found	O
to	O
be	O
the	O
least	O
integrated	O
,	O
with	O
most	O
items	O
never	O
considered	O
.	O

Perhaps	O
the	O
only	O
reason	O
for	O
the	O
higher	O
score	O
of	O
budget	O
planning	O
activities	O
(	O
Table	O
5	O
:	O
items	O
58	O
and	O
77	O
)	O
was	O
that	O
BHNI	O
required	O
each	O
PCCN	O
to	O
design	O
and	O
determine	O
its	O
budgeting	O
arrangement	O
in	O
advance	O
before	O
joining	O
the	O
demonstration	O
project	O
.	O

While	O
slightly	O
more	O
financial	O
involvement	O
was	O
made	O
among	O
network	O
members	O
(	O
Table	O
5	O
:	O
items	O
68	O
,	O
72	O
&	O
73	O
)	O
,	O
possibly	O
due	O
to	O
similar	O
needs	O
,	O
there	O
remains	O
a	O
lot	O
of	O
room	O
for	O
financial	O
integration	O
in	O
the	O
future	O
.	O

There	O
was	O
a	O
need	O
for	O
networks	O
to	O
develop	O
electronic	O
information	O
systems	O
,	O
though	O
creating	O
and	O
managing	O
an	O
integrated	O
information	O
system	O
involves	O
very	O
detailed	O
work	O
.	O

Most	O
of	O
the	O
clinics	O
surveyed	O
have	O
focused	O
more	O
on	O
the	O
individual	O
public	O
members	O
'	O
administrative	O
works	O
such	O
as	O
filing	O
patient	O
medical	O
records	O
,	O
collecting	O
and	O
managing	O
network	O
patient	O
clinical	O
data	O
,	O
and	O
scheduling	O
clinical	O
services	O
,	O
which	O
were	O
required	O
by	O
the	O
BNHI	O
.	O

The	O
factors	O
for	O
the	O
health	O
care	O
managers	O
to	O
adopt	O
the	O
integrated	O
clinical	O
information	O
systems	O
include	O
the	O
decision	O
of	O
make	O
or	O
buy	O
,	O
adoption	O
leadership	O
,	O
adoption	O
objectives	O
,	O
implementation	O
leadership	O
,	O
phased	O
versus	O
simultaneous	O
implementation	O
,	O
parallel	O
systems	O
,	O
information	O
technology	O
implementation	O
policies	O
and	O
practices	O
,	O
use	O
levels	O
and	O
resistance	O
,	O
and	O
realized	O
benefits	O
and	O
return	O
on	O
investment	O
calculation	O
[	O
66	O
]	O
,	O
which	O
might	O
be	O
very	O
cumbersome	O
and	O
time	O
-	O
consuming	O
.	O

It	O
suggests	O
that	O
the	O
network	O
partners	O
might	O
be	O
engaged	O
,	O
firstly	O
,	O
more	O
in	O
simpler	O
network	O
cooperation	O
such	O
as	O
the	O
administrative	O
systems	O
for	O
patient	O
admission	O
to	O
the	O
network	O
members	O
and	O
establishing	O
united	O
web	O
pages	O
for	O
patients	O
to	O
access	O
their	O
family	O
physicians	O
and	O
network	O
members	O
for	O
medical	O
and	O
public	O
promotion	O
purposes	O
.	O

And	O
for	O
further	O
integrated	O
information	O
investments	O
,	O
efforts	O
must	O
be	O
redirected	O
for	O
network	O
members	O
to	O
work	O
together	O
to	O
define	O
the	O
approach	O
to	O
specific	O
classes	O
of	O
integration	O
for	O
the	O
long	O
term	O
[	O
74	O
]	O
.	O

Conclusion	O
This	O
study	O
tried	O
to	O
portray	O
and	O
trace	O
how	O
the	O
facility	O
participants	O
were	O
involved	O
in	O
the	O
Taiwan	O
PCCNs	O
.	O

It	O
was	O
found	O
that	O
Taiwan	O
PCCNs	O
'	O
members	O
had	O
higher	O
involvement	O
in	O
the	O
governance	O
infrastructure	O
,	O
which	O
was	O
usually	O
viewed	O
as	O
the	O
most	O
important	O
for	O
establishment	O
of	O
core	O
values	O
in	O
PCCNs	O
'	O
organization	O
design	O
and	O
management	O
.	O

There	O
existed	O
a	O
higher	O
extent	O
of	O
integration	O
of	O
clinical	O
,	O
marketing	O
,	O
and	O
information	O
infrastructures	O
among	O
the	O
hospital	O
-	O
clinic	O
member	O
relationship	O
than	O
those	O
among	O
clinic	O
members	O
within	O
individual	O
PCCNs	O
.	O

The	O
financial	O
infrastructure	O
was	O
shown	O
the	O
least	O
integrated	O
relative	O
to	O
other	O
functional	O
infrastructures	O
at	O
the	O
early	O
stage	O
of	O
PCCN	O
formation	O
.	O

Page	O
[	O
43	O
]	O
argued	O
that	O
networks	O
form	O
and	O
grow	O
for	O
various	O
reasons	O
,	O
however	O
,	O
only	O
some	O
of	O
them	O
could	O
be	O
compatible	O
with	O
the	O
iterative	O
processes	O
of	O
collaboration	O
.	O

Some	O
participants	O
in	O
the	O
PCCNs	O
may	O
simply	O
seek	O
short	O
-	O
term	O
economic	O
gains	O
and	O
have	O
little	O
interest	O
in	O
joint	O
learning	O
and	O
continuous	O
improvement	O
.	O

From	O
an	O
organizational	O
design	O
perspective	O
,	O
the	O
old	O
phrase	O
proposed	O
by	O
the	O
wisdom	O
of	O
the	O
saying	O
about	O
developing	O
the	O
integrated	O
organizations	O
(	O
networks	O
)	O
should	O
be	O
–	O
""""	O
coming	O
together	O
is	O
the	O
beginning	O
,	O
and	O
working	O
together	O
is	O
the	O
success	O
.	O
""""	O

Page	O
[	O
43	O
]	O
examined	O
the	O
virtual	O
provider	O
organizations	O
such	O
as	O
physician	O
-	O
hospital	O
organizations	O
and	O
pointed	O
out	O
the	O
issue	O
of	O
the	O
provider	O
attitudes	O
and	O
behaviors	O
as	O
the	O
critically	O
successful	O
continuous	O
improvements	O
in	O
the	O
health	O
care	O
environments	O
.	O

A	O
wide	O
variance	O
of	O
degree	O
of	O
network	O
integration	O
in	O
Taiwan	O
PCCNs	O
still	O
leaves	O
room	O
to	O
improve	O
.	O

In	O
this	O
study	O
,	O
the	O
thoroughly	O
surveyed	O
items	O
,	O
that	O
is	O
,	O
the	O
potential	O
network	O
design	O
content	O
,	O
were	O
employed	O
.	O

In	O
addition	O
to	O
provide	O
how	O
the	O
network	O
members	O
have	O
done	O
their	O
initial	O
work	O
at	O
the	O
early	O
stage	O
of	O
network	O
forming	O
in	O
this	O
study	O
,	O
the	O
detailed	O
surveyed	O
items	O
,	O
the	O
concepts	O
proposed	O
by	O
the	O
managerial	O
and	O
theoretical	O
professionals	O
,	O
could	O
be	O
also	O
a	O
guide	O
for	O
those	O
health	O
care	O
providers	O
who	O
have	O
a	O
willingness	O
to	O
join	O
multi	O
-	O
organizations	O
.	O

It	O
suggests	O
that	O
health	O
care	O
providers	O
could	O
take	O
more	O
detailed	O
looks	O
about	O
those	O
surveyed	O
items	O
and	O
give	O
some	O
possible	O
opportunities	O
to	O
create	O
the	O
potential	O
actions	O
.	O

Further	O
research	O
could	O
be	O
empirically	O
done	O
to	O
explore	O
the	O
relative	O
influence	O
of	O
these	O
integration	O
mechanisms	O
on	O
the	O
effectiveness	O
of	O
organizational	O
partnerships	O
.	O

The	O
partnerships	O
within	O
each	O
PCCN	O
represent	O
various	O
relationships	O
that	O
depend	O
on	O
how	O
much	O
the	O
members	O
are	O
engaged	O
in	O
the	O
projects	O
.	O

In	O
addition	O
to	O
the	O
macro	O
concepts	O
including	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
explored	O
in	O
this	O
study	O
,	O
other	O
managerial	O
issues	O
for	O
integrated	O
organizations	O
were	O
also	O
suggested	O
such	O
as	O
formation	O
of	O
an	O
integrated	O
cultural	O
atmosphere	O
,	O
human	B
resources	O
management	O
,	O
physician	O
involvement	O
,	O
mission	O
and	O
commitment	O
establishment	O
,	O
from	O
micro	O
organizational	O
behavior	O
perspective	O
[	O
30	O
-	O
32,34,36,75,76	O
]	O
.	O

Micro	O
managerial	O
and	O
longitudinal	O
research	O
designs	O
could	O
be	O
employed	O
to	O
more	O
precisely	O
catch	O
the	O
never	O
completing	O
integration	O
efforts	O
in	O
the	O
future	O
.	O

Abbreviations	O
primary	O
community	O
care	O
network	O
(	O
PCCN	O
)	O
;	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
BYJL	O
independently	O
designed	O
and	O
conducted	O
this	O
study	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Recombinant	O
activated	O
protein	O
C	O
in	O
sepsis	O
:	O
endothelium	O
protection	O
or	O
endothelium	O
therapy	O
?	O

Abstract	O
Endothelium	O
dysfunction	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
sepsis	O
.	O

Looney	O
and	O
Mattay	O
,	O
in	O
the	O
previous	O
issue	O
of	O
Critical	O
Care	O
,	O
highlight	O
the	O
role	O
of	O
activated	O
protein	O
C	O
(	O
APC	O
)	O
as	O
a	O
protective	O
endothelial	O
drug	O
in	O
septic	O
situations	O
.	O

Nevertheless	O
,	O
the	O
results	O
of	O
in	O
vivo	O
studies	O
are	O
less	O
explicit	O
and	O
it	O
remains	O
uncertain	O
whether	O
these	O
properties	O
are	O
relevant	O
in	O
human	B
septic	O
shock	O
.	O

Before	O
considering	O
recombinant	O
APC	O
(	O
rAPC	O
)	O
as	O
a	O
therapeutic	O
drug	O
for	O
the	O
endothelium	O
,	O
we	O
have	O
to	O
demonstrate	O
its	O
efficiency	O
to	O
protect	O
or	O
to	O
reduce	O
endothelium	O
injury	O
when	O
infused	O
a	O
long	O
time	O
after	O
the	O
septic	O
challenge	O
.	O

Nevertheless	O
,	O
if	O
rAPC	O
is	O
efficient	O
when	O
infused	O
in	O
the	O
early	O
phase	O
of	O
septic	O
challenge	O
,	O
we	O
thus	O
need	O
to	O
treat	O
our	O
patients	O
earlier	O
.	O

At	O
the	O
least	O
,	O
genetically	O
engineered	O
variants	O
have	O
been	O
designed	O
with	O
greater	O
anti	O
-	O
apoptotic	O
activity	O
and	O
reduced	O
anticoagulant	O
activity	O
relative	O
to	O
wild	O
-	O
type	O
APC	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
demonstrate	O
the	O
usefulness	O
of	O
these	O
variants	O
in	O
septic	O
shock	O
therapy	O
.	O

The	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
(	O
rAPC	O
)	O
is	O
one	O
of	O
the	O
hottest	O
topics	O
in	O
septic	O
shock	O
therapy	O
.	O

The	O
pivotal	O
phase	O
3	O
placebo	O
-	O
controlled	O
Protein	O
C	O
Worldwide	O
Evaluation	O
in	O
Severe	O
Sepsis	O
(	O
PROWESS	O
)	O
clinical	O
trial	O
demonstrated	O
a	O
19.4	O
%	O
relative	O
risk	O
reduction	O
in	O
28-day	O
mortality	O
(	O
6.1	O
%	O
absolute	O
risk	O
reduction	O
)	O
with	O
an	O
increased	O
risk	O
(	O
3.5	O
%	O
versus	O
2.0	O
%	O
)	O
of	O
serious	O
bleeding	O
events	O
compared	O
with	O
placebo	O
.	O

Two	O
recent	O
and	O
important	O
articles	O
have	O
highlighted	O
the	O
role	O
of	O
APC	O
as	O
a	O
protective	O
endothelial	O
drug	O
[	O
1	O
]	O
and	O
as	O
a	O
cyto	O
-	O
protective	O
drug	O
[	O
2	O
]	O
.	O

Beneficial	O
effects	O
of	O
rAPC	O
in	O
the	O
PROWESS	O
study	O
were	O
thought	O
to	O
be	O
related	O
to	O
a	O
reduction	O
in	O
coagulation	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
a	O
reduction	O
in	O
inflammatory	O
response	O
to	O
sepsis	O
[	O
3	O
]	O
.	O

Post	O
-	O
PROWESS	O
investigations	O
have	O
been	O
associated	O
with	O
a	O
myriad	O
of	O
cellular	O
or	O
animal	O
studies	O
demonstrating	O
that	O
rAPC	O
,	O
through	O
reactions	O
mediated	O
by	O
endothelial	O
protein	O
C	O
receptor	O
and	O
the	O
effector	O
receptor	O
,	O
protease	O
activated	O
receptor-1	O
,	O
acts	O
directly	O
on	O
cells	O
to	O
exert	O
multiple	O
cytoprotective	O
effects	O
including	O
:	O
down	O
regulation	O
of	O
pro	O
-	O
inflammatory	O
gene	O
expression	O
[	O
4	O
]	O
;	O
anti	O
-	O
inflammatory	O
activities	O
[	O
5	O
]	O
;	O
anti	O
-	O
apoptotic	O
activity	O
[	O
6	O
]	O
;	O
and	O
protection	O
of	O
endothelial	O
barrier	O
function	O
[	O
1,2	O
]	O
.	O

Endothelium	O
dysfunction	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
sepsis	O
[	O
7	O
]	O
.	O

Sepsis	O
,	O
per	O
se	O
,	O
may	O
induce	O
phenotypic	O
modulations	O
of	O
the	O
endothelium	O
through	O
direct	O
or	O
indirect	O
interaction	O
of	O
the	O
endothelial	O
layer	O
with	O
components	O
of	O
the	O
bacterial	O
wall	O
,	O
inducing	O
a	O
myriad	O
of	O
host	O
-	O
derived	O
factors	O
from	O
endothelial	O
cells	O
.	O

Phenotypic	O
modifications	O
include	O
changes	O
in	O
pro	O
-	O
coagulant	O
and	O
proadhesive	O
properties	O
,	O
increased	O
endothelial	O
permeability	O
,	O
endothelial	O
cell	O
apoptosis	O
and	O
changes	O
in	O
vasomotor	O
properties	O
;	O
the	O
last	O
of	O
these	O
is	O
crucial	O
since	O
vasoplegia	O
is	O
directly	O
related	O
to	O
septic	O
shock	O
mortality	O
.	O

Recent	O
animal	O
and	O
human	B
data	O
have	O
suggested	O
that	O
rAPC	O
may	O
improve	O
both	O
vascular	O
and	O
myocardial	O
dysfunction	O
and	O
vascular	O
reactivity	O
to	O
catecholamine	O
during	O
endotoxin	O
and/or	O
septic	O
challenge	O
[	O
8,9	O
]	O
.	O

From	O
bench	O
to	O
bedside	O
Experimental	O
evidence	O
supports	O
a	O
role	O
of	O
APC	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
endothelium	O
through	O
both	O
direct	O
and	O
indirect	O
mechanisms	O
.	O

Nevertheless	O
,	O
the	O
results	O
of	O
in	O
vivo	O
studies	O
are	O
less	O
explicit	O
.	O

In	O
a	O
retrospective	O
study	O
of	O
septic	O
shock	O
in	O
humans	B
,	O
Monnet	O
and	O
colleagues	O
[	O
9	O
]	O
demonstrated	O
that	O
APC	O
infusion	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
delivered	O
norepinephrine	O
.	O

Wiel	O
and	O
colleagues	O
[	O
10	O
]	O
demonstrated	O
in	O
a	O
rabbit	B
model	O
of	O
endotoxin	O
induced	O
shock	O
that	O
APC	O
decreased	O
aorta	O
endothelial	O
injury	O
.	O

By	O
contrast	O
,	O
in	O
a	O
lung	O
model	O
of	O
endotoxin	O
induced	O
inflammation	O
,	O
Robriquet	O
and	O
colleagues	O
[	O
11	O
]	O
demonstrated	O
a	O
trend	O
to	O
an	O
increased	O
vascular	O
permeability	O
using	O
high	O
doses	O
of	O
human	B
APC	O
.	O

This	O
last	O
result	O
was	O
in	O
sharp	O
contrast	O
with	O
the	O
results	O
obtained	O
by	O
Nick	O
and	O
colleagues	O
[	O
12	O
]	O
in	O
a	O
human	B
model	O
of	O
pulmonary	O
endotoxin	O
administration	O
.	O

APC	O
appears	O
to	O
improve	O
mortality	O
in	O
septic	O
shock	O
with	O
a	O
high	O
APACHE	O
2	O
score	O
and	O
is	O
potentially	O
detrimental	O
in	O
severe	O
sepsis	O
.	O

In	O
rats	O
,	O
APC	O
markedly	O
decreased	O
tumour	O
necrosis	O
factor	O
concentrations	O
whereas	O
they	O
remained	O
unchanged	O
in	O
either	O
human	B
septic	O
shock	O
or	O
endotoxemia	O
.	O

The	O
question	O
arises	O
,	O
therefore	O
,	O
as	O
to	O
whether	O
it	O
is	O
truly	O
possible	O
to	O
reconcile	O
all	O
these	O
discrepancies	O
?	O

Moreover	O
,	O
can	O
these	O
stirring	O
laboratory	O
data	O
be	O
translated	O
into	O
clinical	O
practice	O
?	O

Limitations	O
of	O
experimental	O
studies	O
:	O
endothelium	O
protection	O
versus	O
endothelium	O
therapy	O
Clearly	O
,	O
in	O
cellular	O
and	O
animal	O
models	O
,	O
rAPC	O
has	O
been	O
given	O
either	O
as	O
a	O
pre	O
-	O
treatment	O
or	O
concurrent	O
with	O
septic	O
challenge	O
.	O

This	O
mode	O
of	O
administration	O
favours	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
rAPC	O
,	O
which	O
are	O
particularly	O
efficient	O
in	O
murine	O
models	O
in	O
protecting	O
the	O
endothelium	O
from	O
cytokine	O
-	O
mediated	O
apoptosis	O
or	O
upregulation	O
of	O
endothelial	O
adhesion	O
molecules	O
.	O

Thus	O
,	O
studies	O
using	O
post	O
-	O
injury	O
treatment	O
are	O
needed	O
in	O
models	O
that	O
mimic	O
septic	O
shock	O
,	O
such	O
as	O
experimental	O
pneumonia	O
or	O
peritonitis	O
treated	O
by	O
antibiotics	O
and	O
volume	O
resuscitation	O
,	O
and	O
where	O
the	O
effects	O
of	O
rAPC	O
would	O
be	O
investigated	O
16	O
to	O
24	O
hours	O
after	O
septic	O
challenge	O
.	O

If	O
we	O
can	O
demonstrate	O
the	O
efficiency	O
of	O
rAPC	O
to	O
protect	O
or	O
to	O
reduce	O
endothelium	O
injury	O
in	O
these	O
conditions	O
,	O
we	O
can	O
ultimately	O
postulate	O
that	O
rAPC	O
is	O
also	O
a	O
therapeutic	O
drug	O
for	O
the	O
endothelium	O
.	O

The	O
earlier	O
the	O
better	O
If	O
rAPC	O
is	O
efficient	O
when	O
infused	O
in	O
the	O
early	O
phase	O
of	O
septic	O
challenge	O
,	O
we	O
thus	O
need	O
to	O
treat	O
our	O
patients	O
earlier	O
.	O

At	O
least	O
two	O
studies	O
suggest	O
that	O
treatment	O
with	O
rAPC	O
within	O
24	O
hours	O
may	O
carry	O
a	O
larger	O
survival	O
advantage	O
for	O
patients	O
with	O
severe	O
sepsis	O
,	O
compared	O
with	O
those	O
treated	O
more	O
than	O
24	O
hours	O
after	O
organ	O
dysfunction	O
[	O
13	O
]	O
.	O

Interventions	O
directed	O
at	O
specific	O
endpoints	O
,	O
when	O
initiated	O
early	O
in	O
the	O
'	O
golden	O
hours	O
'	O
of	O
a	O
patient	O
's	O
condition	O
,	O
seem	O
to	O
be	O
promising	O
[	O
14	O
]	O
.	O

The	O
beneficial	O
effects	O
of	O
earlier	O
administration	O
of	O
rAPC	O
to	O
appropriate	O
patients	O
may	O
fit	O
into	O
this	O
paradigm	O
.	O

The	O
future	O
Extensive	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
focused	O
on	O
the	O
cytoprotective	O
effects	O
of	O
APC	O
and	O
most	O
authors	O
agree	O
that	O
its	O
anticoagulant	O
and	O
cytoprotective	O
effects	O
are	O
mediated	O
by	O
distinct	O
APC	O
structural	O
features	O
.	O

Positively	O
charged	O
residues	O
in	O
surface	O
loops	O
in	O
the	O
APC	O
protease	O
domain	O
have	O
been	O
identified	O
as	O
participating	O
in	O
the	O
anticoagulant	O
activity	O
but	O
not	O
in	O
cellular	O
effects	O
.	O

Hence	O
,	O
variants	O
have	O
been	O
designed	O
with	O
greater	O
anti	O
-	O
apoptotic	O
activity	O
and	O
reduced	O
anticoagulant	O
activity	O
relative	O
to	O
wild	O
-	O
type	O
APC	O
[	O
2	O
]	O
.	O

Whether	O
these	O
genetically	O
engineered	O
variants	O
actually	O
provide	O
superior	O
pharmacological	O
properties	O
remains	O
to	O
be	O
elucidated	O
in	O
vivo	O
.	O

Such	O
investigations	O
may	O
allow	O
the	O
design	O
of	O
therapeutic	O
APC	O
variants	O
with	O
decreased	O
anticoagulant	O
activity	O
to	O
reduce	O
the	O
risk	O
of	O
bleeding	O
on	O
the	O
one	O
hand	O
,	O
but	O
also	O
with	O
normal	O
cytoprotective	O
properties	O
in	O
order	O
to	O
retain	O
full	O
beneficial	O
effects	O
on	O
sepsis	O
outcome	O
.	O

Abbreviations	O
PROWESS	O
=	O
Protein	O
C	O
Worldwide	O
Evaluation	O
in	O
Severe	O
Sepsis	O
;	O
rAPC	O
=	O
recombinant	O
activated	O
protein	O
C.	O
Competing	O
interests	O
BL	O
has	O
received	O
reimbursements	O
and	O
funding	O
from	O
Eli	O
Lilly	O
,	O
France	O
.	O

The	O
comparative	O
analysis	O
of	O
statistics	O
,	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
,	O
in	O
the	O
automated	O
annotation	O
problem	O
Abstract	O
Background	O
This	O
paper	O
discusses	O
the	O
problem	O
of	O
automated	O
annotation	O
.	O

It	O
is	O
a	O
continuation	O
of	O
the	O
previous	O
work	O
on	O
the	O
A4-algorithm	O
(	O
Adaptive	O
algorithm	O
of	O
automated	O
annotation	O
)	O
developed	O
by	O
Leontovich	O
and	O
others	O
.	O

Results	O
A	O
number	O
of	O
new	O
statistics	O
for	O
the	O
automated	O
annotation	O
of	O
biological	O
sequences	O
is	O
introduced	O
.	O

All	O
these	O
statistics	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
.	O

Conclusion	O
Some	O
of	O
the	O
statistics	O
yield	O
a	O
prediction	O
quality	O
that	O
is	O
significantly	O
higher	O
(	O
up	O
to	O
1.5	O
times	O
higher	O
)	O
in	O
comparison	O
with	O
the	O
results	O
obtained	O
with	O
the	O
A4-procedure	O
.	O

Background	O
Many	O
biological	O
databanks	O
,	O
both	O
dealing	O
with	O
protein	O
sequences	O
(	O
e.g.	O
,	O
SWISS	O
-	O
PROT	O
)	O
and	O
nucleotide	O
sequences	O
(	O
e.g.	O
,	O
GeneBank	O
)	O
,	O
contain	O
not	O
only	O
primary	O
structures	O
of	O
sequences	O
(	O
i.e.	O
,	O
sequences	O
of	O
letters	O
–	O
amino	O
acids	O
or	O
nucleotides	O
)	O
,	O
but	O
also	O
information	O
about	O
functions	O
and	O
properties	O
of	O
these	O
sequences	O
.	O

This	O
information	O
is	O
stored	O
in	O
so	O
called	O
description	O
fields	O
of	O
the	O
sequences	O
.	O

There	O
exist	O
different	O
types	O
of	O
description	O
fields	O
–	O
KW	O
(	O
KeyWords	O
)	O
,	O
DE	O
(	O
Descriptions	O
)	O
,	O
...	O
,	O
FT	O
(	O
Feature	O
Table	O
)	O
,	O
...	O
;	O
elements	O
of	O
description	O
fields	O
are	O
referred	O
to	O
as	O
words	O
.	O

Words	O
from	O
KW	O
,	O
DE	O
,	O
...	O
fields	O
describe	O
a	O
sequence	O
as	O
a	O
whole	O
,	O
while	O
words	O
from	O
FT	O
fields	O
correspond	O
to	O
certain	O
positions	O
(	O
letters	O
)	O
of	O
a	O
sequence	O
.	O

The	O
automated	O
annotation	O
problem	O
can	O
be	O
described	O
as	O
follows	O
.	O

Consider	O
a	O
biological	O
sequence	O
(	O
referred	O
to	O
as	O
a	O
query	O
sequence	O
)	O
with	O
known	O
primary	O
structure	O
(	O
i.e.	O
letter	O
sequence	O
)	O
but	O
unknown	O
properties	O
and	O
functions	O
(	O
i.e.	O
,	O
description	O
fields	O
)	O
.	O

The	O
task	O
is	O
to	O
determine	O
functions	O
and	O
properties	O
of	O
this	O
sequence	O
(	O
in	O
other	O
words	O
,	O
to	O
restore	O
its	O
description	O
fields	O
)	O
on	O
the	O
basis	O
of	O
the	O
primary	O
structure	O
.	O

The	O
annotation	O
should	O
be	O
fully	O
automated	O
.	O

This	O
is	O
the	O
subject	O
of	O
the	O
current	O
paper	O
.	O

There	O
are	O
two	O
main	O
approaches	O
to	O
the	O
solution	O
of	O
this	O
problem	O
.	O

In	O
the	O
first	O
approach	O
(	O
it	O
can	O
be	O
called	O
a	O
static	O
one	O
)	O
a	O
certain	O
fixed	O
protein	O
classification	O
(	O
grouping	O
proteins	O
according	O
to	O
similarity	O
in	O
structure	O
and/or	O
functions	O
)	O
,	O
specified	O
beforehand	O
,	O
is	O
used	O
:	O
for	O
a	O
query	O
protein	O
the	O
search	O
of	O
a	O
relative	O
group	O
(	O
super	O
family	O
)	O
is	O
performed	O
on	O
the	O
basis	O
of	O
primary	O
structures	O
,	O
and	O
properties	O
/	O
functions	O
of	O
this	O
group	O
are	O
extended	O
to	O
the	O
query	O
protein	O
.	O

An	O
example	O
of	O
this	O
approach	O
is	O
described	O
in	O
the	O
paper	O
by	O
W.	O
Fleischmann	O
et	O
al.	O
[	O
1	O
]	O
,	O
it	O
uses	O
the	O
protein	O
classification	O
(	O
more	O
than	O
1000	O
families	O
)	O
,	O
stored	O
in	O
the	O
Prosite	O
databank	O
.	O

The	O
second	O
approach	O
(	O
it	O
can	O
be	O
called	O
a	O
dynamic	O
or	O
an	O
adaptive	O
one	O
)	O
does	O
not	O
use	O
protein	O
classification	O
.	O

Instead	O
,	O
a	O
""""	O
dynamic	O
""""	O
collection	O
of	O
bank	O
sequences	O
that	O
are	O
similar	O
to	O
a	O
query	O
sequence	O
is	O
generated	O
,	O
and	O
then	O
common	O
properties	O
/	O
functions	O
of	O
these	O
bank	O
sequences	O
are	O
extended	O
to	O
the	O
query	O
sequence	O
.	O

One	O
of	O
the	O
first	O
examples	O
of	O
this	O
approach	O
was	O
described	O
by	O
M.A.	O
Andrade	O
et	O
al.	O
[	O
2	O
]	O
.	O

In	O
this	O
paper	O
the	O
prediction	O
was	O
based	O
on	O
so	O
called	O
word	O
reliability	O
function	O
–	O
a	O
function	O
depending	O
on	O
the	O
degree	O
of	O
similarity	O
between	O
a	O
query	O
sequence	O
and	O
corresponding	O
bank	O
sequences	O
.	O

In	O
other	O
examples	O
of	O
annotation	O
procedures	O
based	O
on	O
the	O
dynamic	O
approach	O
prediction	O
was	O
performed	O
in	O
a	O
""""	O
naive	O
""""	O
way	O
–	O
all	O
properties	O
/	O
functions	O
of	O
similar	O
proteins	O
were	O
extended	O
to	O
a	O
query	O
protein	O
,	O
or	O
using	O
stochastic	O
methods	O
–	O
only	O
properties	O
/	O
functions	O
that	O
are	O
most	O
frequent	O
for	O
the	O
collection	O
of	O
similar	O
proteins	O
were	O
extended	O
(	O
see	O
[	O
3,4	O
]	O
)	O
.	O

The	O
current	O
paper	O
uses	O
the	O
dynamic	O
approach	O
.	O

This	O
paper	O
is	O
a	O
sequel	O
to	O
paper	O
[	O
5	O
]	O
that	O
describes	O
the	O
A4	O
algorithm	O
(	O
the	O
Adaptive	O
Algorithm	O
of	O
Automated	O
Annotation	O
)	O
,	O
so	O
results	O
of	O
the	O
paper	O
[	O
5	O
]	O
are	O
constantly	O
used	O
here	O
.	O

The	O
A4	O
algorithm	O
is	O
based	O
on	O
a	O
stochastic	O
approach	O
.	O

More	O
precisely	O
,	O
it	O
is	O
based	O
on	O
the	O
notion	O
of	O
transfer	O
probabilities	O
.	O

Transfer	O
probabilities	O
are	O
the	O
probabilities	O
of	O
word	O
transfer	O
(	O
extension	O
)	O
from	O
description	O
fields	O
of	O
one	O
sequence	O
to	O
description	O
fields	O
of	O
another	O
sequence	O
;	O
they	O
depend	O
on	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
.	O

Transfer	O
probabilities	O
are	O
evaluated	O
on	O
the	O
basis	O
of	O
word	O
transfer	O
frequencies	O
in	O
the	O
found	O
collection	O
of	O
sequences	O
similar	O
to	O
a	O
query	O
sequence	O
.	O

For	O
each	O
word	O
from	O
description	O
fields	O
of	O
sequences	O
included	O
in	O
the	O
collection	O
the	O
prediction	O
of	O
the	O
fact	O
that	O
this	O
word	O
belongs	O
(	O
or	O
does	O
not	O
belong	O
)	O
to	O
the	O
description	O
field	O
of	O
a	O
query	O
sequence	O
is	O
performed	O
;	O
this	O
prediction	O
is	O
based	O
on	O
transfer	O
probabilities	O
.	O

In	O
the	O
current	O
paper	O
we	O
introduce	O
and	O
analyze	O
a	O
number	O
of	O
new	O
statistics	O
for	O
the	O
prediction	O
.	O

All	O
of	O
them	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
[	O
6	O
]	O
(	O
which	O
is	O
the	O
most	O
powerful	O
criterion	O
)	O
.	O

As	O
in	O
[	O
5	O
]	O
,	O
all	O
these	O
statistics	O
are	O
evaluated	O
using	O
transfer	O
probabilities	O
.	O

Two	O
approaches	O
to	O
statistics	O
definition	O
are	O
introduced	O
:	O
a	O
""""	O
discrete	O
""""	O
approach	O
and	O
a	O
""""	O
continuous	O
""""	O
approach	O
.	O

A	O
detailed	O
analysis	O
and	O
comparison	O
of	O
introduced	O
statistics	O
are	O
performed	O
and	O
the	O
best	O
statistics	O
are	O
selected	O
.	O

The	O
emphasis	O
is	O
on	O
a	O
precise	O
description	O
of	O
the	O
way	O
these	O
statistics	O
can	O
be	O
constructed	O
using	O
well	O
-	O
known	O
concepts	O
from	O
statistical	O
decision	O
theory	O
.	O

The	O
current	O
A4	O
algorithm	O
uses	O
SPKW	O
as	O
a	O
language	O
of	O
annotation	O
.	O

Of	O
course	O
,	O
it	O
is	O
possible	O
to	O
use	O
GO	O
terms	O
in	O
A4	O
as	O
well	O
.	O

That	O
would	O
facilitate	O
comparison	O
with	O
other	O
approaches	O
.	O

However	O
,	O
at	O
the	O
current	O
stage	O
of	O
our	O
research	O
we	O
test	O
and	O
choose	O
""""	O
the	O
best	O
decision	O
making	O
algorithm	O
""""	O
,	O
not	O
""""	O
the	O
best	O
annotation	O
terminology	O
""""	O
.	O

Obviously	O
,	O
which	O
annotation	O
is	O
used	O
hardly	O
matters	O
for	O
the	O
problem	O
of	O
finding	O
the	O
optimal	O
""""	O
decision	O
making	O
algorithm	O
""""	O
Results	O
Algorithm	O
description	O
Generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
First	O
,	O
we	O
introduce	O
some	O
notation	O
.	O

For	O
the	O
sake	O
of	O
brevity	O
we	O
write	O
""""	O
a	O
word	O
ω	O
belongs	O
to	O
a	O
sequence	O
π	O
""""	O
instead	O
of	O
""""	O
a	O
word	O
ω	O
belongs	O
to	O
description	O
fields	O
of	O
a	O
sequence	O
π	O
""""	O
.	O

If	O
ω	O
is	O
a	O
KW	O
-	O
type	O
word	O
(	O
to	O
be	O
definite	O
,	O
further	O
in	O
the	O
paper	O
we	O
consider	O
only	O
amino	O
-	O
acid	O
sequences	O
and	O
KW	O
-	O
type	O
words	O
)	O
,	O
we	O
write	O
ω	O
∈	O
KW	O
[	O
π	O
]	O
.	O

The	O
application	O
of	O
an	O
annotation	O
procedure	O
to	O
an	O
unannotated	O
amino	O
-	O
acid	O
query	O
sequence	O
(	O
i.e.	O
,	O
the	O
prediction	O
of	O
description	O
fields	O
)	O
starts	O
with	O
generating	O
a	O
collection	O
of	O
sequences	O
similar	O
to	O
this	O
query	O
sequence	O
with	O
known	O
description	O
fields	O
.	O

These	O
similar	O
sequences	O
are	O
selected	O
from	O
a	O
certain	O
databank	O
that	O
contains	O
annotated	O
amino	O
-	O
acid	O
sequences	O
,	O
e.g.	O
,	O
SWISS	O
-	O
PROT	O
.	O

There	O
exist	O
different	O
approaches	O
to	O
the	O
generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
(	O
see	O
[	O
7	O
]	O
)	O
.	O

This	O
collections	O
can	O
be	O
generated	O
on	O
the	O
basis	O
of	O
global	O
alignments	O
between	O
a	O
query	O
sequence	O
and	O
bank	O
sequences	O
(	O
global	O
alignments	O
can	O
be	O
constructed	O
,	O
e.g.	O
,	O
by	O
CLUSTAL	O
procedure	O
)	O
using	O
an	O
identity	O
percentage	O
or	O
,	O
more	O
generally	O
,	O
a	O
similarity	O
percentage	O
as	O
a	O
similarity	O
measure	O
.	O

Another	O
variant	O
is	O
to	O
use	O
local	O
alignments	O
(	O
i.e.	O
,	O
alignments	O
of	O
most	O
similar	O
fragments	O
of	O
compared	O
sequences	O
,	O
see	O
[	O
7	O
]	O
)	O
instead	O
of	O
global	O
alignments	O
.	O

Local	O
alignments	O
can	O
be	O
constructed	O
,	O
for	O
example	O
,	O
by	O
a	O
well	O
-	O
known	O
BLAST	O
procedure	O
[	O
7,8	O
]	O
,	O
in	O
which	O
sum	O
of	O
weights	O
or	O
a	O
corresponding	O
e	O
-	O
value	O
serves	O
as	O
a	O
measure	O
of	O
similarity	O
between	O
fragments	O
(	O
and	O
thus	O
between	O
compared	O
sequences	O
)	O
.	O

Other	O
alignment	O
procedures	O
are	O
also	O
acceptable	O
;	O
alignment	O
procedure	O
selection	O
does	O
not	O
play	O
a	O
critical	O
role	O
.	O

Since	O
we	O
build	O
on	O
the	O
A4	O
procedure	O
,	O
we	O
briefly	O
summarize	O
that	O
approach	O
.	O

In	O
the	O
A4	O
procedure	O
a	O
collection	O
of	O
similar	O
sequences	O
is	O
generated	O
on	O
the	O
basis	O
of	O
local	O
alignments	O
of	O
a	O
special	O
type	O
.	O

These	O
alignments	O
are	O
constructed	O
by	O
the	O
DotHelix	O
procedure	O
(	O
[	O
9	O
]	O
)	O
,	O
in	O
which	O
the	O
""""	O
power	O
""""	O
(	O
sum	O
of	O
weights	O
divided	O
by	O
the	O
root	O
of	O
the	O
length	O
of	O
the	O
local	O
alignment	O
,	O
see	O
[	O
9,10	O
]	O
for	O
details	O
)	O
serves	O
as	O
a	O
similarity	O
measure	O
.	O

Each	O
local	O
alignment	O
constructed	O
by	O
DotHelix	O
procedure	O
is	O
a	O
chain	O
of	O
closely	O
located	O
gapless	O
local	O
alignments	O
.	O

Local	O
alignments	O
that	O
are	O
generated	O
during	O
the	O
construction	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
are	O
referred	O
to	O
as	O
primary	O
local	O
alignments	O
.	O

Each	O
sequence	O
from	O
a	O
collection	O
of	O
similar	O
sequences	O
π1,	O
...	O
,πn	O
can	O
have	O
several	O
corresponding	O
primary	O
local	O
alignments	O
,	O
but	O
for	O
the	O
sake	O
of	O
simplicity	O
we	O
assume	O
that	O
each	O
similar	O
sequence	O
πi	O
has	O
exactly	O
one	O
corresponding	O
primary	O
local	O
alignment	O
,	O
the	O
one	O
with	O
the	O
maximum	O
similarity	O
measure	O
.	O

Let	O
μi	O
denote	O
the	O
similarity	O
measure	O
(	O
power	O
)	O
of	O
a	O
primary	O
alignment	O
that	O
corresponds	O
to	O
πi	O
.	O

The	O
value	O
of	O
μi	O
characterizes	O
the	O
measure	O
of	O
similarity	O
between	O
fragments	O
that	O
constitute	O
this	O
alignment	O
;	O
at	O
the	O
same	O
time	O
μi	O
can	O
be	O
treated	O
as	O
a	O
measure	O
of	O
similarity	O
between	O
the	O
whole	O
query	O
sequence	O
π0	O
and	O
the	O
whole	O
similar	O
sequence	O
πi	O
.	O

We	O
assume	O
that	O
similar	O
sequences	O
are	O
ordered	O
in	O
such	O
a	O
way	O
that	O
μ1	O
≥	O
μ2	O
≥	O
...	O

≥	O
μn	O
.	O

The	O
exact	O
stochastic	O
formulation	O
of	O
the	O
problem	O
Let	O
π0	O
be	O
an	O
unannotated	O
amino	O
-	O
acid	O
query	O
sequence	O
,	O
π1,	O
...	O
,πn	O
be	O
a	O
collection	O
of	O
sequences	O
similar	O
to	O
π0	O
,	O
and	O
ω	O
be	O
a	O
word	O
that	O
belongs	O
to	O
some	O
similar	O
sequences	O
(	O
i.e.	O
,	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
.	O

for	O
at	O
least	O
one	O
similar	O
sequence	O
πi	O
)	O
.	O

The	O
task	O
is	O
to	O
predict	O
whether	O
this	O
word	O
ω	O
belongs	O
to	O
the	O
query	O
sequence	O
π0	O
or	O
not	O
.	O

Let	O
us	O
put	O
ξi	O
=	O
1	O
,	O
if	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
,	O
and	O
ξi	O
=	O
0	O
,	O
if	O
ω	O
∉	O
KW	O
[	O
πi	O
]	O
(	O
i	O
=	O
1,	O
...	O
,n	O
)	O
.	O

we	O
also	O
put	O
ξ0	O
=	O
1	O
,	O
if	O
ω	O
∈	O
KW	O
[	O
π0	O
]	O
,	O
and	O
ξ0	O
=	O
0	O
,	O
if	O
ω	O
∉	O
KW	O
[	O
π0	O
]	O
.	O

Variables	O
ξi	O
can	O
be	O
treated	O
as	O
random	O
variates	O
Actually	O
,	O
they	O
depend	O
on	O
ω	O
.	O

For	O
the	O
sake	O
of	O
brevity	O
we	O
write	O
ξi	O
instead	O
of	O
ξi	O
(	O
ω	O
)	O
.	O

In	O
this	O
notation	O
the	O
problem	O
can	O
be	O
stated	O
as	O
follows	O
.	O

Measures	O
of	O
similarity	O
μi	O
between	O
the	O
query	O
sequence	O
π0	O
and	O
similar	O
sequences	O
πi	O
and	O
values	O
of	O
random	O
variates	O
ξi	O
,	O
i	O
=	O
1,	O
...	O
,n	O
,	O
are	O
given	O
.	O

The	O
task	O
is	O
to	O
determine	O
whether	O
the	O
word	O
ω	O
belongs	O
to	O
the	O
query	O
sequence	O
π0	O
or	O
not	O
.	O

In	O
other	O
words	O
,	O
two	O
hypotheses	O
are	O
considered	O
,	O
H1	O
:	O
ξ0	O
=	O
1	O
(	O
i.e.	O
,	O
ω	O
∈	O
KW	O
[	O
π0	O
]	O
)	O
,	O
and	O
H0	O
:	O
ξ0	O
=	O
0	O
(	O
i.e.	O
,	O
ω	O
∉	O
KW	O
[	O
π0	O
]	O
)	O
,	O
and	O
the	O
task	O
is	O
to	O
construct	O
a	O
procedure	O
that	O
allows	O
to	O
decide	O
which	O
hypothesis	O
is	O
true	O
on	O
the	O
basis	O
of	O
ξ	O
=	O
(	O
ξ1,	O
...	O
,ξn	O
)	O
.	O

As	O
announced	O
in	O
the	O
introduction	O
,	O
we	O
base	O
our	O
procedures	O
on	O
the	O
likelihood	O
ratio	O
.	O

Let	O
us	O
recall	O
the	O
famous	O
Bayes	O
'	O
Theorem	O
that	O
can	O
be	O
written	O
as	O
P	O
{	O
H1|ξ	O
}	O
P	O
{	O
H0|ξ	O
}	O
=P	O
{	O
ξ0=1|ξ	O
}	O
P	O
{	O
ξ0=0|ξ	O
}	O
=P	O
{	O
ξ0=1,ξ	O
}	O
/	O
P	O
{	O
ξ	O
}	O
P	O
{	O
ξ0=0,ξ	O
}	O
/	O
P	O
{	O
ξ	O
}	O
=P	O
{	O
ξ|ξ0=1	O
}	O
P	O
{	O
ξ|ξ0=0	O
}	O
⋅P	O
{	O
ξ0=1	O
}	O
P	O
{	O
ξ0=0	O
}	O
.	O
Here	O
the	O
left	O
part	O
is	O
the	O
posterior	O
odds	O
,	O
that	O
is	O
the	O
ratio	O
of	O
a	O
posteriori	O
probabilities	O
of	O
hypotheses	O
H1	O
and	O
H0	O
(	O
a	O
posteriori	O
means	O
that	O
values	O
ξ1,	O
...	O
,ξn	O
are	O
known	O
)	O
.	O

It	O
is	O
equal	O
to	O
the	O
product	O
of	O
the	O
likelihood	O
ratio	O
P	O
{	O
ξ|ξ0=1	O
}	O
P	O
{	O
ξ|ξ0=0	O
}	O
(	O
i.e.	O
,	O
the	O
ratio	O
of	O
probabilities	O
that	O
the	O
set	O
of	O
values	O
ξ	O
=	O
ξ	O
(	O
ω	O
)	O
is	O
realized	O
for	O
the	O
word	O
ω	O
given	O
the	O
conditions	O
ξ0	O
=	O
1	O
and	O
ξ0	O
=	O
0	O
respectively	O
)	O
and	O
the	O
prior	O
odds	O
,	O
that	O
is	O
the	O
ratio	O
of	O
a	O
priori	O
probabilities	O
of	O
hypotheses	O
H1	O
and	O
H0	O
.	O

Statistical	O
decision	O
theory	O
tells	O
us	O
that	O
the	O
optimal	O
prediction	O
procedure	O
should	O
be	O
based	O
on	O
the	O
statistic	O
P	O
{	O
H1|ξ	O
}	O
P	O
{	O
H0|ξ	O
}	O
or	O
equivalently	O
on	O
the	O
likelihood	O
ratio	O
.	O

For	O
any	O
statistic	O
a	O
threshold	O
value	O
should	O
be	O
specified	O
for	O
the	O
procedure	O
:	O
if	O
the	O
value	O
of	O
the	O
statistic	O
is	O
greater	O
than	O
the	O
threshold	O
,	O
hypothesis	O
H1	O
is	O
accepted	O
,	O
otherwise	O
hypothesis	O
H0	O
is	O
accepted	O
.	O

The	O
threshold	O
value	O
should	O
be	O
selected	O
in	O
such	O
a	O
way	O
that	O
the	O
total	O
number	O
of	O
incorrect	O
predictions	O
(	O
i.e.	O
,	O
the	O
sum	O
of	O
the	O
number	O
of	O
type	O
1	O
errors	O
and	O
the	O
number	O
of	O
type	O
2	O
errors	O
)	O
would	O
be	O
minimal	O
.	O

It	O
is	O
clear	O
that	O
if	O
the	O
prior	O
odds	O
are	O
equal	O
to	O
1	O
,	O
then	O
a	O
threshold	O
value	O
of	O
one	O
should	O
be	O
selected	O
for	O
the	O
likelihood	O
ratio	O
;	O
total	O
number	O
of	O
errors	O
would	O
(	O
theoretically	O
)	O
be	O
minimal	O
for	O
this	O
threshold	O
.	O

Surely	O
,	O
the	O
assumption	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
equals	O
1	O
does	O
not	O
seem	O
to	O
be	O
natural	O
.	O

Indeed	O
,	O
the	O
number	O
of	O
considered	O
words	O
that	O
do	O
not	O
belong	O
to	O
a	O
query	O
sequence	O
is	O
much	O
greater	O
(	O
approximately	O
8	O
times	O
greater	O
)	O
than	O
the	O
number	O
of	O
considered	O
words	O
that	O
belong	O
to	O
a	O
query	O
sequence	O
.	O

But	O
statistics	O
that	O
are	O
obtained	O
from	O
the	O
assumption	O
that	O
this	O
a	O
priori	O
ratio	O
equals	O
1	O
,	O
and	O
the	O
assumption	O
that	O
this	O
a	O
priori	O
ratio	O
does	O
not	O
equal	O
1	O
,	O
but	O
is	O
constant	O
(	O
i.e.	O
,	O
it	O
does	O
not	O
depend	O
on	O
a	O
word	O
ω	O
)	O
are	O
equivalent	O
.	O

Essentially	O
these	O
are	O
the	O
same	O
statistics	O
(	O
only	O
the	O
threshold	O
value	O
should	O
be	O
changed	O
:	O
a	O
value	O
P	O
{	O
ξ0=0	O
}	O
P	O
{	O
ξ0=1	O
}	O
should	O
be	O
taken	O
instead	O
of	O
1	O
;	O
as	O
it	O
was	O
noted	O
,	O
this	O
value	O
approximately	O
equals	O
8	O
in	O
our	O
data	O
)	O
.	O

Therefore	O
,	O
we	O
assume	O
from	O
now	O
on	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
equals	O
1	O
.	O

Thus	O
all	O
considered	O
statistics	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
(	O
1	O
)	O
P	O
{	O
ξ|ξ0=1	O
}	O
P	O
{	O
ξ|ξ0=0	O
}	O
Assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
.	O

Transfer	O
probabilities	O
By	O
virtue	O
of	O
equation	O
(	O
1	O
)	O
we	O
need	O
to	O
estimate	O
conditional	O
probabilities	O
P	O
{	O
ξ|ξ0	O
=	O
ε	O
}	O
,	O
where	O
ε	O
=	O
1	O
or	O
0	O
in	O
order	O
to	O
calculate	O
the	O
likelihood	O
ratio	O
.	O

Our	O
derivation	O
of	O
these	O
estimates	O
uses	O
the	O
assumption	O
that	O
variables	O
ξi	O
,	O
i	O
=	O
1,	O
...	O
,n	O
,	O
are	O
independent	O
in	O
the	O
aggregate	O
.	O

Surely	O
,	O
this	O
assumption	O
is	O
false	O
.	O

In	O
reality	O
variables	O
ξi	O
are	O
dependent	O
,	O
and	O
the	O
dependence	O
is	O
considerably	O
strong	O
.	O

Nevertheless	O
,	O
in	O
our	O
definition	O
of	O
the	O
likelihood	O
ratio	O
statistic	O
(	O
and	O
the	O
statistic	O
that	O
is	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
)	O
we	O
use	O
the	O
independence	O
assumption	O
.	O

Since	O
variables	O
ξi	O
are	O
not	O
independent	O
,	O
one	O
can	O
not	O
assert	O
that	O
the	O
obtained	O
statistics	O
are	O
the	O
most	O
powerful	O
,	O
but	O
these	O
statistics	O
can	O
be	O
still	O
quite	O
good	O
.	O

In	O
decision	O
theory	O
,	O
this	O
approach	O
is	O
known	O
as	O
the	O
naive	O
Bayes	O
procedure	O
.	O

The	O
independence	O
of	O
variables	O
ξi	O
implies	O
the	O
equality	O
(	O
2	O
)	O
P	O
{	O
ξ|ξ0	O
=	O
ε	O
}	O
=∏i=1nP	O
{	O
ξi|ξ0	O
=	O
ε	O
}	O
,ε=1,0	O
Each	O
variable	O
ξi	O
has	O
exactly	O
two	O
possible	O
values	O
:	O
1	O
and	O
0	O
.	O

Thus	O
,	O
everything	O
is	O
reduced	O
to	O
the	O
following	O
four	O
conditional	O
probabilities	O
:	O
(	O
3	O
)	O
P	O
{	O
ξi	O
=	O
1|ξ0	O
=	O
1	O
}	O
,	O
P	O
{	O
ξi	O
=	O
0|ξ0=	O
1	O
}	O
,	O
P	O
{	O
ξi	O
=	O
1|ξ0	O
=	O
0	O
}	O
,	O
P	O
{	O
ξi	O
=	O
0|ξ0	O
=	O
0	O
}	O
.	O
In	O
addition	O
,	O
it	O
is	O
clear	O
that	O
(	O
4	O
)	O
P	O
{	O
ξi=1|ξ0=1	O
}	O
+P	O
{	O
ξi=0|ξ0=1	O
}	O
=1,P	O
{	O
ξi=1|ξ0=0	O
}	O
+P	O
{	O
ξi=0|ξ0=0	O
}	O
=1	O
,	O
so	O
actually	O
everything	O
is	O
reduced	O
to	O
two	O
conditional	O
probabilities	O
P	O
{	O
ξi	O
=	O
1|ξ0	O
=	O
1	O
}	O
,	O
P	O
{	O
ξi	O
=	O
1|ξ0=	O
0	O
}	O
.	O
Conditional	O
probabilities	O
(	O
3	O
)	O
are	O
a	O
special	O
case	O
of	O
conditional	O
probabilities	O
of	O
the	O
type	O
P	O
{	O
ξi	O
=	O
ε1|ξj	O
=	O
ε2	O
}	O
,	O
where	O
ε1	O
,	O
ε2	O
=	O
1	O
or	O
0	O
,	O
i	O
,	O
j	O
=	O
0,1,	O
...	O
,n	O
(	O
above	O
special	O
case	O
corresponds	O
to	O
j	O
=	O
0	O
)	O
.	O

We	O
call	O
all	O
this	O
conditional	O
probabilities	O
transfer	O
probabilities	O
and	O
denote	O
them	O
by	O
P	O
{	O
ξi	O
=	O
ε1|ξj	O
=	O
ε2	O
}	O
=pε1|ε2	O
.	O

Transfer	O
probabilities	O
depend	O
on	O
i	O
,	O
j	O
(	O
and	O
certainly	O
on	O
the	O
word	O
ω	O
)	O
:	O
pε1|ε2	O
=	O
pε1|ε2	O
(	O
i	O
,	O
j;ω	O
)	O
.	O

Conditional	O
probabilities	O
play	O
a	O
central	O
role	O
in	O
our	O
procedure	O
.	O

According	O
to	O
equation	O
(	O
4	O
)	O
,	O
it	O
suffices	O
to	O
explain	O
how	O
transfer	O
probabilities	O
p1|1	O
,	O
p1|0	O
are	O
evaluated	O
.	O

We	O
suppose	O
that	O
transfer	O
probabilities	O
satisfy	O
the	O
following	O
assumptions	O
(	O
""""	O
axioms	O
""""	O
)	O
(	O
the	O
sense	O
of	O
these	O
assumptions	O
is	O
obvious	O
)	O
.	O

Assumption	O
1	O
)	O

For	O
a	O
fixed	O
word	O
ω	O
and	O
for	O
sequences	O
π0	O
,	O
π1,	O
...	O
,πn	O
(	O
i.e.	O
,	O
for	O
the	O
sequence	O
π0	O
and	O
sequences	O
similar	O
to	O
π0	O
)	O
transfer	O
probabilities	O
depend	O
only	O
on	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
.	O

Thus	O
,	O
we	O
have	O
:	O
p1|1	O
=	O
p1|1	O
(	O
i	O
,	O
j;ω	O
)	O
=	O
p1|1	O
(	O
μij;ω	O
)	O
=	O
p1|1	O
(	O
μij	O
)	O
=	O
1	O
-	O
p0|1	O
(	O
μij	O
)	O
,	O
p1|0	O
=	O
p1|0	O
(	O
i	O
,	O
j;ω	O
)	O
=	O
p1|0	O
(	O
μij;ω	O
)	O
=	O
p1|0	O
(	O
μij	O
)	O
=	O
1	O
-	O
p0|0	O
(	O
μij	O
)	O
,	O
where	O
μij	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
πi	O
,	O
πj	O
(	O
i	O
,	O
j	O
=	O
0,1,	O
...	O
,n	O
)	O
.	O

Particularly	O
,	O
if	O
one	O
of	O
these	O
sequences	O
is	O
the	O
query	O
sequence	O
π0	O
and	O
μj	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
πj	O
,	O
π0	O
,	O
we	O
have	O
(	O
5	O
)	O
P	O
{	O
ξj	O
=	O
1|ξ0	O
=	O
1	O
}	O
=	O
p1|1	O
(	O
μj	O
)	O
,	O
P	O
{	O
ξj	O
=	O
1|ξ0	O
=	O
0	O
}	O
=	O
p1|0	O
(	O
μj	O
)	O
.	O

Assumption	O
2	O
)	O
Transfer	O
probabilities	O
(	O
for	O
an	O
arbitrary	O
fixed	O
word	O
ω	O
)	O
depend	O
on	O
similarity	O
measure	O
μ	O
monotonically	O
:	O
the	O
probability	O
p1|1	O
(	O
μ	O
)	O
increases	O
(	O
does	O
not	O
decrease	O
)	O
and	O
the	O
probability	O
p1|0	O
(	O
μ	O
)	O
decreases	O
(	O
does	O
not	O
increase	O
)	O
as	O
μ	O
increases	O
.	O

Assumption	O
3	O
)	O
The	O
inequality	O
(	O
6	O
)	O
p1|1	O
(	O
μ	O
)	O
>	O
p1|0	O
(	O
μ	O
)	O
always	O
holds	O
(	O
if	O
μ	O
>	O
0	O
)	O
.	O

Transfer	O
probabilities	O
are	O
evaluated	O
on	O
the	O
basis	O
of	O
the	O
measure	O
of	O
similarity	O
between	O
similar	O
sequences	O
for	O
which	O
it	O
is	O
known	O
whether	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
using	O
the	O
so	O
called	O
isotonic	O
regression	O
procedure	O
(	O
see	O
[	O
11	O
]	O
)	O
.	O

(	O
In	O
[	O
5	O
]	O
this	O
procedure	O
was	O
referred	O
to	O
as	O
monotonization	O
procedure	O
)	O
.	O

Results	O
of	O
this	O
procedure	O
are	O
piecewise	O
-	O
constant	O
monotonous	O
functions	O
of	O
the	O
similarity	O
measure	O
μ	O
that	O
increase	O
(	O
do	O
not	O
decrease	O
)	O
for	O
probabilities	O
p1|1	O
(	O
μ	O
)	O
and	O
decrease	O
(	O
do	O
not	O
increase	O
)	O
for	O
probabilities	O
p1|0	O
(	O
μ	O
)	O
.	O

We	O
briefly	O
recall	O
the	O
isotonic	O
regression	O
problem	O
.	O

Let	O
one	O
have	O
two	O
number	O
sets	O
(	O
i.e.	O
,	O
a	O
set	O
of	O
points	O
in	O
the	O
plain	O
)	O
xi	O
,	O
yi	O
,	O
i	O
=	O
1,	O
...	O
,n	O
,	O
for	O
which	O
x1	O
≤	O
x2	O
≤	O
...	O
≤	O
xn	O
.	O

The	O
task	O
is	O
to	O
find	O
values	O
z1	O
,	O
z2,	O
...	O
,zn	O
,	O
z1	O
≤	O
z2	O
≤	O
...	O

≤	O
zn	O
,	O
that	O
minimize	O
the	O
deviation	O
∑i=1n	O
(	O
zi−yi	O
)	O
2	O
.	O

This	O
is	O
the	O
monotone	O
-	O
increasing	O
isotonic	O
regression	O
problem	O
.	O

The	O
monotone	O
-	O
decreasing	O
isotonic	O
regression	O
problem	O
is	O
similar	O
;	O
the	O
only	O
difference	O
is	O
that	O
here	O
z1	O
≥	O
z2	O
≥	O
...	O

≥	O
zn	O
.	O

The	O
isotonic	O
regression	O
procedure	O
constructs	O
a	O
monotonic	O
number	O
sequence	O
z1,	O
...	O
,zn	O
(	O
while	O
in	O
linear	O
regression	O
values	O
of	O
zi	O
are	O
linearly	O
expressed	O
in	O
terms	O
of	O
xi	O
:	O
zi	O
=	O
αxi	O
+	O
β	O
)	O
.	O

An	O
algorithm	O
for	O
the	O
solution	O
of	O
isotonic	O
regression	O
problem	O
can	O
be	O
easily	O
constructed	O
.	O

We	O
do	O
not	O
describe	O
it	O
here	O
.	O

We	O
only	O
note	O
that	O
each	O
zi	O
is	O
the	O
mean	O
value	O
of	O
{	O
yj	O
}	O
over	O
a	O
window	O
of	O
variable	O
length	O
:	O

Li	O
:	O
zi=	O
(	O
∑j	O
=	O
t	O
(	O
i	O
)	O
t	O
(	O
i	O
)	O
+L	O
(	O
i	O
)	O
−1yi	O
)	O
/	O
Li	O
.	O

For	O
different	O
indices	O
these	O
windows	O
either	O
coincide	O
or	O
do	O
not	O
overlap	O
,	O
and	O
the	O
i	O
-	O
th	O
window	O
contains	O
i.	O
We	O
also	O
note	O
that	O
the	O
values	O
of	O
xi	O
are	O
not	O
essential	O
in	O
the	O
isotonic	O
regression	O
problem	O
,	O
only	O
the	O
order	O
of	O
values	O
of	O
yi	O
is	O
essential	O
.	O

To	O
obtain	O
the	O
transfer	O
probabilities	O
using	O
isotonic	O
regression	O
we	O
proceed	O
as	O
follows	O
.	O

For	O
the	O
evaluation	O
of	O
p1|1	O
we	O
consider	O
pairs	O
of	O
similar	O
sequences	O
πi	O
,	O
πj	O
that	O
satisfy	O
the	O
condition	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
.	O

Let	O
μij	O
denote	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
πi	O
,	O
πj	O
.	O

We	O
put	O
ξij	O
=	O
1	O
if	O
the	O
word	O
ω	O
belongs	O
to	O
the	O
sequence	O
πj	O
,	O
and	O
put	O
ξij	O
=	O
0	O
if	O
ω	O
does	O
not	O
belong	O
to	O
πj	O
(	O
recall	O
that	O
the	O
word	O
ω	O
belongs	O
to	O
πi	O
)	O
.	O

Then	O
we	O
apply	O
the	O
monotone	O
-	O
increasing	O
isotonic	O
regression	O
procedure	O
to	O
the	O
collection	O
of	O
points	O
(	O
μij	O
,	O
ξij	O
)	O
,	O
where	O
μij	O
are	O
in	O
ascending	O
order	O
.	O

The	O
resulting	O
values	O
are	O
the	O
estimates	O
of	O
the	O
transfer	O
probabilities	O
p1|1	O
(	O
μij	O
)	O
.	O

Similarly	O
,	O
applying	O
the	O
monotone	O
-	O
decreasing	O
isotonic	O
regression	O
procedure	O
to	O
the	O
collection	O
of	O
points	O
(	O
μij	O
,	O
ξij	O
)	O
that	O
correspond	O
to	O
pairs	O
of	O
similar	O
sequences	O
πi	O
,	O
πj	O
for	O
which	O
ω	O
does	O
not	O
belong	O
to	O
πi	O
,	O
we	O
obtain	O
values	O
of	O
the	O
transfer	O
probabilities	O
p1|0	O
(	O
μij	O
)	O
.	O

As	O
we	O
noted	O
,	O
the	O
probabilities	O
p1|1	O
,	O
p1|0	O
are	O
supposed	O
to	O
satisfy	O
condition	O
(	O
6	O
)	O
.	O

Therefore	O
,	O
if	O
it	O
turns	O
out	O
that	O
functions	O
p1|1	O
(	O
μ	O
)	O
,	O
p1|0	O
(	O
μ	O
)	O
obtained	O
after	O
the	O
application	O
of	O
isotonic	O
regression	O
procedure	O
do	O
not	O
satisfy	O
this	O
condition	O
for	O
some	O
values	O
of	O
μ	O
,	O
then	O
we	O
consider	O
that	O
probabilities	O
p1|1	O
,	O
p1|0	O
are	O
not	O
defined	O
for	O
these	O
values	O
of	O
μ	O
.	O

Hence	O
,	O
it	O
is	O
possible	O
that	O
transfer	O
probabilities	O
are	O
defined	O
only	O
for	O
sufficiently	O
large	O
values	O
of	O
μ	O
,	O
but	O
not	O
for	O
all	O
μ	O
.	O

In	O
particular	O
,	O
it	O
is	O
possible	O
that	O
for	O
some	O
words	O
there	O
are	O
no	O
values	O
of	O
μ	O
such	O
that	O
inequality	O
(	O
6	O
)	O
holds	O
.	O

These	O
words	O
are	O
referred	O
to	O
as	O
degenerate	O
words	O
.	O

Statistics	O
description	O
All	O
statistics	O
considered	O
in	O
this	O
paper	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
,	O
that	O
is	O
on	O
formula	O
(	O
1	O
)	O
under	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
(	O
formula	O
(	O
2	O
)	O
)	O
.	O

Two	O
approaches	O
are	O
used	O
in	O
the	O
definitions	O
of	O
these	O
statistics	O
.	O

One	O
of	O
them	O
can	O
be	O
called	O
a	O
""""	O
discrete	O
""""	O
approach	O
;	O
the	O
other	O
can	O
be	O
called	O
a	O
""""	O
continuous	O
""""	O
approach	O
.	O

The	O
discrete	O
approach	O
is	O
based	O
directly	O
on	O
formulae	O
(	O
1	O
)	O
,	O
(	O
2	O
)	O
and	O
the	O
definition	O
of	O
transfer	O
probabilities	O
.	O

It	O
follows	O
from	O
(	O
5	O
)	O
that	O
the	O
following	O
formulae	O
for	O
conditional	O
probabilities	O
hold	O
:	O
P	O
{	O
ξi|ξ0	O
=	O
1	O
}	O
=	O
p1|1	O
(	O
μi	O
)	O
,	O
if	O
ξi	O
=	O
1	O
,	O
P	O
{	O
ξi|ξ0	O
=	O
1	O
}	O
=	O
p0|1	O
(	O
μi	O
)	O
=	O
1	O
-	O
p1|1	O
(	O
μi	O
)	O
,	O
if	O
ξi	O
=	O
0	O
,	O
and	O
hence	O
(	O
7	O
)	O
P	O
{	O
ξi|ξ0=1	O
}	O
=	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
⋅	O
(	O
p1|1	O
(	O
μi	O
)	O
1−p1|1	O
(	O
μi	O
)	O
)	O
)	O
ξi	O
.	O

Similarly	O
,	O
(	O
8	O
)	O
P	O
{	O
ξi|ξ0=0	O
}	O
=	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
⋅	O
(	O
p1|0	O
(	O
μi	O
)	O
1−p1|0	O
(	O
μi	O
)	O
)	O
ξi	O
.	O

Relations	O
(	O
7	O
)	O
,	O
(	O
8)	O
together	O
with	O
(	O
1	O
)	O
,	O
(	O
2	O
)	O
imply	O
the	O
following	O
formula	O
for	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
:	O
(	O
9	O
)	O
T	O
(	O
1	O
)	O
(	O
ξ;ω	O
)	O
=T	O
(	O
1	O
)	O
(	O
ξ	O
)	O
=ln⁡	O
(	O
∏i=1nP	O
{	O
ξi|ξ0=1	O
}	O
P	O
{	O
ξi|ξ0=0	O
}	O
)	O
=α0+∑i=1nαi⋅ξi	O
,	O
where	O
(	O
10	O
)	O
α0=∑i=1nα0i	O
,	O
α0i	O
=	O
ln⁡1−p1|1	O
(	O
μi	O
)	O
1−p1|0	O
(	O
μi	O
)	O
<0	O
(	O
11	O
)	O
αi	O
=	O
ln⁡p1|1	O
(	O
μi	O
)	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
p1|0	O
(	O
μi	O
)	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
>0	O
.	O

One	O
can	O
see	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
can	O
be	O
expressed	O
as	O
a	O
linear	O
combination	O
of	O
the	O
ξi	O
.	O

As	O
we	O
noted	O
,	O
theoretically	O
the	O
best	O
threshold	O
value	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
equal	O
to	O
1n1	O
=	O
0	O
.	O

However	O
,	O
that	O
is	O
only	O
theoretical	O
.	O

As	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
is	O
incorrect	O
and	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
only	O
a	O
rough	O
estimate	O
of	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
,	O
the	O
best	O
threshold	O
value	O
is	O
not	O
necessarily	O
equal	O
to	O
zero	O
(	O
and	O
this	O
threshold	O
does	O
not	O
really	O
equal	O
zero	O
in	O
practice	O
)	O
.	O

Let	O
us	O
put	O
η	O
=	O
η	O
(	O
ω	O
)	O
=T	O
(	O
1	O
)	O
−α0∑i=1nαi	O
.	O

From	O
the	O
definition	O
of	O
η	O
and	O
relations	O
(	O
9	O
)	O
–	O
(	O
11	O
)	O
it	O
follows	O
that	O
(	O
12	O
)	O
η=∑i=1na^iξi	O
,	O
where	O
(	O
13	O
)	O
a^i	O
=	O
ln⁡p1|1	O
(	O
μi	O
)	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
p1|0	O
(	O
μi	O
)	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
∑i=1nln⁡p1|1	O
(	O
μi	O
)	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
p1|0	O
(	O
μi	O
)	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
>0	O
.	O

We	O
note	O
that	O
(	O
14	O
)	O
∑i=1na^i=1	O
.	O

The	O
variable	O
η	O
(	O
ω	O
)	O
can	O
be	O
treated	O
as	O
a	O
second	O
statistic	O
.	O

Its	O
values	O
lie	O
between	O
0	O
and	O
1	O
.	O

Statistics	O
T	O
(	O
1	O
)	O
and	O
η	O
are	O
linearly	O
dependent	O
,	O
and	O
hence	O
for	O
a	O
fixed	O
word	O
ω	O
these	O
statistics	O
are	O
equivalent	O
.	O

However	O
,	O
the	O
coefficients	O
α0	O
and	O
αi	O
(	O
i	O
=	O
1,	O
...	O
,n	O
)	O
are	O
different	O
for	O
different	O
words	O
ω	O
,	O
so	O
the	O
relation	O
between	O
thresholds	O
,	O
used	O
in	O
the	O
prediction	O
,	O
is	O
different	O
for	O
different	O
words	O
;	O
consequently	O
,	O
the	O
statistics	O
T	O
(	O
1	O
)	O
and	O
η	O
are	O
not	O
equivalent	O
for	O
the	O
whole	O
totality	O
of	O
words	O
(	O
We	O
will	O
see	O
later	O
that	O
if	O
thresholds	O
are	O
well	O
-	O
chosen	O
,	O
then	O
η	O
leads	O
to	O
better	O
results	O
than	O
T	O
(	O
1	O
)	O
)	O
.	O

The	O
other	O
approach	O
to	O
the	O
definition	O
of	O
statistics	O
,	O
used	O
in	O
the	O
annotation	O
procedure	O
,	O
starts	O
from	O
a	O
linear	O
combination	O
η=∑i=1naiξi	O
of	O
the	O
ξi	O
as	O
in	O
formula	O
(	O
12	O
)	O
.	O

Here	O
coefficients	O
αi	O
are	O
not	O
necessarily	O
given	O
by	O
(	O
13	O
)	O
,	O
but	O
should	O
be	O
positive	O
and	O
satisfy	O
the	O
relation	O
(	O
14	O
)	O
.	O

This	O
approach	O
uses	O
the	O
assumption	O
that	O
η	O
has	O
the	O
normal	O
distribution	O
.	O

Certainly	O
this	O
assumption	O
is	O
not	O
correct	O
(	O
at	O
least	O
because	O
the	O
inequality	O
0	O
≤	O
η	O
≤	O
1	O
always	O
holds	O
)	O
.	O

Nevertheless	O
,	O
we	O
use	O
this	O
assumption	O
(	O
and	O
,	O
similarly	O
to	O
the	O
discrete	O
approach	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
(	O
ω	O
)	O
)	O
.	O

(	O
As	O
the	O
normal	O
distribution	O
is	O
continuous	O
,	O
this	O
approach	O
can	O
be	O
called	O
""""	O
continuous	O
""""	O
)	O
.	O

Thus	O
,	O
we	O
consider	O
a	O
random	O
variable	O
(	O
15	O
)	O
η=∑i=1naiξi	O
and	O
assume	O
that	O
it	O
has	O
a	O
normal	O
distribution	O
.	O

Denote	O
by	O
M1η	O
=	O
M	O
(	O
η|ξ0=1	O
)	O
,D1η	O
=	O
D	O
(	O
η|ξ0=1	O
)	O
=σ12,M0η	O
=	O
M	O
(	O
η|ξ0=0	O
)	O
,D0η	O
=	O
D	O
(	O
η|ξ0=0	O
)	O
=σ02	O
the	O
conditional	O
expectations	O
and	O
dispersions	O
of	O
η	O
given	O
that	O
ξ0	O
=	O
1	O
or	O
0	O
respectively	O
.	O

We	O
have	O
M1η	O
=	O
∑aiM	O
(	O
ξi|ξ0	O
=	O
1	O
)	O
=	O
∑aip1|1	O
(	O
μi	O
)	O
,	O
M0η	O
=	O
∑aip1|0	O
(	O
μi	O
)	O
.	O

Further	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
ξi	O
(	O
ω	O
)	O
implies	O
that	O
D1η	O
=	O
σ12=∑iai2⋅p1|1	O
(	O
μi	O
)	O
⋅	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
,D0η	O
=	O
σ02=∑iai2⋅p1|0	O
(	O
μi	O
)	O
⋅	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
.	O

(	O
We	O
note	O
that	O
it	O
is	O
the	O
only	O
place	O
where	O
the	O
independence	O
of	O
ξi	O
is	O
used	O
;	O
therefore	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
ξi	O
is	O
not	O
as	O
essential	O
in	O
this	O
approach	O
as	O
it	O
was	O
in	O
the	O
definition	O
of	O
the	O
statistic	O
T	O
(	O
1	O
)	O
)	O
.	O

It	O
follows	O
from	O
the	O
assumption	O
of	O
a	O
normal	O
distribution	O
that	O
in	O
cases	O
ξ0	O
=	O
1	O
and	O
0	O
the	O
variables	O
(	O
16	O
)	O
η−M1ησ1	O
and	O
η−M0ησ0	O
have	O
standard	O
normal	O
distribution	O
N	O
(	O
0,1	O
)	O
As	O
above	O
,	O
we	O
use	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
as	O
a	O
statistic	O
and	O
in	O
addition	O
assume	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
is	O
equal	O
to	O
1	O
.	O

Let	O
us	O
denote	O
this	O
statistic	O
by	O
T	O
(	O
2	O
)	O
.	O

Relation	O
(	O
16	O
)	O
implies	O
that	O
T	O
(	O
2	O
)	O
(	O
λ	O
)	O
=ln⁡P	O
{	O
λ≤η≤λ+dλ|ξ0=1	O
}	O
P	O
{	O
λ≤η≤λ+dλ|ξ0=0	O
}	O
=ln⁡	O
(	O
1	O
/	O
2π⋅σ1	O
)	O
⋅exp⁡	O
{	O
−12⋅	O
(	O
(	O
λ−M1η	O
)	O
/	O
σ1	O
)	O
2	O
}	O
(	O
1	O
/	O
2π⋅σ0	O
)	O
⋅exp⁡	O
{	O
12⋅	O
(	O
(	O
λ−M0η	O
)	O
/	O
σ0	O
)	O
2	O
}	O
=12⋅	O
{	O
(	O
(	O
λ−M0η	O
)	O
/	O
σ0	O
)	O
2−	O
(	O
(	O
λ−M1η	O
)	O
/	O
σ1	O
)	O
2	O
}	O
+ln⁡	O
(	O
σ0	O
/	O
σ1	O
)	O
.	O

Another	O
variant	O
of	O
this	O
statistic	O
–	O
statistic	O
T^	O
(	O
2	O
)	O
–	O
was	O
used	O
in	O
the	O
paper	O
[	O
5	O
]	O
.	O

The	O
statistic	O
T^	O
(	O
2	O
)	O
is	O
the	O
ratio	O
of	O
type	O
1	O
error	O
to	O
type	O
2	O
error	O
:	O
(	O
17	O
)	O
T^	O
(	O
2	O
)	O
(	O
λ	O
)	O
=ln⁡P	O
(	O
1	O
)	O
(	O
λ	O
)	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
=ln⁡Φ	O
(	O
(	O
λ−M1η	O
)	O
/	O
σ1	O
)	O
1−Φ	O
(	O
(	O
λ−M0η	O
)	O
/	O
σ0	O
)	O
,	O
where	O
Φ	O
(	O
x	O
)	O
is	O
the	O
cumulative	O
normal	O
distribution	O
function	O
:	O
Φ	O
(	O
x	O
)	O
=12π∫−∞xe−z22dz	O
.	O

The	O
statistics	O
η	O
and	O
T^	O
(	O
2	O
)	O
are	O
equivalent	O
for	O
an	O
arbitrary	O
fixed	O
word	O
ω	O
(	O
although	O
not	O
equivalent	O
for	O
the	O
whole	O
totality	O
of	O
words	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
statistics	O
η	O
and	O
T	O
(	O
2	O
)	O
are	O
not	O
necessarily	O
equivalent	O
,	O
as	O
the	O
dependence	O
of	O
T	O
(	O
2	O
)	O
on	O
η	O
may	O
turn	O
out	O
to	O
be	O
not	O
monotonic	O
.	O

Moreover	O
,	O
it	O
is	O
never	O
monotonic	O
for	O
all	O
values	O
of	O
η	O
.	O

However	O
,	O
we	O
are	O
interested	O
only	O
in	O
values	O
0	O
≤	O
η	O
≤	O
1	O
,	O
and	O
usually	O
(	O
though	O
not	O
always	O
)	O
the	O
dependence	O
of	O
T	O
(	O
2	O
)	O
on	O
η	O
is	O
monotonous	O
for	O
these	O
values	O
of	O
η	O
,	O
and	O
in	O
this	O
case	O
the	O
statistics	O
η	O
and	O
T	O
(	O
2	O
)	O
are	O
equivalent	O
(	O
for	O
a	O
fixed	O
word	O
ω	O
)	O
.	O

Furthermore	O
,	O
even	O
in	O
the	O
case	O
where	O
the	O
dependence	O
is	O
not	O
monotonic	O
,	O
the	O
monotonicity	O
is	O
violated	O
only	O
for	O
the	O
values	O
of	O
η	O
close	O
either	O
to	O
0	O
or	O
to	O
1	O
,	O
and	O
the	O
lack	O
of	O
monotonicity	O
can	O
be	O
disregarded	O
.	O

We	O
still	O
have	O
to	O
discuss	O
the	O
question	O
of	O
the	O
choice	O
of	O
coefficients	O
ai	O
in	O
(	O
15	O
)	O
.	O

One	O
of	O
the	O
variants	O
was	O
described	O
above	O
:	O
formula	O
(	O
13	O
)	O
can	O
be	O
applied	O
.	O

Another	O
variant	O
was	O
introduced	O
in	O
[	O
5	O
]	O
.	O

This	O
variant	O
can	O
be	O
described	O
as	O
follows	O
.	O

As	O
above	O
,	O
we	O
assume	O
that	O
the	O
variate	O
η	O
=	O
∑aiξi	O
has	O
a	O
normal	O
distribution	O
.	O

Each	O
set	O
of	O
coefficients	O
ai	O
and	O
each	O
threshold	O
value	O
λ	O
have	O
corresponding	O
theoretical	O
frequencies	O
of	O
type	O
1	O
and	O
type	O
2	O
errors	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
,	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
.	O

The	O
idea	O
is	O
to	O
take	O
the	O
set	O
of	O
coefficients	O
{	O
ai	O
}	O
that	O
gives	O
the	O
minimum	O
sum	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
+	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
,	O
where	O
λ	O
is	O
the	O
best	O
threshold	O
value	O
for	O
this	O
coefficient	O
set	O
.	O

However	O
,	O
analytically	O
it	O
is	O
very	O
cumbersome	O
,	O
so	O
the	O
following	O
simplification	O
was	O
implemented	O
.	O

For	O
a	O
fixed	O
set	O
of	O
coefficients	O
{	O
ai	O
}	O
we	O
select	O
the	O
threshold	O
value	O
λ	O
such	O
that	O
the	O
frequency	O
of	O
type	O
1	O
errors	O
is	O
equal	O
to	O
the	O
frequency	O
of	O
type	O
2	O
errors	O
:	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
=	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
.	O

Then	O
we	O
find	O
the	O
set	O
of	O
coefficients	O
that	O
minimizes	O
these	O
frequencies	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
=	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
.	O

Here	O
the	O
search	O
of	O
the	O
coefficient	O
set	O
can	O
be	O
reduced	O
to	O
a	O
conditional	O
extremum	O
problem	O
.	O

The	O
A4	O
algorithm	O
uses	O
an	O
iterated	O
procedure	O
for	O
the	O
solution	O
of	O
this	O
problem	O
(	O
see	O
[	O
5	O
]	O
)	O
.	O

In	O
order	O
to	O
optimize	O
the	O
automated	O
annotation	O
procedure	O
,	O
that	O
is	O
to	O
increase	O
the	O
prediction	O
quality	O
,	O
certain	O
modifications	O
of	O
the	O
procedure	O
were	O
introduced	O
.	O

For	O
each	O
statistic	O
(	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
)	O
many	O
variants	O
(	O
up	O
to	O
36	O
)	O
,	O
including	O
the	O
variant	O
that	O
was	O
described	O
above	O
,	O
were	O
considered	O
–	O
each	O
variant	O
corresponds	O
to	O
a	O
certain	O
combination	O
of	O
these	O
modifications	O
.	O

Some	O
variants	O
really	O
turned	O
out	O
to	O
be	O
better	O
than	O
the	O
variants	O
described	O
above	O
.	O

A	O
simplified	O
scheme	O
of	O
modifications	O
(	O
and	O
thereby	O
of	O
statistic	O
variants	O
)	O
can	O
be	O
described	O
as	O
follows	O
.	O

1	O
)	O
What	O
primary	O
local	O
alignments	O
are	O
considered	O
?	O

In	O
the	O
described	O
variant	O
of	O
statistics	O
only	O
one	O
primary	O
local	O
alignment	O
(	O
the	O
one	O
with	O
the	O
maximum	O
power	O
)	O
was	O
considered	O
.	O

Meanwhile	O
,	O
all	O
constructed	O
local	O
alignments	O
with	O
sufficiently	O
high	O
power	O
can	O
be	O
considered	O
,	O
as	O
it	O
was	O
done	O
in	O
[	O
5	O
]	O
.	O

In	O
this	O
case	O
indices	O
i	O
in	O
(	O
9	O
)	O
,	O
(	O
12	O
)	O
,	O
(	O
15	O
)	O
correspond	O
not	O
to	O
individual	O
similar	O
sequences	O
,	O
but	O
to	O
primary	O
local	O
alignments	O
of	O
this	O
sequences	O
.	O

2	O
)	O
Are	O
the	O
lengths	O
of	O
primary	O
local	O
alignments	O
taken	O
into	O
consideration	O
?	O

In	O
the	O
described	O
variant	O
lengths	O
of	O
primary	O
local	O
alignments	O
were	O
not	O
taken	O
into	O
consideration	O
,	O
but	O
these	O
lengths	O
can	O
be	O
considered	O
as	O
well	O
.	O

In	O
this	O
case	O
indices	O
i	O
in	O
(	O
9	O
)	O
,	O
(	O
12	O
)	O
,	O
(	O
15	O
)	O
correspond	O
not	O
to	O
similar	O
sequences	O
or	O
primary	O
local	O
alignments	O
,	O
but	O
to	O
individual	O
positions	O
of	O
these	O
primary	O
local	O
alignments	O
(	O
as	O
in	O
case	O
of	O
FT	O
-	O
type	O
words	O
)	O
.	O

In	O
this	O
case	O
the	O
total	O
number	O
of	O
variates	O
ξi	O
is	O
equal	O
to	O
the	O
overall	O
length	O
of	O
all	O
primary	O
local	O
alignments	O
.	O

For	O
these	O
variants	O
of	O
statistics	O
long	O
local	O
alignments	O
turn	O
out	O
to	O
be	O
more	O
significant	O
than	O
short	O
local	O
alignments	O
with	O
the	O
same	O
power	O
.	O

3	O
)	O
How	O
are	O
the	O
coefficients	O
ai	O
calculated	O
?	O

The	O
coefficients	O
ai	O
in	O
(	O
15	O
)	O
can	O
be	O
calculated	O
using	O
different	O
methods	O
–	O
either	O
formula	O
(	O
13	O
)	O
can	O
be	O
used	O
,	O
or	O
an	O
iterative	O
method	O
(	O
described	O
in	O
[	O
5	O
]	O
)	O
can	O
be	O
applied	O
.	O

(	O
For	O
the	O
statistic	O
T	O
(	O
1	O
)	O
the	O
coefficients	O
ai	O
are	O
always	O
calculated	O
using	O
formula	O
(	O
13	O
)	O
)	O
.	O

As	O
there	O
are	O
3	O
modifications	O
,	O
the	O
total	O
number	O
of	O
basic	O
variants	O
(	O
in	O
the	O
described	O
simplified	O
scheme	O
)	O
equals	O
23	O
=	O
8	O
(	O
and	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
it	O
equals	O
4	O
)	O
.	O

So	O
,	O
variants	O
of	O
the	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
are	O
considered	O
in	O
this	O
paper	O
.	O

Moreover	O
,	O
for	O
the	O
purpose	O
of	O
comparison	O
(	O
as	O
in	O
the	O
paper	O
[	O
5	O
]	O
)	O
the	O
simple	O
statistic	O
(	O
18	O
)	O
q	O
=	O
q	O
(	O
ω	O
)	O
=∑inξin	O
(	O
the	O
frequency	O
of	O
occurrence	O
of	O
a	O
word	O
ω	O
in	O
the	O
collection	O
of	O
similar	O
sequences	O
)	O
is	O
also	O
considered	O
.	O

Finally	O
we	O
quote	O
a	O
scheme	O
of	O
the	O
A4	O
algorithm	O
in	O
Figure	O
1	O
(	O
this	O
scheme	O
is	O
essentially	O
taken	O
from	O
[	O
5	O
]	O
)	O
.	O

A	O
short	O
description	O
of	O
each	O
stage	O
can	O
be	O
found	O
in	O
[	O
5	O
]	O
.	O

Here	O
we	O
only	O
note	O
that	O
the	O
most	O
time	O
-	O
consuming	O
stage	O
is	O
the	O
first	O
one	O
–	O
the	O
generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
.	O

We	O
also	O
note	O
that	O
in	O
the	O
current	O
investigation	O
regions	O
were	O
not	O
determined	O
,	O
and	O
the	O
prediction	O
was	O
performed	O
for	O
the	O
whole	O
query	O
sequence	O
.	O

Testing	O
results	O
Testing	O
scheme	O
A	O
collection	O
of	O
518	O
sequences	O
,	O
randomly	O
selected	O
from	O
SWISS	O
-	O
PROT	O
databank	O
,	O
was	O
generated	O
.	O

Note	O
that	O
only	O
initially	O
annotated	O
sequences	O
(	O
i.e.	O
,	O
sequences	O
whose	O
description	O
fields	O
were	O
not	O
obtained	O
by	O
the	O
extension	O
from	O
similar	O
sequences	O
)	O
were	O
selected	O
.	O

The	O
prediction	O
was	O
performed	O
for	O
KW	O
-	O
type	O
words	O
.	O

All	O
selected	O
sequences	O
were	O
divided	O
into	O
two	O
groups	O
.	O

The	O
first	O
group	O
contained	O
210	O
sequences	O
.	O

This	O
group	O
was	O
used	O
during	O
the	O
""""	O
learning	O
stage	O
""""	O
:	O
the	O
procedure	O
was	O
applied	O
to	O
all	O
sequences	O
from	O
the	O
group	O
,	O
and	O
values	O
of	O
procedure	O
parameters	O
(	O
including	O
optimal	O
threshold	O
values	O
)	O
that	O
minimize	O
the	O
total	O
number	O
of	O
errors	O
for	O
the	O
first	O
group	O
were	O
selected	O
.	O

The	O
remaining	O
308	O
sequences	O
were	O
used	O
for	O
the	O
""""	O
main	O
testing	O
""""	O
that	O
was	O
performed	O
using	O
parameter	O
values	O
obtained	O
on	O
the	O
basis	O
of	O
""""	O
learning	O
""""	O
results	O
.	O

A	O
list	O
of	O
all	O
these	O
308	O
sequences	O
is	O
given	O
in	O
Additional	O
file	O
1	O
.	O

The	O
total	O
number	O
of	O
KW	O
-	O
type	O
words	O
in	O
the	O
description	O
fields	O
of	O
308	O
selected	O
sequences	O
,	O
used	O
as	O
query	O
sequences	O
,	O
was	O
equal	O
to	O
1176	O
(	O
the	O
positive	O
prediction	O
was	O
preferable	O
for	O
these	O
words	O
)	O
.	O

As	O
it	O
was	O
noted	O
,	O
a	O
collection	O
of	O
similar	O
sequences	O
was	O
generated	O
for	O
each	O
query	O
sequence	O
;	O
the	O
number	O
of	O
sequences	O
in	O
these	O
collections	O
equaled	O
100	O
.	O

Then	O
the	O
list	O
of	O
all	O
KW	O
-	O
type	O
words	O
from	O
description	O
fields	O
of	O
similar	O
sequences	O
was	O
formed	O
.	O

The	O
majority	O
of	O
these	O
words	O
belonged	O
only	O
to	O
one	O
similar	O
sequence	O
.	O

All	O
such	O
words	O
are	O
degenerate	O
,	O
transfer	O
probabilities	O
are	O
not	O
defined	O
for	O
them	O
.	O

At	O
the	O
same	O
time	O
nearly	O
all	O
these	O
words	O
did	O
not	O
belong	O
to	O
the	O
query	O
sequence	O
.	O

Hence	O
it	O
was	O
sensible	O
to	O
perform	O
prediction	O
only	O
for	O
words	O
that	O
belonged	O
to	O
at	O
least	O
two	O
similar	O
sequences	O
.	O

For	O
all	O
these	O
words	O
transfer	O
probabilities	O
were	O
evaluated	O
,	O
non	O
-	O
degenerate	O
words	O
(	O
i.e.	O
,	O
words	O
with	O
defined	O
transfer	O
probabilities	O
)	O
were	O
determined	O
,	O
and	O
the	O
prediction	O
was	O
performed	O
(	O
for	O
both	O
degenerate	O
and	O
non	O
-	O
degenerate	O
words	O
)	O
.	O

Table	O
1	O
shows	O
certain	O
characteristics	O
of	O
sequences	O
used	O
for	O
the	O
testing	O
.	O

The	O
average	O
number	O
of	O
words	O
considered	O
per	O
query	O
sequence	O
equals	O
30	O
and	O
the	O
entire	O
range	O
was	O
from	O
3	O
to	O
67	O
.	O

Final	O
results	O
Testing	O
results	O
are	O
presented	O
in	O
Table	O
2	O
.	O

The	O
table	O
contains	O
testing	O
results	O
for	O
the	O
basic	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
as	O
well	O
as	O
for	O
the	O
statistics	O
q	O
and	O
SAnd	O
,	O
included	O
into	O
the	O
table	O
for	O
the	O
purpose	O
of	O
comparison	O
(	O
See	O
the	O
Discussion	O
section	O
)	O
.	O

Each	O
line	O
of	O
the	O
table	O
corresponds	O
to	O
a	O
certain	O
variant	O
of	O
studied	O
statistics	O
.	O

The	O
first	O
column	O
shows	O
which	O
statistic	O
and	O
which	O
variant	O
of	O
this	O
statistic	O
corresponds	O
to	O
a	O
line	O
.	O

Variants	O
are	O
given	O
in	O
square	O
brackets	O
:	O
the	O
first	O
number	O
equals	O
0	O
if	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
not	O
considered	O
,	O
and	O
1	O
otherwise	O
;	O
the	O
second	O
number	O
equals	O
0	O
if	O
the	O
coefficients	O
ai	O
are	O
calculated	O
using	O
formula	O
(	O
13	O
)	O
,	O
and	O
1	O
if	O
the	O
coefficients	O
ai	O
are	O
calculated	O
using	O
the	O
iterative	O
procedure	O
(	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
the	O
second	O
number	O
is	O
always	O
0	O
)	O
.	O

The	O
second	O
column	O
contains	O
the	O
number	O
N1	O
of	O
type	O
1	O
errors	O
(	O
i.e.	O
,	O
number	O
of	O
cases	O
when	O
the	O
prediction	O
for	O
a	O
word	O
that	O
belongs	O
to	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
is	O
negative	O
)	O
.	O

The	O
third	O
column	O
contains	O
the	O
number	O
N2	O
of	O
type	O
2	O
errors	O
(	O
i.e.	O
,	O
number	O
of	O
cases	O
when	O
the	O
prediction	O
for	O
a	O
word	O
that	O
does	O
not	O
belong	O
to	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
is	O
positive	O
)	O
.	O

The	O
forth	O
column	O
contains	O
the	O
total	O
number	O
of	O
errors	O
Nall	O
=	O
N1	O
+	O
N2	O
.	O

The	O
next	O
columns	O
contain	O
sums	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
and	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
+	O
)	O
,	O
where	O
P	O
(	O
1	O
)	O
is	O
the	O
proportion	O
of	O
type	O
1	O
errors	O
,	O
P	O
(	O
2	O
)	O
is	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
,	O
and	O
P	O
(	O
+	O
)	O
is	O
the	O
ratio	O
of	O
false	O
positive	O
predictions	O
to	O
the	O
total	O
number	O
of	O
predictions	O
:	O
P	O
(	O
1	O
)	O
=N1nq	O
,	O
P	O
(	O
2	O
)	O
=N2nall−nq	O
,	O
P	O
(	O
+	O
)	O
=N2n+	O
(	O
nall	O
is	O
the	O
total	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
is	O
performed	O
,	O
i.e.	O
,	O
total	O
number	O
of	O
KW	O
-	O
type	O
words	O
in	O
description	O
fields	O
of	O
all	O
sequences	O
,	O
similar	O
to	O
at	O
least	O
one	O
query	O
sequence	O
,	O
nq	O
is	O
the	O
number	O
of	O
words	O
(	O
from	O
the	O
list	O
of	O
these	O
nall	O
words	O
)	O
that	O
belong	O
to	O
query	O
sequences	O
,	O
n+	O
is	O
the	O
total	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
is	O
positive	O
;	O
here	O
nall	O
=	O
9236	O
,	O
nq	O
=	O
1176	O
,	O
nall	O
-	O
nq	O
=	O
8060	O
;	O
the	O
value	O
of	O
n+	O
of	O
depends	O
on	O
the	O
threshold	O
evaluated	O
for	O
the	O
given	O
version	O
of	O
statistic	O
at	O
the	O
""""	O
learning	O
stage	O
""""	O
)	O
.	O

Lines	O
are	O
ordered	O
according	O
to	O
the	O
prediction	O
quality	O
:	O
higher	O
lines	O
correspond	O
to	O
statistic	O
variants	O
with	O
lower	O
total	O
number	O
of	O
errors	O
.	O

For	O
a	O
fixed	O
statistic	O
,	O
lines	O
that	O
correspond	O
to	O
the	O
best	O
variant	O
of	O
this	O
statistic	O
(	O
i.e.	O
,	O
for	O
the	O
variant	O
that	O
leads	O
to	O
the	O
lowest	O
total	O
number	O
of	O
errors	O
)	O
are	O
marked	O
.	O

Recall	O
that	O
the	O
statistic	O
T^	O
(	O
2	O
)	O
[	O
1,0	O
]	O
is	O
exactly	O
the	O
statistic	O
that	O
was	O
considered	O
in	O
[	O
5	O
]	O
(	O
note	O
that	O
it	O
is	O
the	O
best	O
variant	O
for	O
the	O
statistic	O
T^	O
(	O
2	O
)	O
)	O
.	O

The	O
results	O
could	O
also	O
have	O
been	O
presented	O
as	O
a	O
confusion	O
table	O
as	O
laid	O
out	O
in	O
Table	O
3	O
,	O
but	O
doing	O
so	O
for	O
all	O
variants	O
would	O
take	O
a	O
lot	O
of	O
space	O
.	O

The	O
testing	O
results	O
showed	O
that	O
the	O
first	O
modification	O
(	O
consideration	O
of	O
all	O
primary	O
local	O
alignments	O
or	O
only	O
one	O
primary	O
local	O
alignment	O
with	O
the	O
maximum	O
power	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
prediction	O
quality	O
,	O
so	O
results	O
are	O
only	O
presented	O
for	O
one	O
case	O
(	O
all	O
local	O
alignments	O
are	O
considered	O
,	O
similarly	O
to	O
[	O
5	O
]	O
)	O
.	O

Note	O
that	O
the	O
results	O
presented	O
in	O
the	O
Table	O
correspond	O
to	O
the	O
whole	O
totality	O
of	O
words	O
including	O
degenerate	O
words	O
(	O
though	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
,	O
T	O
(	O
nik	O
)	O
were	O
evaluated	O
only	O
for	O
non	O
-	O
degenerate	O
words	O
,	O
for	O
degenerate	O
words	O
the	O
prediction	O
was	O
performed	O
on	O
the	O
basis	O
of	O
the	O
statistic	O
q	O
,	O
i.e.	O
,	O
on	O
the	O
basis	O
of	O
word	O
frequency	O
)	O
.	O

In	O
particular	O
,	O
the	O
total	O
number	O
of	O
errors	O
includes	O
errors	O
for	O
degenerate	O
words	O
.	O

It	O
is	O
worth	O
noticing	O
that	O
the	O
total	O
number	O
of	O
errors	O
for	O
degenerate	O
words	O
in	O
case	O
of	O
the	O
best	O
choice	O
of	O
threshold	O
q0	O
for	O
the	O
frequency	O
q	O
(	O
ω	O
)	O
turned	O
out	O
to	O
be	O
surprisingly	O
small	O
:	O
only	O
13	O
(	O
whereas	O
the	O
number	O
of	O
errors	O
for	O
the	O
whole	O
totality	O
of	O
words	O
was	O
220	O
)	O
;	O
these	O
errors	O
included	O
twelve	O
type	O
1	O
errors	O
and	O
one	O
type	O
2	O
error	O
(	O
recall	O
that	O
the	O
prediction	O
was	O
performed	O
for	O
2029	O
degenerate	O
words	O
,	O
and	O
the	O
prediction	O
was	O
incorrect	O
only	O
in	O
13	O
cases	O
)	O
.	O

Such	O
a	O
small	O
number	O
of	O
errors	O
can	O
seemingly	O
be	O
explained	O
by	O
the	O
fact	O
that	O
for	O
degenerate	O
words	O
the	O
frequency	O
q	O
(	O
ω	O
)	O
is	O
nearly	O
always	O
close	O
either	O
to	O
1	O
or	O
to	O
0	O
,	O
otherwise	O
in	O
almost	O
all	O
cases	O
transfer	O
probabilities	O
p1|1	O
,	O
p1|0	O
can	O
be	O
defined	O
for	O
at	O
least	O
some	O
values	O
of	O
similarity	O
measure	O
μ	O
and	O
hence	O
a	O
word	O
ω	O
turns	O
out	O
to	O
be	O
non	O
-	O
degenerate	O
.	O

We	O
also	O
note	O
that	O
along	O
with	O
type	O
1	O
and	O
type	O
2	O
errors	O
other	O
errors	O
can	O
occur	O
,	O
as	O
it	O
is	O
possible	O
that	O
some	O
words	O
from	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
do	O
not	O
belong	O
to	O
description	O
fields	O
of	O
similar	O
sequences	O
and	O
hence	O
the	O
prediction	O
is	O
not	O
performed	O
for	O
these	O
words	O
at	O
all	O
.	O

However	O
,	O
we	O
used	O
a	O
large	O
number	O
of	O
similar	O
sequences	O
(	O
100	O
)	O
for	O
the	O
prediction	O
,	O
so	O
such	O
errors	O
were	O
extremely	O
rare	O
(	O
only	O
two	O
words	O
for	O
the	O
whole	O
test	O
set	O
of	O
518	O
sequences	O
,	O
whereas	O
the	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
was	O
performed	O
equaled	O
9236	O
)	O
.	O

Hence	O
,	O
in	O
our	O
case	O
these	O
errors	O
can	O
be	O
disregarded	O
.	O

Statistical	O
analysis	O
showed	O
that	O
the	O
precision	O
of	O
the	O
evaluation	O
of	O
N1	O
,	O
N2	O
,	O
Nall	O
is	O
reasonable	O
:	O
it	O
can	O
be	O
checked	O
that	O
the	O
relative	O
precision	O
of	O
Nall	O
(	O
the	O
standard	O
error	O
of	O
ln	O
(	O
Nall	O
)	O
)	O
is	O
in	O
the	O
order	O
of	O
7–10	O
%	O
which	O
is	O
in	O
line	O
with	O
the	O
relative	O
precision	O
of	O
a	O
Poisson	O
random	O
variable	O
that	O
is	O
given	O
by	O
1	O
/	O
Nall	O
.	O

However	O
,	O
since	O
the	O
""""	O
methods	O
""""	O
(	O
the	O
statistics	O
and	O
their	O
variants	O
)	O
are	O
compared	O
on	O
the	O
same	O
sequences	O
,	O
the	O
standard	O
error	O
for	O
the	O
comparison	O
between	O
methods	O
is	O
much	O
smaller	O
due	O
to	O
the	O
high	O
correlation	O
of	O
results	O
for	O
the	O
same	O
sequence	O
and	O
is	O
in	O
the	O
order	O
of	O
2–4	O
%	O
.	O

This	O
implies	O
that	O
""""	O
methods	O
""""	O
for	O
which	O
Nall	O
differ	O
by	O
more	O
than	O
10	O
%	O
can	O
considered	O
to	O
be	O
significantly	O
different	O
.	O

This	O
shows	O
that	O
size	O
of	O
the	O
experiment	O
with	O
210	O
randomly	O
selected	O
sequences	O
in	O
the	O
learning	O
stage	O
and	O
308	O
sequences	O
in	O
the	O
testing	O
stage	O
is	O
large	O
enough	O
to	O
obtain	O
valid	O
statements	O
about	O
the	O
accuracy	O
of	O
the	O
proposed	O
methodology	O
and	O
allows	O
statistical	O
comparisons	O
of	O
different	O
statistics	O
and	O
variants	O
.	O

When	O
the	O
set	O
of	O
tested	O
sequences	O
is	O
fixed	O
,	O
the	O
total	O
number	O
of	O
errors	O
Nall	O
is	O
an	O
objective	O
characteristic	O
of	O
prediction	O
quality	O
,	O
and	O
the	O
optimal	O
threshold	O
values	O
(	O
selected	O
during	O
the	O
""""	O
learning	O
stage	O
""""	O
)	O
provide	O
exactly	O
the	O
minimum	O
of	O
the	O
total	O
number	O
of	O
errors	O
.	O

However	O
,	O
if	O
different	O
testing	O
results	O
(	O
based	O
on	O
different	O
sets	O
of	O
query	O
sequences	O
)	O
are	O
compared	O
,	O
then	O
absolute	O
numbers	O
of	O
errors	O
can	O
not	O
be	O
treated	O
as	O
a	O
procedure	O
quality	O
measure	O
,	O
and	O
relative	O
quantities	O
(	O
proportions	O
)	O
should	O
be	O
considered	O
instead	O
of	O
absolute	O
quantities	O
.	O

Usually	O
a	O
sum	O
of	O
the	O
proportion	O
of	O
type	O
1	O
errors	O
and	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
is	O
used	O
as	O
a	O
quality	O
measure	O
;	O
values	O
of	O
this	O
sum	O
are	O
presented	O
in	O
the	O
fifth	O
column	O
of	O
Table	O
2	O
.	O

However	O
,	O
in	O
our	O
situation	O
the	O
number	O
of	O
words	O
nall	O
-	O
nq	O
that	O
do	O
not	O
belong	O
to	O
query	O
sequences	O
is	O
much	O
larger	O
than	O
nq	O
,	O
and	O
for	O
the	O
majority	O
of	O
these	O
words	O
it	O
is	O
obvious	O
that	O
they	O
do	O
not	O
belong	O
to	O
a	O
query	O
sequence	O
.	O

Consequently	O
,	O
in	O
case	O
of	O
optimal	O
parameter	O
values	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
P	O
(	O
2	O
)	O
is	O
small	O
,	O
it	O
is	O
considerably	O
smaller	O
than	O
P	O
(	O
1	O
)	O
.	O

Thus	O
the	O
quantity	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
is	O
not	O
representative	O
in	O
our	O
case	O
(	O
see	O
[	O
5	O
]	O
)	O
.	O

The	O
ratio	O
P	O
(	O
+	O
)	O
of	O
the	O
number	O
of	O
wrong	O
positive	O
predictions	O
to	O
the	O
total	O
number	O
of	O
positive	O
predictions	O
is	O
more	O
representative	O
than	O
P	O
(	O
2	O
)	O
.	O

Hence	O
,	O
it	O
is	O
natural	O
to	O
measure	O
procedure	O
quality	O
by	O
the	O
sum	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
+	O
)	O
.	O

Exactly	O
this	O
procedure	O
quality	O
measure	O
was	O
used	O
in	O
[	O
5	O
]	O
.	O

In	O
medical	O
decision	O
making	O
(	O
diagnostic	O
testing	O
)	O
the	O
terms	O
sensitivity	O
(	O
sens	O
=	O
1	O
-	O
P	O
(	O
1	O
)	O
)	O
and	O
specificity	O
(	O
spec	O
=	O
1	O
-	O
P	O
(	O
2	O
)	O
)	O
are	O
frequently	O
used	O
to	O
quantify	O
the	O
accuracy	O
of	O
a	O
procedure	O
,	O
while	O
the	O
quantity	O
1	O
-	O
P	O
(	O
+	O
)	O
is	O
known	O
as	O
the	O
positive	O
predictive	O
value	O
.	O

Alternative	O
terminology	O
is	O
discussed	O
in	O
[	O
12	O
]	O
.	O

The	O
ROC	O
curve	O
plotting	O
sens	O
against	O
1	O
-	O
spec	O
is	O
a	O
popular	O
way	O
of	O
showing	O
the	O
overall	O
performance	O
of	O
a	O
diagnostic	O
test	O
without	O
specification	O
of	O
a	O
cut	O
off	O
value	O
.	O

It	O
is	O
also	O
used	O
and	O
discussed	O
in	O
[	O
12	O
]	O
,	O
but	O
with	O
different	O
labels	O
for	O
the	O
axes	O
.	O

Figure	O
2	O
contains	O
ROC	O
curves	O
for	O
the	O
best	O
variants	O
of	O
the	O
statistics	O
(	O
i.e.	O
,	O
for	O
variants	O
that	O
were	O
marked	O
in	O
Table	O
2	O
)	O
applied	O
to	O
the	O
non	O
-	O
degenerate	O
words	O
.	O

Discussion	O
Overall	O
comparison	O
of	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
η	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
Mean	O
values	O
of	O
Nall	O
(	O
where	O
averaging	O
is	O
performed	O
over	O
all	O
variants	O
presented	O
in	O
Table	O
2	O
)	O
for	O
different	O
statistics	O
are	O
the	O
following	O
:	O
241	O
for	O
η	O
,	O
310	O
for	O
T	O
(	O
1	O
)	O
,	O
320	O
for	O
T	O
(	O
2	O
)	O
,	O
and	O
356	O
for	O
T^	O
(	O
2	O
)	O
(	O
recall	O
that	O
differences	O
in	O
the	O
order	O
of	O
10	O
%	O
can	O
be	O
considered	O
to	O
be	O
significant	O
)	O
.	O

These	O
numbers	O
show	O
that	O
the	O
statistics	O
can	O
clearly	O
be	O
ordered	O
with	O
respect	O
to	O
the	O
prediction	O
quality	O
:	O
the	O
best	O
statistic	O
is	O
η	O
,	O
then	O
comes	O
T	O
(	O
1	O
)	O
,	O
then	O
T	O
(	O
2	O
)	O
,	O
and	O
finally	O
T^	O
(	O
2	O
)	O
.	O

For	O
the	O
comparison	O
of	O
the	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
for	O
the	O
comparison	O
of	O
statistics	O
the	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
this	O
conclusion	O
is	O
obvious	O
.	O

For	O
the	O
comparison	O
of	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
it	O
seems	O
to	O
be	O
less	O
obvious	O
,	O
but	O
the	O
consideration	O
of	O
variants	O
in	O
which	O
the	O
calculation	O
of	O
coefficients	O
ai	O
is	O
performed	O
using	O
formula	O
(	O
13	O
)	O
(	O
i.e.	O
,	O
variants	O
[	O
0,0	O
]	O
and	O
[	O
1,0	O
]	O
;	O
recall	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
has	O
only	O
such	O
variants	O
)	O
clearly	O
shows	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
considerably	O
better	O
than	O
T	O
(	O
2	O
)	O
.	O

The	O
same	O
conclusion	O
can	O
be	O
drawn	O
from	O
the	O
comparison	O
of	O
ROC	O
curves	O
presented	O
in	O
Fig.	O
2	O
.	O

Testing	O
results	O
show	O
that	O
the	O
prediction	O
quality	O
for	O
the	O
best	O
variant	O
of	O
the	O
statistic	O
η	O
(	O
see	O
the	O
first	O
line	O
of	O
Table	O
2	O
)	O
is	O
much	O
higher	O
(	O
higher	O
by	O
50	O
%	O
)	O
in	O
comparison	O
with	O
results	O
of	O
[	O
5	O
]	O
(	O
see	O
the	O
line	O
of	O
Table	O
2	O
that	O
corresponds	O
to	O
T^	O
(	O
2	O
)	O
[	O
0,1	O
]	O
)	O
.	O

That	O
is	O
the	O
most	O
striking	O
finding	O
of	O
the	O
current	O
paper	O
.	O

It	O
is	O
interesting	O
to	O
see	O
that	O
the	O
statistic	O
η	O
turned	O
out	O
to	O
be	O
better	O
than	O
T	O
(	O
1	O
)	O
:	O
the	O
latter	O
would	O
be	O
expected	O
to	O
be	O
better	O
as	O
it	O
equals	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
(	O
in	O
reality	O
,	O
it	O
does	O
not	O
equal	O
this	O
logarithm	O
because	O
the	O
ξi	O
are	O
not	O
independent	O
)	O
.	O

We	O
suppose	O
that	O
this	O
fact	O
can	O
be	O
explained	O
as	O
follows	O
.	O

Recall	O
that	O
T	O
(	O
1	O
)	O
and	O
η	O
are	O
equivalent	O
for	O
an	O
arbitrary	O
fixed	O
word	O
ω	O
.	O

These	O
statistics	O
turn	O
out	O
to	O
be	O
not	O
equivalent	O
only	O
if	O
they	O
are	O
compared	O
on	O
the	O
whole	O
totality	O
of	O
words	O
.	O

It	O
is	O
worth	O
noting	O
that	O
the	O
variation	O
of	O
the	O
values	O
of	O
the	O
statistic	O
T	O
(	O
1	O
)	O
(	O
i.e.	O
,	O
the	O
difference	O
between	O
values	O
of	O
T	O
(	O
1	O
)	O
in	O
cases	O
ξ1	O
=	O
....	O
=	O
ξn	O
=	O
0	O
and	O
ξ1	O
=	O
....	O
=	O
ξn	O
=	O
1	O
)	O
significantly	O
depends	O
on	O
a	O
word	O
ω	O
:	O
for	O
some	O
words	O
these	O
values	O
vary	O
from	O
-700	O
to	O
700	O
,	O
for	O
some	O
other	O
from	O
-0.01	O
to	O
0.01	O
.	O

In	O
principle	O
,	O
the	O
optimal	O
threshold	O
value	O
is	O
different	O
for	O
different	O
words	O
.	O

As	O
the	O
ranges	O
of	O
T	O
(	O
1	O
)	O
values	O
essentially	O
vary	O
,	O
then	O
it	O
is	O
probable	O
that	O
optimal	O
thresholds	O
also	O
essentially	O
vary	O
.	O

The	O
optimal	O
threshold	O
for	O
the	O
whole	O
totality	O
of	O
words	O
is	O
a	O
certain	O
mean	O
value	O
of	O
thresholds	O
over	O
individual	O
words	O
ω	O
.	O

Since	O
the	O
optimal	O
thresholds	O
are	O
significantly	O
different	O
for	O
different	O
words	O
,	O
the	O
quality	O
of	O
the	O
mean	O
is	O
low	O
:	O
for	O
certain	O
words	O
(	O
e.g.	O
,	O
words	O
with	O
small	O
variation	O
of	O
T	O
(	O
1	O
)	O
)	O

this	O
mean	O
is	O
completely	O
unrepresentative	O
.	O

In	O
the	O
same	O
time	O
,	O
the	O
range	O
of	O
values	O
of	O
η	O
is	O
the	O
same	O
for	O
all	O
words	O
(	O
these	O
values	O
lie	O
between	O
0	O
and	O
1	O
)	O
.	O

Consequently	O
,	O
the	O
difference	O
between	O
optimal	O
thresholds	O
for	O
individual	O
words	O
is	O
probably	O
not	O
so	O
significant	O
,	O
and	O
the	O
mean	O
gives	O
better	O
quality	O
for	O
individual	O
words	O
in	O
comparison	O
with	O
T	O
(	O
1	O
)	O
.	O

From	O
the	O
point	O
of	O
view	O
of	O
prediction	O
quality	O
the	O
statistic	O
T	O
(	O
2	O
)	O
turned	O
out	O
to	O
be	O
worse	O
than	O
T	O
(	O
1	O
)	O
.	O

It	O
is	O
not	O
surprising	O
,	O
because	O
during	O
the	O
derivation	O
of	O
the	O
formula	O
for	O
T	O
(	O
2	O
)	O
along	O
with	O
the	O
incorrect	O
assumption	O
of	O
independence	O
of	O
ξi	O
we	O
also	O
made	O
the	O
incorrect	O
assumption	O
of	O
the	O
normal	O
distribution	O
of	O
η	O
.	O

This	O
consideration	O
is	O
applicable	O
to	O
T^	O
(	O
2	O
)	O
as	O
well	O
.	O

Since	O
the	O
cut	O
-	O
off	O
points	O
for	O
these	O
statistics	O
are	O
determined	O
empirically	O
in	O
the	O
test	O
set	O
and	O
validated	O
in	O
the	O
training	O
set	O
,	O
the	O
violation	O
of	O
the	O
normality	O
assumption	O
does	O
not	O
invalidate	O
the	O
procedures	O
as	O
such	O
,	O
but	O
might	O
affect	O
their	O
performance	O
.	O

Effect	O
of	O
procedure	O
modifications	O
The	O
next	O
issue	O
is	O
the	O
dependence	O
of	O
prediction	O
quality	O
on	O
procedure	O
modifications	O
.	O

One	O
can	O
see	O
that	O
for	O
a	O
fixed	O
statistic	O
the	O
prediction	O
quality	O
significantly	O
depends	O
on	O
the	O
choice	O
of	O
the	O
variant	O
.	O

Thus	O
,	O
the	O
introduction	O
of	O
modifications	O
turned	O
out	O
to	O
be	O
effective	O
.	O

It	O
is	O
interesting	O
that	O
all	O
statistics	O
for	O
which	O
coefficients	O
aj	O
can	O
be	O
calculated	O
in	O
different	O
ways	O
(	O
these	O
are	O
the	O
statistics	O
η	O
,	O
T	O
(	O
2	O
)	O
T^	O
(	O
2	O
)	O
)	O
prediction	O
quality	O
was	O
better	O
in	O
case	O
when	O
these	O
coefficients	O
were	O
calculated	O
using	O
the	O
iterative	O
procedure	O
.	O

At	O
the	O
same	O
time	O
the	O
dependence	O
of	O
prediction	O
quality	O
on	O
the	O
modification	O
related	O
to	O
the	O
consideration	O
of	O
lengths	O
of	O
primary	O
local	O
alignments	O
is	O
more	O
intricate	O
:	O
for	O
the	O
statistic	O
η	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
for	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
the	O
results	O
are	O
better	O
if	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
considered	O
,	O
but	O
for	O
the	O
statistic	O
T^	O
(	O
2	O
)	O
results	O
are	O
better	O
when	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
not	O
considered	O
.	O

Currently	O
reasons	O
of	O
this	O
fact	O
are	O
not	O
clear	O
for	O
us	O
.	O

As	O
it	O
was	O
noted	O
,	O
the	O
dependence	O
of	O
results	O
on	O
modifications	O
dealing	O
with	O
the	O
number	O
of	O
considered	O
primary	O
local	O
alignments	O
for	O
similar	O
sequences	O
is	O
not	O
essential	O
.	O

(	O
However	O
,	O
we	O
note	O
that	O
for	O
nearly	O
all	O
variants	O
that	O
were	O
described	O
above	O
as	O
well	O
as	O
variants	O
that	O
were	O
not	O
described	O
,	O
prediction	O
quality	O
is	O
better	O
in	O
case	O
when	O
all	O
primary	O
local	O
alignments	O
are	O
considered	O
)	O
.	O

Comparison	O
with	O
other	O
procedures	O
For	O
the	O
purpose	O
of	O
comparison	O
we	O
compared	O
our	O
findings	O
with	O
the	O
simple	O
statistic	O
q	O
(	O
ω	O
)	O
(	O
the	O
frequency	O
of	O
word	O
occurrence	O
in	O
the	O
list	O
of	O
similar	O
sequences	O
,	O
see	O
(	O
18	O
)	O
)	O
was	O
also	O
considered	O
,	O
using	O
a	O
threshold	O
of	O
q	O
=	O
0.422	O
.	O

As	O
expected	O
,	O
q	O
(	O
ω	O
)	O
gave	O
essentially	O
worse	O
results	O
in	O
comparison	O
with	O
T	O
(	O
1	O
)	O
,	O
η	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
(	O
see	O
Table	O
2	O
)	O
.	O

Furthermore	O
,	O
we	O
compared	O
our	O
results	O
with	O
the	O
results	O
,	O
which	O
predicts	O
all	O
of	O
the	O
words	O
for	O
which	O
there	O
is	O
among	O
similar	O
sequences	O
at	O
least	O
one	O
sequence	O
with	O
a	O
power	O
above	O
a	O
certain	O
threshold	O
.	O

Such	O
an	O
approach	O
was	O
used	O
by	O
Andrade	O
M.	O
et	O
al.	O
[	O
2	O
]	O
.	O

This	O
is	O
the	O
statistics	O
SAnd	O
as	O
already	O
mentioned	O
in	O
Table	O
2	O
.	O

It	O
is	O
defined	O
as	O
SAnd	O
(	O
ω	O
)	O
=	O
max	O
μj	O
,	O
where	O
μj	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
π0	O
,	O
πj	O
,	O
and	O
the	O
maximum	O
is	O
taken	O
on	O
the	O
j	O
for	O
which	O
ξj	O
(	O
ω	O
)	O
=	O
1	O
(	O
i.e.	O
the	O
word	O
belongs	O
to	O
these	O
sequences	O
)	O
.	O

In	O
our	O
application	O
similarity	O
is	O
measured	O
by	O
the	O
power	O
value	O
(	O
see	O
[	O
9,10	O
]	O
)	O
as	O
used	O
in	O
the	O
other	O
statistics	O
in	O
this	O
paper	O
and	O
mentioned	O
before	O
,	O
while	O
[	O
2	O
]	O
used	O
the	O
E	O
-	O
value	O
.	O

That	O
makse	O
the	O
cut	O
-	O
offs	O
hard	O
to	O
compare	O
.	O

The	O
results	O
for	O
these	O
statistics	O
are	O
given	O
in	O
the	O
same	O
Table	O
2	O
.	O

The	O
results	O
were	O
better	O
than	O
in	O
the	O
statistics	O
q	O
(	O
ω	O
)	O
,	O
but	O
worse	O
than	O
in	O
any	O
of	O
our	O
statistics	O
.	O

Surprisingly	O
,	O
it	O
turned	O
out	O
that	O
the	O
prediction	O
quality	O
is	O
better	O
when	O
only	O
some	O
similar	O
sequences	O
(	O
e.g.	O
,	O
10	O
from	O
100	O
)	O
are	O
used	O
for	O
the	O
evaluation	O
of	O
a	O
statistic	O
(	O
but	O
not	O
for	O
the	O
evaluation	O
of	O
transfer	O
probabilities	O
!	O
)	O
.	O

It	O
means	O
that	O
a	O
large	O
part	O
of	O
similar	O
sequences	O
only	O
leads	O
to	O
an	O
increase	O
of	O
""""	O
noise	O
""""	O
.	O

(	O
See	O
[	O
13	O
]	O
for	O
details	O
.	O
)	O

We	O
would	O
also	O
like	O
to	O
mention	O
the	O
work	O
[	O
14	O
]	O
on	O
FunCat	O
categories	O
containing	O
a	O
set	O
of	O
about	O
7,500	O
well	O
annotated	O
proteins	O
and	O
providing	O
a	O
benchmarking	O
for	O
different	O
methods	O
of	O
automated	O
annotation	O
.	O

It	O
would	O
be	O
interesting	O
to	O
apply	O
our	O
procedure	O
to	O
this	O
database	O
,	O
but	O
that	O
has	O
not	O
been	O
realized	O
yet	O
.	O

We	O
did	O
not	O
attempt	O
at	O
this	O
stage	O
to	O
apply	O
our	O
approach	O
to	O
the	O
GO	O
annotation	O
.	O

It	O
would	O
be	O
interesting	O
further	O
research	O
to	O
switch	O
to	O
GO	O
data	O
and	O
to	O
compare	O
our	O
approach	O
with	O
other	O
approaches	O
in	O
the	O
literature	O
.	O

There	O
is	O
a	O
similarity	O
with	O
the	O
approach	O
of	O
Kajan	O
et	O
al.	O
[	O
15	O
]	O
.	O

They	O
also	O
base	O
their	O
procedures	O
on	O
the	O
likelihood	O
ratio	O
,	O
but	O
use	O
approximations	O
based	O
on	O
maximal	O
similarity	O
(	O
or	O
minimal	O
distance	O
)	O
,	O
while	O
we	O
attempt	O
to	O
estimate	O
the	O
likelihood	O
ratio	O
from	O
pairwise	O
comparisons	O
within	O
the	O
set	O
of	O
similar	O
sequences	O
.	O

There	O
is	O
also	O
an	O
interesting	O
relation	O
with	O
the	O
GOPET	O
tool	O
presented	O
in	O
[	O
16	O
]	O
based	O
on	O
earlier	O
work	O
by	O
the	O
same	O
authors	O
[	O
17	O
]	O
.	O

These	O
authors	O
use	O
a	O
number	O
of	O
characteristics	O
of	O
the	O
set	O
of	O
found	O
similar	O
sequences	O
for	O
term	O
(	O
word	O
)	O
,	O
such	O
as	O
maximal	O
e	O
-	O
value	O
,	O
frequency	O
of	O
the	O
term	O
etc	O
.	O
,	O
as	O
a	O
coordinates	O
of	O
decision	O
making	O
space	O
.	O

They	O
use	O
more	O
features	O
while	O
we	O
concentrate	O
on	O
the	O
similarity	O
.	O

That	O
might	O
be	O
an	O
advantage	O
for	O
their	O
method	O
.	O

On	O
the	O
other	O
hand	O
we	O
try	O
to	O
use	O
the	O
information	O
from	O
all	O
similar	O
sequences	O
in	O
an	O
optimal	O
way	O
relying	O
on	O
statistical	O
decision	O
theory	O
by	O
means	O
of	O
the	O
use	O
of	O
transfer	O
probabilities	O
and	O
the	O
concept	O
of	O
likelihood	O
ratio	O
.	O

It	O
is	O
an	O
interesting	O
topic	O
of	O
further	O
research	O
to	O
compare	O
the	O
two	O
methods	O
.	O

So	O
far	O
we	O
only	O
predicted	O
the	O
presence	O
of	O
a	O
key	O
word	O
.	O

It	O
is	O
quite	O
a	O
challenge	O
to	O
obtain	O
a	O
true	O
prediction	O
of	O
function	O
.	O

Conclusion	O
The	O
main	O
conclusion	O
of	O
the	O
paper	O
is	O
that	O
the	O
introduction	O
of	O
the	O
concept	O
of	O
likelihood	O
ratio	O
coming	O
from	O
statistical	O
decision	O
theory	O
is	O
very	O
helpful	O
in	O
the	O
development	O
of	O
automated	O
annotation	O
procedures	O
.	O

We	O
obtained	O
a	O
substantial	O
improvement	O
when	O
compared	O
with	O
our	O
previous	O
results	O
.	O

We	O
are	O
sure	O
that	O
there	O
is	O
room	O
for	O
further	O
improvement	O
.	O

Issues	O
for	O
further	O
research	O
are	O
the	O
size	O
of	O
the	O
set	O
of	O
similar	O
sequences	O
and	O
the	O
combination	O
of	O
different	O
statistics	O
into	O
a	O
""""	O
super	O
-	O
predictor	O
""""	O
.	O

Authors	O
'	O
contributions	O
A.M.	O
Leontovich	O
and	O
H.C.	O
van	O
Houwelingen	O
developed	O
the	O
approach	O
.	O

A.M.	O
Leontovich	O
developed	O
the	O
methodology	O
and	O
the	O
algorithms	O
in	O
cooperation	O
with	O
K.Y.	O
Tokmachev	O
and	O
H.C.	O
van	O
Houwelingen	O
.	O

K.Y.	O
Tokmachev	O
carried	O
out	O
all	O
computations	O
.	O

Supplementary	O
Material	O

Carbonic	O
Anhydrase	O
Inhibitors	O
.	O

Part	O
541	O
:	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O
A	O
New	O
Class	O
of	O
Antiglaucoma	O
Agents	O
Abstract	O
Metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
inhibitory	O
properties	O
were	O
recently	O
shown	O
to	O
be	O
useful	O
as	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
lowering	O
agents	O
in	O
experimental	O
animals	O
,	O
and	O
might	O
be	O
developed	O
as	O
a	O
novel	O
class	O
of	O
antiglaucoma	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
CA	O
inhibitor	O
and	O
of	O
the	O
metal	O
complexes	O
containing	O
main	O
group	O
metal	O
ions	O
,	O
such	O
as	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
Al	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
and	O
the	O
new	O
sulfonamide	O
as	O
well	O
as	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
as	O
ligands	O
.	O

The	O
new	O
complexes	O
were	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
CA	O
I	O
,	O
II	O
and	O
IV	O
.	O

Some	O
of	O
them	O
(	O
but	O
not	O
the	O
parent	O
sulfonamides	O
)	O
strongly	O
lowered	O
IOP	O
in	O
rabbits	B
when	O
administered	O
as	O
a	O
2	O
%	O
solution	O
into	O
the	O
eye	O
.	O

CARBONIC	O
ANHYDRASE	O
INHIBITORS	O
.	O

Part	O
54	O
METAL	O
COMPLEXES	O
OF	O
HETEROCYCLIC	O
SULFONAMIDES	O
:	O
A	O
NEW	O
CLASS	O
OF	O
ANTIGLAUCOMA	O
AGENTS	O
Claudiu	O
T.	O
Supuran	O

*	O
,	O
Andrea	O
Scozzafava	O
and	O
Andrei	O
Jitianu	O
2	O
Universit	O
&	O
degli	O
Studi	O
,	O
Dipartimento	O
di	O
Chimica	O
,	O
Laboratorio	O
di	O
Chimica	O
Inorganica	O

e	O
Bioinorganica	O
,	O
Via	O
Gino	O
Capponi	O
7	O
,	O
1	O
-	O
50121	O
,	O
Florence	O
,	O
Italy	O
2	O

""""	O
I.G.	O
Murgulescu	O
""""	O
Institute	O
of	O
Physical	O
Chemistry	O
,	O
Academia	O
Romana	O
,	O
Spl	O
.	O

Independentei	O
202	O
,	O
R-77208	O
Bucharest	O
,	O
Roumania	O
Abstract	O
:	O
Metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
inhibitory	O
properties	O
were	O
recently	O
shown	O
to	O
be	O
useful	O
as	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
lowering	O
agents	O
in	O
experimental	O
animals	O
,	O
and	O
might	O
be	O
developed	O
as	O
a	O
novel	O
class	O
of	O
antiglaucoma	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
CA	O
inhibitor	O
and	O
of	O
the	O
metal	O
complexes	O
containing	O
main	O
group	O
metal	O
ions	O
,	O
such	O
as	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
AI	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
and	O
the	O
new	O
sulfonamide	O
as	O
well	O
as	O
5-amino	O
-	O
l,3,4thiadiazole-2-sulfonamide	O
as	O
ligands	O
.	O

The	O
new	O
complexes	O
were	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
CA	O
I	O
,	O
II	O
and	O
IV	O
.	O

Some	O
of	O
them	O
(	O
but	O
not	O
the	O
parent	O
sulfonamides	O
)	O
strongly	O
lowered	O
IOP	O
in	O
rabbits	B
when	O
administered	O
as	O
a	O
2	O
%	O
solution	O
into	O
the	O
eye	O
.	O

Introduction	O
Sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
,	O
EC	O
4.2.1.1	O
)	O
inhibitory	O
properties	O
[	O
2	O
]	O
such	O
as	O
acetazolamide	O
1	O
,	O
methazolamide	O
2	O
,	O
ethoxzolamide	O
3	O
and	O
dichlorophenamide	O
4	O
have	O
been	O
used	O
for	O
more	O
than	O
40	O
years	O
as	O
pressure	O
lowering	O
systemic	O
drugs	O
in	O
the	O
treatment	O
of	O
open	O
-	O
angle	O
glaucoma	O
[	O
3,4	O
]	O
.	O

Their	O
effect	O
is	O
due	O
to	O
inhibition	O
of	O
at	O
least	O
two	O
CA	O
isozymes	O
present	O
within	O
cilliary	O
processes	O
of	O
the	O
eye	O
,	O
ie	O
,	O
CA	O
II	O
and	O
CA	O
IV	O
,	O
which	O
is	O
followed	O
by	O
lowered	O
bicarbonate	O
formation	O
and	O
reduction	O
of	O
aqueous	O
humor	O
secretion	O
[	O
5	O
-	O
7	O
]	O
.	O

Their	O
main	O
drawback	O
is	O
constituted	O
by	O
side	O
effects	O
such	O
as	O
fatigue	O
,	O
augmented	O
diuresis	O
,	O
or	O
paresthesias	O
,	O
due	O
to	O
CA	O
inhibition	O
in	O
other	O
tissues	O
/	O
organs	O
than	O
the	O
target	O
one	O
,	O
ie	O
,	O
the	O
eye	O
[	O
8	O
]	O
.	O

N	O
--	O
N	O
XN	O
--	O
N	O
EtO	O
S	O
NH	O
2	O
O	O
NH	O
O	O
:	O
S----O	O
NHEt	O
The	O
above	O
-	O
mentioned	O
side	O
effects	O
are	O
absent	O
in	O
the	O
case	O
in	O
which	O
the	O
inhibitor	O
has	O
topical	O
activity	O
,	O
and	O
is	O
applied	O
directly	O
into	O
the	O
eye	O
.	O

This	O
route	O
has	O
been	O
demonstrated	O
only	O
in	O
1983	O
by	O
Maren	O
's	O
group	O
[	O
9	O
]	O
and	O
was	O
followed	O
by	O
the	O
development	O
of	O
the	O
first	O
clinical	O
agent	O
of	O
this	O
type	O
,	O
dorzolamide	O
5	O
[	O
10,11	O
]	O
.	O

Dorzolamide	O
(	O
Trusopt	O
)	O
has	O
been	O
introduced	O
in	O
clinical	O
use	O
in	O
1995	O
in	O
USA	O
and	O
Europe	O
and	O
it	O
constituted	O
the	O
beginning	O
of	O
a	O
radically	O
new	O
treatment	O
of	O
glaucoma	O
,	O
devoid	O
of	O
the	O
severe	O
side	O
effects	O
observed	O
with	O
the	O
systemic	O
inhibitors	O
[	O
4	O
-	O
6	O
]	O
.	O

The	O
success	O
of	O
topical	O
antiglaucoma	O
CA	O
inhibitors	O
fostered	O
much	O
research	O
in	O
the	O
synthesis	O
and	O
clinical	O
evaluation	O
of	O
other	O
types	O
of	O
such	O
compounds	O
[	O
12	O
-	O
15	O
]	O
.	O

307	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O
A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
On	O
the	O
other	O
hand	O
,	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
of	O
type	O
1	O
-	O
5	O
have	O
been	O
recently	O
prepared	O
by	O
two	O
groups	O
16	O
-	O
20	O
]	O
,	O
and	O
it	O
was	O
proved	O
that	O
they	O
possess	O
much	O
stronger	O
CA	O
inhibitory	O
properties	O
than	O
the	O
sulfonamides	O
from	O
which	O
they	O
were	O
prepared	O
18	O
-	O
22	O
]	O
.	O

Although	O
the	O
mechanism	O
of	O
CA	O
inhibition	O
of	O
the	O
metal	O
complexes	O
is	O
presently	O
unknown	O
,	O
it	O
was	O
hypothesized	O
that	O
their	O
increased	O
inhibitory	O
power	O
might	O
be	O
due	O
to	O
two	O
processes	O
,	O
occurring	O
separately	O
or	O
in	O
concert	O
,	O
ie	O
,	O
(	O
i	O
)	O
dissociation	O
of	O
the	O
complex	O
inhibitor	O
in	O
sulfonamide	O
anions	O
and	O
metal	O
ions	O
(	O
in	O
diluted	O
solution	O
)	O
,	O
which	O
in	O
turn	O
both	O
interact	O
thereafter	O
with	O
the	O
enzyme	O
,	O
at	O
different	O
binding	O
sites	O
,	O
and	O
(	O
ii	O
)	O
direct	O
interaction	O
of	O
the	O
undissociated	O
complex	O
with	O
the	O
enzyme	O
,	O
and	O
more	O
specifically	O
with	O
the	O
hydrophilic	O
patch	O
at	O
the	O
entrance	O
of	O
CA	O
II	O
active	O
site	O
[	O
23	O
]	O
,	O
this	O
being	O
the	O
isozyme	O
most	O
susceptible	O
to	O
inhibition	O
with	O
this	O
class	O
of	O
compounds	O
[	O
2,22	O
]	O
.	O

Whether	O
initially	O
the	O
first	O
mechanism	O
of	O
action	O
mentioned	O
above	O
was	O
favored	O
by	O
us	O
[	O
22	O
]	O
,	O
recent	O
evidences	O
suggested	O
that	O
the	O
undissociated	O
complex	O
might	O
be	O
the	O
inhibitory	O
species	O
,	O
at	O
least	O
for	O
some	O
isozymes	O
[	O
24	O
]	O
.	O

Since	O
metal	O
complexes	O
are	O
much	O
more	O
inhibitory	O
than	O
the	O
parent	O
sulfonamide	O
from	O
which	O
they	O
were	O
prepared	O
,	O
it	O
appeared	O
of	O
interest	O
to	O
test	O
whether	O
this	O
property	O
might	O
be	O
useful	O
for	O
their	O
use	O
in	O
lowering	O
IOP	O
in	O
experimental	O
animals	O
and	O
whence	O
as	O
a	O
possible	O
glaucoma	O
therapy	O
.	O

Recently	O
we	O
proved	O
[	O
25	O
,	O
26	O
]	O
that	O
some	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
(	O
which	O
themselves	O
do	O
not	O
possess	O
IOP	O
lowering	O
properties	O
)	O
act	O
as	O
very	O
powerful	O
such	O
agents	O
when	O
administered	O
as	O
diluted	O
solutions	O
directly	O
into	O
the	O
eye	O
of	O
experimental	O
animals	O
,	O
and	O
would	O
thus	O
offer	O
the	O
possibility	O
of	O
developing	O
such	O
totally	O
novel	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
possessing	O
strong	O
CA	O
inhibitory	O
properties	O
,	O
ie	O
,	O
5-	O
(	O
chloroacetamido	O
)	O
-l,3,4-thiadiazole-2-sulfonamide	O
,	O
and	O
of	O
the	O
metal	O
complexes	O
of	O
this	O
sulfonamide	O
and	O
of	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
,	O
containing	O
some	O
main	O
group	O
metal	O
ions	O
.	O

The	O
new	O
compounds	O
have	O
been	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
were	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
hCA	O
I	O
,	O
hCA	O
II	O
and	O
bCA	O
IV	O
(	O
h	O
human	B
;	O
b	O
bovine	B
;	O
these	O
are	O
the	O
isozymes	O
considered	O
to	O
play	O
a	O
critical	O
role	O
in	O
aqueous	O
humour	O
secretion	O
within	O
the	O
eye	O
of	O
higher	O
vertebrates	O
[	O
2	O
-	O
5	O
]	O
)	O
.	O

Materials	O
and	O
Methods	O
Melting	O
points	O
were	O
recorded	O
with	O
a	O
heating	O
plate	O
microscope	O
and	O
are	O
not	O
corrected	O
.	O

IR	O
spectra	O
were	O
recorded	O
in	O
KBr	O
pellets	O
with	O
a	O
Carl	O
Zeiss	O
IR-80	O
instrument	O
.	O

1H	O
-	O
NMR	O
spectra	O
were	O
recorded	O
in	O
DMSO	O
-	O
d6	O
as	O
solvent	O
,	O
with	O
a	O
Bruker	O
CPX200	O
instrument	O
.	O

Chemical	O
shifts	O
are	O
reported	O
as	O
values	O
,	O
relative	O
to	O
Me4Si	O
as	O
internal	O
standard	O
.	O

Conductimetric	O
measurements	O
were	O
done	O
at	O
room	O
temperature	O
(	O
1	O
mM	O
concentration	O
of	O
complex	O
)	O
in	O
DMSO	O
solution	O
with	O
a	O
Fisher	O
conductimeter	O
.	O

Elemental	O
analyses	O
were	O
done	O
by	O
combustion	O
for	O
C	O
,	O
H	O
,	O
N	O
with	O
an	O
automated	O
Carlo	O
Erba	O
analyzer	O
,	O
and	O
gravimetrically	O
for	O
the	O
metal	O
ions	O
,	O
and	O
were	O
0.4	O
%	O
of	O
the	O
theoretical	O
values	O
.	O

Thermogravimetric	O
measurements	O
were	O
done	O
in	O
air	O
,	O
at	O
a	O
heating	O
rate	O
of	O
10C	O
/	O
min	O
.	O
,	O
with	O
a	O
Perkin	O
Elmer	O
3600	O
thermobalance	O
.	O

Sulfonamides	O
used	O
as	O
standards	O
in	O
the	O
enzymatic	O
assay	O
(	O
except	O
for	O
5	O
)	O
,	O
acetazolamide	O
,	O
pyridine	O
,	O
and	O
chloroacetyl	O
chloride	O
used	O
for	O
the	O
preparation	O
of	O
compound	O
7	O
,	O
solvents	O
as	O
well	O
as	O
inorganic	O
reagents	O
were	O
from	O
Sigma	O
,	O
Merck	O
and	O
Carlo	O
Erba	O
.	O

5-Amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
was	O
prepared	O
from	O
acetazolamide	O
by	O
literature	O
procedures	O
[	O
27	O
]	O
,	O
by	O
desacetylation	O
with	O
concentrated	O
hydrochloric	O
acid	O
,	O
followed	O
by	O
neutralization	O
with	O
sodium	O
bicarbonate	O
of	O
the	O
corresponding	O
hydrochloride	O
(	O
Scheme	O
1	O
)	O
.	O

Dorzolamide	O
hydrochloride	O
5	O
was	O
from	O
Merck	O
,	O
Sharp	O
and	O
Dohme	O
or	O
was	O
prepared	O
as	O
described	O
by	O
Ponticello	O
et	O
al	O
10,11	O
]	O
.	O

Human	B
CA	O
and	O
CA	O
II	O
cDNAs	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
strain	O
BL21	O
(	O
DE3	O
)	O
from	O
the	O
plasmids	O
pACA	O
/	O
hCA	O
I	O
and	O
pACAdaCA	O
II	O
described	O
by	O
Forsman	O
et	O
al.	O
[	O
28	O
]	O
(	O
the	O
two	O
plasmids	O
were	O
a	O
gift	O
from	O
Prof.	O
Sven	O
Lindskog	O
,	O
Umea	O
University	O
,	O
Sweden	O
)	O
.	O

Cell	O
growth	O
conditions	O
were	O
those	O
described	O
by	O
Lindskog	O
's	O
group	O
[	O
29	O
]	O
,	O
and	O
enzymes	O
were	O
purified	O
by	O
affinity	O
chromatography	O
according	O
to	O
the	O
method	O
of	O
Khalifah	O
et	O
al	O
[	O
30	O
]	O
.	O

Enzyme	O
concentrations	O
were	O
determined	O
spectrophotometrically	O
at	O
280	O
nm	O
,	O
utilizing	O
a	O
molar	O
absorptivity	O
of	O
49	O
mM	O
-	O
l.cm-1	O
for	O
hCA	O
and	O
54	O
mM	O
-	O
l.cm-1	O
for	O
hCA	O
II	O
,	O
respectively	O
,	O
based	O
on	O
M	O
28.85	O
kDa	O
for	O
hCA	O
I	O
,	O
and	O
29.3	O
kDa	O
for	O
hCA	O
II	O
,	O
respectively	O
[	O
31,32	O
]	O
.	O

bCA	O
IV	O
was	O
isolated	O
from	O
bovine	B
lung	O
microsomes	O
as	O
described	O
by	O
Maren	O
et	O
al	O
,	O
and	O
its	O
concentration	O
has	O
been	O
determined	O
by	O
titration	O
with	O
ethoxzolamide	O
[	O
33	O
]	O
.	O

Synthesis	O
of	O
5-	O
(	O
chloroacetamido	O
)	O
-	O
l	O
,	O
3	O
,	O
4-thiadiazole-2-sulfonamide	O
7	O
An	O
amount	O
of	O
1.80	O
g	O
(	O
10	O
mmol	O
)	O
of	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
6	O
was	O
suspended	O
in	O
20	O
mL	O
of	O
anhydrous	O
acetonitrile	O
and	O
0.9	O
mL	O
(	O
0.87	O
g	O
,	O
11	O
mmol	O
)	O
of	O
pyridine	O
added	O
.	O

The	O
mixture	O
was	O
magnetically	O
stirred	O
at	O
4	O
C	O
for	O
10	O
minutes	O
,	O
then	O
10.5	O
mmol	O
of	O
monochloroacetyl	O
chloride	O
,	O
dissolved	O
in	O
3	O
mL	O
acetonitrile	O
,	O
were	O
added	O
dropwise	O
for	O
5	O
min	O
,	O
and	O
stirring	O
was	O
continued	O
for	O
other	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

After	O
an	O
additional	O
30	O
min	O
of	O
refluxation	O
,	O
followed	O
by	O
cooling	O
,	O
the	O
precipitated	O
crystals	O
were	O
filtered	O
and	O
recrystallized	O
from	O
ethanol	O
.	O

Yield	O
of	O
62	O
%	O
white	O
crystals	O
,	O
mp	O
246	O
-	O
248	O
o	O
lit	O
[	O
34	O
]	O
mp	O
IR	O
(	O
KBr	O
)	O
,	O
cm	O
-	O
l	O
:	O
590	O
,	O
610	O
,	O
660	O
,	O
790	O
,	O
935	O
,	O
1090	O
,	O
1115	O
,	O
1170	O
,	O
1350	O
,	O
1400	O
,	O
1550	O
,	O
1650	O
,	O
1720	O
,	O
2870	O
,	O
3280	O
3370	O
(	O
broad	O
)	O
;	O
UV	O
spectrum	O
,	O
,	O
max	O
,	O
nm	O
(	O
lg	O
)	O
:	O
255	O
(	O
3.50	O
)	O
;	O
288	O
(	O
4.37	O
)	O
H	O
-	O
NMR	O
(	O
DMSO	O
-	O
d6	O
)	O
,	O
i	O
,	O
ppm	O
:	O
2.96	O
(	O
s	O
,	O
2H	O
,	O
CH2	O
)	O
;	O
8.20	O
(	O
s	O
,	O
2H	O
,	O
SOzNH2	O
)	O
;	O
12.22	O
(	O
s	O
,	O
1H	O
,	O
CONH	O
)	O
.	O

Analysis	O
,	O
found	O
:	O
C	O
,	O
18.56	O
;	O
H	O
,	O
1.88	O
;	O
N	O
,	O
21.76	O
;	O
S	O
,	O
24.62	O
%	O
;	O
C4HsC1N403S2	O
requires	O
""""	O
C	O
,	O
18.72	O
;	O
H	O
,	O
1.96	O
;	O
N	O
,	O
21.83	O
;	O
S	O
,	O
24.98	O
%	O
.	O

General	O
procedure	O
for	O
the	O
preparation	O
of	O
compounds	O
8	O
-	O
20	O
An	O
amount	O
of	O
6	O
mmol	O
of	O
sodium	O
salt	O
of	O
sulfonamides	O
6	O
or	O
7	O
was	O
prepared	O
by	O
reacting	O
the	O
corresponding	O
sulfonamide	O
with	O
the	O
required	O
amount	O
of	O
an	O
alcoholic	O
1N	O
NaOH	O
solution	O
,	O
in	O
ethanol	O
as	O
solvent	O
.	O

To	O
this	O
308	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
solution	O
was	O
added	O
the	O
aqueous	O
metal	O
salt	O
(	O
Zn	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
AI	O
(	O
III	O
)	O
,	O
Cd	O
(	O
II	O
)	O
chlorides	O
,	O
and	O
Be	O
(	O
II	O
)	O
,	O
Pb	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
nitrate	O
)	O
solution	O
,	O
working	O
in	O
molar	O
ratios	O
RSOzNH-	O
Mn+	O
of	O
2:1	O
for	O
the	O
divalent	O
cations	O
and	O
3:1	O
for	O
the	O
trivalent	O
cation	O
,	O
respectively	O
.	O

The	O
aqueous	O
-	O
alcoholic	O
reaction	O
mixture	O
was	O
heated	O
on	O
a	O
steam	O
bath	O
for	O
one	O
hour	O
,	O
adjusting	O
the	O
pH	O
at	O
7	O
if	O
necessary	O
,	O
and	O
after	O
being	O
cooled	O
at	O
0	O
C	O
the	O
precipitated	O
complexes	O
were	O
filtered	O
and	O
thoroughly	O
washed	O
with	O
alcohol	O
-	O
water	O
1:1	O
(	O
v	O
/	O
v	O
)	O
and	O
air	O
dried	O
.	O

Yields	O
were	O
in	O
the	O
range	O
of	O
85	O
-	O
90	O
%	O
.	O

The	O
obtained	O
white	O
powders	O
of	O
compounds	O
8	O
-	O
20	O
melted	O
with	O
decomposition	O
at	O
temperatures	O
higher	O
than	O
350	O
C	O
,	O
and	O
were	O
poorly	O
soluble	O
in	O
water	O
and	O
alcohol	O
,	O
but	O
had	O
good	O
solubilities	O
in	O
DMSO	O
,	O
DMF	O
as	O
well	O
as	O
mixtures	O
of	O
DMSO	O
-	O
water	O
,	O
DMF	O
-	O
water	O
.	O

Pharmacology	O
Carbonic	O
anhydrase	O
inhibition	O
Initial	O
rates	O
of	O
4-nitrophenyl	O
acetate	O
hydrolysis	O
catalysed	O
by	O
different	O
CA	O
isozymes	O
were	O
monitored	O
spectrophotometrically	O
,	O
at	O
400	O
rim	O
,	O
with	O
a	O
Cary	O
3	O
instrument	O
interfaced	O
with	O
an	O
IBM	O
compatible	O
PC	O
[	O
35	O
]	O
.	O

Solutions	O
of	O
substrate	O
were	O
prepared	O
in	O
anhydrous	O
acetonitrile	O
;	O
the	O
substrate	O
concentrations	O
varied	O
between	O
2.10	O
-	O
2	O
and	O
1.10	O
-	O
6	O
M	O
,	O
working	O
at	O
25C	O
.	O

A	O
molar	O
absorption	O
coefficient	O
of	O
18,400	O
M	O
-	O
l.cm-1	O
was	O
used	O
for	O
the	O
4-nitrophenolate	O
formed	O
by	O
hydrolysis	O
,	O
in	O
the	O
conditions	O
of	O
the	O
experiments	O
(	O
pH	O
7.40	O
)	O
,	O
as	O
reported	O
in	O
the	O
literature	O
[	O
35	O
]	O
.	O

Non	O
-	O
enzymatic	O
hydrolysis	O
rates	O
were	O
always	O
subtracted	O
from	O
the	O
observed	O
rates	O
.	O

Duplicate	O
experiments	O
were	O
done	O
for	O
each	O
inhibitor	O
concentration	O
,	O
and	O
the	O
values	O
reported	O
throughout	O
the	O
paper	O
are	O
the	O
mean	O
of	O
such	O
results	O
.	O

Stock	O
solutions	O
of	O
inhibitor	O
(	O
1	O
mM	O
)	O
were	O
prepared	O
in	O
distilled	O
-	O
deionized	O
water	O
with	O
1020	O
%	O
(	O
v	O
/	O
v	O
)	O
DMSO	O
(	O
which	O
is	O
not	O
inhibitory	O
at	O
these	O
concentrations	O
[	O
2	O
]	O
)	O
and	O
dilutions	O
up	O
to	O
0.01	O
nM	O
were	O
done	O
thereafter	O
with	O
distilled	O
-	O
deionized	O
water	O
.	O

Inhibitor	O
and	O
enzyme	O
solutions	O
were	O
preincubated	O
together	O
for	O
10	O
min	O
at	O
room	O
temperature	O
prior	O
to	O
assay	O
,	O
in	O
order	O
to	O
allow	O
for	O
the	O
formation	O
of	O
the	O
E	O
-	O
I	O
complex	O
.	O

The	O
inhibition	O
constant	O
KI	O
was	O
determined	O
as	O
described	O
by	O
Pocket	O
and	O
Stone	O
[	O
35	O
]	O
.	O

Enzyme	O
concentrations	O
were	O
3.3	O
nM	O
for	O
hCA	O
II	O
,	O
l0	O
nM	O
for	O
hCA	O
and	O
34	O
nM	O
for	O
bCA	O
IV	O
(	O
this	O
isozyme	O
has	O
a	O
decreased	O
esterase	O
activity	O
[	O
36	O
]	O
and	O
higher	O
concentrations	O
had	O
to	O
be	O
used	O
for	O
the	O
-	O
measurements	O
)	O
.	O

Measurement	O
of	O
tonometric	O
lOP	O
Adult	O
male	O
New	O
Zealand	O
albino	O
rabbits	B
weighing	O
2	O
-	O
3	O
kg	O
were	O
used	O
in	O
the	O
experiments	O
(	O
three	O
animals	O
were	O
used	O
for	O
each	O
inhibitor	O
studied	O
)	O
.	O

The	O
experimental	O
procedures	O
conform	O
to	O
the	O
Association	O
for	O
Research	O
in	O
Vision	O
and	O
Ophthalmology	O
Resolution	O
on	O
the	O
use	O
of	O
animals	O
.	O

The	O
rabbits	B
were	O
kept	O
in	O
individual	O
cages	O
with	O
food	O
and	O
water	O
provided	O
ad	O
libitum	O
.	O

The	O
animals	O
were	O
maintained	O
on	O
a	O
12	O
h	O
:	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
in	O
a	O
temperature	O
controlled	O
room	O
,	O
at	O
22	O
-	O
26	O
C.	O
Solutions	O
of	O
inhibitors	O
(	O
2	O
%	O
,	O
by	O
weight	O
)	O
were	O
obtained	O
in	O
DMSOwater	O
(	O
2:3	O
,	O
v	O
/	O
v	O
)	O
due	O
to	O
the	O
low	O
water	O
solubility	O
of	O
some	O
of	O
these	O
derivatives	O
.	O

Control	O
experiments	O
with	O
DMSO	O
(	O
at	O
the	O
same	O
concentration	O
as	O
that	O
used	O
for	O
obtaining	O
the	O
inhibitors	O
solutions	O
showed	O
that	O
it	O
does	O
not	O
possess	O
IOP	O
lowering	O
or	O
increasing	O
effects	O
.	O

IOP	O
was	O
measured	O
using	O
a	O
Digilab	O
30R	O
pneumatonometer	O
(	O
BioRad	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
as	O
described	O
by	O
Maren	O
's	O
group	O
[	O
37	O
-	O
39	O
]	O
.	O

The	O
pressure	O
readings	O
were	O
matched	O
with	O
two	O
-	O
point	O
standard	O
pressure	O
measurements	O
at	O
least	O
twice	O
each	O
day	O
using	O
a	O
Digilab	O
Calibration	O
verifier	O
.	O

All	O
IOP	O
measurements	O
were	O
done	O
by	O
the	O
same	O
investigator	O
with	O
the	O
same	O
tonometer	O
.	O

One	O
drop	O
of	O
0.2	O
%	O
oxybuprocaine	O
hydrochloride	O
(	O
novesine	O
,	O
Sandoz	O
)	O
diluted	O
"1""1"	O
with	O
saline	O
was	O
instilled	O
in	O
each	O
eye	O
immediately	O
before	O
each	O
set	O
of	O
pressure	O
measurements	O
.	O

IOP	O
was	O
measured	O
three	O
times	O
at	O
each	O
time	O
interval	O
,	O
and	O
the	O
means	O
reported	O
.	O

IOP	O
was	O
measured	O
first	O
immediately	O
before	O
drug	O
administration	O
,	O
then	O
at	O
30	O
min	O
after	O
the	O
instillation	O
of	O
the	O
pharmacological	O
agent	O
,	O
and	O
then	O
each	O
30	O
minutes	O
for	O
a	O
period	O
of	O
several	O
hours	O
.	O

For	O
all	O
IOP	O
experiments	O
drug	O
was	O
administered	O
to	O
only	O
one	O
eye	O
,	O
leaving	O
the	O
contralateral	O
eye	O
as	O
an	O
untreated	O
control	O
.	O

The	O
ocular	O
hypotensive	O
activity	O
is	O
expressed	O
as	O
the	O
average	O
difference	O
in	O
IOP	O
between	O
the	O
treated	O
and	O
control	O
eye	O
,	O
in	O
this	O
way	O
minimizing	O
the	O
diurnal	O
,	O
seasonal	O
and	O
interindividual	O
variations	O
commonly	O
observed	O
in	O
the	O
rabbit	B
[	O
37	O
-	O
39	O
]	O
.	O

All	O
data	O
are	O
expressed	O
as	O
mean	O
SE	O
,	O
using	O
a	O
one	O
-	O
tailed	O
test	O
.	O

Results	O
and	O
Discussion	O
Reaction	O
of	O
5-amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
[	O
19b	O
]	O
with	O
chloroacteyl	O
chloride	O
in	O
the	O
presence	O
of	O
pyridine	O
afforded	O
5-	O
(	O
chloroacetamido	O
)	O
-l,3,4-thiadiazole-2-sulfonamide	O
7	O
,	O
by	O
the	O
procedure	O
already	O
reported	O
by	O
Young	O
et	O
al.	O
[	O
34	O
]	O
(	O
Scheme	O
1	O
)	O
.	O

The	O
sulfonamide	O
7	O
has	O
been	O
characterized	O
by	O
elemental	O
analysis	O
and	O
spectroscopic	O
methods	O
which	O
confirmed	O
its	O
structure	O
(	O
only	O
its	O
m.p	O
.	O
has	O
been	O
reported	O
in	O
ref	O
.	O

[	O
34	O
]	O
)	O
.	O

The	O
sodium	O
salt	O
of	O
sulfonamides	O
6	O
and	O
7	O
,	O
obtained	O
in	O
situ	O
from	O
the	O
corresponding	O
sulfonamide	O
and	O
sodium	O
hydroxide	O
,	O
were	O
then	O
used	O
for	O
the	O
preparation	O
of	O
coordination	O
compounds	O
,	O
containing	O
the	O
following	O
metal	O
ions	O
:	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
Al	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
.	O

Mention	O
should	O
be	O
made	O
that	O
although	O
5-amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
is	O
the	O
parent	O
compound	O
of	O
important	O
sulfonamide	O
CA	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	O
,	O
benzolamide	O
,	O
methazolamide	O
,	O
etc	O
.	O
,	O
its	O
coordination	O
chemistry	O
has	O
been	O
scarcely	O
investigated	O
up	O
to	O
now	O
[	O
22	O
,	O
40	O
]	O
.	O

The	O
new	O
complexes	O
prepared	O
in	O
this	O
work	O
are	O
shown	O
in	O
Table	O
I.	O
Both	O
compounds	O
containing	O
the	O
sulfonamide	O
-	O
deprotonated	O
species	O
of	O
sulfonamide	O
7	O
(	O
LH	O
)	O
,	O
as	O
well	O
as	O
complexes	O
in	O
which	O
the	O
anion	O
of	O
5amino-1,3,4-thiadiazole-2-sulfonamide	O
(	O
tda	O
)	O
act	O
as	O
ligands	O
,	O
have	O
been	O
prepared	O
.	O

In	O
fact	O
in	O
another	O
work	O
[	O
40	O
]	O
it	O
was	O
documented	O
that	O
in	O
some	O
cases	O
,	O
sulfonamides	O
derived	O
from	O
this	O
ring	O
system	O
may	O
undergo	O
hydrolysis	O
to	O
309	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
.	O
""""	O

A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
the	O
moiety	O
substituting	O
the	O
5	O
position	O
,	O
with	O
the	O
formation	O
of	O
5-amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
,	O
which	O
thereafter	O
coordinates	O
metal	O
ions	O
present	O
in	O
solution	O
.	O

N	O
CIH	O
N	O
I	O
N	O
+	O
NaHCO	O
2	O
N	O
2	O
S	O
'	O
-NaCl	O
I	O
S	O
N	O
II	O
SO2NH	O
1_12	O
O	O
Py	O
/	O
MeCN	O
6Htda	O
+	O
CIOCCH2CI	O
0	O
Cl	O
CH	O
2	O
Scheme	O
1	O
HN	O
.I	O

N	O
N	O
S	O
7	O
:	O
LH	O
II	O
SqNH	O
Thus	O
,	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
complex	O
[	O
Zn	O
(	O
tda	O
)	O
2	O
(	O
NH3	O
)	O
]	O
.H20	O
prepared	O
in	O
this	O
way	O
has	O
recently	O
been	O
reported	O
by	O
this	O
group	O
[	O
40	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
the	O
ligand	O
7	O
has	O
not	O
been	O
hydrolyzed	O
(	O
during	O
the	O
preparation	O
of	O
the	O
coordination	O
compounds	O
)	O
in	O
the	O
presence	O
of	O
the	O
metal	O
ion	O
to	O
5-amino	O
-	O
l,3,4-thiadiazole-2sulfonamide	O
and	O
chloroacetate	O
,	O
the	O
metal	O
complexes	O
contining	O
6	O
as	O
ligand	O
have	O
been	O
prepared	O
from	O
the	O
last	O
(	O
pure	O
)	O
compound	O
(	O
as	O
sodium	O
salt	O
)	O
and	O
the	O
corresponding	O
metal	O
salt	O
,	O
by	O
the	O
general	O
procedure	O
described	O
in	O
the	O
Experimental	O
part	O
.	O

Table	O

I	O
:	O
Prepared	O
complexes	O
8	O
-	O
20	O
,	O
containing	O
the	O
conjugate	O
bases	O
of	O
sulfonamides	O
6	O
and	O
7	O
as	O
ligands	O
and	O
their	O
elemental	O
analysis	O
data	O
.	O

L	O
stands	O
for	O
the	O
sulfonamide	O
deprotonated	O
species	O
of	O
7	O
,	O
whereas	O
tda	O
for	O
the	O
sulfonamide	O
deprotonated	O
species	O
of	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
6	O
.	O

No.	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O
Complex	O
Yield	O
(	O
%	O
)	O
%	O
Ma	O
Analysis	O
(	O
calculated	O
/	O
found	O
)	O
%	O
H	O
b	O
%	O
C	O
b	O
13.0	O
/	O
13.1	O
11.0	O
/	O
10.8	O
11.3	O
/	O
11.4	O
10.2	O
/	O
10.1	O
8.5	O
/	O
8.1	O
7.9	O
/	O
7.9	O
12.7	O
/	O
12.8	O
18.4	O
/	O
18.1	O
18.1	O
/	O
17.9	O
16.6	O
/	O
16.2	O
15.3	O
/	O
14.9	O
13.4	O
/	O
13.3	O
12.7	O
/	O
12.5	O
1.6	O
/	O
1.3	O
2.7	O
/	O
2.3	O
1.4	O
/	O
1.1	O
1.2	O
/	O
1.2	O
1.0	O
/	O
1.2	O
1.6	O
/	O
1.3	O
1.6	O
/	O
1.6	O
1.5	O
/	O
1.5	O
1.5	O
/	O
1.3	O
1.3	O
/	O
1.4	O
1.2	O
/	O
1.1	O
1.1	O
/	O
1.2	O
1.0	O
/	O
1.0	O
%	O
N	O
b	O
30.4	O
/	O
30.2	O
25.6	O
/	O
25.5	O
26.4	O
/	O
26.4	O

13.7	O
/	O
23.3	O
20.0	O
/	O
19.8	O

18.6	O
/	O
18.5	O
29.7	O
/	O
29.6	O

21.5	O
/	O
21.3	O
21.1	O
/	O
20.8	O

19.4	O
/	O
19.3	O
17.9	O
/	O
17.8	O
15.7	O
/	O
15.6	O
14.8	O
/	O
14.6	O
[	O
Be	O
(	O
tda	O
)	O
2	O
]	O
[	O
Mg	O
(	O
tda	O
)	O
2	O
]	O
.3	O
H20	O
[	O
Zn	O
(	O
tda	O
)	O
2	O
]	O
[	O
Cd	O
(	O
tda	O
)	O
2	O
]	O
[	O
Hg	O
(	O
tda	O
)	O
2	O
]	O
[	O
Pb	O
(	O
tda	O
)	O
z	O
(	O
OH2	O
)	O
2	O
]	O
[	O
Al	O
(	O
tda	O
)	O
3	O
]	O
[	O
BeL2	O
]	O
[	O
ALL3	O
]	O
[	O
ZnL2	O
]	O
[	O
CdL2	O
]	O
[	O
HgL2	O
]	O
[	O
PbLz	O
(	O
OH2	O
)	O
2	O
]	O
78	O
76	O
83	O
90	O
95	O
84	O
72	O
75	O
59	O
87	O
88	O
92	O
95	O
2.4	O
/	O
2.5	O
5.5	O
/	O
5.1	O
15.4	O
/	O
15.0	O
23.8	O
/	O
24.1	O
35.8	O
/	O
35.7	O
34.4	O
/	O
34.7	O
4.7	O
/	O
4.4	O
1.7	O
/	O
1.6	O
3.4	O
/	O
3.5	O
11.3	O
/	O
11.5	O
18.0	O
/	O
18.1	O
28.1	O
/	O
28.3	O
27.4	O
/	O
27.2	O
aBy	O
gravimetry	O
;	O
bBy	O
combustion	O
.	O

The	O
new	O
complexes	O
have	O
also	O
been	O
characterized	O
by	O
spectroscopic	O
,	O
conductimetric	O
and	O
thermogravimetric	O
measurements	O
(	O
Table	O
II	O
)	O
.	O

By	O
comparing	O
the	O
IR	O
spectra	O
of	O
the	O
complexes	O
and	O
the	O
corresponding	O
ligands	O
,	O
the	O
following	O
observations	O
should	O
be	O
made	O
:	O
(	O
i	O
)	O
the	O
shift	O
of	O
the	O
two	O
sulfonamido	O
vibrations	O
(	O
both	O
the	O
symmetric	O
as	O
well	O
as	O
the	O
the	O
assymetric	O
one	O
)	O
,	O
towards	O
lower	O
wavenumbers	O
in	O
the	O
spectra	O
of	O
the	O
complexes	O
,	O
as	O
compared	O
to	O
the	O
spectra	O
of	O
the	O
corresponding	O
ligand	O
(	O
Table	O
II	O
)	O
,	O
as	O
already	O
documented	O
previously	O
for	O
similar	O
complexes	O
[	O
13	O
-	O
22	O
]	O
.	O

This	O
is	O
a	O
direct	O
indication	O
that	O
the	O
deprotonated	O
sulfonamido	O
310	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
moieties	O
of	O
the	O
ligands	O
interacts	O
with	O
the	O
metal	O
ions	O
in	O
the	O
newly	O
prepared	O
coordination	O
compounds	O
;	O
(	O
ii	O
)	O
the	O
amide	O
vibrations	O
(	O
the	O
most	O
intense	O
such	O
bands	O
at	O
1670	O
-	O
1680	O
cm-1	O
)	O
of	O
ligand	O
7	O
appear	O
unchanged	O
in	O
the	O
IR	O
spectra	O
of	O
complexes	O
15	O
-	O
20	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
these	O
moieties	O
do	O
not	O
participate	O
in	O
coordination	O
of	O
the	O
metal	O
ions	O
;	O
(	O
iii	O
)	O
the	O
C	O
-	O
N	O
stretching	O
vibration	O
in	O
the	O
spectra	O
of	O
the	O
prepared	O
complexes	O
is	O
shifted	O
with	O
5	O
-	O
20	O
cm-1	O
towards	O
lower	O
wavenumbers	O
,	O
as	O
compared	O
to	O
the	O
same	O
vibration	O
in	O
the	O
spectra	O
of	O
sulfonamides	O
6	O
and	O
7	O
,	O
indicating	O
that	O
one	O
of	O
the	O
endocyclic	O
nitrogens	O
of	O
the	O
thiadiazolic	O
ring	O
(	O
presumably	O
N3	O
)	O
acts	O
as	O
donor	O
atom	O
,	O
as	O
already	O
documented	O
by	O
X	O
-	O
ray	O
crystallographic	O
and	O
spectroscopic	O
determinations	O
on	O
complexes	O
of	O
other	O
sulfonamides	O
(	O
such	O
as	O
1	O
-	O
3	O
)	O
with	O
divalent	O
metal	O
ions	O
[	O
13	O
-	O
22	O
]	O
(	O
Table	O
II	O
)	O
;	O
(	O
iv	O
)	O
changes	O
in	O
the	O
region	O
3100	O
-	O
3160	O
cm-	O
,	O
as	O
the	O
bands	O
present	O
in	O
the	O
spectra	O
of	O
sulfonamides	O
6	O
,	O
7	O
are	O
present	O
in	O
the	O
spectra	O
of	O
complexes	O
8	O
-	O
20	O
too	O
,	O
but	O
they	O
are	O
not	O
well	O
resolved	O
,	O
and	O
have	O
a	O
smaller	O
intensity	O
.	O

This	O
is	O
probably	O
due	O
to	O
deprotonation	O
of	O
the	O
SO2NH2	O
moiety	O
and	O
participation	O
in	O
the	O
binding	O
of	O
cations	O
;	O
(	O
v	O
)	O
the	O
amino	O
vibrations	O
from	O
3320	O
cm-	O
in	O
the	O
spectra	O
of	O
6	O
appear	O
unchanged	O
in	O
the	O
spectra	O
of	O
its	O
complexes	O
8	O
-	O
14	O
(	O
data	O
not	O
s.hown	O
)	O
.	O

In	O
the	O
1H	O
-	O
NMR	O
spectra	O
of	O
compound	O
6	O
and	O
its	O
metal	O
complexes	O
,	O
the	O
signal	O
of	O
the	O
amino	O
group	O
has	O
been	O
evidenced	O
as	O
a	O
broad	O
singlet	O
centered	O
at	O
4.54	O
ppm	O
(	O
Table	O
II	O
)	O
,	O
which	O
is	O
not	O
exchangeable	O
by	O
addition	O
of	O
D20	O
into	O
the	O
NMR	O
tube	O
,	O
in	O
contrast	O
to	O
the	O
sulfonamido	O
NH2	O
protons	O
(	O
which	O
readily	O
exchange	O
)	O
.	O

This	O
proves	O
that	O
the	O
5-amino	O
moiety	O
is	O
not	O
involved	O
in	O
binding	O
the	O
metal	O
ions	O
,	O
as	O
already	O
shown	O
in	O
the	O
X	O
-	O
ray	O
crystallographic	O
work	O
of	O
the	O
complex	O
[	O
Zn	O
(	O
tda	O
)	O
z	O
(	O
NH3	O
)	O
]	O
.H20	O
previously	O
reported	O
[	O
40	O
]	O
.	O

For	O
sulfonamide	O
7	O
the	O
CONH	O
proton	O
resonates	O
as	O
a	O
singlet	O
at	O
12.22	O
ppm	O
.	O

In	O
complexes	O
15	O
-	O
20	O
only	O
very	O
minor	O
shifts	O
of	O
this	O
signal	O
were	O
evidenced	O
(	O
Table	O
II	O
)	O
,	O
proving	O
basically	O
that	O
the	O
CONH	O
moiety	O
does	O
not	O
interact	O
with	O
the	O
metal	O
ions	O
in	O
these	O
complexes	O
.	O

Table	O
II	O
:	O
Spectroscopic	O
,	O
thermogravimetric	O
and	O
conductimetric	O
data	O
for	O
compounds	O
6	O
-	O
20	O
.	O

1H	O
-	O
NMR	O
Spectrab	O
Comp	O
.	O

IR	O
Spectraa	O
,	O
cm-1	O
as	O
v	O
(	O
C	O
=	O
N	O
)	O
CONH	O
,	O
i	O
(	O
ppm	O
)	O
v	O
(	O
SO2	O
)	O
S	O
;	O
v	O
(	O
SO2	O
)	O
6	O
8	O
9	O
10	O
11	O
TG	O
analysisc	O
calc.	O
/	O
found	O
Conductimetryd	O
AM	O
(	O
-1	O
x	O
cm2x	O
mol-	O
)	O
2	O
7	O
4	O
5	O
3	O
2	O
2	O
6	O
3	O
4	O
2	O
9	O
3	O
2	O
8	O
12	O
13	O
14	O
7	O
15	O
16	O
17	O
18	O
19	O
20	O
1170	O
;	O
1150	O
;	O
1150	O
;	O
1145	O
;	O
1145	O
;	O
1140	O
;	O
1145	O
;	O
1150	O
;	O
1170	O
;	O
1130	O
;	O
1140	O
;	O
1140	O
;	O
1150	O
;	O
1140	O
;	O
1145	O
;	O
1350	O
1300	O
1305	O
1300	O
1305	O
1300	O
1300	O
1300	O
1350	O
1335	O
1330	O
1330	O
1330	O
1335	O
1330	O
1610	O
1600	O
1600	O
1600	O
1600	O
1590	O
1605	O
1605	O
1610	O
1605	O
1610	O
1610	O
1605	O

1600	O
1600	O
A	O
A	O
A	O
A	O
A	O
A	O
A	O
e	O
e	O
12.3	O
/	O
12.1f	O
e	O
e	O
e	O
5.9	O
/	O
5.7	O
g	O
A	O
12.22	O
(	O
1H	O
)	O
12.19	O
(	O
2H	O
)	O
12.18	O
(	O
3H	O
)	O
12.20	O
(	O
2H	O
)	O
12.18	O
(	O
2H	O
)	O
12.19	O
(	O
2H	O
)	O
12.21	O
(	O
2H	O
)	O
e	O
e	O
e	O
e	O
e	O
e	O
e	O
4.7	O
/	O
4.8	O
g	O
a	O
In	O
KBr	O
;	O
bin	O
DMSO	O
-	O
d6	O
;	O
A	O
the	O
signal	O
of	O
the	O
5-amino	O
group	O
of	O
6	O
(	O
appearing	O
in	O
the	O
ligand	O
at	O
4.54	O
ppm	O
as	O
a	O
broad	O
singlet	O
)	O
appears	O
at	O
the	O
same	O
chemical	O
shift	O
(	O
4.50	O
4.55	O
ppm	O
)	O
in	O
complexes	O
8	O
-	O
14	O
;	O
cWeight	O
loss	O
between	O
70	O
-	O
250	O
C	O
;	O
d	O
mM	O
solution	O
,	O
in	O
DMF	O
,	O
at	O
25C	O
;	O
e	O
No	O
weight	O
loss	O
seen	O
under	O
250	O
C	O
;	O
fCorresponding	O
to	O
three	O
lattice	O
water	O
molecules	O
lost	O
at	O
70	O
-	O
110C	O
,	O
and	O
gCorresponding	O
to	O
two	O
coordinated	O
water	O
molecules	O
,	O
lost	O
at	O
160	O
-	O
180	O
C.	O
Thermogravimetric	O
analysis	O
showed	O
the	O
presence	O
of	O
uncoordinated	O
water	O
molecules	O
in	O
the	O
molecule	O
of	O
complex	O
9	O
(	O
the	O
three	O
waters	O
were	O
lost	O
in	O
a	O
single	O
step	O
,	O
between	O
70	O
-	O
110	O
C	O
)	O
and	O
of	O
coordinated	O
water	O
in	O
the	O
molecules	O
of	O
the	O
lead	O
(	O
II	O
)	O
derivatives	O
13	O
and	O
20	O
.	O

All	O
these	O
compounds	O
behaved	O
as	O
non	O
-	O
electrolytes	O
in	O
DMF	O
as	O
solvent	O
(	O
Table	O
II	O
)	O
.	O

Mention	O
should	O
be	O
made	O
that	O
the	O
Mg	O
(	O
II	O
)	O
complex	O
of	O
sulfonamide	O
7	O
could	O
not	O
be	O
isolated	O
.	O

Instead	O
,	O
only	O
the	O
correponding	O
complex	O
of	O
5-amino	O
-	O
l,3,4-thiadiazole	O
has	O
been	O
obtained	O
from	O
reaction	O
mixtures	O
containing	O
magnesium	O
salts	O
and	O
the	O
sodium	O
salt	O
of	O
7	O
,	O
probably	O
due	O
to	O
a	O
metal	O
ion	O
assisted	O
hydrolysis	O
of	O
7	O
to	O
6	O
and	O
chloroacetate	O
.	O

Generally	O
such	O
hydrolytic	O
processes	O
involve	O
highly	O
acidic	O
conditions	O
and	O
prolonged	O
heating	O
of	O
the	O
5-alkylamido-1,3,4-thiadiazole-2-sulfonamide	O
derivatives	O
[	O
41	O
]	O
,	O
but	O
they	O
might	O
become	O
milder	O
by	O
taking	O
into	O
account	O
the	O
putative	O
catalytic	O
effect	O
of	O
Mg2	O
+	O
ions	O
reported	O
here	O
.	O

The	O
data	O
shown	O
above	O
lead	O
to	O
the	O
conclusion	O
that	O
ligand	O
7	O
shares	O
a	O
common	O
coordination	O
chemistry	O
with	O
acetazolamide	O
1	O
with	O
which	O
it	O
is	O
structurally	O
related	O
,	O
whereas	O
6	O
probably	O
also	O
behaves	O
similarly	O
to	O
acetazolamide	O
in	O
the	O
sense	O
that	O
the	O
5-amino	O
group	O
seems	O
not	O
to	O
be	O
involved	O
in	O
coordinating	O
metal	O
ions	O
,	O
at	O
311	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O

A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
least	O
in	O
the	O
complexes	O
reported	O
by	O
us	O
here	O
(	O
and	O
also	O
in	O
the	O
compound	O
characterized	O
by	O
X	O
-	O
ray	O
crystallography	O
mentioned	O
above	O
[	O
40	O
]	O
)	O
.	O

Thus	O
,	O
in	O
all	O
complexes	O
reported	O
here	O
these	O
sulfonamides	O
(	O
as	O
monodeprotonated	O
species	O
at	O
the	O
SO2NH	O
2	O
moieties	O
)	O
act	O
as	O
bidentate	O
ligands	O
,	O
through	O
the	O
endocyclic	O
N-3	O
and	O
the	O
NH-	O
groups	O
.	O

The	O
proposed	O
formulae	O
of	O
the	O
new	O
complxes	O
are	O
shown	O
below	O
.	O

Except	O
for	O
the	O
two	O
Pb	O
(	O
II	O
)	O
complexes	O
13	O
and	O
20	O
,	O
as	O
well	O
as	O
the	O
AI	O
(	O
III	O
)	O
derivatives	O
14	O
and	O
16	O
,	O
which	O
presumably	O
are	O
pseudo	O
-	O
octahedral	O
,	O
the	O
other	O
derivatives	O
are	O
supposed	O
to	O
contain	O
tetrahedral	O
M	O
(	O
II	O
)	O
ions	O
.	O

R	O
R	O
"13""R"	O
=	O
20	O
""""	O
R=	O
H2N	O
CICH2CONH	O
14	O
:	O
R	O
=	O
16	O
:	O
R	O
=	O
H2N	O
CICH2CONH	O
The	O
compounds	O
6	O
-	O
20	O
together	O
with	O
the	O
standard	O
CA	O
inhibitors	O
1	O
-	O
5	O
were	O
assayed	O
for	O
inhibition	O
against	O
three	O
isozymes	O
,	O
hCA	O
I	O
,	O
hCA	O
II	O
and	O
bCA	O
IV	O
(	O
Table	O
III	O
)	O
.	O

As	O
seen	O
from	O
the	O
above	O
data	O
,	O
the	O
chloracetamido	O
derivative	O
is	O
more	O
inhibitory	O
than	O
acetazolamide	O
,	O
methazolamide	O
and	O
dichlorophenamide	O
,	O
whereas	O
the	O
unacylated	O
compound	O
6	O
is	O
less	O
inhibitory	O
than	O
the	O
above	O
sulfonamides	O
.	O

The	O
metal	O
complexes	O
820	O
are	O
much	O
more	O
inhibitory	O
than	O
the	O
sulfonamides	O
from	O
which	O
they	O
derive	O
6	O
,	O
7	O
and	O
than	O
all	O
other	O
simple	O
sulfonamides	O
assayed	O
.	O

They	O
behave	O
similarly	O
to	O
the	O
metal	O
complexes	O
of	O
acetazolamide	O
,	O
methazolamide	O
or	O
dorzolamide	O
previously	O
reported	O
by	O
this	O
group	O
,	O
which	O
were	O
all	O
more	O
inhibitory	O
than	O
the	O
parent	O
sulfonamide	O
from	O
which	O
were	O
prepared	O
[	O
16	O
-	O
22	O
,	O
40	O
]	O
.	O

Particularly	O
strong	O
inhibition	O
was	O
observed	O
for	O
the	O
Zn	O
(	O
II	O
)	O
,	O
Hg	O
(	O
II	O
)	O
,	O
Pb	O
(	O
II	O
)	O
and	O
Cd	O
(	O
II	O
)	O
complexes	O
,	O
especially	O
against	O
CA	O
II	O
and	O
CA	O
IV	O
,	O
the	O
isozymes	O
critical	O
for	O
aqueous	O
humor	O
formation	O
.	O

In	O
vivo	O
IOP	O
lowering	O
experiments	O
were	O
done	O
in	O
rabbits	B
with	O
some	O
of	O
the	O
new	O
compounds	O
prepared	O
in	O
the	O
present	O
work	O
,	O
such	O
as	O
the	O
sulfonamides	O
6	O
and	O
7	O
,	O
and	O
their	O
Zn	O
(	O
II	O
)	O
complexes	O
,	O
which	O
were	O
among	O
the	O
strong	O
CA	O
II	O
and	O
CA	O
IV	O
inhibitors	O
in	O
the	O
obtained	O
series	O
.	O

Some	O
of	O
the	O
IOP	O
lowering	O
data	O
at	O
half	O
an	O
hour	O
and	O
one	O
hour	O
after	O
the	O
instillation	O
of	O
one	O
drop	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
within	O
the	O
rabbit	B
eye	O
are	O
shown	O
in	O
312	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
Table	O
IV	O
,	O
with	O
dorzolamide	O
(	O
at	O
the	O
same	O
concentration	O
)	O
as	O
standard	O
.	O

In	O
Fig.	O
the	O
time	O
dependence	O
of	O
IOP	O
lowering	O
with	O
dorzolamide	O
5	O
and	O
the	O
two	O
Zn	O
(	O
II	O
)	O
complexes	O
10	O
and	O
17	O
is	O
presented	O
.	O

Table	O
III	O
.	O

CA	O
inhibition	O
data	O
with	O
the	O
standard	O
inhibitors	O
1	O
-	O
5	O
,	O
the	O
sulfonamides	O
6	O
and	O
7	O
,	O
and	O
their	O
metal	O
complexes	O
8	O
-	O
20	O
.	O

No	O
1	O
2	O
3	O
4	O
5	O
6	O
7	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O
a	O
Inhibitor	O
KI	O
hCA	O
Ia	O
900	O
780	O
25	O
1200	O
>	O
50,000	O
1550	O
640	O
1050	O

350	O
50	O
40	O
12	O
80	O
240	O
120	O
80	O
40	O
40	O
9	O
15	O
(	O
nM	O
)	O
bCA	O
IVb	O
220	O
240	O
13	O
380	O
43	O
780	O
24	O
540	O
220	O
25	O
19	O
10	O
26	O
110	O
12	O
16	O
9	O
10	O
5	O
10	O
hCA	O
IIa	O
12	O
14	O
8	O
38	O
9	O
230	O
5	O
190	O
110	O
15	O
14	O
7	O
10	O
76	O
5	O
4	O
3	O
3	O
2	O
5	O
Acetazolamide	O
Methazolamide	O
Ethoxzolamide	O
Dichlorophenamide	O
Dorzolamide	O
Human	B
(	O
cloned	O
)	O
isozymes	O
;	O
b	O
From	O
bovine	B
lung	O
microsomes	O
.	O

Table	O
IV	O
:	O
IOP	O
lowering	O
following	O
topical	O
application	O
of	O
CA	O
inhibitors	O
,	O
half	O
an	O
hour	O
and	O
one	O
hour	O
after	O
instillation	O
into	O
the	O
eye	O
of	O
a	O
drop	O
(	O
50	O
L	O
)	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
.	O

Inhibitor	O
lOP	O
SE	O
1	O
/	O
2	O
h	O
a	O
(	O
mm	O
Hg	O
)	O
lh	O
4.1	O
0.15	O
0	O
0.09	O
0	O
0.09	O
5.0	O
0.12	O
8.1	O
0.21	O
Dorzolamide	O
5	O
6	O
7	O
10	O
17	O
a	O
2.2	O
0.10	O
0	O
0.10	O
0	O
0.10	O
2.00.09	O
8.0	O
0.14	O
IOP	O
IOP	O
control	O
eye	O
""""	O
IOP	O
treated	O
eye	O
(	O
N	O
3	O
)	O
.	O

As	O
seen	O
from	O
the	O
above	O
data	O
,	O
the	O
sulfonamides	O
6	O
and	O
7	O
are	O
totally	O
ineffective	O
as	O
lOP	O
lowering	O
agents	O
,	O
similarly	O
to	O
the	O
classical	O
clinically	O
used	O
inhibitors	O
of	O
type	O
1	O
-	O
5	O
[	O
2,3	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
dorzolamide	O
,	O
the	O
first	O
topical	O
sulfonamide	O
used	O
clinically	O
in	O
the	O
treatment	O
of	O
glaucoma	O
is	O
an	O
effective	O
such	O
agent	O
,	O
with	O
a	O
decrease	O
of	O
lOP	O
of	O
around	O
4	O
mm	O
Hg	O
,	O
one	O
hour	O
after	O
administration	O
directly	O
into	O
the	O
eye	O
(	O
Table	O
IV	O
)	O
.	O

From	O
the	O
data	O
of	O
this	O
table	O
,	O
it	O
is	O
obvious	O
that	O
the	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
investigated	O
by	O
us	O
behave	O
as	O
much	O
more	O
effective	O
IOP	O
lowering	O
agents	O
than	O
dorzolamide	O
,	O
and	O
their	O
effect	O
is	O
generally	O
longerlasting	O
(	O
Fig.	O
1	O
)	O
.	O

A	O
last	O
remark	O
should	O
be	O
made	O
about	O
the	O
possible	O
mechanism	O
of	O
action	O
of	O
the	O
new	O
class	O
of	O
IOP	O
lowering	O
agents	O
.	O

Obviously	O
,	O
their	O
activity	O
is	O
due	O
to	O
inhibition	O
of	O
CA	O
isozymes	O
present	O
in	O
the	O
cilliary	O
processes	O
within	O
the	O
eye	O
,	O
similarly	O
to	O
other	O
topically	O
active	O
sulfonamides	O
[	O
2	O
-	O
6	O
]	O
.	O

The	O
fact	O
that	O
the	O
sulfonamide	O
per	O
se	O
is	O
inactive	O
via	O
the	O
topical	O
route	O
,	O
whereas	O
the	O
metal	O
complexes	O
result	O
much	O
better	O
than	O
the	O
drug	O
313	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
.	O
""""	O

A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
dorzolamide	O
,	O
indicates	O
that	O
the	O
presence	O
of	O
metal	O
ions	O
in	O
the	O
molecules	O
of	O
these	O
CA	O
inhibitors	O
is	O
essential	O
and	O
confers	O
them	O
completely	O
new	O
properties	O
.	O

Lowering	O
of	O
IOP	O
(	O
ram	O
Hg	O
)	O
""""	O
||	O
,	O
/	O
""""	O
,	O
,	O
'	O
""""	O
,	O
.	O
,	O
,	O
<	O
.7	O
,	O
/	O
/	O
.6	O
-0	O
-10	O
0	O
2	O
Time	O
(	O
hours	O
)	O
Fig	O
l	O
""""	O
Time	O
dependence	O
of	O
IOP	O
lowering	O
with	O
dorzolamide	O
(	O
curve	O
1	O
)	O
;	O
the	O
zinc	O
complex	O
10	O
(	O
curve	O
3	O
)	O
and	O
the	O
zinc	O
complex	O
17	O
(	O
curve	O
3	O
)	O
,	O
after	O
topical	O
administration	O
of	O
one	O
drop	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
in	O
rabbit	B
.	O

Preliminary	O
results	O
from	O
this	O
laboratory	O
indicate	O
that	O
the	O
metal	O
complexes	O
of	O
topically	O
active	O
sulfonamides	O
show	O
also	O
increased	O
lOP	O
lowering	O
effects	O
with	O
respect	O
to	O
the	O
complexes	O
prepared	O
in	O
the	O
present	O
study	O
[	O
42	O
]	O
.	O

Our	O
hypothesis	O
is	O
that	O
the	O
presence	O
of	O
the	O
metal	O
ion	O
in	O
the	O
molecules	O
of	O
these	O
complex	O
inhibitors	O
induces	O
a	O
dramatic	O
change	O
in	O
their	O
physico	O
-	O
chemical	O
properties	O
as	O
compared	O
to	O
those	O
of	O
the	O
parent	O
sulfonamide	O
.	O

This	O
phenomenon	O
is	O
certainly	O
governed	O
by	O
the	O
strong	O
polarization	O
induced	O
by	O
the	O
metal	O
ions	O
.	O

In	O
this	O
way	O
,	O
it	O
is	O
quite	O
probable	O
that	O
the	O
right	O
balance	O
between	O
the	O
lipo-	O
and	O
hydrosolubility	O
of	O
these	O
compounds	O
is	O
achieved	O
,	O
which	O
has	O
been	O
considered	O
to	O
be	O
the	O
critical	O
factor	O
for	O
not	O
observing	O
topical	O
activity	O
in	O
the	O
classical	O
CA	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	O
,	O
methazolamide	O
and	O
ethoxzolamide	O
,	O
which	O
were	O
either	O
too	O
lipophilic	O
or	O
too	O
hy.drosoluble	O
[	O
2,3	O
]	O
.	O

So	O
,	O
by	O
choosing	O
different	O
metal	O
ions	O
and	O
diverse	O
sulfonamides	O
,	O
much	O
larger	O
possibilities	O
arise	O
to	O
finely	O
tune	O
the	O
pharmacological	O
properties	O
which	O
strongly	O
influence	O
the	O
value	O
of	O
a	O
drug	O
.	O

In	O
conclusion	O
we	O
describe	O
here	O
a	O
novel	O
class	O
of	O
lOP	O
lowering	O
agents	O
,	O
ie	O
,	O
the	O
metal	O
complexes	O
of	O
sulfonamide	O
CA	O
inhibitors	O
.	O

These	O
derivatives	O
appear	O
to	O
be	O
very	O
active	O
and	O
longer	O
lasting	O
than	O
the	O
drug	O
dorzolamide	O
,	O
and	O
might	O
constitute	O
the	O
premises	O
for	O
a	O
new	O
generation	O
of	O
antiglaucoma	O
drugs	O
.	O

Acknowledgments	O
.	O

We	O
are	O
grateful	O
to	O
Prof.	O
S.	O
Lindskog	O
(	O
Umea	O
Univ	O
.	O
,	O
Sweden	O
)	O
for	O
the	O
gift	O
of	O
the	O
hCA	O
and	O
II	O
plasmids	O
.	O

References	O
Preceding	O
part	O
of	O
this	O
series	O
""""	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Ilies	O
MA	O
,	O
Iorga	O
B	O
,	O
Cristea	O
T	O
,	O
Chiraleu	O
F	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O

Eur	O
J	O
Med	O
Chem	O
,	O
submitted	O
.	O

2	O
Supuran	O
CT	O
(	O
1994	O
)	O
""""	O
Carbonic	O
anhydrase	O
inhibitors	O
""""	O
In	O
Carbonic	O
Anhydrase	O
and	O
Modulation	O
of	O
Physiologic	O
and	O
Pathologic	O
Processes	O
in	O
the	O
Organism	O
,	O
(	O

Puscas	O
I	O
,	O
Ed	O
)	O
Helicon	O
,	O
Timisoara	O
,	O
pp	O
.	O

29	O
-	O
111	O
.	O

3	O
Maren	O
TH	O
(	O
1991	O
)	O
""""	O
The	O
links	O
among	O
biochemistry	O
,	O
physiology	O
and	O
pharmacology	O
in	O
carbonic	O
anhydrase	O
mediated	O
systems	O
""""	O
.	O

In	O
Carbonic	O
Anhydrase	O
From	O
Biochemistry	O
and	O
Genetics	O
to	O
Physiology	O
and	O
Clinical	O
Medicine	O
,	O
(	O
Botr6	O
F	O
,	O
Gros	O
G	O
,	O
Storey	O
BT	O
Eds	O
)	O
VCH	O
,	O
Weinheim	O
,	O
pp	O
.	O

186	O
-	O
207	O
.	O
4	O
Bayer	O
A	O
,	O
Ferrari	O
F	O
,	O
Maren	O
TH	O
,	O
Erb	O
C	O
(	O
1996	O
)	O
dFr	O
Ophtalrnol	O
19	O
,	O
3:57	O
-	O
362	O
.	O
:	O
5	O
Maren	O
TH	O
,	O
Conroy	O
CW	O
,	O
Wynns	O
GC	O
,	O
Levy	O
NS	O
(	O
1997	O
)	O
d	O
Ocul	O
Pharrnacol	O
Therapeut	O
13	O
,	O
23	O
-	O
30	O
.	O
6	O
Sugrue	O
MF	O
(	O
1996	O
)	O
d	O
Ocul	O
Pharmacol	O
Ther	O
12,363	O
-	O
376	O
.	O

7	O
Bartlett	O
JD	O
,	O
Jaanus	O
SD	O
(	O
1989	O
)	O
""""	O
Carbonic	O
anhydrase	O
inhibitors	O
""""	O
.	O

In	O
Clinical	O
Ocular	O
Pharmacology	O
,	O
Second	O
Edition	O
,	O
Butterworths	O
Publishers	O
,	O
Boston	O
,	O
pp	O
.	O

2:54	O
-	O
263	O
.	O
8	O
Alward	O
PD	O
,	O
Wilensky	O
JT	O
(	O
1981	O
)	O
Arch	O
Ophthalmo199	O
,	O
1973	O
-	O
1976	O
.	O

314	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
9	O
Maren	O
TH	O
,	O
Jankowska	O
L	O
,	O
Sanyal	O
G	O
,	O
Edelhauser	O
HF	O
(	O
1983	O
)	O
Exp	O
Eye	O
Res	O
36	O
,	O
457	O
-	O
480	O
.	O
10	O
a	O
)	O

Ponticello	O
GS	O
,	O
Freedman	O
MB	O
,	O
Habecker	O
CN	O
,	O
Lyle	O
PA	O
,	O
Schwam	O
H	O
,	O
Varga	O
SL	O
,	O
Christy	O
ME	O
,	O
Randall	O
WC	O
,	O
Baldwin	O
JJ	O
(	O
1987	O
)	O

J	O
Med	O
Chem	O
30	O
,	O
591	O
-	O
597	O
;	O
b	O
)	O
Greer	O
J	O
,	O
Erickson	O
JW	O
,	O
Baldwin	O
JJ	O
,	O
Varney	O
MD	O
(	O
1994	O
)	O

J	O
Med	O
Chem	O
37	O
,	O
1035	O
-	O
1054	O
.	O
11	O
Baldwin	O
JJ	O
,	O
Ponticello	O
GS	O
,	O
Anderson	O
GS	O
,	O
Christy	O
ME	O
,	O
Murcko	O
MA	O
,	O
Randall	O
WC	O
,	O
Schwam	O
H	O
,	O
Sugrue	O
MF	O
,	O
Springer	O
JP	O
,	O
Gautheron	O
P	O
,	O
Grove	O
J	O
,	O
Mallorga	O
P	O
,	O
Viader	O
MP	O
,	O
McKeever	O
BM	O
,	O
Navia	O
MA	O
(	O
1989	O
)	O

J	O
Med	O
Chem	O
32	O
,	O
2510	O
-	O
2513	O
.	O

12	O
Chow	O
K	O
,	O
Lai	O
R	O
,	O
Holmes	O
JM	O
,	O
Wijono	O
M	O
,	O
Wheeler	O
LA	O
,	O
Garst	O
ME	O
(	O
1996	O
)	O
EurJMed	O
Chem	O
31	O
,	O
175	O
-	O
186	O
.	O

13	O
Supuran	O
CT	O
,	O
Nicolae	O
A	O
,	O
Popescu	O
A	O
(	O
1996	O
)	O
Eur	O
JMed	O
Chem	O
31	O
,	O
431	O
-	O
438	O
.	O

14	O
Supuran	O
CT	O
,	O
Popescu	O
A	O
,	O
Ilisiu	O
M	O
,	O
Costandache	O
A	O
,	O
Banciu	O
MD	O
(	O
1996	O
)	O

Eur	O
JMed	O
Chem	O
31	O
,	O
439	O
-	O
448	O
.	O

15	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Popescu	O
A	O
,	O
Bobes	O
-	O
Tureac	O
R	O
,	O
Banciu	O
A	O
,	O
Creanga	O
A	O
,	O
Bobes	O
-	O
Tureac	O
G	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O

Eur	O
JMed	O
Chem	O
32	O
,	O
445	O
-	O
452	O
.	O

16	O
Alzuet	O
G	O
,	O
Casanova	O
J	O
,	O
Ramirez	O
JA	O
,	O
Borras	O
J	O
,	O
Carugo	O
O	O
(	O
1995	O
)	O
J	O
Inorg	O
Bioehem	O
57	O
,	O
219	O
-	O
234	O
.	O

17	O
Sumalan	O
SL	O
,	O
Casanova	O
J	O
,	O
Alzuet	O
G	O
,	O
Borras	O
J	O
,	O
Castifieiras	O
A	O
,	O
Supuran	O
CT	O
(	O
1996	O
)	O

J	O
Inorg	O
Biochem	O
62	O
,	O
3139	O
.	O

18	O
a	O
)	O
Supuran	O
CT	O
(	O
1995	O
)	O
Metal	O
Based	O
Drugs	O
2	O
,	O
327	O
-	O
330	O
;	O
b	O
)	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Metal	O
Based	O
Drugs	O
4	O
,	O
19	O
-	O
26	O
.	O

19	O
a	O
)	O
Borras	O
J	O
,	O
Cristea	O
T	O
,	O
Supuran	O
CT	O
(	O
1996	O
)	O
,	O
Main	O
Group	O
Met	O
Chem	O
19	O
,	O
339	O
-	O
346	O
;	O
b	O
)	O
Jitianu	O
A	O
,	O
Ilies	O
MA	O
,	O
Briganti	O
F	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Metal	O
Based	O
Drugs	O
4	O
,	O
1	O
-	O
7	O
.	O
20	O
a	O
)	O

Supuran	O
CT	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
12	O
,	O
37	O
-	O
51	O
;	O
b	O
)	O
Supuran	O
CT	O
,	O
Briganti	O
F	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
12	O
,	O
175	O
-	O
190	O
.	O

21	O
Mincione	O
G	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Metal	O
Based	O
Drugs	O
4	O
,	O
27	O
-	O
34	O
.	O
22	O
Alzuet	O
G	O
,	O
Ferrer	O
S	O
,	O
Borras	O
J	O
,	O
Supuran	O
CT	O
(	O
1994	O
)	O
Roum	O
Chem	O
Quart	O
Rev	O
2	O
,	O
283	O
-	O
300	O
.	O

23	O
Briganti	O
F	O
,	O
Mangani	O
S	O
,	O
Orioli	O
P	O
,	O
Scozzafava	O
A	O
,	O
Vernaglione	O
G	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
Biochemistry	O
36	O
,	O
10384	O
-	O
10392	O
.	O

24	O
Borras	O
J	O
,	O
Casanova	O
J	O
,	O
Cristea	O
T	O
,	O
Gheorghe	O
A	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
,	O
Tudor	O
V	O
(	O
1996	O
)	O
Metal	O
Based	O
Drugs	O
3	O
,	O
143	O
-	O
148	O
.	O

25	O
Supuran	O
CT	O
,	O
Mincione	O
F	O
,	O
Scozzafava	O
A	O
,	O
Briganti	O
F	O
,	O
Mincione	O
G	O
,	O
Ilies	O
MA	O
(	O
1997	O
)	O
Eur	O
J	O
Med	O
Chem	O
,	O
in	O
press	O
.	O

26	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Saramet	O
I	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
,	O
in	O
press	O
.	O

27	O
Jitianu	O
A	O
,	O
Ilies	O
MA	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Main	O
Group	O
Met	O
Chem	O
20	O
,	O
151	O
-	O
156	O
.	O

28	O
Forsman	O
C	O
,	O
Behravan	O
G	O
,	O
Osterman	O
A	O
,	O
Jonsson	O
BH	O
(	O
1988	O
)	O
Acta	O
Chem	O
Scand	O
B42	O
,	O
314	O
-	O
318	O
.	O

29	O
Behravan	O
G	O
,	O
Jonasson	O
P	O
,	O
Jonsson	O
BH	O
,	O
Lindskog	O
S	O
(	O
1991	O
)	O
Eur	O
JBiochem	O
198	O
,	O
589	O
-	O
592	O
.	O
30	O
Khalifah	O
RG	O
,	O
Strader	O
DJ	O
,	O
Bryant	O
SH	O
,	O
Gibson	O
SM	O
(	O
1977	O
)	O
Biochemistry	O
16	O
,	O
2241	O
-	O
2247	O
.	O

31	O
Nyman	O
PO	O
,	O
Lindskog	O
S	O
(	O
1964	O
)	O
Biochim	O
Biophys	O
Acta	O
85	O
,	O
141	O
-	O
151	O
.	O

32	O
Henderson	O
LE	O
,	O
Henriksson	O
D	O
,	O
Nyman	O
PO	O
(	O
1976	O
)	O
JBiol	O
Chem	O
251	O
,	O
5457	O
-	O
5463	O
.	O

33	O
Maren	O
TH	O
,	O
Wynns	O
GC	O
,	O
Wistrand	O
PJ	O
(	O
1993	O
)	O
Mol	O
Pharmaco144	O
,	O
901	O
-	O
906	O
.	O

34	O
Young	O
RW	O
,	O
Wood	O
KH	O
,	O
Vaughan	O
JR	O
,	O
Anderson	O
GW	O
(	O
1956	O
)	O
J	O
Am	O
Chem	O
Soc	O
78	O
,	O
4649	O
-	O
4654	O
.	O

35	O
Pocker	O
Y	O
,	O
Stone	O
JT	O
(	O
1967	O
)	O
Biochemistry	O
6	O
,	O
668	O
-	O
678	O
.	O
36	O
Baird	O
TT	O
,	O
Waheed	O
A	O
,	O
Okuyama	O
T	O
,	O
Sly	O
WS	O
,	O
Fierke	O
CA	O
(	O
1997	O
)	O
Biochemistry	O
36	O
,	O
2669	O
-	O
2678	O
.	O

37	O
Maren	O
TH	O
,	O
Bar	O
-	O
Ilan	O
A	O
,	O
Conroy	O
CW	O
,	O
Brechue	O
WF	O
(	O
1990	O
)	O
Exp	O
Eye	O
Res	O
50	O
,	O
27	O
-	O
36	O
.	O

38	O
Maren	O
TH	O
,	O
Brechue	O
WF	O
,	O
Bar	O
-	O
Ilan	O
A	O
(	O
1992	O
)	O

Exp	O
Eye	O
Res	O
55	O
,	O
73	O
-	O
79	O
.	O

39	O
Brechue	O
WF	O
,	O
Maren	O
TH	O
(	O
1993	O
)	O

Invest	O
Ophthalmol	O
Vis	O
Sci	O
34	O
,	O
2581	O
-	O
2587	O
.	O

40	O
Borja	O
P	O
,	O
Alzuet	O
G	O
,	O
Server	O
-	O
Carri6	O
J	O
,	O
Borras	O
J	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
J	O
Biol	O
Inorg	O
Chem	O
(	O
JBIC	O
)	O
,	O
in	O
press	O
.	O

41	O
Supuran	O
CT	O
,	O
Balaban	O
AT	O
,	O
Gheorghiu	O
MD	O
,	O
Schiketanz	O
A	O
,	O
Dinculescu	O
A	O
,	O
Puscas	O
I	O
(	O
1990	O
)	O
Rev	O
Roum	O
Chim	O
35	O
,	O
399	O
-	O
405	O
.	O

42	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
unpublished	O
results	O
.	O

Received	O
:	O
September	O
24	O
,	O
1997	O
Accepted	O
:	O
October	O
17	O
,	O
1997	O
Received	O
in	O
revised	O
camera	O
-	O
ready	O
format	O
""""	O
October	O
23	O
,	O
1997	O
315	O

Purinergic	O
signalling	O
in	O
the	O
subretinal	O
space	O
:	O
a	O
role	O
in	O
the	O
communication	O
between	O
the	O
retina	O
and	O
the	O
RPE	O
Abstract	O
The	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
is	O
separated	O
from	O
the	O
photoreceptor	O
outer	O
segments	O
by	O
the	O
subretinal	O
space	O
.	O

While	O
the	O
actual	O
volume	O
of	O
this	O
space	O
is	O
minimal	O
,	O
the	O
communication	O
that	O
occurs	O
across	O
this	O
microenvironment	O
is	O
important	O
to	O
the	O
visual	O
process	O
,	O
and	O
accumulating	O
evidence	O
suggests	O
the	O
purines	O
ATP	O
and	O
adenosine	O
contribute	O
to	O
this	O
communication	O
.	O

P1	O
and	O
P2	O
receptors	O
are	O
localized	O
to	O
membranes	O
on	O
both	O
the	O
photoreceptor	O
outer	O
segments	O
and	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
which	O
border	O
subretinal	O
space	O
.	O

ATP	O
is	O
released	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
into	O
this	O
space	O
in	O
response	O
to	O
various	O
triggers	O
including	O
glutamate	O
and	O
chemical	O
ischemia	O
.	O

This	O
ATP	O
is	O
dephosphorylated	O
into	O
adenosine	O
by	O
a	O
series	O
of	O
ectoenzymes	O
on	O
the	O
RPE	O
apical	O
membrane	O
.	O

Regulation	O
of	O
release	O
and	O
ectoenzyme	O
activity	O
in	O
response	O
to	O
light	O
-	O
sensitive	O
signals	O
can	O
alter	O
the	O
balance	O
of	O
purines	O
in	O
subretinal	O
space	O
,	O
and	O
thus	O
coordinate	O
communication	O
across	O
subretinal	O
space	O
with	O
the	O
visual	O
process	O
.	O

Introduction	O
The	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
lies	O
between	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptors	O
and	O
the	O
choroidal	O
blood	O
supply	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
RPE	O
combines	O
the	O
functions	O
of	O
epithelial	O
and	O
glial	O
cells	O
,	O
providing	O
a	O
barrier	O
while	O
also	O
supporting	O
the	O
neural	O
photoreceptors	O
and	O
modulating	O
their	O
function	O
.	O

Tight	O
communication	O
between	O
photoreceptors	O
and	O
the	O
RPE	O
is	O
critical	O
to	O
coordinate	O
the	O
multiple	O
levels	O
of	O
interaction	O
,	O
and	O
the	O
purinergic	O
contribution	O
to	O
this	O
communication	O
is	O
becoming	O
apparent	O
.	O

The	O
relevance	O
of	O
this	O
purinergic	O
input	O
is	O
emphasized	O
by	O
the	O
many	O
functional	O
effects	O
of	O
P1	O
and	O
P2	O
receptor	O
stimulation	O
and	O
by	O
the	O
multiple	O
mechanisms	O
in	O
place	O
to	O
regulate	O
subretinal	O
levels	O
of	O
purine	O
agonists	O
.	O

As	O
the	O
dynamics	O
of	O
ATP	O
release	O
and	O
extracellular	O
conversion	O
into	O
adenosine	O
will	O
modify	O
agonist	O
availability	O
,	O
the	O
modulation	O
of	O
these	O
processes	O
can	O
exert	O
a	O
temporal	O
control	O
on	O
purinergic	O
signaling	O
.	O

The	O
following	O
review	O
will	O
outline	O
the	O
main	O
interactions	O
between	O
the	O
RPE	O
and	O
photoreceptors	O
,	O
describe	O
the	O
effects	O
of	O
stimulating	O
purinergic	O
receptors	O
on	O
both	O
sides	O
of	O
subretinal	O
space	O
,	O
and	O
summarize	O
how	O
levels	O
of	O
ATP	O
,	O
ADP	O
,	O
and	O
adenosine	O
are	O
manipulated	O
in	O
this	O
microenvironment	O
.	O

Fig.	O
1Schematic	O
illustration	O
of	O
the	O
key	O
components	O
of	O
purinergic	O
signaling	O
in	O
the	O
subretinal	O
microenvironment	O
.	O

Stimulation	O
of	O
P2	O
receptors	O
on	O
the	O
RPE	O
can	O
enhance	O
transepithelial	O
fluid	O
absorption	O
while	O
P1	O
receptors	O
can	O
modulate	O
phagocytosis	O
.	O

ATP	O
released	O
through	O
CFTR	O
and	O
other	O
Cl−	O
channels	O
can	O
stimulate	O
P2	O
receptors	O
or	O
be	O
converted	O
to	O
ADP	O
,	O
AMP	O
,	O
and	O
adenosine	O
(	O
Ado	O
)	O
by	O
a	O
series	O
of	O
ectonucleotidases	O
present	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
.	O

By	O
controlling	O
the	O
balance	O
of	O
extracellular	O
purines	O
available	O
to	O
stimulate	O
these	O
receptors	O
these	O
mechanisms	O
can	O
control	O
levels	O
of	O
endogenous	O
purines	O
available	O
to	O
activate	O
the	O
receptors	O
.	O

While	O
theoretically	O
possible	O
,	O
it	O
remains	O
to	O
be	O
determined	O
whether	O
these	O
subretinal	O
purines	O
can	O
actually	O
stimulate	O
photoreceptors	O
Purines	O
and	O
subretinal	O
space	O
RPE	O
-	O
photoreceptor	O
interactions	O
across	O
the	O
subretinal	O
space	O
The	O
outer	O
segments	O
of	O
the	O
rods	O
and	O
cones	O
are	O
responsible	O
for	O
the	O
initial	O
stages	O
of	O
vision	O
,	O
converting	O
photon	O
energy	O
into	O
a	O
series	O
of	O
enzymatic	O
reactions	O
that	O
close	O
the	O
light	O
-	O
sensitive	O
channels	O
on	O
the	O
photoreceptor	O
plasma	O
membrane	O
,	O
hyperpolarize	O
the	O
cells	O
,	O
and	O
reduce	O
the	O
release	O
of	O
glutamate	O
from	O
the	O
synaptic	O
terminals	O
[	O
1	O
,	O
2	O
]	O
.	O

Efficient	O
photoreceptor	O
function	O
depends	O
upon	O
both	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
support	O
from	O
the	O
RPE	O
.	O

The	O
critical	O
nature	O
of	O
these	O
interactions	O
is	O
evident	O
from	O
the	O
rapid	O
degeneration	O
of	O
photoreceptors	O
in	O
the	O
absence	O
of	O
a	O
healthy	O
RPE	O
layer	O
and	O
by	O
the	O
RPE	O
localization	O
of	O
defective	O
gene	O
product	O
in	O
some	O
forms	O
of	O
hereditary	O
photoreceptor	O
degeneration	O
[	O
3	O
]	O
.	O

The	O
apical	O
membrane	O
of	O
the	O
RPE	O
is	O
separated	O
from	O
the	O
plasma	O
membrane	O
of	O
the	O
outer	O
segments	O
by	O
an	O
extracellular	O
space	O
of	O
only	O
10–20	O
nm	O
[	O
4	O
]	O
.	O

Although	O
small	O
,	O
this	O
subretinal	O
space	O
contains	O
a	O
highly	O
structured	O
matrix	O
which	O
ensheathes	O
the	O
outer	O
segments	O
and	O
extends	O
to	O
the	O
RPE	O
[	O
5	O
,	O
6	O
]	O
.	O

The	O
presence	O
of	O
enzymes	O
within	O
this	O
interphotoreceptor	O
matrix	O
emphasizes	O
that	O
this	O
extracellular	O
space	O
itself	O
is	O
functionally	O
active	O
[	O
7	O
,	O
8	O
]	O
.	O

This	O
intimate	O
anatomical	O
relationship	O
between	O
photoreceptors	O
and	O
the	O
RPE	O
reflects	O
multiple	O
functional	O
interactions	O
.	O

For	O
example	O
,	O
the	O
RPE	O
accepts	O
,	O
recycles	O
,	O
and	O
exports	O
central	O
components	O
of	O
the	O
phototransduction	O
process	O
[	O
9	O
]	O
.	O

The	O
outer	O
segments	O
are	O
continuously	O
resynthesized	O
,	O
and	O
the	O
phagocytosis	O
,	O
degradation	O
,	O
and	O
processing	O
of	O
shed	O
outer	O
segment	O
tips	O
by	O
the	O
RPE	O
cells	O
is	O
central	O
to	O
this	O
renewal	O
[	O
10	O
]	O
.	O

The	O
ion	O
channels	O
and	O
transporters	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
help	O
regulate	O
the	O
ionic	O
composition	O
of	O
the	O
subretinal	O
space	O
[	O
11	O
]	O
.	O

As	O
extracellular	O
levels	O
of	O
ions	O
can	O
modify	O
the	O
ionic	O
driving	O
forces	O
across	O
the	O
photoreceptor	O
plasma	O
membrane	O
,	O
these	O
RPE	O
transporters	O
can	O
influence	O
the	O
state	O
of	O
neural	O
activity	O
.	O

The	O
transport	O
of	O
fluid	O
and	O
ions	O
from	O
the	O
apical	O
membrane	O
to	O
basolateral	O
membrane	O
of	O
the	O
RPE	O
is	O
also	O
one	O
of	O
the	O
main	O
forces	O
keeping	O
the	O
retina	O
attached	O
[	O
12	O
]	O
.	O

The	O
control	O
of	O
photoreceptor	O
activity	O
by	O
light	O
gives	O
a	O
rapid	O
temporal	O
dependence	O
to	O
some	O
interactions	O
between	O
the	O
photoreceptors	O
and	O
the	O
RPE	O
.	O

The	O
volume	O
of	O
subretinal	O
space	O
increases	O
in	O
response	O
to	O
light	O
[	O
13	O
]	O
,	O
linking	O
small	O
changes	O
in	O
the	O
ionic	O
composition	O
of	O
the	O
subretinal	O
space	O
with	O
activity	O
of	O
the	O
RPE	O
transport	O
mechanisms	O
which	O
maintain	O
this	O
volume	O
[	O
14	O
,	O
15	O
]	O
.	O

Other	O
processes	O
are	O
controlled	O
on	O
a	O
diurnal	O
cycle	O
.	O

The	O
shed	O
tips	O
of	O
the	O
outer	O
segments	O
are	O
phagocytosed	O
by	O
the	O
RPE	O
soon	O
after	O
the	O
onset	O
of	O
light	O
[	O
16	O
,	O
17	O
]	O
.	O

These	O
processes	O
can	O
both	O
be	O
modulated	O
by	O
purine	O
levels	O
in	O
subretinal	O
space	O
,	O
indicating	O
purinergic	O
regulation	O
is	O
important	O
over	O
multiple	O
time	O
scales	O
.	O

Purinergic	O
receptors	O
on	O
photoreceptors	O
A2	O
adenosine	O
receptors	O
were	O
localized	O
to	O
both	O
the	O
inner	O
and	O
outer	O
segments	O
of	O
photoreceptor	O
outer	O
segments	O
over	O
a	O
decade	O
ago	O
by	O
Blazynski	O
and	O
colleagues	O
[	O
18	O
]	O
,	O
with	O
more	O
recent	O
reports	O
emphasizing	O
their	O
functional	O
role	O
.	O

A2	O
agonists	O
inhibit	O
the	O
L	O
-	O
type	O
Ca2	O
+	O
channel	O
on	O
rod	O
outer	O
segments	O
[	O
19	O
]	O
and	O
can	O
inhibit	O
the	O
synaptic	O
release	O
of	O
glutamate	O
from	O
rods	O
,	O
suggesting	O
changes	O
in	O
adenosine	O
levels	O
in	O
subretinal	O
space	O
could	O
modulate	O
light	O
sensitivity	O
[	O
20	O
]	O
.	O

The	O
A2	O
agonist	O
DPMA	O
and	O
the	O
adenosine	O
deaminase	O
inhibitor	O
EHNA	O
reduce	O
mRNA	O
for	O
opsin	O
in	O
rods	O
,	O
suggesting	O
that	O
endogenous	O
levels	O
of	O
adenosine	O
can	O
downregulate	O
opsin	O
message	O
at	O
night	O
[	O
21	O
]	O
.	O

EHNA	O
and	O
the	O
A2A	O
receptor	O
agonist	O
CGS21680	O
also	O
increase	O
the	O
survival	O
of	O
chick	O
embryonic	O
photoreceptors	O
in	O
culture	O
[	O
22	O
]	O
,	O
indicating	O
a	O
long	O
-	O
term	O
neuroprotective	O
role	O
for	O
adenosine	O
.	O

P2	O
receptors	O
are	O
also	O
present	O
in	O
the	O
photoreceptors	O
.	O

mRNA	O
for	O
the	O
P2X2	O
receptor	O
is	O
expressed	O
in	O
the	O
photoreceptor	O
cell	O
bodies	O
,	O
with	O
immunohistochemical	O
localization	O
of	O
the	O
protein	O
to	O
outer	O
segments	O
[	O
23	O
]	O
.	O

In	O
situ	O
hybridization	O
indicates	O
the	O
photoreceptor	O
layer	O
has	O
the	O
highest	O
level	O
of	O
P2Y2	O
receptor	O
of	O
any	O
region	O
in	O
the	O
rabbit	B
retina	O
,	O
although	O
staining	O
was	O
not	O
pronounced	O
in	O
monkey	O
[	O
24	O
]	O
.	O

P2X7	O
receptors	O
have	O
recently	O
been	O
localized	O
to	O
photoreceptor	O
synaptic	O
terminals	O
,	O
with	O
evidence	O
for	O
ecto	O
-	O
ATPase	O
activity	O
in	O
the	O
synapse	O
,	O
and	O
functional	O
evidence	O
suggesting	O
ATP	O
augments	O
transmission	O
of	O
the	O
light	O
response	O
by	O
rods	O
[	O
25	O
]	O
.	O

It	O
was	O
suggested	O
that	O
ATP	O
might	O
be	O
co	O
-	O
released	O
from	O
photoreceptors	O
with	O
glutamate	O
,	O
although	O
this	O
remains	O
to	O
be	O
tested	O
directly	O
.	O

Purinergic	O
receptors	O
on	O
the	O
RPE	O
Stimulation	O
of	O
P1	O
receptors	O
can	O
have	O
a	O
considerable	O
impact	O
on	O
RPE	O
cells	O
.	O

A2	O
receptors	O
have	O
been	O
recognized	O
on	O
cultured	O
and	O
fresh	O
RPE	O
cells	O
for	O
some	O
time	O
[	O
26	O
,	O
27	O
]	O
,	O
with	O
in	O
situ	O
hybridization	O
confirming	O
the	O
presence	O
of	O
A2A	O
receptors	O
in	O
rat	B
RPE	O
[	O
28	O
]	O
.	O

Stimulation	O
of	O
A2	O
receptors	O
reduces	O
the	O
rate	O
of	O
rod	O
outer	O
segment	O
phagocytosis	O
by	O
RPE	O
cells	O
[	O
29	O
]	O
,	O
while	O
application	O
of	O
adenosine	O
to	O
the	O
apical	O
membrane	O
of	O
chick	O
RPE	O
cells	O
increases	O
the	O
basolateral	O
Cl-	O
conductance	O
,	O
the	O
transepithelial	O
potential	O
,	O
and	O
the	O
c	O
-	O
wave	O
,	O
and	O
decreases	O
the	O
hyperpolarization	O
of	O
the	O
basal	O
membrane	O
in	O
response	O
to	O
light	O
[	O
30	O
]	O
.	O

Although	O
adenosine	O
alone	O
does	O
not	O
increase	O
intracellular	O
Ca2	O
+	O
levels	O
[	O
31	O
]	O
,	O
adenosine	O
acts	O
synergistically	O
with	O
ATP	O
to	O
elevate	O
Ca2	O
+	O
levels	O
in	O
human	B
RPE	O
cells	O
by	O
stimulating	O
both	O
A1	O
and	O
A2A	O
receptors	O
[	O
32	O
,	O
33	O
]	O
.	O

Stimulation	O
of	O
A1	O
receptors	O
with	O
high	O
doses	O
of	O
NECA	O
increases	O
the	O
active	O
transport	O
of	O
fluorescein	O
across	O
the	O
RPE	O
,	O
while	O
activation	O
of	O
A2A	O
receptors	O
decreases	O
this	O
transport	O
,	O
and	O
by	O
extension	O
,	O
transport	O
of	O
the	O
ions	O
that	O
underlie	O
fluid	O
movement	O
[	O
34	O
]	O
.	O

Stimulation	O
of	O
A1	O
and	O
A2A	O
receptors	O
produces	O
analogous	O
increases	O
and	O
decreases	O
,	O
respectively	O
,	O
in	O
the	O
absorption	O
of	O
subretinal	O
fluid	O
blebs	O
.	O

This	O
is	O
consistent	O
with	O
the	O
negative	O
coupling	O
of	O
the	O
A1	O
receptor	O
and	O
the	O
positive	O
coupling	O
of	O
the	O
A2	O
receptors	O
to	O
adenylate	O
cyclase	O
,	O
as	O
increasing	O
cAMP	O
inhibits	O
the	O
transport	O
of	O
fluid	O
across	O
the	O
RPE	O
towards	O
the	O
choroid	O
[	O
35–37	O
]	O
.	O

The	O
agonist	O
2-Cl	O
adenosine	O
reverses	O
the	O
deficit	O
in	O
phosphoinositide	O
metabolism	O
found	O
in	O
diabetic	O
RPE	O
cells	O
[	O
38	O
]	O
,	O
suggesting	O
effects	O
on	O
metabolism	O
in	O
addition	O
to	O
transport	O
and	O
phagocytosis	O
.	O

Multiple	O
P2	O
receptors	O
have	O
been	O
localized	O
to	O
the	O
RPE	O
.	O

The	O
P2Y2	O
receptor	O
was	O
initially	O
characterized	O
in	O
cultured	O
human	B
RPE	O
[	O
31	O
]	O
,	O
with	O
subsequent	O
reports	O
localizing	O
transcript	O
for	O
P2Y1	O
,	O
P2Y2	O
,	O
P2Y4	O
,	O
and	O
P2Y6	O
in	O
the	O
rat	B
RPE	O
/	O
choroid	O
[	O
39	O
]	O
and	O
for	O
P2Y1	O
and	O
P2Y12	O
receptors	O
in	O
ARPE-19	O
cells	O
[	O
40	O
]	O
,	O
and	O
functionally	O
identifying	O
a	O
P2X	O
receptor	O
in	O
rat	B
RPE	O
cells	O
[	O
41	O
]	O
.	O

ATP	O
,	O
ADP	O
,	O
and	O
UTP	O
induce	O
numerous	O
effects	O
on	O
RPE	O
physiology	O
[	O
32	O
,	O
33	O
,	O
42	O
,	O
43	O
]	O
.	O

While	O
these	O
effects	O
likely	O
involve	O
multiple	O
different	O
receptor	O
types	O
,	O
the	O
contributions	O
of	O
the	O
P2Y2	O
receptor	O
have	O
been	O
explored	O
in	O
most	O
detail	O
to	O
date	O
.	O

The	O
P2Y2	O
receptor	O
has	O
been	O
specifically	O
localized	O
to	O
the	O
apical	O
membrane	O
of	O
fresh	O
bovine	B
RPE	O
cells	O
,	O
and	O
addition	O
of	O
ATP	O
to	O
this	O
membrane	O
transiently	O
elevates	O
Ca2	O
+	O
,	O
activates	O
a	O
basolateral	O
Cl-	O
conductance	O
,	O
inhibits	O
an	O
apical	O
K+	O
conductance	O
,	O
and	O
increases	O
the	O
apical	O
to	O
basolateral	O
flow	O
of	O
fluid	O
[	O
43	O
]	O
.	O

This	O
increased	O
absorption	O
of	O
fluid	O
from	O
the	O
subretinal	O
space	O
suggests	O
P2Y2	O
receptor	O
stimulation	O
could	O
reduce	O
the	O
excess	O
fluid	O
that	O
accumulates	O
in	O
retinal	O
edemas	O
,	O
and	O
several	O
reports	O
have	O
supported	O
this	O
theory	O
.	O

ATP	O
,	O
UTP	O
,	O
and	O
the	O
P2Y2	O
receptor	O
agonist	O
INS37217	O
decrease	O
the	O
size	O
of	O
subretinal	O
fluid	O
blebs	O
when	O
injected	O
into	O
subretinal	O
space	O
of	O
rats	B
[	O
44	O
]	O
.	O

In	O
both	O
normal	O
and	O
rds	O
+	O
/-	O
mice	B
with	O
experimentally	O
induced	O
detachment	O
,	O
INS31217	O
improves	O
the	O
ERG	O
recovery	O
and	O
decreased	O
cell	O
death	O
[	O
45	O
]	O
.	O

INS37217	O
also	O
reduces	O
subretinal	O
blebs	O
in	O
rabbits	B
[	O
46	O
]	O
.	O

Injection	O
of	O
another	O
P2Y2	O
agonist	O
,	O
INS542	O
,	O
increases	O
the	O
active	O
transport	O
of	O
fluorescein	O
across	O
the	O
RPE	O
,	O
consistent	O
with	O
this	O
upregulation	O
of	O
ion	O
and	O
fluid	O
transport	O
across	O
the	O
tissue	O
[	O
47	O
]	O
.	O

Together	O
these	O
experiments	O
emphasize	O
the	O
clinical	O
potential	O
of	O
treating	O
retinal	O
edema	O
with	O
P2Y2	O
agonists	O
.	O

Regulation	O
of	O
purine	O
levels	O
in	O
subretinal	O
space	O
While	O
synthesized	O
purinergic	O
agonists	O
may	O
prove	O
useful	O
in	O
treating	O
some	O
ocular	O
disorders	O
,	O
the	O
endogenous	O
activation	O
of	O
P1	O
and	O
P2	O
receptors	O
in	O
the	O
subretinal	O
microenvironment	O
will	O
ultimately	O
be	O
determined	O
by	O
availability	O
of	O
agonists	O
.	O

These	O
levels	O
are	O
largely	O
controlled	O
by	O
the	O
release	O
of	O
ATP	O
into	O
the	O
subretinal	O
space	O
,	O
its	O
conversion	O
into	O
other	O
purines	O
including	O
adenosine	O
,	O
and	O
the	O
manipulation	O
of	O
adenosine	O
by	O
enzymes	O
or	O
transporters	O
.	O

Recent	O
work	O
has	O
increased	O
our	O
understanding	O
of	O
both	O
the	O
stimuli	O
that	O
initiate	O
changes	O
in	O
subretinal	O
purine	O
levels	O
and	O
the	O
mechanisms	O
that	O
mediate	O
these	O
changes	O
.	O

Release	O
of	O
ATP	O
by	O
the	O
RPE	O
At	O
least	O
some	O
of	O
the	O
ATP	O
capable	O
of	O
stimulating	O
the	O
purinergic	O
receptors	O
on	O
RPE	O
cells	O
is	O
released	O
from	O
the	O
RPE	O
itself	O
.	O

The	O
resulting	O
autocrine	O
stimulation	O
ensures	O
local	O
delivery	O
,	O
and	O
control	O
,	O
of	O
purines	O
to	O
initiate	O
the	O
physiologic	O
changes	O
in	O
the	O
RPE	O
.	O

The	O
release	O
of	O
ATP	O
by	O
RPE	O
cells	O
is	O
triggered	O
by	O
multiple	O
stimuli	O
including	O
osmotic	O
stress	O
,	O
bFGF	O
,	O
UTP	O
,	O
NMDA	O
,	O
glutamate	O
,	O
and	O
ATP	O
[	O
39	O
,	O
40	O
,	O
48–51	O
]	O
.	O

The	O
ATP	O
release	O
following	O
activation	O
of	O
NMDA	O
receptors	O
by	O
glutamate	O
may	O
have	O
the	O
most	O
interesting	O
implications	O
for	O
communication	O
across	O
subretinal	O
space	O
,	O
given	O
that	O
glutamate	O
confers	O
the	O
light	O
signal	O
from	O
photoreceptors	O
to	O
the	O
rest	O
of	O
the	O
visual	O
system	O
.	O

Glutamate	O
and	O
the	O
specific	O
receptor	O
agonist	O
NMDA	O
triggers	O
ATP	O
release	O
from	O
ARPE-19	O
cells	O
,	O
with	O
the	O
release	O
inhibited	O
by	O
NMDA	O
antagonist	O
MK-801	O
,	O
and	O
by	O
DCKA	O
,	O
which	O
inhibits	O
the	O
glycine	O
B	O
binding	O
site	O
on	O
NMDA	O
receptors	O
[	O
51	O
,	O
52	O
]	O
.	O

Although	O
NMDA	O
raises	O
intracellular	O
Ca2	O
+	O
levels	O
,	O
this	O
increase	O
is	O
prevented	O
by	O
eliminating	O
ATP	O
with	O
apyrase	O
,	O
indicating	O
autostimulation	O
through	O
released	O
ATP	O
is	O
responsible	O
for	O
this	O
Ca2	O
+	O
signal	O
.	O

NMDA	O
also	O
triggers	O
a	O
release	O
of	O
ATP	O
when	O
applied	O
to	O
the	O
intact	O
bovine	B
RPE	O
eyecup	O
[	O
51	O
]	O
.	O

The	O
NMDA	O
receptors	O
and	O
the	O
ATP	O
release	O
sites	O
have	O
been	O
functionally	O
identified	O
to	O
the	O
apical	O
membrane	O
of	O
the	O
bovine	B
RPE	O
,	O
suggesting	O
the	O
neurotransmitter	O
interactions	O
could	O
amplify	O
the	O
signal	O
from	O
any	O
glutamate	O
reaching	O
subretinal	O
space	O
.	O

The	O
ability	O
of	O
both	O
UTP	O
and	O
ATP	O
to	O
stimulate	O
release	O
of	O
ATP	O
from	O
the	O
RPE	O
supports	O
the	O
theory	O
that	O
the	O
system	O
acts	O
to	O
amplify	O
signals	O
.	O

When	O
applied	O
at	O
greater	O
than	O
1	O
μM	O
,	O
ATP	O
triggers	O
a	O
secondary	O
release	O
of	O
ATP	O
peaking	O
10	O
min	O
after	O
the	O
initial	O
stimuli	O
[	O
40	O
]	O
.	O

UTP	O
also	O
initiates	O
a	O
release	O
in	O
extracellular	O
ATP	O
with	O
a	O
similar	O
delay	O
[	O
48	O
]	O
.	O

The	O
rise	O
in	O
ATP	O
triggered	O
by	O
UTP	O
is	O
inhibited	O
by	O
the	O
Cl-	O
channel	O
blocker	O
NPPB	O
,	O
and	O
UDP	O
is	O
much	O
less	O
effective	O
at	O
triggering	O
release	O
than	O
UTP	O
;	O
both	O
observations	O
suggest	O
the	O
P2Y2	O
receptor	O
contributes	O
to	O
the	O
increase	O
in	O
ATP	O
more	O
than	O
diphosphokinase	O
,	O
although	O
influence	O
from	O
the	O
enzyme	O
can	O
not	O
be	O
ruled	O
out	O
[	O
53	O
]	O
.	O

Recent	O
evidence	O
suggests	O
that	O
ischemia	O
may	O
lead	O
to	O
the	O
release	O
of	O
ATP	O
from	O
RPE	O
cells	O
.	O

Chemical	O
ischemia	O
triggers	O
a	O
substantial	O
ATP	O
release	O
from	O
cardiac	O
myocytes	O
[	O
54	O
]	O
,	O
while	O
changes	O
in	O
oxygen	O
levels	O
trigger	O
ATP	O
release	O
in	O
central	O
chemoreceptors	O
[	O
55	O
]	O
.	O

We	O
found	O
that	O
exposure	O
to	O
sodium	O
cyanide	O
led	O
to	O
a	O
rapid	O
release	O
of	O
ATP	O
from	O
ARPE-19	O
cells	O
(	O
Fig.	O
2	O
)	O
.	O

As	O
hypoxic	O
and/or	O
ischemic	O
challenge	O
may	O
lead	O
to	O
changes	O
in	O
the	O
expression	O
of	O
growth	O
factors	O
in	O
RPE	O
cells	O
during	O
certain	O
ocular	O
disorders	O
such	O
as	O
macular	O
degeneration	O
[	O
56	O
]	O
,	O
and	O
as	O
purines	O
can	O
induce	O
expression	O
of	O
VEGF	O
in	O
other	O
cells	O
[	O
57	O
]	O
,	O
this	O
ATP	O
release	O
may	O
contribute	O
to	O
growth	O
factor	O
signaling	O
by	O
the	O
diseased	O
RPE	O
.	O

Fig.	O
2Chemical	O
ischemia	O
triggers	O
ATP	O
release	O
from	O
ARPE-19	O
cells	O
.	O

ATP	O
release	O
was	O
measured	O
in	O
the	O
bath	O
directly	O
from	O
cells	O
plated	O
in	O
96-well	O
plates	O
to	O
which	O
the	O
luciferin-	O
luciferase	O
reaction	O
mixture	O
was	O
added	O
[	O
51	O
]	O
.	O

Left	O
Levels	O
of	O
ATP	O
in	O
the	O
bath	O
after	O
addition	O
of	O
5	O
mM	O
NaCN	O
to	O
the	O
cells	O
.	O

Measurement	O
began	O
1	O
min	O
after	O
addition	O
of	O
NaCN	O
or	O
control	O
solution	O
to	O
wells	O
.	O

Right	O
Levels	O
of	O
ATP	O
measured	O
at	O
the	O
peak	O
,	O
3	O
min	O
after	O
addition	O
of	O
NaCN	O
(	O
n	O
=	O
12	O
)	O
.	O

Levels	O
were	O
normalized	O
to	O
concurrent	O
levels	O
in	O
control	O
(	O
n	O
=	O
14	O
)	O
.	O

Symbols	O
and	O
bars	O
represent	O
mean	O
±	O
SE	O
,	O
*	O
p	O
<	O
0.001	O
The	O
particular	O
conduit	O
for	O
ATP	O
release	O
varies	O
with	O
the	O
stimuli	O
.	O

The	O
release	O
in	O
response	O
to	O
hypotonic	O
challenge	O
is	O
largely	O
dependent	O
upon	O
CFTR	O
,	O
as	O
it	O
was	O
prevented	O
by	O
the	O
specific	O
CFTR	O
inhibitor	O
CFTR172	O
in	O
addition	O
to	O
the	O
more	O
general	O
blocker	O
glybenclamide	O
[	O
50	O
]	O
.	O

While	O
the	O
precise	O
mechanisms	O
by	O
which	O
CFTR	O
contributes	O
to	O
this	O
release	O
are	O
not	O
yet	O
known	O
,	O
a	O
role	O
for	O
CFTR	O
in	O
ATP	O
release	O
into	O
subretinal	O
space	O
is	O
consistent	O
with	O
the	O
reduction	O
of	O
certain	O
ERG	O
components	O
in	O
cftr	O
-	O
/	O
-	O
mice	B
[	O
58	O
]	O
and	O
with	O
the	O
ability	O
of	O
apical	O
ATP	O
to	O
activate	O
conductances	O
associated	O
with	O
these	O
ERG	O
components	O
[	O
43	O
]	O
.	O

The	O
release	O
of	O
ATP	O
is	O
also	O
largely	O
blocked	O
by	O
the	O
vesicular	O
transport	O
inhibitor	O
brefeldin	O
A	O
,	O
suggesting	O
the	O
two	O
processes	O
occurred	O
in	O
series	O
whereby	O
ATP	O
efflux	O
follows	O
the	O
insertion	O
of	O
vesicles	O
containing	O
CFTR	O
into	O
the	O
plasma	O
membrane	O
.	O

Although	O
the	O
Ca2	O
+	O
chelator	O
BAPTA	O
blocks	O
this	O
ATP	O
release	O
[	O
50	O
]	O
,	O
raising	O
Ca2	O
+	O
alone	O
with	O
ionophore	O
ionomycin	O
does	O
not	O
itself	O
initiate	O
release	O
[	O
48	O
]	O
.	O

This	O
necessary	O
but	O
not	O
sufficient	O
contribution	O
of	O
Ca2	O
+	O
also	O
supports	O
a	O
role	O
for	O
vesicular	O
insertion	O
.	O

In	O
contrast	O
to	O
the	O
release	O
following	O
hypotonic	O
challenge	O
,	O
the	O
ATP	O
release	O
in	O
response	O
to	O
NMDA	O
does	O
not	O
involve	O
CFTR	O
[	O
51	O
]	O
.	O

Release	O
is	O
blocked	O
by	O
NPPB	O
,	O
however	O
,	O
suggesting	O
another	O
type	O
of	O
anion	O
channel	O
could	O
serve	O
as	O
a	O
conduit	O
for	O
ATP	O
release	O
.	O

The	O
presence	O
of	O
parallel	O
mechanisms	O
coexisting	O
on	O
the	O
same	O
cell	O
for	O
ATP	O
release	O
triggered	O
by	O
either	O
agonists	O
or	O
by	O
cell	O
swelling	O
has	O
also	O
been	O
reported	O
in	O
astrocytes	O
[	O
59	O
]	O
and	O
may	O
reflect	O
the	O
multiple	O
roles	O
of	O
purinergic	O
signaling	O
within	O
a	O
given	O
tissue	O
.	O

As	O
both	O
stimuli	O
lead	O
to	O
release	O
across	O
the	O
apical	O
membrane	O
into	O
subretinal	O
space	O
,	O
both	O
are	O
expected	O
to	O
influence	O
signaling	O
in	O
the	O
microenvironment	O
.	O

Interconversion	O
of	O
purines	O
in	O
subretinal	O
space	O
The	O
interconversion	O
of	O
nucleotides	O
and	O
nucleosides	O
each	O
capable	O
of	O
stimulating	O
distinct	O
receptors	O
makes	O
the	O
purinergic	O
signaling	O
system	O
of	O
particular	O
interest	O
in	O
a	O
confined	O
region	O
such	O
as	O
the	O
subretinal	O
space	O
.	O

The	O
main	O
enzymes	O
responsible	O
for	O
dephosphorylating	O
extracellular	O
ATP	O
on	O
the	O
RPE	O
cells	O
have	O
been	O
analyzed	O
and	O
a	O
basic	O
understanding	O
of	O
their	O
regulation	O
has	O
begun	O
.	O

This	O
section	O
first	O
describes	O
the	O
enzymes	O
that	O
act	O
on	O
ATP	O
and	O
ADP	O
,	O
followed	O
by	O
enzymes	O
which	O
convert	O
AMP	O
into	O
adenosine	O
.	O

The	O
dephosphorylation	O
of	O
extracellular	O
ATP	O
by	O
RPE	O
cells	O
involves	O
enzymes	O
from	O
multiple	O
families	O
[	O
40	O
]	O
,	O
as	O
found	O
in	O
airway	O
epithelial	O
cells	O
[	O
60	O
]	O
.	O

Degradation	O
of	O
ATP	O
by	O
the	O
apical	O
membrane	O
of	O
the	O
fresh	O
bovine	B
eyecup	O
and	O
by	O
ARPE-19	O
cells	O
is	O
inhibited	O
by	O
ARL67156	O
or	O
βγmATP	O
.	O

Message	O
for	O
eNPP1	O
,	O
eNPP2	O
,	O
and	O
eNPP3	O
is	O
present	O
in	O
ARPE-19	O
cells	O
,	O
consistent	O
with	O
the	O
preference	O
of	O
βγmATP	O
for	O
members	O
of	O
the	O
eNPP	O
family	O
[	O
61	O
]	O
.	O

The	O
cells	O
also	O
express	O
NTPDase2	O
,	O
and	O
NTPDase3	O
,	O
although	O
the	O
intermittent	O
presence	O
of	O
NTPDase1	O
likely	O
reflects	O
a	O
regulated	O
process	O
[	O
40	O
]	O
.	O

Ecto	O
-	O
alkaline	O
phosphatase	O
has	O
no	O
effect	O
on	O
ATP	O
degradation	O
in	O
RPE	O
cells	O
,	O
in	O
contrast	O
to	O
its	O
considerable	O
contribution	O
in	O
airway	O
epithelium	O
[	O
62	O
]	O
.	O

The	O
putative	O
contribution	O
from	O
diphosphokinases	O
to	O
interconversion	O
of	O
subretinal	O
purines	O
is	O
presently	O
unknown	O
.	O

Extracellular	O
AMP	O
is	O
rapidly	O
dephosphorylated	O
into	O
adenosine	O
in	O
subretinal	O
space	O
.	O

The	O
production	O
of	O
adenosine	O
from	O
ATP	O
at	O
the	O
apical	O
membrane	O
of	O
the	O
bovine	B
RPE	O
eyecup	O
is	O
inhibited	O
by	O
the	O
ecto-5′-nucleotidase	O
inhibitor	O
αβmADP	O
,	O
confirming	O
a	O
role	O
for	O
this	O
enzyme	O
[	O
63	O
]	O
.	O

The	O
enzyme	O
is	O
localized	O
to	O
rat	B
RPE	O
and	O
ARPE-19	O
cells	O
immunohistochemically	O
.	O

Degradation	O
of	O
5′AMP	O
is	O
highest	O
near	O
the	O
subretinal	O
space	O
of	O
rat	B
retina	O
[	O
63	O
]	O
,	O
although	O
localization	O
in	O
mouse	B
indicated	O
larger	O
amounts	O
of	O
ecto-5′-nucleotidase	O
at	O
the	O
tips	O
of	O
adjacent	O
Müller	O
cells	O
[	O
64	O
]	O
.	O

Levamisole	O
does	O
not	O
inhibit	O
the	O
dephosphorylation	O
of	O
5′AMP	O
by	O
the	O
RPE	O
,	O
consistent	O
with	O
the	O
absence	O
of	O
substantial	O
ecto	O
-	O
alkaline	O
phosphatase	O
in	O
subretinal	O
space	O
.	O

The	O
presence	O
of	O
light	O
may	O
alter	O
the	O
levels	O
of	O
adenosine	O
in	O
subretinal	O
space	O
.	O

Epinephrine	O
is	O
released	O
at	O
the	O
onset	O
of	O
light	O
[	O
65	O
]	O
and	O
stimulation	O
of	O
the	O
RPE	O
with	O
epinephrine	O
can	O
decrease	O
activity	O
of	O
ecto-5′-nucleotidase	O
[	O
63	O
]	O
.	O

While	O
norepinephrine	O
and	O
phenylephrine	O
lead	O
to	O
similar	O
decreases	O
in	O
enzyme	O
activity	O
,	O
prazosin	O
and	O
corynanthine	O
block	O
the	O
effects	O
of	O
norepinephrine	O
,	O
implicating	O
the	O
α1	O
epinephrine	O
receptor	O
in	O
the	O
inhibition	O
of	O
ecto-5′-nucleotidase	O
[	O
63	O
]	O
.	O

The	O
kinetics	O
of	O
inhibition	O
are	O
consistent	O
with	O
cleavage	O
of	O
the	O
nucleotidase	O
from	O
its	O
GPI	O
anchor	O
.	O

The	O
phagocytosis	O
of	O
rod	O
outer	O
segments	O
is	O
maximal	O
shortly	O
after	O
light	O
onset	O
[	O
16	O
]	O
,	O
and	O
this	O
phagocytosis	O
is	O
inhibited	O
by	O
adenosine	O
[	O
29	O
]	O
.	O

The	O
ability	O
of	O
epinephrine	O
released	O
by	O
the	O
illuminated	O
retina	O
to	O
reduce	O
ecto-5′-nucleotidase	O
activity	O
and	O
consequently	O
adenosine	O
levels	O
may	O
relieve	O
this	O
inhibition	O
and	O
enhance	O
the	O
rate	O
of	O
phagocytosis	O
at	O
light	O
onset	O
.	O

Physiologic	O
effects	O
of	O
subretinal	O
purines	O
on	O
the	O
RPE	O
and	O
photoreceptors	O
The	O
number	O
of	O
purinergic	O
receptors	O
on	O
both	O
photoreceptor	O
and	O
RPE	O
membranes	O
suggests	O
purines	O
make	O
multiple	O
contributions	O
to	O
the	O
physiology	O
of	O
the	O
outer	O
retina	O
.	O

Our	O
increased	O
understanding	O
of	O
how	O
agonist	O
levels	O
in	O
subretinal	O
space	O
are	O
controlled	O
has	O
begun	O
to	O
indicate	O
how	O
and	O
when	O
this	O
contribution	O
may	O
occur	O
.	O

Future	O
research	O
will	O
involve	O
applying	O
these	O
findings	O
from	O
isolated	O
systems	O
to	O
intact	O
RPE	O
-	O
photoreceptor	O
models	O
,	O
and	O
pursuing	O
the	O
role	O
of	O
defective	O
purinergic	O
regulation	O
in	O
ocular	O
disease	O
.	O

While	O
it	O
is	O
unlikely	O
that	O
ATP	O
released	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
can	O
diffuse	O
to	O
these	O
P2	O
receptors	O
in	O
the	O
outer	O
plexiform	O
layer	O
given	O
the	O
ecto	O
-	O
ATPase	O
activity	O
in	O
the	O
synaptic	O
clef	O
[	O
25	O
]	O
,	O
stimulation	O
of	O
receptors	O
elsewhere	O
on	O
the	O
photoreceptor	O
membrane	O
is	O
possible	O
.	O

It	O
would	O
be	O
interesting	O
to	O
determine	O
whether	O
ATP	O
released	O
from	O
the	O
RPE	O
and	O
converted	O
to	O
adenosine	O
by	O
ecto	O
-	O
nucleotidases	O
can	O
actually	O
modulate	O
the	O
response	O
to	O
light	O
by	O
stimulating	O
the	O
A2A	O
receptors	O
on	O
photoreceptor	O
outer	O
segments	O
.	O

The	O
impact	O
of	O
purinergic	O
signaling	O
on	O
chronic	O
ocular	O
diseases	O
is	O
also	O
of	O
interest	O
,	O
such	O
as	O
the	O
role	O
of	O
ischemia	O
-	O
driven	O
ATP	O
release	O
in	O
VEGF	O
production	O
.	O

While	O
the	O
small	O
size	O
of	O
subretinal	O
space	O
can	O
complicate	O
pharmacologic	O
manipulation	O
within	O
the	O
intact	O
RPE	O
-	O
photoreceptor	O
complex	O
,	O
molecular	O
approaches	O
may	O
provide	O
new	O
insight	O
into	O
how	O
endogenous	O
purines	O
in	O
subretinal	O
space	O
affect	O
the	O
physiology	O
,	O
and	O
pathophysiology	O
,	O
of	O
both	O
RPE	O
and	O
photoreceptors	O
.	O

Genomic	O
-	O
Bioinformatic	O
Analysis	O
of	O
Transcripts	O
Enriched	O
in	O
the	O
Third	O
-	O
Stage	O
Larva	O
of	O
the	O
Parasitic	O
Nematode	O
Ascaris	B
suum	I
Abstract	O
Differential	O
transcription	O
in	O
Ascaris	B
suum	I
was	O
investigated	O
using	O
a	O
genomic	O
-	O
bioinformatic	O
approach	O
.	O

A	O
cDNA	O
archive	O
enriched	O
for	O
molecules	O
in	O
the	O
infective	O
third	O
-	O
stage	O
larva	O
(	O
L3	O
)	O
of	O
A.	B
suum	I
was	O
constructed	O
by	O
suppressive	O
-	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
,	O
and	O
a	O
subset	O
of	O
cDNAs	O
from	O
3075	O
clones	O
subjected	O
to	O
microarray	O
analysis	O
using	O
cDNA	O
probes	O
derived	O
from	O
RNA	O
from	O
different	O
developmental	O
stages	O
of	O
A.	B
suum	I
.	O

The	O
cDNAs	O
(	O
n	O
=	O
498	O
)	O
shown	O
by	O
microarray	O
analysis	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
were	O
sequenced	O
and	O
subjected	O
to	O
bioinformatic	O
analyses	O
using	O
a	O
semi	O
-	O
automated	O
pipeline	O
(	O
ESTExplorer	O
)	O
.	O

Using	O
gene	O
ontology	O
(	O
GO	O
)	O
,	O
235	O
of	O
these	O
molecules	O
were	O
assigned	O
to	O
'	O
biological	O
process	O
'	O
(	O
n	O
=	O
68	O
)	O
,	O
'	O
cellular	O
component	O
'	O
(	O
n	O
=	O
50	O
)	O
,	O
or	O
'	O
molecular	O
function	O
'	O
(	O
n	O
=	O
117	O
)	O
.	O

Of	O
the	O
91	O
clusters	O
assembled	O
,	O
56	O
molecules	O
(	O
61.5	O
%	O
)	O
had	O
homologues	O
/	O
orthologues	O
in	O
the	O
free	O
-	O
living	O
nematodes	O
Caenorhabditis	B
elegans	I
and	O
C.	B
briggsae	I
and/or	O
other	O
organisms	O
,	O
whereas	O
35	O
(	O
38.5	O
%	O
)	O
had	O
no	O
significant	O
similarity	O
to	O
any	O
sequences	O
available	O
in	O
current	O
gene	O
databases	O
.	O

Transcripts	O
encoding	O
protein	O
kinases	O
,	O
protein	O
phosphatases	O
(	O
and	O
their	O
precursors	O
)	O
,	O
and	O
enolases	O
were	O
abundantly	O
represented	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
,	O
as	O
were	O
molecules	O
involved	O
in	O
cellular	O
processes	O
,	O
such	O
as	O
ubiquitination	O
and	O
proteasome	O
function	O
,	O
gene	O
transcription	O
,	O
protein	O
–	O
protein	O
interactions	O
,	O
and	O
function	O
.	O

In	O
silico	O
analyses	O
inferred	O
the	O
C.	B
elegans	I
orthologues	O
/	O
homologues	O
(	O
n	O
=	O
50	O
)	O
to	O
be	O
involved	O
in	O
apoptosis	O
and	O
insulin	O
signaling	O
(	O
2	O
%	O
)	O
,	O
ATP	O
synthesis	O
(	O
2	O
%	O
)	O
,	O
carbon	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
fatty	O
acid	O
biosynthesis	O
(	O
2	O
%	O
)	O
,	O
gap	O
junction	O
(	O
2	O
%	O
)	O
,	O
glucose	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
or	O
porphyrin	O
metabolism	O
(	O
2	O
%	O
)	O
,	O
although	O
34	O
(	O
68	O
%	O
)	O
of	O
them	O
could	O
not	O
be	O
mapped	O
to	O
a	O
specific	O
metabolic	O
pathway	O
.	O

Small	O
numbers	O
of	O
these	O
50	O
molecules	O
were	O
predicted	O
to	O
be	O
secreted	O
(	O
10	O
%	O
)	O
,	O
anchored	O
(	O
2	O
%	O
)	O
,	O
and/or	O
transmembrane	O
(	O
12	O
%	O
)	O
proteins	O
.	O

Functionally	O
,	O
17	O
(	O
34	O
%	O
)	O
of	O
them	O
were	O
predicted	O
to	O
be	O
associated	O
with	O
(	O
non	O
-	O
wild	O
-	O
type	O
)	O
RNAi	O
phenotypes	O
in	O
C.	B
elegans	I
,	O
the	O
majority	O
being	O
embryonic	O
lethality	O
(	O
Emb	O
)	O
(	O
13	O
types	O
;	O
58.8	O
%	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
(	O
23.5	O
%	O
)	O
and	O
larval	O
lethality	O
(	O
Lvl	O
)	O
(	O
47	O
%	O
)	O
.	O

A	O
genetic	O
interaction	O
network	O
was	O
predicted	O
for	O
these	O
17	O
C.	B
elegans	I
orthologues	O
,	O
revealing	O
highly	O
significant	O
interactions	O
for	O
nine	O
molecules	O
associated	O
with	O
embryonic	O
and	O
larval	O
development	O
(	O
66.9	O
%	O
)	O
,	O
information	O
storage	O
and	O
processing	O
(	O
5.1	O
%	O
)	O
,	O
cellular	O
processing	O
and	O
signaling	O
(	O
15.2	O
%	O
)	O
,	O
metabolism	O
(	O
6.1	O
%	O
)	O
,	O
and	O
unknown	O
function	O
(	O
6.7	O
%	O
)	O
.	O

The	O
potential	O
roles	O
of	O
these	O
molecules	O
in	O
development	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
known	O
roles	O
of	O
their	O
homologues	O
/	O
orthologues	O
in	O
C.	B
elegans	I
and	O
some	O
other	O
nematodes	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
provide	O
a	O
basis	O
for	O
future	O
functional	O
genomic	O
studies	O
to	O
elucidate	O
molecular	O
aspects	O
governing	O
larval	O
developmental	O
processes	O
in	O
A.	B
suum	I
and/or	O
the	O
transition	O
to	O
parasitism	O
.	O

Introduction	O
Parasitic	O
nematodes	O
are	O
of	O
major	O
socio	O
-	O
economic	O
importance	O
in	O
animals	O
.	O

For	O
example	O
,	O
hundreds	O
of	O
millions	O
of	O
people	O
are	O
infected	O
with	O
geohelminths	O
(	O
soil	O
-	O
transmitted	O
worms	O
)	O
,	O
such	O
as	O
blood	O
-	O
feeding	O
hookworms	O
Ancylostoma	B
duodenale	I
and/or	O
Necator	B
americanus	I
,	O
Trichuris	B
trichiura	I
and	O
Ascaris	O
spp	O
.	O

[	O
1	O
]	O
,	O
causing	O
serious	O
adverse	O
effects	O
on	O
human	B
health	O
,	O
particularly	O
in	O
children	O
.	O

Similarly	O
,	O
parasitic	O
nematodes	O
of	O
livestock	O
,	O
such	O
as	O
pigs	B
,	O
also	O
cause	O
substantial	O
economic	O
losses	O
due	O
to	O
subclinical	O
and	O
clinical	O
diseases	O
,	O
with	O
billions	O
of	O
dollars	O
spent	O
annually	O
on	O
the	O
treatment	O
and	O
control	O
of	O
gastro	O
-	O
intestinal	O
nematodes	O
.	O

In	O
addition	O
to	O
the	O
socioeconomic	O
impact	O
that	O
these	O
parasites	O
have	O
,	O
there	O
is	O
potential	O
for	O
the	O
emergence	O
of	O
resistance	O
in	O
them	O
against	O
all	O
of	O
the	O
main	O
classes	O
of	O
(	O
nematocidal	O
)	O
compounds	O
used	O
to	O
treat	O
the	O
diseases	O
they	O
cause	O
[	O
2	O
]	O
–	O
[	O
5	O
]	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
significant	O
need	O
to	O
work	O
toward	O
discovering	O
new	O
compounds	O
to	O
control	O
these	O
parasites	O
.	O

Gaining	O
an	O
improved	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
parasite	O
development	O
provides	O
such	O
an	O
avenue	O
.	O

Compared	O
with	O
the	O
free	O
-	O
living	O
nematode	O
Caenorhabditis	B
elegans	I
,	O
there	O
is	O
very	O
little	O
information	O
on	O
fundamental	O
molecular	O
aspects	O
of	O
development	O
in	O
parasitic	O
nematodes	O
[	O
6	O
]	O
–	O
[	O
8	O
]	O
.	O

Since	O
the	O
genome	O
sequence	O
of	O
C.	B
elegans	I
was	O
published	O
in	O
1998	O
[	O
9	O
]	O
,	O
many	O
aspects	O
of	O
the	O
molecular	O
biology	O
of	O
this	O
nematode	O
have	O
been	O
elucidated	O
.	O

For	O
instance	O
,	O
microarray	O
analyses	O
have	O
been	O
used	O
to	O
examine	O
developmental	O
and	O
gender	O
-	O
enriched	O
gene	O
expression	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
,	O
and	O
the	O
functions	O
of	O
more	O
than	O
96	O
%	O
of	O
the	O
C.	B
elegans	I
genes	O
have	O
been	O
assessed	O
by	O
double	O
-	O
stranded	O
RNA	O
interference	O
(	O
RNAi	O
,	O
or	O
gene	O
silencing	O
;	O
[	O
12	O
]	O
)	O
[	O
13	O
]	O
–	O
[	O
18	O
]	O
.	O

Comparative	O
analyses	O
of	O
genetic	O
data	O
sets	O
have	O
shown	O
that	O
parasitic	O
nematodes	O
usually	O
share	O
∼50–70	O
%	O
of	O
genes	O
with	O
C.	B
elegans	I
(	O
e.g.	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
)	O
.	O

There	O
is	O
similarity	O
in	O
other	O
features	O
(	O
such	O
as	O
basic	O
body	O
plan	O
and	O
moulting	O
)	O
between	O
C.	B
elegans	I
and	O
parasitic	O
nematodes	O
,	O
suggesting	O
that	O
some	O
molecular	O
pathways	O
are	O
relatively	O
conserved	O
[	O
8	O
]	O
,	O
[	O
21	O
]	O
.	O

Understanding	O
the	O
pathways	O
linked	O
to	O
basic	O
nematode	O
biology	O
and	O
development	O
could	O
have	O
important	O
implications	O
for	O
finding	O
new	O
ways	O
of	O
disrupting	O
these	O
pathways	O
and	O
thus	O
facilitate	O
the	O
identification	O
of	O
new	O
drug	O
targets	O
.	O

Despite	O
the	O
advances	O
in	O
genomic	O
technologies	O
[	O
7	O
]	O
,	O
[	O
22	O
]	O
–	O
[	O
29	O
]	O
and	O
the	O
study	O
of	O
C.	B
elegans	I
,	O
there	O
is	O
a	O
paucity	O
of	O
information	O
on	O
the	O
genomics	O
of	O
parasitic	O
nematodes	O
of	O
animals	O
,	O
particularly	O
in	O
relation	O
to	O
development	O
.	O

Also	O
considering	O
the	O
major	O
socioeconomic	O
impact	O
of	O
Ascaris	O
and	O
ascariasis	O
in	O
humans	B
and	O
pigs	B
[	O
30	O
]	O
–	O
[	O
32	O
]	O
,	O
several	O
characteristics	O
,	O
including	O
the	O
large	O
size	O
of	O
the	O
adult	O
worm	O
(	O
providing	O
the	O
opportunity	O
of	O
investigating	O
individual	O
organ	O
systems	O
and	O
tissues	O
)	O
,	O
the	O
ability	O
to	O
maintain	O
Ascaris	O
in	O
the	O
pig	B
,	O
store	O
eggs	O
and	O
culture	O
larvae	O
in	O
vitro	O
for	O
relatively	O
long	O
periods	O
of	O
time	O
(	O
months	O
to	O
years	O
)	O
[	O
32	O
]	O
as	O
well	O
as	O
the	O
discovery	O
that	O
RNAi	O
achieves	O
""""	O
cross	O
-	O
species	O
""""	O
gene	O
silencing	O
for	O
a	O
selected	O
number	O
of	O
genes	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
and	O
the	O
imminent	O
genome	O
sequence	O
(	O
http://www.sanger.ac.uk/Projects/Helminths/	O
)	O
all	O
indicate	O
that	O
Ascaris	O
could	O
serve	O
as	O
a	O
powerful	O
model	O
system	O
for	O
investigating	O
reproductive	O
and	O
developmental	O
processes	O
in	O
nematodes	O
.	O

In	O
the	O
present	O
study	O
,	O
Ascaris	O
from	O
pigs	B
was	O
used	O
to	O
study	O
molecules	O
abundantly	O
transcribed	O
in	O
the	O
infective	O
third	O
-	O
stage	O
larva	O
(	O
L3	O
)	O
.	O

Following	O
the	O
oral	O
ingestion	O
of	O
Ascaris	O
eggs	O
by	O
the	O
host	O
(	O
human	B
or	O
pig	B
)	O
,	O
L3s	O
are	O
released	O
and	O
then	O
invade	O
/	O
penetrate	O
predominantly	O
the	O
caecal	O
wall	O
[	O
35	O
]	O
to	O
then	O
undergo	O
hepato	O
-	O
pulmonary	O
migration	O
,	O
after	O
which	O
ultimately	O
the	O
adult	O
females	O
and	O
males	O
establish	O
and	O
develop	O
in	O
the	O
small	O
intestine	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

The	O
molecular	O
mechanisms	O
linked	O
to	O
host	O
invasion	O
and	O
parasite	O
development	O
are	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
constructed	O
an	O
L3-enriched	O
cDNA	O
library	O
using	O
the	O
method	O
of	O
suppressive	O
-	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
,	O
explored	O
transcription	O
of	O
a	O
representative	O
subset	O
of	O
molecules	O
by	O
microarray	O
analysis	O
and	O
conducted	O
bioinformatic	O
analyses	O
to	O
characterize	O
these	O
molecules	O
,	O
map	O
them	O
to	O
biochemical	O
pathways	O
and	O
predict	O
genetic	O
interactions	O
based	O
on	O
comparisons	O
with	O
C.	B
elegans	I
and/or	O
other	O
organisms	O
.	O

Materials	O
and	O
Methods	O
Production	O
of	O
Different	O
Developmental	O
Stages	O
of	O
Ascaris	O
Experimental	O
pigs	B
(	O
8–12	O
weeks	O
of	O
age	O
)	O
were	O
purchased	O
from	O
and	O
maintained	O
in	O
the	O
Experimental	O
Animal	O
Center	O
of	O
South	O
China	O
Agricultural	O
University	O
.	O

These	O
pigs	B
were	O
treated	O
humanely	O
,	O
according	O
to	O
the	O
Animal	O
Ethics	O
procedures	O
and	O
guidelines	O
of	O
the	O
People	O
's	O
Republic	O
of	O
China	O
.	O

Adult	O
worms	O
(	O
males	O
and	O
females	O
)	O
of	O
A.	B
suum	I
were	O
collected	O
from	O
the	O
small	O
intestines	O
of	O
pigs	B
from	O
an	O
abattoir	O
in	O
Shenzhen	O
,	O
China	O
.	O

Infective	O
eggs	O
and	O
infective	O
L3s	O
of	O
A.	B
suum	I
were	O
produced	O
according	O
to	O
the	O
methods	O
described	O
previously	O
[	O
38	O
]	O
.	O

In	O
brief	O
,	O
eggs	O
from	O
the	O
uteri	O
of	O
adult	O
females	O
of	O
A.	B
suum	I
were	O
collected	O
and	O
incubated	O
at	O
28	O
°	O
C	O
for	O
28	O
days	O
to	O
allow	O
them	O
to	O
develop	O
to	O
infective	O
eggs	O
(	O
containing	O
infective	O
L3s	O
)	O
.	O

To	O
obtain	O
pure	O
infective	O
L3s	O
,	O
7.5	O
%	O
v	O
/	O
v	O
sodium	O
hypochlorite	O
was	O
used	O
to	O
treat	O
the	O
larvated	O
eggs	O
at	O
37	O
°	O
C	O
overnight	O
and	O
then	O
the	O
eggs	O
were	O
shaken	O
with	O
glass	O
-	O
beads	O
;	O
then	O
,	O
the	O
exsheathed	O
L3s	O
and	O
shells	O
were	O
separated	O
by	O
density	O
gradient	O
centrifugation	O
using	O
lymphocyte	O
separating	O
medium	O
(	O
LSM	O
)	O
[	O
38	O
]	O
.	O

Following	O
the	O
experimental	O
infection	O
of	O
helminth	O
-	O
free	O
pigs	B
with	O
infective	O
Ascaris	O
eggs	O
as	O
described	O
previously	O
[	O
39	O
]	O
,	O
the	O
L3s	O
from	O
livers	O
and	O
in	O
lungs	O
as	O
well	O
as	O
L4s	O
in	O
intestines	O
were	O
isolated	O
according	O
to	O
an	O
established	O
method	O
[	O
40	O
]	O
.	O

All	O
parasite	O
materials	O
were	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	O
prior	O
to	O
storage	O
at	O
−70	O
°	O
C	O
.	O

Construction	O
of	O
the	O
cDNA	O
Library	O
by	O
Subtractive	O
-	O
Suppressive	O
Hybridization	O
(	O
SSH	O
)	O
Total	O
RNA	O
was	O
isolated	O
from	O
adult	O
females	O
and	O
males	O
,	O
different	O
larval	O
stages	O
or	O
eggs	O
of	O
A.	B
suum	I
using	O
TriPure	O
reagent	O
(	O
Roche	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Equal	O
amounts	O
of	O
total	O
RNA	O
from	O
each	O
stage	O
or	O
sex	O
were	O
pooled	O
.	O

The	O
mRNA	O
was	O
isolated	O
using	O
the	O
Oligotex	O
mRNA	O
Kit	O
(	O
Qiagen	O
)	O
,	O
following	O
the	O
manufacturer	O
's	O
protocol	O
.	O

SSH	O
was	O
carried	O
out	O
using	O
the	O
PCR	O
-	O
Select	O
cDNA	O
Subtraction	O
kit	O
(	O
Clontech	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

In	O
brief	O
,	O
cDNA	O
synthesized	O
from	O
mRNAs	O
from	O
infective	O
L3s	O
was	O
subtracted	O
against	O
cDNA	O
synthesized	O
from	O
the	O
pooled	O
mRNA	O
from	O
all	O
other	O
stages	O
included	O
herein	O
.	O

The	O
SSH	O
library	O
was	O
constructed	O
using	O
infective	O
L3s	O
as	O
the	O
tester	O
and	O
pooled	O
cDNAs	O
from	O
all	O
other	O
stages	O
as	O
the	O
driver	O
.	O

The	O
effectiveness	O
of	O
this	O
subtraction	O
process	O
has	O
already	O
been	O
demonstrated	O
in	O
previous	O
studies	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

The	O
cDNA	O
obtained	O
following	O
SSH	O
was	O
cloned	O
into	O
the	O
pGEM	O
-	O
T	O
Easy	O
plasmid	O
vector	O
(	O
Promega	O
)	O
and	O
competent	O
Escherichia	B
coli	I
(	O
JM109	O
)	O
transformed	O
.	O

Positive	O
clones	O
,	O
picked	O
randomly	O
(	O
based	O
on	O
blue	O
/	O
white	O
selection	O
)	O
,	O
were	O
grown	O
overnight	O
in	O
Luria	O
Bertani	O
(	O
LB	O
)	O
medium	O
(	O
shaking	O
,	O
37	O
°	O
C	O
)	O
.	O

Individual	O
inserts	O
were	O
PCR	O
-	O
amplified	O
using	O
""""	O
nested	O
primers	O
""""	O
1	O
and	O
2R	O
from	O
the	O
Subtraction	O
kit	O
(	O
Clontech	O
)	O
and	O
examined	O
by	O
agarose	O
electrophoresis	O
.	O

Preparation	O
of	O
Microarray	O
Slides	O
Clones	O
(	O
n	O
=	O
3075	O
)	O
from	O
the	O
subtracted	O
library	O
were	O
picked	O
and	O
cultured	O
overnight	O
in	O
LB	O
containing	O
ampicillin	O
(	O
1000	O
IU	O
/	O
ml	O
)	O
in	O
sealed	O
96-well	O
blocks	O
.	O

Five	O
µl	O
of	O
culture	O
suspension	O
from	O
each	O
well	O
were	O
transferred	O
into	O
individual	O
wells	O
thermocycling	O
(	O
96-well	O
)	O
plates	O
and	O
the	O
inserts	O
PCR	O
-	O
amplified	O
using	O
primers	O
1	O
and	O
2R	O
.	O

Following	O
a	O
10	O
min	O
denaturation	O
step	O
at	O
94	O
°	O
C	O
,	O
the	O
amplification	O
proceeded	O
for	O
25	O
cycles	O
of	O
10	O
s	O
at	O
94	O
°	O
C	O
,	O
30	O
s	O
at	O
68	O
°	O
C	O
and	O
1.5	O
min	O
at	O
72	O
°	O
C	O
,	O
with	O
a	O
final	O
extension	O
for	O
5	O
min	O
at	O
72	O
°	O
C	O
.	O

Products	O
were	O
resolved	O
in	O
agarose	O
gels	O
,	O
ethanol	O
precipitated	O
,	O
re	O
-	O
suspended	O
in	O
16	O
µl	O
of	O
""""	O
spotting	O
solution	O
""""	O
(	O
Shanghai	O
BioStar	O
Genechip	O
,	O
Inc	O
)	O
to	O
a	O
final	O
concentration	O
of	O
∼500	O
ng	O
per	O
µl	O
,	O
before	O
being	O
printed	O
on	O
to	O
glass	O
slides	O
(	O
in	O
duplicate	O
)	O
using	O
a	O
robotic	O
arrayer	O
.	O

Sixteen	O
blanks	O
(	O
using	O
spotting	O
solution	O
only	O
)	O
and	O
the	O
same	O
number	O
of	O
negative	O
(	O
irrelevant	O
cDNAs	O
with	O
no	O
relationship	O
to	O
Ascaris	O
)	O
were	O
also	O
printed	O
on	O
to	O
slides	O
and	O
served	O
as	O
negative	O
controls	O
;	O
β	O
-	O
actin	O
of	O
A.	B
suum	I
served	O
as	O
a	O
positive	O
control	O
to	O
assess	O
the	O
efficiency	O
of	O
labeling	O
and	O
hybridization	O
.	O

The	O
slides	O
were	O
air	O
-	O
dried	O
for	O
2	O
h	O
,	O
and	O
cDNA	O
in	O
the	O
spots	O
were	O
cross	O
-	O
linked	O
at	O
254	O
mJ.	O
The	O
printed	O
slides	O
were	O
stored	O
at	O
4	O
°	O
C	O
.	O

Labeling	O
of	O
cDNA	O
Probes	O
with	O
Fluorescent	O
Dyes	O
,	O
and	O
Microarray	O
Analysis	O
The	O
cDNAs	O
produced	O
from	O
total	O
RNA	O
from	O
A.	B
suum	I
eggs	O
,	O
infective	O
L3s	O
,	O
L3s	O
isolated	O
from	O
pig	B
liver	O
or	O
lung	O
,	O
fourth	O
-	O
stage	O
larvae	O
(	O
L4s	O
)	O
,	O
adult	O
males	O
or	O
females	O
[	O
as	O
described	O
in	O
the	O
section	O
'	O
Construction	O
of	O
the	O
cDNA	O
Library	O
by	O
Subtractive	O
-	O
Suppressive	O
Hybridization	O
(	O
SSH	O
)	O
'	O
]	O
were	O
labeled	O
with	O
cyanine	O
dyes	O
.	O

Cy3	O
or	O
Cy5-dCTP	O
was	O
incorporated	O
into	O
cDNA	O
produced	O
from	O
30	O
µg	O
of	O
total	O
RNA	O
by	O
direct	O
labeling	O
in	O
a	O
reverse	O
transcription	O
reaction	O
using	O
an	O
oligo	O
(	O
dT	O
)	O
primer	O
.	O

Labeled	O
cDNA	O
was	O
purified	O
using	O
DyeEx	O
columns	O
(	O
Qiagen	O
)	O
.	O

Microarray	O
slides	O
were	O
incubated	O
with	O
a	O
pre	O
-	O
hybridization	O
solution	O
[	O
5	O
×	O
SSC	O
,	O
1	O
%	O
bovine	B
serum	O
albumin	O
(	O
BSA	O
)	O
,	O
0.1	O
%	O
sodium	O
dodecyl	O
-	O
sulphate	O
(	O
SDS	O
)	O
]	O
for	O
6	O
h	O
at	O
42	O
°	O
C	O
.	O

After	O
pre	O
-	O
hybridization	O
,	O
the	O
microarray	O
slides	O
were	O
incubated	O
with	O
'	O
pooled	O
'	O
Cy3	O
and	O
Cy5-labeled	O
probes	O
in	O
hybridization	O
solution	O
(	O
5	O
×	O
SSC	O
,	O
1	O
%	O
BSA	O
,	O
0.1	O
%	O
SDS	O
)	O
,	O
in	O
the	O
dark	O
at	O
42	O
°	O
C	O
for	O
18	O
h	O
,	O
and	O
then	O
washed	O
in	O
solution	O
I	O
(	O
1	O
×	O
SSC	O
,	O
0.2	O
%	O
SDS	O
)	O
for	O
10	O
min	O
,	O
followed	O
by	O
solution	O
II	O
(	O
0.1	O
×	O
SSC	O
,	O
0.2	O
%	O
SDS	O
)	O
for	O
10	O
min	O
at	O
60	O
°	O
C	O
,	O
according	O
to	O
the	O
protocols	O
provided	O
by	O
Shanghai	O
BioStar	O
Genechip	O
,	O
Inc.	O
A	O
""""	O
dye	O
flip	O
""""	O
was	O
carried	O
out	O
to	O
control	O
for	O
any	O
bias	O
in	O
hybridization	O
signal	O
between	O
the	O
Cy	O
-	O
labeled	O
cDNA	O
probes	O
(	O
produced	O
for	O
two	O
distinct	O
mRNA	O
populations	O
)	O
.	O

The	O
slides	O
were	O
dried	O
and	O
scanned	O
(	O
ScanArray	O
4000	O
scanner	O
)	O
using	O
image	O
acquisition	O
software	O
(	O
Shanghai	O
BioStar	O
Genechip	O
Inc.	O
)	O
and	O
a	O
range	O
of	O
laser	O
power	O
and	O
photo	O
-	O
multiplier	O
tube	O
intensities	O
.	O

The	O
mean	O
hybridization	O
signal	O
(	O
derived	O
from	O
four	O
replicates	O
of	O
the	O
same	O
array	O
)	O
were	O
corrected	O
for	O
background	O
,	O
normalized	O
[	O
43	O
]	O
,	O
log2-transformed	O
and	O
then	O
subjected	O
to	O
statistical	O
analysis	O
employing	O
the	O
students	O
t	O
-	O
test	O
in	O
a	O
spreadsheet	O
(	O
Excel	O
,	O
Microsoft	O
,	O
USA	O
)	O
.	O

The	O
microarray	O
data	O
were	O
analysed	O
for	O
differential	O
cDNA	O
hybridization	O
(	O
>	O
2.0-fold	O
to	O
114.3-fold	O
)	O
between	O
L3	O
and	O
each	O
of	O
the	O
other	O
stages	O
(	O
eggs	O
,	O
lung	O
and	O
liver	O
L3s	O
,	O
L4	O
,	O
adult	O
female	O
and	O
adult	O
male	O
)	O
.	O

Verification	O
of	O
Differential	O
Hybridization	O
by	O
Reverse	O
Transcription	O
-	O
Coupled	O
Polymerase	O
Chain	O
Reaction	O
(	O
RT	O
-	O
PCR	O
)	O
Analysis	O
For	O
a	O
subset	O
(	O
n	O
=	O
17	O
)	O
of	O
representative	O
ESTs	O
(	O
rESTs	O
)	O
,	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
verify	O
the	O
differential	O
transcription	O
recorded	O
by	O
microarray	O
analysis	O
.	O

Double	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
total	O
RNA	O
(	O
separately	O
)	O
from	O
each	O
stage	O
or	O
sex	O
of	O
A.	B
suum	I
using	O
reverse	O
transcriptase	O
(	O
Superscript	O
III	O
,	O
Invitrogen	O
)	O
.	O

Briefly	O
,	O
5	O
µg	O
of	O
total	O
RNA	O
were	O
added	O
to	O
14	O
µl	O
of	O
H2O	O
and	O
1	O
µl	O
of	O
oligo	O
d	O
(	O
T	O
)	O
n	O
=	O
12–18	O
primer	O
(	O
0.5	O
µg	O
/	O
µl	O
)	O
,	O
heated	O
to	O
70	O
°	O
C	O
for	O
10	O
min	O
and	O
chilled	O
on	O
ice	O
.	O

First-	O
and	O
second	O
-	O
strand	O
cDNAs	O
were	O
synthesized	O
via	O
the	O
addition	O
of	O
4	O
µl	O
of	O
first	O
-	O
strand	O
cDNA	O
buffer	O
(	O
250	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8.3	O
,	O
375	O
mM	O
KCl	O
and	O
15	O
mM	O
MgCl2	O
)	O
,	O
2	O
µl	O
of	O
0.1	O
M	O
dithiothreitol	O
,	O
and	O
1	O
µl	O
of	O
10	O
mM	O
of	O
each	O
dNTP	O
,	O
followed	O
by	O
an	O
incubation	O
at	O
25	O
°	O
C	O
(	O
10	O
min	O
)	O
,	O
42	O
°	O
C	O
(	O
50	O
min	O
)	O
and	O
70	O
°	O
C	O
(	O
15	O
min	O
)	O
.	O

One	O
-	O
tenth	O
of	O
each	O
double	O
-	O
stranded	O
cDNA	O
produced	O
was	O
then	O
used	O
as	O
a	O
template	O
in	O
the	O
PCR	O
.	O

The	O
transcripts	O
were	O
amplified	O
from	O
individual	O
cDNAs	O
by	O
PCR	O
using	O
oligonucleotide	O
primers	O
(	O
sequences	O
available	O
upon	O
request	O
)	O
designed	O
to	O
each	O
EST	O
.	O

The	O
PCR	O
amplification	O
of	O
a	O
portion	O
(	O
209	O
bp	O
)	O
of	O
the	O
β	O
-	O
actin	O
gene	O
(	O
accession	O
no.	O
BI594141	O
)	O
using	O
forward	O
primer	O
(	O
5′-CTCGAAACAAGAATACGATG-3′	O
)	O
and	O
reverse	O
primer	O
(	O
5′-	O
ACATGTGCCGTTGTATGATG-3′	O
)	O
,	O
previously	O
determined	O
to	O
be	O
present	O
in	O
all	O
developmental	O
stages	O
and	O
both	O
sexes	O
of	O
A.	B
suum	I
[	O
44	O
]	O
,	O
served	O
as	O
a	O
positive	O
control	O
.	O

Samples	O
without	O
template	O
(	O
no	O
-	O
DNA	O
controls	O
)	O
were	O
included	O
in	O
each	O
PCR	O
run	O
.	O

The	O
following	O
cycling	O
conditions	O
were	O
employed	O
:	O
one	O
cycle	O
at	O
94	O
°	O
C	O
(	O
5	O
min	O
)	O
,	O
94	O
°	O
C	O
(	O
30	O
s	O
)	O
,	O
60	O
°	O
C	O
(	O
30	O
s	O
)	O
and	O
72	O
°	O
C	O
(	O
30	O
s	O
)	O
for	O
30	O
cycles	O
,	O
followed	O
by	O
a	O
final	O
extension	O
of	O
70	O
°	O
C	O
(	O
7	O
min	O
)	O
.	O

Following	O
the	O
PCR	O
,	O
5	O
µl	O
of	O
individual	O
amplicons	O
were	O
resolved	O
in	O
ethidium	O
bromide	O
-	O
stained	O
agarose	O
gels	O
(	O
2	O
%	O
)	O
and	O
then	O
photographed	O
upon	O
transillumination	O
.	O

The	O
relative	O
band	O
intensities	O
were	O
analyzed	O
using	O
UVIsoft	O
Image	O
Acquisition	O
and	O
Analysis	O
software	O
(	O
UVITEC	O
)	O
.	O

The	O
specificity	O
and	O
identity	O
of	O
individual	O
amplicons	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
using	O
the	O
same	O
primers	O
(	O
separately	O
)	O
as	O
employed	O
for	O
their	O
amplification	O
.	O

Sequencing	O
and	O
Bioinformatics	O
Analyses	O
Clones	O
from	O
the	O
SSH	O
cDNA	O
library	O
with	O
increased	O
hybridization	O
in	O
microarray	O
analysis	O
to	O
the	O
infective	O
L3	O
compared	O
with	O
other	O
stages	O
were	O
sequenced	O
using	O
standard	O
technology	O
[	O
45	O
]	O
.	O

The	O
nucleotide	O
sequences	O
have	O
been	O
deposited	O
in	O
the	O
GenBank	O
database	O
under	O
accession	O
numbers	O
ES290984-ES291074	O
.	O

Following	O
the	O
processing	O
of	O
the	O
sequences	O
(	O
i.e.	O
,	O
removal	O
of	O
vector	O
sequences	O
,	O
quality	O
assurance	O
and	O
clustering	O
)	O
,	O
contigs	O
or	O
singletons	O
from	O
individual	O
clusters	O
were	O
subjected	O
to	O
BLASTx	O
(	O
NCBI	O
:	O
www.ncbi.nlm.nih.gov	O
)	O
and	O
BLASTn	O
(	O
EMBL	O
-	O
EBI	O
Parasite	O
Genome	O
Blast	O
Server	O
:	O
www.ebi.ac.uk	O
)	O
analysis	O
to	O
identify	O
putative	O
homologues	O
in	O
C.	B
elegans	I
,	O
other	O
nematodes	O
and	O
other	O
organisms	O
(	O
e	O
-	O
value	O
of	O
≤1e-05	O
)	O
.	O

Peptides	O
inferred	O
from	O
ESTs	O
were	O
classified	O
functionally	O
using	O
Interproscan	O
(	O
available	O
at	O
http://www.ebi.ac.uk/InterProScan/	O
)	O
employing	O
the	O
default	O
search	O
parameters	O
.	O

WormBase	O
(	O
www.wormbase.org	O
)	O
was	O
interrogated	O
extensively	O
for	O
relevant	O
information	O
on	O
C.	B
elegans	I
homologues	O
/	O
orthologues	O
,	O
including	O
RNAi	O
phenotypic	O
,	O
transcriptomic	O
,	O
proteomic	O
and	O
interactomic	O
data	O
.	O

ESTs	O
with	O
homologues	O
/	O
orthologues	O
in	O
C.	B
elegans	I
and	O
other	O
nematodes	O
were	O
also	O
subjected	O
to	O
analysis	O
employing	O
the	O
KEGG	O
Orthology	O
-	O
Based	O
Annotation	O
System	O
(	O
KOBAS	O
)	O
(	O
www.kobas.cbi.pku.edu.cn	O
)	O
,	O
which	O
predicts	O
the	O
biochemical	O
pathways	O
in	O
which	O
molecules	O
are	O
involved	O
.	O

The	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
inferred	O
from	O
selected	O
ESTs	O
with	O
orthologues	O
in	O
C.	B
elegans	I
were	O
also	O
subjected	O
to	O
""""	O
secretome	O
analysis	O
""""	O
using	O
the	O
program	O
SignalP	O
v.2.0	O
www.cbs.dtu.dk/services/SignalP/	O
)	O
,	O
employing	O
both	O
the	O
neural	O
network	O
and	O
hidden	O
Markov	O
models	O
to	O
predict	O
signal	O
peptides	O
and/or	O
anchors	O
[	O
46	O
]	O
–	O
[	O
48	O
]	O
.	O

Also	O
,	O
transmembrane	O
domains	O
were	O
predicted	O
using	O
the	O
program	O
TMHMM	O
(	O
www.cbs.dtu.dk/services/TMHMM/	O
;	O
[	O
49	O
]	O
–	O
[	O
51	O
]	O
)	O
,	O
and	O
subcellular	O
localization	O
inferred	O
employing	O
the	O
program	O
WoLF	O
PSORT	O
(	O
http://wolfpsort.org/	O
;	O
[	O
52	O
]	O
)	O
.	O

The	O
method	O
established	O
by	O
Zhong	O
and	O
Sternberg	O
[	O
53	O
]	O
was	O
used	O
to	O
predict	O
the	O
interactions	O
for	O
C.	B
elegans	I
orthologues	O
of	O
the	O
L3-enriched	O
molecules	O
from	O
Ascaris	O
.	O

In	O
brief	O
,	O
interaction	O
,	O
phenotypic	O
,	O
expression	O
and	O
gene	O
ontology	O
data	O
from	O
fruitfly	B
,	O
yeast	B
,	O
mouse	B
and	O
human	B
were	O
integrated	O
using	O
a	O
naïve	O
Bayesian	O
model	O
to	O
predict	O
genetic	O
interactions	O
among	O
C.	B
elegans	I
genes	O
(	O
[	O
45	O
]	O
,	O
[	O
53	O
]	O
;	O
Zhong	O
and	O
Sternberg	O
,	O
unpublished	O
)	O
.	O

The	O
predicted	O
networks	O
resulting	O
from	O
the	O
analyses	O
were	O
saved	O
in	O
a	O
graphic	O
display	O
file	O
(	O
gdf	O
)	O
format	O
and	O
examined	O
using	O
the	O
graph	O
exploration	O
system	O
available	O
at	O
http://graphexploration.cond.org/.	O
Images	O
were	O
labeled	O
and	O
saved	O
in	O
the	O
joint	O
photographic	O
experts	O
group	O
(	O
jpeg	O
)	O
format	O
.	O

Results	O
To	O
identify	O
molecules	O
transcribed	O
abundantly	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
,	O
an	O
enriched	O
cDNA	O
library	O
was	O
constructed	O
by	O
SSH	O
.	O

From	O
a	O
total	O
of	O
3075	O
clones	O
from	O
this	O
library	O
,	O
2921	O
(	O
95	O
%	O
)	O
were	O
shown	O
to	O
contain	O
an	O
insert	O
(	O
which	O
could	O
be	O
amplified	O
by	O
PCR	O
)	O
.	O

From	O
2671	O
(	O
92	O
%	O
)	O
of	O
these	O
clones	O
,	O
amplicons	O
representing	O
single	O
bands	O
of	O
∼400	O
to	O
600	O
bp	O
in	O
size	O
were	O
produced	O
.	O

These	O
latter	O
amplicons	O
were	O
arrayed	O
(	O
in	O
duplicate	O
)	O
on	O
to	O
slides	O
and	O
then	O
hybridized	O
with	O
Cy3-labeled	O
L3-cDNA	O
or	O
with	O
Cy5-labeled	O
cDNA	O
from	O
eggs	O
,	O
liver	O
/	O
lung	O
L3s	O
,	O
L4s	O
,	O
adult	O
female	O
or	O
adult	O
male	O
of	O
Ascaris	O
.	O

Dye	O
flip	O
was	O
conducted	O
to	O
verify	O
the	O
hybridization	O
data	O
.	O

Of	O
the	O
2671	O
(	O
duplicate	O
)	O
spots	O
,	O
1526	O
had	O
a	O
significant	O
difference	O
in	O
hybridization	O
between	O
infective	O
L3	O
cDNA	O
and	O
cDNAs	O
from	O
all	O
other	O
stages	O
or	O
sexes	O
of	O
A.	B
suum	I
,	O
of	O
which	O
515	O
had	O
a	O
>	O
2.0-fold	O
increased	O
hybridization	O
for	O
the	O
L3	O
.	O

In	O
order	O
to	O
independently	O
verify	O
the	O
hybridization	O
results	O
in	O
the	O
microarray	O
,	O
a	O
PCR	O
-	O
based	O
analysis	O
of	O
a	O
selected	O
subset	O
(	O
n	O
=	O
17	O
)	O
clones	O
was	O
conducted	O
using	O
specific	O
primer	O
pairs	O
.	O

Having	O
verified	O
the	O
specificity	O
and	O
identity	O
of	O
individual	O
amplicons	O
by	O
sequencing	O
,	O
PCR	O
results	O
were	O
reproducible	O
(	O
based	O
on	O
multiple	O
runs	O
on	O
different	O
days	O
)	O
and	O
∼94	O
%	O
(	O
16	O
of	O
17	O
)	O
concordant	O
with	O
those	O
of	O
the	O
microarray	O
analysis	O
(	O
not	O
shown	O
)	O
.	O

There	O
was	O
complete	O
concordance	O
for	O
representative	O
clones	O
associated	O
with	O
a	O
differential	O
signal	O
of	O
≥3.0-fold	O
in	O
the	O
microarray	O
.	O

The	O
clones	O
linked	O
to	O
the	O
515	O
spots	O
representing	O
increased	O
transcription	O
(	O
>	O
2.0-fold	O
)	O
in	O
infective	O
L3	O
compared	O
with	O
the	O
other	O
developmental	O
stages	O
or	O
sexes	O
included	O
were	O
subjected	O
to	O
sequencing	O
.	O

The	O
498	O
sequences	O
(	O
length	O
:	O
550±115	O
bp	O
)	O
determined	O
were	O
then	O
subjected	O
to	O
detailed	O
bioinformatic	O
analyses	O
.	O

There	O
were	O
91	O
unique	O
clusters	O
(	O
accession	O
numbers	O
ES290984-ES291074	O
)	O
,	O
of	O
which	O
55	O
were	O
singletons	O
(	O
sequences	O
determined	O
once	O
)	O
.	O

Of	O
56	O
molecules	O
(	O
61.5	O
%	O
)	O
with	O
significant	O
similarity	O
to	O
sequences	O
other	O
than	O
A.	B
suum	I
in	O
the	O
databases	O
interrogated	O
,	O
50	O
(	O
54.9	O
%	O
)	O
had	O
C.	B
elegans	I
or	O
C.	B
briggsae	I
homologues	O
,	O
and	O
six	O
had	O
similarity	O
to	O
ESTs	O
already	O
sequenced	O
from	O
ascaridoid	O
and/or	O
other	O
parasitic	O
nematodes	O
,	O
and/or	O
other	O
organisms	O
(	O
Table	O
1	O
)	O
.	O

A	O
significant	O
proportion	O
(	O
38.4	O
%	O
)	O
did	O
not	O
have	O
any	O
similarity	O
in	O
sequence	O
to	O
any	O
organisms	O
for	O
which	O
data	O
are	O
presently	O
available	O
.	O

Comparative	O
analysis	O
specifically	O
against	O
A.	B
suum	I
EST	O
data	O
sets	O
(	O
n∼42,000	O
)	O
available	O
in	O
public	O
databases	O
confirmed	O
independently	O
that	O
the	O
majority	O
of	O
molecules	O
(	O
>	O
60	O
%	O
)	O
were	O
present	O
exclusively	O
in	O
the	O
infective	O
L3	O
stage	O
or	O
were	O
orphans	O
.	O

As	O
gene	O
ontology	O
(	O
GO	O
)	O
provides	O
a	O
hierarchy	O
that	O
unifies	O
the	O
descriptions	O
of	O
biological	O
,	O
cellular	O
and	O
molecular	O
functions	O
[	O
54	O
]	O
,	O
this	O
approach	O
was	O
employed	O
to	O
predict	O
the	O
classification	O
and	O
gene	O
function	O
of	O
molecules	O
enriched	O
in	O
infective	O
L3	O
of	O
A.	B
suum	I
.	O

A	O
summary	O
of	O
the	O
GO	O
categories	O
of	O
these	O
molecules	O
is	O
displayed	O
in	O
Fig.	O
1	O
.	O

Of	O
the	O
91	O
contigs	O
,	O
32	O
(	O
35	O
%	O
)	O
could	O
be	O
functionally	O
assigned	O
to	O
'	O
biological	O
process	O
'	O
(	O
n	O
=	O
38	O
)	O
,	O
'	O
cellular	O
component	O
'	O
(	O
n	O
=	O
17	O
)	O
and	O
'	O
molecular	O
function	O
'	O
(	O
n	O
=	O
64	O
)	O
.	O

The	O
most	O
common	O
subcategories	O
were	O
gluconeogenesis	O
(	O
13	O
%	O
)	O
and	O
metabolic	O
process	O
(	O
13	O
%	O
)	O
within	O
'	O
biological	O
process	O
'	O
,	O
extracellular	O
region	O
(	O
24	O
%	O
)	O
within	O
'	O
cellular	O
component	O
'	O
,	O
and	O
catalytic	O
activity	O
(	O
11	O
%	O
)	O
and	O
phosphoenolpyruvate	O
carboxykinase	O
activity	O
(	O
8	O
%	O
)	O
within	O
'	O
molecular	O
function	O
'	O
(	O
Table	O
S1	O
)	O
.	O

A	O
focused	O
KOBAS	O
analysis	O
inferred	O
the	O
50	O
C.	B
elegans	I
orthologues	O
/	O
homologues	O
to	O
be	O
involved	O
in	O
apoptosis	O
and	O
insulin	O
signaling	O
(	O
2	O
%	O
)	O
,	O
ATP	O
synthesis	O
(	O
2	O
%	O
)	O
,	O
carbon	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
fatty	O
acid	O
biosynthesis	O
(	O
2	O
%	O
)	O
,	O
gap	O
junction	O
(	O
2	O
%	O
)	O
,	O
glucose	O
metabolism	O
(	O
6	O
%	O
)	O
or	O
porphyrin	O
metabolism	O
(	O
2	O
%	O
)	O
,	O
although	O
34	O
(	O
68	O
%	O
)	O
of	O
them	O
could	O
not	O
be	O
mapped	O
to	O
a	O
specific	O
metabolic	O
pathway	O
(	O
Table	O
2	O
)	O
.	O

Of	O
these	O
50	O
molecules	O
,	O
small	O
numbers	O
were	O
predicted	O
to	O
be	O
secreted	O
(	O
10	O
%	O
)	O
,	O
anchored	O
(	O
2	O
%	O
)	O
and/or	O
transmembrane	O
(	O
12	O
%	O
)	O
proteins	O
(	O
Table	O
2	O
)	O
.	O

Functionally	O
,	O
17	O
(	O
34	O
%	O
)	O
of	O
the	O
50	O
molecules	O
were	O
associated	O
with	O
(	O
non	O
-	O
wild	O
-	O
type	O
)	O
RNAi	O
phenotypes	O
in	O
C.	B
elegans	I
,	O
the	O
majority	O
displaying	O
embryonic	O
lethality	O
(	O
Emb	O
)	O
(	O
13	O
types	O
;	O
58.8	O
%	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
(	O
23.5	O
%	O
)	O
and	O
larval	O
lethality	O
(	O
Lvl	O
)	O
(	O
47	O
%	O
)	O
(	O
Table	O
2	O
)	O
.	O

Extending	O
this	O
analysis	O
,	O
a	O
relatively	O
complex	O
genetic	O
interaction	O
network	O
was	O
predicted	O
for	O
the	O
17	O
C.	B
elegans	I
orthologues	O
(	O
i.e.	O
,	O
with	O
non	O
-	O
wild	O
-	O
type	O
RNAi	O
phenotypes	O
)	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Statistically	O
highly	O
significant	O
interactions	O
were	O
predicted	O
for	O
nine	O
of	O
the	O
C.	B
elegans	I
genes	O
;	O
the	O
top	O
five	O
interactors	O
are	O
displayed	O
in	O
Fig.	O
2	O
.	O

The	O
gene	O
ontology	O
categories	O
for	O
eight	O
selected	O
C.	B
elegans	I
genes	O
(	O
F33D11.10	O
,	O
F55A12.8	O
,	O
kin-2	O
,	O
mec-12	O
,	O
mup-2	O
,	O
pab-1	O
,	O
rpl-22	O
and	O
T21B10.2	O
)	O
included	O
:	O
embryonic	O
development	O
,	O
egg	O
hatching	O
,	O
larval	O
development	O
and/or	O
growth	O
.	O

The	O
other	O
categories	O
included	O
:	O
positive	O
regulation	O
of	O
growth	O
rate	O
(	O
F55A12.8	O
,	O
kin-2	O
,	O
mup-2	O
,	O
pab-1	O
,	O
rpl-22	O
and	O
T21B10.2	O
)	O
and	O
gamete	O
generation	O
and	O
locomotory	O
behaviour	O
(	O
kin-2	O
,	O
mup-2	O
,	O
pab-1	O
and	O
F55A12.8	O
,	O
kin-2	O
,	O
mup-2	O
,	O
respectively	O
)	O
.	O

The	O
C.	B
elegans	I
homologue	O
egl-3	O
was	O
predicted	O
to	O
be	O
involved	O
in	O
proteolysis	O
(	O
see	O
www.wormbase.org	O
)	O
.	O

All	O
nine	O
C.	B
elegans	I
orthologues	O
were	O
predicted	O
to	O
interact	O
directly	O
with	O
a	O
total	O
of	O
296	O
(	O
range	O
:	O
5–75	O
)	O
other	O
genes	O
and	O
,	O
in	O
particular	O
,	O
a	O
direct	O
genetic	O
interaction	O
was	O
predicted	O
between	O
pab-1	O
and	O
T21B10.2	O
(	O
Fig.	O
2	O
)	O
.	O

The	O
296	O
interactors	O
were	O
associated	O
with	O
embryonic	O
and	O
larval	O
development	O
(	O
n	O
=	O
198	O
;	O
66.9	O
%	O
)	O
,	O
information	O
storage	O
and	O
processing	O
(	O
n	O
=	O
15	O
;	O
5.1	O
%	O
)	O
,	O
cellular	O
processes	O
and	O
signalling	O
(	O
n	O
=	O
45	O
;	O
15.2	O
%	O
)	O
and	O
metabolism	O
(	O
n	O
=	O
18	O
;	O
6.1	O
%	O
)	O
;	O
the	O
precise	O
function	O
of	O
some	O
of	O
the	O
interactors	O
(	O
n	O
=	O
20	O
;	O
6.7	O
%	O
)	O
is	O
presently	O
unknown	O
(	O
Table	O
S2	O
)	O
.	O

Discussion	O
The	O
present	O
study	O
investigated	O
transcripts	O
in	O
infective	O
L3s	O
of	O
A.	B
suum	I
using	O
a	O
genomic	O
-	O
bioinformatic	O
platform	O
.	O

The	O
focus	O
was	O
on	O
comparisons	O
with	O
C.	B
elegans	I
homologues	O
/	O
orthologues	O
,	O
because	O
the	O
entire	O
genome	O
sequence	O
of	O
this	O
nematode	O
is	O
known	O
[	O
9	O
]	O
and	O
because	O
there	O
is	O
a	O
wealth	O
of	O
information	O
on	O
the	O
localization	O
and	O
functionality	O
of	O
its	O
molecules	O
(	O
www.wormbase.org	O
;	O
http://elegans.bcgsc.bc.ca/knockout.shtml	O
)	O
.	O

The	O
functions	O
of	O
most	O
genes	O
in	O
C.	B
elegans	I
have	O
been	O
assessed	O
using	O
RNAi	O
(	O
e.g.	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
17	O
]	O
,	O
[	O
55	O
]	O
,	O
[	O
56	O
]	O
)	O
in	O
the	O
hermaphroditic	O
stage	O
,	O
whereas	O
there	O
is	O
a	O
paucity	O
of	O
functional	O
information	O
available	O
for	O
Ascaris	O
and	O
other	O
parasitic	O
nematodes	O
of	O
animals	O
[	O
57	O
]	O
,	O
[	O
58	O
]	O
.	O

Following	O
the	O
microarray	O
analysis	O
of	O
>	O
2500	O
ESTs	O
from	O
the	O
SSH	O
library	O
,	O
498	O
cDNAs	O
inferred	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
,	O
based	O
on	O
hybridization	O
signal	O
,	O
were	O
sequenced	O
and	O
subjected	O
to	O
comprehensive	O
in	O
silico	O
analyses	O
.	O

Of	O
the	O
91	O
clusters	O
of	O
molecules	O
categorized	O
,	O
50	O
(	O
54.9	O
%	O
)	O
had	O
C.	B
elegans	I
homologues	O
/	O
orthologues	O
with	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
could	O
be	O
mapped	O
to	O
key	O
pathways	O
.	O

The	O
statistically	O
significant	O
genetic	O
interactions	O
predicted	O
for	O
9	O
of	O
the	O
50	O
C.	B
elegans	I
orthologues	O
[	O
namely	O
egl-3	O
,	O
F33D11.10	O
,	O
F55A12.8	O
,	O
kin-2	O
,	O
mec-12	O
,	O
mup-2	O
,	O
pab-1	O
,	O
rpl-22	O
and	O
T21B10.2	O
(	O
=	O
enol-1	O
)	O
]	O
and	O
the	O
interaction	O
network	O
included	O
genes	O
encoding	O
kinases	O
,	O
alpha	O
-	O
tubulins	O
,	O
enolases	O
,	O
troponin	O
and	O
other	O
named	O
and	O
unnamed	O
proteins	O
.	O

Eight	O
of	O
these	O
molecules	O
(	O
enol-1	O
,	O
pab-1	O
,	O
F33D11.10	O
,	O
rpl-22	O
,	O
F55A12.8	O
mec-12	O
,	O
mup-2	O
and	O
kin-2	O
)	O
have	O
known	O
or	O
predicted	O
roles	O
in	O
embryonic	O
and	O
larval	O
growth	O
and	O
development	O
,	O
gamete	O
generation	O
,	O
locomotory	O
behaviour	O
or	O
other	O
biological	O
processes	O
in	O
C.	B
elegans	I
(	O
see	O
www.wormbase.org	O
)	O
.	O

The	O
enolase	O
encoded	O
by	O
enol-1	O
is	O
predicted	O
to	O
play	O
a	O
role	O
in	O
glycolysis	O
,	O
gluconeogenesis	O
,	O
phenylalanine	O
,	O
tyrosine	O
and	O
tryptophan	O
biosynthesis	O
(	O
cf	O
.	O

[	O
59	O
]	O
)	O
.	O

Since	O
glucose	O
is	O
the	O
main	O
source	O
for	O
ATP	O
production	O
,	O
the	O
alteration	O
in	O
these	O
key	O
glycolytic	O
enzymes	O
may	O
lead	O
to	O
cellular	O
dysfunction	O
,	O
such	O
as	O
impaired	O
ion	O
-	O
motive	O
ATPase	O
required	O
to	O
maintain	O
potential	O
gradients	O
,	O
operate	O
pumps	O
and	O
maintain	O
membrane	O
lipid	O
asymmetry	O
[	O
60	O
]	O
.	O

Bioinformatic	O
analysis	O
for	O
transmembrane	O
helices	O
(	O
TMHMM	O
)	O
and	O
peptide	O
signal	O
sequences	O
(	O
SignalP	O
)	O
predicted	O
ENOL-1	O
to	O
be	O
a	O
non	O
-	O
secreted	O
protein	O
localized	O
to	O
the	O
cytoplasm	O
(	O
cf	O
.	O

Table	O
2	O
)	O
.	O

Nonetheless	O
,	O
enolases	O
are	O
often	O
detected	O
in	O
the	O
excretory	O
/	O
secretory	O
(	O
ES	O
)	O
products	O
of	O
parasitic	O
helminths	O
,	O
including	O
adult	O
A.	B
suum	I
[	O
61	O
]	O
,	O
and	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
triggering	O
of	O
nitric	O
oxide	O
production	O
by	O
host	O
cells	O
.	O

The	O
enol-1	O
orthologue	O
of	O
C.	B
elegans	I
has	O
been	O
predicted	O
to	O
interact	O
specifically	O
with	O
the	O
polyadenylate	O
binding	O
protein	O
gene	O
,	O
pab-1	O
,	O
inferred	O
to	O
be	O
involved	O
in	O
coordinated	O
gene	O
transcription	O
and	O
expression	O
during	O
normal	O
larval	O
development	O
[	O
16	O
]	O
.	O

Poly	O
(	O
A	O
)	O
-binding	O
proteins	O
(	O
PABPs	O
)	O
are	O
recognized	O
to	O
be	O
central	O
to	O
the	O
regulation	O
of	O
mRNA	O
translation	O
and	O
stability	O
[	O
62	O
]	O
.	O

Present	O
evidence	O
suggests	O
that	O
the	O
expression	O
of	O
PAB-1	O
is	O
regulated	O
by	O
an	O
oligo	O
-	O
pyrimidine	O
tract	O
in	O
response	O
to	O
cell	O
growth	O
and	O
relates	O
to	O
coordinated	O
growth	O
regulation	O
in	O
C.	B
elegans	I
[	O
62	O
]	O
.	O

Furthermore	O
,	O
gene	O
silencing	O
of	O
pab-1	O
and	O
its	O
selected	O
interactors	O
(	O
see	O
Fig.	O
2	O
)	O
leads	O
to	O
embryonic	O
lethal	O
(	O
Emb	O
)	O
,	O
slow	O
growth	O
(	O
Slo	O
)	O
and	O
sterile	O
progeny	O
(	O
Stp	O
)	O
phenotypes	O
(	O
see	O
www.wormbase.org	O
)	O
.	O

Another	O
gene	O
(	O
F33D11.10	O
;	O
EST	O
code	O
4F10	O
;	O
see	O
Table	O
2	O
)	O
which	O
encodes	O
an	O
ATP	O
-	O
dependent	O
RNA	O
helicase	O
and	O
is	O
associated	O
with	O
embryonic	O
lethal	O
(	O
Emb	O
)	O
and	O
larval	O
lethal	O
(	O
Lvl	O
)	O
RNAi	O
phenotypes	O
,	O
was	O
shown	O
to	O
be	O
highly	O
transcribed	O
in	O
infective	O
L3s	O
of	O
A.	B
suum	I
.	O

Helicases	O
are	O
involved	O
in	O
a	O
variety	O
of	O
RNA	O
metabolic	O
processes	O
,	O
including	O
translation	O
initiation	O
,	O
pre	O
-	O
mRNA	O
splicing	O
,	O
pre	O
-	O
rRNA	O
processing	O
,	O
rRNA	O
maturation	O
and	O
RNA	O
degradation	O
[	O
63	O
]	O
,	O
and	O
are	O
crucial	O
for	O
life	O
cycle	O
progression	O
,	O
sex	O
determination	O
and	O
early	O
embryogenesis	O
in	O
C.	B
elegans	I
[	O
60	O
]	O
.	O

The	O
high	O
transcription	O
levels	O
of	O
a	O
homologue	O
/	O
orthologue	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
might	O
suggest	O
a	O
similar	O
role	O
in	O
this	O
ascaridoid	O
.	O

Similarly	O
,	O
the	O
coordination	O
of	O
the	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
is	O
required	O
for	O
normal	O
growth	O
and	O
cell	O
proliferation	O
during	O
larval	O
development	O
.	O

The	O
high	O
transcription	O
level	O
for	O
the	O
ribosomal	O
protein	O
gene	O
homologue	O
rpl-22	O
(	O
large	O
subunit	O
family	O
member	O
;	O
EST	O
code	O
26G12	O
,	O
see	O
Table	O
2	O
)	O
in	O
the	O
infective	O
L3	O
of	O
A.	B
suum	I
compared	O
with	O
other	O
developmental	O
stages	O
is	O
likely	O
to	O
reflect	O
the	O
substantial	O
rate	O
of	O
cell	O
growth	O
in	O
this	O
stage	O
[	O
64	O
]	O
.	O

The	O
gene	O
(	O
F55A12.8	O
,	O
EST	O
code	O
4G11	O
;	O
see	O
Table	O
2	O
)	O
encoding	O
an	O
acetyl	O
-	O
transferase	O
with	O
a	O
putative	O
ATPase	O
domain	O
,	O
shown	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
,	O
was	O
predicted	O
to	O
interact	O
with	O
75	O
other	O
genes	O
all	O
involved	O
in	O
energy	O
production	O
and/or	O
RNA	O
processing	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Several	O
molecules	O
involved	O
in	O
ATP	O
synthesis	O
and	O
mitochondrial	O
pathways	O
(	O
e.g.	O
,	O
cytochrome	O
oxidase	O
c	O
subunits	O
1	O
,	O
2	O
and	O
3	O
,	O
ADP	O
/	O
ATP	O
translocases	O
,	O
NADH	O
dehydrogenases	O
,	O
ATPases	O
and	O
ATP	O
synthetases	O
)	O
have	O
been	O
reported	O
previously	O
to	O
be	O
highly	O
represented	O
in	O
the	O
L3	O
stage	O
of	O
Anisakis	B
simplex	I
[	O
65	O
]	O
,	O
thus	O
supporting	O
the	O
proposal	O
that	O
substantial	O
energy	O
is	O
required	O
for	O
larval	O
development	O
as	O
well	O
as	O
the	O
transition	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
and	O
the	O
invasion	O
of	O
the	O
host	O
.	O

There	O
is	O
also	O
likely	O
to	O
be	O
a	O
substantial	O
energy	O
requirement	O
for	O
muscle	O
contraction	O
linked	O
to	O
larval	O
motility	O
in	O
A.	B
suum	I
,	O
as	O
the	O
L3s	O
penetrate	O
the	O
caecal	O
wall	O
in	O
the	O
porcine	O
host	O
,	O
before	O
undergoing	O
hepato	O
-	O
pulmonary	O
migration	O
[	O
35	O
]	O
.	O

Accordingly	O
,	O
genes	O
encoding	O
a	O
specialized	O
tubulin	O
expressed	O
in	O
mechanoreceptors	O
(	O
mec-12	O
,	O
EST	O
code	O
13E09	O
)	O
and	O
a	O
troponin	O
(	O
mup-2	O
,	O
EST	O
code	O
01G03	O
;	O
see	O
Table	O
2	O
)	O
,	O
both	O
predicted	O
to	O
interact	O
with	O
a	O
total	O
number	O
of	O
32	O
tubulin-	O
and	O
myosin	O
-	O
encoding	O
genes	O
,	O
also	O
supported	O
a	O
link	O
to	O
extensive	O
muscle	O
contraction	O
and	O
motility	O
in	O
A.	B
suum	I
L3s	O
.	O

Also	O
,	O
neuroactive	O
peptides	O
are	O
required	O
to	O
regulate	O
the	O
responsiveness	O
of	O
nematode	O
larvae	O
to	O
mechanical	O
stimuli	O
[	O
66	O
]	O
.	O

A	O
homologue	O
encoded	O
by	O
egl-3	O
was	O
shown	O
to	O
be	O
highly	O
transcribed	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
;	O
EGL-3	O
is	O
predicted	O
to	O
be	O
a	O
pro	O
-	O
hormone	O
convertase	O
involved	O
in	O
the	O
maturation	O
of	O
neuropeptides	O
and	O
could	O
be	O
associated	O
with	O
mechano	O
-	O
sensory	O
responses	O
and	O
touch	O
sensitivity	O
linked	O
to	O
the	O
host	O
invasion	O
.	O

A	O
regulatory	O
subunit	O
of	O
a	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
(	O
kin-2	O
,	O
EST	O
code	O
22H01	O
;	O
see	O
Table	O
2	O
)	O
was	O
predicted	O
to	O
interact	O
with	O
72	O
other	O
genes	O
all	O
involved	O
in	O
diverse	O
cellular	O
processes	O
,	O
such	O
as	O
nuclear	O
trafficking	O
,	O
and	O
DNA	O
replication	O
and	O
repair	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Based	O
on	O
gene	O
ontology	O
terms	O
,	O
kin-2	O
is	O
implicated	O
in	O
gamete	O
generation	O
,	O
growth	O
,	O
larval	O
development	O
,	O
post	O
-	O
embryonic	O
body	O
morphogenesis	O
,	O
signal	O
transduction	O
and/or	O
protein	O
amino	O
acid	O
phosphorylation	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Gene	O
silencing	O
of	O
kin-2	O
in	O
C.	B
elegans	I
leads	O
to	O
phenotypes	O
,	O
such	O
as	O
larval	O
lethal	O
(	O
Lvl	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
,	O
body	O
morphology	O
defect	O
(	O
Bmd	O
)	O
,	O
dumpy	O
(	O
Dpy	O
)	O
,	O
uncoordinated	O
(	O
Unc	O
)	O
and	O
sterile	O
progeny	O
(	O
Stp	O
)	O
(	O
www.wormbase.org	O
)	O
,	O
suggesting	O
that	O
its	O
homologue	O
in	O
A.	B
suum	I
is	O
central	O
to	O
larval	O
maturation	O
.	O

The	O
KOBAS	O
analysis	O
predicted	O
the	O
protein	O
KIN-2	O
to	O
be	O
involved	O
in	O
the	O
insulin	O
-	O
signaling	O
pathway	O
,	O
previously	O
implicated	O
in	O
controlling	O
the	O
exit	O
from	O
dauer	O
in	O
C.	B
elegans	I
and	O
the	O
activation	O
of	O
L3s	O
of	O
the	O
canine	B
hookworm	I
,	O
Ancylostoma	B
caninum	I
,	O
following	O
exsheathment	O
[	O
67	O
]	O
.	O

In	O
a	O
recent	O
study	O
,	O
Brand	O
and	O
Hawdon	O
[	O
68	O
]	O
were	O
able	O
to	O
inhibit	O
(	O
with	O
a	O
phosphoinositide-3-OH	O
-	O
kinase	O
inhibitor	O
)	O
the	O
activation	O
of	O
infective	O
L3s	O
of	O
both	O
of	O
the	O
hookworms	O
Ancylostoma	B
caninum	I
and	O
Ancylostoma	B
ceylanicum	I
via	O
the	O
insulin	O
signaling	O
pathway	O
,	O
thus	O
lending	O
some	O
credence	O
to	O
the	O
hypothesis	O
that	O
this	O
pathway	O
plays	O
an	O
critical	O
role	O
in	O
regulating	O
the	O
transition	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
[	O
68	O
]	O
.	O

Recently	O
,	O
it	O
has	O
been	O
proposed	O
that	O
transcriptional	O
and	O
feeding	O
responses	O
to	O
serum	O
-	O
stimulation	O
in	O
Ancylostoma	B
caninum	I
are	O
regulated	O
by	O
parallel	O
systems	O
,	O
with	O
the	O
insulin	O
signaling	O
pathway	O
playing	O
a	O
significant	O
role	O
in	O
the	O
'	O
resumption	O
of	O
feeding	O
'	O
in	O
activated	O
larvae	O
[	O
69	O
]	O
.	O

Protein	O
kinases	O
are	O
also	O
likely	O
to	O
be	O
involved	O
in	O
pathways	O
linked	O
to	O
sexual	O
maturation	O
in	O
developing	O
larvae	O
.	O

As	O
already	O
proposed	O
for	O
adult	O
stages	O
of	O
H.	B
contortus	I
[	O
45	O
]	O
,	O
the	O
protein	O
kinase	O
gene	O
cdk-1	O
is	O
predicted	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
germline	O
,	O
oogenesis	O
and	O
spermiogenesis	O
pathways	O
of	O
this	O
parasitic	O
nematode	O
.	O

Other	O
protein	O
kinases	O
,	O
such	O
as	O
PEPCK	O
,	O
and	O
phosphatases	O
,	O
were	O
shown	O
herein	O
to	O
be	O
transcribed	O
at	O
high	O
levels	O
in	O
the	O
L3	O
stage	O
compared	O
with	O
other	O
developmental	O
stages	O
of	O
A.	B
suum	I
(	O
see	O
Table	O
2	O
)	O
,	O
which	O
is	O
in	O
accordance	O
to	O
findings	O
reported	O
recently	O
for	O
Anisakis	B
simplex	I
[	O
65	O
]	O
.	O

Due	O
to	O
their	O
major	O
regulatory	O
effects	O
in	O
eukaryotic	O
signaling	O
events	O
and	O
regulatory	O
and	O
sensory	O
functions	O
,	O
protein	O
kinases	O
have	O
been	O
considered	O
interesting	O
targets	O
for	O
anti	O
-	O
parasitic	O
drugs	O
[	O
70	O
]	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
has	O
given	O
some	O
interesting	O
insights	O
into	O
early	O
molecular	O
processes	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
.	O

Approximately	O
60	O
%	O
of	O
the	O
transcripts	O
enriched	O
in	O
the	O
L3	O
stage	O
of	O
A.	B
suum	I
have	O
homologues	O
/	O
orthologues	O
in	O
C.	B
elegans	I
.	O

The	O
bioinformatic	O
analyses	O
of	O
selected	O
molecules	O
suggest	O
that	O
a	O
complex	O
genetic	O
network	O
regulates	O
or	O
controls	O
larval	O
growth	O
and	O
development	O
in	O
A.	B
suum	I
L3s	O
,	O
and	O
some	O
of	O
these	O
might	O
be	O
involved	O
in	O
or	O
regulate	O
the	O
switch	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
.	O

Some	O
caution	O
is	O
warranted	O
in	O
drawing	O
conclusions	O
regarding	O
molecular	O
mechanisms	O
regulating	O
the	O
transition	O
to	O
parasitism	O
in	O
parasitic	O
nematodes	O
from	O
information	O
on	O
C.	B
elegans	I
,	O
as	O
latter	O
is	O
a	O
free	O
-	O
living	O
nematode	O
.	O

Also	O
,	O
while	O
the	O
method	O
of	O
data	O
integration	O
is	O
essential	O
for	O
the	O
reliable	O
prediction	O
of	O
genetic	O
interactions	O
,	O
it	O
might	O
limit	O
the	O
capacity	O
of	O
the	O
approach	O
somewhat	O
to	O
infer	O
nematode	O
-	O
specific	O
interactions	O
.	O

As	O
additional	O
datasets	O
of	O
genes	O
and	O
gene	O
functions	O
become	O
available	O
for	O
various	O
parasitic	O
nematodes	O
,	O
more	O
informed	O
inferences	O
can	O
be	O
made	O
regarding	O
the	O
functions	O
of	O
nematode	O
-	O
specific	O
genes	O
,	O
particularly	O
those	O
involved	O
in	O
the	O
transition	O
to	O
parasitism	O
.	O

The	O
imminent	O
genome	O
sequence	O
of	O
A.	B
suum	I
(	O
http://www.sanger.ac.uk/Projects/Helminths/	O
)	O
should	O
all	O
assist	O
in	O
this	O
endeavour	O
.	O

Also	O
,	O
functional	O
analysis	O
of	O
selected	O
molecules	O
representing	O
selected	O
ESTs	O
identified	O
herein	O
,	O
utilizing	O
gene	O
silencing	O
approaches	O
established	O
recently	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
,	O
could	O
provide	O
some	O
insights	O
into	O
developmental	O
processes	O
in	O
Ascaris	O
and	O
related	O
ascaridoid	O
nematodes	O
and	O
provide	O
avenues	O
for	O
the	O
development	O
of	O
novel	O
approaches	O
for	O
their	O
control	O
.	O

Supporting	O
Information	O

Emergence	O
of	O
Delayed	O
Methylmercury	O
Toxicity	O
after	O
Perinatal	O
Exposure	O
in	O
Metallothionein	O
-	O
Null	O
and	O
Wild	O
-	O
Type	O
C57BL	O
Mice	B
Abstract	O
Background	O
Although	O
a	O
long	O
latency	O
period	O
of	O
toxicity	O
after	O
exposure	O
to	O
methylmercury	O
(	O
MeHg	O
)	O
is	O
known	O
to	O
exist	O
in	O
humans	B
,	O
few	O
animal	O
studies	O
have	O
addressed	O
this	O
issue	O
.	O

Substantiation	O
of	O
delayed	O
MeHg	O
toxicity	O
in	O
animals	O
would	O
affect	O
the	O
risk	O
evaluation	O
of	O
MeHg	O
.	O

Objectives	O
Our	O
goal	O
in	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
existence	O
of	O
a	O
latency	O
period	O
in	O
a	O
rodent	O
model	O
in	O
which	O
the	O
toxicity	O
of	O
perinatal	O
MeHg	O
exposure	O
becomes	O
apparent	O
only	O
later	O
in	O
life	O
.	O

Our	O
study	O
included	O
metallothionein	O
(	O
MT	O
)	O
knockout	O
mice	B
because	O
studies	O
have	O
suggested	O
the	O
potential	O
susceptibility	O
of	O
this	O
strain	O
to	O
the	O
neurodevelopmental	O
toxicity	O
of	O
MeHg	O
.	O

Methods	O
Pregnant	O
MT	O
-	O
null	O
and	O
wild	O
-	O
type	O
C57Bl	O
/	O
6J	O
mice	B
were	O
exposed	O
to	O
MeHg	O
through	O
their	O
diet	O
containing	O
5	O
μg	O
Hg	O
/	O
g	O
during	O
gestation	O
and	O
early	O
lactation	O
.	O

We	O
examined	O
behavioral	O
functions	O
of	O
the	O
offspring	O
using	O
frequently	O
used	O
paradigms	O
,	O
including	O
open	O
field	O
behavior	O
(	O
OPF	O
)	O
,	O
passive	O
avoidance	O
(	O
PA	O
)	O
,	O
and	O
the	O
Morris	O
water	O
maze	O
(	O
MM	O
)	O
,	O
at	O
ages	O
of	O
12–13	O
and	O
52–53	O
weeks	O
.	O

Results	O
At	O
12	O
weeks	O
of	O
age	O
,	O
behavioral	O
effects	O
of	O
MeHg	O
were	O
not	O
detected	O
,	O
except	O
for	O
OPF	O
performance	O
in	O
MeHg	O
-	O
exposed	O
MT	O
-	O
null	O
females	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
the	O
MeHg	O
-	O
exposed	O
groups	O
showed	O
poorer	O
performance	O
both	O
in	O
PA	O
and	O
MM	O
,	O
and	O
their	O
OPF	O
activity	O
differed	O
from	O
controls	O
.	O

These	O
effects	O
of	O
MeHg	O
appeared	O
exaggerated	O
in	O
the	O
MT	O
-	O
null	O
strain	O
.	O

The	O
brain	O
Hg	O
concentration	O
had	O
leveled	O
off	O
by	O
13	O
weeks	O
of	O
age	O
.	O

Conclusions	O
The	O
results	O
suggest	O
the	O
existence	O
of	O
a	O
long	O
latency	O
period	O
after	O
perinatal	O
exposure	O
to	O
low	O
-	O
level	O
MeHg	O
,	O
in	O
which	O
the	O
behavioral	O
effects	O
emerged	O
long	O
after	O
the	O
leveling	O
-	O
off	O
of	O
brain	O
Hg	O
levels	O
.	O

Hence	O
,	O
the	O
initial	O
toxicologic	O
event	O
responsible	O
for	O
the	O
late	O
effects	O
should	O
have	O
occurred	O
before	O
this	O
leveling	O
-	O
off	O
of	O
brain	O
Hg	O
.	O

Methylmercury	O
(	O
MeHg	O
)	O
poses	O
serious	O
and	O
practical	O
concerns	O
for	O
human	B
populations	O
regarding	O
perinatal	O
exposure	O
.	O

Fish	O
,	O
especially	O
large	O
predator	O
(	O
carnivore	O
)	O
fish	O
species	O
,	O
accumulate	O
high	O
concentrations	O
of	O
MeHg	O
through	O
the	O
marine	O
food	O
chain	O
,	O
and	O
exposure	O
of	O
pregnant	O
women	O
to	O
MeHg	O
through	O
the	O
consumption	O
of	O
fish	O
has	O
evoked	O
widespread	O
concern	O
due	O
to	O
potential	O
effects	O
on	O
offspring	O
.	O

Two	O
large	O
-	O
scale	O
cohort	O
studies	O
in	O
fish	O
-	O
eating	O
populations	O
of	O
Seychelles	O
and	O
Faroe	O
islanders	O
are	O
being	O
conducted	O
;	O
although	O
the	O
former	O
has	O
not	O
found	O
consistent	O
adverse	O
developmental	O
effects	O
of	O
MeHg	O
(	O
Myers	O
et	O
al.	O
2007	O
)	O
,	O
the	O
latter	O
has	O
reported	O
adverse	O
effects	O
(	O
Debes	O
et	O
al.	O
2006	O
)	O
.	O

Fundamental	O
reasons	O
for	O
this	O
discrepancy	O
have	O
not	O
been	O
completely	O
elucidated	O
,	O
and	O
many	O
questions	O
remain	O
regarding	O
the	O
neurotoxicity	O
of	O
MeHg	O
,	O
despite	O
extensive	O
study	O
.	O

Among	O
the	O
unanswered	O
questions	O
is	O
whether	O
there	O
is	O
a	O
long	O
latency	O
period	O
for	O
behavioral	O
manifestations	O
after	O
exposure	O
to	O
MeHg	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
;	O
Landrigan	O
et	O
al.	O
2005	O
;	O
Rice	O
1996	O
;	O
Weiss	O
et	O
al.	O
2005a	O
,	O
2005b	O
)	O
.	O

Typical	O
examples	O
of	O
latent	O
toxicity	O
in	O
humans	B
,	O
including	O
both	O
acute	O
and	O
chronic	O
MeHg	O
exposures	O
,	O
have	O
been	O
described	O
in	O
detail	O
elsewhere	O
(	O
Weiss	O
et	O
al.	O
2005a	O
)	O
.	O

Davidson	O
et	O
al.	O
(	O
2006	O
)	O
recently	O
suggested	O
that	O
effects	O
of	O
perinatal	O
exposure	O
to	O
MeHg	O
may	O
emerge	O
9	O
years	O
after	O
birth	O
in	O
the	O
Seychelles	O
cohort	O
.	O

Consequently	O
,	O
risk	O
assessments	O
of	O
MeHg	O
exposure	O
could	O
be	O
inaccurate	O
because	O
studies	O
(	O
human	B
or	O
animal	O
)	O
usually	O
do	O
not	O
focus	O
on	O
later	O
stages	O
of	O
life	O
and	O
therefore	O
could	O
miss	O
delayed	O
effects	O
.	O

The	O
possibility	O
of	O
delayed	O
toxicity	O
is	O
exemplified	O
by	O
the	O
expanded	O
Barker	O
hypothesis	O
,	O
which	O
posits	O
that	O
the	O
origin	O
of	O
some	O
neurodegenerative	O
diseases	O
such	O
as	O
Parkinson	O
and	O
Alzheimer	O
diseases	O
lies	O
in	O
early	O
exposure	O
to	O
environmental	O
chemicals	O
(	O
Landrigan	O
et	O
al.	O
2005	O
)	O
.	O

Although	O
epidemiologic	O
evidence	O
would	O
be	O
ideal	O
for	O
exploring	O
the	O
possibility	O
of	O
delayed	O
toxicity	O
(	O
and	O
,	O
indeed	O
,	O
data	O
from	O
epidemiologic	O
studies	O
form	O
the	O
basis	O
of	O
current	O
risk	O
assessment	O
for	O
developmental	O
toxicity	O
of	O
MeHg	O
)	O
,	O
considering	O
the	O
complex	O
effects	O
of	O
numerous	O
potential	O
confounders	O
and	O
the	O
existence	O
of	O
multiple	O
exposures	O
in	O
human	B
populations	O
,	O
animal	O
models	O
would	O
likely	O
make	O
important	O
contributions	O
to	O
this	O
field	O
.	O

Although	O
numerous	O
animal	O
studies	O
have	O
described	O
the	O
developmental	O
neurotoxicity	O
of	O
MeHg	O
(	O
Watanabe	O
and	O
Satoh	O
,	O
1996	O
)	O
,	O
few	O
have	O
addressed	O
the	O
latency	O
issue	O
.	O

Few	O
studies	O
have	O
evaluated	O
the	O
neurobehavioral	O
effects	O
in	O
rodents	O
longitudinally	O
beyond	O
6	O
months	O
after	O
perinatal	O
exposure	O
.	O

Spyker	O
(	O
1975	O
)	O
addressed	O
this	O
issue	O
in	O
her	O
pioneering	O
work	O
,	O
reporting	O
the	O
late	O
development	O
of	O
behavioral	O
toxicity	O
in	O
mice	B
prenatally	O
exposed	O
to	O
MeHg	O
;	O
it	O
appeared	O
,	O
however	O
,	O
that	O
the	O
substantial	O
mortality	O
and	O
retarded	O
growth	O
among	O
the	O
exposed	O
mice	B
were	O
apparent	O
before	O
weaning	O
,	O
indicating	O
that	O
the	O
doses	O
used	O
(	O
even	O
though	O
some	O
lower	O
dose	O
levels	O
were	O
included	O
)	O
exerted	O
severe	O
toxicity	O
.	O

Using	O
a	O
relatively	O
complex	O
schedule	O
-	O
controlled	O
operant	O
behavior	O
method	O
,	O
rats	B
whose	O
parents	O
were	O
exposed	O
to	O
MeHg	O
(	O
0.5	O
or	O
6.4	O
mg	O
/	O
L	O
)	O
from	O
4	O
weeks	O
before	O
mating	O
and	O
continuing	O
to	O
postnatal	O
day	O
(	O
PND	O
)	O
16	O
were	O
shown	O
to	O
be	O
less	O
sensitive	O
to	O
a	O
change	O
in	O
the	O
reinforcement	O
schedule	O
than	O
were	O
their	O
nonexposed	O
counterparts	O
at	O
28–32	O
months	O
of	O
age	O
(	O
Newland	O
et	O
al.	O
2004	O
)	O
.	O

Mice	B
that	O
were	O
perinatally	O
exposed	O
to	O
1	O
or	O
3	O
mg	O
/	O
L	O
MeHg	O
in	O
drinking	O
water	O
did	O
not	O
show	O
significant	O
deviation	O
from	O
controls	O
in	O
behavioral	O
performance	O
(	O
motor	O
performance	O
,	O
memory	O
,	O
and	O
learning	O
)	O
at	O
5	O
,	O
15	O
,	O
or	O
26	O
months	O
of	O
age	O
,	O
but	O
the	O
lifetime	O
-	O
exposed	O
groups	O
did	O
show	O
a	O
significant	O
deviation	O
(	O
Weiss	O
et	O
al.	O
2005c	O
)	O
.	O

The	O
existence	O
of	O
a	O
latency	O
period	O
(	O
i.e.	O
,	O
the	O
absence	O
of	O
effects	O
earlier	O
in	O
life	O
followed	O
by	O
the	O
emergence	O
of	O
effects	O
at	O
a	O
later	O
stage	O
of	O
life	O
)	O
has	O
not	O
been	O
demonstrated	O
in	O
any	O
rodent	O
study	O
.	O

In	O
nonhuman	O
primates	O
,	O
delayed	O
emergence	O
of	O
the	O
signs	O
of	O
neurotoxicity	O
was	O
observed	O
several	O
years	O
after	O
the	O
cessation	O
of	O
a	O
7-year	O
postnatal	O
exposure	O
(	O
Rice	O
1996	O
)	O
.	O

Metallothionein	O
(	O
MT	O
)	O
protects	O
against	O
the	O
toxicities	O
of	O
a	O
variety	O
of	O
metals	O
.	O

We	O
examined	O
the	O
neurotoxicity	O
and	O
developmental	O
toxicity	O
of	O
metallic	O
Hg	O
in	O
MT	O
I	O
/	O
II	O
-	O
knockout	O
mice	B
(	O
Yoshida	O
et	O
al.	O
2004	O
)	O
and	O
demonstrated	O
the	O
susceptibility	O
of	O
this	O
genetically	O
manipulated	O
strain	O
to	O
the	O
toxicity	O
of	O
metallic	O
Hg	O
.	O

In	O
contrast	O
to	O
metallic	O
Hg	O
,	O
MeHg	O
does	O
not	O
induce	O
MT	O
,	O
and	O
MT	O
would	O
not	O
substantially	O
influence	O
the	O
kinetics	O
of	O
MeHg	O
(	O
Yasutake	O
et	O
al.	O
1998	O
)	O
.	O

Several	O
reports	O
,	O
however	O
,	O
have	O
demonstrated	O
protective	O
effects	O
of	O
MT	O
against	O
MeHg	O
toxicity	O
,	O
which	O
was	O
ascribed	O
to	O
the	O
radical	O
scavenging	O
effect	O
of	O
MT	O
(	O
Yao	O
et	O
al.	O
2000	O
)	O
.	O

We	O
also	O
showed	O
that	O
perinatal	O
exposure	O
to	O
MeHg	O
results	O
in	O
altered	O
metabolism	O
of	O
thyroid	O
hormones	O
in	O
neonates	O
that	O
was	O
more	O
distinct	O
in	O
MT	O
-	O
null	O
strains	O
than	O
their	O
wild	O
-	O
type	O
counterparts	O
(	O
Mori	O
et	O
al.	O
2006	O
)	O
.	O

The	O
vulnerability	O
of	O
the	O
MT	O
-	O
null	O
strain	O
suggests	O
that	O
delayed	O
neurobehavioral	O
toxicity	O
due	O
to	O
MeHg	O
,	O
if	O
it	O
does	O
exist	O
,	O
might	O
be	O
more	O
distinctive	O
in	O
this	O
strain	O
.	O

By	O
utilizing	O
the	O
MT	O
-	O
null	O
strain	O
,	O
we	O
aimed	O
to	O
answer	O
the	O
following	O
two	O
questions	O
:	O
First	O
,	O
could	O
we	O
generate	O
a	O
model	O
in	O
which	O
the	O
toxicity	O
of	O
MeHg	O
would	O
emerge	O
or	O
at	O
least	O
become	O
exaggerated	O
later	O
in	O
life	O
as	O
opposed	O
to	O
earlier	O
in	O
life	O
(	O
i.e.	O
,	O
at	O
3–6	O
months	O
,	O
which	O
was	O
the	O
timing	O
for	O
most	O
of	O
the	O
earlier	O
studies	O
that	O
used	O
behavioral	O
evaluations	O
)	O
?	O

Second	O
,	O
would	O
the	O
MT	O
-	O
null	O
strain	O
be	O
affected	O
more	O
than	O
its	O
parent	O
C57BL	O
strain	O
?	O

Answering	O
either	O
of	O
these	O
questions	O
not	O
only	O
could	O
influence	O
the	O
risk	O
evaluation	O
of	O
MeHg	O
,	O
but	O
it	O
could	O
also	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
toxicity	O
for	O
perinatal	O
MeHg	O
exposure	O
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
used	O
three	O
behavioral	O
paradigms	O
,	O
the	O
open	O
field	O
(	O
OPF	O
)	O
,	O
passive	O
avoidance	O
(	O
PA	O
)	O
,	O
and	O
Morris	O
(	O
water	O
)	O
maze	O
(	O
MM	O
)	O
tests	O
,	O
which	O
are	O
often	O
used	O
in	O
this	O
field	O
and	O
which	O
we	O
used	O
in	O
our	O
previous	O
studies	O
on	O
the	O
effects	O
of	O
Hg	O
vapor	O
(	O
Yoshida	O
et	O
al.	O
2004	O
,	O
2006	O
)	O
.	O

Performances	O
in	O
the	O
MM	O
and	O
PA	O
are	O
said	O
to	O
be	O
the	O
most	O
sensitive	O
to	O
aging	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
.	O

We	O
used	O
a	O
dose	O
of	O
5	O
μg	O
MeHg	O
/	O
g	O
in	O
the	O
diet	O
,	O
which	O
resulted	O
in	O
a	O
brain	O
Hg	O
level	O
relevant	O
to	O
human	B
risk	O
assessment	O
.	O

We	O
evaluated	O
the	O
behavioral	O
end	O
points	O
twice	O
,	O
once	O
around	O
3	O
months	O
of	O
age	O
and	O
the	O
other	O
time	O
around	O
1	O
year	O
;	O
the	O
latter	O
time	O
roughly	O
corresponds	O
to	O
the	O
period	O
when	O
many	O
behavioral	O
performances	O
,	O
including	O
OPF	O
(	O
Acevedoa	O
et	O
al.	O
2006	O
;	O
Carrie	O
et	O
al.	O
1999	O
;	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
,	O
PA	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
,	O
and	O
MM	O
(	O
Bach	O
et	O
al.	O
1999	O
;	O
Carrie	O
et	O
al.	O
1999	O
)	O
,	O
show	O
alterations	O
in	O
this	O
mouse	B
strain	O
.	O

Materials	O
and	O
Methods	O
Animals	O
and	O
MeHg	O
exposure	O
OLA129	O
/	O
C57BL	O
/	O
6J	O
strain	O
mice	B
(	O
wild	O
type	O
)	O
and	O
MT	O
I	O
/	O
II	O
-	O
knockout	O
mice	B
(	O
MT	O
-	O
null	O
)	O
of	O
this	O
strain	O
were	O
provided	O
by	O
K.H.	O
Choo	O
of	O
the	O
Murdoch	O
Institute	O
,	O
Parkville	O
,	O
Australia	O
(	O
Michalska	O
and	O
Choo	O
1993	O
)	O
and	O
were	O
of	O
a	O
mixed	O
genetic	O
background	O
of	O
129	O
/	O
Ola	O
and	O
C57BL	O
/	O
6	O
strains	O
.	O

F1	O
hybrid	O
mice	B
were	O
mated	O
with	O
C57BL	O
/	O
6	O
mice	B
for	O
six	O
generations	O
at	O
the	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
(	O
Tsukuba	O
,	O
Japan	O
)	O
.	O

At	O
10	O
weeks	O
of	O
age	O
,	O
single	O
male	O
and	O
female	O
mice	B
were	O
allowed	O
to	O
cohabit	O
;	O
every	O
female	O
mouse	B
was	O
checked	O
each	O
morning	O
for	O
the	O
presence	O
of	O
a	O
vaginal	O
plug	O
.	O

When	O
a	O
plug	O
was	O
confirmed	O
,	O
the	O
day	O
was	O
designated	O
as	O
day	O
0	O
of	O
gestation	O
(	O
GD0	O
)	O
.	O

The	O
diet	O
,	O
NIH-07PLD	O
formula	O
(	O
CLEA	O
Japan	O
,	O
Inc.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
contained	O
vitamins	O
and	O
trace	O
elements	O
as	O
follows	O
(	O
per	O
kilogram	O
diet	O
)	O
:	O
3.2	O
mg	O
CuSO4	O
,	O
88	O
mg	O
FeSO4	O
,	O
149	O
mg	O
MnSO4	O
,	O
25	O
mg	O
ZnCO3	O
,	O
1.6	O
mg	O
Ca	O
(	O
IO3	O
)	O
2	O
,	O
11	O
mg	O
vitamin	O
B1	O
,	O
4.7	O
mg	O
vitamin	O
B2	O
,	O
1.9	O
mg	O
vitamin	O
B6	O
,	O
44	O
mg	O
vitamin	O
E	O
,	O
in	O
addition	O
to	O
5	O
μg	O
MeHg	O
/	O
g	O
.	O

This	O
diet	O
was	O
fed	O
to	O
the	O
pregnant	O
mice	B
starting	O
from	O
GD0	O
through	O
10	O
days	O
after	O
delivery	O
(	O
i.e.	O
,	O
PND10	O
)	O
.	O

Thereafter	O
,	O
we	O
switched	O
mice	B
to	O
a	O
diet	O
that	O
did	O
not	O
contain	O
MeHg	O
.	O

We	O
chose	O
GD0	O
as	O
the	O
beginning	O
of	O
exposure	O
because	O
exposures	O
that	O
started	O
before	O
conception	O
often	O
resulted	O
in	O
fairly	O
high	O
Hg	O
concentrations	O
in	O
fetal	O
/	O
neonatal	O
brains	O
(	O
Kakita	O
et	O
al.	O
2003	O
)	O
,	O
and	O
we	O
chose	O
PND10	O
to	O
cover	O
the	O
early	O
neonatal	O
period	O
,	O
in	O
which	O
considerable	O
brain	O
growth	O
occurs	O
.	O

In	O
our	O
experimental	O
setting	O
,	O
the	O
neonatal	O
mice	B
started	O
to	O
eat	O
from	O
the	O
diet	O
bucket	O
and	O
drink	O
from	O
the	O
water	O
bottle	O
from	O
PND10	O
onward	O
.	O

Control	O
mice	B
were	O
kept	O
on	O
the	O
same	O
diet	O
but	O
without	O
MeHg	O
(	O
<	O
0.01	O
μg	O
Hg	O
/	O
g	O
)	O
.	O

On	O
PND1	O
,	O
to	O
avoid	O
the	O
confounding	O
effects	O
due	O
to	O
different	O
litter	O
size	O
,	O
we	O
reduced	O
each	O
litter	O
to	O
six	O
pups	O
(	O
three	O
males	O
and	O
three	O
females	O
when	O
possible	O
)	O
,	O
and	O
on	O
PND10	O
,	O
two	O
males	O
and	O
two	O
females	O
from	O
each	O
litter	O
were	O
killed	O
for	O
chemical	O
analyses	O
.	O

The	O
remaining	O
male	O
and	O
female	O
offspring	O
per	O
litter	O
were	O
weaned	O
on	O
PND28	O
and	O
used	O
for	O
subsequent	O
behavioral	O
analyses	O
(	O
either	O
at	O
12–13	O
weeks	O
or	O
52–53	O
weeks	O
,	O
depending	O
on	O
the	O
litter	O
)	O
as	O
described	O
below	O
.	O

We	O
measured	O
body	O
weights	O
of	O
the	O
weaned	O
mice	B
every	O
2	O
weeks	O
.	O

Thus	O
,	O
four	O
experimental	O
groups	O
were	O
used	O
(	O
with	O
or	O
without	O
MeHg	O
exposure	O
for	O
two	O
strains	O
)	O
,	O
and	O
each	O
group	O
consisted	O
of	O
12–13	O
litters	O
.	O

For	O
half	O
of	O
the	O
litters	O
,	O
the	O
behavioral	O
analyses	O
were	O
conducted	O
at	O
12–13	O
weeks	O
of	O
age	O
,	O
and	O
upon	O
completion	O
of	O
the	O
behavioral	O
analyses	O
,	O
the	O
animals	O
were	O
killed	O
under	O
ether	O
anesthesia	O
.	O

We	O
then	O
dissected	O
the	O
organs	O
(	O
brain	O
,	O
liver	O
,	O
and	O
kidneys	O
)	O
for	O
Hg	O
analyses	O
.	O

For	O
the	O
remaining	O
half	O
of	O
the	O
litters	O
,	O
we	O
conducted	O
the	O
behavioral	O
tests	O
at	O
52–53	O
weeks	O
of	O
age	O
.	O

The	O
mice	B
were	O
treated	O
humanely	O
and	O
with	O
regard	O
to	O
alleviation	O
of	O
suffering	O
according	O
to	O
the	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
'	O
Guidelines	O
for	O
Animal	O
Welfare	O
and	O
the	O
guidelines	O
of	O
St.	O
Marianna	O
University	O
.	O

Behavioral	O
evaluations	O
The	O
details	O
of	O
each	O
behavioral	O
procedure	O
have	O
been	O
described	O
elsewhere	O
(	O
Yoshida	O
et	O
al.	O
2006	O
)	O
.	O

Brief	O
descriptions	O
follow	O
.	O

For	O
the	O
OPF	O
test	O
,	O
we	O
used	O
an	O
OPF	O
apparatus	O
(	O
Ohara	O
Co.	O
,	O
Ltd.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
with	O
a	O
60	O
×	O
60-cm	O
floor	O
surrounded	O
by	O
walls	O
60	O
cm	O
high	O
.	O

The	O
experimental	O
room	O
light	O
was	O
turned	O
off	O
,	O
and	O
a	O
dim	O
light	O
of	O
80	O
lux	O
was	O
lit	O
during	O
the	O
experiment	O
.	O

We	O
placed	O
a	O
mouse	B
in	O
the	O
center	O
of	O
the	O
floor	O
and	O
monitored	O
its	O
behavior	O
for	O
10	O
min	O
using	O
a	O
CCD	O
camera	O
connected	O
to	O
a	O
computer	O
.	O

The	O
position	O
of	O
the	O
center	O
of	O
gravity	O
was	O
calculated	O
by	O
image	O
-	O
analyzing	O
software	O
,	O
which	O
was	O
used	O
to	O
calculate	O
the	O
total	O
distance	O
traveled	O
by	O
the	O
mouse	B
as	O
well	O
as	O
the	O
positional	O
preference	O
(	O
either	O
center	O
or	O
peripheral	O
,	O
where	O
peripheral	O
was	O
defined	O
as	O
the	O
area	O
within	O
10	O
cm	O
from	O
the	O
wall	O
)	O
.	O

We	O
cleaned	O
the	O
OPF	O
apparatus	O
with	O
70	O
%	O
ethanol	O
between	O
trials	O
.	O

The	O
apparatus	O
for	O
the	O
PA	O
test	O
(	O
Ohara	O
Co.	O
Ltd.	O
)	O
consisted	O
of	O
a	O
light	O
compartment	O
that	O
illuminated	O
by	O
a	O
400-lux	O
light	O
and	O
a	O
dark	O
compartment	O
with	O
black	O
opaque	O
walls	O
and	O
lids	O
.	O

The	O
two	O
compartments	O
were	O
separated	O
by	O
a	O
mobile	O
guillotine	O
door	O
.	O

On	O
the	O
first	O
day	O
(	O
training	O
trial	O
)	O
,	O
we	O
placed	O
each	O
mouse	B
in	O
the	O
light	O
compartment	O
facing	O
away	O
from	O
the	O
guillotine	O
door	O
,	O
which	O
was	O
closed	O
.	O

After	O
30	O
sec	O
of	O
introduction	O
,	O
the	O
door	O
was	O
opened	O
;	O
when	O
the	O
mouse	B
entered	O
the	O
dark	O
compartment	O
,	O
a	O
brief	O
electric	O
shock	O
(	O
4	O
mA	O
for	O
2	O
sec	O
)	O
was	O
delivered	O
through	O
the	O
metal	O
grid	O
floor	O
.	O

This	O
would	O
force	O
the	O
mouse	B
back	O
to	O
the	O
light	O
component	O
.	O

The	O
interval	O
between	O
the	O
opening	O
of	O
the	O
door	O
and	O
the	O
entry	O
to	O
the	O
dark	O
room	O
(	O
in	O
seconds	O
)	O
was	O
recorded	O
and	O
defined	O
as	O
the	O
latency	O
.	O

On	O
the	O
next	O
day	O
,	O
the	O
same	O
procedure	O
was	O
repeated	O
,	O
but	O
without	O
the	O
electric	O
shock	O
(	O
retaining	O
trail	O
)	O
.	O

In	O
this	O
PA	O
paradigm	O
,	O
aversive	O
learning	O
was	O
assumed	O
to	O
be	O
established	O
in	O
the	O
training	O
trial	O
,	O
and	O
we	O
used	O
its	O
retention	O
in	O
the	O
retaining	O
trail	O
as	O
the	O
index	O
of	O
learning	O
.	O

Between	O
each	O
individual	O
trial	O
,	O
we	O
cleaned	O
the	O
apparatus	O
with	O
ethanol	O
.	O

The	O
cutoff	O
time	O
of	O
the	O
retention	O
session	O
was	O
300	O
sec.	O
The	O
MM	O
test	O
apparatus	O
(	O
Ohara	O
Co.	O
,	O
Ltd.	O
)	O
was	O
a	O
round	O
-	O
shaped	O
water	O
pool	O
with	O
a	O
diameter	O
of	O
120	O
cm	O
.	O

A	O
small	O
platform	O
was	O
submerged	O
in	O
the	O
water	O
,	O
which	O
provided	O
a	O
place	O
for	O
mice	B
to	O
escape	O
from	O
the	O
water	O
(	O
i.e.	O
,	O
an	O
aversive	O
stimulus	O
,	O
water	O
temperature	O
=	O
23	O
±	O
1	O
°	O
C	O
)	O
.	O

The	O
water	O
was	O
made	O
opaque	O
by	O
adding	O
white	O
paint	O
so	O
that	O
the	O
mouse	B
could	O
not	O
see	O
the	O
submerged	O
platform	O
.	O

In	O
each	O
trial	O
,	O
we	O
released	O
a	O
mouse	B
into	O
the	O
pool	O
from	O
a	O
determined	O
position	O
along	O
the	O
wall	O
,	O
and	O
the	O
performance	O
of	O
the	O
mouse	B
was	O
monitored	O
by	O
a	O
CCD	O
camera	O
/	O
image	O
analyzer	O
.	O

The	O
time	O
required	O
to	O
reach	O
the	O
platform	O
was	O
recorded	O
.	O

If	O
a	O
mouse	B
could	O
not	O
find	O
the	O
platform	O
within	O
60	O
sec	O
after	O
release	O
,	O
it	O
was	O
led	O
to	O
the	O
platform	O
and	O
placed	O
on	O
it	O
for	O
20	O
sec	O
before	O
being	O
removed	O
.	O

In	O
these	O
cases	O
,	O
a	O
latency	O
of	O
60	O
sec	O
was	O
recorded	O
.	O

We	O
conducted	O
the	O
trial	O
once	O
a	O
day	O
up	O
to	O
the	O
fifth	O
day	O
for	O
each	O
mouse	B
,	O
and	O
the	O
order	O
of	O
each	O
mouse	B
was	O
counterbalanced	O
across	O
the	O
day	O
.	O

On	O
the	O
sixth	O
day	O
,	O
a	O
transfer	O
test	O
(	O
or	O
probe	O
test	O
)	O
,	O
which	O
is	O
a	O
trial	O
without	O
the	O
platform	O
,	O
was	O
conducted	O
;	O
in	O
this	O
procedure	O
,	O
we	O
counted	O
the	O
number	O
of	O
times	O
that	O
the	O
mouse	B
crossed	O
the	O
position	O
where	O
the	O
platform	O
had	O
been	O
.	O

Tissue	O
Hg	O
concentration	O
The	O
tissue	O
samples	O
were	O
homogenized	O
(	O
10	O
%	O
weight	O
/	O
volume	O
)	O
in	O
distilled	O
water	O
using	O
a	O
Polytron	O
homogenizer	O
(	O
Kinematica	O
GmbH	O
,	O
Littau	O
,	O
Switzerland	O
)	O
.	O

We	O
determined	O
Hg	O
levels	O
in	O
the	O
homogenates	O
by	O
the	O
oxygen	O
combustion	O
–	O
gold	O
amalgamation	O
method	O
(	O
Ohkawa	O
et	O
al.	O
1977	O
)	O
using	O
an	O
atomic	O
absorption	O
Hg	O
detector	O
MD-1	O
(	O
Nippon	O
Instruments	O
,	O
Co.	O
Ltd.	O
,	O
Osaka	O
,	O
Japan	O
)	O
.	O

To	O
ensure	O
the	O
accuracy	O
of	O
the	O
measurement	O
,	O
we	O
included	O
reference	O
material	O
from	O
a	O
dogfish	O
(	O
DORM-2	O
;	O
National	O
Research	O
Council	O
of	O
Canada	O
,	O
Ottawa	O
,	O
Ontario	O
,	O
Canada	O
)	O
with	O
a	O
certified	O
value	O
of	O
4.64	O
±	O
0.26	O
μg	O
/	O
g	O
in	O
the	O
analyses	O
;	O
the	O
observed	O
values	O
fell	O
within	O
the	O
certified	O
range	O
.	O

The	O
detection	O
limit	O
of	O
the	O
measurement	O
was	O
0.1	O
ng	O
Hg	O
.	O

Statistics	O
We	O
analyzed	O
behavioral	O
data	O
for	O
OPF	O
and	O
PA	O
by	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
taking	O
sex	O
,	O
strain	O
,	O
and	O
MeHg	O
exposure	O
as	O
the	O
factors	O
.	O

All	O
the	O
interactions	O
among	O
these	O
factors	O
were	O
put	O
into	O
the	O
model	O
.	O

When	O
any	O
of	O
the	O
interactions	O
was	O
highly	O
significant	O
,	O
we	O
analyzed	O
the	O
data	O
separately	O
in	O
an	O
appropriate	O
way	O
;	O
for	O
example	O
,	O
if	O
sex	O
×	O
Hg	O
was	O
significant	O
,	O
the	O
data	O
for	O
males	O
and	O
females	O
were	O
separately	O
analyzed	O
for	O
the	O
effects	O
of	O
strain	O
and	O
Hg	O
.	O

Whenever	O
appropriate	O
,	O
ANOVAs	O
were	O
followed	O
by	O
Mann	O
-	O
Whitney	O
U	O
or	O
Student	O
's	O
t	O
-	O
tests	O
,	O
depending	O
on	O
the	O
nature	O
and	O
distribution	O
of	O
the	O
variables	O
.	O

We	O
analyzed	O
data	O
for	O
the	O
MM	O
by	O
repeated	O
-	O
measures	O
ANOVA	O
,	O
taking	O
the	O
exposure	O
as	O
between	O
-	O
group	O
and	O
trials	O
as	O
within	O
-	O
group	O
variables	O
.	O

The	O
test	O
was	O
performed	O
for	O
each	O
of	O
the	O
four	O
sex	O
and	O
strain	O
combinations	O
separately	O
.	O

The	O
significance	O
level	O
was	O
set	O
at	O
p	O
<	O
0.05	O
.	O

Results	O
Body	O
weight	O
Up	O
to	O
20	O
weeks	O
of	O
age	O
,	O
the	O
body	O
weight	O
values	O
of	O
the	O
control	O
and	O
MeHg	O
-	O
exposed	O
groups	O
were	O
not	O
different	O
,	O
regardless	O
of	O
strain	O
or	O
sex	O
.	O

After	O
28	O
weeks	O
,	O
except	O
for	O
the	O
wild	O
-	O
type	O
female	O
groups	O
,	O
the	O
MeHg	O
-	O
exposed	O
groups	O
weighed	O
significantly	O
less	O
than	O
the	O
controls	O
(	O
Figure	O
1	O
)	O
.	O

OPF	O
At	O
12	O
weeks	O
of	O
age	O
,	O
a	O
three	O
-	O
way	O
ANOVA	O
of	O
the	O
locomotion	O
distance	O
revealed	O
that	O
only	O
strain	O
was	O
a	O
significant	O
factor	O
(	O
p	O
<	O
0.001	O
)	O
,	O
reflecting	O
the	O
longer	O
distance	O
traveled	O
by	O
the	O
MT	O
-	O
null	O
mice	B
(	O
Figure	O
2A	O
)	O
.	O

Strain	O
was	O
also	O
a	O
significant	O
factor	O
for	O
the	O
proportion	O
of	O
the	O
central	O
-	O
area	O
locomotion	O
(	O
Figure	O
3A	O
)	O
,	O
and	O
Hg	O
exposure	O
marginally	O
affected	O
this	O
outcome	O
.	O

In	O
MT	O
-	O
null	O
females	O
,	O
the	O
proportion	O
of	O
central	O
-	O
area	O
locomotion	O
was	O
higher	O
in	O
MeHg	O
-	O
exposed	O
mice	B
than	O
in	O
the	O
controls	O
;	O
this	O
difference	O
was	O
not	O
observed	O
in	O
any	O
other	O
strain	O
–	O
sex	O
combination	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
the	O
strain	O
×	O
Hg	O
interaction	O
was	O
highly	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
in	O
an	O
ANOVA	O
of	O
locomotion	O
distance	O
(	O
Figure	O
2B	O
)	O
;	O
MeHg	O
exposure	O
was	O
associated	O
with	O
decreased	O
locomotion	O
distance	O
in	O
wild	O
-	O
type	O
mice	B
and	O
with	O
increased	O
distance	O
in	O
MT	O
-	O
null	O
mice	B
.	O

A	O
strain	O
-	O
wise	O
two	O
-	O
way	O
ANOVA	O
(	O
with	O
sex	O
and	O
Hg	O
as	O
the	O
factors	O
)	O
revealed	O
that	O
only	O
Hg	O
was	O
significant	O
in	O
both	O
strains	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Regarding	O
the	O
proportion	O
of	O
the	O
central	O
-	O
area	O
locomotion	O
,	O
the	O
effects	O
of	O
MeHg	O
appeared	O
to	O
depend	O
on	O
sex	O
[	O
i.e.	O
,	O
sex	O
×	O
Hg	O
was	O
highly	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
three	O
-	O
way	O
ANOVA	O
;	O
Figure	O
3B	O
]	O
.	O

Indeed	O
,	O
a	O
sex	O
-	O
wise	O
two	O
-	O
way	O
ANOVA	O
showed	O
significant	O
effects	O
of	O
Hg	O
only	O
in	O
females	O
(	O
p	O
<	O
0.001	O
)	O
.	O

PA	O
At	O
12	O
weeks	O
of	O
age	O
,	O
all	O
the	O
groups	O
showed	O
prolonged	O
latency	O
in	O
the	O
second	O
(	O
retention	O
)	O
trial	O
,	O
and	O
no	O
consistent	O
effect	O
of	O
MeHg	O
was	O
recognized	O
regardless	O
of	O
strain	O
or	O
sex	O
(	O
Figure	O
4A	O
)	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
a	O
three	O
-	O
way	O
ANOVA	O
revealed	O
a	O
significant	O
interaction	O
between	O
strain	O
and	O
Hg	O
(	O
p	O
<	O
0.05	O
)	O
;	O
strain	O
-	O
wise	O
two	O
-	O
way	O
ANOVAs	O
revealed	O
a	O
significant	O
effect	O
of	O
Hg	O
on	O
learning	O
in	O
MT	O
-	O
null	O
mice	B
of	O
both	O
sexes	O
;	O
these	O
groups	O
of	O
mice	B
showed	O
significantly	O
shorter	O
(	O
less	O
than	O
half	O
)	O
latency	O
times	O
compared	O
to	O
control	O
mice	B
(	O
Figure	O
4B	O
)	O
.	O

A	O
notable	O
difference	O
between	O
the	O
results	O
at	O
52	O
weeks	O
of	O
age	O
and	O
those	O
at	O
12	O
weeks	O
was	O
that	O
many	O
of	O
the	O
tested	O
mice	B
exceeded	O
the	O
cutoff	O
time	O
in	O
the	O
retention	O
trials	O
at	O
52	O
weeks	O
,	O
except	O
for	O
the	O
MT	O
-	O
null	O
groups	O
.	O

MM	O
At	O
13	O
weeks	O
of	O
age	O
,	O
repeated	O
-	O
measures	O
ANOVA	O
did	O
not	O
indicate	O
any	O
effects	O
of	O
MeHg	O
(	O
Figure	O
5A	O
)	O
.	O

At	O
52	O
weeks	O
of	O
age	O
(	O
Figure	O
5B	O
)	O
,	O
wild	O
-	O
type	O
males	O
and	O
MT	O
-	O
null	O
females	O
shared	O
the	O
same	O
statistical	O
results	O
;	O
Hg	O
as	O
well	O
as	O
the	O
Hg	O
×	O
trial	O
interaction	O
were	O
statistically	O
significant	O
.	O

Thus	O
,	O
in	O
both	O
cases	O
,	O
the	O
MeHg	O
groups	O
showed	O
a	O
longer	O
latency	O
,	O
hampering	O
learning	O
performance	O
.	O

Tissue	O
Hg	O
concentration	O
At	O
PND10	O
,	O
which	O
was	O
immediately	O
after	O
the	O
exposure	O
,	O
brain	O
Hg	O
concentrations	O
of	O
the	O
neonatal	O
mice	B
were	O
approximately	O
≤	O
0.5	O
μg	O
/	O
g	O
(	O
Table	O
1	O
)	O
.	O

Although	O
the	O
MT	O
-	O
null	O
mice	B
and	O
females	O
showed	O
slightly	O
higher	O
brain	O
Hg	O
concentrations	O
than	O
the	O
corresponding	O
wild	O
-	O
type	O
group	O
and	O
males	O
,	O
respectively	O
,	O
neither	O
of	O
these	O
differences	O
was	O
significant	O
.	O

At	O
13	O
weeks	O
,	O
when	O
the	O
behavioral	O
tests	O
were	O
completed	O
,	O
the	O
brain	O
Hg	O
concentration	O
was	O
comparable	O
to	O
the	O
control	O
(	O
nonexposed	O
)	O
level	O
(	O
approximately	O
5	O
ng	O
/	O
g	O
in	O
both	O
the	O
exposed	O
and	O
control	O
brains	O
)	O
.	O

Interestingly	O
,	O
MT	O
-	O
null	O
mice	B
had	O
a	O
significantly	O
lower	O
brain	O
Hg	O
concentration	O
than	O
the	O
corresponding	O
wild	O
-	O
type	O
groups	O
.	O

Discussion	O
Results	O
of	O
the	O
present	O
study	O
demonstrate	O
the	O
delayed	O
emergence	O
of	O
neurobehavioral	O
toxicity	O
due	O
to	O
perinatal	O
MeHg	O
exposure	O
,	O
which	O
presumably	O
developed	O
after	O
brain	O
MeHg	O
concentrations	O
had	O
leveled	O
off	O
.	O

This	O
emergent	O
toxicity	O
was	O
exaggerated	O
in	O
MT	O
-	O
null	O
mice	B
and	O
was	O
more	O
distinct	O
in	O
females	O
.	O

To	O
our	O
knowledge	O
,	O
our	O
findings	O
show	O
the	O
first	O
clear	O
-	O
cut	O
demonstrations	O
of	O
a	O
long	O
latency	O
period	O
of	O
MeHg	O
neurobehavioral	O
toxicity	O
in	O
rodents	O
and	O
possible	O
genetic	O
susceptibility	O
for	O
the	O
emergent	O
toxicity	O
.	O

The	O
exposure	O
level	O
should	O
be	O
considered	O
before	O
discussing	O
the	O
end	O
points	O
.	O

On	O
PND10	O
,	O
immediately	O
after	O
the	O
cessation	O
of	O
MeHg	O
exposure	O
,	O
the	O
brain	O
Hg	O
concentration	O
was	O
approximately	O
0.5	O
μg	O
/	O
g	O
,	O
regardless	O
of	O
the	O
strain	O
or	O
sex	O
.	O

In	O
a	O
previous	O
study	O
,	O
the	O
brain	O
Hg	O
concentration	O
in	O
mice	B
perinatally	O
exposed	O
to	O
6	O
mg	O
MeHg	O
/	O
L	O
(	O
via	O
water	O
)	O
peaked	O
between	O
PND0	O
and	O
PND4	O
and	O
was	O
approximately	O
three	O
times	O
higher	O
than	O
on	O
PND21	O
(	O
Goulet	O
et	O
al.	O
2003	O
)	O
.	O

Therefore	O
,	O
the	O
peak	O
brain	O
Hg	O
concentration	O
,	O
which	O
is	O
presumably	O
observed	O
around	O
birth	O
,	O
can	O
be	O
estimated	O
as	O
about	O
3-fold	O
higher	O
than	O
that	O
on	O
PND10	O
and	O
would	O
be	O
approximately	O
1.5	O
μg	O
/	O
g	O
(	O
0.5	O
μg	O
/	O
g	O
×	O
3	O
)	O
,	O
which	O
is	O
one	O
of	O
the	O
lowest	O
levels	O
among	O
recent	O
rodent	O
studies	O
.	O

As	O
shown	O
by	O
Sakamoto	O
et	O
al.	O
(	O
2002	O
)	O
in	O
their	O
Figure	O
2	O
,	O
prenatal	O
exposure	O
of	O
rats	B
to	O
MeHg	O
showed	O
a	O
peak	O
brain	O
Hg	O
concentration	O
around	O
PND1	O
that	O
was	O
four	O
to	O
five	O
times	O
greater	O
than	O
the	O
level	O
on	O
PND10	O
.	O

Also	O
,	O
Newland	O
and	O
Rasmussen	O
(	O
2000	O
)	O
reported	O
a	O
slight	O
alteration	O
of	O
a	O
complex	O
operant	O
behavior	O
in	O
rats	B
at	O
ages	O
<	O
2	O
years	O
at	O
brain	O
Hg	O
concentrations	O
as	O
low	O
as	O
0.5	O
μg	O
/	O
g	O
at	O
birth	O
,	O
although	O
statistical	O
significance	O
of	O
this	O
particular	O
effect	O
was	O
not	O
clear	O
.	O

It	O
should	O
be	O
noted	O
that	O
rats	B
have	O
different	O
Hg	O
kinetics	O
(	O
Hirayama	O
and	O
Yasutake	O
1986	O
;	O
Yasutake	O
and	O
Hirayama	O
1990	O
)	O
due	O
to	O
the	O
high	O
affinity	O
of	O
rat	O
hemoglobin	O
for	O
MeHg	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
)	O
.	O

The	O
most	O
important	O
observation	O
of	O
the	O
present	O
study	O
was	O
that	O
the	O
effects	O
of	O
low	O
-	O
level	O
MeHg	O
exposure	O
were	O
detected	O
only	O
at	O
later	O
stages	O
in	O
the	O
lives	O
of	O
the	O
mice	B
.	O

Except	O
for	O
the	O
central	O
-	O
area	O
occupancy	O
in	O
OPF	O
in	O
MT	O
-	O
null	O
females	O
,	O
no	O
statistically	O
significant	O
effects	O
of	O
MeHg	O
were	O
observed	O
in	O
any	O
of	O
the	O
three	O
behavioral	O
tests	O
at	O
12	O
weeks	O
of	O
age	O
.	O

In	O
contrast	O
,	O
significant	O
effects	O
were	O
observed	O
in	O
all	O
three	O
tests	O
at	O
52	O
weeks	O
of	O
age	O
.	O

The	O
brain	O
Hg	O
concentration	O
of	O
the	O
exposed	O
groups	O
had	O
leveled	O
off	O
and	O
was	O
not	O
distinguishable	O
from	O
the	O
non	O
-	O
exposed	O
group	O
at	O
13	O
weeks	O
of	O
age	O
,	O
immediately	O
after	O
the	O
first	O
phase	O
of	O
the	O
behavioral	O
testing	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
latency	O
period	O
in	O
which	O
the	O
dose	O
and	O
effects	O
could	O
not	O
be	O
detected	O
,	O
although	O
effects	O
were	O
observed	O
9	O
months	O
later	O
.	O

Another	O
notable	O
observation	O
was	O
that	O
the	O
emergent	O
manifestation	O
of	O
toxicity	O
was	O
also	O
recognized	O
in	O
the	O
suppression	O
of	O
body	O
weight	O
(	O
except	O
for	O
wild	O
-	O
type	O
females	O
)	O
,	O
which	O
only	O
became	O
apparent	O
on	O
or	O
after	O
28	O
weeks	O
of	O
age	O
.	O

The	O
existence	O
of	O
a	O
latency	O
period	O
of	O
as	O
long	O
as	O
several	O
years	O
after	O
chronic	O
(	O
7	O
years	O
from	O
birth	O
)	O
,	O
low	O
-	O
level	O
exposure	O
to	O
MeHg	O
has	O
been	O
described	O
in	O
nonhuman	O
primates	O
(	O
Rice	O
1996	O
)	O
.	O

In	O
that	O
case	O
,	O
however	O
,	O
the	O
Hg	O
concentration	O
in	O
the	O
brain	O
remained	O
elevated	O
,	O
presumably	O
as	O
a	O
result	O
of	O
the	O
long	O
exposure	O
.	O

Indeed	O
,	O
Rice	O
(	O
1996	O
)	O
argued	O
that	O
the	O
minute	O
amount	O
of	O
residual	O
brain	O
Hg	O
could	O
have	O
caused	O
the	O
delayed	O
toxicity	O
.	O

This	O
was	O
clearly	O
not	O
the	O
case	O
in	O
the	O
present	O
study	O
because	O
the	O
Hg	O
concentration	O
leveled	O
off	O
around	O
the	O
time	O
of	O
the	O
first	O
phase	O
of	O
the	O
behavioral	O
study	O
.	O

The	O
absence	O
of	O
behavioral	O
effects	O
at	O
12	O
weeks	O
of	O
age	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
residual	O
behavioral	O
effects	O
were	O
due	O
to	O
elevated	O
Hg	O
early	O
in	O
life	O
.	O

Therefore	O
,	O
the	O
behavioral	O
toxicity	O
that	O
surfaced	O
at	O
52	O
weeks	O
of	O
age	O
must	O
have	O
had	O
its	O
origin	O
before	O
the	O
brain	O
Hg	O
concentration	O
leveled	O
off	O
(	O
at	O
or	O
before	O
13	O
weeks	O
of	O
age	O
)	O
,	O
although	O
the	O
redistribution	O
of	O
Hg	O
to	O
the	O
brain	O
from	O
other	O
sites	O
of	O
deposition	O
,	O
such	O
as	O
the	O
liver	O
,	O
can	O
not	O
be	O
completely	O
excluded	O
.	O

The	O
long	O
silent	O
period	O
before	O
the	O
manifestations	O
of	O
toxicity	O
emerged	O
suggests	O
that	O
a	O
slow	O
process	O
plays	O
a	O
role	O
in	O
this	O
latent	O
toxicity	O
.	O

Although	O
an	O
example	O
of	O
a	O
slow	O
process	O
is	O
aging	O
,	O
52	O
weeks	O
of	O
age	O
might	O
not	O
be	O
sufficiently	O
old	O
for	O
a	O
mouse	B
to	O
be	O
considered	O
aged	O
in	O
the	O
physiologic	O
sense	O
because	O
C57BL	O
/	O
6	O
mice	B
have	O
a	O
relatively	O
long	O
life	O
span	O
among	O
mouse	B
strains	O
[	O
median	O
survival	O
of	O
27–31	O
months	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
]	O
and	O
a	O
survival	O
rate	O
at	O
18–19	O
months	O
as	O
high	O
as	O
90	O
%	O
(	O
Institute	O
on	O
Aging	O
HP	O
)	O
(	O
National	O
Institute	O
on	O
Aging	O
2008	O
)	O
.	O

Nevertheless	O
,	O
various	O
behavioral	O
examinations	O
have	O
shown	O
age	O
-	O
related	O
changes	O
in	O
the	O
performance	O
of	O
mice	B
at	O
approximately	O
1	O
year	O
of	O
age	O
in	O
the	O
OPF	O
(	O
Acevedoa	O
et	O
al.	O
2006	O
;	O
Carrie	O
et	O
al.	O
1999	O
)	O
,	O
MM	O
(	O
Bach	O
et	O
al.	O
1999	O
;	O
Carrie	O
et	O
al.	O
1999	O
)	O
,	O
and	O
PA	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
tests	O
.	O

The	O
observed	O
effects	O
of	O
MeHg	O
,	O
including	O
the	O
deterioration	O
in	O
the	O
PA	O
and	O
MM	O
and	O
suppression	O
in	O
the	O
OPF	O
(	O
in	O
wild	O
-	O
type	O
mice	B
)	O
,	O
were	O
consistent	O
with	O
these	O
reported	O
effects	O
of	O
aging	O
on	O
behavioral	O
function	O
(	O
in	O
the	O
sense	O
described	O
above	O
)	O
,	O
except	O
for	O
the	O
increased	O
OPF	O
activity	O
in	O
the	O
MT	O
-	O
null	O
mice	B
.	O

Regardless	O
of	O
its	O
neural	O
basis	O
,	O
the	O
basis	O
of	O
neurobehavioral	O
toxicity	O
should	O
be	O
sought	O
in	O
early	O
life	O
stages	O
when	O
the	O
brain	O
Hg	O
concentration	O
is	O
highly	O
elevated	O
(	O
approximately	O
1.5	O
μg	O
/	O
g	O
at	O
its	O
peak	O
)	O
.	O

Some	O
in	O
vivo	O
experiments	O
have	O
demonstrated	O
several	O
candidate	O
mechanisms	O
of	O
perinatal	O
exposure	O
to	O
MeHg	O
,	O
including	O
abnormal	O
migration	O
of	O
neurons	O
and/or	O
glias	O
(	O
Kakita	O
et	O
al.	O
2003	O
;	O
Rodier	O
et	O
al.	O
1984	O
)	O
,	O
but	O
at	O
higher	O
Hg	O
concentrations	O
.	O

Using	O
exactly	O
the	O
same	O
exposure	O
protocol	O
as	O
the	O
present	O
study	O
,	O
we	O
found	O
suppressed	O
activity	O
of	O
type	O
III	O
iodo	O
-	O
thyronine	O
deiodinase	O
,	O
a	O
thyroid	O
hormone	O
-	O
metabolizing	O
enzyme	O
,	O
in	O
the	O
brains	O
of	O
PND10	O
mouse	B
neonates	O
(	O
Mori	O
et	O
al.	O
2006	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
study	O
of	O
higher	O
MeHg	O
doses	O
(	O
Watanabe	O
et	O
al.	O
1999	O
)	O
.	O

This	O
perturbation	O
could	O
be	O
one	O
of	O
the	O
candidate	O
mechanisms	O
responsible	O
for	O
the	O
later	O
anomalous	O
behaviors	O
because	O
even	O
a	O
transient	O
change	O
in	O
thyroid	O
hormones	O
during	O
the	O
critical	O
period	O
of	O
perinatal	O
life	O
exerts	O
long	O
-	O
term	O
consequences	O
(	O
Auso	O
et	O
al.	O
2004	O
)	O
.	O

The	O
effects	O
of	O
MeHg	O
at	O
52	O
weeks	O
of	O
age	O
were	O
influenced	O
by	O
two	O
potential	O
modifying	O
factors	O
,	O
sex	O
and	O
strain	O
.	O

In	O
the	O
OPF	O
,	O
while	O
the	O
locomotion	O
was	O
affected	O
in	O
both	O
strains	O
(	O
although	O
the	O
direction	O
was	O
opposite	O
)	O
,	O
center	O
occupancy	O
was	O
significantly	O
increased	O
only	O
in	O
the	O
MT	O
-	O
null	O
mice	B
.	O

In	O
addition	O
,	O
the	O
effects	O
on	O
PA	O
were	O
significant	O
only	O
in	O
MT	O
-	O
null	O
mice	B
,	O
whereas	O
MeHg	O
at	O
a	O
higher	O
dose	O
was	O
reported	O
to	O
worsen	O
PA	O
performance	O
in	O
rats	B
(	O
6–8	O
weeks	O
of	O
age	O
;	O
Sakamoto	O
et	O
al.	O
2002	O
)	O
.	O

In	O
addition	O
,	O
body	O
weight	O
gain	O
was	O
suppressed	O
in	O
both	O
male	O
and	O
female	O
MT	O
-	O
null	O
mice	B
,	O
whereas	O
in	O
wild	O
-	O
type	O
mice	B
the	O
suppression	O
was	O
observed	O
only	O
in	O
males	O
.	O

Taken	O
together	O
,	O
the	O
MT	O
-	O
null	O
strain	O
appeared	O
to	O
be	O
slightly	O
more	O
susceptible	O
to	O
the	O
late	O
-	O
emergent	O
effects	O
of	O
MeHg	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
shown	O
that	O
MT	O
-	O
I	O
,	O
II	O
is	O
protective	O
against	O
the	O
toxicity	O
of	O
MeHg	O
(	O
Leiva	O
-	O
Presa	O
et	O
al.	O
2004	O
;	O
Yao	O
et	O
al.	O
2000	O
)	O
,	O
and	O
the	O
present	O
results	O
were	O
basically	O
consistent	O
with	O
these	O
reports	O
.	O

We	O
have	O
also	O
reported	O
the	O
susceptibility	O
of	O
the	O
MT	O
-	O
null	O
strain	O
to	O
the	O
neurotoxic	O
effects	O
of	O
metallic	O
Hg	O
(	O
Yoshida	O
et	O
al.	O
2004	O
,	O
2006	O
)	O
.	O

The	O
difference	O
in	O
the	O
susceptibility	O
to	O
MeHg	O
between	O
sexes	O
is	O
still	O
debated	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
;	O
National	O
Research	O
Council	O
2000	O
;	O
Vahter	O
2007	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
some	O
responses	O
to	O
MeHg	O
were	O
different	O
between	O
the	O
sexes	O
,	O
including	O
OPF	O
performance	O
at	O
12	O
and	O
52	O
weeks	O
of	O
age	O
and	O
MM	O
performance	O
at	O
52	O
weeks	O
.	O

The	O
fact	O
that	O
the	O
MT	O
-	O
null	O
female	O
group	O
was	O
the	O
only	O
group	O
affected	O
by	O
MeHg	O
at	O
12	O
weeks	O
may	O
suggest	O
the	O
particular	O
susceptibility	O
of	O
females	O
in	O
this	O
strain	O
.	O

This	O
point	O
needs	O
to	O
be	O
clarified	O
in	O
further	O
experiments	O
.	O

The	O
question	O
remains	O
of	O
why	O
MT	O
-	O
null	O
mice	B
are	O
susceptible	O
to	O
the	O
delayed	O
neurotoxicity	O
of	O
perinatal	O
MeHg	O
.	O

Apparently	O
kinetics	O
play	O
only	O
a	O
minor	O
role	O
because	O
the	O
strain	O
did	O
not	O
show	O
distinct	O
effects	O
on	O
the	O
brain	O
Hg	O
concentration	O
at	O
PND10	O
.	O

The	O
significantly	O
lower	O
brain	O
Hg	O
concentration	O
in	O
MT	O
-	O
null	O
mice	B
compared	O
with	O
corresponding	O
wild	O
-	O
type	O
mice	B
at	O
13	O
weeks	O
of	O
age	O
indicated	O
that	O
MT	O
-	O
I	O
,	O
II	O
might	O
play	O
a	O
significant	O
role	O
in	O
the	O
retention	O
of	O
Hg	O
(	O
or	O
MeHg	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
results	O
of	O
studies	O
of	O
metallic	O
Hg	O
exposure	O
(	O
Yoshida	O
et	O
al.	O
2004	O
,	O
2005	O
)	O
;	O
a	O
lower	O
brain	O
Hg	O
concentration	O
may	O
not	O
guarantee	O
lower	O
toxicity	O
,	O
supporting	O
the	O
protective	O
role	O
of	O
the	O
protein	O
.	O

Earlier	O
studies	O
suggest	O
that	O
brain	O
MT	O
-	O
I	O
,	O
II	O
has	O
an	O
important	O
role	O
both	O
in	O
the	O
response	O
to	O
oxidative	O
injury	O
(	O
Potter	O
et	O
al.	O
2007	O
)	O
and	O
in	O
the	O
process	O
of	O
aging	O
(	O
Kojima	O
et	O
al.	O
1999	O
)	O
.	O

Therefore	O
,	O
the	O
lack	O
of	O
MT	O
can	O
exaggerate	O
the	O
toxicity	O
of	O
MeHg	O
by	O
enhancing	O
the	O
initial	O
effects	O
due	O
to	O
oxygen	O
radicals	O
and/or	O
by	O
accelerating	O
functional	O
aging	O
.	O

Apart	O
from	O
this	O
,	O
an	O
intriguing	O
possibility	O
is	O
that	O
the	O
brain	O
-	O
specific	O
isoform	O
,	O
MT	O
-	O
III	O
,	O
might	O
contribute	O
to	O
the	O
results	O
we	O
obtained	O
because	O
the	O
expression	O
of	O
MT	O
-	O
III	O
,	O
together	O
with	O
MT	O
-	O
I	O
,	O
is	O
increased	O
in	O
the	O
brain	O
of	O
old	O
rats	B
,	O
resulting	O
in	O
the	O
low	O
availability	O
of	O
free	O
zinc	O
for	O
synapses	O
(	O
Mocchegiani	O
et	O
al.	O
2004	O
)	O
.	O

The	O
age	O
-	O
dependent	O
expressions	O
of	O
MT	O
isoforms	O
might	O
be	O
modified	O
in	O
MT	O
-	O
null	O
mice	B
.	O

Results	O
of	O
the	O
present	O
study	O
might	O
allow	O
the	O
possibility	O
of	O
alternative	O
interpretations	O
due	O
to	O
some	O
potentially	O
confounding	O
factors	O
.	O

For	O
example	O
,	O
except	O
for	O
the	O
wild	O
-	O
type	O
females	O
,	O
we	O
observed	O
significant	O
differences	O
in	O
body	O
weight	O
between	O
MeHg	O
-	O
exposed	O
and	O
non	O
-	O
exposed	O
groups	O
.	O

Because	O
these	O
differences	O
only	O
became	O
clear	O
later	O
in	O
life	O
,	O
they	O
might	O
be	O
associated	O
with	O
the	O
toxicity	O
that	O
also	O
emerged	O
later	O
in	O
life	O
.	O

Manipulation	O
of	O
body	O
weight	O
in	O
rodents	O
alters	O
activity	O
levels	O
,	O
although	O
the	O
reported	O
results	O
are	O
not	O
always	O
consistent	O
with	O
each	O
other	O
(	O
Harrison	O
and	O
Archer	O
1987	O
;	O
Samuelsson	O
et	O
al.	O
2008	O
)	O
.	O

Also	O
,	O
the	O
differential	O
performance	O
in	O
PA	O
could	O
be	O
related	O
with	O
the	O
potential	O
effects	O
of	O
MeHg	O
on	O
(	O
electric	O
)	O
shock	O
sensitivity	O
,	O
which	O
we	O
did	O
not	O
examine	O
.	O

At	O
least	O
one	O
high	O
-	O
dose	O
study	O
with	O
adult	O
rats	B
showed	O
reduced	O
electric	O
sensitivity	O
due	O
to	O
mercury	O
exposure	O
(	O
Wu	O
et	O
al.	O
1985	O
)	O
.	O

These	O
possibilities	O
need	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

To	O
summarize	O
,	O
the	O
present	O
results	O
suggest	O
that	O
an	O
initial	O
(	O
or	O
triggering	O
)	O
toxicologic	O
event	O
occurs	O
before	O
the	O
brain	O
Hg	O
concentration	O
stabilizes	O
and	O
that	O
the	O
nature	O
of	O
this	O
event	O
should	O
be	O
either	O
an	O
acceleration	O
of	O
the	O
aging	O
process	O
or	O
interaction	O
with	O
the	O
aging	O
process	O
.	O

Thus	O
,	O
by	O
identifying	O
the	O
physiologic	O
events	O
associated	O
with	O
the	O
functional	O
aging	O
of	O
the	O
examined	O
behavioral	O
tasks	O
,	O
the	O
fundamental	O
toxicologic	O
scar	O
might	O
be	O
revealed	O
.	O

Potentiation	O
of	O
Nerve	O
Growth	O
Factor	O
-	O
Induced	O
Neurite	O
Outgrowth	O
by	O
Fluvoxamine	O
:	O
Role	O
of	O
Sigma-1	O
Receptors	O
,	O
IP3	O
Receptors	O
and	O
Cellular	O
Signaling	O
Pathways	O
Abstract	O
Background	O
Selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
been	O
widely	O
used	O
and	O
are	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O

However	O
,	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
.	O

The	O
SSRI	O
fluvoxamine	O
,	O
with	O
sigma-1	O
receptor	O
agonism	O
,	O
is	O
shown	O
to	O
potentiate	O
nerve	O
-	O
growth	O
factor	O
(	O
NGF	O
)	O
-induced	O
neurite	O
outgrowth	O
in	O
PC	O
12	O
cells	O
.	O

However	O
,	O
the	O
precise	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
potentiation	O
by	O
fluvoxamine	O
are	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
cellular	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
sigma-1	O
receptor	O
agonists	O
.	O

Methods	O
and	O
Findings	O
The	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
and	O
three	O
sigma-1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
4-phenyl-1-	O
(	O
4-phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
and	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
-sulfate	O
)	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
were	O
examined	O
.	O

Also	O
examined	O
were	O
the	O
effects	O
of	O
the	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
,	O
inositol	O
1,4,5-triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
,	O
and	O
specific	O
inhibitors	O
of	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
selective	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
.	O

Fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma-1	O
receptor	O
agonists	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulfate	O
significantly	O
potentiated	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
potentiation	O
by	O
fluvoxamine	O
and	O
the	O
three	O
sigma-1	O
receptor	O
agonists	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
,	O
suggesting	O
that	O
sigma-1	O
receptors	O
play	O
a	O
role	O
in	O
blocking	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Moreover	O
,	O
the	O
potentiation	O
by	O
SA4503	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C.	O
In	O
addition	O
,	O
the	O
specific	O
inhibitors	O
of	O
phospholipase	O
C	O
(	O
PLC	O
-	O
γ	O
)	O
,	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3	O
K	O
)	O
,	O
p38MAPK	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathways	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Conclusion	O
These	O
findings	O
suggest	O
that	O
stimulation	O
of	O
sigma-1	O
receptors	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
,	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38MAPK	O
,	O
JNK	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
MAPK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
mechanisms	O
of	O
action	O
of	O
sigma-1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
SA4503	O
.	O

Introduction	O
Selective	O
serotonin	O
(	O
5-HT	O
;	O
5-hydroxytryptamine	O
)	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
emerged	O
as	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O

SSRIs	O
are	O
the	O
treatment	O
of	O
choice	O
for	O
many	O
indications	O
,	O
including	O
major	O
depressive	O
disorder	O
,	O
dysthymia	O
,	O
panic	O
disorder	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
eating	O
disorders	O
,	O
and	O
premenstrual	O
dysphoric	O
disorder	O
.	O

In	O
contrast	O
,	O
it	O
is	O
well	O
known	O
that	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
,	O
although	O
all	O
of	O
them	O
block	O
5-HT	O
transporters	O
,	O
thus	O
increasing	O
5-HT	O
levels	O
throughout	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
[	O
1	O
]	O
–	O
[	O
9	O
]	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
sigma-1	O
receptors	O
,	O
which	O
are	O
intracellular	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
proteins	O
,	O
are	O
involved	O
in	O
both	O
the	O
neuroplasticity	O
and	O
pathophysiology	O
of	O
neuropsychiatric	O
diseases	O
such	O
as	O
major	O
depressive	O
disorder	O
,	O
anxiety	O
,	O
schizophrenia	O
,	O
and	O
Alzheimer	O
's	O
disease	O
[	O
10	O
]	O
–	O
[	O
18	O
]	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
some	O
SSRIs	O
possess	O
high	O
to	O
moderate	O
affinities	O
for	O
sigma-1	O
receptors	O
in	O
the	O
rat	B
brain	O
.	O

The	O
rank	O
order	O
of	O
SSRIs	O
affinities	O
for	O
sigma-1	O
receptors	O
is	O
fluvoxamine	O
(	O
Ki	O
=	O
36	O
nM	O
)	O
>sertraline	O
(	O
Ki	O
=	O
57	O
nM	O
)	O
>>paroxetine	O
(	O
Ki	O
=	O
1893	O
nM	O
)	O
[	O
19	O
]	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
fluvoxamine	O
,	O
but	O
not	O
paroxetine	O
,	O
significantly	O
ameliorated	O
cognitive	O
deficits	O
in	O
mice	B
after	O
repeated	O
phencyclidine	O
administration	O
,	O
and	O
that	O
the	O
effects	O
of	O
fluvoxamine	O
were	O
antagonized	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
[	O
20	O
]	O
,	O
suggesting	O
that	O
sigma-1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
[	O
9	O
]	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
sigma-1	O
receptor	O
agonists	O
including	O
fluvoxamine	O
could	O
potentiate	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
NE-100	O
blocked	O
the	O
potentiation	O
by	O
sigma-1	O
receptor	O
agonists	O
,	O
suggesting	O
sigma-1	O
receptors	O
are	O
involved	O
in	O
neuroplasticity	O
[	O
21	O
]	O
.	O

However	O
,	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
potentiation	O
by	O
sigma-1	O
receptor	O
agonists	O
are	O
not	O
fully	O
understood	O
[	O
13	O
]	O
,	O
[	O
21	O
]	O
.	O

It	O
is	O
therefore	O
of	O
great	O
interest	O
to	O
study	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
enhancement	O
by	O
fluvoxamine	O
on	O
NGF	O
-	O
induced	O
neurite	O
sprouting	O
in	O
PC12	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
a	O
sigma-1	O
receptor	O
agonist	O
(	O
4-phenyl-1-	O
(	O
4-phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
dehydroepiandrosterone	O
-	O
sulphate	O
(	O
DHEA	O
)	O
-sulfate	O
)	O
[	O
9	O
]	O
,	O
[	O
22	O
]	O
–	O
[	O
28	O
]	O
and	O
the	O
selective	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
[	O
29	O
]	O
,	O
[	O
30	O
]	O
,	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
also	O
known	O
that	O
sigma-1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17,18	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE-100	O
and	O
xestospongin	O
C	O
(	O
a	O
selective	O
inositol	O
1,4,5-triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
)	O
[	O
31	O
]	O
in	O
order	O
to	O
investigate	O
the	O
roles	O
of	O
sigma-1	O
receptors	O
and	O
IP3	O
receptors	O
in	O
the	O
mechanisms	O
underlying	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
examined	O
the	O
effects	O
of	O
specific	O
inhibitors	O
of	O
several	O
cellular	O
signaling	O
targets	O
on	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
since	O
several	O
signal	O
transduction	O
molecules	O
have	O
been	O
implicated	O
in	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
[	O
32	O
]	O
.	O

Materials	O
and	O
Methods	O
Drugs	O
The	O
drugs	O
were	O
obtained	O
from	O
the	O
following	O
sources	O
:	O
fluvoxamine	O
maleate	O
(	O
Solvay	O
Seiyaku	O
K.K.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
;	O
paroxetine	O
hydrochloride	O
,	O
dehydroepiandosterone	O
-	O
sulfate	O
(	O
DHEA	O
-	O
sulfate	O
)	O
,	O
LY294002	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
;	O
sertraline	O
(	O
Toronto	O
Research	O
Chemicals	O
Inc.	O
,	O
North	O
York	O
,	O
ON	O
,	O
Canada	O
)	O
;	O
SA4503	O
(	O
M	O
's	O
Science	O
Corporation	O
,	O
Kobe	O
,	O
Japan	O
)	O
;	O
NGF	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
;	O
xestospongin	O
C	O
,	O
lovastatin	O
,	O
PD98059	O
,	O
GW5074	O
,	O
SB203580	O
,	O
MEK	O
1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
)	O
,	O
and	O
SP600125	O
(	O
Calbiochem	O
-	O
Novabiochem	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
selective	O
sigma-1	O
receptor	O
antagonists	O
NE-100	O
and	O
4-phenyl-1-	O
(	O
4-phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
were	O
synthesized	O
in	O
our	O
laboratory	O
.	O

Other	O
drugs	O
were	O
purchased	O
from	O
commercial	O
sources	O
.	O

Cell	O
culture	O
PC12	O
sells	O
(	O
RIKEN	O
Cell	O
Bank	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
were	O
cultured	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
with	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
5	O
%	O
heat	O
-	O
inactivated	O
fetal	O
bovine	B
serum	O
(	O
FBS	O
)	O
,	O
10	O
%	O
heat	O
-	O
inactivated	O
horse	B
serum	O
,	O
and	O
1	O
%	O
penicillin	O
.	O

The	O
medium	O
was	O
changed	O
two	O
or	O
three	O
times	O
a	O
week	O
.	O

PC12	O
cells	O
were	O
plated	O
onto	O
24-well	O
tissue	O
culture	O
plates	O
coated	O
with	O
poly	O
-	O
D	O
-	O
lysine	O
/	O
laminin	O
.	O

Cells	O
were	O
plated	O
at	O
relatively	O
low	O
density	O
(	O
0.25	O
×	O
104	O
cells	O
/	O
cm2	O
)	O
in	O
DMEM	O
medium	O
containing	O
0.5	O
%	O
FBS	O
,	O
1	O
%	O
penicillin	O
streptomycin	O
.	O

Medium	O
containing	O
a	O
minimal	O
level	O
of	O
serum	O
(	O
0.5	O
%	O
FBS	O
)	O
was	O
used	O
,	O
since	O
serum	O
is	O
known	O
to	O
contain	O
steroid	O
hormones	O
that	O
bind	O
to	O
sigma-1	O
receptors	O
[	O
21	O
]	O
.	O

First	O
,	O
we	O
examined	O
the	O
optimal	O
concentration	O
of	O
NGF	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

NGF	O
(	O
2.5	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
ng	O
/	O
ml	O
)	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
1	O
)	O
.	O

In	O
the	O
subsequent	O
studies	O
,	O
2.5	O
ng	O
/	O
ml	O
of	O
NGF	O
was	O
used	O
to	O
study	O
the	O
potentiating	O
effects	O
of	O
sigma-1	O
receptor	O
agonists	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
plating	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
DMEM	O
medium	O
containing	O
0.5	O
%	O
FBS	O
and	O
1	O
%	O
penicillin	O
streptomycin	O
with	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
several	O
drugs	O
.	O

Quantification	O
of	O
neurite	O
sprouting	O
Five	O
days	O
after	O
incubation	O
with	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
the	O
several	O
drugs	O
,	O
morphometric	O
analysis	O
was	O
performed	O
on	O
digitized	O
images	O
of	O
live	O
cells	O
taken	O
under	O
phase	O
-	O
contrast	O
illumination	O
with	O
an	O
inverted	O
microscope	O
linked	O
to	O
a	O
camera	O
.	O

Images	O
of	O
three	O
fields	O
per	O
well	O
were	O
taken	O
,	O
with	O
an	O
average	O
of	O
100	O
cells	O
per	O
field	O
.	O

Differentiated	O
cells	O
were	O
counted	O
by	O
visual	O
examination	O
of	O
the	O
field	O
;	O
only	O
cells	O
that	O
had	O
at	O
least	O
one	O
neurite	O
with	O
a	O
length	O
equal	O
to	O
the	O
cell	O
body	O
diameter	O
were	O
counted	O
,	O
and	O
were	O
then	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
total	O
cells	O
in	O
the	O
field	O
.	O

The	O
counting	O
was	O
performed	O
in	O
a	O
blinded	O
manner	O
.	O

Immunocytochemistry	O
Cells	O
were	O
fixed	O
for	O
30	O
min	O
at	O
room	O
temperature	O
with	O
4	O
%	O
paraformaldehyde	O
then	O
permeabilized	O
with	O
0.2	O
%	O
Triton	O
and	O
blocked	O
with	O
1.5	O
%	O
normal	O
goat	B
serum	O
,	O
0.1	O
%	O
bovine	B
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
0.1	O
M	O
phosphate	O
-	O
buffer	O
saline	O
for	O
1	O
h	O
to	O
reduce	O
nonspecific	O
binding	O
.	O

Cells	O
were	O
incubated	O
overnight	O
at	O
4	O
°	O
C	O
with	O
anti	O
-	O
microtubule	O
-	O
associated	O
protein	O
2	O
(	O
MAP-2	O
)	O
antibodies	O
(	O
1∶1000	O
dilution	O
in	O
blocking	O
solution	O
,	O
Chemicon	O
International	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
immunolabeling	O
was	O
visualized	O
with	O
secondary	O
antibodies	O
conjugated	O
to	O
Alexa-488	O
(	O
1∶1000	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

MAP-2	O
immuncytochemistry	O
was	O
visualized	O
with	O
a	O
fluorescence	O
microscope	O
(	O
Axiovert	O
200	O
,	O
Carl	O
Zeiss	O
,	O
Oberkocken	O
,	O
Germany	O
)	O
.	O

Statistical	O
analysis	O
Data	O
are	O
expressed	O
as	O
means±S.E.M.	O
Statistical	O
analysis	O
was	O
performed	O
by	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	O
post	O
hoc	O
Bonferroni	O
/	O
Dunn	O
test	O
.	O

P	O
values	O
less	O
than	O
0.05	O
were	O
considered	O
statistically	O
significant	O
.	O

Results	O
Effects	O
of	O
SSRIs	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
Fluvoxamine	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
2	O
and	O
4	O
)	O
.	O

In	O
contrast	O
,	O
sertraline	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
and	O
paroxetine	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
did	O
not	O
increase	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
.	O

A	O
higher	O
concentration	O
(	O
10	O
µM	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
significantly	O
decreased	O
the	O
number	O
of	O
cells	O
with	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
suggesting	O
the	O
cellular	O
toxicity	O
of	O
these	O
drugs	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
sigma-1	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
SA4503	O
The	O
selective	O
and	O
potent	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
(	O
0.01	O
,	O
0.1	O
,	O
or	O
1.0	O
µM	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
and	O
4	O
)	O
.	O

In	O
addition	O
,	O
other	O
sigma-1	O
receptor	O
agonists	O
–	O
PPBP	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
[	O
22	O
]	O
–	O
[	O
26	O
]	O
and	O
DHEA	O
-	O
sulphate	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
[	O
9	O
]	O
,	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
–significantly	O
increased	O
the	O
number	O
of	O
such	O
cells	O
,	O
also	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
)	O
.	O

In	O
the	O
absence	O
of	O
NGF	O
,	O
sigma-1	O
receptor	O
agonists	O
did	O
not	O
produce	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
sigma-1	O
receptors	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE-100	O
(	O
a	O
selective	O
sigma-1	O
receptor	O
antagonist	O
)	O
on	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
,	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulphate	O
.	O

Co	O
-	O
administration	O
of	O
NE-100	O
(	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
such	O
potentiation	O
by	O
fluvoxamine	O
(	O
10	O
µM	O
)	O
,	O
SA4503	O
(	O
1.0	O
µM	O
)	O
,	O
PPBP	O
(	O
10	O
µM	O
)	O
,	O
or	O
DHEA	O
-	O
sulphate	O
(	O
10	O
µM	O
)	O
(	O
Figure	O
2	O
and	O
3	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
NE-100	O
(	O
1.0	O
µM	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
IP3	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
Sigma-1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17,18,33–35	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
IP3	O
receptors	O
in	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
we	O
examined	O
the	O
effects	O
of	O
xestospongin	O
C	O
(	O
a	O
selective	O
,	O
reversible	O
,	O
and	O
membrane	O
-	O
permeable	O
inhibitor	O
of	O
IP3	O
receptors	O
)	O
[	O
31	O
]	O
on	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Co	O
-	O
administration	O
of	O
xestospongin	O
C	O
(	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1.0	O
µM	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
xestospongin	O
C	O
(	O
1.0	O
µM	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
5	O
)	O
.	O

Role	O
of	O
signaling	O
molecules	O
proximal	O
to	O
TrkA	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
the	O
specific	O
inhibitors	O
of	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38	O
MAPK	O
,	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
since	O
these	O
signaling	O
molecules	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
36	O
]	O
.	O

The	O
PLC	O
-	O
γ	O
inhibitor	O
(	O
U73122	O
;	O
1.0	O
µM	O
)	O
,	O
PI3	O
K	O
inhibitor	O
(	O
LY294002	O
;	O
1.0	O
µM	O
)	O
,	O
p38	O
MAPK	O
inhibitor	O
(	O
SB203580	O
;	O
1.0	O
µM	O
)	O
,	O
and	O
JNK	O
inhibitor	O
(	O
SP600125	O
;	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1.0	O
µM	O
)	O
(	O
Figure	O
6	O
)	O
.	O

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

Role	O
of	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
The	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
is	O
known	O
to	O
be	O
involved	O
in	O
NGF	O
-	O
induced	O
outgrowth	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
this	O
pathway	O
's	O
specific	O
inhibitors	O
.	O

The	O
Ras	O
inhibitor	O
(	O
GW5074	O
;	O
1.0	O
µM	O
)	O
,	O
Raf	O
inhibitor	O
(	O
lovastatin	O
;	O
1.0	O
µM	O
)	O
,	O
MEK1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
;	O
1.0	O
µM	O
)	O
,	O
and	O
MAPK	O
inhibitor	O
(	O
PD98059	O
;	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1.0	O
µM	O
)	O
(	O
Figure	O
7	O
)	O
.	O

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma-1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
PPBP	O
,	O
DHEA	O
-	O
sulfate	O
)	O
could	O
potentiate	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
the	O
effects	O
of	O
these	O
drugs	O
were	O
blocked	O
by	O
co	O
-	O
incubation	O
with	O
the	O
selective	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
.	O

These	O
findings	O
suggest	O
that	O
agonism	O
at	O
sigma-1	O
receptors	O
for	O
these	O
drugs	O
is	O
involved	O
in	O
the	O
mechanisms	O
underlying	O
the	O
drugs	O
'	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
NGF	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
,	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

To	O
examine	O
whether	O
or	O
not	O
the	O
NGF	O
levels	O
are	O
altered	O
by	O
incubation	O
with	O
sigma-1	O
receptor	O
agonists	O
,	O
we	O
measured	O
the	O
levels	O
of	O
NGF	O
in	O
PC12	O
cells	O
with	O
or	O
without	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
.	O

No	O
differences	O
of	O
NGF	O
levels	O
were	O
shown	O
in	O
the	O
between	O
control	O
group	O
and	O
SA4503-treated	O
group	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
is	O
,	O
therefore	O
,	O
unlikely	O
that	O
the	O
potentaition	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
might	O
be	O
due	O
to	O
increased	O
levels	O
of	O
NGF	O
.	O

Unlike	O
fluvoxamine	O
,	O
sertraline	O
,	O
which	O
has	O
a	O
moderate	O
affinity	O
for	O
sigma-1	O
receptors	O
,	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

The	O
reasons	O
underlying	O
this	O
discrepancy	O
between	O
these	O
two	O
SSRIs	O
are	O
currently	O
unclear	O
.	O

One	O
possibility	O
may	O
involve	O
the	O
difference	O
in	O
pharmacological	O
actions	O
(	O
agonist	O
vs.	O
antagonist	O
)	O
between	O
these	O
SSRIs	O
at	O
sigma-1	O
receptors	O
.	O

Interestingly	O
,	O
we	O
recently	O
found	O
that	O
,	O
in	O
a	O
novel	O
object	O
recognition	O
test	O
,	O
phencyclidine	O
-	O
induced	O
cognitive	O
deficits	O
could	O
be	O
significantly	O
improved	O
by	O
subsequent	O
subchronic	O
(	O
14	O
days	O
)	O
administration	O
of	O
fluvoxamine	O
,	O
but	O
not	O
of	O
sertraline	O
,	O
suggesting	O
that	O
sigma-1	O
receptor	O
agonism	O
is	O
involved	O
in	O
fluvoxamine	O
's	O
mechanism	O
of	O
action	O
[	O
9	O
]	O
,	O
Ishima	O
et	O
al.	O
,	O
submitted	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
fluvoxamine	O
and	O
sertraline	O
may	O
function	O
as	O
an	O
agonist	O
and	O
an	O
antagonist	O
at	O
sigma-1	O
receptors	O
,	O
respectively	O
,	O
although	O
further	O
study	O
is	O
necessary	O
.	O

Another	O
possibility	O
may	O
be	O
that	O
other	O
pharmacological	O
activities	O
of	O
sertraline	O
mask	O
the	O
effects	O
of	O
sigma-1	O
receptor	O
agonism	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
found	O
that	O
high	O
concentration	O
(	O
10	O
µM	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
,	O
but	O
not	O
fluvoxamine	O
,	O
showed	O
cytotoxicity	O
in	O
PC12	O
cells	O
,	O
suggesting	O
that	O
fluvoxamine	O
may	O
be	O
a	O
safe	O
drug	O
than	O
paroxetine	O
and	O
sertraline	O
.	O

Sigma-1	O
receptors	O
have	O
been	O
shown	O
to	O
affect	O
intracellular	O
Ca2	O
+	O
signaling	O
,	O
although	O
the	O
precise	O
molecular	O
and	O
cellular	O
mechanisms	O
underlying	O
this	O
effect	O
are	O
unknown	O
.	O

Sigma-1	O
receptors	O
bind	O
to	O
IP3	O
receptors	O
in	O
ER	O
,	O
and	O
sigma-1	O
receptors	O
regulate	O
Ca2	O
+	O
release	O
from	O
intracellular	O
Ca2	O
+	O
storage	O
sites	O
[	O
12	O
]	O
.	O

Very	O
recently	O
,	O
Hayashi	O
and	O
Su	O
[	O
17	O
]	O
reported	O
that	O
sigma-1	O
receptors	O
function	O
as	O
novel	O
ligand	O
-	O
operated	O
chaperones	O
that	O
specifically	O
target	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
.	O

Furthermore	O
,	O
sigma-1	O
receptors	O
form	O
Ca2	O
+	O
-sensitive	O
chaperone	O
machinery	O
with	O
another	O
chaperone	O
,	O
BiP	O
,	O
and	O
prolong	O
Ca2	O
+	O
signaling	O
from	O
ER	O
into	O
mitochondria	O
by	O
stabilizing	O
IP3	O
receptors	O
at	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
[	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
the	O
role	O
of	O
IP3	O
receptors	O
on	O
sigma-1	O
receptor	O
-	O
mediated	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
stimulation	O
at	O
sigma-1	O
receptors	O
by	O
sigma-1	O
receptor	O
agonists	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
.	O

NGF	O
binds	O
to	O
the	O
high	O
-	O
affinity	O
tyrosine	O
receptor	O
TrkA	O
,	O
initiating	O
several	O
signaling	O
pathways	O
affecting	O
both	O
morphological	O
and	O
transcriptional	O
targets	O
[	O
32	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

The	O
signaling	O
molecules	O
,	O
including	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38	O
MAPK	O
,	O
and	O
JNK	O
,	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
38	O
]	O
.	O

PLC	O
-	O
γ	O
catalyzes	O
the	O
hydrolysis	O
of	O
phosphatidylinositol-4,5-bisphosphate	O
(	O
PIP2	O
)	O
to	O
diacylglycerol	O
(	O
DAG	O
)	O
and	O
inositol	O
triphosphate	O
(	O
IP3	O
)	O
.	O

DAG	O
activates	O
protein	O
kinase	O
C	O
,	O
and	O
IP3	O
promotes	O
transient	O
release	O
of	O
Ca2	O
+	O
from	O
the	O
ER	O
[	O
39	O
]	O
.	O

The	O
pathway	O
via	O
PLC	O
-	O
γ	O
is	O
responsible	O
for	O
NGF	O
-	O
induced	O
cell	O
differentiation	O
[	O
40	O
]	O
and	O
neurite	O
outgrowth	O
[	O
41	O
]	O
.	O

Furthermore	O
,	O
stimulation	O
of	O
PI3	O
K	O
is	O
reported	O
to	O
be	O
involved	O
in	O
the	O
promotion	O
of	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
[	O
42	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
PLC	O
-	O
γ	O
inhibitor	O
U73122	O
and	O
the	O
PI3	O
K	O
inhibitor	O
LY294002	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
both	O
the	O
p38MAPK	O
inhibitor	O
SB203580	O
and	O
the	O
JNK	O
inhibitor	O
SP600125	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

In	O
addition	O
,	O
it	O
is	O
also	O
interesting	O
that	O
neurite	O
outgrowth	O
induced	O
by	O
low	O
concentration	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
of	O
NGF	O
was	O
not	O
blocked	O
by	O
these	O
inihibitors	O
,	O
consistent	O
with	O
a	O
previous	O
report	O
[	O
43	O
]	O
,	O
[	O
44	O
]	O
,	O
suggesting	O
the	O
existence	O
of	O
novel	O
pathway	O
(	O
s	O
)	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38MAPK	O
,	O
and	O
JNK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
(	O
Figure	O
8)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
specific	O
inhibitors	O
for	O
the	O
Raf	O
/	O
Ras	O
/	O
MEK	O
/	O
MAPK	O
pathways	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
that	O
these	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
(	O
Figure	O
8)	O
.	O

Our	O
recent	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
demonstrated	O
that	O
,	O
after	O
a	O
single	O
oral	O
administration	O
,	O
fluvoxamine	O
bound	O
to	O
sigma-1	O
receptors	O
in	O
the	O
living	O
human	B
brain	O
[	O
45	O
]	O
.	O

This	O
finding	O
suggests	O
that	O
sigma-1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
in	O
the	O
human	B
brain	O
[	O
45	O
]	O
.	O

Taken	O
together	O
,	O
the	O
past	O
and	O
present	O
findings	O
suggest	O
that	O
,	O
unlike	O
paroxetine	O
and	O
sertraline	O
,	O
the	O
SSRI	O
fluvoxamine	O
,	O
with	O
its	O
sigma-1	O
receptor	O
agonistic	O
activity	O
,	O
might	O
be	O
a	O
unique	O
therapeutic	O
drug	O
for	O
neuropsychiatric	O
diseases	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
results	O
suggest	O
that	O
,	O
as	O
a	O
sigma-1	O
receptor	O
agonist	O
,	O
fluvoxamine	O
could	O
potentiate	O
the	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
likely	O
that	O
interaction	O
with	O
IP3	O
receptors	O
and	O
several	O
subsequent	O
signaling	O
molecules	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
pharmacological	O
action	O
of	O
sigma-1	O
receptor	O
agonists	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
sigma-1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
DHEA	O
-	O
sulfate	O
,	O
which	O
are	O
available	O
around	O
the	O
world	O
,	O
would	O
be	O
unique	O
therapeutic	O
drugs	O
for	O
neuropsychiatric	O
diseases	O
.	O

A	O
Novel	O
Role	O
of	O
the	O
NRF2	O
Transcription	O
Factor	O
in	O
the	O
Regulation	O
of	O
Arsenite	O
-	O
Mediated	O
Keratin	O
16	O
Gene	O
Expression	O
in	O
Human	B
Keratinocytes	O
Abstract	O
Background	O
Inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
skin	O
hyperkeratosis	O
and	O
cancer	O
.	O

Objectives	O
We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
the	O
keratin	O
16	O
(	O
K16	O
)	O
gene	O
by	O
iAs	O
in	O
the	O
human	B
keratinocyte	O
cell	O
line	O
HaCaT.	O
Methods	O
We	O
performed	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
,	O
luciferase	O
assays	O
,	O
Western	O
blots	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
to	O
determine	O
the	O
transcriptional	O
regulation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
.	O

We	O
used	O
gene	O
overexpression	O
approaches	O
to	O
elucidate	O
the	O
nuclear	O
factor	O
erythroid	O
-	O
derived	O
2	O
related	O
factor	O
2	O
(	O
NRF2	O
)	O
involved	O
in	O
the	O
K16	O
induction	O
.	O

Results	O
iAs	O
induced	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
K16	O
.	O

We	O
also	O
found	O
that	O
the	O
expression	O
of	O
K16	O
was	O
transcriptionally	O
induced	O
by	O
iAs	O
through	O
activator	O
protein-1–like	O
sites	O
and	O
an	O
antioxidant	O
response	O
element	O
(	O
ARE	O
)	O
in	O
its	O
gene	O
promoter	O
region	O
.	O

Treatment	O
with	O
iAs	O
also	O
enhanced	O
the	O
production	O
and	O
translocation	O
of	O
the	O
NRF2	O
transcription	O
factor	O
,	O
an	O
ARE	O
-	O
binding	O
protein	O
,	O
into	O
the	O
nucleus	O
without	O
modification	O
of	O
its	O
mRNA	O
expression	O
.	O

In	O
addition	O
,	O
iAs	O
elongated	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
.	O

When	O
overexpressed	O
in	O
HaCaT	O
cells	O
,	O
NRF2	O
was	O
also	O
directly	O
involved	O
in	O
not	O
only	O
the	O
up	O
-	O
regulation	O
of	O
the	O
detoxification	O
gene	O
thioredoxin	O
but	O
also	O
K16	O
gene	O
expression	O
.	O

Conclusions	O
Our	O
data	O
clearly	O
indicate	O
that	O
the	O
K16	O
gene	O
is	O
a	O
novel	O
target	O
of	O
NRF2	O
.	O

Furthermore	O
,	O
our	O
findings	O
also	O
suggest	O
that	O
NRF2	O
has	O
opposing	O
roles	O
in	O
the	O
cell	O
—	O
in	O
the	O
activation	O
of	O
detoxification	O
pathways	O
and	O
in	O
promoting	O
the	O
development	O
of	O
skin	O
disorders	O
.	O

Inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
)	O
,	O
a	O
ubiquitous	O
element	O
,	O
is	O
one	O
of	O
the	O
most	O
toxic	O
metals	O
present	O
in	O
the	O
natural	O
environment	O
(	O
Bagla	O
and	O
Kaiser	O
1996	O
)	O
.	O

Arsenicals	O
are	O
found	O
as	O
naturally	O
occurring	O
constituents	O
of	O
soil	O
,	O
food	O
,	O
and	O
drinking	O
water	O
(	O
Wu	O
et	O
al.	O
1989	O
;	O
Yoshida	O
et	O
al.	O
2004	O
)	O
,	O
and	O
exposure	O
to	O
iAs	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
disease	O
outcomes	O
,	O
including	O
disorders	O
of	O
the	O
skin	O
,	O
urinary	O
bladder	O
,	O
liver	O
,	O
and	O
lung	O
(	O
Tchounwou	O
et	O
al.	O
2004	O
)	O
.	O

In	O
particular	O
,	O
skin	O
hyperkeratosis	O
is	O
a	O
characteristic	O
dermatologic	O
lesion	O
associated	O
with	O
ingestion	O
of	O
arsenic	O
from	O
contaminated	O
groundwater	O
(	O
McLellan	O
2002	O
;	O
Yoshida	O
et	O
al.	O
2004	O
)	O
.	O

There	O
is	O
also	O
a	O
significant	O
association	O
between	O
hyperkeratosis	O
,	O
nonmelanoma	O
skin	O
cancer	O
(	O
e.g.	O
,	O
basal	O
cell	O
carcinoma	O
and	O
squamous	O
cell	O
carcinoma	O
)	O
,	O
and	O
Bowen	O
disease	O
(	O
Col	O
et	O
al.	O
1999	O
;	O
Rossman	O
et	O
al.	O
2004	O
)	O
.	O

Furthermore	O
,	O
the	O
pathologic	O
features	O
associated	O
with	O
arsenic	O
-	O
induced	O
hyperkeratosis	O
present	O
as	O
typical	O
acanthotic	O
types	O
of	O
psoriasis	O
-	O
like	O
keratosis	O
,	O
characterized	O
by	O
the	O
aberrant	O
proliferation	O
and	O
terminal	O
differentiation	O
of	O
epidermal	O
keratinocytes	O
(	O
Lee	O
et	O
al.	O
2006	O
)	O
.	O

Many	O
epidemiologic	O
studies	O
have	O
shown	O
that	O
hyperkeratoses	O
are	O
the	O
most	O
frequent	O
precursor	O
lesions	O
of	O
some	O
skin	O
cancers	O
(	O
Bagla	O
and	O
Kaiser	O
1996	O
;	O
Col	O
et	O
al.	O
1999	O
)	O
.	O

The	O
keratins	O
are	O
the	O
most	O
prominent	O
cytoskeletal	O
proteins	O
in	O
keratinocytes	O
and	O
comprise	O
a	O
large	O
family	O
of	O
proteins	O
that	O
form	O
intermediate	O
filament	O
networks	O
in	O
all	O
epithelial	O
cell	O
types	O
(	O
Moll	O
et	O
al.	O
1982	O
)	O
.	O

Keratin	O
16	O
(	O
K16	O
)	O
and	O
keratin	O
6	O
(	O
K6	O
)	O
genes	O
are	O
constitutively	O
expressed	O
in	O
a	O
number	O
of	O
stratified	O
epithelial	O
levels	O
,	O
including	O
the	O
palmar	O
and	O
plantar	O
epidermis	O
(	O
Moll	O
et	O
al.	O
1982	O
)	O
.	O

In	O
skin	O
diseases	O
characterized	O
by	O
aberrant	O
proliferation	O
and	O
differentiation	O
,	O
such	O
as	O
psoriasis	O
and	O
cancer	O
,	O
K16	O
is	O
detectable	O
at	O
higher	O
levels	O
compared	O
with	O
normal	O
tissue	O
(	O
Haider	O
et	O
al.	O
2006	O
)	O
.	O

Furthermore	O
,	O
the	O
tissue	O
-	O
specific	O
overexpression	O
of	O
wild	O
-	O
type	O
K16	O
in	O
the	O
epidermis	O
of	O
transgenic	O
mice	B
results	O
in	O
the	O
hyperproliferation	O
of	O
keratinocytes	O
and	O
aberrant	O
keratinization	O
of	O
cornified	O
layers	O
,	O
leading	O
to	O
hyperkeratosis	O
of	O
the	O
skin	O
(	O
Takahashi	O
et	O
al.	O
1994	O
)	O
.	O

Nuclear	O
factor	O
erythoid	O
-	O
derived	O
2	O
related	O
factor	O
2	O
(	O
NRF2	O
)	O
,	O
a	O
""""	O
cap	O
'	O
n	O
'	O
collar	O
""""	O
basic	O
leucine	O
zipper	O
transcription	O
factor	O
,	O
regulates	O
a	O
transcriptional	O
program	O
that	O
maintains	O
cellular	O
redox	O
homeostasis	O
and	O
protects	O
cells	O
from	O
oxidative	O
stress	O
and	O
xenobiotic	O
agents	O
(	O
Ishii	O
et	O
al.	O
2000	O
;	O
Moi	O
et	O
al.	O
1994	O
)	O
.	O

Several	O
detoxifying	O
and	O
antioxidant	O
genes	O
,	O
including	O
glutathione	O
-	O
S	O
-	O
transferases	O
(	O
GSTs	O
)	O
,	O
heme	O
oxygenase-1	O
(	O
HMOX1	O
)	O
,	O
and	O
thioredoxin	O
(	O
TXN	O
)	O
,	O
are	O
regulated	O
by	O
NRF2	O
through	O
the	O
antioxidant	O
responsive	O
element	O
(	O
ARE	O
)	O
in	O
the	O
respective	O
promoter	O
regions	O
of	O
these	O
genes	O
(	O
McMahon	O
et	O
al.	O
2001	O
;	O
Wakabayashi	O
et	O
al.	O
2004	O
)	O
.	O

NRF2	O
is	O
held	O
in	O
the	O
cytoplasm	O
by	O
a	O
cytoskeletal	O
-	O
associated	O
specific	O
inhibitory	O
protein	O
(	O
kelch	O
-	O
like	O
ECH	O
-	O
associated	O
protein	O
1	O
;	O
KEAP1	O
)	O
under	O
normal	O
cellular	O
redox	O
state	O
conditions	O
,	O
where	O
it	O
is	O
continuously	O
targeted	O
by	O
the	O
proteasomal	O
degradation	O
pathway	O
(	O
McMahon	O
et	O
al.	O
2003	O
)	O
.	O

Upon	O
exposure	O
of	O
the	O
cell	O
to	O
oxidative	O
stress	O
or	O
electrophiles	O
,	O
NRF2	O
can	O
escape	O
this	O
KEAP1-mediated	O
repression	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
activate	O
the	O
expression	O
of	O
its	O
target	O
genes	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al.	O
2002	O
;	O
McMahon	O
et	O
al.	O
2003	O
)	O
.	O

Recently	O
,	O
studies	O
of	O
Keap1–	O
/	O
–mice	O
have	O
shown	O
that	O
NRF2	O
accumulates	O
in	O
the	O
nucleus	O
and	O
constitutively	O
activates	O
the	O
transcription	O
of	O
its	O
target	O
genes	O
,	O
even	O
in	O
the	O
absence	O
of	O
stress	O
signals	O
(	O
Wakabayashi	O
et	O
al.	O
2003	O
)	O
.	O

Most	O
interestingly	O
,	O
however	O
,	O
the	O
skin	O
,	O
esophagus	O
,	O
and	O
forestomach	O
of	O
Keap1-deficient	O
mice	B
show	O
cornified	O
layer	O
and	O
hyperkeratosis	O
phenotypes	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
have	O
also	O
shown	O
that	O
the	O
expression	O
of	O
NRF2	O
and	O
ARE	O
-	O
controlled	O
genes	O
is	O
induced	O
by	O
iAs	O
in	O
some	O
cell	O
types	O
(	O
Pi	O
et	O
al.	O
2003	O
;	O
Sakurai	O
et	O
al.	O
2005	O
)	O
.	O

Furthermore	O
,	O
histochemical	O
analyses	O
have	O
indicated	O
that	O
the	O
expression	O
of	O
K16	O
is	O
increased	O
in	O
Bowen	O
disease	O
,	O
basal	O
cell	O
carcinoma	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
induced	O
by	O
arsenicals	O
(	O
Yu	O
et	O
al.	O
1993	O
)	O
.	O

However	O
,	O
it	O
remains	O
to	O
be	O
determined	O
whether	O
NRF2	O
can	O
regulate	O
the	O
transcriptional	O
activation	O
of	O
K16	O
upon	O
iAs	O
exposure	O
in	O
human	B
keratinocytes	O
.	O

Hence	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
-	O
induced	O
NRF2	O
mediation	O
.	O

Materials	O
and	O
Methods	O
Chemicals	O
and	O
reagents	O
A	O
purified	O
preparation	O
of	O
inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
;	O
NaAsO2	O
;	O
Merck	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
was	O
dissolved	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
and	O
added	O
directly	O
to	O
the	O
culture	O
medium	O
.	O

A	O
fresh	O
iAs	O
solution	O
was	O
prepared	O
for	O
each	O
new	O
experiment	O
.	O

Cycloheximide	O
(	O
CHX	O
)	O
,	O
dimethyl	O
-	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
and	O
a	O
protease	O
inhibitor	O
cocktail	O
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

CHX	O
was	O
dissolved	O
in	O
DMSO	O
and	O
stored	O
–20	O
°	O
C	O
until	O
use	O
.	O

Cells	O
and	O
culture	O
conditions	O
The	O
human	B
keratinocyte	O
HaCaT	O
cell	O
line	O
was	O
obtained	O
from	O
N.E.	O
Fusenig	O
(	O
German	O
Cancer	O
Research	O
Center	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

Cells	O
were	O
maintained	O
in	O
monolayer	O
cultures	O
in	O
95	O
%	O
air	O
and	O
5	O
%	O
CO2	O
at	O
37	O
°	O
C	O
in	O
Dulbecco	O
's	O
modified	O
Eagles	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
50	O
U	O
/	O
mL	O
penicillin	O
and	O
50	O
mg	O
/	O
mL	O
streptomycin	O
and	O
nonessential	O
amino	O
acids	O
(	O
Gibco	O
BRL	O
,	O
Paisley	O
,	O
UK	O
)	O
.	O

RNA	O
preparation	O
and	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
We	O
determined	O
RNA	O
expression	O
levels	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
analysis	O
as	O
described	O
previously	O
(	O
Sugioka	O
et	O
al.	O
2004	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
HaCaT	O
cells	O
using	O
the	O
GeneElute	O
Mammalian	O
Total	O
RNA	O
Kit	O
(	O
Sigma	O
)	O
.	O

The	O
specific	O
primers	O
used	O
for	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
and	O
PCR	O
were	O
as	O
follows	O
:	O
K16	O
[	O
forward	O
,	O
5′-GAT	O
GCT	O
TGC	O
TCT	O
GAG	O
AGG	O
TC-3′	O
,	O
and	O
reverse	O
,	O
5′-CCA	O
GCA	O
AGA	O
TCT	O
GGT	O
ACT	O
CC-3′	O
;	O
Gene	O
Bank	O
accession	O
no.	O
NM_005557	O
(	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
2007	O
)	O
]	O
;	O
c	O
-	O
Jun	O
(	O
forward	O
,	O
5′-CCT	O
GTT	O
GCG	O
GCC	O
CCG	O
AAA	O
CT-3′	O
,	O
and	O
reverse	O
,	O
5′-ACC	O
ATG	O
CCT	O
GCC	O
CCG	O
TTG	O
AC-3′	O
;	O
NM_002228	O
)	O
;	O
c	O
-	O
Fos	O
(	O
forward	O
,	O
5′-TTT	O
GCC	O
TAA	O
CCG	O
CCA	O
CGA	O
TGA	O
T-3′	O
,	O
and	O
reverse	O
,	O
5′-TTG	O
CCG	O
CTT	O
TCT	O
GCC	O
ACC	O
TC-3′	O
;	O
NM_005252	O
)	O
;	O
NRF2	O
(	O
forward	O
,	O
5′-AGA	O
TTC	O
ACA	O
GGC	O
CTT	O
TCT	O
CG-3′	O
,	O
and	O
reverse	O
,	O
5′-CAG	O
CTC	O
TCC	O
CTA	O
CCG	O
TTG	O
GA-3′	O
;	O
AF323119	O
)	O
;	O
KEAP1	O
(	O
forward	O
,	O
5′-CAG	O
AGG	O
TGG	O
TGG	O
TGT	O
TGC	O
TTA	O
T-3′	O
,	O
and	O
reverse	O
,	O
5′-AGC	O
TCG	O
TTC	O
ATG	O
ATG	O
CCA	O
AAG-3′	O
;	O
NM_012289	O
)	O
;	O
TXN	O
(	O
forward	O
,	O
5′-CAG	O
GGG	O
AAT	O
GAA	O
AGA	O
AAG	O
G-3′	O
,	O
and	O
reverse	O
,	O
5′-CAA	O
GGT	O
GAA	O
GCA	O
GAT	O
CG-3′	O
;	O
NM_003329	O
)	O
,	O
and	O
glyceraldehyde	O
3-phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
as	O
a	O
loading	O
control	O
(	O
forward	O
,	O
5′-ACC	O
ACA	O
GTC	O
CAT	O
GCC	O
ATC	O
AC-3′	O
,	O
and	O
reverse	O
,	O
5′-TCC	O
ACC	O
ACC	O
CTG	O
TTG	O
CTG	O
TA-3′	O
,	O
NM_002046	O
)	O
.	O

PCR	O
products	O
were	O
separated	O
on	O
a	O
1.8	O
%	O
agarose	O
gel	O
and	O
stained	O
with	O
ethidium	O
bromide	O
.	O

Western	O
blot	O
analysis	O
We	O
performed	O
Western	O
blot	O
analysis	O
as	O
described	O
previously	O
(	O
Sugioka	O
et	O
al.	O
2004	O
)	O
.	O

Briefly	O
,	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
were	O
extracted	O
using	O
the	O
NE	O
-	O
PER	O
nuclear	O
and	O
cytoplasmic	O
extraction	O
kit	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

For	O
protein	O
extraction	O
,	O
the	O
cells	O
were	O
lysed	O
in	O
a	O
buffer	O
containing	O
complete	O
protease	O
inhibitor	O
cocktail	O
.	O

We	O
measured	O
protein	O
concentrations	O
using	O
the	O
DC	O
Protein	O
Assay	O
Kit	O
(	O
Bio	O
-	O
Rad	O
,	O
Richmond	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Equal	O
amounts	O
of	O
protein	O
were	O
then	O
resolved	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
transferred	O
to	O
a	O
polyvinylidene	O
fluoride	O
membrane	O
(	O
Amersham	O
Biosciences	O
,	O
Bucks	O
,	O
UK	O
)	O
.	O

Immunoblotting	O
was	O
carried	O
out	O
with	O
specific	O
antibodies	O
in	O
Tris	O
-	O
buffered	O
saline	O
with	O
0.05	O
%	O
Tween	O
20	O
.	O

The	O
primary	O
antibodies	O
were	O
as	O
follows	O
:	O
K16	O
(	O
Neomarkers	O
,	O
Fremont	O
,	O
CA	O
,	O
USA	O
)	O
,	O
NRF2	O
and	O
KEAP1	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
,	O
c	O
-	O
Jun	O
(	O
Cell	O
Signaling	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
,	O
and	O
β	O
-	O
actin	O
(	O
Sigma	O
)	O
.	O

After	O
washing	O
,	O
the	O
membranes	O
were	O
probed	O
with	O
horseradish	B
peroxidase	O
-	O
conjugated	O
secondary	O
antibodies	O
and	O
developed	O
by	O
chemiluminescence	O
using	O
the	O
ECL	O
Plus	O
Detection	O
Kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Plasmids	O
,	O
transfections	O
,	O
and	O
luciferase	O
assays	O
Human	B
K16	O
promoter	O
regions	O
of	O
varying	O
lengths	O
(	O
pXK-1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
1	O
,	O
and	O
5	O
-	O
2	O
)	O
were	O
provided	O
by	O
Y	O
-	O
N	O
Wang	O
(	O
National	O
Cheng	O
Kung	O
University	O
,	O
Taiwan	O
)	O
.	O

These	O
DNA	O
fragments	O
were	O
prepared	O
from	O
HaCaT	O
cells	O
and	O
were	O
ligated	O
into	O
the	O
pXP-1	O
luciferase	O
vector	O
(	O
Wang	O
and	O
Chang	O
2003	O
)	O
.	O

The	O
p3xARE	O
/	O
Luc	O
vector	O
,	O
harboring	O
three	O
tandem	O
repeats	O
of	O
ARE	O
,	O
was	O
donated	O
by	O
X.L.	O
Chen	O
(	O
Discovery	O
Research	O
,	O
AtheroGenics	O
Inc.	O
,	O
Alpharetta	O
,	O
GA	O
,	O
USA	O
)	O
(	O
Chen	O
et	O
al.	O
2003	O
)	O
.	O

The	O
wild	O
-	O
type	O
NRF2	O
expression	O
vector	O
(	O
WT	O
-	O
NRF2	O
)	O
was	O
a	O
gift	O
from	O
H.S.	O

So	O
(	O
Wonkwang	O
University	O
School	O
of	O
Medicine	O
,	O
Korea	O
)	O
(	O
So	O
et	O
al.	O
2006	O
)	O
.	O

NRF2	O
cDNA	O
was	O
subcloned	O
into	O
a	O
pcDNA3.1	O
(	O
+	O
)	O
vector	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
the	O
transfection	O
of	O
reporter	O
plasmids	O
,	O
we	O
seeded	O
HaCaT	O
cells	O
into	O
six	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
80	O
%	O
the	O
previous	O
day	O
.	O

Cells	O
were	O
then	O
transfected	O
with	O
a	O
total	O
of	O
each	O
luciferase	O
reporter	O
construct	O
(	O
2.5	O
μg	O
)	O
using	O
LipofectAMINE	O
plus	O
(	O
Invitrogen	O
)	O
.	O

To	O
control	O
for	O
the	O
efficiency	O
of	O
transfection	O
,	O
Renilla	O
luciferase	O
gene	O
expression	O
was	O
monitored	O
using	O
either	O
the	O
pRL	O
-	O
CMV	O
or	O
pRL	O
-	O
TK	O
vectors	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

For	O
overexpression	O
of	O
WT	O
-	O
NRF2	O
,	O
we	O
normalized	O
the	O
total	O
plasmid	O
concentration	O
using	O
the	O
pcDNA3.1	O
(	O
+	O
)	O
empty	O
vector	O
.	O

Thirty	O
-	O
six	O
hours	O
after	O
transfection	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
fresh	O
medium	O
containing	O
either	O
vehicle	O
(	O
PBS	O
)	O
or	O
iAs	O
for	O
6	O
hr	O
.	O

After	O
iAs	O
exposure	O
,	O
we	O
harvested	O
cells	O
and	O
analyzed	O
them	O
for	O
luciferase	O
activity	O
using	O
a	O
Dual	O
-	O
Luciferase	O
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
.	O

For	O
the	O
investigation	O
of	O
the	O
role	O
of	O
NRF2	O
in	O
regulating	O
K16	O
gene	O
expression	O
,	O
transfection	O
of	O
an	O
NRF2	O
expression	O
plasmid	O
into	O
HaCaT	O
cells	O
was	O
carried	O
out	O
using	O
LipofectAMINE	O
2000	O
(	O
Invitrogen	O
)	O
.	O

Cells	O
were	O
cultured	O
in	O
100-mm	O
plates	O
24	O
hr	O
before	O
transfection	O
.	O

The	O
expression	O
plasmid	O
WT	O
-	O
NRF2	O
(	O
15	O
μg	O
)	O
was	O
then	O
transfected	O
into	O
the	O
cells	O
for	O
48–60	O
hr	O
.	O

As	O
a	O
negative	O
control	O
,	O
we	O
used	O
15	O
μg	O
of	O
the	O
pcDNA3.1	O
(	O
+	O
)	O
empty	O
vector	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
(	O
EMSA	O
)	O
We	O
extracted	O
and	O
measured	O
nuclear	O
proteins	O
as	O
described	O
above	O
.	O

Nuclear	O
protein	O
/	O
DNA	O
complexes	O
were	O
subjected	O
to	O
electrophoresis	O
in	O
nondenaturing	O
5	O
%	O
polyacrylamide	O
gels	O
containing	O
2	O
%	O
glycerol	O
in	O
0.25	O
%	O
Tris	O
-	O
borate	O
/	O
EDTA	O
buffer	O
and	O
transferred	O
to	O
Hybond	O
-	O
N+	O
nylon	O
transfer	O
membranes	O
(	O
Amersham	O
Biosciences	O
)	O
for	O
detection	O
using	O
the	O
Light	O
-	O
Shift	O
EMSA	O
kit	O
(	O
Pierce	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
,	O
with	O
minor	O
modifications	O
.	O

We	O
incubated	O
10-μg	O
aliquots	O
of	O
nuclear	O
extract	O
with	O
the	O
DNA	O
probe	O
in	O
a	O
binding	O
reaction	O
buffer	O
containing	O
10	O
mM	O
Tris	O
/	O
HCl	O
(	O
pH	O
7.6	O
)	O
,	O
50	O
mM	O
KCl	O
,	O
0.5	O
mM	O
dithiothreitol	O
,	O
0.25	O
mM	O
EDTA	O
,	O
5	O
%	O
glycerol	O
,	O
2.5	O
mM	O
MgCl2	O
,	O
0.05	O
%	O
NP-40	O
detergent	O
,	O
and	O
2	O
μg	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
·poly	O
(	O
dI	O
-	O
dC	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

For	O
supershift	O
assays	O
,	O
2	O
μg	O
of	O
either	O
a	O
polyclonal	O
anti	O
-	O
NRF2	O
or	O
an	O
anti	O
-	O
c	O
-	O
Jun	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
was	O
added	O
with	O
the	O
nuclear	O
protein	O
for	O
2	O
hr	O
at	O
4	O
°	O
C	O
before	O
the	O
labeled	O
oligonucleotide	O
probe	O
was	O
added	O
.	O

Biotin	O
-	O
labeled	O
,	O
double	O
-	O
stranded	O
oligonucleotides	O
WT	O
-	O
K16ARE	O
(	O
–157	O
/	O
–132	O
,	O
5′-GGGGAACCTGGAGTCAGCAGT	O
-	O
TAGGA-3′	O
)	O
,	O
containing	O
an	O
ARE	O
site	O
(	O
–148	O
/	O
–140	O
,	O
underlined	O
)	O
in	O
the	O
human	B
K16	O
promoter	O
region	O
,	O
and	O
Mut	O
-	O
K16ARE	O
(	O
5′-GGGGAA	O
-	O
CCTGGAGTCAaaAGTTAGGA-3′	O
,	O
mutated	O
GC	O
box	O
in	O
the	O
ARE	O
)	O
were	O
prepared	O
by	O
Fasmac	O
(	O
Kanagawa	O
,	O
Japan	O
)	O
.	O

A	O
consensus	O
ARE	O
probe	O
was	O
purchased	O
from	O
Panomics	O
,	O
Inc.	O
(	O
Redwood	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
competition	O
binding	O
of	O
the	O
K16	O
ARE	O
-	O
complexes	O
,	O
we	O
used	O
an	O
unlabeled	O
AP-1	O
consensus	O
oligonucleotide	O
(	O
5′-TATC	O
-	O
GATAAGCTATGAGTCATCCGGG-3′	O
)	O
.	O

The	O
binding	O
specificity	O
was	O
confirmed	O
in	O
each	O
case	O
by	O
the	O
addition	O
of	O
a	O
100-fold	O
molar	O
excess	O
of	O
unlabeled	O
oligonucleotide	O
.	O

CHX	O
chase	O
experiment	O
We	O
investigated	O
the	O
posttranscriptional	O
regulation	O
of	O
both	O
the	O
steady	O
-	O
state	O
levels	O
and	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
by	O
CHX	O
chase	O
analysis	O
.	O

Cells	O
were	O
incubated	O
in	O
serum	O
-	O
free	O
medium	O
in	O
the	O
absence	O
or	O
presence	O
of	O
iAs	O
for	O
6	O
hr	O
.	O

The	O
culture	O
medium	O
was	O
then	O
replaced	O
with	O
serum	O
-	O
free	O
medium	O
containing	O
CHX	O
(	O
100	O
μg	O
/	O
mL	O
)	O
.	O

We	O
prepared	O
cell	O
lysates	O
at	O
0	O
,	O
10	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
240	O
min	O
after	O
iAs	O
treatment	O
.	O

Whole	O
-	O
cell	O
lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotted	O
with	O
antibodies	O
against	O
NRF2	O
.	O

Statistics	O
All	O
the	O
data	O
generated	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
and	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
were	O
analyzed	O
by	O
the	O
Student	O
's	O
t	O
-	O
test	O
.	O

Statistical	O
comparisons	O
were	O
made	O
by	O
logarithmic	O
transformation	O
of	O
the	O
normalized	O
values	O
.	O

We	O
considered	O
p	O
-	O
values	O
<	O
0.01	O
to	O
be	O
statistically	O
significant	O
.	O

Results	O
K16	O
expression	O
is	O
induced	O
by	O
iAs	O
in	O
HaCaT	O
cells	O
We	O
wanted	O
to	O
determine	O
whether	O
the	O
K16	O
mRNA	O
is	O
transcriptionally	O
regulated	O
by	O
iAs	O
,	O
and	O
treated	O
HaCaT	O
cells	O
with	O
this	O
compound	O
for	O
various	O
time	O
periods	O
over	O
a	O
range	O
of	O
doses	O
.	O

After	O
treatment	O
of	O
HaCaT	O
cells	O
with	O
1–20	O
μM	O
iAs	O
,	O
the	O
expression	O
of	O
K16	O
mRNA	O
was	O
increased	O
compared	O
with	O
the	O
control	O
at	O
6	O
hr	O
(	O
Figure	O
1A	O
)	O
but	O
had	O
declined	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

The	O
increase	O
in	O
the	O
K16	O
protein	O
levels	O
after	O
6	O
hr	O
of	O
iAs	O
exposure	O
was	O
just	O
detectable	O
at	O
10–20	O
μM	O
,	O
but	O
a	O
dose	O
-	O
dependent	O
increase	O
was	O
more	O
evident	O
at	O
10	O
hr	O
(	O
Figure	O
1B	O
)	O
.	O

This	O
enhancement	O
of	O
K16	O
expression	O
had	O
declined	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

Identification	O
of	O
the	O
iAs	O
responsive	O
region	O
in	O
the	O
K16	O
gene	O
promoter	O
To	O
investigate	O
the	O
mechanisms	O
underlying	O
the	O
transactivation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
,	O
we	O
first	O
examined	O
the	O
response	O
of	O
the	O
K16	O
regulatory	O
region	O
to	O
this	O
compound	O
using	O
a	O
luciferase	O
reporter	O
gene	O
assay	O
.	O

The	O
dose	O
-	O
dependent	O
activation	O
of	O
K16	O
transcription	O
after	O
iAs	O
treatment	O
was	O
observed	O
with	O
a	O
construct	O
containing	O
a	O
515-bp	O
fragment	O
of	O
the	O
K16	O
promoter	O
(	O
Figure	O
2A	O
)	O
.	O

To	O
further	O
elucidate	O
the	O
region	O
containing	O
the	O
iAs	O
responsive	O
element	O
,	O
we	O
examined	O
a	O
series	O
of	O
deletions	O
of	O
the	O
5′-flanking	O
region	O
of	O
K16	O
gene	O
.	O

The	O
ARE	O
sequence	O
in	O
the	O
pXK-5–1	O
vector	O
contains	O
an	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
–like	O
element	O
followed	O
by	O
a	O
GC	O
box	O
.	O

As	O
shown	O
in	O
Figure	O
2B	O
,	O
an	O
enhancement	O
in	O
the	O
reporter	O
activity	O
levels	O
was	O
observed	O
for	O
the	O
promoter	O
constructs	O
,	O
pXK-1	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
-	O
1	O
,	O
in	O
response	O
to	O
20	O
μM	O
iAs	O
.	O

A	O
decline	O
in	O
reporter	O
activity	O
,	O
however	O
,	O
depended	O
on	O
the	O
number	O
of	O
AP-1–like	O
sites	O
,	O
and	O
the	O
results	O
for	O
the	O
pXK-5	O
-	O
1	O
construct	O
show	O
also	O
that	O
ARE	O
is	O
activated	O
by	O
iAs	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
activation	O
was	O
observed	O
using	O
a	O
pXK-5	O
-	O
2	O
construct	O
in	O
response	O
to	O
20	O
μM	O
iAs	O
.	O

Expression	O
of	O
AP-1	O
transcriptions	O
factor	O
and	O
c	O
-	O
Jun	O
production	O
following	O
iAs	O
treatment	O
We	O
examined	O
AP-1	O
transcription	O
factors	O
c	O
-	O
Jun	O
and	O
c	O
-	O
Fos	O
expression	O
in	O
iAs	O
-	O
treated	O
HaCaT	O
cells	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

iAs	O
-	O
induced	O
c	O
-	O
Jun	O
expression	O
was	O
observed	O
during	O
the	O
first	O
3	O
hr	O
after	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

An	O
appreciable	O
induction	O
of	O
c	O
-	O
Jun	O
was	O
also	O
confirmed	O
after	O
6	O
hr	O
,	O
but	O
this	O
was	O
down	O
-	O
regulated	O
by	O
24	O
hr	O
after	O
iAs	O
treatment	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
c	O
-	O
Fos	O
was	O
only	O
transiently	O
detectable	O
at	O
3	O
hr	O
(	O
data	O
not	O
shown	O
)	O
but	O
was	O
not	O
observed	O
during	O
the	O
6–24	O
hr	O
period	O
of	O
this	O
experiment	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
iAs	O
-	O
enhanced	O
c	O
-	O
Jun	O
production	O
can	O
be	O
observed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
at	O
6	O
hr	O
,	O
but	O
it	O
declines	O
from	O
10	O
to	O
24	O
hr	O
.	O

iAs	O
potently	O
induces	O
the	O
translocation	O
of	O
NRF2	O
and	O
activates	O
the	O
ARE	O
of	O
the	O
K16	O
promoter	O
The	O
results	O
of	O
our	O
reporter	O
assays	O
suggested	O
that	O
iAs	O
stimulates	O
not	O
only	O
the	O
AP-1–like	O
sites	O
but	O
also	O
the	O
ARE	O
site	O
within	O
the	O
K16	O
gene	O
promoter	O
in	O
HaCaT	O
cells	O
(	O
Figure	O
3	O
)	O
.	O

In	O
addition	O
,	O
several	O
oxidative	O
stress	O
agents	O
and	O
toxic	O
chemicals	O
,	O
including	O
iAs	O
,	O
have	O
been	O
reported	O
to	O
induce	O
the	O
expression	O
of	O
ARE	O
-	O
dependent	O
genes	O
in	O
several	O
cell	O
types	O
(	O
Pi	O
et	O
al.	O
2003	O
;	O
Sakurai	O
et	O
al.	O
2005	O
)	O
.	O

On	O
the	O
basis	O
of	O
our	O
observations	O
and	O
some	O
recent	O
reports	O
,	O
we	O
thus	O
hypothesized	O
that	O
iAs	O
would	O
have	O
the	O
ability	O
to	O
activate	O
the	O
ARE	O
of	O
the	O
K16	O
gene	O
promoter	O
directly	O
,	O
resulting	O
in	O
the	O
induction	O
of	O
K16	O
expression	O
in	O
HaCaT	O
cells	O
.	O

To	O
confirm	O
that	O
the	O
K16	O
ARE	O
indeed	O
functions	O
as	O
an	O
iAs	O
-	O
responsive	O
transcriptional	O
control	O
element	O
,	O
we	O
performed	O
transient	O
transfections	O
of	O
HaCaT	O
cells	O
with	O
a	O
p3xARE	O
/	O
Luc	O
construct	O
and	O
then	O
subjected	O
these	O
cells	O
to	O
iAs	O
for	O
6	O
hr	O
.	O

As	O
shown	O
in	O
Figure	O
4A	O
,	O
treatment	O
of	O
HaCaT	O
cells	O
with	O
iAs	O
results	O
in	O
a	O
dramatic	O
increase	O
in	O
ARE	O
-	O
driven	O
promoter	O
activity	O
.	O

Likewise	O
,	O
EMSA	O
using	O
a	O
consensus	O
ARE	O
probe	O
show	O
that	O
iAs	O
-	O
induced	O
ARE	O
-	O
binding	O
complexes	O
increase	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
(	O
Figure	O
4B	O
)	O
.	O

These	O
results	O
indicate	O
that	O
iAs	O
has	O
the	O
ability	O
to	O
activate	O
the	O
ARE	O
-	O
driven	O
genes	O
.	O

We	O
performed	O
further	O
EMSA	O
experiments	O
using	O
an	O
ARE	O
probe	O
specific	O
to	O
the	O
K16	O
proximal	O
promoter	O
region	O
(	O
WT	O
-	O
K16ARE	O
)	O
and	O
found	O
that	O
K16ARE	O
–	O
nuclear	O
protein	O
complexes	O
formation	O
is	O
augmented	O
by	O
iAs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
4C	O
)	O
.	O

Moreover	O
,	O
the	O
formation	O
of	O
these	O
complexes	O
is	O
specifically	O
inhibited	O
by	O
the	O
addition	O
of	O
excess	O
unlabeled	O
oligonucleotide	O
competitor	O
(	O
Figure	O
4B	O
,	O
C	O
)	O
,	O
whereas	O
an	O
excess	O
of	O
an	O
unlabeled	O
AP-1	O
probe	O
competes	O
only	O
marginally	O
for	O
K16ARE	O
binding	O
(	O
Figure	O
4C	O
)	O
.	O

The	O
NRF2	O
transcription	O
factor	O
has	O
been	O
shown	O
to	O
bind	O
to	O
AREs	O
upon	O
translocation	O
into	O
the	O
nucleus	O
,	O
resulting	O
in	O
the	O
induction	O
of	O
ARE	O
-	O
mediated	O
genes	O
(	O
Wakabayashi	O
et	O
al.	O
2004	O
)	O
.	O

To	O
examine	O
whether	O
iAs	O
induces	O
and	O
translocates	O
NRF2	O
into	O
the	O
nucleus	O
in	O
HaCaT	O
cells	O
,	O
we	O
treated	O
these	O
cells	O
with	O
iAs	O
for	O
either	O
3	O
or	O
6	O
hr	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
a	O
dose	O
-	O
dependent	O
accumulation	O
of	O
NRF2	O
protein	O
was	O
observed	O
in	O
the	O
nucleus	O
upon	O
treatment	O
with	O
iAs	O
for	O
6	O
hr	O
.	O

This	O
was	O
not	O
observed	O
in	O
the	O
parallel	O
experiment	O
performed	O
over	O
the	O
3-hr	O
time	O
course	O
.	O

Supershift	O
EMSA	O
analysis	O
using	O
an	O
NRF2	O
antibody	O
showed	O
that	O
the	O
iAs	O
-	O
induced	O
and	O
iAs	O
-	O
translocated	O
NRF2	O
protein	O
binds	O
to	O
the	O
WT	O
-	O
K16ARE	O
probe	O
containing	O
the	O
ARE	O
sequence	O
of	O
the	O
K16	O
proximal	O
promoter	O
region	O
(	O
5′-GGAGTCAGC-3′	O
)	O
that	O
comprises	O
an	O
AP-1–like	O
site	O
and	O
a	O
GC	O
box	O
,	O
whereas	O
the	O
supershift	O
of	O
c	O
-	O
Jun	O
was	O
not	O
observed	O
(	O
Figure	O
4E	O
)	O
.	O

To	O
identify	O
whether	O
the	O
GC	O
box	O
is	O
dispensable	O
for	O
the	O
iAs	O
-	O
stimulated	O
binding	O
activity	O
of	O
NRF2	O
,	O
we	O
next	O
performed	O
EMSA	O
analyses	O
with	O
either	O
WT-	O
or	O
a	O
Mut	O
-	O
K16ARE	O
probe	O
containing	O
an	O
intact	O
AP-1–like	O
element	O
but	O
a	O
mutated	O
GC	O
box	O
.	O

As	O
shown	O
in	O
Figure	O
4F	O
,	O
the	O
K16ARE	O
–	O
nuclear	O
protein	O
complexes	O
and	O
supershifted	O
bands	O
that	O
were	O
enhanced	O
by	O
iAs	O
treatment	O
were	O
largely	O
abolished	O
by	O
the	O
addition	O
of	O
the	O
Mut	O
-	O
K16ARE	O
probe	O
.	O

iAs	O
stabilizes	O
the	O
NRF2	O
protein	O
We	O
examined	O
the	O
effects	O
of	O
iAs	O
treatment	O
on	O
the	O
function	O
of	O
KEAP1	O
in	O
HaCaT	O
cells	O
.	O

Treatment	O
with	O
iAs	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
KEAP1	O
mRNA	O
or	O
protein	O
over	O
either	O
a	O
3	O
or	O
6	O
hr	O
time	O
course	O
(	O
Figure	O
5A	O
)	O
.	O

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
iAs	O
on	O
the	O
expression	O
of	O
NRF2	O
mRNA	O
in	O
HaCaT	O
cells	O
.	O

Exposure	O
to	O
iAs	O
did	O
not	O
significantly	O
alter	O
the	O
steady	O
-	O
state	O
levels	O
of	O
NRF2	O
mRNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

Production	O
of	O
NRF2	O
protein	O
,	O
however	O
,	O
was	O
observed	O
to	O
increase	O
in	O
both	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
(	O
Figure	O
4D	O
)	O
.	O

To	O
further	O
examine	O
the	O
stabilization	O
of	O
NRF2	O
protein	O
by	O
iAs	O
,	O
we	O
monitored	O
the	O
decay	O
of	O
basal	O
and	O
iAs	O
-	O
induced	O
NRF2	O
proteins	O
after	O
inhibition	O
of	O
protein	O
synthesis	O
by	O
CHX	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
results	O
of	O
this	O
analysis	O
revealed	O
that	O
the	O
NRF2	O
protein	O
levels	O
decrease	O
by	O
approximately	O
50	O
%	O
within	O
30	O
min	O
of	O
treatment	O
with	O
CHX	O
in	O
cells	O
that	O
had	O
not	O
been	O
exposed	O
to	O
iAs	O
.	O

Only	O
trace	O
amounts	O
of	O
NRF2	O
are	O
then	O
detectable	O
after	O
60	O
min	O
of	O
exposure	O
to	O
CHX	O
in	O
these	O
cells	O
.	O

The	O
HaCaT	O
cells	O
were	O
then	O
pretreated	O
with	O
iAs	O
for	O
6	O
hr	O
before	O
their	O
exposure	O
to	O
CHX	O
in	O
a	O
similar	O
timecourse	O
experiment	O
.	O

The	O
levels	O
of	O
NRF2	O
in	O
these	O
iAs	O
-	O
treated	O
cells	O
were	O
again	O
found	O
to	O
decrease	O
by	O
about	O
50	O
%	O
,	O
but	O
only	O
after	O
120	O
min	O
of	O
CHX	O
exposure	O
.	O

NRF2	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
K16	O
gene	O
expression	O
in	O
HaCaT	O
cells	O
To	O
confirm	O
the	O
functional	O
role	O
of	O
NRF2	O
in	O
the	O
induction	O
of	O
K16	O
gene	O
expression	O
by	O
iAs	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
of	O
K16	O
mRNA	O
is	O
induced	O
by	O
the	O
overexpression	O
of	O
NRF2	O
(	O
WT	O
-	O
NRF2	O
)	O
in	O
HaCaT	O
cells	O
.	O

We	O
also	O
investigated	O
the	O
expression	O
of	O
the	O
detoxification	O
gene	O
TXN	O
,	O
which	O
is	O
highly	O
induced	O
by	O
a	O
variety	O
of	O
oxidative	O
stimuli	O
through	O
NRF2-mediated	O
ARE	O
transactivation	O
(	O
Kim	O
et	O
al.	O
2001	O
)	O
.	O

The	O
expression	O
of	O
TXN	O
gene	O
in	O
untransfected	O
cells	O
after	O
treatment	O
with	O
iAs	O
was	O
stronger	O
than	O
that	O
of	O
the	O
control	O
cells	O
(	O
Figure	O
6A	O
)	O
.	O

When	O
the	O
cells	O
were	O
transfected	O
with	O
WT	O
-	O
NRF2	O
and	O
then	O
treated	O
with	O
or	O
without	O
iAs	O
,	O
the	O
expression	O
of	O
TXN	O
mRNA	O
was	O
augmented	O
markedly	O
compared	O
with	O
the	O
empty	O
-	O
vector	O
control	O
.	O

Similarly	O
,	O
the	O
expression	O
of	O
K16	O
mRNA	O
was	O
also	O
induced	O
in	O
cells	O
transfected	O
with	O
WT	O
-	O
NRF2	O
in	O
the	O
absence	O
or	O
presence	O
of	O
iAs	O
.	O

We	O
next	O
performed	O
a	O
transient	O
transfection	O
of	O
HaCaT	O
cells	O
with	O
the	O
pXK-5–1	O
luciferase	O
vector	O
together	O
with	O
the	O
WT	O
-	O
NRF2	O
vector	O
.	O

The	O
overexpression	O
of	O
NRF2	O
in	O
increasing	O
concentrations	O
resulted	O
in	O
significant	O
enhancement	O
of	O
the	O
ARE	O
-	O
mediated	O
K16	O
promoter	O
activation	O
(	O
Figure	O
6B	O
)	O
.	O

Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
showed	O
for	O
the	O
first	O
time	O
that	O
iAs	O
induces	O
the	O
transcriptional	O
activation	O
of	O
K16	O
in	O
the	O
human	B
keratinocyte	O
cell	O
line	O
,	O
HaCaT	O
,	O
through	O
the	O
ARE	O
present	O
in	O
its	O
gene	O
promoter	O
.	O

It	O
has	O
been	O
reported	O
previously	O
that	O
treatment	O
with	O
iAs	O
enhances	O
the	O
production	O
and	O
translocation	O
of	O
NRF2	O
into	O
the	O
nucleus	O
in	O
several	O
cell	O
types	O
.	O

However	O
,	O
until	O
now	O
it	O
has	O
remained	O
uncertain	O
whether	O
the	O
induction	O
of	O
NRF2	O
by	O
iAs	O
mediates	O
the	O
transcriptional	O
activation	O
of	O
the	O
K16	O
gene	O
in	O
keratinocytes	O
.	O

In	O
our	O
current	O
experiments	O
,	O
we	O
demonstrated	O
that	O
iAs	O
elongates	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
,	O
which	O
results	O
in	O
its	O
increased	O
expression	O
levels	O
.	O

Furthermore	O
,	O
this	O
iAs	O
-	O
induced	O
NRF2	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
the	O
ARE	O
sequences	O
in	O
the	O
promoter	O
region	O
of	O
the	O
K16	O
gene	O
.	O

Finally	O
,	O
by	O
overexpressing	O
NRF2	O
,	O
we	O
have	O
clarified	O
that	O
its	O
induction	O
is	O
involved	O
in	O
not	O
only	O
the	O
gene	O
expression	O
of	O
the	O
detoxification	O
gene	O
TXN	O
,	O
but	O
also	O
in	O
the	O
upregulation	O
of	O
K16	O
expression	O
in	O
HaCaT	O
cells	O
through	O
the	O
ARE	O
in	O
the	O
K16	O
gene	O
promoter	O
.	O

These	O
experiments	O
indicate	O
an	O
important	O
and	O
novel	O
function	O
for	O
NRF2	O
in	O
the	O
regulation	O
of	O
K16	O
in	O
keratinocytes	O
and	O
also	O
help	O
to	O
further	O
explain	O
the	O
molecular	O
mechanisms	O
underlying	O
arsenic	O
-	O
mediated	O
epidermal	O
hyperkeratosis	O
.	O

In	O
our	O
present	O
experiments	O
,	O
the	O
expression	O
levels	O
of	O
K16	O
mRNA	O
and	O
protein	O
were	O
indeed	O
found	O
to	O
be	O
enhanced	O
by	O
iAs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
1	O
)	O
.	O

In	O
addition	O
,	O
luciferase	O
assays	O
of	O
the	O
K16	O
promoter	O
revealed	O
that	O
iAs	O
enhances	O
its	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
which	O
is	O
stimulated	O
by	O
AP-1–like	O
sites	O
and	O
an	O
ARE	O
(	O
Figure	O
2	O
)	O
.	O

The	O
promoter	O
of	O
the	O
human	B
K16	O
gene	O
was	O
recently	O
cloned	O
and	O
sequenced	O
,	O
and	O
several	O
AP-1–like	O
sites	O
were	O
found	O
within	O
the	O
–515-bp	O
region	O
of	O
the	O
gene	O
(	O
Wang	O
and	O
Chang	O
2003	O
)	O
.	O

AP-1	O
transcription	O
factor	O
can	O
be	O
formed	O
by	O
the	O
dimerization	O
of	O
either	O
Jun	O
or	O
Jun	O
/	O
Fos	O
family	O
members	O
(	O
Eferl	O
and	O
Wagner	O
2003	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
increased	O
expression	O
of	O
c	O
-	O
Jun	O
,	O
but	O
not	O
c	O
-	O
Fos	O
was	O
evident	O
in	O
the	O
nuclei	O
of	O
HaCaT	O
cells	O
after	O
iAs	O
treatment	O
(	O
Figure	O
3	O
)	O
.	O

Our	O
findings	O
thus	O
suggest	O
that	O
the	O
activation	O
of	O
c	O
-	O
Jun	O
/	O
AP-1	O
is	O
one	O
of	O
the	O
essential	O
steps	O
in	O
the	O
regulation	O
of	O
K16	O
gene	O
expression	O
by	O
iAs	O
exposure	O
in	O
HaCaT	O
cells	O
.	O

It	O
has	O
been	O
well	O
documented	O
that	O
the	O
ARE	O
core	O
sequence	O
includes	O
an	O
AP-1–like	O
binding	O
site	O
(	O
TGAC	O
/	O
GTCA	O
)	O
,	O
followed	O
by	O
a	O
GC	O
box	O
(	O
Rushmore	O
et	O
al.	O
1991	O
;	O
Xie	O
et	O
al.	O
1995	O
)	O
.	O

We	O
have	O
found	O
in	O
our	O
current	O
analyses	O
that	O
the	O
AP-1–like	O
site	O
within	O
the	O
K16	O
promoter	O
region	O
from	O
–148	O
to	O
–140	O
bp	O
(	O
5′-GGAGTCAGC-3′	O
)	O
resembles	O
a	O
consensus	O
ARE	O
sequence	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
AREs	O
can	O
be	O
specifically	O
bound	O
by	O
complexes	O
of	O
several	O
basic	O
-	O
leucine	O
zipper	O
transcription	O
factors	O
,	O
including	O
NRF2	O
(	O
Ishii	O
et	O
al.	O
2000	O
;	O
Moi	O
et	O
al.	O
1994	O
)	O
.	O

NRF2	O
heterodimerizes	O
with	O
either	O
AP-1	O
or	O
small	O
MAF	O
(	O
MAFG	O
,	O
MAFK	O
,	O
and	O
MAFF	O
)	O
proteins	O
(	O
MAF	O
,	O
v	O
-	O
maf	O
musculoaponeurotic	O
fibrosarcoma	O
oncogene	O
homolog	O
)	O
and	O
binds	O
to	O
the	O
ARE	O
to	O
induce	O
the	O
transcription	O
of	O
ARE	O
-	O
mediated	O
genes	O
(	O
Motohashi	O
et	O
al.	O
2002	O
)	O
.	O

In	O
the	O
present	O
investigation	O
,	O
EMSA	O
and	O
supershift	O
assays	O
showed	O
that	O
the	O
NRF2	O
proteins	O
in	O
the	O
nuclei	O
bind	O
to	O
the	O
ARE	O
sequences	O
of	O
K16	O
promoter	O
region	O
after	O
iAs	O
exposure	O
.	O

iAs	O
-	O
induced	O
c	O
-	O
Jun	O
,	O
however	O
,	O
does	O
not	O
bind	O
to	O
this	O
ARE	O
(	O
Figure	O
4E	O
)	O
.	O

c	O
-	O
Jun	O
may	O
thus	O
act	O
on	O
other	O
AP-1	O
sites	O
within	O
the	O
K16	O
promoter	O
region	O
.	O

These	O
results	O
also	O
suggest	O
that	O
other	O
heterodimer	O
partners	O
of	O
NRF2	O
are	O
involved	O
in	O
the	O
ARE	O
regulation	O
of	O
K16	O
promoter	O
region	O
underlying	O
iAs	O
-	O
mediated	O
the	O
K16	O
gene	O
expression	O
.	O

Gel	O
shifts	O
with	O
an	O
K16Mut	O
-	O
ARE	O
probe	O
(	O
harboring	O
a	O
mutation	O
in	O
the	O
ARE	O
GC	O
box	O
)	O
clearly	O
show	O
that	O
the	O
ARE	O
sequence	O
in	O
the	O
K16	O
promoter	O
,	O
particularly	O
the	O
terminal	O
GC	O
dinucleotide	O
,	O
is	O
essential	O
for	O
mediating	O
iAs	O
-	O
induced	O
K16	O
transactivation	O
and	O
NRF2	O
binding	O
(	O
Figure	O
4F	O
)	O
.	O

Several	O
investigations	O
have	O
suggested	O
that	O
the	O
GC	O
nucleotides	O
within	O
the	O
ARE	O
are	O
essential	O
for	O
both	O
the	O
basal	O
and	O
oxidative	O
stress	O
–	O
induced	O
activities	O
of	O
the	O
ARE	O
-	O
related	O
genes	O
,	O
NAD	O
(	O
P	O
)	O
H	O
dehydrogenase	O
quinone	O
1	O
(	O
NQO1	O
)	O
and	O
glutamate	O
-	O
cysteine	O
ligase	O
catalytic	O
subunit	O
(	O
GCLC	O
)	O
(	O
Wasserman	O
and	O
Fahl	O
1997	O
;	O
Wild	O
et	O
al.	O
1998	O
)	O
.	O

Our	O
current	O
results	O
are	O
consistent	O
with	O
these	O
earlier	O
studies	O
in	O
showing	O
that	O
the	O
formation	O
of	O
the	O
iAs	O
-	O
responsive	O
NRF2	O
/	O
ARE	O
complexes	O
is	O
reduced	O
by	O
a	O
mutation	O
in	O
the	O
GC	O
box	O
.	O

Collectively	O
,	O
our	O
present	O
observations	O
reveal	O
a	O
new	O
molecular	O
mechanism	O
in	O
which	O
iAs	O
-	O
induced	O
K16	O
gene	O
expression	O
is	O
also	O
regulated	O
by	O
activation	O
NRF2	O
/	O
ARE	O
pathways	O
.	O

It	O
has	O
been	O
widely	O
accepted	O
that	O
oxidative	O
stress	O
disrupts	O
sequestration	O
of	O
NRF2	O
by	O
KEAP1	O
,	O
permits	O
NRF2	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
transactivates	O
the	O
expression	O
of	O
various	O
NRF2-mediated	O
genes	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al.	O
2002	O
;	O
McMahon	O
et	O
al.	O
2003	O
)	O
.	O

Our	O
present	O
study	O
showed	O
that	O
iAs	O
elongates	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
but	O
has	O
no	O
effects	O
upon	O
KEAP1	O
expression	O
(	O
Figure	O
5	O
)	O
.	O

Other	O
studies	O
have	O
also	O
demonstrated	O
that	O
the	O
production	O
of	O
NRF2	O
is	O
increased	O
by	O
various	O
inducers	O
via	O
posttranscriptional	O
control	O
(	O
Nguyen	O
et	O
al.	O
2003	O
;	O
Stewart	O
et	O
al.	O
2003	O
)	O
.	O

Several	O
earlier	O
reports	O
also	O
indicated	O
that	O
either	O
oxidative	O
stress	O
or	O
antioxidant	O
substances	O
stabilize	O
the	O
expression	O
of	O
the	O
NRF2	O
protein	O
,	O
either	O
by	O
directly	O
modifying	O
the	O
cysteine	O
residues	O
on	O
KEAP1	O
to	O
disrupt	O
the	O
NRF2	O
/	O
KEAP1	O
complex	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al.	O
2002	O
)	O
or	O
by	O
facilitating	O
the	O
release	O
of	O
NRF2	O
through	O
the	O
phosphorylation	O
of	O
the	O
NRF2	O
/	O
KEAP1	O
complex	O
(	O
Bloom	O
and	O
Jaiswal	O
2003	O
)	O
.	O

These	O
findings	O
are	O
largely	O
consistent	O
with	O
our	O
present	O
finding	O
that	O
iAs	O
stabilizes	O
the	O
expression	O
of	O
NRF2	O
in	O
HaCaT	O
cells	O
by	O
elongating	O
the	O
protein	O
half	O
-	O
life	O
.	O

Recently	O
,	O
Wakabayashi	O
et	O
al.	O
(	O
2003	O
)	O
demonstrated	O
that	O
NRF2	O
accumulates	O
in	O
the	O
nucleus	O
at	O
constitutively	O
high	O
levels	O
and	O
produces	O
various	O
cytoprotective	O
genes	O
in	O
embryonic	O
fibroblast-	O
and	O
liver	O
-	O
derived	O
Keap1-null	O
mice	B
.	O

Surprisingly	O
,	O
these	O
Keap1-deficient	O
mice	B
also	O
show	O
a	O
thicker	O
stratum	O
corneum	O
epidermis	O
,	O
abnormal	O
keratinization	O
,	O
and	O
cornification	O
in	O
the	O
esophagus	O
and	O
forestomach	O
(	O
hyperkeratosis	O
)	O
.	O

K6	O
was	O
found	O
to	O
be	O
strongly	O
expressed	O
in	O
the	O
esophageal	O
epithelium	O
of	O
these	O
mice	B
.	O

These	O
results	O
indicate	O
that	O
K6	O
is	O
also	O
a	O
target	O
gene	O
of	O
NRF2	O
.	O

In	O
addition	O
,	O
the	O
promoter	O
of	O
the	O
K6	O
gene	O
bears	O
a	O
remarkable	O
sequence	O
similarity	O
to	O
the	O
K16	O
promoter	O
(	O
Jiang	O
et	O
al.	O
1993	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
K16	O
gene	O
expression	O
is	O
also	O
regulated	O
by	O
NRF2	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
gene	O
expression	O
and	O
transactivation	O
of	O
K16	O
were	O
dramatically	O
induced	O
by	O
transfection	O
with	O
WT	O
-	O
NRF2	O
via	O
in	O
HaCaT	O
cells	O
,	O
clearly	O
demonstrating	O
that	O
NRF2	O
acts	O
as	O
a	O
direct	O
transcriptional	O
regulator	O
of	O
the	O
K16	O
gene	O
(	O
Figure	O
6	O
)	O
.	O

In	O
addition	O
,	O
we	O
also	O
showed	O
that	O
transfection	O
of	O
HaCaT	O
cells	O
with	O
WT	O
-	O
NRF2	O
induces	O
the	O
expression	O
of	O
detoxification	O
gene	O
TXN	O
(	O
Figure	O
6A	O
)	O
.	O

NRF2	O
may	O
thus	O
have	O
a	O
major	O
role	O
to	O
play	O
in	O
the	O
development	O
of	O
hyperkeratosis	O
,	O
whereas	O
the	O
expression	O
and	O
induction	O
of	O
NRF2	O
is	O
implicated	O
in	O
cell	O
protection	O
against	O
a	O
variety	O
of	O
genotoxic	O
and	O
cytotoxic	O
effects	O
.	O

Hence	O
,	O
based	O
on	O
these	O
results	O
and	O
on	O
the	O
findings	O
from	O
studies	O
of	O
Keap1	O
knockout	O
mice	B
,	O
iAs	O
may	O
both	O
cause	O
hyperkeratosis	O
and	O
induce	O
detoxification	O
enzymes	O
via	O
the	O
modification	O
of	O
NRF2	O
.	O

Given	O
that	O
there	O
are	O
both	O
beneficial	O
and	O
adverse	O
effects	O
of	O
NRF2	O
activity	O
,	O
caution	O
will	O
therefore	O
be	O
needed	O
when	O
using	O
antioxidants	O
for	O
prevention	O
and	O
therapy	O
.	O

Although	O
further	O
investigations	O
are	O
needed	O
,	O
we	O
believe	O
that	O
our	O
findings	O
provide	O
important	O
clues	O
for	O
the	O
design	O
of	O
future	O
therapies	O
for	O
arsenic	O
-	O
mediated	O
hyperkeratosis	O
and	O
for	O
treatments	O
involving	O
the	O
molecular	O
targeting	O
of	O
NRF2	O
.	O

Conclusion	O
Our	O
findings	O
clearly	O
demonstrate	O
that	O
the	O
induction	O
of	O
the	O
K16	O
gene	O
in	O
human	B
keratinocytes	O
by	O
iAs	O
depends	O
on	O
NRF2	O
activation	O
.	O

Our	O
results	O
thus	O
represent	O
a	O
valuable	O
initial	O
effort	O
to	O
elucidate	O
the	O
relationship	O
between	O
the	O
K16	O
gene	O
and	O
the	O
NRF2	O
transcription	O
factor	O
,	O
which	O
may	O
be	O
responsible	O
for	O
hyperkeratosis	O
.	O

Identification	O
and	O
Analysis	O
of	O
Co	O
-	O
Occurrence	O
Networks	O
with	O
NetCutter	O
Abstract	O
Background	O
Co	O
-	O
occurrence	O
analysis	O
is	O
a	O
technique	O
often	O
applied	O
in	O
text	O
mining	O
,	O
comparative	O
genomics	O
,	O
and	O
promoter	O
analysis	O
.	O

The	O
methodologies	O
and	O
statistical	O
models	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
association	O
between	O
co	O
-	O
occurring	O
entities	O
are	O
quite	O
diverse	O
,	O
however	O
.	O

Methodology	O
/	O
Principal	O
Findings	O
We	O
present	O
a	O
general	O
framework	O
for	O
co	O
-	O
occurrence	O
analysis	O
based	O
on	O
a	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
,	O
a	O
novel	O
co	O
-	O
occurrence	O
statistic	O
,	O
and	O
software	O
performing	O
co	O
-	O
occurrence	O
analysis	O
as	O
well	O
as	O
generation	O
and	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
.	O

We	O
show	O
that	O
the	O
overall	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
depends	O
critically	O
on	O
the	O
choice	O
of	O
the	O
null	O
-	O
model	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
and	O
find	O
that	O
random	O
sampling	O
from	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
optimal	O
stringency	O
.	O

We	O
show	O
that	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
is	O
the	O
most	O
natural	O
co	O
-	O
occurrence	O
probability	O
distribution	O
when	O
vertex	O
degrees	O
of	O
the	O
bipartite	O
graph	O
are	O
variable	O
,	O
which	O
is	O
usually	O
the	O
case	O
.	O

Calculation	O
of	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
is	O
difficult	O
,	O
however	O
.	O

Therefore	O
,	O
we	O
propose	O
a	O
fast	O
bi	O
-	O
binomial	O
approximation	O
for	O
calculation	O
of	O
P	O
-	O
values	O
and	O
show	O
that	O
this	O
statistic	O
is	O
superior	O
to	O
other	O
measures	O
of	O
association	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
and	O
the	O
uncertainty	O
coefficient	O
.	O

Furthermore	O
,	O
co	O
-	O
occurrence	O
analysis	O
of	O
more	O
than	O
two	O
entities	O
can	O
be	O
performed	O
using	O
the	O
same	O
statistical	O
model	O
,	O
which	O
leads	O
to	O
increased	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
,	O
robustness	O
towards	O
noise	O
,	O
and	O
the	O
identification	O
of	O
implicit	O
relationships	O
between	O
co	O
-	O
occurring	O
entities	O
.	O

Using	O
NetCutter	O
,	O
we	O
identify	O
a	O
novel	O
protein	O
biosynthesis	O
related	O
set	O
of	O
genes	O
that	O
are	O
frequently	O
coordinately	O
deregulated	O
in	O
human	B
cancer	O
related	O
gene	O
expression	O
studies	O
.	O

NetCutter	O
is	O
available	O
at	O
http://bio.ifom-ieo-campus.it/NetCutter/	O
)	O
.	O

Conclusion	O
Our	O
approach	O
can	O
be	O
applied	O
to	O
any	O
set	O
of	O
categorical	O
data	O
where	O
co	O
-	O
occurrence	O
analysis	O
might	O
reveal	O
functional	O
relationships	O
such	O
as	O
clinical	O
parameters	O
associated	O
with	O
cancer	O
subtypes	O
or	O
SNPs	O
associated	O
with	O
disease	O
phenotypes	O
.	O

The	O
stringency	O
of	O
our	O
approach	O
is	O
expected	O
to	O
offer	O
an	O
advantage	O
in	O
a	O
variety	O
of	O
applications	O
.	O

Introduction	O
Biological	O
research	O
has	O
experienced	O
a	O
paradigm	O
shift	O
in	O
the	O
last	O
decade	O
catalyzed	O
by	O
the	O
availability	O
of	O
genome	O
sequences	O
and	O
the	O
resulting	O
development	O
of	O
high	O
-	O
throughput	O
technologies	O
.	O

The	O
large	O
data	O
volumes	O
produced	O
by	O
these	O
novel	O
technologies	O
are	O
often	O
published	O
as	O
supplementary	O
material	O
and/or	O
stored	O
in	O
extensive	O
data	O
repositories	O
[	O
1	O
]	O
.	O

Functional	O
interpretation	O
of	O
these	O
data	O
is	O
an	O
ongoing	O
challenge	O
.	O

Co	O
-	O
occurrence	O
analysis	O
,	O
based	O
on	O
the	O
hypothesis	O
that	O
co	O
-	O
occurring	O
entities	O
are	O
functionally	O
linked	O
,	O
is	O
a	O
technique	O
that	O
has	O
been	O
used	O
in	O
three	O
main	O
areas	O
of	O
biological	O
research	O
:	O
Co	O
-	O
occurrence	O
of	O
genes	O
in	O
sequenced	O
genomes	O
relies	O
on	O
the	O
fact	O
that	O
proteins	O
do	O
not	O
function	O
in	O
isolation	O
and	O
are	O
dependent	O
on	O
other	O
proteins	O
,	O
either	O
as	O
direct	O
binding	O
partners	O
,	O
or	O
as	O
catalysts	O
of	O
substrates	O
.	O

Thus	O
,	O
when	O
two	O
proteins	O
significantly	O
co	O
-	O
occur	O
in	O
a	O
large	O
number	O
of	O
genomes	O
or	O
can	O
be	O
observed	O
as	O
fusion	O
proteins	O
in	O
a	O
subset	O
of	O
genomes	O
,	O
they	O
are	O
likely	O
to	O
be	O
binding	O
partners	O
or	O
enzymes	O
needed	O
for	O
a	O
specific	O
metabolic	O
pathway	O
.	O

Examples	O
of	O
those	O
studies	O
have	O
been	O
reported	O
by	O
[	O
2	O
]	O
–	O
[	O
7	O
]	O
.	O

Text	O
mining	O
is	O
a	O
quickly	O
evolving	O
field	O
that	O
aims	O
at	O
developing	O
technologies	O
helping	O
to	O
cope	O
with	O
the	O
functional	O
interpretation	O
of	O
large	O
volumes	O
of	O
publications	O
.	O

Co	O
-	O
occurrence	O
of	O
gene	O
names	O
in	O
publication	O
abstracts	O
,	O
entire	O
publications	O
,	O
or	O
other	O
gene	O
-	O
related	O
databases	O
has	O
been	O
used	O
to	O
derive	O
co	O
-	O
occurrence	O
networks	O
with	O
clear	O
evidence	O
that	O
edges	O
in	O
those	O
networks	O
are	O
reflecting	O
functionally	O
relevant	O
relationships	O
[	O
8	O
]	O
–	O
[	O
11	O
]	O
.	O

Gene	O
names	O
have	O
also	O
been	O
analyzed	O
for	O
co	O
-	O
occurrence	O
with	O
other	O
entities	O
such	O
as	O
mutations	O
[	O
12	O
]	O
,	O
chemical	O
compounds	O
[	O
13	O
]	O
,	O
and	O
disease	O
related	O
keywords	O
[	O
14	O
]	O
.	O

From	O
the	O
resulting	O
networks	O
,	O
hypotheses	O
about	O
candidate	O
genes	O
involved	O
in	O
inherited	O
diseases	O
and	O
drug	O
targets	O
can	O
be	O
derived	O
.	O

Clustering	O
of	O
gene	O
related	O
publications	O
using	O
keywords	O
has	O
been	O
applied	O
to	O
enhance	O
the	O
quality	O
of	O
gene	O
expression	O
clusters	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

More	O
general	O
(	O
non	O
gene	O
-	O
centric	O
)	O
approaches	O
try	O
to	O
organize	O
the	O
literature	O
into	O
functional	O
areas	O
based	O
on	O
co	O
-	O
occurrence	O
of	O
MeSH	O
terms	O
,	O
keywords	O
,	O
diseases	O
,	O
phenotypes	O
,	O
chemicals	O
,	O
and	O
similar	O
objects	O
of	O
biomedical	O
research	O
interest	O
[	O
17	O
]	O
–	O
[	O
21	O
]	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
transcription	O
factor	O
binding	O
motifs	O
has	O
been	O
carried	O
out	O
in	O
a	O
variety	O
of	O
slightly	O
differing	O
ways	O
in	O
a	O
wide	O
range	O
of	O
organisms	O
,	O
including	O
humans	B
.	O

[	O
22	O
]	O
–	O
[	O
33	O
]	O
.	O

The	O
underlying	O
hypothesis	O
is	O
that	O
co	O
-	O
regulated	O
genes	O
,	O
identified	O
usually	O
by	O
gene	O
expression	O
studies	O
,	O
should	O
contain	O
specific	O
combinations	O
of	O
transcription	O
factor	O
binding	O
motifs	O
in	O
their	O
upstream	O
regulatory	O
regions	O
,	O
the	O
identification	O
of	O
which	O
would	O
allow	O
the	O
reverse	O
-	O
engineering	O
of	O
transcription	O
regulatory	O
networks	O
[	O
34	O
]	O
.	O

We	O
have	O
recently	O
applied	O
co	O
-	O
occurrence	O
analysis	O
to	O
studying	O
published	O
gene	O
expression	O
signatures	O
and	O
showed	O
that	O
co	O
-	O
occurrence	O
patterns	O
of	O
genes	O
reflect	O
cancer	O
signaling	O
pathways	O
[	O
35	O
]	O
.	O

Although	O
co	O
-	O
occurrence	O
analysis	O
has	O
a	O
respectable	O
history	O
,	O
the	O
methodologies	O
used	O
in	O
the	O
studies	O
mentioned	O
above	O
could	O
not	O
be	O
easily	O
applied	O
to	O
studying	O
gene	O
expression	O
signatures	O
.	O

There	O
are	O
three	O
main	O
reasons	O
that	O
dictated	O
the	O
use	O
of	O
a	O
different	O
approach	O
.	O

First	O
,	O
gene	O
expression	O
signatures	O
can	O
vary	O
in	O
size	O
by	O
orders	O
of	O
magnitude	O
.	O

Obviously	O
,	O
the	O
larger	O
a	O
signature	O
the	O
more	O
likely	O
it	O
is	O
to	O
find	O
two	O
or	O
more	O
genes	O
co	O
-	O
occurring	O
in	O
that	O
signature	O
.	O

Thus	O
,	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
must	O
be	O
evaluated	O
in	O
the	O
presence	O
of	O
considerable	O
heterogeneity	O
of	O
co	O
-	O
occurrence	O
probabilities	O
among	O
gene	O
lists	O
.	O

As	O
a	O
consequence	O
,	O
the	O
statistics	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
events	O
must	O
reflect	O
this	O
heterogeneity	O
.	O

In	O
particular	O
,	O
it	O
must	O
be	O
based	O
on	O
list	O
-	O
specific	O
co	O
-	O
occurrence	O
probabilities	O
.	O

Second	O
,	O
in	O
the	O
vast	O
majority	O
of	O
previous	O
studies	O
,	O
co	O
-	O
occurrence	O
is	O
analyzed	O
for	O
pair	O
-	O
wise	O
combinations	O
of	O
co	O
-	O
occurring	O
entities	O
.	O

We	O
found	O
that	O
the	O
resulting	O
stringency	O
of	O
this	O
approach	O
is	O
not	O
adequate	O
for	O
the	O
analysis	O
of	O
published	O
gene	O
expression	O
signatures	O
[	O
35	O
]	O
.	O

Third	O
,	O
the	O
null	O
-	O
model	O
against	O
which	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
is	O
tested	O
does	O
not	O
work	O
well	O
for	O
gene	O
expression	O
signatures	O
.	O

A	O
common	O
procedure	O
is	O
to	O
use	O
generic	O
randomization	O
of	O
the	O
entire	O
data	O
set	O
under	O
analysis	O
or	O
to	O
select	O
subsets	O
of	O
data	O
entries	O
randomly	O
for	O
comparison	O
purposes	O
.	O

However	O
,	O
gene	O
expression	O
signatures	O
are	O
composed	O
of	O
distinct	O
gene	O
sets	O
and	O
the	O
null	O
-	O
model	O
must	O
maintain	O
this	O
property	O
,	O
which	O
is	O
not	O
guaranteed	O
using	O
these	O
approaches	O
.	O

Furthermore	O
,	O
the	O
list	O
-	O
specific	O
nature	O
of	O
co	O
-	O
occurrence	O
probabilities	O
can	O
not	O
be	O
dealt	O
with	O
properly	O
.	O

NetCutter	O
was	O
developed	O
to	O
address	O
these	O
challenges	O
and	O
to	O
provide	O
a	O
generic	O
tool	O
for	O
generating	O
and	O
analyzing	O
co	O
-	O
occurrence	O
networks	O
.	O

Although	O
NetCutter	O
has	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
gene	O
expression	O
signatures	O
,	O
it	O
is	O
based	O
on	O
abstract	O
concepts	O
that	O
make	O
it	O
applicable	O
to	O
a	O
wide	O
variety	O
of	O
problems	O
.	O

The	O
input	O
is	O
represented	O
by	O
a	O
bipartite	O
graph	O
that	O
is	O
composed	O
of	O
list	O
-	O
entry	O
pairs	O
,	O
which	O
are	O
stored	O
in	O
tab	O
-	O
separated	O
text	O
format	O
.	O

Co	O
-	O
occurrence	O
of	O
entries	O
in	O
lists	O
is	O
analyzed	O
using	O
pair	O
-	O
wise	O
or	O
higher	O
order	O
combinations	O
of	O
entries	O
.	O

The	O
significance	O
of	O
co	O
-	O
occurrence	O
is	O
tested	O
using	O
a	O
novel	O
bi	O
-	O
binomial	O
approximation	O
of	O
Poisson	O
-	O
binomial	O
statistics	O
(	O
which	O
is	O
a	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
that	O
handles	O
list	O
-	O
length	O
-	O
heterogeneity	O
properly	O
and	O
provides	O
a	O
novel	O
measure	O
of	O
association	O
that	O
is	O
found	O
to	O
be	O
superior	O
to	O
the	O
Jaccard	O
and	O
the	O
uncertainty	O
coefficients	O
.	O

Occurrence	O
probabilities	O
are	O
obtained	O
from	O
an	O
edge	O
-	O
swapping	O
procedure	O
that	O
maintains	O
vertex	O
degrees	O
in	O
the	O
underlying	O
bipartite	O
graph	O
and	O
distinct	O
sets	O
of	O
entries	O
per	O
list	O
.	O

As	O
we	O
shall	O
see	O
below	O
,	O
this	O
procedure	O
has	O
a	O
number	O
of	O
advantages	O
over	O
other	O
possible	O
null	O
-	O
models	O
and	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
near	O
maximum	O
stringency	O
.	O

Last	O
but	O
not	O
least	O
,	O
NetCutter	O
is	O
equipped	O
with	O
a	O
number	O
of	O
algorithms	O
for	O
the	O
identification	O
of	O
network	O
communities	O
,	O
vertex	O
ranking	O
,	O
and	O
convenience	O
tools	O
needed	O
in	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
or	O
any	O
undirected	O
graph	O
.	O

We	O
illustrate	O
the	O
utility	O
of	O
NetCutter	O
in	O
the	O
identification	O
of	O
corresponding	O
clusters	O
of	O
genes	O
and	O
publications	O
from	O
the	O
PubLiME	O
data	O
set	O
.	O

PubLiME	O
(	O
Published	O
Lists	O
of	O
Microarray	O
Experiments	O
)	O
is	O
a	O
repository	O
of	O
published	O
cancer	O
related	O
gene	O
expression	O
signatures	O
(	O
http://bio.ifom-ieo-campus.it/Publime	O
)	O
.	O

The	O
concept	O
of	O
cluster	O
correspondence	O
follows	O
from	O
the	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
.	O

Reversing	O
the	O
list	O
-	O
entry	O
order	O
in	O
the	O
bipartite	O
graph	O
permits	O
identifying	O
communities	O
of	O
entries	O
as	O
well	O
as	O
communities	O
of	O
lists	O
.	O

We	O
show	O
that	O
communities	O
of	O
publications	O
corresponding	O
to	O
communities	O
of	O
genes	O
in	O
the	O
PubLiME	O
data	O
set	O
can	O
be	O
used	O
to	O
generate	O
hypotheses	O
about	O
the	O
putative	O
function	O
of	O
gene	O
communities	O
.	O

Results	O
The	O
bipartite	O
graph	O
model	O
of	O
co	O
-	O
occurrence	O
analysis	O
Co	O
-	O
occurrence	O
analysis	O
using	O
NetCutter	O
is	O
based	O
on	O
the	O
abstraction	O
of	O
list	O
-	O
entry	O
pairs	O
.	O

Any	O
entity	O
that	O
co	O
-	O
occurs	O
with	O
some	O
other	O
entity	O
must	O
be	O
confined	O
to	O
some	O
sort	O
of	O
container	O
where	O
co	O
-	O
occurrence	O
is	O
observed	O
.	O

For	O
example	O
,	O
in	O
the	O
case	O
of	O
gene	O
name	O
co	O
-	O
occurrence	O
in	O
PubMed	O
abstracts	O
,	O
the	O
abstract	O
is	O
the	O
container	O
and	O
the	O
gene	O
names	O
are	O
the	O
co	O
-	O
occurring	O
entities	O
.	O

Similarly	O
,	O
co	O
-	O
occurrence	O
of	O
transcription	O
factor	O
binding	O
motifs	O
is	O
observed	O
in	O
gene	O
promoters	O
.	O

The	O
promoters	O
are	O
the	O
containers	O
where	O
motif	O
entities	O
co	O
-	O
occur	O
.	O

The	O
containers	O
generally	O
host	O
more	O
than	O
one	O
entity	O
(	O
otherwise	O
co	O
-	O
occurrence	O
would	O
be	O
impossible	O
)	O
and	O
can	O
be	O
conveniently	O
interpreted	O
as	O
lists	O
.	O

The	O
co	O
-	O
occurring	O
entities	O
are	O
the	O
list	O
entries	O
.	O

Lists	O
and	O
entries	O
form	O
a	O
bipartite	O
graph	O
with	O
one	O
part	O
of	O
the	O
graph	O
representing	O
lists	O
and	O
the	O
other	O
part	O
representing	O
entries	O
.	O

The	O
presence	O
of	O
a	O
given	O
entry	O
in	O
a	O
given	O
list	O
is	O
indicated	O
by	O
an	O
edge	O
between	O
the	O
corresponding	O
list	O
and	O
entry	O
vertices	O
.	O

It	O
is	O
required	O
that	O
each	O
entry	O
can	O
be	O
linked	O
to	O
the	O
same	O
list	O
only	O
once	O
.	O

Without	O
loss	O
of	O
generality	O
,	O
let	O
's	O
consider	O
genes	O
as	O
entries	O
and	O
PubMedID_listIDs	O
as	O
lists	O
in	O
the	O
following	O
,	O
unless	O
otherwise	O
specified	O
(	O
Fig.	O
1A	O
)	O
.	O

This	O
interpretation	O
of	O
lists	O
and	O
entries	O
has	O
been	O
applied	O
in	O
the	O
co	O
-	O
occurrence	O
analysis	O
of	O
published	O
gene	O
expression	O
signatures	O
[	O
35	O
]	O
.	O

Occurrence	O
probabilities	O
and	O
null	O
-	O
models	O
A	O
prerequisite	O
for	O
co	O
-	O
occurrence	O
analysis	O
is	O
the	O
availability	O
of	O
occurrence	O
probabilities	O
of	O
genes	O
per	O
list	O
.	O

The	O
occurrence	O
probabilities	O
can	O
be	O
derived	O
from	O
randomizing	O
the	O
bipartite	O
graph	O
and	O
are	O
dependent	O
on	O
the	O
choice	O
of	O
the	O
null	O
-	O
model	O
.	O

A	O
null	O
-	O
model	O
creates	O
an	O
occurrence	O
probability	O
matrix	O
where	O
the	O
occurrence	O
probability	O
for	O
each	O
list	O
–	O
gene	O
pair	O
is	O
listed	O
.	O

As	O
a	O
general	O
property	O
of	O
this	O
matrix	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
must	O
equal	O
the	O
number	O
of	O
edges	O
in	O
the	O
bipartite	O
graph	O
.	O

This	O
is	O
because	O
each	O
edge	O
is	O
linked	O
to	O
either	O
side	O
of	O
the	O
bipartite	O
graph	O
with	O
certainty	O
and	O
therefore	O
the	O
sum	O
of	O
occurrence	O
probabilities	O
over	O
all	O
lists	O
(	O
which	O
can	O
be	O
calculated	O
as	O
the	O
row	O
sum	O
if	O
genes	O
are	O
listed	O
vertically	O
or	O
as	O
the	O
column	O
sum	O
if	O
genes	O
are	O
listed	O
horizontally	O
)	O
followed	O
by	O
summing	O
the	O
results	O
over	O
all	O
genes	O
must	O
be	O
1	O
for	O
every	O
edge	O
.	O

The	O
number	O
of	O
matrix	O
elements	O
is	O
given	O
by	O
#	O
genes*#lists	O
and	O
therefore	O
the	O
average	O
occurrence	O
probability	O
for	O
any	O
null	O
-	O
model	O
must	O
be	O
#	O
edges	O
/	O
(	O
#genes*#lists	O
)	O
.	O

As	O
a	O
consequence	O
,	O
different	O
null	O
-	O
models	O
will	O
only	O
be	O
distinguished	O
by	O
the	O
way	O
they	O
attribute	O
occurrence	O
probabilities	O
to	O
vertices	O
with	O
different	O
vertex	O
degrees	O
but	O
not	O
by	O
the	O
average	O
occurrence	O
probability	O
.	O

We	O
consider	O
six	O
different	O
strategies	O
to	O
randomize	O
the	O
bipartite	O
graph	O
.	O

First	O
,	O
we	O
could	O
reconnect	O
all	O
edges	O
of	O
the	O
graph	O
randomly	O
.	O

The	O
probability	O
of	O
being	O
connected	O
by	O
an	O
edge	O
for	O
a	O
given	O
list	O
-	O
gene	O
pair	O
is	O
given	O
by	O
(	O
1	O
/	O
#genes	O
)	O
*	O
(	O
1	O
/	O
#lists	O
)	O
.	O

Since	O
there	O
are	O
#	O
edges	O
edges	O
to	O
be	O
reconnected	O
,	O
the	O
occurrence	O
probability	O
for	O
a	O
single	O
list	O
-	O
gene	O
pair	O
is	O
#	O
edges	O
/	O
(	O
#genes*#lists	O
)	O
,	O
i.e.	O
equal	O
to	O
the	O
average	O
occurrence	O
probability	O
.	O

Thus	O
,	O
this	O
model	O
provides	O
equal	O
occurrence	O
probabilities	O
for	O
all	O
gene	O
-	O
list	O
pairs	O
and	O
does	O
not	O
consider	O
vertex	O
degrees	O
.	O

We	O
call	O
this	O
model	O
the	O
generic	O
randomization	O
(	O
GR	O
)	O
model	O
in	O
the	O
following	O
.	O

Second	O
,	O
we	O
could	O
disconnect	O
the	O
edges	O
on	O
only	O
the	O
list	O
side	O
of	O
the	O
bipartite	O
graph	O
and	O
reconnect	O
them	O
randomly	O
.	O

The	O
occurrence	O
probability	O
of	O
a	O
gene	O
vertex	O
would	O
be	O
given	O
by	O
(	O
gene	O
vertex	O
degree	O
)	O
/	O
#lists	O
.	O

The	O
sum	O
of	O
these	O
probabilities	O
over	O
all	O
lists	O
is	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
and	O
the	O
sum	O
of	O
all	O
gene	O
vertex	O
degrees	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Thus	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
equal	O
to	O
the	O
number	O
of	O
edges	O
,	O
as	O
required	O
.	O

Since	O
this	O
model	O
considers	O
gene	O
vertex	O
degrees	O
,	O
we	O
call	O
it	O
the	O
gene	O
vertex	O
degree	O
(	O
GVD	O
)	O
model	O
.	O

Third	O
,	O
we	O
disconnect	O
the	O
edges	O
on	O
the	O
gene	O
side	O
of	O
the	O
bipartite	O
graph	O
and	O
reconnect	O
them	O
randomly	O
.	O

The	O
probability	O
of	O
a	O
list	O
vertex	O
being	O
connected	O
to	O
a	O
gene	O
would	O
be	O
given	O
by	O
(	O
list	O
vertex	O
degree	O
)	O
/	O
#genes	O
.	O

The	O
sum	O
of	O
these	O
probabilities	O
over	O
all	O
genes	O
is	O
equal	O
to	O
the	O
list	O
vertex	O
degree	O
and	O
the	O
sum	O
of	O
all	O
list	O
vertex	O
degrees	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Again	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Since	O
this	O
model	O
considers	O
list	O
vertex	O
degrees	O
,	O
we	O
call	O
it	O
the	O
list	O
vertex	O
degree	O
(	O
LVD	O
)	O
model	O
.	O

In	O
model	O
four	O
and	O
five	O
,	O
we	O
reconnect	O
edges	O
considering	O
both	O
gene	O
and	O
list	O
vertex	O
degrees	O
and	O
allow	O
multiple	O
edges	O
between	O
list	O
-	O
gene	O
pairs	O
.	O

The	O
occurrence	O
probabilities	O
in	O
model	O
four	O
are	O
calculated	O
according	O
to	O
the	O
binomial	O
distribution	O
.	O

We	O
calculate	O
the	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
for	O
being	O
connected	O
as	O
the	O
cumulative	O
binomial	O
probability	O
of	O
the	O
list	O
-	O
gene	O
pair	O
being	O
chosen	O
at	O
least	O
once	O
in	O
the	O
process	O
of	O
randomly	O
reconnecting	O
the	O
edges	O
.	O

This	O
can	O
be	O
achieved	O
by	O
setting	O
the	O
number	O
of	O
trials	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
,	O
the	O
probability	O
of	O
success	O
equal	O
to	O
the	O
list	O
vertex	O
degree	O
divided	O
by	O
the	O
total	O
number	O
of	O
edges	O
,	O
and	O
the	O
number	O
of	O
successes	O
equal	O
to	O
0	O
.	O

The	O
occurrence	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
is	O
then	O
given	O
by	O
the	O
complement	O
of	O
this	O
probability	O
.	O

This	O
model	O
is	O
called	O
the	O
binomial	O
(	O
BN	O
)	O
model	O
.	O

In	O
model	O
five	O
,	O
we	O
calculate	O
occurrence	O
probabilities	O
according	O
to	O
the	O
hypergeometric	O
distribution	O
.	O

The	O
number	O
of	O
successes	O
in	O
the	O
sample	O
is	O
equal	O
to	O
0	O
,	O
the	O
sample	O
size	O
is	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
,	O
the	O
number	O
of	O
successes	O
in	O
the	O
population	O
is	O
set	O
to	O
the	O
list	O
vertex	O
degree	O
,	O
and	O
the	O
population	O
size	O
is	O
the	O
total	O
number	O
of	O
edges	O
.	O

Again	O
,	O
the	O
occurrence	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
is	O
obtained	O
as	O
the	O
complement	O
of	O
this	O
probability	O
.	O

We	O
call	O
this	O
model	O
the	O
hypergeometric	O
(	O
HG	O
)	O
model	O
.	O

Calculating	O
occurrence	O
probabilities	O
in	O
this	O
manner	O
does	O
not	O
guarantee	O
that	O
the	O
matrix	O
elements	O
add	O
up	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Therefore	O
,	O
the	O
matrices	O
are	O
normalized	O
such	O
that	O
this	O
condition	O
is	O
satisfied	O
by	O
multiplying	O
each	O
matrix	O
element	O
with	O
the	O
factor	O
#	O
edges	O
/	O
(	O
observed	O
matrix	O
sum	O
)	O
,	O
which	O
is	O
generally	O
quite	O
close	O
to	O
1	O
,	O
however	O
.	O

In	O
model	O
six	O
,	O
we	O
again	O
consider	O
vertex	O
degrees	O
,	O
but	O
we	O
require	O
that	O
each	O
list	O
is	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

Thus	O
,	O
multiple	O
edges	O
are	O
forbidden	O
.	O

This	O
condition	O
is	O
satisfied	O
by	O
applying	O
an	O
edge	O
-	O
swapping	O
procedure	O
during	O
graph	O
randomization	O
.	O

Edge	O
-	O
swapping	O
works	O
by	O
randomly	O
choosing	O
two	O
list	O
-	O
gene	O
pairs	O
from	O
the	O
bipartite	O
graph	O
and	O
prior	O
to	O
performing	O
the	O
edge	O
-	O
swap	O
,	O
a	O
test	O
is	O
performed	O
to	O
ensure	O
that	O
the	O
two	O
genes	O
are	O
not	O
already	O
linked	O
to	O
the	O
respective	O
target	O
lists	O
.	O

This	O
procedure	O
is	O
performed	O
a	O
large	O
number	O
of	O
times	O
.	O

To	O
ensure	O
complete	O
randomization	O
of	O
the	O
graph	O
,	O
the	O
number	O
of	O
swaps	O
performed	O
should	O
be	O
significantly	O
larger	O
than	O
the	O
number	O
of	O
edges	O
.	O

After	O
performing	O
R	O
randomizations	O
of	O
the	O
graph	O
and	O
counting	O
the	O
number	O
of	O
times	O
a	O
gene	O
has	O
been	O
linked	O
to	O
a	O
particular	O
list	O
,	O
division	O
of	O
this	O
number	O
by	O
R	O
gives	O
the	O
occurrence	O
probability	O
of	O
a	O
gene	O
in	O
a	O
given	O
list	O
.	O

As	O
will	O
be	O
shown	O
below	O
,	O
edge	O
-	O
swapping	O
produces	O
occurrence	O
probabilities	O
that	O
closely	O
approximate	O
occurrence	O
probabilities	O
obtained	O
by	O
generating	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
,	O
counting	O
the	O
number	O
of	O
times	O
a	O
gene	O
is	O
found	O
part	O
of	O
a	O
list	O
,	O
and	O
dividing	O
this	O
number	O
by	O
the	O
total	O
number	O
of	O
permutations	O
.	O

In	O
the	O
permutation	O
model	O
,	O
the	O
sum	O
of	O
occurrence	O
probabilities	O
of	O
a	O
gene	O
over	O
all	O
lists	O
equals	O
the	O
gene	O
vertex	O
degree	O
(	O
see	O
below	O
)	O
and	O
thus	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
the	O
number	O
of	O
edges	O
.	O

Since	O
permutation	O
sets	O
of	O
bipartite	O
graphs	O
are	O
difficult	O
to	O
calculate	O
,	O
we	O
use	O
the	O
edge	O
-	O
swapping	O
procedure	O
as	O
a	O
close	O
approximation	O
and	O
call	O
this	O
model	O
the	O
edge	O
-	O
swapping	O
(	O
ES	O
)	O
model	O
.	O

Fig.	O
1	O
shows	O
the	O
occurrence	O
probabilities	O
of	O
the	O
different	O
null	O
-	O
models	O
for	O
the	O
bipartite	O
graph	O
shown	O
in	O
Fig.	O
1A	O
.	O

The	O
GR	O
model	O
yields	O
identical	O
occurrence	O
probabilities	O
for	O
all	O
list	O
-	O
gene	O
pairs	O
,	O
which	O
is	O
equal	O
to	O
the	O
average	O
occurrence	O
probability	O
in	O
all	O
models	O
.	O

In	O
the	O
other	O
models	O
,	O
the	O
occurrence	O
probabilities	O
deviate	O
to	O
varying	O
extent	O
from	O
the	O
average	O
occurrence	O
probability	O
as	O
a	O
function	O
of	O
vertex	O
degrees	O
.	O

In	O
the	O
GVD	O
model	O
,	O
the	O
deviations	O
are	O
a	O
function	O
of	O
gene	O
vertex	O
degree	O
and	O
in	O
the	O
LVD	O
model	O
the	O
deviations	O
are	O
dependent	O
on	O
list	O
vertex	O
degrees	O
.	O

In	O
the	O
remaining	O
models	O
,	O
the	O
deviations	O
are	O
functions	O
of	O
both	O
the	O
gene	O
and	O
the	O
list	O
vertex	O
degrees	O
.	O

In	O
all	O
cases	O
,	O
larger	O
than	O
average	O
occurrence	O
probabilities	O
are	O
obtained	O
for	O
larger	O
vertex	O
degrees	O
at	O
the	O
expense	O
of	O
smaller	O
than	O
average	O
occurrence	O
probabilities	O
for	O
smaller	O
vertex	O
degrees	O
.	O

From	O
these	O
data	O
,	O
it	O
is	O
difficult	O
to	O
choose	O
the	O
most	O
effective	O
null	O
-	O
model	O
.	O

A	O
hint	O
can	O
be	O
gleaned	O
from	O
gene1	O
,	O
however	O
.	O

Gene1	O
is	O
present	O
in	O
all	O
lists	O
.	O

Therefore	O
,	O
the	O
co	O
-	O
occurrence	O
probability	O
of	O
gene1	O
with	O
other	O
genes	O
,	O
which	O
is	O
calculated	O
by	O
multiplying	O
the	O
occurrence	O
probabilities	O
of	O
gene1	O
and	O
geneX	O
for	O
every	O
list	O
under	O
study	O
,	O
should	O
depend	O
only	O
on	O
the	O
occurrence	O
probability	O
of	O
this	O
other	O
gene	O
.	O

In	O
other	O
words	O
,	O
the	O
occurrence	O
probability	O
of	O
gene1	O
in	O
all	O
lists	O
should	O
be	O
1.0	O
.	O

Only	O
two	O
models	O
satisfy	O
this	O
constraint	O
:	O
The	O
GVD	O
and	O
the	O
ES	O
models	O
.	O

Since	O
the	O
GVD	O
model	O
does	O
not	O
consider	O
list	O
vertex	O
degrees	O
,	O
it	O
seems	O
that	O
the	O
ES	O
model	O
is	O
the	O
preferred	O
null	O
-	O
model	O
.	O

Expected	O
number	O
of	O
co	O
-	O
occurrences	O
As	O
a	O
general	O
criterion	O
for	O
comparing	O
the	O
effectiveness	O
of	O
different	O
null	O
-	O
models	O
,	O
we	O
have	O
to	O
compare	O
them	O
for	O
the	O
number	O
of	O
expected	O
co	O
-	O
occurrences	O
.	O

The	O
most	O
effective	O
null	O
-	O
model	O
will	O
be	O
the	O
one	O
that	O
maximizes	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

If	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
larger	O
,	O
an	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
in	O
a	O
real	O
bipartite	O
graph	O
will	O
be	O
less	O
significant	O
and	O
thus	O
such	O
a	O
null	O
-	O
model	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
higher	O
stringency	O
.	O

The	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
depends	O
in	O
an	O
obvious	O
fashion	O
on	O
the	O
list	O
vertex	O
degree	O
.	O

If	O
pair	O
-	O
wise	O
co	O
-	O
occurrences	O
are	O
considered	O
,	O
the	O
number	O
of	O
co	O
-	O
occurrences	O
in	O
a	O
list	O
of	O
vertex	O
degree	O
N	O
is	O
given	O
by	O
the	O
binomial	O
coefficient	O
N	O
over	O
2	O
.	O

Larger	O
lists	O
will	O
give	O
rise	O
to	O
more	O
co	O
-	O
occurrences	O
and	O
the	O
number	O
increases	O
quickly	O
with	O
list	O
vertex	O
degree	O
.	O

The	O
dependency	O
of	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
on	O
the	O
gene	O
vertex	O
degree	O
is	O
less	O
obvious	O
and	O
depends	O
strongly	O
on	O
the	O
null	O
-	O
model	O
.	O

A	O
gene	O
that	O
is	O
part	O
of	O
a	O
list	O
with	O
vertex	O
degree	O
N	O
will	O
give	O
rise	O
to	O
N-1	O
co	O
-	O
occurrences	O
in	O
that	O
list	O
.	O

The	O
null	O
-	O
model	O
permits	O
calculating	O
the	O
probability	O
to	O
find	O
this	O
gene	O
in	O
a	O
given	O
list	O
.	O

Thus	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
of	O
a	O
gene	O
is	O
given	O
by	O
the	O
sum	O
of	O
expected	O
co	O
-	O
occurrences	O
in	O
all	O
lists	O
where	O
for	O
a	O
single	O
list	O
the	O
expected	O
co	O
-	O
occurrences	O
are	O
given	O
by	O
(	O
Nl−1	O
)	O
*pl	O
.	O

Nl	O
is	O
the	O
list	O
vertex	O
degree	O
and	O
pl	O
is	O
the	O
occurrence	O
probability	O
of	O
the	O
gene	O
in	O
that	O
list	O
as	O
determined	O
by	O
the	O
null	O
-	O
model	O
.	O

We	O
used	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
to	O
calculate	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
with	O
different	O
null	O
-	O
models	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
2A	O
.	O

The	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
was	O
calculated	O
for	O
all	O
genes	O
in	O
all	O
lists	O
using	O
all	O
null	O
-	O
models	O
and	O
the	O
sum	O
of	O
expected	O
co	O
-	O
occurrences	O
per	O
gene	O
is	O
shown	O
as	O
a	O
scatter	O
plot	O
with	O
the	O
gene	O
vertex	O
degree	O
on	O
the	O
x	O
-	O
axis	O
and	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
on	O
the	O
y	O
-	O
axis	O
.	O

The	O
results	O
in	O
Fig.	O
2A	O
suggest	O
the	O
following	O
ranking	O
of	O
null	O
-	O
models	O
:	O
GR	O
<	O
GVD	O
<	O
LVD	O
<	O
BN	O
=	O
HG	O
<	O
ES	O
.	O

The	O
BN	O
and	O
the	O
HG	O
models	O
perform	O
in	O
an	O
essentially	O
identical	O
way	O
.	O

However	O
,	O
the	O
ES	O
model	O
is	O
the	O
model	O
that	O
yields	O
the	O
largest	O
estimates	O
of	O
expected	O
co	O
-	O
occurrences	O
.	O

The	O
results	O
are	O
also	O
in	O
line	O
with	O
the	O
intuitive	O
expectation	O
that	O
genes	O
with	O
higher	O
vertex	O
degree	O
give	O
rise	O
to	O
more	O
co	O
-	O
occurrences	O
.	O

However	O
,	O
it	O
can	O
be	O
seen	O
that	O
this	O
is	O
not	O
true	O
for	O
all	O
null	O
-	O
models	O
.	O

In	O
particular	O
,	O
it	O
is	O
not	O
true	O
for	O
the	O
GR	O
and	O
the	O
LVD	O
models	O
,	O
which	O
do	O
not	O
consider	O
gene	O
vertex	O
degrees	O
.	O

As	O
outlined	O
above	O
,	O
it	O
is	O
expected	O
that	O
the	O
null	O
-	O
model	O
that	O
yields	O
the	O
highest	O
estimates	O
of	O
expected	O
co	O
-	O
occurrences	O
should	O
permit	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
.	O

In	O
Fig.	O
2B	O
,	O
this	O
hypothesis	O
is	O
tested	O
directly	O
again	O
using	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
.	O

For	O
all	O
null	O
-	O
models	O
,	O
co	O
-	O
occurrence	O
analysis	O
was	O
carried	O
out	O
using	O
module	O
size	O
3	O
and	O
support	O
5	O
(	O
co	O
-	O
occurrence	O
modules	O
must	O
be	O
present	O
in	O
at	O
least	O
five	O
publications	O
)	O
.	O

The	O
choice	O
of	O
these	O
parameters	O
has	O
been	O
discussed	O
in	O
[	O
35	O
]	O
.	O

The	O
number	O
of	O
co	O
-	O
occurrence	O
modules	O
was	O
then	O
determined	O
that	O
have	O
a	O
Z	O
-	O
score	O
higher	O
or	O
equal	O
than	O
the	O
cut	O
-	O
off	O
shown	O
in	O
Fig.	O
2B	O
.	O

The	O
Z	O
-	O
score	O
is	O
calculated	O
from	O
the	O
mean	O
and	O
variance	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
as	O
shown	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
and	O
published	O
in	O
[	O
35	O
]	O
.	O

More	O
details	O
on	O
the	O
probability	O
distribution	O
will	O
be	O
provided	O
below	O
.	O

The	O
GR	O
and	O
GVD	O
models	O
perform	O
very	O
poorly	O
and	O
identify	O
large	O
numbers	O
of	O
modules	O
with	O
high	O
Z	O
-	O
scores	O
.	O

The	O
LVD	O
model	O
performs	O
a	O
little	O
better	O
and	O
approximates	O
the	O
BN	O
and	O
HG	O
models	O
at	O
higher	O
Z	O
-	O
score	O
cut	O
-	O
offs	O
.	O

The	O
BN	O
and	O
HG	O
models	O
give	O
essentially	O
identical	O
results	O
.	O

However	O
,	O
the	O
ES	O
model	O
is	O
the	O
model	O
that	O
yields	O
the	O
fewest	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
and	O
is	O
thus	O
the	O
most	O
stringent	O
.	O

The	O
increased	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
the	O
BN	O
and	O
HG	O
models	O
is	O
also	O
reflected	O
in	O
a	O
higher	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
calculated	O
as	O
the	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
divided	O
by	O
the	O
number	O
of	O
modules	O
found	O
in	O
a	O
randomized	O
bipartite	O
graph	O
(	O
Fig.	O
2C	O
)	O
.	O

The	O
reason	O
for	O
the	O
superior	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
all	O
other	O
models	O
can	O
be	O
explained	O
by	O
examining	O
the	O
average	O
occurrence	O
probability	O
per	O
gene	O
and	O
list	O
vertex	O
degree	O
.	O

Fig.	O
2D	O
and	O
E	O
show	O
the	O
average	O
occurrence	O
probability	O
of	O
genes	O
with	O
the	O
same	O
gene	O
vertex	O
degree	O
as	O
a	O
function	O
of	O
the	O
gene	O
vertex	O
degree	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
ES	O
model	O
yields	O
higher	O
occurrence	O
probability	O
estimates	O
for	O
genes	O
with	O
higher	O
vertex	O
degrees	O
as	O
compared	O
to	O
the	O
BN	O
and	O
HG	O
models	O
.	O

In	O
GR	O
and	O
LVD	O
models	O
,	O
gene	O
vertex	O
degrees	O
are	O
ignored	O
and	O
occurrence	O
probabilities	O
for	O
genes	O
with	O
large	O
vertex	O
degree	O
are	O
very	O
small	O
,	O
which	O
is	O
compensated	O
by	O
larger	O
occurrence	O
probabilities	O
for	O
genes	O
with	O
small	O
vertex	O
degree	O
.	O

The	O
GVD	O
model	O
is	O
identical	O
to	O
the	O
ES	O
model	O
in	O
this	O
setting	O
.	O

Fig.	O
2E	O
shows	O
the	O
average	O
occurrence	O
probability	O
of	O
all	O
lists	O
with	O
the	O
same	O
vertex	O
degree	O
as	O
a	O
function	O
of	O
list	O
vertex	O
degree	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
ES	O
model	O
provides	O
higher	O
occurrence	O
probability	O
estimates	O
for	O
large	O
lists	O
as	O
compared	O
to	O
the	O
BN	O
and	O
HG	O
models	O
.	O

In	O
this	O
setting	O
,	O
the	O
LVD	O
model	O
performs	O
like	O
the	O
ES	O
model	O
while	O
the	O
GR	O
and	O
GVD	O
models	O
yield	O
small	O
occurrence	O
probabilities	O
for	O
large	O
lists	O
.	O

Since	O
it	O
has	O
been	O
shown	O
above	O
that	O
long	O
lists	O
and	O
genes	O
with	O
high	O
vertex	O
degree	O
are	O
responsible	O
for	O
a	O
large	O
part	O
of	O
the	O
total	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
the	O
most	O
stringent	O
null	O
-	O
models	O
,	O
the	O
null	O
-	O
model	O
that	O
provides	O
larger	O
occurrence	O
probability	O
estimates	O
for	O
genes	O
and	O
lists	O
with	O
high	O
vertex	O
degree	O
at	O
the	O
expense	O
of	O
lower	O
estimates	O
for	O
smaller	O
degrees	O
will	O
be	O
the	O
most	O
stringent	O
because	O
large	O
occurrence	O
probabilities	O
make	O
co	O
-	O
occurrence	O
more	O
likely	O
and	O
thus	O
less	O
significant	O
.	O

By	O
these	O
criteria	O
,	O
the	O
ES	O
model	O
is	O
the	O
most	O
stringent	O
of	O
all	O
models	O
tested	O
.	O

The	O
ES	O
model	O
as	O
an	O
approximation	O
of	O
the	O
permutation	O
null	O
-	O
model	O
The	O
data	O
shown	O
above	O
have	O
revealed	O
that	O
the	O
ES	O
model	O
is	O
the	O
best	O
of	O
the	O
models	O
tested	O
.	O

One	O
may	O
wonder	O
,	O
however	O
,	O
whether	O
yet	O
more	O
effective	O
null	O
-	O
models	O
can	O
be	O
found	O
.	O

An	O
obvious	O
choice	O
would	O
be	O
the	O
permutation	O
model	O
.	O

In	O
the	O
permutation	O
model	O
,	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
is	O
created	O
such	O
that	O
each	O
list	O
is	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

The	O
number	O
of	O
graphs	O
where	O
a	O
gene	O
is	O
present	O
in	O
a	O
given	O
list	O
divided	O
by	O
the	O
total	O
number	O
of	O
permutations	O
then	O
provides	O
the	O
occurrence	O
probability	O
estimate	O
.	O

The	O
permutation	O
model	O
is	O
the	O
ideal	O
null	O
-	O
model	O
because	O
it	O
is	O
exhaustive	O
.	O

The	O
problem	O
is	O
that	O
a	O
complete	O
permutation	O
set	O
of	O
bipartite	O
graphs	O
of	O
some	O
complexity	O
is	O
very	O
time	O
consuming	O
to	O
calculate	O
.	O

For	O
example	O
,	O
the	O
simple	O
bipartite	O
graph	O
from	O
Fig.	O
1A	O
is	O
part	O
of	O
a	O
permutation	O
set	O
of	O
455	O
graphs	O
.	O

The	O
number	O
of	O
permutations	O
is	O
increasing	O
quickly	O
as	O
the	O
numbers	O
of	O
genes	O
and	O
lists	O
grow	O
.	O

However	O
,	O
since	O
edge	O
-	O
swapping	O
ensures	O
that	O
gene	O
lists	O
are	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
,	O
each	O
edge	O
-	O
swap	O
produces	O
a	O
graph	O
that	O
is	O
part	O
of	O
the	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
.	O

Edge	O
-	O
swapping	O
can	O
thus	O
be	O
viewed	O
as	O
a	O
random	O
sampling	O
procedure	O
from	O
the	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
.	O

Therefore	O
,	O
occurrence	O
probability	O
estimates	O
derived	O
by	O
edge	O
-	O
swapping	O
should	O
approximate	O
those	O
obtained	O
from	O
the	O
permutation	O
model	O
.	O

We	O
generated	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
graph	O
shown	O
in	O
Fig.	O
1A	O
to	O
verify	O
this	O
hypothesis	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

Fig.	O
3A	O
shows	O
how	O
the	O
number	O
of	O
possible	O
permutations	O
can	O
be	O
calculated	O
.	O

Gene1	O
is	O
present	O
in	O
all	O
lists	O
and	O
does	O
not	O
have	O
an	O
impact	O
on	O
the	O
total	O
number	O
of	O
permutations	O
.	O

Gene2	O
,	O
having	O
vertex	O
degree	O
two	O
,	O
is	O
present	O
in	O
two	O
out	O
of	O
three	O
lists	O
in	O
one	O
out	O
of	O
three	O
possible	O
ways	O
.	O

The	O
remaining	O
genes	O
have	O
vertex	O
degree	O
1	O
and	O
can	O
be	O
freely	O
chosen	O
to	O
fill	O
the	O
empty	O
slots	O
.	O

We	O
can	O
now	O
count	O
exactly	O
how	O
many	O
times	O
a	O
gene	O
is	O
linked	O
to	O
a	O
list	O
and	O
divide	O
these	O
counts	O
by	O
455	O
,	O
the	O
size	O
of	O
the	O
permutation	O
set	O
,	O
to	O
obtain	O
exact	O
occurrence	O
probabilities	O
.	O

These	O
numbers	O
are	O
shown	O
in	O
graphical	O
form	O
in	O
Fig.	O
3B	O
and	O
in	O
numerical	O
form	O
in	O
Fig.	O
3C	O
.	O

Fig.	O
3B	O
also	O
shows	O
the	O
occurrence	O
probability	O
estimates	O
obtained	O
by	O
edge	O
-	O
swapping	O
side	O
-	O
by	O
-	O
side	O
to	O
the	O
exact	O
occurrence	O
probabilities	O
.	O

The	O
graph	O
in	O
Fig.	O
1A	O
was	O
subjected	O
to	O
edge	O
-	O
swapping	O
1000	O
times	O
and	O
the	O
number	O
of	O
times	O
a	O
gene	O
was	O
found	O
present	O
in	O
a	O
list	O
was	O
divided	O
by	O
1000	O
to	O
obtain	O
the	O
occurrence	O
probability	O
.	O

At	O
each	O
run	O
,	O
100	O
random	O
edge	O
swaps	O
were	O
performed	O
to	O
ensure	O
complete	O
randomization	O
of	O
the	O
graph	O
.	O

This	O
procedure	O
was	O
repeated	O
10	O
times	O
and	O
the	O
mean	O
and	O
standard	O
deviation	O
of	O
occurrence	O
probability	O
estimates	O
for	O
each	O
gene	O
in	O
each	O
list	O
are	O
shown	O
.	O

In	O
all	O
cases	O
,	O
the	O
mean	O
differs	O
from	O
the	O
real	O
probability	O
by	O
less	O
than	O
two	O
standard	O
deviations	O
,	O
in	O
most	O
cases	O
by	O
less	O
than	O
one	O
standard	O
deviation	O
.	O

Thus	O
,	O
edge	O
-	O
swapping	O
provides	O
reliable	O
estimates	O
of	O
exact	O
occurrence	O
probabilities	O
as	O
determined	O
from	O
a	O
complete	O
permutation	O
set	O
.	O

As	O
an	O
interesting	O
observation	O
,	O
we	O
provide	O
evidence	O
that	O
occurrence	O
probabilities	O
are	O
non	O
-	O
linear	O
functions	O
of	O
vertex	O
degrees	O
in	O
the	O
edge	O
-	O
swapping	O
model	O
.	O

This	O
is	O
illustrated	O
in	O
Fig.	O
3C	O
.	O

Individual	O
and	O
average	O
occurrence	O
probabilities	O
are	O
shown	O
as	O
a	O
function	O
of	O
gene	O
and	O
list	O
vertex	O
degrees	O
.	O

Non	O
-	O
linearity	O
of	O
individual	O
occurrence	O
probabilities	O
can	O
be	O
verified	O
from	O
the	O
counts	O
table	O
underneath	O
the	O
plots	O
.	O

However	O
,	O
the	O
average	O
occurrence	O
probability	O
is	O
found	O
to	O
depend	O
on	O
vertex	O
degrees	O
in	O
a	O
linear	O
fashion	O
instead	O
.	O

This	O
is	O
a	O
consequence	O
of	O
the	O
fact	O
that	O
occurrence	O
probabilities	O
of	O
a	O
gene	O
over	O
all	O
lists	O
add	O
up	O
to	O
the	O
gene	O
vertex	O
degree	O
and	O
that	O
the	O
occurrence	O
probabilities	O
of	O
all	O
genes	O
for	O
a	O
given	O
list	O
add	O
up	O
to	O
the	O
list	O
vertex	O
degree	O
.	O

At	O
the	O
same	O
time	O
,	O
since	O
the	O
most	O
stringent	O
permutation	O
based	O
null	O
-	O
model	O
predicts	O
non	O
-	O
linear	O
dependencies	O
of	O
individual	O
occurrence	O
probabilities	O
on	O
vertex	O
degrees	O
,	O
assuming	O
such	O
linearity	O
in	O
statistical	O
models	O
of	O
co	O
-	O
occurrence	O
will	O
be	O
linked	O
to	O
loss	O
of	O
stringency	O
.	O

We	O
conclude	O
that	O
the	O
ES	O
null	O
-	O
model	O
is	O
the	O
null	O
-	O
model	O
that	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
among	O
the	O
models	O
tested	O
and	O
that	O
it	O
closely	O
approximates	O
occurrence	O
probabilities	O
derived	O
from	O
an	O
ideal	O
permutation	O
model	O
.	O

The	O
increased	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
other	O
models	O
is	O
a	O
consequence	O
of	O
higher	O
occurrence	O
probabilities	O
for	O
genes	O
and	O
list	O
with	O
high	O
vertex	O
degrees	O
,	O
which	O
are	O
giving	O
rise	O
to	O
a	O
large	O
part	O
of	O
all	O
co	O
-	O
occurrences	O
in	O
the	O
bipartite	O
graph	O
.	O

Since	O
large	O
occurrence	O
probabilities	O
make	O
co	O
-	O
occurrence	O
more	O
likely	O
,	O
the	O
analysis	O
becomes	O
more	O
stringent	O
.	O

Co	O
-	O
occurrence	O
probabilities	O
Co	O
-	O
occurrence	O
analysis	O
can	O
be	O
thought	O
of	O
as	O
a	O
Bernoulli	O
experiment	O
with	O
a	O
binomial	O
outcome	O
(	O
a	O
given	O
combination	O
of	O
entries	O
is	O
either	O
present	O
or	O
not	O
present	O
in	O
a	O
given	O
list	O
)	O
.	O

Thus	O
,	O
the	O
Binomial	O
distribution	O
(	O
BD	O
)	O
is	O
a	O
natural	O
choice	O
for	O
judging	O
the	O
significance	O
of	O
the	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

However	O
,	O
the	O
BD	O
is	O
defined	O
for	O
a	O
probability	O
of	O
success	O
which	O
is	O
equal	O
in	O
all	O
trials	O
.	O

The	O
list	O
-	O
specific	O
nature	O
of	O
occurrence	O
probabilities	O
is	O
not	O
compatible	O
with	O
this	O
condition	O
(	O
analysis	O
of	O
each	O
list	O
represents	O
one	O
trial	O
)	O
,	O
which	O
means	O
that	O
co	O
-	O
occurrence	O
analysis	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
better	O
described	O
as	O
a	O
series	O
of	O
Poisson	O
trials	O
,	O
where	O
the	O
probability	O
of	O
success	O
varies	O
from	O
trial	O
to	O
trial	O
.	O

Therefore	O
,	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
must	O
be	O
evaluated	O
using	O
a	O
binomial	O
distribution	O
with	O
trial	O
-	O
specific	O
probabilities	O
,	O
i.e.	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
PBD	O
)	O
.	O

The	O
probability	O
of	O
success	O
in	O
a	O
single	O
Poisson	O
trial	O
can	O
be	O
calculated	O
by	O
multiplying	O
the	O
list	O
-	O
specific	O
occurrence	O
probabilities	O
for	O
the	O
combination	O
of	O
genes	O
under	O
study	O
.	O

The	O
number	O
of	O
occurrence	O
probabilities	O
that	O
need	O
to	O
be	O
multiplied	O
is	O
equal	O
to	O
the	O
module	O
size	O
,	O
i.e.	O
the	O
number	O
of	O
genes	O
whose	O
combination	O
is	O
studied	O
.	O

An	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
a	O
combination	O
of	O
genes	O
can	O
then	O
be	O
evaluated	O
using	O
the	O
PBD	O
,	O
which	O
is	O
given	O
by	O
the	O
formula	O
[	O
36	O
]	O
:	O
(	O
18	O
)	O
The	O
structure	O
of	O
this	O
formula	O
is	O
very	O
similar	O
to	O
the	O
structure	O
of	O
the	O
formula	O
used	O
to	O
calculate	O
the	O
binomial	O
distribution	O
,	O
except	O
that	O
multiplication	O
with	O
a	O
binomial	O
coefficient	O
is	O
replaced	O
by	O
summation	O
over	O
individual	O
terms	O
,	O
which	O
makes	O
calculation	O
of	O
P	O
-	O
values	O
using	O
(	O
18	O
)	O
inefficient	O
(	O
note	O
that	O
equation	O
numbering	O
starts	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
)	O
.	O

Here	O
,	O
Ak	O
denotes	O
the	O
kth	O
set	O
of	O
indices	O
of	O
the	O
i	O
lists	O
where	O
genes	O
are	O
co	O
-	O
occurring	O
(	O
""""	O
success	O
""""	O
)	O
.	O

There	O
are	O
possible	O
sets	O
and	O
summation	O
is	O
carried	O
out	O
accordingly	O
.	O

denotes	O
the	O
set	O
of	O
indices	O
of	O
N−i	O
lists	O
where	O
genes	O
are	O
not	O
co	O
-	O
occurring	O
(	O
""""	O
failure	O
""""	O
)	O
.	O

[	O
36	O
]	O
have	O
reported	O
two	O
fast	O
procedures	O
for	O
calculating	O
exact	O
PBD	O
P	O
-	O
values	O
.	O

However	O
,	O
both	O
procedures	O
work	O
with	O
probability	O
ratios	O
and	O
suffer	O
from	O
numerical	O
overflow	O
/	O
underflow	O
problems	O
for	O
large	O
numbers	O
of	O
trials	O
.	O

NetCutter	O
uses	O
two	O
workarounds	O
to	O
circumvent	O
this	O
problem	O
.	O

One	O
is	O
based	O
on	O
using	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
,	O
which	O
can	O
be	O
calculated	O
very	O
easily	O
instead	O
(	O
see	O
below	O
)	O
.	O

The	O
other	O
relies	O
on	O
a	O
fast	O
approximation	O
procedure	O
for	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
,	O
which	O
we	O
call	O
bi	O
-	O
binomial	O
approximation	O
(	O
BBA	O
)	O
or	O
bi	O
-	O
binomial	O
distribution	O
(	O
BBD	O
)	O
.	O

Z	O
-	O
scores	O
and	O
P	O
-	O
values	O
of	O
BBD	O
Given	O
the	O
mean	O
μ	O
(	O
1	O
)	O
and	O
variance	O
σ2	O
(	O
2	O
)	O
of	O
PBD	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
,	O
the	O
Z	O
-	O
score	O
associated	O
with	O
a	O
given	O
number	O
of	O
co	O
-	O
occurrences	O
x	O
is	O
obtained	O
as:	O
(	O
19	O
)	O
Considering	O
the	O
structure	O
of	O
formulae	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
(	O
Materials	O
and	O
Methods	O
section	O
)	O
,	O
PBD	O
Z	O
-	O
scores	O
can	O
be	O
calculated	O
very	O
easily	O
and	O
provide	O
a	O
simple	O
estimate	O
of	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
modules	O
.	O

However	O
,	O
in	O
contrast	O
to	O
normally	O
distributed	O
Z	O
-	O
scores	O
,	O
binomial	O
and	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
do	O
not	O
correspond	O
to	O
the	O
same	O
P	O
-	O
value	O
for	O
different	O
sets	O
of	O
probabilities	O
of	O
success	O
.	O

To	O
see	O
this	O
,	O
calculate	O
for	O
example	O
the	O
probability	O
of	O
success	O
in	O
a	O
series	O
of	O
100	O
Bernoulli	O
trials	O
with	O
success	O
probability	O
0.1	O
and	O
0.9	O
for	O
the	O
expectation	O
of	O
10	O
and	O
90	O
successes	O
,	O
respectively	O
.	O

The	O
Z	O
-	O
score	O
will	O
be	O
0	O
in	O
both	O
cases	O
but	O
the	O
corresponding	O
cumulative	O
P	O
-	O
values	O
are	O
0.5832	O
and	O
0.5487	O
.	O

Therefore	O
,	O
exact	O
levels	O
of	O
significance	O
can	O
not	O
be	O
derived	O
from	O
Z	O
-	O
scores	O
alone	O
.	O

Thus	O
,	O
a	O
fast	O
and	O
reliable	O
procedure	O
for	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
is	O
needed	O
.	O

The	O
BBD	O
approximation	O
was	O
developed	O
to	O
solve	O
this	O
problem	O
.	O

The	O
BBD	O
approximation	O
of	O
PBD	O
P	O
-	O
values	O
follows	O
from	O
the	O
relationship	O
between	O
the	O
variance	O
of	O
PBD	O
and	O
the	O
population	O
variance	O
of	O
trial	O
-	O
specific	O
probabilities	O
of	O
success	O
.	O

This	O
relationship	O
is	O
shown	O
in	O
Materials	O
and	O
Methods	O
to	O
be	O
described	O
by	O
(	O
4	O
)	O
:	O
(	O
4	O
)	O
This	O
equation	O
shows	O
that	O
there	O
is	O
an	O
inverse	O
linear	O
relationship	O
between	O
the	O
population	O
variance	O
S2	O
of	O
the	O
N	O
trial	O
probabilities	O
and	O
the	O
variance	O
of	O
PBD	O
σ2	O
,	O
which	O
means	O
that	O
PBD	O
becomes	O
increasingly	O
narrow	O
as	O
the	O
variance	O
of	O
trial	O
probabilities	O
grows	O
.	O

It	O
also	O
shows	O
that	O
,	O
for	O
constant	O
mean	O
μ	O
and	O
number	O
of	O
trials	O
N	O
,	O
the	O
shape	O
of	O
PBD	O
depends	O
only	O
on	O
the	O
variance	O
of	O
trial	O
probabilities	O
.	O

Therefore	O
,	O
relationship	O
(	O
4	O
)	O
suggests	O
an	O
easy	O
way	O
to	O
approximate	O
PBD	O
P	O
-	O
values	O
.	O

The	O
P	O
-	O
value	O
can	O
be	O
obtained	O
by	O
constructing	O
a	O
set	O
of	O
trial	O
probabilities	O
with	O
equal	O
variance	O
as	O
the	O
original	O
set	O
of	O
trial	O
probabilities	O
,	O
which	O
,	O
however	O
,	O
are	O
not	O
all	O
different	O
.	O

In	O
other	O
words	O
,	O
the	O
series	O
of	O
Poisson	O
trials	O
can	O
be	O
replaced	O
by	O
two	O
sets	O
of	O
Bernoulli	O
trials	O
with	O
trial	O
probabilities	O
p1	O
and	O
p2	O
constructed	O
such	O
that	O
the	O
variance	O
is	O
equal	O
to	O
the	O
original	O
set	O
of	O
trial	O
probabilities	O
.	O

This	O
strategy	O
is	O
illustrated	O
in	O
Fig.	O
4	O
and	O
explains	O
why	O
this	O
approximation	O
is	O
called	O
bi	O
-	O
binomial	O
.	O

The	O
details	O
on	O
how	O
to	O
obtain	O
the	O
values	O
of	O
the	O
two	O
sets	O
of	O
Bernoulli	O
trial	O
probabilities	O
and	O
the	O
number	O
of	O
trials	O
with	O
p1	O
and	O
p2	O
as	O
probabilities	O
of	O
success	O
are	O
provided	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

The	O
precision	O
of	O
the	O
BBD	O
approximation	O
is	O
discussed	O
in	O
supplementary	O
material	O
Simulation	O
S1	O
.	O

In	O
order	O
to	O
evaluate	O
whether	O
BBD	O
P	O
-	O
values	O
as	O
a	O
significance	O
measure	O
of	O
co	O
-	O
occurrence	O
offer	O
an	O
advantage	O
over	O
other	O
measures	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
or	O
the	O
uncertainty	O
coefficient	O
,	O
pair	O
-	O
wise	O
co	O
-	O
occurrence	O
of	O
two	O
genes	O
in	O
200	O
lists	O
with	O
and	O
without	O
list	O
-	O
length	O
-	O
heterogeneity	O
was	O
studied	O
(	O
Fig.	O
5	O
)	O
.	O

Each	O
gene	O
is	O
assumed	O
to	O
occur	O
in	O
100	O
lists	O
.	O

Therefore	O
,	O
the	O
occurrence	O
probabilities	O
of	O
both	O
genes	O
over	O
all	O
200	O
lists	O
must	O
add	O
up	O
to	O
100	O
,	O
regardless	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

For	O
simplicity	O
,	O
occurrence	O
probabilities	O
of	O
both	O
genes	O
are	O
assumed	O
to	O
be	O
equal	O
in	O
any	O
particular	O
list	O
.	O

The	O
co	O
-	O
occurrence	O
probability	O
in	O
a	O
list	O
is	O
then	O
given	O
by	O
the	O
square	O
of	O
the	O
occurrence	O
probability	O
in	O
that	O
list	O
.	O

For	O
all	O
possible	O
co	O
-	O
occurrences	O
from	O
0	O
to	O
100	O
,	O
the	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
were	O
calculated	O
as	O
detailed	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

In	O
addition	O
,	O
cumulative	O
BBD	O
P	O
-	O
values	O
were	O
calculated	O
using	O
the	O
co	O
-	O
occurrence	O
probabilities	O
as	O
trial	O
probabilities	O
.	O

To	O
illustrate	O
the	O
advantage	O
of	O
BBD	O
over	O
BD	O
as	O
co	O
-	O
occurrence	O
probability	O
distribution	O
,	O
cumulative	O
BD	O
P	O
-	O
values	O
of	O
a	O
BD	O
with	O
the	O
same	O
mean	O
as	O
BBD	O
but	O
constant	O
trial	O
probabilities	O
is	O
shown	O
.	O

These	O
trial	O
probabilities	O
can	O
be	O
obtained	O
by	O
dividing	O
the	O
mean	O
of	O
BBD	O
by	O
the	O
number	O
of	O
lists	O
.	O

Three	O
different	O
cases	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
are	O
considered	O
in	O
Fig.	O
5	O
:	O
No	O
heterogeneity	O
(	O
standard	O
deviation	O
0	O
)	O
,	O
heterogeneity	O
with	O
standard	O
deviation	O
0.283	O
and	O
heterogeneity	O
with	O
standard	O
deviation	O
0.401	O
in	O
the	O
occurrence	O
probabilities	O
.	O

The	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
are	O
by	O
definition	O
insensitive	O
to	O
list	O
-	O
length	O
-	O
heterogeneity	O
because	O
differences	O
in	O
co	O
-	O
occurrence	O
probabilities	O
in	O
a	O
given	O
list	O
can	O
not	O
be	O
considered	O
in	O
their	O
calculation	O
.	O

This	O
is	O
because	O
both	O
coefficients	O
are	O
defined	O
by	O
the	O
counts	O
of	O
the	O
four	O
list	O
classes	O
:	O
both	O
genes	O
absent	O
,	O
both	O
genes	O
present	O
,	O
first	O
gene	O
absent	O
second	O
gene	O
present	O
,	O
and	O
first	O
gene	O
present	O
second	O
gene	O
absent	O
,	O
i.e.	O
by	O
the	O
corresponding	O
contingency	O
table	O
,	O
which	O
does	O
not	O
change	O
with	O
different	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

In	O
the	O
absence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
cumulative	O
P	O
-	O
values	O
of	O
BD	O
and	O
BBD	O
(	O
which	O
are	O
perfectly	O
overlapping	O
as	O
expected	O
)	O
assume	O
0.5	O
at	O
50	O
co	O
-	O
occurrences	O
,	O
which	O
corresponds	O
to	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
calculated	O
as	O
(	O
50	O
=	O
100	O
occurrences	O
per	O
gene	O
/	O
200	O
lists	O
)	O
ˆ2	O
*	O
200	O
lists	O
.	O

The	O
uncertainty	O
coefficient	O
is	O
found	O
to	O
be	O
0	O
and	O
the	O
Jaccard	O
coefficient	O
is	O
0.33333	O
at	O
that	O
point	O
.	O

When	O
there	O
is	O
modest	O
list	O
-	O
length	O
-	O
heterogeneity	O
(	O
standard	O
deviation	O
0.283	O
)	O
,	O
the	O
mean	O
of	O
BBD	O
is	O
shifting	O
to	O
the	O
right	O
.	O

This	O
is	O
because	O
the	O
sum	O
of	O
squares	O
of	O
varying	O
occurrence	O
probabilities	O
(	O
i.e.	O
the	O
sum	O
of	O
co	O
-	O
occurrence	O
probabilities	O
used	O
as	O
trial	O
probabilities	O
,	O
which	O
is	O
equal	O
to	O
the	O
mean	O
of	O
BBD	O
)	O
is	O
always	O
larger	O
than	O
the	O
sum	O
of	O
squares	O
of	O
constant	O
occurrence	O
probabilities	O
with	O
the	O
same	O
average	O
occurrence	O
probability	O
(	O
0.5	O
)	O
.	O

The	O
corresponding	O
BD	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
obtained	O
by	O
dividing	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
by	O
the	O
total	O
number	O
of	O
lists	O
,	O
which	O
means	O
assuming	O
equal	O
co	O
-	O
occurrences	O
in	O
all	O
lists	O
.	O

This	O
visualization	O
is	O
shown	O
to	O
illustrate	O
how	O
BBD	O
(	O
which	O
is	O
narrower	O
than	O
the	O
corresponding	O
BD	O
)	O
gives	O
rise	O
to	O
a	O
steeper	O
cumulative	O
distribution	O
of	O
P	O
-	O
values	O
and	O
as	O
a	O
consequence	O
to	O
more	O
significant	O
P	O
-	O
values	O
for	O
numbers	O
of	O
co	O
-	O
occurrence	O
that	O
are	O
far	O
from	O
the	O
expectation	O
.	O

As	O
the	O
level	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
grows	O
(	O
standard	O
deviation	O
of	O
occurrence	O
probabilities	O
0.401	O
)	O
,	O
the	O
mean	O
of	O
BBD	O
is	O
shifted	O
even	O
further	O
to	O
the	O
right	O
and	O
BBD	O
P	O
-	O
values	O
are	O
distributed	O
in	O
a	O
still	O
steeper	O
fashion	O
as	O
compared	O
to	O
corresponding	O
BD	O
P	O
-	O
values	O
and	O
the	O
interval	O
of	O
non	O
-	O
significant	O
co	O
-	O
occurrences	O
is	O
shrinking	O
further	O
.	O

With	O
modest	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
66	O
,	O
which	O
is	O
associated	O
with	O
a	O
Jaccard	O
coefficient	O
of	O
0.49	O
and	O
an	O
uncertainty	O
coefficient	O
of	O
0.075	O
.	O

In	O
the	O
case	O
of	O
large	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
82	O
with	O
J	O
=	O
0.69	O
and	O
UC	O
=	O
0.32	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
varies	O
strongly	O
with	O
the	O
level	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
and	O
that	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
associated	O
with	O
different	O
values	O
of	O
UC	O
and	O
J.	O
To	O
complicate	O
matters	O
further	O
,	O
66	O
co	O
-	O
occurrences	O
(	O
J	O
=	O
0.49	O
,	O
UC	O
=	O
0.075	O
)	O
represent	O
significant	O
positive	O
association	O
(	O
PBBD	O
=	O
0.996	O
)	O
with	O
equal	O
list	O
lengths	O
,	O
no	O
significant	O
association	O
with	O
modest	O
differences	O
in	O
list	O
length	O
(	O
PBBD	O
=	O
0.536	O
)	O
and	O
strongly	O
negative	O
association	O
(	O
meaning	O
one	O
gene	O
excludes	O
the	O
other	O
)	O
with	O
strong	O
list	O
-	O
length	O
-	O
heterogeneity	O
(	O
PBBD	O
=	O
0.00016	O
)	O
.	O

Thus	O
,	O
the	O
same	O
J	O
and	O
UC	O
association	O
measure	O
is	O
obtained	O
for	O
positive	O
,	O
negative	O
,	O
and	O
absence	O
of	O
association	O
.	O

Therefore	O
,	O
the	O
meaning	O
of	O
these	O
measures	O
can	O
not	O
be	O
interpreted	O
properly	O
in	O
the	O
absence	O
of	O
knowledge	O
about	O
the	O
occurrence	O
probabilities	O
of	O
the	O
co	O
-	O
occurring	O
entities	O
.	O

Furthermore	O
,	O
the	O
data	O
in	O
Fig.	O
5	O
also	O
show	O
that	O
neither	O
J	O
nor	O
UC	O
can	O
distinguish	O
between	O
positive	O
and	O
negative	O
association	O
while	O
this	O
is	O
easy	O
with	O
cumulative	O
BBD	O
P	O
-	O
values	O
:	O
Large	O
P	O
-	O
values	O
mean	O
positive	O
association	O
and	O
low	O
P	O
-	O
values	O
mean	O
negative	O
association	O
.	O

In	O
summary	O
,	O
we	O
conclude	O
that	O
BBD	O
provides	O
a	O
novel	O
association	O
measure	O
that	O
offers	O
a	O
number	O
of	O
advantages	O
over	O
the	O
existing	O
contingency	O
table	O
based	O
association	O
measures	O
Jaccard	O
coefficient	O
and	O
uncertainty	O
coefficient	O
.	O

The	O
results	O
in	O
Fig.	O
5	O
also	O
show	O
that	O
significance	O
of	O
association	O
depends	O
critically	O
on	O
the	O
specific	O
distribution	O
of	O
co	O
-	O
occurring	O
entities	O
over	O
lists	O
of	O
varying	O
length	O
(	O
because	O
this	O
distribution	O
determines	O
the	O
occurrence	O
probabilities	O
)	O
and	O
that	O
contingency	O
table	O
based	O
methods	O
(	O
which	O
can	O
not	O
capture	O
this	O
distribution	O
)	O
should	O
be	O
avoided	O
in	O
the	O
presence	O
of	O
significant	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

Generation	O
of	O
co	O
-	O
occurrence	O
networks	O
and	O
the	O
identification	O
of	O
communities	O
The	O
procedures	O
outlined	O
above	O
allow	O
the	O
identification	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
any	O
type	O
of	O
bipartite	O
graph	O
.	O

Three	O
user	O
defined	O
parameters	O
have	O
an	O
impact	O
on	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
:	O
The	O
module	O
size	O
,	O
the	O
support	O
,	O
and	O
the	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
.	O

The	O
module	O
size	O
determines	O
how	O
many	O
entries	O
will	O
be	O
tested	O
for	O
co	O
-	O
occurrence	O
,	O
the	O
support	O
sets	O
a	O
lower	O
boundary	O
on	O
the	O
required	O
number	O
of	O
co	O
-	O
occurrences	O
,	O
and	O
the	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
sets	O
the	O
significance	O
threshold	O
.	O

In	O
general	O
,	O
higher	O
module	O
size	O
leads	O
to	O
more	O
stringent	O
co	O
-	O
occurrence	O
analysis	O
at	O
the	O
cost	O
of	O
computational	O
complexity	O
.	O

The	O
support	O
parameter	O
allows	O
limiting	O
this	O
complexity	O
by	O
filtering	O
out	O
co	O
-	O
occurrence	O
modules	O
which	O
co	O
-	O
occur	O
less	O
frequently	O
than	O
required	O
by	O
the	O
support	O
.	O

The	O
significance	O
cutoff	O
permits	O
adjusting	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
,	O
which	O
is	O
calculated	O
as	O
the	O
number	O
of	O
co	O
-	O
occurrence	O
modules	O
observed	O
in	O
the	O
real	O
versus	O
a	O
randomized	O
bipartite	O
graph	O
.	O

The	O
impact	O
of	O
these	O
parameters	O
on	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
has	O
been	O
reported	O
previously	O
for	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
and	O
is	O
illustrated	O
in	O
a	O
simulation	O
study	O
provided	O
as	O
supplementary	O
material	O
Simulation	O
S1	O
.	O

From	O
the	O
set	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
,	O
a	O
co	O
-	O
occurrence	O
network	O
is	O
generated	O
by	O
considering	O
each	O
entry	O
a	O
vertex	O
and	O
drawing	O
an	O
edge	O
between	O
any	O
two	O
vertices	O
,	O
which	O
have	O
been	O
part	O
of	O
the	O
same	O
significant	O
co	O
-	O
occurrence	O
module	O
[	O
35	O
]	O
.	O

An	O
important	O
question	O
in	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
regards	O
the	O
presence	O
of	O
network	O
communities	O
.	O

Communities	O
can	O
be	O
understood	O
as	O
groups	O
of	O
vertices	O
with	O
the	O
property	O
that	O
the	O
number	O
of	O
edges	O
running	O
within	O
groups	O
is	O
larger	O
than	O
expected	O
by	O
chance	O
and	O
that	O
the	O
number	O
of	O
edges	O
running	O
between	O
groups	O
is	O
lower	O
than	O
expected	O
by	O
chance	O
[	O
37	O
]	O
.	O

This	O
problem	O
of	O
partitioning	O
a	O
graph	O
is	O
often	O
referred	O
to	O
as	O
the	O
graph	O
-	O
cut	O
problem	O
(	O
hence	O
the	O
name	O
NetCutter	O
)	O
.	O

NetCutter	O
is	O
built	O
on	O
the	O
Java	O
Universal	O
Network	O
and	O
Graph	O
framework	O
(	O
JUNG	O
)	O
software	O
package	O
(	O
http://jung.sourceforge.net	O
)	O
,	O
which	O
provides	O
algorithms	O
for	O
solving	O
this	O
problem	O
.	O

In	O
particular	O
,	O
NetCutter	O
implements	O
the	O
Bicomponent	O
clustering	O
algorithm	O
[	O
38	O
]	O
,	O
the	O
Edge	O
-	O
Betweenness	O
clustering	O
algorithm	O
[	O
39	O
]	O
,	O
and	O
the	O
Exact	O
Flow	O
Community	O
algorithm	O
[	O
40	O
]	O
.	O

Furthermore	O
,	O
there	O
is	O
a	O
clustering	O
tool	O
that	O
is	O
not	O
part	O
of	O
the	O
JUNG	O
package	O
,	O
namely	O
an	O
algorithm	O
identifying	O
communities	O
using	O
eigenvectors	O
of	O
the	O
modularity	O
matrix	O
[	O
37	O
]	O
.	O

The	O
code	O
for	O
this	O
algorithm	O
was	O
kindly	O
provided	O
by	O
Mark	O
Newman	O
in	O
C++	O
and	O
ported	O
to	O
Java	O
.	O

In	O
addition	O
to	O
these	O
tools	O
,	O
NetCutter	O
provides	O
a	O
number	O
of	O
convenience	O
functions	O
for	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
such	O
as	O
testing	O
the	O
significance	O
of	O
lists	O
reporting	O
a	O
set	O
of	O
entries	O
making	O
up	O
a	O
network	O
community	O
,	O
ranking	O
of	O
vertices	O
,	O
random	O
graph	O
generators	O
for	O
topological	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
and	O
others	O
.	O

Details	O
on	O
all	O
functions	O
are	O
provided	O
in	O
the	O
NetCutter	O
software	O
documentation	O
.	O

One	O
of	O
the	O
possible	O
applications	O
of	O
NetCutter	O
is	O
illustrated	O
below	O
.	O

This	O
application	O
is	O
tightly	O
linked	O
to	O
the	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
.	O

Namely	O
,	O
NetCutter	O
can	O
be	O
used	O
to	O
perform	O
co	O
-	O
occurrence	O
analysis	O
of	O
genes	O
or	O
list	O
derived	O
from	O
the	O
same	O
bipartite	O
graph	O
.	O

The	O
network	O
communities	O
identified	O
in	O
each	O
both	O
reflect	O
the	O
same	O
underlying	O
structure	O
of	O
the	O
bipartite	O
graph	O
.	O

In	O
the	O
case	O
of	O
gene	O
expression	O
signatures	O
stored	O
in	O
PubLiME	O
,	O
clusters	O
of	O
genes	O
correspond	O
to	O
clusters	O
of	O
publications	O
,	O
which	O
can	O
reveal	O
possible	O
functions	O
of	O
gene	O
clusters	O
.	O

Cluster	O
correspondence	O
and	O
association	O
studies	O
The	O
co	O
-	O
occurrence	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
published	O
previously	O
[	O
35	O
]	O
identified	O
5	O
major	O
network	O
communities	O
of	O
genes	O
with	O
consistent	O
functional	O
annotations	O
that	O
are	O
deregulated	O
in	O
cancer	O
related	O
gene	O
expression	O
signatures	O
.	O

This	O
analysis	O
was	O
performed	O
by	O
considering	O
all	O
genes	O
mentioned	O
in	O
a	O
particular	O
publication	O
as	O
a	O
single	O
signature	O
,	O
even	O
though	O
they	O
might	O
have	O
been	O
part	O
of	O
different	O
tables	O
and	O
cluster	O
analyses	O
.	O

Here	O
we	O
present	O
an	O
advanced	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
where	O
each	O
table	O
and/or	O
cluster	O
identified	O
in	O
a	O
given	O
publication	O
is	O
considered	O
as	O
a	O
separate	O
signature	O
.	O

This	O
brings	O
the	O
total	O
number	O
of	O
signatures	O
to	O
be	O
analyzed	O
to	O
1015	O
comprising	O
a	O
total	O
of	O
7358	O
differentially	O
regulated	O
genes	O
derived	O
from	O
233	O
publications	O
reporting	O
cancer	O
related	O
signatures	O
derived	O
from	O
human	B
samples	O
.	O

We	O
use	O
this	O
analysis	O
to	O
illustrate	O
three	O
major	O
points	O
:	O
First	O
,	O
the	O
set	O
of	O
communities	O
reported	O
previously	O
is	O
reproduced	O
by	O
this	O
more	O
fine	O
-	O
grained	O
analysis	O
.	O

Second	O
,	O
the	O
set	O
of	O
gene	O
communities	O
corresponds	O
to	O
a	O
set	O
of	O
publication	O
communities	O
.	O

Third	O
,	O
associations	O
between	O
publications	O
and	O
gene	O
communities	O
can	O
be	O
calculated	O
with	O
higher	O
stringency	O
using	O
the	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
in	O
conjunction	O
with	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
as	O
compared	O
to	O
binomial	O
or	O
hypergeometric	O
statistics	O
.	O

The	O
bipartite	O
graph	O
to	O
be	O
analyzed	O
is	O
composed	O
of	O
PubMedID_listID	O
-	O
gene	O
pairs	O
(	O
see	O
supplementary	O
material	O
Table	O
S1	O
)	O
.	O

Co	O
-	O
occurrence	O
analysis	O
was	O
carried	O
out	O
in	O
two	O
ways	O
:	O
First	O
,	O
gene	O
co	O
-	O
occurrence	O
was	O
analyzed	O
and	O
communities	O
of	O
co	O
-	O
occurring	O
genes	O
were	O
defined	O
by	O
edge	O
-	O
betweenness	O
clustering	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Second	O
,	O
co	O
-	O
occurrence	O
of	O
PubMedID_listIDs	O
was	O
analyzed	O
.	O

To	O
this	O
end	O
,	O
the	O
order	O
of	O
PubMedID_listID	O
-	O
gene	O
pairs	O
was	O
reversed	O
to	O
form	O
GENE	O
-	O
PUBMEDID_LISTID	O
pairs	O
.	O

Thus	O
,	O
the	O
lists	O
in	O
the	O
resulting	O
bipartite	O
graph	O
are	O
formed	O
by	O
genes	O
and	O
the	O
entries	O
are	O
the	O
PubMedID_listIDs	O
where	O
the	O
genes	O
are	O
reported	O
as	O
differentially	O
regulated	O
.	O

Occurrence	O
probabilities	O
for	O
the	O
reversed	O
bipartite	O
graph	O
can	O
be	O
obtained	O
by	O
transposing	O
the	O
occurrence	O
probability	O
matrix	O
of	O
the	O
original	O
bipartite	O
graph	O
.	O

Since	O
the	O
gene	O
communities	O
identified	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
reflect	O
the	O
structure	O
inherent	O
in	O
the	O
bipartite	O
graph	O
(	O
which	O
is	O
not	O
affected	O
by	O
reversing	O
the	O
list	O
-	O
entry	O
order	O
)	O
,	O
co	O
-	O
occurrence	O
analysis	O
of	O
the	O
reversed	O
bipartite	O
graph	O
will	O
result	O
in	O
PubMedID_listID	O
communities	O
that	O
reflect	O
the	O
same	O
underlying	O
structure	O
in	O
the	O
bipartite	O
graph	O
.	O

In	O
other	O
words	O
,	O
PubMedID_listID	O
communities	O
correspond	O
to	O
gene	O
communities	O
.	O

In	O
less	O
abstract	O
terms	O
,	O
the	O
PubMedID_listID	O
communities	O
should	O
correspond	O
to	O
sets	O
of	O
publications	O
that	O
report	O
similar	O
sets	O
of	O
genes	O
as	O
differentially	O
regulated	O
.	O

The	O
identification	O
of	O
communities	O
of	O
publications	O
can	O
help	O
the	O
researcher	O
to	O
easily	O
identify	O
publications	O
studying	O
genes	O
in	O
a	O
gene	O
community	O
that	O
is	O
of	O
interest	O
to	O
the	O
researcher	O
.	O

The	O
results	O
of	O
both	O
types	O
of	O
co	O
-	O
occurrence	O
analysis	O
are	O
displayed	O
in	O
Fig.	O
6	O
.	O

Fig.	O
6A	O
shows	O
the	O
gene	O
clusters	O
identified	O
.	O

The	O
clusters	O
are	O
named	O
after	O
significant	O
enrichments	O
of	O
gene	O
categories	O
as	O
determined	O
by	O
functional	O
category	O
enrichment	O
using	O
DAVID	O
[	O
41	O
]	O
.	O

The	O
P	O
-	O
values	O
shown	O
are	O
Benjamini	O
corrected	O
for	O
multiple	O
testing	O
as	O
reported	O
by	O
DAVID	O
.	O

The	O
clusters	O
are	O
very	O
similar	O
to	O
the	O
clusters	O
published	O
previously	O
[	O
35	O
]	O
.	O

There	O
is	O
one	O
new	O
cluster	O
that	O
is	O
strongly	O
enriched	O
for	O
ribosomal	O
proteins	O
(	O
""""	O
protein	O
biosynthesis	O
""""	O
cluster	O
)	O
,	O
which	O
has	O
not	O
reached	O
significance	O
in	O
our	O
previous	O
analysis	O
.	O

The	O
""""	O
surface	O
antigen	O
""""	O
cluster	O
contains	O
many	O
genes	O
that	O
had	O
been	O
reported	O
as	O
part	O
of	O
the	O
""""	O
signal	O
transduction	O
""""	O
cluster	O
.	O

Altogether	O
,	O
however	O
,	O
these	O
results	O
strongly	O
support	O
the	O
notion	O
that	O
the	O
gene	O
clusters	O
in	O
the	O
PubLiME	O
data	O
set	O
can	O
be	O
reproduced	O
by	O
the	O
more	O
fine	O
-	O
grained	O
analysis	O
that	O
considers	O
sublists	O
in	O
each	O
publication	O
as	O
separate	O
signatures	O
.	O

The	O
corresponding	O
clusters	O
of	O
PubMedID_listIDs	O
are	O
shown	O
in	O
Fig.	O
6B	O
.	O

There	O
are	O
five	O
clusters	O
,	O
which	O
have	O
been	O
named	O
after	O
their	O
corresponding	O
gene	O
cluster	O
.	O

Only	O
one	O
cluster	O
(	O
the	O
""""	O
extracellular	O
matrix	O
-	O
immune	O
response	O
cluster	O
""""	O
)	O
can	O
not	O
be	O
separated	O
by	O
edge	O
-	O
betweenness	O
clustering	O
at	O
the	O
point	O
of	O
maximal	O
graph	O
modularity	O
.	O

To	O
see	O
that	O
this	O
naming	O
is	O
indeed	O
justified	O
,	O
we	O
needed	O
to	O
investigate	O
how	O
strongly	O
a	O
given	O
PubMedID_listID	O
is	O
associated	O
with	O
a	O
given	O
gene	O
cluster	O
,	O
i.e.	O
how	O
significant	O
is	O
the	O
overlap	O
of	O
the	O
genes	O
reported	O
in	O
a	O
gene	O
cluster	O
and	O
the	O
genes	O
reported	O
in	O
a	O
PubMedID_listID	O
.	O

Binomial	O
or	O
hypergemetric	O
statistics	O
are	O
generally	O
used	O
to	O
calculate	O
this	O
significance	O
.	O

However	O
,	O
the	O
bipartite	O
graph	O
model	O
in	O
conjunction	O
with	O
the	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
offers	O
a	O
more	O
fine	O
-	O
grained	O
approach	O
based	O
on	O
bi	O
-	O
binomial	O
statistics	O
.	O

The	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
determines	O
occurrence	O
probabilities	O
in	O
such	O
a	O
way	O
that	O
the	O
number	O
of	O
genes	O
in	O
a	O
given	O
PubMedID_listID	O
is	O
associated	O
with	O
insignificant	O
P	O
-	O
values	O
in	O
the	O
context	O
of	O
the	O
complete	O
bipartite	O
graph	O
.	O

However	O
,	O
when	O
a	O
subset	O
of	O
genes	O
is	O
analyzed	O
,	O
e.g.	O
all	O
the	O
genes	O
that	O
are	O
reported	O
in	O
a	O
particular	O
list	O
,	O
the	O
P	O
-	O
value	O
associated	O
with	O
the	O
number	O
of	O
genes	O
contained	O
in	O
this	O
list	O
will	O
likely	O
be	O
highly	O
significant	O
according	O
to	O
how	O
unlikely	O
it	O
is	O
to	O
obtain	O
all	O
the	O
genes	O
contained	O
in	O
a	O
given	O
list	O
in	O
a	O
random	O
draw	O
from	O
all	O
genes	O
present	O
in	O
the	O
bipartite	O
graph	O
.	O

Thus	O
,	O
PubMedID_listID	O
association	O
with	O
a	O
set	O
of	O
genes	O
in	O
the	O
bipartite	O
graph	O
model	O
can	O
be	O
calculated	O
in	O
the	O
following	O
way	O
:	O
The	O
set	O
of	O
genes	O
that	O
is	O
used	O
to	O
analyze	O
association	O
is	O
used	O
to	O
extract	O
a	O
subgraph	O
from	O
the	O
original	O
bipartite	O
graph	O
where	O
occurrence	O
probabilities	O
for	O
each	O
gene	O
-	O
PubMedID_listID	O
pair	O
are	O
identical	O
to	O
those	O
in	O
the	O
original	O
bipartite	O
graph	O
(	O
i.e.	O
they	O
are	O
not	O
recalculated	O
by	O
edge	O
-	O
swapping	O
)	O
.	O

The	O
vertex	O
degree	O
of	O
the	O
PubMedID_listID	O
vertices	O
in	O
the	O
subgraph	O
indicates	O
the	O
number	O
of	O
genes	O
contained	O
in	O
each	O
PubMedID_listID	O
overlapping	O
with	O
the	O
set	O
of	O
genes	O
used	O
to	O
extract	O
the	O
subgraph	O
.	O

From	O
the	O
occurrence	O
probabilities	O
of	O
the	O
genes	O
in	O
a	O
given	O
PubMedID_listID	O
,	O
the	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
can	O
then	O
be	O
calculated	O
for	O
every	O
list	O
vertex	O
degree	O
observed	O
in	O
the	O
subgraph	O
.	O

In	O
Fig.	O
7	O
,	O
the	O
significance	O
of	O
association	O
of	O
the	O
PubMedID_listIDs	O
(	O
see	O
Fig.	O
6B	O
)	O
with	O
the	O
cell	O
cycle	O
cluster	O
of	O
genes	O
(	O
Fig.	O
6A	O
)	O
is	O
calculated	O
.	O

For	O
comparison	O
,	O
binomial	O
and	O
hypergeometric	O
P	O
-	O
values	O
are	O
also	O
shown	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
is	O
larger	O
than	O
the	O
binomial	O
and	O
hypergeometric	O
P	O
-	O
values	O
,	O
which	O
means	O
that	O
the	O
strength	O
of	O
association	O
is	O
evaluated	O
in	O
a	O
more	O
stringent	O
manner	O
using	O
BBD	O
statistics	O
(	O
see	O
Discussion	O
for	O
an	O
explanation	O
of	O
this	O
observation	O
)	O
.	O

The	O
analysis	O
of	O
significant	O
associations	O
between	O
PubMedID_listIDs	O
and	O
gene	O
clusters	O
now	O
permit	O
answering	O
the	O
question	O
whether	O
there	O
is	O
correspondence	O
between	O
gene	O
clusters	O
and	O
PubMedID_listID	O
clusters	O
.	O

The	O
naming	O
of	O
PubMedID_listID	O
clusters	O
shown	O
in	O
Fig.	O
6B	O
is	O
based	O
on	O
the	O
number	O
of	O
PubMedID_listID	O
that	O
are	O
significantly	O
associated	O
with	O
gene	O
clusters	O
shown	O
in	O
Fig.	O
6A	O
.	O

First	O
,	O
for	O
each	O
gene	O
cluster	O
,	O
all	O
the	O
PubMedID_listIDs	O
that	O
are	O
associated	O
with	O
that	O
cluster	O
with	O
more	O
than	O
95	O
%	O
confidence	O
(	O
i.e.	O
cumulative	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
>	O
=	O
0.95	O
)	O
were	O
identified	O
.	O

Second	O
,	O
the	O
number	O
of	O
significant	O
PubMedID_listIDs	O
in	O
each	O
PubMedID_listID	O
cluster	O
was	O
counted	O
for	O
every	O
gene	O
cluster	O
.	O

The	O
significance	O
of	O
this	O
number	O
was	O
then	O
calculated	O
using	O
binomial	O
statistics	O
.	O

The	O
results	O
of	O
this	O
analysis	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Negative	O
decadic	O
logarithms	O
of	O
the	O
binomial	O
P	O
-	O
value	O
are	O
displayed	O
.	O

It	O
is	O
apparent	O
that	O
each	O
PubMedID_listID	O
cluster	O
is	O
strongly	O
associated	O
with	O
at	O
least	O
one	O
gene	O
cluster	O
,	O
except	O
for	O
the	O
""""	O
extracellular	O
matrix	O
-	O
immune	O
response	O
""""	O
cluster	O
,	O
which	O
is	O
associated	O
with	O
two	O
gene	O
clusters	O
.	O

The	O
strength	O
of	O
these	O
associations	O
suggests	O
that	O
the	O
PubMedID_listID	O
clusters	O
are	O
indeed	O
corresponding	O
to	O
the	O
gene	O
clusters	O
and	O
that	O
both	O
the	O
gene	O
and	O
the	O
PubMedID_listID	O
clusters	O
reflect	O
the	O
structure	O
of	O
the	O
bipartite	O
graph	O
representing	O
the	O
PubLiME	O
data	O
set	O
.	O

Details	O
about	O
all	O
the	O
lists	O
analyzed	O
are	O
attached	O
as	O
supplementary	O
material	O
Table	O
S2	O
.	O

Looking	O
at	O
these	O
lists	O
,	O
some	O
general	O
conclusions	O
about	O
the	O
gene	O
clusters	O
can	O
be	O
drawn	O
.	O

Cell	O
cycle	O
cluster	O
genes	O
have	O
been	O
found	O
deregulated	O
in	O
a	O
wide	O
variety	O
of	O
tumor	O
types	O
such	O
as	O
colon	O
cancer	O
,	O
breast	O
cancer	O
,	O
in	O
biliary	O
tract	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
gastric	O
cancer	O
,	O
prostate	O
cancer	O
,	O
T	O
-	O
cell	O
leukemia	O
,	O
glioma	O
,	O
acute	O
lymphoblastic	O
and	O
myeloblastic	O
leukemias	O
,	O
soft	O
tissue	O
sarcoma	O
,	O
neuroblastoma	O
,	O
as	O
well	O
as	O
in	O
a	O
number	O
of	O
cellular	O
model	O
systems	O
in	O
response	O
to	O
different	O
stimuli	O
.	O

Thus	O
,	O
the	O
cell	O
cycle	O
cluster	O
seems	O
to	O
consist	O
of	O
genes	O
with	O
a	O
general	O
role	O
in	O
oncogenesis	O
.	O

The	O
surface	O
antigen	O
cluster	O
instead	O
seems	O
to	O
be	O
derived	O
preferentially	O
from	O
studies	O
on	O
leukemia	O
.	O

The	O
interferon	O
cluster	O
genes	O
are	O
found	O
deregulated	O
in	O
virus	O
induced	O
pathologies	O
such	O
as	O
papilloma	O
virus	O
induced	O
cervical	O
cancer	O
,	O
and	O
viral	O
hepatitis	O
.	O

Immune	O
response	O
cluster	O
genes	O
were	O
reported	O
as	O
differentially	O
regulated	O
in	O
inflammatory	O
conditions	O
such	O
as	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
,	O
and	O
Helicobacter	B
pylori	I
infections	O
.	O

Genes	O
of	O
the	O
extracellular	O
matrix	O
cluster	O
seem	O
to	O
be	O
associated	O
with	O
cancer	O
progression	O
studies	O
and	O
metastatic	O
potential	O
.	O

For	O
the	O
protein	O
biosynthesis	O
cluster	O
,	O
there	O
are	O
15	O
signatures	O
that	O
are	O
significantly	O
enriched	O
for	O
those	O
genes	O
.	O

The	O
cancers	O
studied	O
comprise	O
medulloblastoma	O
,	O
glioblastoma	O
,	O
pancreatic	O
cancer	O
,	O
soft	O
tissue	O
sarcoma	O
,	O
lung	O
carcinoma	O
,	O
breast	O
carcinoma	O
,	O
prostate	O
carcinoma	O
,	O
multiple	O
myeloma	O
,	O
and	O
lymphocytic	O
leukemia	O
.	O

The	O
genes	O
are	O
also	O
found	O
deregulated	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

Although	O
the	O
number	O
of	O
signatures	O
is	O
limited	O
,	O
the	O
variation	O
in	O
conditions	O
where	O
the	O
genes	O
are	O
deregulated	O
is	O
compatible	O
with	O
the	O
hypothesis	O
that	O
protein	O
biosynthesis	O
genes	O
,	O
as	O
cell	O
cycle	O
genes	O
,	O
are	O
deregulated	O
in	O
many	O
cancer	O
types	O
,	O
which	O
might	O
reflect	O
the	O
general	O
property	O
of	O
cancer	O
cells	O
to	O
divide	O
and	O
grow	O
in	O
an	O
uncontrolled	O
fashion	O
.	O

Discussion	O
Here	O
we	O
have	O
investigated	O
basic	O
aspects	O
of	O
co	O
-	O
occurrence	O
analysis	O
and	O
present	O
a	O
software	O
tool	O
,	O
NetCutter	O
,	O
which	O
can	O
be	O
used	O
to	O
identify	O
and	O
analyze	O
generic	O
co	O
-	O
occurrence	O
networks	O
.	O

In	O
NetCutter	O
,	O
a	O
co	O
-	O
occurrence	O
data	O
set	O
is	O
represented	O
as	O
a	O
bipartite	O
graph	O
with	O
one	O
part	O
representing	O
lists	O
and	O
the	O
other	O
part	O
list	O
entries	O
whose	O
co	O
-	O
occurrence	O
patterns	O
are	O
studied	O
.	O

The	O
bipartite	O
graph	O
representation	O
of	O
co	O
-	O
occurrence	O
data	O
sets	O
allows	O
the	O
efficacy	O
of	O
different	O
null	O
-	O
models	O
to	O
be	O
tested	O
systematically	O
.	O

We	O
have	O
shown	O
that	O
an	O
edge	O
-	O
swapping	O
procedure	O
used	O
to	O
randomize	O
the	O
bipartite	O
graph	O
generates	O
a	O
null	O
-	O
model	O
that	O
allows	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
.	O

The	O
other	O
null	O
-	O
models	O
tested	O
here	O
tend	O
to	O
underestimate	O
occurrence	O
probabilities	O
of	O
entries	O
per	O
list	O
for	O
lists	O
and	O
genes	O
with	O
high	O
vertex	O
degrees	O
,	O
i.e.	O
for	O
lists	O
and	O
genes	O
where	O
most	O
co	O
-	O
occurrences	O
are	O
observed	O
.	O

As	O
a	O
result	O
,	O
co	O
-	O
occurrences	O
are	O
judged	O
more	O
significant	O
than	O
they	O
really	O
are	O
.	O

Co	O
-	O
occurrence	O
data	O
sets	O
with	O
exactly	O
equal	O
lists	O
lengths	O
are	O
likely	O
to	O
be	O
the	O
exception	O
from	O
the	O
rule	O
.	O

It	O
can	O
be	O
assumed	O
that	O
some	O
list	O
-	O
length	O
-	O
heterogeneity	O
will	O
be	O
present	O
in	O
most	O
circumstances	O
.	O

An	O
important	O
consequence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
regards	O
the	O
co	O
-	O
occurrence	O
probability	O
distribution	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
the	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

Co	O
-	O
occurrence	O
analysis	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
best	O
performed	O
using	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
a	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
.	O

However	O
,	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
for	O
large	O
numbers	O
of	O
lists	O
is	O
difficult	O
using	O
existing	O
procedures	O
[	O
36	O
]	O
.	O

We	O
have	O
presented	O
an	O
approximation	O
to	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
,	O
called	O
bi	O
-	O
binomial	O
distribution	O
,	O
which	O
is	O
based	O
on	O
replacing	O
the	O
set	O
of	O
Poisson	O
trials	O
by	O
two	O
sets	O
of	O
Bernoulli	O
trials	O
.	O

The	O
resulting	O
distribution	O
reproduces	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
nearly	O
exactly	O
and	O
its	O
P	O
-	O
values	O
can	O
be	O
calculated	O
with	O
ease	O
even	O
for	O
thousands	O
of	O
lists	O
(	O
see	O
also	O
supplementary	O
material	O
Simulation	O
S1	O
for	O
details	O
on	O
the	O
precision	O
of	O
BBD	O
)	O
.	O

Importantly	O
,	O
BBD	O
provides	O
a	O
novel	O
measure	O
of	O
association	O
,	O
which	O
is	O
shown	O
to	O
be	O
superior	O
to	O
existing	O
measures	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
and	O
the	O
uncertainty	O
coefficient	O
,	O
whose	O
values	O
can	O
not	O
be	O
interpreted	O
properly	O
in	O
the	O
absence	O
of	O
knowledge	O
about	O
the	O
occurrence	O
probabilities	O
of	O
co	O
-	O
occurring	O
entities	O
.	O

It	O
is	O
worth	O
noting	O
that	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
are	O
distinguished	O
from	O
Gaussian	O
Z	O
-	O
scores	O
by	O
the	O
fact	O
that	O
they	O
do	O
not	O
correspond	O
to	O
the	O
same	O
P	O
-	O
value	O
for	O
different	O
PBDs	O
,	O
BBDs	O
,	O
and	O
even	O
BDs	O
.	O

This	O
is	O
because	O
the	O
Z	O
-	O
score	O
is	O
an	O
explicit	O
part	O
of	O
the	O
function	O
defining	O
the	O
normal	O
probability	O
density	O
while	O
it	O
is	O
not	O
part	O
of	O
the	O
definitions	O
of	O
BD	O
,	O
PBD	O
,	O
and	O
BBD	O
densities	O
.	O

As	O
a	O
consequence	O
,	O
the	O
simple	O
Poisson	O
-	O
binomial	O
Z	O
-	O
score	O
based	O
approach	O
to	O
evaluating	O
significance	O
of	O
co	O
-	O
occurrence	O
must	O
be	O
complemented	O
with	O
the	O
BBD	O
to	O
approximate	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
in	O
order	O
to	O
enable	O
multiple	O
testing	O
corrections	O
and	O
to	O
allow	O
calculation	O
of	O
confidence	O
levels	O
in	O
association	O
studies	O
precisely	O
.	O

However	O
,	O
NetCutter	O
is	O
equipped	O
with	O
a	O
bipartite	O
graph	O
randomization	O
tool	O
that	O
permits	O
measuring	O
the	O
number	O
of	O
false	O
positives	O
due	O
to	O
multiple	O
testing	O
directly	O
by	O
comparing	O
the	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
to	O
the	O
corresponding	O
number	O
in	O
a	O
randomized	O
version	O
thereof	O
.	O

Randomization	O
is	O
performed	O
by	O
edge	O
-	O
swapping	O
in	O
order	O
to	O
preserve	O
vertex	O
degrees	O
.	O

The	O
resulting	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
that	O
are	O
plotted	O
for	O
each	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
provide	O
a	O
highly	O
reliable	O
and	O
visually	O
intuitive	O
defense	O
mechanism	O
against	O
false	O
positives	O
(	O
see	O
also	O
supplementary	O
material	O
Simulation	O
S1	O
)	O
.	O

In	O
the	O
vast	O
majority	O
of	O
co	O
-	O
occurrence	O
studies	O
,	O
pair	O
-	O
wise	O
co	O
-	O
occurrences	O
have	O
been	O
analyzed	O
using	O
different	O
statistical	O
models	O
.	O

We	O
have	O
observed	O
that	O
the	O
stringency	O
of	O
pair	O
-	O
wise	O
co	O
-	O
occurrence	O
analysis	O
is	O
far	O
below	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
using	O
higher	O
order	O
combinations	O
of	O
co	O
-	O
occurring	O
entities	O
[	O
35	O
]	O
.	O

In	O
NetCutter	O
,	O
co	O
-	O
occurrence	O
analysis	O
is	O
preceded	O
by	O
occurrence	O
analysis	O
,	O
i.e.	O
the	O
occurrence	O
probability	O
of	O
each	O
entry	O
in	O
each	O
list	O
is	O
determined	O
.	O

Starting	O
from	O
occurrence	O
probabilities	O
,	O
co	O
-	O
occurrence	O
probabilities	O
for	O
any	O
size	O
of	O
co	O
-	O
occurrence	O
modules	O
under	O
study	O
can	O
be	O
obtained	O
by	O
multiplying	O
the	O
respective	O
list	O
-	O
specific	O
occurrence	O
probabilities	O
.	O

Given	O
the	O
list	O
-	O
specific	O
co	O
-	O
occurrence	O
probabilities	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
are	O
then	O
calculated	O
in	O
exactly	O
the	O
same	O
way	O
for	O
any	O
module	O
size	O
.	O

As	O
a	O
consequence	O
,	O
NetCutter	O
can	O
perform	O
co	O
-	O
occurrence	O
analysis	O
for	O
higher	O
order	O
combinations	O
of	O
co	O
-	O
occurring	O
entries	O
(	O
i.e.	O
larger	O
module	O
sizes	O
)	O
using	O
the	O
same	O
statistical	O
model	O
.	O

One	O
of	O
the	O
benefits	O
of	O
using	O
higher	O
module	O
sizes	O
is	O
robustness	O
of	O
the	O
analyses	O
in	O
the	O
presence	O
of	O
noise	O
.	O

This	O
is	O
because	O
each	O
edge	O
in	O
the	O
resulting	O
co	O
-	O
occurrence	O
network	O
is	O
evaluated	O
many	O
times	O
since	O
every	O
pair	O
of	O
co	O
-	O
occurring	O
entries	O
can	O
be	O
part	O
of	O
many	O
higher	O
order	O
co	O
-	O
occurrence	O
modules	O
[	O
35	O
]	O
.	O

Another	O
advantage	O
is	O
that	O
implicit	O
relationships	O
between	O
entries	O
,	O
which	O
have	O
never	O
occurred	O
together	O
[	O
18	O
]	O
,	O
can	O
be	O
derived	O
as	O
a	O
natural	O
by	O
-	O
product	O
of	O
using	O
module	O
sizes	O
larger	O
than	O
2	O
.	O

As	O
shown	O
in	O
a	O
simulation	O
study	O
(	O
supplementary	O
material	O
Simulation	O
S1	O
)	O
,	O
the	O
result	O
is	O
a	O
dramatic	O
reduction	O
of	O
misclassifications	O
at	O
higher	O
module	O
sizes	O
.	O

NetCutter	O
can	O
be	O
used	O
to	O
calculate	O
the	O
strength	O
of	O
association	O
between	O
a	O
subset	O
of	O
entries	O
and	O
lists	O
reporting	O
those	O
entries	O
.	O

In	O
this	O
case	O
,	O
the	O
analysis	O
is	O
performed	O
on	O
a	O
subgraph	O
of	O
the	O
original	O
bipartite	O
graph	O
.	O

The	O
subgraph	O
can	O
correspond	O
to	O
communities	O
of	O
entries	O
in	O
the	O
co	O
-	O
occurrence	O
network	O
,	O
or	O
any	O
set	O
of	O
entries	O
of	O
interest	O
.	O

NetCutter	O
will	O
then	O
calculate	O
the	O
significance	O
of	O
observing	O
a	O
given	O
number	O
of	O
occurrences	O
of	O
an	O
entry	O
in	O
the	O
user	O
defined	O
subset	O
of	O
lists	O
using	O
bi	O
-	O
binomal	O
statistics	O
.	O

This	O
analysis	O
mode	O
corresponds	O
to	O
association	O
studies	O
with	O
the	O
advantage	O
that	O
the	O
structure	O
of	O
the	O
underlying	O
bipartite	O
graph	O
(	O
i.e.	O
list	O
length	O
heterogeneity	O
)	O
is	O
considered	O
and	O
handled	O
appropriately	O
using	O
the	O
bi	O
-	O
binomial	O
distribution	O
.	O

As	O
a	O
consequence	O
,	O
association	O
studies	O
can	O
be	O
performed	O
with	O
higher	O
stringency	O
.	O

This	O
result	O
can	O
be	O
understood	O
by	O
examining	O
the	O
occurrence	O
probability	O
matrix	O
that	O
is	O
implicitly	O
assumed	O
in	O
performing	O
binomial	O
or	O
hypergeometric	O
tests	O
for	O
the	O
significance	O
of	O
overlaps	O
.	O

In	O
both	O
tests	O
,	O
a	O
gene	O
is	O
assumed	O
to	O
have	O
an	O
equal	O
opportunity	O
to	O
be	O
present	O
in	O
a	O
list	O
.	O

Therefore	O
,	O
the	O
probability	O
of	O
success	O
for	O
a	O
gene	O
to	O
be	O
part	O
of	O
a	O
list	O
is	O
given	O
by	O
the	O
list	O
vertex	O
degree	O
divided	O
by	O
the	O
total	O
number	O
of	O
genes	O
.	O

In	O
other	O
words	O
,	O
both	O
tests	O
are	O
implicitly	O
based	O
on	O
the	O
list	O
vertex	O
degree	O
model	O
,	O
which	O
has	O
been	O
shown	O
previously	O
to	O
underestimate	O
the	O
occurrence	O
probability	O
and	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
genes	O
with	O
high	O
vertex	O
degree	O
(	O
see	O
Fig.	O
2A	O
)	O
.	O

Since	O
the	O
BBD	O
P	O
-	O
values	O
are	O
calculated	O
from	O
the	O
ES	O
-	O
model	O
,	O
which	O
assigns	O
higher	O
occurrence	O
probabilities	O
to	O
genes	O
with	O
higher	O
vertex	O
degree	O
and	O
more	O
expected	O
co	O
-	O
occurrences	O
,	O
the	O
observed	O
number	O
of	O
overlaps	O
between	O
a	O
set	O
of	O
genes	O
of	O
interest	O
and	O
the	O
content	O
of	O
a	O
given	O
list	O
(	O
which	O
can	O
be	O
viewed	O
as	O
co	O
-	O
occurrence	O
of	O
the	O
overlapping	O
genes	O
in	O
that	O
list	O
)	O
will	O
be	O
judged	O
less	O
significant	O
when	O
the	O
overlapping	O
genes	O
are	O
of	O
high	O
vertex	O
degree	O
(	O
and	O
vice	O
versa	O
when	O
the	O
overlapping	O
genes	O
are	O
of	O
low	O
vertex	O
degree	O
)	O
as	O
compared	O
to	O
binomial	O
or	O
hypergeometric	O
tests	O
.	O

Since	O
the	O
BBD	O
P	O
-	O
values	O
are	O
derived	O
from	O
the	O
most	O
stringent	O
ES	O
null	O
-	O
model	O
,	O
BBD	O
P	O
-	O
values	O
provide	O
a	O
more	O
reliable	O
estimate	O
for	O
the	O
significance	O
of	O
overlap	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
data	O
represented	O
as	O
bipartite	O
graphs	O
permits	O
visualizing	O
the	O
structure	O
of	O
the	O
bipartite	O
graph	O
either	O
as	O
communities	O
of	O
list	O
entries	O
(	O
genes	O
)	O
or	O
as	O
communities	O
of	O
lists	O
(	O
PubMedID_ListID	O
)	O
in	O
co	O
-	O
occurrence	O
networks	O
.	O

We	O
have	O
analyzed	O
the	O
PubLiME	O
data	O
set	O
for	O
the	O
presence	O
of	O
corresponding	O
gene	O
and	O
list	O
clusters	O
.	O

In	O
addition	O
to	O
previously	O
published	O
clusters	O
of	O
genes	O
,	O
we	O
describe	O
a	O
novel	O
gene	O
cluster	O
that	O
is	O
composed	O
of	O
protein	O
biosynthesis	O
associated	O
genes	O
[	O
35	O
]	O
.	O

We	O
found	O
that	O
the	O
corresponding	O
clusters	O
of	O
PubMedID_ListID	O
(	O
gene	O
expression	O
signatures	O
)	O
are	O
in	O
general	O
strongly	O
enriched	O
for	O
genes	O
reported	O
in	O
the	O
corresponding	O
gene	O
cluster	O
and	O
that	O
interrogation	O
of	O
corresponding	O
clusters	O
can	O
be	O
used	O
to	O
deduct	O
hypotheses	O
about	O
the	O
putative	O
function	O
of	O
gene	O
clusters	O
.	O

In	O
addition	O
to	O
co	O
-	O
occurrence	O
analysis	O
,	O
NetCutter	O
offers	O
a	O
number	O
of	O
tools	O
for	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
or	O
any	O
undirected	O
graph	O
.	O

In	O
particular	O
,	O
community	O
identification	O
is	O
supported	O
by	O
four	O
different	O
community	O
identification	O
algorithms	O
.	O

NetCutter	O
also	O
offers	O
a	O
range	O
of	O
convenience	O
functions	O
that	O
are	O
of	O
help	O
in	O
network	O
analysis	O
.	O

Worthy	O
of	O
mentioning	O
are	O
the	O
random	O
graph	O
generators	O
that	O
can	O
provide	O
control	O
graphs	O
for	O
topological	O
studies	O
.	O

The	O
complete	O
set	O
of	O
options	O
is	O
described	O
in	O
the	O
software	O
documentation	O
.	O

In	O
summary	O
,	O
we	O
present	O
a	O
general	O
framework	O
for	O
co	O
-	O
occurrence	O
analysis	O
with	O
many	O
potential	O
applications	O
.	O

We	O
illustrate	O
a	O
number	O
of	O
advantages	O
of	O
using	O
the	O
bipartite	O
graph	O
representation	O
of	O
data	O
and	O
the	O
associated	O
statistics	O
.	O

In	O
particular	O
,	O
the	O
identification	O
of	O
corresponding	O
clusters	O
permits	O
the	O
identification	O
of	O
functional	O
subunits	O
such	O
as	O
gene	O
clusters	O
on	O
the	O
one	O
hand	O
,	O
and	O
the	O
generation	O
of	O
hypotheses	O
about	O
the	O
function	O
of	O
those	O
units	O
by	O
analyzing	O
the	O
corresponding	O
list	O
clusters	O
on	O
the	O
other	O
hand	O
.	O

Future	O
developments	O
will	O
be	O
directed	O
towards	O
the	O
analysis	O
of	O
data	O
sets	O
that	O
are	O
considerably	O
larger	O
than	O
the	O
data	O
sets	O
analyzed	O
so	O
far	O
.	O

For	O
example	O
,	O
co	O
-	O
occurrence	O
analysis	O
might	O
be	O
of	O
interest	O
for	O
the	O
analysis	O
of	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
data	O
sets	O
and	O
association	O
studies	O
of	O
genome	O
variability	O
with	O
disease	O
.	O

Each	O
patient	O
is	O
characterized	O
by	O
a	O
specific	O
range	O
of	O
SNPs	O
.	O

Co	O
-	O
occurrence	O
patterns	O
of	O
patients	O
according	O
to	O
their	O
SNPs	O
could	O
be	O
compared	O
to	O
clinical	O
parameters	O
with	O
the	O
aim	O
of	O
identifying	O
genomic	O
regions	O
associated	O
with	O
disease	O
.	O

The	O
increased	O
stringency	O
of	O
association	O
studies	O
offered	O
by	O
NetCutter	O
may	O
be	O
of	O
use	O
in	O
the	O
analysis	O
of	O
polygenic	O
diseases	O
where	O
conventional	O
methods	O
fail	O
.	O

For	O
being	O
useful	O
in	O
this	O
setting	O
,	O
NetCutter	O
must	O
be	O
capable	O
of	O
analyzing	O
bipartite	O
graphs	O
with	O
millions	O
instead	O
of	O
thousands	O
of	O
vertices	O
.	O

Materials	O
and	O
Methods	O
Implementation	O
of	O
NetCutter	O
NetCutter	O
is	O
written	O
in	O
Java	O
using	O
NetBeans6	O
software	O
(	O
http://www.netbeans.info/	O
)	O
and	O
tested	O
on	O
the	O
Java	O
Runtime	O
environment	O
1.6.0.0	O
.	O

on	O
a	O
Windows	O
XP	O
Professional	O
computer	O
.	O

The	O
Java	O
Runtime	O
environment	O
,	O
which	O
can	O
be	O
downloaded	O
from	O
http://java.sun.com/	O
,	O
must	O
be	O
installed	O
on	O
a	O
computer	O
that	O
is	O
intended	O
to	O
run	O
NetCutter	O
.	O

NetCutter	O
is	O
provided	O
as	O
a	O
single	O
jar	O
file	O
and	O
should	O
run	O
by	O
double	O
clicking	O
the	O
jar	O
file	O
,	O
provided	O
that	O
the	O
Java	O
runtime	O
environment	O
is	O
properly	O
installed	O
.	O

NetCutter	O
makes	O
use	O
of	O
the	O
following	O
software	O
packages	O
and	O
classes	O
:	O
JUNG	O
version	O
1.3	O
(	O
http://jung.sourceforge.net/download.html	O
)	O
,	O
Apache	O
Jakarta	O
Commons	O
Collections	O
3.1	O
(	O
http://jakarta.apache.org/commons/collections/	O
)	O
,	O
Cern	O
Colt	O
Scientific	O
Library	O
1.2.0	O
(	O
http://dsd.lbl.gov/hoschek/colt/	O
)	O
,	O
Xerces	O
(	O
http://xerces.apache.org/xerces2-j/index.html	O
)	O
,	O
Jama	O
(	O
http://math.nist.gov/javanumerics/jama/	O
)	O
,	O
Netlib	O
Java	O
LAPACK	O
(	O
http://www.netlib.org/lapack/	O
)	O
,	O
JFreeChart	O
(	O
http://www.jfree.org/jfreechart/	O
)	O
,	O
partition.java	O
(	O
http://astro.u-strasbg.fr/fmurtagh/mda-sw/java/partition.java	O
)	O
.	O

Bi	O
-	O
binomial	O
approximation	O
of	O
Poisson	O
-	O
binomial	O
distribution	O
The	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
has	O
recently	O
been	O
proposed	O
as	O
a	O
statistic	O
that	O
properly	O
handles	O
largely	O
differing	O
sizes	O
of	O
gene	O
expression	O
signatures	O
in	O
meta	O
-	O
analysis	O
of	O
gene	O
expression	O
data	O
[	O
35	O
]	O
.	O

Z	O
-	O
scores	O
have	O
been	O
used	O
to	O
estimate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
because	O
P	O
-	O
value	O
calculation	O
is	O
cumbersome	O
and	O
error	O
prone	O
.	O

Two	O
methods	O
reported	O
by	O
[	O
36	O
]	O
suffer	O
from	O
numerical	O
overflow	O
/	O
underflow	O
problems	O
when	O
large	O
numbers	O
of	O
Poisson	O
trials	O
with	O
probabilities	O
deviating	O
significantly	O
from	O
0.5	O
are	O
being	O
analyzed	O
.	O

Therefore	O
,	O
we	O
propose	O
a	O
fast	O
approximation	O
of	O
P	O
-	O
values	O
based	O
on	O
a	O
bi	O
-	O
binomial	O
distribution	O
.	O

The	O
bi	O
-	O
binomial	O
distribution	O
is	O
a	O
special	O
case	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
where	O
the	O
probability	O
of	O
success	O
can	O
assume	O
only	O
two	O
values	O
.	O

In	O
order	O
to	O
achieve	O
a	O
good	O
approximation	O
of	O
the	O
underlying	O
Poisson	O
-	O
binomial	O
distribution	O
,	O
the	O
values	O
of	O
these	O
two	O
probabilities	O
and	O
the	O
number	O
of	O
trials	O
where	O
they	O
are	O
assumed	O
must	O
be	O
determined	O
carefully	O
.	O

As	O
is	O
shown	O
in	O
the	O
following	O
,	O
the	O
values	O
of	O
the	O
two	O
trial	O
probabilities	O
and	O
their	O
number	O
of	O
occurrences	O
follow	O
from	O
the	O
formula	O
used	O
to	O
calculate	O
the	O
variance	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
and	O
from	O
the	O
formula	O
yielding	O
the	O
population	O
variance	O
of	O
trial	O
probabilities	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
to	O
be	O
approximated	O
.	O

The	O
mean	O
μ	O
and	O
the	O
variance	O
σ2	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
are	O
given	O
by	O
equation	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
respectively.	O
(	O
1	O
)	O
(	O
2	O
)	O
pi	O
is	O
the	O
trial	O
-	O
specific	O
probability	O
of	O
success	O
and	O
N	O
is	O
the	O
total	O
number	O
of	O
trials	O
.	O

For	O
the	O
sake	O
of	O
completeness	O
,	O
a	O
formal	O
proof	O
of	O
equation	O
(	O
1	O
)	O
is	O
reported	O
as	O
supplementary	O
material	O
Proof	O
S1	O
and	O
the	O
proof	O
of	O
equation	O
(	O
2	O
)	O
can	O
be	O
obtained	O
in	O
an	O
analogous	O
fashion	O
.	O

The	O
population	O
variance	O
S2	O
of	O
trial	O
probabilities	O
pi	O
is	O
given	O
by	O
equation	O
(	O
3	O
)	O
.	O
(	O
3	O
)	O
Rearranging	O
equation	O
(	O
3	O
)	O
considering	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
leads	O
to	O
(	O
4	O
)	O
and	O
(	O
5	O
)	O
,	O
where	O
pa	O
denotes	O
the	O
average	O
trial	O
probability	O
of	O
success	O
and	O
qa	O
its	O
complement.	O
(	O
4	O
)	O
(	O
5	O
)	O
Now	O
let	O
's	O
define	O
two	O
trial	O
probabilities	O
p1	O
and	O
p2	O
,	O
which	O
are	O
used	O
N1	O
and	O
N2	O
times	O
during	O
the	O
Poisson	O
trials	O
,	O
respectively	O
.	O

Thus	O
,	O
N1	O
and	O
N2	O
add	O
up	O
to	O
N.	O
(	O
6	O
)	O
Considering	O
(	O
1	O
)	O
,	O
the	O
average	O
trial	O
probability	O
pa	O
can	O
then	O
be	O
obtained	O
from	O
(	O
7	O
)	O
.	O
(	O
7	O
)	O
Using	O
(	O
7	O
)	O
,	O
p1	O
can	O
thus	O
be	O
calculated	O
as	O
(	O
8	O
)	O
.	O
(	O
8	O
)	O
Similarly	O
,	O
considering	O
(	O
2	O
)	O
,	O
the	O
variance	O
σ2	O
is	O
given	O
by	O
(	O
9	O
)	O
.	O
(	O
9	O
)	O
Substituting	O
p1	O
in	O
(	O
9	O
)	O
using	O
(	O
8)	O
followed	O
by	O
substituting	O
σ2	O
in	O
(	O
5	O
)	O
by	O
(	O
9	O
)	O
leads	O
to	O
a	O
quadratic	O
equation	O
for	O
p2	O
as	O
a	O
function	O
of	O
pa	O
,	O
N	O
,	O
and	O
S2	O
,	O
as	O
shown	O
in	O
equation	O
(	O
10	O
)	O
.	O
(	O
10	O
)	O
The	O
solution	O
to	O
(	O
10	O
)	O
is	O
given	O
by	O
(	O
11	O
)	O
.	O
(	O
11	O
)	O
Setting	O
p2	O
to	O
(	O
12	O
)	O
p1	O
can	O
be	O
obtained	O
from	O
(	O
8)	O
and	O
shown	O
to	O
be	O
given	O
by	O
formula	O
(	O
13	O
)	O
:	O
(	O
13	O
)	O
Choosing	O
p2	O
as	O
(	O
12a	O
)	O
leads	O
to	O
p1	O
(	O
13a	O
)	O
Comparing	O
(	O
13a	O
)	O
to	O
(	O
12	O
)	O
and	O
(	O
12a	O
)	O
to	O
(	O
13	O
)	O
,	O
it	O
can	O
be	O
seen	O
that	O
the	O
formulae	O
are	O
identical	O
except	O
for	O
the	O
fact	O
that	O
N1	O
and	O
N2	O
are	O
reversed	O
.	O

Since	O
the	O
assignment	O
of	O
which	O
set	O
of	O
trials	O
is	O
called	O
N1	O
and	O
which	O
set	O
of	O
trials	O
is	O
called	O
N2	O
is	O
completely	O
arbitrary	O
,	O
we	O
can	O
limit	O
the	O
remaining	O
analysis	O
on	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
without	O
loss	O
of	O
generality	O
.	O

Note	O
that	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
do	O
not	O
guarantee	O
that	O
p1	O
and	O
p2	O
are	O
always	O
confined	O
between	O
0	O
and	O
1	O
for	O
any	O
combination	O
of	O
N1	O
and	O
N2	O
.	O

While	O
probabilities	O
smaller	O
than	O
0	O
or	O
bigger	O
than	O
1	O
would	O
still	O
result	O
in	O
a	O
distribution	O
with	O
the	O
same	O
overall	O
variance	O
as	O
the	O
original	O
distribution	O
,	O
P	O
-	O
value	O
calculation	O
will	O
be	O
imprecise	O
because	O
the	O
tails	O
of	O
the	O
distribution	O
will	O
deviate	O
significantly	O
from	O
the	O
original	O
distribution	O
.	O

Thus	O
,	O
we	O
need	O
to	O
define	O
the	O
values	O
N1	O
and	O
N2	O
in	O
such	O
a	O
way	O
that	O
p2	O
<	O
=	O
1	O
and	O
p1	O
>	O
=	O
0	O
.	O

This	O
can	O
be	O
achieved	O
by	O
evaluating	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
.	O

Evaluating	O
(	O
12	O
)	O
for	O
the	O
condition	O
that	O
p2	O
<	O
=	O
1	O
,	O
solving	O
the	O
resulting	O
inequality	O
for	O
N2	O
,	O
and	O
considering	O
(	O
5	O
)	O
,	O
which	O
relates	O
S2	O
and	O
σ2	O
,	O
we	O
obtain	O
(	O
14	O
)	O
.	O
(	O
14	O
)	O
Similarly	O
,	O
evaluating	O
(	O
13	O
)	O
for	O
the	O
condition	O
p1	O
>	O
=	O
0	O
,	O
solving	O
the	O
resulting	O
inequality	O
for	O
N2	O
,	O
considering	O
(	O
5	O
)	O
,	O
which	O
relates	O
S2	O
and	O
σ2	O
,	O
and	O
defining	O
μf	O
the	O
expected	O
number	O
of	O
failures	O
as	O
N	O
*	O
(	O
1−pa	O
)	O
(	O
15	O
)	O
,	O
(	O
15	O
)	O
we	O
obtain	O
(	O
16	O
)	O
(	O
16	O
)	O
The	O
meaning	O
of	O
these	O
boundaries	O
is	O
best	O
illustrated	O
by	O
considering	O
a	O
Poisson	O
-	O
binomial	O
distribution	O
whose	O
variance	O
is	O
0	O
,	O
i.e.	O
that	O
assumes	O
1	O
at	O
X	O
=	O
μ	O
and	O
0	O
otherwise	O
.	O

In	O
this	O
case	O
(	O
14	O
)	O
requires	O
N2	O
<	O
=	O
μ	O
while	O
(	O
16	O
)	O
requires	O
N2	O
>	O
=	O
μ	O
.	O

These	O
conditions	O
can	O
only	O
be	O
fulfilled	O
contemporaneously	O
when	O
N2	O
is	O
set	O
to	O
μ	O
.	O

Intuitively	O
,	O
this	O
means	O
that	O
there	O
are	O
μ	O
trials	O
with	O
probability	O
of	O
success	O
1	O
and	O
N−μ	O
trials	O
with	O
probability	O
of	O
0	O
,	O
resulting	O
in	O
a	O
Poisson	O
-	O
binomial	O
distribution	O
with	O
variance	O
σ2	O
=	O
0	O
and	O
mean	O
μ	O
.	O

When	O
σ2	O
is	O
larger	O
than	O
0	O
,	O
the	O
choice	O
of	O
N1	O
and	O
N2	O
is	O
more	O
flexible	O
.	O

However	O
,	O
since	O
the	O
choice	O
of	O
N2	O
=	O
μ	O
is	O
valid	O
for	O
all	O
possible	O
values	O
of	O
σ2	O
,	O
this	O
is	O
how	O
NetCutter	O
determines	O
N1	O
and	O
N2	O
.	O

When	O
μ	O
is	O
not	O
an	O
integer	O
,	O
N2	O
is	O
set	O
to	O
the	O
integer	O
closest	O
to	O
μ	O
.	O

Having	O
determined	O
p2	O
(	O
12	O
)	O
and	O
p1	O
(	O
13	O
)	O
as	O
well	O
a	O
N1	O
and	O
N2	O
(	O
14	O
,	O
16	O
,	O
6	O
)	O
,	O
we	O
can	O
now	O
calculate	O
the	O
bi	O
-	O
binomial	O
approximation	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
in	O
a	O
fashion	O
that	O
is	O
very	O
similar	O
to	O
calculate	O
the	O
binomial	O
P	O
-	O
value	O
.	O

With	O
q1	O
=	O
1−p1	O
and	O
q2	O
=	O
1−p2	O
we	O
obtain:	O
(	O
17	O
)	O
The	O
summation	O
is	O
necessary	O
because	O
i	O
successes	O
can	O
be	O
obtained	O
from	O
any	O
combination	O
of	O
j	O
p1	O
and	O
i−j	O
p2	O
trials	O
,	O
where	O
j	O
can	O
assume	O
any	O
value	O
from	O
0	O
to	O
i.	O
Calculating	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
For	O
the	O
purpose	O
of	O
comparing	O
the	O
efficacy	O
of	O
the	O
bi	O
-	O
binomial	O
distribution	O
as	O
a	O
significance	O
measure	O
of	O
co	O
-	O
occurrence	O
,	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
(	O
which	O
are	O
also	O
called	O
measures	O
of	O
association	O
)	O
were	O
calculated	O
using	O
the	O
formulae	O
:	O
The	O
Jaccard	O
coefficient	O
J	O
is	O
calculated	O
as	O
the	O
number	O
of	O
times	O
A	O
and	O
B	O
occur	O
together	O
divided	O
by	O
the	O
number	O
of	O
times	O
A	O
occurs	O
without	O
B	O
plus	O
the	O
number	O
of	O
times	O
B	O
occurs	O
without	O
A	O
plus	O
the	O
number	O
of	O
times	O
A	O
and	O
B	O
occur	O
together	O
[	O
42	O
]	O
.	O

The	O
uncertainty	O
coefficient	O
[	O
42	O
]	O
is	O
calculated	O
as	O
:	O
H	O
is	O
the	O
entropy	O
associated	O
with	O
A	O
,	O
B	O
,	O
and	O
AB	O
.	O

For	O
A	O
,	O
the	O
entropy	O
is	O
calculated	O
from	O
the	O
probabilities	O
of	O
A	O
occurring	O
in	O
n1	O
out	O
of	O
N	O
lists	O
(	O
n1	O
/	O
N	O
)	O
and	O
A	O
not	O
occurring	O
in	O
n2	O
out	O
of	O
N	O
lists	O
(	O
n2	O
/	O
N	O
)	O
.	O

Analogous	O
calculations	O
lead	O
to	O
the	O
entropy	O
associated	O
with	O
B.	O
For	O
H	O
(	O
A	O
,	O
B	O
)	O
,	O
the	O
probabilities	O
of	O
A	O
occurring	O
without	O
B	O
,	O
B	O
occurring	O
without	O
A	O
,	O
A	O
and	O
B	O
occurring	O
together	O
,	O
and	O
neither	O
A	O
nor	O
B	O
occurring	O
in	O
the	O
lists	O
are	O
used	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
The	O
bipartite	O
graph	O
to	O
be	O
analyzed	O
is	O
composed	O
of	O
27619	O
PubMedID_listID	O
-	O
gene	O
pairs	O
(	O
see	O
supplementary	O
material	O
Table	O
S1	O
)	O
.	O

Edge	O
-	O
swapping	O
(	O
1000	O
simulations	O
,	O
see	O
above	O
)	O
was	O
used	O
to	O
determine	O
occurrence	O
probabilities	O
and	O
gene	O
co	O
-	O
occurrence	O
was	O
analyzed	O
using	O
module	O
size	O
3	O
(	O
co	O
-	O
occurrence	O
of	O
three	O
genes	O
)	O
,	O
bi	O
-	O
binomial	O
Z	O
-	O
score	O
cutoff	O
6	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
cutoff	O
1.0E-5	O
,	O
and	O
support	O
5	O
.	O

Supplementary	O
material	O
Simulation	O
S1	O
provides	O
details	O
on	O
why	O
module	O
size	O
3	O
is	O
chosen	O
.	O

The	O
support	O
parameter	O
ensures	O
that	O
each	O
3-gene	O
co	O
-	O
occurrence	O
module	O
is	O
present	O
in	O
at	O
least	O
5	O
signatures	O
.	O

We	O
identified	O
1654	O
significant	O
modules	O
in	O
the	O
test	O
data	O
compared	O
to	O
5	O
modules	O
in	O
a	O
randomized	O
bipartite	O
graph	O
,	O
corresponding	O
to	O
a	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
331	O
.	O

The	O
co	O
-	O
occurrence	O
network	O
was	O
generated	O
from	O
the	O
significant	O
co	O
-	O
occurrence	O
modules	O
by	O
drawing	O
an	O
edge	O
between	O
each	O
pair	O
wise	O
combination	O
of	O
genes	O
that	O
are	O
part	O
of	O
the	O
same	O
co	O
-	O
occurrence	O
module	O
.	O

Gene	O
communities	O
were	O
identified	O
in	O
this	O
network	O
by	O
edge	O
-	O
betweenness	O
clustering	O
removing	O
4	O
edges	O
,	O
which	O
resulted	O
in	O
a	O
maximal	O
network	O
modularity	O
of	O
0.63	O
.	O

Modularity	O
is	O
calculated	O
as	O
described	O
by	O
[	O
43	O
]	O
.	O

For	O
the	O
identification	O
of	O
PubMedID_listID	O
clusters	O
,	O
the	O
PubMedID_listID	O
-	O
gene	O
pairs	O
in	O
the	O
original	O
bipartite	O
graph	O
were	O
reversed	O
to	O
form	O
gene	O
-	O
PubMedID_listID	O
pairs	O
.	O

Occurrence	O
probabilities	O
were	O
obtained	O
by	O
transposing	O
the	O
original	O
occurrence	O
probability	O
matrix	O
determined	O
by	O
edge	O
-	O
swapping	O
as	O
described	O
above	O
.	O

PubMedID_listID	O
co	O
-	O
occurrence	O
was	O
analyzed	O
using	O
module	O
size	O
5	O
,	O
Z	O
-	O
score	O
cutoff	O
6	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
cutoff	O
1.0E-5	O
,	O
and	O
support	O
3	O
.	O

Please	O
note	O
that	O
the	O
choice	O
of	O
these	O
parameters	O
is	O
dictated	O
by	O
the	O
parameters	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
.	O

The	O
reversal	O
of	O
the	O
bipartite	O
graph	O
necessitates	O
the	O
support	O
parameter	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
(	O
5	O
)	O
to	O
be	O
used	O
as	O
module	O
size	O
in	O
PubMedID_listID	O
co	O
-	O
occurrence	O
analysis	O
and	O
the	O
module	O
size	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
(	O
3	O
)	O
to	O
be	O
used	O
as	O
the	O
support	O
parameter	O
in	O
PubMedID_listID	O
co	O
-	O
occurrence	O
analysis	O
if	O
the	O
scope	O
of	O
the	O
analysis	O
is	O
the	O
identification	O
of	O
PubMedID_listID	O
clusters	O
that	O
correspond	O
to	O
gene	O
clusters	O
identified	O
before	O
.	O

The	O
significance	O
cutoffs	O
remain	O
unchanged	O
.	O

PubMedID_listID	O
co	O
-	O
occurrence	O
analysis	O
revealed	O
448	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
and	O
6	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
randomized	O
bipartite	O
graph	O
with	O
a	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
75	O
.	O

Communities	O
in	O
the	O
resulting	O
co	O
-	O
occurrence	O
network	O
were	O
identified	O
by	O
edge	O
-	O
betweenness	O
clustering	O
removing	O
130	O
edges	O
.	O

The	O
resulting	O
maximal	O
network	O
modularity	O
was	O
found	O
to	O
be	O
0.47	O
.	O

Supporting	O
Information	O

Personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
and	O
physical	O
activity	O
in	O
a	O
deprived	O
urban	O
population	O
Abstract	O
Background	O
Environmental	O
characteristics	O
may	O
be	O
associated	O
with	O
patterns	O
of	O
physical	O
activity	O
in	O
general	O
or	O
with	O
particular	O
types	O
of	O
physical	O
activity	O
such	O
as	O
active	O
travel	O
(	O
walking	O
or	O
cycling	O
for	O
transport	O
)	O
.	O

However	O
,	O
most	O
studies	O
in	O
this	O
field	O
have	O
been	O
conducted	O
in	O
North	O
America	O
and	O
Australia	O
,	O
and	O
hypotheses	O
about	O
putative	O
correlates	O
should	O
be	O
tested	O
in	O
a	O
wider	O
range	O
of	O
sociospatial	O
contexts	O
.	O

We	O
therefore	O
examined	O
the	O
contribution	O
of	O
putative	O
personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
in	O
deprived	O
urban	O
neighbourhoods	O
in	O
Glasgow	O
,	O
Scotland	O
as	O
part	O
of	O
the	O
baseline	O
for	O
a	O
longitudinal	O
study	O
of	O
the	O
effects	O
of	O
opening	O
a	O
new	O
urban	O
motorway	O
(	O
freeway	O
)	O
.	O

Methods	O
We	O
conducted	O
a	O
postal	O
survey	O
of	O
a	O
random	O
sample	O
of	O
residents	O
(	O
n	O
=	O
1322	O
)	O
,	O
collecting	O
data	O
on	O
socioeconomic	O
status	O
,	O
perceptions	O
of	O
the	O
local	O
environment	O
,	O
travel	O
behaviour	O
,	O
physical	O
activity	O
and	O
general	O
health	O
and	O
wellbeing	O
using	O
a	O
new	O
14-item	O
neighbourhood	O
rating	O
scale	O
,	O
a	O
travel	O
diary	O
,	O
the	O
short	O
form	O
of	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
and	O
the	O
SF-8	O
.	O

We	O
analysed	O
the	O
correlates	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
using	O
multivariate	O
logistic	O
regression	O
,	O
first	O
building	O
models	O
using	O
personal	O
(	O
individual	O
and	O
household	O
)	O
explanatory	O
variables	O
and	O
then	O
adding	O
environmental	O
variables	O
.	O

Results	O
Active	O
travel	O
was	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
a	O
long	O
distance	O
to	O
work	O
and	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
whereas	O
overall	O
physical	O
activity	O
was	O
associated	O
with	O
living	O
in	O
social	O
rented	O
accommodation	O
and	O
not	O
being	O
overweight	O
.	O

After	O
adjusting	O
for	O
personal	O
characteristics	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
the	O
objective	O
proximity	O
of	O
respondents	O
'	O
homes	O
to	O
motorway	O
or	O
major	O
road	O
infrastructure	O
explained	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
although	O
we	O
did	O
identify	O
a	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
.	O

Conclusion	O
Apart	O
from	O
access	O
to	O
local	O
amenities	O
,	O
environmental	O
characteristics	O
may	O
have	O
limited	O
influence	O
on	O
active	O
travel	O
in	O
deprived	O
urban	O
populations	O
characterised	O
by	O
a	O
low	O
level	O
of	O
car	O
ownership	O
,	O
in	O
which	O
people	O
may	O
have	O
less	O
capacity	O
for	O
making	O
discretionary	O
travel	O
choices	O
than	O
the	O
populations	O
studied	O
in	O
most	O
published	O
research	O
on	O
the	O
environmental	O
correlates	O
of	O
physical	O
activity	O
.	O

Background	O
Until	O
recently	O
,	O
research	O
on	O
correlates	O
of	O
physical	O
activity	O
was	O
dominated	O
by	O
studies	O
of	O
individual	O
demographic	O
and	O
psychosocial	O
characteristics	O
[	O
1	O
]	O
.	O

This	O
reflected	O
an	O
emphasis	O
on	O
promoting	O
sport	O
,	O
recreation	O
or	O
health	O
-	O
directed	O
exercise	O
using	O
techniques	O
to	O
encourage	O
individual	O
behaviour	O
change	O
[	O
2	O
]	O
.	O

However	O
,	O
there	O
is	O
little	O
evidence	O
that	O
such	O
approaches	O
are	O
effective	O
in	O
increasing	O
physical	O
activity	O
in	O
the	O
medium	O
-	O
to	O
-	O
long	O
term	O
[	O
3	O
]	O
.	O

If	O
habitual	O
patterns	O
of	O
behaviour	O
are	O
environmentally	O
cued	O
,	O
sustained	O
change	O
is	O
likely	O
to	O
require	O
a	O
supportive	O
environment	O
in	O
which	O
people	O
can	O
be	O
active	O
[	O
4,5	O
]	O
.	O

There	O
is	O
therefore	O
increasing	O
interest	O
in	O
the	O
influence	O
of	O
the	O
social	O
and	O
physical	O
environment	O
on	O
physical	O
activity	O
.	O

With	O
respect	O
to	O
the	O
physical	O
(	O
natural	O
or	O
built	O
)	O
environment	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
suggests	O
that	O
certain	O
environmental	O
characteristics	O
may	O
be	O
associated	O
with	O
patterns	O
of	O
physical	O
activity	O
in	O
general	O
or	O
with	O
particular	O
types	O
of	O
physical	O
activity	O
such	O
as	O
walking	O
or	O
cycling	O
as	O
modes	O
of	O
transport	O
[	O
4	O
-	O
10	O
]	O
.	O

Among	O
the	O
correlates	O
most	O
frequently	O
identified	O
in	O
such	O
reviews	O
–	O
some	O
ascertained	O
using	O
'	O
objective	O
'	O
measures	O
,	O
and	O
others	O
in	O
terms	O
of	O
people	O
's	O
perceptions	O
–	O
are	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
,	O
the	O
presence	O
of	O
pavements	O
(	O
sidewalks	O
)	O
,	O
the	O
convenience	O
of	O
facilities	O
for	O
being	O
active	O
,	O
the	O
availability	O
of	O
green	O
space	O
,	O
access	O
to	O
amenities	O
(	O
destinations	O
)	O
within	O
walking	O
or	O
cycling	O
distance	O
,	O
safety	O
from	O
traffic	O
and	O
personal	O
attack	O
,	O
and	O
the	O
lack	O
of	O
heavy	O
traffic	O
.	O

Some	O
of	O
these	O
local	O
characteristics	O
reflect	O
higher	O
-	O
order	O
aspects	O
of	O
urban	O
design	O
and	O
spatial	O
policy	O
such	O
as	O
population	O
density	O
,	O
connectivity	O
and	O
mixed	O
land	O
use	O
[	O
6,8	O
]	O
.	O

Importantly	O
,	O
different	O
characteristics	O
may	O
be	O
associated	O
with	O
different	O
types	O
of	O
physical	O
activity	O
;	O
for	O
example	O
,	O
Owen	O
and	O
colleagues	O
found	O
that	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
was	O
associated	O
with	O
walking	O
for	O
exercise	O
or	O
recreation	O
and	O
with	O
walking	O
in	O
general	O
,	O
but	O
not	O
with	O
walking	O
for	O
transport	O
,	O
whereas	O
perceptions	O
of	O
traffic	O
were	O
associated	O
with	O
walking	O
for	O
transport	O
and	O
walking	O
in	O
general	O
,	O
but	O
not	O
with	O
walking	O
for	O
exercise	O
or	O
recreation	O
[	O
5	O
]	O
.	O

Despite	O
the	O
growing	O
volume	O
of	O
published	O
studies	O
in	O
this	O
field	O
,	O
many	O
authors	O
remain	O
circumspect	O
in	O
their	O
interpretation	O
of	O
the	O
available	O
evidence	O
.	O

Giles	O
-	O
Corti	O
and	O
Donovan	O
have	O
described	O
access	O
to	O
a	O
supportive	O
physical	O
environment	O
as	O
a	O
necessary	O
,	O
but	O
insufficient	O
,	O
condition	O
for	O
an	O
increase	O
in	O
physical	O
activity	O
in	O
the	O
population	O
[	O
11	O
]	O
,	O
while	O
Handy	O
found	O
'	O
convincing	O
'	O
evidence	O
of	O
an	O
association	O
between	O
physical	O
activity	O
and	O
the	O
built	O
environment	O
in	O
general	O
but	O
'	O
less	O
convincing	O
'	O
evidence	O
as	O
to	O
which	O
specific	O
environmental	O
characteristics	O
were	O
most	O
strongly	O
associated	O
[	O
7	O
]	O
.	O

One	O
limitation	O
of	O
the	O
available	O
evidence	O
is	O
that	O
most	O
research	O
has	O
been	O
conducted	O
in	O
North	O
America	O
and	O
Australia	O
[	O
9,12	O
]	O
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
associations	O
observed	O
in	O
those	O
countries	O
are	O
generalisable	O
to	O
other	O
settings	O
with	O
different	O
aggregate	O
socioeconomic	O
characteristics	O
(	O
e.g.	O
wealth	O
or	O
access	O
to	O
private	O
cars	O
)	O
or	O
environmental	O
characteristics	O
(	O
e.g.	O
climate	O
,	O
patterns	O
of	O
land	O
use	O
,	O
or	O
availability	O
of	O
public	O
transport	O
)	O
.	O

For	O
example	O
,	O
North	O
American	O
researchers	O
are	O
often	O
interested	O
in	O
the	O
presence	O
or	O
absence	O
of	O
pavements	O
(	O
sidewalks	O
)	O
,	O
but	O
it	O
is	O
unusual	O
for	O
streets	O
in	O
the	O
United	O
Kingdom	O
(	O
UK	O
)	O
not	O
to	O
have	O
a	O
pavement	O
or	O
footpath	O
beside	O
them	O
.	O

Hypotheses	O
about	O
putative	O
environmental	O
correlates	O
of	O
physical	O
activity	O
therefore	O
need	O
to	O
be	O
tested	O
in	O
a	O
wider	O
range	O
of	O
settings	O
.	O

A	O
more	O
profound	O
limitation	O
of	O
the	O
available	O
evidence	O
is	O
that	O
identifying	O
a	O
relationship	O
between	O
,	O
for	O
example	O
,	O
urban	O
form	O
and	O
walking	O
for	O
transport	O
is	O
not	O
the	O
same	O
thing	O
as	O
showing	O
that	O
changing	O
the	O
built	O
environment	O
will	O
lead	O
to	O
a	O
change	O
in	O
behaviour	O
[	O
13	O
]	O
.	O

Few	O
researchers	O
have	O
taken	O
up	O
the	O
opportunity	O
(	O
or	O
challenge	O
)	O
presented	O
by	O
'	O
natural	O
experiments	O
'	O
to	O
investigate	O
the	O
effects	O
of	O
environmental	O
interventions	O
on	O
physical	O
activity	O
[	O
14	O
]	O
.	O

We	O
therefore	O
established	O
a	O
longitudinal	O
study	O
to	O
examine	O
changes	O
associated	O
with	O
the	O
opening	O
of	O
a	O
new	O
urban	O
section	O
of	O
the	O
M74	O
motorway	O
(	O
freeway	O
)	O
currently	O
under	O
construction	O
in	O
Glasgow	O
,	O
Scotland	O
.	O

The	O
rationale	O
and	O
design	O
for	O
this	O
study	O
have	O
been	O
described	O
previously	O
[	O
15	O
]	O
.	O

It	O
is	O
claimed	O
that	O
the	O
new	O
motorway	O
,	O
which	O
will	O
mostly	O
pass	O
through	O
or	O
close	O
to	O
densely	O
-	O
populated	O
urban	O
neighbourhoods	O
,	O
will	O
contribute	O
to	O
the	O
regeneration	O
of	O
a	O
region	O
which	O
includes	O
some	O
of	O
the	O
most	O
deprived	O
and	O
least	O
healthy	O
working	O
-	O
class	O
communities	O
in	O
Europe	O
[	O
16	O
]	O
.	O

It	O
is	O
also	O
claimed	O
that	O
the	O
new	O
motorway	O
will	O
divert	O
traffic	O
from	O
local	O
streets	O
,	O
reduce	O
traffic	O
noise	O
and	O
bring	O
new	O
local	O
employment	O
opportunities	O
,	O
thereby	O
improving	O
characteristics	O
of	O
the	O
local	O
environment	O
held	O
to	O
be	O
associated	O
with	O
active	O
travel	O
.	O

Others	O
claim	O
that	O
the	O
new	O
motorway	O
will	O
encourage	O
car	O
use	O
,	O
degrade	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
and	O
reduce	O
the	O
safety	O
and	O
attractiveness	O
of	O
routes	O
for	O
pedestrians	O
and	O
cyclists	O
across	O
the	O
line	O
of	O
the	O
motorway	O
–	O
all	O
changes	O
which	O
may	O
be	O
expected	O
to	O
discourage	O
active	O
travel	O
[	O
15	O
]	O
.	O

The	O
eventual	O
aim	O
of	O
the	O
M74	O
study	O
will	O
be	O
to	O
assess	O
the	O
effects	O
of	O
this	O
major	O
modification	O
to	O
the	O
urban	O
built	O
environment	O
and	O
transport	O
infrastructure	O
on	O
perceptions	O
of	O
the	O
local	O
environment	O
and	O
on	O
population	O
health	O
and	O
health	O
-	O
related	O
behaviour	O
,	O
the	O
primary	O
outcome	O
of	O
interest	O
being	O
a	O
change	O
in	O
the	O
quantity	O
of	O
'	O
active	O
travel	O
'	O
(	O
walking	O
and	O
cycling	O
for	O
transport	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
findings	O
from	O
the	O
cross	O
-	O
sectional	O
(	O
baseline	O
)	O
phase	O
of	O
the	O
study	O
which	O
contribute	O
evidence	O
on	O
the	O
environmental	O
correlates	O
of	O
physical	O
activity	O
in	O
this	O
comparatively	O
deprived	O
urban	O
population	O
.	O

We	O
focus	O
on	O
two	O
specific	O
hypotheses	O
:	O
first	O
,	O
that	O
levels	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
vary	O
with	O
demographic	O
and	O
socioeconomic	O
characteristics	O
,	O
but	O
not	O
necessarily	O
in	O
the	O
same	O
way	O
;	O
second	O
,	O
that	O
these	O
relationships	O
may	O
be	O
partly	O
explained	O
by	O
the	O
perceived	O
characteristics	O
of	O
the	O
local	O
environment	O
in	O
which	O
people	O
live	O
and	O
by	O
their	O
objectively	O
-	O
assessed	O
proximity	O
to	O
motorway	O
and	O
major	O
road	O
infrastructure	O
.	O

Methods	O
Delineation	O
of	O
study	O
areas	O
We	O
used	O
spatially	O
referenced	O
census	O
and	O
transport	O
infrastructure	O
data	O
held	O
and	O
analysed	O
in	O
a	O
geographical	O
information	O
system	O
(	O
GIS	O
)	O
,	O
combined	O
with	O
field	O
visits	O
,	O
to	O
delineate	O
three	O
study	O
areas	O
in	O
Glasgow	O
with	O
similar	O
aggregate	O
socioeconomic	O
characteristics	O
and	O
broadly	O
similar	O
topographical	O
characteristics	O
apart	O
from	O
their	O
proximity	O
to	O
urban	O
motorway	O
infrastructure	O
(	O
Table	O
1	O
,	O
Figure	O
1	O
)	O
.	O

All	O
three	O
study	O
areas	O
extended	O
from	O
inner	O
mixed	O
-	O
use	O
districts	O
close	O
to	O
the	O
city	O
centre	O
to	O
residential	O
suburbs	O
,	O
contained	O
major	O
arterial	O
roads	O
other	O
than	O
motorways	O
,	O
and	O
contained	O
a	O
mixture	O
of	O
housing	O
stock	O
including	O
traditional	O
high	O
-	O
density	O
tenements	O
,	O
high	O
-	O
rise	O
flats	O
and	O
new	O
housing	O
developments	O
(	O
Figure	O
2	O
)	O
.	O

Sampling	O
and	O
survey	O
administration	O
We	O
used	O
the	O
Royal	O
Mail	O
Postcode	O
Address	O
File	O
(	O
PAF	O
)	O
(	O
version	O
2005.3	O
)	O
to	O
identify	O
all	O
residential	O
addresses	O
whose	O
unit	O
postcode	O
(	O
zip	O
code	O
)	O
was	O
within	O
one	O
of	O
the	O
study	O
areas	O
(	O
total	O
n	O
=	O
35601	O
)	O
and	O
drew	O
a	O
random	O
sample	O
of	O
3000	O
households	O
from	O
each	O
area	O
.	O

Unit	O
postcodes	O
(	O
e.g.	O
G12	O
8RZ	O
)	O
are	O
the	O
smallest	O
available	O
unit	O
of	O
postal	O
geography	O
in	O
the	O
UK	O
;	O
residential	O
unit	O
postcodes	O
cover	O
about	O
15	O
addresses	O
on	O
average	O
.	O

We	O
sent	O
the	O
survey	O
to	O
all	O
households	O
(	O
total	O
n	O
=	O
9000	O
)	O
between	O
28	O
September	O
and	O
4	O
October	O
2005	O
and	O
resent	O
the	O
survey	O
to	O
all	O
non	O
-	O
responding	O
households	O
between	O
26	O
and	O
31	O
October	O
2005	O
.	O

We	O
alerted	O
households	O
to	O
the	O
survey	O
by	O
means	O
of	O
a	O
postcard	O
sent	O
a	O
few	O
days	O
in	O
advance	O
,	O
used	O
coloured	O
paper	O
for	O
some	O
of	O
the	O
survey	O
materials	O
,	O
and	O
posted	O
survey	O
packs	O
in	O
white	O
envelopes	O
printed	O
with	O
the	O
university	O
crest	O
;	O
these	O
techniques	O
have	O
been	O
shown	O
in	O
a	O
meta	O
-	O
analysis	O
to	O
be	O
associated	O
with	O
increased	O
response	O
rates	O
to	O
postal	O
surveys	O
[	O
17	O
]	O
.	O

We	O
asked	O
householders	O
to	O
ensure	O
that	O
the	O
questionnaire	O
was	O
completed	O
by	O
a	O
resident	O
aged	O
16	O
or	O
over	O
;	O
if	O
more	O
than	O
one	O
resident	O
was	O
eligible	O
,	O
we	O
asked	O
householders	O
to	O
select	O
the	O
person	O
with	O
the	O
most	O
recent	O
birthday	O
.	O

Respondents	O
who	O
consented	O
to	O
follow	O
-	O
up	O
were	O
entered	O
into	O
a	O
prize	O
draw	O
to	O
win	O
a	O
£	O
50	O
(	O
€	O
63	O
;	O
US$	O
92	O
)	O
gift	O
voucher	O
.	O

Responses	O
received	O
more	O
than	O
three	O
months	O
after	O
the	O
first	O
mailing	O
wave	O
were	O
disregarded	O
in	O
analysis	O
.	O

Data	O
collection	O
The	O
questionnaire	O
included	O
items	O
on	O
demographic	O
and	O
socioeconomic	O
characteristics	O
,	O
health	O
and	O
wellbeing	O
(	O
including	O
the	O
the	O
SF-8	O
scale	O
)	O
,	O
perceptions	O
of	O
the	O
local	O
environment	O
,	O
travel	O
behaviour	O
and	O
the	O
short	O
form	O
of	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
(	O
Additional	O
file	O
1	O
)	O
.	O

We	O
developed	O
a	O
new	O
'	O
neighbourhood	O
scale	O
'	O
to	O
assess	O
perceptions	O
of	O
relevant	O
characteristics	O
of	O
the	O
local	O
environment	O
(	O
aesthetics	O
,	O
green	O
space	O
,	O
access	O
to	O
amenities	O
,	O
convenience	O
of	O
routes	O
,	O
traffic	O
,	O
road	O
safety	O
and	O
personal	O
safety	O
)	O
.	O

The	O
development	O
,	O
principal	O
components	O
analysis	O
and	O
reliability	O
of	O
the	O
items	O
in	O
this	O
scale	O
and	O
the	O
derivation	O
and	O
reliability	O
of	O
summary	O
variables	O
are	O
reported	O
in	O
an	O
accompanying	O
paper	O
[	O
18	O
]	O
.	O

Data	O
cleaning	O
and	O
derivation	O
of	O
variables	O
Demographic	O
and	O
socioeconomic	O
characteristics	O
We	O
excluded	O
from	O
analysis	O
all	O
respondents	O
who	O
failed	O
to	O
enter	O
their	O
age	O
or	O
sex	O
.	O

We	O
then	O
examined	O
the	O
distributions	O
of	O
all	O
raw	O
variables	O
and	O
carried	O
out	O
range	O
and	O
consistency	O
checks	O
to	O
identify	O
any	O
anomalous	O
values	O
or	O
variables	O
with	O
a	O
high	O
proportion	O
of	O
missing	O
responses	O
.	O

As	O
a	O
consequence	O
,	O
we	O
collapsed	O
responses	O
on	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
,	O
housing	O
tenure	O
,	O
car	O
access	O
and	O
working	O
situation	O
into	O
fewer	O
categories	O
by	O
merging	O
categories	O
with	O
small	O
numbers	O
of	O
responses	O
;	O
we	O
also	O
disregarded	O
household	O
composition	O
and	O
working	O
situation	O
of	O
spouse	O
or	O
partner	O
in	O
analysis	O
because	O
of	O
the	O
large	O
numbers	O
of	O
missing	O
values	O
for	O
these	O
variables	O
.	O

Health	O
and	O
wellbeing	O
We	O
calculated	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
by	O
converting	O
,	O
where	O
necessary	O
,	O
self	O
-	O
reported	O
heights	O
and	O
weights	O
from	O
imperial	O
to	O
metric	O
units	O
and	O
dividing	O
the	O
height	O
in	O
metres	O
by	O
the	O
square	O
of	O
the	O
weight	O
in	O
kilograms	O
;	O
we	O
also	O
categorised	O
respondents	O
into	O
quintiles	O
of	O
BMI	O
.	O

We	O
calculated	O
physical	O
(	O
PCS-8	O
)	O
and	O
mental	O
(	O
MCS-8	O
)	O
health	O
summary	O
scores	O
from	O
the	O
SF-8	O
data	O
and	O
scaled	O
these	O
to	O
population	O
norms	O
using	O
the	O
method	O
and	O
coefficients	O
given	O
in	O
the	O
SF-8	O
manual	O
[	O
19	O
]	O
.	O

Objective	O
environmental	O
characteristics	O
We	O
linked	O
each	O
record	O
to	O
the	O
unit	O
postcode	O
of	O
residence	O
.	O

We	O
then	O
constructed	O
concentric	O
buffers	O
at	O
100-metre	O
intervals	O
up	O
to	O
500	O
metres	O
around	O
the	O
routes	O
and	O
access	O
points	O
of	O
existing	O
and	O
planned	O
motorways	O
and	O
around	O
the	O
network	O
of	O
other	O
major	O
(	O
A-	O
and	O
B-	O
class	O
)	O
roads	O
,	O
and	O
assigned	O
each	O
respondent	O
to	O
a	O
category	O
of	O
proximity	O
to	O
each	O
type	O
of	O
road	O
infrastructure	O
(	O
within	O
100	O
metres	O
,	O
101–200	O
metres	O
,	O
etc	O
.	O
)	O

based	O
on	O
the	O
location	O
of	O
the	O
centroid	O
of	O
their	O
unit	O
postcode	O
.	O

Travel	O
behaviour	O
For	O
travel	O
time	O
analysis	O
we	O
included	O
travel	O
diaries	O
which	O
recorded	O
no	O
travel	O
at	O
all	O
,	O
but	O
we	O
disregarded	O
travel	O
data	O
from	O
respondents	O
who	O
had	O
not	O
been	O
at	O
home	O
on	O
the	O
day	O
of	O
the	O
travel	O
diary	O
,	O
whose	O
questionnaire	O
had	O
been	O
misprinted	O
such	O
that	O
the	O
travel	O
diary	O
pages	O
were	O
unusable	O
,	O
who	O
had	O
recorded	O
journeys	O
without	O
reporting	O
valid	O
quantitative	O
data	O
on	O
the	O
durations	O
of	O
those	O
journeys	O
,	O
or	O
whose	O
completed	O
travel	O
diary	O
appeared	O
implausible	O
.	O

We	O
also	O
disregarded	O
journeys	O
whose	O
purpose	O
was	O
not	O
stated	O
or	O
was	O
beyond	O
the	O
scope	O
of	O
the	O
travel	O
diary	O
(	O
Additional	O
file	O
1	O
,	O
page	O
8)	O
.	O

We	O
summed	O
the	O
reported	O
travel	O
time	O
for	O
each	O
mode	O
of	O
transport	O
,	O
calculated	O
a	O
total	O
travel	O
time	O
by	O
active	O
modes	O
(	O
walking	O
plus	O
cycling	O
)	O
and	O
by	O
all	O
modes	O
combined	O
,	O
and	O
calculated	O
the	O
proportion	O
of	O
total	O
travel	O
time	O
contributed	O
by	O
each	O
mode	O
of	O
transport	O
.	O

Physical	O
activity	O
We	O
cleaned	O
and	O
analysed	O
IPAQ	O
data	O
in	O
accordance	O
with	O
the	O
IPAQ	O
scoring	O
protocol	O
.	O

We	O
therefore	O
disregarded	O
physical	O
activity	O
data	O
from	O
respondents	O
who	O
had	O
reported	O
more	O
than	O
16	O
hours	O
of	O
physical	O
activity	O
per	O
day	O
or	O
who	O
had	O
missing	O
or	O
internally	O
inconsistent	O
data	O
on	O
the	O
frequency	O
or	O
duration	O
of	O
any	O
of	O
the	O
three	O
categories	O
of	O
physical	O
activity	O
(	O
walking	O
,	O
moderate	O
-	O
intensity	O
activity	O
or	O
vigorous	O
activity	O
)	O
.	O

We	O
also	O
recoded	O
reported	O
durations	O
of	O
activity	O
of	O
less	O
than	O
ten	O
minutes	O
to	O
zero	O
,	O
and	O
of	O
greater	O
than	O
180	O
minutes	O
to	O
180	O
minutes	O
.	O

We	O
calculated	O
the	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
for	O
each	O
respondent	O
(	O
MET	O
-	O
min	O
/	O
week	O
)	O
and	O
used	O
a	O
combination	O
of	O
frequency	O
,	O
duration	O
and	O
total	O
energy	O
expenditure	O
to	O
assign	O
each	O
respondent	O
to	O
a	O
'	O
high	O
'	O
,	O
'	O
moderate	O
'	O
or	O
'	O
low	O
'	O
category	O
of	O
overall	O
physical	O
activity	O
in	O
accordance	O
with	O
the	O
prescribed	O
IPAQ	O
algorithm	O
.	O

The	O
'	O
high	O
'	O
category	O
corresponds	O
to	O
a	O
sufficient	O
level	O
of	O
physical	O
activity	O
to	O
meet	O
current	O
public	O
health	O
recommendations	O
for	O
adults	O
[	O
20	O
]	O
.	O

Analysis	O
We	O
considered	O
it	O
unlikely	O
that	O
the	O
statistical	O
assumptions	O
required	O
for	O
linear	O
regression	O
could	O
be	O
met	O
because	O
the	O
distributions	O
of	O
time	O
spent	O
walking	O
and	O
cycling	O
and	O
of	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
were	O
both	O
strongly	O
positively	O
skewed	O
and	O
dominated	O
by	O
a	O
large	O
number	O
of	O
zero	O
values	O
which	O
meant	O
that	O
the	O
data	O
were	O
not	O
amenable	O
to	O
log	O
-	O
transformation	O
.	O

We	O
therefore	O
modelled	O
the	O
correlates	O
of	O
active	O
travel	O
and	O
physical	O
activity	O
using	O
multivariate	O
logistic	O
regression	O
.	O

We	O
defined	O
'	O
active	O
travel	O
'	O
as	O
a	O
binary	O
condition	O
achieved	O
by	O
any	O
respondent	O
who	O
had	O
reported	O
at	O
least	O
30	O
minutes	O
of	O
travel	O
by	O
walking	O
,	O
cycling	O
or	O
both	O
in	O
their	O
travel	O
diary	O
,	O
reflecting	O
the	O
current	O
recommendation	O
that	O
adults	O
should	O
accumulate	O
at	O
least	O
30	O
minutes	O
of	O
moderate	O
-	O
intensity	O
physical	O
activity	O
on	O
most	O
days	O
of	O
the	O
week	O
[	O
20	O
]	O
,	O
and	O
we	O
defined	O
'	O
physical	O
activity	O
'	O
as	O
a	O
binary	O
condition	O
achieved	O
by	O
any	O
respondent	O
whose	O
overall	O
physical	O
activity	O
was	O
categorised	O
as	O
'	O
high	O
'	O
using	O
IPAQ	O
.	O

We	O
then	O
built	O
separate	O
multivariate	O
models	O
for	O
active	O
travel	O
and	O
physical	O
activity	O
following	O
the	O
method	O
of	O
Hosmer	O
and	O
Lemeshow	O
[	O
21	O
]	O
,	O
first	O
including	O
only	O
'	O
personal	O
'	O
(	O
individual	O
or	O
household	O
)	O
variables	O
and	O
then	O
adding	O
'	O
environmental	O
'	O
variables	O
(	O
Additional	O
file	O
2	O
)	O
.	O

Results	O
Response	O
We	O
received	O
1345	O
completed	O
questionnaires	O
.	O

After	O
subtracting	O
from	O
the	O
numerator	O
23	O
completed	O
questionnaires	O
with	O
missing	O
critical	O
demographic	O
data	O
(	O
age	O
or	O
sex	O
)	O
,	O
and	O
after	O
subtracting	O
from	O
the	O
denominator	O
676	O
addresses	O
from	O
which	O
survey	O
packs	O
were	O
returned	O
as	O
undeliverable	O
,	O
this	O
left	O
1322	O
valid	O
responses	O
to	O
be	O
entered	O
into	O
analysis	O
–	O
a	O
response	O
rate	O
of	O
1322	O
/	O
(	O
9000	O
-	O
676	O
)	O
=	O
15.9	O
%	O
.	O

Characteristics	O
of	O
study	O
participants	O
Demographic	O
and	O
socioeconomic	O
characteristics	O
Respondents	O
were	O
aged	O
between	O
16	O
and	O
89	O
years	O
(	O
median	O
age	O
48	O
years	O
)	O
.	O

804	O
(	O
61	O
%	O
)	O
were	O
women	O
.	O

Only	O
136	O
(	O
26	O
%	O
)	O
of	O
the	O
men	O
and	O
145	O
(	O
18	O
%	O
)	O
of	O
the	O
women	O
reported	O
having	O
access	O
to	O
a	O
bicycle	O
.	O

For	O
those	O
who	O
usually	O
travelled	O
to	O
a	O
place	O
of	O
work	O
or	O
study	O
,	O
the	O
median	O
reported	O
distance	O
was	O
3.5	O
miles	O
(	O
about	O
5.5	O
kilometres	O
)	O
.	O

Other	O
characteristics	O
of	O
study	O
participants	O
are	O
summarised	O
in	O
Table	O
2	O
.	O

Health	O
and	O
wellbeing	O
25	O
%	O
of	O
respondents	O
reported	O
difficulty	O
walking	O
for	O
a	O
quarter	O
of	O
a	O
mile	O
,	O
39	O
%	O
reported	O
a	O
long	O
-	O
term	O
health	O
problem	O
or	O
disability	O
,	O
and	O
50	O
%	O
were	O
overweight	O
(	O
median	O
BMI	O
25.1	O
kg	O
/	O
m2	O
)	O
.	O

The	O
median	O
mental	O
health	O
summary	O
score	O
(	O
MCS-8	O
)	O
was	O
significantly	O
lower	O
(	O
i.e.	O
poorer	O
)	O
than	O
the	O
population	O
norm	O
(	O
median	O
47.3	O
,	O
95	O
%	O
CI	O
46.4	O
to	O
48.1	O
)	O
;	O
the	O
median	O
physical	O
health	O
summary	O
score	O
(	O
PCS-8	O
)	O
was	O
not	O
significantly	O
different	O
from	O
the	O
population	O
norm	O
(	O
median	O
50.9	O
,	O
95	O
%	O
CI	O
49.6	O
to	O
51.7	O
)	O
.	O

Descriptive	O
data	O
on	O
travel	O
behaviour	O
and	O
physical	O
activity	O
Travel	O
behaviour	O
1099	O
travel	O
diaries	O
were	O
suitable	O
for	O
travel	O
time	O
analysis	O
.	O

Men	O
and	O
women	O
were	O
equally	O
likely	O
to	O
have	O
returned	O
usable	O
travel	O
time	O
data	O
,	O
but	O
respondents	O
who	O
were	O
older	O
,	O
retired	O
,	O
or	O
living	O
in	O
social	O
rented	O
accommodation	O
or	O
who	O
did	O
not	O
have	O
access	O
to	O
a	O
car	O
were	O
less	O
likely	O
to	O
have	O
returned	O
usable	O
data	O
.	O

On	O
average	O
,	O
respondents	O
recorded	O
about	O
an	O
hour	O
's	O
travel	O
per	O
day	O
(	O
mean	O
61.5	O
minutes	O
,	O
median	O
50.0	O
minutes	O
)	O
,	O
of	O
which	O
a	O
minority	O
was	O
spent	O
using	O
active	O
modes	O
of	O
transport	O
(	O
walking	O
or	O
cycling	O
:	O
mean	O
20.0	O
minutes	O
,	O
median	O
10.0	O
minutes	O
)	O
(	O
Table	O
3	O
)	O
.	O

304	O
respondents	O
(	O
28	O
%	O
)	O
recorded	O
at	O
least	O
30	O
minutes	O
of	O
active	O
travel	O
,	O
of	O
whom	O
294	O
(	O
97	O
%	O
)	O
recorded	O
at	O
least	O
30	O
minutes	O
of	O
walking	O
.	O

Physical	O
activity	O
833	O
respondents	O
returned	O
complete	O
physical	O
activity	O
data	O
suitable	O
for	O
analysis	O
.	O

Women	O
and	O
respondents	O
who	O
were	O
older	O
,	O
retired	O
,	O
or	O
living	O
in	O
social	O
rented	O
accommodation	O
or	O
who	O
did	O
not	O
have	O
access	O
to	O
a	O
car	O
were	O
less	O
likely	O
to	O
have	O
returned	O
usable	O
data	O
.	O

Respondents	O
reported	O
a	O
mean	O
of	O
318	O
minutes	O
'	O
walking	O
per	O
week	O
and	O
a	O
mean	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
of	O
3000	O
MET	O
-	O
minutes	O
per	O
week	O
(	O
Table	O
4	O
)	O
.	O

Only	O
316	O
respondents	O
(	O
38	O
%	O
)	O
were	O
categorised	O
as	O
having	O
achieved	O
a	O
'	O
high	O
'	O
(	O
i.e.	O
sufficient	O
)	O
level	O
of	O
physical	O
activity	O
.	O

Correlates	O
of	O
active	O
travel	O
Active	O
travel	O
was	O
significantly	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
more	O
than	O
four	O
miles	O
to	O
work	O
,	O
having	O
access	O
to	O
a	O
bicycle	O
,	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
and	O
the	O
absence	O
of	O
any	O
difficulty	O
walking	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
'	O
personal	O
'	O
correlates	O
of	O
active	O
travel	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
13.04	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0.11	O
)	O
and	O
explained	O
nearly	O
one	O
-	O
fifth	O
of	O
the	O
total	O
variance	O
in	O
active	O
travel	O
(	O
Nagelkerke	O
's	O
R2	O
=	O
18.7	O
%	O
)	O
(	O
Table	O
5	O
)	O
.	O

Adding	O
'	O
environmental	O
'	O
variables	O
to	O
the	O
model	O
showed	O
an	O
additional	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
,	O
and	O
an	O
additional	O
significant	O
negative	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
also	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
10.61	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0.23	O
)	O
and	O
explained	O
slightly	O
more	O
of	O
the	O
total	O
variance	O
in	O
active	O
travel	O
than	O
did	O
the	O
personal	O
model	O
alone	O
(	O
Nagelkerke	O
's	O
R2	O
=	O
20.1	O
%	O
)	O
(	O
Figure	O
3	O
)	O
.	O

In	O
order	O
to	O
aid	O
interpretation	O
,	O
we	O
also	O
partitioned	O
the	O
dataset	O
into	O
two	O
strata	O
(	O
'	O
No	O
car	O
available	O
'	O
and	O
'	O
Car	O
available	O
'	O
)	O
and	O
refitted	O
the	O
final	O
model	O
separately	O
to	O
each	O
stratum	O
of	O
the	O
dataset	O
(	O
Table	O
6	O
)	O
.	O

This	O
showed	O
that	O
the	O
subset	O
of	O
respondents	O
with	O
no	O
access	O
to	O
a	O
car	O
accounted	O
for	O
the	O
significant	O
overall	O
relationship	O
between	O
active	O
travel	O
and	O
access	O
to	O
a	O
bicycle	O
,	O
whereas	O
those	O
with	O
access	O
to	O
a	O
car	O
accounted	O
for	O
the	O
significant	O
overall	O
relationships	O
with	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
and	O
perceptions	O
of	O
the	O
local	O
environment	O
.	O

The	O
relationship	O
with	O
difficulty	O
walking	O
was	O
also	O
stronger	O
in	O
this	O
group	O
than	O
in	O
those	O
without	O
access	O
to	O
a	O
car	O
.	O

Correlates	O
of	O
physical	O
activity	O
Physical	O
activity	O
was	O
significantly	O
associated	O
with	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
,	O
not	O
being	O
overweight	O
,	O
and	O
the	O
absence	O
of	O
any	O
difficulty	O
walking	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
'	O
personal	O
'	O
correlates	O
of	O
physical	O
activity	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
3.89	O
,	O
df	O
=	O
7	O
;	O
P	O
=	O
0.89	O
)	O
and	O
explained	O
about	O
one	O
-	O
sixth	O
of	O
the	O
total	O
variance	O
in	O
physical	O
activity	O
(	O
Nagelkerke	O
's	O
R2	O
=	O
15.9	O
%	O
)	O
(	O
Table	O
7	O
)	O
.	O

Adding	O
'	O
environmental	O
'	O
variables	O
to	O
the	O
model	O
showed	O
an	O
additional	O
significant	O
negative	O
association	O
between	O
physical	O
activity	O
and	O
perception	O
of	O
traffic	O
volume	O
(	O
i.e.	O
respondents	O
who	O
perceived	O
there	O
to	O
be	O
a	O
higher	O
volume	O
of	O
traffic	O
were	O
more	O
likely	O
to	O
report	O
physical	O
activity	O
)	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
personal	O
and	O
environmental	O
correlates	O
of	O
physical	O
activity	O
also	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
3.86	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0.87	O
)	O
and	O
explained	O
slightly	O
more	O
of	O
the	O
total	O
variance	O
in	O
physical	O
activity	O
than	O
did	O
the	O
personal	O
model	O
alone	O
(	O
Nagelkerke	O
's	O
16.6	O
%	O
)	O
(	O
Figure	O
3	O
)	O
.	O

Discussion	O
Principal	O
findings	O
In	O
this	O
deprived	O
urban	O
population	O
,	O
the	O
likelihood	O
of	O
reporting	O
active	O
travel	O
was	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
a	O
long	O
distance	O
to	O
work	O
and	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
whereas	O
overall	O
physical	O
activity	O
was	O
associated	O
with	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
and	O
not	O
being	O
overweight	O
.	O

After	O
adjusting	O
for	O
individual	O
and	O
household	O
characteristics	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
the	O
objective	O
proximity	O
of	O
respondents	O
'	O
homes	O
to	O
motorway	O
or	O
major	O
road	O
infrastructure	O
appeared	O
to	O
explain	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
although	O
we	O
did	O
find	O
a	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
.	O

Representativeness	O
and	O
completeness	O
of	O
survey	O
data	O
Our	O
difficulty	O
in	O
obtaining	O
a	O
representative	O
sample	O
of	O
the	O
resident	O
population	O
is	O
not	O
unique	O
to	O
our	O
study	O
.	O

Although	O
our	O
final	O
response	O
rate	O
was	O
low	O
,	O
it	O
was	O
almost	O
identical	O
to	O
that	O
achieved	O
in	O
a	O
recent	O
population	O
-	O
based	O
intervention	O
study	O
elsewhere	O
in	O
Glasgow	O
[	O
22	O
]	O
.	O

Some	O
of	O
the	O
challenges	O
of	O
recruiting	O
research	O
participants	O
in	O
areas	O
of	O
deprivation	O
have	O
been	O
described	O
elsewhere	O
[	O
23	O
]	O
;	O
these	O
are	O
superimposed	O
on	O
a	O
downward	O
trend	O
in	O
participation	O
in	O
even	O
the	O
best	O
-	O
resourced	O
national	O
population	O
surveys	O
[	O
24	O
]	O
and	O
an	O
upward	O
(	O
and	O
socially	O
biased	O
)	O
trend	O
in	O
opt	O
-	O
outs	O
from	O
the	O
main	O
alternative	O
sampling	O
frame	O
,	O
the	O
edited	O
electoral	O
register	O
[	O
25	O
]	O
.	O

Although	O
our	O
achieved	O
sample	O
contained	O
a	O
higher	O
proportion	O
of	O
respondents	O
from	O
owner	O
-	O
occupied	O
and	O
car	O
-	O
owning	O
households	O
than	O
predicted	O
from	O
2001	O
census	O
data	O
for	O
the	O
same	O
census	O
output	O
areas	O
,	O
these	O
differences	O
may	O
be	O
partly	O
accounted	O
for	O
by	O
an	O
upward	O
background	O
trend	O
in	O
owner	O
occupation	O
and	O
car	O
access	O
between	O
2001	O
and	O
2005	O
.	O

Our	O
achieved	O
sample	O
is	O
still	O
clearly	O
disadvantaged	O
overall	O
,	O
in	O
terms	O
of	O
socioeconomic	O
and	O
health	O
status	O
,	O
compared	O
with	O
the	O
country	O
as	O
a	O
whole	O
.	O

It	O
also	O
contains	O
sufficient	O
heterogeneity	O
to	O
enable	O
us	O
to	O
examine	O
,	O
in	O
time	O
,	O
how	O
the	O
effects	O
of	O
the	O
intervention	O
are	O
distributed	O
between	O
socioeconomic	O
groups	O
.	O

We	O
therefore	O
consider	O
our	O
achieved	O
sample	O
fit	O
for	O
purpose	O
.	O

We	O
had	O
to	O
disregard	O
a	O
substantial	O
proportion	O
of	O
cases	O
in	O
analysis	O
because	O
respondents	O
had	O
returned	O
unusable	O
travel	O
time	O
data	O
or	O
had	O
returned	O
physical	O
activity	O
data	O
that	O
were	O
incomplete	O
,	O
internally	O
inconsistent	O
or	O
included	O
a	O
'	O
Do	O
n't	O
know	O
'	O
response	O
and	O
were	O
therefore	O
unacceptable	O
according	O
to	O
the	O
IPAQ	O
scoring	O
protocol	O
.	O

Most	O
published	O
studies	O
using	O
the	O
same	O
,	O
short	O
form	O
of	O
IPAQ	O
have	O
either	O
not	O
reported	O
the	O
distribution	O
of	O
the	O
continuous	O
summary	O
measures	O
or	O
have	O
not	O
reported	O
data	O
for	O
the	O
UK	O
separately	O
from	O
those	O
for	O
other	O
countries	O
where	O
higher	O
levels	O
of	O
physical	O
activity	O
are	O
reported	O
.	O

Despite	O
the	O
high	O
proportion	O
of	O
missing	O
physical	O
activity	O
data	O
in	O
our	O
dataset	O
,	O
however	O
,	O
the	O
aggregate	O
continuous	O
data	O
we	O
obtained	O
were	O
broadly	O
comparable	O
to	O
those	O
reported	O
in	O
Rütten	O
and	O
colleagues	O
'	O
study	O
of	O
a	O
random	O
sample	O
of	O
UK	O
adults	O
[	O
26	O
]	O
.	O

We	O
could	O
have	O
included	O
more	O
cases	O
in	O
physical	O
activity	O
analysis	O
by	O
,	O
for	O
example	O
,	O
imputing	O
missing	O
values	O
,	O
but	O
the	O
results	O
would	O
not	O
have	O
been	O
comparable	O
with	O
others	O
'	O
owing	O
to	O
the	O
substantial	O
deviations	O
from	O
the	O
scoring	O
protocol	O
which	O
would	O
have	O
been	O
required	O
.	O

The	O
frequency	O
of	O
unusable	O
responses	O
was	O
not	O
reported	O
in	O
the	O
international	O
multi	O
-	O
centre	O
study	O
which	O
originally	O
established	O
the	O
validity	O
and	O
reliability	O
of	O
IPAQ	O
[	O
27	O
]	O
.	O

It	O
is	O
possible	O
that	O
offering	O
a	O
'	O
Do	O
n't	O
know	O
'	O
option	O
in	O
the	O
self	O
-	O
completed	O
IPAQ	O
questionnaire	O
encourages	O
respondents	O
to	O
select	O
this	O
rather	O
than	O
to	O
enter	O
what	O
may	O
be	O
a	O
reasonably	O
precise	O
estimate	O
of	O
the	O
actual	O
time	O
spent	O
in	O
physical	O
activity	O
;	O
the	O
respondent	O
has	O
no	O
way	O
of	O
knowing	O
that	O
a	O
single	O
'	O
Do	O
n't	O
know	O
'	O
response	O
will	O
result	O
in	O
all	O
of	O
their	O
physical	O
activity	O
data	O
being	O
disregarded	O
in	O
analysis	O
.	O

This	O
should	O
be	O
considered	O
in	O
any	O
future	O
revision	O
of	O
the	O
IPAQ	O
questionnaire	O
and	O
scoring	O
protocol	O
.	O

Contribution	O
of	O
active	O
travel	O
to	O
overall	O
physical	O
activity	O
The	O
explanatory	O
variables	O
that	O
were	O
significantly	O
associated	O
with	O
active	O
travel	O
but	O
not	O
with	O
physical	O
activity	O
(	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
,	O
access	O
to	O
a	O
bicycle	O
,	O
access	O
to	O
a	O
car	O
,	O
perceived	O
proximity	O
to	O
shops	O
,	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
)	O
all	O
have	O
an	O
obvious	O
intuitive	O
relationship	O
with	O
the	O
use	O
of	O
walking	O
or	O
cycling	O
as	O
modes	O
of	O
transport	O
.	O

That	O
they	O
were	O
not	O
significantly	O
associated	O
with	O
overall	O
physical	O
activity	O
suggests	O
either	O
that	O
active	O
travel	O
contributes	O
only	O
a	O
minority	O
of	O
respondents	O
'	O
overall	O
physical	O
activity	O
or	O
that	O
other	O
factors	O
not	O
measured	O
in	O
this	O
study	O
are	O
more	O
important	O
correlates	O
of	O
overall	O
physical	O
activity	O
than	O
those	O
which	O
determine	O
active	O
travel	O
.	O

A	O
crude	O
comparision	O
of	O
the	O
quantity	O
of	O
active	O
travel	O
reported	O
in	O
the	O
one	O
-	O
day	O
travel	O
diaries	O
with	O
the	O
quantities	O
of	O
physical	O
activity	O
reported	O
using	O
IPAQ	O
suggests	O
that	O
on	O
average	O
,	O
active	O
travel	O
may	O
indeed	O
make	O
only	O
a	O
small	O
(	O
~15	O
%	O
)	O
contribution	O
to	O
overall	O
physical	O
activity	O
in	O
this	O
study	O
population	O
.	O

However	O
,	O
the	O
real	O
contribution	O
may	O
be	O
substantially	O
greater	O
than	O
this	O
if	O
,	O
as	O
has	O
been	O
shown	O
previously	O
,	O
respondents	O
tend	O
to	O
over	O
-	O
report	O
their	O
physical	O
activity	O
using	O
IPAQ	O
[	O
28	O
]	O
.	O

There	O
can	O
be	O
little	O
doubt	O
that	O
active	O
travel	O
makes	O
a	O
substantial	O
contribution	O
to	O
the	O
total	O
quantity	O
of	O
walking	O
reported	O
in	O
this	O
study	O
population	O
.	O

Irrespective	O
of	O
the	O
true	O
contribution	O
of	O
active	O
travel	O
to	O
overall	O
physical	O
activity	O
,	O
however	O
,	O
it	O
remains	O
likely	O
that	O
other	O
unmeasured	O
personal	O
and	O
social	O
factors	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
may	O
be	O
more	O
important	O
correlates	O
of	O
overall	O
physical	O
activity	O
.	O

Socio	O
-	O
spatial	O
patterning	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
Respondents	O
living	O
in	O
owner	O
-	O
occupied	O
households	O
were	O
more	O
likely	O
to	O
report	O
active	O
travel	O
than	O
those	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
,	O
but	O
less	O
likely	O
to	O
report	O
sufficient	O
overall	O
physical	O
activity	O
.	O

Since	O
neither	O
working	O
situation	O
nor	O
perceived	O
financial	O
situation	O
emerged	O
as	O
significantly	O
associated	O
with	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
housing	O
tenure	O
and	O
car	O
access	O
are	O
the	O
remaining	O
explanatory	O
variables	O
in	O
this	O
dataset	O
which	O
can	O
be	O
interpreted	O
as	O
markers	O
of	O
socioeconomic	O
status	O
.	O

Although	O
having	O
access	O
to	O
a	O
car	O
clearly	O
reflects	O
the	O
possession	O
of	O
a	O
material	O
asset	O
,	O
it	O
has	O
been	O
argued	O
that	O
this	O
is	O
a	O
less	O
direct	O
marker	O
of	O
socioeconomic	O
status	O
than	O
some	O
other	O
markers	O
because	O
,	O
in	O
Scotland	O
at	O
least	O
,	O
access	O
to	O
a	O
car	O
is	O
a	O
more	O
-	O
or	O
-	O
less	O
essential	O
requirement	O
for	O
living	O
in	O
many	O
rural	O
areas	O
,	O
whereas	O
it	O
is	O
possible	O
to	O
live	O
in	O
a	O
dense	O
urban	O
settlement	O
such	O
as	O
Glasgow	O
without	O
using	O
a	O
car	O
.	O

In	O
the	O
final	O
models	O
in	O
this	O
study	O
,	O
therefore	O
,	O
housing	O
tenure	O
may	O
be	O
regarded	O
as	O
the	O
primary	O
marker	O
of	O
socioeconomic	O
status	O
.	O

The	O
findings	O
consequently	O
suggest	O
conflicting	O
socioeconomic	O
gradients	O
in	O
prevalence	O
:	O
more	O
advantaged	O
respondents	O
were	O
more	O
likely	O
to	O
report	O
active	O
travel	O
,	O
but	O
more	O
disadvantaged	O
respondents	O
were	O
more	O
likely	O
to	O
report	O
sufficient	O
overall	O
physical	O
activity	O
.	O

The	O
higher	O
prevalence	O
of	O
sufficient	O
overall	O
physical	O
activity	O
among	O
the	O
more	O
disadvantaged	O
despite	O
their	O
lower	O
propensity	O
for	O
active	O
travel	O
is	O
likely	O
to	O
reflect	O
higher	O
quantities	O
of	O
physical	O
activity	O
in	O
other	O
domains	O
,	O
particularly	O
occupational	O
and	O
domestic	O
activities	O
,	O
since	O
leisure	O
-	O
time	O
physical	O
activity	O
tends	O
to	O
be	O
higher	O
among	O
more	O
advantaged	O
groups	O
[	O
29	O
]	O
.	O

Environmental	O
characteristics	O
:	O
paradoxical	O
,	O
unmeasured	O
,	O
or	O
irrelevant	O
?	O

The	O
two	O
environmental	O
variables	O
that	O
emerged	O
as	O
significantly	O
associated	O
with	O
active	O
travel	O
,	O
particularly	O
among	O
those	O
without	O
access	O
to	O
a	O
car	O
,	O
were	O
perceived	O
proximity	O
to	O
shops	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
.	O

The	O
positive	O
association	O
with	O
perceived	O
proximity	O
to	O
shops	O
suggests	O
that	O
for	O
active	O
travel	O
to	O
be	O
undertaken	O
in	O
this	O
population	O
,	O
it	O
may	O
be	O
more	O
important	O
that	O
people	O
live	O
close	O
to	O
the	O
amenities	O
they	O
need	O
than	O
that	O
they	O
live	O
in	O
an	O
environment	O
with	O
more	O
favourable	O
subjective	O
or	O
discretionary	O
considerations	O
such	O
as	O
attractiveness	O
or	O
noise	O
.	O

This	O
would	O
be	O
consistent	O
with	O
an	O
understanding	O
that	O
walking	O
as	O
a	O
mode	O
of	O
transport	O
is	O
primarily	O
a	O
way	O
of	O
undertaking	O
journeys	O
which	O
have	O
to	O
be	O
made	O
anyway	O
,	O
as	O
opposed	O
to	O
more	O
discretionary	O
(	O
recreational	O
)	O
forms	O
of	O
walking	O
which	O
may	O
be	O
more	O
susceptible	O
to	O
the	O
influence	O
of	O
less	O
-	O
structural	O
characteristics	O
.	O

Although	O
the	O
negative	O
association	O
with	O
perceived	O
road	O
safety	O
for	O
cyclists	O
appears	O
counter	O
-	O
intuitive	O
,	O
similar	O
'	O
paradoxical	O
inverse	O
relationships	O
'	O
have	O
been	O
reported	O
elsewhere	O
,	O
for	O
example	O
by	O
Titze	O
and	O
colleagues	O
in	O
a	O
study	O
of	O
the	O
correlates	O
of	O
cycling	O
among	O
students	O
[	O
30	O
]	O
and	O
by	O
Humpel	O
and	O
colleagues	O
in	O
a	O
study	O
of	O
correlates	O
of	O
walking	O
for	O
pleasure	O
[	O
31	O
]	O
.	O

Titze	O
and	O
colleagues	O
suggest	O
that	O
respondents	O
who	O
cycle	O
regularly	O
are	O
more	O
likely	O
to	O
be	O
aware	O
of	O
,	O
and	O
report	O
,	O
the	O
danger	O
posed	O
by	O
traffic	O
than	O
non	O
-	O
cyclists	O
or	O
infrequent	O
cyclists	O
.	O

A	O
similar	O
phenomenon	O
could	O
explain	O
the	O
negative	O
association	O
between	O
physical	O
activity	O
and	O
perception	O
of	O
traffic	O
volume	O
.	O

Overall	O
,	O
the	O
influence	O
of	O
the	O
putative	O
environmental	O
characteristics	O
examined	O
in	O
this	O
study	O
on	O
active	O
travel	O
and	O
physical	O
activity	O
appeared	O
small	O
compared	O
with	O
that	O
of	O
the	O
personal	O
characteristics	O
found	O
to	O
be	O
significant	O
,	O
and	O
including	O
environmental	O
characteristics	O
in	O
the	O
models	O
did	O
not	O
substantially	O
modify	O
the	O
influence	O
of	O
personal	O
characteristics	O
.	O

On	O
the	O
one	O
hand	O
,	O
this	O
could	O
reflect	O
an	O
artefact	O
of	O
the	O
research	O
methods	O
(	O
a	O
false	O
negative	O
error	O
)	O
,	O
which	O
could	O
have	O
arisen	O
in	O
various	O
ways	O
.	O

In	O
particular	O
,	O
the	O
'	O
wrong	O
'	O
environmental	O
exposure	O
may	O
have	O
been	O
measured	O
,	O
in	O
that	O
the	O
environmental	O
characteristics	O
examined	O
were	O
those	O
of	O
the	O
immediate	O
surroundings	O
of	O
respondents	O
'	O
homes	O
,	O
whereas	O
the	O
propensity	O
to	O
choose	O
active	O
modes	O
of	O
transport	O
may	O
be	O
more	O
strongly	O
influenced	O
by	O
the	O
characteristics	O
of	O
the	O
environment	O
elsewhere	O
on	O
their	O
routes	O
[	O
30	O
]	O
,	O
for	O
example	O
the	O
perceived	O
danger	O
of	O
cycling	O
in	O
the	O
city	O
centre	O
–	O
an	O
association	O
which	O
may	O
be	O
absent	O
,	O
or	O
at	O
least	O
diluted	O
,	O
when	O
the	O
'	O
exposure	O
'	O
examined	O
is	O
limited	O
to	O
the	O
residential	O
environment	O
.	O

It	O
could	O
also	O
be	O
argued	O
that	O
the	O
apparently	O
weak	O
influence	O
of	O
environmental	O
characteristics	O
in	O
this	O
study	O
reflects	O
a	O
reliance	O
on	O
respondents	O
'	O
perceptions	O
which	O
have	O
not	O
been	O
objectively	O
verified	O
and	O
may	O
therefore	O
be	O
a	O
weak	O
proxy	O
for	O
the	O
'	O
true	O
'	O
objectively	O
-	O
measured	O
characteristics	O
of	O
their	O
surroundings	O
.	O

However	O
,	O
as	O
recent	O
reviews	O
have	O
pointed	O
out	O
,	O
the	O
current	O
weight	O
of	O
evidence	O
for	O
objective	O
environmental	O
correlates	O
of	O
walking	O
is	O
no	O
greater	O
than	O
that	O
for	O
subjective	O
environmental	O
correlates	O
[	O
5	O
]	O
and	O
it	O
is	O
entirely	O
plausible	O
that	O
people	O
's	O
perceptions	O
of	O
their	O
environment	O
may	O
be	O
at	O
least	O
as	O
important	O
as	O
their	O
objective	O
conditions	O
in	O
influencing	O
their	O
behaviour	O
[	O
6	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
may	O
have	O
demonstrated	O
a	O
real	O
absence	O
of	O
any	O
major	O
association	O
.	O

Although	O
at	O
first	O
sight	O
this	O
appears	O
at	O
odds	O
with	O
the	O
growing	O
body	O
of	O
review	O
-	O
level	O
evidence	O
for	O
environmental	O
correlates	O
of	O
physical	O
activity	O
,	O
Wendel	O
-	O
Vos	O
and	O
colleagues	O
noted	O
that	O
of	O
all	O
the	O
environmental	O
factors	O
examined	O
in	O
all	O
the	O
studies	O
included	O
in	O
their	O
review	O
,	O
analysis	O
showed	O
a	O
'	O
null	O
association	O
'	O
in	O
76	O
%	O
of	O
cases	O
[	O
9	O
]	O
,	O
and	O
our	O
finding	O
that	O
personal	O
factors	O
account	O
for	O
a	O
much	O
larger	O
proportion	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
physical	O
activity	O
than	O
is	O
accounted	O
for	O
by	O
environmental	O
factors	O
is	O
consistent	O
with	O
those	O
of	O
some	O
other	O
European	O
studies	O
[	O
32,33	O
]	O
.	O

In	O
the	O
particular	O
context	O
of	O
this	O
study	O
,	O
residents	O
may	O
simply	O
have	O
adapted	O
to	O
adverse	O
conditions	O
in	O
their	O
local	O
environment	O
in	O
the	O
ways	O
identified	O
by	O
Hedges	O
in	O
a	O
qualitative	O
study	O
of	O
people	O
living	O
close	O
to	O
new	O
roads	O
built	O
in	O
the	O
UK	O
in	O
the	O
1970s	O
[	O
34	O
]	O
–	O
particularly	O
by	O
attitudinal	O
adaptation	O
,	O
which	O
Hedges	O
characterises	O
as	O
developing	O
an	O
attitude	O
that	O
it	O
is	O
futile	O
to	O
resist	O
.	O

One	O
can	O
imagine	O
that	O
in	O
the	O
most	O
deprived	O
areas	O
of	O
Glasgow	O
,	O
people	O
may	O
have	O
become	O
resigned	O
to	O
the	O
nature	O
of	O
their	O
surroundings	O
,	O
seeing	O
them	O
as	O
inevitable	O
and	O
not	O
amenable	O
to	O
change	O
either	O
through	O
environmental	O
improvement	O
or	O
through	O
their	O
moving	O
to	O
another	O
area	O
.	O

Conclusion	O
After	O
demographic	O
and	O
socioeconomic	O
characteristics	O
were	O
taken	O
into	O
account	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
objective	O
proximity	O
to	O
major	O
road	O
infrastructure	O
appeared	O
to	O
explain	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
in	O
this	O
study	O
.	O

Our	O
study	O
population	O
may	O
be	O
both	O
objectively	O
constrained	O
by	O
their	O
socioeconomic	O
circumstances	O
(	O
including	O
comparatively	O
limited	O
access	O
to	O
private	O
cars	O
)	O
and	O
adapted	O
to	O
living	O
in	O
conditions	O
which	O
others	O
would	O
consider	O
to	O
pose	O
a	O
barrier	O
to	O
active	O
travel	O
.	O

Under	O
these	O
circumstances	O
,	O
environmental	O
characteristics	O
which	O
have	O
been	O
found	O
to	O
influence	O
discretionary	O
active	O
travel	O
in	O
studies	O
in	O
other	O
,	O
more	O
affluent	O
populations	O
may	O
simply	O
be	O
irrelevant	O
in	O
a	O
population	O
which	O
is	O
more	O
captive	O
in	O
its	O
travel	O
choices	O
.	O

Environmental	O
correlates	O
of	O
active	O
travel	O
should	O
not	O
be	O
assumed	O
to	O
be	O
generalisable	O
between	O
populations	O
;	O
researchers	O
should	O
continue	O
to	O
test	O
hypotheses	O
about	O
putative	O
environmental	O
correlates	O
in	O
different	O
settings	O
,	O
and	O
policymakers	O
should	O
recognise	O
that	O
the	O
effects	O
of	O
interventions	O
to	O
change	O
the	O
environment	O
are	O
likely	O
to	O
vary	O
between	O
populations	O
and	O
between	O
socioeconomic	O
groups	O
within	O
populations	O
.	O

Competing	O
interests	O
This	O
paper	O
is	O
based	O
on	O
material	O
contained	O
in	O
the	O
first	O
author	O
's	O
PhD	O
thesis	O
.	O

Authors	O
'	O
contributions	O
DO	O
had	O
the	O
original	O
idea	O
for	O
the	O
study	O
,	O
designed	O
the	O
study	O
and	O
the	O
survey	O
materials	O
,	O
applied	O
for	O
ethical	O
approval	O
,	O
cleaned	O
and	O
coded	O
the	O
survey	O
data	O
,	O
carried	O
out	O
all	O
the	O
geographical	O
and	O
statistical	O
analyses	O
and	O
wrote	O
the	O
paper	O
.	O

MP	O
was	O
DO	O
's	O
PhD	O
supervisor	O
.	O

RM	O
,	O
NM	O
,	O
MP	O
and	O
SP	O
constituted	O
the	O
steering	O
group	O
for	O
the	O
study	O
,	O
contributed	O
to	O
and	O
advised	O
on	O
the	O
design	O
of	O
the	O
study	O
and	O
the	O
interpretation	O
of	O
the	O
emerging	O
findings	O
,	O
and	O
contributed	O
to	O
the	O
critical	O
revision	O
of	O
the	O
paper	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Supplementary	O
Material	O

TOPS++FATCAT	O
:	O
Fast	O
flexible	O
structural	O
alignment	O
using	O
constraints	O
derived	O
from	O
TOPS+	O
Strings	O
Model	O
Abstract	O
Background	O
Protein	O
structure	O
analysis	O
and	O
comparison	O
are	O
major	O
challenges	O
in	O
structural	O
bioinformatics	O
.	O

Despite	O
the	O
existence	O
of	O
many	O
tools	O
and	O
algorithms	O
,	O
very	O
few	O
of	O
them	O
have	O
managed	O
to	O
capture	O
the	O
intuitive	O
understanding	O
of	O
protein	O
structures	O
developed	O
in	O
structural	O
biology	O
,	O
especially	O
in	O
the	O
context	O
of	O
rapid	O
database	O
searches	O
.	O

Such	O
intuitions	O
could	O
help	O
speed	O
up	O
similarity	O
searches	O
and	O
make	O
it	O
easier	O
to	O
understand	O
the	O
results	O
of	O
such	O
analyses	O
.	O

Results	O
We	O
developed	O
a	O
TOPS++FATCAT	O
algorithm	O
that	O
uses	O
an	O
intuitive	O
description	O
of	O
the	O
proteins	O
'	O
structures	O
as	O
captured	O
in	O
the	O
popular	O
TOPS	O
diagrams	O
to	O
limit	O
the	O
search	O
space	O
of	O
the	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
in	O
the	O
flexible	O
alignment	O
of	O
protein	O
structures	O
performed	O
by	O
the	O
FATCAT	O
algorithm	O
.	O

The	O
TOPS++FATCAT	O
algorithm	O
is	O
faster	O
than	O
FATCAT	O
by	O
more	O
than	O
an	O
order	O
of	O
magnitude	O
with	O
a	O
minimal	O
cost	O
in	O
classification	O
and	O
alignment	O
accuracy	O
.	O

For	O
beta	O
-	O
rich	O
proteins	O
its	O
accuracy	O
is	O
better	O
than	O
FATCAT	O
,	O
because	O
the	O
TOPS+	O
strings	O
models	O
contains	O
important	O
information	O
of	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
-	O
bond	O
patterns	O
between	O
the	O
beta	O
-	O
strand	O
SSEs	O
(	O
Secondary	O
Structural	O
Elements	O
)	O
.	O

We	O
show	O
that	O
the	O
TOPS++FATCAT	O
errors	O
,	O
rare	O
as	O
they	O
are	O
,	O
can	O
be	O
clearly	O
linked	O
to	O
oversimplifications	O
of	O
the	O
TOPS	O
diagrams	O
and	O
can	O
be	O
corrected	O
by	O
the	O
development	O
of	O
more	O
precise	O
secondary	O
structure	O
element	O
definitions	O
.	O

Software	O
Availability	O
The	O
benchmark	O
analysis	O
results	O
and	O
the	O
compressed	O
archive	O
of	O
the	O
TOPS++FATCAT	O
program	O
for	O
Linux	O
platform	O
can	O
be	O
downloaded	O
from	O
the	O
following	O
web	O
site	O
:	O
Conclusion	O
TOPS++FATCAT	O
provides	O
FATCAT	O
accuracy	O
and	O
insights	O
into	O
protein	O
structural	O
changes	O
at	O
a	O
speed	O
comparable	O
to	O
sequence	O
alignments	O
,	O
opening	O
up	O
a	O
possibility	O
of	O
interactive	O
protein	O
structure	O
similarity	O
searches	O
.	O

Background	O
Structural	O
biology	O
is	O
one	O
of	O
the	O
most	O
successful	O
fields	O
of	O
modern	O
biology	O
.	O

Over	O
50,000	O
solved	O
protein	O
structures	O
illustrate	O
details	O
of	O
many	O
specific	O
biological	O
processes	O
.	O

The	O
same	O
data	O
also	O
provide	O
us	O
with	O
information	O
about	O
the	O
global	O
features	O
of	O
protein	O
structure	O
space	O
and	O
can	O
be	O
studied	O
to	O
discover	O
the	O
evolutionary	O
,	O
physical	O
,	O
and	O
mathematical	O
rules	O
governing	O
them	O
.	O

How	O
many	O
fundamentally	O
different	O
protein	O
shapes	O
(	O
folds	O
)	O
are	O
there	O
?	O

How	O
do	O
protein	O
structures	O
evolve	O
?	O

How	O
do	O
new	O
structural	O
features	O
appear	O
,	O
and	O
if	O
they	O
are	O
coupled	O
with	O
changes	O
in	O
function	O
,	O
how	O
does	O
this	O
process	O
occur	O
?	O

Such	O
questions	O
can	O
be	O
studied	O
by	O
classifying	O
,	O
comparing	O
and	O
analyzing	O
known	O
protein	O
structures	O
.	O

Two	O
different	O
,	O
but	O
synergistic	O
strategies	O
are	O
typically	O
used	O
for	O
this	O
purpose	O
.	O

In	O
classification	O
systems	O
such	O
as	O
SCOP	O
[	O
1	O
]	O
or	O
CATH	O
[	O
2	O
]	O
,	O
human	B
intuition	O
is	O
used	O
to	O
simplify	O
the	O
description	O
of	O
protein	O
structures	O
to	O
a	O
manageable	O
size	O
,	O
and	O
a	O
human	B
eye	O
,	O
sometimes	O
supported	O
by	O
automated	O
analysis	O
,	O
can	O
recognize	O
patterns	O
and	O
types	O
of	O
structures	O
.	O

In	O
the	O
second	O
approach	O
,	O
specialized	O
comparison	O
algorithms	O
,	O
such	O
as	O
DALI	O
[	O
3	O
]	O
,	O
CE	O
[	O
4	O
]	O
,	O
or	O
FATCAT	O
[	O
5	O
]	O
can	O
be	O
used	O
to	O
calculate	O
a	O
distance	O
-	O
like	O
metric	O
in	O
the	O
protein	O
structure	O
space	O
.	O

This	O
in	O
turn	O
can	O
be	O
used	O
to	O
cluster	O
proteins	O
into	O
groups	O
.	O

Many	O
such	O
algorithms	O
have	O
been	O
developed	O
over	O
the	O
past	O
few	O
decades	O
and	O
have	O
been	O
mostly	O
used	O
for	O
the	O
classification	O
of	O
protein	O
structures	O
into	O
families	O
.	O

An	O
exact	O
solution	O
of	O
an	O
alignment	O
between	O
two	O
structures	O
is	O
formally	O
equivalent	O
to	O
a	O
threading	O
problem	O
and	O
is	O
therefore	O
NP	O
-	O
complete	O
[	O
6	O
]	O
.	O

However	O
,	O
a	O
practical	O
solution	O
can	O
be	O
obtained	O
by	O
heuristics	O
reducing	O
the	O
problem	O
to	O
a	O
manageable	O
size	O
[	O
7	O
]	O
.	O

In	O
human	B
classification	O
systems	O
,	O
the	O
protein	O
is	O
usually	O
reduced	O
to	O
a	O
set	O
of	O
several	O
structural	O
elements	O
,	O
which	O
obviously	O
involve	O
many	O
arbitrary	O
thresholds	O
.	O

Automated	O
algorithms	O
have	O
the	O
same	O
problem	O
and	O
also	O
suffer	O
from	O
inconsistencies	O
between	O
different	O
numerical	O
measures	O
of	O
protein	O
structure	O
similarity	O
[	O
8	O
]	O
.	O

Interestingly	O
,	O
despite	O
these	O
problems	O
,	O
results	O
of	O
different	O
approaches	O
are	O
broadly	O
similar	O
.	O

They	O
all	O
identify	O
approximately	O
a	O
few	O
hundred	O
general	O
classes	O
of	O
protein	O
structures	O
,	O
usually	O
called	O
folds	O
[	O
1	O
]	O
or	O
topologies	O
[	O
2	O
]	O
,	O
distinguished	O
by	O
how	O
the	O
main	O
chain	O
of	O
the	O
protein	O
folds	O
around	O
itself	O
in	O
the	O
three	O
-	O
dimensional	O
space	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
comparison	O
of	O
different	O
approaches	O
,	O
both	O
between	O
and	O
within	O
the	O
two	O
classes	O
,	O
shows	O
that	O
fold	O
/	O
topologies	O
(	O
or	O
cluster	O
)	O
definitions	O
are	O
somewhat	O
fuzzy	O
,	O
with	O
some	O
proteins	O
being	O
occasionally	O
difficult	O
to	O
classify	O
and	O
joining	O
different	O
groups	O
depending	O
on	O
various	O
assumptions	O
.	O

This	O
lead	O
some	O
to	O
question	O
the	O
concept	O
of	O
the	O
fold	O
[	O
9	O
]	O
,	O
but	O
practical	O
application	O
of	O
protein	O
structure	O
comparison	O
leaves	O
little	O
doubt	O
that	O
protein	O
structure	O
space	O
has	O
some	O
natural	O
granularity	O
that	O
overlaps	O
well	O
with	O
the	O
traditional	O
fold	O
classification	O
.	O

Comparison	O
and	O
classification	O
of	O
protein	O
structures	O
is	O
significantly	O
simplified	O
by	O
the	O
fact	O
that	O
proteins	O
have	O
naturally	O
modular	O
structures	O
,	O
being	O
mostly	O
composed	O
of	O
locally	O
regular	O
structures	O
:	O
alpha	O
helices	O
and	O
beta	O
strands	O
.	O

These	O
two	O
types	O
of	O
secondary	O
structures	O
constitute	O
a	O
little	O
over	O
50	O
%	O
of	O
an	O
average	O
protein	O
's	O
length	O
.	O

With	O
the	O
average	O
length	O
of	O
a	O
secondary	O
structure	O
being	O
around	O
10	O
amino	O
acids	O
,	O
this	O
makes	O
it	O
possible	O
to	O
describe	O
protein	O
structure	O
as	O
an	O
arrangement	O
of	O
a	O
much	O
smaller	O
number	O
of	O
elements	O
.	O

Protein	O
structures	O
are	O
often	O
visualized	O
in	O
a	O
simplified	O
form	O
,	O
with	O
the	O
so	O
-	O
called	O
ribbon	O
diagram	O
with	O
secondary	O
structures	O
shown	O
as	O
helices	O
and	O
arrows	O
being	O
the	O
most	O
popular	O
(	O
see	O
Figure	O
1	O
)	O
.	O

This	O
picture	O
can	O
be	O
simplified	O
further	O
by	O
showing	O
individual	O
secondary	O
structure	O
elements	O
as	O
simple	O
symbols	O
(	O
circles	O
or	O
boxes	O
/	O
triangles	O
)	O
.	O

These	O
depictions	O
,	O
called	O
fold	O
diagrams	O
,	O
originally	O
proposed	O
in	O
the	O
70s	O
[	O
10	O
-	O
12	O
]	O
are	O
best	O
captured	O
by	O
a	O
TOPS	O
(	O
Topology	O
of	O
Protein	O
Structures	O
)	O
algorithm	O
,	O
which	O
attempts	O
to	O
automate	O
the	O
process	O
of	O
creation	O
of	O
the	O
topology	O
cartoon	O
[	O
13	O
]	O
.	O

While	O
useful	O
in	O
protein	O
classification	O
,	O
such	O
simplified	O
descriptions	O
are	O
not	O
used	O
in	O
the	O
most	O
popular	O
automated	O
protein	O
structure	O
comparison	O
algorithms	O
such	O
as	O
DALI	O
[	O
3	O
]	O
or	O
CE	O
[	O
4	O
]	O
.	O

Kleywegt	O
and	O
Jones	O
developed	O
a	O
method	O
for	O
finding	O
similar	O
motifs	O
based	O
on	O
comparing	O
distance	O
matrices	O
that	O
are	O
constructed	O
by	O
representing	O
protein	O
as	O
a	O
set	O
of	O
SSEs	O
with	O
their	O
directional	O
vectors	O
and	O
angle	O
between	O
those	O
vectors	O
[	O
14	O
]	O
.	O

Programs	O
that	O
used	O
SSEs	O
either	O
for	O
structure	O
comparison	O
based	O
on	O
hierarchical	O
superposition	O
of	O
both	O
SSEs	O
and	O
atomic	O
representation	O
[	O
15	O
]	O
or	O
for	O
finding	O
common	O
substructures	O
in	O
the	O
comparison	O
process	O
based	O
on	O
subgraph	O
isomorphism	O
,	O
such	O
as	O
[	O
16,17	O
]	O
and	O
recent	O
applications	O
of	O
the	O
TOPS	O
diagram	O
[	O
18,19	O
]	O
,	O
usually	O
struggle	O
with	O
translating	O
the	O
comparison	O
results	O
from	O
the	O
secondary	O
structure	O
to	O
the	O
individual	O
residue	O
level	O
.	O

Although	O
the	O
SSM	O
method	O
uses	O
graph	O
-	O
matching	O
procedures	O
at	O
the	O
SSE	O
level	O
followed	O
by	O
an	O
interactive	O
3D	O
alignment	O
of	O
the	O
protein	O
C	O
-	O
alpha	O
atom	O
[	O
20	O
]	O
,	O
it	O
lacks	O
the	O
topological	O
relationships	O
between	O
the	O
SSEs	O
,	O
which	O
are	O
essential	O
features	O
in	O
identifying	O
common	O
scaffolds	O
in	O
distantly	O
related	O
proteins	O
.	O

A	O
TOPS	O
pattern	O
was	O
used	O
to	O
guide	O
the	O
sequence	O
alignment	O
,	O
for	O
instance	O
,	O
to	O
build	O
multiple	O
structural	O
alignments	O
of	O
the	O
distantly	O
related	O
family	O
of	O
beta	O
-	O
rich	O
protein	O
domains	O
[	O
21	O
]	O
.	O

The	O
Multiple	O
Sequence	O
Alignment	O
Tool	O
(	O
MSAT	O
)	O
automates	O
this	O
approach	O
,	O
merging	O
it	O
with	O
a	O
popular	O
ClustalW	O
program	O
[	O
22	O
]	O
.	O

DALI	O
[	O
3	O
]	O
,	O
CE	O
[	O
4	O
]	O
or	O
FATCAT	O
[	O
5	O
]	O
introduce	O
their	O
own	O
methods	O
of	O
decomposing	O
the	O
protein	O
structure	O
into	O
smaller	O
units	O
,	O
such	O
as	O
7	O
×	O
7	O
dense	O
distance	O
map	O
fragments	O
(	O
DALIs	O
)	O
or	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
(	O
CE	O
and	O
FATCAT	O
)	O
.	O

The	O
large	O
number	O
of	O
such	O
fragments	O
and	O
the	O
combinations	O
of	O
the	O
fragments	O
that	O
need	O
to	O
be	O
evaluated	O
by	O
structure	O
comparison	O
programs	O
is	O
the	O
main	O
reason	O
for	O
the	O
significant	O
computational	O
requirements	O
of	O
such	O
algorithms	O
.	O

However	O
,	O
more	O
importantly	O
,	O
TOPS+	O
method	O
is	O
used	O
here	O
to	O
enable	O
a	O
structural	O
comparison	O
that	O
takes	O
into	O
account	O
flexibility	O
in	O
protein	O
structures	O
and	O
not	O
only	O
classifies	O
the	O
differences	O
,	O
but	O
also	O
can	O
recognize	O
such	O
rearrangements	O
–	O
which	O
is	O
a	O
first	O
such	O
application	O
using	O
the	O
SSEs	O
language	O
.	O

In	O
this	O
contribution	O
,	O
we	O
explore	O
the	O
question	O
of	O
whether	O
it	O
would	O
be	O
possible	O
to	O
combine	O
insights	O
provided	O
by	O
topology	O
diagrams	O
into	O
automated	O
protein	O
structure	O
alignment	O
algorithms	O
,	O
focusing	O
on	O
the	O
FATCAT	O
program	O
developed	O
previously	O
in	O
our	O
group	O
.	O

Methods	O
Flexible	O
structure	O
alignment	O
method	O
FATCAT	O
FATCAT	O
[	O
5	O
]	O
is	O
a	O
unique	O
structure	O
alignment	O
method	O
that	O
allows	O
for	O
flexibility	O
in	O
the	O
structures	O
being	O
compared	O
.	O

It	O
builds	O
the	O
alignment	O
by	O
chaining	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
[	O
23	O
]	O
together	O
using	O
a	O
unified	O
scoring	O
function	O
where	O
AFP	O
extensions	O
,	O
gaps	O
,	O
and	O
twists	O
each	O
have	O
their	O
specific	O
scores	O
(	O
Figure	O
2	O
)	O
.	O

Introducing	O
a	O
twist	O
into	O
the	O
alignment	O
is	O
penalized	O
,	O
but	O
this	O
penalty	O
may	O
be	O
compensated	O
for	O
by	O
the	O
gain	O
in	O
the	O
score	O
of	O
the	O
resulting	O
alignment	O
(	O
i.e.	O
,	O
longer	O
alignment	O
and/or	O
better	O
RMSD	O
)	O
.	O

Rigid	O
alignment	O
can	O
be	O
treated	O
as	O
a	O
special	O
case	O
,	O
in	O
which	O
no	O
twist	O
is	O
allowed	O
in	O
chaining	O
AFPs	O
.	O

FATCAT	O
program	O
provides	O
alignment	O
in	O
both	O
,	O
""""	O
rigid	O
""""	O
mode	O
and	O
""""	O
flexible	O
""""	O
(	O
default	O
)	O
mode	O
.	O

FATCAT	O
,	O
as	O
well	O
as	O
most	O
other	O
protein	O
structure	O
comparison	O
programs	O
,	O
is	O
very	O
slow	O
when	O
compared	O
to	O
sequence	O
alignments	O
.	O

The	O
computing	O
time	O
of	O
FATCAT	O
is	O
determined	O
by	O
the	O
size	O
of	O
the	O
collection	O
of	O
AFPs	O
detected	O
between	O
the	O
two	O
structures	O
being	O
compared	O
.	O

FATCAT	O
is	O
available	O
from	O
a	O
server	O
with	O
an	O
option	O
to	O
search	O
in	O
SCOP	O
or	O
PDB	O
databases	O
for	O
similar	O
structures	O
.	O

This	O
search	O
typically	O
takes	O
between	O
8	O
to	O
16	O
hours	O
of	O
CPU	O
time	O
,	O
and	O
this	O
is	O
the	O
main	O
obstacle	O
to	O
broader	O
use	O
of	O
this	O
option	O
.	O

FATCAT	O
has	O
been	O
used	O
to	O
construct	O
a	O
Flexible	O
Structure	O
Neighborhood	O
(	O
FSN	O
)	O
database	O
that	O
contains	O
pre	O
-	O
computed	O
results	O
of	O
structure	O
similarity	O
searches	O
and	O
it	O
takes	O
several	O
weeks	O
of	O
CPU	O
time	O
to	O
update	O
the	O
FSN	O
database	O
.	O

Other	O
protein	O
structure	O
comparison	O
resources	O
,	O
such	O
as	O
DALI	O
or	O
CE	O
have	O
very	O
similar	O
problems	O
.	O

TOPS	O
cartoons	O
and	O
TOPS	O
graph	O
models	O
As	O
discussed	O
in	O
the	O
Background	O
,	O
TOPS	O
cartoons	O
capture	O
the	O
simplified	O
,	O
fold	O
-	O
level	O
description	O
of	O
protein	O
structure	O
and	O
at	O
the	O
same	O
time	O
can	O
be	O
automated	O
[	O
24	O
]	O
.	O

The	O
TOPS	O
algorithm	O
uses	O
structural	O
features	O
such	O
as	O
hydrogen	O
bonds	O
and	O
chirality	O
of	O
the	O
beta	O
strands	O
to	O
provide	O
a	O
scoring	O
function	O
to	O
optimize	O
the	O
cartoon	O
(	O
see	O
Figure	O
1	O
(	O
b	O
)	O
)	O
.	O

In	O
TOPS	O
,	O
the	O
secondary	O
structural	O
elements	O
(	O
SSEs	O
)	O
are	O
derived	O
from	O
the	O
DSSP	O
program	O
[	O
25	O
]	O
.	O

Based	O
on	O
TOPS	O
cartoons	O
,	O
a	O
formal	O
graph	O
model	O
and	O
graph	O
-	O
based	O
definitions	O
of	O
protein	O
topology	O
and	O
pattern	O
discovery	O
and	O
comparison	O
methods	O
were	O
developed	O
[	O
26,27	O
]	O
.	O

The	O
TOPS	O
database	O
and	O
comparison	O
,	O
pattern	O
discovery	O
and	O
matching	O
programs	O
are	O
accessible	O
from	O
.	O

Novel	O
TOPS+	O
and	O
TOPS+	O
strings	O
models	O
The	O
TOPS	O
model	O
was	O
further	O
enhanced	O
to	O
incorporate	O
features	O
such	O
as	O
protein	O
-	O
ligand	O
interaction	O
information	O
and	O
more	O
detailed	O
secondary	O
structural	O
segment	O
information	O
.	O

This	O
enhanced	O
model	O
is	O
called	O
TOPS+	O
model	O
(	O
see	O
Figure	O
3a	O
)	O
.	O

This	O
TOPS+	O
model	O
can	O
be	O
described	O
formally	O
in	O
a	O
TOPS+	O
strings	O
language	O
(	O
Figure	O
3b	O
)	O
at	O
a	O
reduced	O
linear	O
level	O
.	O

The	O
enhanced	O
TOPS+	O
strings	O
models	O
can	O
be	O
used	O
in	O
fast	O
string	O
-	O
based	O
structure	O
matching	O
and	O
comparison	O
,	O
at	O
the	O
same	O
time	O
avoiding	O
issues	O
of	O
NP	O
-	O
completeness	O
associated	O
with	O
graph	O
alignments	O
.	O

In	O
detail	O
,	O
each	O
node	O
(	O
SSE	O
segment	O
)	O
of	O
the	O
TOPS+	O
strings	O
is	O
described	O
by	O
its	O
type	O
,	O
orientation	O
,	O
PDB	O
start	O
number	O
,	O
segment	O
length	O
,	O
total	O
number	O
of	O
incoming	O
(	O
InArc	O
)	O
and	O
outgoing	O
(	O
OutArc	O
)	O
arcs	O
(	O
edges	O
)	O
,	O
total	O
number	O
of	O
ArcTypes	O
,	O
and	O
total	O
number	O
of	O
ligand	O
arcs	O
(	O
LigArc	O
)	O
.	O

The	O
type	O
of	O
the	O
segment	O
(	O
SSEType	O
)	O
could	O
be	O
one	O
of	O
[	O
E	O
,	O
e	O
,	O
H	O
,	O
h	O
,	O
U	O
,	O
u	O
]	O
,	O
where	O
,	O
""""	O
E	O
""""	O
and	O
""""	O
e	O
""""	O
represent	O
the	O
""""	O
"up""-"	O
and	O
""""	O
down	O
"""-"	O
oriented	O
beta	O
strands	O
;	O
""""	O
H	O
""""	O
and	O
""""	O
h	O
""""	O
indicate	O
the	O
""""	O
"up""-"	O
and	O
""""	O
down	O
"""-"	O
oriented	O
alpha	O
helices	O
;	O
and	O
""""	O
U	O
""""	O
and	O
""""	O
u	O
""""	O
represent	O
ligand	O
-	O
bound	O
and	O
ligand	O
-	O
free	O
loops	O
.	O

The	O
InArcType	O
can	O
be	O
classified	O
as	O
an	O
/	O
a	O
[	O
R	O
,	O
L	O
,	O
P	O
,	O
A	O
]	O
,	O
where	O
""""	O
R	O
""""	O
and	O
""""	O
L	O
""""	O
represent	O
right	O
and	O
left	O
chiralities	O
;	O
and	O
""""	O
P	O
""""	O
and	O
""""	O
A	O
""""	O
represent	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
bonds	O
,	O
respectively	O
.	O

The	O
OutArcType	O
is	O
represented	O
in	O
a	O
similar	O
manner	O
by	O
[	O
R	O
'	O
,	O
L	O
'	O
,	O
P	O
'	O
,	O
A	O
'	O
]	O
.	O

Ligand	O
arcs	O
are	O
indicated	O
by	O
LT	O
=	O
AA	O
,	O
where	O
LT	O
is	O
the	O
ligand	O
type	O
and	O
AA	O
is	O
the	O
PDB	O
number	O
.	O

For	O
example	O
,	O
Figure	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
b	O
)	O
contain	O
visual	O
representations	O
of	O
TOPS+	O
and	O
TOPS+	O
strings	O
models	O
,	O
respectively	O
,	O
for	O
the	O
protein	O
domain	O
d1fnb_1	O
.	O

Here	O
the	O
triangles	O
represent	O
the	O
beta	O
strands	O
;	O
the	O
red	O
curve	O
represents	O
the	O
alpha	O
helix	O
;	O
gray	O
ellipsoids	O
indicate	O
loops	O
;	O
and	O
green	O
arcs	O
indicate	O
hydrogen	O
bonds	O
between	O
two	O
beta	O
strands	O
,	O
called	O
anti	O
-	O
parallel	O
beta	O
sheets	O
.	O

The	O
length	O
of	O
a	O
TOPS+	O
strings	O
model	O
is	O
defined	O
by	O
number	O
of	O
SSEs	O
;	O
thus	O
,	O
the	O
length	O
of	O
d1fnb_1	O
is	O
19	O
.	O

For	O
further	O
details	O
,	O
see	O
[	O
28	O
]	O
.	O

TOPS+	O
strings	O
comparison	O
method	O
TOPS+	O
is	O
a	O
comparison	O
method	O
that	O
computes	O
a	O
distance	O
between	O
TOPS+	O
strings	O
models	O
of	O
two	O
proteins	O
based	O
on	O
a	O
dynamic	O
programming	O
approach	O
and	O
identifies	O
the	O
longest	O
common	O
subsequence	O
(	O
LCS	O
)	O
,	O
consisting	O
of	O
the	O
list	O
of	O
the	O
topologically	O
equivalent	O
SSEs	O
between	O
two	O
proteins	O
.	O

For	O
example	O
,	O
Figure	O
3	O
(	O
c	O
)	O
shows	O
the	O
TOPS+	O
strings	O
alignment	O
between	O
Dihydropteridine	O
reductase	O
proteins	O
from	O
rat	O
(	O
1dhr	O
)	O
and	O
human	B
(	O
1hdr	O
)	O
.	O

The	O
TOPS+	O
strings	O
models	O
for	O
1dhr	O
and	O
1hdr	O
are	O
represented	O
by	O
a	O
linear	O
string	O
-	O
model	O
,	O
where	O
a	O
yellow	O
triangle	O
and	O
red	O
curves	O
indicate	O
the	O
beta	O
strands	O
and	O
alpha	O
helices	O
in	O
their	O
""""	O
up	O
""""	O
or	O
""""	O
down	O
""""	O
orientations	O
,	O
respectively	O
.	O

The	O
grey	O
line	O
and	O
purple	O
stubs	O
represent	O
the	O
loop	O
regions	O
and	O
the	O
NAD	O
ligand	O
interactions	O
,	O
respectively	O
.	O

Note	O
that	O
the	O
ligand	O
-	O
interaction	O
information	O
is	O
optional	O
and	O
in	O
this	O
work	O
we	O
have	O
not	O
used	O
it	O
.	O

The	O
incoming	O
and	O
outgoing	O
arcs	O
are	O
depicted	O
in	O
the	O
SSEs	O
(	O
top	O
and	O
bottom	O
of	O
the	O
beta	O
strands	O
)	O
,	O
where	O
red	O
and	O
green	O
arcs	O
represent	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
-	O
bond	O
interactions	O
that	O
show	O
beta	O
-	O
sheet	O
information	O
,	O
while	O
yellow	O
and	O
blue	O
arcs	O
indicate	O
the	O
right	O
and	O
left	O
chirality	O
relationships	O
between	O
the	O
SSEs	O
.	O

A	O
pink	O
arrow	O
between	O
the	O
TOPS+	O
strings	O
elements	O
indicates	O
the	O
conserved	O
SSE	O
.	O

The	O
dotted	O
arrows	O
indicate	O
the	O
conserved	O
alpha	O
helices	O
and	O
beta	O
strands	O
,	O
while	O
the	O
plain	O
arrows	O
indicate	O
the	O
conserved	O
loop	O
regions	O
.	O

TOPS++FATCAT	O
method	O
In	O
this	O
work	O
,	O
we	O
want	O
to	O
test	O
the	O
general	O
idea	O
of	O
pruning	O
the	O
search	O
space	O
of	O
the	O
FATCAT	O
comparison	O
process	O
using	O
topological	O
constraints	O
derived	O
from	O
the	O
TOPS+	O
strings	O
alignment	O
.	O

Many	O
of	O
the	O
AFPs	O
considered	O
in	O
the	O
FATCAT	O
alignment	O
could	O
be	O
easily	O
eliminated	O
from	O
the	O
comparison	O
by	O
constraining	O
the	O
alignment	O
region	O
.	O

Here	O
we	O
explore	O
constraints	O
obtained	O
from	O
the	O
TOPS+	O
strings	O
alignment	O
,	O
which	O
identifies	O
topologically	O
equivalent	O
secondary	O
structure	O
elements	O
(	O
alpha	O
helices	O
,	O
beta	O
strands	O
,	O
and	O
loops	O
)	O
for	O
this	O
purpose	O
.	O

Such	O
equivalences	O
define	O
blocks	O
that	O
restrict	O
the	O
alignment	O
region	O
;	O
AFPs	O
that	O
fall	O
outside	O
these	O
regions	O
are	O
simply	O
not	O
considered	O
(	O
see	O
Figure	O
4	O
(	O
b	O
)	O
)	O
.	O

We	O
introduce	O
a	O
parameter	O
r	O
to	O
control	O
the	O
strictness	O
of	O
constraints	O
by	O
TOPS+	O
strings	O
alignments	O
;	O
r	O
equals	O
0	O
if	O
the	O
alignment	O
region	O
is	O
strictly	O
restrained	O
by	O
TOPS+	O
strings	O
alignment	O
,	O
and	O
r	O
is	O
set	O
to	O
1	O
by	O
default	O
in	O
our	O
program	O
to	O
allow	O
certain	O
flexibility	O
to	O
the	O
constrained	O
alignment	O
region	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

We	O
then	O
can	O
speed	O
up	O
the	O
FATCAT	O
alignment	O
by	O
considering	O
only	O
the	O
AFPs	O
within	O
the	O
constrained	O
alignment	O
area	O
(	O
Figure	O
4	O
(	O
d	O
)	O
)	O
.	O

The	O
rigid	O
structural	O
alignment	O
can	O
be	O
treated	O
as	O
a	O
special	O
case	O
of	O
TOPS++FATCAT	O
,	O
in	O
which	O
no	O
twist	O
is	O
allowed	O
in	O
chaining	O
AFPs	O
.	O

However	O
,	O
the	O
TOPS++FATCAT	O
program	O
provides	O
alignment	O
in	O
both	O
,	O
""""	O
rigid	O
""""	O
mode	O
and	O
""""	O
flexible	O
""""	O
mode	O
(	O
default	O
)	O
.	O

Benchmarking	O
For	O
benchmarking	O
and	O
comparison	O
,	O
we	O
have	O
used	O
the	O
PDB40	O
dataset	O
of	O
1,901	O
protein	O
domain	O
pairs	O
(	O
DP	O
)	O
corresponding	O
to	O
SCOP	O
version	O
1.61	O
from	O
the	O
ASTRAL	O
database	O
[	O
29	O
]	O
.	O

Table	O
1	O
provides	O
the	O
SCOP	O
superfamily	O
level	O
homolog	O
versus	O
non	O
-	O
homolog	O
statistics	O
for	O
the	O
four	O
main	O
SCOP	O
classes	O
i.e.	O
,	O
all	O
-	O
alpha	O
,	O
all	O
-	O
beta	O
,	O
alpha	O
/	O
beta	O
,	O
alpha+beta	O
,	O
and	O
all	O
proteins	O
regardless	O
of	O
their	O
structural	O
classes	O
.	O

Evaluation	O
Analyses	O
We	O
performed	O
the	O
Receiver	O
Operating	O
Characteristics	O
(	O
ROC	O
)	O
curve	O
and	O
the	O
AUC	O
(	O
Area	O
Under	O
the	O
ROC	O
Curve	O
)	O
analyses	O
to	O
compare	O
the	O
performance	O
of	O
the	O
TOPS++FATCAT	O
method	O
with	O
the	O
original	O
FATCAT	O
method	O
,	O
using	O
SCOP	O
classification	O
at	O
the	O
superfamily	O
level	O
as	O
a	O
standard	O
of	O
comparison	O
[	O
30	O
]	O
.	O

Results	O
ROC	O
and	O
AUC	O
Analyses	O
We	O
have	O
compared	O
the	O
performance	O
of	O
the	O
TOPS++FATCAT	O
method	O
against	O
the	O
original	O
FATCAT	O
method	O
using	O
the	O
SCOP	O
classification	O
information	O
at	O
the	O
superfamily	O
level	O
.	O

We	O
have	O
plotted	O
the	O
ROC	O
curves	O
based	O
on	O
P	O
-	O
values	O
obtained	O
from	O
the	O
FATCAT	O
and	O
the	O
TOPS++FATCAT	O
methods	O
.	O

We	O
have	O
plotted	O
the	O
ROC	O
curves	O
separately	O
for	O
the	O
main	O
SCOP	O
classes	O
,	O
i.e.	O
,	O
all	O
-	O
alpha	O
,	O
all	O
-	O
beta	O
,	O
alpha	O
/	O
beta	O
,	O
alpha+beta	O
,	O
and	O
all	O
proteins	O
regardless	O
of	O
the	O
class	O
they	O
belong	O
to	O
(	O
see	O
Figure	O
5	O
(	O
a	O
)	O
to	O
5	O
(	O
e	O
)	O
)	O
.	O

In	O
the	O
graph	O
,	O
the	O
x-	O
and	O
y	O
-	O
axes	O
represent	O
the	O
false	O
positive	O
and	O
true	O
positive	O
rates	O
of	O
the	O
performance	O
of	O
the	O
comparison	O
methods	O
respectively	O
.	O

In	O
the	O
legend	O
,	O
rF	O
-	O
pvalue	O
and	O
fF	O
-	O
pvalue	O
indicate	O
results	O
from	O
the	O
rigid	O
and	O
flexible	O
FATCAT	O
methods	O
,	O
respectively	O
;	O
similarly	O
,	O
rT2F	O
-	O
pvalue	O
and	O
fT2F	O
-	O
pvalue	O
represent	O
the	O
rigid	O
and	O
flexible	O
TOPS++FATCAT	O
methods	O
,	O
respectively	O
.	O

We	O
have	O
calculated	O
the	O
AUC	O
values	O
for	O
all	O
the	O
SCOP	O
classes	O
based	O
on	O
ROC	O
curves	O
obtained	O
from	O
the	O
FATCAT	O
and	O
TOPS++FATCAT	O
methods	O
with	O
the	O
flexible	O
/	O
rigid	O
options	O
(	O
see	O
Table	O
2	O
)	O
.	O

For	O
all	O
protein	O
classes	O
,	O
the	O
rigid	O
FATCAT	O
performs	O
best	O
,	O
usually	O
followed	O
by	O
the	O
flexible	O
FATCAT	O
,	O
the	O
rigid	O
TOPS++FATCAT	O
,	O
and	O
the	O
flexible	O
TOPS++FATCAT	O
.	O

The	O
performance	O
of	O
all	O
four	O
methods	O
is	O
best	O
for	O
all	O
alpha	O
and	O
all	O
beta	O
proteins	O
,	O
and	O
all	O
four	O
perform	O
markedly	O
worse	O
(	O
but	O
similar	O
to	O
each	O
other	O
)	O
for	O
alpha	O
/	O
beta	O
proteins	O
.	O

Only	O
alpha+beta	O
proteins	O
show	O
a	O
clear	O
difference	O
between	O
the	O
FATCAT	O
and	O
TOPS++FATCAT	O
methods	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
TOPS+	O
strings	O
models	O
consider	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
properties	O
of	O
the	O
beta	O
-	O
sheet	O
information	O
in	O
the	O
form	O
of	O
total	O
number	O
of	O
incoming	O
and	O
outgoing	O
arcs	O
with	O
their	O
ArcTypes	O
.	O

Thus	O
,	O
the	O
TOPS++FATCAT	O
method	O
discriminates	O
the	O
protein	O
domain	O
pairs	O
more	O
efficiently	O
compared	O
to	O
the	O
original	O
FATCAT	O
method	O
.	O

For	O
example	O
,	O
in	O
the	O
all	O
-	O
beta	O
protein	O
domain	O
pairs	O
,	O
both	O
the	O
flexible	O
and	O
the	O
rigid	O
TOPS++FATCAT	O
methods	O
perform	O
well	O
.	O

The	O
flexible	O
TOPS++FATCAT	O
method	O
covers	O
nearly	O
84	O
%	O
of	O
protein	O
domains	O
with	O
0	O
%	O
false	O
positives	O
,	O
but	O
the	O
flexible	O
and	O
rigid	O
FATCAT	O
methods	O
cover	O
only	O
76	O
%	O
and	O
49	O
%	O
of	O
the	O
true	O
positives	O
,	O
respectively	O
,	O
with	O
0	O
%	O
false	O
positives	O
.	O

The	O
zoomed	O
-	O
in	O
version	O
of	O
the	O
ROC	O
curves	O
with	O
up	O
to	O
10	O
%	O
false	O
positives	O
for	O
all	O
-	O
beta	O
rich	O
protein	O
families	O
is	O
shown	O
in	O
Figure	O
5	O
(	O
f	O
)	O
;	O
where	O
both	O
the	O
rigid	O
TOPS++FATCAT	O
(	O
green	O
)	O
and	O
flexible	O
(	O
red	O
)	O
TOPS++FATCAT	O
methods	O
have	O
coverage	O
rates	O
of	O
82	O
%	O
and	O
84	O
%	O
true	O
positives	O
respectively	O
with	O
0	O
%	O
false	O
positives	O
.	O

The	O
overall	O
results	O
for	O
all	O
protein	O
classes	O
show	O
that	O
TOPS++FATCAT	O
performance	O
is	O
only	O
slightly	O
lower	O
(	O
3%–7	O
%	O
AUC	O
value	O
difference	O
(	O
see	O
Table	O
2	O
)	O
)	O
as	O
compared	O
to	O
FATCAT	O
while	O
providing	O
a	O
significant	O
,	O
more	O
than	O
10-fold	O
speedup	O
(	O
see	O
next	O
section	O
)	O
.	O

AFP	O
and	O
Runtime	O
Analyses	O
We	O
tested	O
both	O
the	O
FATCAT	O
and	O
TOPS++FATCAT	O
methods	O
using	O
the	O
Mac	O
OS	O
X	O
version	O
10.4.10	O
computer	O
system	O
with	O
a	O
2	O
×	O
2.66-GHz	O
Dual	O
-	O
Core	O
Intel	O
Xeon	O
processor	O
and	O
1-GB	O
667	O
MHz	O
memory	O
.	O

We	O
have	O
performed	O
runtime	O
analysis	O
on	O
1,901	O
protein	O
domain	O
pairs	O
and	O
counted	O
the	O
total	O
number	O
of	O
AFPs	O
and	O
the	O
corresponding	O
runtime	O
from	O
both	O
the	O
FATCAT	O
and	O
the	O
TOPS++FATCAT	O
methods	O
.	O

The	O
results	O
show	O
an	O
exponential	O
increase	O
in	O
AFPs	O
(	O
Figure	O
6	O
(	O
b	O
)	O
)	O
and	O
corresponding	O
runtime	O
(	O
Figure	O
6	O
(	O
a	O
)	O
)	O
for	O
the	O
FATCAT	O
method	O
as	O
compared	O
to	O
the	O
TOPS++FATCAT	O
method	O
(	O
see	O
Table	O
3	O
)	O
For	O
example	O
,	O
the	O
average	O
number	O
of	O
AFPs	O
for	O
the	O
TOPS++FATCAT	O
method	O
is	O
530	O
,	O
but	O
the	O
average	O
number	O
of	O
AFPs	O
for	O
the	O
FATCAT	O
method	O
is	O
15,019	O
.	O

This	O
represents	O
the	O
number	O
of	O
average	O
AFPs	O
used	O
by	O
the	O
FATCAT	O
method	O
is	O
increased	O
by	O
a	O
factor	O
of	O
28	O
(	O
see	O
Table	O
3	O
)	O
.	O

This	O
result	O
leads	O
to	O
the	O
conclusion	O
that	O
TOPS++FATCAT	O
is	O
22	O
times	O
faster	O
compared	O
to	O
the	O
FATCAT	O
because	O
this	O
method	O
must	O
take	O
into	O
account	O
more	O
number	O
of	O
AFPs	O
in	O
the	O
comparison	O
process	O
(	O
see	O
Table	O
3	O
)	O
.	O

Case	O
Studies	O
While	O
the	O
overall	O
accuracy	O
of	O
both	O
rigid	O
and	O
flexible	O
FATCAT	O
methods	O
is	O
better	O
than	O
their	O
TOPS++FATCAT	O
equivalents	O
,	O
an	O
interesting	O
example	O
where	O
the	O
opposite	O
is	O
true	O
lies	O
in	O
the	O
comparison	O
of	O
two	O
proteins	O
,	O
d2trxa	O
_	O
(	O
108	O
aa	O
)	O
from	O
Escherichia	B
coli	I
and	O
d1kte	O
_	O
_	O
(	O
105	O
aa	O
)	O
from	O
Sus	B
scrofa	I
(	O
pig	B
)	O
from	O
the	O
thioredoxin	O
-	O
like	O
superfamily	O
.	O

For	O
this	O
pair	O
,	O
the	O
flexible_TOPS++FATCAT	O
method	O
provides	O
an	O
alignment	O
with	O
88	O
equivalent	O
positions	O
with	O
1.67	O
Å	O
chain	O
RMSD	O
and	O
3.06	O
Å	O
of	O
optimal	O
RMSD	O
without	O
any	O
twist	O
,	O
giving	O
the	O
alignment	O
with	O
10	O
%	O
sequence	O
identity	O
(	O
see	O
Table	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
flexible_FATCAT	O
method	O
provides	O
an	O
alignment	O
with	O
86	O
aligned	O
positions	O
using	O
a	O
twist	O
in	O
the	O
C	O
-	O
terminal	O
region	O
;	O
it	O
has	O
a	O
higher	O
chain	O
RMSD	O
of	O
5.14	O
Å	O
,	O
and	O
its	O
optimal	O
RMSD	O
is	O
3.48	O
Å.	O
For	O
more	O
information	O
regarding	O
the	O
chain	O
and	O
optimal	O
RMSDs	O
refer	O
[	O
5	O
]	O
.	O

The	O
flexible_FATCAT	O
method	O
uses	O
the	O
twist	O
to	O
align	O
a	O
helix	O
in	O
the	O
C	O
-	O
terminal	O
region	O
,	O
which	O
is	O
positioned	O
incorrectly	O
with	O
a	O
beta	O
-	O
sheet	O
core	O
(	O
see	O
Table	O
4	O
)	O
.	O

Figure	O
7	O
(	O
a	O
)	O
shows	O
the	O
superposition	O
of	O
d2trxa	O
_	O
(	O
gray	O
)	O
and	O
d1kte	O
_	O
_	O
(	O
orange	O
)	O
domains	O
from	O
the	O
flexible_FATCAT	O
method	O
,	O
where	O
the	O
blue	O
color	O
indicates	O
the	O
d1kte	O
_	O
_	O
protein	O
domain	O
from	O
the	O
flexible_TOPS++FATCAT	O
method	O
.	O

The	O
incorrect	O
alignment	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
alpha	O
helix	O
of	O
the	O
d1kte	O
_	O
_	O
domain	O
(	O
orange	O
)	O
is	O
visible	O
in	O
the	O
core	O
of	O
the	O
beta	O
-	O
sheet	O
region	O
.	O

Figure	O
7	O
(	O
b	O
)	O
and	O
7	O
(	O
c	O
)	O
shows	O
the	O
AFPs	O
from	O
the	O
flexible_FATCAT	O
and	O
flexible_TOPS++FATCAT	O
methods	O
,	O
respectively	O
.	O

The	O
hinge	O
region	O
provides	O
a	O
twist	O
in	O
the	O
flexible_FATCAT	O
method	O
indicated	O
by	O
an	O
arrow	O
and	O
the	O
AFPs	O
represented	O
by	O
a	O
different	O
color	O
(	O
see	O
Figure	O
7	O
(	O
b	O
)	O
)	O
.	O

In	O
this	O
case	O
,	O
the	O
alignment	O
constraints	O
from	O
the	O
TOPS+	O
strings	O
alignment	O
allow	O
the	O
TOPS++FATCAT	O
method	O
to	O
avoid	O
a	O
spurious	O
alignment	O
.	O

The	O
Erythrocruorin	O
protein	O
domain	O
d1eca	O
_	O
_	O
(	O
136	O
aa	O
)	O
from	O
Chironomus	B
thummi	I
and	O
the	O
Phycocyanin	O
alpha	O
subunit	O
protein	O
domain	O
d1cpca	O
_	O
(	O
162	O
aa	O
)	O
from	O
Fremyella	B
diplosiphon	I
(	O
Cyanobacterium	O
)	O
belong	O
to	O
the	O
Globin	O
-	O
like	O
superfamily	O
.	O

For	O
these	O
protein	O
domain	O
pairs	O
,	O
the	O
FATCAT	O
method	O
provides	O
a	O
better	O
alignment	O
with	O
120	O
and	O
118	O
aligned	O
positions	O
with	O
the	O
chain	O
RMSD	O
of	O
4.02	O
Å	O
based	O
on	O
the	O
flexible	O
and	O
rigid	O
options	O
,	O
respectively	O
.	O

The	O
flexible_TOPS++FATCAT	O
method	O
gives	O
an	O
alignment	O
of	O
63	O
aligned	O
positions	O
with	O
the	O
3.23	O
Å	O
optimal	O
RMSD	O
and	O
the	O
6.28	O
Å	O
chain	O
RMSD	O
.	O

In	O
this	O
case	O
,	O
the	O
flexible_TOPS++FATCAT	O
method	O
misses	O
the	O
N	O
-	O
terminal	O
region	O
helix	O
and	O
misaligns	O
some	O
helices	O
.	O

For	O
example	O
,	O
Figure	O
8	O
(	O
a	O
)	O
shows	O
the	O
superposition	O
of	O
d1eca	O
_	O
_	O
(	O
gray	O
)	O
and	O
d1cpca	O
_	O
(	O
orange	O
)	O
domains	O
from	O
the	O
flexible_FATCAT	O
method	O
,	O
while	O
d1cpca	O
_	O
(	O
blue	O
)	O
domain	O
is	O
from	O
the	O
flexible_TOPS++FATCAT	O
method	O
.	O

The	O
AFP	O
chaining	O
alignment	O
and	O
the	O
actual	O
alignment	O
from	O
FATCAT	O
are	O
shown	O
in	O
Figure	O
8	O
(	O
b	O
)	O
and	O
8	O
(	O
e	O
)	O
,	O
respectively	O
.	O

Figure	O
8	O
(	O
c	O
)	O
shows	O
the	O
AFP	O
alignment	O
from	O
TOPS++FATCAT	O
,	O
in	O
which	O
this	O
method	O
misses	O
the	O
N	O
-	O
terminal	O
region	O
and	O
incorrectly	O
aligns	O
some	O
of	O
the	O
C	O
-	O
terminal	O
regions	O
(	O
see	O
Figure	O
8	O
(	O
d	O
)	O
)	O
.	O

However	O
,	O
the	O
rigid_TOPS++FATCAT	O
method	O
produces	O
an	O
alignment	O
of	O
108	O
aligned	O
positions	O
with	O
optimal	O
and	O
chain	O
RMSDs	O
of	O
3.22	O
Å	O
and	O
6.28	O
Å	O
respectively	O
.	O

In	O
general	O
,	O
TOPS	O
comparison	O
does	O
not	O
work	O
well	O
for	O
alpha	O
-	O
rich	O
proteins	O
due	O
to	O
the	O
lack	O
of	O
hydrogen	O
bonds	O
between	O
SSEs	O
[	O
26	O
]	O
.	O

The	O
same	O
is	O
true	O
for	O
TOPS+	O
strings	O
comparison	O
to	O
some	O
extent	O
;	O
however	O
,	O
this	O
method	O
takes	O
advantage	O
of	O
ligand	O
-	O
interaction	O
information	O
to	O
compare	O
protein	O
domains	O
more	O
efficiently	O
;	O
for	O
example	O
the	O
DNA	O
binding	O
motifs	O
such	O
as	O
helix	O
-	O
turn	O
-	O
helix	O
and	O
helix	O
-	O
loop	O
-	O
helix	O
can	O
be	O
easily	O
recognized	O
[	O
28	O
]	O
.	O

However	O
,	O
we	O
have	O
not	O
explored	O
that	O
ligand	O
pattern	O
discovery	O
option	O
within	O
the	O
TOPS+	O
strings	O
comparison	O
in	O
this	O
paper	O
.	O

In	O
addition	O
,	O
the	O
TOPS+	O
strings	O
alignment	O
provides	O
only	O
a	O
basic	O
alignment	O
;	O
the	O
scoring	O
function	O
to	O
find	O
the	O
best	O
alignment	O
has	O
not	O
been	O
optimized	O
.	O

These	O
problems	O
can	O
be	O
addressed	O
in	O
future	O
development	O
by	O
considering	O
the	O
advanced	O
TOPS+	O
and	O
TOPS+	O
strings	O
models	O
based	O
on	O
helix	O
-	O
helix	O
packing	O
relationships	O
and	O
SSE	O
-	O
ligand	O
interaction	O
properties	O
together	O
with	O
the	O
right	O
and	O
left	O
chiralities	O
.	O

Furthermore	O
,	O
the	O
TOPS+	O
strings	O
comparison	O
can	O
be	O
optimized	O
in	O
both	O
the	O
comparison	O
process	O
as	O
well	O
as	O
in	O
the	O
alignment	O
process	O
in	O
order	O
to	O
take	O
into	O
account	O
indels	O
(	O
insertion	O
/	O
deletion	O
)	O
of	O
SSEs	O
which	O
exist	O
in	O
nature	O
across	O
the	O
different	O
members	O
of	O
the	O
protein	O
superfamilies	O
[	O
31	O
]	O
.	O

Discussion	O
and	O
conclusion	O
The	O
overall	O
results	O
for	O
all	O
protein	O
classes	O
show	O
that	O
TOPS++FATCAT	O
performance	O
is	O
only	O
slightly	O
lower	O
(	O
3%–7	O
%	O
AUC	O
value	O
difference	O
)	O
as	O
compared	O
to	O
FATCAT	O
while	O
providing	O
a	O
significant	O
,	O
more	O
than	O
10-fold	O
speedup	O
.	O

The	O
main	O
reason	O
for	O
the	O
discrepancies	O
is	O
that	O
TOPS+	O
strings	O
alignments	O
occasionally	O
misalign	O
the	O
secondary	O
structure	O
elements	O
and	O
subsequent	O
FATCAT	O
alignment	O
,	O
constrained	O
by	O
the	O
TOPS+	O
strings	O
alignment	O
,	O
can	O
not	O
overcome	O
the	O
earlier	O
errors	O
.	O

There	O
is	O
a	O
clear	O
trade	O
-	O
off	O
between	O
the	O
runtime	O
and	O
the	O
accuracy	O
;	O
limiting	O
the	O
pool	O
of	O
fragments	O
being	O
compared	O
speeds	O
up	O
the	O
algorithm	O
but	O
results	O
in	O
(	O
slightly	O
)	O
lower	O
accuracy	O
.	O

At	O
the	O
same	O
time	O
,	O
these	O
results	O
offer	O
clear	O
suggestions	O
for	O
future	O
development	O
.	O

Using	O
a	O
more	O
advanced	O
version	O
of	O
the	O
TOPS+	O
strings	O
comparison	O
method	O
would	O
remove	O
some	O
of	O
the	O
false	O
positives	O
might	O
be	O
at	O
a	O
cost	O
of	O
significantly	O
slowing	O
the	O
total	O
performance	O
of	O
the	O
TOPS++FATCAT	O
method	O
.	O

Authors	O
'	O
contributions	O
MV	O
developed	O
the	O
TOPS++FATCAT	O
algorithm	O
,	O
performed	O
the	O
calculations	O
and	O
prepared	O
the	O
figures	O
,	O
YY	O
provided	O
advice	O
and	O
oversight	O
in	O
the	O
project	O
,	O
verified	O
the	O
code	O
and	O
provided	O
FATCAT	O
results	O
for	O
comparison	O
,	O
AG	O
contributed	O
to	O
the	O
original	O
idea	O
and	O
to	O
writing	O
of	O
the	O
manuscript	O
.	O

A	O
life	O
threatening	O
uterine	O
inversion	O
and	O
massive	O
post	O
partum	O
hemorrhage	O
caused	O
by	O
placenta	O
accrete	O
during	O
Caesarean	O
section	O
in	O
a	O
primigravida	O
:	O
a	O
case	O
report	O
Abstract	O
Background	O
A	O
32-year	O
-	O
old	O
Caucasian	O
primigravida	O
was	O
admitted	O
for	O
elective	O
Caesarean	O
Section	O
at	O
36	O
weeks	O
and	O
6	O
days	O
with	O
the	O
diagnosis	O
of	O
preeclampsia	O
.	O

Case	O
presentation	O
Traction	O
of	O
the	O
umbilical	O
cord	O
after	O
delivery	O
of	O
a	O
healthy	O
baby	O
resulted	O
in	O
uterine	O
inversion	O
.	O

The	O
placenta	O
was	O
found	O
to	O
be	O
densely	O
adherent	O
to	O
the	O
posterior	O
uterine	O
wall	O
.	O

Piecemeal	O
excision	O
of	O
the	O
placenta	O
as	O
close	O
as	O
possible	O
to	O
the	O
uterine	O
lining	O
was	O
then	O
performed	O
.	O

Conclusion	O
In	O
this	O
way	O
we	O
were	O
able	O
to	O
control	O
a	O
massive	O
post	O
partum	O
hemorrhage	O
and	O
preserve	O
the	O
fertility	O
of	O
the	O
patient	O
.	O

Background	O
Placenta	O
accreta	O
is	O
defined	O
as	O
abnormal	O
adherence	O
,	O
either	O
in	O
whole	O
or	O
in	O
part	O
of	O
the	O
afterbirth	O
to	O
the	O
underlying	O
uterine	O
wall	O
.	O

Placenta	O
accreta	O
and	O
other	O
pathological	O
placentations	O
(	O
such	O
as	O
increta	O
,	O
percreta	O
)	O
are	O
rare	O
complications	O
of	O
pregnancy	O
with	O
potential	O
life	O
threatening	O
and	O
fertility	O
threatening	O
consequences	O
.	O

The	O
incidence	O
of	O
placenta	O
accreta	O
has	O
increased	O
ten	O
times	O
over	O
the	O
last	O
fifteen	O
years	O
,	O
which	O
reflects	O
the	O
increase	O
in	O
the	O
rate	O
of	O
Caesarean	O
Sections	O
(	O
CS	O
)	O
[	O
1	O
]	O
.	O

Placenta	O
accreta	O
has	O
become	O
the	O
most	O
important	O
cause	O
of	O
peripartum	O
hysterectomy	O
.	O

A	O
life	O
threatening	O
acute	O
uterine	O
inversion	O
and	O
massive	O
PPH	O
can	O
be	O
caused	O
by	O
placenta	O
accreta	O
during	O
CS	O
but	O
seldom	O
in	O
a	O
primigravida	O
(	O
Figure	O
1	O
)	O
.	O

Case	O
presentation	O
A	O
32	O
year	O
old	O
,	O
primigravida	O
,	O
was	O
admitted	O
in	O
a	O
District	O
General	O
Hospital	O
for	O
elective	O
Caesarean	O
section	O
at	O
36	O
weeks	O
and	O
6	O
days	O
with	O
the	O
diagnosis	O
of	O
preeclampsia	O
.	O

She	O
had	O
two	O
antenatal	O
ultrasound	O
examinations	O
showing	O
a	O
healthy	O
fetus	O
and	O
posterior	O
fundal	O
placenta	O
.	O

The	O
patient	O
had	O
lower	O
segment	O
CS	O
of	O
a	O
healthy	O
male	O
infant	O
under	O
spinal	O
anesthesia	O
.	O

The	O
placenta	O
was	O
found	O
to	O
be	O
densely	O
adherent	O
to	O
the	O
posterior	O
uterine	O
wall	O
.	O

Traction	O
of	O
the	O
umbilical	O
cord	O
was	O
applied	O
and	O
subsequently	O
resulted	O
in	O
uterine	O
inversion	O
.	O

The	O
placenta	O
was	O
removed	O
by	O
'	O
piecemeal	O
'	O
excising	O
as	O
close	O
as	O
possible	O
to	O
the	O
uterine	O
lining	O
.	O

About	O
80	O
%	O
of	O
the	O
placental	O
tissue	O
was	O
removed	O
until	O
the	O
uterine	O
inversion	O
was	O
corrected	O
.	O

The	O
uterus	O
was	O
closed	O
in	O
two	O
layers	O
.	O

Two	O
intra	O
-	O
abdominal	O
drains	O
were	O
sited	O
.	O

The	O
estimated	O
blood	O
loss	O
was	O
2.5	O
litres	O
and	O
five	O
units	O
of	O
blood	O
were	O
transfused	O
together	O
with	O
2	O
units	O
of	O
FFP	O
during	O
intra	O
-	O
operative	O
and	O
post	O
-	O
operative	O
period	O
.	O

In	O
addition	O
,	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
oxytocin	O
infusion	O
,	O
pr	O
misoprostol	O
and	O
antibiotics	O
.	O

On	O
the	O
second	O
post	O
partum	O
day	O
,	O
vaginal	O
Doppler	O
ultrasound	O
scan	O
showed	O
significant	O
amount	O
of	O
placental	O
tissues	O
with	O
increased	O
vascularity	O
measuring	O
2.7	O
×	O
6.6	O
×	O
6.8	O
cms	O
within	O
the	O
endometrial	O
cavity	O
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
was	O
discharged	O
on	O
the	O
fifth	O
post	O
-	O
operative	O
day	O
with	O
a	O
conservative	O
management	O
.	O

A	O
follow	O
up	O
Ultrasound	O
scan	O
after	O
two	O
weeks	O
showed	O
reduction	O
of	O
placental	O
mass	O
(	O
Figure	O
3	O
)	O
.	O

In	O
addition	O
,	O
there	O
was	O
significant	O
decrease	O
in	O
serum	O
beta	O
HCG	O
levels	O
from	O
2300	O
u	O
/	O
L	O
on	O
day	O
1	O
to	O
13	O
u	O
/	O
L	O
at	O
four	O
weeks	O
post	O
operatively	O
.	O

The	O
patient	O
remained	O
with	O
minimal	O
vaginal	O
bleeding	O
without	O
abdominal	O
pain	O
.	O

She	O
had	O
two	O
normal	O
periods	O
after	O
stopping	O
breastfeeding	O
and	O
was	O
feeling	O
well	O
.	O

She	O
was	O
discharged	O
from	O
the	O
early	O
pregnancy	O
unit	O
.	O

Discussion	O
A	O
life	O
-	O
threatening	O
uterine	O
inversion	O
can	O
be	O
rarely	O
caused	O
by	O
placenta	O
accreta	O
[	O
2	O
]	O
.	O

Placenta	O
accreta	O
classically	O
presents	O
with	O
retained	O
placenta	O
and	O
hemorrhage	O
.	O

The	O
association	O
between	O
uterine	O
inversion	O
and	O
placenta	O
accreta	O
is	O
unclear	O
,	O
however	O
,	O
strong	O
traction	O
on	O
the	O
umbilical	O
cord	O
with	O
fundal	O
placenta	O
,	O
excessive	O
fundal	O
pressure	O
,	O
relaxed	O
uterus	O
,	O
short	O
umbilical	O
cord	O
,	O
uterine	O
anomalies	O
and	O
antepartum	O
use	O
of	O
magnesium	O
sulphate	O
are	O
known	O
associated	O
factors	O
[	O
2	O
]	O
.	O

Uterine	O
inversion	O
and	O
retain	O
placenta	O
accreta	O
can	O
both	O
be	O
fatal	O
complications	O
[	O
3	O
]	O
.	O

In	O
the	O
case	O
described	O
the	O
placenta	O
accreta	O
was	O
complicated	O
by	O
uterine	O
inversion	O
and	O
subsequent	O
massive	O
post	O
partum	O
hemorrhage	O
,	O
significantly	O
increasing	O
the	O
risk	O
of	O
maternal	O
mortality	O
.	O

Massive	O
post	O
partum	O
hemorrhage	O
is	O
a	O
major	O
cause	O
of	O
maternal	O
mortality	O
in	O
the	O
United	O
Kingdom	O
(	O
why	O
women	O
die	O
latest	O
report	O
)	O
[	O
4	O
]	O
.	O

In	O
this	O
case	O
,	O
the	O
placenta	O
was	O
clamped	O
as	O
close	O
to	O
the	O
uterine	O
cavity	O
as	O
possible	O
and	O
cut	O
.	O

The	O
base	O
of	O
the	O
placenta	O
was	O
overrun	O
with	O
haemostatic	O
sutures	O
and	O
this	O
was	O
repeated	O
until	O
as	O
much	O
of	O
the	O
placenta	O
as	O
possible	O
was	O
removed	O
(	O
Figure	O
4	O
)	O
.	O

Placental	O
removal	O
enabled	O
correction	O
of	O
uterine	O
inversion	O
.	O

Despite	O
the	O
many	O
conditions	O
associated	O
with	O
uterine	O
inversion	O
risk	O
assessment	O
is	O
often	O
lacking	O
making	O
the	O
condition	O
usually	O
unexpected	O
at	O
the	O
time	O
of	O
presentation	O
.	O

The	O
association	O
between	O
abnormal	O
placentation	O
such	O
as	O
placenta	O
accreta	O
and	O
uterine	O
inversion	O
is	O
well	O
supported	O
[	O
2	O
]	O
.	O

Therefore	O
,	O
we	O
advocate	O
antenatal	O
evaluation	O
and	O
risk	O
assessment	O
for	O
placenta	O
accreta	O
[	O
5	O
]	O
.	O

Prenatal	O
Ultrasound	O
reported	O
sensitivity	O
of	O
94	O
%	O
and	O
specificity	O
of	O
79	O
%	O
for	O
placenta	O
accreta	O
,	O
but	O
offer	O
no	O
more	O
than	O
provisional	O
diagnostic	O
probability	O
statement	O
[	O
6	O
]	O
.	O

Moreover	O
,	O
because	O
45	O
%	O
of	O
placenta	O
accreta	O
cases	O
were	O
not	O
detected	O
by	O
ultrasound	O
,	O
it	O
is	O
important	O
to	O
consider	O
avoiding	O
manual	O
removal	O
of	O
placenta	O
if	O
there	O
were	O
intraoperative	O
signs	O
of	O
accreta	O
[	O
6	O
]	O
.	O

If	O
clinically	O
or	O
sonographically	O
the	O
patient	O
is	O
suspected	O
antenatally	O
to	O
be	O
at	O
risk	O
of	O
placenta	O
accreta	O
,	O
appropriate	O
management	O
options	O
should	O
be	O
considered	O
,	O
such	O
as	O
attempted	O
conservative	O
management	O
or	O
hysterectomy	O
and	O
counseling	O
provided	O
about	O
potential	O
sequelae	O
[	O
6	O
]	O
.	O

The	O
traditional	O
management	O
is	O
abdominal	O
hysterectomy	O
,	O
but	O
this	O
operation	O
terminates	O
fertility	O
and	O
may	O
have	O
devastating	O
psychological	O
effects	O
.	O

However	O
,	O
in	O
correct	O
circumstances	O
,	O
a	O
conservative	O
approach	O
may	O
be	O
suitable	O
.	O

Conservative	O
management	O
of	O
abnormally	O
invasive	O
placentation	O
can	O
be	O
effective	O
and	O
fertility	O
can	O
be	O
preserved	O
.	O

It	O
should	O
be	O
only	O
considered	O
in	O
highly	O
selected	O
cases	O
when	O
blood	O
loss	O
is	O
minimal	O
and	O
there	O
is	O
wish	O
for	O
fertility	O
preservation	O
[	O
7	O
]	O
.	O

For	O
women	O
who	O
want	O
to	O
preserve	O
their	O
fertility	O
the	O
placenta	O
should	O
be	O
left	O
intact	O
if	O
possible	O
after	O
caesarean	O
delivery	O
as	O
this	O
approach	O
lowers	O
the	O
risk	O
of	O
subsequent	O
hysterectomy	O
from	O
85	O
%	O
to	O
15	O
%	O
.	O

For	O
women	O
who	O
have	O
completed	O
their	O
family	O
,	O
hysterectomy	O
with	O
placenta	O
left	O
in	O
situ	O
is	O
preferable	O
to	O
lower	O
the	O
maternal	O
morbidity	O
rates	O
[	O
6	O
]	O
.	O

This	O
case	O
report	O
involved	O
conservative	O
management	O
.	O

Peripartum	O
hysterectomy	O
was	O
avoided	O
and	O
the	O
aim	O
was	O
to	O
preserve	O
fertility	O
.	O

Prophylactic	O
antibiotics	O
,	O
post	O
partum	O
oxytocics	O
and	O
the	O
use	O
of	O
misoprostol	O
post	O
operatively	O
helped	O
to	O
prevent	O
further	O
post	O
partum	O
hemorrhage	O
.	O

When	O
a	O
patient	O
isinitially	O
opted	O
for	O
conservative	O
management	O
,	O
the	O
possibility	O
of	O
recurrence	O
should	O
be	O
discussed	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
placentation	O
should	O
be	O
carefully	O
monitored	O
for	O
recurrence	O
in	O
any	O
subsequent	O
pregnancy	O
,	O
particularly	O
if	O
the	O
placenta	O
is	O
located	O
at	O
the	O
same	O
site	O
as	O
the	O
previous	O
placenta	O
accreta	O
.	O

Conservative	O
treatment	O
for	O
placenta	O
accreta	O
may	O
be	O
an	O
alternative	O
procedure	O
in	O
some	O
selected	O
cases	O
.	O

Conclusion	O
We	O
suggest	O
an	O
alternative	O
approach	O
for	O
managing	O
uterine	O
inversion	O
caused	O
by	O
placenta	O
accreta	O
that	O
involved	O
conservative	O
management	O
.	O

This	O
way	O
hysterectomy	O
was	O
avoided	O
and	O
fertility	O
was	O
preserved	O
.	O

Abbreviations	O
CS	O
:	O
Caesarean	O
Section	O
;	O
FFP	O
:	O

Fresh	O
Frozen	O
Plasma	O
Consent	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
accompanying	O
images	O
.	O

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
–	O
in	O
Chief	O
of	O
this	O
journal	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
All	O
authors	O
have	O
made	O
substantial	O
contribution	O
to	O
concept	O
this	O
case	O
report	O
.	O

Neurogenin2	O
Directs	O
Granule	O
Neuroblast	O
Production	O
and	O
Amplification	O
while	O
NeuroD1	O
Specifies	O
Neuronal	O
Fate	O
during	O
Hippocampal	O
Neurogenesis	O
Abstract	O
The	O
specification	O
and	O
differentiation	O
of	O
dentate	O
gyrus	O
granule	O
neurons	O
in	O
the	O
hippocampus	O
require	O
temporally	O
and	O
spatially	O
coordinated	O
actions	O
of	O
both	O
intrinsic	O
and	O
extrinsic	O
molecules	O
.	O

The	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factor	O
Neurogenin2	O
(	O
Ngn2	O
)	O
and	O
NeuroD1	O
are	O
key	O
regulators	O
in	O
these	O
processes	O
.	O

Based	O
on	O
existing	O
classification	O
,	O
we	O
analyzed	O
the	O
molecular	O
events	O
occurring	O
during	O
hippocampal	O
neurogenesis	O
,	O
primarily	O
focusing	O
on	O
juvenile	O
animals	O
.	O

We	O
found	O
that	O
Ngn2	O
is	O
transiently	O
expressed	O
by	O
late	O
type-2a	O
amplifying	O
progenitors	O
.	O

The	O
Ngn2	O
progenies	O
mature	O
into	O
hippocampal	O
granule	O
neurons	O
.	O

Interestingly	O
,	O
the	O
loss	O
of	O
Ngn2	O
at	O
early	O
stages	O
of	O
development	O
leads	O
to	O
a	O
robust	O
reduction	O
in	O
neurogenesis	O
,	O
but	O
does	O
not	O
disturb	O
granule	O
neuron	O
maturation	O
per	O
se	O
.	O

We	O
found	O
that	O
the	O
role	O
of	O
Ngn2	O
is	O
to	O
maintain	O
progenitors	O
in	O
an	O
undifferentiated	O
state	O
,	O
allowing	O
them	O
to	O
amplify	O
prior	O
to	O
their	O
maturation	O
into	O
granule	O
neurons	O
upon	O
NeuroD1	O
induction	O
.	O

When	O
we	O
overexpressed	O
Ngn2	O
and	O
NeuroD1	O
in	O
vivo	O
,	O
we	O
found	O
NeuroD1	O
to	O
exhibit	O
a	O
more	O
pronounced	O
neuron	O
-	O
inductive	O
effect	O
,	O
leading	O
to	O
granule	O
neuron	O
commitment	O
,	O
than	O
that	O
displayed	O
by	O
Ngn2	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
all	O
markers	O
expressed	O
during	O
the	O
transcriptional	O
control	O
of	O
hippocampal	O
neurogenesis	O
in	O
rodents	O
are	O
also	O
present	O
in	O
the	O
human	B
hippocampus	O
.	O

Taken	O
together	O
,	O
we	O
demonstrate	O
a	O
critical	O
role	O
of	O
for	O
Ngn2	O
and	O
NeuroD1	O
in	O
controlling	O
neuronal	O
commitment	O
and	O
hippocampal	O
granule	O
neuroblast	O
formation	O
,	O
both	O
during	O
embryonic	O
development	O
and	O
in	O
post	O
-	O
natal	O
hippocampal	O
granule	O
neurogenesis	O
.	O

Introduction	O
Neurons	O
are	O
born	O
not	O
only	O
during	O
development	O
of	O
the	O
central	O
nervous	O
system	O
,	O
but	O
neurogenesis	O
also	O
continues	O
into	O
adulthood	O
.	O

In	O
both	O
rodent	B
and	O
human	B
adult	O
brain	O
,	O
neurogenesis	O
is	O
active	O
in	O
two	O
distinct	O
zones	O
of	O
the	O
forebrain	O
:	O
the	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
of	O
the	O
lateral	O
ventricle	O
and	O
the	O
subgranular	O
zone	O
(	O
SGZ	O
)	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
(	O
DG	O
)	O
[	O
1	O
]	O
–	O
[	O
5	O
]	O
.	O

The	O
molecular	O
mechanism	O
underlying	O
neurogenesis	O
in	O
the	O
DG	O
is	O
not	O
fully	O
understood	O
.	O

Clearly	O
,	O
a	O
cascade	O
of	O
transcriptional	O
events	O
controls	O
the	O
specification	O
of	O
neuronal	O
identity	O
in	O
the	O
DG	O
[	O
3	O
]	O
,	O
[	O
6	O
]	O
–	O
[	O
8	O
]	O
,	O
but	O
details	O
of	O
the	O
expression	O
pattern	O
and	O
function	O
of	O
each	O
transcription	O
factor	O
remain	O
elusive	O
.	O

The	O
paired	O
-	O
box	O
homeodomain	O
transcription	O
factor	O
Pax6	O
and	O
the	O
bHLH	O
transcription	O
factors	O
Ngn2	O
and	O
NeuroD1	O
are	O
important	O
when	O
cells	O
acquire	O
a	O
pan	O
-	O
neuronal	O
character	O
and	O
a	O
specific	O
neuronal	O
subtype	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

In	O
the	O
developing	O
neocortex	O
,	O
Pax6	O
is	O
expressed	O
in	O
dividing	O
radial	O
glial	O
cells	O
at	O
the	O
ventricular	O
surface	O
[	O
9	O
]	O
.	O

In	O
the	O
adult	O
hippocampus	O
,	O
Pax6	O
is	O
expressed	O
in	O
astrocytes	O
in	O
the	O
SGZ	O
and	O
are	O
considered	O
to	O
be	O
the	O
true	O
stem	O
cells	O
[	O
9	O
]	O
,	O
[	O
11	O
]	O
.	O

Loss-	O
and	O
gain	O
-	O
of	O
-	O
function	O
studies	O
indicate	O
that	O
Pax6	O
is	O
involved	O
in	O
regulating	O
the	O
proliferation	O
of	O
neocortical	O
and	O
hippocampal	O
progenitors	O
[	O
9	O
]	O
,	O
[	O
12	O
]	O
–	O
[	O
16	O
]	O
.	O

During	O
neocorticogenesis	O
,	O
high	O
concentrations	O
of	O
Pax6	O
induce	O
the	O
expression	O
of	O
the	O
bHLH	O
transcription	O
factor	O
Neurogenin2	O
(	O
Ngn2	O
)	O
[	O
17	O
]	O
.	O

In	O
turn	O
,	O
Ngn2	O
causes	O
cell	O
cycle	O
exit	O
[	O
18	O
]	O
,	O
an	O
event	O
that	O
takes	O
place	O
when	O
NeuroD1	O
starts	O
to	O
be	O
expressed	O
[	O
19	O
]	O
.	O

In	O
the	O
developing	O
hippocampus	O
,	O
the	O
absence	O
of	O
Ngn2	O
leads	O
to	O
a	O
reduced	O
number	O
of	O
granule	O
neurons	O
[	O
20	O
]	O
.	O

NeuroD1	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
essential	O
for	O
the	O
differentiation	O
and	O
survival	O
of	O
hippocampal	O
granule	O
neurons	O
[	O
10	O
]	O
.	O

Interestingly	O
,	O
in	O
the	O
absence	O
of	O
Ngn2	O
,	O
NeuroD1	O
can	O
still	O
be	O
activated	O
and	O
neuronal	O
differentiation	O
can	O
still	O
take	O
place	O
[	O
20	O
]	O
.	O

This	O
has	O
led	O
to	O
the	O
idea	O
that	O
the	O
primary	O
role	O
of	O
Ngn2	O
is	O
not	O
to	O
direct	O
neuronal	O
differentiation	O
.	O

Only	O
a	O
small	O
number	O
of	O
studies	O
have	O
addressed	O
the	O
role	O
of	O
Ngn2	O
and	O
NeuroD1	O
in	O
hippocampal	O
neurogenesis	O
[	O
10	O
]	O
,	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

Therefore	O
,	O
we	O
now	O
re	O
-	O
examine	O
their	O
roles	O
in	O
hippocampal	O
neurogenesis	O
in	O
detail	O
,	O
using	O
gain-	O
and	O
loss	O
-	O
of	O
-	O
function	O
experiments	O
.	O

We	O
first	O
establish	O
a	O
hierarchy	O
of	O
transcriptional	O
events	O
that	O
occur	O
during	O
neurogenesis	O
in	O
the	O
DG	O
and	O
then	O
define	O
the	O
place	O
that	O
Ngn2	O
,	O
NeuroD1	O
and	O
other	O
transcription	O
factors	O
have	O
in	O
this	O
cascade	O
.	O

We	O
find	O
that	O
a	O
lack	O
of	O
Ngn2	O
expression	O
result	O
in	O
a	O
markedly	O
smaller	O
hippocampus	O
and	O
an	O
almost	O
complete	O
absence	O
of	O
the	O
DG	O
.	O

We	O
show	O
that	O
Ngn2	O
is	O
required	O
for	O
granule	O
neuroblasts	O
production	O
/	O
amplification	O
.	O

Gain	O
-	O
of	O
-	O
function	O
of	O
NeuroD1	O
during	O
development	O
of	O
the	O
DG	O
results	O
in	O
an	O
efficient	O
generation	O
of	O
granule	O
neuroblasts	O
,	O
an	O
effect	O
that	O
we	O
do	O
not	O
observe	O
when	O
we	O
overexpress	O
Ngn2	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
the	O
same	O
transcription	O
factors	O
and	O
cellular	O
markers	O
seen	O
in	O
mouse	B
and	O
rat	B
tissue	O
are	O
also	O
present	O
in	O
the	O
human	B
hippocampus	O
.	O

Results	O
Expression	O
of	O
transcription	O
factors	O
and	O
cellular	O
markers	O
define	O
different	O
phases	O
of	O
postnatal	O
hippocampal	O
granule	O
neuron	O
maturation	O
We	O
first	O
analyzed	O
in	O
detail	O
the	O
chronology	O
of	O
expression	O
of	O
different	O
transcription	O
factors	O
and	O
cell	O
-	O
specific	O
markers	O
during	O
DG	O
granule	O
neuron	O
formation	O
and	O
correlated	O
our	O
findings	O
to	O
the	O
previously	O
established	O
classification	O
of	O
adult	O
hippocampal	O
neurogenesis	O
[	O
3	O
]	O
.	O

The	O
current	O
classification	O
describes	O
hippocampal	O
stem	O
cells	O
and	O
progenies	O
into	O
three	O
categories	O
(	O
type-1	O
,	O
-2	O
and	O
-3	O
cells	O
)	O
depending	O
on	O
the	O
markers	O
they	O
express	O
as	O
they	O
mature	O
.	O

In	O
the	O
adult	O
mouse	B
DG	O
,	O
only	O
a	O
very	O
small	O
proportion	O
of	O
cells	O
undergo	O
mitosis	O
at	O
any	O
one	O
given	O
time	O
[	O
22	O
]	O
.	O

Consequently	O
,	O
in	O
adult	O
animals	O
it	O
is	O
difficult	O
to	O
analyze	O
which	O
transcription	O
factors	O
are	O
involved	O
in	O
the	O
transition	O
phase	O
from	O
one	O
cell	O
category	O
to	O
the	O
next	O
.	O

Therefore	O
,	O
we	O
studied	O
2	O
week	O
-	O
old	O
rodents	O
which	O
have	O
higher	O
numbers	O
of	O
maturing	O
granule	O
neurons	O
in	O
the	O
DG	O
.	O

We	O
performed	O
triple	O
immunohistochemistry	O
for	O
all	O
markers	O
of	O
interest	O
and	O
compared	O
results	O
from	O
2	O
week-	O
and	O
2	O
month	O
-	O
old	O
mice	B
(	O
Figure	O
1	O
and	O
figure	O
S1	O
)	O
.	O

We	O
first	O
confirmed	O
that	O
stem	O
cells	O
in	O
the	O
SGZ	O
exhibit	O
characteristics	O
of	O
radial	O
glia	O
[	O
3	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
16	O
]	O
.	O

They	O
extend	O
radial	O
processes	O
from	O
the	O
SGZ	O
to	O
the	O
apex	O
of	O
the	O
subgranular	O
layer	O
(	O
SGL	O
)	O
and	O
the	O
basal	O
molecular	O
layer	O
.	O

Moreover	O
,	O
they	O
express	O
the	O
intermediate	O
filament	O
protein	O
nestin	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
and	O
glial	O
glutamate	O
transporter	O
(	O
GLAST	O
)	O
[	O
16	O
]	O
(	O
Figure	O
1A	O
and	O
B	O
and	O
figure	O
S1A	O
and	O
S1B	O
)	O
.	O

The	O
GFAP-	O
and	O
GLAST+	O
cells	O
are	O
defined	O
as	O
type-1	O
cells	O
[	O
3	O
]	O
.	O

They	O
also	O
express	O
the	O
paired	O
-	O
homeodomain	O
transcription	O
factor	O
Pax6	O
(	O
Figure	O
1B	O
)	O
.	O

These	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
divide	O
relatively	O
infrequently	O
,	O
and	O
are	O
believed	O
to	O
undergo	O
symmetric	O
division	O
(	O
giving	O
rise	O
to	O
two	O
identical	O
stem	O
cells	O
)	O
under	O
some	O
conditions	O
.	O

They	O
can	O
also	O
divide	O
asymmetrically	O
and	O
give	O
rise	O
to	O
a	O
new	O
stem	O
cell	O
and	O
one	O
neuronal	O
progenitor	O
,	O
which	O
usually	O
is	O
defined	O
as	O
a	O
type-2	O
cell	O
(	O
Figure	O
2B	O
)	O
[	O
3	O
]	O
.	O

Type-2	O
cells	O
are	O
divided	O
into	O
two	O
different	O
populations	O
:	O
type-2a	O
expressing	O
nestin	O
and	O
type-2b	O
co	O
-	O
expressing	O
nestin	O
and	O
doublecortin	O
(	O
Dcx	O
)	O
[	O
23	O
]	O
.	O

Based	O
on	O
a	O
previous	O
report	O
[	O
24	O
]	O
,	O
we	O
examined	O
the	O
expression	O
pattern	O
of	O
the	O
T	O
-	O
domain	O
transcription	O
factors	O
Tbr1	O
and	O
Tbr2	O
.	O

We	O
found	O
that	O
Tbr2	O
is	O
expressed	O
in	O
type-2a	O
cells	O
,	O
in	O
agreement	O
with	O
a	O
recent	O
report	O
[	O
25	O
]	O
.	O

In	O
the	O
SGZ	O
of	O
2	O
week	O
-	O
old	O
mice	B
,	O
we	O
found	O
an	O
average	O
of	O
50–70	O
Tbr2	O
+	O
cells	O
per	O
30	O
µm	O
-	O
thick	O
section	O
throughout	O
the	O
rostro	O
-	O
caudal	O
axis	O
of	O
the	O
dorsal	O
hippocampus	O
.	O

This	O
number	O
was	O
reduced	O
by	O
35	O
%	O
in	O
2	O
month	O
-	O
old	O
mice	B
(	O
Figure	O
1C	O
with	O
figure	O
S1C	O
and	O
data	O
not	O
shown	O
)	O
.	O

As	O
opposed	O
to	O
Tbr1	O
(	O
Figure	O
1D	O
and	O
figure	O
S1D	O
)	O
,	O
Tbr2	O
+	O
cells	O
did	O
not	O
co	O
-	O
express	O
Dcx	O
or	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
1C	O
and	O
figure	O
S1C	O
)	O
.	O

We	O
observed	O
that	O
Tbr1-immuoreactivity	O
gradually	O
decreased	O
as	O
neurons	O
matured	O
and	O
started	O
to	O
express	O
NeuN	O
(	O
Figure	O
1H	O
and	O
figure	O
S1H	O
)	O
.	O

Thus	O
,	O
Tbr2	O
labels	O
type-2	O
cells	O
,	O
while	O
Tbr1	O
is	O
expressed	O
by	O
immature	O
granule	O
neurons	O
.	O

We	O
then	O
examined	O
the	O
molecular	O
phenotype	O
of	O
type-3	O
cells	O
,	O
a	O
cell	O
type	O
that	O
transiently	O
expresses	O
Calretinin	O
[	O
26	O
]	O
.	O

We	O
hypothesized	O
that	O
hippocampal	O
type-3	O
cells	O
might	O
also	O
express	O
the	O
bHLH	O
transcription	O
factor	O
NeuroD1	O
,	O
known	O
to	O
partially	O
overlap	O
with	O
Tbr2	O
and	O
Tbr1	O
in	O
different	O
brain	O
regions	O
[	O
24	O
]	O
.	O

We	O
found	O
that	O
NeuroD1	O
expression	O
in	O
the	O
hippocampus	O
starts	O
in	O
Tbr2	O
+	O
cells	O
and	O
extends	O
to	O
post	O
-	O
mitotic	O
Tbr1	O
+	O
cells	O
,	O
which	O
also	O
express	O
the	O
hippocampal	O
granule	O
identity	O
transcription	O
factor	O
Prox1	O
(	O
Figure	O
1	O
G	O
and	O
1I	O
and	O
figure	O
S1	O
G	O
and	O
S1I	O
)	O
.	O

While	O
Tbr1	O
expression	O
ceases	O
during	O
granule	O
maturation	O
,	O
that	O
of	O
NeuroD1	O
is	O
weakly	O
maintained	O
when	O
NeuN	O
expression	O
starts	O
(	O
Figure	O
1	O
G	O
and	O
1H	O
and	O
figure	O
S1	O
G	O
and	O
S1H	O
)	O
.	O

We	O
found	O
that	O
calretinin	O
expression	O
decreased	O
during	O
granule	O
neuron	O
maturation	O
,	O
before	O
NeuroD1	O
was	O
reduced	O
(	O
Figure	O
1F	O
)	O
.	O

Thus	O
NeuroD1	O
is	O
expressed	O
in	O
type-2b	O
and	O
type-3	O
cells	O
,	O
as	O
well	O
as	O
immature	O
granule	O
neurons	O
.	O

Finally	O
,	O
we	O
found	O
that	O
NeuroD2	O
starts	O
to	O
be	O
expressed	O
just	O
after	O
NeuroD1	O
and	O
,	O
unlike	O
NeuroD1	O
,	O
continues	O
to	O
be	O
highly	O
expressed	O
in	O
mature	O
neurons	O
(	O
Figure	O
1J	O
and	O
data	O
not	O
shown	O
)	O
.	O

Mash1	O
and	O
Ngn2	O
define	O
the	O
early	O
versus	O
late	O
type-2a	O
stage	O
in	O
2	O
weeks	O
old	O
mice	B
Having	O
established	O
the	O
hierarchy	O
of	O
transcription	O
factors	O
and	O
cellular	O
markers	O
appearing	O
during	O
hippocampal	O
neurogenesis	O
,	O
we	O
set	O
out	O
to	O
clarify	O
the	O
position	O
of	O
the	O
two	O
bHLH	O
transcription	O
factors	O
Ngn2	O
and	O
Mash1	O
,	O
in	O
this	O
process	O
.	O

We	O
found	O
that	O
more	O
than	O
90	O
%	O
of	O
Ngn2-immunoreactive	O
cells	O
are	O
Pax6	O
positive	O
(	O
Figure	O
2A	O
)	O
,	O
and	O
almost	O
all	O
co	O
-	O
express	O
Tbr2	O
(	O
Figure	O
2B	O
)	O
.	O

Thus	O
,	O
Ngn2	O
appears	O
to	O
be	O
expressed	O
by	O
type-2a	O
cells	O
.	O

As	O
our	O
antibodies	O
against	O
Ngn2	O
and	O
NeuroD1	O
were	O
made	O
in	O
the	O
same	O
species	O
,	O
we	O
could	O
not	O
determine	O
if	O
there	O
was	O
an	O
overlap	O
between	O
these	O
two	O
proteins	O
.	O

However	O
,	O
by	O
comparing	O
their	O
overlapping	O
expression	O
pattern	O
with	O
that	O
of	O
Tbr2	O
,	O
we	O
propose	O
that	O
some	O
Ngn2	O
+	O
cells	O
co	O
-	O
express	O
NeuroD1	O
,	O
and	O
that	O
they	O
appear	O
at	O
the	O
onset	O
of	O
NeuroD1	O
expression	O
and	O
downregulation	O
of	O
Ngn2	O
.	O

We	O
base	O
this	O
assumption	O
on	O
the	O
facts	O
that	O
more	O
than	O
50	O
%	O
of	O
the	O
Tbr2	O
+	O
cells	O
are	O
Ngn2	O
+	O
and	O
more	O
than	O
50	O
%	O
of	O
Tbr2	O
+	O
cells	O
also	O
express	O
NeuroD1	O
.	O

The	O
expression	O
of	O
Ngn2	O
in	O
adult	O
hippocampus	O
was	O
hard	O
to	O
detect	O
using	O
immunohistochemistry	O
due	O
to	O
the	O
low	O
expression	O
of	O
the	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
it	O
is	O
present	O
,	O
as	O
previously	O
described	O
using	O
reporter	O
mice	B
and	O
as	O
revealed	O
by	O
in	O
situ	O
hybridization	O
[	O
21	O
]	O
.	O

We	O
next	O
examined	O
the	O
expression	O
of	O
Mash1	O
and	O
compared	O
it	O
with	O
that	O
of	O
Ngn2	O
,	O
Pax6	O
and	O
Tbr2	O
.	O

We	O
found	O
some	O
Mash1	O
+	O
cells	O
(	O
10–20	O
cells	O
per	O
section	O
)	O
in	O
the	O
dorsal	O
hippocampus	O
.	O

Almost	O
all	O
of	O
them	O
co	O
-	O
expressed	O
Pax6	O
(	O
Figure	O
2C	O
)	O
.	O

Only	O
few	O
cells	O
co	O
-	O
expressed	O
Tbr2	O
(	O
Figure	O
2D	O
)	O
or	O
Ngn2	O
(	O
Figure	O
2E	O
)	O
,	O
suggesting	O
that	O
Mash1	O
is	O
downregulated	O
when	O
these	O
two	O
proteins	O
are	O
expressed	O
.	O

None	O
of	O
the	O
Mash1-expressing	O
cells	O
were	O
positive	O
for	O
NeuroD1	O
(	O
Figure	O
2F	O
)	O
.	O

Mash1	O
+	O
cells	O
were	O
still	O
undergoing	O
mitosis	O
(	O
Figure	O
2C	O
)	O
and	O
consequently	O
over	O
90	O
%	O
of	O
them	O
co	O
-	O
labeled	O
with	O
the	O
cell	O
-	O
cycle	O
marker	O
Ki67	O
(	O
Figure	O
S1J	O
)	O
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
Mash1	O
and	O
Ngn2	O
are	O
expressed	O
in	O
early	O
and	O
late	O
stages	O
of	O
maturation	O
of	O
type2a	O
progenitors	O
,	O
respectively	O
,	O
and	O
that	O
both	O
transcription	O
factors	O
are	O
co	O
-	O
expressed	O
briefly	O
when	O
cells	O
transit	O
from	O
early	O
to	O
late	O
phase	O
type2a	O
cells	O
.	O

Ngn2	O
progenies	O
become	O
hippocampal	O
granule	O
neurons	O
Previous	O
work	O
has	O
shown	O
that	O
in	O
Mash1	O
null	O
mutant	O
mice	B
hippocampal	O
neurogenesis	O
is	O
not	O
reduced	O
and	O
the	O
hippocampus	O
is	O
not	O
malformed	O
[	O
20	O
]	O
.	O

Therefore	O
we	O
focused	O
our	O
initial	O
analysis	O
on	O
the	O
role	O
of	O
Ngn2	O
in	O
hippocampal	O
neurogenesis	O
.	O

We	O
characterized	O
the	O
fate	O
of	O
Ngn2-expressing	O
cells	O
using	O
Ngn2	O
Knock	O
-	O
in	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
mice	B
(	O
Ngn2+	O
/	O
GFP	O
)	O
[	O
27	O
]	O
.	O

In	O
the	O
SGZ	O
of	O
2	O
week	O
-	O
old	O
hippocampi	O
,	O
we	O
found	O
bright	O
GFP	O
-	O
expressing	O
cells	O
that	O
were	O
positive	O
for	O
Tbr2	O
(	O
Figure	O
2H	O
)	O
,	O
the	O
immature	O
neuronal	O
marker	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
2I	O
)	O
and	O
NeuroD1	O
(	O
Figure	O
2J	O
)	O
.	O

Furthermore	O
,	O
Prox1	O
+	O
,	O
NeuroD2	O
+	O
and	O
calretinin+	O
cells	O
were	O
also	O
weakly	O
positive	O
for	O
GFP	O
.	O

We	O
made	O
similar	O
observations	O
in	O
2	O
month	O
-	O
old	O
mice	B
(	O
data	O
not	O
shown	O
)	O
confirming	O
earlier	O
published	O
results	O
[	O
21	O
]	O
)	O
.	O

We	O
did	O
not	O
observe	O
Mash1+	O
/	O
GFP+	O
and	O
NeuN+	O
/	O
GFP+	O
cells	O
(	O
Figure	O
2	O
G	O
)	O
.	O

These	O
data	O
from	O
Ngn2+	O
/	O
GFP	O
mice	B
are	O
entirely	O
consistent	O
with	O
our	O
earlier	O
observations	O
using	O
immunocytochemistry	O
to	O
label	O
Ngn2-expressing	O
cells	O
and	O
with	O
GFP	O
undergoing	O
slow	O
degradation	O
after	O
the	O
expression	O
of	O
Ngn2	O
has	O
ceased	O
.	O

Importantly	O
,	O
none	O
of	O
the	O
GFP	O
-	O
expressing	O
cells	O
,	O
including	O
those	O
only	O
weakly	O
fluorescent	O
,	O
residing	O
in	O
the	O
SGL	O
expressed	O
the	O
astrocytic	O
marker	O
GFAP	O
or	O
the	O
oligodendrocytic	O
markers	O
CNPase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
the	O
data	O
show	O
that	O
Ngn2	O
progenies	O
become	O
neurons	O
and	O
never	O
generate	O
astrocytes	O
or	O
oligodendrocytes	O
.	O

Marked	O
reduction	O
of	O
hippocampal	O
granule	O
neurons	O
in	O
absence	O
of	O
Ngn2	O
To	O
determine	O
the	O
role	O
of	O
Ngn2	O
during	O
the	O
initiation	O
of	O
hippocampal	O
granule	O
neurogenesis	O
,	O
we	O
analyzed	O
the	O
hippocampus	O
of	O
mice	B
lacking	O
Ngn2	O
(	O
Ngn2GFP	O
/	O
GFP	O
)	O
.	O

In	O
contrast	O
to	O
the	O
mice	B
use	O
by	O
Galichet	O
and	O
coworkers	O
,	O
our	O
mice	B
have	O
a	O
lifespan	O
of	O
only	O
2	O
weeks	O
after	O
birth	O
.	O

Therefore	O
,	O
we	O
analyzed	O
2	O
week	O
-	O
old	O
and	O
younger	O
mice	B
.	O

Consistent	O
with	O
previous	O
observations	O
[	O
20	O
]	O
,	O
the	O
hippocampus	O
in	O
Ngn2GFP	O
/	O
GFP	O
mutants	O
is	O
clearly	O
malformed	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
two	O
week	O
-	O
old	O
Ngn2GFP	O
/	O
GFP	O
mice	B
,	O
the	O
ventral	O
blade	O
of	O
the	O
DG	O
is	O
completely	O
absent	O
.	O

Already	O
on	O
postnatal	O
day	O
1–2	O
,	O
the	O
ventral	O
blade	O
of	O
the	O
DG	O
is	O
malformed	O
along	O
its	O
whole	O
rostro	O
-	O
caudal	O
axis	O
(	O
Figure	O
3B	O
)	O
.	O

As	O
neither	O
migration	O
defects	O
nor	O
cell	O
death	O
cause	O
the	O
reduced	O
number	O
of	O
hippocampal	O
neurons	O
in	O
Ngn2	O
null	O
mice	B
[	O
20	O
]	O
,	O
we	O
asked	O
if	O
Ngn2	O
is	O
necessary	O
for	O
production	O
of	O
hippocampal	O
granule	O
neuroblasts	O
.	O

We	O
first	O
injected	O
2	O
day	O
-	O
old	O
mouse	B
pups	O
with	O
BrdU	O
2	O
hours	O
prior	O
to	O
sacrifice	O
,	O
allowing	O
us	O
to	O
evaluate	O
cell	O
proliferation	O
and	O
ongoing	O
neurogenesis	O
.	O

We	O
also	O
injected	O
BrdU	O
into	O
female	O
mice	B
on	O
their	O
final	O
day	O
of	O
pregnancy	O
and	O
examined	O
the	O
brains	O
of	O
their	O
pups	O
48	O
hours	O
later	O
(	O
corresponding	O
to	O
P1–P2	O
old	O
pups	O
)	O
.	O

This	O
allowed	O
us	O
to	O
assess	O
the	O
number	O
of	O
neurons	O
derived	O
from	O
the	O
last	O
day	O
of	O
intrauterine	O
development	O
.	O

Regardless	O
of	O
whether	O
the	O
mice	B
were	O
WT	O
or	O
hetero	O
/	O
homozygous	O
mutant	O
pups	O
,	O
we	O
found	O
cells	O
that	O
had	O
incorporated	O
BrdU	O
in	O
the	O
hippocampal	O
subventricular	O
zone	O
(	O
hSVZ	O
)	O
,	O
fimbria	O
and	O
the	O
DG	O
(	O
Figure	O
4A	O
and	O
B	O
;	O
[	O
28	O
]	O
)	O
,	O
suggesting	O
that	O
progenitors	O
originating	O
in	O
the	O
hSVZ	O
divide	O
while	O
migrating	O
towards	O
the	O
DG	O
.	O

Most	O
of	O
them	O
were	O
organized	O
in	O
chains	O
typical	O
of	O
migrating	O
cells	O
(	O
Figure	O
4A	O
and	O
B	O
and	O
figure	O
S2	O
)	O
.	O

In	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
mice	B
injected	O
with	O
BrdU	O
2	O
hours	O
prior	O
to	O
sacrifice	O
,	O
we	O
observed	O
a	O
decrease	O
in	O
the	O
number	O
of	O
BrdU+	O
cells	O
compared	O
to	O
heterozygous	O
littermates	O
.	O

Thus	O
,	O
the	O
numbers	O
of	O
newborn	O
cells	O
were	O
reduced	O
in	O
the	O
hSVZ	O
/	O
fimbria	O
(	O
133.3±7.5	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
69.7±5.0	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
and	O
DG	O
(	O
132.0±9.1	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
42.6±2.2	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
(	O
Figure	O
4C	O
and	O
D	O
)	O
.	O

We	O
also	O
examined	O
the	O
number	O
of	O
newborn	O
cells	O
differentiating	O
into	O
neurons	O
,	O
and	O
identified	O
them	O
by	O
the	O
co	O
-	O
expression	O
of	O
BrdU	O
and	O
NeuroD1	O
.	O

As	O
expected	O
,	O
they	O
were	O
relatively	O
few	O
in	O
numbers	O
because	O
the	O
short	O
delay	O
(	O
2	O
hours	O
)	O
between	O
BrdU	O
administration	O
and	O
sacrifice	O
in	O
this	O
first	O
experimental	O
paradigm	O
.	O

In	O
Ngn2GFP	O
/	O
GFP	O
null	O
mutants	O
,	O
we	O
found	O
the	O
number	O
of	O
cells	O
differentiating	O
into	O
neurons	O
to	O
be	O
reduced	O
by	O
60	O
%	O
and	O
71	O
%	O
in	O
the	O
hSVZ	O
/	O
fimbria	O
(	O
8.6±1.4	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
3.4±0.5	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
and	O
DG	O
(	O
9.7±1.1	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
2.8±0.6	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
,	O
respectively	O
,	O
(	O
Figure	O
4E	O
and	O
F	O
)	O
.	O

As	O
a	O
result	O
,	O
the	O
number	O
of	O
NeuroD1	O
+	O
cells	O
in	O
the	O
DG	O
was	O
reduced	O
by	O
80	O
%	O
(	O
580.3±27.7	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
116.2±7.3	O
for	O
Ngn2GFP	O
/	O
GFP	O
;	O
Figure	O
4	O
G	O
)	O
.	O

We	O
obtained	O
similar	O
results	O
in	O
the	O
second	O
paradigm	O
,	O
i.e.	O
in	O
mice	B
that	O
we	O
sacrificed	O
48	O
hours	O
after	O
BrdU	O
administration	O
and	O
in	O
which	O
a	O
larger	O
number	O
of	O
the	O
newborn	O
cells	O
had	O
time	O
to	O
mature	O
into	O
neurons	O
.	O

In	O
this	O
case	O
,	O
the	O
number	O
of	O
BrdU+	O
/	O
NeuroD1	O
+	O
cells	O
in	O
the	O
DG	O
was	O
reduced	O
by	O
73	O
%	O
of	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
animals	O
(	O
91.5±24.1	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
26.4±3.3	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
(	O
Figure	O
4J	O
)	O
.	O

We	O
found	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
BrdU+	O
cells	O
that	O
expressed	O
NeuroD1	O
in	O
Ngn2+	O
/	O
GFP	O
and	O
Ngn2GFP	O
/	O
GFP	O
mice	B
(	O
14.2±1.0	O
%	O
and	O
17.4±1.8	O
%	O
respectively	O
;	O
Figure	O
4	O
K	O
)	O
.	O

This	O
shows	O
that	O
the	O
few	O
cells	O
that	O
manage	O
to	O
proliferate	O
in	O
the	O
Ngn2	O
null	O
mice	B
have	O
the	O
same	O
ability	O
to	O
differentiate	O
into	O
neurons	O
as	O
those	O
in	O
mice	B
with	O
one	O
Ngn2	O
allele	O
.	O

Interestingly	O
,	O
the	O
absence	O
of	O
Ngn2	O
did	O
not	O
alter	O
the	O
identity	O
of	O
neurons	O
in	O
the	O
DG	O
granule	O
layer	O
in	O
2	O
week	O
-	O
old	O
Ngn2	O
null	O
mice	B
.	O

The	O
maturing	O
granule	O
progenitors	O
sequentially	O
expressed	O
Pax6	O
,	O
Tbr2	O
(	O
Figure	O
S3A	O
and	O
S3B	O
)	O
,	O
NeuroD1	O
and	O
Calretinin	O
(	O
Figure	O
4L	O
)	O
,	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
4N	O
)	O
,	O
Tbr1	O
(	O
data	O
not	O
shown	O
)	O
and	O
Prox1	O
(	O
Figure	O
4	O
M	O
)	O
.	O

We	O
confirmed	O
that	O
the	O
same	O
transcriptional	O
cascade	O
is	O
active	O
in	O
the	O
20	O
%	O
(	O
compared	O
to	O
mice	B
with	O
one	O
Ngn2	O
allele	O
)	O
residual	O
granule	O
neurons	O
that	O
are	O
formed	O
two	O
day	O
-	O
old	O
in	O
Ngn2GFP	O
/	O
GFP	O
mice	B
(	O
Figure	O
S3D	O
–	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

We	O
next	O
investigated	O
if	O
the	O
cells	O
that	O
failed	O
to	O
develop	O
into	O
neurons	O
in	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
mice	B
,	O
became	O
glial	O
cells	O
.	O

We	O
found	O
that	O
cells	O
expressing	O
GFP	O
never	O
co	O
-	O
labeled	O
with	O
the	O
astrocyte	O
marker	O
GFAP	O
(	O
Figure	O
4N	O
)	O
or	O
the	O
oligodendrocyte	O
marker	O
CNPase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Altogether	O
,	O
our	O
results	O
show	O
that	O
Ngn2	O
plays	O
an	O
important	O
role	O
during	O
the	O
production	O
/	O
amplification	O
of	O
hippocampal	O
granule	O
neuroblasts	O
,	O
but	O
not	O
the	O
acquisition	O
of	O
the	O
granule	O
neuron	O
identity	O
(	O
Figure	O
S7	O
)	O
.	O

Ngn2	O
controls	O
the	O
amplification	O
of	O
granule	O
neuron	O
progenitors	O
We	O
next	O
monitored	O
the	O
mitogenic	O
activity	O
of	O
Ngn2	O
+	O
cells	O
in	O
the	O
DG	O
of	O
2	O
week	O
-	O
old	O
WT	O
mice	B
.	O

We	O
observed	O
that	O
over	O
50	O
%	O
of	O
Ngn2	O
+	O
cells	O
in	O
the	O
DG	O
of	O
WT	O
mice	B
co	O
-	O
expressed	O
the	O
mitosis	O
marker	O
Ki67	O
(	O
Figure	O
5A	O
)	O
.	O

Inspired	O
by	O
this	O
finding	O
,	O
we	O
injected	O
BrdU	O
into	O
2	O
week	O
-	O
old	O
WT	O
and	O
Ngn2GFP	O
/	O
GFP	O
mice	B
and	O
compared	O
cell	O
proliferation	O
in	O
the	O
DG	O
.	O

We	O
observed	O
92	O
%	O
reduction	O
in	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
SGZ	O
of	O
Ngn2	O
null	O
mutant	O
mice	B
(	O
6.7±0.5	O
)	O
compared	O
to	O
WT	O
(	O
83.6±1.2	O
)	O
and	O
heterozygotic	O
(	O
data	O
not	O
shown	O
)	O
littermates	O
(	O
Figure	O
5B	O
–	O
C	O
)	O
.	O

This	O
data	O
confirm	O
the	O
importance	O
of	O
Ngn2	O
during	O
the	O
amplification	O
of	O
granule	O
progenitor.s	O
.	O

To	O
further	O
explore	O
whether	O
Ngn2	O
+	O
cells	O
become	O
post	O
-	O
mitotic	O
or	O
still	O
proliferate	O
after	O
Ngn2	O
is	O
downregulated	O
,	O
we	O
performed	O
immunohistochemistry	O
on	O
sections	O
through	O
the	O
DG	O
of	O
Ngn2+	O
/	O
GFP	O
mice	B
.	O

We	O
stained	O
them	O
with	O
the	O
mitosis	O
marker	O
Phospho	O
-	O
histone	O
3	O
(	O
PH3	O
)	O
and	O
NeuroD1	O
,	O
which	O
is	O
downstream	O
of	O
Ngn2	O
in	O
the	O
transcriptional	O
cascade	O
controlling	O
neurogenesis	O
.	O

Thus	O
,	O
in	O
the	O
same	O
sections	O
we	O
could	O
identify	O
whether	O
cells	O
that	O
had	O
initiated	O
Ngn2	O
expression	O
(	O
GFP	O
labeled	O
)	O
,	O
continued	O
to	O
divide	O
(	O
PH3	O
+	O
)	O
or	O
committed	O
to	O
neuronal	O
differentiation	O
(	O
NeuroD1	O
+	O
)	O
.	O

We	O
observed	O
some	O
GFP+	O
cells	O
that	O
co	O
-	O
expressed	O
PH3	O
.	O

They	O
all	O
exhibited	O
morphological	O
characteristics	O
of	O
one	O
of	O
the	O
five	O
mitotic	O
phases	O
:	O
prophase	O
,	O
metaphase	O
,	O
anaphase	O
,	O
telophase	O
and	O
cytokinesis	O
(	O
Figure	O
5D	O
and	O
data	O
not	O
shown	O
)	O
.	O

Unexpectedly	O
,	O
cells	O
that	O
colabeled	O
for	O
GFP	O
,	O
PH3	O
and	O
NeuroD1	O
(	O
Figure	O
5E	O
and	O
figure	O
S4A	O
and	O
S4B	O
)	O
were	O
rare	O
.	O

This	O
indicates	O
that	O
Ngn2	O
+	O
cells	O
undergo	O
division	O
/	O
amplification	O
and	O
that	O
they	O
mature	O
into	O
post	O
-	O
mitotic	O
neurons	O
upon	O
NeuroD1	O
expression	O
.	O

In	O
mice	B
lacking	O
Ngn2	O
,	O
we	O
found	O
the	O
cells	O
expressing	O
GFP	O
localized	O
to	O
the	O
malformed	O
ventral	O
blade	O
of	O
the	O
DG	O
(	O
Figure	O
5F	O
and	O
G	O
)	O
.	O

All	O
of	O
these	O
cells	O
were	O
Ki67	O
+	O
and	O
they	O
only	O
very	O
rarely	O
expressed	O
PH3	O
(	O
Figure	O
5F	O
and	O
G	O
,	O
and	O
figure	O
S4C	O
)	O
in	O
the	O
absence	O
of	O
Ngn2	O
most	O
of	O
the	O
cells	O
are	O
arrested	O
in	O
the	O
cell	O
cycle	O
prior	O
to	O
entering	O
the	O
M	O
phase	O
and	O
their	O
mitosis	O
is	O
impaired	O
.	O

These	O
data	O
suggest	O
that	O
the	O
mechanism	O
of	O
action	O
of	O
Ngn2	O
is	O
conserved	O
from	O
development	O
of	O
the	O
DG	O
to	O
postnatal	O
hippocampal	O
neurogenesis	O
.	O

Our	O
findings	O
suggest	O
that	O
Ngn2	O
regulates	O
amplification	O
and	O
cell	O
cycle	O
exit	O
of	O
DG	O
granule	O
progenitors	O
.	O

To	O
examine	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
effects	O
of	O
Ngn2	O
and	O
NeuroD1	O
on	O
mitotic	O
activity	O
in	O
embryonic	O
cortico	O
-	O
hippocampal	O
neurosphere	O
-	O
derived	O
progenitors	O
,	O
5	O
days	O
upon	O
transduction	O
,	O
in	O
vitro	O
.	O

In	O
cultures	O
transduced	O
with	O
Ngn2	O
retrovirus	O
,	O
we	O
found	O
that	O
27.2	O
%	O
(	O
±4.1	O
%	O
)	O
of	O
the	O
PH3	O
+	O
cells	O
had	O
been	O
transduced	O
(	O
Figure	O
I1–J	O
)	O
.	O

These	O
cells	O
were	O
immunopositive	O
for	O
MAP2	O
(	O
Figure	O
5I1	O
and	O
I2	O
)	O
and	O
therefore	O
represented	O
dividing	O
neuroblasts	O
.	O

By	O
contrast	O
,	O
in	O
NeuroD1	O
transduced	O
cultures	O
,	O
only	O
7.3	O
%	O
of	O
PH3	O
+	O
cells	O
were	O
GFP+	O
(	O
Figure	O
5H1	O
,	O
H2	O
and	O
J	O
)	O
.	O

All	O
of	O
the	O
NeuroD1-transduced	O
cells	O
became	O
MAP2	O
+	O
(	O
Figure	O
5H	O
)	O
.	O

To	O
confirm	O
this	O
data	O
we	O
pulse	O
-	O
labeled	O
transduced	O
cultures	O
with	O
chlorodeoxyuridine	O
(	O
CldU	O
)	O
for	O
48	O
hours	O
,	O
five	O
days	O
after	O
differentiation	O
.	O

In	O
contrast	O
to	O
NeuroD1-transduced	O
cultures	O
,	O
we	O
observed	O
dividing	O
cells	O
transduced	O
with	O
Ngn2	O
retrovirus	O
that	O
were	O
positive	O
for	O
PH3	O
and	O
that	O
had	O
incorporated	O
CldU	O
(	O
Figure	O
5K	O
–	O
L2	O
)	O
.	O

As	O
the	O
number	O
of	O
cells	O
PH3+	O
/	O
CldU+	O
/	O
GFP+	O
we	O
observed	O
was	O
low	O
,	O
we	O
did	O
not	O
quantify	O
this	O
finding	O
.	O

Collectively	O
,	O
we	O
have	O
shown	O
that	O
Ngn2	O
is	O
required	O
for	O
granule	O
neuroblast	O
production	O
and	O
amplification	O
and	O
that	O
in	O
the	O
absence	O
of	O
Ngn2	O
the	O
progenitors	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

NeuroD1	O
,	O
on	O
the	O
other	O
hand	O
,	O
induces	O
cell	O
cycle	O
exit	O
and	O
promotes	O
rapid	O
neuronal	O
maturation	O
.	O

NeuroD1	O
directs	O
neuronal	O
differentiation	O
and	O
maturation	O
Based	O
on	O
our	O
previous	O
observations	O
we	O
proposed	O
that	O
Ngn2	O
primarily	O
controls	O
amplification	O
of	O
granule	O
neuroblasts	O
and	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
overexpressed	O
Ngn2	O
or	O
NeuroD1	O
in	O
E14.5	O
cortico	O
-	O
hippocampal	O
neurospheres	O
and	O
compared	O
their	O
effects	O
after	O
5	O
days	O
of	O
differentiation	O
of	O
the	O
progenitors	O
.	O

All	O
cortico	O
-	O
hippocampal	O
progenitors	O
expressed	O
Pax6	O
prior	O
to	O
differentiation	O
(	O
Figure	O
S5	O
)	O
.	O

After	O
5	O
days	O
,	O
both	O
factors	O
suppressed	O
Pax6	O
and	O
Sox2	O
(	O
Figure	O
S5	O
,	O
figure	O
6C	O
)	O
and	O
induced	O
expression	O
of	O
Tbr1	O
,	O
Map2	O
,	O
NeuroD1	O
and	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6D	O
and	O
E	O
)	O
.	O

Interestingly	O
,	O
all	O
Ngn2-overexpressing	O
cells	O
co	O
-	O
expressed	O
NeuroD1	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
next	O
explored	O
whether	O
Ngn2	O
overexpression	O
induces	O
NeuroD1	O
expression	O
,	O
and	O
if	O
NeuroD1	O
in	O
turn	O
directs	O
neuronal	O
differentiation	O
.	O

We	O
compared	O
the	O
effects	O
of	O
both	O
transcription	O
factors	O
in	O
progenitors	O
that	O
either	O
do	O
or	O
do	O
not	O
normally	O
express	O
them	O
.	O

Thus	O
,	O
we	O
expressed	O
Ngn2	O
in	O
E14.5	O
neural	O
progenitors	O
isolated	O
from	O
three	O
different	O
brain	O
regions	O
:	O
cortex	O
/	O
hippocampus	O
,	O
lateral	O
ganglionic	O
eminence	O
(	O
LGE	O
)	O
and	O
ventral	O
mesencephalon	O
(	O
VM	O
)	O
.	O

Ngn2	O
expression	O
in	O
the	O
developing	O
forebrain	O
is	O
normally	O
limited	O
to	O
the	O
neocortex	O
,	O
and	O
it	O
does	O
not	O
appear	O
in	O
LGE	O
tissue	O
[	O
29	O
]	O
.	O

In	O
the	O
developing	O
VM	O
,	O
both	O
Ngn2	O
and	O
NeuroD1	O
are	O
expressed	O
,	O
but	O
not	O
when	O
neural	O
progenitors	O
from	O
this	O
region	O
are	O
cultured	O
in	O
vitro	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

In	O
our	O
experiments	O
,	O
cortico	O
-	O
hippocampal	O
progenitors	O
could	O
differentiate	O
into	O
neurons	O
,	O
although	O
they	O
did	O
not	O
normally	O
express	O
NeuroD1	O
(	O
Figure	O
6E	O
)	O
.	O

When	O
we	O
overexpressed	O
Ngn2	O
in	O
VM	O
and	O
LGE	O
progenitors	O
,	O
the	O
cells	O
started	O
to	O
express	O
both	O
NeuroD1	O
and	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6F	O
and	O
G	O
)	O
.	O

We	O
then	O
overexpressed	O
NeuroD1	O
in	O
the	O
same	O
types	O
of	O
cultured	O
progenitors	O
and	O
found	O
that	O
the	O
cells	O
became	O
immunoreactive	O
for	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
NeuroD1	O
is	O
sufficient	O
to	O
direct	O
neuronal	O
differentiation	O
in	O
cortico	O
-	O
hippocampal-	O
,	O
LGE-	O
and	O
VM	O
-	O
derived	O
progenitors	O
.	O

Our	O
results	O
from	O
in	O
vitro	O
cultures	O
and	O
the	O
analysis	O
of	O
the	O
DG	O
of	O
Ngn2	O
mutant	O
animals	O
collectively	O
show	O
the	O
neuron	O
-	O
inducing	O
effect	O
of	O
NeuroD1	O
in	O
hippocampal	O
granule	O
cell	O
progenitors	O
[	O
32	O
]	O
.	O

NeuroD1	O
directs	O
exclusive	O
neuronal	O
differentiation	O
of	O
hippocampal	O
granule	O
neuron	O
progenitors	O
As	O
the	O
next	O
step	O
,	O
we	O
tested	O
the	O
effects	O
of	O
NeuroD1	O
in	O
vivo	O
and	O
compared	O
them	O
with	O
those	O
of	O
Ngn2	O
.	O

We	O
injected	O
retroviruses	O
carrying	O
the	O
gene	O
for	O
either	O
Ngn2	O
[	O
33	O
]	O
or	O
NeuroD1	O
,	O
and	O
the	O
reporter	O
gene	O
eGFP	O
into	O
the	O
ventricles	O
E15.5	O
rat	B
embryos	O
,	O
in	O
utero	O
(	O
Figure	O
7A	O
)	O
.	O

Three	O
weeks	O
later	O
,	O
when	O
the	O
rats	B
were	O
about	O
two	O
weeks	O
old	O
,	O
we	O
examined	O
their	O
hippocampi	O
and	O
analyzed	O
the	O
eGFP+	O
cells	O
.	O

The	O
rats	B
injected	O
with	O
control	O
vector	O
exhibited	O
eGFP+	O
cells	O
within	O
the	O
hippocampus	O
that	O
were	O
either	O
star	O
-	O
shaped	O
,	O
progenitor	O
/	O
glial	O
-	O
like	O
cells	O
(	O
14.8±3.4	O
%	O
)	O
or	O
neuron	O
-	O
like	O
cells	O
with	O
long	O
neurites	O
(	O
85.3±3.4	O
%	O
)	O
(	O
Figure	O
7B	O
)	O
.	O

In	O
rats	B
that	O
we	O
had	O
injected	O
with	O
the	O
vector	O
encoding	O
Ngn2	O
,	O
the	O
eGFP	O
-	O
labeled	O
,	O
the	O
transduced	O
hippocampal	O
cells	O
were	O
composed	O
of	O
31.9	O
%	O
(	O
±5.7	O
%	O
)	O
progenitor	O
/	O
glia	O
-	O
like	O
cells	O
and	O
69.4	O
%	O
(	O
±6.1	O
%	O
)	O
neuron	O
-	O
like	O
cells	O
(	O
Figure	O
7B	O
)	O
.	O

The	O
glia	O
-	O
like	O
subpopulation	O
was	O
immunopositive	O
for	O
the	O
astrocytic	O
marker	O
GFAP	O
(	O
Figure	O
7C	O
–	O
D	O
)	O
.	O

In	O
contrast	O
,	O
virtually	O
all	O
of	O
the	O
transduced	O
cells	O
in	O
rats	B
injected	O
with	O
the	O
NeuroD1	O
vector	O
became	O
neuron	O
-	O
like	O
cells	O
(	O
99.9%±0.1	O
;	O
Figure	O
7B	O
)	O
.	O

None	O
of	O
these	O
cells	O
stained	O
for	O
GFAP	O
(	O
Figure	O
7E	O
and	O
F	O
)	O
.	O

They	O
were	O
positioned	O
in	O
the	O
external	O
layers	O
of	O
both	O
the	O
ventral	O
and	O
dorsal	O
blades	O
of	O
the	O
DG	O
(	O
Figure	O
7B3	O
,	O
E	O
and	O
I	O
and	O
figure	O
S6A	O
)	O
.	O

When	O
we	O
examined	O
neuronal	O
maturation	O
of	O
Ngn2-	O
and	O
NeuroD1-transduced	O
cells	O
,	O
we	O
observed	O
that	O
only	O
a	O
few	O
of	O
those	O
transduced	O
with	O
the	O
NeuroD1	O
vector	O
expressed	O
the	O
early	O
mature	O
neuronal	O
marker	O
Tbr1	O
(	O
3.1±1.4	O
%	O
;	O
Figure	O
7I	O
and	O
J	O
)	O
.	O

They	O
were	O
located	O
within	O
the	O
basal	O
layers	O
,	O
near	O
the	O
SGL	O
,	O
of	O
the	O
ventral	O
and	O
dorsal	O
blades	O
of	O
the	O
DG	O
.	O

In	O
contrast	O
,	O
a	O
greater	O
proportion	O
of	O
the	O
cells	O
transduced	O
with	O
Ngn2	O
still	O
expressed	O
Tbr1	O
(	O
19.6%±3.3	O
%	O
;	O
Figure	O
7H	O
and	O
J	O
)	O
,	O
indicating	O
that	O
they	O
were	O
less	O
mature	O
than	O
the	O
vast	O
majority	O
of	O
the	O
NeuroD1-transduced	O
cells	O
.	O

Immunohistochemistry	O
for	O
NeuN	O
confirmed	O
these	O
data	O
(	O
Figure	O
7	O
M	O
and	O
O	O
,	O
and	O
figure	O
S6A	O
)	O
.	O

Indeed	O
,	O
when	O
we	O
overexpressed	O
Ngn2	O
the	O
proportion	O
of	O
hippocampal	O
progenitors	O
that	O
became	O
NeuN+	O
was	O
no	O
greater	O
than	O
in	O
rats	B
transduced	O
with	O
the	O
control	O
virus	O
(	O
Figure	O
7F	O
)	O
.	O

As	O
a	O
whole	O
,	O
our	O
in	O
utero	O
injection	O
experiments	O
confirm	O
that	O
NeuroD1	O
has	O
a	O
stronger	O
neuron	O
-	O
inducing	O
effect	O
than	O
Ngn2	O
when	O
overexpressed	O
in	O
hippocampal	O
progenitors	O
.	O

Involvement	O
of	O
Mash1	O
,	O
Ngn2	O
,	O
Tbr	O
and	O
NeuroD	O
proteins	O
during	O
human	B
hippocampal	O
neurogenesis	O
Finally	O
,	O
we	O
examined	O
whether	O
the	O
transcription	O
factors	O
and	O
cellular	O
markers	O
that	O
are	O
expressed	O
in	O
rodents	O
are	O
also	O
expressed	O
in	O
human	B
hippocampus	O
.	O

We	O
performed	O
immunohistochemistry	O
on	O
aged	O
human	B
hippocampal	O
DG	O
and	O
found	O
GFAP-	O
,	O
Sox2-	O
,	O
Pax6-	O
,	O
Nestin-	O
,	O
Prox1-	O
and	O
NeuN	O
-	O
immunopositive	O
cells	O
.	O

This	O
indicates	O
that	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
,	O
neural	O
progenitors	O
and	O
mature	O
granule	O
neurons	O
are	O
present	O
in	O
the	O
aged	O
human	B
hippocampus	O
(	O
Figure	O
8A	O
–	O
E	O
)	O
.	O

While	O
Prox1	O
is	O
found	O
mainly	O
in	O
granule	O
neurons	O
,	O
Sox2	O
and	O
Pax6	O
are	O
exclusively	O
localized	O
to	O
cells	O
in	O
the	O
SGZ	O
(	O
Figure	O
8D	O
and	O
E	O
)	O
.	O

As	O
for	O
aged	O
rodents	O
,	O
we	O
did	O
not	O
observe	O
the	O
presence	O
of	O
Mash1	O
,	O
Ngn2	O
,	O
Tbr2	O
,	O
Tbr1	O
and	O
NeuroD1	O
proteins	O
in	O
aged	O
human	B
hippocampus	O
,	O
using	O
immunohistochemistry	O
.	O

However	O
,	O
we	O
could	O
identify	O
the	O
presence	O
of	O
the	O
transcripts	O
,	O
using	O
RT	O
-	O
PCR	O
(	O
Figure	O
8F	O
)	O
.	O

In	O
addition	O
,	O
we	O
detected	O
mRNA	O
for	O
Prox1	O
,	O
Calbindin1	O
and	O
Calbindin2	O
/	O
Calretinin	O
(	O
Figure	O
8F	O
)	O
.	O

Interestingly	O
,	O
we	O
also	O
observed	O
Sonic	O
Hedgehog	O
and	O
Wnt-3A	O
transcripts	O
,	O
indicating	O
that	O
they	O
are	O
present	O
in	O
the	O
human	B
DG	O
and	O
supporting	O
previous	O
claims	O
that	O
they	O
are	O
important	O
for	O
the	O
regulation	O
of	O
adult	O
hippocampal	O
neurogenesis	O
(	O
Figure	O
8F	O
;	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
)	O
.	O

Finally	O
,	O
we	O
also	O
found	O
mRNA	O
for	O
GLAST	O
,	O
Pax6	O
and	O
GFAP	O
which	O
suggests	O
that	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
are	O
present	O
in	O
the	O
adult	O
human	B
hippocampus	O
,	O
and	O
may	O
play	O
a	O
role	O
in	O
adult	O
human	B
hippocampal	O
neurogenesis	O
(	O
Figure	O
8F	O
;	O
[	O
8	O
]	O
)	O
.	O

Overall	O
,	O
our	O
data	O
show	O
that	O
different	O
proteins	O
known	O
to	O
play	O
key	O
roles	O
in	O
rodent	B
hippocampal	O
granule	O
neurogenesis	O
are	O
present	O
in	O
the	O
adult	O
human	B
hippocampus	O
.	O

Discussion	O
In	O
this	O
study	O
we	O
determine	O
the	O
functions	O
of	O
Ngn2	O
and	O
NeuroD1	O
during	O
hippocampal	O
neurogenesis	O
.	O

First	O
,	O
we	O
map	O
the	O
hierarchy	O
of	O
molecular	O
markers	O
of	O
neurogenesis	O
in	O
the	O
DG	O
.	O

Second	O
,	O
we	O
describe	O
that	O
Ngn2	O
is	O
necessary	O
for	O
granule	O
progenitor	O
production	O
/	O
amplification	O
.	O

Third	O
,	O
we	O
demonstrate	O
that	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
of	O
granule	O
progenitors	O
.	O

Finally	O
,	O
we	O
show	O
that	O
different	O
cellular	O
markers	O
expressed	O
during	O
hippocampal	O
neurogenesis	O
in	O
rodents	O
are	O
present	O
in	O
human	B
.	O

Sequential	O
expression	O
of	O
different	O
transcription	O
factors	O
and	O
cellular	O
markers	O
during	O
hippocampal	O
neurogenesis	O
We	O
clarified	O
the	O
pattern	O
of	O
expression	O
of	O
various	O
markers	O
expressed	O
during	O
postnatal	O
and	O
adult	O
hippocampal	O
granule	O
neurogenesis	O
in	O
detail	O
.	O

We	O
found	O
that	O
the	O
transcription	O
factor	O
Pax6	O
is	O
initially	O
expressed	O
by	O
both	O
radial	O
glia	O
stem	O
cells	O
(	O
type-1	O
)	O
and	O
early	O
amplifying	O
progenitors	O
(	O
type-2a	O
)	O
.	O

The	O
next	O
transcription	O
factor	O
to	O
appear	O
in	O
chronology	O
is	O
Mash1	O
.	O

Mash1	O
expression	O
characterizes	O
the	O
early	O
stage	O
of	O
hippocampal	O
progenitor	O
amplification	O
(	O
early	O
type-2a	O
)	O
.	O

The	O
role	O
of	O
Mash1	O
during	O
hippocampal	O
granule	O
neurogenesis	O
is	O
still	O
unclear	O
.	O

Mash1	O
null	O
mutant	O
mice	B
do	O
not	O
display	O
any	O
clear	O
malformation	O
of	O
the	O
DG	O
[	O
20	O
]	O
.	O

However	O
,	O
overexpression	O
of	O
Mash1	O
alone	O
in	O
the	O
DG	O
leads	O
to	O
the	O
generation	O
of	O
oligodendrocytes	O
[	O
36	O
]	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
hypothesize	O
that	O
Mash1-expressing	O
cells	O
are	O
not	O
yet	O
committed	O
towards	O
a	O
granule	O
cell	O
fate	O
.	O

They	O
may	O
still	O
have	O
the	O
potential	O
to	O
generate	O
both	O
neurons	O
and	O
oligodendrocytes	O
,	O
as	O
is	O
the	O
case	O
in	O
the	O
SVZ	O
[	O
37	O
]	O
.	O

In	O
agreement	O
with	O
different	O
developing	O
brain	O
regions	O
,	O
we	O
found	O
that	O
Ngn2	O
starts	O
to	O
be	O
expressed	O
in	O
Mash1-positive	O
transiently	O
amplifying	O
progenitors	O
,	O
i.e.	O
""""	O
late	O
type-2a	O
cells	O
""""	O
according	O
to	O
the	O
classification	O
we	O
propose	O
.	O

We	O
observed	O
that	O
Pax6	O
expression	O
persisted	O
longer	O
than	O
that	O
of	O
Mash1	O
,	O
in	O
Ngn2-expressing	O
cells	O
(	O
late	O
type-2a	O
cells	O
)	O
,	O
in	O
juvenile	O
but	O
not	O
adult	O
DG	O
(	O
Fig.	O
1	O
and	O
figure	O
S1	O
)	O
.	O

Later	O
on	O
,	O
Ngn2	O
is	O
downregulated	O
,	O
whilst	O
Tbr2	O
expression	O
persists	O
(	O
type-2b	O
cells	O
)	O
.	O

The	O
transition	O
from	O
amplifying	O
progenitor	O
to	O
neuroblast	O
is	O
defined	O
by	O
the	O
expression	O
of	O
NeuroD1	O
.	O

Thus	O
,	O
Ngn2	O
is	O
expressed	O
at	O
the	O
beginning	O
of	O
the	O
transiently	O
amplifying	O
progenitor	O
phase	O
while	O
NeuroD1	O
marks	O
the	O
end	O
of	O
that	O
period	O
.	O

This	O
applies	O
both	O
to	O
the	O
juvenile	O
and	O
adult	O
rat	B
brain	O
[	O
21	O
]	O
,	O
[	O
25	O
]	O
.	O

After	O
NeuroD1	O
is	O
turned	O
on	O
the	O
progenitors	O
leave	O
the	O
cell	O
cycle	O
,	O
gradually	O
mature	O
,	O
express	O
PSA	O
-	O
NCAM	O
,	O
NeuroD2	O
,	O
Calretinin	O
,	O
Prox1	O
,	O
Tbr1	O
and	O
,	O
finally	O
,	O
NeuN.	O
NeuroD1	O
expression	O
persists	O
at	O
low	O
levels	O
in	O
mature	O
neurons	O
(	O
Figure	O
9	O
;	O
[	O
10	O
]	O
)	O
.	O

We	O
found	O
the	O
sequential	O
expression	O
of	O
these	O
markers	O
conserved	O
in	O
juvenile	O
(	O
P2	O
and	O
2	O
weeks	O
)	O
and	O
adult	O
rodent	B
brains	O
.	O

Importantly	O
,	O
we	O
observed	O
that	O
the	O
same	O
transcription	O
factors	O
and	O
neuronal	O
markers	O
are	O
also	O
present	O
in	O
the	O
adult	O
human	B
hippocampus	O
and	O
arranged	O
spatially	O
in	O
a	O
manner	O
reminiscent	O
with	O
what	O
we	O
saw	O
in	O
rodents	O
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
some	O
of	O
these	O
markers	O
are	O
expressed	O
for	O
longer	O
or	O
shorter	O
periods	O
at	O
postnatal	O
and	O
adult	O
stages	O
of	O
hippocampal	O
progenitor	O
maturation	O
.	O

Moreover	O
,	O
one	O
can	O
ask	O
to	O
which	O
extent	O
the	O
number	O
of	O
divisions	O
occurring	O
during	O
neuroblasts	O
maturation	O
is	O
conserved	O
at	O
postnatal	O
and	O
adult	O
stages	O
of	O
neurogenesis	O
.	O

A	O
new	O
function	O
for	O
Ngn2	O
in	O
maintenance	O
of	O
a	O
progenitor	O
state	O
for	O
granule	O
neuron	O
production	O
/	O
amplification	O
during	O
embryonic	O
and	O
postnatal	O
hippocampal	O
neurogenesis	O
In	O
agreement	O
with	O
earlier	O
work	O
,	O
we	O
confirm	O
that	O
Ngn2	O
is	O
indispensable	O
for	O
hippocampal	O
development	O
and	O
plays	O
a	O
vital	O
role	O
in	O
postnatal	O
hippocampal	O
granule	O
neurogenesis	O
.	O

Ngn2	O
null	O
mutant	O
animals	O
display	O
a	O
reduced	O
size	O
of	O
the	O
cornu	O
ammonis	O
and	O
a	O
malformed	O
DG	O
(	O
Figure	O
3	O
and	O
4	O
;	O
[	O
20	O
]	O
)	O
.	O

We	O
show	O
that	O
the	O
number	O
of	O
newborn	O
neurons	O
(	O
incorporated	O
BrdU	O
)	O
is	O
decreased	O
in	O
absence	O
of	O
Ngn2	O
,	O
but	O
hippocampal	O
granule	O
neuron	O
subtype	O
specification	O
is	O
not	O
affected	O
,	O
post	O
-	O
nataly	O
.	O

Likewise	O
,	O
neurons	O
from	O
other	O
brain	O
regions	O
,	O
e.g.	O
ventral	O
midbrain	O
dopamine	O
neurons	O
,	O
can	O
be	O
generated	O
in	O
the	O
absence	O
of	O
Ngn2	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

The	O
reduced	O
numbers	O
of	O
mature	O
neurons	O
in	O
the	O
hippocampus	O
and	O
ventral	O
midbrain	O
of	O
Ngn2	O
null	O
mutant	O
animals	O
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
cell	O
death	O
or	O
migration	O
defects	O
[	O
20	O
]	O
,	O
[	O
31	O
]	O
.	O

Instead	O
it	O
may	O
be	O
due	O
to	O
a	O
defect	O
in	O
the	O
generation	O
and/or	O
amplification	O
of	O
neuronal	O
progenitors	O
.	O

Indeed	O
,	O
in	O
the	O
hippocampus	O
of	O
postnatal	O
animals	O
,	O
we	O
observed	O
that	O
cells	O
lacking	O
Ngn2	O
arrest	O
in	O
the	O
cell	O
cycle	O
,	O
maintain	O
Pax6	O
expression	O
and	O
cease	O
to	O
proliferate	O
.	O

When	O
overexpressed	O
in	O
neural	O
progenitors	O
in	O
vitro	O
,	O
Ngn2	O
lead	O
to	O
up	O
-	O
regulation	O
of	O
NeuroD1	O
and	O
caused	O
neuronal	O
differentiation	O
(	O
Figure	O
6	O
)	O
,	O
which	O
was	O
not	O
always	O
the	O
case	O
when	O
we	O
overexpressed	O
the	O
same	O
factor	O
in	O
vivo	O
(	O
Figure	O
7L	O
,	O
N	O
and	O
O	O
)	O
.	O

We	O
also	O
saw	O
that	O
Ngn2	O
does	O
not	O
always	O
efficiently	O
induce	O
cell	O
cycle	O
exit	O
.	O

Typically	O
some	O
mitotically	O
active	O
eGFP+	O
cells	O
were	O
present	O
in	O
the	O
DG	O
of	O
rats	B
injected	O
with	O
the	O
Ngn2	O
retrovirus	O
(	O
Figure	O
7P	O
)	O
,	O
and	O
we	O
observed	O
that	O
cultured	O
Ngn2-transduced	O
cells	O
are	O
still	O
capable	O
of	O
dividing	O
.	O

Thus	O
,	O
Ngn2	O
does	O
not	O
always	O
promote	O
cell	O
cycle	O
exit	O
and	O
neuronal	O
commitment	O
,	O
but	O
depending	O
on	O
the	O
state	O
of	O
the	O
cells	O
,	O
Ngn2	O
may	O
instead	O
promote	O
alternate	O
cellular	O
fates	O
[	O
38	O
]	O
–	O
[	O
40	O
]	O
.	O

Indeed	O
,	O
an	O
earlier	O
study	O
has	O
shown	O
that	O
Ngn2-overexpressing	O
progenitors	O
generate	O
oligodendrocytes	O
when	O
grafted	O
to	O
the	O
adult	O
spinal	O
cord	O
[	O
40	O
]	O
.	O

We	O
have	O
also	O
seen	O
that	O
Ngn2-overexpressing	O
neural	O
progenitors	O
from	O
the	O
embryonic	O
midbrain	O
form	O
astrocytes	O
when	O
grafted	O
to	O
the	O
striatum	O
(	O
unpublished	O
observations	O
)	O
.	O

Probably	O
,	O
Ngn2	O
can	O
not	O
influence	O
already	O
committed	O
cells	O
,	O
but	O
rather	O
would	O
control	O
neuroblasts	O
production	O
.	O

One	O
could	O
speculate	O
that	O
Ngn2	O
oscillates	O
during	O
granule	O
neuron	O
formation	O
,	O
as	O
recently	O
demonstrated	O
during	O
neocorticogenesis	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

NeuroD1	O
,	O
but	O
not	O
Ngn2	O
,	O
is	O
obligatory	O
for	O
granule	O
neuron	O
progenitor	O
differentiation	O
Hippocampal	O
granule	O
progenitors	O
can	O
mature	O
and	O
express	O
Tbr1	O
and	O
Prox1	O
,	O
both	O
during	O
the	O
development	O
and	O
postnatally	O
,	O
even	O
in	O
the	O
absence	O
of	O
Ngn2	O
.	O

Because	O
neuronal	O
differentiation	O
still	O
occurs	O
in	O
Ngn2	O
null	O
mice	B
,	O
it	O
is	O
clear	O
that	O
compensatory	O
,	O
Ngn2-independent	O
mechanisms	O
induce	O
NeuroD1	O
expression	O
.	O

One	O
candidate	O
is	O
Ngn1	O
,	O
which	O
is	O
expressed	O
during	O
neocorticogenesis	O
,	O
the	O
specification	O
of	O
olfactory	O
sensory	O
neurons	O
and	O
during	O
embryonic	O
rat	B
hippocampal	O
development	O
[	O
43	O
]	O
–	O
[	O
47	O
]	O
.	O

Both	O
Ngn1	O
and	O
Ngn2	O
regulate	O
NeuroD1	O
[	O
19	O
]	O
,	O
[	O
48	O
]	O
.	O

The	O
introduction	O
of	O
two	O
mutant	O
forms	O
of	O
Ngn1	O
,	O
a	O
deletion	O
of	O
the	O
basic	O
region	O
of	O
Ngn1	O
and	O
a	O
substitution	O
of	O
two	O
amino	O
acids	O
in	O
the	O
C	O
-	O
terminal	O
basic	O
region	O
,	O
prevents	O
NeuroD1	O
expression	O
and	O
neuronal	O
differentiation	O
[	O
48	O
]	O
.	O

The	O
double	O
null	O
Ngn1	O
/	O
Ngn2	O
mutant	O
displays	O
a	O
more	O
severe	O
phenotype	O
than	O
single	O
gene	O
(	O
Ngn1	O
or	O
Ngn2	O
)	O
mutant	O
mice	B
.	O

For	O
example	O
,	O
the	O
total	O
brain	O
size	O
of	O
the	O
double	O
mutants	O
is	O
much	O
smaller	O
[	O
10	O
]	O
,	O
[	O
32	O
]	O
.	O

If	O
the	O
role	O
of	O
Ngn1	O
during	O
hippocampal	O
neurogenesis	O
is	O
to	O
activate	O
NeuroD1	O
and	O
that	O
of	O
Ngn2	O
is	O
to	O
control	O
granule	O
neuroblasts	O
production	O
/	O
amplification	O
,	O
the	O
DG	O
of	O
double	O
Ngn1	O
/	O
Ngn2	O
knockout	O
mice	B
should	O
resemble	O
that	O
of	O
NeuroD1	O
null	O
mutant	O
mice	B
.	O

We	O
demonstrated	O
that	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
progenitors	O
isolated	O
from	O
different	O
embryonic	O
brain	O
regions	O
and	O
cultured	O
in	O
vitro	O
,	O
we	O
found	O
that	O
overexpression	O
of	O
NeuroD1	O
induced	O
neuronal	O
differentiation	O
.	O

The	O
neurons	O
generated	O
expressed	O
PSA	O
-	O
NCAM	O
,	O
Dcx	O
and	O
MAP2	O
.	O

After	O
in	O
utero	O
retroviral	O
vector	O
-	O
mediated	O
gene	O
delivery	O
,	O
virtually	O
all	O
cells	O
transduced	O
with	O
NeuroD1	O
became	O
neurons	O
.	O

In	O
contrast	O
,	O
progenitors	O
transduced	O
with	O
Ngn2	O
or	O
control	O
retroviruses	O
adopted	O
a	O
neuron	O
-	O
like	O
morphology	O
in	O
only	O
70–85	O
%	O
of	O
cases	O
.	O

Under	O
in	O
vitro	O
cell	O
culture	O
conditions	O
,	O
when	O
we	O
overexpressed	O
Ngn2	O
in	O
progenitors	O
derived	O
from	O
the	O
LGE	O
we	O
observed	O
robust	O
expression	O
of	O
NeuroD1	O
and	O
neuronal	O
differentiation	O
.	O

These	O
in	O
vitro	O
results	O
differ	O
from	O
those	O
we	O
obtained	O
when	O
we	O
transduced	O
the	O
embryonic	O
brain	O
with	O
a	O
viral	O
vector	O
expressing	O
Ngn2	O
.	O

In	O
this	O
latter	O
case	O
,	O
Ngn2	O
did	O
not	O
induce	O
neurons	O
and	O
the	O
transduced	O
cells	O
did	O
not	O
express	O
NeuroD1	O
.	O

Therefore	O
,	O
Ngn2	O
appears	O
to	O
direct	O
non	O
-	O
neuronal	O
cell	O
type	O
specification	O
in	O
vivo	O
[	O
38	O
]	O
–	O
[	O
40	O
]	O
.	O

Taken	O
together	O
,	O
we	O
have	O
confirmed	O
that	O
NeuroD1	O
plays	O
a	O
key	O
role	O
in	O
neuronal	O
differentiation	O
in	O
the	O
hippocampus	O
,	O
both	O
during	O
development	O
and	O
in	O
the	O
adult	O
brain	O
.	O

Concluding	O
remark	O
We	O
present	O
a	O
detailed	O
classification	O
of	O
different	O
stages	O
in	O
hippocampal	O
neurogenesis	O
.	O

Our	O
detailed	O
molecular	O
mapping	O
of	O
hippocampal	O
neurogenesis	O
allows	O
for	O
a	O
more	O
accurate	O
analysis	O
of	O
how	O
new	O
factors	O
stimulate	O
neurogenesis	O
at	O
different	O
steps	O
in	O
the	O
development	O
of	O
granule	O
neurons	O
.	O

Thereby	O
we	O
hope	O
to	O
facilitate	O
the	O
development	O
of	O
new	O
agents	O
,	O
which	O
stimulate	O
endogenous	O
progenitors	O
in	O
the	O
treatment	O
of	O
diseases	O
.	O

Materials	O
and	O
Methods	O
Animal	O
tissue	O
preparation	O
The	O
creation	O
of	O
the	O
Ngn2	O
transgenic	O
mice	B
was	O
reported	O
elsewhere	O
(	O
ref	O
guillemot	O
)	O
.	O

Heterozygote	O
male	O
and	O
female	O
mice	B
were	O
crossed	O
to	O
obtain	O
WT	O
,	O
heterozygote	O
(	O
Ngn2+	O
/	O
GFP	O
)	O
and	O
null	O
mutant	O
(	O
Ngn2GFP	O
/	O
GFP	O
)	O
animals	O
.	O

Tails	O
of	O
the	O
Ngn2	O
offspring	O
were	O
used	O
to	O
obtain	O
DNA	O
for	O
determination	O
of	O
the	O
genotype	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
as	O
previously	O
reported	O
[	O
31	O
]	O
.	O

As	O
null	O
mutant	O
Ngn2GFP	O
/	O
GFP	O
do	O
not	O
survive	O
longer	O
than	O
2.5–3	O
weeks	O
after	O
birth	O
,	O
Ngn2GFP	O
/	O
GFP	O
and	O
their	O
littermates	O
were	O
sacrificed	O
at	O
the	O
postnatal	O
ages	O
of	O
two	O
days	O
(	O
P2	O
)	O
or	O
two	O
weeks	O
for	O
this	O
study	O
.	O

Neurogenesis	O
was	O
assessed	O
in	O
two	O
weeks	O
or	O
two	O
months	O
old	O
WT	O
mice	B
.	O

Sprague	O
Dawley	O
pregnant	O
rats	B
were	O
ordered	O
from	O
B&K	O
Universal	O
Ltd	O
,	O
Sollentuna	O
,	O
Sweden	O
(	O
hppt://www.bku.com	O
)	O
.	O

All	O
animals	O
were	O
housed	O
in	O
groups	O
with	O
ad	O
libitum	O
access	O
to	O
food	O
and	O
water	O
at	O
a	O
12-h	O
light	O
/	O
dark	O
cycle	O
.	O

All	O
experimental	O
procedures	O
conducted	O
in	O
this	O
study	O
had	O
been	O
approved	O
by	O
the	O
Ethical	O
Committee	O
at	O
Lund	O
University	O
.	O

For	O
immunohistochemical	O
analysis	O
,	O
mice	B
(	O
from	O
two	O
weeks	O
old	O
and	O
adult	O
stage	O
)	O
and	O
juvenile	O
rats	B
were	O
sacrificed	O
by	O
transcardial	O
perfusion	O
with	O
saline	O
for	O
5–10	O
minutes	O
,	O
followed	O
by	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
10	O
minutes	O
.	O

Brains	O
were	O
kept	O
in	O
PFA	O
overnight	O
at	O
4	O
°	O
C	O
and	O
subsequently	O
cryopreserved	O
in	O
a	O
20–30	O
%	O
sucrose	O
/	O
0.1	O
M	O
phosphate	O
buffer	O
solution	O
until	O
sectioning	O
on	O
a	O
microtome	O
apparatus	O
(	O
30	O
µm	O
thickness	O
sections	O
,	O
Microm	O
Zeiss	O
)	O
.	O

Seven	O
series	O
of	O
coronal	O
sections	O
were	O
cut	O
throughout	O
the	O
brain	O
.	O

Free	O
-	O
floating	O
sections	O
were	O
preserved	O
in	O
antifreeze	O
solution	O
until	O
immunohistochemistry	O
was	O
performed	O
.	O

Heads	O
of	O
postanatal	O
two	O
days	O
old	O
mice	B
were	O
decapitated	O
and	O
soaked	O
in	O
PFA	O
4	O
%	O
for	O
24	O
hours	O
,	O
at	O
4	O
°	O
C	O
and	O
transferred	O
into	O
sucrose	O
solution	O
until	O
sectioning	O
on	O
cryostat	O
apparatus	O
(	O
16	O
µm	O
thickness	O
;	O
Leica	O
CM3000	O
)	O
.	O

Sections	O
were	O
mounted	O
on	O
Superfrost	O
glass	O
slides	O
and	O
stored	O
at	O
−80	O
°	O
C	O
until	O
immunohistochemistry	O
was	O
performed	O
.	O

Cloning	O
,	O
subcloning	O
,	O
virus	O
production	O
and	O
titer	O
measurement	O
The	O
Moloney	O
leukemia	O
-	O
derived	O
retroviral	O
vectors	O
used	O
in	O
this	O
study	O
,	O
pCMMP	O
-	O
IRES2eGFP	O
-	O
WPRE	O
and	O
pCMMP	O
-	O
Ngn2-IRES2eGFP	O
-	O
WPRE	O
were	O
previously	O
described	O
[	O
40	O
]	O
,	O
[	O
49	O
]	O
.	O

To	O
generate	O
the	O
construct	O
pCMMP	O
-	O
NeuroD1-IRES2eGFP	O
-	O
WPRE	O
,	O
mouse	B
NeuroD1	O
cDNA	O
was	O
amplified	O
from	O
a	O
pCS2+mtNeuroD1	O
plasmid	O
(	O
kindly	O
provided	O
by	O
Professor	O
Jackie	O
Lee	O
,	O
Denver	O
university	O
,	O
Boulder	O
,	O
USA	O
)	O
by	O
PCR	O
to	O
introduce	O
the	O
restriction	O
sites	O
PmeI	O
in	O
5′	O
and	O
XhoI	O
in	O
3′.	O
Amplification	O
of	O
cDNA	O
was	O
performed	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
construction	O
was	O
verified	O
by	O
enzymatic	O
restriction	O
and	O
by	O
DNA	O
sequencing	O
using	O
BigDye	O
3.1	O
(	O
ABI	O
)	O
.	O

All	O
infectious	O
particles	O
were	O
produced	O
using	O
the	O
producer	O
cell	O
line	O
293VSV	O
-	O
G	O
and	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
titer	O
of	O
each	O
retrovirus	O
was	O
measured	O
by	O
flow	O
-	O
cytometry	O
based	O
on	O
eGFP	O
expression	O
,	O
four	O
days	O
following	O
infection	O
of	O
HT1080	O
cells	O
and	O
ranged	O
from	O
0.5	O
×	O
109−2.1	O
×	O
109	O
TU	O
/	O
ml	O
(	O
All	O
details	O
on	O
how	O
to	O
produce	O
infectious	O
particles	O
can	O
be	O
provided	O
upon	O
request	O
)	O
.	O

Neurosphere	O
generation	O
,	O
transduction	O
and	O
differentiation	O
Pregnant	O
female	O
Sprague	B
-	I
Dawley	I
rats	I
(	O
B	O
&	O
K	O
Universal	O
,	O
Sollentuna	O
,	O
Sweden	O
)	O
were	O
terminally	O
anesthetized	O
by	O
an	O
overdose	O
of	O
sodium	O
pentobarbital	O
(	O
i.p	O
.	O
,	O
60	O
ng	O
/	O
ml	O
)	O
.	O

Embryos	O
at	O
stage	O
embryonic	O
day	O
E14.5	O
(	O
Plug	O
day	O
as	O
day	O
0	O
)	O
were	O
collected	O
and	O
cortical	O
-	O
hippocampal	O
neurospheres	O
were	O
generated	O
following	O
dissection	O
of	O
the	O
dorso	O
-	O
posterior	O
part	O
of	O
the	O
cortical	O
tissue	O
,	O
and	O
generated	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

In	O
this	O
study	O
,	O
second	O
passage	O
(	O
P2	O
)	O
neurospheres	O
were	O
used	O
to	O
study	O
the	O
effect	O
of	O
the	O
overexpression	O
of	O
Ngn2	O
and	O
NeuroD1	O
on	O
neuronal	O
differentiation	O
.	O

Each	O
well	O
,	O
containing	O
an	O
equal	O
starting	O
population	O
of	O
200,000	O
cells	O
/	O
ml	O
,	O
corresponding	O
to	O
15–25	O
neurospheres	O
,	O
was	O
transduced	O
independently	O
with	O
each	O
retrovirus	O
at	O
a	O
multiplicity	O
of	O
infection	O
(	O
MOI	O
)	O
of	O
1	O
,	O
in	O
proliferation	O
medium	O
supplemented	O
by	O
protamine	O
-	O
sulfate	O
(	O
4	O
mg	O
/	O
ml	O
,	O
Sigma	O
)	O
.	O

To	O
induce	O
differentiation	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
normal	O
basic	O
differentiation	O
medium	O
two	O
days	O
post	O
-	O
transduction	O
and	O
subsequently	O
changed	O
every	O
other	O
day	O
until	O
fixation	O
.	O

Immunocytochemistry	O
,	O
immunohistochemistry	O
and	O
microscopy	O
The	O
antibodies	O
used	O
in	O
this	O
study	O
are	O
:	O
rabbit	B
anti	O
-	O
GFAP	O
(	O
1∶1000	O
;	O
DAKO	O
)	O
,	O
mouse	B
anti	O
-	O
Nestin	O
(	O
1∶100	O
;	O
BD	O
PharMingen	O
)	O
,	O
guinea	B
pig	I
anti	O
-	O
Glast	O
(	O
1∶500	O
;	O
Chemicon	O
)	O
,	O
rabbit	B
anti	O
-	O
Prox1	O
(	O
1∶1000	O
;	O
Covance	O
)	O
,	O
goat	B
anti	O
-	O
Ngn2	O
(	O
1∶20	O
;	O
Santa	O
Cruz	O
)	O
,	O
goat	B
anti	O
-	O
NeuroD1	O
(	O
1∶200	O
;	O
Santa	O
Cruz	O
)	O
,	O
rabbit	B
anti	O
-	O
Pax6	O
(	O
1∶150	O
;	O
Covance	O
)	O
,	O
rabbit	B
anti	O
-	O
Trb2	O
(	O
1∶500	O
;	O
Chemicon	O
)	O
,	O
rabbit	B
anti	O
-	O
Trb1	O
:	O
(	O
1∶1000	O
;	O
Chemicon	O
)	O
,	O
goat	B
anti	O
-	O
Dcx	O
:	O
(	O
1∶500	O
;	O
Santa	O
Cruz	O
)	O
,	O
mouse	B
anti	O
-	O
PSA	O
-	O
NCAM	O
:	O
(	O
1∶500	O
;	O
Chemicon	O
)	O
,	O
mouse	B
anti	O
-	O
NeuN	O
(	O
1∶300	O
;	O
Chemicon	O
)	O
,	O
rabbit	B
anti	O
-	O
Calretinin	O
(	O
1∶500	O
;	O
Swant	O
)	O
;	O
mouse	B
anti	O
-	O
Sox2	O
(	O
1∶100	O
;	O
R&D	O
systems	O
)	O
,	O
mouse	B
anti	O
-	O
Mash1	O
(	O
1∶100	O
;	O
BD	O
PharMingen	O
)	O
,	O
rabbit	B
anti	O
-	O
NeuroD2	O
(	O
1∶300	O
;	O
ABCAM	O
)	O
,	O
mouse	B
anti	O
-	O
MAP2	O
(	O
1∶500	O
;	O
Sigma	O
)	O
,	O
rabbit	B
anti	O
-	O
Ki67	O
(	O
1∶150	O
;	O
NovaCastra	O
)	O
and	O
rabbit	B
anti	O
-	O
phospho	O
-	O
Histone	O
H3	O
.	O

The	O
secondary	O
antibodies	O
(	O
1∶200	O
)	O
Cy2	O
,	O
FITC	O
,	O
Cy3	O
and	O
Cy5	O
were	O
from	O
Jackson	O
IR	O
laboratories	O
,	O
Alexa	O
-	O
fluor	O
488	O
,	O
568	O
,	O
595	O
and	O
647	O
from	O
Invitrogen	O
-	O
Molecular	O
Probes	O
.	O

DAPI	O
(	O
1∶1000	O
)	O
was	O
purchased	O
from	O
Sigma	O
.	O

For	O
immunocytochemistry	O
,	O
cultures	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
at	O
day	O
five	O
,	O
rinsed	O
with	O
PBS	O
three	O
times	O
prior	O
to	O
pre	O
-	O
incubation	O
with	O
a	O
blocking	O
solution	O
(	O
10	O
%	O
donkey	B
serum	O
,	O
0.25	O
%	O
TritonX100	O
in	O
PBS	O
)	O
for	O
1	O
hour	O
.	O

The	O
remainder	O
of	O
the	O
procedure	O
was	O
performed	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

Specimen	O
analyses	O
were	O
performed	O
using	O
a	O
Leica	O
confocal	O
microscope	O
(	O
Leica	O
software	O
,	O
equipped	O
with	O
a	O
GreNe	O
and	O
a	O
HeNe	O
laser	O
,	O
using	O
the	O
following	O
lines	O
of	O
excitation	O
:	O
488	O
nm	O
,	O
594	O
nm	O
and	O
647	O
nm	O
)	O
.	O

Samples	O
were	O
analyzed	O
using	O
20	O
×	O
,	O
40	O
×	O
and	O
63	O
×	O
objectives	O
,	O
sometimes	O
zoomed	O
.	O

Figures	O
were	O
composed	O
in	O
CANVAS	O
-	O
X	O
software	O
.	O

Bromo	O
-	O
deoxyuridine	O
(	O
BrdU	O
)	O
and	O
Cloro	O
-	O
deoxyuridine	O
(	O
CldU	O
)	O
pulse	O
labeling	O
and	O
immunohisto-	O
and	O
immunocyto	O
-	O
chemistry	O
To	O
assess	O
cell	O
proliferation	O
and	O
ongoing	O
neurogenesis	O
in	O
vivo	O
,	O
animals	O
were	O
injected	O
with	O
BrdU	O
(	O
100	O
mg	O
/	O
kg	O
,	O
Sigma	O
)	O
,	O
two	O
hours	O
prior	O
to	O
sacrifice	O
(	O
for	O
both	O
P2	O
and	O
two	O
weeks	O
old	O
Ngn2	O
mice	B
)	O
.	O

To	O
assess	O
neurogenesis	O
,	O
BrdU	O
(	O
100	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
48	O
hours	O
prior	O
to	O
sacrifice	O
(	O
for	O
P2	O
animals	O
,	O
BrdU	O
was	O
injected	O
in	O
pregnant	O
dams	O
half	O
day	O
prior	O
to	O
give	O
birth	O
)	O
.	O

Immunohistochemistry	O
was	O
carried	O
on	O
as	O
described	O
above	O
using	O
a	O
rat	B
anti	O
-	O
CldU	O
/	O
BrdU	O
primary	O
antibody	O
(	O
1∶200	O
,	O
monoclonal	O
,	O
Immunologicalsdirect	O
,	O
Oxfordshire	O
,	O
UK	O
)	O
,	O
with	O
an	O
additional	O
denaturation	O
in	O
1	O
M	O
HCl	O
for	O
30	O
minutes	O
prior	O
to	O
pre	O
-	O
incubation	O
with	O
serum	O
.	O

To	O
assess	O
the	O
neuronal	O
-	O
inducing	O
activity	O
of	O
Ngn2	O
and	O
NeuroD1	O
,	O
transduced	O
cultures	O
were	O
incubated	O
with	O
CldU	O
(	O
20	O
µM	O
,	O
Sigma	O
)	O
for	O
2	O
days	O
,	O
after	O
a	O
period	O
of	O
differentiation	O
of	O
five	O
days	O
.	O

For	O
immunocytochemistry	O
,	O
cultures	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
at	O
day	O
7	O
,	O
rinsed	O
with	O
PBS	O
three	O
times	O
,	O
treated	O
with	O
1	O
M	O
HCl	O
at	O
65	O
°	O
C	O
for	O
5–10	O
min	O
,	O
pre	O
-	O
incubated	O
and	O
then	O
incubated	O
with	O
a	O
rat	B
anti	O
-	O
CldU	O
/	O
BrdU	O
antibody	O
and	O
other	O
primary	O
antibodies	O
.	O

The	O
remainder	O
of	O
the	O
procedure	O
was	O
performed	O
according	O
to	O
the	O
protocol	O
for	O
immunohistochemistry	O
already	O
mentioned	O
.	O

In	O
utero	O
surgery	O
Timed	O
pregnant	O
female	O
Sprague	B
Dawley	I
rats	I
with	O
embryos	O
at	O
gestational	O
age	O
E15.5	O
were	O
anesthetized	O
with	O
halothane	O
.	O

The	O
mother	O
was	O
placed	O
in	O
the	O
lower	O
level	O
of	O
a	O
two	O
-	O
level	O
wooden	O
stage	O
.	O

The	O
abdomen	O
was	O
shaved	O
with	O
an	O
electric	O
razor	O
and	O
then	O
cleaned	O
with	O
70	O
%	O
alcohol	O
.	O

A	O
2–3	O
cm	O
midline	O
laparotomy	O
was	O
performed	O
.	O

Each	O
uterine	O
horn	O
was	O
carefully	O
taken	O
out	O
individually	O
and	O
the	O
number	O
of	O
embryos	O
recorded	O
.	O

One	O
horn	O
was	O
then	O
placed	O
back	O
inside	O
the	O
mother	O
,	O
whilst	O
the	O
other	O
horn	O
was	O
prepared	O
for	O
injection	O
.	O

The	O
embryos	O
were	O
kept	O
moist	O
with	O
constant	O
application	O
of	O
warm	O
saline	O
to	O
prevent	O
dehydration	O
.	O

Approximately	O
2	O
µl	O
of	O
viral	O
suspension	O
(	O
1	O
×	O
10∧9TU	O
/	O
ml	O
)	O
was	O
injected	O
into	O
the	O
lateral	O
ventricle	O
of	O
each	O
embryo	O
,	O
except	O
for	O
the	O
embryo	O
closest	O
to	O
the	O
vagina	O
.	O

After	O
the	O
injections	O
,	O
the	O
uterine	O
horns	O
were	O
placed	O
back	O
into	O
the	O
abdomen	O
.	O

The	O
abdominal	O
wall	O
and	O
the	O
overlying	O
skin	O
were	O
then	O
sutured	O
.	O

Care	O
was	O
taken	O
not	O
to	O
damage	O
abdominal	O
muscles	O
so	O
that	O
normal	O
delivery	O
of	O
the	O
pups	O
was	O
possible	O
at	O
term	O
.	O

The	O
entire	O
surgery	O
generally	O
took	O
about	O
45	O
minutes	O
to	O
one	O
hour	O
.	O

Each	O
mother	O
was	O
allowed	O
to	O
recover	O
in	O
her	O
cage	O
before	O
being	O
returned	O
to	O
the	O
animal	O
stable	O
.	O

Shredded	O
paper	O
was	O
added	O
to	O
each	O
cage	O
to	O
encourage	O
nesting	O
and	O
special	O
care	O
was	O
taken	O
not	O
to	O
stress	O
the	O
mothers	O
.	O

Following	O
normal	O
delivery	O
,	O
the	O
pups	O
were	O
allowed	O
to	O
develop	O
to	O
adulthood	O
up	O
to	O
two	O
weeks	O
.	O

Quantification	O
For	O
the	O
in	O
vivo	O
experiment	O
,	O
manual	O
cell	O
counting	O
was	O
performed	O
on	O
18	O
and	O
30	O
µm	O
thick	O
brain	O
sections	O
for	O
two	O
days	O
and	O
two	O
weeks	O
old	O
animals	O
,	O
respectively	O
.	O

The	O
brain	O
of	O
P2	O
animals	O
was	O
cut	O
into	O
10	O
series	O
of	O
coronal	O
sections	O
;	O
the	O
brain	O
of	O
two	O
-	O
weeks	O
old	O
animals	O
was	O
cut	O
into	O
7–8	O
series	O
of	O
coronal	O
sections	O
.	O

For	O
each	O
staining	O
,	O
one	O
-	O
two	O
series	O
from	O
three	O
to	O
five	O
different	O
individuals	O
were	O
analyzed	O
per	O
genotype	O
using	O
a	O
confocal	O
microscope	O
with	O
1	O
,	O
2	O
or	O
3	O
lines	O
of	O
excitation	O
,	O
in	O
sequential	O
scanning	O
in	O
order	O
to	O
avoid	O
false	O
positives	O
.	O

When	O
two	O
series	O
were	O
analyzed	O
,	O
only	O
one	O
series	O
was	O
counted	O
.	O

The	O
mean	O
number	O
of	O
cells	O
per	O
hippocampus	O
expressing	O
the	O
markers	O
of	O
interest	O
,	O
was	O
calculated	O
for	O
each	O
brain	O
,	O
based	O
on	O
the	O
analysis	O
of	O
6–8	O
consecutive	O
dorsal	O
hippocampal	O
sections	O
.	O

The	O
final	O
mean	O
number	O
of	O
cells	O
per	O
section	O
was	O
calculated	O
by	O
adding	O
the	O
mean	O
number	O
from	O
each	O
individual	O
.	O

We	O
expressed	O
the	O
data	O
as	O
the	O
mean	O
number	O
of	O
positive	O
cells±standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

In	O
this	O
study	O
,	O
more	O
than	O
25	O
Ngn2	O
null	O
,	O
>	O
45	O
Ngn2	O
heterozygotes	O
,	O
and	O
>	O
60	O
WT	O
individuals	O
(	O
including	O
rats	B
injected	O
with	O
retroviruses	O
)	O
were	O
analyzed	O
,	O
in	O
total	O
.	O

Statistical	O
comparison	O
was	O
performed	O
using	O
one	O
-	O
factor	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
with	O
transcription	O
factor	O
,	O
cellular	O
marker	O
,	O
genotype	O
or	O
time	O
as	O
variables	O
,	O
followed	O
by	O
post	O
-	O
hoc	O
analysis	O
when	O
significant	O
differences	O
were	O
observed	O
,	O
using	O
Statview	O
5.0	O
software	O
(	O
SAS	O
institute	O
Inc.	O
)	O
.	O

For	O
cell	O
culture	O
experiments	O
,	O
three	O
independent	O
experiments	O
were	O
performed	O
,	O
each	O
in	O
duplicate	O
.	O

The	O
counting	O
was	O
based	O
on	O
seven	O
randomly	O
chosen	O
different	O
fields	O
of	O
view	O
.	O

For	O
each	O
diagram	O
,	O
the	O
level	O
of	O
significance	O
(	O
p	O
-	O
value	O
)	O
is	O
represented	O
as	O
follows	O
:	O
P<0.05	O
=	O
*	O
;	O
P<0.001	O
=	O
*	O
*	O
;	O
P<0.0001	O
=	O
*	O
*	O
*	O
.	O

All	O
data	O
are	O
expressed	O
as±standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

Human	B
sample	O
and	O
RT	O
-	O
PCR	O
The	O
brain	O
from	O
a	O
64	O
year	O
-	O
old	O
male	O
was	O
provided	O
by	O
the	O
Harvard	O
Brain	O
Tissue	O
Resource	O
Center	O
.	O

The	O
individual	O
whose	O
brain	O
tissue	O
was	O
being	O
analyzed	O
gave	O
written	O
consent	O
for	O
storage	O
and	O
use	O
of	O
his	O
tissue	O
for	O
research	O
.	O

Five	O
millimeters	O
thick	O
fresh	O
human	B
hippocampal	O
tissue	O
sample	O
was	O
snap	O
frozen	O
.	O

The	O
frozen	O
tissue	O
block	O
was	O
cut	O
into	O
20	O
series	O
of	O
coronal	O
sections	O
,	O
using	O
a	O
cryostat	O
.	O

Every	O
10	O
sections	O
,	O
one	O
section	O
was	O
placed	O
in	O
an	O
Eppendorf	O
tube	O
,	O
on	O
dry	O
ice	O
.	O

Pooled	O
sections	O
were	O
used	O
for	O
RT	O
-	O
PCR	O
.	O

Total	O
RNA	O
was	O
prepared	O
using	O
Trizol	O
and	O
RNAeasy	O
,	O
supplemented	O
with	O
RNAGuard	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
RNA	O
was	O
digested	O
with	O
shrimp	O
DNAse	O
before	O
cDNA	O
synthesis	O
,	O
which	O
was	O
performed	O
using	O
a	O
mix	O
of	O
oligo	O
-	O
dT	O
and	O
random	O
hexamer	O
primers	O
and	O
SuperscriptII	O
reverse	O
transcriptase	O
.	O

Advantage2	O
polymerase	O
mix	O
(	O
Clontech	O
/	O
BRL	O
)	O
was	O
used	O
for	O
PCR	O
,	O
with	O
the	O
following	O
cycling	O
conditions	O
:	O
10	O
cycles	O
of	O
94	O
°	O
C	O
for	O
30	O
seconds	O
,	O
68	O
°	O
C	O
for	O
2	O
minutes	O
,	O
30	O
cycles	O
of	O
94	O
°	O
C	O
for	O
30	O
seconds	O
,	O
60	O
°	O
C	O
for	O
1	O
minute	O
,	O
68	O
°	O
C	O
for	O
1	O
minute	O
and	O
30	O
seconds	O
,	O
one	O
cycle	O
of	O
68	O
°	O
C	O
for	O
2	O
minutes	O
,	O
soak	O
at	O
16	O
°	O
C	O
.	O

Primers	O
marked	O
*	O
were	O
designed	O
by	O
PrimerBank	O
.	O

hRPS18	O
(	O
sense	O
)	O
5′-GCCTTTGCCATCACTGCCATT	O
and	O
hRPS18	O
(	O
antisense	O
)	O
5′-GCCAGTGGTCTTGGTGTGCT	O
,	O
hPAX6	O
(	O
sense	O
)	O
5′-GCCCTGGAGAAAGAGTTTGAGAGAACCCATT	O
hPAX6	O
(	O
antisense	O
)	O
5′-GGGGAAATGAGTCCTGTTGAAGTGGTGC	O
,	O
hTBR1	O
(	O
sense	O
)	O
5′-GCGGACACCAATGTGCAAGGAAATCG	O
and	O
hTBR1	O
(	O
antisense	O
)	O
5′-CGAGGGGGTCAGGCGGTCCATGTCACAGC	O
,	O
hTBR2	O
(	O
sense	O
)	O
5′-GACCTGTGGCAAAGCCGACAATAACATGC	O
and	O
hTBR2	O
(	O
antisense	O
)	O
5′-GGGGGTGTCTCTATCCAAGAAGAGCCAAT	O
,	O
hPDHX	O
(	O
=	O
PROX1	O
)	O
(	O
sense	O
)	O
5′-GGGACACTACGGTTCCGTTTAAGTCCAGC	O
and	O
hPDHX	O
(	O
antisense	O
)	O
5′-CTCTCCATCCCAGCTTACATTAACATCTGGCATTTGT	O
,	O
hNGN2	O
(	O
sense	O
)	O
*	O
5′-CATCAAGAAGACCCGTAGACTGA	O
and	O
hNGN2	O
(	O
antisense	O
)	O
*	O
5′-CAACACTGCCTCGGAGAAG	O
,	O
hMASH1	O
(	O
sense	O
)	O
5′-CCTGGATCCGCATGGAAAGCTCTGCCAAGATGGAG	O
and	O
hMASH1	O
(	O
antisense	O
)	O
5′-CCTGGATCCCCCCTCAGAACCAGTTGGTGAAGTCGA	O
,	O
hNEUROD1	O
(	O
sense	O
)	O
5′-GCTCAGGACCTACTAACAACAAAGGAAATCGAAACATG	O
and	O
hNEUROD1	O
(	O
antisense	O
)	O
5′-CAAAGCGTCTGAACGAAGGAGACCAGGT	O
,	O
hGLAST	O
(	O
sense	O
)	O
5′-CATCAGGGAAGATGGGAATGCGAGCTGTAGTCTATTAT	O
and	O
hGLAST	O
(	O
antisense	O
)	O
5′-CCACGGGGGCATACCACATTATTACTGCTACC	O
,	O
hNEST	O
(	O
sense	O
)	O
5′-CAGGAGCGGCTGCGGGCTACTGAAAAGTTCC	O
and	O
hNEST	O
(	O
antisense	O
)	O
5′-CAGGGCTGAGGGGTGGTGCCAAGGAGG	O
,	O
hGFAP	O
(	O
sense	O
)	O
5′-CCACGAGGAGGAGGTTCGGGAACTCCAGGAGC	O
and	O
hGFAP	O
(	O
antisense	O
)	O
5-GGAATGGTGATCCGGTTCTCCTCGCCCTCTAGC	O
,	O
hCALB2	O
(	O
=	O
Calretinin	O
)	O
(	O
sense	O
)	O
5′-GGCTCTGGCATGATGTCAAAGAGTGACAACTTT	O
and	O
hCALB2	O
(	O
antisense	O
)	O
5′-GGGCATCCAGCTCATGCTCGTCAATGTAGCC	O
,	O
hCALB1	O
(	O
sense	O
)	O
5′-GCGAAAGAAGGCTGGATTGGAGTTATCACC	O
and	O
hCALB1	O
(	O
antisense	O
)	O
5′-CCCTCCATCCGACAAAGCCATTATGTTCTTCTTGTATG	O
,	O
hSOX2	O
(	O
sense	O
)	O
5′-GGAGAACCCCAAGATGCACAACTCGGAGAT	O
and	O
hSOX2	O
(	O
antisense	O
)	O
5′-GAGGAAGAGGTAACCACAGGGGGGCTGGAGC	O
,	O
hWNT3A	O
(	O
sense	O
)	O
5′-CCGAGGGCATCAAGATTGGCATCCAGGAGTGC	O
and	O
hWNT3A	O
(	O
antisense	O
)	O
5′-TCGGGTTGCGACCACCAGCATGTCTTCACCTC	O
,	O
hSHH	O
*	O
(	O
sense	O
)	O
5′-ACTCCGAGCGATTTAAGGAACT	O
and	O
hSHH	O
*	O
(	O
antisense	O
)	O
5′-CAGACGTGGTGATGTCCACTG	O
.	O

Supporting	O
Information	O

Organization	O
and	O
structure	O
of	O
the	O
mouse	B
interleukin-2	O
gene	O
.	O

Abstract	O
We	O
have	O
cloned	O
a	O
chromosomal	O
DNA	O
segment	O
which	O
covers	O
the	O
entire	O
sequence	O
for	O
the	O
murine	O
interleukin-2	O
gene	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
gene	O
.	O

The	O
coding	O
regions	O
are	O
separated	O
into	O
four	O
blocks	O
by	O
three	O
introns	O
each	O
of	O
which	O
is	O
located	O
similarly	O
to	O
the	O
corresponding	O
human	B
gene	O
.	O

The	O
exon	O
sequences	O
can	O
be	O
aligned	O
perfectly	O
with	O
the	O
previously	O
cloned	O
cDNA	O
sequence	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
sequences	O
within	O
the	O
5'-flanking	O
region	O
which	O
are	O
highly	O
conserved	O
between	O
mouse	B
and	O
man	B
.	O

The	O
conserved	O
region	O
which	O
spans	O
more	O
than	O
400	O
base	O
pairs	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
.	O

Images	O
Volume	O
12	O
Number	O
24	O
1984	O
Nucleic	O
Acids	O
Research	O
Organization	O
and	O
structure	O
of	O
the	O
mouse	B
interleukin-2	O
gene	O
Akira	O
Fuse	O

*	O
,	O
Takashi	O
Fujita	O
,	O
Hidetaro	O
Yasumitsu	O
,	O
Nobukazu	O
Kashima+	O
,	O
Katsushige	O
Hasegawa	O
and	O
Tadatsugu	O
Taniguchi	O
?	O

Department	O
of	O
Biochemistry	O
,	O
Cancer	O
Institute	O
,	O
Japanese	O
Foundation	O
for	O
Cancer	O
Research	O
,	O
Toshimaku	O
,	O
Tokyo	O
170	O
and	O
Institute	O
for	O
Molecular	O
and	O
Cellular	O
Biology	O
,	O
Osaka	O
University	O
,	O
Suita	O
-	O
shi	O
,	O

Osaka	O
565	O
,	O
Japan	O
Received	O
10	O
October	O
1984	O
;	O
Revised	O
and	O
Accepted	O
20	O
November	O
1984	O
ABSTRACT	O
We	O
have	O
cloned	O
a	O
chromosomal	O
DNA	O
segment	O
which	O
covers	O
the	O
entire	O
sequence	O
for	O
the	O
murine	O
interleukin-2	O
gene	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
gene	O
.	O

The	O
coding	O
regions	O
are	O
separated	O
into	O
four	O
blocks	O
by	O
three	O
introns	O
each	O
of	O
which	O
is	O
located	O
similarly	O
to	O
the	O
corresponding	O
human	B
gene	O
.	O

The	O
exon	O
sequences	O
can	O
be	O
aligned	O
perfectly	O
with	O
the	O
previously	O
cloned	O
cDNA	O
sequence	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
sequences	O
within	O
the	O
5'flanking	O
region	O
which	O
are	O
highly	O
conserved	O
between	O
mouse	B
and	O
man	B
.	O

The	O
conserved	O
region	O
which	O
spans	O
more	O
than	O
400	O
base	O
pairs	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
.	O

INTRODUCTION	O
Interleukin-2	O
(	O
IL-2	O
)	O
is	O
a	O
lymphokine	O
produced	O
by	O
T	O
cells	O
upon	O
antigenic	O
or	O
mitogenic	O
stimulation	O
and	O
is	O
required	O
for	O
the	O
proliferation	O
of	O
T	O
cells	O
(	O
1,2	O
)	O
.	O

Several	O
other	O
biological	O
activities	O
of	O
IL-2	O
which	O
appear	O
to	O
be	O
crucial	O
in	O
the	O
immune	O
regulation	O
have	O
also	O
been	O
reported	O
(	O
3	O
,	O
4	O
.	O
5	O
.	O
6	O
.	O
7	O
.	O
)	O
.	O

We	O
previously	O
reported	O
isolation	O
and	O
sequence	O
analysis	O
of	O
the	O
cDNA	O
for	O
human	B
IL-2	O
(	O
8)	O
,	O
as	O
well	O
as	O
the	O
chromosomal	O
gene	O
(	O
9	O
)	O
.	O

More	O
recently	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
which	O
encodes	O
murine	O
IL-2	O
(	O
Kashima	O
et	O
al.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

The	O
cDNA	O
contains	O
a	O
unique	O
tandem	O
repeat	O
of	O
CAG	O
sequence	O
which	O
would	O
encode	O
12	O
consecutive	O
glutamine	O
residues	O
in	O
the	O
active	O
IL-2	O
molecule	O
.	O

In	O
order	O
to	O
study	O
the	O
structure	O
of	O
the	O
murine	O
IL-2	O
chromosomal	O
gene	O
and	O
its	O
controlling	O
region	O
,	O
we	O
isolated	O
and	O
analysed	O
a	O
A	O
phage	O
clone	O
containing	O
the	O
gene	O
and	O
its	O
flanking	O
sequences	O
.	O

MATERIALS	O
AND	O
METHODS	O
Southern	O
blotting	O
of	O
total	O
mouse	B
DNA	O
Mouse	B
chromosomal	O
DNA	O
was	O
extracted	O
from	O
liver	O
of	O
BALB	O
/	O
c6	O
?	O

I	O
R	O
L	O
Press	O
Limited	O
,	O
Oxford	O
,	O
England	O
.	O

Nucleic	O
Acids	O
Research	O
Volume	O
12	O
Number	O
24	O
1984	O
9323	O
Nucleic	O
Acids	O
Research	O
mouse	B
as	O
described	O
before	O
(	O
10	O
)	O
.	O

High	O
molecular	O
genomic	O
DNA	O
was	O
digested	O
with	O
various	O
restriction	O
enzymes	O
and	O
electrophoresed	O
on	O
0.8	O
%	O
agarose	O
gel	O
.	O

Blotting	O
analysis	O
of	O
DNA	O
was	O
carried	O
out	O
by	O
the	O
method	O
of	O
Southern	O
(	O
11	O
)	O
.	O

Hybridization	O
was	O
carried	O
out	O
as	O
described	O
previously	O
and	O
filters	O
were	O
washed	O
either	O
in	O
3	O
x	O
SSC	O
at	O
650C	O
(	O
lower	O
stringent	O
condition	O
)	O
or	O
in	O
0.1	O
x	O
SSC	O
at	O
650C	O
(	O
higher	O
stringent	O
condition	O
)	O
.	O

Screening	O
of	O
genomic	O
DNA	O
library	O
A	O
bacteriophage	O
XCharon	O
4A	O
/	O
mouse	B
genomic	O
DNA	O
library	O
prepared	O
with	O
partial	O
EcoRI	O
digests	O
of	O
mouse	B
DNA	O
from	O
MPC	O
11	O
plasmacytoma	O
cells	O
was	O
kindly	O
provided	O
by	O
Dr.	O
T.	O
Honjo	O
.	O

Mouse	B
IL-2-specific	O
clones	O
were	O
screened	O
by	O
the	O
method	O
of	O
Benton	O
and	O
Davis	O
(	O
12	O
)	O
,	O
using	O
700	O
bp	O
PstI	O
-	O
AccI	O
fragment	O
of	O
a	O
cDNA	O
clone	O
,	O
pMIL2	O
-	O
45	O
as	O
the	O
probe	O
(	O
Kashima	O
et	O
al.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

Hybridization	O
was	O
performed	O
as	O
described	O
previously	O
(	O
13	O
)	O
.	O

Positive	O
clones	O
were	O
rescreened	O
at	O
least	O
twice	O
.	O

Subcloninq	O
and	O
sequencing	O
of	O
the	O
mouse	B
IL-2	O
gene	O
Two	O
EcoRI	O
fragments	O
of	O
3.3	O
Kbp	O
and	O
2.8	O
Kbp	O
from	O
the	O
positive	O
recombinant	O
X	O
phage	O
were	O
subcloned	O
into	O
EcoRI	O
site	O
of	O
plasmid	O
pBR322	O
.	O

DNA	O
segments	O
derived	O
from	O
subcloned	O
3.3	O
Kbp	O
and	O
2.8	O
Kbp	O
fragments	O
were	O
labelled	O
at	O
either	O
3	O
'	O
end	O
or	O
5	O
'	O
end	O
,	O
and	O
subjected	O
to	O
sequence	O
analysis	O
by	O
the	O
chemical	O
degradation	O
method	O
(	O
14	O
)	O
.	O

The	O
0.8	O
Kbp	O
EcoRI	O
fragment	O
from	O
the	O
same	O
X	O
phage	O
clone	O
was	O
directly	O
subjected	O
to	O
sequence	O
analysis	O
by	O
the	O
dideoxy	O
chain	O
termination	O
method	O
(	O
15	O
)	O
.	O

RESULTS	O
Total	O
DNA	O
blotting	O
analysis	O
In	O
order	O
to	O
study	O
structural	O
organization	O
of	O
the	O
mouse	B
IL-2	O
gene	O
,	O
we	O
first	O
subjected	O
total	O
mouse	B
DNA	O
to	O
the	O
blotting	O
analysis	O
by	O
using	O
various	O
probes	O
specific	O
for	O
IL-2	O
gene	O
.	O

When	O
mouse	B
DNA	O
was	O
digested	O
with	O
various	O
restriction	O
endonucleases	O
and	O
then	O
probed	O
with	O
a	O
7	O
kb	O
human	B
chromosomal	O
DNA	O
segment	O
which	O
contains	O
the	O
human	B
IL-2	O
gene	O
and	O
its	O
flanking	O
region	O
(	O
Fig.	O
1	O
lane	O
1	O
-	O
8	O
,	O
ref	O
.	O

9	O
.	O
)	O
,	O
single	O
positive	O
band	O
appeared	O
at	O
lower	O
but	O
not	O
at	O
higher	O
stringent	O
condition	O
for	O
washing	O
the	O
filters	O
(	O
see	O
Figure	O
legend	O
)	O
.	O

Additional	O
bands	O
corresponding	O
to	O
those	O
observed	O
by	O
using	O
mouse	B
IL-2	O
cDNA	O
probes	O
(	O
lane	O
13	O
-	O
17	O
)	O
also	O
appeared	O
by	O
longer	O
9324	O
Nucleic	O
Acids	O
Research	O
M	O
1	O
2	O
3	O
4	O
M	O
5	O
6	O
7	O
8	O
M	O
9	O
101112	O
M	O
13	O
141516	O
17	O
a~	O
~	O
3	O
..	O

I	O
pMIL2	O
-	O
45	O
SacI	O
Acc	O
I	O
CZI~~1	O
1	O
t	O
L2-	O
20	O
Acc	O
I	O
1	O
00	O
tp	O
lX	O
i	O
Fig.	O
1	O
.	O

Blot	O
hybridization	O
analysis	O
of	O
mouse	B
chromosomal	O
DNA	O
.	O

High	O
molecular	O
DNA	O
prepared	O
from	O
Liver	O
BALB	O
/	O
C6	O
mouse	B
was	O
digested	O
with	O
various	O
restriction	O
endonucleases	O
(	O
BamHI	O
for	O
lanes	O
1	O
,	O
5	O
,	O
9	O
,	O
13	O
;	O
EcoRI	O
for	O
lanes	O
2	O
,	O
6	O
,	O
10	O
,	O
14	O
,	O
17	O
;	O
HindIII	O
for	O
lanes	O
3	O
,	O
7	O
,	O
11	O
,	O
15	O
;	O
XbaI	O
for	O
lanes	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
)	O
.	O

The	O
resulting	O
digests	O
were	O
fractionated	O
on	O
0.8	O
%	O
agarose	O
gel	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
filter	O
.	O

Filters	O
were	O
hybridized	O
by	O
the	O
published	O
procedure	O
(	O
13	O
)	O
either	O
with	O
the	O
nick	O
-	O
translated	O
chromosomal	O
DNA	O
containing	O
human	B
IL-2	O
gene	O
and	O
its	O
flanking	O
region	O
(	O
total	O
length	O
,	O
7.0	O
kb	O
,	O
ref	O
.	O

9	O
)	O
(	O
lane	O
1	O
-	O
8	O
)	O
or	O
with	O
the	O
nick	O
-	O
translated	O
cDNA	O
for	O
mouse	B
IL-2	O
(	O
see	O
figure	O
)	O
.	O

Filters	O
were	O
then	O
washed	O
either	O
in	O
3	O
x	O
SSC	O
at	O
65	O
%	O
(	O
lower	O
stringent	O
condition	O
)	O
(	O
lane	O
1	O
-	O
4	O
,	O
9	O
-	O
12	O
)	O
or	O
0.1	O
x	O
SSC	O
at	O
65	O
OC	O
(	O
higher	O
stringent	O
condition	O
)	O
(	O
lane	O
5	O
-	O
8	O
,	O
13	O
-	O
17	O
)	O
.	O

Lane	O
M	O
each	O
contains	O
7	O
size	O
markers	O
with	O
their	O
size	O
being	O
23.7	O
kb	O
,	O
9.5	O
kb	O
,	O
6.7	O
kb	O
,	O
4.3	O
kb	O
,	O
2.3	O
kb	O
,	O
2.0	O
kb	O
and	O
0.6	O
kb	O
,	O
respectively	O
.	O

Brief	O
restriction	O
endonuclease	O
cleavage	O
map	O
for	O
the	O
mouse	B
IL-2	O
cDNAs	O
is	O
presented	O
in	O
the	O
lower	O
part	O
of	O
the	O
figure	O
.	O

exposure	O
of	O
the	O
film	O
(	O
data	O
not	O
shown	O
)	O
.	O

Those	O
results	O
suggest	O
the	O
presence	O
of	O
highly	O
conserved	O
sequences	O
between	O
human	B
and	O
mouse	B
DNA	O
either	O
in	O
the	O
flanking	O
regions	O
or	O
in	O
the	O
introns	O
of	O
the	O
IL-2	O
gene	O
,	O
since	O
the	O
coding	O
regions	O
apparently	O
show	O
lower	O
degree	O
of	O
sequence	O
homology	O
as	O
evidenced	O
in	O
this	O
series	O
of	O
blotting	O
analysis	O
(	O
see	O
below	O
)	O
.	O

When	O
the	O
PstI	O
insert	O
of	O
a	O
mouse	B
IL-2	O
cDNA	O
clone	O
,	O
pMIL2	O
-	O
20	O
,	O
was	O
used	O
as	O
the	O
probe	O
,	O
a	O
simple	O
pattern	O
was	O
9325	O
Nucleic	O
Acids	O
Research	O
obtained	O
at	O
higher	O
stringent	O
condition	O
(	O
lane	O
13	O
-	O
17	O
)	O
.	O

While	O
the	O
EcoRI	O
-	O
digested	O
DNA	O
gave	O
rise	O
to	O
two	O
positive	O
bands	O
(	O
2.8	O
kb	O
and	O
0.8	O
kb	O
)	O
(	O
Fig	O
.	O

1	O
,	O
lane	O
14	O
)	O
by	O
this	O
analysis	O
,	O
one	O
additional	O
band	O
of	O
3.3	O
kb	O
also	O
appeared	O
when	O
the	O
same	O
DNA	O
was	O
probed	O
with	O
a	O
longer	O
cDNA	O
insert	O
from	O
another	O
clone	O
,	O
pMIL2	O
-	O
45	O
(	O
Fig.	O
1	O
,	O
lane	O
17	O
)	O
.	O

The	O
3.3	O
kb	O
band	O
was	O
similar	O
in	O
its	O
size	O
with	O
the	O
positive	O
band	O
which	O
became	O
detectable	O
by	O
probing	O
the	O
same	O
DNA	O
with	O
the	O
7.0	O
kb	O
human	B
DNA	O
probe	O
(	O
Fig.	O
1	O
,	O
lane	O
2	O
)	O
.	O

Since	O
this	O
band	O
appeared	O
with	O
the	O
cDNA	O
probe	O
extending	O
further	O
upstream	O
,	O
it	O
is	O
likely	O
that	O
the	O
5	O
'	O
region	O
of	O
the	O
gene	O
is	O
located	O
within	O
this	O
DNA	O
segment	O
(	O
see	O
below	O
)	O
.	O

Indeed	O
,	O
this	O
3.3	O
kb	O
band	O
did	O
not	O
appear	O
even	O
after	O
longer	O
exposure	O
of	O
lane	O
14	O
(	O
result	O
not	O
shown	O
)	O
.	O

BamHI	O
digest	O
of	O
the	O
mouse	B
DNA	O
(	O
Fig.	O
1	O
,	O
lane	O
1	O
,	O
13	O
)	O
constantly	O
gave	O
a	O
very	O
faint	O
signal	O
which	O
would	O
correspond	O
to	O
a	O
DNA	O
larger	O
than	O
15	O
kb	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggested	O
the	O
presence	O
of	O
a	O
single	O
copy	O
gene	O
for	O
murine	O
IL-2	O
.	O

On	O
the	O
other	O
hand	O
appearance	O
of	O
the	O
multiple	O
positive	O
bands	O
at	O
lower	O
stringent	O
washing	O
condition	O
(	O
lane	O
9	O
-	O
12	O
)	O
indicates	O
the	O
presence	O
of	O
IL-2	O
related	O
sequences	O
within	O
the	O
mouse	B
genome	O
.	O

Screening	O
of	O
recombinant	O
phaqe	O
libraries	O
We	O
next	O
screened	O
a	O
gene	O
library	O
from	O
partial	O
EcoRIdigested	O
DNA	O
from	O
MPC	O
11	O
cells	O
and	O
by	O
using	O
0.8	O
Kbp	O
SacI	O
-	O
AccI	O
cDNA	O
fragment	O
as	O
the	O
probe	O
and	O
isolated	O
14	O
positive	O
clones	O
containing	O
sequences	O
specific	O
to	O
the	O
mouse	B
IL-2	O
gene	O
.	O

Three	O
of	O
the	O
clones	O
analysed	O
all	O
contained	O
three	O
EcoRI	O
fragments	O
whose	O
size	O
is	O
in	O
agreement	O
with	O
the	O
result	O
of	O
blotting	O
analysis	O
of	O
the	O
chromosomal	O
DNA	O
as	O
shown	O
in	O
Fig.	O
1	O
(	O
lane	O
17	O
)	O
.	O

One	O
of	O
these	O
is	O
designated	O
MIL-2G70	O
.	O

Nucleotide	O
sequence	O
analysis	O
Two	O
DNA	O
fragments	O
of	O
3.3	O
Kbp	O
and	O
2.8	O
Kbp	O
were	O
excised	O
from	O
the	O
phage	O
clone	O
MIL-2G70	O
by	O
EcoRI	O
digestion	O
and	O
they	O
were	O
subcloned	O
into	O
pBR322	O
.	O

DNA	O
sequences	O
were	O
determined	O
for	O
selected	O
regions	O
of	O
both	O
inserts	O
and	O
compared	O
to	O
the	O
known	O
cDNA	O
sequences	O
(	O
Kashima	O
et	O
al.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

The	O
strategy	O
used	O
for	O
sequence	O
analysis	O
of	O
the	O
genomic	O
DNA	O
is	O
presented	O
in	O
Fig.	O
2	O
.	O

Comparison	O
of	O
the	O
mouse	B
genomic	O
IL-2	O
sequence	O
with	O
mouse	B
IL-2	O
cDNA	O
sequence	O
revealed	O
that	O
,	O
like	O
the	O
human	B
gene	O
,	O
the	O
gene	O
is	O
divided	O
into	O
four	O
exons	O
.	O

A	O
putative	O
9326	O
Nucleic	O
Acids	O
Research	O
E	O
E	O
E	O
E	O
E	O
500bp	O
s	O
7S	O
P	O
HBH	O
H	O
\A	O
200	O
bp	O

*	O
,	O
-	O
4	O
I	O
4	O
-	O
4	O
-	O
---	O

*	O
*	O
-	O
--4	O
Fig.	O
2	O
.	O

Restriction	O
map	O
and	O
sequencing	O
strategy	O
of	O
mouse	B
IL-2	O
gene	O
.	O

Horizontal	O
lines	O
indicate	O
the	O
length	O
of	O
mouse	B
DNA	O
inserted	O
into	O
the	O
X	O
phage	O
Charon	O
4A	O
or	O
plasmid	O
subclones	O
.	O

Filled	O
blocks	O
,	O
dashed	O
blocks	O
and	O
open	O
blocks	O
indicate	O
protein	O
coding	O
regions	O
,	O
untranslated	O
regions	O
and	O
introns	O
,	O
respectively	O
.	O

Horizontal	O
arrows	O
indicate	O
the	O
direction	O
and	O
extent	O
of	O
sequence	O
determination	O
without	O
ambiguity	O
.	O

Dashed	O
arrows	O
:	O
determination	O
was	O
done	O
by	O
the	O
chain	O
termination	O
method	O
(	O
15	O
)	O
after	O
subcloning	O
the	O
0.8	O
kb	O
fragment	O
into	O
M13	O
.	O

Rest	O
of	O
the	O
sequence	O
determination	O
was	O
carried	O
out	O
by	O
the	O
method	O
of	O
Maxam	O
and	O
Gilbert	O
(	O
14	O
)	O
.	O

A	O
AccI	O
site	O
,	O
B	O
;	O
BamHI	O
site	O
,	O
E	O
;	O
EcoRI	O
site	O
,	O
H	O
;	O
HindIII	O
site	O
,	O
P	O
;	O
PstI	O
site	O
,	O
S	O
;	O
SacI	O
site	O
.	O

capping	O
site	O
or	O
the	O
transcription	O
initiation	O
site	O
was	O
located	O
32	O
bp	O
downstream	O
from	O
a	O
TATAAA	O
consensus	O
promotor	O
sequence	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
first	O
ATG	O
triplet	O
was	O
located	O
79	O
bp	O
downstream	O
from	O
the	O
TATA	O
box	O
.	O

As	O
seen	O
also	O
in	O
the	O
murine	O
IL-2	O
cDNA	O
,	O
there	O
is	O
an	O
unusual	O
repeat	O
of	O
CAG	O
triplet	O
coding	O
for	O
12	O
glutamine	O
residues	O
in	O
a	O
row	O
in	O
the	O
first	O
exon	O
.	O

The	O
second	O
exon	O
(	O
60	O
bp	O
)	O
is	O
separated	O
from	O
the	O
first	O
exon	O
by	O
a	O
short	O
intron	O
consisting	O
of	O
97	O
bp	O
.	O

The	O
second	O
,	O
the	O
third	O
and	O
the	O
fourth	O
exons	O
are	O
interrupted	O
by	O
longer	O
introns	O
whose	O
size	O
is	O
about	O
2.3	O
Kbp	O
and	O
1.6	O
Kbp	O
,	O
respectively	O
.	O

As	O
far	O
as	O
the	O
available	O
sequence	O
data	O
are	O
concerned	O
,	O
it	O
seems	O
that	O
,	O
despite	O
their	O
identical	O
location	O
,	O
intron	O
sequences	O
are	O
distinctly	O
dissimilar	O
except	O
for	O
the	O
junction	O
regions	O
between	O
the	O
human	B
and	O
mouse	B
IL-2	O
genes	O
.	O

There	O
are	O
two	O
potential	O
poly	O
(	O
A	O
)	O
addition	O
signals	O
within	O
the	O
mouse	B
gene	O
(	O
nucleotide	O
positions	O
793	O
-	O
798	O
and	O
924	O
-	O
929	O
in	O
Fig.	O
3	O
)	O
and	O
,	O
based	O
on	O
our	O
sequence	O
data	O
for	O
various	O
cDNA	O
clones	O
,	O
both	O
signals	O
seem	O
to	O
function	O
and	O
give	O
rise	O
to	O
heterogeneous	O
termini	O
of	O
the	O
mRNA	O
in	O
the	O
LBRM-33	O
cells	O
(	O
16	O
)	O
.	O

We	O
have	O
also	O
determined	O
the	O
sequence	O
of	O
about	O
500	O
bp	O
of	O
5'-flanking	O
region	O
of	O
mouse	B
IL-2	O
gene	O
,	O
since	O
(	O
i	O
)	O
promoter	O
/	O
regulatory	O
sequences	O
are	O
located	O
in	O
this	O
region	O
in	O
many	O
other	O
genes	O
of	O
eukaryotes	O
and	O
(	O
ii	O
)	O
this	O
region	O
appeared	O
to	O
contain	O
sequences	O
which	O
show	O
strongest	O
cross	O
-	O
hybridization	O
between	O
human	B
and	O
mouse	B
DNA	O
around	O
the	O
IL-2	O
gene	O
(	O
Fig.	O
1	O
)	O
.	O

Comparison	O
of	O
the	O
nucleotide	O
sequences	O
for	O
the	O
5	O
'	O
flanking	O
region	O
9327	O
Nucleic	O
Acids	O
Research	O
-4.0	O
TAGGAGGTAAACCATCTCGAAACGGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAG	O
-400	O
-350	O
GATTTATTCTTTTCATCTATCTCCTCTTGCGCCCGTCCACCACAACAGGCTGCTTACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTT	O
-300	O
-250	O
CATGAGTTACTTTTGTGTCTCCACCCCAAAGAGGAAAATTTTGTTCATACGAAAGGCGTTCATTGTATGAATTAAAACTGCCACCTAAGAG	O
-200	O
-150	O
TGGGCTAACCCGACCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATATGGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAA	O
-100	O
-50	O
AAACAAAGGTAATACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTAATATGTAAAACATCGTGACACCCCCATATTATTTTTC	O
CAGCATTAACAGTATAAATTGCCTCCCATGCTGAAGAGCTGCC	O
TCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGC	O
50	O
100	O
ATG	O
TAC	O
AGC	O
ATG	O
CAG	O
CTC	O
GCA	O
TCC	O
TGT	O
GTC	O
ACA	O
TTG	O
ACA	O
CTT	O
GTG	O
CTC	O
CTT	O
GTC	O
AAC	O
AGC	O
GCA	O
CCC	O
ACT	O
Met	O
Tyr	O
Ser	O
Met	O
Gln	O
Leu	O
Ala	O
Ser	O
Cys	O

Val	O
Thr	O
Leu	O
Thr	O
Leu	O
Val	O
Leu	O
Leu	O
Val	O
Asn	O
Ser	O
Ala	O
Pro	O
Thr	O
150	O
TCA	O
AGC	O
TCC	O
ACT	O
TCA	O
AGC	O
TCT	O
ACA	O
GCG	O
GAA	O
GCA	O

CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
Ser	O
Ser	O
Ser	O
Thr	O
Ser	O
Ser	O
Ser	O
Thr	O
Ala	O
Glu	O
Ala	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
200	O
CAC	O
CTG	O
GAG	O
CAG	O
CTG	O
TTG	O
ATG	O
GAC	O
CTA	O
CAG	O
GAG	O
CTC	O
CTG	O
AGC	O
AGG	O
ATG	O
GAG	O
GTAAGTGCACAGCCATCCCATC	O

His	O
Leu	O
Glu	O
Gln	O
Leu	O
Leu	O
Met	O
Asp	O
Leu	O
Gln	O
Glu	O
Leu	O
Leu	O
Ser	O

Arg	O
Met	O
Glu	O

TATAGGCAATACCTTTAGCTTTCTTGCCAAAGGCTGTGTTTAATAACCTTTAATAATAATGTTACGCTTTCTCAG	O
AAT	O
TAC	O
AGG	O
AAC	O
lAsn	O
Tyr	O
Arg	O
Asn	O
250	O
CTG	O
AAA	O
CTC	O
CCC	O
AGG	O
ATG	O
CTC	O
ACC	O
TTC	O
AAA	O
TTT	O
TAC	O
TTG	O
CCC	O
AAG	O
CAG	O
GTGAGTGAGTTTCTGTTTAACTGGTGC	O
Leu	O
Lys	O
Leu	O

Pro	O
Arg	O
Met	O
Leu	O

Thr	O
Phe	O
Lys	O
Phe	O
Tyr	O
Leu	O
Pro	O
Lys	O
Gln	O
TCTAATG----------------------------------------------------------	O
_	O
_	O
?	O

_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
-----------------------	O
2000	O
bp	O
--------------------?----------------------------------------------------------	O
AATGTGAACCTTGTAGTTTCTTTGTAGATTGGAACAATAGTCTGAACTTGTGT	O
TATGCATTGGTAGAGAAACACAGACTTTTTACAAAGTCTAATGAAGCCAGAAGAGCTCACTAGAGTGGCCTAACAGTTAAGGTGACCCTTA	O
TGGTTGTGAGCTCTTGCTCTTCTAGATTTATGGCATCGATTACCTCAGTCCCCCTTTACAGAGGACAGGGAGTGGTAAAAGCTATGTGCTG	O
CCTTCTCTTGATTAGAGAGACTGCAGACTAACTTTCTGGCTCTTCAGTATGTGGTGAGCTGAGCTGATGGTTAAGCTTATTACTCCTCTAG	O
300	O
350	O
GCC	O
ACA	O
GAA	O
TTG	O
AAA	O
GAT	O
CTT	O
CAG	O
TGC	O
CTA	O
GAA	O
GAT	O
GAA	O
CTT	O
GGA	O
CCT	O
CTG	O
CGG	O
CAT	O
GTT	O
CTG	O
GAT	O
TTG	O
Ala	O
Thr	O
Glu	O
Leu	O
Lys	O
Asp	O
Leu	O
Gln	O
Cys	O
Leu	O
Glu	O
Asp	O
Glu	O
Leu	O

Gly	O
Pro	O
Leu	O

Arg	O

His	O
Val	O
Leu	O
Asp	O
Leu	O
490	O
ACT	O
CAA	O
AGC	O
AAA	O
AGC	O
TTT	O
CAA	O
TTG	O
GAA	O
GAT	O
GCT	O
GAG	O
AAT	O
TTC	O
ATC	O
AGC	O
AAT	O
ATC	O
AGA	O
GTA	O
ACT	O
GTT	O

GTA	O
Thr	O
Gln	O
Ser	O
Lys	O
Ser	O
Phe	O
Gln	O
Leu	O
Glu	O
Asp	O
Ala	O
Glu	O
Asn	O
Phe	O
Ile	O
Ser	O
Asn	O
Ile	O
Arg	O
Val	O
Thr	O
Val	O
Val	O
AAA	O
CTA	O
AAG	O
GTAAGGTGTTGCTTTATTTGCTAATCTGGAAATAAAATAGAGAAGAAATGCATTTTTAAGTGGCTTGCCATTTCTGGT	O
Lys	O
Leu	O
Lys	O
CTTTGATGGGTTCTGTGCATTTAGTCAACCAAAGTTTAAAGTCACTGTGCAAGTGAATCC	O
--------------------------------------------------------------------	O

-1000	O
bp	O
------	O
---------------------------------------------------------------	O

GAATTCTACAGAAGTGTTCAGTGTTCCCATCAAATGCTCGTTGGTAATCAACTCTGGAGAGCTT	O
TATTTTTTATGCTTTACCATTTGATATCATAATAAAACATAACCCAATAATTGTGATCATTTCAGAAATGTGAATGTTCAATATATTTAAC	O
CAGTGTTAAAATAAATGCCTAAAAGCTCCGTTGAAGAATAATTATATGCAAAGTAAGCTACCTTAGCCTACAATTTTATATTCTTTTTTAG	O
450	O
500	O
GGC	O
TCT	O
GAC	O
AAC	O
ACA	O
TTT	O
GAG	O
TGC	O
CAA	O
TTC	O
GAT	O
GAT	O
GAG	O
TCA	O
GCA	O
ACT	O
GTG	O
GTG	O

GAC	O
TTT	O
CTG	O
AGG	O
AGA	O
Gly	O
Ser	O
Asp	O
Asn	O
Thr	O
Phe	O
Glu	O
Cys	O
Gln	O
Phe	O
Asp	O
Asp	O
GlU	O
Ser	O
Ala	O
Thr	O
Val	O
Val	O
Asp	O
Phe	O
Leu	O
Arg	O

Arg	O
550	O
TGG	O
ATA	O
GCC	O
TTC	O
TGT	O
CAA	O
AGC	O
ATC	O
ATC	O
TCA	O
ACA	O
AGC	O
CCT	O
CAA	O
TAACTATGTACCTCCTGCTTACAACACATAAGGC	O
Trp	O
Ile	O
Ala	O
Phe	O
Cys	O
Gln	O
Ser	O
Ile	O
Ile	O
Ser	O
Thr	O
Ser	O
Pro	O
Gln	O

600	O

650	O
TCTCTATTTAT4TAAATATTTAACTTTAATTTATTTTTGGATGTATTGTTTACTATCTTTTGTAACTACTAGTCTTCAGATGATAAATATG	O
700	O
750	O
GATCTTTAAAGATTCTTTTTGTAAGCCCCAAGGGCTCAAAAATGTTTTAAACTATTTATCTGAAATTATT+ATTATATTGAATTGTTAAAT	O
<	O
4>800	O
850	O
ATCATGTGTAGGTAGACTcATTCA	O
TAAAAGTAmAGATGATTCAAATATAAATAAGCTCAGATGTCTGTCATTTTTAGGACAGCACAAAG	O
900	O
0	O
""""	O
TAAGCGCTAAAATAACTTCTCAGTTATTCCTGTGAACTcTATGTTAATCAGTGTTTTCAAGAAATAAAGCTCTCCTCT	O
AAA	O
GATGGCTTGTGGGAAAAGATCTCCTCTCCAGGGAGCTAACATCAGCTCAGAGTTTACTCAAGAATTC	O
Fig.	O
3	O
.	O
Nucleotide	O
sequence	O
of	O
mouse	B
IL-2	O
gene	O
.	O

Four	O
exons	O
are	O
framed	O
.	O

Numbers	O
refer	O
to	O
nucleotide	O
positions	O
of	O
exons	O
from	O
the	O
presumed	O
cap	O
site	O
.	O

Dots	O
and	O
open	O
circles	O
indicate	O
TATA	O
box	O
and	O
poly	O
A	O
additional	O
signals	O
,	O
respectively	O
.	O

9328	O
Nucleic	O
Acids	O
Research	O
-4	O
5	O
0	O
-400	O
TAGGAGGT	O
AAACCA	O
T	O
CTCGAAAC	O
GGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAGGATTTATTCTTTTCATCTATCTCC	O
.0	O

*	O
.0	O

.-	O

*	O
.	O

*	O
..	O

*	O
--	O
.	O

--	O
.*-@	O
..	O
............	O
--	O
-*-	O
*	O
*	O
TAAAAAGGTAAAACCAGTTCT	O
GAAACAGGAAACCAATACACTTCCTGTTTAATCAACAAATCTAAA	O
CATTTATTCTTTTCATCTGTTTAC	O
-350	O
-300	O
TCTTGCGCCCGTCCACCACAACAGGCTGCT	O
T	O
ACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTTCATGAGTTACTTTTGTGTCTC	O
TCTTGCTCTTGTTCACCACAATA	O
TGCTATTCACATGTTCAGTGTAGTTTTATGACAAAGAAAATTTTC	O
TGAGTTACTTTTGTATCCC	O
-250	O
CA	O
CCCC	O
AAAG	O
AGGAAAATTTGTTTCATACGAAAGGCGTTCATTGTATGAATTAAAACT	O
CCACCTAAGAGTGGGCTAACCCGA	O

*	O
~~~	O
~~	O
.....	O

*	O
.--	O

*	O
..	O

-	O
*	O
.--	O
.	O

*	O
*	O
.	O

*	O
-	O
.	O

--	O
.	O

*	O
-	O
*	O
-	O
-	O
-	O
*	O
-	O
0	O
@	O

*	O
--	O
0	O
..	O
.	O

CACCCCCTTAAAGAAAGGAGGAAAAACTGTTTCATACAGAAGGCGTTAATTGCATGAATTAGAGCTATCACCTAAGTGTGGGCTAATGTAA	O
-200	O
-150	O
CCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATAT	O
GGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAAAAACAAAGGTAA	O
CAAAGAGGGATTTCACCTACATCCATTCAGTCAGTCTTTGGGGGTTTAAA	O
AAATTCCAAAGAGTCATCAGAAGAGGAAAAATGAAGGTAA	O
-100	O
-50	O
TACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTXATATTAAAACATCGTGACACCCCCATATiXrTCCAGCATTAACAG	O
TGTTTTTT	O
CAGACAGGTAAAGTC	O
TTTGAAAATATGTGTAATATGTAAAACATTTTGACACCCCCATAATATTTTTCCAGAATTAACAG	O
ATAAGCCTCCCATGCTGAAGAGCTGCCTATCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGCATG	O
Mouse	B
rTATGCATCTCTTGTTCAAGAGTTCCCTATCACTCTCTTTAATCACTACACACAGTAACCTCAACTCCTGCCACTATG	O
Human	B
Fig.	O
4	O
.	O

Comparison	O
of	O
5'-flanking	O
regions	O
of	O
mouse	B
and	O
human	B
IL-2	O
genes	O
.	O

In	O
aligning	O
the	O
sequences	O
for	O
both	O
genes	O
,	O
gaps	O
were	O
introduced	O
to	O
maximize	O
homology	O
.	O

Dots	O
indicate	O
identical	O
nucleotide	O
sequences	O
.	O

Number	O
1	O
indicates	O
putative	O
transcription	O
initiation	O
site	O
.	O

Inverted	O
repeats	O
are	O
indicated	O
by	O
bars	O
and	O
dashed	O
lines	O
.	O

TATA	O
box	O
is	O
framed	O
.	O

of	O
both	O
genes	O
is	O
illustrated	O
in	O
Fig.	O
4	O
.	O

The	O
nucleotide	O
sequence	O
homology	O
from	O
the	O
TATA	O
box	O
to	O
-470	O
is	O
85	O
%	O
.	O

The	O
highest	O
region	O
of	O
homology	O
was	O
observed	O
between	O
the	O
TATA	O
box	O
and	O
position	O
-97	O
(	O
60	O
bp	O
matches	O
out	O
of	O
64	O
bp	O
)	O
of	O
both	O
genes	O
.	O

DISCUSSION	O
We	O
have	O
isolated	O
recombinant	O
clones	O
for	O
mouse	B
IL-2	O
gene	O
from	O
a	O
phage	O
Charon	O
4A	O
/	O
mouse	B
genomic	O
DNA	O
library	O
and	O
determined	O
the	O
entire	O
sequence	O
of	O
the	O
gene	O
except	O
for	O
the	O
sequence	O
of	O
the	O
internal	O
portion	O
of	O
the	O
second	O
and	O
third	O
introns	O
.	O

The	O
mouse	B
IL-2	O
cDNA	O
sequence	O
was	O
aligned	O
with	O
the	O
genomic	O
sequence	O
and	O
both	O
sequences	O
matched	O
completely	O
each	O
other	O
.	O

The	O
unusual	O
CAG	O
repeats	O
encoding	O
12	O
glutamines	O
which	O
was	O
found	O
previously	O
in	O
the	O
cloned	O
cDNA	O
was	O
shown	O
to	O
be	O
present	O
also	O
in	O
the	O
chromosomal	O
gene	O
.	O

This	O
finding	O
further	O
excludes	O
the	O
possibility	O
that	O
the	O
unique	O
repeat	O
is	O
generated	O
by	O
artifacts	O
during	O
the	O
cDNA	O
cloning	O
process	O
.	O

Although	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
for	O
the	O
deletion	O
of	O
this	O
sequence	O
in	O
the	O
human	B
IL-2	O
gene	O
,	O
it	O
is	O
more	O
likely	O
that	O
the	O
CAG	O
repeat	O
has	O
been	O
generated	O
in	O
the	O
mouse	B
genome	O
rather	O
recently	O
.	O

The	O
repeat	O
could	O
have	O
been	O
generated	O
either	O
by	O
a	O
direct	O
insertion	O
of	O
the	O
sequence	O
or	O
by	O
the	O
duplication	O
after	O
insertion	O
of	O
a	O
unit	O
sequence	O
.	O

9329	O
Nucleic	O
Acids	O
Research	O
Organization	O
of	O
the	O
mouse	B
IL-2	O
gene	O
resembles	O
to	O
that	O
of	O
the	O
human	B
gene	O
(	O
Fig.	O
2	O
.	O
,	O
ref	O
.	O

9	O
)	O
.	O

There	O
seems	O
to	O
be	O
little	O
sequence	O
homology	O
between	O
corresponding	O
introns	O
of	O
mouse	B
and	O
human	B
IL-2	O
genes	O
,	O
except	O
for	O
the	O
intron	O
-	O
exon	O
junctions	O
part	O
of	O
which	O
is	O
thought	O
to	O
be	O
necessary	O
for	O
the	O
RNA	O
splicing	O
(	O
17	O
,	O
18	O
)	O
.	O

Dissimilarity	O
of	O
the	O
intron	O
sequences	O
among	O
the	O
genes	O
which	O
are	O
derived	O
from	O
a	O
common	O
ancestor	O
has	O
been	O
reported	O
in	O
other	O
genes	O
(	O
19	O
,	O
20	O
)	O
.	O

In	O
spite	O
of	O
the	O
divergence	O
in	O
sequence	O
of	O
introns	O
,	O
the	O
size	O
and	O
position	O
of	O
the	O
introns	O
are	O
very	O
similar	O
between	O
the	O
murine	O
and	O
human	B
IL-2	O
genes	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
highly	O
conserved	O
sequences	O
in	O
the	O
5	O
'	O
-flanking	O
region	O
of	O
the	O
human	B
and	O
mouse	B
IL-2	O
gene	O
(	O
Fig.	O
4	O
)	O
.	O

Whereas	O
the	O
coding	O
region	O
shows	O
nucleotide	O
sequence	O
homology	O
of	O
72	O
%	O
between	O
the	O
two	O
genes	O
,	O
the	O
5	O
'	O
upstream	O
region	O
spanning	O
about	O
500	O
bp	O
(	O
Fig.	O
4	O
)	O
shows	O
85	O
%	O
homology	O
which	O
was	O
readily	O
detectable	O
by	O
the	O
blotting	O
analysis	O
(	O
Fig.	O
1	O
,	O
lane	O
1	O
-	O
4	O
)	O
.	O

Since	O
we	O
have	O
not	O
yet	O
determined	O
the	O
nucleotide	O
sequence	O
further	O
upstream	O
of	O
the	O
mouse	B
gene	O
,	O
we	O
do	O
not	O
know	O
whether	O
or	O
not	O
this	O
similarity	O
extends	O
further	O
.	O

It	O
is	O
likely	O
that	O
such	O
sequences	O
are	O
involved	O
in	O
the	O
controlled	O
expression	O
of	O
the	O
IL-2	O
genes	O
in	O
activated	O
T	O
-	O
lymphocytes	O
.	O

Work	O
is	O
in	O
progress	O
to	O
identify	O
such	O
DNA	O
sequences	O
by	O
introducing	O
the	O
cloned	O
genes	O
into	O
various	O
lymphocytic	O
cell	O
lines	O
.	O

Our	O
preliminary	O
results	O
indicate	O
that	O
the	O
5	O
'	O
-flanking	O
sequence	O
of	O
the	O
human	B
IL-2	O
gene	O
mediates	O
mitogen	O
induced	O
expression	O
of	O
the	O
gene	O
in	O
T	O
-	O
lymphocytic	O
cells	O
(	O
Fujita	O
&	O
Taniguchi	O
,	O
unpublished	O
observation	O
)	O
.	O

ACKNOWLEDGEMENTS	O
We	O
thank	O
Dr.	O
T.	O
Honjo	O
for	O
mouse	B
gene	O
library	O
.	O

We	O
are	O
also	O
indepted	O
to	O
Ms.	O
M.	O
Nagatsuka	O
for	O
typing	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Special	O
Project	O
Research	O
,	O
Cancer	O
-	O
Bioscience	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
and	O
Culture	O
,	O
Japan	O
.	O

?	O

To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
*	O
Present	O
address	O
:	O
Department	O
of	O
Microbiology	O
,	O
School	O
of	O
Medicine	O
,	O
Chiba	O
University	O
,	O
Chiba	O
280	O
,	O
Japan	O
+	O
Present	O
address	O
:	O
Central	O
Research	O
Laboratory	O
,	O
Ajinomoto	O
Co.	O

Inc.	O
,	O
Totsuka	O
-	O
ku	O
,	O
Yokohama	O
244	O
,	O
Japan	O
9330	O
Nucleic	O
Acids	O
Research	O
REFERENCES	O
1	O
.	O

Morgan	O
,	O
D.	O
A.	O
,	O
Ruscetti	O
,	O
F.	O
W.	O
and	O
Gallo	O
,	O
R.	O
(	O
1976	O
)	O
Science	O
,	O
193	O
,	O
1007	O
-	O
1008	O
.	O

2	O
.	O

Gil	O
lis	O
,	O
S.	O
Ferm	O
,	O
M.	O
M.	O
,	O
Ou	O
,	O
W.	O
and	O
Smith	O
,	O
K.	O
(	O
1	O
978	O
)	O
J.	O
Immunol	O
.	O
,	O
120	O
,	O
2023	O
-	O
2027	O
.	O

3	O
.	O

Chen	O
,	O
B.	O
M.	O
and	O
Di	O
Sabato	O
,	O
G.	O
(	O
1976	O
)	O
Cell	O
.	O

Immunol	O
.	O
,	O
22	O
,	O
211	O
224	O
.	O

4	O
.	O

Henney	O
,	O
C.	O
S.	O
,	O
Kuribayashi	O
,	O
K.	O
,	O
Kern	O
,	O
D.	O
E.	O
and	O
Gillis	O
,	O
S.	O
(	O
1981	O
)	O
Nature	O
,	O
291	O
,	O
335	O
-	O
338	O
.	O

5	O
.	O

Wagner	O
,	O
H.	O
,	O
Hardt	O
,	O
C.	O
,	O
Heeg	O
,	O
K.	O
,	O
Rollinghoff	O
,	O
M.	O
and	O
Pfizenmaier	O
,	O
K.	O
(	O
1980	O
)	O
Nature	O
,	O
284	O
,	O
278	O
-	O
280	O
.	O

6	O
.	O

Farrar	O
,	O
J.	O
J.	O
,	O
Benjamin	O
,	O
W.	O
R.	O
,	O
Hilfikr	O
M.	O
L.	O
,	O
Howard	O
,	O
M.	O
,	O
Farrar	O
,	O
W.	O
L.	O
and	O
Fuller	O
-	O
Farrar	O
,	O
J.	O
(	O
1982	O
)	O
Immunol	O
.	O

Rev.	O
63	O
,	O
129	O
-	O
166	O
.	O

7	O
.	O

Pearlstein	O
,	O
K.	O
,	O
Palladino	O
,	O
M.	O
A.	O
,	O
Welte	O
,	O
K.	O
and	O
Vilcek	O
,	O
J.	O
(	O
1983	O
)	O
Cell	O
.	O

Immunol	O
.	O
,	O
80	O
,	O
1	O
-	O
9	O
.	O

8	O
.	O

Taniguchi	O
,	O
T.	O
,	O
Matsui	O
,	O
H.	O
,	O
Fujita	O
,	O
T.	O
,	O
Takaoka	O
,	O
C.	O
,	O
Kashima	O
,	O
N.	O
,	O
Yoshimoto	O
,	O
R.	O
and	O
Hamuro	O
,	O
J.	O
(	O
1983	O
)	O
Nature	O
302	O
,	O
305	O
-	O
310	O
.	O

9	O
.	O

Fujita	O
,	O
T.,Takaoka	O
,	O
C.	O
,	O
Matsui	O
,	O
H.	O
and	O
Taniguchi	O
T.	O
(	O
1983	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
80	O
,	O
7437	O
-	O
7411	O
.	O

10	O
.	O

Ohno	O
,	O
S.	O
and	O
Taniguchi	O
,	O
T.	O
(	O
1982	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

10	O
,	O
967	O
977	O
.	O

11	O
.	O

Southern	O
,	O
E.	O
M.	O
(	O
1975	O
)	O
J.	O
Mol	O
.	O

Biol	O
.	O

98	O
,	O
503	O
-	O
517	O
.	O

12	O
.	O

Benton	O
,	O
W.	O
D.	O
and	O
Davis	O
,	O
R.	O
W.	O
(	O
1977	O
)	O
Science	O
196	O
,	O
180	O
-	O
182	O
.	O

13	O
.	O

Ohno	O
,	O
S.	O
and	O
Taniguchi	O
,	O
T.	O
(	O
1981	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
78	O
,	O
5305	O
-	O
5309	O
.	O

14	O
.	O

Maxam	O
,	O
A.	O
M.	O
and	O
Gilbert	O
,	O
W.	O
(	O
1980	O
)	O
Meth	O
.	O

Enzymol	O
.	O
65	O
,	O
560	O
580	O
.	O

15	O
.	O

Sanger	O
,	O
F.	O
,	O
Nicklen	O
,	O
S.	O
and	O
Coulson	O
,	O
A.	O
R.	O
(	O
1977	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
74	O
,	O
5463	O
-	O
5467	O
.	O

16	O
.	O

Gillis	O
,	O
S.	O
,	O
Scheid	O
,	O
M.	O
and	O
Watson	O
,	O
J.	O
D.	O
(	O
1980	O
)	O
J.	O
Immunol	O
.	O

,	O
125	O
,	O
2570	O
-	O
2580	O
.	O

17	O
.	O

Breathnach	O
,	O
R.	O
,	O
Benoist	O
,	O
C.	O
,	O
O'Hare	O
,	O
K.	O
,	O
Gannon	O
,	O
F.	O
and	O
Chambon	O
,	O
P.	O
(	O
1978	O
)	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
75	O
,	O
4853	O
-	O
4857	O
.	O

18	O
.	O

Lerner	O
,	O
M.	O
R.	O
,	O
Boyle	O
,	O
J.	O
A.	O
,	O
Mount	O
,	O
S.	O
M.	O
,	O
Wolin	O
,	O
S.	O
L.	O
and	O
Steitz	O
,	O
J.	O
A.	O
(	O
1980	O
)	O
Nature	O
,	O
283	O
,	O
220	O
-	O
224	O
.	O

19	O
.	O

Van	O
Ooyen	O
,	O
A.	O
,	O
Van	O
den	O
Berg	O
,	O
J.	O
,	O
Mantei	O
,	O
N.	O
and	O
Weissmann	O
,	O
C.	O
(	O
1979	O
)	O
Science	O
,	O
206	O
,	O
337	O
-	O
344	O
.	O

20	O
.	O

Searle	O
,	O
P.	O
F.	O
,	O
Davison	O
,	O
B.	O
L.	O
,	O
Stuart	O
,	O
G.	O
W.	O
,	O
Wilkie	O
,	O
T.	O
M.	O
,	O
Norstedt	O
,	O
G.	O
and	O
Palmiter	O
,	O
R.	O
D.	O
(	O
1984	O
)	O
Mol	O
.	O

Cell	O
.	O

Biol	O
.	O

4	O
,	O
1221	O
-	O
1230	O
.	O

9331	O

Preparation	O
of	O
oligodeoxyribonucleoside	O
methylphosphonates	O
on	O
a	O
polystyrene	O
support	O
.	O

Abstract	O
An	O
efficient	O
procedure	O
is	O
described	O
for	O
synthesizing	O
deoxyribonucleoside	O
methylphosphonates	O
on	O
polystyrene	O
polymer	O
supports	O
which	O
involves	O
condensing	O
5'-dimethoxytrityldeoxynucleoside	O
3'-methylphosphonates	O
.	O

The	O
oligomers	O
are	O
removed	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
hydrolyzed	O
by	O
treatment	O
with	O
ethylenediamine	O
in	O
ethanol	O
,	O
which	O
avoids	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
.	O

Two	O
types	O
of	O
oligomers	O
were	O
synthesized	O
:	O
those	O
containing	O
only	O
methylphosphonate	O
linkages	O
,	O
d	O
-	O
Np	O
(	O
Np	O
)	O
nN	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5	O
'	O
nucleotide	O
residue	O
,	O
dNp	O
(	O
Np	O
)	O
nN.	O
The	O
latter	O
oligomers	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
,	O
and	O
are	O
separated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
according	O
to	O
their	O
chain	O
length	O
.	O

Piperdine	O
randomly	O
cleaves	O
the	O
oligomer	O
methylphosphonate	O
linkages	O
and	O
generates	O
a	O
series	O
of	O
shorter	O
oligomers	O
whose	O
number	O
corresponds	O
to	O
the	O
length	O
of	O
the	O
original	O
oligomer	O
.	O

Apurinic	O
sites	O
introduced	O
by	O
acid	O
treatment	O
spontaneously	O
hydrolyze	O
to	O
give	O
oligomers	O
which	O
terminate	O
with	O
free	O
3	O
'	O
and	O
5	O
'	O
OH	O
groups	O
.	O

These	O
reactions	O
may	O
be	O
used	O
to	O
characterize	O
the	O
oligomers	O
.	O

Images	O
Vlue1Nubr1193NcecAisRsah	O
Preparation	O
of	O
oligodeoxyribonucleoside	O
methylphosphonates	O
on	O
a	O
polystyrene	O
support	O
P.S.Miller	O
,	O
C.H.Agris	O
,	O
A.Murakami	O
,	O
P.M.Reddy	O
,	O
S.A.Spitz	O
and	O
P.O.P.Ts'o	O
Division	O
of	O
Biophysics	O
,	O
Johns	O
Hopkins	O
University	O
,	O
School	O
of	O
Hygiene	O
and	O
Public	O
Health	O
,	O
Baltimore	O
,	O
MD	O
21205	O
,	O
USA	O
Received	O
26	O
July	O
1983	O
;	O
Accepted	O
5	O
September	O
1983	O
ABSTRACT	O
An	O
efficient	O
procedure	O
is	O
described	O
for	O
synthesizing	O
deoxyribonucleoside	O
methylphosphonates	O
on	O
polystyrene	O
polyner	O
supports	O
which	O
involves	O
condensing	O
5'-dimethoxytrityldeoxynucleoside	O
3'-methylphosphonates	O
.	O

The	O
oligomers	O
are	O
removed	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
hydrolyzed	O
by	O
treatment	O
with	O
ethylenediamine	O
in	O
ethanol	O
,	O
which	O
avoids	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
.	O

Two	O
types	O
of	O
oligomers	O
were	O
synthesized	O
:	O
those	O
containing	O
only	O
methylphosphonate	O
linkages	O
,	O
d	O
-	O
Np	O
(	O
Np	O
)	O
N	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5	O
'	O
nucleotide	O
residue	O
,	O
dNp	O
(	O
Np	O
)	O
N	O
.-	O
J	O
he	O
latter	O
oligomers	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
,	O
and	O
are	O
separated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
according	O
to	O
their	O
chain	O
length	O
.	O

Piperdine	O
randomly	O
cleaves	O
the	O
oligomer	O
methylphosphonate	O
linkages	O
and	O
generates	O
a	O
series	O
of	O
shorter	O
oligomers	O
whose	O
number	O
corresponds	O
to	O
the	O
length	O
of	O
the	O
original	O
oligomer	O
.	O

Apurinic	O
sites	O
introduced	O
by	O
acid	O
treatment	O
spontaneously	O
hydrolyze	O
to	O
give	O
oligomers	O
which	O
terminate	O
with	O
free	O
3	O
'	O
and	O
5	O
'	O
OH	O
groups	O
.	O

These	O
reactions	O
may	O
be	O
used	O
to	O
characterize	O
the	O
oligomers	O
.	O

INTRODUCTION	O
Oligonucleoside	O
methylphosphonates	O
have	O
been	O
used	O
to	O
st	O
-	O
udy	O
the	O
function	O
of	O
specific	O
RNA	O
sequences	O
in	O
biochemical	O
and	O
intact	O
cellular	O
systems	O
(	O
1,2	O
)	O
.	O

Since	O
these	O
nonionic	O
nucleic	O
acid	O
analogs	O
can	O
be	O
taken	O
up	O
intact	O
by	O
mammalian	O
cells	O
and	O
certain	O
bacterial	O
cells	O
in	O
culture	O
,	O
these	O
compounds	O
promise	O
to	O
be	O
useful	O
reagents	O
for	O
exploring	O
and	O
regulating	O
the	O
function	O
of	O
nucleic	O
acids	O
within	O
living	O
cells	O
.	O

In	O
order	O
to	O
carry	O
out	O
more	O
extensive	O
biochemical	O
and	O
biological	O
studies	O
,	O
an	O
efficient	O
method	O
for	O
synthesis	O
of	O
oligonucleoside	O
methylphosphonates	O
of	O
defined	O
sequence	O
is	O
needed	O
.	O

Previously	O
we	O
described	O
the	O
synthesis	O
of	O
methylphosphonate	O
analogs	O
on	O
a	O
silica	O
gel	O
support	O
(	O
3	O
)	O
.	O

Protected	O
nucleoside	O
3'-methylphosphonic	O
chlorides	O
or	O
tetrazolides	O
were	O
used	O
as	O
synthetic	O
intermediates	O
.	O

While	O
oligothymidine	O
methylphosphonates	O
could	O
be	O
efficiently	O
synthesized	O
by	O
this	O
procedure	O
,	O
low	O
yields	O
were	O
encountered	O
when	O
other	O
nucleosides	O
,	O
particularly	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuG	O
were	O
used	O
.	O

Recently	O
Sinha	O
et	O
al.	O
?	O
)	O

I	O
RL	O
Press	O
Limited	O
,	O
Oxford	O
,	O
England	O
.	O

Nucleic	O
Acids	O
Research	O
Volume	O
1	O
1	O
Number	O
18	O
1983	O
6225	O
Nucleic	O
Acids	O
Research	O
described	O
the	O
preparation	O
of	O
oligonucleoside	O
methylphosphophonates	O
on	O
a	O
glass	O
support	O
using	O
nucleoside	O
3'-methylphosphine	O
chlorides	O
as	O
reactive	O
intermediates	O
(	O
4	O
)	O
.	O

In	O
this	O
paper	O
we	O
describe	O
a	O
set	O
of	O
useful	O
methods	O
for	O
the	O
synthesis	O
and	O
analysis	O
of	O
these	O
analogs	O
.	O

The	O
synthesis	O
involves	O
condensation	O
of	O
protected	O
nucleoside	O
3'-methylphosphonate	O
triethylammonium	O
salts	O
with	O
nucleosides	O
or	O
oligomers	O
linked	O
to	O
a	O
polystyrene	O
support	O
.	O

This	O
method	O
has	O
proven	O
to	O
be	O
easy	O
to	O
use	O
and	O
allows	O
relatively	O
rapid	O
synthesis	O
of	O
oligomers	O
of	O
defined	O
sequence	O
up	O
to	O
nine	O
nucleosides	O
in	O
length	O
.	O

We	O
have	O
also	O
developed	O
conditions	O
for	O
the	O
efficient	O
removal	O
of	O
base	O
protecting	O
groups	O
and	O
subsequent	O
purification	O
of	O
the	O
oligomers	O
.	O

A	O
novel	O
hydrolysis	O
reaction	O
which	O
can	O
be	O
used	O
as	O
a	O
basis	O
for	O
characterizing	O
and	O
sequencing	O
these	O
oligonucleotide	O
analogs	O
occurs	O
at	O
apurinic	O
sites	O
created	O
by	O
acid	O
treatment	O
of	O
the	O
oligomers	O
.	O

EXPERIMENTAL	O
Materials	O
and	O
Methods	O
Protected	O
nucleosides	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
N	O
,	O
were	O
purchased	O
from	O
P.L.	O
Biochemicals	O
and	O
were	O
used	O
without	O
further	O
purification	O
.	O

Protected	O
nucleoside	O
3'-methylphosphonate	O
triethylammoni	O
um	O
salts	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np*Et3NH	O
,	O
were	O
prepared	O
as	O
previously	O
described	O
(	O
3	O
)	O
.	O

5-Dimethoxytrityl	O
protected	O
nucleosides	O
esterified	O
to	O
1	O
%	O
or	O
2	O
%	O
crosslinked	O
polystyrene	O
were	O
purchased	O
from	O
Chem	O
Genes	O

Inc.	O

The	O
nucleoside	O
loading	O
level	O
was	O
40	O
to	O
120	O
pmol	O
of	O
nucleoside	O
/	O
g	O
of	O
support	O
.	O

Mesitylenesulfonyl-3-nitrotriazole	O
(	O
MSNT	O
)	O
was	O
purchased	O
from	O
Vega	O
Biochemicals	O
.	O

Anhydrous	O
pyridine	O
was	O
prepared	O
by	O
refluxing	O
previously	O
purified	O
pyridine	O
(	O
5	O
)	O
over	O
calcium	O
hydride	O
chips	O
for	O
several	O
hours	O
followed	O
by	O
distillation	O
onto	O
calcium	O
hydride	O
chips	O
in	O
5	O
ml	O
V	O
-	O
vials	O
fitted	O
with	O
Teflon	O
-	O
lined	O
septum	O
caps	O
(	O
Wheaton	O
Scientific	O
)	O
.	O

Lyophilized	O
spleen	O
phosphodiesterase	O
was	O
obtained	O
from	O
P.L.	O
Biochemicals	O
.	O

T-4	O
polynucleotide	O
kinase	O
and	O
[	O
y-32P	O
]	O
-ATP	O
were	O
obtained	O
from	O
New	O
England	O
Nuclear	O
.	O

Reversed	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
carried	O
out	O
on	O
Whatman	O
Inc.	O
C-18	O
(	O
ODS-3	O
)	O
columns	O
(	O
0.4	O
x	O
25	O
cm	O
)	O
.	O

Analytical	O
columns	O
were	O
eluted	O
with	O
50	O
ml	O
linear	O
gradients	O
of	O
acetonitrile	O
in	O
water	O
or	O
acetonitrile	O
in	O
0.1	O
M	O
ammonium	O
acetate	O
(	O
pH	O
5.8	O
)	O
at	O
a	O
flow	O
rate	O
of	O
2.5	O
ml	O
/	O
min	O
.	O

The	O
eluate	O
was	O
monitored	O
at	O
254	O
nm	O
.	O

The	O
following	O
molar	O
extinction	O
coefficients	O
were	O
used	O
at	O
254	O
nm	O
:	O
d	O
-	O
T	O
7,250	O
,	O
dA	O
13,270	O
,	O
dC	O
6,260	O
,	O
dG	O
13,700	O
.	O

Unless	O
otherwise	O
noted	O
,	O
all	O
reactions	O
and	O
operations	O
were	O
carried	O
out	O
at	O
room	O
temperature	O
.	O

General	O
Procedure	O
for	O
Preparing	O
Oligonucleoside	O
Methylphosphonates	O
.	O

The	O
following	O
procedure	O
represents	O
the	O
current	O
method	O
used	O
in	O
our	O
laboratory	O
to	O
6226	O
Nucleic	O
Acids	O
Research	O
synthesize	O
methylphosphonate	O
oligomers	O
.	O

Table	O
I	O
lists	O
some	O
of	O
the	O
oligomers	O
which	O
have	O
been	O
synthesized	O
on	O
polystyrene	O
supports	O
.	O

Oligomers	O
7	O
,	O
8	O
,	O
and	O
10	O
were	O
synthesized	O
as	O
described	O
below	O
.	O

The	O
other	O
oligomers	O
were	O
synthesized	O
in	O
essentially	O
the	O
same	O
manner	O
except	O
the	O
condensation	O
reactions	O
were	O
run	O
in	O
1	O
ml	O
V	O
-	O
vials	O
or	O
in	O
glass	O
reaction	O
columns	O
purchased	O
from	O
Bachem	O
Inc.	O

When	O
the	O
reactions	O
were	O
run	O
in	O
V	O
-	O
vials	O
,	O
the	O
support	O
was	O
dried	O
by	O
several	O
evaporations	O
with	O
anhydrous	O
pyridine	O
in	O
the	O
V	O
-	O
vial	O
(	O
3	O
)	O
.	O

When	O
the	O
reactions	O
were	O
run	O
in	O
the	O
glass	O
reaction	O
column	O
,	O
the	O
support	O
was	O
dried	O
by	O
a	O
single	O
evaporation	O
with	O
anhydrous	O
pyridine	O
overnight	O
at	O
room	O
temperature	O
.	O

Synthesis	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
.	O

The	O
synthetic	O
reactions	O
are	O
most	O
conveniently	O
carried	O
out	O
in	O
a	O
polypropylene	O
col	O
umn	O
(	O
Bio	O
Rad	O
Econo	O
column	O
)	O
fitted	O
with	O
a	O
Teflon	O
3-way	O
valve	O
(	O
Bio	O
Rad	O
)	O
and	O
a	O
rubber	O
septum	O
cap	O
(	O
Wheaton	O
Scientific	O
)	O
.	O

During	O
washing	O
operations	O
,	O
the	O
septum	O
cap	O
is	O
removed	O
and	O
the	O
3-way	O
valve	O
is	O
connected	O
to	O
a	O
filter	O
flask	O
via	O
a	O
Luerer	O
adaptor	O
and	O
tubing	O
set	O
(	O
Bio	O
Rad	O
)	O
.	O

Generally	O
vacuum	O
is	O
not	O
required	O
to	O
wash	O
the	O
support	O
.	O

During	O
the	O
drying	O
step	O
,	O
one	O
port	O
of	O
the	O
3-way	O
valve	O
is	O
connected	O
to	O
a	O
cold	O
trap	O
and	O
vacuum	O
pump	O
via	O
the	O
barrel	O
of	O
a	O
1	O
ml	O
plastic	O
syringe	O
.	O

The	O
other	O
port	O
is	O
connected	O
to	O
a	O
Drierite	O
column	O
filled	O
with	O
dry	O
argon	O
.	O

A	O
reaction	O
cycle	O
consists	O
of	O
the	O
following	O
10	O
steps	O
:	O
1	O
)	O
The	O
support	O
(	O
60	O
mg	O
,	O
1	O
%	O
crosslinked	O
)	O
in	O
the	O
column	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
(	O
85:15	O
,	O
v	O
/	O
v	O
)	O
.	O

2	O
)	O
The	O
support	O
is	O
treated	O
with	O
2	O
ml	O
of	O
1	O
M	O
zinc	O
bromide	O
in	O
methylene	O
chloride	O
/	O
isopropanol	O
solution	O
.	O

Two	O
fiveminute	O
treatments	O
are	O
used	O
when	O
the	O
support	O
-	O
bound	O
nucleoside	O
is	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
or	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuG	O
,	O
while	O
four	O
treatments	O
are	O
used	O
when	O
the	O
nucleoside	O
is	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
or	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC.	O
After	O
each	O
treatment	O
the	O
orange	O
solution	O
is	O
collected	O
in	O
a	O
clean	O
flask	O
.	O

3	O
)	O
The	O
support	O
is	O
washed	O
with	O
two	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
and	O
the	O
washings	O
are	O
collected	O
in	O
same	O
flask	O
used	O
in	O
step	O
2	O
)	O
.	O

The	O
solution	O
is	O
diluted	O
to	O
50	O
ml	O
and	O
a	O
0.20	O
ml	O
aliquot	O
is	O
dissolved	O
in	O
0.80	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
(	O
3:2	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
absorbance	O
is	O
determined	O
at	O
500	O
nm	O
and	O
the	O
amount	O
of	O
trityl	O
cation	O
is	O
determined	O
using	O
a	O
molar	O
extinction	O
coefficient	O
of	O
89,000	O
.	O

4	O
)	O
The	O
column	O
is	O
attached	O
to	O
a	O
waste	O
flask	O
and	O
the	O
support	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
0.5	O
M	O
triethylammonium	O
acetate	O
in	O
dimethylformamide	O
;	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
and	O
three	O
2	O
ml	O
portions	O
of	O
diethyl	O
ether	O
.	O

5	O
)	O
The	O
column	O
is	O
fitted	O
with	O
the	O
septum	O
cap	O
and	O
set	O
up	O
in	O
the	O
drying	O
mode	O
under	O
house	O
vacuum	O
for	O
at	O
least	O
5	O
min	O
.	O

6	O
)	O
The	O
support	O
is	O
dried	O
by	O
adding	O
300	O
jl	O
of	O
anhydrous	O
pyridine	O
via	O
a	O
gas	O
tight	O
syringe	O
(	O
Hamilton	O
)	O
.	O

After	O
the	O
support	O
has	O
swollen	O
,	O
the	O
vacuum	O
(	O
oil	O
pump	O
)	O
is	O
applied	O
and	O
the	O
support	O
is	O
warmed	O
with	O
a	O
6227	O
Nucleic	O
Acids	O
Research	O
stream	O
of	O
air	O
from	O
a	O
hair	O
dryer	O
.	O

Evaporation	O
is	O
continued	O
for	O
10	O
min	O
.	O

Dry	O
argon	O
is	O
then	O
admitted	O
and	O
the	O
drying	O
operation	O
is	O
repeated	O
two	O
more	O
times	O
.	O

7	O
)	O
The	O
coupling	O
mixture	O
is	O
prepared	O
by	O
dissolving	O
0.20	O
mmol	O
of	O
MSNT	O
in	O
320	O
pl	O
of	O
anhydrous	O
pyridine	O
.	O

The	O
solution	O
is	O
then	O
transferred	O
to	O
the	O
vial	O
containing	O
0.06	O
mmol	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np	O
-	O
Et3NH	O
.	O

The	O
nucleotide	O
is	O
dissolved	O
by	O
vortexing	O
and	O
the	O
coupling	O
solution	O
is	O
then	O
added	O
dropwise	O
to	O
the	O
support	O
.	O

It	O
is	O
important	O
to	O
add	O
the	O
solution	O
slowly	O
and	O
to	O
allow	O
the	O
support	O
to	O
swell	O
.	O

Trapped	O
gas	O
bubbles	O
may	O
be	O
removed	O
by	O
gently	O
tapping	O
the	O
column	O
.	O

This	O
entire	O
operation	O
is	O
carried	O
out	O
using	O
one	O
predried	O
syringe	O
.	O

The	O
syringe	O
is	O
left	O
in	O
the	O
V	O
-	O
vial	O
while	O
the	O
reagents	O
are	O
being	O
dissolved	O
.	O

8)	O
The	O
reaction	O
mixture	O
is	O
kept	O
at	O
room	O
temperature	O
for	O
two	O
hrs	O
.	O

9	O
)	O
The	O
column	O
is	O
set	O
up	O
in	O
the	O
washing	O
mode	O
and	O
the	O
support	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
.	O

The	O
solution	O
,	O
which	O
contains	O
unreacted	O
nucleoside	O
3'-methylphosphonate	O
and	O
MSNT	O
,	O
is	O
collected	O
in	O
a	O
separate	O
flask	O
.	O

A	O
50	O
%	O
aqueous	O
pyridine	O
solution	O
(	O
1	O
ml	O
)	O
is	O
added	O
and	O
the	O
solution	O
is	O
kept	O
at	O
40C	O
for	O
later	O
purification	O
and	O
recovery	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np	O
.	O

10	O
)	O
The	O
support	O
is	O
treated	O
with	O
a	O
solution	O
containing	O
2	O
ml	O
of	O
anhydrous	O
pyridine	O
,	O
1	O
ml	O
of	O
acetic	O
anhydride	O
and	O
20	O
mg	O
of	O
dimethylaminopyridine	O
for	O
30	O
min	O
.	O

(	O
This	O
step	O
was	O
not	O
included	O
for	O
the	O
synthesis	O
of	O
oligomer	O
10	O
)	O
.	O

11	O
)	O
Return	O
to	O
step	O
1	O
,	O
for	O
the	O
next	O
cycle	O
.	O

Removal	O
of	O
Base	O
Protecting	O
Groups	O
.	O

The	O
following	O
general	O
procedure	O
was	O
found	O
to	O
be	O
the	O
most	O
effective	O
method	O
for	O
cleaving	O
the	O
oligonucleotide	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
and	O
for	O
removing	O
the	O
base	O
protecting	O
groups	O
with	O
minimal	O
hydrolysis	O
of	O
the	O
phosphonate	O
backbone	O
.	O

The	O
following	O
steps	O
were	O
used	O
for	O
deprotecting	O
oligomers	O
7	O
,	O
8	O
and	O
10	O
.	O

Oligomer	O
9	O
was	O
deprotected	O
in	O
a	O
similar	O
fashion	O
except	O
step	O
4	O
)	O
was	O
carried	O
out	O
at	O
650C	O
for	O
3	O
hrs	O
.	O

For	O
oligomers	O
1	O
-	O
6	O
,	O
step	O
3	O
)	O
was	O
not	O
included	O
and	O
step	O
4	O
)	O
was	O
carried	O
out	O
at	O
650	O
for	O
3	O
hrs	O
.	O

1	O
)	O
After	O
the	O
final	O
condensation	O
step	O
the	O
support	O
(	O
60	O
mg	O
)	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
;	O
three	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
and	O
three	O
2	O
ml	O
portions	O
of	O
diethyl	O
ether	O
.	O

The	O
support	O
is	O
then	O
dried	O
under	O
house	O
vacuum	O
.	O

2	O
)	O
The	O
support	O
is	O
swollen	O
by	O
addition	O
of	O
2	O
ml	O
of	O
pyridine	O
and	O
the	O
excess	O
is	O
removed	O
under	O
house	O
vacuum	O
.	O

3	O
)	O
The	O
support	O
is	O
treated	O
with	O
3	O
ml	O
of	O
0.017	O
M	O
tetra	O
-	O
n	O
-	O
butylammonium	O
fluoride	O
in	O
tetrahydrofuran	O
/	O
pyridine	O
/	O
water	O
(	O
8:1:1	O
,	O
v	O
/	O
v	O
)	O
for	O
40	O
hrs	O
at	O
room	O
temperature	O
.	O

No	O
shaking	O
is	O
required	O
.	O

The	O
support	O
is	O
then	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
50	O
%	O
pyridine	O
/	O
water	O
;	O
three	O
2	O
ml	O
portions	O
of	O
pyridine	O
;	O
and	O
three	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
.	O

4	O
)	O
The	O
support	O
is	O
treated	O
with	O
3	O
ml	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
for	O
7	O
hrs	O
at	O
room	O
temperature	O
6228	O
Nucleic	O
Acids	O
Research	O
without	O
shaking	O
.	O

The	O
solution	O
is	O
collected	O
and	O
the	O
support	O
is	O
washed	O
with	O
four	O
2	O
ml	O
portions	O
of	O
pyridine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
and	O
four	O
2	O
ml	O
portions	O
of	O
N	O
,	O
N	O
-	O
dimethylformamide	O
.	O

The	O
combined	O
eluate	O
and	O
washings	O
are	O
evaporated	O
at	O
250C	O
and	O
the	O
oily	O
residue	O
is	O
co	O
-	O
evaporated	O
several	O
time	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

Purification	O
of	O
Oligonucleoside	O
Methylphosphonates	O
.	O

For	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
(	O
1	O
-	O
6	O
)	O
,	O
the	O
residue	O
from	O
step	O
4	O
)	O
of	O
the	O
previous	O
section	O
is	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
solution	O
is	O
chromatographed	O
on	O
a	O
C-18	O
reversed	O
phase	O
column	O
(	O
0.46	O
cm	O
x	O
25	O
cm	O
for	O
100	O
A254	O
units	O
or	O
less	O
;	O
0.9	O
cm	O
x	O
50	O
cm	O
for	O
more	O
than	O
100	O
A254	O
units	O
)	O
using	O
a	O
linear	O
gradient	O
of	O
0	O
%	O
to	O
25	O
%	O
(	O
8-mer	O
or	O
less	O
)	O
or	O
0	O
%	O
to	O
35	O
%	O
(	O
9	O
mer	O
)	O
acetonitrile	O
in	O
water	O
to	O
remove	O
non	O
-	O
tritylated	O
oligomers	O
.	O

The	O
desired	O
tritylated	O
oligomer	O
is	O
eluted	O
with	O
50	O
%	O
acetonitrile	O
in	O
water	O
.	O

The	O
solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
treated	O
with	O
1	O
ml	O
of	O
80	O
%	O
acetic	O
acid	O
in	O
water	O
for	O
1	O
hr	O
at	O
room	O
temperature	O
.	O

The	O
solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
repeatedly	O
evaporated	O
with	O
ethanol	O
to	O
ensure	O
complete	O
removal	O
of	O
acetic	O
acid	O
.	O

The	O
oligomer	O
is	O
then	O
purified	O
by	O
C-18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
25	O
%	O
or	O
30	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

For	O
oligomers	O
which	O
terminate	O
with	O
a	O
5'-nucleoside	O
phosphodiester	O
linkage	O
(	O
7	O
-	O
10	O
)	O
the	O
residue	O
from	O
step	O
4	O
)	O
described	O
in	O
the	O
preceeding	O
section	O
is	O
treated	O
with	O
80	O
%	O
acetic	O
acid	O
in	O
water	O
for	O
15	O
min	O
at	O
room	O
temperature	O
.	O

After	O
removal	O
of	O
the	O
acetic	O
acid	O
by	O
evaporation	O
,	O
the	O
residue	O
is	O
dissolved	O
in	O
20	O
ml	O
of	O
50	O
%	O
aqueous	O
ethanol	O
and	O
the	O
solution	O
is	O
passed	O
through	O
a	O
DEAE	O
cellulose	O
column	O
(	O
2.5	O
x	O
8	O
cm	O
,	O
bicarbonate	O
form	O
)	O
which	O
has	O
been	O
previously	O
washed	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
column	O
is	O
monitored	O
at	O
254	O
nm	O
and	O
washed	O
with	O
50	O
%	O
aqueous	O
ethanol	O
until	O
the	O
pen	O
returns	O
to	O
the	O
baseline	O
.	O

The	O
desired	O
oligomer	O
is	O
then	O
eluted	O
with	O
0.15	O
M	O
triethylammonium	O
bicarbonate	O
in	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
buffer	O
is	O
removed	O
by	O
evaporation	O
and	O
co	O
-	O
evaporated	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
oligomer	O
is	O
then	O
further	O
purified	O
by	O
C-18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
0.10	O
M	O
ammonium	O
acetate	O
(	O
pH	O
5.8	O
)	O
gradient	O
.	O

The	O
oligomer	O
is	O
freed	O
of	O
ammonium	O
acetate	O
by	O
desalting	O
on	O
a	O
Bio	O
-	O
Gel	O
P-2	O
column	O
(	O
1.5	O
x	O
20	O
cm	O
)	O
.	O

Removal	O
of	O
the	O
5'-Terminal	O
Nucleotide	O
Unit	O
.	O

Oligomers	O
which	O
terminate	O
with	O
a	O
5'-nucleotide	O
phosphodiester	O
may	O
be	O
converted	O
to	O
the	O
oligonucleoside	O
methylphosphonate	O
by	O
the	O
following	O
procedure	O
.	O

The	O
oligomer	O
(	O
3	O
A254	O
units	O
)	O
is	O
dissolved	O
in	O
40	O
pl	O
of	O
water	O
and	O
treated	O
at	O
370C	O
for	O
2	O
hrs	O
with	O
10	O
PI	O
(	O
1	O
-	O
2	O
units	O
)	O
of	O
spleen	O
phosphodiesterase	O
dissolved	O
in	O
water	O
.	O

The	O
completeness	O
of	O
the	O
reaction	O
is	O
determined	O
by	O
reversed	O
phase	O
HPLC	O
.	O

The	O
solution	O
is	O
then	O
6229	O
Nucleic	O
Acids	O
Research	O
diluted	O
with	O
50	O
ul	O
of	O
water	O
and	O
passed	O
through	O
a	O
DEAE	O
cellulose	O
column	O
(	O
0.5	O
x	O
1	O
cm	O
)	O
.	O

The	O
column	O
is	O
washed	O
with	O
500	O
Pl	O
of	O
water	O
and	O
the	O
oligomer	O
is	O
recovered	O
by	O
lyophilization	O
.	O

Recovery	O
of	O
Protected	O
Nucleoside	O
3'-Methylphosphonates	O
.	O

The	O
aqueous	O
pyridine	O
solution	O
from	O
step	O
9	O
)	O
described	O
in	O
General	O
Procedure	O
for	O
Preparing	O
Oligonucleoside	O
Methylphosphonates	O
,	O
is	O
evaporated	O
after	O
addition	O
of	O
0.1	O
ml	O
of	O
triethylamine	O
.	O

The	O
residue	O
is	O
dissolved	O
in	O
50	O
ml	O
of	O
chloroform	O
and	O
the	O
solution	O
is	O
extracted	O
twice	O
with	O
50	O
ml	O
of	O
1	O
M	O
ammonium	O
bicarbonate	O
.	O

The	O
chloroform	O
layer	O
is	O
dried	O
over	O
anhydrous	O
sodium	O
sulfate	O
.	O

Several	O
drops	O
of	O
triethylamine	O
are	O
added	O
to	O
clarify	O
the	O
solution	O
.	O

After	O
filtration	O
the	O
solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
evaporated	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
on	O
an	O
oil	O
pump	O
.	O

The	O
foamy	O
residue	O
is	O
dissolved	O
in	O
2	O
ml	O
of	O
dry	O
methylene	O
chloride	O
and	O
the	O
solution	O
is	O
added	O
dropwise	O
to	O
a	O
stirred	O
solution	O
of	O
1	O
%	O
triethylamine	O
in	O
hexane	O
.	O

The	O
resulting	O
precipitate	O
is	O
collected	O
via	O
filtration	O
on	O
a	O
sintered	O
glass	O
filter	O
,	O
washed	O
with	O
hexane	O
and	O
dried	O
in	O
a	O
vacuum	O
desiccator	O
.	O

Removal	O
of	O
Base	O
Protecting	O
Groups	O
with	O
Ethylenediamine	O
.	O

Several	O
mg	O
of	O
d	O
-	O
I	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC	O
and	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibu	O
G	O
were	O
each	O
dissolved	O
in	O
250	O
pl	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1,v	O
/	O
v	O
)	O
.	O

The	O
solutions	O
were	O
incubated	O
at	O
room	O
temperature	O
.	O

At	O
various	O
times	O
aliquots	O
were	O
chromatographed	O
on	O
silica	O
gel	O
TLC	O
plates	O
which	O
were	O
eluted	O
with	O
10	O
%	O
methanol	O
in	O
chloroform	O
.	O

The	O
spots	O
corresponding	O
to	O
the	O
starting	O
material	O
and	O
the	O
product	O
were	O
cut	O
out	O
and	O
treated	O
with	O
1.5	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
(	O
3:2	O
,	O
v	O
/	O
v	O
)	O
for	O
30	O
min	O
.	O

The	O
absorbance	O
of	O
each	O
solution	O
was	O
measured	O
at	O
500	O
nm	O
and	O
the	O
percent	O
reaction	O
was	O
determined	O
.	O

The	O
half	O
-	O
lives	O
of	O
the	O
reactions	O
are	O
given	O
in	O
Table	O
II	O
.	O

Removal	O
of	O
Protected-	O
Nucleosides	O
from	O
Polystyrene	O
Support	O
.	O

Five	O
mg	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
(	O
ED	O
(	O
1	O
%	O
crosslinked	O
)	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
O?	O
(	O
1	O
%	O
crosslinked	O
)	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC	O
(	O
?	O
)	O
(	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
)	O
and	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuGcD	O
(	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
)	O
were	O
each	O
treated	O
with	O
500	O
ul	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
solution	O
at	O
room	O
temperature	O
.	O

At	O
various	O
times	O
,	O
10	O
pl	O
aliquots	O
were	O
removed	O
,	O
the	O
solvent	O
was	O
evaporated	O
and	O
the	O
residue	O
was	O
dissolved	O
in	O
1	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
solution	O
(	O
3:2	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
amount	O
of	O
dimethoxytrityl	O
cation	O
and	O
hence	O
the	O
amount	O
of	O
nucleoside	O
cleaved	O
from	O
the	O
support	O
was	O
determined	O
by	O
measuring	O
the	O
absorbance	O
at	O
500	O
nm	O
.	O

The	O
half	O
lives	O
of	O
the	O
cleavage	O
reactions	O
are	O
given	O
in	O
Table	O
II	O
.	O

Hydrolysis	O
of	O
the	O
Methylphosphonate	O
Linkage	O
by	O
Ethylenediamine	O
.	O

Oligonucleoside	O
methylphosphonates	O
(	O
1.25	O
A254	O
units	O
each	O
)	O
were	O
treated	O
with	O
50	O
il	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
room	O
temperature	O
.	O

Aliquots	O
6230	O

Nucleic	O
Acids	O
Research	O
(	O
10	O
pl	O
)	O
were	O
withdrawn	O
at	O
various	O
times	O
and	O
the	O
solvents	O
were	O
evaporated	O
.	O

The	O
residue	O
was	O
dissolved	O
in	O
20	O
PI	O
of	O
50	O
%	O
aqueous	O
ethanol	O
and	O
the	O
solution	O
examined	O
by	O
C-18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
25	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

The	O
mole	O
percent	O
of	O
starting	O
oligomer	O
remaining	O
after	O
100	O
hrs	O
of	O
treatment	O
is	O
given	O
in	O
Table	O
III	O
.	O

Hydrolysis	O
of	O
Oligonucleoside	O
Methylphosphonates	O
in	O
Acid	O
.	O

Six	O
A254	O
units	O
of	O
oligomer	O
were	O
dissolved	O
in	O
100	O
pl	O
of	O
0.01	O
M	O
hydrochloric	O
acid	O
solution	O
.	O

The	O
solution	O
was	O
heated	O
at	O
either	O
450	O
or	O
650C	O
.	O

Aliquots	O
(	O
10	O
Pil	O
)	O
were	O
withdrawn	O
at	O
various	O
times	O
and	O
added	O
to	O
10	O
pl	O
of	O
0.015	O
M	O
ammonium	O
hydroxide	O
at	O
0?C.	O
The	O
samples	O
were	O
then	O
injected	O
directly	O
onto	O
a	O
C-18	O
reversed	O
phase	O
column	O
which	O
was	O
eluted	O
with	O
50	O
ml	O
of	O
a	O
linear	O
gradient	O
of	O
0	O
%	O
to	O
25	O
%	O
acetonitrile	O
in	O
water	O
at	O
a	O
flow	O
rate	O
of	O
2.5	O
ml	O
/	O
min	O
.	O

The	O
products	O
of	O
the	O
reaction	O
were	O
determined	O
by	O
comparison	O
with	O
authentic	O
samples	O
.	O

Labeling	O
5'-End	O
of	O
Oligonucleoside	O
Methylphosphonates	O
with	O
T4-Polynucleotide	O
Kinase	O
.	O

Oligonucleoside	O
methylphosphonates	O
(	O
2	O
nmol	O
)	O
were	O
dissolved	O
in	O
a	O
buffer	O
solution	O
containing	O
50	O
mM	O
Tris	O
-	O
HC1	O
(	O
pH	O
9.0	O
)	O
,	O
10	O
mM	O
MgCl2	O
,	O
5	O
mM	O
dithiothreitol	O
,	O
20	O
pM	O
spermidine	O
,	O
and	O
[	O
y-32P	O
]	O
ATP	O
(	O
8	O
ljCi	O
,	O
4Ci	O
/	O
mmol	O
)	O
.	O

T4-polynucleotide	O
kinase	O
(	O
4	O
units	O
)	O
was	O
added	O
to	O
the	O
solution	O
,	O
which	O
was	O
made	O
up	O
to	O
50	O
ul	O
by	O
adding	O
water	O
.	O

The	O
solutions	O
were	O
incubated	O
at	O
370C	O
for	O
2	O
hrs	O
.	O

The	O
reaction	O
was	O
checked	O
by	O
PEI	O
-	O
cellulose	O
TLC	O
.	O

The	O
PEI	O
-	O
cellulose	O
plate	O
(	O
12x2Ocm	O
,	O
Merck	O
)	O
was	O
preactivated	O
by	O
elution	O
with	O
1.2	O
M	O
pyridinium	O
formate	O
(	O
pH	O
3.5	O
)	O
.	O

Small	O
aliquots	O
(	O
0.1	O
pl	O
)	O
of	O
PNK	O
reaction	O
solutions	O
were	O
applied	O
and	O
developed	O
with	O
1.5	O
M	O
pyridinium	O
formate	O
(	O
pH	O
3.5	O
)	O
.	O

The	O
TLC	O
plate	O
was	O
dried	O
and	O
autoradiographed	O
using	O
an	O
intensifying	O
screen	O
at	O
room	O
temperature	O
.	O

Gel	O
Electrophoresis	O
of	O
5'-Labeled	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Polyacrylamide	O
gels	O
were	O
prepared	O
by	O
polymerizing	O
a	O
solution	O
containing	O
18	O
%	O
(	O
w	O
/	O
v	O
)	O
acrylamide	O
,	O
0.8	O
%	O
(	O
w	O
/	O
v	O
)	O
N	O
,	O
N'-methylenebisacrylamide	O
.	O

7	O
M	O
urea	O
,	O
89	O
mM	O
Tris	O
-	O
borate	O
(	O
pH	O
8.2	O
)	O
,	O
2	O
mM	O
EDTA	O
,	O
0.07	O
%	O
(	O
w	O
/	O
v	O
)	O
ammonium	O
persulfate	O
,	O
in	O
the	O
presence	O
of	O
N	O
,	O
N	O
,	O
N',N'-tetramethylethylenediamine	O
(	O
20	O
Pil	O
/	O
20	O
ml	O
solution	O
)	O
.	O

The	O
solution	O
was	O
poured	O
into	O
a	O
0.75	O
x	O
140	O
x	O
150	O
mm	O
mold	O
and	O
allowed	O
to	O
polymerize	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
.	O

5'-Labeled	O
oligonucleoside	O
methylphosphonates	O
were	O
dissolved	O
in	O
10	O
%	O
aqueous	O
glycerol	O
solution	O
containing	O
0.04	O
%	O
bromophenol	O
blue	O
and	O
applied	O
to	O
the	O
gel	O
.	O

The	O
electrophoresis	O
was	O
run	O
using	O
89	O
mM	O
Tris	O
-	O
Borate	O
buffer	O
containing	O
10	O
mM	O
EDTA	O
.	O

After	O
electrophoresis	O
the	O
gel	O
was	O
dried	O
using	O
a	O
gel	O
-	O
dryer	O
and	O
autoradiographed	O
using	O
intensifying	O
screens	O
at	O
room	O
temperature	O
.	O

Pa	O
rti	O
al	O
Cl	O
eavage	O
of	O
01	O
i	O
gonucl	O
eosi	O
de	O
Methyl	O
phosphonates	O
wi	O
th	O
Hydrochl	O
ori	O
c	O
Aci	O
d	O
or	O
Piperidine	O
.	O

Aliquots	O
(	O
1	O
,	O
jl	O
)	O
from	O
the	O
polynucleotide	O
kinase	O
reaction	O
6231	O
Nucleic	O
Acids	O
Research	O
mixture	O
were	O
incubated	O
with	O
1	O
il	O
of	O
1	O
M	O
hydrochloric	O
acid	O
at	O
37?C	O
for	O
30	O
min	O
.	O

After	O
incubation	O
the	O
solution	O
was	O
neutralized	O
with	O
1	O
Pl	O
of	O
1	O
M	O
ammonium	O
hydroxide	O
and	O
then	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
10	O
min	O
before	O
cooling	O
to	O
00	O
.	O

Alternatively	O
,	O
aliquots	O
(	O
1	O
pl	O
)	O
from	O
the	O
phosphorylation	O
reaction	O
were	O
incubated	O
with	O
1	O
ul	O
of	O
1	O
M	O
aqueous	O
piperidine	O
at	O
370C	O
for	O
10	O
min	O
after	O
which	O
the	O
solution	O
was	O
cooled	O
to	O
0	O
?	O
and	O
evaporated	O
.	O

The	O
treated	O
samples	O
were	O
then	O
subjected	O
to	O
polyacrylamide	O
gel	O
electrophoresis	O
as	O
described	O
above	O
without	O
further	O
purification	O
.	O

RESULTS	O
AND	O
DISCUSSION	O
Synthesis	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Table	O
I	O
shows	O
some	O
of	O
the	O
protected	O
oligonucleoside	O
methylphosphonates	O
which	O
have	O
been	O
synthesized	O
on	O
aminomethyl	O
succinyl	O
-	O
derivatized	O
polystyrene	O
supports	O
.	O

The	O
basic	O
synthetic	O
steps	O
which	O
are	O
shown	O
in	O
Figure	O
1	O
are	O
described	O
in	O
detail	O
in	O
the	O
Experimental	O
section	O
.	O

These	O
steps	O
are	O
:	O
(	O
1	O
)	O
removal	O
of	O
the	O
dimethoxytrityl	O
group	O
with	O
1	O
M	O
zinc	O
bromide	O
solution	O
;	O
(	O
2	O
)	O
drying	O
the	O
support	O
via	O
co	O
-	O
evaporation	O
with	O
anhydrous	O
pyridine	O
;	O
(	O
3	O
)	O
reaction	O
of	O
the	O
support	O
-	O
bound	O
nucleoside	O
or	O
oligonucleotide	O
with	O
a	O
coupling	O
mixture	O
containing	O
0.15	O
to	O
0.2	O
M	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
)	O
-NpjEt3NH	O
and	O
0.3	O
to	O
0.6	O
M	O
mesitylenesulfonyl-3-nitrotriazole	O
in	O
anhydrous	O
pyridine	O
and	O
(	O
4	O
)	O
acetylation	O
of	O
unreacted	O
5'-OH	O
groups	O
with	O
acetic	O
anhydride	O
.	O

The	O
reactions	O
and	O
washing	O
steps	O
were	O
most	O
conveniently	O
carried	O
out	O
in	O
a	O
polypropylene	O
Econo	O
Column	O
fitted	O
with	O
a	O
septum	O
cap	O
and	O
a	O
3-way	O
Teflon	O
DMTrO	O
,	O
O	O
Figure	O
1	O
:	O
Preparation	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
on	O
a	O
1	O
T	O
o	O
w	O
Polystyrene	O
Support	O
0	O
H	O
BFvON	O
DlDTrOjO4B	O
U	O
)	O
I	O
CH3-gd	O
-	O
OEt	O
3NH	O
0	O
6232	O
Nucleic	O
Acids	O
Research	O
stopcock	O
.	O

Thus	O
no	O
transfers	O
of	O
the	O
support	O
are	O
required	O
using	O
this	O
apparatus	O
.	O

The	O
synthetic	O
procedure	O
is	O
analogous	O
to	O
the	O
phosphotriester	O
approach	O
used	O
to	O
prepared	O
protected	O
oligonucleotide	O
phosphotriesters	O
on	O
polystyrene	O
supports	O
(	O
6	O
)	O
.	O

However	O
,	O
we	O
found	O
the	O
methylphosrhonate	O
coupling	O
reaction	O
to	O
be	O
extremely	O
sensitive	O
to	O
moisture	O
.	O

Drying	O
procedures	O
such	O
as	O
washing	O
with	O
anhydrous	O
solvent	O
or	O
blowing	O
dry	O
nitrogen	O
gas	O
through	O
the	O
support	O
which	O
are	O
satisfactory	O
for	O
phosphotriester	O
synthesis	O
resulted	O
in	O
low	O
yields	O
of	O
the	O
methylphosphonates	O
.	O

The	O
best	O
yields	O
were	O
obtained	O
when	O
the	O
support	O
was	O
co	O
-	O
evaporated	O
with	O
anhydrous	O
pyridine	O
by	O
directly	O
attaching	O
the	O
reaction	O
column	O
to	O
a	O
vacuum	O
pump	O
and	O
dry	O
-	O
ice	O
trap	O
.	O

Three	O
10	O
min	O
co	O
-	O
evaporations	O
were	O
sufficient	O
to	O
render	O
the	O
support	O
anhydrous	O
.	O

The	O
protected	O
nucleoside	O
3'-methylphosphonate	O
triethylammonium	O
salts	O
used	O
in	O
the	O
coupling	O
reactions	O
were	O
prepared	O
from	O
their	O
cyanoethyl	O
ester	O
derivatives	O
(	O
3	O
)	O
.	O

These	O
monomers	O
were	O
recovered	O
after	O
each	O
coupling	O
step	O
and	O
were	O
freed	O
of	O
unreacted	O
MSNT	O
by	O
a	O
simple	O
extraction	O
step	O
.	O

After	O
precipitation	O
and	O
drying	O
,	O
the	O
monomers	O
could	O
be	O
reused	O
for	O
other	O
syntheses	O
.	O

The	O
ability	O
to	O
recover	O
the	O
unreacted	O
monomers	O
is	O
particularly	O
important	O
for	O
large	O
scale	O
synthesis	O
since	O
large	O
excesses	O
of	O
these	O
materials	O
are	O
employed	O
in	O
the	O
coupling	O
step	O
.	O

This	O
recovery	O
step	O
represents	O
a	O
potential	O
advantage	O
over	O
the	O
phosphine	O
synthetic	O
method	O
(	O
4	O
)	O
,	O
since	O
it	O
is	O
not	O
clear	O
that	O
nucleoside	O
3'-methylphosphine	O
chlorides	O
can	O
be	O
recovered	O
after	O
reaction	O
.	O

Two	O
types	O
of	O
methylphosphonate	O
oligomers	O
were	O
prepared	O
;	O
those	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
,	O
oligomers	O
1	O
-	O
6	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5'-nucleoside	O
3'-p	O
-	O
chlorophenyl	O
phosphotriester	O
moiety	O
,	O
oligomers	O
7	O
-	O
10	O
.	O

Oligomers	O
were	O
synthesized	O
on	O
both	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
supports	O
.	O

As	O
shown	O
in	O
Table	O
I	O
,	O
the	O
average	O
yield	O
per	O
coupling	O
step	O
which	O
was	O
determined	O
by	O
trityl	O
group	O
analysis	O
was	O
approximately	O
82	O
%	O
,	O
for	O
both	O
types	O
of	O
support	O
.	O

This	O
yield	O
is	O
adequate	O
to	O
allow	O
preparation	O
of	O
protected	O
octamers	O
or	O
nonamers	O
in	O
25	O
%	O
and	O
20	O
%	O
overall	O
yield	O
,	O
respectively	O
.	O

Deprotection	O
.	O

Our	O
previous	O
studies	O
(	O
1	O
)	O
and	O
those	O
of	O
Sinha	O
et	O
al.	O
(	O
4	O
)	O
show	O
that	O
methylphosphonate	O
linkages	O
are	O
cleaved	O
by	O
base	O
.	O

We	O
found	O
this	O
hydrolysis	O
reaction	O
to	O
depend	O
to	O
some	O
extent	O
upon	O
the	O
nucleoside	O
sequence	O
of	O
the	O
oligomer	O
.	O

Hydrolysis	O
of	O
methylphosphonate	O
linkages	O
by	O
concentrated	O
ammonium	O
hydroxide	O
in	O
pyridine	O
(	O
1:1	O
v	O
/	O
v	O
)	O
,	O
the	O
reagent	O
commonly	O
used	O
to	O
remove	O
oligonucleotide	O
base	O
protecting	O
groups	O
,	O
can	O
be	O
largely	O
suppressed	O
if	O
the	O
reactions	O
are	O
run	O
at	O
0?C	O
(	O
1	O
)	O
.	O

However	O
,	O
these	O
conditions	O
are	O
unsatisfactory	O
for	O
removal	O
of	O
oligonucleoside	O
methylphosphonates	O
from	O
the	O
polystyrene	O
6233	O
Nucleic	O
Acids	O
Research	O
Table	O
I.	O
Syntheses	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
on	O
Polystyrene	O
Supports	O
Support	O
Average	O
cross-	O
yield	O
Protected	O
oligomer	O
(	O
a	O
)	O
linking	O
per	O
(	O
%	O
)	O
coupling	O
step	O
(	O
%	O
)	O
1	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCpbzCpbzApT	O
-	O
O	O
1	O
81	O
2	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuGpbzCpbzCpbzApT-	O
1	O
82	O
3	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCpbzApi	O
buGpi	O
buGpTpbzApbzA	O
-	O
G1i	O
2	O
83	O
4	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCLpTpT	O
bzApbzCpbzCpTpibuG-	O
?	O

2	O
85	O
5	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
TpbzCpbzCpTpbzCpbzCpTpibuG-	O
(	O
?	O

2	O
86	O
6	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
TpTpTpbzApbzCpbzCpTpT-	O
?	O

1	O
83	O
7	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApbzApbzA-	O
?	O

1	O
83	O
8	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA4bzCpbzCpbzApT-	O
?	O

1	O
81	O
9	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApibuGpbzCpbzApbzApibuG-	O
(	O
2	O
74	O
10	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApbzApbzApbzApibuGpbzCpbzApbzApibuG-	O
(	O
Q	O
1	O
86	O
(	O
a	O
)	O
p	O
=	O
methylphosphonate	O
linkage	O
T	O
=	O
p	O
-	O
chlorophenyl	O
phosphotriester	O
linkage	O
(	O
Q=	O
polystyrene	O
support	O
(	O
b	O
)	O
Determined	O
by	O
analysis	O
of	O
the	O
dimethoxytrityl	O
group	O
after	O
each	O
coupling	O
step	O
.	O

support	O
.	O

We	O
therefore	O
examined	O
other	O
deprotection	O
procedures	O
.	O

Recently	O
Barnett	O
and	O
Letsinger	O
described	O
removal	O
of	O
base	O
protecting	O
groups	O
from	O
oligonucleotide	O
B	O
,	O
B,0-trichloroethylphosphotriesters	O
using	O
a	O
mixture	O
of	O
ethylenediamine	O
in	O
phenol	O
(	O
7	O
)	O
.	O

We	O
have	O
found	O
ethylenediamine	O
in	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
rapidly	O
and	O
cleanly	O
removes	O
benzoyl	O
and	O
isobutyryl	O
protecting	O
groups	O
from	O
dA	O
,	O
dC	O
and	O
dG	O
nucleosides	O
.	O

This	O
reagent	O
is	O
particularly	O
attractive	O
since	O
it	O
can	O
be	O
easily	O
removed	O
by	O
evaporation	O
.	O

In	O
our	O
initial	O
investigations	O
,	O
ol	O
igonucleoside	O
methylphosphonates	O
were	O
cleaved	O
from	O
the	O
support	O
and	O
base	O
protecting	O
groups	O
were	O
removed	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
65?C	O
for	O
3	O
hrs	O
.	O

Although	O
preliminary	O
results	O
indicated	O
the	O
methylphosphonate	O
linkages	O
of	O
several	O
dimers	O
were	O
stable	O
to	O
these	O
conditions	O
,	O
we	O
later	O
found	O
that	O
the	O
linkages	O
of	O
onger	O
6234	O
Nucleic	O
Acids	O
Research	O
Table	O
II	O
.	O

Hydrolysis	O
of	O
Protected	O
Nucleosides	O
by	O
Ethylenediamine	O
at	O
220C	O
Protected	O
Time	O
required	O
to	O
Time	O
required	O
to	O
nucleoside	O
remove	O
50	O
%	O
of	O
the	O
cleave	O
50	O
%	O
of	O
the	O
base	O
protecting	O
nucleoside	O
from	O
the	O
groups	O
(	O
min	O
)	O
1	O
%	O
crosslinked	O
support	O
(	O
min	O
)	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
)	O
bzA	O
10	O
105	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
bzC	O
20	O
105	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
i	O
buG	O
40	O
54	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
_	O
105	O
oligomers	O
were	O
hydrolyzed	O
to	O
various	O
extents	O
by	O
this	O
procedure	O
.	O

This	O
of	O
course	O
resulted	O
in	O
loss	O
of	O
product	O
as	O
was	O
evidenced	O
by	O
the	O
presence	O
of	O
shorter	O
oligomers	O
in	O
amounts	O
greater	O
than	O
expected	O
based	O
upon	O
the	O
coupling	O
yields	O
.	O

To	O
circumvent	O
this	O
problem	O
we	O
examined	O
the	O
deprotection	O
reactions	O
at	O
lower	O
temperatures	O
and	O
found	O
they	O
could	O
be	O
run	O
effectively	O
at	O
room	O
temperature	O
.	O

Table	O
II	O
shows	O
the	O
half	O
-	O
lives	O
for	O
removing	O
the	O
base	O
protecting	O
groups	O
from	O
nucleosides	O
at	O
room	O
temperature	O
.	O

While	O
the	O
isobutryl	O
protecting	O
group	O
is	O
removed	O
at	O
the	O
slowest	O
rate	O
,	O
all	O
the	O
groups	O
are	O
completely	O
removed	O
within	O
240	O
min	O
.	O

The	O
sole	O
product	O
of	O
each	O
reaction	O
is	O
the	O
5'-O	O
-	O
dimethoxytritylnucleoside	O
as	O
shown	O
by	O
TLC	O
.	O

Table	O
II	O
also	O
shows	O
the	O
half	O
-	O
lives	O
for	O
cleavage	O
of	O
protected	O
nucleosides	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
.	O

The	O
deoxyguanosine	O
nucleoside	O
is	O
cleaved	O
most	O
rapidly	O
while	O
the	O
other	O
three	O
nucleosides	O
have	O
essentially	O
the	O
same	O
rates	O
of	O
hydrolysis	O
.	O

All	O
the	O
nucleosides	O
are	O
completely	O
removed	O
from	O
the	O
support	O
within	O
7	O
hrs	O
.	O

In	O
contrast	O
,	O
very	O
different	O
rates	O
were	O
observed	O
for	O
the	O
2	O
%	O
crosslinked	O
supports	O
.	O

In	O
these	O
cases	O
,	O
very	O
little	O
cleavage	O
occurred	O
during	O
the	O
first	O
4	O
hrs	O
of	O
incubation	O
after	O
which	O
increasing	O
amounts	O
of	O
nucleoside	O
were	O
released	O
over	O
a	O
24	O
hr	O
period	O
.	O

This	O
effect	O
may	O
be	O
due	O
to	O
the	O
slower	O
swelling	O
rate	O
of	O
the	O
2	O
%	O
crosslinked	O
support	O
versus	O
the	O
1	O
%	O
support	O
.	O

The	O
results	O
of	O
these	O
experiments	O
suggest	O
that	O
,	O
although	O
condensation	O
reactions	O
occur	O
with	O
equal	O
efficiencies	O
on	O
both	O
the	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
supports	O
,	O
the	O
1	O
%	O
support	O
is	O
preferred	O
for	O
syntheses	O
since	O
the	O
oligomers	O
can	O
be	O
removed	O
more	O
readily	O
under	O
mild	O
conditions	O
.	O

The	O
stability	O
of	O
the	O
methylphosphonate	O
linkage	O
in	O
a	O
number	O
of	O
oligomers	O
of	O
varying	O
chain	O
length	O
and	O
base	O
composition	O
was	O
examined	O
following	O
prolonged	O
exposure	O
to	O
ethylenediamine	O
/	O
ethanol	O
at	O
room	O
temperature	O
.	O

As	O
shown	O
in	O
Table	O
III	O
,	O
some	O
of	O
these	O
oligomers	O
,	O
most	O
notably	O
the	O
dimer	O
and	O
d	O
-	O
GpGpT	O
,	O
were	O
6235	O
Nucleic	O
Acids	O
Research	O
Table	O
III	O
.	O

Hydrolysis	O
of	O
Oligonucleoside	O
Methylphosphonates	O
by	O
Ethylenediamine	O
at	O
22?C	O
|	O
Oligomer	O
Mole	O
percent	O
of	O
oligomer	O
remaining	O
after	O
treatment	O
for	O
24	O
hrs	O
48	O
hrs	O
96	O
hrs	O
d	O
-	O
T	O
A	O
100	O
100	O
100	O
d	O
-	O
A5r	O
100	O
100	O
100	O
d	O
-	O
TpT	O
100	O
100	O
100	O
d	O
-	O
l	O
pT	O
95	O
97	O
91	O
d	O
-	O
qgG	O
{	O
T	O
100	O
100	O
100	O
d	O
-	O
ApApA	O
93	O
87	O
75	O
d	O
-	O
C	O
pC	O
ApT	O
92	O
83	O

67	O
completely	O
stable	O
over	O
a	O
96	O
hr	O
period	O
.	O

The	O
maximum	O
rate	O
of	O
hydrolysis	O
for	O
a	O
methylphosphonate	O
linkage	O
in	O
those	O
oligomers	O
which	O
were	O
hydrolyzed	O
is	O
estimated	O
to	O
be	O
0.13	O
mole	O
%	O
/hr	O
.	O

The	O
results	O
of	O
these	O
studies	O
show	O
that	O
the	O
oligonucleoside	O
methylphosphonates	O
could	O
be	O
cleaved	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
and	O
completely	O
freed	O
of	O
base	O
protecting	O
groups	O
with	O
little	O
or	O
no	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkage	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
room	O
temperature	O
for	O
7	O
hrs	O
.	O

These	O
conditions	O
were	O
subsequently	O
adopted	O
for	O
the	O
deprotection	O
step	O
.	O

Purification	O
of	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Two	O
methods	O
were	O
employed	O
to	O
purify	O
oligomers	O
following	O
cleavage	O
from	O
the	O
support	O
.	O

For	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
,	O
the	O
tritylated	O
oligomer	O
was	O
isolated	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

This	O
separation	O
is	O
based	O
upon	O
the	O
greater	O
affinity	O
of	O
the	O
tritylated	O
oligomer	O
for	O
the	O
hydrophobic	O
C-18	O
matrix	O
of	O
the	O
column	O
.	O

Shorter	O
,	O
non	O
-	O
tritylated	O
oligomers	O
were	O
first	O
eluted	O
with	O
a	O
0	O
%	O
to	O
25	O
%	O
or	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

The	O
tritylated	O
product	O
was	O
then	O
eluted	O
with	O
a	O
step	O
gradient	O
of	O
50	O
%	O
acetonitrile	O
in	O
water	O
.	O

The	O
dimethoxytrityl	O
group	O
was	O
removed	O
from	O
the	O
material	O
in	O
the	O
50	O
%	O
acetonitrile	O
fraction	O
by	O
treatment	O
with	O
80	O
%	O
acetic	O
acid	O
at	O
room	O
temperature	O
.	O

Because	O
these	O
oligomers	O
were	O
originally	O
cleaved	O
from	O
the	O
support	O
by	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
65?C	O
,	O
we	O
usually	O
found	O
that	O
the	O
tritylated	O
oligomer	O
fraction	O
contained	O
shorter	O
oligomers	O
in	O
addition	O
to	O
the	O
desired	O
product	O
.	O

These	O
were	O
easily	O
separated	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

While	O
this	O
purification	O
procedure	O
is	O
qualitatively	O
satisfactory	O
,	O
recoveries	O
from	O
the	O
reversed	O
phase	O
columns	O
varied	O
from	O
50	O
%	O
to	O
90	O
%	O
.	O

These	O
losses	O
which	O
appeared	O
to	O
be	O
due	O
to	O
irreverisble	O
absorption	O
of	O
the	O
oligomers	O
to	O
the	O
column	O
varied	O
depending	O
on	O
the	O
base	O
composition	O
of	O
the	O
oligomers	O
.	O

6236	O
Nucleic	O
Acids	O
Research	O
Figure	O
2	O
:	O
Purification	O
of	O
d	O
-	O
ApApApApGpCpApApG.	O
(	O
a	O
)	O
Ol	O
igomers	O
obtained	O
after	O
treatment	O
of	O
support	O
wi	O
th	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
.	O

(	O
b	O
)	O
Ol	O
igomers	O
obtained	O
after	O
treatment	O
of	O
the	O
mixture	O
in	O
(	O
a	O
)	O
with	O
80	O
%	O
acetic	O
acid	O
.	O

(	O
c	O
)	O
Oligomers	O
eluted	O
from	O
DEAE	O
cellulose	O
column	O
with	O
0.15	O
M	O
triethylammonium	O
bicarbonate	O
.	O

(	O
d	O
)	O
Nonamer	O
obtained	O
after	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

Peaks	O
marked	O
with	O
the	O
symbol	O
(	O
X	O
)	O
are	O
derived	O
from	O
impurities	O
in	O
the	O
solvents	O
used	O
to	O
elute	O
the	O
oligomer	O
from	O
the	O
polystyrene	O
support	O
.	O

d	O
""""	O
AAAGCAAGc	O
O	O
I	O
t10	O
15	O
20	O
25	O
Time	O
(	O
min	O
)	O
For	O
the	O
oligomers	O
which	O
terminate	O
with	O
a	O
5'-nucleoside	O
phosphotriester	O
group	O
,	O
the	O
support	O
was	O
first	O
treated	O
for	O
40	O
hrs	O
with	O
tetra	O
-	O
n	O
-	O
butylammonium	O
fluoride	O
(	O
8)	O
to	O
remove	O
the	O
p	O
-	O
chlorophenyl	O
protecting	O
group	O
.	O

These	O
oligomers	O
6237	O
b	O
Nucleic	O
Acids	O

Research	O
were	O
then	O
cleaved	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
were	O
removed	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
for	O
7	O
hrs	O
at	O
room	O
temperature	O
.	O

For	O
example	O
,	O
the	O
reversed	O
phase	O
HPLC	O
profile	O
for	O
products	O
obtained	O
after	O
cleavage	O
of	O
the	O
nonamer	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ApAjApApGpCpApApG	O
,	O
is	O
shown	O
in	O
Figure	O
2a	O
.	O

The	O
peaks	O
marked	O
with	O
(	O
X	O
)	O
are	O
from	O
impurities	O
in	O
the	O
solvents	O
used	O
to	O
elute	O
the	O
oligomer	O
from	O
the	O
support	O
.	O

The	O
tritylated	O
nonamer	O
appears	O
at	O
22	O
min	O
in	O
the	O
chromatogram	O
and	O
is	O
eluted	O
with	O
50	O
%	O
aqueous	O
acetonitrile	O
.	O

After	O
removal	O
of	O
the	O
dimethoxytrityl	O
group	O
,	O
the	O
nonamer	O
elutes	O
at	O
15.2	O
min	O
(	O
Figure	O
2b	O
)	O
.	O

The	O
peaks	O
which	O
appear	O
between	O
19	O
and	O
25	O
min	O
are	O
shorter	O
oligomers	O
which	O
contain	O
a	O
5'-mesitylenesulfonate	O
group	O
.	O

At	O
this	O
stage	O
,	O
the	O
nonamer	O
was	O
partially	O
purified	O
by	O
ion	O
exchange	O
chromatography	O
on	O
a	O
DEAE	O
cellulose	O
column	O
.	O

This	O
step	O
,	O
which	O
resulted	O
in	O
84	O
%	O
recovery	O
of	O
material	O
loaded	O
onto	O
the	O
column	O
,	O
removed	O
most	O
of	O
the	O
shorter	O
oligomers	O
as	O
shown	O
in	O
Figure	O
2c	O
.	O

After	O
removal	O
of	O
the	O
buffer	O
,	O
the	O
nonamer	O
was	O
purified	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
0.1	O
M	O
ammonium	O
acetate	O
gradient	O
.	O

The	O
recovery	O
of	O
material	O
from	O
the	O
column	O
(	O
84	O
%	O
)	O
appears	O
to	O
be	O
higher	O
when	O
ammonium	O
acetate	O
is	O
used	O
.	O

The	O
pure	O
nonamer	O
(	O
Figure	O
2d	O
)	O
was	O
obtained	O
in	O
10	O
%	O
overall	O
yield	O
based	O
on	O
the	O
amount	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2	O
Tr	O
]	O
ibuG	O
originally	O
bound	O
to	O
the	O
polystyrene	O
support	O
.	O

The	O
oligomer	O
was	O
desalted	O
on	O
a	O
Bio	O
-	O
Gel	O
P-2	O
gel	O
filtration	O
column	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
the	O
other	O
oligomers	O
purified	O
by	O
this	O
method	O
.	O

Thus	O
,	O
for	O
example	O
dApApA	O
and	O
d	O
-	O
ApCpCpApT	O
were	O
obtained	O
in	O
44	O
%	O
and	O
22	O
%	O
isolated	O
yields	O
respectively	O
based	O
upon	O
the	O
amount	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
N.	O
The	O
5'-terminal	O
nucleotide	O
may	O
be	O
removed	O
enzynatically	O
to	O
give	O
an	O
oligomer	O
which	O
contains	O
only	O
methylphosphonate	O
linkages	O
.	O

Thus	O
treatment	O
of	O
the	O
nonamer	O
,	O
d	O
-	O
ApApApApGpCpApApG	O
,	O
with	O
spleen	O
phosphodiesterase	O
gave	O
d	O
-	O
Ap	O
and	O
the	O
octamer	O
d	O
-	O
ApApApGpCpApApG	O
whose	O
retention	O
time	O
is	O
16.4	O
min	O
on	O
the	O
reversed	O
phase	O
column	O
.	O

The	O
noncharged	O
octamer	O
was	O
freed	O
of	O
d	O
-	O
Ap	O
and	O
enzyne	O
by	O
simply	O
passing	O
it	O
through	O
a	O
small	O
DEAE	O
cellulose	O
column	O
.	O

Characterization	O
.	O

Methylphosphonate	O
linkages	O
are	O
cleaved	O
by	O
base	O
.	O

We	O
have	O
found	O
piperdine	O
is	O
particularly	O
effective	O
.	O

The	O
cleavage	O
occurs	O
in	O
a	O
random	O
manner	O
giving	O
nucleosides	O
,	O
nucleoside	O
3'-	O
or	O
5'-methylphosphonates	O
and	O
nucleoside	O
3',5'-bis	O
-	O
methylphosphonates	O
.	O

This	O
hydrolysis	O
reaction	O
may	O
be	O
used	O
to	O
characterize	O
dimers	O
,	O
since	O
the	O
identity	O
and	O
ratio	O
of	O
the	O
products	O
formed	O
are	O
easily	O
determined	O
by	O
reversed	O
phase	O
HPLC	O
.	O

However	O
,	O
the	O
method	O
becomes	O
less	O
satisfactory	O
for	O
longer	O
oligomers	O
.	O

Purine	O
-	O
containing	O
oligonucleoside	O
methylphosphonates	O
may	O
be	O
depurinated	O
by	O
treatment	O
with	O
hydrochloric	O
acid	O
at	O
650	O
.	O

The	O
methylphosphonate	O
linkage	O
is	O
6238	O
Nucleic	O
Acids	O
Research	O
9	O
0	O
OH	O
cH3P	O
:	O
O	O
cH	O
CH3P	O
9	O
9	O
CH	O
-	O
P	O
:O	O
C	O
cH	O
:	O
0pO	O
O~~	O
~j4	O
HO	O
OP	O
3	O
0	O
H	O
0	O
0OH0	O
9	O
S	O
S	O
Figure	O
3	O
:	O
Hydrolysis	O
of	O
the	O
internucleoside	O
methylphsophonate	O
linkages	O
at	O
an	O
apurinic	O
site	O
produced	O
by	O
treatment	O
of	O
the	O
oligomer	O
with	O
hydrochloric	O
acid	O
at	O
pH	O
2	O
.	O

resistant	O
to	O
hydrolysis	O
by	O
these	O
conditions	O
as	O
shown	O
by	O
the	O
stability	O
of	O
d	O
-	O
TpT	O
and	O
d	O
-	O
TpTpT.	O
On	O
the	O
other	O
hand	O
,	O
dimers	O
or	O
trimers	O
containing	O
purine	O
bases	O
such	O
as	O
d	O
-	O
ApA	O
,	O
dApT	O
,	O
dTpA	O
or	O
d	O
-	O
ApApA	O
have	O
half	O
-	O
lives	O
between	O
92	O
and	O
144	O
min	O
in	O
0.01	O
M	O
hydrochloric	O
acid	O
.	O

Following	O
neutralization	O
with	O
ammonium	O
hydroxide	O
,	O
the	O
products	O
of	O
these	O
reactions	O
were	O
characterized	O
by	O
reversed	O
phase	O
HPLC	O
.	O

d	O
-	O
ApA	O
gave	O
adenine	O
,	O
while	O
both	O
d	O
-	O
ApT	O
and	O
d	O
-	O
TpA	O
gave	O
adenine	O
and	O
thymidine	O
as	O
the	O
sole	O
products	O
of	O
the	O
reaction	O
.	O

Adenine	O
and	O
d	O
-	O
ApA	O
were	O
the	O
only	O
products	O
observed	O
when	O
d	O
-	O
ApApA	O
was	O
partially	O
hydrolyzed	O
.	O

When	O
d	O
-	O
CpCpApT	O
was	O
completely	O
hydrolyzed	O
in	O
acid	O
three	O
products	O
,	O
d	O
-	O
CpC	O
,	O
adenine	O
and	O
thynidine	O
,	O
were	O
observed	O
in	O
a	O
molar	O
ratio	O
of	O
1:1:1	O
.	O

In	O
contrast	O
to	O
the	O
base	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
group	O
,	O
apurinic	O
sites	O
produced	O
by	O
acid	O
treatment	O
are	O
further	O
hydrolyzed	O
to	O
nucleosides	O
or	O
oligomers	O
with	O
free	O
5'-	O
and	O
3'-OH	O
groups	O
.	O

The	O
absence	O
of	O
terminal	O
phosphonate	O
residues	O
suggests	O
hydrolysis	O
occurs	O
as	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
OH	O
group	O
on	O
the	O
4'-carbon	O
generated	O
by	O
opening	O
the	O
ribose	O
at	O
the	O
apurinic	O
site	O
may	O
participate	O
in	O
an	O
intramolecular	O
attack	O
on	O
the	O
adjacent	O
phosphonate	O
linkages	O
which	O
results	O
in	O
removal	O
of	O
the	O
phosphonate	O
residues	O
from	O
the	O
neighboring	O
nucleoside	O
hydroxyls	O
.	O

Previous	O
studies	O
by	O
Agarwal	O
and	O
Riftina	O
indicated	O
dithymidine	O
methyl-	O
or	O
phenylphosphonates	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
(	O
9	O
)	O
.	O

Sinha	O
et	O
al.	O
reported	O
that	O
dimers	O
but	O
not	O
trimers	O
or	O
tetramers	O
served	O
as	O
substrates	O
for	O
this	O
enzyme	O
(	O
4	O
)	O
.	O

We	O
were	O
unable	O
to	O
phosphorylate	O
tetramers	O
or	O
longer	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
.	O

However	O
,	O
those	O
oligomers	O
which	O
terminate	O
with	O
a	O
5'-dAp	O
-	O
residue	O
are	O
readily	O
6239	O
Nucleic	O
Acids	O
Research	O
a	O
ATP	O
1	O
1	O
2	O
3	O
4	O
b	O
6	O
mer	O
Mik	O
6	O
mer	O
go	O
3mer	O
a	O
a	O
a	O
X	O
2mer	O
do	O
ATP	O
411	O
12	O
w	O
34	O
1	O
2	O
3	O
4	O
5	O
6	O
Figure	O
4	O
:	O
(	O
a	O
)	O
PEI	O
-	O
cellulose	O
TLC	O
of	O
T4	O
polynucleotide	O
kinase	O
reactions	O
.	O

1	O
)	O
[	O
y-32p	O
]	O
ATP	O
;	O
2	O
)	O
d	O
-	O
ApApA	O
reaction	O
mixture	O
;	O
3	O
)	O
d	O
-	O
ApGpCpApApG	O
reaction	O
mixture	O
;	O
4	O
)	O
d	O
-	O
ApApApApG_pCpApAeG	O
reaction	O
mixture	O
.	O

The	O
chromatogram	O
was	O
eluted	O
wi	O
th1.5	O
M	O
pyridinium	O
formate	O
,	O
pH	O
3.5	O
.	O

(	O
b	O
)	O
Polyacrylamide	O
gel	O
electrophoresis	O
of	O
phosphoryljted	O
olihonucleoside	O
methylghosphonates	O
.	O

1	O
)	O
markers	O
:	O
d-	O
pTpT	O
(	O
2	O
mer	O
)	O
;	O
d-,3pApApA	O
(	O
3	O
mer	O
)	O
;	O
d-	O
2pApGpCpApApG	O
(	O
6	O
mer	O
)	O
;	O
d-32pApApApApGpCpApApG	O
(	O
9	O
mer	O
.	O

Lanes	O
2	O
-	O
4	O
:	O
products	O
obtained	O
after	O
partTaT	O
fy?rlysis	O
of	O
dl2pApApA	O
(	O
2	O
)	O
;	O
d-	O
2pApGpCpApApG	O
(	O
3	O
)	O
and	O
d-32pApARApApGpCpAZARG	O
;	O
(	O
4	O
)	O
with	O
0.5	O
M	O
piperidine	O
at	O
377C	O
for	O
10	O
min	O
Lanel	O
t	O
:	O
products	O
obtained	O
Wfter	O
partial	O
hydrolysis	O
of	O
d-3Kp	O
-	O
ApGRCpApApG	O
(	O
5	O
)	O
and	O
d-32p	O
-	O
ApApAppGpjCppAjG	O
(	O
6	O
)	O
with	O
0.5	O
M	O
HC1	O
at	O
371C	O
fCor30	O
min	O
.	O

Electrophoresis	O
was	O
carried	O
out	O
at	O
constant	O
voltage	O
(	O
800	O
v	O
)	O
until	O
the	O
bromphenol	O
blue	O
marker	O
dye	O
had	O
migrated	O
halfway	O
down	O
the	O
gel	O
.	O

phosphorylated	O
by	O
polynucleotide	O
kinase	O
.	O

The	O
phosphorylation	O
reaction	O
is	O
easily	O
followed	O
by	O
PEI	O
-	O
cellulose	O
TLC	O
.	O

As	O
shown	O
in	O
Figure	O
4a	O
,	O
the	O
phosphorylated	O
oligomers	O
have	O
a	O
higher	O
Rf	O
values	O
than	O
does	O
d	O
-	O
ATP	O
.	O

The	O
phosphorylated	O
methylphosphonate	O
oligomers	O
can	O
be	O
separated	O
according	O
to	O
their	O
chain	O
lengths	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
on	O
an	O
18	O
%	O
gel	O
containing	O
7	O
M	O
urea	O
as	O
shown	O
in	O
Figure	O
4	O
(	O
b	O
)	O
.	O

Lane	O
1	O
shows	O
the	O
separation	O
of	O
a	O
trimer	O
,	O
hexamer	O
and	O
nonamer	O
.	O

The	O
band	O
which	O
appears	O
directly	O
below	O
the	O
nonamer	O
may	O
arise	O
from	O
traces	O
of	O
contaminating	O
octamer	O
which	O
were	O
not	O
removed	O
during	O
the	O
purification	O
of	O
d	O
-	O
ApApApApGpCpApApG.	O
6240	O
Nucleic	O
Acids	O
Research	O
When	O
the	O
oligomers	O
were	O
partially	O
hydrolyzed	O
with	O
piperidine	O
,	O
a	O
series	O
of	O
new	O
bands	O
appears	O
corresponding	O
to	O
shorter	O
oligomers	O
produced	O
via	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
(	O
Lanes	O
2	O
-	O
4	O
)	O
.	O

Because	O
of	O
the	O
random	O
nature	O
of	O
this	O
cleavage	O
reaction	O
,	O
the	O
oligomers	O
should	O
terminate	O
with	O
either	O
a	O
3'-OH	O
or	O
a	O
3'-methylphosphonate	O
group	O
.	O

In	O
the	O
case	O
of	O
the	O
trimer	O
,	O
32pApApA	O
,	O
hydrolysis	O
gives	O
two	O
bands	O
which	O
correspond	O
to	O
d-32pApA	O
and	O
d-32pApAp	O
(	O
Lane	O
2	O
)	O
.	O

The	O
same	O
products	O
are	O
observed	O
for	O
hydrolysis	O
of	O
the	O
nonamer	O
,	O
d-32pApApApApGpCpApApG	O
(	O
Lane	O
4	O
)	O
.	O

A	O
similar	O
situation	O
is	O
observed	O
for	O
d32pApGpCpApApG	O
although	O
the	O
dimers	O
d-32pApG	O
and	O
d-32pApGp	O
have	O
somewhat	O
different	O
mobilities	O
(	O
Lane	O
3	O
)	O
.	O

These	O
dimers	O
can	O
not	O
be	O
separated	O
when	O
the	O
gel	O
is	O
run	O
in	O
the	O
absence	O
of	O
urea	O
.	O

It	O
is	O
possible	O
to	O
determine	O
the	O
chain	O
lengths	O
of	O
the	O
original	O
oligomers	O
by	O
counting	O
the	O
number	O
of	O
oligomers	O
produced	O
by	O
partial	O
piperidine	O
hydrolysis	O
.	O

For	O
example	O
,	O
starting	O
with	O
the	O
trimer	O
band	O
,	O
one	O
can	O
observe	O
3	O
bands	O
corresponding	O
to	O
tetramer	O
,	O
pentamer	O
and	O
hexamer	O
for	O
the	O
hydrolysis	O
products	O
of	O
d-32pApGpCpApApG	O
(	O
Lane	O
3	O
)	O
and	O
6	O
bands	O
corresponding	O
to	O
tetramer	O
,	O
pentamer	O
,	O
hexamer	O
,	O
heptamer	O
,	O
octamer	O
and	O
nonamer	O
for	O
the	O
hydrolysis	O
products	O
of	O
32pApApApApGpCpApApG	O
(	O
Lane	O
4	O
)	O
.	O

The	O
positions	O
of	O
the	O
oligomers	O
of	O
the	O
same	O
chain	O
length	O
appear	O
to	O
be	O
very	O
similar	O
which	O
suggests	O
that	O
the	O
mobilities	O
are	O
not	O
greatly	O
affected	O
by	O
base	O
composition	O
on	O
the	O
urea	O
-	O
containing	O
gel	O
.	O

This	O
procedure	O
thus	O
provides	O
a	O
rapid	O
and	O
convenient	O
method	O
for	O
characterizing	O
the	O
methyl	O
phosphonate	O
ol	O
i	O
gomers	O
.	O

Treatment	O
of	O
the	O
phosphorylated	O
oligomers	O
with	O
acid	O
produces	O
shorter	O
oligomers	O
which	O
result	O
from	O
chain	O
cleavage	O
at	O
apurinic	O
sites	O
.	O

In	O
this	O
case	O
the	O
oligomers	O
terminate	O
with	O
a	O
3'-OH	O
group	O
.	O

Treatment	O
of	O
32pApGpCpApALpG	O
produces	O
an	O
intense	O
band	O
corresponding	O
to	O
the	O
pentamer	O
,	O
d-32pApGjCpAjA	O
(	O
Lane	O
5	O
)	O
while	O
treatment	O
of	O
32pApApApApGpCpApApG	O
produces	O
an	O
intense	O
band	O
corresponding	O
to	O
the	O
octamer	O
d-32pApApAPApGpCpApA	O
and	O
fainter	O
bands	O
corresponding	O
to	O
the	O
heptamer	O
,	O
hexamer	O
,	O
tetramer	O
and	O
trimer	O
.	O

These	O
results	O
suggest	O
that	O
under	O
the	O
conditions	O
of	O
the	O
experiment	O
,	O
hydrolysis	O
occurs	O
preferentially	O
at	O
the	O
3'-terminal	O
G	O
residue	O
of	O
both	O
oligomers	O
.	O

It	O
should	O
be	O
possible	O
to	O
extend	O
this	O
methodology	O
to	O
other	O
base	O
specific	O
depurination	O
or	O
depyrimidination	O
reactions	O
similar	O
to	O
those	O
employed	O
in	O
the	O
Maxam	O
-	O
Gilbert	O
sequencing	O
method	O
(	O
10	O
)	O
.	O

Experiments	O
directed	O
toward	O
this	O
goal	O
are	O
currently	O
in	O
progress	O
and	O
will	O
be	O
reported	O
in	O
a	O
future	O
communication	O
.	O

ACKNOWLEDGEMENT	O
:	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
the	O
following	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
:	O
GM	O
16066	O
(	O
P.O.P.T.	O
)	O
and	O
GM	O
31927	O
6241	O
Nucleic	O
Acids	O
Research	O
(	O
P.S.M.	O
)	O
,	O
and	O
from	O
a	O
grant	O
from	O
Association	O
for	O
International	O
Cancer	O
Research	O
.	O

REFERENCES	O
:	O
1	O
.	O

MTTITr	O
,	O
P.S.	O
,	O
McParland	O
,	O
K.B.	O
,	O
Jayaraman	O
,	O
K.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1981	O
)	O
Biochemistry	O
20	O
,	O
1874	O
-	O
1880	O
.	O

2	O
.	O

Jayaraman	O
,	O
K.	O
,	O
McParland	O
,	O
K.B.	O
,	O
Miller	O
,	O
P.S.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1981	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O
78	O
,	O
1537	O
-	O
1541	O
.	O

3	O
.	O

Miller	O
,	O
P.S.	O
,	O
Agris	O
,	O
C.H.	O
,	O
Blandin	O
,	O
M.	O
,	O
Murakami	O
,	O
A.	O
,	O
Reddy	O
,	O
P.M.	O
,	O
Spitz	O
,	O
S.A.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1983	O
)	O
Nucleic	O
Acids	O
Res	O
.	O
,	O
submitted	O
for	O
publ	O
ication	O
.	O

4	O
.	O

Sinha	O
,	O
N.D.	O
Grossbruchaus	O
,	O
V.	O
and	O
Koester	O
,	O
H.	O
(	O
1983	O
)	O
Tetrahedron	O
Letters	O
24	O
,	O
877	O
-	O
880	O
.	O

5	O
.	O

Miller	O
,	O
P.S.	O
,	O
Cheng	O
,	O
D.M.	O
,	O
Dreon	O
,	O
N.	O
,	O
Jayaraman	O
,	O
K.	O
,	O
Kan	O
,	O
L	O
.-	O
S.	O
,	O
Leutzinger	O
,	O
E.E.	O
,	O
Pulford	O
,	O
S.M.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1980	O
)	O
Biochemistry	O
19	O
,	O
4688	O
-	O
4698	O
.	O

6	O
.	O

Ito	O
,	O
H.	O
,	O
Ike	O
,	O
Y.	O
,	O
Ikuta	O
,	O
S.	O
and	O
Itakura	O
,	O
K.	O
,	O
(	O
1982	O
)	O

Nucleic	O
Acids	O
Res	O
10	O
,	O
1755	O
-	O
1769	O
.	O

7	O
.	O

Barnett	O
,	O
R.W.	O
and	O
Letsinger	O
,	O
R.L.	O
(	O
1981	O
)	O

Tetrahedron	O
Letters	O
22	O
,	O
991	O
-	O
994	O
.	O

6242	O

Enzymatic	O
multiplex	O
DNA	O
sequencing	O
.	O

Abstract	O
The	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
has	O
been	O
reformulated	O
using	O
an	O
easily	O
implemented	O
,	O
multiplex	O
version	O
of	O
enzymatic	O
DNA	O
sequencing	O
.	O

By	O
utilizing	O
a	O
uniquely	O
tagged	O
primer	O
for	O
each	O
base	O
-	O
specific	O
sequencing	O
reaction	O
,	O
the	O
four	O
reactions	O
can	O
be	O
pooled	O
and	O
electrophoresed	O
in	O
a	O
single	O
lane	O
.	O

This	O
approach	O
has	O
been	O
previously	O
proposed	O
for	O
use	O
with	O
fluorescently	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
and	O
is	O
analogous	O
to	O
the	O
principle	O
used	O
in	O
four	O
-	O
dye	O
fluorescence	O
sequencing	O
except	O
that	O
the	O
signals	O
are	O
resolved	O
following	O
electrophoresis	O
(	O
2	O
)	O
.	O

After	O
transfer	O
to	O
a	O
nylon	O
membrane	O
,	O
images	O
are	O
obtained	O
separately	O
for	O
each	O
of	O
the	O
four	O
reactions	O
by	O
hybridization	O
using	O
oligonucleotide	O
probes	O
.	O

The	O
images	O
can	O
then	O
be	O
superimposed	O
to	O
reconstitute	O
a	O
complete	O
sequence	O
pattern	O
.	O

In	O
this	O
way	O
the	O
correction	O
of	O
gel	O
distortion	O
effects	O
and	O
accurate	O
band	O
registration	O
are	O
considerably	O
simplified	O
,	O
as	O
each	O
of	O
the	O
four	O
base	O
-	O
specific	O
ladders	O
require	O
very	O
similar	O
corrections	O
.	O

The	O
methods	O
therefore	O
provide	O
the	O
basis	O
for	O
a	O
second	O
generation	O
of	O
more	O
accurate	O
and	O
reliable	O
film	O
reading	O
programs	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
conventional	O
multiplex	O
sequencing	O
.	O

Unlike	O
the	O
original	O
multiplex	O
protocol	O
(	O
3	O
)	O
,	O
the	O
approach	O
described	O
is	O
suitable	O
for	O
small	O
projects	O
,	O
as	O
multiple	O
cloning	O
vectors	O
are	O
not	O
used	O
.	O

Although	O
more	O
than	O
one	O
vector	O
can	O
be	O
utilized	O
,	O
only	O
a	O
library	O
of	O
fragments	O
cloned	O
into	O
any	O
single	O
phage	O
,	O
phagemid	O
or	O
plasmid	O
vector	O
is	O
actually	O
required	O
,	O
together	O
with	O
a	O
set	O
of	O
tagged	O
oligonucleotide	O
primers	O
.	O

Images	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
3301	O
Enzymatic	O
multiplex	O
DNA	O
sequencing	O
Mark	O
Chee	O
Medical	O
Research	O
Council	O
Laboratory	O
of	O
Molecular	O
Biology	O
,	O
Hills	O
Road	O
,	O
Cambridge	O
CB2	O
20H	O
,	O
UK	O
Received	O
March	O
15	O
,	O
1991	O
;	O
Revised	O
and	O
Accepted	O
May	O
2	O
,	O
1991	O
ABSTRACT	O
The	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
has	O
been	O
reformulated	O
using	O
an	O
easily	O
implemented	O
,	O
multiplex	O
version	O
of	O
enzymatic	O
DNA	O
sequencing	O
.	O

By	O
utilizing	O
a	O
uniquely	O
tagged	O
primer	O
for	O
each	O
base	O
-	O
specific	O
sequencing	O
reaction	O
,	O
the	O
four	O
reactions	O
can	O
be	O
pooled	O
and	O
electrophoresed	O
in	O
a	O
single	O
lane	O
.	O

This	O
approach	O
has	O
been	O
previously	O
proposed	O
for	O
use	O
with	O
fluorescently	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
and	O
is	O
analogous	O
to	O
the	O
principle	O
used	O
in	O
four	O
-	O
dye	O
fluorescence	O
sequencing	O
except	O
that	O
the	O
signals	O
are	O
resolved	O
following	O
electrophoresis	O
(	O
2	O
)	O
.	O

After	O
transfer	O
to	O
a	O
nylon	O
membrane	O
,	O
images	O
are	O
obtained	O
separately	O
for	O
each	O
of	O
the	O
four	O
reactions	O
by	O
hybridization	O
using	O
oligonucleotide	O
probes	O
.	O

The	O
images	O
can	O
then	O
be	O
superimposed	O
to	O
reconstitute	O
a	O
complete	O
sequence	O
pattern	O
.	O

In	O
this	O
way	O
the	O
correction	O
of	O
gel	O
distortion	O
effects	O
and	O
accurate	O
band	O
registration	O
are	O
considerably	O
simplified	O
,	O
as	O
each	O
of	O
the	O
four	O
basespecific	O
ladders	O
require	O
very	O
similar	O
corrections	O
.	O

The	O
methods	O
therefore	O
provide	O
the	O
basis	O
for	O
a	O
second	O
generation	O
of	O
more	O
accurate	O
and	O
reliable	O
film	O
reading	O
programs	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
conventional	O
multiplex	O
sequencing	O
.	O

Unlike	O
the	O
original	O
multiplex	O
protocol	O
(	O
3	O
)	O
,	O
the	O
approach	O
described	O
is	O
suitable	O
for	O
small	O
projects	O
,	O
as	O
multiple	O
cloning	O
vectors	O
are	O
not	O
used	O
.	O

Although	O
more	O
than	O
one	O
vector	O
can	O
be	O
utilized	O
,	O
only	O
a	O
library	O
of	O
fragments	O
cloned	O
into	O
any	O
single	O
phage	O
.	O

phagemid	O
or	O
plasmid	O
vector	O
is	O
actually	O
required	O
,	O
together	O
with	O
a	O
set	O
of	O
tagged	O
oligonucleotide	O
primers	O
.	O

INTRODUCTION	O
The	O
community	O
of	O
biologists	O
is	O
undertaking	O
the	O
sequencing	O
of	O
representative	O
genomes	O
of	O
various	O
free	O
-	O
living	O
organisms	O
,	O
ranging	O
in	O
size	O
from	O
Mycoplasma	O
(	O
800	O
kb	O
)	O
to	O
mammals	O
(	O
3	O
Gb	O
)	O
(	O
4	O
)	O
.	O

However	O
,	O
the	O
largest	O
contiguous	O
DNA	O
sequences	O
which	O
have	O
been	O
determined	O
so	O
far	O
are	O
the	O
genomes	O
of	O
several	O
dsDNA	O
eukaryotic	O
viruses	O
(	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
)	O
and	O
plant	O
chloroplasts	O
(	O
10	O
,	O
11	O
,	O
12	O
)	O
.	O

The	O
largest	O
of	O
these	O
is	O
the	O
229	O
kb	O
genome	O
of	O
human	B
cytomegalovirus	I
(	O
8)	O
.	O

The	O
difficulty	O
in	O
sequencing	O
millions	O
of	O
base	O
pairs	O
of	O
DNA	O
is	O
that	O
several	O
steps	O
in	O
the	O
methods	O
are	O
relatively	O
labour	O
intensive	O
,	O
although	O
the	O
sequencing	O
reactions	O
themselves	O
are	O
rapid	O
and	O
easily	O
performed	O
.	O

Two	O
limiting	O
steps	O
in	O
conventional	O
procedures	O
are	O
the	O
size	O
fractionation	O
of	O
sequencing	O
reaction	O
products	O
by	O
gel	O
electrophoresis	O
and	O
the	O
subsequent	O
reading	O
of	O
sequence	O
ladders	O
.	O

The	O
former	O
problem	O
can	O
be	O
overcome	O
by	O
multiplexing	O
,	O
which	O
theoretically	O
allows	O
an	O
enormous	O
amount	O
of	O
data	O
to	O
be	O
obtained	O
from	O
a	O
single	O
gel	O
by	O
processing	O
clones	O
as	O
mixtures	O
rather	O
than	O
individually	O
(	O
3	O
)	O
.	O

Each	O
sequence	O
in	O
the	O
mixture	O
is	O
labelled	O
by	O
a	O
unique	O
short	O
oligonucleotide	O
'	O
tag	O
'	O
sequence	O
.	O

This	O
allows	O
the	O
mixture	O
to	O
be	O
resolved	O
following	O
electrophoresis	O
:	O
the	O
superimposed	O
sequence	O
ladders	O
are	O
blotted	O
from	O
the	O
gel	O
to	O
a	O
nylon	O
membrane	O
,	O
and	O
detected	O
one	O
at	O
a	O
time	O
by	O
hybridization	O
using	O
tag	O
-	O
specific	O
oligonucleotide	O
probes	O
.	O

In	O
practice	O
,	O
at	O
least	O
50	O
sets	O
of	O
sequences	O
can	O
be	O
obtained	O
from	O
a	O
single	O
gel	O
(	O
3	O
)	O
.	O

Unfortunately	O
,	O
a	O
bottleneck	O
in	O
the	O
multiplex	O
procedure	O
is	O
the	O
reading	O
of	O
sequence	O
films	O
.	O

In	O
previous	O
large	O
-	O
scale	O
sequencing	O
projects	O
this	O
task	O
has	O
been	O
performed	O
with	O
the	O
aid	O
of	O
a	O
sonic	O
digitizer	O
(	O
13	O
,	O
14	O
)	O
.	O

Although	O
film	O
reading	O
programs	O
have	O
been	O
under	O
development	O
for	O
some	O
time	O
(	O
15	O
)	O
,	O
and	O
some	O
programs	O
are	O
commercially	O
available	O
,	O
their	O
error	O
rates	O
are	O
presently	O
more	O
variable	O
and	O
unpredictable	O
than	O
that	O
of	O
a	O
skilled	O
person	O
and	O
the	O
accurate	O
interpretation	O
of	O
film	O
-	O
imaged	O
sequence	O
ladders	O
by	O
computer	O
programs	O
is	O
difficult	O
to	O
achieve	O
in	O
routine	O
practice	O
.	O

Programs	O
specifically	O
designed	O
to	O
read	O
multiplex	O
films	O
have	O
an	O
advantage	O
.	O

This	O
is	O
because	O
a	O
sequence	O
image	O
can	O
be	O
used	O
as	O
an	O
'	O
internal	O
standard	O
'	O
to	O
help	O
interpret	O
other	O
images	O
derived	O
from	O
the	O
same	O
membrane	O
(	O
3	O
)	O
.	O

However	O
,	O
the	O
original	O
implementation	O
of	O
the	O
multiplex	O
strategy	O
used	O
chemical	O
sequencing	O
(	O
16	O
)	O
,	O
which	O
yields	O
a	O
more	O
complex	O
sequence	O
ladder	O
than	O
the	O
enzymatic	O
dideoxynucleotide	O
chain	O
-	O
termination	O
method	O
(	O
17	O
)	O
.	O

Most	O
successful	O
large	O
scale	O
sequencing	O
projects	O
have	O
used	O
the	O
chaintermination	O
method	O
and	O
bacteriophage	B
M13	I
vectors	O
,	O
which	O
allows	O
the	O
routine	O
production	O
of	O
clean	O
and	O
easily	O
interpretable	O
sequences	O
(	O
18	O
)	O
.	O

It	O
was	O
therefore	O
decided	O
to	O
adapt	O
the	O
original	O
multiplex	O
protocol	O
for	O
use	O
with	O
enzymatic	O
sequencing	O
,	O
using	O
tagged	O
primers	O
.	O

MATERIALS	O
AND	O
METHODS	O
Eight	O
oligonucleotide	O
sequencing	O
primers	O
were	O
synthesized	O
,	O
each	O
37	O
nucleotides	O
in	O
length	O
.	O

The	O
3	O
'	O
end	O
of	O
each	O
primer	O
consists	O
of	O
the	O
17	O
nucleotide	O
M13	O
universal	O
priming	O
sequence	O
[	O
GTAAAACGACGGCCAGT3	O
'	O
]	O
.	O

The	O
5	O
'	O
ends	O
of	O
the	O
primers	O
bear	O
different	O
20mer	O
tag	O
sequences	O
(	O
Figure	O
1	O
)	O
.	O

In	O
four	O
of	O
the	O
primers	O
,	O
UEO1C	O
,	O
UPOIC	O
,	O
UE02C	O
and	O
UP02C	O
,	O
these	O
tags	O
are	O
complementary	O
to	O
the	O
EO1	O
,	O
PO1	O
,	O
E02	O
and	O
P02	O
probe	O
sequences	O
respectively	O
(	O
copied	O
from	O
the	O
original	O
'	O
plex	O
'	O
vectors	O
(	O
3	O
)	O
)	O
.	O

A	O
second	O
set	O
of	O
four	O
primers	O
,	O
UJOL14C	O
,	O
UJOL15C	O
,	O
UJOL16C	O
and	O
UJOL17C	O
,	O
have	O
the	O
following	O
tag	O
sequences	O
:	O
5	O
'	O
CAAGTTTGAAGGTACTCATT	O
,	O
TATCAATTAAATTGTllTGAC	O
,	O
GTGTTGCTACCCAAGAAGCA	O
,	O
and	O
TGTCACTAGAGCTGTCACTT	O
,	O
respectively	O
.	O

The	O
?	O
=)	O
1991	O
Oxford	O
University	O
Press	O
3302	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
oligonucleotides	O
were	O
gel	O
-	O
purified	O
(	O
19	O
)	O
and	O
used	O
to	O
sequence	O
ssDNA	O
templates	O
prepared	O
by	O
phenol	O
extraction	O
(	O
20	O
)	O
or	O
SDS	O
denaturation	O
(	O
21	O
)	O
.	O

Conventional	O
sequencing	O
reactions	O
were	O
performed	O
as	O
previously	O
described	O
(	O
20	O
)	O
.	O

For	O
hybridization	O
experiments	O
,	O
radioactively	O
labelled	O
nucleotides	O
were	O
omitted	O
from	O
the	O
sequencing	O
reactions	O
.	O

Instead	O
,	O
the	O
21d	O
of	O
each	O
nucleotide	O
mix	O
added	O
to	O
the	O
reaction	O
mixture	O
consisted	O
of	O
the	O
following	O
:	O
'	O
A	O
'	O
mix	O
:	O
6.25MtM	O
dATP	O
,	O
62.5lM	O
ddATP	O
;	O
'	O
C	O
'	O
mix	O
:	O
6.25MM	O
dCTP	O
,	O
40MtM	O
ddCTP	O
;	O
'	O
G	O
'	O
mix	O
:	O
6.25MtM	O
dGTP	O
,	O
80MtM	O
ddGTP	O
;	O
'	O
T	O
'	O
mix	O
:	O
6.25MM	O
dTTP	O
,	O
250yM	O
ddTTP	O
;	O
as	O
well	O
as	O
125MM	O
of	O
each	O
of	O
the	O
three	O
other	O
dNTPs	O
in	O
each	O
mix	O
.	O

Apart	O
from	O
the	O
use	O
of	O
these	O
modified	O
mixes	O
,	O
no	O
changes	O
were	O
made	O
to	O
the	O
conventional	O
sequencing	O
procedure	O
(	O
20	O
)	O
.	O

Sequencing	O
reactions	O
were	O
pooled	O
and	O
ethanol	O
precipitated	O
as	O
appropriate	O
.	O

Precipitation	O
in	O
microtitre	O
trays	O
was	O
carried	O
out	O
as	O
follows	O
:	O
a	O
mixture	O
of	O
3.2M1	O
3	O
M	O
NaAc	O
pH	O
5.0	O
and	O
112Mi1	O
EtOH	O
was	O
dispensed	O
to	O
individual	O
wells	O
of	O
a	O
microtitre	O
plate	O
(	O
Falcon	O
3911	O
or	O
Corning	O
25855	O
)	O
using	O
an	O
8-channel	O
pipettor	O
.	O

Each	O
set	O
of	O
four	O
reactions	O
was	O
added	O
to	O
the	O
EtOH	O
/	O
NaAc	O
mixture	O
,	O
and	O
the	O
tray	O
sealed	O
using	O
a	O
Falcon	O
3073	O
plate	O
sealer	O
.	O

The	O
samples	O
were	O
mixed	O
by	O
inversion	O
and	O
stored	O
at	O
-20?C	O
for	O
30	O
minutes	O
.	O

The	O
DNA	O
was	O
collected	O
by	O
a	O
20	O
minute	O
centrifugation	O
at	O
4	O
000	O
rpm	O
in	O
an	O
IEC	O
Centra	O
3C	O
centrifuge	O
.	O

The	O
sealer	O
was	O
removed	O
,	O
and	O
the	O
plate	O
inverted	O
to	O
discard	O
the	O
supernatant	O
.	O

After	O
blotting	O
the	O
tray	O
on	O
tissue	O
paper	O
,	O
200MI	O
of	O
95	O
%	O
EtOH	O
was	O
added	O
to	O
each	O
well	O
.	O

The	O
plate	O
was	O
covered	O
with	O
a	O
plastic	O
lid	O
and	O
recentrifuged	O
for	O
2	O
minutes	O
.	O

The	O
EtOH	O
was	O
discarded	O
and	O
the	O
plate	O
inverted	O
for	O
several	O
minutes	O
on	O
tissue	O
paper	O
,	O
then	O
left	O
for	O
20	O
minutes	O
to	O
air	O
dry	O
.	O

Precipitated	O
samples	O
were	O
resuspended	O
in	O
6M1	O
deionized	O
water	O
by	O
vortexing	O
on	O
an	O
SMI	O
multi	O
-	O
tube	O
vortexer	O
for	O
1	O
minute	O
.	O

Samples	O
were	O
denatured	O
and	O
electrophoresed	O
on	O
6	O
%	O
polyacrylamide	O
buffer	O
gradient	O
gels	O
as	O
previously	O
described	O
(	O
20	O
)	O
.	O

Following	O
electrophoresis	O
,	O
the	O
gel	O
was	O
transferred	O
to	O
a	O
dry	O
piece	O
of	O
Whatman	O
3MM	O
blotting	O
paper	O
,	O
and	O
placed	O
on	O
a	O
second	O
sheet	O
of	O
blotting	O
paper	O
supported	O
on	O
a	O
glass	O
plate	O
and	O
saturated	O
in	O
4	O
x	O
SSC	O
(	O
SSC	O
:	O
150mM	O
NaCl	O
,	O
l5mM	O
trisodium	O
citrate	O
)	O
.	O

This	O
sheet	O
was	O
wicked	O
in	O
a	O
tray	O
containing	O
1	O
litre	O
of	O
4	O
x	O
SSC	O
.	O

The	O
DNA	O
was	O
transferred	O
to	O
a	O
nylon	O
membrane	O
(	O
Amersham	O
Hybond	O
N	O
)	O
by	O
capillary	O
blotting	O
overnight	O
(	O
22	O
)	O
.	O

DNA	O
was	O
fixed	O
to	O
the	O
membranes	O
by	O
U.V.	O
crosslinking	O
(	O
23	O
)	O
.	O

Plex	O
oligonucleotide	O
probes	O
were	O
a	O
kind	O
gift	O
of	O
Dr.	O

George	O
Church	O
.	O

Probes	O
were	O
tailed	O
at	O
their	O
3	O
'	O
ends	O
using	O
[	O
a-32p	O
]	O
dCTP	O
as	O
previously	O
described	O
(	O
3	O
)	O
.	O

For	O
the	O
preparation	O
of	O
digoxigenin	O
(	O
DIG	O
)	O
labelled	O
probes	O
,	O
identical	O
tailing	O
reactions	O
were	O
carried	O
out	O
substituting	O
I0pmols	O
of	O
DIG	O
-	O
II	O
dUTP	O
(	O
Boehringer	O
Mannheim	O
)	O
for	O
[	O
a-32P	O
]	O
dCTP	O
.	O

Membranes	O
were	O
prehybridized	O
for	O
at	O
least	O
10	O
minutes	O
in	O
4	O
x	O
SSC	O
,	O
5	O
x	O
Denhardts	O
'	O
(	O
0.1	O
%	O
(	O
w	O
/	O
v	O
)	O
each	O
of	O
BSA	O
(	O
heated	O
at	O
80?C	O
for	O
30	O
minutes	O
to	O
inactivate	O
any	O
alkaline	O
phosphatase	O
activity	O
)	O
,	O
Ficoll	O
(	O
Pharmacia	O
)	O
and	O
polyvinylpyrrolidone	O
)	O
,	O
0.5	O
%	O
(	O
w	O
/	O
v	O
)	O
SDS	O
,	O
5mM	O
NaHPO4	O
(	O
23	O
)	O
.	O

Hybridization	O
was	O
carried	O
out	O
in	O
25	O
-	O
50M1	O
of	O
prehybridization	O
buffer	O
per	O
cm2	O
of	O
membrane	O
.	O

The	O
probe	O
concentration	O
was	O
approximately	O
lnM.	O
After	O
lh	O
at	O
42?C	O
,	O
unbound	O
probe	O
was	O
removed	O
by	O
five	O
1	O
minute	O
washes	O
at	O
room	O
temperature	O
in	O
1	O
x	O
SSC	O
,	O
0.5	O
%	O
SDS	O
(	O
200MI	O
/	O
cm2	O
membrane	O
)	O
.	O

Radioactive	O
blots	O
were	O
covered	O
in	O
Saran	O
wrap	O
and	O
exposed	O
to	O
film	O
immediately	O
.	O

Detection	O
of	O
DIG	O
labelled	O
probes	O
used	O
an	O
anti	O
-	O
DIG	O
antibodyalkaline	O
phosphatase	O
conjugate	O
(	O
Boehringer	O
Mannheim	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
,	O
except	O
that	O
all	O
volumes	O
were	O
reduced	O
by	O
70	O
%	O
and	O
the	O
conjugate	O
was	O
used	O
at	O
a	O
1:10	O
000	O
dilution	O
.	O

Blots	O
were	O
developed	O
in	O
25M1	O
of	O
100mM	O
Tris	O
.	O

Cl	O
pH9.5	O
,	O
mantane4-methoxy4	O
(	O
3	O
""""	O
-phosphoryloxy	O
)	O
phenyl-1	O
,	O
2-dioxetane	O
)	O
;	O
Tropix	O
)	O
/	O
cm2	O
for	O
30	O
minutes	O
at	O
37?C	O
,	O
prior	O
to	O
exposure	O
to	O
film	O
.	O

Probes	O
and	O
dioxetane	O
were	O
stripped	O
from	O
the	O
membranes	O
by	O
two	O
10	O
minute	O
washes	O
at	O
700C	O
with	O
0.2	O
%	O
SDS	O
,	O
2mM	O
EDTA	O
(	O
200,ul	O
/	O
cm2	O
membrane	O
)	O
.	O

The	O
hybridization	O
and	O
washing	O
procedures	O
were	O
carried	O
out	O
in	O
plastic	O
bags	O
.	O

However	O
,	O
washing	O
steps	O
have	O
also	O
been	O
performed	O
with	O
gentle	O
agitation	O
in	O
a	O
perspex	O
tub	O
(	O
43	O
x	O
27	O
x	O
15	O
cm	O
)	O
mounted	O
on	O
a	O
reciprocal	O
shaker	O
,	O
with	O
equivalent	O
results	O
.	O

In	O
the	O
latter	O
case	O
a	O
minimum	O
wash	O
volume	O
of	O
500mls	O
was	O
used	O
.	O

The	O
use	O
of	O
a	O
tub	O
is	O
more	O
convenient	O
for	O
batch	O
processing	O
and	O
should	O
be	O
straightforward	O
to	O
automate	O
.	O

RESULTS	O
Autoradiograms	O
revealed	O
no	O
difference	O
in	O
sequence	O
quality	O
when	O
tagged	O
primers	O
were	O
used	O
instead	O
of	O
the	O
17mer	O
universal	O
primer	O
in	O
conventional	O
[	O
a-35S	O
]	O
dATP	O
labelled	O
sequencing	O
reactions	O
and	O
in	O
multiplex	O
hybridization	O
experiments	O
using	O
[	O
a-32P	O
]	O
dCTP	O
-	O
tailed	O
probes	O
(	O
results	O
not	O
shown	O
)	O
.	O

Experiments	O
were	O
then	O
conducted	O
to	O
determine	O
the	O
feasibility	O
of	O
pooling	O
the	O
four	O
base	O
reactions	O
for	O
each	O
clone	O
and	O
fractionating	O
them	O
in	O
a	O
single	O
lane	O
to	O
obtain	O
a	O
superimposed	O
but	O
interpretable	O
set	O
of	O
sequence	O
ladders	O
.	O

The	O
question	O
addressed	O
was	O
whether	O
or	O
not	O
difficulties	O
in	O
band	O
registration	O
might	O
arise	O
as	O
a	O
result	O
of	O
mobility	O
differences	O
between	O
the	O
different	O
primer	O
sequences	O
and/or	O
distortion	O
of	O
the	O
membrane	O
between	O
probings	O
.	O

It	O
is	O
relevant	O
that	O
an	O
automated	O
film	O
reader	O
employing	O
an	O
internal	O
standard	O
requires	O
that	O
the	O
nylon	O
membrane	O
does	O
not	O
undergo	O
significant	O
distortions	O
between	O
probings	O
(	O
George	O
Church	O
,	O
personal	O
communication	O
)	O
.	O

Clones	O
were	O
sequenced	O
using	O
the	O
four	O
tagged	O
primers	O
UEOlC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
,	O
one	O
for	O
each	O
base	O
reaction	O
(	O
Figure	O
1	O
)	O
.	O

The	O
A	O
,	O
C	O
,	O
G	O
and	O
T	O
reactions	O
for	O
each	O
clone	O
were	O
pooled	O
,	O
and	O
processed	O
as	O
described	O
above	O
.	O

A	O
complete	O
set	O
of	O
sequence	O
autoradiograms	O
was	O
obtained	O
from	O
four	O
consecutive	O
rounds	O
of	O
probing	O
with	O
[	O
a-32P	O
]	O
dCTP	O
-	O
labelled	O
oligonucleotides	O
.	O

Alignment	O
of	O
the	O
films	O
showed	O
that	O
sequence	O
-	O
specific	O
mobility	O
effects	O
and	O
distortion	O
of	O
the	O
membrane	O
between	O
probings	O
were	O
sufficiently	O
minor	O
to	O
allow	O
accurate	O
registration	O
of	O
the	O
bands	O
,	O
and	O
hence	O
accurate	O
reading	O
of	O
the	O
sequence	O
.	O

At	O
least	O
200	O
nucleotides	O
of	O
sequence	O
could	O
be	O
read	O
accurately	O
from	O
a	O
single	O
clone	O
by	O
simply	O
tracing	O
the	O
four	O
sets	O
of	O
bands	O
using	O
different	O
colours	O
,	O
overlaying	O
the	O
tracings	O
,	O
and	O
reading	O
the	O
bands	O
sequentially	O
.	O

In	O
order	O
to	O
assess	O
the	O
practicality	O
of	O
reading	O
the	O
sequences	O
by	O
machine	O
,	O
the	O
images	O
were	O
scanned	O
to	O
provide	O
optical	O
density	O
profiles	O
(	O
Figure	O
2	O
)	O
.	O

These	O
profiles	O
were	O
overlaid	O
,	O
and	O
were	O
found	O
to	O
be	O
sufficiently	O
in	O
register	O
to	O
allow	O
accurate	O
interpretation	O
of	O
the	O
sequence	O
for	O
at	O
least	O
300	O
nucleotides	O
.	O

This	O
was	O
essentially	O
the	O
limit	O
of	O
resolution	O
of	O
the	O
gel	O
for	O
accurate	O
manual	O
reading	O
.	O

In	O
order	O
to	O
ensure	O
that	O
the	O
relatively	O
minor	O
mobility	O
differences	O
observed	O
between	O
the	O
four	O
primers	O
were	O
not	O
coincidental	O
to	O
the	O
oligonucleotides	O
used	O
,	O
a	O
second	O
set	O
of	O
four	O
tagged	O
M13	O
universal	O
primers	O
was	O
synthesised	O
,	O
this	O
time	O
incorporating	O
20mer	O
sequences	O
derived	O
from	O
the	O
genome	O
of	O
murine	O
herpesvirus-68	O
(	O
UJOL14C	O
,	O
15C	O
,	O
16C	O
,	O
17C	O
)	O
.	O

Sequencing	O
reactions	O
were	O
performed	O
using	O
[	O
cx-35S	O
]	O
dATP	O
to	O
label	O
the	O
DNA	O
directly	O
.	O

Various	O
templates	O
were	O
sequenced	O
,	O
and	O
in	O
all	O
cases	O
correctly	O
ordered	O
sequence	O
ladders	O
were	O
obtained	O
following	O
conventional	O
electrophoresis	O
in	O
which	O
the	O
four	O
reactions	O
were	O
run	O
side	O
-	O
by	O
-	O
side	O
(	O
results	O
not	O
shown	O
)	O
.	O

Initial	O
hybridization	O
experiments	O
were	O
conducted	O
using	O
[	O
f	O
-32p	O
]	O
dCTP	O
tailed	O
oligonucleotide	O
probes	O
.	O

However	O
,	O
the	O
use	O
of	O
lOOmM	O
NaCl	O
,	O
5OmM	O
MgC12	O
,	O
0.15mM	O
AMPPD	O
(	O
[	O
3-	O
(	O
2'-ada	O

B	O
C	O
'	O
Ordinary	O
'	O
Plex	O
'	O
4-CJ3	O
4-rn	O
+	O
Primeir	O
Primer	O
""""	O
All	O
""""	O
C	O
""""	O
""""	O
G	O
""""	O
""""	O
T	O
""""	O
'	O
Plex	O
'	O
'	O
Ordinary	O
'	O
Pool	O
and	O
Vector	O
Vector	O
fractionate	O
Resolve	O
by	O
sequential	O
hybridizations	O
Sequencing	O
reactions	O
SequencingreactIo	O
product	O
Sequencing	O
reaction	O
product	O
-	O
n	O
;	O
=	O
=	O
-	O
=	O
-	O
n	O
:	O
=	O
Figure	O
1	O
.	O

Approaches	O
to	O
enzymatic	O
multiplex	O
DNA	O
sequencing	O
.	O

a	O
)	O
A	O
set	O
of	O
sequence	O
-	O
tagged	O
vectors	O
can	O
be	O
used	O
.	O

The	O
tag	O
site	O
is	O
shown	O
in	O
red	O
,	O
and	O
the	O
insert	O
to	O
be	O
sequenced	O
in	O
blue	O
.	O

However	O
,	O
the	O
original	O
plex	O
vectors	O
(	O
3	O
)	O
are	O
plasmids	O
,	O
and	O
therefore	O
amenable	O
only	O
to	O
dsDNA	O
sequencing	O
.	O

Sets	O
of	O
bacteriophage	B
M13	I
vectors	O
have	O
been	O
constructed	O
bearing	O
either	O
one	O
(	O
32	O
)	O
or	O
two	O
[	O
Chee	O
,	O
unpublished	O
]	O
of	O
the	O
plex	O
tag	O
sites	O
flanking	O
the	O
polylinker	O
,	O
which	O
can	O
be	O
used	O
for	O
this	O
approach	O
.	O

b	O
)	O
The	O
strategy	O
used	O
in	O
this	O
paper	O
.	O

In	O
this	O
case	O
the	O
tag	O
site	O
is	O
carried	O
on	O
the	O
primer	O
.	O

c	O
)	O
If	O
tagged	O
primers	O
are	O
used	O
,	O
there	O
is	O
no	O
practical	O
impediment	O
to	O
performing	O
each	O
base	O
reaction	O
using	O
a	O
different	O
primer	O
,	O
as	O
depicted	O
.	O

The	O
reactions	O
can	O
then	O
be	O
pooled	O
in	O
any	O
combination	O
desired	O
.	O

The	O
configuration	O
shown	O
,	O
in	O
which	O
the	O
four	O
reactions	O
are	O
electrophoresed	O
in	O
a	O
single	O
lane	O
,	O
is	O
designed	O
to	O
facilitate	O
accurate	O
band	O
registration	O
and	O
reading	O
by	O
an	O
automatic	O
film	O
reader	O
.	O

In	O
order	O
to	O
read	O
the	O
sequence	O
manually	O
,	O
base	O
reactions	O
would	O
be	O
run	O
side	O
-	O
by	O
-	O
side	O
.	O

The	O
logistics	O
of	O
processing	O
the	O
reactions	O
are	O
essentially	O
the	O
same	O
with	O
either	O
configuration	O
;	O
the	O
same	O
number	O
of	O
probings	O
are	O
required	O
.	O

Figure	O
2	O
.	O

Four	O
overlaid	O
one	O
-	O
dimensional	O
optical	O
density	O
profiles	O
for	O
a	O
single	O
clone	O
shown	O
in	O
two	O
overlapping	O
sections	O
.	O

The	O
optical	O
density	O
profiles	O
are	O
unprocessed	O
,	O
except	O
for	O
a	O
simple	O
transform	O
to	O
correct	O
for	O
the	O
relative	O
displacement	O
(	O
translation	O
and	O
rotation	O
)	O
of	O
the	O
four	O
images	O
from	O
which	O
they	O
are	O
extracted	O
.	O

The	O
profiles	O
read	O
5	O
'	O
to	O
3	O
'	O
from	O
right	O
to	O
left	O
.	O

Nucleotides	O
positions	O
66	O
to	O
214	O
from	O
the	O
start	O
of	O
the	O
universal	O
priming	O
site	O
are	O
shown	O
.	O

The	O
sequence	O
is	O
that	O
of	O
Bluescribe	O
M13	O
+	O
(	O
template	O
DNA	O
obtained	O
by	O
rescue	O
with	O
M13K07	O
helper	O
phage	O
(	O
30	O
)	O
)	O
,	O
and	O
was	O
determined	O
using	O
the	O
primers	O
UEOIC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
for	O
the	O
T	O
,	O
C	O
,	O
G	O
and	O
A	O
specific	O
reactions	O
respectively	O
.	O

Detection	O
was	O
by	O
autoradiography	O
following	O
hybridization	O
with	O
[	O
a-	O
32p	O
]	O
dCTP	O
tailed	O
plex	O
probes	O
.	O

A	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
3303	O
I	O
3304	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
a	O
)	O
175-	O
...	O

-w	O
.m	O
;	O
b	O
)	O
182	O
a	O
:	O
......	O

F.VW	O
an	O
-	O
w	O
-1	O
S	O
-	O
K~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~i	O
'	O
F	O
C	O
C	O
;	O
A	O
I1	O
'	O
CG	O
A	O
Figure	O
3	O
.	O

Four	O
separate	O
base	O
-	O
specific	O
reactions	O
imaged	O
from	O
a	O
single	O
lane	O
using	O
chemiluminescent	O
detection	O
.	O

The	O
clones	O
sequenced	O
are	O
:	O
a	O
)	O
Bluescribe	O
M13	O
+	O
(	O
obtained	O
by	O
rescue	O
with	O
M13K07	O
helper	O
phage	O
(	O
30	O
)	O
)	O
and	O
b	O
)	O
an	O
M13	O
recombinant	O
clone	O
prepared	O
in	O
a	O
microtitre	O
tray	O
(	O
21	O
)	O
(	O
a	O
kind	O
gift	O
of	O
Victoria	O
Smith	O
)	O
.	O

Nucleotide	O
positions	O
shown	O
on	O
the	O
figure	O
are	O
numbered	O
from	O
the	O
start	O
of	O
the	O
universal	O
priming	O
site	O
.	O

The	O
clones	O
were	O
sequenced	O
using	O
UEOlC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
for	O
the	O
T	O
,	O
C	O
,	O
G	O
and	O
A	O
specific	O
reactions	O
respectively	O
.	O

The	O
blot	O
was	O
probed	O
with	O
corresponding	O
DIG-11-dUTP	O
labelled	O
oligonucleotides	O
.	O

radioactivity	O
on	O
the	O
scale	O
envisioned	O
for	O
a	O
large	O
sequencing	O
project	O
is	O
undesirable	O
for	O
reasons	O
of	O
safety	O
.	O

The	O
relatively	O
long	O
exposure	O
times	O
required	O
(	O
6	O
to	O
24	O
hours	O
)	O
and	O
the	O
short	O
half	O
lives	O
of	O
the	O
probes	O
might	O
also	O
be	O
inconvenient	O
.	O

It	O
has	O
been	O
shown	O
that	O
a	O
biotin	O
/	O
streptavidin	O
/	O
alkaline	O
phosphatase	O
based	O
detection	O
system	O
used	O
in	O
conjunction	O
with	O
a	O
chemiluminescent	O
dioxetane	O
substrate	O
overcomes	O
these	O
disadvantages	O
(	O
24	O
,	O
25	O
,	O
26	O
)	O
.	O

We	O
utilized	O
a	O
different	O
bridging	O
system	O
with	O
similar	O
results	O
.	O

Digoxigenin	O
(	O
DIG	O
)	O
labelled	O
oligonucleotide	O
probes	O
were	O
detected	O
using	O
anti	O
-	O
DIG	O
antibody	O
-	O
alkaline	O
phosphatase	O
conjugates	O
and	O
a	O
chemiluminescent	O
dioxetane	O
substrate	O
.	O

Exposure	O
times	O
of	O
10	O
to	O
15	O
minutes	O
were	O
typically	O
required	O
,	O
following	O
a	O
one	O
hour	O
preincubation	O
period	O
(	O
Figure	O
3	O
)	O
.	O

In	O
our	O
hands	O
the	O
DIG	O
bridging	O
system	O
was	O
similar	O
in	O
sensitivity	O
to	O
the	O
streptavidin	O
based	O
system	O
(	O
24	O
)	O
,	O
and	O
the	O
practical	O
lower	O
limit	O
of	O
template	O
ssDNA	O
required	O
in	O
order	O
to	O
obtain	O
an	O
easily	O
interpretable	O
sequencing	O
ladder	O
was	O
estimated	O
to	O
be	O
in	O
the	O
range	O
of	O
20	O
to	O
50fmols	O
per	O
reaction	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
detection	O
was	O
limited	O
only	O
by	O
enzymaticallytriggered	O
background	O
luminescence	O
,	O
and	O
not	O
by	O
the	O
level	O
of	O
signal	O
obtained	O
.	O

The	O
nonradioactive	O
methods	O
described	O
have	O
been	O
used	O
successfully	O
in	O
an	O
8-plex	O
system	O
.	O

DISCUSSION	O
Although	O
the	O
original	O
multiplex	O
protocol	O
was	O
based	O
on	O
a	O
set	O
of	O
tagged	O
vectors	O
(	O
3	O
)	O
,	O
tagged	O
primers	O
have	O
also	O
been	O
used	O
or	O
proposed	O
for	O
various	O
forms	O
of	O
multiplex	O
DNA	O
sequencing	O
(	O
George	O
Church	O
,	O
personal	O
communication	O
;	O
2	O
,	O
27	O
)	O
.	O

For	O
example	O
,	O
a	O
proposal	O
was	O
recently	O
put	O
forward	O
for	O
multiplex	O
sequencing	O
using	O
sequence	O
-	O
labelled	O
primers	O
and	O
fluorophor	O
-	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
similar	O
in	O
principle	O
to	O
the	O
methods	O
used	O
here	O
.	O

However	O
,	O
we	O
use	O
tagged	O
primers	O
and	O
the	O
superposition	O
of	O
the	O
four	O
sequencing	O
reactions	O
to	O
address	O
the	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
;	O
a	O
part	O
of	O
this	O
solution	O
is	O
to	O
utilize	O
M13	O
dideoxynucleotide	O
sequencing	O
,	O
thereby	O
improving	O
the	O
quality	O
of	O
the	O
data	O
to	O
be	O
analyzed	O
.	O

In	O
addition	O
,	O
the	O
proposal	O
for	O
fluorophor	O
-	O
labelled	O
probes	O
does	O
not	O
take	O
into	O
consideration	O
any	O
of	O
the	O
practical	O
sequencing	O
problems	O
addressed	O
here	O
,	O
and	O
,	O
in	O
the	O
version	O
described	O
,	O
remains	O
a	O
promising	O
but	O
unproven	O
scheme	O
for	O
large	O
scale	O
DNA	O
sequencing	O
.	O

There	O
are	O
several	O
advantages	O
to	O
tagging	O
primers	O
instead	O
of	O
vectors	O
.	O

Firstly	O
,	O
there	O
is	O
no	O
need	O
to	O
prepare	O
multiple	O
libraries	O
of	O
clones	O
in	O
special	O
vectors	O
.	O

This	O
means	O
that	O
workers	O
can	O
use	O
vector	O
/	O
host	O
combinations	O
that	O
yield	O
good	O
results	O
in	O
their	O
hands	O
,	O
and	O
an	O
increased	O
depth	O
of	O
multiplexing	O
can	O
easily	O
be	O
accomodated	O
by	O
synthesizing	O
more	O
primers	O
.	O

This	O
should	O
make	O
multiplexing	O
more	O
accessible	O
to	O
workers	O
undertaking	O
smaller	O
projects	O
.	O

A	O
theoretical	O
disadvantage	O
of	O
tagged	O
primers	O
is	O
that	O
the	O
procedure	O
can	O
only	O
be	O
multiplexed	O
following	O
primer	O
annealing	O
(	O
1	O
)	O
,	O
or	O
following	O
the	O
sequencing	O
reactions	O
(	O
this	O
paper	O
;	O
in	O
practice	O
,	O
pooling	O
immediately	O
after	O
the	O
annealing	O
step	O
might	O
lead	O
to	O
increased	O
backgrounds	O
if	O
one	O
or	O
more	O
primers	O
were	O
present	O
in	O
excess	O
over	O
their	O
template	O
DNAs	O
)	O
.	O

This	O
is	O
a	O
relatively	O
late	O
stage	O
.	O

In	O
the	O
original	O
procedure	O
(	O
3	O
)	O
,	O
clones	O
were	O
pooled	O
prior	O
to	O
amplification	O
by	O
growth	O
,	O
an	O
early	O
step	O
.	O

However	O
,	O
we	O
do	O
not	O
believe	O
the	O
sacrifice	O
to	O
be	O
of	O
practical	O
importance	O
when	O
using	O
phage	O
vectors	O
.	O

In	O
our	O
experience	O
,	O
recombinant	O
M13	O
phage	O
have	O
variable	O
growth	O
rates	O
and	O
the	O
effects	O
of	O
competition	O
are	O
likely	O
to	O
severely	O
limit	O
the	O
number	O
of	O
clones	O
that	O
can	O
usefully	O
be	O
pooled	O
for	O
growth	O
.	O

In	O
contrast	O
,	O
by	O
growing	O
clones	O
individually	O
,	O
the	O
depth	O
of	O
multiplexing	O
is	O
only	O
really	O
limited	O
by	O
probe	O
sensitivity	O
.	O

We	O
have	O
not	O
investigated	O
the	O
factors	O
influencing	O
variability	O
in	O
phage	O
growth	O
rates	O
.	O

It	O
is	O
worth	O
noting	O
that	O
reliable	O
protocols	O
have	O
been	O
developed	O
for	O
growing	O
large	O
numbers	O
of	O
individual	O
M13	O
clones	O
and	O
preparing	O
high	O
quality	O
ssDNA	O
templates	O
in	O
microtitre	O
trays	O
(	O
28	O
,	O
21	O
)	O
.	O

It	O
is	O
relatively	O
simple	O
to	O
prepare	O
manually	O
two	O
microtitre	O
trays	O
of	O
ssDNA	O
templates	O
(	O
192	O
clones	O
)	O
in	O
a	O
day	O
.	O

Sufficient	O
clones	O
can	O
be	O
prepared	O
in	O
a	O
week	O
to	O
sequence	O
a	O
20	O
kb	O
fragment	O
to	O
a	O
redundancy	O
of	O
10	O
(	O
Victoria	O
Smith	O
,	O
personal	O
communication	O
)	O
.	O

In	O
this	O
laboratory	O
,	O
ssDNA	O
is	O
now	O
prepared	O
with	O
the	O
aid	O
of	O
a	O
commercially	O
available	O
robotic	O
workstation	O
(	O
21	O
)	O
.	O

As	O
sequencing	O
reactions	O
are	O
also	O
carried	O
out	O
in	O
microtitre	O
trays	O
,	O
manually	O
or	O
robotically	O
(	O
20	O
,	O
29	O
)	O
,	O
the	O
entire	O
M13-based	O
dideoxynucleotide	O
sequencing	O
procedure	O
is	O
amenable	O
to	O
automation	O
(	O
29	O
)	O
.	O

For	O
these	O
reasons	O
we	O
see	O
little	O
practical	O
advantage	O
in	O
pooling	O
clones	O
early	O
.	O

Finally	O
,	O
by	O
not	O
pooling	O
clones	O
early	O
,	O
the	O
ability	O
to	O
easily	O
retrieve	O
individual	O
clones	O
is	O
retained	O
,	O
which	O
may	O
facilitate	O
directed	O
sequencing	O
later	O
in	O
a	O
project	O
should	O
this	O
become	O
necessary	O
.	O

Multiplex	O
DNA	O
sequencing	O
is	O
currently	O
limited	O
by	O
the	O
lack	O
of	O
a	O
robust	O
computer	O
program	O
which	O
can	O
correct	O
for	O
the	O
large	O
variety	O
of	O
gel	O
and	O
sequencing	O
artefacts	O
that	O
are	O
normally	O
encountered	O
.	O

The	O
foundation	O
of	O
a	O
film	O
reading	O
program	O
is	O
the	O
ability	O
to	O
bring	O
into	O
register	O
precisely	O
vertical	O
arrays	O
of	O
base	O
-	O
specific	O
bands	O
.	O

This	O
requires	O
the	O
ability	O
to	O
track	O
lanes	O
,	O
correct	O
for	O
distortions	O
,	O
and	O
order	O
bands	O
based	O
on	O
their	O
relative	O
spacing	O
.	O

A	O
method	O
of	O
sequencing	O
which	O
has	O
successfully	O
overcome	O
the	O
problem	O
of	O
sequence	O
reading	O
uses	O
real	O
-	O
time	O
detection	O
of	O
fluorescently	O
labelled	O
DNA	O
samples	O
migrating	O
through	O
the	O
gel	O
(	O
2	O
)	O
.	O

This	O
system	O
also	O
utilizes	O
the	O
principle	O
of	O
running	O
the	O
four	O
base	O
reactions	O
down	O
the	O
same	O
lane	O
(	O
2	O
)	O
.	O

However	O
,	O
bands	O
are	O
detected	O
at	O
a	O
fixed	O
location	O
in	O
space	O
,	O
and	O
their	O
detection	O
is	O
separated	O
in	O
time	O
.	O

Hence	O
the	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O
19	O
,	O
No.	O
12	O
3305	O
problem	O
of	O
gel	O
distortion	O
is	O
essentially	O
avoided	O
,	O
although	O
corrections	O
for	O
the	O
different	O
mobilities	O
of	O
the	O
four	O
dyes	O
must	O
be	O
carried	O
out	O
.	O

In	O
contrast	O
,	O
we	O
utilize	O
the	O
advantages	O
of	O
single	O
lane	O
electrophoresis	O
to	O
address	O
the	O
problem	O
of	O
superimposing	O
four	O
relatively	O
large	O
and	O
complex	O
two	O
-	O
dimensional	O
images	O
.	O

Furthermore	O
,	O
by	O
using	O
sequence	O
-	O
tagged	O
oligonucleotides	O
which	O
are	O
detected	O
by	O
hybridization	O
,	O
a	O
much	O
greater	O
depth	O
of	O
multiplexing	O
can	O
realistically	O
be	O
achieved	O
than	O
by	O
real	O
-	O
time	O
detection	O
.	O

The	O
use	O
of	O
two	O
-	O
dimensional	O
colour	O
traces	O
to	O
depict	O
the	O
processed	O
output	O
of	O
a	O
film	O
reader	O
is	O
consistent	O
with	O
the	O
method	O
of	O
displaying	O
fluorescence	O
traces	O
,	O
and	O
should	O
facilitate	O
the	O
checking	O
and	O
editing	O
of	O
sequence	O
databases	O
in	O
which	O
both	O
kinds	O
of	O
data	O
have	O
been	O
entered	O
.	O

The	O
sequence	O
compilation	O
programs	O
used	O
in	O
this	O
laboratory	O
,	O
which	O
are	O
already	O
capable	O
of	O
handling	O
large	O
shotgun	O
databases	O
(	O
8	O
,	O
31	O
)	O
,	O
have	O
recently	O
undergone	O
extensive	O
improvements	O
(	O
Rodger	O
Staden	O
,	O
personal	O
communication	O
)	O
.	O

There	O
is	O
now	O
an	O
interactive	O
database	O
editor	O
which	O
allows	O
the	O
graphical	O
display	O
of	O
fluorescence	O
traces	O
,	O
and	O
it	O
is	O
envisaged	O
that	O
this	O
feature	O
could	O
be	O
extended	O
to	O
allow	O
the	O
handling	O
of	O
data	O
from	O
a	O
film	O
reader	O
when	O
a	O
suitable	O
machine	O
is	O
developed	O
.	O

ACKNOWLEDGEMENTS	O

I	O
am	O
particularly	O
grateful	O
to	O
George	O
Church	O
for	O
thought	O
-	O
provoking	O
discussions	O
and	O
gifts	O
of	O
vectors	O
and	O
oligonucleotide	O
probes	O
and	O
to	O
John	O
Sulston	O
for	O
advice	O
.	O

I	O
also	O
thank	O
Victoria	O
Smith	O
for	O
the	O
gift	O
of	O
DNA	O
samples	O
,	O
Bart	O
Barrell	O
for	O
long	O
-	O
term	O
support	O
,	O
Tom	O
O'Keefe	O
of	O
Milligen	O
/	O
Biosearch	O
for	O
lessons	O
in	O
multiplexing	O
and	O
Amersham	O
International	O
for	O
the	O
optical	O
density	O
overlays	O
shown	O
in	O
Figure	O
2	O
.	O

M.C.	O
is	O
supported	O
by	O
a	O
fellowship	O
from	O
Applied	O
Biosystems	O
.	O

12	O
.	O

Hiratsuka	O
,	O
J.	O
,	O
Shimada	O
,	O
H.	O
,	O
Whittier	O
,	O
R.	O
,	O
Ishibashi	O
,	O
T.	O
,	O
Sakamoto	O
,	O
M.	O
,	O
Mori	O
,	O
M.	O
,	O
Kondo	O
,	O
C.	O
,	O
Honju	O
,	O
Y.	O
,	O
Sun	O
,	O
C.	O
-R	O
,	O
Meng	O
,	O
B.	O
-Y	O
,	O
Li	O
,	O
Y.	O
-Q	O
,	O
Kanno	O
,	O
A.	O
,	O
Nisizawa	O
,	O
Y.	O
,	O
Hirai	O
,	O
A.	O
,	O
Shinozaki	O
,	O
K.	O
and	O
Sugiura	O
,	O
M.	O
(	O
1989	O
)	O
Molecular	O
and	O
General	O
Genetics	O
,	O
217	O
,	O
185	O
-	O
194	O
.	O

13	O
.	O

Komaromy	O
,	O
M.	O
and	O
Govan	O
,	O
H.	O
(	O
1984	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
12	O
,	O
675	O
-	O
678	O
.	O
14	O
.	O

Staden	O
,	O
R.	O
(	O
1984	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
12	O
,	O
499	O
-	O
503	O
.	O

15	O
.	O

Elder	O
,	O
J.	O
K.	O
,	O
Green	O
,	O
D.	O
K.	O
and	O
Southern	O
,	O
E.	O
M.	O
(	O
1986	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
14	O
,	O
417	O
-	O
424	O
.	O

16	O
.	O

Maxam	O
,	O
A.	O
M.	O
and	O
Gilbert	O
,	O
W.	O
(	O
1977	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
74	O
,	O
560	O
-	O
564	O
.	O

17	O
.	O

Sanger	O
,	O
F.	O
,	O
Nicklen	O
,	O
S.	O
and	O
Coulson	O
,	O
A.	O
R.	O
(	O
1977	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
74	O
,	O
5463	O
-	O
5467	O
.	O

18	O
.	O

Sanger	O
,	O
F.	O
,	O
Coulson	O
,	O
A.	O
R.	O
,	O
Barrell	O
,	O
B.	O
G.	O
,	O
Smith	O
,	O
A.	O
J.	O
H.	O
and	O
Roe	O
,	O
B.	O
A.	O
(	O
1980	O
)	O
Journal	O
of	O
Molecular	O
Biology	O
,	O
143	O
,	O
161	O
-	O
178	O
.	O

19	O
.	O

Applied	O
Biosystems	O
User	O
Bulletin	O
(	O
1987	O
)	O
13	O
,	O
11	O
-	O
16	O
.	O

20	O
.	O

Bankier	O
,	O
A.	O
T.	O
,	O
Weston	O
,	O
K.	O
M.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1987	O
)	O
Methods	O
in	O
Enzymology	O
,	O
155	O
,	O
51	O
-	O
93	O
.	O

21	O
.	O

Smith	O
,	O
V.	O
,	O
Brown	O
,	O
C.	O
M.	O
,	O
Bankier	O
,	O
A.	O
T.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1990	O
)	O
DNA	O
Sequence	O
,	O
1	O
,	O
73	O
-	O
78	O
.	O

22	O
.	O

Southern	O
,	O
E.	O
M.	O
(	O
1975	O
)	O
Journal	O
of	O
Molecular	O
Biology	O
,	O
98	O
,	O
503	O
-	O
517	O
.	O

23	O
.	O

Church	O
,	O
G.	O
M.	O
and	O
Gilbert	O
,	O
W.	O
(	O
1984	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
81	O
,	O
1991	O
-	O
1995	O
.	O

24	O
.	O

Beck	O
,	O
S.	O
,	O
O'Keefe	O
,	O
T.	O
,	O
Coull	O
,	O
J.	O
M.	O
and	O
Koster	O
,	O
H.	O
(	O
1989	O
)	O

Nucleic	O
Acids	O
Research	O
,	O
17	O
,	O
5115	O
-	O
5123	O
.	O

25	O
.	O

Tizard	O
,	O
R.	O
,	O
Cate	O
,	O
R.	O
L.	O
,	O
Ramachandran	O
,	O
K.	O
L.	O
,	O
Wysk	O
,	O
M.	O
,	O
Voyta	O
,	O
J.	O
C.	O
,	O
Murphy	O
,	O
0	O
.	O
J.	O
and	O
Bronstein	O
,	O
I.	O
(	O
1990	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
87	O
,	O
4514	O
-	O
4518	O
.	O

26	O
.	O

Beck	O
,	O
S.	O
and	O
Koster	O
,	O
H.	O
(	O
1990	O
)	O
Analytical	O
Chemistry	O
,	O
62	O
,	O
2558	O
-	O
2570	O
.	O

27	O
.	O

Jacobson	O
,	O
K.	O
B.	O
,	O
Arlinghaus	O
,	O
H.	O
F.	O
,	O
Schmitt	O
,	O
H.	O
W.	O
,	O
Sachleben	O
,	O
R.	O
A.	O
,	O
Brown	O
,	O
G.	O
M.	O
,	O
Thonnard	O
,	O
N.	O
,	O
Sloop	O
,	O
F.	O
V.	O
,	O
Foote	O
,	O
R.	O
S.	O
,	O
Larimer	O
,	O
F.	O
W.	O
,	O
Woychik	O
,	O
R.	O
P.	O
,	O
England	O
,	O
M.	O
W.	O
,	O
Burchett	O
,	O
K.	O
L.	O
and	O
Jacobson	O
,	O
D.	O
A.	O
(	O
1991	O
)	O
Genomics	O
,	O
9	O
,	O
51	O
-	O
59	O
.	O

28	O
.	O

Eperon	O
,	O
I.	O
C.	O
(	O
1986	O
)	O
Analytical	O
Biochemistry	O
,	O
56	O
,	O
406	O
-	O
412	O
.	O

29	O
.	O

Bankier	O
,	O
A.	O
T.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1989	O
)	O
In	O
Howe	O
,	O
C.	O
J.	O
and	O
Ward	O
,	O
E.	O
S.	O
(	O
ed	O
)	O
,	O
Nucleic	O
acids	O
sequencing	O
:	O
a	O
practical	O
approach	O
.	O

IRL	O
Press	O
,	O
Oxford	O
,	O
Vol	O
.	O

1	O
,	O
pp	O
.	O

37	O
-	O
78	O
.	O

30	O
.	O

Vieira	O
,	O
J.	O
and	O
Messing	O
,	O
J.	O
(	O
1987	O
)	O
Methods	O
in	O
Enzymology	O
,	O
153	O
,	O
3	O
-	O
11	O
.	O
31	O
.	O

Davison	O
,	O
A.	O
DNA	O
Sequence	O
,	O
in	O
press	O
.	O

32	O
.	O

Heller	O
,	O
C.	O
,	O
Radley	O
,	O
E.	O
,	O
Khurshid	O
,	O
F.	O
A.	O
and	O
Beck	O
,	O
S.	O
Gene	O
,	O
in	O
press	O
.	O

REFERENCES	O
1	O
.	O

Yang	O
,	O
M.	O
M.	O
and	O
Youvan	O
,	O
D.	O
C.	O
(	O
1989	O
)	O
Biotechnology	O
,	O
7	O
,	O
576	O
-	O
580	O
.	O

2	O
.	O

Smith	O
,	O
L.	O
M.	O
,	O
Sanders	O
,	O
J.	O
Z.	O
,	O
Kaiser	O
,	O
R.	O
J.	O
,	O
Hughes	O
,	O
P.	O
,	O
Dodd	O
,	O
C.	O
,	O
Connell	O
,	O
C.	O
R.	O
,	O
Heiner	O
,	O
C.	O
,	O
Kent	O
,	O
S.	O
B.	O
H.	O
and	O
Hood	O
,	O
L.	O
E.	O
(	O
1986	O
)	O
Nature	O
,	O
321	O
,	O
674	O
-	O
679	O
.	O

3	O
.	O

Church	O
,	O
G.	O
M.	O
and	O
Kieffer	O
-	O
Higgins	O
,	O
S.	O
(	O
1988	O
)	O
Science	O
,	O
240	O
,	O
185	O
-	O
188	O
.	O
4	O
.	O

Watson	O
,	O
J.	O
D.	O
(	O
1990	O
)	O
Science	O
,	O
248	O
,	O
44	O
-	O
49	O
.	O

5	O
.	O

Baer	O
,	O
R.	O
,	O
Bankier	O
,	O
A.	O
T.	O
,	O
Biggin	O
,	O
M.	O
D.	O
,	O
Deininger	O
,	O
P.	O
L.	O
,	O
Farrell	O
,	O
P.	O
J.	O
,	O
Gibson	O
,	O
T.	O
J.	O
,	O
Hatfull	O
,	O
G.	O
,	O
Hudson	O
,	O
G.	O
S.	O
,	O
Satchwell	O
,	O
S.	O
C.	O
,	O
Seguin	O
,	O
C.	O
,	O
Tuffnell	O
,	O
P.	O
S.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1984	O
)	O
Nature	O
,	O
310	O
,	O
207	O
-	O
211	O
.	O

6	O
.	O

Davison	O
,	O
A.	O
J.	O
and	O
Scott	O
,	O
J.	O
E.	O
(	O
1986	O
)	O
Journal	O
of	O
General	O
Virology	O
,	O
67	O
,	O
1759	O
-	O
1816	O
.	O

7	O
.	O

McGeoch	O
,	O
D.	O
J.	O
,	O
Dalrymple	O
,	O
M.	O
A.	O
,	O
Davison	O
,	O
A.	O
J.	O
,	O
Dolan	O
,	O
A.	O
,	O
Frame	O
,	O
M.	O
C.	O
,	O
McNab	O
,	O
D.	O
,	O
Perry	O
,	O
L.	O
J.	O
,	O
Scott	O
,	O
J.	O
E.	O
and	O
Taylor	O
,	O
P.	O
(	O
1988	O
)	O
Journal	O
of	O
General	O
Virology	O
,	O
69	O
,	O
1531	O
-	O
1574	O
.	O

8	O
.	O

Chee	O
,	O
M.	O
S.	O
,	O
Bankier	O
,	O
A.	O
T.	O
,	O
Beck	O
,	O
S.	O
,	O
Bohni	O
,	O
R.	O
,	O
Brown	O
,	O
C.	O
M.	O
,	O
Cerny	O
,	O
R.	O
,	O
Horsnell	O
,	O
T.	O
,	O
Hutchison	O
III	O
,	O
C.	O
A.	O
,	O
Kouzarides	O
,	O
T.	O
,	O
Martignetti	O
,	O
J.	O
A.	O
,	O
Satchwell	O
,	O
S.	O
C.	O
,	O
Tomlinson	O
,	O
P.	O
,	O
Weston	O
,	O
K.	O
M.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1990	O
)	O
Current	O
Topics	O
in	O
Microbiology	O
and	O
Immunology	O
,	O
154	O
,	O
125	O
-	O
169	O
.	O

9	O
.	O

Goebel	O
,	O
S.	O
J.	O
,	O
Johnson	O
,	O
G.	O
P.	O
,	O
Perkus	O
,	O
M.	O
E.	O
,	O
Davis	O
,	O
S.	O
W.	O
,	O
Winslow	O
,	O
J.	O
P.	O
and	O
Paoletti	O
,	O
E.	O
(	O
1990	O
)	O
Virology	O
,	O
179	O
,	O
247	O
-	O
266	O
.	O

10	O
.	O

Ohyama	O
,	O
K.	O
,	O
Fukuzawa	O
,	O
H.	O
,	O
Kohchi	O
,	O
T.	O
,	O
Shirai	O
,	O
H.	O
,	O
Sano	O
,	O
T.	O
,	O
Sano	O
,	O
S.	O
,	O
Umesono	O
,	O
K.	O
,	O
Shiki	O
,	O
Y.	O
,	O
Takeuchi	O
,	O
M.	O
,	O
Chang	O
,	O
Z.	O
,	O
Aota	O
,	O
S.	O
-I	O
,	O
Inokuchi	O
,	O
H.	O
and	O
Ozeki	O
,	O
H.	O
(	O
1986	O
)	O
Nature	O
,	O
322	O
,	O
572	O
-	O
574	O
.	O

11	O
.	O

Shinozaki	O
,	O
K.	O
,	O
Ohme	O
,	O
M.	O
,	O
Tanaka	O
,	O
M.	O
,	O
Wakasugi	O
,	O
T.	O
,	O
Hayashida	O
,	O
N.	O
,	O
Matsubayashi	O
,	O
T.	O
,	O
Zaita	O
,	O
N.	O
,	O
Chunwongse	O
,	O
J.	O
,	O
Obokata	O
,	O
J.	O
,	O
YamaguchiShinozaki	O
,	O
K.	O
,	O
Ohto	O
,	O
C.	O
,	O
Torazawa	O
,	O
K.	O
,	O
Meng	O
,	O
B.	O
Y.	O
,	O
Sugita	O
,	O
M.	O
,	O
Deno	O
,	O
H.	O
,	O
Kamogashira	O
,	O
T.	O
,	O
Yamada	O
,	O
K.	O
,	O
Kusuda	O
,	O
J.	O
,	O
Takaiwa	O
,	O
F.	O
,	O
Kato	O
,	O
A.	O
,	O
Tohdoh	O
,	O
N.	O
,	O
Shimada	O
,	O
H.	O
and	O
Sugiura	O
,	O
M.	O
(	O
1986	O
)	O
EMBO	O
Journal	O
,	O
5	O
,	O
2043	O
-	O
2049	O
.	O

Down	O
-	O
regulation	O
of	O
the	O
M6P	O
/	O
IGF	O
-	O
II	O
receptor	O
increases	O
cell	O
proliferation	O
and	O
reduces	O
apoptosis	O
in	O
neonatal	O
rat	B
cardiac	O
myocytes	O
Abstract	O
Background	O
The	O
mannose	O
6-phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
II	O
receptor	O
(	O
M6P	O
/	O
IGF2R	O
)	O
is	O
a	O
multi	O
-	O
functional	O
protein	O
that	O
has	O
been	O
implicated	O
in	O
regulation	O
of	O
cell	O
growth	O
and	O
apoptosis	O
.	O

Cardiac	O
myocytes	O
express	O
relatively	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
,	O
and	O
cardiomyocyte	O
apoptosis	O
has	O
been	O
identified	O
in	O
a	O
variety	O
of	O
cardiovascular	O
disorders	O
,	O
such	O
as	O
myocardial	O
infarction	O
and	O
heart	O
failure	O
.	O

However	O
,	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
the	O
pathogenesis	O
of	O
these	O
conditions	O
has	O
not	O
been	O
determined	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
growth	O
and	O
apoptosis	O
.	O

Results	O
We	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
M6P	O
/	O
IGF2R	O
in	O
neonatal	O
rat	B
cardiac	O
myocytes	O
and	O
examined	O
the	O
effect	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Infection	O
of	O
neonatal	O
cardiomyocytes	O
with	O
an	O
adenovirus	O
expressing	O
a	O
ribozyme	O
targeted	O
against	O
the	O
M6P	O
/	O
IGF2R	O
significantly	O
reduced	O
the	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
,	O
as	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
Ribonuclease	O
Protection	O
Assay	O
(	O
RPA	O
)	O
.	O

M6P	O
-	O
containing	O
protein	O
binding	O
and	O
endocytosis	O
as	O
well	O
as	O
the	O
M6P	O
/	O
IGF2R	O
-	O
mediated	O
internalization	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
were	O
lower	O
in	O
the	O
ribozyme	O
-	O
treated	O
cells	O
than	O
the	O
control	O
myocytes	O
,	O
indicating	O
that	O
the	O
number	O
of	O
functional	O
M6P	O
/	O
IGF2R	O
in	O
the	O
ribozyme	O
treated	O
cells	O
was	O
reduced	O
.	O

Accordingly	O
,	O
a	O
marked	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
reduced	O
cell	O
susceptibility	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
were	O
observed	O
in	O
the	O
ribozyme	O
-	O
treated	O
cells	O
.	O

Conclusions	O
These	O
findings	O
suggest	O
that	O
M6P	O
/	O
IGF2R	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
growth	O
and	O
apoptosis	O
.	O

Down	O
regulation	O
of	O
this	O
gene	O
in	O
cardiac	O
tissues	O
might	O
be	O
a	O
new	O
approach	O
to	O
prevention	O
of	O
cell	O
death	O
or	O
promotion	O
of	O
mitogenesis	O
for	O
certain	O
heart	O
diseases	O
.	O

Background	O
The	O
mannose	O
6-phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
II	O
receptor	O
(	O
M6P	O
/	O
IGF2R	O
)	O
is	O
a	O
unique	O
protein	O
that	O
interacts	O
with	O
multiple	O
ligands	O
,	O
some	O
of	O
which	O
are	O
important	O
growth	O
regulatory	O
factors	O
[	O
1	O
]	O
.	O

The	O
M6P	O
/	O
IGF2R	O
participates	O
in	O
internalization	O
and	O
lysosomal	O
degradation	O
of	O
IGF	O
-	O
II	O
,	O
a	O
mitogen	O
normally	O
acting	O
through	O
the	O
IGF	O
-	O
I	O
receptor	O
to	O
stimulate	O
cell	O
proliferation	O
[	O
2	O
]	O
.	O

The	O
M6P	O
/	O
IGF2	O
receptor	O
is	O
required	O
for	O
the	O
activation	O
of	O
TGF	O
-	O
β	O
[	O
3	O
]	O
,	O
a	O
potent	O
growth	O
inhibitor	O
for	O
many	O
cell	O
types	O
.	O

This	O
receptor	O
is	O
also	O
involved	O
in	O
the	O
binding	O
,	O
transport	O
and	O
activation	O
of	O
newly	O
-	O
synthesized	O
lysosomal	O
enzymes	O
,	O
such	O
as	O
cathepsins	O
[	O
4,5	O
]	O
,	O
which	O
have	O
been	O
recently	O
implicated	O
in	O
the	O
induction	O
of	O
apoptosis	O
[	O
6	O
]	O
.	O

On	O
the	O
basis	O
of	O
these	O
functions	O
,	O
the	O
M6P	O
/	O
IGF2R	O
has	O
been	O
proposed	O
to	O
play	O
a	O
significant	O
role	O
in	O
regulation	O
of	O
cell	O
growth	O
and	O
apoptosis	O
[	O
7	O
]	O
.	O

Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
is	O
a	O
tightly	O
regulated	O
process	O
used	O
to	O
remove	O
excess	O
,	O
hazardous	O
or	O
damaged	O
somatic	O
cells	O
,	O
and	O
is	O
crucial	O
for	O
the	O
development	O
,	O
maintenance	O
and	O
survival	O
of	O
an	O
organism	O
.	O

However	O
,	O
alterations	O
in	O
the	O
control	O
of	O
apoptosis	O
have	O
also	O
been	O
shown	O
to	O
contribute	O
to	O
human	B
diseases	O
.	O

In	O
fact	O
,	O
morphological	O
and	O
biochemical	O
markers	O
of	O
apoptosis	O
have	O
been	O
identified	O
in	O
a	O
wide	O
variety	O
of	O
cardiovascular	O
disorders	O
,	O
including	O
myocardial	O
infarction	O
and	O
heart	O
failure	O
.	O

This	O
suggests	O
that	O
activation	O
of	O
apoptotic	O
pathways	O
contributes	O
to	O
cardiomyocyte	O
loss	O
and	O
subsequent	O
cardiac	O
dysfunction	O
in	O
these	O
conditions	O
.	O

A	O
number	O
of	O
factors	O
involved	O
in	O
cardiomyocyte	O
apoptosis	O
are	O
currently	O
known	O
and	O
include	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
(	O
IGF	O
-	O
I	O
)	O
,	O
stress	O
-	O
activated	O
protein	O
kinases	O
(	O
SAPKs	O
)	O
and	O
the	O
anti	O
-	O
apoptotic	O
Bcl-2	O
family	O
[	O
8	O
]	O
.	O

There	O
are	O
indications	O
that	O
other	O
factors	O
may	O
be	O
involved	O
in	O
induction	O
and	O
regulation	O
of	O
cardiac	O
apoptosis	O
.	O

However	O
,	O
these	O
potential	O
factors	O
and	O
their	O
corresponding	O
mechanisms	O
have	O
not	O
been	O
identified	O
.	O

Several	O
lines	O
of	O
evidence	O
point	O
to	O
the	O
potential	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
cardiac	O
myocyte	O
proliferation	O
and	O
apoptosis	O
.	O

Cardiac	O
myocytes	O
express	O
relatively	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
and	O
transgenic	O
mice	B
containing	O
a	O
homologous	O
deletion	O
of	O
the	O
M6P	O
/	O
IGF2R	O
gene	O
manifest	O
ventricular	O
hyperplasia	O
due	O
to	O
an	O
increase	O
in	O
cell	O
number	O
[	O
9,10	O
]	O
,	O
suggesting	O
that	O
the	O
M6P	O
/	O
IGF2R	O
normally	O
acts	O
to	O
suppress	O
cardiac	O
myocyte	O
cell	O
growth	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
TGF	O
-	O
β	O
,	O
a	O
potent	O
growth	O
suppressor	O
whose	O
activation	O
requires	O
the	O
binding	O
of	O
latent	O
TGF	O
-	O
β	O
to	O
M6P	O
/	O
IGF2R	O
[	O
3	O
]	O
,	O
is	O
commonly	O
upregulated	O
in	O
chronic	O
heart	O
failure	O
[	O
11	O
]	O
.	O

Additional	O
evidence	O
for	O
the	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
apoptosis	O
comes	O
from	O
studies	O
of	O
tumorigenesis	O
.	O

It	O
has	O
been	O
shown	O
that	O
M6P	O
/	O
IGF2R	O
expression	O
is	O
significantly	O
reduced	O
in	O
a	O
variety	O
of	O
tumors	O
and	O
loss	O
of	O
heterozygocity	O
(	O
LOH	O
)	O
at	O
the	O
M6P	O
/	O
IGF2R	O
gene	O
locus	O
6q26	O
have	O
been	O
found	O
in	O
breast	O
,	O
liver	O
cancers	O
and	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
lung	O
[	O
12	O
-	O
15	O
]	O
.	O

Although	O
several	O
studies	O
have	O
examined	O
the	O
effect	O
of	O
M6P	O
/	O
IGF2R	O
over	O
-	O
expression	O
on	O
cell	O
growth	O
[	O
7	O
]	O
,	O
it	O
is	O
not	O
known	O
whether	O
down	O
-	O
regulation	O
of	O
this	O
receptor	O
protein	O
leads	O
to	O
cellular	O
protection	O
against	O
apoptosis	O
.	O

Ribozymes	O
are	O
catalytic	O
RNA	O
molecules	O
that	O
cleave	O
a	O
complementary	O
mRNA	O
sequence	O
[	O
16	O
]	O
,	O
thereby	O
inactivating	O
specific	O
mRNAs	O
and	O
suppressing	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
17,18	O
]	O
.	O

Ribozymes	O
have	O
been	O
shown	O
to	O
be	O
highly	O
specific	O
,	O
efficient	O
and	O
stable	O
.	O

They	O
can	O
be	O
packaged	O
into	O
viral	O
vectors	O
to	O
enhance	O
transfer	O
into	O
cells	O
and	O
to	O
achieve	O
longer	O
expression	O
compared	O
with	O
naked	O
oligonucleotides	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
employed	O
ribozyme	O
technology	O
to	O
study	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
cell	O
growth	O
.	O

A	O
hammerhead	O
ribozyme	O
against	O
the	O
M6P	O
/	O
IGF2R	O
mRNA	O
was	O
constructed	O
and	O
packaged	O
in	O
an	O
adenoviral	O
vector	O
.	O

We	O
then	O
examined	O
the	O
effect	O
of	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
on	O
cell	O
growth	O
and	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

Results	O
Cleavage	O
reaction	O
of	O
the	O
ribozyme	O
in	O
vitro	O
The	O
M6P	O
/	O
IGF2R	O
ribozyme	O
we	O
constructed	O
has	O
13-bp	O
binding	O
arms	O
complementary	O
to	O
the	O
target	O
site	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
,	O
and	O
a	O
catalytic	O
core	O
(	O
Fig.	O
1A	O
)	O
.	O

To	O
evaluate	O
the	O
bioactivity	O
of	O
the	O
ribozyme	O
and	O
the	O
accessibility	O
of	O
the	O
target	O
site	O
,	O
a	O
cleavage	O
reaction	O
was	O
performed	O
in	O
vitro	O
.	O

The	O
substrates	O
,	O
[	O
α-32P	O
]	O
labeled	O
RNA	O
transcripts	O
containing	O
45	O
bp	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
or	O
an	O
unmatched	O
sequence	O
,	O
were	O
incubated	O
with	O
the	O
ribozyme	O
as	O
described	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
ribozyme	O
cleaved	O
only	O
the	O
specific	O
M6P	O
/	O
IGF2R	O
mRNA	O
into	O
the	O
expected	O
products	O
.	O

In	O
the	O
assay	O
of	O
time	O
course	O
,	O
the	O
hammerhead	O
ribozyme	O
was	O
able	O
to	O
cleave	O
24.2	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
within	O
10	O
minutes	O
of	O
incubation	O
,	O
50.3	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
within	O
40	O
minutes	O
of	O
incubation	O
,	O
and	O
by	O
640	O
minutes	O
,	O
80.8	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
was	O
converted	O
to	O
the	O
expected	O
products	O
(	O
Fig.	O
1B	O
)	O
.	O

This	O
ribozyme	O
did	O
not	O
digest	O
the	O
unmatched	O
sequence	O
(	O
Fig.	O
1B	O
)	O
.	O

These	O
results	O
indicate	O
a	O
high	O
efficiency	O
and	O
specificity	O
of	O
the	O
ribozyme	O
in	O
vitro	O
.	O

Ribozymes	O
down	O
-	O
regulate	O
M6P	O
/	O
IGF2R	O
expression	O
in	O
cardiac	O
myocytes	O
To	O
examine	O
the	O
ability	O
of	O
the	O
ribozyme	O
to	O
reduce	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
in	O
cultured	O
cardiac	O
myocytes	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
,	O
and	O
subjected	O
to	O
RT	O
-	O
PCR	O
using	O
M6P	O
/	O
IGF2R	O
-	O
specific	O
primers	O
.	O

Primers	O
specific	O
for	O
β	O
-	O
actin	O
were	O
added	O
to	O
a	O
parallel	O
reaction	O
to	O
serve	O
as	O
an	O
internal	O
standard	O
.	O

Cells	O
were	O
used	O
4	O
days	O
after	O
infection	O
,	O
with	O
average	O
infection	O
efficiency	O
of	O
70–80	O
%	O
(	O
for	O
which	O
a	O
viral	O
dose	O
used	O
had	O
minimal	O
cytotoxicity	O
)	O
.	O

The	O
RT	O
-	O
PCR	O
product	O
of	O
M6P	O
/	O
IGF2R	O
was	O
856	O
bp	O
,	O
and	O
the	O
β	O
-	O
actin	O
product	O
was	O
285	O
bp	O
.	O

As	O
shown	O
in	O
Fig.	O
2A	O
,	O
the	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
-	O
infected	O
cells	O
exhibited	O
a	O
significantly	O
lower	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
than	O
Ad	O
-	O
GFP	O
-	O
infected	O
cells	O
,	O
with	O
a	O
reduction	O
of	O
about	O
50	O
%	O
.	O

This	O
result	O
was	O
confirmed	O
by	O
ribonuclease	O
protection	O
assay	O
(	O
RPA	O
)	O
,	O
in	O
which	O
GAPDH	O
was	O
used	O
as	O
a	O
control	O
(	O
Fig.	O
2C	O
&	O
2D	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
between	O
Ad	O
-	O
GFP	O
-	O
infected	O
cells	O
and	O
uninfected	O
cells	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
infection	O
with	O
the	O
adenovirus	O
itself	O
did	O
not	O
alter	O
the	O
endogenous	O
M6P	O
/	O
IGF2R	O
mRNA	O
level	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
ribozyme	O
was	O
highly	O
effective	O
in	O
suppressing	O
M6P	O
/	O
IGF2R	O
expression	O
in	O
cultured	O
cardiac	O
myocytes	O
.	O

Effect	O
of	O
ribozyme	O
expression	O
on	O
the	O
functional	O
activity	O
of	O
M6P	O
/	O
IGF2R	O
To	O
determine	O
the	O
effect	O
of	O
the	O
ribozyme	O
on	O
the	O
functional	O
activity	O
of	O
M6P	O
/	O
IGF2R	O
,	O
binding	O
and	O
internalization	O
of	O
exogenous	O
125I	O
-	O
IGF	O
-	O
II	O
was	O
measured	O
in	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

As	O
shown	O
in	O
Fig.	O
3A	O
,	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
showed	O
a	O
54	O
%	O
reduction	O
in	O
125I	O
-	O
IGF	O
-	O
II	O
internalization	O
when	O
compared	O
with	O
the	O
control	O
cells	O
(	O
infected	O
with	O
Ad	O
-	O
GFP	O
)	O
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
the	O
ribozyme	O
on	O
the	O
M6P	O
-	O
binding	O
activity	O
of	O
the	O
M6P	O
/	O
IGF2R	O
using	O
the	O
M6P	O
-	O
bearing	O
lysosomal	O
enzyme	O
,	O
β	O
-	O
glucuronidase	O
,	O
as	O
a	O
probe	O
.	O

The	O
results	O
showed	O
that	O
the	O
maximal	O
M6P	O
-	O
binding	O
capacity	O
of	O
cells	O
treated	O
with	O
the	O
ribozyme	O
was	O
about	O
50	O
%	O
less	O
than	O
that	O
of	O
controls	O
(	O
Fig.	O
3B	O
)	O
.	O

Furthermore	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
cells	O
to	O
internalize	O
exogenous	O
β	O
-	O
glucuronidase	O
after	O
treatment	O
with	O
ribozyme	O
.	O

Similarly	O
,	O
the	O
M6P	O
-	O
inhibitable	O
endocytosis	O
of	O
β	O
-	O
glucuronidase	O
by	O
ribozyme	O
-	O
treated	O
cells	O
was	O
about	O
52	O
%	O
less	O
than	O
that	O
of	O
control	O
cells	O
(	O
Fig.	O
3C	O
)	O
.	O

These	O
results	O
confirm	O
that	O
the	O
number	O
of	O
functional	O
M6P	O
/	O
IGF2R	O
in	O
ribozyme	O
-	O
treated	O
cells	O
was	O
reduced	O
.	O

Adenoviral	O
delivery	O
of	O
ribozymes	O
increases	O
the	O
proliferation	O
of	O
cardiac	O
myocytes	O
We	O
examined	O
the	O
effects	O
of	O
the	O
ribozyme	O
on	O
the	O
growth	O
of	O
cultured	O
neonatal	O
rat	B
cardiac	O
myocytes	O
.	O

Morphological	O
evaluation	O
showed	O
a	O
remarkable	O
difference	O
in	O
growth	O
pattern	O
between	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
-	O
infected	O
cells	O
and	O
the	O
control	O
cells	O
:	O
the	O
ribozyme	O
-	O
expressing	O
cells	O
formed	O
larger	O
and	O
more	O
spread	O
colonies	O
(	O
Fig.	O
4	O
)	O
.	O

Assessment	O
of	O
cell	O
proliferative	O
activity	O
by	O
the	O
MTT	O
assay	O
and	O
counts	O
of	O
viable	O
cells	O
showed	O
that	O
the	O
number	O
of	O
cardiac	O
myocytes	O
in	O
ribozyme	O
-	O
expressing	O
cultures	O
was	O
significantly	O
higher	O
than	O
in	O
control	O
cultures	O
(	O
Fig.	O
5	O
)	O
.	O

These	O
results	O
indicate	O
that	O
treatment	O
with	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
can	O
promote	O
cardiac	O
myocyte	O
proliferation	O
.	O

Effect	O
of	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
expression	O
on	O
apoptosis	O
of	O
cardiac	O
myocytes	O
We	O
examined	O
the	O
effects	O
of	O
ribozyme	O
expression	O
on	O
TNF	O
-	O
α	O
and	O
hypoxia	O
-	O
induced	O
apoptosis	O
of	O
cultured	O
cardiac	O
myocytes	O
.	O

After	O
a	O
24	O
hr	O
challenge	O
with	O
hypoxia	O
,	O
the	O
number	O
of	O
apoptotic	O
cells	O
in	O
M6P	O
/	O
IGF2R	O
-	O
Rz	O
expressing	O
cultures	O
was	O
38	O
%	O
lower	O
than	O
in	O
control	O
cultures	O
as	O
determined	O
by	O
Hoechst	O
staining	O
(	O
which	O
highlights	O
the	O
nuclei	O
of	O
apoptotic	O
cells	O
)	O
and	O
ELISA	O
(	O
Fig.	O
6A	O
,	O
7A	O
)	O
.	O

MTT	O
analysis	O
showed	O
that	O
the	O
number	O
of	O
viable	O
cells	O
in	O
ribozyme	O
-	O
treated	O
cultures	O
was	O
40	O
%	O
higher	O
than	O
in	O
control	O
cultures	O
(	O
Fig.	O
7A	O
)	O
.	O

After	O
treatment	O
with	O
TNF	O
-	O
α	O
,	O
as	O
shown	O
in	O
Fig.	O
6B	O
,	O
a	O
large	O
number	O
of	O
control	O
cells	O
underwent	O
apoptosis	O
,	O
as	O
indicated	O
by	O
morphological	O
changes	O
(	O
small	O
round	O
shape	O
)	O
and	O
bright	O
blue	O
nuclear	O
staining	O
.	O

There	O
were	O
significantly	O
more	O
apoptotic	O
cells	O
in	O
control	O
cultures	O
than	O
in	O
cultures	O
expressing	O
the	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

The	O
number	O
of	O
apoptotic	O
cells	O
,	O
as	O
measured	O
by	O
the	O
cell	O
death	O
ELISA	O
assay	O
,	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
was	O
significantly	O
(	O
about	O
40	O
%	O
)	O
lower	O
than	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
(	O
Fig.	O
7B	O
)	O
.	O

Accordingly	O
,	O
the	O
number	O
of	O
viable	O
cells	O
,	O
as	O
measured	O
by	O
MTT	O
analysis	O
,	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
was	O
significantly	O
(	O
about	O
45	O
%	O
)	O
higher	O
than	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
(	O
Fig.	O
7B	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
decreasing	O
M6P	O
/	O
IGF2R	O
expression	O
by	O
ribozyme	O
treatment	O
can	O
reduce	O
cell	O
apoptosis	O
.	O

Discussion	O
Some	O
62,000,000	O
Americans	O
have	O
one	O
or	O
more	O
types	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
and	O
CVD	O
is	O
the	O
leading	O
cause	O
(	O
40.1	O
%	O
)	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O

Myocardial	O
infarction	O
and	O
heart	O
failure	O
,	O
conditions	O
accompanied	O
by	O
cardiac	O
myocyte	O
apoptosis	O
,	O
represent	O
23	O
%	O
of	O
all	O
CVDs	O
and	O
are	O
a	O
growing	O
clinical	O
challenge	O
in	O
need	O
of	O
novel	O
therapeutic	O
strategies	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
M6P	O
/	O
IGF2R	O
as	O
a	O
potential	O
new	O
therapeutic	O
target	O
for	O
reduction	O
of	O
cardiac	O
apoptosis	O
and	O
cardiac	O
injury	O
in	O
these	O
conditions	O
.	O

Using	O
ribozyme	O
technology	O
we	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
the	O
M6P	O
/	O
IGF2R	O
in	O
neonatal	O
cardiac	O
myocytes	O
.	O

We	O
then	O
examined	O
cell	O
proliferation	O
and	O
apoptosis	O
under	O
normal	O
conditions	O
and	O
post	O
challenge	O
with	O
either	O
hypoxia	O
,	O
a	O
model	O
of	O
ischemia	O
-	O
reperfusion	O
,	O
or	O
TNF	O
-	O
α	O
,	O
a	O
cytokine	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
heart	O
failure	O
[	O
19	O
]	O
.	O

Our	O
results	O
demonstrate	O
an	O
association	O
of	O
a	O
decrease	O
in	O
the	O
expression	O
and	O
function	O
of	O
the	O
M6P	O
/	O
IGF2R	O
with	O
increased	O
cell	O
proliferation	O
and	O
decreased	O
cell	O
susceptibility	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

Expression	O
of	O
the	O
ribozyme	O
targeted	O
against	O
the	O
M6P	O
/	O
IGF2R	O
in	O
cardiomyocytes	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
,	O
as	O
measured	O
by	O
RT	O
-	O
PCR	O
and	O
RPA	O
,	O
and	O
of	O
M6P	O
/	O
IGF2R	O
function	O
,	O
as	O
indicated	O
by	O
a	O
decrease	O
in	O
internalization	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
,	O
and	O
β	O
-	O
glucuronidase	O
binding	O
and	O
endocytosis	O
.	O

MTT	O
analysis	O
and	O
viable	O
cell	O
counts	O
showed	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
cell	O
proliferation	O
of	O
cardiomyocytes	O
,	O
which	O
normally	O
express	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
[	O
20	O
]	O
and	O
have	O
limited	O
proliferative	O
capabilities	O
[	O
21	O
]	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
findings	O
of	O
previous	O
knockout	O
studies	O
[	O
9,10	O
]	O
.	O

Since	O
the	O
M6P	O
/	O
IGF2R	O
has	O
multiple	O
actions	O
on	O
cell	O
growth	O
,	O
its	O
proliferative	O
effect	O
on	O
the	O
heart	O
cells	O
observed	O
in	O
this	O
study	O
might	O
involve	O
multiple	O
mechanisms	O
.	O

However	O
,	O
it	O
is	O
likely	O
that	O
unchecked	O
IGF	O
-	O
II	O
stimulation	O
plays	O
a	O
key	O
role	O
in	O
the	O
effect	O
.	O

Because	O
the	O
M6P	O
/	O
IGF2R	O
is	O
believed	O
to	O
sequester	O
and	O
degrade	O
IGF	O
-	O
II	O
[	O
2	O
]	O
,	O
a	O
decrease	O
in	O
M6P	O
/	O
IGF2R	O
expression	O
and	O
function	O
could	O
result	O
in	O
decreased	O
degradation	O
and	O
hence	O
increased	O
bioavailability	O
of	O
IGF	O
-	O
II	O
to	O
the	O
IGF	O
-	O
I	O
receptor	O
,	O
which	O
mediates	O
the	O
growth	O
-	O
promoting	O
effect	O
of	O
IGF	O
-	O
II	O
.	O

Supporting	O
evidence	O
for	O
the	O
involvement	O
of	O
IGF	O
-	O
II	O
in	O
the	O
proliferative	O
effect	O
resulting	O
from	O
loss	O
of	O
M6P	O
/	O
IGF2R	O
function	O
comes	O
from	O
studies	O
of	O
M6P	O
/	O
IGF2R	O
knock	O
-	O
out	O
mice	B
.	O

M6P	O
/	O
IGF2R	O
-	O
null	O
mice	B
display	O
global	O
hyperplasia	O
that	O
coincides	O
with	O
elevated	O
levels	O
of	O
IGF	O
-	O
II	O
.	O

Most	O
importantly	O
,	O
however	O
,	O
the	O
lethal	O
nature	O
of	O
an	O
M6P	O
/	O
IGF2R	O
-	O
null	O
phenotype	O
is	O
reversed	O
in	O
an	O
IGF	O
-	O
II	O
-	O
null	O
background	O
[	O
9	O
]	O
.	O

Our	O
results	O
showing	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
lead	O
to	O
a	O
decrease	O
in	O
IGF	O
-	O
II	O
internalization	O
support	O
the	O
above	O
possibility	O
.	O

However	O
,	O
further	O
investigation	O
to	O
confirm	O
this	O
mechanism	O
is	O
warranted	O
.	O

More	O
importantly	O
,	O
our	O
results	O
also	O
showed	O
that	O
M6P	O
/	O
IGF2R	O
down	O
-	O
regulation	O
resulted	O
in	O
decreased	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

There	O
is	O
evidence	O
that	O
lysosomal	O
enzymes	O
,	O
such	O
as	O
cathepsins	O
B	O
and	O
D	O
contribute	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
in	O
vitro	O
[	O
22	O
-	O
25	O
]	O
and	O
in	O
vivo	O
[	O
26,27	O
]	O
.	O

The	O
M6P	O
/	O
IGF2R	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
binding	O
,	O
transport	O
and	O
activation	O
of	O
lysosomal	O
enzymes	O
,	O
including	O
cathepsins	O
[	O
4,5	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
down	O
-	O
regulation	O
of	O
the	O
M6P	O
/	O
IGF2R	O
results	O
in	O
improper	O
trafficking	O
and	O
activation	O
of	O
cathepsins	O
.	O

This	O
,	O
in	O
turn	O
would	O
eliminate	O
the	O
apoptotic	O
cascades	O
triggered	O
by	O
these	O
enzymes	O
under	O
hypoxia	O
and	O
TNF	O
stimulation	O
and	O
result	O
in	O
decreased	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
apoptosis	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
TNF	O
stimulation	O
involves	O
the	O
activation	O
of	O
TGF	O
-	O
β	O
[	O
28	O
-	O
30	O
]	O
,	O
a	O
ligand	O
of	O
M6P	O
/	O
IGF2R	O
that	O
has	O
been	O
implicated	O
in	O
the	O
progression	O
of	O
chronic	O
heart	O
failure	O
[	O
11,31	O
]	O
.	O

Therefore	O
,	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
could	O
also	O
lead	O
to	O
a	O
decreased	O
bioavailability	O
of	O
activated	O
TGF	O
-	O
β	O
,	O
thereby	O
decreasing	O
the	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
the	O
TNF	O
/	O
TGF	O
-	O
β	O
apoptotic	O
pathway	O
.	O

The	O
detailed	O
mechanism	O
of	O
the	O
observed	O
effects	O
is	O
unknown	O
and	O
requires	O
further	O
investigation	O
.	O

Conclusions	O
The	O
present	O
study	O
demonstrates	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
expression	O
and	O
functional	O
activity	O
of	O
the	O
M6P	O
/	O
IGF2R	O
results	O
in	O
a	O
decrease	O
in	O
the	O
susceptibility	O
of	O
cardiac	O
myocytes	O
to	O
apoptotic	O
stimuli	O
.	O

These	O
findings	O
suggest	O
that	O
this	O
receptor	O
might	O
be	O
involved	O
in	O
cardiac	O
cell	O
growth	O
and	O
apoptosis	O
.	O

The	O
ability	O
of	O
the	O
M6P	O
/	O
IGF2R	O
ribozyme	O
to	O
reduce	O
M6P	O
/	O
IGF2R	O
expression	O
and	O
function	O
in	O
transfected	O
cells	O
verifies	O
the	O
utility	O
of	O
the	O
ribozyme	O
in	O
studying	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
cardiomyocyte	O
growth	O
and	O
apoptosis	O
.	O

In	O
addition	O
to	O
its	O
utility	O
as	O
a	O
research	O
tool	O
,	O
the	O
ribozyme	O
,	O
with	O
further	O
exploration	O
and	O
development	O
,	O
might	O
have	O
potential	O
application	O
as	O
a	O
therapeutic	O
agent	O
to	O
prevent	O
cell	O
death	O
or	O
promote	O
mitogenesis	O
for	O
certain	O
clinical	O
conditions	O
,	O
such	O
as	O
,	O
myocardial	O
infarction	O
and	O
chronic	O
heart	O
failure	O
.	O

Methods	O
Construction	O
of	O
recombinant	O
M6P	O
/	O
IGF2R	O
-	O
RZ	O
adenoviral	O
vector	O
The	O
nucleotide	O
numbers	O
of	O
the	O
rat	B
M6P	O
/	O
IGF2R	O
sequence	O
targeted	O
by	O
the	O
hammerhead	O
ribozyme	O
is	O
1147–1160	O
after	O
coding	O
site	O
(	O
exon	O
9	O
)	O
.	O

The	O
structure	O
of	O
the	O
M6P	O
/	O
IGF2R	O
hammerhead	O
ribozyme	O
is	O
shown	O
in	O
Fig.	O
1	O
.	O

A	O
49	O
bp	O
M6P	O
/	O
IGF2R	O
ribozyme	O
oligonucleotide	O
,	O
5'-GAATTCCCC	O
ACACTG	O
ATGAGCCGCTTCGGCGGCGAAACATTCAAC	O
GCGT-3	O
'	O
and	O
the	O
corresponding	O
reverse	O
complementary	O
strand	O
were	O
synthesized	O
.	O

The	O
fragments	O
were	O
subcloned	O
to	O
produce	O
a	O
plasmid	O
containing	O
a	O
ribozyme	O
against	O
M6P	O
/	O
IGF2R	O
.	O

For	O
construction	O
of	O
the	O
recombinant	O
adenovirus	O
containing	O
the	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
(	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
)	O
,	O
the	O
segments	O
containing	O
the	O
ribozymes	O
were	O
amplified	O
by	O
PCR	O
and	O
cloned	O
into	O
a	O
pAdTrack	O
-	O
CMV	O
vector	O
and	O
then	O
recombined	O
homologously	O
with	O
an	O
adenoviral	O
backbone	O
pAdEasy	O
1	O
vector	O
to	O
generate	O
(	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
)	O
,	O
following	O
the	O
protocol	O
described	O
by	O
He	O
et	O
al.	O
[	O
32	O
]	O
.	O

The	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
carries	O
both	O
the	O
IGF2R	O
-	O
Rz	O
and	O
GFP	O
(	O
as	O
reporter	O
)	O
genes	O
,	O
each	O
under	O
the	O
control	O
of	O
separate	O
cytomegalovirus	O
(	O
CMV	O
)	O
promoters	O
.	O

Another	O
viral	O
vector	O
,	O
pAd	O
-	O
GFP	O
,	O
which	O
carries	O
the	O
GFP	O
gene	O
only	O
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
,	O
was	O
generated	O
and	O
used	O
as	O
a	O
control	O
vector	O
.	O

The	O
adenoviral	O
vector	O
DNA	O
were	O
linerized	O
with	O
Pac	O
I	O
and	O
transfected	O
into	O
the	O
replication	O
-	O
permissive	O
293	O
cells	O
(	O
E1A	O
transcomplementing	O
cell	O
line	O
)	O
by	O
using	O
Lipofectamine	O
(	O
Life	O
Technologies	O
)	O
to	O
produce	O
E1-deleted	O
,	O
replication	O
-	O
defective	O
recombinant	O
adenovirus	O
as	O
described	O
previously	O
[	O
33	O
]	O
.	O

Large	O
-	O
scale	O
amplification	O
of	O
recombinant	O
adenovirus	O
in	O
293	O
cells	O
was	O
followed	O
by	O
purification	O
using	O
a	O
discontinuous	O
CsCl	O
gradient	O
.	O

The	O
constructs	O
were	O
confirmed	O
by	O
enzymatic	O
digestion	O
and	O
DNA	O
sequencing	O
.	O

Transcription	O
and	O
cleavage	O
reaction	O
of	O
ribozyme	O
in	O
vitro	O
Plasmids	O
containing	O
the	O
ribozyme	O
or	O
the	O
substrate	O
(	O
either	O
45	O
bp	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
or	O
an	O
unmatched	O
sequence	O
5'-GTGCTGTCTGTATG-3	O
'	O
)	O
were	O
linearized	O
with	O
MluI	O
,	O
respectively	O
.	O

All	O
transcripts	O
were	O
generated	O
with	O
T7	O
RNA	O
polymerase	O
(	O
Promega	O
)	O
.	O

Substrate	O
transcripts	O
were	O
labeled	O
by	O
incorporation	O
of	O
[	O
α-32P	O
]	O
UTP	O
(	O
NEN	O
Life	O
Science	O
Products	O
,	O
Inc.	O
)	O
.	O

Specific	O
activity	O
of	O
the	O
[	O
α-32P	O
]	O
UTP	O
(	O
10	O
μCi	O
/	O
μl	O
)	O
and	O
the	O
base	O
composition	O
of	O
each	O
substrate	O
molecule	O
were	O
used	O
to	O
calculate	O
the	O
substrate	O
concentration	O
.	O

Ribozyme	O
transcripts	O
were	O
quantified	O
spectrophotometrically	O
.	O

(	O
The	O
half	O
-	O
life	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
is	O
about	O
280	O
minutes	O
)	O
.	O

Cleavage	O
reaction	O
mixture	O
contained	O
substrate	O
RNA	O
(	O
40	O
nM	O
)	O
,	O
increasing	O
amounts	O
of	O
ribozyme	O
(	O
60	O
nM	O
)	O
,	O
20	O
mM	O
MgCl2	O
and	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH8.0	O
,	O
in	O
a	O
final	O
volume	O
of	O
10	O
μl	O
.	O

The	O
mixture	O
was	O
incubated	O
at	O
37	O
°	O
C	O
for	O
a	O
time	O
-	O
course	O
of	O
cleavage	O
reaction	O
from	O
0	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
,	O
80	O
,	O
160	O
,	O
320	O
,	O
to	O
640	O
minutes	O
and	O
the	O
cleavage	O
reaction	O
was	O
stopped	O
by	O
addition	O
of	O
loading	O
buffer	O
(	O
80	O
%	O
formamide	O
,	O
10	O
mM	O
Na2EDTA	O
,	O
pH	O
8.0	O
,	O
and	O
1	O
mg	O
/	O
ml	O
each	O
bromophenol	O
blue	O
and	O
xylene	O
cyanol	O
)	O
.	O

Cleavage	O
products	O
were	O
analyzed	O
on	O
a	O
15	O
%	O
polyacrylamide	O
and	O
8	O
M	O
urea	O
gel	O
.	O

Product	O
and	O
substrate	O
fragments	O
were	O
quantitated	O
by	O
using	O
NIH	O
Imager	O
.	O

Cell	O
cultures	O
and	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
Rz	O
-	O
IGF2R	O
and	O
Ad	O
-	O
GFP	O
Cardiac	O
myocytes	O
were	O
isolated	O
from	O
1-day	O
-	O
old	O
newborn	O
rats	B
using	O
the	O
Neonatal	O
Cardiomyocyte	O
Isolation	O
System	O
(	O
Worthington	O
)	O
.	O

The	O
isolated	O
cells	O
were	O
plated	O
in	O
6-well	O
plates	O
and	O
cultured	O
in	O
F-10	O
medium	O
containing	O
5	O
%	O
(	O
vol	O
/	O
vol	O
)	O
FBS	O
and	O
10	O
%	O
(	O
vol	O
/	O
vol	O
)	O
horse	B
serum	O
at	O
37	O
°	O
C	O
in	O
a	O
tissue	O
culture	O
incubator	O
with	O
5	O
%	O
CO2	O
and	O
98	O
%	O
relative	O
humidity	O
.	O

Cells	O
were	O
used	O
for	O
experiments	O
after	O
2–3	O
days	O
of	O
culture	O
.	O

Viral	O
infections	O
were	O
carried	O
out	O
by	O
adding	O
viral	O
particles	O
at	O
various	O
concentrations	O
(	O
usually	O
,	O
2	O
×	O
108	O
virus	O
particles	O
/	O
ml	O
)	O
to	O
culture	O
medium	O
containing	O
2	O
%	O
(	O
vol	O
/	O
vol	O
)	O
FBS	O
.	O

Initially	O
,	O
optimal	O
viral	O
concentration	O
was	O
determined	O
by	O
using	O
Ad	O
-	O
GFP	O
to	O
achieve	O
an	O
optimal	O
balance	O
of	O
high	O
gene	O
expression	O
and	O
low	O
viral	O
titer	O
to	O
minimize	O
cytotoxicity	O
.	O

After	O
24	O
hours	O
of	O
incubation	O
,	O
the	O
infection	O
medium	O
was	O
replaced	O
with	O
normal	O
(	O
15	O
%	O
vol	O
/	O
vol	O
serum	O
)	O
culture	O
medium	O
.	O

For	O
treatment	O
with	O
IGF	O
-	O
II	O
,	O
cells	O
were	O
incubated	O
with	O
50	O
ng	O
/	O
ml	O
IGF	O
-	O
II	O
after	O
24	O
hours	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
.	O

Four	O
days	O
after	O
infection	O
,	O
cells	O
were	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
of	O
M6P	O
/	O
IGF2R	O
and	O
its	O
effect	O
on	O
cell	O
growth	O
and	O
apoptosis	O
.	O

Analysis	O
of	O
gene	O
expression	O
in	O
cardiac	O
myocytes	O
The	O
M6P	O
/	O
IGF2R	O
transcripts	O
were	O
determined	O
by	O
both	O
RT	O
-	O
PCR	O
and	O
Ribonuclease	O
Protection	O
Assay	O
(	O
RPA	O
)	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
using	O
the	O
GeneAmp	O
EZ	O
rTth	O
RNA	O
PCR	O
kit	O
(	O
Roche	O
)	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
cultured	O
cells	O
using	O
an	O
RNA	O
isolation	O
kit	O
(	O
Qiagen	O
,	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

M6P	O
/	O
IGF2R	O
transcripts	O
were	O
amplified	O
using	O
the	O
primers	O
(	O
5'-GACAGGCTCGTTCTGACTTA-3	O
'	O
)	O
and	O
(	O
5'-CTTCCACTCTTATCCACAGC-3	O
'	O
)	O
specific	O
to	O
the	O
M6P	O
/	O
IGF2R	O
.	O

Each	O
RT	O
-	O
PCR	O
assay	O
was	O
performed	O
in	O
triplicate	O
and	O
product	O
levels	O
varied	O
by	O
less	O
than	O
3.2	O
%	O
for	O
each	O
RNA	O
sample	O
.	O

Primers	O
specific	O
for	O
β	O
-	O
actin	O
cDNA	O
were	O
added	O
to	O
a	O
parallel	O
reaction	O
to	O
standardize	O
for	O
variations	O
in	O
PCR	O
between	O
samples	O
.	O

PCR	O
products	O
were	O
resolved	O
on	O
a	O
1.0	O
%	O
agarose	O
gel	O
,	O
visualized	O
under	O
UV	O
light	O
and	O
quantitated	O
using	O
NIH	O
Imager	O
.	O

RPA	O
was	O
performed	O
using	O
the	O
RPA	O
III	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
cultured	O
cells	O
using	O
a	O
total	O
RNA	O
isolation	O
reagent	O
(	O
TRIzol	O
,	O
Gibco	O
BRL	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

The	O
plasmid	O
containing	O
the	O
rat	B
M6P	O
/	O
IGF2R	O
gene	O
was	O
linearized	O
and	O
used	O
as	O
a	O
transcription	O
template	O
.	O

Antisense	O
RNA	O
probes	O
were	O
transcribed	O
in	O
vitro	O
using	O
[	O
33P	O
]	O
-UTP	O
,	O
T7	O
polymerase	O
(	O
Riboprobea	O
System	O
T7	O
kit	O
,	O
Promega	O
)	O
,	O
hybridized	O
with	O
the	O
total	O
RNA	O
extracted	O
from	O
the	O
rat	B
cardiomyocytes	O
,	O
and	O
digested	O
with	O
ribonuclease	O
to	O
remove	O
non	O
-	O
hybridized	O
RNA	O
and	O
probe	O
.	O

The	O
protected	O
RNA·RNA	O
was	O
resolved	O
on	O
a	O
denaturing	O
5	O
%	O
sequence	O
gel	O
and	O
subjected	O
to	O
autoradiography	O
.	O

A	O
probe	O
targeting	O
the	O
GAPDH	O
gene	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

Measurement	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
internalization	O
Cells	O
were	O
incubated	O
at	O
37	O
°	O
C	O
for	O
2	O
hrs	O
in	O
serum	O
-	O
free	O
F-10	O
culture	O
medium	O
containing	O
125I	O
-	O
labeled	O
IGF	O
-	O
II	O
(	O
0.5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
excess	O
unlabeled	O
IGF	O
-	O
II	O
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

Following	O
the	O
incubation	O
,	O
the	O
cells	O
were	O
washed	O
three	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
,	O
and	O
cell	O
-	O
associated	O
radioactivity	O
was	O
determined	O
by	O
a	O
γ	O
counter	O
.	O

Specific	O
internalized	O
125I	O
-	O
IGF	O
-	O
II	O
was	O
calculated	O
by	O
subtracting	O
the	O
count	O
of	O
samples	O
with	O
excessive	O
unlabeled	O
IGF	O
-	O
II	O
from	O
that	O
without	O
unlabeled	O
IGF	O
-	O
II	O
,	O
and	O
normalized	O
to	O
protein	O
contents	O
.	O

Beta	O
-	O
glucuronidase	O
binding	O
assay	O
Binding	O
of	O
β	O
-	O
glucuronidase	O
was	O
assayed	O
as	O
described	O
previously	O
[	O
34,35	O
]	O
.	O

Briefly	O
,	O
cells	O
were	O
permeabilized	O
with	O
0.25	O
%	O
saponin	O
in	O
50	O
mM	O
Hepes	O
(	O
pH	O
7.0	O
)	O
,	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
β	O
-	O
glycerophosphate	O
,	O
0.5	O
%	O
human	B
serum	O
albumin	O
,	O
and	O
10	O
mM	O
mannose-6-phosphate	O
(	O
M6P	O
)	O
for	O
30	O
minutes	O
on	O
ice	O
.	O

The	O
cells	O
were	O
washed	O
three	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
containing	O
0.05	O
%	O
saponin	O
.	O

They	O
were	O
incubated	O
with	O
20,000	O
units	O
/	O
ml	O
β	O
-	O
glucuronidase	O
from	O
bovine	B
liver	O
(	O
Sigma	O
)	O
in	O
50	O
mM	O
Hepes	O
(	O
pH	O
7.5	O
)	O
containing	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
β	O
-	O
glycerophosphate	O
,	O
0.5	O
%	O
human	B
serum	O
albumin	O
,	O
0.5	O
%	O
saponin	O
with	O
or	O
without	O
10	O
mM	O
M6P	O
overnight	O
on	O
ice	O
.	O

Cells	O
were	O
washed	O
five	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
containing	O
0.05	O
%	O
saponin	O
and	O
sonicated	O
in	O
100	O
mM	O
sodium	O
acetate	O
(	O
pH	O
4.6	O
)	O
.	O

The	O
protein	O
concentration	O
of	O
solubilized	O
cell	O
extract	O
was	O
measured	O
and	O
enzyme	O
activity	O
was	O
assayed	O
as	O
follows	O
:	O
for	O
each	O
reaction	O
50	O
ul	O
cell	O
extract	O
were	O
added	O
to	O
500	O
ul	O
of	O
100	O
mM	O
sodium	O
acetate	O
(	O
pH	O
4.0	O
)	O
containing	O
1	O
mM	O
paranitrophenyl	O
(	O
PNP	O
)	O
-β	O
-	O
glucuronide	O
(	O
Sigma	O
)	O
as	O
substrate	O
.	O

After	O
an	O
incubation	O
period	O
of	O
3	O
hours	O
at	O
37	O
°	O
C	O
,	O
500	O
ul	O
1	O
M	O
Na2CO3	O
were	O
added	O
to	O
each	O
reaction	O
and	O
the	O
absorbance	O
was	O
measured	O
at	O
400	O
nm	O
.	O

Experimental	O
values	O
were	O
compared	O
to	O
a	O
standard	O
curve	O
that	O
was	O
constructed	O
using	O
1–100	O
nM	O
solutions	O
of	O
PNP	O
(	O
Sigma	O
)	O
in	O
500	O
ul	O
100	O
mM	O
sodium	O
acetate	O
and	O
500	O
u1	O
1	O
M	O
Na2CO3	O
.	O

Specific	O
activity	O
was	O
calculated	O
as	O
nM	O
of	O
PNP	O
produced	O
/	O
hour	O
/	O
mg	O
of	O
protein	O
.	O

Beta	O
-	O
glucuronidase	O
endocytosis	O
assay	O
Beta	O
-	O
glucuronidase	O
endocytosis	O
assay	O
was	O
carried	O
out	O
as	O
described	O
previously	O
[	O
36	O
]	O
.	O

Briefly	O
,	O
confluent	O
cell	O
cultures	O
were	O
washed	O
twice	O
with	O
pre	O
-	O
warmed	O
serum	O
-	O
free	O
DMEM	O
followed	O
by	O
incubation	O
with	O
DMEM	O
containing	O
5	O
mg	O
/	O
ml	O
human	B
serum	O
albumin	O
and	O
10	O
mM	O
M6P	O
for	O
20	O
minutes	O
.	O

Following	O
incubation	O
cells	O
were	O
washed	O
3	O
times	O
with	O
pre	O
-	O
warmed	O
DMEM	O
.	O

Cells	O
were	O
then	O
incubated	O
in	O
DMEM	O
containing	O
5	O
mg	O
/	O
ml	O
human	B
serum	O
albumin	O
alone	O
or	O
4000	O
units	O
β	O
-	O
glucuronidase	O
with	O
or	O
without	O
10	O
mM	O
M6P	O
for	O
2	O
hours	O
at	O
37	O
°	O
C	O
.	O

Following	O
the	O
incubation	O
,	O
the	O
cells	O
were	O
washed	O
5	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
subjected	O
to	O
enzyme	O
activity	O
assay	O
as	O
described	O
above	O
.	O

Cell	O
proliferation	O
assay	O
(	O
MTT	O
assay	O
and	O
cell	O
counts	O
)	O
Cardiac	O
myocytes	O
were	O
grown	O
in	O
culture	O
plates	O
(	O
tissue	O
culture	O
grade	O
,	O
12	O
wells	O
,	O
flat	O
bottom	O
)	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
serum	O
-	O
containing	O
culture	O
medium	O
per	O
well	O
,	O
in	O
a	O
humidified	O
atmosphere	O
(	O
37	O
°	O
C	O
and	O
5	O
%	O
C02	O
)	O
for	O
3	O
days	O
.	O

After	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
,	O
cells	O
were	O
incubated	O
with	O
or	O
without	O
50	O
ng	O
/	O
ml	O
IGF	O
-	O
II	O
for	O
4	O
days	O
.	O

Following	O
supplementation	O
with	O
IGF	O
-	O
II	O
,	O
100	O
μl	O
MTT	O
labeling	O
reagent	O
(	O
Roche	O
)	O
were	O
added	O
to	O
each	O
well	O
and	O
cells	O
were	O
incubated	O
for	O
4	O
hours	O
,	O
followed	O
by	O
addition	O
of	O
1	O
ml	O
solubilization	O
solution	O
into	O
each	O
well	O
.	O

The	O
plate	O
was	O
placed	O
in	O
an	O
incubator	O
at	O
37	O
°	O
C	O
overnight	O
.	O

Spectrophotometrical	O
absorbency	O
of	O
the	O
samples	O
was	O
measured	O
using	O
an	O
UV	O
-	O
visible	O
Recording	O
Spectrophotometer	O
with	O
wavelength	O
of	O
550–690	O
nm	O
.	O

In	O
addition	O
,	O
the	O
total	O
number	O
of	O
viable	O
cells	O
in	O
each	O
treatment	O
was	O
counted	O
by	O
trypan	O
blue	O
exclusion	O
method	O
using	O
a	O
hemocytometer	O
.	O

Induction	O
and	O
analysis	O
of	O
cell	O
apoptosis	O
Cells	O
were	O
infected	O
with	O
Ad	O
-	O
GFP	O
or	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

Seventy	O
-	O
two	O
hours	O
post	O
infection	O
,	O
cells	O
were	O
treated	O
with	O
TNF	O
(	O
0.1	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
or	O
subjected	O
to	O
hypoxia	O
.	O

For	O
induction	O
of	O
apoptosis	O
by	O
hypoxia	O
,	O
cell	O
culture	O
medium	O
was	O
changed	O
to	O
serum	O
-	O
free	O
F-10	O
saturated	O
with	O
95	O
%	O
N2	O
/	O
5	O
%	O
CO2	O
and	O
cells	O
were	O
placed	O
in	O
a	O
37	O
°	O
C	O
airtight	O
box	O
saturated	O
with	O
95	O
%	O
N2	O
/	O
5	O
%	O
CO2	O
for	O
24	O
hrs	O
.	O

For	O
normoxic	O
controls	O
,	O
culture	O
medium	O
was	O
changed	O
to	O
F-10	O
/	O
5%F	O
BS	O
/	O
10	O
%	O
HS	O
and	O
cells	O
were	O
placed	O
in	O
a	O
37	O
°	O
C	O
/	O
5	O
%	O
CO2	O
incubator	O
for	O
24	O
hrs	O
before	O
analysis	O
.	O

Apoptotic	O
cells	O
were	O
identified	O
by	O
Hoechst	O
staining	O
using	O
the	O
Vybrant	O
™	O
Apoptosis	O
Kit	O
#	O
5	O
(	O
Molecular	O
Probes	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

In	O
addition	O
,	O
after	O
infection	O
with	O
Ad	O
-	O
GFP	O
or	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
and	O
challenge	O
with	O
either	O
TNF	O
or	O
hypoxia	O
,	O
cell	O
viability	O
was	O
assessed	O
using	O
the	O
MTT	O
assay	O
Kit	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
and	O
cell	O
apoptosis	O
was	O
determined	O
using	O
the	O
Cell	O
Death	O
Detection	O
ELISA	O
Kit	O
assay	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Statistical	O
analysis	O
Students	O
'	O
t	O
-	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
difference	O
between	O
two	O
values	O
.	O

Each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
.	O

Statistical	O
significance	O
was	O
accepted	O
at	O
the	O
level	O
of	O
p	O
<	O
0.05	O
.	O

List	O
of	O
abbreviations	O
used	O
Ad	O
-	O
GFP	O
,	O
adenovirus	O
carrying	O
GFP	O
gene	O
;	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
,	O
adenovirus	O
carrying	O
both	O
the	O
ribozyme	O
against	O
M6P	O
/	O
IGF2R	O
and	O
the	O
GFP	O
gene	O
;	O
GFP	O
,	O
green	O
fluorescent	O
protein	O
;	O
IGF	O
-	O
II	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
;	O
M6P	O
/	O
IGF2R	O
,	O
mannose	O
6-phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
receptor	O
;	O
Rz	O
,	O
ribozyme	O
.	O

Authors	O
'	O
contributions	O
ZC	O
carried	O
out	O
construction	O
of	O
the	O
ribozyme	O
,	O
production	O
of	O
the	O
viruses	O
,	O
cellular	O
experiments	O
,	O
biochemical	O
assays	O
and	O
data	O
analysis	O
.	O

YG	O
carried	O
out	O
the	O
RPA	O
assay	O
and	O
participated	O
in	O
the	O
molecular	O
biological	O
studies	O
.	O

JXK	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

Medicinal	O
herb	O
use	O
among	O
asthmatic	O
patients	O
attending	O
a	O
specialty	O
care	O
facility	O
in	O
Trinidad	O
Abstract	O
Background	O
There	O
is	O
an	O
increasing	O
prevalence	O
of	O
asthma	O
in	O
the	O
Caribbean	O
and	O
patients	O
remain	O
non	O
-	O
compliant	O
to	O
therapy	O
despite	O
the	O
development	O
of	O
guidelines	O
for	O
management	O
and	O
prevention	O
.	O

Some	O
patients	O
may	O
self	O
-	O
medicate	O
with	O
medicinal	O
herbs	O
for	O
symptomatic	O
relief	O
,	O
as	O
there	O
is	O
a	O
long	O
tradition	O
of	O
use	O
for	O
a	O
variety	O
of	O
ailments	O
.	O

The	O
study	O
assessed	O
the	O
prevalence	O
of	O
use	O
and	O
the	O
factors	O
affecting	O
the	O
decision	O
to	O
use	O
herbs	O
in	O
asthmatic	O
patients	O
attending	O
a	O
public	O
specialty	O
care	O
clinic	O
in	O
Trinidad	O
.	O

Methods	O
A	O
descriptive	O
,	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
at	O
the	O
Chest	O
Clinic	O
in	O
Trinidad	O
using	O
a	O
de	O
novo	O
,	O
pilot	O
-	O
tested	O
,	O
researcher	O
-	O
administered	O
questionnaire	O
between	O
June	O
and	O
July	O
2003	O
.	O

Results	O
Fifty	O
-	O
eight	O
out	O
of	O
191	O
patients	O
(	O
30.4	O
%	O
)	O
reported	O
using	O
herbal	O
remedies	O
for	O
symptomatic	O
relief	O
.	O

Gender	O
,	O
age	O
,	O
ethnicity	O
,	O
and	O
asthma	O
severity	O
did	O
not	O
influence	O
the	O
decision	O
to	O
use	O
herbs	O
;	O
however	O
,	O
62.5	O
%	O
of	O
patients	O
with	O
tertiary	O
level	O
schooling	O
used	O
herbs	O
,	O
p	O
=	O
0.025	O
.	O

Thirty	O
-	O
four	O
of	O
these	O
58	O
patients	O
(	O
58.6	O
%	O
)	O
obtained	O
herbs	O
from	O
their	O
backyards	O
or	O
the	O
supermarket	O
;	O
only	O
14	O
patients	O
(	O
24.1	O
%	O
)	O
obtained	O
herbs	O
from	O
an	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
.	O

Relatives	O
and	O
friends	O
were	O
the	O
sole	O
source	O
of	O
information	O
for	O
most	O
patients	O
(	O
70.7	O
%	O
)	O
,	O
and	O
only	O
10.3	O
%	O
consulted	O
an	O
herbalist	O
.	O

Ginger	B
,	O
garlic	B
,	O
aloes	O
,	O
shandileer	B
,	O
wild	O
onion	B
,	O
pepper	O
and	O
black	B
sage	I
were	O
the	O
most	O
commonly	O
used	O
herbs	O
.	O

Conclusions	O
Among	O
patients	O
attending	O
the	O
Chest	O
Clinic	O
in	O
Trinidad	O
the	O
use	O
of	O
herbal	O
remedies	O
in	O
asthma	O
is	O
relatively	O
common	O
on	O
the	O
advice	O
of	O
relatives	O
and	O
friends	O
.	O

It	O
is	O
therefore	O
becoming	O
imperative	O
for	O
healthcare	O
providers	O
to	O
become	O
more	O
knowledgeable	O
on	O
this	O
modality	O
and	O
to	O
keep	O
abreast	O
with	O
the	O
latest	O
developments	O
.	O

Background	O
Recent	O
reports	O
from	O
the	O
Caribbean	O
suggest	O
that	O
the	O
incidence	O
of	O
asthma	O
is	O
following	O
the	O
global	O
trend	O
of	O
increasing	O
prevalence	O
.	O

In	O
Jamaica	O
,	O
a	O
prevalence	O
of	O
20.8	O
%	O
for	O
exercise	O
-	O
induced	O
asthma	O
was	O
estimated	O
in	O
a	O
cross	O
-	O
sectional	O
study	O
in	O
schoolchildren	O
[	O
1	O
]	O
.	O

About	O
one	O
in	O
ten	O
patients	O
attending	O
an	O
Accident	O
and	O
Emergency	O
Department	O
in	O
Trinidad	O
were	O
treated	O
for	O
acute	O
severe	O
asthma	O
[	O
2	O
]	O
and	O
over	O
15,000	O
patients	O
attended	O
four	O
A&E	O
departments	O
throughout	O
the	O
island	O
over	O
a	O
12-month	O
period	O
[	O
3	O
]	O
.	O

Inhaled	O
corticosteroids	O
as	O
prophylaxis	O
and	O
'	O
as	O
required	O
'	O
bronchodilator	O
for	O
symptomatic	O
relief	O
are	O
established	O
modalities	O
for	O
asthma	O
management	O
and	O
prevention	O
and	O
the	O
Commonwealth	O
Caribbean	O
Medical	O
Research	O
Council	O
/	O
Global	O
Initiative	O
for	O
Asthma	O
guidelines	O
were	O
adopted	O
in	O
the	O
Caribbean	O
in	O
1997	O
[	O
4	O
]	O
.	O

It	O
has	O
been	O
noted	O
that	O
inefficient	O
management	O
predisposes	O
patients	O
to	O
frequent	O
hospitalization	O
and	O
reduced	O
quality	O
of	O
life	O
.	O

In	O
Trinidad	O
,	O
non	O
-	O
compliance	O
and	O
inadequate	O
inhaler	O
technique	O
negatively	O
impact	O
on	O
effective	O
disease	O
management	O
[	O
5,6	O
]	O
.	O

The	O
frequent	O
unavailability	O
of	O
medication	O
at	O
public	O
health	O
facilities	O
and	O
the	O
prohibitive	O
cost	O
at	O
private	O
pharmacies	O
are	O
significantly	O
associated	O
with	O
non	O
-	O
compliance	O
and	O
consequently	O
poor	O
disease	O
control	O
.	O

In	O
these	O
studies	O
,	O
some	O
patients	O
indicated	O
their	O
use	O
of	O
herbal	O
remedies	O
as	O
an	O
alternative	O
to	O
conventional	O
medicines	O
.	O

Over	O
the	O
last	O
few	O
decades	O
,	O
a	O
global	O
resurgence	O
in	O
the	O
use	O
of	O
herbal	O
remedies	O
has	O
fuelled	O
the	O
growing	O
multi	O
-	O
billion	O
dollar	O
international	O
trade	O
of	O
botanical	O
products	O
.	O

Many	O
patients	O
,	O
dissatisfied	O
with	O
conventional	O
medicines	O
because	O
they	O
expect	O
permanent	O
cures	O
,	O
believe	O
that	O
herbal	O
remedies	O
are	O
'	O
natural	O
'	O
and	O
sometimes	O
self	O
-	O
medicate	O
without	O
informing	O
their	O
attending	O
physician	O
.	O

Although	O
there	O
is	O
a	O
long	O
history	O
of	O
traditional	O
use	O
of	O
medicinal	O
herbs	O
throughout	O
the	O
Caribbean	O
[	O
7,8	O
]	O
few	O
studies	O
were	O
done	O
to	O
assess	O
the	O
prevalence	O
of	O
use	O
.	O

Surveys	O
in	O
Jamaica	O
reported	O
an	O
almost	O
100	O
%	O
use	O
of	O
herbal	O
teas	O
and	O
remedies	O
by	O
respondents	O
throughout	O
the	O
island	O
[	O
9	O
]	O
and	O
71	O
%	O
in	O
paediatrics	O
inpatients	O
at	O
the	O
University	O
Hospital	O
[	O
10	O
]	O
.	O

These	O
studies	O
,	O
however	O
,	O
assessed	O
only	O
the	O
lifetime	O
use	O
of	O
medicinal	O
herbs	O
and	O
did	O
not	O
identify	O
their	O
use	O
for	O
any	O
particular	O
disease	O
.	O

In	O
Trinidad	O
and	O
Tobago	O
,	O
the	O
use	O
of	O
'	O
bush	O
medicine	O
'	O
in	O
diabetic	O
patients	O
attending	O
primary	O
healthcare	O
facilities	O
throughout	O
the	O
island	O
was	O
assessed	O
and	O
although	O
42	O
%	O
reportedly	O
used	O
herbs	O
,	O
only	O
24	O
%	O
used	O
this	O
healthcare	O
modality	O
for	O
self	O
-	O
management	O
of	O
diabetes	O
[	O
11	O
]	O
.	O

Another	O
survey	O
conducted	O
at	O
an	O
outpatient	O
surgical	O
facility	O
in	O
Trinidad	O
indicated	O
a	O
lifetime	O
prevalence	O
of	O
86	O
%	O
among	O
patients	O
[	O
12	O
]	O
for	O
any	O
healthcare	O
issue	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
extent	O
of	O
use	O
of	O
herbal	O
remedies	O
by	O
asthmatic	O
patients	O
attending	O
a	O
specialty	O
chest	O
clinic	O
in	O
Trinidad	O
for	O
symptomatic	O
relief	O
and	O
to	O
determine	O
the	O
factors	O
influencing	O
the	O
patient	O
's	O
decision	O
to	O
use	O
herbs	O
.	O

Methods	O
The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Faculty	O
of	O
Medical	O
Sciences	O
,	O
University	O
of	O
the	O
West	O
Indies	O
,	O
St.	O
Augustine	O
campus	O
and	O
permission	O
to	O
interview	O
patients	O
was	O
granted	O
by	O
the	O
Director	O
of	O
the	O
Chest	O
Clinic	O
of	O
the	O
Ministry	O
of	O
Health	O
,	O
Trinidad	O
and	O
Tobago	O
.	O

The	O
study	O
was	O
conducted	O
over	O
the	O
two	O
-	O
month	O
period	O
June	O
to	O
July	O
2003	O
.	O

Sample	O
and	O
setting	O
The	O
Chest	O
Clinic	O
was	O
chosen	O
as	O
the	O
source	O
of	O
subjects	O
as	O
this	O
is	O
the	O
only	O
national	O
tertiary	O
level	O
health	O
facility	O
specializing	O
in	O
the	O
management	O
of	O
respiratory	O
diseases	O
.	O

Patients	O
entering	O
the	O
study	O
were	O
physician	O
-	O
diagnosed	O
asthmatics	O
based	O
on	O
self	O
-	O
reporting	O
symptoms	O
of	O
wheezing	O
,	O
chest	O
tightness	O
and	O
nocturnal	O
coughing	O
in	O
the	O
previous	O
year	O
.	O

Patients	O
were	O
recruited	O
by	O
consecutive	O
sampling	O
and	O
the	O
nature	O
and	O
purpose	O
of	O
the	O
study	O
were	O
explained	O
on	O
an	O
individual	O
basis	O
.	O

Those	O
confirming	O
their	O
willingness	O
to	O
participate	O
signed	O
their	O
informed	O
consent	O
and	O
were	O
interviewed	O
using	O
a	O
de	O
novo	O
,	O
pilot	O
-	O
tested	O
,	O
researcher	O
-	O
administered	O
questionnaire	O
.	O

Interview	O
instrument	O
The	O
questionnaire	O
assessed	O
demographic	O
data	O
such	O
as	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
residential	O
district	O
,	O
education	O
,	O
employment	O
and	O
socioeconomic	O
status	O
.	O

Subjects	O
reported	O
their	O
disease	O
severity	O
as	O
intermittent	O
,	O
moderate	O
or	O
severe	O
as	O
determined	O
by	O
the	O
Global	O
Initiative	O
for	O
Asthma	O
(	O
GINA	O
)	O
guidelines	O
with	O
respect	O
to	O
symptom	O
frequency	O
[	O
4	O
]	O
.	O

Patients	O
also	O
reported	O
their	O
use	O
of	O
herbal	O
remedies	O
,	O
identified	O
the	O
herbs	O
used	O
,	O
the	O
frequency	O
of	O
use	O
,	O
source	O
of	O
herbal	O
medicines	O
and	O
the	O
reasons	O
for	O
the	O
use	O
of	O
herbs	O
.	O

Statistical	O
analysis	O
The	O
sample	O
size	O
was	O
calculated	O
as	O
185	O
patients	O
assuming	O
a	O
prevalence	O
of	O
86	O
%	O
[	O
13	O
]	O
with	O
a	O
confidence	O
level	O
of	O
95	O
%	O
.	O

Since	O
all	O
variables	O
were	O
categorical	O
,	O
χ2	O
tests	O
were	O
performed	O
to	O
determine	O
whether	O
there	O
were	O
statistically	O
significant	O
associations	O
between	O
the	O
use	O
of	O
herbs	O
and	O
these	O
variables	O
.	O

The	O
p	O
value	O
was	O
set	O
at	O
<	O
0.05	O
for	O
statistical	O
significance	O
.	O

The	O
data	O
was	O
analyzed	O
using	O
SPSS	O
for	O
Windows	O
(	O
Version	O
9.0	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

Results	O
Demography	O
During	O
the	O
study	O
period	O
one	O
hundred	O
and	O
ninety	O
one	O
patients	O
consented	O
to	O
participate	O
.	O

The	O
demographic	O
details	O
of	O
the	O
sample	O
are	O
given	O
in	O
Table	O
1	O
.	O

Patients	O
between	O
35	O
and	O
64	O
years	O
of	O
age	O
formed	O
the	O
largest	O
portion	O
of	O
the	O
sample	O
(	O
62.3	O
%	O
)	O
.	O

There	O
was	O
a	O
significant	O
gender	O
difference	O
with	O
females	O
outnumbering	O
males	O
by	O
a	O
2:1	O
ratio	O
,	O
p	O
<	O
0.01	O
.	O

Most	O
patients	O
were	O
of	O
Asian	O
Indian	O
origin	O
(	O
58.1	O
%	O
)	O
and	O
resided	O
in	O
suburban	O
areas	O
(	O
60.2	O
%	O
)	O
.	O

There	O
was	O
a	O
high	O
level	O
of	O
unemployment	O
(	O
30.4	O
%	O
)	O
;	O
this	O
could	O
be	O
correlated	O
to	O
primary	O
schooling	O
(	O
seven	O
or	O
less	O
years	O
of	O
formal	O
education	O
)	O
being	O
the	O
highest	O
educational	O
level	O
attained	O
in	O
52.9	O
%	O
and	O
no	O
formal	O
schooling	O
in	O
5.2	O
%	O
of	O
the	O
sample	O
population	O
.	O

Income	O
was	O
low	O
,	O
with	O
42.9	O
%	O
of	O
the	O
sample	O
population	O
earning	O
below	O
US$	O
4,000	O
per	O
year	O
.	O

Antiasthmatic	O
drug	O
use	O
The	O
GINA	O
guidelines	O
were	O
recently	O
adopted	O
in	O
the	O
Caribbean	O
and	O
asthmatic	O
patients	O
are	O
currently	O
treated	O
according	O
to	O
their	O
symptom	O
severity	O
.	O

In	O
our	O
sample	O
population	O
,	O
particularly	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
symptoms	O
,	O
corticosteroids	O
(	O
controllers	O
)	O
and	O
β2-agonists	O
(	O
relievers	O
)	O
were	O
prescribed	O
at	O
very	O
high	O
rates	O
,	O
Table	O
2	O
.	O

Almost	O
90	O
%	O
of	O
all	O
patients	O
with	O
moderate	O
symptoms	O
were	O
prescribed	O
drugs	O
in	O
these	O
classes	O
.	O

Almost	O
all	O
patients	O
with	O
severe	O
symptoms	O
were	O
prescribed	O
β2-agonists	O
.	O

This	O
high	O
level	O
of	O
prescription	O
and	O
use	O
of	O
β2-agonists	O
suggest	O
a	O
lack	O
of	O
symptomatic	O
control	O
in	O
our	O
sample	O
population	O
.	O

Theophylline	O
and	O
anticholinergics	O
were	O
prescribed	O
in	O
both	O
categories	O
of	O
patients	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

Factors	O
influencing	O
the	O
use	O
of	O
herbal	O
remedies	O
Gender	O
,	O
age	O
,	O
ethnicity	O
,	O
residential	O
district	O
,	O
employment	O
status	O
,	O
income	O
and	O
asthma	O
severity	O
had	O
no	O
statistically	O
significant	O
effect	O
on	O
the	O
use	O
of	O
herbal	O
remedies	O
within	O
the	O
sample	O
population	O
,	O
Table	O
3	O
.	O

However	O
,	O
almost	O
two	O
-	O
thirds	O
(	O
62.5	O
%	O
)	O
of	O
patients	O
with	O
tertiary	O
education	O
used	O
herbal	O
remedies	O
for	O
asthma	O
,	O
p	O
=	O
0.025	O
.	O

Characteristics	O
of	O
patients	O
using	O
herbal	O
remedies	O
Most	O
patients	O
(	O
70.7	O
%	O
)	O
using	O
herbs	O
were	O
advised	O
by	O
a	O
relative	O
or	O
friend	O
and	O
only	O
10.3	O
%	O
sought	O
the	O
advice	O
of	O
an	O
herbalist	O
,	O
Table	O
4	O
.	O

A	O
cultural	O
/	O
traditional	O
basis	O
was	O
the	O
reason	O
for	O
herbal	O
remedy	O
usage	O
in	O
twenty	O
-	O
one	O
(	O
36.2	O
%	O
)	O
patients	O
and	O
another	O
twelve	O
(	O
20.7	O
%	O
)	O
patients	O
used	O
herbs	O
because	O
they	O
felt	O
that	O
were	O
either	O
'	O
natural	O
'	O
or	O
'	O
healthy	O
'	O
.	O

Twelve	O
(	O
20.7	O
%	O
)	O
patients	O
used	O
herbs	O
because	O
they	O
believed	O
that	O
their	O
physician	O
-	O
prescribed	O
allopathic	O
medicines	O
were	O
not	O
working	O
.	O

Most	O
patients	O
(	O
58.6	O
%	O
)	O
obtained	O
their	O
herbs	O
or	O
medicinal	O
plants	O
from	O
either	O
their	O
backyards	O
or	O
the	O
supermarket	O
.	O

Only	O
fourteen	O
(	O
24.1	O
%	O
)	O
obtained	O
their	O
herbal	O
supplies	O
from	O
an	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
.	O

Seventeen	O
(	O
29.3	O
%	O
)	O
of	O
these	O
patients	O
reported	O
using	O
herbs	O
within	O
the	O
last	O
week	O
and	O
most	O
these	O
patients	O
(	O
60.3	O
%	O
)	O
used	O
herbs	O
within	O
the	O
last	O
six	O
months	O
.	O

Many	O
of	O
these	O
patients	O
were	O
using	O
both	O
physician	O
-	O
prescribed	O
antiasthmatic	O
drugs	O
and	O
herbal	O
remedies	O
,	O
Table	O
5	O
.	O

No	O
patient	O
with	O
either	O
moderate	O
or	O
severe	O
symptoms	O
indicated	O
that	O
herbal	O
remedies	O
alone	O
were	O
sufficient	O
to	O
relieve	O
symptomatic	O
episodes	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
most	O
patients	O
with	O
moderate	O
symptoms	O
(	O
57.1	O
%	O
)	O
believed	O
that	O
concurrent	O
use	O
of	O
conventional	O
medications	O
and	O
herbs	O
gave	O
better	O
symptomatic	O
relieve	O
.	O

One	O
the	O
other	O
hand	O
,	O
most	O
patients	O
with	O
severe	O
symptoms	O
(	O
53.8	O
%	O
)	O
believed	O
that	O
physician	O
-	O
prescribed	O
medications	O
worked	O
better	O
than	O
herbal	O
remedies	O
,	O
while	O
23.1	O
%	O
believed	O
that	O
neither	O
relieved	O
their	O
symptoms	O
.	O

Herbs	O
used	O
in	O
asthma	O
Most	O
patients	O
in	O
the	O
sample	O
used	O
more	O
than	O
one	O
medicinal	O
herb	O
simultaneously	O
,	O
which	O
were	O
usually	O
prepared	O
and	O
administered	O
as	O
mixtures	O
in	O
teas	O
.	O

Almost	O
one	O
in	O
four	O
patients	O
using	O
medicinal	O
herbs	O
(	O
22.5	O
%	O
)	O
used	O
either	O
garlic	B
(	O
Allium	B
sativum	I
)	O
or	O
ginger	B
(	O
Zingiber	B
officinale	I
)	O
for	O
symptomatic	O
relief	O
of	O
asthma	O
,	O
Table	O
6	O
.	O

Aloes	O
(	O
Aloe	B
vera	I
)	O
shandileer	B
(	O
Leonotis	B
nepetifolia	I
)	O
,	O
wild	O
onion	B
(	O
Hymenocallis	B
tubiflora	I
)	O
,	O
pepper	O
(	O
Capsicum	O
spp	O
.	O
)	O

tulsi	B
(	O
Ocimum	B
gratissimum	I
)	O
,	O
black	B
sage	I
(	O
Cordia	B
curassavica	I
)	O
,	O
shadon	B
beni	I
(	O
Eryngium	B
foetidium	I
)	O
,	O
lemongrass	B
(	O
Cymbopogon	B
citratus	I
)	O
and	O
nutmeg	B
(	O
Myristica	B
fragrans	I
)	O
were	O
the	O
more	O
popular	O
traditional	O
indigenous	O
West	O
Indian	O
medicinal	O
plants	O
used	O
.	O

Two	O
patients	O
reported	O
using	O
marijuana	O
(	O
leaves	O
and	O
roots	O
)	O
.	O

Herbs	O
of	O
European	O
and	O
North	O
American	O
origin	O
,	O
identified	O
as	O
Echinacea	O
(	O
Echinacea	B
purpurea	I
)	O
,	O
Golden	B
Seal	I
(	O
Hydrastis	B
canadensis	I
)	O
and	O
Chamomile	B
(	O
Matricaria	B
chamomilla	I
)	O
were	O
less	O
frequently	O
used	O
.	O

Five	O
patients	O
reported	O
using	O
trade	O
name	O
imported	O
tablets	O
for	O
asthma	O
.	O

Effect	O
of	O
income	O
and	O
education	O
on	O
the	O
use	O
of	O
herbs	O
Patients	O
using	O
easily	O
accessible	O
herbs	O
such	O
as	O
ginger	B
(	O
Zingiber	B
officinale	I
)	O
and	O
aloes	O
(	O
Aloe	B
vera	I
)	O
,	O
and	O
traditional	O
indigenous	O
medicinal	O
herbs	O
such	O
as	O
shandileer	B
(	O
Leonotis	B
nepetifolia	I
)	O
and	O
tulsi	B
(	O
Ocimum	B
gratissimum	I
)	O
were	O
more	O
likely	O
to	O
be	O
earning	O
less	O
than	O
US$	O
12,000	O
,	O
Table	O
7	O
.	O

Herbs	O
of	O
European	O
or	O
North	O
American	O
origin	O
(	O
Echinacea	B
purpurea	I
and	O
Matricaria	B
chamomilla	I
)	O
were	O
more	O
likely	O
to	O
be	O
used	O
by	O
patients	O
earning	O
in	O
excess	O
of	O
US$	O
12,000	O
per	O
annum	O
.	O

Income	O
did	O
not	O
affect	O
the	O
use	O
of	O
either	O
garlic	B
or	O
cocoa	O
onion	B
.	O

Aloes	O
(	O
Aloe	B
vera	I
)	O
,	O
tulsi	B
(	O
Ocimum	B
gratissimum	I
)	O
and	O
golden	O
seal	O
were	O
preferred	O
in	O
patients	O
with	O
at	O
least	O
twelve	O
years	O
of	O
formal	O
education	O
,	O
Table	O
7	O
.	O

Garlic	B
and	O
Echinacea	B
were	O
the	O
preferred	O
herbal	O
medicines	O
in	O
patients	O
with	O
more	O
than	O
twelve	O
years	O
formal	O
education	O
.	O

Educational	O
level	O
did	O
not	O
affect	O
the	O
patients	O
'	O
decision	O
to	O
use	O
shandileer	B
(	O
Leonotis	B
nepetifolia	I
)	O
,	O
wild	O
onion	B
(	O
Hymenocallis	B
tubiflora	I
)	O
or	O
ginger	B
(	O
Zingibe	B
officinale	I
)	O
.	O

Discussion	O
This	O
is	O
the	O
first	O
study	O
of	O
its	O
kind	O
in	O
the	O
Caribbean	O
to	O
assess	O
the	O
use	O
of	O
medicinal	O
herbs	O
by	O
asthmatic	O
patients	O
attending	O
a	O
specialty	O
care	O
clinic	O
.	O

The	O
findings	O
of	O
this	O
study	O
are	O
instructive	O
as	O
the	O
use	O
of	O
medicinal	O
herbs	O
for	O
self	O
-	O
medication	O
in	O
disease	O
management	O
has	O
far	O
reaching	O
implications	O
on	O
the	O
quality	O
of	O
healthcare	O
delivery	O
[	O
14	O
]	O
.	O

We	O
report	O
a	O
prevalence	O
of	O
30.4	O
%	O
in	O
our	O
patient	O
sample	O
,	O
which	O
is	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
UK	O
,	O
Denmark	O
,	O
Singapore	O
and	O
in	O
the	O
US	O
[	O
15	O
-	O
18	O
]	O
.	O

Most	O
patients	O
using	O
medicinal	O
herbs	O
relied	O
on	O
the	O
advice	O
of	O
relatives	O
and	O
friends	O
as	O
their	O
sole	O
source	O
of	O
information	O
,	O
as	O
were	O
caregivers	O
of	O
children	O
in	O
a	O
US	O
study	O
[	O
19	O
]	O
.	O

We	O
suggest	O
that	O
this	O
information	O
on	O
the	O
use	O
of	O
medicinal	O
plants	O
could	O
have	O
come	O
from	O
traditional	O
/	O
cultural	O
knowledge	O
,	O
anecdotal	O
evidence	O
or	O
from	O
the	O
greater	O
public	O
awareness	O
through	O
information	O
networks	O
such	O
as	O
the	O
internet	O
on	O
the	O
potential	O
medicinal	O
benefits	O
of	O
herbs	O
.	O

Asthma	O
is	O
an	O
emerging	O
chronic	O
disease	O
in	O
the	O
Caribbean	O
and	O
we	O
suggest	O
that	O
the	O
traditional	O
knowledge	O
in	O
this	O
area	O
may	O
be	O
relatively	O
'	O
new	O
'	O
and	O
exist	O
in	O
relation	O
to	O
other	O
diseases	O
affecting	O
the	O
respiratory	O
tract	O
,	O
such	O
as	O
cough	O
,	O
the	O
common	O
cold	O
and	O
the	O
flu	O
.	O

This	O
may	O
be	O
one	O
of	O
the	O
reasons	O
for	O
the	O
low	O
prevalence	O
of	O
use	O
of	O
herbs	O
in	O
elderly	O
asthmatic	O
patients	O
,	O
as	O
a	O
strong	O
traditional	O
knowledge	O
may	O
not	O
have	O
existed	O
.	O

We	O
expected	O
a	O
higher	O
prevalence	O
of	O
herbal	O
use	O
in	O
individuals	O
living	O
in	O
rural	O
areas	O
as	O
these	O
districts	O
are	O
depots	O
for	O
traditional	O
knowledge	O
as	O
was	O
reported	O
in	O
Jamaica	O
where	O
rural	O
respondents	O
used	O
a	O
larger	O
variety	O
of	O
herbs	O
than	O
those	O
living	O
in	O
urban	O
areas	O
[	O
10	O
]	O
.	O

As	O
suggested	O
earlier	O
,	O
we	O
suspect	O
that	O
due	O
to	O
the	O
recent	O
emergence	O
of	O
asthma	O
as	O
a	O
chronic	O
disease	O
in	O
the	O
Caribbean	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
traditional	O
knowledge	O
in	O
the	O
management	O
of	O
this	O
disease	O
is	O
not	O
strong	O
and	O
our	O
results	O
are	O
indicative	O
of	O
this	O
.	O

We	O
suspected	O
that	O
employment	O
status	O
could	O
have	O
predicted	O
the	O
use	O
of	O
herbs	O
,	O
however	O
,	O
this	O
was	O
not	O
the	O
case	O
in	O
our	O
study	O
sample	O
.	O

Unemployed	O
patients	O
did	O
not	O
improvise	O
more	O
in	O
their	O
use	O
of	O
herbal	O
remedies	O
than	O
those	O
in	O
other	O
income	O
groups	O
,	O
even	O
though	O
most	O
of	O
the	O
herbs	O
used	O
were	O
relatively	O
common	O
,	O
readily	O
available	O
and	O
cheap	O
.	O

The	O
low	O
socioeconomic	O
status	O
of	O
the	O
majority	O
of	O
the	O
sample	O
may	O
have	O
prohibited	O
both	O
consultation	O
with	O
qualified	O
herbalists	O
and	O
the	O
purchase	O
of	O
imported	O
,	O
processed	O
herbs	O
that	O
would	O
have	O
incurred	O
additional	O
out	O
-	O
of	O
-	O
pocket	O
expense	O
to	O
the	O
patient	O
.	O

What	O
we	O
noted	O
was	O
that	O
there	O
was	O
no	O
difference	O
in	O
the	O
use	O
of	O
herbs	O
across	O
the	O
income	O
ranges	O
and	O
that	O
in	O
fact	O
,	O
patients	O
earning	O
relatively	O
modest	O
annual	O
incomes	O
between	O
$	O
US12,000	O
and	O
$	O
US19,999	O
were	O
most	O
likely	O
to	O
use	O
herbs	O
,	O
although	O
this	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Attaining	O
a	O
higher	O
education	O
positively	O
influence	O
the	O
decision	O
to	O
use	O
herbs	O
.	O

We	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
traditional	O
knowledge	O
regarding	O
the	O
medicinal	O
use	O
of	O
herbs	O
for	O
asthma	O
,	O
a	O
higher	O
educational	O
level	O
may	O
predispose	O
an	O
individual	O
to	O
greater	O
access	O
to	O
general	O
knowledge	O
,	O
especially	O
with	O
greater	O
exposure	O
to	O
the	O
internet	O
and	O
other	O
sources	O
of	O
information	O
,	O
and	O
this	O
could	O
be	O
a	O
factor	O
in	O
positively	O
influencing	O
the	O
individual	O
's	O
decision	O
to	O
use	O
medicinal	O
herbs	O
.	O

The	O
availability	O
of	O
scientific	O
evidence	O
-	O
based	O
information	O
on	O
the	O
efficacy	O
of	O
herbs	O
for	O
diverse	O
healthcare	O
problems	O
may	O
be	O
particularly	O
significant	O
in	O
patients	O
with	O
the	O
resources	O
to	O
avail	O
themselves	O
to	O
such	O
information	O
,	O
particularly	O
those	O
with	O
higher	O
educational	O
and	O
income	O
levels	O
.	O

This	O
is	O
particularly	O
true	O
for	O
garlic	B
and	O
Echinacea	B
,	O
which	O
have	O
been	O
extensively	O
researched	O
and	O
furthermore	O
patients	O
with	O
higher	O
educational	O
and	O
income	O
levels	O
would	O
be	O
more	O
likely	O
be	O
at	O
an	O
advantage	O
to	O
access	O
information	O
via	O
literature	O
or	O
on	O
the	O
world	O
wide	O
web	O
regarding	O
the	O
use	O
of	O
these	O
medicinal	O
plants	O
.	O

Patients	O
using	O
imported	O
,	O
processed	O
,	O
and	O
obviously	O
more	O
expensive	O
herbal	O
medications	O
were	O
on	O
the	O
higher	O
end	O
of	O
the	O
socioeconomic	O
scale	O
and	O
were	O
more	O
likely	O
to	O
afford	O
these	O
medications	O
.	O

It	O
was	O
also	O
observed	O
that	O
garlic	B
and	O
Echinacea	B
were	O
the	O
herbs	O
of	O
choice	O
in	O
patients	O
with	O
higher	O
educational	O
levels	O
.	O

These	O
herbs	O
have	O
a	O
long	O
tradition	O
of	O
use	O
and	O
are	O
widely	O
researched	O
in	O
Europe	O
and	O
North	O
America	O
.	O

The	O
traditional	O
use	O
and	O
strong	O
scientific	O
evidence	O
to	O
support	O
their	O
therapeutic	O
efficacy	O
could	O
be	O
important	O
factors	O
influencing	O
the	O
patient	O
's	O
decision	O
.	O

It	O
has	O
been	O
suggested	O
elsewhere	O
that	O
patients	O
with	O
higher	O
educational	O
levels	O
also	O
tend	O
be	O
more	O
involved	O
in	O
the	O
management	O
of	O
their	O
health	O
;	O
they	O
tend	O
to	O
self	O
-	O
medicate	O
or	O
even	O
suggest	O
to	O
their	O
physicians	O
the	O
course	O
of	O
therapy	O
.	O

Although	O
one	O
in	O
five	O
patients	O
using	O
medicinal	O
herbs	O
stated	O
that	O
""""	O
conventional	O
medicines	O
were	O
not	O
working	O
""""	O
as	O
the	O
reason	O
for	O
using	O
this	O
alternative	O
healthcare	O
modality	O
,	O
we	O
noted	O
that	O
asthma	O
severity	O
does	O
not	O
affect	O
the	O
decision	O
to	O
use	O
herbs	O
.	O

In	O
previous	O
studies	O
,	O
poor	O
management	O
was	O
associated	O
with	O
non	O
-	O
compliance	O
with	O
prescribed	O
pharmacotherapy	O
and	O
poor	O
inhaler	O
technique	O
[	O
5,6	O
]	O
.	O

The	O
backyard	O
and	O
home	O
garden	O
were	O
major	O
sources	O
of	O
readily	O
available	O
herbs	O
such	O
as	O
aloes	O
,	O
shadon	B
beni	I
and	O
lemongrass	B
.	O

Wild	O
growing	O
'	O
weeds	O
'	O
such	O
as	O
shandileer	B
,	O
tulsi	B
,	O
cocoa	O
onion	B
and	O
black	B
sage	I
were	O
also	O
identified	O
.	O

The	O
supermarket	O
was	O
a	O
major	O
source	O
of	O
inexpensive	O
common	O
medicinal	O
herbs	O
such	O
as	O
garlic	B
,	O
ginger	B
and	O
nutmeg	B
.	O

The	O
identification	O
of	O
these	O
medicinal	O
herbs	O
provides	O
an	O
opportunity	O
to	O
investigate	O
West	O
Indian	O
plants	O
used	O
to	O
treat	O
asthma	O
to	O
determine	O
whether	O
they	O
possess	O
pharmacological	O
properties	O
.	O

Scientific	O
investigations	O
have	O
shown	O
that	O
some	O
of	O
these	O
herbs	O
possess	O
pharmacological	O
and	O
anti	O
-	O
inflammatory	O
properties	O
,	O
and	O
these	O
may	O
be	O
useful	O
in	O
suppressing	O
the	O
characteristic	O
exaggerated	O
immune	O
response	O
in	O
asthma	O
[	O
20	O
-	O
24	O
]	O
.	O

Pepper	O
and	O
bayleaf	B
have	O
also	O
been	O
shown	O
to	O
exhibit	O
anti	O
-	O
inflammatory	O
properties	O
[	O
[	O
25,26	O
]	O
27	O
]	O
.	O

There	O
is	O
an	O
imperative	O
to	O
commence	O
scientific	O
investigations	O
on	O
traditional	O
West	O
Indian	O
medicinal	O
plants	O
to	O
determine	O
their	O
therapeutic	O
efficacy	O
and	O
safety	O
.	O

The	O
survey	O
instrument	O
specifically	O
asked	O
questions	O
on	O
the	O
use	O
of	O
medicinal	O
herbs	O
in	O
asthma	O
and	O
did	O
not	O
inquire	O
about	O
the	O
use	O
of	O
herbs	O
as	O
customary	O
teas	O
or	O
tonics	O
.	O

We	O
therefore	O
did	O
not	O
determine	O
lifetime	O
prevalence	O
for	O
the	O
use	O
of	O
herbs	O
in	O
our	O
patient	O
sample	O
,	O
but	O
we	O
suppose	O
that	O
had	O
this	O
been	O
included	O
that	O
there	O
might	O
have	O
been	O
a	O
prevalence	O
similar	O
to	O
those	O
reported	O
in	O
the	O
Jamaica	O
[	O
10,11	O
]	O
and	O
Trinidad	O
[	O
13	O
]	O
surveys	O
.	O

The	O
survey	O
was	O
also	O
limited	O
in	O
that	O
by	O
electing	O
to	O
conduct	O
the	O
study	O
at	O
a	O
public	O
health	O
facility	O
we	O
obviously	O
had	O
a	O
bias	O
towards	O
patients	O
at	O
the	O
lower	O
rung	O
of	O
the	O
socioeconomic	O
ladder	O
,	O
with	O
lower	O
income	O
and	O
educational	O
status	O
.	O

As	O
a	O
consequence	O
,	O
the	O
results	O
reflected	O
patients	O
from	O
this	O
demographic	O
background	O
.	O

We	O
may	O
have	O
expected	O
a	O
different	O
outcome	O
in	O
asthmatic	O
patients	O
attending	O
private	O
institutions	O
,	O
where	O
their	O
characteristics	O
would	O
have	O
been	O
slightly	O
different	O
,	O
as	O
we	O
noted	O
that	O
even	O
in	O
our	O
sample	O
the	O
small	O
number	O
of	O
persons	O
with	O
higher	O
income	O
and	O
educational	O
status	O
tended	O
to	O
use	O
more	O
medicinal	O
herbs	O
for	O
symptomatic	O
relief	O
.	O

We	O
did	O
not	O
assess	O
whether	O
patients	O
informed	O
their	O
attending	O
physician	O
at	O
the	O
clinic	O
about	O
their	O
use	O
of	O
herbs	O
or	O
determined	O
whether	O
the	O
knowledge	O
or	O
attitudes	O
of	O
these	O
physicians	O
regarding	O
the	O
use	O
of	O
herbs	O
influenced	O
the	O
patients	O
'	O
decision	O
to	O
use	O
herbs	O
.	O

The	O
study	O
was	O
also	O
limited	O
in	O
that	O
we	O
did	O
not	O
ascertain	O
the	O
out	O
-	O
of	O
-	O
pocket	O
expense	O
for	O
herbal	O
remedies	O
by	O
patients	O
,	O
although	O
most	O
stated	O
that	O
herbal	O
medicines	O
(	O
which	O
we	O
supposed	O
were	O
processed	O
,	O
imported	O
products	O
)	O
were	O
more	O
expensive	O
than	O
conventional	O
medicines	O
.	O

We	O
assumed	O
that	O
an	O
additional	O
expense	O
would	O
have	O
only	O
been	O
incurred	O
by	O
those	O
patients	O
purchasing	O
processed	O
,	O
imported	O
herbs	O
obtained	O
from	O
a	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
(	O
24.1	O
%	O
)	O
and	O
who	O
actually	O
consulted	O
a	O
herbalist	O
(	O
10.3	O
%	O
)	O
.	O

We	O
also	O
reasoned	O
that	O
since	O
all	O
the	O
other	O
herbs	O
used	O
were	O
inexpensive	O
and	O
available	O
from	O
either	O
the	O
backyard	O
garden	O
or	O
supermarket	O
(	O
58.6	O
%	O
)	O
that	O
the	O
cost	O
to	O
patients	O
selecting	O
these	O
remedies	O
was	O
minimal	O
.	O

Conclusions	O
The	O
findings	O
of	O
this	O
study	O
are	O
important	O
in	O
that	O
local	O
medicinal	O
plants	O
in	O
Trinidad	O
have	O
been	O
identified	O
in	O
the	O
self	O
-	O
management	O
of	O
asthma	O
in	O
a	O
significant	O
number	O
of	O
patients	O
attending	O
the	O
specialty	O
clinic	O
.	O

These	O
identified	O
herbs	O
can	O
now	O
be	O
targeted	O
for	O
scientific	O
investigation	O
to	O
determine	O
whether	O
their	O
pharmacological	O
efficacy	O
will	O
assist	O
in	O
the	O
development	O
of	O
viable	O
healthcare	O
alternatives	O
in	O
a	O
developing	O
country	O
.	O

These	O
findings	O
are	O
also	O
important	O
for	O
policymakers	O
in	O
the	O
health	O
sector	O
who	O
are	O
given	O
the	O
mandate	O
to	O
regulate	O
issues	O
pertaining	O
to	O
the	O
public	O
's	O
health	O
.	O

We	O
are	O
also	O
becoming	O
more	O
aware	O
of	O
the	O
potential	O
for	O
critical	O
interplay	O
between	O
herbs	O
and	O
drugs	O
when	O
taken	O
concomitantly	O
to	O
produce	O
life	O
-	O
threatening	O
interactions	O
.	O

Since	O
herbs	O
are	O
here	O
to	O
stay	O
and	O
patients	O
will	O
continue	O
to	O
self	O
-	O
medicate	O
with	O
increasing	O
frequency	O
,	O
it	O
is	O
imperative	O
that	O
healthcare	O
providers	O
become	O
more	O
knowledgeable	O
on	O
this	O
modality	O
and	O
keep	O
abreast	O
with	O
the	O
latest	O
developments	O
in	O
herbal	O
therapy	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
YNC	O
was	O
the	O
P.I.	O
in	O
this	O
study	O
.	O

He	O
was	O
responsible	O
for	O
the	O
study	O
concept	O
,	O
development	O
of	O
methodology	O
,	O
coordinating	O
the	O
research	O
activities	O
,	O
analyzing	O
the	O
data	O
,	O
and	O
writing	O
the	O
manuscript	O
.	O

AFW	O
was	O
responsible	O
for	O
data	O
input	O
and	O
analysis	O
.	O

DA	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
,	O
data	O
input	O
and	O
analysis	O
and	O
presentation	O
at	O
regional	O
conference	O
.	O

RC	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
,	O
data	O
input	O
and	O
analysis	O
.	O

NW	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

RM	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

OS	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

DW	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

